name,description,indication
Lepirudin,lepirudin recombinant hirudin formed 65 amino acid act highly specific direct thrombin inhibitor l41539 l41569 natural hirudin endogenous anticoagulant found _hirudo medicinalis_ leech l41539 lepirudin produced yeast cell identical natural hirudin except absence sulfate tyrosine residue position 63 substitution leucine isoleucine position 1 n-terminal end a246609 lepirudin used anticoagulant patient heparin-induced thrombocytopenia hit immune reaction associated high risk thromboembolic complication a3 l41539 hit caused expression immunoglobulin g igg antibody bind complex formed heparin platelet factor 4 activates endothelial cell platelet enhances formation thrombus a246609 bayer ceased production lepirudin refludan effective may 31 2012 l41574 ,lepirudin indicated anticoagulation adult patient acute coronary syndrome ac unstable angina acute myocardial infarction without st elevation patient ac lepirudin intended use aspirin l41539 lepirudin also indicated anticoagulation patient heparin-induced thrombocytopenia hit associated thromboembolic disease order prevent thromboembolic complication l41539 
Cetuximab,cetuximab recombinant chimeric human/mouse igg1 monoclonal antibody competitively bind epidermal growth factor receptor egfr competitively inhibits binding epidermal growth factor egf a227973 egfr member erbb family receptor tyrosine kinase found normal tumour cell responsible regulating epithelial tissue development homeostasis a228083 egfr implicated various type cancer often overexpressed malignant cell a227973 egfr overexpression linked advanced disease poor prognosis a227963 egfr often mutated certain type cancer serf driver tumorigenesis a228083 _in vitro_ cetuximab shown mediate anti-tumour effect numerous cancer cell line human tumour xenograft a227963 approved fda february 2004 brand name erbitux cetuximab used treatment head neck cancer metastatic kras wild-type colorectal cancer metastatic colorectal cancer braf v600e mutation a227963 l39045 also investigated advanced colorectal cancer egfr-expressing non-small cell lung cancer nsclc unresectable squamous cell skin cancer l31418 cetuximab administered via intravenous infusion used monotherapy combination chemotherapy including platinum agent radiation therapy leucovorin fluorouracil irinotecan l30448 ,cetuximab indicated treatment locally regionally advanced squamous cell carcinoma head neck combination radiation therapy indicated treating recurrent locoregional disease metastatic squamous cell carcinoma head neck combination platinum-based therapy fluorouracil indicated recurrent metastatic squamous cell carcinoma head neck progressing platinum-based therapy l30448 cetuximab also indicated k-ras wild-type egfr-expressing metastatic colorectal cancer determined fda-approved test combination folfiri chemotherapy combination includes leucovorin fluorouracil irinotecan combination irinotecan patient refractory irinotecan-based chemotherapy monotherapy patient failed oxaliplatin- irinotecan-based chemotherapy intolerant irinotecan l30448 additionally cetuximab also indicated metastatic colorectal cancer braf v600e mutation-positive determined fda-approved test combination encorafenib prior therapy l39045 cetuximab indicated treatment ras-mutant colorectal cancer result ra mutation test unknown l30448 
Dornase alfa,dornase alfa biosynthetic form human deoxyribunuclease dnase enzyme produced genetically modified chinese hamster ovary cho cell using recombinant dna technology 260-amino acid sequence dornase alfa identical endogenous human enzyme dornase alfa cleaves extracellular dna 5´-phosphodinucleotide 5´-phosphooligonucleotide end product without affecting intracellular dna individual cystic fibrosis extracellular dna extremely viscous anion released degenerating leukocyte accumulate inflammatory response infection enzymatic breakdown extracellular dna appears reduce sputum viscosity viscoelasticity ,used adjunct therapy treatment cystic fibrosis 
Denileukin diftitox, recombinant dna-derived cytotoxic protein composed amino acid sequence diphtheria toxin fragment b met 1-thr 387 -his followed sequence interleukin-2 il-2 ala 1-thr 133 produced e. coli expression system , treatment cutaneous t-cell lymphoma
Etanercept,dimeric fusion protein consisting extracellular ligand-binding portion human 75 kilodalton p75 tumor necrosis factor receptor tnfr linked fc portion human igg1 l14862 a216522 fc component etanercept contains ch2 domain ch3 domain hinge region ch1 domain igg1 etanercept produced recombinant dna technology chinese hamster ovary cho mammalian cell expression system consists 934 amino acid used treat manage variety inflammatory condition including rheumatoid arthritis ra ankylosing spondylitis juvenile idiopathic poly-articular arthritis jia ,etanercept indicated treatment moderately severely active rheumatoid arthritis adult chronic moderate severe plaque psoriasis patient 4 year age older l14862 also used manage sign symptom polyarticular idiopathic arthritis aged 2 year older etanercept also used manage symptom psoriatic arthritis ankylosing spondylitis 
Bivalirudin,bivalirudin synthetic 20 residue peptide thrombin inhibitor reversibly inhibits thrombin bound active site thrombin activate fibrinogen fibrin crucial step formation thrombus administered intravenously cause blood stagnation important monitor change hematocrit activated partial thromboplastin time international normalized ratio blood pressure , treatment heparin-induced thrombocytopenia prevention thrombosis bivalirudin indicated use patient undergoing percutaneous coronary intervention pci patient moderate high risk acute coronary syndrome due unstable angina non-st segment elevation pci planned 
Leuprolide,leuprolide synthetic 9-residue peptide analogue gonadotropin-releasing hormone gnrh unlike endogenous decapeptide gnrh leuprolide contains single d-amino acid d-leucyl residue help increase circulating half-life three four minute approximately three hour a203222 gnrh mimic leuprolide capable binding gnrh receptor gnrhr inducing downstream modulation gonadotropin hormone sex steroid level prolonged activation gnrhr result significant downregulation sex steroid level primarily responsible clinical efficacy leuprolide diverse condition including advanced prostate cancer endometriosis central precocious puberty a203126 a203132 leuprolide first approved 1985 daily subcutaneous injection tradename lupron™ abbvie endocrine inc. l13850 since initial approval various long-acting intramuscular subcutaneous product developed patient dosed every six month l13781 l13790 leuprolide remains frontline therapy condition indicated use ,leuprolide indicated treatment advanced prostate cancer l13781 l34415 palliative treatment advanced prostate cancer l13790 also used treatment pediatric patient central precocious puberty cpp l13784 l13787 combination oral norethisterone also known norethindrone leuprolide also indicated initial treatment symptom endometriosis l10310 finally combination iron supplementation leuprolide indicated preoperative hematological improvement anemic patient uterine leiomyomata uterine fibroid l13814 
Peginterferon alfa-2a,peginterferon alfa-2a form recombinant interferon used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas resulting le use peginterferon alfa-2a peginterferon alfa-2a derived alfa-2a moeity recombinant human interferon act binding human type 1 interferon receptor activation dimerization receptor induces body 's innate antiviral response activating janus kinase/signal transducer activator transcription jak/stat pathway use peginterferon alfa-2a associated wide range severe adverse effect including aggravation development endocrine autoimmune disorder retinopathy cardiovascular neuropsychiatric complication increased risk hepatic decompensation patient cirrhosis use peginterferon alfa-2a largely declined since newer interferon-free antiviral therapy developed joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa longer recommend peginterferon alfa-2a treatment hepatitis c a19593 peginterferon alfa-2a used alongside db00811 intent cure achieve sustained virologic response svr 48 week therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 peginterferon alfa-2a available fixed dose injector tradename pegasys used treatment chronic hepatitis c. approved 2002 fda pegasys indicated treatment hcv db00811 antiviral drug fda label combined together peginterferon alfa-2a db00811 shown achieve svr 36 genotype 1 59 genotype 2-6 48 week treatment ,peginterferon alfa-2a indicated treatment hcv combination antiviral drug patient 5 year age compensated liver disease fda label may used monotherapy patient contraindication significant intolerance anti-viral therapy peginterferon alfa-2a also indicated monotherapy adult patient hbeag positive hbeag negative chronic hepatitis b infection compensated liver disease evidence viral replication liver inflammation fda label 
Alteplase,alteplase recombinant tissue plasminogen activator rt-pa used thrombolytic agent l43125 cleaves plasminogen form plasmin enzyme involved degradation fibrin clot absence fibrin alteplase-mediated conversion plasminogen limited thanks high affinity alteplase fibrin a252330 l43125 alteplase purified glycoprotein 527 amino acid expressed chinese hamster ovary cho cell a252345 l43125 first approved fda 1987 management thromboembolic disease including acute myocardial infarction ami a252270 use alteplase manage ami decreased thanks availability safer treatment angioplasty stenting however use treatment acute ischemic stroke ai increased year a252340 new thrombolytic agent derived tissue plasminogen activator desmoteplase tenecteplase reteplase also developed a252270 a252345 alteplase also available cathflo activase intracatheter instillation restoration function central venous access device l34864 ,alteplase indicated treatment acute ischemic stroke ai use acute myocardial infarction ami reduction mortality incidence heart failure alteplase also indicated lysis acute massive pulmonary embolism defined acute pulmonary embolus obstructing blood flow lobe multiple lung segment acute pulmonary embolus accompanied unstable hemodynamics l43125 
Sermorelin,sermorelin acetate acetate salt amidated synthetic 29-amino acid peptide grf 1-29 nh 2 corresponds amino-terminal segment naturally occurring human growth hormone-releasing hormone ghrh grf consisting 44 amino acid residue, treatment dwarfism prevention hiv-induced weight loss
Interferon alfa-n1,interferon alfa-n1 consists purified natural n natural alpha interferon subtypes least two glycosylated differs recombinant alpha interferon individual non-glycosylated protein produced individual alpha interferon gene , treatment venereal genital wart caused human papiloma virus 
Darbepoetin alfa,human erythropoietin 2 aa substitution enhance glycosylation 5 n-linked chain 165 residue mw=37 kd produced chinese hamster ovary cho cell recombinant dna technology , treatment anemia renal transplant certain hiv treatment 
Urokinase,urokinase endogenous peptide cleaved presence plasmin lysine 158 isoleucine 159 yield active urokinase a191943 urokinase remains connected 2 chain sulfhydryl bond a191943 urokinase granted fda approval 16 january 1978 l12138 , canada urokinase indicated lysis acute massive pulmonary embolus acute thrombus obstructing coronary artery occlusive thromboemboli peripheral artery graft restoration patency intravenous catheter l12141 
Goserelin,goserelin synthetic hormone men stop production hormone testosterone may stimulate growth cancer cell woman goserelin decrease production hormone estradiol may stimulate growth cancer cell level similar postmenopausal state medication stopped hormone level return normal ,goserelin indicated use combination flutamide management locally confined carcinoma prostate palliative treatment advanced carcinoma prostate management endometriosis use endometrial-thinning agent prior endometrial ablation dysfunctional uterine bleeding use palliative treatment advanced breast cancer pre- perimenopausal woman
Reteplase,human tissue plasminogen activator purified glycosylated 355 residue purified cho cell retavase considered `` third-generation '' thrombolytic agent genetically engineered retain delete certain portion human tpa retavase deletion mutein human tpa formed deleting various amino acid present endogenous human tpa retavase contains 355 527 amino acid native human tpa amino acid 1-3 176-527 retains activity-related kringle-2 serine protease domain human tpa three domain deleted retavase kringle-1 finger epidermal growth factor egf , lysis acute pulmonary embolus intracoronary embolus management myocardial infarction 
Erythropoietin,"erythropoietin epo growth factor produced kidney stimulates production red blood cell work promoting division differentiation committed erythroid progenitor bone marrow fda label epoetin alfa epoge developed amgen inc. 1983 first rhepo commercialized united state followed alfa beta formulation epoetin alfa 165-amino acid erythropoiesis-stimulating glycoprotein produced cell culture using recombinant dna technology used treatment patient anemia associated various clinical condition chronic renal failure antiviral drug therapy chemotherapy high risk perioperative blood loss surgical procedure fda label molecular weight approximately 30,400 dalton produced mammalian cell human erythropoietin gene introduced product contains identical amino acid sequence isolated natural erythropoietin biological activity endogenous erythropoietin epoetin alfa biosimilar retacrit epoetin alfa-epbx epoetin zeta formulated allow access treatment option patient market l2784 biosimilar approved fda ema safe effective affordable biological product display equivalent clinical efficacy potency purity reference product a7504 epoetin alfa formulation administered intravenously subcutaneously ",indicated adult paediatric patient treatment anemia due chronic kidney disease ckd patient dialysis dialysis treatment anemia due zidovudine patient hiv-infection treatment anemia due effect concomitant myelosuppressive chemotherapy upon initiation minimum two additional month planned chemotherapy reduction allogeneic rbc transfusion patient undergoing elective noncardiac nonvascular surgery 
Salmon calcitonin,synthetic peptide 32 residue long formulated nasal spray ,used treatment symptomatic paget 's disease patient unresponsive alternate treatment intolerant treatment addition used emergency situation serum calcium level must decreased quickly underlying condition identified also added existing therapeutic regimen hypercalcemia intravenous fluid furosemide oral phosphate corticosteroid agent calcitonin used patient azotemia case intravenous fluid would contraindicated due limited cardiac reserve also treatment post-menopausal osteoporosis woman 5 year post-menopause 
Interferon alfa-n3,purified natural n natural human interferon alpha protein consists 3 form polymorphism including 2a 2b 2c 166 residue glycosylated mw range 16 kd 27 kd , intralesional treatment refractory recurring external condylomata acuminata 
Pegfilgrastim,pegfilgrastim pegylated form recombinant human granulocyte colony-stimulating factor g-csf analogue filgrastim a187601 drug approved use decrease incidence infection manifested febrile neutropenia susceptible patient non-myeloid cancer receiving myelosuppressive anti-cancer treatment l9746 although risk developing febrile neutropenia le 20 many readily used chemotherapy regimen a248855 infection pose risk hospitalization mortality a187631 due relatively short circulating half-life filgrastim 20 kda peg moiety covalently conjugated n-terminus filgrastim methionine residue develop longer-acting pegfilgrastim a29 a187607 due longer half-life slower elimination rate filgrastim pegfilgrastim requires le frequent dosing filgrastim however pegfilgrastim comparable pharmacological activity filgrastim bind g-csf receptor stimulate proliferation differentiation activation neutrophil a187607 first developed amgen pegfilgrastim initially approved fda 2002 marketed neulasta typically administered via subcutaneous injection several pegfilgrastim biosimilars fulphila pelgraz lapelga pelmeg udenyca ziextenzo grasustek fylnetra stimufend health canada european union eu fda approved reduce infection risk l9779 l9785 l43050 biosimilars highly similar reference product neulasta term pharmacological pharmacokinetic profile condition use l9974 ,pegfilgrastim indicated decrease incidence infection manifested febrile neutropenia patient non­ myeloid malignancy receiving myelosuppressive anti-cancer drug associated clinically significant incidence febrile neutropenia l44221 also indicated increase survival patient acutely exposed myelosuppressive dos radiation hematopoietic subsyndrome acute radiation syndrome l44221 
Sargramostim,sargramostim human recombinant granulocyte macrophage colony-stimulating factor gm-csf expressed yeast glycoprotein 127 residue substitution leu23 lead difference native protein , treatment cancer bone marrow transplant
Peginterferon alfa-2b,peginterferon alfa-2b form recombinant interferon used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas resulting le use peginterferon alfa-2b peginterferon alfa-2b derived alfa-2b moeity recombinant human interferon act binding human type 1 interferon receptor activation dimerization receptor induces body 's innate antiviral response activating janus kinase/signal transducer activator transcription jak/stat pathway use peginterferon alfa-2b associated wide range severe adverse effect including aggravation development endocrine autoimmune disorder retinopathy cardiovascular neuropsychiatric complication increased risk hepatic decompensation patient cirrhosis use peginterferon alfa-2b largely declined since newer interferon-free antiviral therapy developed joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa longer recommend peginterferon alfa-2b treatment hepatitis c a19593 peginterferon alfa-2b used alongside db00811 intent cure achieve sustained virologic response svr 48 week therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 peginterferon alfa-2b available variable dose injectable product tradename pegintron used treatment chronic hepatitis c. approved 2001 fda pegintron indicated treatment hcv ribavirin antiviral drug fda label combined together peginterferon alfa-2b ribavirin shown achieve svr 41 genotype 1 75 genotype 2-6 48 week treatment ,peginterferon alfa-2b indicated treatment hcv combination db00811 ns3/4a protease inhibitor genotype 1 without ns3/4a protease inhibitor genotype 2-6 fda label may used monotherapy patient contraindication significant intolerance anti-viral therapy 
Asparaginase Escherichia coli,asparaginase derived _escherichia coli_ l-asparagine amidohydrolase ec 3.5.1.1 enzyme responsible metabolism l-asparagine catalyzing l-asparagine l-aspartic acid ammonia also facilitates production oxaloacetate needed general cellular metabolism asparaginase _e coli_ clinically shown exhibit antitumor action model leukaemia a31996 a31997 l-asparaginase _e coli_ marketed several different trade name including elspar treatment acute lymphoblastic leukemia part multi-agent chemotherapeutic regimen available intramuscular intravenous injection therapeutic l-asparaginase _e coli_ work depleting level non-essential amino acid asparagine lymphoblastic leukemic cell thus promoting apoptotic cell death a31999 patient develop hypersensitivity _e coli_-derived formulation l-asparaginase use pegylated non-pegylated db08886 recommended a31999 ,indicated component multi-agent chemotherapeutic regimen treatment patient acute lymphoblastic leukemia l39809 
Thyrotropin alfa,thyrotropin alfa recombinant form thyroid stimulating hormone used performing certain test patient thyroid cancer also used along radioactive agent destroy remaining thyroid tissue certain patient thyroid gland removed thyroid cancer heterodimeric glycoprotein comprised two non-covalently linked subunit alpha subunit 92 amino acid residue containing two n-linked glycosylation site beta subunit 112 residue containing one n-linked glycosylation site alpha subunit thyrotropin alfa effector region responsible stimulation adenylate cyclase display close structural similarity alpha subunit human chorionic gonadotropin hcg luteinizing hormone lh follicle-stimulating hormone fsh beta subunit tshb bestows receptor specificity due uniqueness tsh amino acid sequence thyrotropin alfa identical human pituitary thyroid stimulating hormone , detection residueal recurrent thyroid cancer
"Antihemophilic factor, human recombinant",human recombinant antihemophilic factor ahf factor viii 2332 residue glycosylated produced cho cell, human recombinant antihemophilic factor indicated use adult child hemophilia control prevention bleeding episode perioperative management routine prophylaxis prevent reduce frequency bleeding episode l41025 l36130 
Anakinra,anakinra recombinant human interleukin-1 il-1 receptor antagonist il-1ra composed 153 amino acid residue unlike native human il-1ra anakinra additional methionine residue amino terminus drug bind il-1 receptor competing inhibiting activity il-1 alpha beta l35415 anakinra indicated management rheumatoid arthritis ra patient 18 year age older failed one disease-modifying antirheumatic drug dmards well treatment neonatal-onset multisystem inflammatory disease nomid deficiency interleukin-1 receptor antagonist dira l35415 since il-1 important role inflammation immunological response anakinra also used off-label treatment inflammatory disease a247000 anakinra produced using _e coli_ bacterial expression system november 14 2001 approved fda treatment rheumatoid arthritis later approved treatment nomid dira december 21 2012 december 18 2020 respectively study evaluated use anakinra treatment coronavirus disease 2019 covid-19 a247265 november 8 2022 fda issued emergency use authorization eua anakinra treatment covid-19 hospitalized patient risk progressing severe respiratory failure l43932 ,anakinra interleukin-1 receptor antagonist indicated reduction sign symptom slowing progression structural damage moderately severely active rheumatoid arthritis ra patient 18 year age older failed one disease-modifying antirheumatic drug dmards anakinra used alone combination dmards tumor necrosis factor tnf blocking agent l35415 anakinra also indicated treatment neonatal-onset multisystem inflammatory disease nomid treatment deficiency interleukin-1 receptor antagonist dira l35415 anakinra also used off-label treatment several inflammatory disease a247000 fda issued emergency use authorization eua emergency use anakinra treatment coronavirus disease 2019 covid-19 hospitalized adult positive result direct sars-cov-2 viral testing pneumonia requiring supplemental oxygen low- high-flow oxygen risk progressing severe respiratory failure likely elevated plasma soluble urokinase plasminogen activator receptor supar since anakinra approved condition eua drug used alternative treatment available l43927 
Gramicidin D,gramcidin heterogeneous mixture three antibiotic compound gramicidin b c making 80 6 14 respectively obtained soil bacterial specie bacillus brevis called collectively gramicidin d. gramcidins 15 residue peptide alternating l amino acid assemble inside hydrophobic interior cellular lipid bilayer form β-helix active gram-positive bacteria gram-negative organism gramicidin used primarily topical antibiotic also found polysporin ophthalmic solution , treatment skin lesion surface wound eye infection 
Human immunoglobulin G,intravenous immunoglobulin ivig mixture igg1 antibody derived healthy human plasma via cohn fractionation purification process includes cold alcohol fractionation polyethylene glycol precipitation ion exchange chromatography ivig contains distribution igg antibody subclass found general human population igg subclass fully represented following proportion 70.3 igg1 24.7 igg2 3.1 igg3 1.9 igg4 ivig used treatment immunodeficiency well autoimmune inflammatory disorder ,human immunoglobulin g indicated following condition primary immunodeficiency treatment primary immunodeficiency adult pediatric patient l39920 l39930 l39935 l39940 l39945 l39950 l39955 l39960 l39965 l39975 l39980 l40029 l40034 l40044 combination hyaluronidase human recombinant treatment primary immunodeficiency adult l40039 immune thrombocytopenic purpura itp treatment acute chronic immune thrombocytopenic purpura adult pediatric patient l39940 l39950 l39960 l39965 l39970 l39975 l39980 chronic inflammatory demyelinating polyneuropathy cidp treatment cidp adult patient l39965 l39975 l39980 l40034 multifocal motor neuropathy mmn maintenance therapy improve muscle strength disability adult patient mmn l39955 prophylaxis bacterial infection prevention bacterial infection patient hypogammaglobulinemia and/or b-cell chronic lymphocytic leukemia l39960 coronary artery aneurysm associated kawasaki syndrome prevention coronary artery aneurysm pediatric patient kawasaki syndrome l39960 dermatomyositis treatment dermatomyositis adult patient l39970 
Anistreplase,human tissue plasminogen activator purified glycosylated 527 residue purified cho cell eminase lyophilized freeze-dried formulation anistreplase p-anisoyl derivative primary lys-plasminogen-streptokinase activator complex complex lys-plasminogen streptokinase p-anisoyl group chemically conjugated complex bacterial-derived streptokinase human plasma-derived lys-plasminogen protein , lysis acute pulmonary embolus intracoronary embolus management myocardial infarction
Insulin human,human insulin also known regular insulin short-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes human insulin produced recombinant dna technology identical endogenously produced insulin typically prescribed management diabetes mellitus insulin peptide hormone produced beta cell pancreas promotes glucose metabolism insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle absorption glucose cell allows transformation glycogen fat storage insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level result people t1d rely primarily exogenous form insulin lower glucose level blood insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell insulin typically prescribed later course t2d trying several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin marketed brand name product humulin r novolin r human insulin begin exert effect within 30 minute subcutaneous administration peak level occur 3-4 hour administration due quick onset action human insulin considered `` bolus insulin '' provides high level insulin short period time mimic release endogenous insulin pancreas meal bolus insulin often combined daily long-acting `` basal insulin '' db01307 db09564 db00047 provide low concentration background insulin keep blood sugar stable meal overnight use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia human insulin also available inhalable form intended used bolus meal-time insulin exubera first inhaled insulin available market developed inhale therapeutic later named nektar therapeutic unfortunately limited uptake physician patient poor sale bulky packaging concern possible impact lung cancer development resulted exubera product withdrawn u market a176005 exubera followed afrezza monomeric inhaled insulin developed mannkind corporation received fda approval 2016 still available u afrezza similar concern associated use fda `` black box '' warning added warn use patient chronic lung disease afrezza currently health canada european medicine agency approval marketing canada eu human insulin 51 residue peptide hormone produced recombinant dna technology inserting human insulin gene escherichia coli bacteria saccharomyces cerevisiae structure identical native human insulin two amino acid chain covalently linked disulfide bond human insulin also available intermediate-acting form nph neutral protamine hagedorn marketed product novolin n humulin n. nph insulin provided crystalline suspension insulin protamine zinc resulting onset action 1 3 hour duration action 24 hour peak action 6 8 hour due added crystal nph insulin typically cloudy compared form insulin neutral ph without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy ,human insulin indicated improve glycemic control adult pediatric patient diabetes mellitus 
Tenecteplase,tenecteplase tissue plasminogen activator tpa developed modification natural human tpa complementary dna cdna 527 amino acid substitution threonine 103 asparagine substitution asparagine 117 glutamine within kringle 1 domain tetra-alanine substitution amino acid 296-299 protease domain , treatment myocardial infarction lysis intracoronary embolus
Menotropins,menotropins contains follicle stimulating hormone fsh luteinizing hormone lh purified urine postmenopausal woman used fertility medication injected either subcutaneously intramuscularly composed lh 2 subunit alpha 92 residue beta 121 residue fsh 2 subunit alpha 92 residue beta=111 residue , treatment female infertility
Interferon gamma-1b,human interferon gamma-1b 140 residue produced e. coli production actimmune achieved fermentation genetically engineered escherichia coli bacterium containing dna encodes human protein purification product achieved conventional column chromatography sequence displayed cdna sequence code human interferon gamma described gray et al specifically interferon gamma 1b ,interferon gamma-1b used treatment chronic granulomatous disease osteopetrosis 
Interferon alfa-2a,interferon human leukocyte protein moiety reduced type interferon consisting 165 amino acid residue lysine position 23 protein produced recombinant dna technology resembles interferon secreted leukocyte used extensively antiviral antineoplastic agent oral form developed amarillo bioscience , treatment chronic hepatitis c hairy cell leukemia aids-related kaposi 's sarcoma chronic myelogenous leukemia also treatment oral wart arising hiv infection 
Desmopressin,desmopressin ddavp synthetic analogue 8-arginine vasopressin adh antidiuretic peptide drug modified deamination 1-cysteine substitution 8-l-arginine 8-d-arginine adh endogenous pituitary hormone crucial role control water content body upon release stimulation increased plasma osmolarity decreased circulating blood volume adh mainly act cell distal part nephron collecting tubule kidney t28 hormone interacts v1 v2 v3 receptor differing signal cascade system desmopressin display enhanced antidiuretic potency fewer pressor effect due v2-selective action prolonged half-life duration action compared endogenous adh a31661 employed clinically since 1972 available various formulation including intranasal solution intravenous solution oral tablet oral lyophilisate a31662 desmopressin indicated treatment polyuric condition including primary nocturnal enuresis nocturia diabetes insipidus also newly approved treatment mild classical hemophilia von willebrand 's disease minor surgery active ingredient formulation desmopressin acetate nocdurna desmopressin acetate approved fda june 21st 2018 treatment nocturia due nocturnal polyuria adult available sublingual tablet , indicated treatment nocturia due nocturnal polyuria adult awaken least 2 time per night void intranasal indicated antidiuretic replacement therapy management central cranial diabetes insipidus management temporary polyuria polydipsia following head trauma surgery pituitary region intranasal/parenteral indicated patient hemophilia factor viii coagulant activity level greater 5 mild moderate classic von willebrand 's disease type factor viii level greater 5 surgical procedure postoperatively maintain hemostasis parenteral 
Coagulation factor VIIa Recombinant Human,recombinant human coagulation factor viia rfviia intended promoting hemostasis activating extrinsic pathway coagulation cascade novoseven vitamin k-dependent glycoprotein consisting 406 amino acid residue cloned expressed hamster kidney cell protein catalytically active two-chain form , treatment hemorrhagic complication hemophilia b 
Oprelvekin,"oprelvekin active ingredient neumega® recombinant interleukin-11 il-11 produced escherichia coli e. coli recombinant dna technology molecular mass approximately 19,000 dalton non-glycosylated protein 177 amino acid length comparison natural il-11 178 amino acid long however display comparable biological activity compared natural il-11 _in vitro_ _in vivo_ oprelvekin work stimulating megakaryocytopoiesis thrombopoiesis mouse nonhuman primate study animal moderate severe myelosuppression addition compromised hematopoiesis oprelvekin shown potently induce thrombopoiesis improve platelet nadir accelerated platelet recovery compared control animal study oprelvekin also shown regulate intestinal epithelium growth enhancing healing gastrointestinal lesion inhibit adiopegenesis macrophageal released pro-inflammatory cytokine induce acute phase protein synthesis ",indicated prevention severe thrombocytopenia reduction need platelet transfusion following myelosuppressive chemotherapy adult patient nonmyeloid malignancy high risk severe thrombocytopenia label 
Palifermin,palifermin recombinant human keratinocyte growth factor kgf 140 residue long produced using e. coli palifermin granted fda approval 15 december 2004 l17933 , treatment oral mucositis associated chemotherapy radiation therapy 
Glucagon,glucagon 29 amino acid hormone used diagnostic aid radiologic exam temporarily inhibit movement gastrointestinal tract treat severe hypoglycemia l7634 l7637 l7640 l7643 l8519 glucagon raise blood sugar activation hepatic glucagon receptor stimulating glycogenolysis release glucose l7640 l7643 glucagon granted fda approval 14 november 1960 l7631 ,glucagon indicated diagnostic aid radiologic exam temporarily inhibit movement gastrointestinal tract treat severe hypoglycemia l7634 l7637 l7640 l7643 l8519 
Aldesleukin,aldesleukin lymphokine produced recombinant dna technology using genetically engineered e. coli strain containing analog human interleukin-2 gene genetic engineering technique used modify human il-2 gene resulting expression clone encodes modified human interleukin-2 recombinant form differs native interleukin-2 following way aldesleukin glycosylated derived e. coli b molecule n-terminal alanine codon amino acid deleted genetic engineering procedure c molecule serine substituted cysteine amino acid position 125 , treatment adult metastatic renal cell carcinoma 
Botulinum toxin type B,neurotoxin produced fermentation clostridium botulinum type b protein exists noncovalent association hemagglutinin nonhemagglutinin protein neurotoxin complex neurotoxin complex recovered fermentation process purified series precipitation chromatography step , treatment patient cervical dystonia reduce severity abnormal head position neck pain associated cervical dystonia 
Omalizumab,"omalizumab manufactured _genentech_ first fda approved 2003 treat adult child 12 year age older moderate severe persistent allergic asthma controlled inhaled steroid l4670 since u.s. approval 200,000 patient older 12 allergic asthma treated l4670 september 2018 new prefilled syringe formulation drug approved fda l4671 ", drug anti-ige antibody indicated 1 moderate severe persistent asthma patient 6 year age older positive skin test vitro reactivity perennial aeroallergen symptom inadequately controlled inhaled corticosteroid fda label 2 chronic idiopathic urticaria adult adolescent 12 year age older remain symptomatic despite h1 antihistamine treatment fda label 
Lutropin alfa,lutropin alfa recombinant human luteinizing hormone produced yeast 2 subunit alpha 92 residue beta 121 residue heterodimeric glycoprotein made monomeric unit lutropin alfa first recombinant human form luteinizing hormone lh developed use stimulation follicular development pharmacological action mimic biological activity endogenous lh acute rise lh lh surge female trigger ovulation development corpous luteum male lh stimulates leydig cell produce testosterone , treatment infertility woman hypothalamic pituitary insufficiency hypogonadotropic hypogonadism profound lh deficiency lh 1.2 international unit iu /l 
Lyme disease vaccine (recombinant OspA),vaccine lyme disease contains lipoprotein ospa outer surface protein borrelia burgdorferi sensu stricto zs7 expressed escherichia coli lipoprotein ospa single polypeptide chain 257 amino acid lipid covalently bonded n terminus conjugated alum aluminum hydroxide adjuvant , prophylactic treatment lyme disease
Insulin lispro,insulin lispro rapid-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes insulin prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle absorption glucose cell allows transformation glycogen fat storage insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce insulin needed manage circulating blood sugar level result people t1d rely primarily exogenous form insulin insulin lispro lower glucose level blood insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell insulin typically prescribed later course t2d several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin marketed brand name product humalog insulin lispro begin exert effect within 15 minute subcutaneous administration peak level occur 30 90 minute administration due duration action around 5 hour humalog considered `` bolus insulin '' provides high level insulin short period time mimic release endogenous insulin pancreas meal bolus insulin often combined daily long-acting `` basal insulin '' db01307 db09564 db00047 provide low concentration background insulin keep blood sugar stable meal overnight use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia insulin lispro produced recombinant dna technology utilizing non-pathogenic laboratory strain escherichia coli first commercially available insulin analog formerly called lyspro chemical nomenclature lys b28 pro b29 insulin lispro differs human insulin amino acid proline position b28 replaced lysine lysine position b29 replaced proline biochemical change result reduced tendency self-association resulting dissolution dimer monomer absorbed rapidly subcutaneous injection compared endogenous human insulin without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy ,insulin lispro indicated improve glycemic control adult child diabetes mellitus 
Insulin glargine,insulin glargine long-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes insulin typically prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle absorption glucose cell allows transformation glycogen fat storage insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level result people t1d rely primarily exogenous form insulin insulin glargine lower glucose level blood insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell insulin typically prescribed later course t2d several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin available brand name product lantus insulin glargine duration action 24 hour allowing once-daily dosing typically bedtime due duration action lantus considered `` basal insulin '' provides low concentration background insulin keep blood sugar stable meal overnight basal insulin often combined short-acting `` bolus insulin '' db00046 db01309 db01306 provide higher dos insulin required following meal use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia insulin glargine also available biosimilar `` follow-on '' product basaglar u abasaglar eu 2015 insulin glargine reformulated sanofi product toujeo extra-concentrated form containing 300iu/ml compared 100iu/ml contained lantus use higher concentrated toujeo compared lantus result slightly different pharmacokinetics later onset 6 hour duration action 30 hour 2021 another biosimilar semglee insulin glargine-yfgn l34959 became first interchangeable lantus biosimilar insulin receive fda approval l34964 insulin glargine produced recombinant dna technology using non-pathogenic laboratory strain escherichia coli k12 production organism insulin glargine differs endogenous human insulin replacement asparagine residue position a21 a-chain glycine addition two arginine c-terminus position b31 32 b-chain resulting protein soluble ph 4 form microprecipitates physiological ph 7.4 allowing slow release small amount insulin glargine giving drug long duration action pronounced peak concentration without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy ,insulin glargine indicated improve glycemic control adult pediatric patient type 1 diabetes mellitus adult type 2 diabetes mellitus l12474 l43532 l43587 
Collagenase clostridium histolyticum,collagenase clostridium histolyticum enzyme produced bacterium clostridium histolyticum beneficial breakdown collagen plaque treatment dupuytren 's contracture peyronie 's disease l14882 topical formulation used debridement necrotic tissue due burn chronic ulcer l14912 july 6 2020 combination injectable bacterial collagenase approved fda treatment cellulite adult woman l14872 also known qwo injection first approved injectable treatment cellulite developed endo international l14892 ,collagenase clostridium histolyticum indicated treatment adult dupuytren 's contracture palpable cord additionally used treat men peyronie 's disease diagnosed penile curvature deformity least 30-degree angle beginning therapy addition palpable plaque l14882 collagenase ointment used tissue debridement chronic dermal ulcer severely burned tissue l14952 combination collagenase product also known qwo used treatment moderate severe cellulite buttock adult woman l14872 
Rasburicase,rasburicase recombinant urate-oxidase enzyme produced genetically modified saccharomyces cerevisiae /i strain cdna coding rasburicase cloned strain _aspergillus flavus_ , treatment hyperuricemia reduces elevated plasma uric acid level chemotherapy 
Cetrorelix,cetrorelix man-made hormone block effect gonadotropin releasing hormone gnrh gnrh control another hormone called luteinizing hormone lh hormone start ovulation menstrual cycle undergoing hormone treatment sometimes premature ovulation occur leading egg ready fertilization released cetrorelix allow premature release egg occur , inhibition premature lh surge woman undergoing controlled ovarian stimulation
Adalimumab,adalimumab subcutaneously administered biological disease modifier treatment rheumatoid arthritis chronic debilitating disease mediated tumor necrosis factor a39984 a39999 originally launched abbvie u.s. approved 2002 fda a39983 drug frequently known _humira_ produced recombinant dna technology using mammalian cell expression system drug available prefilled syringe form convenient pen form subcutaneous self-administered dos a39983 new biosimilar adalimumab named _adalimumab-adaz_ approved fda october 31 2018 biosimilar known _hyrimoz_ trademark novartis ag l4799 biosimilars adalimumab include adalimumab-fkjp approved july 2022 l42495 hadlima adalimumab-bwwd approved august 2022 l42935 ,adalimumab indicated treat following condition moderately severely active rheumatoid arthritis adult moderately severely active juvenile idiopathic arthritis patient 2 year age older active psoriatic arthritis adult active ankylosing spondylitis adult moderately severely active crohn 's disease patient 6 year age older moderately severely active ulcerative colitis adult moderate severe chronic plaque psoriasis adult candidate systemic therapy phototherapy systemic therapy medically le appropriate l35370 adalimumab also used off-label treat pyoderma gangrenosum a40001 a40002 
Somatotropin,human growth hormone hgh also known somatotropin peptide hormone synthesized secreted somatotropic cell anterior pituitary gland a228183 growth hormone play essential role growth regulation childhood well basal metabolic function muscle fat mass regulation blood glucose level regulation lipid regulation child adult a228183 l31508 synthesized strain _escherichia coli_ recombinant hgh polypeptide hormone contains 191 amino acid residue molecular weight 22 kda identical primary protein structure endogenous human growth hormone a228188 recombinant hgh commercially available since 1985 development genentech somatrem first available recombinant hgh largely replaced somatropin another form recombinant hgh a228183 growth hormone therapy approved various disorder growth hormone deficiency growth failure short stature including turner syndrome chronic renal insufficiency transplantation prader-willi syndrome history fetal growth restriction short stature homeobox shox haploinsufficiency noonan syndrome idiopathic short stature adult- childhood-onset growth hormone deficiency a228188 recombinant growth hormone available subcutaneous injection child adult wide variety brand name ,somatotropin indicated treatment pediatric patient growth failure due inadequate secretion endogenous growth hormone short stature associated turner syndrome prader-willi syndrome pws idiopathic short stature i short stature growth failure short stature homeobox-containing gene shox deficiency short stature born small gestational age sga l31513 l31518 indicated treatment growth failure child associated chronic kidney disease time renal transplantation l31523 also indicated adult adult-onset growth hormone deficiency either alone associated multiple hormone deficiency hypopituitarism result pituitary disease hypothalamic disease surgery radiation therapy trauma also used treat childhood-onset growth hormone deficiency adult due congenital genetic acquired idiopathic cause l31518 somatotropin indicated treatment wasting cachexia patient human immunodeficiency virus hiv receiving antiretroviral therapy increase lean body mass body weight improve physical endurance l31498 somatotropin indicated treatment short bowel syndrome adult patient receiving specialized nutritional support l31493 
Imiglucerase,human beta-glucocerebrosidase beta-d-glucosyl-n-acylsphingosine glucohydrolase e.c 3.2.1.45 497 residue protein n-linked carbohydrate mw=59.3 kd alglucerase prepared modification oligosaccharide chain human beta-glucocerebrosidase modification alters sugar residue non-reducing end oligosaccharide chain glycoprotein predominantly terminated mannose residue , treatment gaucher 's disease deficiency glucocerebrosidase 
Abciximab,abciximab fab fragment chimeric human-murine monoclonal antibody 7e3 abciximab bind glycoprotein gp iib/iiia receptor human platelet inhibits platelet aggregation preventing binding fibrinogen von willebrand factor adhesive molecule also bind vitronectin αvβ3 receptor found platelet vessel wall endothelial smooth muscle cell ,abciximab indicated adjunct percutaneous coronary intervention prevention cardiac ischemic complication patient undergoing percutaneous coronary intervention patient unstable angina responding conventional medical therapy percutaneous coronary intervention planned within 24 hour abciximab intended use aspirin heparin studied setting 
Drotrecogin alfa,drotrecogin alfa activated human protein c synthesized recombinant dna technology glycoprotein approximately 55 kilodalton molecular weight consisting heavy chain light chain linked disulfide bond drotrecogin alfa withdrawn market major study indicated effective improving outcome patient sepsis , reduction mortality patient severe sepsis 
Gemtuzumab ozogamicin,gemtuzumab ozogamicin recombinant humanized igg4 kappa antibody conjugated calicheamicin derivative cytotoxic antitumor antibiotic isolated fermentation micromonospora echinospora ssp calichensis gemtuzumab ozogamicin approximately 50 antibody loaded 4-6 mole calicheamicin per mole antibody fda label antibody specifically directed cd33 antigen present leukemic myeloblast patient acute myeloid leukemia aml binding cd33 antigen tumor cytotoxic agent block growth cancerous cell cause cell death marketing approval gemtuzumab ozogamicin granted may 17 2000 fda treatment patient cd33-positive aml first relapse 60 year age older considered candidate cytotoxic chemotherapy a98 however voluntarily withdrawn market 2010 due safety concern increased patient death insufficient evidence clinical benefit confirmatory trial l941 september 1 2017 gemtuzumab ozogamicin approved treatment adult newly diagnosed cd33-positive acute myeloid leukemia lower dosing regimen different schedule combination chemotherapy l941 also indicated treatment patient aged 2 year older cd33-positive aml experienced relapse responded initial treatment refractory l941 ,indicated treatment patient cd33 positive acute myeloid leukemia first relapse 60 year age older considered candidate cytotoxic chemotherapy indicated treatment patient aged 2 year older cd33-positive aml experienced relapse responded initial treatment refractory 
Indium In-111 satumomab pendetide,tumor associated glycoprotein tag 72 b72.3 monoclonal antibody conjugated indium 111 radioimaging colon tumor satumomab pendetide trade name oncoscint® longer commercially available , diagnosis extrahepatic malignant cancer
Alpha-1-proteinase inhibitor,human alpha-1 proteinase inhibitor alpha-1-antitrypsin prepared human plasma via cohn alcohol fractionation followed peg zinc chloride fractionation , chronic augmentation maintenance therapy individual alpha1-proteinase inhibitor a1-pi deficiency clinical evidence emphysema 
Pegaspargase,pegylated l-asparagine amidohydrolase e. coli pegylation substantially factor 4 extends protein half life , treatment acute lymphoblastic leukemia
Interferon beta-1a,human interferon beta 166 residue glycosylated mw=22.5kd produced mammalian cell chinese hamster ovary cell human interferon beta gene introduced amino acid sequence identical natural human interferon beta , treatment relapsing/remitting multiple sclerosis also condyloma acuminatum
Pegademase,bovine adenosine deaminase derived bovine intestine extensively pegylated extended serum half life , treatment adenosine deaminase deficiency
Albumin human,human serum albumin primary protein present human blood plasma main function albumin maintain oncotic pressure blood a33706 bind water cation ca2+ na+ k+ fatty acid hormone bilirubin thyroxine t4 pharmaceutical including barbiturate albumin represents approximately 50 total protein content healthy human a40060 human albumin small globular protein molecular weight 66.5 kda consisting single chain 585 amino acid organized three repeated homolog domain site ii iii domain comprises two separate sub-domains b a40060 various preparation albumin well established widely available clinical setting l3108 l3109 l3101 also known _albuminex_ 5 25 one brand human serum albumin prepared pooled plasma u donor fda-licensed facility u f229 biosimilar drug existing human serum albumin approved biological license 5 25 concentration fda june 21 2018 l3101 ,albuminex solution indicated adult child hypovolemia ascites hypoalbuminemia including burn acute nephrosis acute respiratory distress syndrome cardipulmonary bypass f229 
Eptifibatide,synthetic cyclic hexapeptide bind platelet receptor glycoprotein inhibits platelet aggregation derived venom southeastern pygmy rattlesnake sistrurus miliarus barbouri eptifibatide cyclic heptapeptide belongs class arginin-glycin-aspartat-mimetics , treatment myocardial infarction acute coronary syndrome 
Infliximab,infliximab tumor necrosis factor tnf-alpha tnf-α blocker chimeric monoclonal igg1 antibody composed human constant 75 murine variable 25 region a31469 infliximab produced recombinant cell line cultured continuous perfusion tumor necrosis factor-alpha tnf-α key proinflammatory cytokine involved chronic inflammatory disease a31469 hyperactivity enhanced signalling pathway observed inflammatory disease activates pro-inflammatory cascade binding soluble subunit membrane-bound precursor tnf-α a106 infliximab disrupts interaction tnf-α receptor may also cause lysis cell produce tnf-α a106 infliximab first approved fda 1998 market name remicade intravenous injection indicated treatment various inflammatory disorder adult pediatric chron 's disease adult pediatric ulcerative colitis rheumatoid arthritis combination methotrexate ankylosing spondyliti psoriatic arthritis plaque psoriasis fda label clinical trial multiple infusion infliximab displayed reduction sign symptom inflammatory disease induction remission patient inadequate response alternative first-line therapy disorder fda label currently two biosilimars infliximab available u market demonstrate high degree similarity reference product remicade approved eligible indication reference product inflectra first biosimilar drug product approved 2016 december 2017 ixifi second biosimilar developed pfizer granted approval fda , indicated reducing sign symptom inducing maintaining clinical remission adult pediatric ≥ 6 year age patient moderately severely active crohn ’ disease inadequate response conventional therapy indicated reducing number draining enterocutaneous rectovaginal fistula maintaining fistula closure adult patient fistulizing crohn ’ disease indicated reducing sign symptom inducing maintaining clinical remission mucosal healing eliminating corticosteroid use adult pediatric ≥ 6 year age patient moderately severely active ulcerative colitis inadequate response conventional therapy indicated combination methotrexate reducing sign symptom inhibiting progression structural damage improving physical function patient moderately severely active rheumatoid arthritis indicated reducing sign symptom patient active ankylosing spondylitis indicated reducing sign symptom active arthritis inhibiting progression structural damage improving physical function patient psoriatic arthritis indicated treatment adult patient chronic severe i.e. extensive and/or disabling plaque psoriasis candidate systemic therapy systemic therapy medically le appropriate 
Follitropin,follitropin human follicle stimulating hormone fsh preparation recombinant dna origin consists two non-covalently linked non-identical glycoprotein designated alpha- beta- subunit alpha- beta- subunit 92 111 amino acid alpha subunit glycosylated asn 51 asn 78 beta subunit glycosylated asn 7 asn 24 follitropin beta produced genetically engineered chinese hamster cell line cho nomenclature “ beta ” differentiates another recombinant human fsh product marketed earlier follitropin alpha follitropin important development follicle produced ovary given subcutaneous injection used combination human chorionic gonadotropin hcg assist ovulation fertility follitropin may also used cause ovary produce several follicle harvested use gamete intrafallopian transfer gift vitro fertilization ivf numerous physio-chemical test bioassay indicate follitropin beta follitropin alpha indistinguishable however recent study showed may slight clinical difference alpha form tending towards higher pregnancy rate beta form tending towards lower pregnancy rate significantly higher estradiol e2 level structural analysis show amino acid sequence follitropin beta identical natural human follicle stimulating hormone fsh ogliosaccharide side chain similar completely identical natural fsh however small difference affect bioactivity compared natural fsh , woman diagnosed primary ovarian failure used combination human chorionic gonadotropin hcg assist ovulation fertility men hypogonadotrophic hypogonadism used induce spermatogenesis follitropin may also used cause ovary produce several follicle harvested use gamete intrafallopian transfer gift vitro fertilization ivf 
Vasopressin,vasopressin arginine-vasopressin antidiuretic hormone nonapeptide primarily produced hypothalamus exhibit diverse physiological function related diuresis hemodynamic modulation behaviour a110 a111 a112 a113 a228008 vasopressin similar oxytocin differing third eighth amino acid a228013 despite wide variety function exogenous vasopressin primarily used control blood pressure systemic shock increasing vasoconstriction renal fluid reuptake acting v sub 1 /sub v sub 2 /sub cellular receptor a228008 a228013 a228018 l31413 vasopressive effect posterior pituitary gland extract noted 1895 vasopressin purified 1951 used five decade varying condition including variceal bleeding diabetes insipidus recently vasodilatory shock a228013 currently marketed trademark vasostrict® par pharmaceutical l31413 ,vasopressin indicated increase blood pressure adult vasodilatory shock refractory application fluid catecholamine l31413 
Interferon beta-1b,human interferon beta 165 residue cysteine 17 substituted serine produced e. coli carbohydrate mw=18.5kd,interferon beta-1b drug used treatment relapsing/remitting multiple sclerosis shown slow advance disease well decrease frequency attack 
Interferon alfacon-1,"interferon alfacon-1 recombinant non-naturally occurring type-i interferon 166-amino acid sequence interferon alfacon-1 derived scanning sequence several natural interferon alpha subtypes assigning frequently observed amino acid corresponding position four additional amino acid change made facilitate molecular construction corresponding synthetic dna sequence constructed using chemical synthesis methodology interferon alfacon-1 differs interferon alfa-2b 20/166 amino acid 88 homology comparison interferon-beta show identity 30 amino acid position interferon alfacon-1 produced escherichia coli e. coli cell genetically altered insertion synthetically constructed sequence code interferon alfacon-1 prior final purification interferon alfacon-1 allowed oxidize native state final purity achieved sequential passage series chromatography column protein molecular weight 19,434 dalton ", treatment hairy cell leukemia malignant melanoma aids-related kaposi 's sarcoma
Hyaluronidase (ovine),highly purified sheep hyaluronidase administration injection vitreous eye , increase absorption distribution injected drug rehydration 
Insulin pork,insulin isolated pig pancreas composed alpha beta chain processed pro-insulin form hexameric structure , treatment type ii diabetes mellitus 
Trastuzumab,produced cho cell culture trastuzumab recombinant igg1 kappa humanized monoclonal antibody a40276 selectively bind high affinity cell-based assay kd 5 nm extracellular domain human epidermal growth factor receptor protein her2 l14015 used treatment human epidermal growth factor receptor -2+ metastatic breast cancer proven amplification her-2 oncogene over-expression her-2 protein tumour suggested overexpression gene amplification her2 found 20–30 breast cancer elevated activation her2 trigger multiple downstream pathway leading abnormal proliferation cancer cell a121 trastuzumab bind her2 suppresses cancer cell growth proliferation survival directly indirectly a121 december 2017 fda approved ogivri trastuzumab-dkst biosimilar herceptin trastuzumab treatment patient breast metastatic stomach cancer gastric gastroesophageal junction adenocarcinoma whose tumor overexpress her2 gene her2+ display biosimilar property herceptin according clinical data ogivri first biosimilar approved u.s. treatment breast cancer stomach cancer second biosimilar approved u.s. treatment cancer herzuma trastuzumab-pkrb biosimilar drug approved december 2018 treatment her2-overexpressing breast cancer kanjinti trastuzumab-anns another biosimilar approved fda june 2019 l14135 ontruzant another biosimilar herceptin approved health canada february 2022 l40303 l40308 , adjuvant treatment her2-overexpressing breast cancer trastuzumab indicated several clinical setting part treatment regimen consisting doxorubicin cyclophosphamide either paclitaxel docetaxel part treatment regimen docetaxel carboplatin monotherapy following multi-modality anthracycline-based therapy l14015 trastuzumab indicated first-line treatment combination paclitaxel metastatic her2-overexpressing breast cancer monotherapy patient previously received one chemotherapy regimen metastatic setting l14015 trastuzumab also indicated combination cisplatin capecitabine 5-fluorouracil treatment patient her2-overexpressing metastatic gastric gastroesophageal junction adenocarcinoma received prior treatment metastatic disease l14015 trastuzumab indicated subcutaneous administration combination either hyaluronidase l14132 hyaluronidase pertuzumab l14510 treatment adult her2-positive breast cancer 
Rituximab,rituximab genetically engineered chimeric murine/human monoclonal antibody directed cd20 antigen found surface normal malignant b lymphocyte antibody igg1 kappa immunoglobulin containing murine light heavy-chain variable region sequence human constant region sequence a40017 fda label originally approved u.s. fda 1997 single agent treat patient b-cell non-hodgkin 's lymphoma nhl l4811 however approved variety condition fda label november 28 2018 u fda approved _truxima_ first biosimilar rituxan rituximab l4808 ,rituximab indicated treatment adult patient relapsed refractory low-grade follicular cd20-positive b-cell non-hodgkin ’ lymphoma nhl single agent also indicated treatment adult patient previously untreated follicular cd20-positive b-cell nhl combination first line chemotherapy patient achieving complete partial response rituximab product combination chemotherapy single-agent maintenance therapy l26641 l42025 l42030 l42035 l42040 additionally rituximab indicated treatment adult patient non-progressing including stable disease low-grade cd20-positive b-cell nhl single agent first-line cyclophosphamide vincristine prednisone cvp chemotherapy previously untreated diffuse large b-cell cd20-positive nhl combination cyclophosphamide doxorubicin vincristine prednisone chop anthracycline-based chemotherapy regimen l26641 l42025 l42030 l42035 l42040 rituximab combination fludarabine cyclophosphamide fc indicated treatment adult patient previously untreated previously treated cd20-positive chronic lymphocytic leukemia cll l26641 l42025 l42030 l42035 l42040 combination methotrexate rituximab indicated treatment adult patient moderately-to severely-active rheumatoid arthritis inadequate response one tnf antagonist therapy l26641 l42025 l42030 l42035 additionally rituximab combination glucocorticoid indicated treatment adult pediatric patient 2 year age older granulomatosis polyangiitis gpa wegener ’ granulomatosis microscopic polyangiitis mpa l26641 l42025 l42030 l42035 rituxan rituximab injection intravenous use indicated treatment pediatric patient aged 6 month older previously untreated advanced stage cd20-positive diffuse large b-cell lymphoma dlbcl burkitt lymphoma bl burkitt-like lymphoma bll mature b-cell acute leukemia b-al combination chemotherapy well treatment adult patient moderate severe pemphigus vulgaris l26641 indication rituxan included label rituximab biosimilar product rituximab-arrx rituximab-abbs rituximab-pvvr l42025 l42030 l42035 combination product rituxan hycela rituximab hyaluronidase human injection subcutaneous use indicated treatment non-malignant condition l42040 
Basiliximab, recombinant chimeric murine/human monoclonal antibody igg1k function immunosuppressive agent specifically binding blocking interleukin-2 receptor a-chain il-2r alpha also known cd25 antigen surface activated t-lymphocytes 144 kda glycoprotein obtained fermentation established mouse myeloma cell line genetically engineered express plasmid containing human heavy light chain constant region gene mouse heavy light chain variable region gene encoding rft5 antibody bind selectively il-2r alpha , prophylactic treatment kidney transplant rejection
Muromonab,murine monoclonal antibody specific cd3 t-cell lymphocyte antigen specifically purified murine mouse monoclonal antibody directed cd3 t3 receptor surface human t-cells t-lymphocytes cultured using murine ascites method muromonab 93 monomeric immune globulin g type 2a igg2a , treatment organ transplant recipient prevention organ rejection
Digoxin Immune Fab (Ovine),digoxin immune fab sheep antibody 26-10 fab fragment sheep immunized digoxin derivative digoxindicarboxymethylamine used antidote overdose digoxin , treatment digitoxin overdose digitalis glycoside toxicity 
Ibritumomab tiuxetan,indium yttrium conjugated murine igg1 kappa monoclonal antibody directed cd20 antigen found surface normal malignant b lymphocyte ibritumomab produced chinese hamster ovary cell composed two murine gamma 1 heavy chain 445 amino acid two kappa light chain 213 amino acid , treatment non-hodgkin 's lymphoma
Daptomycin,daptomycin cyclic lipopeptide antibacterial agent broad spectrum activity gram-positive bacteria including methicillin-susceptible -resistant _staphylococcus aureus_ mssa/mrsa vancomycin-resistant enterococci vre a231379 a231384 l32534 chemically daptomycin comprises 13 amino acid including several non-standard d-amino acid c-terminal 10 amino acid forming ester-linked ring n-terminal tryptophan covalently bonded decanoic acid a231374 l32534 daptomycin first discovered early 1980s researcher eli lilly soil sample mount ararat turkey a231384 early work developing daptomycin abandoned due observed myopathy resumed 1997 cubist pharmaceutical inc. licensed daptomycin found once-daily dosing scheme reduced side effect retaining efficacy a231379 daptomycin approved fda september 12 2003 marketed name cubicin® cubist pharmaceutical llc merck co. l32534 ,daptomycin indicated treatment complicated skin skin structure infection csssi patient one year age older also indicated treatment _staphylococcus aureus_ bloodstream infection bacteremia patient one year age older including adult patient right-sided infective endocarditis l32534 daptomycin indicated treatment pneumonia left-sided infective endocarditis due _s aureus_ use recommended pediatric patient younger one year age due risk potential effect muscular neuromuscular and/or nervous system either peripheral and/or central l32534 antibacterial drug strongly suggested perform sufficient testing treatment initiation order confirm infection caused susceptible bacteria failure may result suboptimal treatment treatment failure development drug-resistant bacteria l32534 
Tositumomab,murine igg2a lambda monoclonal antibody cd20 antigen 2 heavy chain 451 residue 2 lambda chain 220 residue produced antibiotic-free culture mammalian cell covalently linked iodine 131 radioactive isotope iodine , treatment non-hodgkin 's lymphoma cd20 positive follicular 
Pegvisomant,pegvisomant highly selective growth hormone gh receptor antagonist used treat acromegaly unlike dopamine somatostatin analog inhibit growth hormone secretion drug actually block hepatic gh-mediated production insulin like growth factor igf-1 main mediator growth hormone activity ,pegvisomant growth hormone receptor antagonist used treatment acromegaly 
Botulinum toxin type A, 2002 botulinum toxin also known onabotulinumtoxina botox first type botulism toxin introduced market cosmetic use a231824 wide variety application favourable safety profile botulinum toxin injection minimally invasive promising treatment cosmetic imperfection muscle spasm condition a231819 l32569 popular use botox treatment facial wrinkle line however many us botulinum toxin treatment dystonia incontinence migraine blepharospasm hyperhidrosis l32494 l32559 ,botulinum toxin indicated variety condition depending preparation cosmetically used treatment facial fine line wrinkle specifically upper facial rhytides including forehead lateral canthus glabellar line l32559 addition indication botulinum toxin used following condition treatment adult symptomatic overactive bladder without incontinence treatment incontinence adult patient candidate anticholinergic therapy treatment neurogenic detrusor overactivity ndo patient 5 year undergo anticholinergic therapy botulinum toxin indicated prevention chronic migraine treatment muscle spasm cervical dystonia axillary hyperhidrosis strabismus l32494 disorder 7th cranial nerve l32569 off-label botulinum toxin used variety condition temporomandibular joint tmj disorder myofascial pain a231874 neurogenic thoracic outlet syndrome epicondylitis post-stroke pain post-herpetic neuralgia diabetic neuropathy trigeminal neuralgia neuropathic pain spinal cord injury bladder pain a231879 
Pancrelipase,pancrelipase general composed mixture pancreatic enzyme include amylase lipase protease enzyme extracted porcine pancreatic gland l2509 pancrelipase mixture developed ortho-mcneil-janssen pharmaceutical inc fda approved april 12 2010 l2510 information component mixture please visit db11065 db11066 db13147 , use pancrelipase amylase part pancreatic enzyme replacement therapy therapy indicated treatment pancreatic insufficiency attributed cystic fibrosis chronic pancreatitis medically defined pancreatic disease might require a32721 a32736 pancreatic disease associated deterioration pancreatic parenchyma dual physiological function pancreas established pancreatic insufficiency result malnutrition weight loss steatorrhea a32723 
Streptokinase,streptokinase sterile purified preparation bacterial protein elaborated group c beta -hemolytic streptococci , treatment acute evolving transmural myocardial infarction pulmonary embolism deep vein thrombosis arterial thrombosis emolism occlusion arteriovenous cannulae
Alemtuzumab,alemtuzumab humanized monoclonal antibody specific lymphocyte antigen recombinant dna-derived humanized monoclonal antibody campath-1h directed 21-28 kd cell surface glycoprotein cd52 campath-1h antibody igg1 kappa human variable framework constant region complementarity-determining region murine rat monoclonal antibody campath-1g alemtuzumab produced mammalian cell chinese hamster ovary suspension culture medium containing neomycin l43397 alemtuzumab approved fda 2001 l43397 marketed lemtrada multiple sclerosis m treatment camptah b-cell chronic lymphocytic leukemia b-cll dose alemtuzumab used b-cll much higher m also frequent dosing l43397 l30335 ,lemtrada indicated treatment relapsing form multiple sclerosis m including relapsing-remitting disease active secondary progressive disease adult safety profile use lemtrada generally reserved patient inadequate response two drug indicated treatment ms. l43397 lemtrada contains active ingredient alemtuzumab found campath campath approved treatment b-cell chronic lymphocytic leukemia b-cll although generally administered higher frequent dos e.g. 30 mg recommended treatment ms. l43397 
Alglucerase,human beta-glucocerebrosidase beta-d-glucosyl-n-acylsphingosine glucohydrolase e.c 3.2.1.45 497 residue protein n-linked carbohydrate mw=59.3 kd alglucerase prepared modification oligosaccharide chain human beta-glucocerebrosidase modification alters sugar residue non-reducing end oligosaccharide chain glycoprotein predominantly terminated mannose residue alglucerase first approved fda 1991 a254816 however later discontinued market ,alglucerase indicated use long-term enzyme replacement therapy patient type gaucher disease exhibit sign symptom severe enough result moderate-to-severe anemia thrombocytopenia bone disease significant hepato- splenomegaly l44266 
Capromab pendetide,capromab murine igg1 monoclonal 7e11-c5.3 antibody recognizes prostate specific membrane antigen psma – also known glutamate carboxypeptidase 2 prostate cancer cell normal prostate tissue linked pendetide capromab used chelating agent radionuclide indium in-111 imaging evaluate extent prostate cancer , diagnosis prostate cancer detection intra-pelvic metastasis 
Laronidase,human recombinant alpha-l-iduronidase 628 residue mature form produced recombinant dnatechnology chinese hamster ovary cell line laronidase glycoprotein molecular weight approximately 83 kd predicted amino acid sequence recombinant form well nucleotide sequence encodes identical polymorphic form human a-l-iduronidase contains 6 n-linked oligosaccharide modification site , treatment mucopolysaccharidosis
Cyclosporine,cyclosporine calcineurin inhibitor known immunomodulatory property prevent organ transplant rejection treat various inflammatory autoimmune condition isolated fungus _beauveria nivea_ a174049 initially manufactured sandoz approved use fda 1983 cyclosporine available various product novartis previously known sandoz l11097 l3734 l11118 ,cyclosporine approved variety condition firstly approved prophylaxis organ rejection allogeneic kidney liver heart transplant also used prevent bone marrow transplant rejection indication cyclosporine used conjunction azathioprine corticosteroid finally cyclosporine used patient chronic transplant rejection received previous immunosuppressive therapy l3002 prevent treat graft-versus-host disease gvhd l11097 secondly cyclosporine used treatment patient severe active rheumatoid arthritis ra longer respond methotrexate alone l3734 used treatment adult non-immunocompromised patient severe recalcitrant plaque psoriasis failed respond least one systemic therapy systemic therapy tolerated contraindicated l3734 ophthalmic solution cyclosporine indicated increase tear production patient suffering keratoconjunctivitis sicca l11097 addition cyclosporine approved treatment steroid dependent steroid-resistant nephrotic syndrome due glomerular disease may include minimal change nephropathy focal segmental glomerulosclerosis membranous glomerulonephritis l11097 cyclosporine ophthalmic emulsion indicated treatment vernal keratoconjunctivitis adult child l34694 off-label cyclosporine commonly used treatment various autoimmune inflammatory condition atopic dermatitis blistering disorder ulcerative colitis juvenile rheumatoid arthritis uveitis connective tissue disease well idiopathic thrombocytopenic purpura a139 a174085 a189393 a189396 a189399 
Alefacept,immunosuppressive dimeric fusion protein consists extracellular cd2-binding portion human leukocyte function antigen-3 lfa-3 linked fc hinge ch2 ch3 domain portion human igg1 produced cho cell mw 91.4 kd , immunosuppressive drug alefacept used treatment moderate severe chronic plaque psoriasis
Felypressin, synthetic nonapeptide comprising cysteinyl phenylalanyl phenylalanyl glutaminyl asparaginyl cysteinyl prolyl lysyl glycinamide residue sequence disulfide bridge joining two cysteine residue antidiuretic effect le vasopressin non-catecholamine vasoconstrictor used local anaesthetic injection dental use ingredient preparation used treatment pain inflammation mouth , use alternative adrenaline localising agent provided local ischaemia essential 
Urofollitropin,urofollitropin urinary-derived follicle-stimulating hormone fsh extracted purified human urine sample consists two non-covalently linked non-identical glycoprotein designated alpha- beta- subunit alpha- beta- subunit 92 111 amino acid alpha subunit glycosylated asn 51 asn 78 beta subunit glycosylated asn 7 asn 24 urofollitropin typically used injected subcutaneously combination human chorionic gonadotropin hcg induce ovulation urofollitropin may also used cause ovary produce several follicle harvested use gamete intrafallopian transfer gift vitro fertilization ivf , treatment female infertility
Efalizumab,humanized igg1 kappa isotype monoclonal antibody bind human cd11a efalizumab molecular weight approximately 150 kilodaltons produced chinese hamster ovary mammalian cell expression system nutrient medium containing antibiotic gentamicin fda approved efalizumab 2003 later withdrawn 2009 due potential risk progressive multifocal leukoencephalopathy pml l43797 , treatment adult patient moderate severe chronic plaque psoriasis candidate phototherapy systemic therapy 
Choriogonadotropin alfa,recombinant human chorionic gonadotropin 2 subunit alpha 92 residue beta 145 residue n-and o-linked carbohydrate moiety linked asn-52 asn-78 alpha subunit asn-13 asn-30 ser-121 ser-127 ser-132 ser-138 beta subunit primary structure alpha-chain r-hcg identical alpha-chain hcg fsh lh , treatment female infertility
Antithymocyte immunoglobulin (rabbit),rabbit anti-thymocyte globulin thymoglobulin polyclonal antibody suppresses certain type immune cell responsible acute organ rejection transplant patient thymoglobulin mixture antibody intended bind various cell surface antigen common mode action thymoglobulin via selective depletion t-cells , prevention renal transplant rejection
Filgrastim,filgrastim short-acting recombinant non-pegylated human granulocyte colony-stimulating factor g-csf analog produced recombinant dna technology amino acid sequence identical endogenous g-csf non-glycosylated unlike endogenous g-csf n-terminal methionine added sequence expression _e coli_ l40714 human g-csf glycoprotein regulates production release neutrophil bone marrow filgrastim mimic biological action g-csf increase level neutrophil blood l40719 number therapeutic us including management prevention infection febrile neutropenia patient receiving myelosuppressive chemotherapy radiation therapy also used manage severe chronic neutropenia mobilize hematopoietic progenitor cell peripheral blood collection leukapheresis patient undergoing peripheral blood progenitor cell collection therapy l40714 filgrastim approved u 1991 biosimilars available similar therapeutic indication a245858 tbo-filgrastim approved fda august 29 2012 l36325 filgrastim-sndz approved march 6 2015 l40768 filgrastim-ayow approved march 2 2022 l40773 long-acting pegylated g-csf pegfilgrastim made available increase duration action drug ,filgrastim indicated decrease incidence infection‚ manifested febrile neutropenia‚ patient nonmyeloid malignancy receiving myelosuppressive anti-cancer drug associated significant incidence severe neutropenia fever l40714 filgrastim indicated reducing time neutrophil recovery duration fever following induction consolidation chemotherapy treatment patient acute myeloid leukemia l40714 filgrastim indicated reduce duration neutropenia neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia patient nonmyeloid malignancy undergoing myeloablative chemotherapy followed bone marrow transplantation l40714 filgrastim indicated mobilization autologous hematopoietic progenitor cell peripheral blood collection leukapheresis l40714 filgrastim indicated chronic administration reduce incidence duration sequela neutropenia e.g.‚ fever‚ infections‚ oropharyngeal ulcer symptomatic patient congenital neutropenia‚ cyclic neutropenia‚ idiopathic neutropenia l40714 filgrastim indicated increase survival patient acutely exposed myelosuppressive dos radiation l40714 
Coagulation Factor IX (Recombinant),recombinant coagulation factor ix purified factor ix glycoprotein produced recombinant dna technology primary amino acid sequence identical ala148 allelic form human factor ix structural functional characteristic similar endogenous factor ix derived human blood unlike human factor ix complex instead produced genetically engineered chinese hamster ovary cho cell line secretes recombinant factor ix cell medium processed purified use pharmaceutical agent recombinant factor ix indicated control prevention bleeding episode adult pediatric patient congenital factor ix deficiency hemophilia b , treatment hemophilia christmas disease 
Becaplermin,becaplermin produced recombinant dna technology insertion gene b chain platelet derived growth factor pdgf yeast saccharomyces cerevisiae becaplermin molecular weight approximately 25 kd homodimer composed two identical polypeptide chain bound together disulfide bond , topical treatment skin ulcer diabetes 
Agalsidase beta,agalsidase beta recombinant human α-galactosidase similar agalsidase alfa patient generally experience clinically significant difference outcome two drug patient may experience greater benefit agalsidase beta a220228 a220233 use agalsidase beta decreased europe favor agalsidase alfa contamination event 2009 a220343 agalsidase beta granted fda approval 24 april 2003 l16383 ,agalsidase beta indicated treatment fabry disease l16383 
Octreotide,acromegaly disorder caused excess growth hormone gh increasing growth body tissue causing metabolic dysfunction l14501 case result anterior pituitary growth hormone-releasing tumor typically foot hand face grow abnormally large organomegaly insulin resistance may also occur acromegaly life-threatening disease requiring life-long management l14501 octreotide long-acting drug pharmacologic activity mimic natural hormone somatostatin inhibits secretion growth hormone l14513 additionally used treatment acromegaly symptom arising various tumor including carcinoid tumor vasoactive intestinal tumor vipomas l14513 past octreotide administered solely injection june 26 2020 first approved delayed-release oral somatostatin analog mycapssa received fda approval long term maintenance treatment acromegaly drug developed chiasma inc. l14495 l14507 l14528 ,octreotide injection used treatment acromegaly reduction flushing diarrhea symptom related carcinoid tumor and/or vasoactive intestinal peptide vipoma tumor l14513 delayed-release oral formulation used long-term treatment acromegaly patient tolerate respond adequately injectable octreotide lanreotide l14507 
Interferon alfa-2b,interferon alpha 2b human leukocyte clone hif-sn 206 protein moiety reduced type interferon consisting 165 amino acid residue arginine position 23 protein produced recombinant dna technology resembles interferon secreted leukocyte used extensively antiviral antineoplastic agent , treatment hairy cell leukemia malignant melanoma aids-related kaposi 's sarcoma 
Abarelix,synthetic decapeptide antagonist gonadotropin releasing hormone gnrh marketed praecis pharmaceutical plenaxis praecis announced june 2006 voluntarily withdrawing drug market , palliative treatment advanced prostate cancer 
Oxytocin,sir henry h. dale first identified oxytocin uterine contractile property 1906 a229008 a228593 a229108 like neurohypophysial hormone oxytocin composed nine amino acid disulfide bridge cys 1 6 residue a229008 a228593 mid-1950s synthetic oxytocin successfully synthesized biochemist named vincent du vigneaud later recognized nobel prize work a229108 oxytocin continues important tool modern obstetrics induce labor indicated manage postpartum hemorrhage a229108 a229113 estimated labor induction oxytocin used almost 10 delivery globally a228593 noted risk associated oxytocin intervention childbirth oxytocin used judiciously necessary experienced healthcare practitioner a229113 although commonly linked labor delivery oxytocin actually broad peripheral central effect a229008 play important role pair bonding social cognition functioning even fear conditioning a229013 oxytocin also serf role metabolic homeostasis cardiovascular regulation a228593 a229098 ,administration exogenous oxytocin indicated antepartum period initiate improve uterine contraction vaginal delivery situation fetal maternal concern l31433 example may used induce labor case rh sensitization maternal diabetes preeclampsia near term delivery indicated due prematurely ruptured membrane a229018 l31433 importantly oxytocin approved indicated elective induction labor oxytocin may used reinforce labor select case uterine inertia adjunctive therapy management incomplete inevitable abortion postpartum period oxytocin may used induced contraction 3rd stage labor control postpartum bleeding hemorrhage l31433 
Natalizumab,humanized igg4k monoclonal antibody produced murine myeloma cell natalizumab contains human framework region complementarity-determining region murine antibody bind a4-integrin natalizumab voluntarily withdrawn u.s. market risk progressive multifocal leukoencephalopathy pml returned market july 2006 , treatment multiple sclerosis 
Enfuvirtide,enfuvirtide 36 amino acid biomimetic peptide structurally similar hiv protein responsible fusion virus cell membrane subsequent intracellular uptake first agent novel class antiretroviral drug called hiv fusion inhibitor enfuvirtide work inhibiting hiv-1 fusion cd4 cell ,enfuvirtide antiretroviral drug used combination therapy treatment hiv-1/aids 
Palivizumab,humanized monoclonal antibody igg1k produced recombinant dna technology directed epitope antigenic site f protein respiratory syncytial virus rsv synagis composite human 95 murine 5 antibody sequence human heavy chain sequence derived constant domain human igg1 variable framework region vh gene cor 1 ce 2 human lightchain sequence derived constant domain ck variable framework region vl gene k104 withjk-4 palivizumab expressed stable murine mouse myeloma cell line ns0 palivizumab composed heavy chain 50.6 kda two light chain 27.6 kda contains 1-2 carbohydrate weight molecular weight 147.7 kda +/- 1 kda maldi-tof , prophylaxis respiratory disease casued respiratory syncytial virus 
Daclizumab,humanized igg1 mab bind human interleukin-2 receptor anti-tac anti-cd25 daclizumab composite human 90 murine 10 antibody sequence human sequence derived constant domain human igg1 variable framework region eu myeloma antibody murine sequence derived complementarity-determining region murine anti-tac antibody 22 april 2008 roche registration limited chose voluntarily withdraw marketing authorization product zenapax daclizumab indicated prophylaxis acute organ rejection de novo allogeneic renal transplantation used concomitantly immunosuppressive regimen like cyclosporine corticosteroid patient hight immunized commercial reason confirmed decision related safety concern associated use zenapax daclizumab l1744 regardless withdrawal zenapax biogen abbvie 's zinbryta daclizumab indicated treatment adult patient relapsing form multiple sclerosis approved use fda 2016 l1746 despite approved use zinbryta daclizumab 's complex pre-existing safety profile consisting restricted availability risk evaluation mitigation strategy program l1738 black box warning possible hepatic injury autoimmune hepatitis immune mediated disorder l1738 meant therapeutic usage adverse effect prescribing information subject continuous monitoring updating although zinbryta daclizumab available patient needed 30 april 2018 biogen abbvie announced voluntary withdrawal product zinbryta daclizumab global market 2 march 2018 l1738 withdrawal concurrent european medicine agency announcement recall owing 12 worldwide report serious inflammatory brain disorder associated use zinbryta daclizumab l1738 ,zenapax humanized monoclonal antibody used prevention renal transplant rejection
Bevacizumab, great deal evidence indicating vascular endothelial growth factor vegf important survival proliferation cancer cell a192939 a192837 a192891 a193275 vegf play important role angiogenesis lymphangiogenesis tumor growth factor contribute attractiveness therapeutic target anti-cancer therapy a192834 a192888 a192837 a192891 a192894 2004 bevacizumab avastin gained fda approval specific type cancer became first antiangiogenic agent introduced market a193272 a193275 humanized monoclonal igg antibody inhibits angiogenesis binding neutralizing vegf-a a192888 a192939 bevacizumab generally indicated use combination different chemotherapy regimen specific type severity stage cancer l12648 bevacizumab approved european commission april 21 2021 l43130 also biosimilars bevacizumab available bevacizumab-awwb bevacizumab-maly bevacizumab-adcd interestingly researcher identified higher vegf expression patient covid-19 may contribute lung pathology including acute respiratory syndrome ards acute lung injury ali l12699 bevacizumab investigated treatment lung complication associated severe case covid-19 l12699 , vascular endothelial growth factor vegf inhibitor bevacizumab used several chemotherapy regimen treat metastatic colorectal cancer metastatic unresectable locally advanced recurrent non-squamous non-small cell lung cancer metastatic renal cell carcinoma metastatic persistent recurrent cervical cancer primary peritoneal cancer epithelial ovarian cancer fallopian tube cancer breast cancer recurrent glioblastoma l12648 l39233 l41514 l43130 l43302 interestingly bevacizumab currently investigation treatment covid-19 complication including acute respiratory distress syndrome ards acute lung injury ali l12699 
Technetium Tc-99m arcitumomab,"reduced fab fragment murine igg1 monoclonal antibody immu-4 also called np-4 specificity carcinoembryonic antigen cea covalently labeled technitium 99 molecule molecular weight ~54,000 dalton ", imaging colorectal tumor
Pyridoxal phosphate, active form vitamin b6 serving coenzyme synthesis amino acid neurotransmitter serotonin norepinephrine sphingolipids aminolevulinic acid transamination amino acid pyridoxal phosphate transiently converted pyridoxamine phosphate pyridoxamine , nutritional supplementation treating dietary shortage imbalance 
Cyanocobalamin,cyanocobalamin commonly known vitamin b12 highly complex essential vitamin owing name fact contains mineral cobalt vitamin produced naturally bacteria a175276 necessary dna synthesis cellular energy production vitamin b12 many form including cyano- methyl- deoxyadenosyl- hydroxy-cobalamin form _cyano_ form widely used form supplement prescription drug a175255 fda label several pharmaceutical form cyanocobalamin developed including tablet injection nasal spray form fda label l5542 l5545 drug initially approved fda 1942 fda label , nasal spray cyanocobalamin nasal spray indicated maintenance vitamin b12 concentration normalization intramuscular vitamin b12 therapy patient deficiency vitamin nervous system involvement fda label note calomist fda label nasal spray form evaluated treatment newly diagnosed vitamin b12 deficiency injection form subcutaneous intramuscular form indicated vitamin b12 deficiency due various cause without neurologic manifestation f3736 vitamin b12 deficiency frequently caused malabsorption often associated following condition l5545 addisonian pernicious anemia gastrointestinal pathology dysfunction surgery including gluten enteropathy sprue small bowel bacterial overgrowth total partial gastrectomy fish tapeworm infestation malignancy pancreas bowel folic acid deficiency oral form vitamin b12 supplement widely available indicated patient require supplementation various reason dose requirement vitamin b12 higher normal caused pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic renal disease usually achieved oral supplementation l5545 oral product vitamin b12 recommended patient malabsorption form primarily absorbed gastrointestinal tract f3739 
Tetrahydrofolic acid,"tetrahydrofolic acid folic acid derivative produced dihydrofolic acid conversion dihydrofolate reductase converted 5,10-methylenetetrahydrofolate serine hydroxymethyltransferase soluble coenzyme many reaction especially metabolism amino acid nucleic acid ", nutritional supplementation also treating dietary shortage imbalance 
Histidine, essential amino acid required production histamine , action supplemental l-histidine entirely unclear may immunomodulatory well antioxidant activity l-histidine may indicated use rheumatoid arthritis indicated treatment anemia uremia lowering serum cholesterol 
Ademetionine,physiologic methyl radical donor involved enzymatic transmethylation reaction present living organism posse anti-inflammatory activity used treatment chronic liver disease merck 11th ed ,s-adenosylmethionine used drug europe treatment depression liver disorder fibromyalgia osteoarthritis also introduced united state market dietary supplement support bone joint health well mood emotional well 
Pyruvic acid, intermediate compound metabolism carbohydrate protein fat thiamine deficiency oxidation retarded accumulates tissue especially nervous structure stedman 26th ed , nutritional supplementation also treating dietary shortage imbalance
Phenylalanine,phenylalanine essential aromatic amino acid precursor melanin dopamine noradrenalin norepinephrine thyroxine ,l-phenylalanine may helpful depression may also useful treatment vitiligo evidence l-phenylalanine may exacerbate tardive dyskinesia schizophrenic patient used neuroleptic drug 
Biotin, water-soluble enzyme co-factor present minute amount every living cell occurs mainly bound protein polypeptide abundant liver kidney pancreas yeast milk , nutritional supplementation also treating dietary shortage imbalance 
Choline, basic constituent lecithin found many plant animal organ important precursor acetylcholine methyl donor various metabolic process lipid metabolism , nutritional supplementation also treating dietary shortage imbalance
Lysine,lysine abbreviated lys k α-amino acid chemical formula ho2cch nh2 ch2 4nh2 amino acid essential amino acid mean human synthesize codon aaa aag lysine base arginine histidine ε-amino group act site hydrogen binding general base catalysis common posttranslational modification include methylation ε-amino group giving methyl- dimethyl- trimethyllysine latter occurs calmodulin posttranslational modification include acetylation collagen contains hydroxylysine derived lysine lysyl hydroxylase o-glycosylation lysine residue endoplasmic reticulum golgi apparatus used mark certain protein secretion cell ,supplemental lysine putative anti-herpes simplex virus activity preliminary research suggesting may anti-osteoporotic activity 
Arginine, essential amino acid physiologically active l-form ,used nutritional supplementation also treating dietary shortage imbalance 
Ascorbic acid, six carbon compound related glucose found naturally citrus fruit many vegetable ascorbic acid essential nutrient human diet necessary maintain connective tissue bone biologically active form vitamin c function reducing agent coenzyme several metabolic pathway vitamin c considered antioxidant ,used treat vitamin c deficiency scurvy delayed wound bone healing urine acidification general antioxidant also suggested effective antiviral agent 
Spermine,spermine spermidine-derived biogenic polyamine found polycation ph value found various tissue organism often act essential growth factor bacterial specie spermine associated nucleic acid particularly virus thought stabilize helical structure , nutritional supplementation also treating dietary shortage imbalance
Aspartic acid,one non-essential amino acid commonly occurring l-form found animal plant especially sugar cane sugar beet may neurotransmitter , support claim aspartates exercise performance enhancer i.e ergogenic aid 
Ornithine,produced urea cycle ornithine amino acid produced splitting urea arginine l-ornithine allows disposal excess nitrogen act precursor citrulline arginine ,used nutritional supplementation also treating dietary shortage imbalance claimed ornithine improves athletic performance anabolic effect wound-healing effect immuno-enhancing 
L-Glutamine, non-essential amino acid present abundantly throughout body involved many metabolic process synthesized glutamic acid ammonia principal carrier nitrogen body important energy source many cell oral formulation l-glutamine approved fda july 2017 use sickle cell disease l892 oral formulation marketed tradename endari emmaus medical ,used nutritional supplementation also treating dietary shortage imbalance used reduce acute complication sickle cell disease adult pediatric patient 5 year age older fda label 
Adenosine phosphate,adenosine phosphate adenylic acid adenine nucleotide containing one phosphate group esterified sugar moiety 2 39 3 39 5 39 -position adenosine phosphate withdrawn fda since considered neither safe effective intended us vasodilator anti-inflammatory l43937 , nutritional supplementation also treating dietary shortage imbalance
alpha-Linolenic acid,alpha-linolenic acid ala polyunsaturated omega-3 fatty acid component many common vegetable oil important human nutrition , nutritional supplementation treating dietary shortage imbalance 
Serine, non-essential amino acid occurring natural form l-isomer synthesized glycine threonine involved biosynthesis purine pyrimidine amino acid ,used natural moisturizing agent cosmetic skin care product 
Methionine, sulfur containing essential amino acid important many body function chelating agent heavy metal ,used protein synthesis including formation l-homocysteine l-cysteine taurine sulfate 
Tyrosine,tyrosine non-essential amino acid animal synthesized phenylalanine also precursor epinephrine thyroid hormone melanin ,tyrosine claimed act effective antidepressant however result mixed tyrosine also claimed reduce stress combat narcolepsy chronic fatigue however claim refuted study 
Calcitriol,"calcitriol active metabolite vitamin 3 hydroxyl oh group commonly referred 1,25-dihydroxycholecalciferol 1alpha,25-dihydroxyvitamin sub 3 /sub 1,25-dihydroxyvitamin sub 3 /sub produced body series conversion step 7-dehydrocholesterol exposure uv light 7-dehydrocholesterol converted db00169 vitamin d3 skin converted db00146 liver kidney db00146 undergoes hydroxylation form calcitriol via 1α-hydroxylase cyp27b1 activity a26353 calcitriol considered potent metabolite vitamin human a3366 renal production calcitriol stimulated response pth low calcium low phosphate a26353 calcitriol play role plasma calcium regulation concert parathyroid hormone pth enhancing absorption dietary calcium phosphate gastrointestinal tract promoting renal tubular reabsorption calcium kidney stimulating release calcium store skeletal system addition promoting fatty acid synthesis inhibiting lipolysis calcitriol demonstrated increase energy efficiency suppressing ucp2 expression modulated signaling pathway classical nuclear receptor nvdr calcitriol act natural ligand a175615 also evidence calcitriol modulates action cytokine may regulate immune inflammatory response cell turnover cell differentiation a26353 administered orally intravenously calcitriol commonly used medication treatment secondary hyperparathyroidism resultant metabolic bone disease hypocalcemia patient undergoing chronic renal dialysis osteoporosis also available topical form treatment mild moderate plaque psoriasis adult calcitriol marketed various trade name including rocaltrol roche calcijex abbott decostriol mibe jesalis ",used treat vitamin deficiency insufficiency refractory rickets vitamin resistant rickets familial hypophosphatemia hypoparathyroidism management hypocalcemia renal osteodystrophy patient chronic renal failure undergoing dialysis also used conjunction calcium management prevention primary corticosteroid-induced osteoporosis 
Lutein,lutein xanthophyll one 600 known naturally occurring carotenoid lutein synthesized plant like xanthophyll found high quantity green leafy vegetable spinach kale yellow carrot green plant xanthophyll act modulate light energy serve non-photochemical quenching agent deal triplet chlorophyll excited form chlorophyll overproduced high light level photosynthesis ,xanthophyll taken nutritional supplementation also treating dietary shortage imbalance 
Cystine, covalently linked dimeric nonessential amino acid formed oxidation cysteine two molecule cysteine joined together disulfide bridge form cystine , claimed l-cysteine anti-inflammatory property protect various toxin might helpful osteoarthritis rheumatoid arthritis research done l-cysteine indicated condition research date mostly animal model 
Succinic acid, water-soluble colorless crystal acid taste used chemical intermediate medicine manufacture lacquer make perfume ester also used food sequestrant buffer neutralizing agent hawley 's condensed chemical dictionary 12th ed p1099 mcgraw-hill dictionary scientific technical term 4th ed p1851 , nutritional supplementation also treating dietary shortage imbalance
Riboflavin,nutritional factor found milk egg malted barley liver kidney heart leafy vegetable richest natural source yeast occurs free form retina eye whey urine principal form tissue cell flavin mononucleotide flavin-adenine dinucleotide , treatment ariboflavinosis vitamin b2 deficiency 
N-Acetylglucosamine, n-acetyl derivative glucosamine , treatment prevention osteoarthritis combination chondroitin sulfate 
Glutamic acid, peptide homopolymer glutamic acid ,considered nature 's `` brain food '' improving mental capacity help speed healing ulcer give `` lift '' fatigue help control alcoholism schizophrenia craving sugar 
Glutathione, tripeptide many role cell conjugate drug make soluble excretion cofactor enzyme involved protein disulfide bond rearrangement reduces peroxide , nutritional supplementation also treating dietary shortage imbalance
Phosphatidyl serine,phosphatidyl serine p phospholipid nutrient found fish green leafy vegetable soybean rice essential normal functioning neuronal cell membrane activates protein kinase c pkc shown involved memory function apoptosis phosphatidyl serine transferred outer leaflet plasma membrane part process cell targeted phagocytosis p shown slow cognitive decline animal model p investigated small number double-blind placebo trial shown increase memory performance elderly potentail cognitive benefit phosphatidylserine substance sold dietary supplement people believe benefit increased intake dietary supplement originally processed bovine source however prion disease scare 1990s outlawed process soy-based alternative adopted ,phosphatidylserine demonstrated usefulness treating cognitive impairment including alzheimer 's disease age-associated memory impairment non-alzheimer 's dementia research needed phosphatidylserine indicated immune enhancement reduction exercise stress 
Glycine, non-essential amino acid found primarily gelatin silk fibroin used therapeutically nutrient also fast inhibitory neurotransmitter ,supplemental glycine may antispastic activity early finding suggest may also antipsychotic activity well antioxidant anti-inflammatory activity 
Calcifediol, major circulating metabolite vitamin d3 cholecalciferol produced liver best indicator body 's vitamin store effective treatment rickets osteomalacia azotemic non-azotemic patient calcifediol also mineralizing property ,used treat vitamin deficiency insufficiency refractory rickets vitamin resistant rickets familial hypophosphatemia hypoparathyroidism management hypocalcemia renal osteodystrophy patient chronic renal failure undergoing dialysis also used conjunction calcium management prevention primary corticosteroid-induced osteoporosis 
Pyridoxal, 4-carboxyaldehyde form vitamin b 6 converted pyridoxal phosphate coenzyme synthesis amino acid neurotransmitter serotonin norepinephrine sphingolipids aminolevulinic acid pubchem ,pyridoxal one natural form available vitamin b6 therefore used nutritional supplementation treating dietary shortage imbalance 
Creatine, amino acid derivative occurs vertebrate tissue urine muscle tissue creatine generally occurs phosphocreatine creatine excreted creatinine urine , nutritional supplementation also treating dietary shortage imbalance 
Leucine, essential branched-chain amino acid important hemoglobin formation ,indicated assist prevention breakdown muscle protein sometimes occur trauma severe stress 
Tryptophan, essential amino acid necessary normal growth infant nitrogen balance adult precursor indole alkaloid plant precursor serotonin hence use antidepressant sleep aid precursor niacin albeit inefficiently mammal ,tryptophan may useful increasing serotonin production promoting healthy sleep managing depression enhancing mental emotional well-being managing pain tolerance managing weight 
Cysteine, thiol-containing non-essential amino acid oxidized form cystine , prevention liver damage kidney damage associated overdoses acetaminophen
Thiamine,thiamine thiamin also known vitamin b1 colorless compound chemical formula c12h17n4os soluble water insoluble alcohol thiamine decomposes heated thiamine first discovered umetaro suzuki japan researching rice bran cured patient beriberi thiamine play key role intracellular glucose metabolism thought thiamine inhibits effect glucose insulin arterial smooth muscle cell proliferation thiamine play important role helping body convert carbohydrate fat energy essential normal growth development help maintain proper functioning heart nervous digestive system thiamine stored body however absorbed vitamin concentrated muscle tissue , treatment thiamine niacin deficiency state korsakov 's alcoholic psychosis wernicke-korsakov syndrome delirium peripheral neuritis 
Ergocalciferol,ergocalciferol inactivated vitamin analog a177526 synthesized plant presence uvb light t577 production ergocalciferol prompted identification dietary deficiency specifically vitamin main causative factor development rickets ergocalciferol isolated first time yeast 1931 structure elucidated 1932 t580 ergocalciferol considered first vitamin analog differentiated cholecalciferol presence double bond c22 c23 presence methyl group c24 modification reduce affinity ergocalciferol vitamin binding protein resulting faster clearance limit activation alters catabolism a177637 first approved product containing ergocalciferol fda record developed u pharm holding fda approved 1941 l6058 ,ergocalciferol indicated treatment hypoparathyroidism refractory rickets familial hypophosphatemia fda label hypoparathyroidism result inadequate parathyroid hormone production occurs due presence damage removal parathyroid gland condition produce decreased calcium increased phosphorus level l6082 rickets condition produced due deficiency vitamin calcium phosphorus however condition also related renal disease characterized present weak soft bone a177664 familial hypophosphatemia characterized impaired transport phosphate altered vitamin metabolism kidney presence condition derive presence osteomalacia bone softening rickets l6085 
Dihomo-gamma-linolenic acid," 20-carbon-chain fatty acid unsaturated position 8 11 14 differs arachidonic acid 5,8,11,14-eicosatetraenoic acid position 5 ", nutritional supplementation also treating dietary shortage imbalance
Citrulline,citrulline amino acid made ornithine carbamoyl phosphate one central reaction urea cycle also produced arginine by-product reaction catalyzed no family name derived citrullus latin word watermelon first isolated ,used nutritional supplementation also treating dietary shortage imbalance 
Threonine, essential amino acid occurring naturally l-form active form found egg milk gelatin protein ,l-threonine make collagen elastin enamel protein aid proper fat metabolism liver help digestive intestinal tract function smoothly assist metabolism assimilation 
NADH,nadh reduced form nad+ nad+ oxidized form nadh coenzyme composed ribosylnicotinamide 5'-diphosphate coupled adenosine 5'-phosphate pyrophosphate linkage found widely nature involved numerous enzymatic reaction serf electron carrier alternately oxidized nad+ reduced nadh form nadp addition phosphate group 2 position adenosyl nucleotide ester linkage dorland 27th ed , evidence suggests nadh might useful treating parkinson 's disease chronic fatigue syndrome alzheimer 's disease cardiovascular disease 
Folic acid,folic acid also known folate vitamin b9 member b vitamin family essential cofactor enzyme involved dna rna synthesis specifically folic acid required body synthesis purine pyrimidine methionine incorporation dna protein folic acid particularly important phase rapid cell division infancy pregnancy erythropoiesis play protective factor development cancer human unable synthesize folic acid endogenously diet supplementation necessary prevent deficiency example folic acid present green vegetable bean avocado fruit l5744 order function within body folic acid must first reduced enzyme dihydrofolate reductase dhfr cofactor dihydrofolate dhf tetrahydrofolate thf important pathway required de novo synthesis nucleic acid amino acid disrupted anti-metabolite therapy db00563 function dhfr inhibitor prevent dna synthesis rapidly dividing cell therefore prevent formation dhf thf used high dos cancer therapy low dos rheumatoid arthritis psoriasis db00563 impedes body 's ability create folic acid result deficiency coenzyme resultant buildup toxic substance responsible numerous adverse side effect result supplementation 1-5mg folic acid recommended prevent deficiency number side effect associated mtx therapy including mouth ulcer gastrointestinal irritation db00650 also known folinic acid supplementation typically used high-dose mtx regimen treatment cancer levoleucovorin leucovorin analog tetrahydrofolate thf able bypass dhfr reduction act cellular replacement co-factor thf also several antiepileptic drug aeds associated reduced serum red blood cell folate including db00564 cbz db00252 pht barbiturate a37004 folic acid therefore often provided supplementation individual using medication particularly woman child-bearing age inadequate folate level result number health concern including cardiovascular disease megaloblastic anemia cognitive deficiency neural tube defect ntds folic acid typically supplemented pregnancy prevent development ntds individual alcoholism prevent development neurological disorder example ,folic acid indicated treatment folic acid deficiency megaloblastic anemia anemia nutritional origin pregnancy infancy childhood 
Icosapent,important polyunsaturated fatty acid found fish oil serf precursor prostaglandin-3 thromboxane-3 family diet rich eicosapentaenoic acid lower serum lipid concentration reduces incidence cardiovascular disorder prevents platelet aggregation inhibits arachidonic acid conversion thromboxane-2 prostaglandin-2 family ,epa used lowering elevated triglyceride hyperglyceridemic addition epa may play therapeutic role patient cystic fibrosis reducing disease severity may play similar role type 2 diabetic slowing progression diabetic nephropathy 
Alanine,alanine non-essential amino acid occurs high level free state plasma produced pyruvate transamination involved sugar acid metabolism increase immunity provides energy muscle tissue brain central nervous system ,used protein synthesis 
Valine,valine branched-chain essential amino acid stimulant activity promotes muscle growth tissue repair precursor penicillin biosynthetic pathway ,promotes mental vigor muscle coordination calm emotion may also use minority patient hepatic encephalopathy phenylketonuria 
Vitamin A,retinol derivative retinol play essential role metabolic functioning retina growth differentiation epithelial tissue growth bone reproduction immune response dietary vitamin derived variety carotenoid found plant enriched liver egg yolk fat component dairy product , treatment vitamin deficiency 
Vitamin E, 1922 vitamin e demonstrated essential nutrient a32448 vitamin e term used describe 8 different fat soluble tocopherol tocotrienols alpha-tocopherol biologically active a176104 vitamin e act antioxidant protecting cell membrane oxidative damage a176104 antioxidant effect currently researched use treatment disease causing bone loss cardiovascular disease diabetes mellitus associated comorbidities eye disease inflammatory disease including skin condition lipid disorder neurological disease radiation damage a176369 though research far inconclusive vitamin e remains popular supplement generally considered safe fda fda label ,vitamin e supplementation indicated treatment vitamin e deficiency occur cystic fibrosis cholestasis severe liver disease abetalipoproteinemia simply poor diet a176104 l3063 
Pyridoxine,pyridoxine 4-methanol form vitamin b6 important water-soluble vitamin naturally present many food classification vitamin implies vitamin b6 pyridoxine essential nutrient required normal functioning many biological system within body many plant microorganism able synthesize pyridoxine endogenous biological process animal must obtain diet specifically pyridoxine converted pyridoxal 5-phosphate body important coenzyme synthesis amino acid neurotransmitter serotonin norepinephrine sphingolipids aminolevulinic acid 's important note vitamin b6 collective term group three related compound pyridoxine pyridoxal pyridoxamine phosphorylated derivative pyridoxine 5'-phosphate pyridoxal 5'-phosphate pyridoxamine 5'-phosphate although six compound technically referred vitamin b6 term vitamin b6 commonly used interchangeably one pyridoxine a32836 vitamin b6 principally biologically active coenzyme form pyridoxal 5'-phosphate involved wide range biochemical reaction including metabolism amino acid glycogen synthesis nucleic acid hemogloblin sphingomyelin sphingolipids synthesis neurotransmitter serotonin dopamine norepinephrine gamma-aminobutyric acid gaba a32837 pyridoxine used medically treatment vitamin b6 deficiency prophylaxis isoniazid-induced peripheral neuropathy due db00951 's mechanism action competitively inhibits action pyridoxine above-mentioned metabolic function also used combination db00366 commercially available product diclectin treatment nausea vomiting pregnancy ,pyridoxine indicated treatment vitamin b6 deficiency prophylaxis db00951 -induced peripheral neuropathy also approved health canada treatment nausea vomiting pregnancy combination product db00366 commercially available product diclectin 
Lipoic acid, vitamin-like antioxidant , nutritional supplementation also treating dietary shortage imbalance 
Isoleucine, essential branched-chain aliphatic amino acid found many protein isomer leucine important hemoglobin synthesis regulation blood sugar energy level , branched-chain amino acid may antihepatic encephalopathy activity may also anticatabolic antitardive dyskinesia activity 
Aspartame,flavoring agent sweeter sugar metabolized phenylalanine aspartic acid ,used diet supplement sugar substitute 
Cholecalciferol,vitamin general secosteroid generated skin 7-dehydrocholesterol located interacts ultraviolet irradiation like commonly found sunlight l5689 endogenous form vitamin result 7-dehydrocholesterol transformation vitamin d3 cholecalciferol plant-derived form vitamin d2 ergocalciferol considered main form vitamin found various type food daily intake l5689 structurally ergocalciferol differs cholecalciferol posse double bond c22 c23 additional methyl group c24 l5689 finally ergocalciferol pharmacologically le potent cholecalciferol make vitamin d3 preferred agent medical use l5689 appropriate level vitamin must upheld body order maintain calcium phosphorus level healthy physiologic range sustain variety metabolic function transcription regulation bone metabolism a223 l5689 l1782 l5771 f4027 f4042 f4048 however study also ongoing determine whether cholecalciferol may also play certain role cancer autoimmune disorder cardiovascular disease medical condition may associated vitamin deficiency l5689 ,cholecalciferol use indicated treatment specific medical condition like refractory rickets vitamin resistant rickets hypoparathyroidism familial hypophosphatemia f4027 f4042 concurrently one commonly utilized form vitamin cholecalciferol also frequently used supplement individual maintain sufficient vitamin level body treat vitamin deficiency well various medical condition associated directly indirectly vitamin insufficiency like osteoporosis chronic kidney disease among others a176041 a176044 f4051 
Menadione, synthetic naphthoquinone without isoprenoid side chain biological activity converted active vitamin k2 menaquinone alkylation vivo , primary known function vitamin k assist normal clotting blood may also play role normal bone calcification 
ATP, adenine nucleotide containing three phosphate group esterified sugar moiety addition crucial role metabolism adenosine triphosphate neurotransmitter , nutritional supplementation also treating dietary shortage imbalance
Proline,proline one twenty amino acid used living organism building block protein proline sometimes called imino acid although iupac definition imine requires carbon-nitrogen double bond proline non-essential amino acid synthesized glutamic acid essential component collagen important proper functioning joint tendon ,l-proline extremely important proper functioning joint tendon also help maintain strengthen heart muscle 
Adenine, purine base fundamental unit adenine nucleotide , nutritional supplementation also treating dietary shortage imbalance
Asparagine, non-essential amino acid involved metabolic control cell function nerve brain tissue biosynthesized aspartic acid ammonia asparagine synthetase concise encyclopedia biochemistry molecular biology 3rd ed ,used nutritional supplementation also treating dietary shortage imbalance 
Pravastatin,pravastatin 6-alpha-hydroxy acid form mevastatin t303 pravastatin firstly approved 1991 becoming second available statin united state first statin administered active form prodrug t274 drug developed sankyo co. ltd. however first approved pravastatin product developed bristol myers squibb fda approved 1991 l6142 pravastatin made fermentation process mevastatin first obtained manufacturing process followed hydrolysis lactone group biological hydroxylation _streptomyces carbophilus_ introduce allylic 6-alcohol group t239 ,pravastatin indicated primary prevention coronary event hypercholesterolemic patient without clinical evidence coronary heart disease use includes reduction risk myocardial infarction undergoing myocardial revascularization procedure cardiovascular mortality t274 well pravastatin used secondary prevention agent cardiovascular event patient clinically evident coronary heart disease indication includes reduction risk total mortality reducing coronary death myocardial infarction undergoing myocardial revascularization procedure stroke stroke/transient ischemic attack well slow progression coronary atherosclerosis t274 term cardiovascular event correspond incident produce damage heart muscle including interruption blood flow l6028 adjunctive therapy diet pravastatin used patient primary hypercholesterolemia mixed dyslipidemias including hyperlipidemia type iia iib patient elevated serum triglyceride including type iv hyperlipidemia patient heterozygous familial hypercholesterolemia patient 8 year age low-density lipoprotein ldl cholesterol higher 190 mg/dl diet modification ldl level higher 160 mg/dl familial history premature cardiovascular disease least two cardiovascular risk factor t274 patient respond adequately diet pravastatin used treat patient primary dysbetalipoproteinemia type iii hyperlipidemia t274 dyslipidemia defined elevation plasma cholesterol triglyceride well presence low level high-density lipoprotein condition represents increased risk development atherosclerosis l6025 
Fluvoxamine,"fluvoxamine antidepressant function pharmacologically selective serotonin reuptake inhibitor though class ssri drug often used treat obsessive-compulsive disorder fluvoxamine use clinical practice since 1983 clinical trial database comprised approximately 35,000 patient launched u december 1994 japan june 1999 end 1995 10 million patient worldwide treated fluvoxamine ",indicated predominantly management depression obsessive compulsive disorder ocd fda label also used management bulimia nervosa a250 
Valsartan,valsartan belongs angiotensin ii receptor blocker arb family drug also includes telmisartan candesartan losartan olmesartan irbesartan arb selectively bind angiotensin receptor 1 at1 prevent protein angiotensin ii binding exerting hypertensive effect include vasoconstriction stimulation synthesis aldosterone adh cardiac stimulation renal reabsorption sodium among others overall valsartan 's physiologic effect lead reduced blood pressure lower aldosterone level reduced cardiac activity increased excretion sodium valsartan also affect renin-angiotensin aldosterone system raas play important role hemostasis regulation kidney vascular cardiac function pharmacological blockade raas via at1 receptor blockade inhibits negative regulatory feedback within raas contributing factor pathogenesis progression cardiovascular disease heart failure renal disease particular heart failure associated chronic activation raas leading inappropriate fluid retention vasoconstriction ultimately decline left ventricular function arb shown protective effect heart improving cardiac function reducing afterload increasing cardiac output preventing ventricular hypertrophy remodelling a174154 comparison angiotensin-converting enzyme inhibitor acei class medication includes drug ramipril lisinopril perindopril inhibit conversion angiotensin angiotensin ii inhibition ace enzyme however prevent formation angiotensin ii within body angiotensin ii receptor blocker arb family drug unique block angiotensin ii activity regardless synthesized valsartan commonly used management hypertension heart failure type 2 diabetes-associated nephropathy particularly patient unable tolerate ace inhibitor arb valsartan shown number large-scale clinical outcome trial improve cardiovascular outcome including reducing risk myocardial infarction stroke progression heart failure hospitalization a174124 a178153 a173869 a185324 a185327 a185333 a185342 a185345 valsartan also slows progression diabetic nephropathy due renoprotective effect a174157 a174160 a174163 improvement chronic kidney disease valsartan include clinically statistically significant decrease urinary albumin protein excretion patient diagnosed type 2 diabetes nondiabetic patient diagnosed chronic kidney disease a174124 a173869 valsartan initially approved 1996 europe treatment hypertension adult shortly 1997 drug approved united state a174124 valsartan generally well-tolerated side-effect profile superior antihypertensive drug a174130 a174133 ,valsartan indicated treatment hypertension reduce risk fatal nonfatal cardiovascular event primarily stroke myocardial infarction also indicated treatment heart failure nyha class ii-iv left ventricular dysfunction failure myocardial infarction use angiotensin-converting enzyme inhibitor acei appropriate f4703 l11305 also used combination sacubitril l36445 
Ramipril,ramipril prodrug belonging angiotensin-converting enzyme ace inhibitor class medication metabolized ramiprilat liver lesser extent kidney ramiprilat potent competitive inhibitor ace enzyme responsible conversion angiotensin ati angiotensin ii atii atii regulates blood pressure key component renin-angiotensin-aldosterone system raas ramipril may used treatment hypertension congestive heart failure nephropathy reduce rate death myocardial infarction stroke individual high risk cardiovascular event , management mild severe hypertension may used reduce cardiovascular mortality following myocardial infarction hemodynamically stable individual develop clinical sign congestive heart failure within day following myocardial infarction fda label reduce rate death myocardial infarction stroke individual high risk cardiovascular event may used slow progression renal disease individual hypertension diabetes mellitus microalubinuria overt nephropathy t116 
Masoprocol, potent lipoxygenase inhibitor interferes arachidonic acid metabolism compound also inhibits formyltetrahydrofolate synthetase carboxylesterase cyclooxygenase lesser extent also serf antioxidant fat oil pubchem ,used treatment actinic keratoses precancerous skin growth become malignant left untreated 
Flunisolide,flunisolide marketed aerobid nasalide nasarel corticosteroid anti-inflammatory action often prescribed treatment allergic rhinitis principle mechanism action involves activation glucocorticoid receptor , maintenance treatment asthma prophylactic therapy 
Baclofen,baclofen gamma-aminobutyric acid gaba agonist used skeletal muscle relaxant although originally designed 1962 treat epilepsy baclofen effective treating condition instead shown reduce spasticity selected patient a245338 baclofen reintroduced 1971 treatment spasticity later approved fda 1977 a245323 a245338 baclofen used manage severe muscle spasm cerebral spinal cord origin including multiple sclerosis traumatic brain injury l39429 baclofen investigated use alcohol dependence withdrawal however evidence limited inconsistent evidence suggest clinical efficacy managing alcohol dependence withdrawal symptom a173905 a173908 a245338 ,oral baclofen indicated treatment spasticity resulting multiple sclerosis particularly useful relief flexor spasm concomitant pain clonus muscular rigidity may also used treat patient spinal cord injury spinal cord disease baclofen used treat skeletal muscle spasm resulting rheumatic disorder l39434 intrathecal baclofen also indicated management severe spasticity cerebral spinal original patient 4 year age older reserved patient unresponsive oral baclofen therapy experience intolerable central nervous system side effect effective dos use spasticity due traumatic brain injury baclofen considered least one year injury l39429 
Amphetamine,amphetamine compound discovered 100 year ago one restricted controlled drug previously used large variety condition changed point use highly restricted amphetamine chemical formula alpha-methylphenethylamine discovered 1910 first synthesized 1927 proven reduce drug-induced anesthesia produce arousal insomnia amphetamine racemic mix registered smith kline french 1935 amphetamine structure present one chiral center exists form dextro- levo-isomers a18540 first product smith kline french approved fda 1976 l5194 world war ii amphetamine used promote wakefulness soldier use derived large overproduction amphetamine surplus war finalized ended black market producing initiation illicit abuse a18540 ,amphetamine indicated treatment attention-deficit/hyperactivity disorder adhd well treatment central nervous system disorder narcolepsy a18540 adhd complex disorder associated substantial heterogeneity etiology clinical presentation treatment outcome adhd come complex interplay interdependent genetic non-genetic factor cause complex mental disorder child teenager a174271 hand narcolepsy chronic sleep disorder typically resenting adolescence characterized excessive daytime sleepiness a174274 amphetamine also used nowadays off-label treatment obesity depression chronic pain a174268 a174283 
Pentagastrin, synthetic pentapeptide mimic action endogenous gastrin given parenterally work stimulating secretion gastric acid pepsin intrinsic factor also used diagnostic aid ,used diagnostic aid evaluation gastric acid secretory function
Nicotine,nicotine highly toxic alkaloid prototypical agonist nicotinic cholinergic receptor dramatically stimulates neuron ultimately block synaptic transmission nicotine also important medically presence tobacco smoke , relief nicotine withdrawal symptom aid smoking cessation 
Cevimeline,cevimeline parasympathomimetic agent act agonist muscarinic acetylcholine receptor m1 m3 indicated food drug administration treatment dry mouth associated sjögren 's syndrome , treatment symptom dry mouth patient sj ouml gren 's syndrome 
Lorazepam,lorazepam short-acting rapidly cleared benzodiazepine used commonly sedative anxiolytic a957 developed dj richards presented marketed initially wyeth pharmaceutical usa 1977 first historic fda label approval reported 1985 company mutual pharm l5095 ,lorazepam fda-approved short-term relief anxiety symptom related anxiety disorder anxiety associated depressive symptom anxiety-associated insomnia well used anesthesia premedication adult relieve anxiety produce sedation/amnesia treatment status epilepticus t385 off-label indication lorazepam include rapid tranquilization agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasm insomnia panic disorder delirium chemotherapy-associated anticipatory nausea vomiting psychogenic catatonia t385 
Esmolol,esmolol commonly marketed trade name brevibloc cardioselective beta-1 receptor blocker rapid onset short duration action without causing significant intrinsic sympathomimetic membrane stabilizing activity recommended therapeutic dos work blocking beta-adrenergic receptor heart lead decreased force rate heart contraction esmolol prevents action two naturally occurring substance epinephrine norepinephrine fda withdrew approval use parenteral dosage form drug product containing esmolol hydrochloride supply 250 milligrams/milliliter concentrated esmolol per 10-milliliter ampule esmolol formulation still available use l43942 , rapid control ventricular rate patient atrial fibrillation atrial flutter perioperative postoperative emergent circumstance short term control ventricular rate short-acting agent desirable also used noncompensatory sinus tachycardia rapid heart rate requires specific intervention 
Bortezomib,bortezomib dipeptide boronic acid derivative proteasome inhibitor used treat multiple myeloma mantle cell lymphoma a204083 26 proteasome protein complex degrades ubiquitinated protein ubiquitin-proteasome pathway reversible inhibition 26 proteasome leading cell cycle arrest apoptosis cancer cell thought main mechanism action bortezomib l14180 however multiple mechanism may involved anticancer activity bortezomib a204083 bortezomib first synthesized 1995 a204083 may 2003 bortezomib became first anticancer proteasome inhibitor approved fda trade name velcade a204146 phase ii iii iv clinical trial undergoing investigate therapeutic efficacy bortezomib leukemia myasthenia gravis systemic lupus erythematosus rheumatoid arthritis solid tumour a214307 ,bortezomib indicated treatment adult multiple myeloma mantle cell lymphoma l44341 
Ethchlorvynol,ethchlorvynol sedative hypnotic drug used treat insomnia largely superseded offered intolerance allergy drug exists ,used short-term hypnotic therapy management insomnia period one week duration however medication generally replaced sedative-hypnotic agent 
Carbidopa,carbidopa present chemical denomination n-amino-alpha-methyl-3-hydroxy-l-tyrosine monohydrate potently inhibits aromatic amino acid decarboxylase ddc due chemical property cross blood-brain barrier due activity carbidopa always administered concomitantly levodopa individual formulation containing solely carbidopa generated treat nausea patient combination therapy levodopa /carbidopa efficient reducing nausea t394 first approved product fda containing carbidopa developed amerigens pharmaceutical ltd approved 2014 l5110 hand combination treatment carbidopa/levodopa originally developed watson lab historical information fda brings back approval combination therapy developed mayne pharma 1992 l5113 ,carbidopa indicated levodopa treatment symptom idiopathic parkinson disease postencephalitic parkinsonism symptomatic parkinsonism followed carbon monoxide manganese intoxication fda label combination therapy administered reduction levodopa -driven nausea vomiting fda label product carbidopa used patient combination therapy carbidopa/ levodopa provide le adequate daily dosage fda label well carbidopa used patient dosage carbidopa levodopa require individual titration fda label 
Phentermine,phentermine sympathomimetic amine anorectic agent introduced 1959 part anti-obesity combination drug a174361 a174364 chemically related amphetamine commonly referred atypical amphetamine a174370 phentermine reported addictive potential allows agent classified schedule iv drug low abuse potential a174367 phentermine fda approved short-term weight management 1959 became widely used 1960 initial product formed combination phentermine fenfluramine dexfenfluramine discontinued finding several report abnormal valve nearly 30 consumer a174376 t403 later phentermine approved alone combination topiramate 2012 new alternative required lower dos phentermine obtain desired effect a174373 ,phentermine indicated alone combination topiramate short-term adjunct pas week regimen weight reduction based exercise behavioral modification caloric restriction management exogenous obesity patient initial body mass index bmi greater 30 kg/m2 greater 27 kg/m2 presence risk factor controller hypertension diabetes hyperlipidemia fda label exogenous obesity considered overweight caused consuming food person activity level warrant condition commonly cause increase fat storage epidemic condition united state two-thirds adult overweight obese one three american obese world incidence obesity nearly doubled a174391 
Indecainide,indecainide rarely used antidysrhythmic indecainide local anesthetic activity belongs membrane stabilizing class 1 group antiarrhythmic agent electrophysiologic effect characteristic ic class antiarrhythmic , treatment life-threatening dysrhythmias sustained ventricular tachycardia 
Tramadol,tramadol centrally acting synthetic opioid analgesic snri serotonin/norepinephrine reuptake-inhibitor structurally related codeine morphine due good tolerability profile multimodal mechanism action tramadol generally considered lower-risk opioid option treatment moderate severe pain considered step 2 option world health organization 's pain ladder 1/10th potency morphine tramadol differs traditional opioid medication n't act μ-opioid agonist also affect monoamine modulating effect neurotransmitter involved modulation pain serotonin norepinpehrine activate descending pain inhibitory pathway a182279 tramadol 's effect serotonin norepinephrine mimic effect snri antidepressant duloxetine venlafaxine tramadol exists racemic mixture consisting two pharmacologically active enantiomer contribute analgesic property different mechanism also metabolized active metabolite -tramadol primary metabolite -o-desmethyl-tramadol m1 agonist μ opioid receptor -tramadol inhibits serotonin reuptake -tramadol inhibits norepinephrine reuptake pathway complementary synergistic improving tramadol 's ability modulate perception response pain a4269 a183842 tramadol also shown affect number pain modulators within central nervous system well non-neuronal inflammatory marker immune mediator a183728 a183734 a183761 a17159 a182300 due broad spectrum target involved pain inflammation 's surprising evidence shown tramadol effective number pain type including neuropathic pain post-operative pain lower back pain well pain associated labour osteoarthritis fibromyalgia cancer due snri activity tramadol also anxiolytic antidepressant anti-shivering effect frequently found comorbidities pain a182300 similar opioid medication tramadol pose risk development tolerance dependence abuse used higher dos opioids dose-related risk overdose respiratory depression death a183830 f4679 however unlike opioid medication tramadol use also carry risk seizure serotonin syndrome particularly used serotonergic medication a183836 a179926 ,tramadol approved management moderate severe pain adult l9257 f4679 tramadol also used off-label treatment premature ejaculation a173986 
Vidarabine, nucleoside antibiotic isolated streptomyces antibioticus antineoplastic property broad spectrum activity dna virus cell culture significant antiviral activity infection caused variety virus herpes virus vaccinia virus varicella zoster virus , treatment chickenpox varicella herpes zoster herpes simplex
Betaxolol, cardioselective beta-1-adrenergic antagonist partial agonist activity , management hypertension 
Fluconazole,fluconazole commonly known _diflucan_ antifungal drug used treatment systemic superficial fungal infection variety tissue initially approved fda 1990 drug _azole_ antifungal drug family ketoconazole itraconazole fluconazole many advantage antifungal drug including option oral administration side effect profile drug minimal demonstrated efficacious treatment vaginal yeast infection one single dose a174325 ,fluconazole administered treatment following fungal infection l11043 1 vaginal yeast infection caused candida 2 systemic candida infection 3 esophageal oropharyngeal candidiasis 4 cryptococcal meningitis 5 uti urinary tract infection candida 6 peritonitis inflammation peritoneum caused candida note fungal infection prophylaxis patient receiving bone marrow transplantation treated cytotoxic chemotherapy and/or radiation therapy may predisposed candida infection may receive fluconazole prophylactic therapy l11043 note laboratory testing obtaining specimen fungal culture important laboratory study serology pathology advised starting fluconazole therapy order isolate organism eliminated treatment permissible start therapy result available however adjusting therapy laboratory result confirm causative organism may necessary l11043 
Troglitazone,troglitazone withdrawn 2000 due risk hepatotoxicity superseded pioglitazone rosiglitazone , treatment type ii diabetes mellitus used alone combination sulfonylurea metformin insulin adjunct diet exercise 
Oseltamivir,oseltamivir marketed product tamifluⓡ antiviral neuraminidase inhibitor used treatment prophylaxis infection influenza virus including pandemic h1n1 b. oseltamivir exerts antiviral activity inhibiting activity viral neuraminidase enzyme found surface virus prevents budding host cell viral replication infectivity clinical benefit use oseltamivir greatest administered within 48 hour onset influenza symptom since effectiveness decrease significantly point time generally benefit use beyond 48 hour healthy low-risk individual influenza self-limiting illness a180574 l7267 a180580 however antiviral treatment might beneficial initiated 48 hour patient severe complicated progressive illness hospitalized patient a180583 according cdc data clinical trial observational study demonstrated early antiviral treatment shorten duration fever illness symptom may reduce risk complication including pneumonia respiratory failure recommend use oseltamivir people higher risk developing complication including child younger 2 year people 65 year people chronic condition immunosuppression pregnant woman resident long term care facility indigenous community example l7264 benefit oseltamivir use controversial 2014 cochrane review evidence found oseltamivir treatment limited benefit author concluded oseltamivir use healthy adult small non-specific effect symptom time first alleviation symptom reduced 7 6.3 day effect hospitalization evidence reduction complication influenza pneumonia a179962 a179965 a179968 due risk adverse effect nausea vomiting psychiatric effect renal adverse event adult vomiting child harm generally considered outweigh small clinical benefit use oseltamivir notably 2017 world health organization downgraded oseltamivir essential medicine list `` core '' drug `` complementary '' drug due limited cost-effectiveness a179086 yearly vaccination influenza vaccine still considered best preventative measure ,according fda prescribing information oseltamivir indicated treatment acute uncomplicated illness due influenza b infection patient 2 week age older symptomatic 48 hour f3094 particular agent indicated adult child including full-term neonate present symptom typical influenza influenza virus circulating community efficacy demonstrated treatment initiated within two day first onset symptom f3097 oseltamivir also indicated prophylaxis influenza patient one year older f3094 specifically post-exposure prevention individual one year age older following contact clinically diagnosed influenza case influenza virus circulating community qualifies prophylactic therapy oseltamivir would indicated post-exposure prevention influenza infant le 1 year age pandemic influenza outbreak f3097 
Erythromycin,erythromycin bacteriostatic antibiotic drug produced strain saccharopolyspora erythraea formerly streptomyces erythraeus belongs macrolide group antibiotic consists azithromycin clarithromycin spiramycin others originally discovered 1952 l5245 erythromycin widely used treating variety infection including caused gram-positive gram-negative bacteria l5245 l7261 available administration various form including intravenous topical eye drop preparation l5245 ,erythromycin indicated treatment infection caused susceptible strain various bacteria l7261 indication erythromycin summarized body system respiratory infection mild moderate upper respiratory tract infection caused streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae used concomitantly appropriate dos sulfonamide treated erythromycin l7261 mild moderate lower-respiratory tract infection due susceptible strain streptococcus pneumoniae streptococcus pyogenes may also treated erythromycin treat listeriosis caused listeria monocytogenes may also treated erythromycin l7261 erythromycin indicated treat pertussis whooping cough caused bordetella pertussis effective eliminating causative organism nasopharynx infected individual rendering noninfectious clinical study suggest erythromycin may aid prevention pertussis infection individual exposed bacteria l7261 respiratory tract infection due mycoplasma pneumoniae may also treated erythromycin l7261 despite fact controlled clinical efficacy study conducted date vitro certain preliminary clinical study result indicate erythromycin may effective treatment legionnaire ’ disease l7261 finally erythromycin indicated treat diphtheria infection due corynebacterium diphtheriae adjunct antitoxin prevent carrier status eradicate organism existing carrier l7261 addition prevention diphtheria erythromycin used prevent rheumatic fever penicillin intolerant patient l7261 skin infection mild moderate skin skin structure infection caused streptococcus pyogenes staphylococcus aureus may treated erythromycin however resistant staphylococcal organism may emerge l7261 erythromycin also used treat erythrasma infectious condition caused corynebacterium minutissimum l7261 gastrointestinal infection intestinal amebiasis caused entamoeba histolytica treated oral erythromycin extraenteric amebiasis warrant treatment antimicrobial drug l7261 genital infections/stis erythromycin used alternative drug treating acute pelvic inflammatory disease caused n. gonorrheae female patient demonstrated hypersensitivity intolerance penicillin l7261 syphilis caused treponema pallidum treated erythromycin serf alternative treatment primary syphilis patient demonstrated penicillin hypersensitivity erythromycin also used primary stage primary syphilis l7261 another approved indication erythromycin treat chlamydial infection cause conjunctivitis newborn pneumonia infancy urogenital infection occurring pregnancy indicated alternative option tetracycline treatment uncomplicated rectal urethral endocervical infection adult caused chlamydia trachomatis l7261 erythromycin used nongonococcal urethritis used tetracycline administered finally erythromycin indicated treat nongonococcal urethritis due ureaplasma urealyticum l7261 
Hydroxocobalamin,hydroxocobalamin also known vitamin b12a hydroxycobalamin injectable form vitamin b 12 used therapeutically treat vitamin b 12 deficiency also used cyanide poisoning leber 's optic atrophy toxic amblyopia , treatment pernicious anemia prevention treatment vitamin b12 deficiency arising alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepatic-biliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diet macrobiotic diet restrictive diet also treatment known suspected cyanide poisoning 
Caffeine,caffeine drug methylxanthine class used variety purpose including certain respiratory condition premature newborn pain relief combat drowsiness caffeine similar chemical structure theophylline theobromine a187691 l9851 sourced coffee bean also occurs naturally various tea cacao bean different coffee bean t716 caffeine also used variety cosmetic product administered topically orally inhalation injection t716 caffeine citrate injection used apnea premature newborn initially approved fda 1999 l9863 according article 2017 15 million baby born prematurely worldwide correlate 1 10 birth premature birth lead apnea bronchopulmonary dysplasia condition interferes lung development may eventually cause asthma early onset emphysema born prematurely a187694 caffeine beneficial preventing treating apnea bronchopulmonary dysplasia newborn improving quality life premature infant t716 ,caffeine indicated short term treatment apnea prematurity infant label prevention treatment bronchopulmonary dysplasia caused premature birth t716 l9851 addition indicated combination sodium benzoate treat respiratory depression resulting overdose cns depressant drug l9899 caffeine broad range counter us found energy supplement athletic enhancement product pain relief product well cosmetic product t716 l9854 l9872 
Succinylcholine,succinylcholine depolarizing skeletal muscle relaxant consisting two molecule endogenous neurotransmitter acetylcholine ach linked acetyl group a19054 widely used 50 year a299 commonly chloride salt form mean neuromuscular blockade intubation surgical procedure rapid onset offset effect beginning within 60 second intravenous administration lasting four six minute make succinylcholine particularly useful setting short medical procedure requiring brief period muscle relaxation l9004 ,succinylcholine indicated adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation surgery mechanical ventilation l9004 
Sildenafil, eliciting mechanism action sildenafil ultimately prevents minimizes breakdown cyclic guanosine monophosphate cgmp inhibiting cgmp specific phosphodiesterase type 5 pde5 f3850 f3853 f3856 f3859 f3883 f3886 l5611 l5614 result allows cgmp present penis pulmonary vasculature elicit smooth muscle relaxation vasodilation subsequently facilitates relief pulmonary arterial hypertension increased flow blood spongy erectile tissue penis consequently allows grow size become erect rigid f3850 f3853 f3856 f3859 f3883 f3886 l5611 l5614 interestingly enough precisely via mechanism sildenafil first researched potential treatment angina chest pain associated inadequate blood flow heart serendipitously indicated treating erectile dysfunction late 1980s a175732 nevertheless mechanism sildenafil also indicated treating pulmonary arterial hypertension also additionally notorious interacting various anti-anginal anti-hypertensive agent develop potentially rapid excessive and/or fatal hypotensive crisis a175579 a175582 a175654 regardless sildenafil among variety similar related pde5 inhibitor become common effective treatment erectile dysfunction since formal approval medical use public 1998 a175732 continues see million prescription written internationally although medication historically popularly recognized pfizer 's brand name viagra sildenafil currently available generically even non-prescription counter medication country l5656 ,sildenafil phosphodiesterase-5 pde5 inhibitor predominantly employed two primary indication 1 treatment erectile dysfunction a175582 l5611 f3853 f3856 f3886 2 treatment pulmonary hypertension u fda specifically indicates sildenafil treatment pulmonary arterial hypertension pah group adult improve exercise ability delay clinical worsening f3850 delay clinical worsening demonstrated sildenafil added background epoprostenol therapy f3850 study establishing effectiveness short-term 12 16 week included predominately patient new york heart association nyha functional class ii-iii symptom idiopathic etiology 71 associated connective tissue disease ctd 25 f3850 b canadian product monograph specifically indicates sildenafil treatment primary pulmonary arterial hypertension pph pulmonary hypertension secondary connective tissue disease ctd adult patient functional class ii iii responded conventional therapy f3859 addition improvement exercise ability delay clinical worsening demonstrated adult patient already stabilized background epoprostenol therapy f3859 c ema product information specifically indicates sildenafil treatment adult patient pulmonary arterial hypertension classified functional class ii iii improve exercise capacity f3883 efficacy shown primary pulmonary hypertension pulmonary hypertension associated connective tissue disease f3883 ema label also indicates sildenafil treatment pediatric patient aged 1 year 17 year old pulmonary arterial hypertension f3883 efficacy term improvement exercise capacity pulmonary hemodynamics shown primary pulmonary hypertension pulmonary hypertension associated congenital heart disease f3883 
Dofetilide,dofetilide class iii antiarrhythmic agent approved food drug administration fda maintenance sinus rhythm individual prone formation atrial fibrillation flutter chemical cardioversion sinus rhythm atrial fibrillation flutter , maintenance normal sinus rhythm delay time recurrence atrial fibrillation/atrial flutter af/afl patient atrial fibrillation/atrial flutter greater one week duration converted normal sinus rhythm
Pyrimethamine,one folic acid antagonist used antimalarial sulfonamide treat toxoplasmosis , treatment toxoplasmosis acute malaria prevention malaria area non-resistant pyrimethamine
Reserpine, alkaloid found root rauwolfia serpentina r. vomitoria reserpine inhibits uptake norepinephrine storage vesicle resulting depletion catecholamine serotonin central peripheral axon terminal used antihypertensive antipsychotic well research tool adverse effect limit clinical use fda withdrew approval use oral dosage form drug product containing 1 mg reserpine l43942 , treatment hypertension
Azithromycin,azithromycin broad-spectrum macrolide antibiotic long half-life high degree tissue penetration a174172 initially approved fda 1991 a174175 primarily used treatment respiratory enteric genitourinary infection may used instead macrolides sexually transmitted enteric infection structurally related erythromycin a174169 azithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin part _azalide_ subclass macrolides contains 15-membered ring methyl-substituted nitrogen instead carbonyl group 9a position aglycone ring allows prevention metabolism differentiates azithromycin type macrolides a174175 march 2020 small study funded french government investigate treatment covid-19 combination azithromycin anti-malaria drug hydroxychloroquine result positive patient taking combination virologically cured within 6 day treatment however larger study required a192546 ,azithromycin used treat prevent infection proven strongly suspected caused susceptible bacteria order prevent development antimicrobial resistance maintain efficacy azithromycin fda label azithromycin indicated treatment patient mild moderate infection caused susceptible strain microorganism listed specific condition recommended dosage duration therapy consideration various patient population may vary among infection refer fda label `` indication '' section drug entry detailed information fda label adult acute bacterial exacerbation chronic obstructive pulmonary disease due _haemophilus influenzae_ _moraxella catarrhalis_ _streptococcus pneumoniae_ acute bacterial sinusitis due _haemophilus influenzae_ _moraxella catarrhalis_ _streptococcus pneumoniae_ community-acquired pneumonia due _chlamydophila pneumoniae_ _haemophilus influenzae_ _mycoplasma pneumoniae_ _streptococcus pneumoniae_ patient appropriate oral therapy pharyngitis/tonsillitis caused _streptococcus pyogenes_ alternative first-line therapy individual use first-line therapy uncomplicated skin skin structure infection due _staphylococcus aureus_ _streptococcus pyogenes_ _streptococcus agalactiae_ abscess usually require surgical drainage urethritis cervicitis due _chlamydia trachomatis_ _neisseria gonorrhoeae_ genital ulcer disease men due _haemophilus ducreyi_ chancroid due small number woman included clinical trial efficacy azithromycin treatment chancroid woman established pediatric patient acute otitis medium caused _haemophilus influenzae_ _moraxella catarrhalis_ _streptococcus pneumoniae_ community-acquired pneumonia due _chlamydophila pneumoniae_ _haemophilus influenzae_ _mycoplasma pneumoniae_ _streptococcus pneumoniae_ patient appropriate oral therapy pharyngitis/tonsillitis caused _streptococcus pyogenes_ alternative first-line therapy individual use first-line therapy 
Ticlopidine,ticlopidine effective inhibitor platelet aggregation prodrug metabolised active form block adp receptor involved gpiib/iiia receptor activation leading platelet aggregation ticlopidine marketed brand name ticlid indicated patient take aspirin aspirin worked prevent thrombotic stroke fda label includes black-box warning neutropenia aplastic anemia thrombotic thrombocytopenia purpura agranulocytosis necessary monitor patient wbc platelet taking ticlopidine ,used patient stroke stroke precursor take aspirin aspirin worked try prevent another thrombotic stroke 
Trospium,trospium antispasmodic agent used treat symptom overactive bladder condition cause bladder muscle contract uncontrollably l6208 overactive bladder lead increased urge urinate frequent urination sometimes loss control urination l6208 trospium manufactured _indevus pharmaceutical inc._ granted fda approval 2007 l6211 , treatment overactive bladder symptom urge urinary incontinence urgency urinary frequency detrusor instability frequency micturition 
Adapalene,acne vulgaris multifactorial disorder pilosebaceous unit involving increased sebum production inflammation hyperproliferation/hyperkeratinization follicular infundibulum also associated _cutibacterium acnes_ also known _propionibacterium acnes_ adapalene third-generation topical retinoid used treatment acne vulgaris a193518 adapalene similar efficacy superior safety profile compared tretinoin a193521 tazarotene efficacious adapalene designated pregnancy category x hence contraindicated pregnant woman a193518 adapalene also combined benzoyl peroxide bpo posse bactericidal property a193524 either adapalene alone adapalene bpo combination product commonly used treat mild-to-severe acne a193518 differin® produced galderma lab first granted fda approval may 31st 1996 0.1 adapalene topical solution differin later made available 0.1 gel cream lotion 0.3 gel product december 8th 2008 galderma lab gained fda approval epiduo® 0.1 adapalene 2.5 bpo combination gel l12873 ,adapalene indicated topical treatment acne vulgaris patient aged 12 l12873 
Midodrine, ethanolamine derivative adrenergic alpha agonist used vasoconstrictor agent treatment hypotension , treatment symptomatic orthostatic hypotension oh 
Remikiren,remikiren orally active high specificity renin inhibitor , treatment hypertension heart failure
Pantoprazole,pantoprazole first-generation proton pump inhibitor ppi used management gastroesophageal reflux disease gerd gastric protection prevent recurrence stomach ulcer gastric damage chronic use nsaid treatment pathological hypersecretory condition including zollinger-ellison ze syndrome also found quadruple regimen treatment _h pylori_ infection along antibiotic including amoxicillin clarithromycin metronidazole example a177271 f4498 efficacy considered similar medication within ppi class including omeprazole esomeprazole lansoprazole dexlansoprazole rabeprazole pantoprazole exerts stomach acid-suppressing effect preventing final step gastric acid production covalently binding sulfhydryl group cysteine found h+ k+ -atpase enzyme secretory surface gastric parietal cell effect lead inhibition basal stimulated gastric acid secretion irrespective stimulus binding pantoprazole h+ k+ -atpase enzyme irreversible new enzyme need expressed order resume acid secretion pantoprazole 's duration antisecretory effect persists longer 24 hour fda label due good safety profile several ppis available counter without prescription current use north america widespread long term use ppis pantoprazole associated possible adverse effect however including increased susceptibility bacterial infection including gastrointestinal _c difficile_ reduced absorption micronutrient including iron b12 increased risk developing hypomagnesemia hypocalcemia may contribute osteoporosis bone fracture later life a177571 ppis pantoprazole also shown inhibit activity dimethylarginine dimethylaminohydrolase ddah enzyme necessary cardiovascular health ddah inhibition cause consequent accumulation nitric oxide synthase inhibitor asymmetric dimethylarginie adma thought cause association ppis increased risk cardiovascular event patient unstable coronary syndrome a177577 a177580 pantoprazole dos slowly lowered tapered discontinuing rapid discontinuation ppis pantoprazole may cause rebound effect short term increase hypersecretion a177574 , pantoprazole injection treatment gastroesophageal reflux disease associated history erosive esophagitis pantoprazole injection indicated short-term treatment 7-10 day patient gastroesophageal reflux disease gerd history erosive esophagitis alternative oral medication patient unable continue taking pantoprazole delayed-release tablet _safety efficacy pantoprazole injection initial treatment patient gerd history erosive esophagitis demonstrated time_ fda label pathological hypersecretion associated zollinger-ellison syndrome pantoprazole injection indicated treatment pathological hypersecretory condition associated zollinger-ellison syndrome neoplastic condition fda label pantoprazole delayed-release oral suspension short-term treatment erosive esophagitis associated gastroesophageal reflux disease gerd indicated adult pediatric patient five year age short-term treatment 8 week healing symptomatic relief erosive esophagitis adult patient healed 8 week treatment additional 8-week course pantoprazole may considered safety treatment beyond 8 week pediatric patient determined f3202 maintenance healing erosive esophagitis indicated maintenance healing erosive esophagitis reduction relapse rate daytime nighttime heartburn symptom adult patient gerd f3202 pathological hypersecretory condition including zollinger-ellison syndrome indicated long-term treatment condition f3202 
Torasemide,torasemide high-ceiling loop diuretic a174463 structurally pyridine-sulfonylurea used antihypertensive agent a319 torasemide first approved clinical use fda 1993 l5257 ,torasemide indicated treatment edema associated congestive heart failure renal hepatic disease condition observed torasemide effective case kidney failure fda label well torasemide approved used antihypertensive agent either alone combination antihypertensive fda label 
Citalopram,citalopram belongs class antidepressant agent known selective _serotonin-reuptake inhibitors_ ssri widely used treat symptom depression chemical structure unrelated ssri tricyclic tetracyclic prescribed antidepressant fda label citalopram also known _celexa_ available tablet solution form fda label drug initially approved fda 1998 l5230 , treatment depression indicated fda label fda label off-label indication include limited treatment sexual dysfunction post-stroke behavioural change ethanol abuse obsessive-compulsive disorder ocd child diabetic neuropathy fda label a321 a322 a323 a324 a174406 a174409 a174412 
Eletriptan,eletriptan second generation triptan drug developed pfizer inc treatment migraine headache , acute treatment migraine without aura adult 
Bethanidine, guanidinium antihypertensive agent act blocking adrenergic transmission , treatment hypertension 
Moxifloxacin,moxifloxacin synthetic fluoroquinolone antibiotic agent bayer ag developed drug initially called bay 12-8039 marketed worldwide hydrochloride brand name avelox country also avalox oral treatment , treatment sinus lung infection sinusitis pneumonia secondary infection chronic bronchitis also treatment bacterial conjunctivitis pinkeye 
Oxyphenonium, quaternary ammonium anticholinergic agent peripheral side effect similar atropine used adjunct treatment gastric duodenal ulcer relieve visceral spasm drug also used form eye drop mydriatic effect pubchem , treatment visceral spasm
Nelfinavir,nelfinavir potent hiv-1 protease inhibitor used combination antiviral drug treatment hiv adult child nelfinavir inhibits hiv viral proteinase enzyme prevents cleavage gag-pol polyprotein resulting noninfectious immature viral particle l36485 ,used combination antiviral drug treatment hiv adult child l36485 
Isoetharine,isoetharine selective adrenergic beta-2 agonist used fast acting bronchodilator emphysema bronchitis asthma , treatment asthma wheezing chronic asthmatic bronchitis 
Glimepiride,first introduced 1995 glimepiride member second-generation sulfonylurea su drug class used management type 2 diabetes mellitus t2dm improve glycemic control type 2 diabetes metabolic disorder increasing prevalence worldwide characterized insulin resistance accordance progressive β cell failure long-term microvascular macrovascular complication lead co-morbidities mortality sulfonylurea one insulin secretagogues widely used management type 2 diabetes lower blood glucose level main effect sus thought effective residual pancreatic β-cells present a177715 work stimulating release insulin pancreatic beta cell also thought exert extra-pancreatic effect increasing insulin-mediated peripheral glucose uptake a177709 glimepiride work stimulating secretion insulin granule pancreatic islet beta cell blocking atp-sensitive potassium channel k sub atp /sub channel causing depolarization beta cell compared glipizide another second su drug glimepiride longer duration action sometimes classified third-generation su larger substitution second-generation sus a177703 compared sus glimepiride associated lower risk developing hypoglycemia weight gain clinical trial a177709 well fewer cardiovascular effect sus due minimal effect ischemic preconditioning cardiac myocytes a177703 effective reducing fasting plasma glucose postprandial glucose glycosylated hemoglobin level considered useful cost-effective treatment option managing type 2 diabetes mellitus a177703 glimepiride approved food drug administration fda united state 1995 treatment t2dm commonly marketed brand name amaryl oral tablet typically administered daily ,glimepiride indicated management type 2 diabetes adult adjunct diet exercise improve glycemic control monotherapy may also indicated use combination metformin insulin lower blood glucose patient type 2 diabetes whose high blood sugar level controlled diet exercise conjunction oral hypoglycemic drug used lower blood sugar level agent alone l10322 
Diflorasone,diflorasone topical corticosteroid used treat itching inflammation skin , relief inflammatory pruritic manifestation corticosteroid responsive dermatosis 
Indinavir, potent specific hiv protease inhibitor appears good oral bioavailability pubchem ,indinavir antiretroviral drug treatment hiv infection 
Gadodiamide,gadodiamide paramagnetic gadolinium-based contrast agent gbca used mr imaging procedure assist visualization blood vessel intravenously injected commonly marketed trade name omniscan , intravenous use mri visualize lesion abnormal vascularity thought cause abnormality blood-brain barrier brain intracranial lesion spine associated tissue 
Guanadrel,guanadrel antihypertensive agent postganglionic adrenergic blocking agent ,used treat control hypertension 
Lovastatin,lovastatin also known brand name product mevacor lipid-lowering drug fungal metabolite derived synthetically fermentation product _aspergillus terreus_ a174550 originally named mevinolin lovastatin belongs statin class medication used lower risk cardiovascular disease manage abnormal lipid level inhibiting endogenous production cholesterol liver a174553 specifically statin medication competitively inhibit enzyme hydroxymethylglutaryl-coenzyme hmg-coa reductase a181421 catalyzes conversion hmg-coa mevalonic acid third step sequence metabolic reaction involved production several compound involved lipid metabolism transport including cholesterol low-density lipoprotein ldl sometimes referred `` bad cholesterol '' low-density lipoprotein vldl prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd type 2 diabetes clear evidence benefit statin use coupled minimal side effect long term effect resulted class becoming one widely prescribed medication north america a181087 a181406 lovastatin drug statin class medication including atorvastatin pravastatin rosuvastatin fluvastatin simvastatin considered first-line option treatment dyslipidemia a181087 a181406 increasing use statin class drug largely due fact cardiovascular disease cvd includes heart attack atherosclerosis angina peripheral artery disease stroke become leading cause death high-income country major cause morbidity around world a181084 elevated cholesterol level particular elevated low-density lipoprotein ldl level important risk factor development cvd a181087 a181553 use statin target reduce ldl level shown number landmark study significantly reduce risk development cvd all-cause mortality a181090 a181093 a181096 a181427 a181475 a181538 statin considered cost-effective treatment option cvd due evidence reducing all-cause mortality including fatal non-fatal cvd well need surgical revascularization angioplasty following heart attack a181087 a181406 evidence shown even low-risk individual 10 risk major vascular event occurring within 5 year statin cause 20 -22 relative reduction major cardiovascular event heart attack stroke coronary revascularization coronary death every 1 mmol/l reduction ldl without significant side effect risk a181397 a181403 statin medication considered equally effective clinical standpoint rosuvastatin considered potent dos 10 40mg rosuvastatin per day found clinical study result 45.8 54.6 decrease ldl cholesterol level lovastatin found average decrease ldl-c 25-40 a174580 a181409 a181535 a181538 a1793 potency thought correlate tissue permeability lipophilic statin lovastatin thought enter endothelial cell passive diffusion opposed hydrophilic statin pravastatin rosuvastatin taken hepatocytes oatp1b1 organic anion transporter protein 1b1 -mediated transport a181424 a181460 despite difference potency several trial demonstrated minimal difference term clinical outcome statin a181538 a181427 ,lovastatin indicated reduce risk myocardial infarction unstable angina need coronary revascularization procedure individual without symptomatic cardiovascular disease average moderately elevated total-c ldl-c average hdl-c indicated intervention alternative individual presenting dyslipidemia risk developing atherosclerotic vascular disease administration agent accompanied implementation fat cholesterol-restricted diet f4661 therapy lipid-altering agent component multiple risk factor intervention individual significantly increased risk atherosclerotic vascular disease due hypercholesterolemia lovastatin indicated adjunct diet reduction elevated total-c ldl-c level patient primary hypercholesterolemia type iia iib2 response diet restricted saturated fat cholesterol nonpharmacological measure alone inadequate f4661 f4664 lovastatin also indicated slow progression coronary atherosclerosis patient coronary heart disease part treatment strategy lower total-c ldl-c target level f4661 lovastatin indicated adjunct diet reduce total-c ldl-c apolipoprotein b level adolescent boy girl heterozygous familial hypercholesterolemia hefh least one year post-menarche 10 17 year age hefh adequate trial diet therapy following finding present ldl-c remains greater 189 mg/dl ldl-c remains greater 160 mg/dl positive family history premature cardiovascular disease two cvd risk factor present adolescent patient administering lovastatin important rule presence secondary cause hypercholesterolemia lipid profile performed prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd statin-indicated condition include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl-c level a181087 a181406 
Enflurane,enflurane halogenated inhalational anesthetic initially approved fda 1972 since date withdrawn u market l13646 l13649 unlike inhalational anesthetic counterpart including isoflurane halothane enflurane known induce seizure activity addition known cause increased cardio depressant effect compared inhaled anesthetic a202022 ,enflurane may used induction maintenance general anesthesia also used induce analgesia vaginal delivery low concentration enflurane also used adjunct general anesthetic drug delivery cesarean section l13646 
Cefotiam,one cephalosporin broad spectrum activity gram-positive gram-negative microorganism , treatment severe infection caused susceptible bacteria 
Pregabalin,pregabalin structurally similar gamma-aminobutyric acid gaba inhibitory neurotransmitter a173995 may used manage neuropathic pain postherpetic neuralgia fibromyalgia among condition a187190 although per fda label mechanism action definitively defined evidence pregabalin exerts effect binding α2δ subunit voltage-dependent calcium channel a187190 l7066 pregabalin marketed pfizer trade name lyrica lyrica cr extended release l1006 l7066 may dependence liability misused risk appears highest patient current past substance use disorder a31161 ,pregabalin indicated management neuropathic pain associated diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain associated spinal cord injury adjunctive therapy treatment partial-onset seizure patient 1 month age older l7066 
Temazepam,temazepam like many similar related benzodiazepine act gamma-aminobutyric acid gaba modulator capable eliciting variety action including sedation hypnosis skeletal muscle relaxation anticonvulsant activity anxiolytic action a175207 a175210 f3718 f3721 although chemical synthesis temazepam established 1965 a175333 mainstream contemporary use medication occur 's legitimate use treatment insomnia accepted approved later particular temazepam saw regular prescription use civilian still employed u military sedative-hypnotic medication taken soldier pilot etc obtain necessary rest required medical recovery scheduled maneuver operation a175339 regardless temazepam become one frequently prescribed medication internationally see million prescription every year unfortunately however given frequent use inherent nature pharmacological effect temazepam like many benzodiazepine posse high potential misuse genuinely capable developing drug tolerance physical dependence addiction user ,temazepam specifically indicated short-term management insomnia fda label l5539 furthermore management generally predominantly associated symptomatic relief transient short-term insomnia characterized difficulty falling asleep frequent nocturnal awakening and/or early morning awakening f3718 particular official prescribing information temazepam typically specifies instruction issued dispensed prescription medication indicate specifically patient expected use therapy short period time usually 7-10 day general fda label f3718 subsequently treatment temazepam usually exceed 7 10 consecutive day prescribed quantity exceeding one-month supply f3718 regional prescribing information also note temazepam may used premedication prior minor surgery related procedure l5539 
Methyclothiazide, thiazide diuretic property similar hydrochlorothiazide martindale extra pharmacopoeia 30th ed p825 , use management hypertension either sole therapeutic agent enhance effect antihypertensive drug severe form hypertension also used adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy 
Aminosalicylic acid, antitubercular agent often administered association isoniazid sodium salt drug better tolerated free acid , treatment tuberculosis
Reboxetine,reboxetine antidepressant drug used treatment clinical depression panic disorder add/adhd mesylate i.e methanesulfonate salt sold tradenames including edronax norebox prolift solvex davedax vestra reboxetine two chiral center exists two enantiomer r r -reboxetine , treatment clinical depression 
Milrinone,heart failure multifactorial condition affect roughly 1-2 adult population often result long-term myocardial ischemia cardiomyopathy cardiac insult heart failure result inability heart perfuse peripheral tissue sufficient oxygen metabolite resulting complex systemic pathology heart failure underpinned numerous physiological change including alteration β-adrenergic signalling cyclic adenosine monophosphate camp production affect heart 's contractile function cardiac output a228323 milrinone second-generation bipyridine phosphodiesterase pde inhibitor created chemical modification amrinone a228333 pde-iii inhibitor milrinone result increased camp level improves cardiac function peripheral vasodilation acute decongested heart failure a228338 a11759 a228323 a228333 a228348 l31483 milrinone originally synthesized sterling winthrop research institute 1980s a228333 approved fda december 31 1987 marketed trademark primacor® sanofi-aventis u discontinued l31483 ,milrinone indicated short-term 48 hour le treatment patient acute decompensated heart failure milrinone administration occur together close monitoring using appropriate electrocardiographic equipment occur facility equipped immediate treatment potential cardiac event including ventricular arrhythmia l31483 
Pipobroman, antineoplastic agent act alkylation , treatment polycythaemia vera refractory chronic myeloid leukaemia 
Butabarbital,butabarbital butisol fast onset barbiturate short duration action compared barbiturate a201977 l13613 make butabarbital useful drug treating severe insomnia pre-operative anxiety a201977 l13613 butabarbital le commonly used recent year patient typically prescribed benzodiazepine a19735 short duration action give butabarbital high abuse potential comparable secobarbital a201977 a201980 butabarbital granted fda approval 5 june 1939 l13613 ,butabarbital indicated use sedative hypnotic l13613 butabarbital used treat insomnia longer 2 week l13613 
Nevirapine, potent non-nucleoside reverse transcriptase inhibitor nnrti used combination nucleoside analogue treatment human immunodeficiency virus type 1 hiv-1 infection aid structurally nevirapine belongs dipyridodiazepinone chemical class , use combination antiretroviral drug ongoing treatment hiv-1 infection 
Oxiconazole,oxiconazole antifungal agent commonly found topical formulation marketed brand name oxistat oxistat used treatment various skin infection athlete 's foot jock itch ringworm , treatment dermal fungal infection 
Alclometasone,alclometasone synthetic glucocorticoid steroid topical use dermatology anti-inflammatory antipruritic antiallergic antiproliferative vasoconstrictive agent , relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Butalbital,butalbital 5-allyl-5-isobutylbarbituric acid derivative barbituric acid hydrogen position 5 substituted allyl group isobutyl group short-to-intermediate acting member barbiturate exhibit muscle-relaxing anti-anxiety property produce central nervous system cns depression range mild sedation general anesthesia a177754 butalbital low degree selectivity narrow therapeutic index a177754 typically indicated manage tension muscle contraction headache butalbital often combined one therapeutic agent acetylsalicylic acid acetaminophen aspirin caffeine clinical trial evaluate clinical efficacy butalbital migraine a177754 thus indicated condition barbiturate butalbital carry risk abuse misuse potential intoxication hangover tolerance dependence overdosage possibly leading death l10370 butalbital‐containing analgesic also produce drug‐induced headache addition tolerance dependence due risk use butalbital-containing combination product typically limited use case medication deemed ineffective usage advised carefully monitored a177754 ,indicated management symptom complex tension muscle contraction headache non-opioid analgesic alternative treatment inadequate various combination acetaminophen aspirin caffeine codeine l10370 
Cladribine, antineoplastic agent used treatment lymphoproliferative disease including hairy-cell leukemia , treatment active hairy cell leukemia leukemic reticuloendotheliosis defined clinically significant anemia neutropenia thrombocytopenia disease-related symptom also used alternative agent treatment chronic lymphocytic leukemia cll low-grade non-hodgkin 's lymphoma cutaneous t-cell lymphoma 
Ranolazine,chronic angina common cardiovascular condition affecting million worldwide cause significant disability interfering daily activity a189234 ranolazine well-tolerated piperazine derivative used management condition offering relief uncomfortable debilitating symptom l3580 mechanism action different drug used treat condition ranolazine promising anti-anginal therapy originally approved fda 2006 l5440 ,ranolazine indicated treatment chronic angina used alone conjunction nitrate beta-blockers angiotensin receptor blocker anti-platelet drug calcium channel blocker lipid-lowering drug ace inhibitor l3580 ranolazine also used off-label treatment certain arrhythmia including ventricular tachycardia however use strongly supported scientific evidence a174940 ranolazine also studied treatment acute coronary syndrome microvascular coronary dysfunction arrhythmia glycemic control yet approved indication a174898 l3580 
Mesalazine, anti-inflammatory agent structurally related salicylate non-steroidal anti-inflammatory drug like acetylsalicylic acid active inflammatory bowel disease a174022 although demonstrably effective treating maintaining remission ulcerative colitis mesalazine historically faced number issue regarding lack stability pharmaceutical agent a174019 throughout late seventy eighty important research initiative developed stable mesalazine formulation like eudragit-s coating asacol brand mesalazine pentasa brand 's encapsulation mesalazine within microgranules a174019 present day contemporary research regarding novel method stabilize mesalazine continues interest agent 's capacity decrease inflammatory activity subsequently potentially reduce risk colorectal cancer condition like ulcerative colitis maintained a174019 a174022 ,mesalazine indicated treatment mildly moderately active ulcerative colitis adult patient 5 year older. l36280 l36275 mesalazine also indicated maintenance remission ulcerative colitis adult maintenance remission crohn 's ileocolitis l44196 l5101 
Benzatropine,benztropine chemical formula 3alpha-diphenylmethoxytropane tropane-based dopamine inhibitor used symptomatic treatment parkinson 's disease combination molecule tropane ring similar cocaine diphenyl ether dialkylpiperazines determined dopamine uptake inhibitor since 1970 generation structure-activity relationship proved benztropine derivative presence chlorine substituent para position one phenyl ring produce increased potency dopamine uptake inhibition well decreased inhibition serotonin norepinephrine a37914 benztropine developed usl pharma officially approved fda 1996 l5500 ,benztropine indicated used adjunct therapy form parkinsonism also used control extrapyramidal disorder due neuroleptic drug t203 extrapyramidal symptom defined drug-induced disorder include symptom dystonia akathisia parkinsonism bradykinesia tremor dyskinesia a175120 parkinsonism general term refers group neurological disorder produce symptom similar parkinson 's disease tremor slow movement stiffness parkinsonism includes large number disorder clearly defined l5509 
Ziprasidone,disorder schizophrenia bipolar disorder significantly impair mood cognition behavior a190525 mental illness often accompanied comorbidities depression substance abuse significantly impact quality life patient caregiver a190525 luckily several treatment option psychotic disorder introduced market since realization chlorpromazine 's antipsychotic property 1952 a190525 second generation antipsychotic commonly referred atypical antipsychotic include clozapine quetiapine olanzapine aripiprazole ziprasidone among others generally thought efficacious first generation antipsychotic differ adverse effect profile a190525 a190534 first generation antipsychotic associated extrapyramidal adverse effect atypical antipsychotic linked weight gain impaired glucose tolerance metabolic syndrome a190534 a190537 ziprasidone used treat schizophrenia bipolar disorder a180748 effectively reduce rate time relapse schizophrenia used treat manic episode bipolar disorder although mechanism action unknown a180748 although ziprasidone classified atypical antipsychotic appears lower incidence metabolic adverse effect compared medication class a190525 , oral form ziprasidone approved treatment schizophrenia monotherapy acute treatment manic mixed episode related bipolar disorder adjunctive therapy lithium valproate maintenance treatment bipolar disorder l7342 injectable formulation approved treatment acute agitation schizophrenia l7342 
Methysergide, ergot derivative congener lysergic acid diethylamide antagonizes effect serotonin blood vessel gastrointestinal smooth muscle property ergot alkaloid methysergide used prophylactically migraine vascular headache antagonize serotonin carcinoid syndrome , treatment vascular headache
Cabergoline,cabergoline ergot derivative long-acting dopamine agonist prolactin inhibitor used treat hyperprolactinemic disorder parkinsonian syndrome cabergoline posse potent agonist activity dopamine d2 receptor , treatment hyperprolactinemic disorder either idiopathic due prolactinoma prolactin-secreting adenoma may also used manage symptom parkinsonian syndrome monotherapy initial symptomatic management adjunct levodopa therapy advanced stage disease 
Idoxuridine, analog deoxyuridine inhibits viral dna synthesis drug used antiviral agent , use keratoconjunctivitis keratitis caused herpes simplex virus 
Dapsone, sulfone active wide range bacteria mainly employed action mycobacterium leprae mechanism action probably similar sulfonamide involves inhibition folic acid synthesis susceptible organism also used pyrimethamine treatment malaria martindale extra pharmacopoeia 30th ed p157-8 , treatment management leprosy dermatitis herpetiformis 
Terconazole,terconazole anti-fungal drug mainly used treat vaginal yeast infection vaginal candidiasis classified _triazole ketal derivative_ a178096 terconazole initially approved fda 1987 fda label drug available cream suppository form demonstrated high level safety efficacy tolerability clinical trial a178093 due existence 2 stereocentres 4 possible stereoisomers terconazole , treatment candidiasis yeast-like fungal infection vulva vagina 
Phenytoin,phenytoin classified hydantoin derivative despite narrow therapeutic index one commonly used anticonvulsant a33595 a188832 a189219 since 's introduction 80 year ago phenytoin established effective anti-epileptic also investigated several indication bipolar disorder retina protection wound healing a188826 a188832 clinician advised initiate therapeutic drug monitoring patient require phenytoin since even small deviation recommended therapeutic range lead suboptimal treatment adverse effect a189219 a35884 parenteral oral formulation phenytoin available market a189219 ,phenytoin indicated treat grand mal seizure complex partial seizure prevent treat seizure following neurosurgery l9362 injectable phenytoin fosphenytoin phosphate ester prodrug formulation phenytoin a188571 indicated treat tonic-clonic status epilepticus prevention treatment seizure occurring neurosurgery l10740 
Medrysone,medrysone corticosteroid used ophthalmology , treatment allergic conjunctivitis vernal conjunctivitis episcleritis epinephrine sensitivity 
Doxycycline,doxycycline broad-spectrum antibiotic synthetically derived oxytetracycline l42880 second-generation tetracycline first discovered 1967 a19429 second-generation tetracycline exhibit lesser toxicity first-generation tetracycline a174034 doxycycline used treat wide variety gram-positive gram-negative bacterial infection also used treat acne malaria a251730 ,doxycycline indicated treatment various infection gram-positive gram-negative bacteria aerobe anaerobe well type bacteria including early lyme disease evidenced erythema migraine due _borrelia burgdorferi_ adult pediatric patient 8 year age older weighing 45 kg l42875 rickettsial infection l42870 rocky mountain spotted fever typhus fever typhus group q fever rickettsialpox tick fever l42880 sexually transmitted infection l42870 respiratory tract infection l42870 caused _mycoplasma pneumoniae_ _haemophilus influenzae_ l42880 specific bacterial infection l42870 indicative bacteriologic testing include infection caused _escherichia coli_ _enterobacter aerogenes_ _shigella_ specie _acinetobacter_ specie _klebsiella_ specie l42880 ophthalmic infection l42870 inclusion conjunctivitis caused _chlamydia trachomatis_ l42880 anthrax including inhalational anthrax post-exposure l42870 alternative treatment selected infection penicillin contraindicated l42870 adjunctive therapy acute intestinal amebiasis severe acne l42870 l42880 lymphogranuloma venereum caused _chlamydia trachomatis_ l42880 psittacosis ornithosis caused _chlamydophila psittaci_ l42880 trachoma caused _chlamydia trachomatis_ although infectious agent always eliminated judged immunofluorescence l42880 uncomplicated urethral endocervical rectal infection adult caused _chlamydia trachomatis_ l42880 nongonococcal urethritis caused _ureaplasma urealyticum_ l42880 relapsing fever due _borrelia recurrentis_ l42880 prophylaxis malaria due _plasmodium falciparum_ short-term traveler 4 month area chloroquine and/or pyrimethamine-sulfadoxine resistant strain l42870 l42880 also used treat infection caused following gram-negative microorganism chancroid caused _haemophilus ducreyi_ l42880 plague due _yersinia pestis_ l42880 tularemia due _francisella tularensis_ l42880 cholera caused _vibrio cholerae_ l42880 campylobacter fetus infection caused _campylobacter fetus_ l42880 brucellosis due _brucella_ specie conjunction streptomycin l42880 bartonellosis due _bartonella bacilliformis_ l42880 granuloma inguinale caused _klebsiella granulomatis_ l42880 
Diethylstilbestrol, synthetic nonsteroidal estrogen used treatment menopausal postmenopausal disorder also used formerly growth promoter animal according fourth annual report carcinogen ntp 85-002 1985 diethylstilbestrol listed known carcinogen merck 11th ed fda withdrew approval use oral parenteral drug product containing 25 milligram diethylstilbestrol per unit dose l43942 ,used treatment prostate cancer previously used prevention miscarriage premature delivery pregnant woman prone miscarriage premature delivery 
Lymecycline,lymecycline broad-spectrum second-generation tetracycline antibiotic used treatment acne susceptible bacterial infection l13880 l13883 proven cost-effective alternative treatment minocycline comparable safety efficacy a203255 lymecycline initially discovered 1961 marketed galderma used uk well new zealand addition country lymecycline marketed usa however equivalent drug available minocycline tetracycline a19429 l13880 ,lymecycline used treatment acne addition susceptible infection propionibacterium often cause acne l13880 infection treated lymecycline include upper respiratory tract infection urinary tract infection bronchitis chlamydial infection rickettsial infection l13883 
Clotrimazole, drug broad spectrum antimycotic antifungal agent clotrimazole 's antimycotic property discovered late 1960s a174094 clotrimazole fall _imidazole_ category _azole_ antifungal possessing broad-spectrum antimycotic activity a174094 available various preparation including cream pessary troche formulation slowly dissolving tablet well antifungal activity clotrimazole become drug interest treating several disease sickle cell disease malaria cancer a174094 minimal side effect profile drug uncomplicated metabolic profile led gain widespread acceptance treatment mycotic outbreak vaginal yeast infection well athlete 's foot a174097 , topical preparation clotrimazole topical cream indicated topical treatment following dermal infection f3088 f3121 tinea pedis tinea cruris tinea corporis due _trichophyton rubrum_ _trichophyton mentagrophytes_ _epidermophyton floccosum_ candidiasis due _candida albicans_ tinea versicolor due _malassezia furfur_ diaper rash infected _candida albicans_ preparation clotrimazole may combined betamethasone dipropionate corticosteroid f3121 oral preparation oral troche preparation indicated local treatment oropharyngeal candidiasis fda label also indicated prophylactic drug reduce incidence oropharyngeal candidiasis patient immunocompromised condition chemotherapy radiotherapy steroid therapy utilized treatment leukemia solid tumor renal transplantation fda label troche preparation indicated treatment systemic mycoses fda label 
Calcium acetate, chemical compound calcium acetate calcium salt acetic acid commonly referred acetate lime anhydrous form hygroscopic therefore monohydrate common form ,calcium acetate one number calcium salt used treat hyperphosphatemia much phosphate blood patient kidney disease 
Sulfanilamide,sulfanilamide molecule containing sulfonamide functional group attached aniline , treatment vulvovaginitis caused candida albicans /i 
Cycloserine,antibiotic substance produced streptomyces garyphalus ,used combination 5 drug treatment mycobacterium avium complex mac also used treat tuberculosis tb 
Anagrelide,anagrelide platelet-reducing agent used lower dangerously elevated platelet level i.e treat thrombocythemia patient myeloproliferative neoplasm l14153 oral imidazoquinazoline first approved use u 1997 a214274 appears carry better response rate thrombocythemia treatment e.g busulfan hydroxyurea may better tolerated a214274 ,anagrelide indicated treatment thrombocythemia secondary malignant neoplasm reduce platelet count associated risk thrombosis also beneficial amelioration thrombocythemia symptom including thrombo-hemorrhagic event l14153 
Carmustine, cell-cycle phase nonspecific alkylating antineoplastic agent used treatment brain tumor various malignant neoplasm martindale extra pharmacopoeia 30th ed p462 substance may reasonably anticipated carcinogen according fourth annual report carcinogen ntp 85-002 1985 merck index 11th ed , treatment brain tumor multiple myeloma hodgkin 's disease non-hodgkin 's lymphoma 
Sulfisoxazole, short-acting sulfonamide antibacterial activity wide range gram- negative gram-positive organism , treatment severe repeated long-lasting urinary tract infection meningococcal meningitis acute otitis medium trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria bacterial infection 
Metoprolol,metoprolol selective beta-1 blocker commonly employed succinate tartrate derivative depending formulation designed immediate release extended release a175159 l5530 possibility generation formulation come lower systemic bioavailability succinate derivative t274 date one preferred beta-blockers general clinical guideline widely prescribed netherlands new zealand u a175162 metoprolol developed since 1969 u pharmaceutical holding fda approved 1978 l5527 ,metoprolol indicated treatment angina heart failure myocardial infarction atrial fibrillation atrial flutter hypertension a175141 off-label us metoprolol include supraventricular tachycardia thyroid storm a175141 indication metoprolol part cardiovascular disease condition correspond number disease involve function heart blood vessel underlying cause condition variable due genetic disposition lifestyle decision smoking obesity diet lack exercise comorbidity condition diabetes cardiovascular disease leading cause death global scale l5533 
Crotamiton,crotamiton scabicidal antipruritic agent available cream lotion topical use colorless slightly yellowish oil faint amine-like odor miscible alcohol methanol , eradication scabies sarcoptes scabiei /i symptomatic treatment pruritic skin 
Dicoumarol,dicoumarol oral anticoagulant agent work interfering metabolism vitamin k. addition clinical use also used biochemical experiment inhibitor reductase , decreasing blood clotting often used along heparin treatment deep vein thrombosis 
Cefmenoxime,cefmenoxime novel broad-spectrum third-generation cephalosporin antibiotic typically used treatment female gynecologic obstetric infection reported exhibit high activity wide variety gram-positive gram-negative bacteria ,used treat female gynecologic obstetric infection caused susceptible aerobic including gonococcus anaerobic bacteria 
Ropinirole,ropinirole also known _requip_ non-ergoline dopamine agonist used parkinson 's disease restless leg syndrome fda label a174547 manufactured glaxosmithkline pharmaceutical ropinirole initially approved 1997 fda fda label management parkinson 's disease 2005 first drug approved u management primary moderate severe restless leg syndrome a174547 2008 extended-release capsule ropinirole approved allowing le frequent dosing therefore increased compliance offering similar side effect profile efficacy previous formulation ropinirole a35711 , treatment sign symptom parkinson 's disease treatment primary moderate-severe restless leg syndrome fda label 
Chlorotrianisene, powerful synthetic non-steroidal estrogen pubchem ,used treat symptom menopause deficiency ovary function including underdevelopment female sexual characteristic type infertility rare case prostate cancer chlorotrianisene may also used prevent breast engorgement following childbirth 
Isradipine,isradipine belongs dihydropyridine dhp class calcium channel blocker ccbs widely used class ccbs structurally related felodipine nifedipine nimodipine potent calcium-channel blocking agent dhp class isradipine bind calcium channel high affinity specificity inhibits calcium flux cardiac arterial smooth muscle cell exhibit greater selectivity towards arterial smooth muscle cell owing alternative splicing alpha-1 subunit channel increased prevalence inactive channel smooth muscle cell isradipine may used treat mild moderate essential hypertension , management mild moderate essential hypertension may used alone concurrently thiazide-type diuretic 
Diatrizoate, commonly used x-ray contrast medium diatrizoate meglumine diatrizoate sodium used gastrointestinal study angiography urography ,used alone combination wide variety diagnostic imaging method including angiography urography cholangiography computed tomography hysterosalpingography retrograde pyelography used imaging gastrointestinal tract patient allergic barium 
Betazole, histamine h2 agonist used clinically test gastric secretory function , use clinically test gastric secretory function 
Topiramate,topiramate anti-epileptic drug used manage seizure prevent migraine a175249 initially approved fda 1996 2004 topiramate approved prevention migraine adult a188309 l10544 l43478 since 2012 extended-release formulation approved combination phentermine chronic weight management therapy adult l10550 characteristic distinguish topiramate antiepileptic drug monosaccharide chemical structure containing sulfamate 40 mass accounted oxygen a175249 interestingly topiramate discovered chance attempt made formulate novel antidiabetic drug a188330 ,topiramate indicated following condition 1 monotherapy partial onset primary generalized tonic-clonic seizure patient 2 year age 2 adjunctive therapy partial onset seizure primary generalized tonic-clonic seizure adult pediatric patient 2 year old 3 adjunctive therapy seizure associated lennox-gastaut syndrome patient 2 year age 4 prophylaxis migraine child 12 year age older adult l10544 topiramate also used off-label adjunct therapy weight management l10550 mood disorder a188312 
Cefmetazole, semisynthetic cephamycin antibiotic broad spectrum activity gram-positive gram-negative microorganism high rate efficacy many type infection date severe side effect noted , treatment infection caused susceptible organism 
Olmesartan,olmesartan belongs angiotensin ii receptor blocker arb family drug also includes telmisartan candesartan losartan valsartan irbesartan arb selectively bind angiotensin receptor 1 at1 prevent protein angiotensin ii binding exerting hypertensive effect include vasoconstriction stimulation synthesis aldosterone adh cardiac stimulation renal reabsorption sodium among others overall olmesartan 's physiologic effect lead reduced blood pressure lower aldosterone level reduced cardiac activity increased excretion sodium olmesartan also affect renin-angiotensin aldosterone system raas play important role hemostasis regulation kidney vascular cardiac function pharmacological blockade raas via at1 receptor blockade inhibits negative regulatory feedback within raas contributing factor pathogenesis progression cardiovascular disease heart failure renal disease particular heart failure associated chronic activation raas leading inappropriate fluid retention vasoconstriction ultimately decline left ventricular function arb shown protective effect heart improving cardiac function reducing afterload increasing cardiac output preventing ventricular hypertrophy remodelling a174154 comparison angiotensin-converting enzyme inhibitor acei class medication includes drug ramipril lisinopril perindopril inhibit conversion angiotensin angiotensin ii inhibition ace enzyme however prevent formation angiotensin ii within body angiotensin ii receptor blocker arb family drug unique block angiotensin ii activity regardless synthesized olmesartan commonly used management hypertension type 2 diabetes-associated nephropathy particularly patient unable tolerate ace inhibitor arb olmesartan shown number large-scale clinical outcome trial improve cardiovascular outcome including reducing risk myocardial infarction stroke progression heart failure hospitalization a174124 a178153 a173869 a185324 a185327 a185333 a185342 a185345 like arb olmesartan blockade raas slows progression diabetic nephropathy due renoprotective effect a185906 a185909 a185912 orally available olmesartan produced prodrug olmesartan medoxomil rapidly converted _in vivo_ pharmacologically active olmesartan a175330 developed daiichi sankyo pharmaceutical approved 2002 a175345 l12882 ,olmesartan indicated treatment hypertension either alone combination antihypertensive agent f4709 f4712 a173869 olmesartan also used off-label management type 2 diabetes-associated nephropathy heart failure post-myocardial infarction particularly patient unable tolerate ace inhibitor a178153 a185912 a185915 arb olmesartan shown number large-scale clinical outcome trial improve cardiovascular outcome including reducing risk myocardial infarction stroke progression heart failure hospitalization a174124 a178153 a173869 a185324 a185327 a185333 a185342 a185345 like arb olmesartan blockade raas slows progression diabetic nephropathy due renoprotective effect a185906 a185909 a185912 
Amsacrine,aminoacridine derivative potent intercalating antineoplastic agent effective treatment acute leukemia malignant lymphoma poor activity treatment solid tumor frequently used combination antineoplastic agent chemotherapy protocol produce consistent acceptable myelosuppression cardiotoxic effect , treatment acute myeloid leukaemia 
Theophylline, methylxanthine derivative tea diuretic smooth muscle relaxant bronchial dilation cardiac central nervous system stimulant activity mechanistically theophylline act phosphodiesterase inhibitor adenosine receptor blocker histone deacetylase activator theophylline marketed several brand name uniphyl theochron indicated mainly asthma bronchospasm copd , treatment symptom reversible airflow obstruction associated chronic asthma chronic lung disease emphysema chronic bronchitis 
Argatroban,argatroban direct selective thrombin inhibitor american college cardiologist acc recommend using bivalirudin argatroban patient risk heparin induced thrombocytopenia hit undergoing percutaneous coronary intervention argatroban non-heparin anticoagulant shown normalize platelet count patient hit prevent formation thrombus parental anticoagulant must stopped baseline activated partial thromboplastin time must obtained prior administering argatroban ,argatroban indicated prevention treatment thrombosis caused heparin-induced thrombocytopenia hit also indicated use patient risk hit undergoing percutaneous coronary intervention 
Liothyronine,liothyronine thyroidal hormone t3 normally produced thyroid gland ratio 4:1 compared t4 t3 liothyronine active form thyroxine composed basic chemical structure tyrosine bound iodine t457 exogenous liothyronine product developed king pharmaceutical fda approved 1956 l5578 ,liothyronine officially approved following indication replacement therapy primary thyroidal secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism adjunct therapy surgery radioiodine management thyroid cancer diagnostic agent suppression test mild hyperthyroidism thyroid gland autonomy fda label general term exogenous liothyronine used replace insufficient hormonal production restore t3 plasma level t457 lack liothyronine presented pale puffy face coarse brittle hair dry skin croaky voice constipation well irregular period drowsiness lethargy t457 liothyronine never used suppression benign nodule nontoxic diffuse goiter iodine-sufficient patient treatment hyperthyroidism recovery phase subacute thyroiditis fda label 
Disopyramide, class anti-arrhythmic agent one interferes directly depolarization cardiac membrane thus serf membrane-stabilizing agent depressant action heart similar guanidine also posse anticholinergic local anesthetic property , treatment documented ventricular arrhythmia sustained ventricular tachycardia ventricular pre-excitation cardiac dysrhythmias class ia antiarrhythmic drug 
Lidocaine,ever since discovery availability sale use late 1940s lidocaine become exceptionally commonly used medication t583 particular lidocaine 's principal mode action acting local anesthetic numbs sensation tissue mean agent indicated facilitating local anesthesia large variety surgical procedure f4349 l5930 l5948 ultimately elicits numbing activity blocking sodium channel neuron local tissue medication applied transiently incapable signaling brain regarding sensation f4349 l5930 l5948 however block decrease muscle contractile resulting effect like vasodilation hypotension irregular heart rate among others f4349 l5930 l5948 result lidocaine also considered class ib anti-arrhythmic agent l5930 l5948 f4468 nevertheless lidocaine 's local anesthetic action see use many medical situation circumstance may benefit action including treatment premature ejaculation a177625 regardless lidocaine currently available relatively non-expensive generic medication written million prescription internationally yearly basis even included world health organization 's list essential medicine l6055 ,lidocaine anesthetic amide group indicated production local regional anesthesia infiltration technique percutaneous injection intravenous regional anesthesia peripheral nerve block technique brachial plexus intercostal central neural technique lumbar caudal epidural block f4349 l5930 
Pamidronic acid,pamidronic acid second generation nitrogen containing bisphosphonate similar neridronic acid alendronic acid a203111 pamidronic acid first described literature 1977 a203267 second generation bisphosphonates le common third generation bisphosphonates ibandronic acid zoledronic acid minodronic acid risedronic acid becoming popular a203111 pamidronic acid granted fda approval 31 october 1991 l13835 ,pamidronate indicated treat moderate severe hypercalcemia malignancy moderate severe paget 's disease bone osteolytic bone metastasis breast cancer osteolytic lesion multiple myeloma l13838 
Clemastine, ethanolamine-derivative first generation histamine h1 antagonist used hay fever rhinitis allergic skin condition pruritus cause drowsiness , relief symptom associated allergic rhinitis sneezing rhinorrhea pruritus acrimation also management mild uncomplicated allergic skin manifestation urticaria angioedema used self-medication temporary relief symptom associated common cold 
Acarbose,acarbose complex oligosaccharide act inhibitor several enzyme responsible breakdown complex carbohydrate intestine inhibits pancreatic alpha-amylase membrane-bound alpha-glucosidases including intestinal glucoamylase sucrase maltase isomaltase responsible metabolism complex starch oligo- tri- disaccharide absorbable simple sugar l31633 a37868 inhibiting activity enzyme acarbose limit absorption dietary carbohydrate subsequent postprandial increase blood glucose insulin level acarbose therefore used conjunction diet exercise pharmacotherapies management blood sugar level patient type 2 diabetes l31628 l31633 acarbose one two approved alpha-glucosidase inhibitor miglitol receiving first fda approval 1995 brand name precose since discontinued l31668 class antidiabetic therapy widely used due relatively modest impact a1c requirement thrice-daily dosing potential significant gastrointestinal adverse effect l31668 ,acarbose indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus l31628 
Venlafaxine,venlafaxine antidepressant serotonin norepinephrine reuptake inhibitor snri active metabolite desvenlafaxine work blocking reuptake serotonin norepinephrine key neurotransmitter mood regulation venlafaxine officially approved treat major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder panic disorder adult l43030 immediate formulation drug marketed effexor first approved fda 1993 extended-release formulation effexor xr later introduced 1997 a252065 venlafaxine used first-line treatment mdd gad social anxiety disorder panic disorder canada many year also considered second-line treatment obsessive-compulsive disorder ocd a177226 a177235 venlafaxine also investigated off-label us prophylaxis migraine headache a413 a177229 reduction vasomotor symptom associated menopause a177238 management neuropathic pain although minimal evidence efficacy condition a177232 ,venlafaxine indicated management major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder sad panic disorder l43030 
Conjugated estrogens, conjugated estrogen noncrystalline mixture purified female sex hormone obtained either isolation urine pregnant mare synthetic generation vegetal material product later conjugated natrium sulfate ester bond order make water soluble l5605 t475 conjugated estrogen product contains mix estrogen 50 represented estrone sulfate followed 25 equilin sulfate 15 17-alpha-dehydroequilenin sulfate 3 equilenin sulfate 5 17-alpha 17-beta-dihydroequilenin sulfate 2 17-alpha-estradiolsulfate 3 17-beta-estradiolsulfate also present large number unidentified molecule weak estrogenic activity well non-human molecule obtained pregnant mare urine t475 conjugated estrogen mixture approved marketing u 1942 based efficacy certain condition however 1986 official clinical trial performed product determined effective treatment osteoporosis t484 currently approved product conjugated estrogen developed wyeth ayerst fda approved 2003 l5608 , conjugated estrogen indicated several different condition including treatment moderate severe vasomotor symptom due menopause treatment moderate severe symptom vulvar vaginal atrophy due menopause treatment hypoestrogenism due hypogonadism castration primary ovarian failure palliative treatment breast cancer appropriately selected patient metastatic disease palliative treatment androgen-dependent carcinoma prostate preventive therapy postmenopausal osteoporosis a38238 
Travoprost,travoprost ophthalmic solution topical medication used controlling progression glaucoma ocular hypertension reducing intraocular pressure fda label synthetic prostaglandin f2alpha analog fda label well-received therapeutic agent demonstrated efficacy safety travoprost currently approved u fda first-line treatment lowering intraocular pressure patient open-angle glaucoma ocular hypotension l5155 furthermore approval also solidifies medication first prostaglandin analog approved fda first-line treatment glaucoma patient contain preservative benzalkonium chloride l5155 moreover travoprost also currently approved eu decrease elevated intraocular pressure paediatric patient aged 2 month 18 year ocular hypertension paediatric glaucoma l5146 l5152 ,travoprost ophthalmic solution indicated reduction elevated intraocular pressure patient open-angle glaucoma ocular hypertension f3061 f3064 l5146 travoprost also currently indicated decrease elevated intraocular pressure paediatric patient aged 2 month 18 year ocular hypertension paediatric glaucoma l5146 
Amcinonide,amcinonide corticosteroid , relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Atomoxetine,atomoxetine selective norepinephrine ne reuptake inhibitor used treatment attention deficit hyperactivity disorder adhd also known marketed product strattera atomoxetine used treatment modality psychological educational cognitive behaviour therapy etc improve developmentally inappropriate symptom associated adhd including distractibility short attention span hyperactivity emotional lability impulsivity although underlying pathophysiology cause adhd remains unclear evidence suggests dysregulation noradrenergic dopaminergic pathway play critical role suboptimal executive functioning within prefrontal region brain involved attention memory a178090 atomoxetine shown specifically increase na da within prefrontal cortex nucleus accumbens na striatum a18262 beneficial treatment adhd da activation subcortical na striatum associated many stimulant-associated side effect increase abuse potential limiting factor associated use stimulant medication db00422 db01576 db01255 a18262 use non-stimulant medication atomoxetine therefore thought offer clinical advantage use traditional medication management adhd recently positron emission tomography pet imaging study rhesus monkey shown atomoxetine also bind serotonin transporter sert a178111 block n-methyl-d-aspartate nmda receptor a18263 indicating role glutamatergic system pathophysiology adhd long-acting formulation psychostimulants db00422 db01576 db01255 typically considered effective first-line treatment adhd adult child recommended caddra canadian adhd resource alliance l6037 however stimulant medication limited dose-related side effect concern abuse many contain blackbox warning stating cns stimulant including methylphenidate-containing product amphetamine high potential abuse dependence particular increased dopamine key area caused stimulant medication associated reinforcing addictive property even amplifies potency reinforcing effect drug abuse amphetamine making adhd sufferer susceptible addictive effect a177556 concern abuse potential spurred research medication fewer effect da use non-stimulant adhd medication including atomoxetine db00745 db01018 non-stimulant norepinephrine/dopamine reuptake inhibitor db01156 commonly used treatment depression smoking cessation also shown effective treatment adhd a178099 ,atomoxetine indicated treatment attention deficit hyperactivity disorder adhd child adult 
Bleomycin, complex related glycopeptide antibiotic streptomyces verticillus /i consisting bleomycin a2 b2 b2 ca 9060-10-0 inhibits dna metabolism used antineoplastic especially solid tumor bleomycin a2 used representative structure bleomycin , palliative treatment management malignant neoplasm trachea bronchus lung squamous cell carcinoma lymphoma 
Chlorambucil, nitrogen mustard alkylating agent used antineoplastic agent treatment various malignant nonmalignant disease although le toxic nitrogen mustard listed known carcinogen fourth annual report carcinogen ntp 85-002 1985 merck index 11th ed , treatment chronic lymphatic lymphocytic leukemia childhood minimal-change nephrotic syndrome malignant lymphoma including lymphosarcoma giant follicular lymphoma hodgkin 's disease non-hodgkin 's lymphoma waldenström ’ macroglobulinemia 
Etomidate,imidazole derivative anesthetic hypnotic little effect blood gas ventilation cardiovascular system proposed induction anesthetic ,used induction general anesthesia 
Raltitrexed,raltitrexed brand name tomudex reg chemotherapy drug manufactured astrazeneca company antimetabolite used chemotherapy inhibitor thymidylate synthase , treatment malignant neoplasm colon rectum
Etonogestrel,etonogestrel molecule 3-ketodesogestrel 19-nortestosterone synthetic biologically active metabolite progestin desogestrel a37184 first product including etonogestrel developed merck subsidiary organon fda approved 2001 l5692 ,etonogestrel administered subdermal implant long-acting reversible contraception known effective postpartum insertion including breastfeeding woman a175990 etonogestrel part long-acting contraceptive implant prevent pregnancy implant 's effect remain 5 year l5698 
Morphine,morphine main alkaloid opium first obtained poppy seed 1805 a176035 potent analgesic though use limited due tolerance withdrawal risk abuse a176050 morphine still routinely used today though number semi-synthetic opioids varying strength codeine fentanyl methadone hydrocodone hydromorphone meperidine oxycodone morphine granted fda approval 1941 l12114 ,morphine used management chronic moderate severe pain a176050 opiods including morphine effective short term management pain patient taking opioids long term may need monitored development physical dependence addiction disorder drug abuse l5728 
Ropivacaine,ropivacaine aminoamide local anesthetic drug marketed astrazeneca trade name naropin exists racemate s- r-enantiomers although marketed form supplied purified s-enantiomer l42140 ,ropivacaine indicated adult patient induction regional local anesthesia surgery acute pain management l42140 
Bupivacaine,bupivacaine widely used local anesthetic agent , implant bupivacaine indicated adult placement surgical site produce postsurgical analgesia 24 hour following open inguinal hernia repair l41270 bupivacaine liposome suspension indicated patient aged 6 year older single-dose infiltration produce postsurgical local analgesia adult also indicated interscalene brachial plexus nerve block produce postsurgical regional analgesia l40418 bupivacaine combination meloxicam indicated postsurgical analgesia adult patient 72 hour following foot ankle small-to-medium open abdominal lower extremity total joint arthroplasty surgical procedure l34100 bupivacaine alone combination epinephrine indicated adult production local regional anesthesia analgesia surgery dental oral surgery procedure diagnostic therapeutic procedure obstetrical procedure specific concentration presentation recommended type block indicated produce local regional anesthesia analgesia finally use indicated block given clinically significant risk associated use l30533 
Dapiprazole,dapiprazole u.s. trade name rev-eyes alpha blocker found ophthalmic solution used reverse mydriasis eye examination ,used treatment iatrogenically induced mydriasis produced adrenergic phenylephrine parasympatholytic tropicamide agent used certain eye examination 
Penciclovir,penciclovir synthetic acyclic guanine derivative antiviral activity used treatment various herpes simplex virus hsv infection displaying low toxicity good selectivity penciclovir nucleoside analogue ,used treat recurrent cold sore lip face various herpesvirus invections 
Tenofovir disoproxil,tenofovir disoproxil fumarate prodrug tenofovir marketed gilead science trade name _viread_ belongs class antiretroviral drug known nucleotide analogue reverse transcriptase inhibitor nrti drug prescribed combination drug management hiv infection well hepatitis b therapy tenofovir disoproxil initially approved 2001 fda label ,tenofovir disoproxil indicated combination antiretroviral agent treatment hiv-1 infection patient ≥2 year old weighing ≥10 kg l12600 also indicated treatment chronic hepatitis b patient ≥2 year old weighing ≥10 kg l12600 tenofovir disoproxil also ingredient several combination product indicated either alone combination antiretrovirals treatment hiv-1 infection l9848 l4385 l9842 l41010 l9587 l41015 l9833 addition tenofovir disoproxil available combination emtricitabine brand name truvada use pre-exposure prophylaxis prep at-risk adult adolescent weighing ≥ 35kg reduce risk sexually-acquired hiv-1 infection l9833 
Flucloxacillin,antibiotic analog cloxacillin ,used treat bacterial infection susceptible microorganism 
Tranexamic acid,tranexamic acid synthetic derivative lysine used antifibrinolytic treatment prevention major bleeding posse similar mechanism action aminocaproic acid approximately 10-fold potent l31883 first patented 1957 a230108 received initial u approval 1986 l31858 ,taken orally tranexamic acid indicated treatment hereditary angioedema l31883 cyclic heavy menstrual bleeding premenopausal female l31858 instance significant bleeding context hyperfibrinolysis l31883 given intravenously tranexamic acid indicated short-term use 2-8 day patient hemophilia prevent reduce bleeding following tooth extraction l31853 
Ertapenem,ertapenem carbapenem antibiotic drug marketed trade name invanz merck co. pharmaceutical company structurally similar meropenem posse 1-beta-methyl group ,ertapenem indicated treat following moderate severe infection caused susceptible bacteria adult pediatric patient three month age older l14339 l44416 complicated intra-abdominal infection l14339 l44416 complicated skin skin structure infection including diabetic foot infection without osteomyelitis l14339 l44416 community-acquired pneumonia l14339 l44416 complicated urinary tract infection including pyelonephritis l14339 acute pelvic infection including postpartum endomyometritis septic abortion post-surgical gynecologic infection l14339 acute gynecological infection l44416 ertapenem also used adult prophylaxis surgical site infection following elective colorectal surgery l14339 l44416 
Desogestrel,desogestrel prodrug third generation progestogen a176315 hence member gonane family largely used europe approved u canada a176339 firstly generated study showed 11-beta 11-alkylidene substituent nortestosterone enhance biological activity t521 desogestrel produced semi-synthetically naturally occurred plant steroid f4127 u desogestrel found combination ethinyl estradiol a176342 first approved drug containing desogestrel developed organon usa inc 1972 fda approved 1992 l5762 ,oral desogestrel used combination ethinylestradiol contraceptive agent prevention pregnancy fda label desogestrel part combined oral contraceptive contain mix estrogen progestin inhibit ovulation l5698 
Mitomycin,mitomycin antineoplastic antibiotic first isolated japanese microbiologist 1950s culture _streptomyces caespitosus_ l12867 a193419 alkylating agent inhibits dna synthesis higher concentration rna protein synthesis cross-linking complementary strand dna double helix a193419 antibiotic discovered work via alkylating mechanism making mitomycin relatively unique space microbiota-derived therapy a193419 mitomycin 's cross-linking activity resulted approval treatment variety cancer recent april 2020 approval use low-grade upper tract urothelial cancer lg-utuc l12867 well adjunctly _ab externo_ glaucoma surgery , treatment malignant neoplasm lip oral cavity pharynx digestive organ peritoneum female breast urinary bladder also used adjunct ab externo glaucoma surgery mitomycin also indicated pyelocalyceal solution treatment adult low-grade upper tract urothelial cancer lg-utuc l12867 
Talbutal,talbutal also called 5-allyl-5-sec-butylbarbituric acid barbiturate short intermediate duration action talbutal schedule iii drug u.s , use sedative hypnotic 
Bexarotene,bexarotene targretin antineoplastic agent indicated fda cutaneous cell lymphoma used off-label lung cancer breast cancer kaposi 's sarcoma ,used orally treatment skin manifestation cutaneous t-cell lymphoma ctcl patient refractory least one prior systemic therapy also used topically treatment skin lesion early stage ia ib ctcl patient experience refractory persistent disease use therapy intolerant therapy 
Ibutilide,ibutilide class iii antiarrhythmic agent available intravenous formulation indicated conversion acute atrial flutter recent onset atrial fibrillation normal sinus rhythm nsr ,indicated rapid conversion atrial fibrillation atrial flutter recent onset sinus rhythm 
Vindesine,vinblastine derivative antineoplastic activity cancer major side effect myelosuppression neurotoxicity vindesine used extensively chemotherapy protocol antineoplastic combined chemotherapy protocol , treatment acute leukaemia malignant lymphoma hodgkin 's disease acute erythraemia acute panmyelosis
Chlorthalidone,chlorthalidone thiazide-like diuretic used treatment hypertension management edema caused condition heart failure renal impairment chlorthalidone improves blood pressure swelling preventing water absorption kidney inhibition na+/cl− symporter distal convoluted tubule cell kidney exact mechanism chlorthalidone 's anti-hypertensive effect debate however thought increased diuresis result decreased plasma extracellular fluid volume decreased cardiac output therefore overall reduction blood pressure a176324 chlorthalidone considered first-line therapy management uncomplicated hypertension strong evidence meta-analyses thiazide diuretic chlorthalidone reduce risk stroke myocardial infarction heart failure cardiovascular all-cause mortality patient hypertension a173863 particular allhat trial confirmed role thiazide diuretic first-line therapy demonstrated chlorthalidone statistically significant lower incidence stroke heart failure compared db00722 db00381 db00590 a173884 a173887 study indicated low-dose thiazide good secondary endpoint better β-blockers ace inhibitor calcium channel blocker arb chlorthalidone shown number pleiotropic effect differentiate diuretic db00999 addition antihypertensive effect chlorthalidone also shown decrease platelet aggregation vascular permeability well promote angiogenesis vitro thought partly result reduction carbonic anhydrase–dependent pathway pathway may play role chlorthalidone 's cardiovascular risk reduction effect a176330 ,chlorthalidone indicated management hypertension either sole therapeutic agent enhance effect antihypertensive drug severe form hypertension chlorthalidone indicated adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy chlorthalidone also found useful edema due various form renal dysfunction nephrotic syndrome acute glomerulonephritis chronic renal failure 
Ethoxzolamide,ethoxzolamide sulfonamide used diuretic glaucoma inhibits carbonic anhydrase activity proximal renal tubule decrease reabsorption water sodium potassium bicarbonate pharmacological activity thus confers risk hypokalemia , use treatment duodenal ulcer diuretic treatment glaucoma may also useful treatment seizure associated epilepsy 
Pentobarbital, short-acting barbiturate effective sedative hypnotic anti-anxiety agent usually given orally prescribed frequently sleep induction sedation like similar agent may lose effectiveness second week continued administration ama drug evaluation annual 1994 p236 , short-term treatment insomnia 
Valproic acid,valproic acid valproate fatty acid derivative anticonvulsant originally synthesized 1881 beverly burton a178051 enjoyed use popular organic solvent industry pharmaceutical manufacturing nearly century 1963 serendipitous discovery made george carraz investigation anticonvulsant effect khelline found sample dissolved valproic acid exerted similar degree anticonvulsive activity first received approval february 28 1978 fda trade name depakene l6190 since investigated neuroprotective anti-manic anti-migraine effect currently compound interest field oncology anti-proliferative effect subject many clinical trial variety cancer type , indicated label 1 use monotherapy adjunctive therapy management complex partial seizure simple complex absence seizure 2 adjunctive therapy management multiple seizure type include absence seizure 3 prophylaxis migraine headache 4 acute management mania associated bipolar disorder off-label us include 1 maintenance therapy bipolar disorder a177919 2 treatment acute bipolar depression a177928 a177931 a177934 3 emergency treatment status epilepticus a177955 
Capreomycin,cyclic peptide antibiotic similar viomycin produced streptomyces capreolus ,used treatment tuberculosis combination drug 
Zolmitriptan,zolmitriptan member triptan class 5-hydroxytryptamine 5-ht sub 1b/1d/ 1f /sub receptor agonist used treat acute migraine a462 l12978 sumatriptan first triptan developed poor oral bioavailability lipophilicity led development second-generation triptans including almotriptan eletriptan frovatriptan naratriptan rizatriptan zolmitriptan a193791 triptans administered alone combination nsaid like naproxen represent current `` gold standard '' acute migraine treatment a193797 zolmitriptan first approved fda sale zeneca pharmaceutical trade name zomig® november 25 1997 currently available tablet nasal spray form l12978 ,zolmitriptan indicated acute treatment migraine without aura patient aged 18 l12978 
Acetaminophen,acetaminophen paracetamol also commonly known _tylenol_ commonly taken analgesic worldwide recommended first-line therapy pain condition world health organization a176318 also used antipyretic effect helping reduce fever f4124 drug initially approved u.s. fda 1951 available variety form including syrup form regular tablet effervescent tablet injection suppository form l5756 l5774 f4124 label acetaminophen often found combined drug 600 counter otc allergy medication cold medication sleep medication pain reliever product l5783 confusion dosing drug may caused availability different formula strength dosage instruction child different age l5783 due possibility fatal overdose liver failure associated incorrect use acetaminophen important follow current available national manufacturer dosing guideline drug taken prescribed l5786 l5789 label , general acetaminophen used treatment mild moderate pain reduction fever f4124 available counter various form common oral form acetaminophen _injection_ indicated management mild moderate pain management moderate severe pain adjunctive opioid analgesic reduction fever label low risk causing allergic reaction drug administered patient intolerant salicylate allergic tendency including bronchial asthmatic f4124 specific dosing guideline followed administering acetaminophen child l5780 
Gefitinib,gefitinib originally coded zd1839 drug used treatment certain type cancer acting similar manner erlotinib marketed tarceva gefitinib selectively target mutant protein malignant cell marketed astrazeneca trade name iressa , continued treatment patient locally advanced metastatic non-small cell lung cancer failure either platinum-based docetaxel chemotherapy 
Codeine, relief pain analgesia primary goal enhancing quality life patient increasing ability patient engage day day activity codeine opioid analgesic originally approved u 1950 drug used decrease pain increasing threshold pain without impairing consciousness altering sensory function opiate codeine derived poppy plant _papaver somniferum_ papaveraceae a175096 codeine utilized central analgesic sedative hypnotic antinociceptive antiperistaltic agent also recommended certain disease incessant coughing label a175096 ,codeine sulfate form drug commonly used available tablet form fda label indicated relief mild moderately severe pain use opioid analgesic appropriate fda label solution form used combined syrup drug used cough suppressant adult aged 18 l5521 l5524 
Piperacillin,semisynthetic broad-spectrum ampicillin derived ureidopenicillin antibiotic proposed pseudomonas infection also used combination antibiotic , treatment polymicrobial infection 
Dihydroergotamine," 9,10alpha-dihydro derivative ergotamine dihydroergotamine used abortive therapy migraine l38469 use largely supplanted triptans current therapy due class 's greater selectivity favourable side effect profile recent improvement made design intranasal delivery device allowing greater delivery dihydroergotamine solution vasculature-rich upper nasal cavity a239569 recently approved precision olfactory delivery technology developed impel neuropharma technology correlated increase 3-fold cmax 4-fold auc despite solution formulated 75 strength existing intranasal product ",dihydroergotamine dhe formulation indicated acute treatment migraine without aura adult l38459 l38464 l38469 injection dhe also indicated acute treatment cluster headache episode l38459 dhe indicated migraine prevention management hemiplegic basilar migraine l38459 l38464 l38469 
Amitriptyline,amitriptyline hydrochloride also known _elavil_ tricyclic antidepressant tca analgesic property widely used treat depression neuropathic pain a174658 originally approved fda 1977 manufactured sandoz l5308 , drug indicated following condition fda label major depressive disorder adult management neuropathic pain adult prophylactic treatment chronic tension-type headache ctth adult prophylactic treatment migraine adult treatment nocturnal enuresis child aged 6 year organic pathology including spina bifida related disorder excluded response achieved non-drug drug treatment including antispasmodic vasopressin-related product product prescribed healthcare professional expertise management persistent enuresis fda label off-label us irritable bowel syndrome sleep disorder diabetic neuropathy agitation fibromyalgia insomnia
Floxuridine, antineoplastic antimetabolite metabolized fluorouracil administered rapid injection floxuridine available sterile nonpyrogenic lyophilized powder reconstitution administered slow continuous intra-arterial infusion converted floxuridine monophosphate used treat hepatic metastasis gastrointestinal adenocarcinoma palliation malignant neoplasm liver gastrointestinal tract , palliative management gastrointestinal adenocarcinoma metastatic liver given continuous regional intra-arterial infusion carefully selected patient considered incurable surgery mean also palliative management liver cancer usually administered hepatic intra-arterial infusion 
Tolcapone,tolcapone drug inhibits enzyme catechol-o-methyl transferase comt used treatment parkinson 's disease adjunct levodopa/carbidopa medication yellow odorless non-hygroscopic crystalline compound tolcapone associated risk hepatotoxicity ,used adjunct levodopa/carbidopa therapy symptomatic treatment parkinson 's disease drug generally reserved patient parkinsonian syndrome receiving levodopa/carbidopa experiencing symptom fluctuation responding adequately candidate adjunctive therapy 
Fluorometholone, glucocorticoid employed usually eye drop treatment allergic inflammatory condition eye also used topically treatment various skin disorder martindale extra pharmacopoeia 30th ed p732 , ophthalmic treatment corticosteroid-responsive inflammation palpebral bulbar conjunctiva cornea anterior segment globe 
Nitroprusside,nitroprusside serf source nitric oxide potent peripheral vasodilator affect arteriole venule venule arteriole nitroprusside often administered intravenously patient experiencing hypertensive emergency , immediate reduction blood pressure patient hypertensive crisis reduce bleeding surgery treatment acute congestive heart failure
Calcium glucoheptonate,calcium supplement calcium gluceptate taken individual unable get enough calcium regular diet need calcium used prevent treat several condition may cause hypocalcemia enough calcium blood body need calcium make strong bone calcium also needed heart muscle nervous system work properly , treatment mild hypocalcemia due neonatal tetany tetany due parathyroid deficiency vitamin deficiency alkalosis prophylaxis hypocalcemia exchange transfusion treatment intestinal malabsorption replenish electrolyte 
Hydromorphone,hydromorphone pure opioid a176468 semi-synthetic hydrogenated ketone derivative morphine available clinically since 1920 structurally hydromorphone derived morphine modification hydroxyl group carbon 6 carbonyl absence double bond carbon 7 8 due modification present high potency comparable side effect profile parent compound a176471 even though hydromorphone present 6-hydroxyl group categorized family phenanthrenes considered chemical schedule ii medical purpose high addiction potential a176495 first reported approved product containing hydromorphone form hydromorphone hydrochloride developed fresenius kabi usa fda approved 1984 l5795 ,hydromorphone indicated management moderate severe acute pain severe chronic pain due addictive potential overdose risk hydromorphone prescribed first-line treatment failed a176468 proposed three-step ladder management pain suggested start non-opioid medication followed addition weak opioids non-opioid treatment moderate pain finishing use strong opioids hydromorphone along existing regimen case severe pain a176471 off-label hydromorphone administered suppression refractory cough a176468 
Indomethacin,indometacin indomethacin non-steroidal anti-inflammatory drug nsaid anti-inflammatory analgesic antipyretic property nsaid consist agent structurally unrelated nsaid chemical classification indometacin indole-acetic acid derivative chemical name 1- p-chlorobenzoyl 25-methoxy-2-methylindole-3-acetic acid a177871 pharmacological effect indometacin fully understood however thought mediated potent nonselective inhibition enzyme cyclooxygenase cox main enzyme responsible catalyzes rate-limiting step prostaglandin thromboxane biosynthesis via arachidonic acid aa pathway indometacin first discovered 1963 first approved use u.s. food drug administration 1965 a486 along acetic acid derivative diclofenac sulindac also developed 1960s a177871 since indometacin extensively studied clinical trial one potent nsaid blocking prostaglandin synthesis among first nsaid used symptomatic treatment migraine headache eventually became known “ indomethacin-responsive ” headache disorder a177871 commonly used rheumatoid arthritis ankylosing spondylitis osteoarthritis acute shoulder pain acute gouty arthritis indometacin currently available oral capsule well method administration including rectal intravenous formulation intravenous indometacin administered close hemodynamically significant patent ductus arteriosus indicated clinical evidence premature infant l10553 ophthalmic indometacin studied used symptomatic treatment postoperative ocular inflammation pain and/or complication cataract surgery although deemed effective reducing ocular inflammation clinical study topical nsaid also associated potential reduction corneal sensitivity accompanied increased risk superficial punctate keratitis subjective symptom discomfort including pain burning pricking tingling sensation instillation cul‐de‐sac a177949 ,oral indometacin indicated symptomatic management moderate severe rheumatoid arthritis including acute flare chronic disease moderate severe ankylosing spondylitis moderate severe osteoarthritis acute painful shoulder bursitis and/or tendinitis acute gouty arthritis a177871 l6778 intravenous indometacin indicated induce closure hemodynamically significant patent ductus arteriosus premature infant weighing 500 1750 g 48 hour usual medical management e.g. fluid restriction diuretic digitalis respiratory support etc ineffective l10553 
Ethambutol,ethambutol bacteriostatic agent indicated alongside medication isoniazid rifampin pyrazinamide treatment pulmonary tuberculosis l31743 ethambutol first described literature 1961 a229048 developed need therapy active isoniazid resistant strain _mycobacterium tuberculosis_ a229048 ethambutol granted fda approval 6 november 1967 l31663 ,ethambutol indicated combination anti-tuberculosis drug treatment pulmonary tuberculosis l31663 ethambutol commonly used combination isoniazid rifampin pyrazinamide l31743 
Metformin,metformin biguanide antihyperglycemic agent first-line pharmacotherapy used management type ii diabetes l12207 a176173 metformin considered antihyperglycemic drug lower blood glucose concentration type ii diabetes without causing hypoglycemia commonly described `` insulin sensitizer '' leading decrease insulin resistance clinically significant reduction plasma fasting insulin level a176173 another well-known benefit drug modest weight loss making effective choice obese patient type ii diabetes a36559 metformin first approved canada 1972 a36552 received subsequent fda approval u 1995 l12207 , metformin immediate-release formulation metformin indicated adjunct diet exercise improve glycemic control adult pediatric patient ≥10 year old type 2 diabetes mellitus l40243 metformin extended-release tablet xr extended-release formulation metformin indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus safety child determined date l12207 metformin combination product metformin component variety combination product anti-diabetic agent indicated along diet exercise improve glycemic control adult patient type 2 diabetes mellitus combination dpp-4 inhibitor sitagliptin linagliptin alogliptin saxagliptin l11479 l40248 l40253 l40258 l40263 combination sglt2 inhibitor canagliflozin empagliflozin ertugliflozin dapagliflozin l11479 l30503 l1134 l13679 l38729 combination pioglitazone l11419 
Ipratropium,ipratropium quaternary ammonium derivative atropine a176957 act anticholinergic agent a176939 commonly administered inhalation allows producing local effect without presenting significant systemic absorption a176957 ipratropium therapeutic agent developed boehringer ingelheim first monotherapy product fda approved 1986 combination product ipratropium albuterol approved 1996 l5894 l5891 ,inhaled ipratropium indicated combination inhaled beta-agonist systemic corticosteroid management severe exacerbation asthma flare requiring treatment a176939 asthma exacerbation characterized progressive increase one asthma symptom accompanied decrease expiratory flow l5900 single agent ipratropium indicated symptomatic relief rhinorrhea associated common cold seasonal allergic rhinitis patient 5 year older alleviate nasal congestion sneezing fda label rhinorrhea refers recurrent chronic watery nasal discharge condition debilitating pathogenesis etiology complex well understood presenting substantial cost burden l5903 additionally ipratropium indicated bronchodilator maintenance treatment bronchospasm associated chronic obstructive pulmonary disease including chronic bronchitis emphysema fda label chronic obstructive pulmonary disease includes large number condition characterized breathlessness includes several condition etiology symptom treatment diverse l5906 ipratropium also studied used treatment sialorrhea a176942 sialorrhea common symptom accompanies different neurologic condition characterized drooling excessive salivation a176963 
Methadone,methadone potent synthetic analgesic work full µ-opioid receptor mor agonist n-methyl-d-aspartate nmda receptor antagonist full mor agonist methadone mimic natural effect body 's opioids endorphin enkephalin release neurotransmitter involved pain transmission also number unique characteristic led increased use last two decade particular methadone lower risk neuropsychiatric toxicity compared opioids due lack active metabolite minimal accumulation renal failure good bioavailability low cost long duration action f4685 f4688 f4691 a185885 a185900 a185903 due unique mechanism action methadone particularly useful management hard treat pain syndrome neuropathic pain cancer pain requiring higher frequent dos shorter-acting opioids a185888 a185891 a185897 compared morphine gold standard reference opioid methadone also act agonist κ- σ-opioid receptor antagonist n-methyl-d-aspartate nmda receptor inhibitor serotonin norepinephrine uptake a497 a5344 specifically inhibiting nmda receptor methadone dampens major excitatory pain pathway within central nervous system a185876 compared opioids methadone 's effect nmda inhibition may explain 's improved analgesic efficacy reduced opioid tolerance a185891 a185894 methadone share similar effect risk opioids morphine hydromorphone oxycodone fentanyl however also unique pharmacokinetic profile compared short-acting even extended-release formulation morphine methadone display comparatively longer duration action half-life effect make methadone good option treatment severe pain addiction fewer dos needed maintain analgesia prevent opioid withdrawal symptom however methadone also unpredictable half-life interindividual variability lead unpredictable risk respiratory depression overdose initiating titrating therapy a183995 overall methadone 's pharmacological action result analgesia suppression opioid withdrawal symptom sedation miosis sweating hypotension bradycardia nausea vomiting via binding within chemoreceptor trigger zone constipation higher dos methadone use result respiratory depression overdose death f4685 f4688 f4691 treatment opioid addiction methadone buprenorphine slow-release oral morphine srom termed opioid agonist treatment oat opioid substitution therapy ost intention substitution illicit opioids long-acting opioids used oat prevent withdrawal symptom 24-36 hour following dosing ultimately reduce craving drug-seeking behaviour use oat also intended lead social stabilization reducing crime rate incarceration use illicit opioids heroin fentanyl ultimately marginalization a185882 illegally purchased opioids present many harm addition overdose injected may laced substance increase risk harm overdose provision oat often combined education harm reduction including use clean needle injection supply effort reduce risk associated injection drug use contraction hiv hepatitis c complication including skin infection abscess endocarditis ,methadone indicated management pain severe enough require opioid analgesic alternative treatment option inadequate 's recommended use reserved use patient alternative treatment option eg nonopioid analgesic opioid combination product ineffective tolerated would otherwise inadequate provide sufficient management pain f4688 methadone also indicated detoxification treatment opioid addiction heroin morphine-like drug maintenance substitution treatment opioid dependence adult conjunction appropriate social medical service f4685 f4691 
Olanzapine,olanzapine thienobenzodiazepine classified atypical second-generation antipsychotic agent a176996 second-generation antipsychotic introduced 90 quickly gained traction due impressive efficacy reduced risk extrapyramidal side effect reduced susceptibility drug-drug interaction a177011 olanzapine closely resembles clozapine differs two additional methyl group absence chloride moiety t554 discovered scientist eli lilly approved marketed u 1996 t548 ,olanzapine initially used orally intramuscularly chronic treatment schizophrenia patient 13 year old psychiatric disorder bipolar disorder including mixed manic episode a177014 olanzapine also indicated combination lithium valproate short-term treatment acute manic mixed episode associated bipolar disorder adult fda label well olanzapine indicated combination fluoxetine treatment episode depression associated bipolar disorder type 1 treatment-resistant depression patient 10 year old a177014 olanzapine also approved management psychomotor agitation associated schizophrenia bipolar mania fda label schizophrenia complex biochemical brain disorder affect person 's ability differentiate reality usually observed presence delusion hallucination social withdrawal disturbed thinking l5936 bipolar disorder mental health condition defined period extreme mood disturbance categorized different type type 1 known involve episode severe mania often depression type 2 present le severe form mania l5939 olanzapine also indicated combination samidorphan treatment bipolar disorder either adjunct lithium valproate monotherapy acute treatment manic mixed episode maintenance therapy treatment schizophrenia adult l34359 
Atenolol,"atenolol cardioselective beta-blocker used variety cardiovascular condition sir james black scottish pharmacologist pioneered use beta-blockers management angina pectoris 1958 received nobel prize a178429 beta-blockers quickly became popular clinical use subsequently investigated use myocardial infarction arrhythmia hypertension 1960s later continued investigated use heart failure throughout 1970-1980s atenolol developed early history alvogen malta trade name tenormin received fda approval september 1981 label despite one widely prescribed beta blocker evidence suggests atenolol may significantly reduce mortality modestly reduce risk cardiovascular disease patient hypertension a235850 a235855 cochrane review patient treated primary hypertension show atenolol show risk ratio 0.88 cardiovascular disease risk risk ratio 0.99 mortality a235850 a235855 similar result found meta-analyses a235860 a235865 meta-analysis 145,000 patient showed risk stroke patient taking atenolol may depend age patient a235865 use atenolol may need based patient factor hypertension alone a235850 a235855 a235860 a235865 ", indicated label 1 management hypertension alone combination antihypertensive 2 management angina pectoris associated coronary atherosclerosis 3 management acute myocardial infarction hemodynamically stable patient heart rate greater 50 beat per minute systolic blood pressure 100 mmhg off-label us include 1 secondary prevention myocardial infarction a178156 2 management heart failure a178153 3 management atrial fibrillation a178141 4 management supraventricular tachycardia a178162 5 management ventricular arrythmias congenital long-qt arrhythmogenic right ventricular cardiomyopathy a178168 6 management symptomatic thyrotoxicosis combination methimazole a178147 7 prophylaxis migraine headache a178171 8 management alcohol withdrawal a178174 a178177 
Nitrofural,nitrofural nitrofurazone topical anti-infective agent effective gram-negative gram-positive bacteria used superficial wound burn ulcer skin infection nitrofural also administered orally treatment trypanosomiasis except topical drug product formulated dermatologic application fda withdrew approval use drug product containing nitrofurazone l43942 , treatment bacterial skin infection including pyodermas infected dermatosis infection cut wound burn ulcer due susceptible organism 
Pimecrolimus,pimecrolimus immunomodulating agent first marketed novartis trade name elidel promoted canada galderma since early 2007 currently available topic cream used treatment atopic dermatitis eczema , treatment mild moderate atopic dermatitis 
Omeprazole,originally approved fda 1989 omeprazole _proton-pump inhibitor_ used treat gastric acid-related disorder disorder may include gastroesophageal reflux disease gerd peptic ulcer disease disease characterized oversecretion gastric acid drug first clinical useful drug class approval followed formulation many proton pump inhibitor drug a174232 omeprazole generally effective well-tolerated promoting popular use child adult fda label ,omeprazole according fda label fda label proton pump inhibitor ppi used following purpose • treatment active duodenal ulcer adult • eradication helicobacter pylorus reduce risk duodenal ulcer recurrence adult • treatment active benign gastric ulcer adult • treatment symptomatic gastroesophageal reflux disease gerd patient 1 year age older • treatment erosive esophagitis ee due acid-mediated gerd patient 1 month age older • maintenance healing ee due acid-mediated gerd patient 1 year age older • pathologic hypersecretory condition adult
Pyrazinamide, pyrazine used therapeutically antitubercular agent , initial treatment active tuberculosis adult child combined antituberculous agent 
Metixene,metixene methixene anticholinergic used antiparkinsonian agent ,used symptomatic treatment parkinsonism 
Cetirizine,cetirizine also commonly known _zyrtec_ orally active second-generation histamine h1 antagonist proven effective treatment various allergic symptom sneezing coughing nasal congestion hive symptom a175051 a175054 one common us drug condition called _allergic rhinitis_ prevalence allergic rhinitis united state 15 according physician diagnosis 30 according self-reported nasal symptom allergic rhinitis associated multiple missed unproductive day work school problem sleep difficulty day day activity many individual a175057 furthermore antihistamine agent used treat condition cause undesirable sedating effect a175060 cetirizine one first second-generation h1 antihistamine sgahs formulated selectively inhibit h1 receptor without sedating effect a175054 , seasonal allergic rhinitis indicated relief symptom associated seasonal allergic rhinitis caused allergen ragweed grass tree pollen adult child 2 year age symptom treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing redness eye fda label perennial allergic rhinitis drug indicated relief symptom associated perennial allergic rhinitis due allergen including dust mite animal dander mold adult child 6 month age older symptom treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus tearing fda label chronic urticaria cetirizine indicated treatment uncomplicated skin manifestation chronic idiopathic urticaria adult child 6 month age older markedly reduces occurrence severity duration hive significantly reduces pruritus fda label 
Terfenadine, u.s. terfenadine superseded fexofenadine 1990s due risk cardiac arrhythmia caused qt interval prolongation , treatment allergic rhinitis hay fever allergic skin disorder 
Diltiazem,diltiazem benzothiazepine derivative antihypertensive vasodilating property approved 1982 fda member non-dihydropyridine calcium channel blocker drug class work various mechanism action primarily work inhibiting calcium influx cardiac vascular smooth muscle depolarization l10556 compared dihydropyridine drug nifedipine preferentially act vascular smooth muscle verapamil directly act heart muscle diltiazem display intermediate specificity target cardiac vascular smooth muscle t28 potent vasodilator diltiazem used clinically antihypertensive anti-arrhythmic anti-anginal agent l6289 management cardiovascular condition hypertension chronic stable angina atrial fibrillation atrial flutter apart main fda-approved indication diltiazem also used numerous off-label indication anal fissure topical formulation migraine prophylaxis pulmonary hypertension rest-related cramp lower extremity l6289 typically available extended-release oral intravenous formulation diltiazem marketed various brand name cardizem tiazac common one , oral indicated management hypertension lower blood pressure alone combination antihypertensive agent l10556 indicated use improve exercise tolerance patient chronic stable angina l10556 indicated management variant angina prinzmetal 's angina l6298 intravenous indicated short-term management atrial fibrillation atrial flutter temporary control rapid ventricular rate l6292 indicated rapid conversion paroxysmal supraventricular tachycardia psvt sinus rhythm includes av nodal reentrant tachycardia reciprocating tachycardia associated extranodal accessory pathway wpw syndrome short pr syndrome l6292 off-label indicated off-label us anal fissure topical formulation migraine prophylaxis cramp lower leg related rest pulmonary hypertension l6289 idiopathic dilated cardiomyopathy proteinuria associated diabetic nephropathy l6298 
Protriptyline,protriptyline hydrochloride dibenzocycloheptene-derivative tricyclic antidepressant tca tcas structurally similar phenothiazine contain tricyclic ring system alkyl amine substituent central ring non-depressed individual protriptyline affect mood arousal may cause sedation depressed individual protriptyline exerts positive effect mood tcas potent inhibitor serotonin norepinephrine reuptake addition tcas down-regulate cerebral cortical beta -adrenergic receptor sensitize post-synaptic serotonergic receptor chronic use antidepressant effect tcas thought due overall increase serotonergic neurotransmission tcas also block histamine h sub 1 /sub receptor alpha sub 1 /sub -adrenergic receptor muscarinic receptor account sedative hypotensive anticholinergic effect e.g blurred vision dry mouth constipation urinary retention respectively see toxicity section complete listing side effect protriptyline may used treatment depression , treatment depression 
Aminohippuric acid, glycine amide 4-aminobenzoic acid sodium salt used diagnostic aid measure effective renal plasma flow erpf excretory capacity pubchem ,used measure effective renal plasma flow erpf determine functional capacity tubular excretory mechanism 
Alfuzosin,benign prostatic hyperplasia bph refers benign growth hyperplasia prostate lead lower urinary tract symptom men urgency frequency change urine flow prevalence bph high 50 -60 male 60 's prevalence increase 80 -90 70 a228483 alfuzosin alpha-1 adrenergic blocker used symptomatic treatment bph work relaxing muscle prostate bladder neck l31593 initially approved fda 2003 marketed several pharmaceutical company l9251 ,alfuzosin used treat sign symptom benign prostatic hyperplasia bph l9251 
Trimethadione, anticonvulsant effective absence seizure generally reserved refractory case toxicity ama drug evaluation annual 1994 p378 ,used control absence petit mal seizure refractory treatment medication 
Nitisinone,nitisinone synthetic reversible inhibitor 4-hydroxyphenylpyruvate dioxygenase used treatment hereditary tyrosinemia type 1 sold brand name orfadin ,used adjunct dietary restriction tyrosine phenylalanine treatment hereditary tyrosinemia type 1 
Clobazam,"clobazam belongs 1,5-benzodiazepine class drug expected better side-effect profile compared older 1,4-benzodiazepines marketed anxiolytic since 1975 anticonvulsant since 1984 oral preparation fda approved october 21 2011 oral suspension expected available 2013 ", treatment management epilepsy seizure associated lennox-gastaut syndrome difficult-to-treat form childhood epilepsy 
Minoxidil, potent direct-acting peripheral vasodilator vasodilator agent reduces peripheral resistance produce fall blood pressure , treatment severe hypertension topical treatment regrowth androgenic alopecia male female stabilisation hair loss patient androgenic alopecia 
Megestrol acetate,"17-hydroxy-6-methylpregna-3,6-diene-3,20-dione progestational hormone used commonly acetate ester acetate potent progesterone progestagen ovulation inhibitor also used palliative treatment breast cancer ", treatment anorexia cachexia unexplained significant weight loss patient diagnosis acquired immunodeficiency syndrome aid also used palliative management recurrent inoperable metastatic breast cancer endometrial cancer prostate cancer canada country 
Tioguanine, antineoplastic compound also antimetabolite action drug used therapy acute leukemia , remission induction remission consolidation treatment acute nonlymphocytic leukemia 
Methylergometrine, homolog ergonovine containing one ch2 group merck index 11th ed , prevention control excessive bleeding following vaginal childbirth
Buclizine,buclizine antihistamine medication antiemetic anticholinergic effect l6220 belonging _piperazine derivative_ family drug manufactured stuart pharms initially approved fda 1957 l6217 following touted effective appetite stimulant child administered syrup form however indication validated a178102 addition condition buclizine studied treatment migraine attack treatment nausea vomiting pregnancy a178105 a178108 , prevention treatment nausea vomiting dizziness associated motion sickness vertigo dizziness caused medical problem 
Aztreonam, monocyclic beta-lactam antibiotic originally isolated chromobacterium violaceum resistant beta-lactamase used gram-negative infection especially meninges bladder kidney may cause superinfection gram-positive organism , treatment following infection caused susceptible gram-negative microorganism urinary tract infection lower respiratory tract infection septicemia skin skin-structure infection intra-abdominal infection gynecologic infection 
Chlorzoxazone, centrally acting central muscle relaxant sedative property claimed inhibit muscle spasm exerting effect primarily level spinal cord subcortical area brain martindale extra pharmacopoea 30th ed p1202 , relief discomfort associated acute painful musculoskeletal condition 
Aminoglutethimide, aromatase inhibitor produce state `` medical '' adrenalectomy blocking production adrenal steroid also block conversion androgen estrogen aminoglutethimide used treatment advanced breast prostate cancer formerly used weak anticonvulsant property martindale extra pharmacopoeia 30th ed p454 , suppression adrenal function selected patient cushing 's syndrome malignant neoplasm female breast carcinoma situ breast 
Mefloquine,malaria protozoan disease place enormous burden human health endemic area around world 2020 world health organization malaria report indicates 60 decrease global malaria fatality rate 2000 2019 l30618 despite malaria remains significant cause morbidity mortality 90 death malaria occur africa individual highest risk malaria disease naïve population child age 5 refugee central eastern africa nonimmune civilian military traveler pregnant woman immigrant traveling place origin l30623 mefloquine commonly known lariam antimalarial drug used prevention treatment malaria caused infection plasmodium vivax plasmodium falciparum drug initially discovered walter reed army institute research wrair malaria drug discovery program 1963 1976 approved fda 1989 first marketed hoffman laroche a226838 drug subject widespread controversy due concern regarding neurotoxic effect product information warns potential serious neuropsychiatric effect a226838 l8953 ,mefloquine indicated treatment mild moderate case malaria caused plasmodium falciparum plasmodium vivax effective chloroquine-resistant form plasmodium falciparum mefloquine also indicated prophylaxis malaria caused plasmodium falciparum plasmodium vivax including chloroquine-resistant form plasmodium falciparum l8953 
Sulfadiazine,one short-acting sulfonamide used combination pyrimethamine treat toxoplasmosis patient acquired immunodeficiency syndrome newborn congenital infection , treatment rheumatic fever meningococcal meningitis
Sapropterin,sapropterin tetrahydrobiopterin bh4 cofactor synthesis nitric oxide also essential conversion phenylalanine tyrosine enzyme phenylalanine-4-hydroxylase conversion tyrosine l-dopa enzyme tyrosine hydroxylase conversion tryptophan 5-hydroxytryptophan via tryptophan hydroxylase , treatment tetrahydrobiopterin bh4 deficiency 
Vinorelbine,vinorelbine anti-mitotic chemotherapy drug used treatment several type malignancy including breast cancer non-small cell lung cancer nsclc l1998 initially approved usa 1990 's treatment nsclc l2010 third-generation vinca alkaloid introduction third-generation drug vinorelbine gemcitabine taxanes platinum combination improved survival patient advanced nsclc similar result various drug treatment toxicity considerable combination treatment setting a32347 study done clearance rate vinorelbine individual various single polymorphonuclear mutation found 4.3-fold variation vinorelbine clearance across cohort suggesting strong influence genetics clearance drug l2002 ,vinorelbine tartrate indicated adult treatment advanced non-small cell lung cancer nsclc single therapy combination chemotherapeutic drug l1998 used relapsed refractory hodgkin lymphoma combination chemotherapy agent l2011 treatment desmoid tumor aggressive fibromatosis combination methotrexate l2011 treatment recurrent metastatic squamous cell head neck cancer l2011 treatment recurrent ovarian cancer l2011 treatment metastatic breast cancer patient previously treated anthracyline and/or taxane therapy l2011 treatment her2-positive trastuzumab-resistant advanced breast cancer patient previously treated taxane combination trastuzumab everolimus l2011 
Anidulafungin,anidulafungin eraxis anti-fungal drug manufactured pfizer gained approval food drug administration fda february 21 2006 previously known ly303366 preliminary evidence similar safety profile caspofungin , use treatment following fungal infection candidemia form candida /i infection intra-abdominal abscess peritonitis aspergillus infection esophageal candidiasis also considered alternative treatment oropharyngeal canaidiasis 
Clozapine, tricyclic dibenzodiazepine classified atypical antipsychotic agent bind several type central nervous system receptor display unique pharmacological profile clozapine serotonin antagonist strong binding 5-ht 2a/2c receptor subtype also display strong affinity several dopaminergic receptor show weak antagonism dopamine d2 receptor receptor commonly thought modulate neuroleptic activity agranulocytosis major adverse effect associated administration agent , use patient treatment-resistant schizophrenia 
Sucralfate,sucralfate medication widely used prevent treat number disease gastrointestinal tract duodenal ulcer fda label gastro-esophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer addition dyspepsia a177655 considered _cytoprotective agent_ protecting cell gastrointestinal tract damage caused agent gastric acid bile salt alcohol acetylsalicylic acid aspirin among substance a177655 f4519 sucralfate shown well-tolerated safe drug sold many brand available tablet suspension form approved fda 1982 tablet form 1994 suspension form l6073 l6076 , sucralfate suspension fda label tablet f4534 used treatment active duodenal ulcer 8 week tablet form may used lower dose healed duodenal ulcer purpose maintaining healing preventing recurrence f4519 f4534 sucralfate also used prevention and/or treatment gastro-esophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer addition dyspepsia a177655 f4519 
Grepafloxacin,grepafloxacin oral broad-spectrum quinoline antibacterial agent used treat bacterial infection due qtc-prolonging potential indicated change qt interval electrocardiogram risk cardiovascular adverse event grepafloxacin withdrawn united state , treatment adult mild moderate infection caused susceptible strain haemophilus influenzae /i streptococcus pneumoniae /i moraxella catarrhalis /i 
Doxylamine,histamine h1 antagonist pronounced sedative property used allergy antitussive antiemetic hypnotic doxylamine also administered veterinary application formerly used parkinsonism ,used alone short-term sleep aid combination drug night-time cold allergy relief drug also used combination vitamin b6 pyridoxine prevent morning sickness pregnant woman 
Levonorgestrel,levonorgestrel lng synthetic progestogen similar progesterone used contraception hormone therapy a181988 t659 also known plan b used single agent emergency contraception hormonal contraceptive released intrauterine device commonly referred iud device known jaydess kyleena mirena subdermal implant levonorgestrel slowly release hormone long-term period also available l7823 addition us levonorgestrel used component long-term combination contraceptive a181991 l7760 l7778 globally levonorgestrel commonly used emergency contraceptive initially granted fda approval 1982 first emergency contraceptive containing progesterone showing high level efficacy lack estrogenic adverse effect compared older emergency contraceptive regimen a181976 a181994 l7760 , emergency contraception levonorgestrel single-agent emergency contraceptive form indicated prevention pregnancy confirmed suspected failure contraception method following unprotected intercourse distributed prescription patient 17 counter age l7760 levonorgestrel-only form contraception indicated regular contraception must taken soon possible within 72 hour intercourse a181976 l7760 shown lower efficacy used label within 96 hour t659 long-term contraception nonemergency contraception addition indication emergency contraception levonorgestrel combined contraceptive contraceptive formulation designed regular use example ethinyl estradiol l7766 used various hormone-releasing intrauterine device long-term contraception ranging duration 3-5 year l7778 l7781 l7787 product labeling mirena specifically mention recommended woman least 1 child indicated prevention pregnancy 8 year l7778 l42950 subdermal implant also available prevention pregnancy 5 year l7823 hormone therapy off-label us levonorgestrel prescribed combination estradiol hormone therapy menopause manage vasomotor symptom prevent osteoporosis l7805 off-label levonorgestrel may used treat menorrhagia endometrial hyperplasia endometriosis t659 
Norepinephrine,precursor epinephrine secreted adrenal medulla widespread central autonomic neurotransmitter norepinephrine principal transmitter postganglionic sympathetic fiber diffuse projection system brain arising locus ceruleus also found plant used pharmacologically sympathomimetic ,mainly used treat patient vasodilatory shock state septic shock neurogenic shock shown survival benefit dopamine also used vasopressor medication patient critical hypotension 
Cidofovir,cidofovir injectable antiviral medication employed treatment cytomegalovirus cmv retinitis patient diagnosed aid suppresses cmv replication selective inhibition viral dna synthesis fda label manufactured _gilead_ initially approved fda 1996 since discontinued l6223 , treatment cmv retinitis patient acquired immunodeficiency syndrome aid 
Mirtazapine,mirtazapine tetracyclic _piperazino-azepine_ antidepressant agent initially approved treatment major depressive disorder mdd netherlands 1994 a177946 drug first manufactured organon inc. received fda approval 1997 treatment major depressive disorder t595 l6157 effect drug may observed early 1 week beginning therapy a178144 l6160 addition beneficial effect depression mirtazapine reported efficacious off-label management various condition may improve symptom neurological disorder reverse weight loss caused medical condition improve sleep prevent nausea vomiting surgery a177811 , drug indicated treatment major depressive disorder associated symptom fda label mirtazapine used off-label variety condition including panic disorder generalized anxiety disorder dysthymia tension headache hot flush post-traumatic stress disorder ptsd sleep disorder substance abuse disorder sexual disorder among others a177811 a177946 
Meprobamate, carbamate hypnotic sedative muscle relaxant property although therapeutic dos reduction anxiety rather direct effect may responsible muscle relaxation meprobamate reported anticonvulsant action petit mal seizure grand mal seizure may exacerbated used treatment anxiety disorder also short-term management insomnia largely superseded benzodiazepine martindale extra pharmacopoeia 30th ed p603 meprobamate controlled substance u.s , management anxiety disorder short-term relief symptom anxiety 
Thiethylperazine, dopamine antagonist particularly useful treating nausea vomiting associated anesthesia mildly emetic cancer chemotherapy agent radiation therapy toxin piperazine phenothiazine prevent vertigo motion sickness ama drug evaluation annual 1994 p457 , treatment relief nausea vomiting 
Timolol,timolol nonselective beta-adrenergic antagonist given eye drop solution reduce intraocular pressure pressure eye l6724 also used tablet form drug treat hypertension l6727 timolol first approved fda 1978 l6724 drug marketed several manufacturer l6736 effective agent management condition open-angle glaucoma hypertension ,ophthalmic timolol indicated treatment increased intraocular pressure patient ocular hypertension open-angle glaucoma oral form drug used treat high blood pressure l6724 l6727 certain case timolol used prevention migraine headache a179530 l6742 
Treprostinil,treprostinil stable tricyclic analogue prostacyclin a248770 promotes vasodilation pulmonary systemic arterial vascular bed inhibition platelet aggregation l41855 l41860 l41865 reduces symptom patient pulmonary arterial hypertension pah pulmonary hypertension associated interstitial lung disease l41855 l41860 first agent approved treatment pah epoprostenol synthetic prostacyclin significantly increase patient quality life however use epoprostenol limited due short half-life 3-5 min instability room temperature a248770 a248775 use stable alternative treprostinil provides patient pah treatment option treprostinil approved fda 2002 treatment pulmonary arterial hypertension l41860 available following route administration subcutaneous intravenous inhaled oral first generic form treprostinil became available 2019 a248775 , fda indicated treprostinil treatment pulmonary arterial hypertension l41855 l41860 l41865 pulmonary hypertension associated interstitial lung disease l41855 improve exercise ability also used treat pulmonary arterial hypertension patient requiring transition epoprostenol l41860 health canada label specifies treprostinil indicated long-term treatment pulmonary arterial hypertension nyha class iii iv patient respond adequately conventional therapy l24244 l24244
Colestipol,bile acid sequestrants like colestipol use since 1970s fda label f4555 f4567 l6262 even though agent may well useful reducing elevated cholesterol level decreasing risk atherosclerotic vascular disease due hypercholesterolemia colestipol still generally employed adjunct therapy relatively physical nature pharmacological activity sometimes limit usefulness fda label f4555 f4567 l6262 particular colestipol 's general mechanism action ultimately result decreased absorption enhanced secretion bile acid lipid feces patient take complicated medication regimen experience constipation biliary obstruction etc may good candidate using agent owing physical effect gut fda label f4555 f4567 l6262 alternatively colestipol predominantly elicits activity within gut environment undergoes little absorption metabolism fda label f4555 f4567 l6262 resultant lack systemic exposure consequently mean medication generally demonstrates adverse effect inside body fda label f4555 f4567 l6262 ,colestipol indicated adjunctive therapy diet reduction elevated serum total low-density lipoprotein cholesterol ldl-c patient primary hypercholesterolemia condition feature elevated ldl-c respond adequately dietary change fda label l6115 f4555 therapy lipid-altering agent like colestipol component multiple risk factor intervention individual significantly increased risk atherosclerotic vascular disease due hypercholesterolemia fda label l6115 f4555 treatment begin continue dietary therapy fda label l6115 f4555 general minimum six month intensive dietary therapy counseling carried prior initiation drug therapy colestipol fda label f4555 shorter period may considered patient severe elevation ldl-c definite coronary heart disease fda label f4555 although colestipol effective type hypercholesterolemia regional prescribing information note particular medically appropriate patient fredrickson 's type ii hyperlipoproteinemia l6115 nevertheless patient combined hypercholesterolemia hypertriglyceridemia although colestipol may helpful reducing elevated cholesterol formally indicated hypertriglyceridemia abnormality greatest concern f4567 
Trihexyphenidyl,trihexyphenidyl centrally acting muscarinic antagonist used treatment parkinsonism drug-induced extrapyramidal disorder l31773 l31778 discovery published 1949 study looking drug antispasmodic activity a229103 trihexyphenidyl rarely used treatment parkinsonism first line treatment due significant adverse effect l31843 largely replaced drug levodopa l31843 trihexyphenidyl granted fda approval 13 may 1949 l31768 ,tihexyphenidyl indicated adjunct treatment parkinsonism adjuvant treatment parkinsonism levodopa control extrapyramidal disorder caused central nervous system drug l31773 l31778 
Palonosetron,palonosetron inn trade name aloxi antagonist 5-ht3 receptor indicated prevention treatment chemotherapy-induced nausea vomiting cinv effective 5-ht3 antagonist controlling delayed cinv nausea vomiting appear 24 hour first dose course chemotherapy drug class approved use u.s. food drug administration 2008 recent 5-ht3 antagonist enter clinical use , prevention acute delayed nausea vomiting associated initial repeat course moderately emetogenic cancer chemotherapy well prevention acute nausea vomiting associated highly emetogenic cancer chemotherapy also used prevention postoperative nausea vomiting 24 hour post operation 
Dydrogesterone, synthetic progestational hormone androgenic estrogenic property unlike many progestational compound dydrogesterone produce increase temperature inhibit ovulation ,used treat irregular duration cycle irregular occurrence duration period caused progesterone deficiency also used prevent natural abortion patient history habitual abortion 
Mexiletine,antiarrhythmic agent pharmacologically similar lidocaine may anticonvulsant property , treatment ventricular tachycardia symptomatic premature ventricular beat prevention ventricular fibrillation 
Dexrazoxane, antimitotic agent immunosuppressive property dexrazoxane -enantiomorph razoxane provides cardioprotection anthracycline toxicity appears inhibit formation toxic iron-anthracycline complex pubchem food drug administration designated dexrazoxane orphan drug use prevention reduction incidence severity anthracycline-induced cardiomyopathy , reducing incidence severity cardiomyopathy associated doxorubicin administration woman metastatic breast cancer received cumulative doxorubicin hydrochloride dose 300 mg/m^2 would benefit continued doxorubicin therapy also approved treatment extravasation intravenous anthracyclines 
Amlodipine,amlodipine initially approved fda 1987 popular antihypertensive drug belonging group drug called _dihydropyridine calcium channel blockers_ due selectivity peripheral blood vessel dihydropyridine calcium channel blocker associated lower incidence myocardial depression cardiac conduction abnormality calcium channel blocker a175327 amlodipine commonly used treatment high blood pressure angina amlodipine antioxidant property ability enhance production nitric oxide important vasodilator decrease blood pressure a175321 option single daily dosing amlodipine attractive feature drug fda label ,amlodipine may used alone combination antihypertensive antianginal agent treatment following condition fda label • hypertension • coronary artery disease • chronic stable angina • vasospastic angina prinzmetal ’ variant angina • angiographically documented coronary artery disease patient without heart failure ejection fraction 40 
Tacrine, centerally active cholinesterase inhibitor used counter effect muscle relaxant respiratory stimulant treatment alzheimer 's disease central nervous system disorder tacrine discontinued united state market , palliative treatment mild moderate dementia alzheimer 's type 
Oxyphencyclimine,oxyphencyclimine anticholinergic drug trade name daricon used treating peptic ulcer , treatment peptic ulcer disease relief smooth muscle spasm gastrointestinal disorder 
Triamterene,"triamterene 2,4,7-triamino-6-phenylpteridine potassium-sparing diuretic used management hypertension work promoting excretion sodium ion water decreasing potassium excretion distal part nephron kidney working lumenal side a177985 since act distal nephron small fraction sodium ion reabsorption occurs triamterene reported limited diuretic efficacy t28 due effect increased serum potassium level triamterene associated risk producing hyperkalemia triamterene weak antagonist folic acid photosensitizing drug l6163 triamterene approved food drug administration u.s. 1964 l6163 currently triamterene used treatment edema associated various condition monotherapy approved use diuretic enhance diuretic potassium-sparing effect l6166 also found combination product hydrochlorothiazide used management hypertension treatment edema patient develop hypokalemia hydrochlorothiazide alone ",triamterene indicated treatment edema associated congestive heart failure cirrhosis liver nephrotic syndrome also steroid-induced edema idiopathic edema edema due secondary hyperaldosteronism l6166 triamterene combination hydrochlorothiazide indicated managment hypertension treatment edema patient develop hypokalemia following hydrochlorothiazide monotherapy patient require thiazide diuretic development hypokalemia risked l6169 triamterene allows maintenance potassium balance given combination loop diuretic thiazide t28 
Valrubicin,valrubicin n-trifluoroacetyladriamycin-14-valerate chemotherapy drug commonly marketed trade name valstar semisynthetic analog doxorubicin anthracycline drug used treatment bladder cancer valrubicin administered direct infusion bladder , treatment cancer bladder 
Procyclidine, muscarinic antagonist cross blood-brain barrier used treatment drug-induced extrapyramidal disorder parkinsonism , treatment form parkinson 's disease well control extrapyramidal reaction induced antipsychotic agent 
Phenylephrine,phenylephrine alpha-1 adrenergic receptor agonist used treat hypotension l9416 l9410 dilate pupil l9413 induce local vasoconstriction a187370 action phenylephrine neo-synephrine first described literature 1930s a187376 phenylephrine granted fda approval 1939 l9413 ,phenylephrine injection indicated treat hypotension caused shock anesthesia l9416 l9410 ophthalmic formulation indicated dilate pupil l9413 induce vasoconstriction intranasal formulation used treat congestion topical formulation used treat hemorrhoid a187370 off-label us include situation require local blood flow restriction treatment priapism a187370 
Carbimazole, imidazole antithyroid agent carbimazole metabolized methimazole responsible antithyroid activity , treatment hyperthyroidism thyrotoxicosis also used prepare patient thyroidectomy 
Digoxin,digoxin one oldest cardiovascular medication used today a178225 common agent used manage atrial fibrillation symptom heart failure a178234 digoxin classified cardiac glycoside initially approved fda 1954 l9143 drug originates foxglove plant also known _digitalis_ plant t610 studied william withering english physician botanist 1780s a178237 a178240 prior welsh family historically referred _physicians myddvai_ formulated drug plant one first prescribe cardiac glycoside according ancient literature dating early 1250s a178240 ,digoxin indicated following condition 1 treatment mild moderate heart failure adult patient l9143 2 increase myocardial contraction child diagnosed heart failure l9143 3 maintain control ventricular rate adult patient diagnosed chronic atrial fibrillation l9143 adult heart failure clinically possible digoxin administered conjunction diuretic angiotensin-converting enzyme ace inhibitor optimum effect l9143 
Sulpiride,sulpiride first appeared published literature 1967 a229538 clinical study show greater effect treating negative symptom schizophrenia rather positive symptom low dos though effect equal higher dos a229683 sulpiride approved fda health canada ema though approved individual european country l24679 ,sulpiride indicated treatment acute chronic schizophrenia l31933 
Profenamine,profenamine medication derived phenothiazine primarily used antidyskinetic treat parkinsonism sold trade name parsidol united state parsidan canada , use treatment parkinson 's disease also used control severe reaction certain medicine reserpine 
Nimodipine,"nimodipine 1,4-dihydropyridine calcium channel blocker act primarily vascular smooth muscle cell stabilizing voltage-gated l-type calcium channel inactive conformation inhibiting influx calcium smooth muscle cell nimodipine prevents calcium-dependent smooth muscle contraction subsequent vasoconstriction compared calcium channel blocking agent nimodipine exhibit greater effect cerebral circulation peripheral circulation nimodipine used adjunct improve neurologic outcome following subarachnoid hemorrhage ruptured intracranial aneurysm ", use adjunct improve neurologic outcome following subarachnoid hemorrhage sah ruptured intracranial berry aneurysm reducing incidence severity ischemic deficit 
Beclomethasone dipropionate,beclomethasone dipropionate second-generation a179842 synthetic corticosteroid diester beclomethasone structurally similar dexamethasone l6871 prodrug active metabolite beclomethasone 17-monopropionate 17-bmp a179839 act glucocorticoid receptor mediates therapeutic action beclomethasone dipropionate pose weak glucocorticoid receptor binding affinity rapidly converted 17-bmp upon administration a179839 formulation oral inhalation intranasal topical use available beclomethasone dipropionate beclomethasone dipropionate became first available pressurized metered-dose inhaler 1972 later dry powder inhaler aqueous nasal spray a179839 due anti-inflammatory antipruritic anti-allergy property beclomethasone dipropionate used various inflammatory condition asthma allergic rhinitis dermatosis reduce symptom inhaled proposed beclomethasone dipropionate remains active locally lung without causing significant side effect associated systemic corticosteroid a180010 compared earlier corticosteroid dexamethasone prednisolone beclomethasone dipropionate reported le irritating nasal mucosa longer duration action administered intranasally a179848 ,indicated oral inhalation use maintenance treatment asthma prophylactic therapy patient 5 year age older aerosol form beclomethasone diproprionate indicated relief acute bronchospasm l6871 indicated intranasal use relieve symptom seasonal perennial allergic nonallergic vasomotor rhinitis prevent recurrence nasal polyp following surgical removal l6880 indicated relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis patient 13 year age older l10782 corticosteroid-responsive dermatosis include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis anogenital senile pruritus l6886 
Carisoprodol,originally approved fda 1959 fda label carisoprodol centrally acting muscle relaxant used painful musculoskeletal condition conjunction physical therapy medication a176047 drug available oral tablet combined aspirin fixed-dose combination aspirin codeine fda label f4060 f4069 january 2012 drug classified schedule iv substance controlled substance act several u state due alarming rate abuse a176062 a176077 despite low potential abuse addition low risk dependence l5074 ,carisoprodol indicated relief discomfort related acute painful musculoskeletal condition fda label important limitation use fda label • used acute treatment period two three week • adequate evidence effectiveness prolonged use established • recommended pediatric patient le 16 year age
Progesterone,progesterone hormone occurs naturally female essential endometrial receptivity embryo implantation successful establishment pregnancy low progesterone concentration insufficient response progesterone cause infertility pregnancy loss a175609 progesterone used various contraceptive preparation prevent ovulation fertilization t481 a175612 well formulation promote support pregnancy please see medroxyprogesterone acetate megestrol acetate dydrogesterone hydroxyprogesterone entry information various form progesterone pharmaceutical progesterone made plant source starting material chemically identical progesterone human ovarian origin fda label progesterone available gelatinized capsule form vaginal gel form tablet form vaginal insert form injection form used various purpose label f3898 f3904 f3901 f3907 , gelatinized capsule gelatinized capsule indicated use prevention endometrial hyperplasia non-hysterectomized postmenopausal woman receiving conjugated estrogen tablet also indicated use secondary amenorrhea fda label vaginal gel progesterone gel 8 indicated progesterone supplementation replacement part assisted reproductive technology “ art ” treatment infertile woman progesterone deficiency lower concentration progesterone gel 4 used treatment secondary amenorrhea use 8 concentration therapeutic response 4 gel f3898 vaginal insert form indicated support embryo implantation early pregnancy supplementation corpus luteal function part assisted reproductive technology art treatment program infertile woman f3901 injection intramuscular drug indicated amenorrhea abnormal uterine bleeding due hormonal imbalance absence organic pathology submucous fibroid uterine cancer f3907 tablet contraceptive tablet form progesterone contraceptive formulation indicated prevention pregnancy f3904 
Phenylpropanolamine,phenylpropanolamine sympathomimetic agent act nonselective adrenergic receptor agonist norepinephrine reuptake inhibitor used decongestant appetite suppressant currently withdrawn market canada united state due risk hemorrahgic stroke , treatment nasal congestion control urinary incontinence priapism obesity 
Sorafenib,sorafenib rinn marketed nexavar bayer drug approved treatment advanced renal cell carcinoma primary kidney cancer also received `` fast track '' designation fda treatment advanced hepatocellular carcinoma primary liver cancer since performed well phase iii trial sorafenib small molecular inhibitor raf kinase pdgf platelet-derived growth factor vegf receptor 2 3 kinase c kit receptor stem cell factor growing number drug target pathway originality sorafenib lay simultaneous targeting raf/mek/erk pathway ,sorafenib indicated treatment unresectable hepatocellular carcinoma advanced renal cell carcinoma 
Zoledronic acid,zoledronic acid cgp 42'446 a203120 third generation nitrogen containing bisphosphonate similar ibandronic acid minodronic acid risedronic acid a203111 zoledronic acid used treat prevent multiple form osteoporosis hypercalcemia malignancy multiple myeloma bone metastasis solid tumor paget ’ disease bone l13712 l13715 l13721 zoledronic acid first described literature 1994 a203120 zoledronic acid granted fda approval 20 august 2001 l13712 ,zoledronic acid indicated treat hypercalcemia malignancy multiple myeloma bone metastasis solid tumor osteoporosis men postmenopausal woman glucocorticoid induced osteoporosis paget 's disease bone men woman l13712 l13715 l13721 zoledronic acid also indicated prevention osteoporosis post menopausal woman glucocorticoid induced osteoporosis l13712 l13715 l13721 
Griseofulvin, antifungal antibiotic griseofulvin may given mouth treatment tinea infection , treatment ringworm infection skin hair nail namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap condition caused trichophyton /i microsporum /i fungi 
Nisoldipine,"nisoldipine 1,4-dihydropyridine calcium channel blocker act primarily vascular smooth muscle cell stabilizing voltage-gated l-type calcium channel inactive conformation inhibiting influx calcium smooth muscle cell nisoldipine prevents calcium-dependent smooth muscle contraction subsequent vasoconstriction nisoldipine may used alone combination agent management hypertension ", treatment hypertension may used alone combination antihypertensive agent 
Eszopiclone,eszopiclone marketed sepracor brand-name lunesta nonbenzodiazepine hypnotic drug used treat insomnia active stereoisomer zopiclone belonging class drug known _cyclopyrrolones_ a179638 l6850 cyclopyrrolone drug demonstrate high efficacy low toxicity a179827 offering safer alternative drug used insomnia one major benefit eszopiclone approved fda long-term treatment insomnia set apart many hypnotic sedative generally approved relief short-term 6-8 week insomnia eszopiclone initially approved fda 2004 l6769 ,eszopiclone indicated treatment insomnia l6769 
Ceruletide,caerulein specific decapeptide similar action composition natural gastrointestinal peptide hormone cholecystokinin exerts stimulatory effect gastric biliary pancreatic secretion well certain smooth muscle ,caerulein used treatment paralytic ileus diagnostic aid pancreatic malfunction 
Alprazolam,alprazolam triazolobenzodiazepine indicated treatment anxiety panic disorder l34783 l34788 mainly metabolized cyp3as contraindicated cyp3a inhibitor like ketoconazole itraconazole l34783 l34788 benzodiazepine treatment stopped gradually tapering patient 's dose avoid withdrawal symptom a18125 alprazolam 's adverse effect generally related sedation cause a18125 alprazolam mixed alcohol drug abuse potentiate sedative effect drug may lead coma death a18125 alprazolam given fda approval october 16 1981 l6148 ,alprazolam indicated acute treatment generalized anxiety disorder adult l34783 alprazolam also indicated either standard extended-release formulation treatment panic disorder without agoraphobia adult l34783 l34788 alprazolam may also prescribed off-label insomnia premenstrual syndrome depression a177973 
Dexbrompheniramine,dexbrompheniramine maleate antihistamine agent used treatment allergic condition hay fever urticaria , treatment relief symptom allergy hay fever cold
Gentian violet cation, dye mixture violet rosanilinis antibacterial antifungal anthelmintic property , treatment bacterial fungal infection inside mouth thrush skin also prevention transmission chaga disease blood additive 
Ardeparin,"ardeparin marketed u trade name normiflo low molecular weight heparin lmwh anticoagulant used prevention postoperative venous thrombosis ardeparin derived via peroxide degradation heparin extracted porcine intestinal mucosa molecular weight range 2000 15,000 average molecular weight 5500 6500 normiflo withdrawn u market march 2000 ", prevention deep vein thrombosis may result pulmonary embolism following knee surgery 
Loxapine, antipsychotic agent used schizophrenia pubchem , management manifestation psychotic disorder schizophrenia
Remoxipride,remoxipride atypical antipsychotic agent specific dopamine sub 2 /sub receptor a215422 gained approval uk 1989 withdrawn 1993 found associated increased incidence aplastic anemia a215422 a215512 ,remoxipride atypical antipsychotic used treatment schizophrenia a215532 
Mupirocin,mupirocin formerly termed pseudomonic acid a178531 novel antibacterial agent unique chemical structure mode action apart antibiotic agent produced fermentation using organism _pseudomonas fluorescens_ mupirocin naturally-occurring antibiotic display broad-specturm activity many gram-positive bacteria certain gram-negative bacteria _in vitro_ l10580 primarily work inhibiting bacterial protein synthesis due unique mode action inhibiting activity bacterial isoleucyl-trna synthetase mupirocin demonstrate cross-resistance class antimicrobial agent giving therapeutic advantage l10580 available topical formulation due extensive systemic metabolism a178531 used treatment impetigo caused _staphylococcus aureus_ _streptococcus pyogenes_ traumatic skin lesion due secondary skin infection caused _s aureus_ _s pyogenes_ also clinical evidence suggests potential role mupirocin eradicating nasal carriage staphylococci administered intranasally a178531 a178591 mupirocin commonly marketed brand name bactroban ,indicated treatment impetigo secondary skin infection leading traumatic skin lesion due _staphylococcus aureus_ _streptococcus pyogenes_ l10580 
Carbamoylcholine,carbamoylcholine also known carbachol muscarinic agonist discovered 1932 a226315 carbamoylcholine initially used treatment migraine a226365 induction diuresis a226370 parasympathetic effect carbamoylcholine granted fda approval 28 september 1972 l30245 ,carbamoylcholine indicated induce miosis surgery reduce intraocular pressure elevation first 24 hour cataract surgery l30245 
Rosiglitazone,rosiglitazone anti-diabetic drug thiazolidinedione class drug marketed pharmaceutical company glaxosmithkline stand-alone drug avandia combination metformin avandamet glimepiride avandaryl like thiazolidinediones mechanism action rosiglitazone activation intracellular receptor class peroxisome proliferator-activated receptor ppars specifically pparγ rosiglitazone selective ligand pparγ pparα-binding action apart effect insulin resistance appears anti-inflammatory effect nuclear factor kappa-b nfκb level fall inhibitor iκb level increase patient rosiglitazone recent research suggested rosiglitazone may also benefit subset patient alzheimer 's disease expressing apoe4 allele subject clinical trial currently underway ,rosiglitazone indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus 
Pramipexole,pramipexole drug used treat symptom parkinson 's disease pd _non-ergot dopamine agonist_ drug efficacious treating various parkinson 's symptom tremor rigidity bradykinesia slow movement a176867 first approved fda 1997 l5882 parkinson 's disease one common neurodegenerative disorder cause high level disability patient a176855 leading increased difficulty performing activity daily living due symptom progress time a176858 prevalence parkinson 's disease worldwide increased approximately 2.5 million 1990 6.1 million 2016 a176861 increase may attributed aging population along contributing factor a176861 addition fda approval parkinson 's disease pramipexole also approved fda 2006 treatment restless leg syndrome rls a176873 rls sleep-related disorder characterized unpleasant sensation lower extremity often accompanied uncontrollable urge move leg a176876 , drug indicated symptomatic treatment parkinson ’ disease fda label drug administered monotherapy conjunction levodopa also indicated symptomatic treatment moderate severe primary restless leg syndrome rls fda label 
Acetohexamide, sulfonylurea hypoglycemic agent metabolized liver 1-hydrohexamide acetohexamide discontinued u market ,used management diabetes mellitus type 2 adult-onset 
Ampicillin,ampicillin semi-synthetic derivative penicillin function orally active broad-spectrum antibiotic , treatment infection respiratory gi uti meningitis due e. coli p. mirabilis enterococci shigella s. typhosa salmonella nonpenicillinase-producing n. gononhoeae h. influenzae staphylococci streptococci including streptoc
Metocurine iodide,metocurine iodide benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent used anesthesia adjunct induce skeletal muscle relaxation reduce intensity muscle contraction convulsive therapy metocurine iodide moderate risk inducing histamine release ganglion blocking activity metocurine iodide used advantageously muscle twitch response peripheral nerve stimulation monitored ass degree muscle relaxation metocurine iodide longer available u market , use anesthesia adjunct induce skeletal muscle relaxation reduce intensity muscle contraction convulsive therapy 
Phenoxymethylpenicillin,phenoxymethylpenicillin narrow spectrum antibiotic also commonly referred penicillin v penicillin vk a178609 phenoxymethyl analog penicillin g benzylpenicillin orally active naturally penicillin phenoxymethylpenicillin used treat mild moderate infection respiratory tract skin soft tissue caused penicillin g­-sensitive microorganism phenoxymethylpenicillin also used case prophylaxis susceptible organism controlled clinical efficacy study conducted phenoxymethylpenicillin suggested american heart association american dental association use oral regimen prophylaxis bacterial endocarditis patient congenital heart disease rheumatic acquired valvular heart disease undergo dental procedure surgical procedure upper respiratory tract except elevated risk endocarditis label ,indicated treatment mild moderately severe infection due penicillin g­-sensitive microorganism use bacteriological study including sensitivity test clinical response label phenoxymethylpenicillin may used treatment mild moderate infection upper respiratory tract scarlet fever mild erysipelas caused streptococcus without bacteremia mild moderately severe infection respiratory tract caused pneumococcus mild infection skin soft tissue caused penicillin g-sensitive staphylococcus mild moderately severe infection oropharynx caused fusospirochetosis including vincent ’ gingivitis pharyngitis usually respond oral penicillin therapy off-label indicated use prophylaxis bacterial endocarditis patient congenital heart disease rheumatic acquired valvular heart disease undergo dental procedure surgical procedure upper respiratory tract label 
Secobarbital,secobarbital marketed eli lilly company brand name seconal tuinal barbiturate derivative drug anaesthetic anticonvulsant sedative hypnotic property commonly known quinalbarbitone united kingdom , short-term treatment intractable insomnia patient habituated barbiturate
Miglustat,miglustat commonly marketed trade name zavesca drug used treat gaucher disease inhibits enzyme glucosylceramide synthase essential enzyme synthesis glycosphingolipids used patient treated enzyme replacement therapy imiglucerase miglustat first approved therapy patient niemann-pick disease type c np-c recently approved treatment progressive neurological symptom adult pediatric patient european union brazil south korea miglustat first developed anti-hiv agent 1990s however clinical experience miglustat showed therapeutic level drug could achieved patient without high incidence adverse effect , treatment adult patient mild moderate type 1 nonneuropathic gaucher 's disease enzyme replacement therapy therapeutic option e.g due constraint allergy hypersensitivity poor venous access approved country treatment progressive neurological symptom adult pediatric patient niemann-pick disease type c np-c 
Promazine, phenothiazine action similar chlorpromazine le antipsychotic activity primarily used short-term treatment disturbed behavior antiemetic currently approved use united state ,used adjunct short term treatment moderate severe psychomotor agitation also used treat agitation restlessness elderly 
Spironolactone,spironolactone potassium sparing diuretic like eplerenone competitively inhibits mineralocorticoid receptor distal convoluted tubule promote sodium water excretion potassium retention a11837 spironolactone originally developed purely ability pharmacodynamic property drug discovered a11837 a178246 indicated treat number condition including heart failure deem hyperaldosteronism adrenal hyperplasia hypertension nephrotic syndrome label label us spironolactone involving antiandrogenic activity include hirsutism female pattern hair loss adult acne vulgaris a178135 spironolactone also frequently used medical gender transition a178138 spironolactone developed 1957 marketed 1959 approved fda january 21 1960 a178243 l6187 ,spironolactone indicated treatment new york heart association class iii-iv heart failure management edema cirrhotic adult responsive fluid sodium restriction primary hyperaldosteronism short-term preoperatively primary hyperaldosteronism long-term patient aldosterone producing adrenal adenoma candidate surgery patient bilarteral micro/macronodular adrenal hyperplasia add-on therapy hypertension nephrotic syndrome treatment disease well fluid sodium restriction diuretic inadequate label spironolactone antiandrogenic activity lead many label us spironolactone used label treatment hirsutism female pattern hair loss adult acne vulgaris a178135 spironolactone also frequently used antiandrogenic effect transgender female patient due low cost reducing male-pattern hair growth a178138 
Methylphenidate,methylphenidate central nervous system stimulant used commonly treatment attention-deficit/hyperactivity disorder adhd narcolepsy also known marketed product ritalin concerta biphentin methylphenidate used treatment modality psychological educational cognitive behaviour therapy etc improve following group developmentally inappropriate symptom associated adhd moderate-to-severe distractibility short attention span hyperactivity emotional lability impulsivity long-acting formulation psychostimulants methylphenidate db01576 db01255 considered effective widely used treatment adhd considered first-line option child adolescent adult recommended caddra canadian adhd resource alliance l6037 caddra recommends use methylphenidate due long term study twenty year duration show methylphenidate safe effective exact mechanism unclear methylphenidate mph shown act norepinephrine dopamine reuptake inhibitor ndri thereby increasing presence neurotransmitter extraneuronal space prolonging action a177541 dose-related effect psychostimulants receptor stimulation higher dos shown increase norepinephrine ne dopamine da efflux throughout brain result impaired cognition locomotor-activating effect contrast low dos found selectively activate ne da neurotransmission within prefrontal cortex area brain thought play prominent role adhd pathophysiology thereby improving clinical efficacy preventing side effect a177547 lower dos used treat adhd associated locomotor-activating effect associated higher dos instead reduce movement impulsivity increase cognitive function including sustained attention working memory a177541 a177544 methylphenidate 's beneficial effect sustaining attention also shown mediated alpha-1 adrenergic receptor activity a177550 clinical finding shown child adhd abnormality dopamine transporter gene dat1 d4 receptor gene drd-4 and/or d2 receptor gene may least partly overcome dopaminergic effect methylphenidate suggesting possible mode action f4474 provided biphentin® methylphenidate released multi-layer release delivery system mlrtm 40 dose provided immediate release 60 provided gradual release biphentin designed alternative separate dos immediate-release ir methylphenidate providing biphasic concentration-time profile given single dose mlrtm release system allows sustained effect 10-12 hour allowing once-daily dosing cover major time adhd impairment might occur school homework period work day etc provided concerta® methylphenidate released patented osmotic controlled-release oral delivery oros system 22 dose provided immediate release 78 provided gradual release a631 oros comprised osmotically active trilayer core surrounded semipermeable membrane immediate-release drug overcoat within aqueous environment stomach drug overcoat consists 22 dose dissolve within one hour providing initial immediate-release formulation methylphenidate water permeates membrane tablet core osmotically active polymer excipients expand allowing methylphenidate release slowly orifice period 6-7 hour concerta also provides sustained 10-12 hour effect allowing once-daily dosing methylphenidate contains blackbox warning stating cns stimulant including methylphenidate-containing product amphetamine high potential abuse dependence abuse potential likely related effect associated higher dos methylphenidate induce surface expression dopamine transporter dat a177553 particular increased dopamine key brain area associated reinforcing addictive property psychostimulants methylphenidate even amplifies potency reinforcing effect drug abuse amphetamine making adhd sufferer susceptible addictive effect a177556 concern abuse potential spurred research medication fewer effect dat use non-stimulant adhd medication including db00289 db01018 ,methylphenidate indicated treatment attention deficit hyperactivity disorder adhd patient 6 year age older treatment narcolepsy 
Methocarbamol,methocarbamol developed early 1950s treatment muscle spasticity associated pain a178441 a178450 guaiacol glyceryl ether a178450 methocarbamol tablet intramuscular injection prescription medicine indicated united state adjunct rest physical therapy measure relief discomfort associated acute painful musculoskeletal condition label l6268 canada methocarbamol sold counter oral medicine lower dose may combined acetaminophen ibuprofen l6295 combination product acetylsalicylic acid codeine available canada prescription l6295 methocarbamol fda approved 16 july 1957 l6265 ,methocarbamol tablet intramuscular injection indicated united state adjunct rest physical therapy measure relief discomfort associated acute painful musculoskeletal condition label l6268 oral methocarbamol america may given 1500mg 4 time daily 2-3 day a31312 canada methocarbamol containing oral formulation sold counter pain associated muscle spasm l6295 however combination formulation include codeine prescription l6295 
Hyoscyamine,hyoscyamine tropane alkaloid levo-isomer atropine a228423 commonly extracted plant _solanaceae_ nightshade family a228423 research action hyoscyamine published literature date back 1826 a228713 hyoscyamine used wide variety treatment therapeutic due antimuscarinic property l31548 l31553 although hyoscyamine marketed united state fda approved l31548 l31553 , drug fda approved hyscyamine official indication l31548 l31553 intravenous hysocyamine used reduce gastric motility reduce pancreatic pain secretion facilitate imaging gastrointestinal tract treat anticholinesterase toxicity treat certain case partial heart block improve visualization kidney symptomatic relief biliary renal colic l31548 intravenous hyoscyamine also used pre-operatively reduce secretion mouth respiratory tract facilitate intubation l31548 oral hyoscyamine used treat functional intestinal disorder symptomatic relief biliary renal colic symptomatic relief acute rhinitis l31553 
Zolpidem,zolpidem also known _ambien_ hypnotic drug initially approved fda 1992 fda label zolpidem improves sleep patient insomnia aimed use patient difficulty initiating sleep drug decrease time fall asleep sleep latency increase duration sleep decrease number awakening sleep patient temporary transient insomnia available immediate acting extended release form fda label f3802 tolerability profile favorable administered according manufacturer ’ instruction low risk drug withdrawal drug dependence drug tolerance a175426 addition zolpidem improves sleep quality patient suffering chronic insomnia show mild muscle relaxant property l5584 research also show zolpidem rapid effective restoring brain function patient vegetative state following brain injury drug propensity completely partially reverse abnormal metabolism damaged brain cell injury l5584 a175444 , drug indicated short-term treatment insomnia adult characterized difficulty sleep initiation fda label 
Famciclovir,famciclovir marketed famvir novartis guanine analogue used treat herpes virus infection commonly used treat herpes zoster shingle famciclovir prodrug penciclovir higher oral bioavailability , treatment acute herpes zoster shingle also treatment suppression recurrent genital herpes immunocompetent patient treatment recurrent mucocutaneous herpes simplex infection hiv infected patient 
Triprolidine,first generation histamine h1 antagonist used allergic rhinitis asthma urticaria component cough cold medicine may cause drowsiness , symptomatic relief seasonal perennial allergic rhinitis nonallergic rhinitis allergic conjunctivitis mild uncomplicated allergic skin manifestation urticaria angioedema also used combination agent symptomatic relief symptom associated common cold 
Streptozocin, antibiotic produced stretomyces achromogenes used antineoplastic agent induce diabetes experimental animal , treatment malignant neoplasm pancreas metastatic islet cell carcinoma 
Carboprost tromethamine, nonsteroidal abortifacient agent effective first second trimester pregnancy , aborting pregnancy 13th 20th week gestation calculated first day last normal menstrual period following condition related second trimester abortion 1 failure expulsion fetus course treatment another method 2 premature rupture membrane intrauterine method loss drug insufficient absent uterine activity 3 requirement repeat intrauterine instillation drug expulsion fetus 4 inadvertent spontaneous rupture membrane presence previable fetus absence adequate activity expulsion also treatment postpartum hemorrhage due uterine atony responded conventional method management 
Cefpiramide,cefpiramide third-generation cephalosporin antibiotic , treatment severe infection caused susceptible bacteria p. aeruginosa 
Lindane, organochlorine insecticide used pediculicide scabicide lindane banned california united kingdom australia many western country due concern neurotoxicity adverse effect environment canada lindane recommmended first-line therapy due report resistance neurotoxicity bone marrow suppression approved fda second-line therapy topical treatment pediculosis capitis head louse pediculosis pubis pubic louse scabies patient greater two year age tolerate failed first-line treatment lindane still allowed pharmaceutical use 2015 , treatment patient infested sarcoptes scabiei pediculosis capitis either failed respond adequate dos intolerant approved therapy 
Trifluridine,trifluridine fluorinated pyrimidine nucleoside structurally related idoxuridine a35271 active antiviral agent ophthalmic solution used mainly treatment primary keratoconjunctivitis recurrent epithelial keratitis due herpes simplex virus display effective antiviral activity herpes simplex virus type 1 2 a35271 combination product trifluridine tipiracil marketed lonsurf approved japan united state european union treatment adult patient metastatic colorectal cancer previously treated fluoropyrimidine- oxaliplatin- irinotecan-based chemotherapy anti-vegf biological therapy ra wild-type anti-egfr therapy anticancer therapy trifluridine act thymidine-based nucleoside metabolic inhibitor get incorporated dna cancer cell following cell uptake aberrate dna function cell replication f649 ,trifluridine used treatment primay keratoconjunctivitis recurrent epithelial keratitis due herpes simplex virus type 1 2 ophthalmic solution trifluridine combination tipiracil indicated treatment adult patient metastatic colorectal cancer previously treated fluoropyrimidine- oxaliplatin- irinotecan-based chemotherapy anti-vegf biological therapy ra wild-type anti-egfr therapy combination use also used treat metastatic gastric gastroesophageal junction adenocarcinoma previously treated least two prior line chemotherapy included fluoropyrimidine platinum either taxane irinotecan appropriate her2/neu-targeted therapy l41250 
Prochlorperazine,prochlorperazine also known compazine piperazine phenothiazine first-generation antipsychotic drug used treatment severe nausea vomiting well short-term management psychotic disorder generalized non-psychotic anxiety schizophrenia label mainly work depressing chemoreceptor trigger zone blocking d2 dopamine receptor brain shown also block histaminergic cholinergic noradrenergic receptor l6637 prochlorperazine first developed 1950s l6643 first approved fda 1956 although newer antiemetic agent 5-ht3 antagonist heavily promoted prochlorperazine still widely used nausea vomiting l6640 ,indicated symptomatic treatment severe nausea vomiting label indicated management manifestation psychotic disorder schizophrenia generalized non-psychotic anxiety use prochlorperazine management generalized non-psychotic anxiety typically first-line therapy limited dos le 20 mg per day shorter 12 week label l6634 off-label us include use emergency setting adult pediatric migraine american headache society recommends use prochlorperazine first-line medication setting pediatric migraine non-steroidal anti-inflammatory agent often used combination dopamine antagonist l6637 
Cyproheptadine,cyproheptadine potent competitive antagonist serotonin histamine receptor l32474 used primarily treat allergic symptom though perhaps notable use appetite stimulation l32519 off-label use treatment serotonin syndrome a231274 , u prescription cyproheptadine indicated treatment various allergic symptomatologies including dermatographia rhinitis conjunctivitis urticaria well adjunctive therapy management anaphylaxis following treatment epinephrine l32474 canada cyproheptadine available over-the-counter indicated treatment pruritus appetite stimulation l32519 australia cyproheptadine additionally indicated treatment vascular headache l32479 cyproheptadine also used off-label treatment serotonin syndrome a231274 
Nitric Oxide,nitric oxide nitrogen monoxide chemical compound chemical formula gas important signaling molecule body mammal including human extremely important intermediate chemical industry also toxic air pollutant produced automobile engine power plant nitric oxide confused nitrous oxide n2o general anaesthetic nitrogen dioxide no2 another poisonous air pollutant nitric oxide molecule free radical relevant understanding high reactivity reacts ozone air form nitrogen dioxide signalled appearance reddish-brown color , treatment term near-term gt 34 week neonate hypoxic respiratory failure
Bendroflumethiazide, thiazide diuretic action us similar hydrochlorothiazide used treatment familial hyperkalemia hypertension edema urinary tract disorder martindale extra pharmacopoeia 30th ed p810 , treatment high blood pressure management edema related heart failure 
Allopurinol,gout disease occurs deposition monosodium urate crystal msu body tissue especially around joint a175942 disease well-documented historical medical record appears biography several prominent historically recognized individual a175942 allopurinol xanthine oxidase enzyme inhibitor considered one effective drug used decrease urate level frequently used treatment chronic gout a36705 initially approved fda 1966 l5674 formulated several manufacturer l5677 ,allopurinol indicated fda label 1 management patient sign symptom primary secondary gout acute attack tophus joint destruction uric acid lithiasis and/or nephropathy 2 management patient leukemia lymphoma malignancy receiving cancer therapy cause elevation serum urinary uric acid level treatment allopurinol discontinued potential overproduction uric acid longer present 3 management patient recurrent calcium oxalate calculus whose daily uric acid excretion exceeds 800 mg/day male patient 750 mg/day female patient therapy patient carefully assessed initially reassessed periodically determine case treatment beneficial benefit outweigh risk 
Ceftazidime,bacteria posse cell wall comprising glycopeptide polymer commonly known peptidoglycan synthesized remodelled action family enzyme known `` penicillin-binding protein '' pbps a232920 β-lactam antibiotic including cephalosporin pbp inhibitor inhibition essential pbps result impaired cell wall homeostasis loss cell integrity ultimately bacterial cell death a232920 a232925 a232930 ceftazidime third-generation cephalosporin broad-spectrum antibacterial activity including treatment-resistant bacteria _pseudomonas aeruginosa_ l32935 ceftazidime approved fda july 19 1985 currently available either alone combination non-β-lactam β-lactamase inhibitor avibactam treat variety bacterial infection l32935 l32940 ,ceftazidime indicated treatment lower respiratory tract infection skin skin structure infection urinary tract infection bacterial septicemia bone joint infection gynecologic infection intra-abdominal infection including peritonitis central nervous system infection including meningitis caused susceptible bacteria l32935 ceftazidime indicated combination avibactam treat infection caused susceptible gram-negative organism including complicated intra-abdominal infection ciai conjunction metronidazole complicated urinary tract infection cuti including pyelonephritis patient aged three month older combination also indicated treat hospital-acquired ventilator-associated bacterial pneumonia habp/vabp patient aged 18 year older l32940 case mitigate risk bacterial resistance preserve clinical efficacy ceftazidime used infection confirmed strongly suspected caused susceptible bacterial strain l32935 l32940 
Cerivastatin, august 8 2001 u.s. food drug administration fda announced bayer pharmaceutical division voluntarily withdrew baycol u.s. market due report fatal rhabdomyolysis severe adverse reaction cholesterol-lowering lipid-lowering product also withdrawn canadian market a669 l43942 ,used adjunct diet reduction elevated total ldl cholesterol level patient primary hypercholesterolemia mixed dyslipidemia fredrickson type iia iib response dietary restriction saturated fat cholesterol non-pharmacological measure alone inadequate 
Trimethoprim,trimethoprim antifolate antibacterial agent inhibits bacterial dihydrofolate reductase dhfr critical enzyme catalyzes formation tetrahydrofolic acid thf prevents synthesis bacterial dna ultimately continued bacterial survival l11893 trimethoprim often used combination sulfamethoxazole due complementary synergistic mechanism may used monotherapy treatment and/or prophylaxis urinary tract infection l11893 l11830 structurally chemically related pyrimethamine another antifolate antimicrobial used treatment plasmodial infection t707 , monotherapy trimethoprim indicated treatment acute episode uncomplicated urinary tract infection caused susceptible bacteria including _e coli._ _k pneumoniae_ _enterobacter spp._ _p mirabilis_ coagulase-negative _staphylococcus_ specie l11893 l11890 various formulation combination sulfamethoxazole trimethoprim indicated following infection caused bacteria documented susceptibility urinary tract infection acute otitis medium pediatric patient clinically indicated acute exacerbation chronic bronchitis adult enteritis caused susceptible _shigella_ prophylaxis treatment _pneumocystis jiroveci_ pneumonia traveler diarrhea caused enterotoxigenic _e coli_ l11830 l11863 trimethoprim available ophthalmic solution combination polymyxin b treatment acute bacterial conjunctivitis blepharitis blepharoconjunctivitis caused susceptible bacteria l11887 
Gemcitabine,gemcitabine nucleoside analog chemotherapeutic agent originally investigated antiviral effect used anticancer therapy various cancer a233135 gemcitabine cytidine analog two fluorine atom replacing hydroxyl ribose a233145 prodrug gemcitabine transformed active metabolite work replacing building block nucleic acid dna elongation arresting tumour growth promoting apoptosis malignant cell l32960 structure metabolism mechanism action gemcitabine similar cytarabine gemcitabine wider spectrum antitumour activity a233140 gemcitabine marketed gemzar available intravenous injection approved fda treat advanced ovarian cancer combination carboplatin metastatic breast cancer combination paclitaxel non-small cell lung cancer combination cisplatin pancreatic cancer monotherapy l32950 also investigated cancer tumour type ,gemcitabine chemotherapeutic agent used monotherapy combination anticancer agent combination carboplatin indicated treatment advanced ovarian cancer relapsed least 6 month completion platinum-based therapy l32950 gemcitabine combination paclitaxel indicated first-line treatment patient metastatic breast cancer failure prior anthracycline-containing adjuvant chemotherapy unless anthracyclines clinically contraindicated l32950 combination cisplatin gemcitabine indicated first-line treatment patient inoperable locally advanced stage iiia iiib metastatic stage iv non-small cell lung cancer nsclc l32950 dual therapy cisplatin also used treat patient stage iv locally advanced metastatic transitional cell carcinoma tcc bladder l32955 gemcitabine indicated first-line treatment patient locally advanced nonresectable stage ii stage iii metastatic stage iv adenocarcinoma pancreas gemcitabine indicated patient previously treated fluorouracil l32950 
Entecavir,entecavir oral antiviral drug used treatment hepatitis b infection marketed trade name baraclude bm entecavir guanine analogue inhibits three step viral replication process manufacturer claim efficacious previous agent used treat hepatitis b lamivudine adefovir approved u.s. food drug administration fda march 2005 , treatment chronic hepatitis b virus infection adult evidence active viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease 
Betamethasone,betamethasone long-acting corticosteroid immunosuppressive antiinflammatory property a192444 used topically manage inflammatory skin condition eczema parenterally manage several disease state including autoimmune disorder a192444 betamethasone potent glucocorticoid activity negligible mineralocorticoid activity a192444 , member corticosteroid family betamethasone indicated treatment several inflammatory condition topical monotherapy betamethasone indicated relieve pruritic inflammatory symptom corticosteroid-responsive-dermatoses l11991 l10782 l11997 betamethasone used topically combination vitamin analog calcipotriene treat plaque psoriasis l12000 corticosteroid also available injectable suspension used manage range inflammatory condition including endocrine disorder gastrointestinal disorder rheumatic disorder among condition l11994 
Teniposide,teniposide semisynthetic derivative podophyllotoxin exhibit antitumor activity teniposide inhibits dna synthesis forming complex topoisomerase ii dna complex induces break double stranded dna prevents repair topoisomerase ii binding accumulated break dna prevent cell entering mitotic phase cell cycle lead cell death teniposide act primarily g2 phase cycle ,teniposide used treatment refractory acute lymphoblastic leukaemia
Epirubicin, anthracycline 4 39 -epi-isomer doxorubicin compound exerts antitumor effect interference synthesis function dna , use component adjuvant therapy patient evidence axillary node tumor involvement following resection primary breast cancer 
Chloramphenicol, antibiotic first isolated culture _streptomyces venequelae_ 1947 produced synthetically relatively simple structure first broad-spectrum antibiotic discovered act interfering bacterial protein synthesis mainly bacteriostatic martindale extra pharmacopoeia 29th ed p106 fda withdrawn oral drug product containing chloramphenicol due high risk fatal aplastic anemia associated specific route administration l43942 l44022 ,used treatment cholera destroys vibrio decrease diarrhea effective tetracycline-resistant vibrio also used eye drop ointment treat bacterial conjunctivitis 
Loracarbef,loracarbef carbacephem antibiotic sometimes grouped together second-generation cephalosporin antibiotic marketed trade name lorabid ,used treat upper respiratory tract bacterial infection chronic bronchitis pneumonia sinusitis pharyntitis tonsillitis skin absceses urinary tract infection pyelonephritis caused e coli /i pyogenes /i aureus /i saprphyticus /i penumoniae /i h influenzae /i catarrhalis /i 
Lansoprazole,lansoprazole marketed brand prevacid proton pump inhibitor ppi structurally classified substituted benzimidazole a177065 reduces gastric acid secretion targeting gastric h k-atpase pump thus effective promoting healing ulcerative disease treating gastroesophageal reflux disease gerd along pathology caused excessive acid secretion a177053 ,lansoprazole used reduce gastric acid secretion approved short term treatment active gastric ulcer active duodenal ulcer erosive reflux oesophagitis symptomatic gastroesophageal reflux disease non-steroidal anti-inflammatory drug nsaid induced gastric duodenal ulcer a4892 a177065 fda label may used maintenance healing several gastric condition including duodenal ulcer nsaid related gastric ulcer erosive esophagitis fda label lansoprazole prevents recurrence gastric ulcer patient documented history gastric ulcer also use nsaid chronically fda label predictably also useful management hypersecretory condition including zollinger-ellison syndrome fda label lansoprazole effective eradicating h. pylorus used conjunction amoxicillin clarithromycin triple therapy amoxicillin alone dual therapy fda label 
Dipivefrin,dipivefrin prodrug adrenaline used treat glaucoma available ophthalmic solution eye drop ,dipivefrin prodrug used initial therapy control intraocular pressure chronic open-angle glaucoma 
Droperidol, butyrophenone general property similar haloperidol used conjunction opioid analgesic fentanyl maintain patient calm state neuroleptanalgesia indifference surroundings still able cooperate surgeon also used premedicant antiemetic control agitation acute psychosis martindale extra pharmacopoeia 29th ed p593 ,droperidol used produce tranquilization reduce incidence nausea vomiting surgical diagnostic procedure 
Levothyroxine,levothyroxine synthetically produced form thyroxine major endogenous hormone secreted thyroid gland f4633 also known l-thyroxine brand name product synthroid levothyroxine used primarily treat hypothyroidism condition thyroid gland longer able produce sufficient quantity thyroid hormone sub 4 /sub tetraiodothyronine thyroxine sub 3 /sub triiodothyronine db00279 resulting diminished down-stream effect hormone without sufficient quantity circulating thyroid hormone symptom hypothyroidism begin develop fatigue increased heart rate depression a179620 dry skin hair muscle cramp constipation weight gain memory impairment poor tolerance cold temperature f4636 a35722 response thyroid stimulating hormone tsh release pituitary gland normally functioning thyroid gland produce secrete sub 4 /sub converted deiodination type type ii 5′-deiodinases a179941 active metabolite sub 3 /sub sub 4 /sub major product secreted thyroid gland sub 3 /sub exerts majority physiological effect thyroid hormone sub 4 /sub sub 3 /sub relative potency ~1:4 t4 t3 f4633 sub 4 /sub sub 3 /sub act nearly every cell body particularly strong effect cardiac system a179935 result many cardiac function including heart rate cardiac output systemic vascular resistance closely linked thyroid status a179938 prior development levothyroxine db09100 desiccated thyroid used mainstay treatment hypothyroidism however longer recommended majority patient due several clinical concern including limited controlled trial supporting use desiccated thyroid product contain ratio t4 t3 4.2:1 significantly lower 14:1 ratio secretion human thyroid gland higher proportion t3 desiccated thyroid product lead supraphysiologic level t3 may put patient risk thyrotoxicosis thyroid extract therapy adjusted according serum tsh a35722 f4636 ,levothyroxine indicated replacement therapy primary thyroidal secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism also indicated adjunct surgery radioiodine therapy management thyrotropin-dependent well-differentiated thyroid cancer 
Framycetin, component neomycin produced streptomyces fradiae hydrolysis yield neamine neobiosamine b merck index 11th ed , treatment bacterial blepharitis bacterial bonjunctivitis corneal injury corneal ulcer meibomianitis prophylaxis ocular infection following foreign body removal
Clomocycline,clomocycline tetracycline used treat bacterial infection , treatment management brucellosis mycoplasma infection acne vulgaris chlamydial infection chronic bronchitis
Meperidine, narcotic analgesic used relief type moderate severe pain including postoperative pain pain labor prolonged use may lead dependence morphine type withdrawal symptom appear rapidly morphine shorter duration ,used control moderate severe pain 
Loratadine,loratadine second generation antihistamine used manage symptom allergic rhinitis a176435 lack sedative cns adverse effect make loratadine along second generation antihistamine preferable 1st generation counterpart many clinical situation a176441 ,loratadine 2nd generation antihistamine used manage symptom allergic rhinitis wheal formation urticaria allergic dermatologic condition a176435 a176438 l8486 
Cefalotin,cefalotin cephalosporin antibiotic ,used prevent infection surgery treat many kind infection blood bone joint respiratory tract skin urinary tract 
Prazosin,prazosin also known _minipress_ drug used treat hypertension prazosin marketed _pfizer_ initially approved fda 1988 l5828 belongs class drug known alpha-1 antagonist fda label a176630 recently many study evaluated benefit drug controlling symptom post-traumatic stress disorder ptsd associated nightmare a176618 a176621 a176624 , drug indicated treatment hypertension high blood pressure prazosin given alone given blood pressure-lowering drug including diuretic beta-adrenergic blocking agent fda label prazosin negatively impact lung function therefore may used manage hypertension patient asthmatic patient chronic obstructive lung disease copd a176630 
Imipramine,imipramine prototypical tricyclic antidepressant tca dibenzazepine-derivative tca tcas structurally similar phenothiazine contain tricyclic ring system alkyl amine substituent central ring non-depressed individual imipramine affect mood arousal may cause sedation depressed individual imipramine exerts positive effect mood tcas potent inhibitor serotonin norepinephrine reuptake tertiary amine tcas imipramine amitriptyline potent inhibitor serotonin reuptake secondary amine tcas nortriptyline desipramine tcas also block histamine h sub 1 /sub receptor alpha sub 1 /sub -adrenergic receptor muscarinic receptor account sedative hypotensive anticholinergic effect e.g blurred vision dry mouth constipation urinary retention respectively a6584 imipramine le sedative anticholinergic effect tertiary amine tcas amitriptyline clomipramine imipramine may used treat depression nocturnal enuresis child fda label unlabeled indication include chronic neuropathic pain including diabetic neuropathy panic disorder attention-deficit/hyperactivity disorder adhd post-traumatic stress disorder ptsd l1349 l1348 a31900 l1351 l1352 l1353 a31904 , relief symptom depression temporary adjunctive therapy reducing enuresis child aged 6 year older fda label may also used off-label manage panic disorder without agoraphobia second line agent adhd child adolescent manage bulimia nervosa short-term management acute depressive episode bipolar disorder schizophrenia treatment acute stress disorder posttraumatic stress disorder symptomatic treatment postherpetic neuralgia painful diabetic neuropathy l1349 l1348 a31900 l1351 l1352 l1353 a31904 
Acitretin, oral retinoid effective treatment psoriasis major metabolite etretinate advantage much shorter half-life compared etretinate , treatment severe psoriasis adult 
Verteporfin,verteporfin marketed visudyne benzoporphyrin derivative used photosensitizer photodynamic therapy eliminate abnormal blood vessel wet form macular degeneration verteporfin accumulates abnormal blood vessel stimulated nonthermal red light wavelength 693 nm presence oxygen produce highly reactive short-lived singlet oxygen reactive oxygen radical resulting local damage endothelium blockage vessel , treatment patient predominantly classic subfoveal choroidal neovascularization due age-related macular degeneration pathologic myopia presumed ocular histoplasmosis syndrome verteporfin also used destroy tumor 
Nabumetone,nabumetone originally developed non-acidic non-steroidal anti-inflammatory drug nsaid label thought avoid trapping drug stomach making unable dissociate ion believed reduce gi toxicity limiting local action a179077 slightly reduced possibly due degree cyclooxygenase-2 selectivity cox-2 nabumetone still produce significant adverse effect gi tract label a178903 molecule pro-drug 6-methoxy-2-naphthylacetic acid 6-mna metabolite acting potent cox inhibitor similar structure naproxen nabumetone developed smithkline beecham trade name relafen first received fda approval december 1991 l6568 , indicated label 1 symptomatic relief rheumatoid arthritis 2 symptomatic relief osteoarthritis 
Methscopolamine bromide, muscarinic antagonist used study binding characteristic muscarinic cholinergic receptor ,used adjunctive therapy treatment peptic ulcer also used treat nausea vomiting due motion sickness 
Metharbital,metharbital barbiturate anticonvulsant similar phenobarbital marketed gemonil abbott laboratory patented 1905 emil fischer merck ,metharbital used treatment epilepsy 
Sodium tetradecyl sulfate, anionic surface-active agent used wetting property industry used medicine irritant sclerosing agent hemorrhoid varicose vein , treatment small uncomplicated varicose vein lower extremity show simple dilation competent valve 
Ketorolac,ketorolac non-steroidal anti-inflammatory drug nsaid commercially available oral tablet injectable nasal spray ophthalmic solution l6358 l6508 l11055 l3674 l11070 's analgesic property make useful pain management tool across many setting including postoperative pain rheumatoid arthritis osteoarthritis menstrual disorder headache spinal soft tissue pain ankylosing spondylitis l6520 impressively ketorolac similar efficacy standard dos morphine meperidine making useful opioid sparing agent l6511 ,ketorolac non-steroidal anti-inflammatory drug nsaid antipyretic analgesic anti-inflammatory property a176131 indicated short term management acute pain requires calibre pain management offered opioids l3674 clinician may choose initiate ketorolac manage post-operative pain spinal soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorder headache among ailment l6520 regardless etiology pain patient use lowest possible dose avoid using ketorolac extended period time ideally ≤ 5 day l3674 benefit choosing ketorolac analgesic similar potency appear risk dependence tolerance ketorolac use a176131 
Picrotoxin, noncompetitive antagonist gaba-a receptor thus convulsant picrotoxin block gamma-aminobutyric acid-activated chloride ionophore although often used research tool used cns stimulant antidote poisoning cns depressant especially barbiturate pubchem ,used internally relieving respiratory distress also use antidote poisoning cns depressant especially barbiturate 
Enoxacin, broad-spectrum 6-fluoronaphthyridinone antibacterial agent fluoroquinolones structurally related nalidixic acid , treatment adult ge 18 year age following infection caused susceptible strain designated microorganism 1 uncomplicated urethral cervical gonorrhea due neisseria gonorrhoeae /i 2 uncomplicated urinary tract infection cystitis due escherichia coli /i staphylococcus epidermidis /i staphylococcus saprophyticus /i 3 complicated urinary tract infection due escherichia coli /i klebsiella pneumoniae /i proteus mirabilis /i pseudomonas aeruginosa /i staphylococcus epidermidis /i enterobacter cloaca /i 
Quinine, alkaloid derived bark cinchona tree used antimalarial drug active ingredient extract cinchona used purpose since 1633 quinine also mild antipyretic analgesic used common cold preparation purpose used commonly bitter flavoring agent still useful treatment babesiosis quinine also useful muscular disorder especially nocturnal leg cramp myotonia congenita direct effect muscle membrane sodium channel mechanism antimalarial effect well understood , treatment malaria leg cramp
Tenoxicam,tenoxicam antiinflammatory agent analgesic antipyretic property used treat osteoarthritis control acute pain , treatment rheumatoid arthritis osteoarthritis backache pain 
Dronabinol,dronabinol marketed marinol synthetic form delta-9-tetrahydrocannabinol δ⁹-thc primary psychoactive component cannabis marijuana thc demonstrates effect weak partial agonist activity cannabinoid-1 cb1r cannabinoid-2 cb2r receptor result well-known effect smoking cannabis increased appetite reduced pain change emotional cognitive process due evidence appetite stimulant anti-nauseant dronabinol approved use anorexia associated weight loss patient aid treatment nausea vomiting associated cancer chemotherapy patient failed respond adequately conventional antiemetic treatment fda label tetrahydrocannabinol thc cannabidiol cbd two abundant cannabinoids found naturally resin marijuana plant pharmacologically active due interaction cannabinoid receptor found throughout body a32830 cbd thc used medicinal purpose different receptor activity function physiological effect provided activated form synthetic form like dronabinol db00486 thc cbd obtained conversion precursor tetrahydrocannabinolic acid-a thca-a cannabidiolic acid cbda decarboxylation reaction achieved heating smoking vaporization baking dried unfertilized female cannabis flower pharmacological perspective cannabis diverse receptor profile explains potential application wide variety medical condition cannabis contains 400 different chemical compound 61 considered cannabinoids class compound act upon endogenous cannabinoid receptor body a32584 endocannabinoid system widely distributed throughout central peripheral nervous system via cannabinoid receptor cb1 cb2 play role many physiological process inflammation cardiovascular function learning pain memory stress emotional regulation sleep/wake cycle among many others a32824 cb1 receptor found central peripheral nervous system abundant hippocampus amygdala area brain responsible short-term memory storage emotional regulation cb2 receptor mainly located peripheral nervous system found lymphoid tissue involved regulation immune function a32676 ,dronabinol indicated treatment anorexia associated weight loss patient aid nausea vomiting associated cancer chemotherapy patient failed respond adequately conventional antiemetic treatment l43438 
Montelukast,montelukast first approved clinical use u fda 1998 merck 's brand name singulair l6301 medication member leukotriene receptor antagonist ltra category drug l6301 l6304 l6307 l6310 l6325 l6328 l6331 although capable demonstrating effectiveness use ltras like montelukast typically addition complementary use inhaled corticosteroid agent asthma step therapy a178645 regardless 2008-2009 fda-led investigation possibility montelukast elicit neuropsychiatric effect like agitation hallucination suicidal behaviour others individual used medication a178651 although kind effect currently included official prescribing information montelukast l6301 l6304 l6307 l6310 l6325 l6328 l6331 drug still see extensive use worldwide via million prescription annually since become available generic brand name product ,montelukast indicated prophylaxis chronic treatment asthma adult pediatric patient 12 month age older l6301 although regional health authority specifically note indication adult adolescent 15 year older l6304 l6307 also include indication preventing day night-time symptom treatment acetylsalicylic acid-sensitive asthma l6304 b prevention exercise-induced bronchoconstriction eib patient 6 year age older l6301 although regional health authority specifically note indication adult adolescent 15 year older l6304 l6307 c relief symptom seasonal allergic rhinitis patient 2 year age older perennial allergic rhinitis patient 6 month age older l6301 although regional health authority specifically note relief seasonal allergic rhinitis symptom adult adolescent 15 year older l6304 l6307 furthermore formulation like chewable montelukast tablet may also specifically indicated particular regulatory body prophylaxis chronic treatment asthma including prevention day night-time symptom treatment acetylsalicylic acid based asthma prevention exercise-induced bronchoconstriction adult pediatric patient aged 2 older l6328 age 2 5 l6325 age 6 14 year l6331 moreover employed indication montelukast considered effective monotherapy combined medication indicated maintenance treatment chronic asthma l6304 l6328 instance montelukast inhaled corticosteroid used concomitantly demonstrate additive effect control asthma decrease necessary inhaled corticosteroid dose still maintaining clinical stability l6304 l6328 additionally patient continue experience asthma symptom montelukast also combined 'as required short-acting beta-agonist inhaled corticosteroid inhaled corticosteroid paired long-acting beta-agonist l6304 l6328 
Fluoxetine,fluoxetine 2nd generation antidepressant categorized selective serotonin reuptake inhibitor ssri a181673 gained fda approval 1987 although initially intended treatment depression today commonly prescribed manage depression addition various pathology l7721 ,fluoxetine indicated acute maintenance treatment major depressive disorder obsessive compulsive disorder bulimia nervosa however indicated acute treatment panic disorder independent whether agoraphobia present l7664 fluoxetine may also used combination olanzapine treat depression related bipolar disorder treatment resistant depression l7664 fluoxetine additionally indicated treatment female patient premenstrual dysphoric disorder pmdd l40833 
Hexylcaine,hexylcaine hydrochloride also known cyclaine osmocaine short acting local anesthetic act inhibition sodium channel patient experience overdose may present headache tinnitus numbness tingling around mouth tongue convulsion inability breathe decreased heart function hexylcaine discontinued u market ,used local anesthetic surface application infiltration nerve block
Methohexital, intravenous anesthetic short duration action may used induction anesthesia ,methohexital indicated use intravenous anaesthetic also commonly used induce deep sedation 
Chlordiazepoxide, anxiolytic benzodiazepine derivative anticonvulsant sedative amnesic property also used symptomatic treatment alcohol withdrawal , management anxiety disorder short-term relief symptom anxiety withdrawal symptom acute alcoholism preoperative apprehension anxiety 
Duloxetine,duloxetine dual serotonin norepinephrine reuptake inhibitor label originally discovered 1993 developed eli lilly company ly248686 a178741 duloxetine first received approval fda august 2004 cymbalta treatment major depressive disorder l6454 since received approval variety indication including treatment neuropathic pain generalized anxiety disorder osteoarthritis stress incontinence duloxetine continues investigated treatment pain cancer surgery , indicated 1 management major depressive disorder label 2 management generalized anxiety disorder label 3 management diabetic peripheral neuropathy label 4 management fibromyalgia label 5 management chronic musculoskeletal pain label 6 management osteoarthritis knee adult l6364 7 management chronic lower back pain adult l6364 8 management stress urinary incontinence adult woman l6367 off-label us include 1 management chemotherapy-induced peripheral neuropathy a178603 2 management stress urinary incontinence adult men prostatectomy recovery complete l6370 
Chlorpromazine, prototypical phenothiazine antipsychotic drug like drug class chlorpromazine 's antipsychotic action thought due long-term adaptation brain blocking dopamine receptor chlorpromazine several action therapeutic us including antiemetic treatment intractable hiccup , treatment schizophrenia control nausea vomiting relief restlessness apprehension surgery acute intermittent porphyria adjunct treatment tetanus control manifestation manic type manic-depressive illness relief intractable hiccup treatment severe behavioral problem child 1 12 year age marked combativeness and/or explosive hyperexcitable behavior proportion immediate provocation short-term treatment hyperactive child show excessive motor activity accompanying conduct disorder consisting following symptom impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance 
Rimantadine, rna synthesis inhibitor used antiviral agent prophylaxis treatment influenza , prophylaxis treatment illness caused various strain influenza virus adult 
Amikacin,amikacin semi-synthetic aminoglycoside antibiotic derived kanamycin fda label amikacin synthesized acylation l- -γ-amino-α-hydroxybutyryl side chain c-1 amino group deoxystreptamine moiety kanamycin a39531 amikacin 's unique property exerts activity resistant gram-negative bacillus acinetobacter baumanii pseudomonas aeruginosa amikacin also exerts excellent activity aerobic gram-negative bacillus enterobacteriaceae family including nocardia mycobacterium m. avium-intracellulare m. chelonae m. fortuitum l4680 m. avium-intracellulare mac type nontuberculous mycobacteria ntm found water soil symptom disease include persistent cough fatigue weight loss night sweat shortness breath coughing blood l4680 several form amikacin used currently including intravenous iv intramuscular im injection f1949 september 2018 liposomal inhalation suspension drug approved fda treatment lung disease caused mycobacterium avium complex mac bacteria small population patient disease respond traditional treatment l4680 l4681 , amikacin sulfate injection indicated short-term treatment serious bacterial infection due susceptible strain gram-negative bacteria including pseudomonas specie escherichia coli specie indole-positive indole-negative proteus providencia specie klebsiella-enterobacter-serratia specie well acinetobacter mima-herellea specie f1954 clinical study shown amikacin sulfate injection effective bacterial septicemia including neonatal sepsis serious infection respiratory tract bone joint central nervous system including meningitis skin soft tissue intra-abdominal infection including peritonitis burn postoperative infection including post-vascular surgery f1954 clinical study shown amikacin also effective serious complicated recurrent urinary tract infection due organism aminoglycosides including amikacin indicated uncomplicated first-time episode urinary tract infection unless causative organism susceptible antibiotic le toxic f1954 september 2018 new indication new dosage route approved drug amikacin liposome inhalation suspension approved treatment lung disease caused group bacteria mycobacterium avium complex mac limited population patient disease respond conventional treatment refractory disease l4673 indication approved accelerated approval based achieving sputum culture conversion defined 3 consecutive negative monthly sputum culture month 6 treatment clinical benefit yet established label important note regarding staphylococcus sensitivity testing staphylococcus aureus including methicillin-resistant strain principal gram-positive organism sensitive amikacin use amikacin treatment staphylococcal infection restricted second-line therapy limited patient suffering severe infection caused susceptible strain staphylococcus specie failed show sensitivity available antibiotic f1949 bacteriologic study performed identify causative organism susceptibility amikacin amikacin may used initial therapy suspected gram-negative infection therapy may initiated obtaining result susceptibility testing label f1949 f1954 
Lenalidomide,lenalidomide previously referred cc-5013 immunomodulatory drug potent antineoplastic anti-angiogenic anti-inflammatory property a228553 4-amino-glutamyl analogue thalidomide a228543 like thalidomide lenalidomide exists racemic mixture active r form a228708 however lenalidomide much safer potent thalidomide fewer adverse effect toxicity a714 a228543 thalidomide analogue including lenalidomide referred immunomodulatory imide drug also known cereblon modulators class immunomodulatory drug contain imide group lenalidomide work various mechanism action promote malignant cell death enhance host immunity a228708 available oral capsule lenalidomide approved fda eu treatment multiple myeloma myelodysplastic syndrome mantle cell lymphoma follicular lymphoma marginal zone lymphoma selected patient l16028 due severe teratogenicity pregnancy must excluded start treatment patient must enroll lenalidomide risk evaluation mitigation strategy rem program ensure contraception adherence a228708 ,lenalidomide indicated treatment adult patient multiple myeloma mm combination dexamethasone also indicated maintenance therapy multiple myeloma following autologous hematopoietic stem cell transplantation auto-hsct indicated treatment adult patient transfusion-dependent anemia due low- intermediate-1-risk myelodysplastic syndrome md associated deletion 5q cytogenetic abnormality without additional cytogenetic abnormality lenalidomide indicated treatment adult patient mantle cell lymphoma mcl whose disease relapsed progressed two prior therapy one included bortezomib combination rituximab product lenalidomide indicated treatment adult patient previously treated follicular lymphoma fl previously treated marginal zone lymphoma mzl l16028 
Raloxifene,raloxifene second generation selective estrogen receptor modulator serm mediates anti-estrogenic effect breast uterine tissue estrogenic effect bone lipid metabolism blood coagulation a4979 t28 exhibiting tissue-specific effect distinct estradiol raloxifene first benzothiophene group antiestrogens labelled serm a4977 available many country worldwide raloxifene initially approved fda december 1997 market name evista® management prevention osteoporosis postmenopausal woman reduction risk invasive breast cancer postmenopausal woman osteoporosis high risk invasive breast cancer however negligible effect altering development progression breast cancer label common cause osteoporosis include postmenopausal deficiency estrogen age-related deterioration bone homeostasis due risk bone fracture may lead morbidity reduced quality life management osteoporosis postmenopausal woman use therapeutic agent addition concurrent therapy critical due decline estrogen level postmenopausal osteoporosis hormone replacement therapy hrt estradiol used ameliorate condition however due off-target action hrt newer non-hormonal agent raloxifene tamoxifen developed reduce adverse event selective pharmacological action tissue-specific therapeutic target t28 main effect raloxifene preserve bone mineral density decrease risk breast cancer postmenopausal woman compared estrogen tamoxifen raloxifene associated increased risk uterine cancer cause endometrial proliferation a716 although rare increased risk venous thromboembolism clinical trial postmenopausal woman receiving raloxifene addition clinical study consisting postmenopausal woman documented coronary heart disease increased risk coronary event showed increased risk fatal stroke raloxifene therapy compared placebo label strongly advised risk-benefit ratio considered starting raloxifene therapy woman risk thromboembolic disease stroke prior history stroke transient ischemic attack atrial fibrillation hypertension cigarette smoking label ,indicated prevention treatment osteoporosis postmenopausal woman well prevention treatment corticosteroid-induced bone loss label indicated reduction risk invasive breast cancer postmenopausal woman osteoporosis postmenopausal woman high risk invasive breast cancer label 
Celecoxib,celecoxib selective cyclooxygenase-2 cox-2 inhibitor nonsteroidal anti-inflammatory drug nsaid known decreased risk causing gastrointestinal bleeding compared nsaid a181544 used manage symptom various type arthritis pain familial adenomatous polyposis fap reduce precancerous polyp colon a181532 marketed pfizer brand name celebrex initially granted fda approval 1998 l7604 interestingly selective cox-2 inhibitor especially celecoxib evaluated potential cancer chemopreventive therapeutic drug clinical trial variety malignancy a34124 ,celecoxib indicated symptomatic treatment adult osteoarthritis oa adult rheumatoid arthritis ra l7646 celecoxib substitute aspirin cardiovascular event prophylaxis l7646 may also used treat acute pain various source juvenile rheumatoid arthritis child 2 ankylosing spondylitis primary dysmenorrhea l7646 celecoxib combination tramadol indicated management acute pain adult severe enough require opioid analgesic alternative treatment inadequate l38949 
Gallamine triethiodide, synthetic nondepolarizing blocking drug action gallamine triethiodide similar tubocurarine agent block cardiac vagus may cause sinus tachycardia occasionally hypertension increased cardiac output used cautiously patient risk increased heart rate may preferred patient bradycardia ama drug evaluation annual 1992 p198 , use adjunct anesthesia induce skeletal muscle relaxation facilitate management patient undergoing mechanical ventilation
Brimonidine,brimonidine alpha-adrenergic agonist 2-imidazoline derivative first introduced 1996 a178951 considered third generation alpha-2 aadrenergic receptor agonist since display preferential binding alpha-2 adrenoceptors alpha-1 receptor a179002 brimonidine display higher selectivity toward alpha-2 adrenergic receptor clonidine apraclonidine also alpha-2 adrenergic agonist a178969 alpha-2 adrenergic agonist member ocular hypotensive agent drug class used chronic treatment glaucoma early treatment management glaucoma predominantly involves lowering intraocular pressure critical since glaucoma considered common cause blindness worldwide a178948 a178969 ophthalmically brimonidine used lower intraocular pressure reducing aqueous humor production increasing uveoscleral outflow oxidately stable brimonidine associated fewer report ocular allergic reaction compared alpha-2 adrenergic agonist a178969 ophthalmic solution brimonidine first approved fda 1996 alphagan label brimonidine selective alpha-adrenergic receptor agonist approved chronic treatment glaucoma a36674 brimonidine also found ophthalmic solution combination brinzolamide market name simbrinza reduction intraocular pressure unlike nonselective beta-blockers used ocular hypertension brimonidine associated significantly adverse cardiopulmonary side effect a178945 thus brimonidine effective safe alternative beta-blockers patient high risk cardiopulmonary disease a178948 topical form brimonidine approved fda august 2013 symptomatic treatment persistent facial erythema rosacea adult marketed brand name mirvaso l6535 brimonidine first topical treatment approved facial erythema rosacea a178978 , opthalmic indicated lowering intraocular pressure iop patient open-angle glaucoma ocular hypertension label monotherapy combination product brinzolamide topical indicated treatment persistent non-transient facial erythema rosacea adult 18 year age older l6535 
Dicloxacillin,one penicillin resistant penicillinase ,used treat infection caused penicillinase-producing staphylococci demonstrated susceptibility drug 
Nabilone,nabilone marketed cesamet synthetic form delta-9-tetrahydrocannabinol δ⁹-thc primary psychoactive component cannabis marijuana although structurally distinct thc nabilone mimic thc 's structure pharmacological activity weak partial agonist activity cannabinoid-1 cb1r cannabinoid-2 cb2r receptor however considered twice active δ⁹-thc nabilone approved fda treatment nausea vomiting associated cancer chemotherapy patient failed respond adequately conventional antiemetic treatment fda label tetrahydrocannabinol thc cannabidiol cbd two abundant cannabinoids found naturally resin marijuana plant pharmacologically active due interaction cannabinoid receptor found throughout body a32830 cbd thc used medicinal purpose different receptor activity function physiological effect provided activated form synthetic form like nabilone db00470 thc cbd obtained conversion precursor tetrahydrocannabinolic acid-a thca-a cannabidiolic acid cbda decarboxylation reaction achieved heating smoking vaporization baking dried unfertilized female cannabis flower pharmacological perspective cannabis diverse receptor profile explains potential application wide variety medical condition cannabis contains 400 different chemical compound 61 considered cannabinoids class compound act upon endogenous cannabinoid receptor body a32584 endocannabinoid system widely distributed throughout central peripheral nervous system via cannabinoid receptor cb1 cb2 play role many physiological process inflammation cardiovascular function learning pain memory stress emotional regulation sleep/wake cycle among many others a32824 cb1 receptor found central peripheral nervous system abundant hippocampus amygdala area brain responsible short-term memory storage emotional regulation cb2 receptor mainly located peripheral nervous system found lymphoid tissue involved regulation immune function a32676 canada united state united kingdom mexico nabilone marketed cesamet approved 1985 united state fda treatment chemotherapy-induced nausea vomiting responded conventional antiemetic though approved fda 1985 drug began marketing united state 2006 also approved use treatment anorexia weight loss patient aid nabilone racemate consisting r r isomer ,nabilone indicated treatment nausea vomiting associated cancer chemotherapy patient failed respond adequately conventional antiemetic treatment restriction required substantial proportion group patient treated nabilone expected experience disturbing psychotomimetic reaction observed antiemetic agent 
Pefloxacin, synthetic broad-spectrum fluoroquinolone antibacterial agent active gram-negative gram-positive bacteria , treatment uncomplicated gonococcal urethritis male gram-negative-bacterial infection gastrointestinal system genitourinary tract 
Altretamine, alkylating agent proposed antineoplastic also act chemosterilant male housefly insect , use single agent palliative treatment patient persistent recurrent ovarian cancer following first-line therapy cisplatin and/or alkylating agent-based combination 
Sotalol,sotalol methanesulfonanilide developed 1960 a178579 first class iii anti arrhythmic drug a178579 sotalol first approved oral tablet 30 october 1992 l6334 racemic mixture sotalol currently formulated tablet oral solution intravenous injection indicated life threatening ventricular arrhythmia maintaining normal sinus rhythm atrial fibrillation flutter label l6373 l6376 ,sotalol indicated treat life threatening ventricular arrhytmias maintain normal sinus rhythm patient atrial fibrillation flutter label also oral solution intravenous injection indicated patient requiring sotalol tablet would appropriate label l6373 l6376 
Buspirone,buspirone novel anxiolytic agent unique structure pharmacological profile belonging azaspirodecanedione drug class a180991 buspirone serotonin 5-ht sub 1a /sub receptor agonist chemically pharmacologically related benzodiazepine barbiturate sedative/anxiolytic drug l4478 unlike many drug used treat anxiety buspirone exhibit anticonvulsant sedative hypnotic muscle-relaxant property due characteristic buspirone termed 'anxioselective a180985 first synthesized 1968 patented 1975 l7375 commonly marketed brand name buspar® buspirone first approved 1986 fda a181751 used treat anxiety disorder generalized anxiety disorder gad relieve symptom anxiety also used second-line therapy unipolar depression use selective serotonin reuptake inhibitor ssri deemed clinically inadequate inappropriate l7375 potential use buspirone combination melatonin depression cognitive impairment via promoting neurogenesis also investigated a181751 ,indicated management anxiety disorder short-term relief symptom anxiety l4478 
Miglitol,miglitol inhibits breakdown complex carbohydrate glucose primarily used diabetes mellitus type 2 establishing greater glycemic control preventing digestion carbohydrate disaccharide oligosaccharide polysaccharide monosaccharide absorbed body miglitol taken start meal maximal effect effect depend amount poly oligosaccharide diet miglitol inhibits alpha-glucosidase making le sugar available digestion reducing postprandial hyperglycemia unlike drug class miglitol metabolized unmetabolized drug excreted kidney , use adjunct diet improve glycemic control patient non-insulin-dependent diabetes mellitus niddm whose hyperglycemia managed diet alone 
Fosinopril,fosinopril phosphinic acid-containing ester prodrug belongs angiotensin-converting enzyme ace inhibitor class medication rapidly hydrolyzed fosinoprilat principle active metabolite fosinoprilat inhibits ace enzyme responsible conversion angiotensin ati angiotensin ii atii atii regulates blood pressure key component renin-angiotensin-aldosterone system raas fosinopril may used treat mild moderate hypertension adjunct treatment congestive heart failure slow rate progression renal disease hypertensive individual diabetes mellitus microalbuminuria overt nephropathy , treating mild moderate hypertension use adjunct treating congestive heart failure may used slow rate progression renal disease hypertensive individual diabetes mellitus microalbuminuria overt nephropathy 
Cefotaxime,cefotaxime third-generation cephalosporin antibiotic like third-generation cephalosporin broad spectrum activity gram positive gram negative bacteria case considered equivalent ceftriaxone term safety efficacy cefotaxime sodium marketed various trade name including claforan sanofi-aventis ,used treat gonorrhoea meningitis severe infection including infection kidney pyelonephritis urinary system also used operation prevent infection surgery 
Entacapone,entacapone selective reversible catechol-o-methyl transferase comt inhibitor treatment parkinson 's disease member class nitrocatechols administered concomittantly levodopa decarboxylase inhibitor e.g. carbidopa increased sustained plasma levodopa concentration reached compared administration levodopa decarboxylase inhibitor ,used adjunct levodopa carbidopa symptomatic treatment patient idiopathic parkinson 's disease experience sign symptom end-of-dose `` wearing-off '' 
Zidovudine, dideoxynucleoside compound 3 39 -hydroxy group sugar moiety replaced azido group modification prevents formation phosphodiester linkage needed completion nucleic acid chain compound potent inhibitor hiv replication acting chain-terminator viral dna reverse transcription improves immunologic function partially revers hiv-induced neurological dysfunction improves certain clinical abnormality associated aid principal toxic effect dose-dependent suppression bone marrow resulting anemia leukopenia pubchem ,used combination antiretroviral agent treatment human immunovirus hiv infection 
Darifenacin,darifenacin enablex® novartis medication used treat urinary incontinence darifenacin block m3 muscarinic acetylcholine receptor mediate bladder muscle contraction block reduces urgency urinate used people urinary retention unknown m3 receptor selectivity clinically advantageous overactive bladder syndrome treatment , treatment overactive bladder symptom urge urinary incontinence urgency frequency 
Oxycodone,oxycodone semisynthetic opioid analgesic derived thebaine germany 1917 a178696 currently indicated immediate release product moderate severe pain extended release product chronic moderate severe pain requiring continuous opioid analgesic extended period label first oxycodone containing product percodan approved fda april 12 1950 l6460 ,oxycodone indicated treatment moderate severe pain label also extended release formulation indicated chronic moderate severe pain requiring continuous opioid analgesic extended period label 
Phenindione, indandione used anticoagulant phenindione action similar warfarin rarely employed higher incidence severe adverse effect martindale extra pharmacopoeia 30th ed p234 , treatment pulmonary embolism cardiomyopathy atrial fibrillation flutter cerebral embolism mural thrombosis thrombophili also used anticoagulant prophylaxis 
Flutamide, antiandrogen potency cyproterone rodent canine specie , management locally confined stage b2-c stage d2 metastatic carcinoma prostate
Tolmetin, non-steroidal anti-inflammatory agent anti-inflammatory agent non-steroidal similar mode action indomethacin , relief sign symptom rheumatoid arthritis osteoarthritis including treatment acute flare long-term management also treatment juvenile rheumatoid arthritis 
Cimetidine, histamine congener competitively inhibits histamine binding histamine h2 receptor cimetidine range pharmacological action inhibits gastric acid secretion well pepsin gastrin output also block activity cytochrome p-450 might explain proposal use neoadjuvant therapy ,cimetidine indicated reduce gastric acid secretion treat following disease state duodenal ulcer non-malignant gastric ulcer gastroesophageal reflux disease pathological hypersecretion associated zollinger-ellison syndrome systemic mastocytosis multiple endocrine adenoma l30280 indicated prophylaxis recurrent gastric duodenal ulcer adjunctive therapy management cystic fibrosis child treat nsaid induced lesion gastrointestinal symptom l30280 
Haloperidol,haloperidol high potency first-generation typical antipsychotic one frequently used antipsychotic medication used worldwide a180616 haloperidol demonstrated pharmacologic activity number receptor brain a27477 exerts antipsychotic effect strong antagonism dopamine receptor mainly d2 particularly within mesolimbic mesocortical system brain haloperidol indicated treatment manifestation several psychotic disorder including schizophrenia acute psychosis tourette syndrome severe behavioural state f4645 also used off-label management chorea associated huntington 's disease treatment intractable hiccup potent antiemetic dopamine-antagonizing medication haloperidol though improve psychotic symptom state caused over-production dopamine schizophrenia theorized caused hyperdopaminergic state within limbic system brain a34360 use first-generation antipsychotic including haloperidol considered highly effective management `` positive '' symptom schizophrenia including hallucination hearing voice aggression/hostility disorganized speech psychomotor agitation however class drug also limited development movement disorder induced dopamine-blockade drug-induced parkinsonism akathisia dystonia tardive dyskinesia well side effect including sedation weight gain prolactin change limited high-quality study comparing haloperidol lower-potency first-generation antipsychotic db00477 db01624 db00623 db01403 haloperidol typically demonstrates least amount side effect within class demonstrates stronger disposition causing extrapyramidal symptom eps a180613 a180616 a180625 low‐potency antipsychotic limited lower affinity dopamine receptor requires higher dose effectively treat symptom schizophrenia addition block many receptor primary target dopamine receptor cholinergic histaminergic receptor resulting higher incidence side effect sedation weight gain hypotension interestingly vivo pharmacogenetic study demonstrated metabolism haloperidol may modulated genetically determined polymorphic _cyp2d6_ activity however finding contradict finding study vitro human liver microsome drug interaction study vivo inter-ethnic pharmacogenetic difference haloperidol metabolism may possibly explain observation a32346 first-generation antipsychotic drug largely replaced second- third-generation atypical antipsychotic db00734 db00334 db00363 db01224 db01238 db00246 however haloperidol use remains widespread considered benchmark comparison trial newer generation antipsychotic a180625 efficacy haloperidol first established controlled trial 1960s a180610 ,haloperidol indicated number condition including treatment schizophrenia manifestation psychotic disorder control tic vocal utterance tourette ’ disorder child adult treatment severe behavior problem child combative explosive hyperexcitability accounted immediate provocation haloperidol also indicated short-term treatment hyperactive child show excessive motor activity accompanying conduct disorder consisting following symptom impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance haloperidol reserved two group child failure respond psychotherapy medication antipsychotic f4645 
Ritonavir,ritonavir hiv protease inhibitor interferes reproductive cycle hiv although initially developed independent antiviral agent shown posse advantageous property combination regimen low-dose ritonavir protease inhibitor commonly used booster protease inhibitor available liquid formulation capsule ritonavir active antiviral agent hepatitis c virus hcv infection added combination therapy indicated treatment hcv infection booster ritonavir potent cyp3a inhibitor increase peak trough plasma drug concentration protease inhibitor db09297 overall drug exposure american association study liver disease aasld infectious disease society america idsa guideline recommend ritonavir-boosted combination therapy first-line therapy hcv genotype 1a/b 4 treatment-naïve patient without cirrhosis ritonavir found fixed-dose combination product db09296 db09183 db09297 fda-approved product viekira pak first approved december 2014 viekira pak indicated treatment hcv genotype 1b without cirrhosis compensated cirrhosis combined ribavirin treatment hcv genotype 1a without cirrhosis compensated cirrhosis ritonavir also available fixed-dose combination product db09296 db09297 fda- health canada-approved product technivie first approved july 2015 technivie indicated combination ribavirin treatment patient genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis canada ritonavir also available fixed-dose combination product db09296 db09183 db09297 health canada-approved commercially available product holkira pak first approved january 2015 holkira pak indicated treatment hcv genotype 1b without cirrhosis combined ribavirin treatment hcv genotype 1a without cirrhosis inclusion ritonavir select hiv-1 protease inhibitor resistance-associated substitution hcv/hiv-1 co-infected patient treated ritonavir-containing combination therapy also suppressive antiretroviral drug regimen reduce risk hiv-1 protease inhibitor drug resistance ritonavir used combination drug treat coronavirus disease 2019 covid-19 patient risk progressing severe form disease ,ritonavir indicated combination antiretroviral agent treatment hiv-1 infection ritonavir also authorized fda emergency use paxlovid covid-19 antiviral treatment includes nirmatrelvir treatment mild-to-moderate covid-19 adult pediatric patient 12 year age older weighing least 40 kg positive result direct sars-cov-2 viral testing high risk progression severe covid-19 including hospitalization death l39539 l39544 canada ritonavir indicated combination nirmatrelvir treatment sars-cov-2 positive adult patient mild-to-moderate covid-19 high risk progression severe disease l39840 
Levallorphan, opioid antagonist property similar naloxone addition also posse agonist property used cautiously levallorphan revers severe opioid-induced respiratory depression may exacerbate respiratory depression induced alcohol non-opioid central depressant martindale extra pharmacopoeia 30th ed p683 , complete partial reversal narcotic depression including respiratory depression induced opioids 
Tridihexethyl,tridihexethyl synthetic anticholinergic agent shown experimental clinical study pronounced antispasmodic antisecretory effect gastrointestinal tract tridihexethyl antimuscarinic anticholinergic drug tridihexethyl longer available u market ,used adjunct treatment peptic ulcer disease acquired nystagmus
Nitazoxanide,nitazoxanide belongs class drug known _thiazolides_ nitazoxanide ntz broad-spectrum anti-infective drug markedly modulates survival growth proliferation range extracellular intracellular protozoa helminth anaerobic microaerophilic bacteria addition virus drug effective treatment gastrointestinal infection including cryptosporidium parvum giardia lamblia healthy subject generally well tolerated nitazoxanide first-line standard treatment illness caused c. parvum g. lamblia infection healthy immunosuppressed adult child may also considered treatment illness caused protozoa helminth a31976 recently drug studied broad-spectrum antiviral agent due ability inhibit replication several rna dna virus a31977 , treatment diarrhea adult child caused protozoa giardia lamblia /i treatment diarrhea child caused protozoan cryptosporidium parvum /i fda label nitazoxanide shown superior placebo medication management diarrhea caused cryptosporidium parvum patient hiv/immunodeficiency fda label a31973 a31976 
Triflupromazine, phenothiazine used antipsychotic agent antiemetic ,used mainly management psychosis also used control nausea vomiting 
Dextrothyroxine, major hormone derived thyroid gland thyroxine synthesized via iodination tyrosine monoiodotyrosine coupling iodotyrosine diiodotyrosine thyroglobulin thyroxine released thyroglobulin proteolysis secreted blood thyroxine peripherally deiodinated form triiodothyronine exerts broad spectrum stimulatory effect cell metabolism ,used lower high cholesterol level blood 
Acetyldigitoxin,cardioactive derivative lanatoside digitoxin used fast digitalization congestive heart failure ,used fast digitalization congestive heart failure 
Vancomycin,antibacterial obtained streptomyces orientalis glycopeptide related ristocetin inhibits bacterial cell wall assembly toxic kidney inner ear january 29 2018 cutispharma 's firvanq fda approved vancomycin oral liquid treatment option available treatment _clostridium difficile_ associated diarrhea enterocolitis caused _staphylococcus aureus_ including methicillin-resistant strain lp1196 oral liquid formulation expected make _clostridium difficile_ associated diarrhea therapy accessible comparison previously available specialty compounding product lp1196 ,administered intravenously vancomycin indicated adult pediatric patient treatment septicemia infective endocarditis skin skin structure infection bone infection lower respiratory tract infection l41529 administered orally vancomycin indicated adult pediatric patient treatment _clostridium difficile_-associated diarrhea enterocolitis caused _staphylococcus aureus_ including methicillin-resistant strain l41534 
Aminocaproic acid, antifibrinolytic agent act inhibiting plasminogen activator fibrinolytic property , use treatment excessive postoperative bleeding 
Dextromethorphan,dextromethorphan levorphanol derivative codeine analog commonly used cough suppressant also drug abuse a215412 although similar structure opioids minimal interaction opioid receptor a215412 dextromethorphan granted fda approval 3 december 1957 a215412 l14997 ,dextromethorphan indicated combination brompheniramine pseudoephedrine treatment cough upper respiratory symptom associated allergy common cold l14366 dextromethorphan also used combination guaifenesin over-the-counter product relieve cough l14369 dextromethorphan combination quinidine indicated treatment pseudobulbar affect l14363 
Cisplatin,cisplatin cisplatinum cis-diamminedichloroplatinum ii cddp platinum-based chemotherapy drug used treat various type cancer including sarcoma carcinoma e.g small cell lung cancer ovarian cancer lymphoma germ cell tumor first member class also includes carboplatin oxaliplatin , treatment metastatic testicular tumor metastatic ovarian tumor advanced bladder cancer 
Bentoquatam,bentoquatam topical medication intended act shield exposure irritating substance urushiol found plant poison ivy poison oak bentoquatam contains bentonite clay effective long film visible skin ,used prevent reduce severity allergic contact dermatitis due urushiol allergenic resin poison ivy poison oak poison sumac 
Anisotropine methylbromide,anisotropine methylbromide quaternary ammonium compound use treatment adjunct peptic ulcer replaced use effective agent depending dose anisotropine methylbromide may reduce motility secretory activity gastrointestinal system tone ureter urinary bladder may slight relaxant action bile duct gallbladder general smaller dos anisotropine methylbromide inhibit salivary bronchial secretion sweating accommodation cause dilatation pupil increase heart rate larger dos required decrease motility gastrointestinal urinary tract inhibit gastric acid secretion , use conjunction antacid histamine h sub 2 /sub -receptor antagonist treatment peptic ulcer reduce gastric acid secretion delay gastric emptying 
Albendazole, benzimidazole broad-spectrum anthelmintic structurally related mebendazole effective many disease martindale extra pharmacopoeia 30th ed p38 , treatment parenchymal neurocysticercosis due active lesion caused larval form pork tapeworm taenia solium /i treatment cystic hydatid disease liver lung peritoneum caused larval form dog tapeworm echinococcus granulosus /i 
Trandolapril,trandolapril non-sulhydryl prodrug belongs angiotensin-converting enzyme ace inhibitor class medication metabolized biologically active diacid form trandolaprilat liver trandolaprilat inhibits ace enzyme responsible conversion angiotensin ati angiotensin ii atii atii regulates blood pressure key component renin-angiotensin-aldosterone system raas trandolapril may used treat mild moderate hypertension improve survival following myocardial infarction clinically stable patient left ventricular dysfunction adjunct treatment congestive heart failure slow rate progression renal disease hypertensive individual diabetes mellitus microalbuminuria overt nephropathy , treatment mild moderate hypertension adjunct treatment congestive heart failure chf improve survival following myocardial infarction mi individual hemodynamically stable demonstrate symptom left ventricular systolic dysfunction sign chf within day following acute mi slow progression renal disease hypertensive patient diabetes mellitus microalbuminuria overt nephropathy 
Caspofungin,"caspofungin brand name cancidas worldwide antifungal drug first member new drug class called echinocandins coined merck co. inc typically administered intravenously show activity infection aspergillus candida work inhibiting β 1,3 -d-glucan fungal cell wall ", treatment esophageal candidiasis invasive aspergillosis patient refractory intolerant therapy 
Carteolol, beta-adrenergic antagonist used anti-arrhythmia agent anti-angina agent antihypertensive agent antiglaucoma agent , treatment intraocular hypertension chronic open-angle glaucoma
Bentiromide,bentiromide dipeptide used bentiromide test screening test evaluating pancreatic exocrine function monitoring adequacy supplemental pancreatic therapy typically administered orally case headache gastrointestinal disturbance reported use bentiromide bentiromide currently available u.s. canada ,indicated screening test exocrine pancreatic insufficiency monitor adequacy supplemental pancreatic therapy 
Alitretinoin, important regulator gene expression growth development neoplasm tretinoin also known retinoic acid derived maternal vitamin essential normal growth embryonic development excess tretinoin teratogenic used treatment psoriasis acne vulgaris several skin disease also approved use promyelocytic leukemia leukemia promyelocytic acute , topical treatment cutaneous lesion patient aids-related kaposi 's sarcoma 
Metolazone, quinazoline-sulfonamide considered thiazide-like diuretic long-acting useful chronic renal failure also tends lower blood pressure increase potassium loss , treatment hypertension alone combination antihypertensive drug different class 
Tolnaftate,tolnaftate synthetic over-the-counter anti-fungal agent may come cream powder spray liquid aerosol used treat jock itch athlete 's foot ringworm sold several brand name notably tinactin odor eater ,tolnaftate topical used treat skin infection athlete 's foot jock itch ringworm infection tolnaftate also used along antifungal treat infection nail scalp palm sol foot powder powder aerosol may used prevent athlete 's foot 
Oxaliplatin,oxaliplatin platinum-based chemotherapy drug family cisplatin carboplatin typically administered combination fluorouracil leucovorin combination known folfox treatment colorectal cancer compared cisplatin two amine group replaced cyclohexyldiamine improved antitumour activity chlorine ligand replaced oxalato bidentate derived oxalic acid order improve water solubility oxaliplatin marketed sanofi-aventis trademark eloxatin reg ,used combination infusional 5-fu/lv indicated treatment advanced carcinoma colon rectum adjuvant treatment stage iii colon cancer patient undergone complete resection primary tumor 
Cinchocaine, local anesthetic amide type generally used surface anesthesia one potent toxic long-acting local anesthetic parenteral use restricted spinal anesthesia martindale extra pharmacopoeia 30th ed p1006 , production local regional anesthesia infiltration technique percutaneous injection intravenous regional anesthesia peripheral nerve block technique brachial plexus intercostal central neural technique lumbar caudal epidural block 
Lercanidipine,lercanidipine calcium channel blocker dihydropyridine class sold various commercial name including zanidip , treatment hypertension management angina pectoris raynaud 's syndrome
Foscarnet, antiviral agent used treatment cytomegalovirus retinitis foscarnet also show activity human herpes virus hiv , treatment cmv retinitis patient acquired immunodeficiency syndrome aid treatment acyclovir-resistant mucocutaneous hsv infection immunocompromised patient 
Erlotinib,erlotinib inhibitor epidermal growth factor receptor egfr tyrosine kinase used treatment non-small cell lung cancer pancreatic cancer several type cancer typically marketed trade name tarceva erlotinib bind epidermal growth factor receptor egfr tyrosine kinase reversible fashion adenosine triphosphate atp binding site receptor recent study demonstrate erlotinib also potent inhibitor jak2v617f mutant form tyrosine kinase jak2 found patient polycythemia vera pv substantial proportion patient idiopathic myelofibrosis essential thrombocythemia finding introduces potential use erlotinib treatment jak2v617f-positive pv myeloproliferative disorder ,erlotinib indicated treatment metastatic non-small cell lung cancer nsclc tumor showing epidermal growth factor receptor egfr exon 19 deletion exon 21 l858r substitution mutation fda label combination first-line treatment patient diagnosed locally advanced unresectable metastatic pancreatic cancer fda label safety efficacy erlotinib established patient nsclc whose tumor show egfr mutation additionally recommended use combination platinum-based chemotherapy fda label 
Cyclophosphamide,precursor alkylating nitrogen mustard antineoplastic immunosuppressive agent must activated liver form active aldophosphamide used treatment lymphoma leukemia side effect alopecia used defleecing sheep cyclophosphamide may also cause sterility birth defect mutation cancer ,cyclophosphamide indicated treatment malignant lymphoma multiple myeloma leukemia mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma ovary retinoblastoma carcinoma breast also indicated treatment biopsy-proven minimal change nephrotic syndrome pediatric patient 
Mephenytoin,mephenytoin used treatment refractory partial epilepsy mephenytoin solid compound belongs phenylhydantoins heterocyclic aromatic compound containing imiazolidinedione moiety substituted phenyl group mephenytoin known target sodium channel protein type 5 subunit alpha cytochrome p450 2c19 cytochrome p450 2c8 cytochrome p450 2c9 cytochrome p450 2b6 cytochrome p450 1a2 cytochrome p450 2d6 known metabolize mephenytoin mephenytoin hydantoin-derivative anticonvulsant used control various partial seizure mephenytoin oxazolidinedione derivative associated higher incidence blood dyscrasia compared anticonvulsant , treatment refractory partial epilepsy 
Rofecoxib,"rofecoxib used treatment osteoarthritis rheumatoid arthritis acute pain adult primary dysmenorrhea well acute treatment migraine attack without aura rofecoxib solid compound belongs stilbenes organic compound containing 1,2-diphenylethylene moiety stilbenes c6-c2-c6 derived common phenylpropene c6-c3 skeleton building block introduction one hydroxyl group phenyl ring lead stilbenoids rofecoxib half-life 17 hour mean oral bioavailability therapeutically recommended dos 125 25 50 mg approximately 93 protein rofecoxib target include elastin prostaglandin g/h synthase 2 cytochrome p450 1a2 cytochrome p450 3a4 cytochrome p450 2c9 cytochrome p450 2c8 prostaglandin g/h synthase 1 known metabolize rofecoxib september 30 2004 merck voluntarily withdrew rofecoxib market concern increased risk heart attack stroke associated long-term high-dosage use ", treatment osteoarthritis rheumatoid arthritis acute pain adult primary dysmenorrhea well acute treatment migraine attack without aura 
Chlormerodrin,chlormerodrin mercurial compound toxic side effect previously used diuretic radiolabeled form used diagnostic research tool longer used replaced new class diuretic drug ,previously used diuretic radiolabeled form used diagnostic research tool 
Cefdinir,cefdinir also known omnicef semi-synthetic broad-spectrum antibiotic belonging third generation cephalosporin class proven effective treatment common bacterial infection ear sinus throat lung skin cefdinir approved fda 1997 treat variety mild moderate infection initially marketed abbvie a180739 chemical structure effective organism resistant first-line cephalosporin therapy due production beta-lactamase enzyme a180724 a180727 ,cefdinir indicated treat acute bacterial otitis medium acute maxillary sinusitis community-acquired ca pneumonia acute bacterial exacerbation chronic bronchitis pharyngitis/tonsillitis uncomplicated skin skin structure infection child adult l7330 a180739 organism susceptible cefdinir listed addition associated clinical condition may treated cefdinir l7330 various beta-lactamase producing organism may treated indicated certain section respiratory acute bacterial exacerbation chronic bronchitis caused haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin-susceptible moraxella catarrhalis community-acquired pneumonia caused haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin-susceptible moraxella catarrhalis ear nose throat acute bacterial otitis medium caused haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae penicillin-susceptible tonsillitis caused streptococcus pyogenes pharyngitis caused streptococcus pyogenes acute maxillary sinusitis caused haemophilus pneumoniae streptococcus pneumoniae penicillin-susceptible moraxella catarrhalis skin skin structure infection uncomplicated skin skin structure infection caused staphylococcus aureus streptococcus pyogenes
Guanidine, strong organic base existing primarily guanidium ion physiological ph found urine normal product protein metabolism also used laboratory research protein denaturant martindale extra pharmacopoeia 30th ed merck index 12th ed also used treatment myasthenia fluorescent probe hplc , reduction symptom muscle weakness easy fatigability associated myasthenic syndrome eaton-lambert indicated treating myasthenia gravis 
Ciprofloxacin,ciprofloxacin second generation fluoroquinolone spawned many derivative antibiotic a178870 formulated oral intravenous intratympanic ophthalmic otic administration number bacterial infection l6469 l6472 l6475 l6478 l6481 l6484 l6487 l6490 l6493 first ciprofloxacin containing product fda approved 22 october 1987 l6463 ,ciprofloxacin indicated infection caused susceptible bacteria l6469 l6472 l6475 l6478 l6481 l6484 l6487 l6490 l6493 ciprofloxacin immediate release tablet oral suspension intravenous injection indicated treatment skin skin structure infection bone joint infection complicated intra-abdominal infection nosocomial pneumonia febrile neutropenia adult inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infection including acute exacerbation chronic bronchitis urinary tract infection complicated urinary tract infection pediatrics complicated pyelonephritis pediatrics acute sinusitis l6481 l6478 ciprofloxacin otic solution otic suspension hydrocortisone indicated acute otitis externa l6469 l6484 ciprofloxacin suspension dexamethasone indicated acute otitis medium pediatric patient tympanostomy tube acute otitis externa l6490 ciprofloxacin intratympanic injection indicated pediatric patient bilateral otitis medium effusion tympanostomy tube placed pediatric patient 6 month older acute otitis externa l6493 ciprofloxacin eye drop indicated bacterial corneal ulcer conjunctivitis l6472 ciprofloxacin eye ointment indicated bacterial conjunctivitis l6475 ciprofloxacin extended release tablet indicated uncomplicated urinary tract infection complicated urinary tract infection acute uncomplicated pyelonephritis l6487 
Gadoversetamide,gadoversetamide marketed trade name optimark gadolinium compound used contrast agent magnetic resonance imaging mri particularly imaging brain spine liver ,gadoversetamide mri contrast agent used mri diagnostic procedure provide increased enhancement visualization lesion brain spine liver including tumor 
Toremifene, first generation nonsteroidal selective estrogen receptor modulator serm structurally related tamoxifen like tamoxifen estrogen agonist bone tissue cholesterol metabolism antagonistic mammary uterine tissue , treatment metastatic breast cancer postmenopausal woman estrogen receptor-positive receptor-unknown tumor toremifene currently investigation preventative agent prostate cancer men high-grade prostatic intraepithelial neoplasia evidence prostate cancer 
Nortriptyline,nortriptyline hydrochloride active metabolite amitriptyline tricyclic antidepressant tca l11878 used treatment major depression also used off-label chronic pain condition l11881 ,nortriptyline indicated relief symptom major depressive disorder mdd l11878 off-label us drug include treatment chronic pain myofascial pain neuralgia irritable bowel syndrome a191083 l11878 
Vincristine,vincristine antitumor vinca alkaloid isolated vinca rosea marketed several brand name many different formulation marqibo liposomal injection vincasar vincristine indicated treatment acute leukaemia malignant lymphoma hodgkin 's disease acute erythraemia acute panmyelosis vincristine sulfate often chosen part polychemotherapy lack significant bone–marrow suppression recommended dos unique clinical toxicity neuropathy ,treatment acute lymphocytic leukemia hodgkin lymphoma non-hodgkin lymphoma wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine indicated treatment relapsed philadelphia chromosome-negative ph- acute lymphoblastic leukemia 
Benazepril,benazepril brand name lotensin medication used treat high blood pressure hypertension congestive heart failure chronic renal failure a838 a837 upon cleavage ester group liver benazepril converted active form benazeprilat non-sulfhydryl angiotensin-converting enzyme ace inhibitor a836 ,benazepril indicated treatment hypertension a840 may used alone combination thiazide diuretic fda label 
Amoxapine,amoxapine n /i -demethylated derivative antipsychotic agent loxapine dibenzoxazepine-derivative tricyclic antidepressant tca tcas structurally similar phenothiazine contain tricyclic ring system alkyl amine substituent central ring non-depressed individual amoxapine affect mood arousal may cause sedation depressed individual amoxapine exerts positive effect mood tcas potent inhibitor serotonin norepinephrine reuptake addition tcas down-regulate cerebral cortical beta -adrenergic receptor sensitize post-synaptic serotonergic receptor chronic use antidepressant effect tcas thought due overall increase serotonergic neurotransmission tcas also block histamine h sub 1 /sub receptor alpha sub 1 /sub -adrenergic receptor muscarinic receptor account sedative hypotensive anticholinergic effect e.g blurred vision dry mouth constipation urinary retention respectively see toxicity section complete listing side effect amoxapine may used treat neurotic reactive depressive disorder endogenous psychotic depression mixed symptom depression anxiety agitation , relief symptom depression patient neurotic reactive depressive disorder well endogenous psychotic depression may also used treat depression accompanied anxiety agitation 
Fluorouracil, pyrimidine analog antineoplastic antimetabolite interferes dna synthesis blocking thymidylate synthetase conversion deoxyuridylic acid thymidylic acid , topical treatment multiple actinic solar keratoses 5 strength also useful treatment superficial basal cell carcinoma conventional method impractical multiple lesion difficult treatment site fluorouracil injection indicated palliative management type cancer including colon esophageal gastric rectum breast biliary tract stomach head neck cervical pancreas renal cell carcinoid 
Pyridostigmine,myasthenia gravis autoimmune disease involving dysfunction neuromuscular junction commonly due autoantibody directed acetylcholine receptor achr result muscle tone loss muscle weakness fatigue a231004 acetylcholinesterase inhibitor symptomatic treatment choice myasthenia gravis since 1930s early use physostigmine neostigmine inhibiting breakdown acetylcholine neuromuscular junction increase signalling relieve symptom a231004 l32408 l32413 pyridostigmine current drug choice superior pharmacokinetics reduced side effect compared neostigmine l32408 l32413 addition treating myasthenia gravis pyridostigmine used reverse neuromuscular block relieve symptom congenital myasthenic syndrome protect certain nerve agent notably gulf war a231009 a231014 l32413 l32418 pyridostigmine granted initial fda approval april 6 1955 oral tablet possible dose form expanded include extended-release tablet syrup injection marketed various brand generic name l32408 l32413 ,pyridostigmine indicated treatment myasthenia gravis l32408 administered intravenously indicated reversal antagonism neuromuscular blocking effect nondepolarizing muscle relaxant l32413 pyridostigmine also used prophylactic agent irreversible organophosphorus acetylcholinesterase inhibitor primarily military capacity l32418 
Adinazolam,adinazolam deracyn® benzodiazepine derivative anxiolytic anticonvulsant sedative antidepressant property adinazolam first developed enhance antidepressant effect alprazolam never approved fda clinical use , treatment anxiety status epilepticus 
Desoximetasone, topical anti-inflammatory glucocorticoid used dermatosis skin allergy psoriasis etc , relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Azelaic acid,azelaic acid saturated dicarboxylic acid found naturally wheat rye barley also produced _malassezia furfur_ also known _pityrosporum ovale_ specie fungus normally found human skin azelaic acid effective number skin condition mild moderate acne applied topically cream formulation 20 work part stopping growth skin bacteria cause acne keeping skin pore clear azelaic acid 's antimicrobial action may attributable inhibition microbial cellular protein synthesis , topical treatment mild-to-moderate inflammatory acne vulgaris 
Zafirlukast,zafirlukast oral leukotriene receptor antagonist ltra maintenance treatment asthma often used conjunction inhaled steroid and/or long-acting bronchodilator available tablet usually dosed twice daily another leukotriene receptor antagonist montelukast singulair usually taken daily zafirlukast block action cysteinyl leukotrienes cyslt1 receptor thus reducing constriction airway build-up mucus lung inflammation breathing passage , prophylaxis chronic treatment asthma 
Propylthiouracil, thiourea antithyroid agent propythiouracil inhibits synthesis thyroxine inhibits peripheral conversion throxine tri-iodothyronine used treatment hyperthyroidism martindale extra pharmacopeoia 30th ed p534 ,used manage hyperthyroidism due overactive thyroid gland grave 's disease 
Acetohydroxamic acid,acetohydroxamic acid synthetic drug derived hydroxylamine ethyl acetate similar structure urea urine act antagonist bacterial enzyme urease acetohydroxamic acid direct antimicrobial action acidify urine directly used addition antibiotic medical procedure treat chronic urea-splitting urinary infection ,used addition antibiotic medical procedure treat chronic urea-splitting urinary infection 
Pentostatin, potent inhibitor adenosine deaminase drug effective treatment many lymphoproliferative malignancy particularly hairy-cell leukemia also synergistic antineoplastic agent immunosuppressive activity , treatment hairy cell leukaemia refractory alpha interferon 
Methoxsalen, naturally occurring furocoumarin compound found several specie plant including psoralea corylifolia photoactive substance form dna adduct presence ultraviolet irradiation , treatment psoriasis vitiligo
Piroxicam, cyclooxygenase inhibiting non-steroidal anti-inflammatory agent nsaid well established treating rheumatoid arthritis osteoarthritis used musculoskeletal disorder dysmenorrhea postoperative pain long half-life enables administered daily , treatment osteoarthritis rheumatoid arthritis 
Lamotrigine,lamotrigine antiepileptic drug belonging phenyltriazine class used treatment epilepsy mood stabilizer bipolar disorder lamotrigine first medication since lithium granted food drug administration fda approval maintenance treatment bipolar type approved use 30 country a191350 lamotrigine relatively side-effects require laboratory monitoring indicated epilepsy bipolar disorder evidence lamotrigine could clinical efficacy certain neuropathic pain state a849 a850 ,lamotrigine indicated adjunctive therapy following seizure type patient ≥2 year age partial seizure primary generalized tonic-clonic seizure generalized seizure due lennox-gastaut syndrome l9404 also indicated process conversion drug monotherapy least 16 year age older partial seizure currently receiving treatment carbamazepine phenytoin phenobarbital primidone valproate single antiepileptic drug aed l9404 addition lamotrigine also indicated maintenance treatment bipolar disorder delaying time mood episode may include mania hypomania depression mixed episode adult least 18 year older treated acute mood symptom standard therapy l9404 limitation use important note lamotirigine used treatment acute mood episode efficacy established context l9404 
Perflutren,perflutren diagnostic drug intended used contrast enhancement indicated echocardiographic procedure comprised lipid-coated microspheres filled octafluoropropane ofp gas exposed ultrasound wave microspheres resonate `` echo '' strong signal back ultrasound machine difference density gas-filled bubble blood around creates increased level contrast visible resulting ultrasound image echocardiography activated perflutren enhances image inner edge border heart producing improved image may enable physician better diagnose patient ,used ultrasound contrast imaging cardiology radiology 
Hydroxyzine,hydroxyzine first-generation histamine h sub 1 /sub -receptor antagonist dephenylmethane piperazine class exhibit sedative anxiolytic antiemetic property a1257 a187589 first developed 1955 a189726 since remained relatively common treatment allergic condition pruritus urticaria dermatosis histamine-mediated pruritus l9677 active metabolite hydroxyzine cetirizine also available active ingredient allergic medication responsible much hydroxyzine 's antihistaminic effect a189753 hydroxyzine also used generalized anxiety disorder tension caused psychoneurosis condition manifestation anxiety l9677 ,hydroxyzine indicated symptomatic relief anxiety tension associated psychoneurosis adjunct organic disease state anxiety manifested l9677 also indicated treatment histamine-mediated pruritus pruritus due allergic condition chronic urticaria l9677 canadian labeling state hydroxyzine also indicated adult child premedication prior medical procedure dental surgery l9680 also used control nausea vomiting excluding nausea vomiting pregnancy l9680 
Zanamivir, guanido-neuraminic acid used inhibit neuraminidase , prevention treatment influenza b 
Bosentan,bosentan dual endothelin receptor antagonist marketed trade name tracleer actelion pharmaceutical bosentan used treat pulmonary hypertension blocking action endothelin molecule would otherwise promote narrowing blood vessel lead high blood pressure ,used treatment pulmonary arterial hypertension pah improve exercise ability decrease rate clinical worsening patient class iii iv symptom 
Tigecycline,tigecycline glycylcycline antibiotic developed marketed wyeth brand name tygacil developed response growing prevalence antibiotic resistance bacteria staphylococcus aureus granted fast-track approval u.s. food drug administration fda june 17 2005 , treatment infection caused susceptible strain designated microorganism following condition complicated skin skin structure infection caused escherichia coli /i enterococcus faecalis /i vancomycin-susceptible isolates staphylococcus aureus /i methicillin-susceptible -resistant isolates streptococcus agalactiae /i streptococcus anginosus /i grp includes anginosus /i intermedius /i constellatus /i streptococcus pyogenes /i bacteroides fragilis /i complicated intra-abdominal infection caused citrobacter freundii /i enterobacter cloaca /i escherichia coli /i klebsiella oxytoca /i klebsiella pneumoniae /i enterococcus faecalis /i vancomycin-susceptible isolates staphylococcus aureus /i methicillin-susceptible isolates streptococcus anginosus /i grp includes anginosus /i intermedius /i constellatus /i bacteroides fragilis /i bacteroides thetaiotaomicron /i bacteroides uniformis /i bacteroides vulgatus /i clostridium perfringens /i peptostreptococcus micros /i 
Doxapram, central respiratory stimulant brief duration action martindale extra pharmocopoeia 30th ed p1225 , use temporary measure hospitalized patient acute respiratory insufficiency superimposed chronic obstructive pulmonary disease 
Benzthiazide,benzthiazide used treat hypertension edema like thiazide benzthiazide promotes water loss body diuretic inhibit na+/cl- reabsorption distal convoluted tubule kidney thiazide also cause loss potassium increase serum uric acid thiazide often used treat hypertension hypotensive effect necessarily due diuretic activity thiazide shown prevent hypertension-related morbidity mortality although mechanism fully understood thiazide cause vasodilation activating calcium-activated potassium channel large conductance vascular smooth muscle inhibiting various carbonic anhydrases vascular tissue , treatment high blood pressure management edema 
Methotrexate,methotrexate folate derivative inhibits several enzyme responsible nucleotide synthesis a180322 inhibition lead suppression inflammation well prevention cell division a180322 effect methotrexate often used treat inflammation caused arthritis control cell division neoplastic disease breast cancer non-hodgkin 's lymphoma a180322 l7144 l7147 l7150 l7180 due toxic effect methotrexate indicated treatment form arthritis severe psoriasis first line treatment failed patient intolerant treatment l7180 methotrexate granted fda approval 7 december 1953 l7198 ,methotrexate oral solution indicated pediatric acute lymphoblastic leukemia pediatric polyarticular juvenile idiopathic arthritis l7144 methotrexate injection subcutaneous use indicated severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis severe recalcitrant disabling psoriasis l7147 l7150 l10457 formulation indicated treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer head neck advanced mycosis fungoides lung cancer advanced non-hodgkin 's lymphoma l7180 also used maintenance acute lymphocytic leukemia l7180 methotrexate also given treatment leucovorin prolong relapse-free survival following surgical removal tumour non-metastatic osteosarcoma l7180 
Carbamazepine,carbamazepine also known tegretol anticonvulsant drug analgesic drug used control seizure treat pain resulting trigeminal neuralgia initially approved fda 1965 a180301 aside us drug also given control symptom bipolar 1 l1335 interestingly carbamazepine first anticonvulsant used treat individual bipolar disorder a180319 ,carbamazepine indicated treatment epilepsy pain associated true trigeminal neuralgia l1335 particular carbamazepine shown efficacy treating mixed seizure partial seizure complex symptom generalized tonic-clonic seizure a180301 l1335 carbamazepine also indicated treatment manic episode mixed manic-depressive episode caused bipolar disorder l1335 off-label unapproved us carbamazepine include treatment alcohol withdrawal syndrome restless leg syndrome a180415 a180421 
Cisatracurium,cisatracurium non-depolarising neuromuscular blocking agent benzylisoquinolinium class available salt form cisatracurium besylate a243416 a253592 cisatracurium intermediate duration action one commonly used neuromuscular blocking agent intensive care. a253592 a253597 cisatracurium act cholinergic receptor blocking neuromuscular transmission action antagonized acetylcholinesterase inhibitor neostigmine a243416 a253592 cisatracurium r-cis-r-cis isomer atracurium approximately 3 time neuromuscular blocking potency a243416 compared atracurium cisatracurium produce lower degree histamine release a253597 ,cisatracurium indicated adjunct general anesthesia facilitate tracheal intubation adult pediatric patient 1 month 12 year age cisatracurium also indicated provide skeletal muscle relaxation surgery adult pediatric patient 2 12 year age bolus infusion maintenance mechanical ventilation icu adult l43577 
Succimer, mercaptodicarboxylic acid used antidote heavy metal poisoning form strong chelate , treatment lead poisoning pediatric patient blood lead level 45 micro g/dl may also used treat mercury arsenic poisoning 
Cephalexin,cephalexin first first generation cephalosporin a179071 a179074 antibiotic contains beta lactam dihydrothiazide a179071 cephalexin used treat number susceptible bacterial infection inhibition cell wall synthesis a179083 label cephalexin approved fda 4 january 1971 l6547 ,cephalexin indicated treatment certain infection caused susceptible bacteria label l6550 l6553 infection include respiratory tract infection otitis medium skin skin structure infection bone infection genitourinary tract infection label l6550 l6553 
Cinnarizine,first synthesized janssen pharmaceutical 1955 cinnarizine anti-histaminic drug mainly used control vestibular disorder motion sickness cinnarizine specific calcium channel blocker primarily work central vestibular system interfere signal transmission vestibular apparatus inner ear vomiting centre hypothalamus cinnarizine could also viewed nootropic drug vasorelaxating ability due calcium channel blockage happen mostly brain combination use cinnarizine nootropics piracetam resulted enhanced effect boosting brain oxygen supply , treatment vertigo/meniere 's disease nausea vomiting motion sickness also useful vestibular symptom origin 
Fondaparinux,fondaparinux arixtra synthetic anticoagulant agent consisting five monomeric sugar unit o-methyl group reducing end molecule structurally similar polymeric glycosaminoglycan heparin heparan sulfate h cleaved monomeric unit monomeric sequence heparin h thought form high affinity binding site natural anti-coagulant factor antithrombin iii atiii bound heparin h anticoagulant activity atiii potentiated 1000-fold fondaparinux potentiates neutralizing action atiii activated factor x 300-fold fondaparinux may used prevent venous thromboembolism patient undergone orthopedic surgery lower limb e.g hip fracture hip replacement knee surgery prevent vte patient undergoing abdominal surgery high risk thromboembolic complication treatment deep vein thrombosis dvt pumonary embolism pe management unstable angina ua non-st segment elevation myocardial infarction nstemi management st segment elevation myocardial infarction stemi ,approved 1 prophylaxis vte one month post surgery patient undergoing orthopedic surgery lower limb hip fracture hip replacement knee surgery 2 prophylaxis vte patient undergoing abdominal surgery high risk thromboembolic complication e.g patient undergoing abdominal cancer surgery 3 treatment acute dvt pe 4 management ua nstemi prevention death subsequent myocardial infarction mi 5 management stemi prevention death myocardial reinfarction patient managed thrombolytic initially receive form reperfusion therapy fondaparinux used sole anticoagulant percutaneous coronary intervention pci due increased risk guiding catheter thrombosis 
Vinblastine,antitumor alkaloid isolated vinca rosea merck 11th ed , treatment breast cancer testicular cancer lymphoma neuroblastoma hodgkin 's non-hodgkin 's lymphoma mycosis fungoides histiocytosis kaposi 's sarcoma 
Propranolol,propranolol racemic mixture 2 enantiomer -enantiomer approximately 100 time binding affinity beta adrenergic receptor l6904 propranolol used treat number condition commonly used hypertension l6901 l6904 l6907 propranolol granted fda approval 13 november 1967 l6904 ,propranolol indicated treat hypertension l6907 l6904 propranolol also indicated treat angina pectoris due coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma proliferating infantile hemangioma l6904 l6907 
Atropine,atropine alkaloid originally synthesized atropa belladonna racemic mixture d-and l-hyoscyamine l-hyoscyamine pharmacologically active a251670 l42835 atropine generally available sulfate salt administered intravenous subcutaneous intramuscular intraosseous endotracheal ophthalmic method oral atropine available combination product a251660 l42840 atropine competitive reversible antagonist muscarinic receptor block effect acetylcholine choline ester a251660 l42815 l42825 l42835 variety therapeutic application including pupil dilation treatment anticholinergic poisoning symptomatic bradycardia absence reversible cause a251660 atropine relatively inexpensive drug included world health organization list essential medicine a251675 , intravenous intramuscular subcutaneous intraosseous endotracheal use atropine indicated temporary blockade severe life-threatening muscarinic effect l42815 l42835 intramuscular use atropine form pen injector indicated treatment poisoning susceptible organophosphorus nerve agent cholinesterase activity well organophosphorus carbamate insecticide adult pediatric patient l42825 ophthalmic use atropine indicated mydriasis cycloplegia penalization healthy eye treatment amblyopia l42830 combination difenoxin diphenoxylate tablet oral use atropine indicated adjunctive therapy management acute nonspecific diarrhea l42840 l42865 
Fenoprofen, anti-inflammatory analgesic antipyretic highly bound plasma protein pharmacologically similar aspirin cause le gastrointestinal bleeding , relief sign symptom rheumatoid arthritis osteoarthritis also relief mild moderate pain 
Fenfluramine,dravet syndrome pediatric encephalopathy typically manifest within first year life following exposure elevated temperature characterized recurrent pharmacoresistant seizure increase frequency severity disease progression concomitantly seizure patient typically display delayed development neurocognitive impairment a214694 a214709 a214712 a214715 fenfluramine serotonergic phenethylamine originally used appetite suppressant concern regarding cardiotoxicity obese patient lead withdrawal market 1997 a214694 a214718 a11906 ability modulate neurotransmission fenfluramine reemerged effective therapy pharmacoresistant seizure involved dravet syndrome a214688 a214691 a214700 fenfluramine granted initial fda approval 1973 prior withdrawal granted new fda approval june 25 2020 treatment patient dravet syndrome lennox-gastaut syndrome restricted fintepla rem program currently sold name fintepla® zogenix inc. l14522 ,fenfluramine indicated treatment seizure associated dravet syndrome lennox-gastaut syndrome patient aged two year older l14522 
Clonidine,clonidine imidazole derivate act agonist alpha-2 adrenoceptors a180559 activity useful treatment hypertension severe pain adhd l7237 l7240 l7243 l7246 clonidine granted fda approval 3 september 1974 l7237 ,clonidine tablet transdermal system indicated treatment hypertension alone combination medication l7237 l7240 clonidine injection indicated use opiate treatment severe cancer pain opiate alone insufficient l7243 extended release tablet clonidine indicated treatment adhd either alone combination medication l7246 clonidine also used diagnosis pheochromocytoma a180565 treatment nicotine dependance a180568 opiate withdrawal a180571 
Sulfamethizole, sulfathiazole antibacterial agent , treatment urinary tract infection
Valaciclovir,valaciclovir valacyclovir also known _valtrex_ antiviral drug used manage treat various herpes infection 2 decade initially approved fda 1995 fda label marketed glaxosmithkline l5671 valacyclovir l-valine ester aciclovir member purine guanine nucleoside analog drug class f3949 class drug form important part hepatitis hiv cytomegalovirus drug regimen a175900 one major use valacyclovir treatment genital herpes episode outbreak genital herpes frequently diagnosed sexually transmitted disease currently affect 400 million individual worldwide caused infection herpes simplex virus hsv infection virus lifelong periodic episode reactivation a175903 ,valacyclovir nucleoside analog dna polymerase inhibitor indicated fda label adult • cold sore herpes labialis • genital herpes • treatment genital herpes lesion immunocompetent patient initial recurrent episode • suppression genital herpes lesion immunocompetent hiv-infected patient • reduction viral transmission • herpes zoster pediatric patient • cold sore herpes labialis • chickenpox limitation use fda label efficacy safety valacyclovir established immunocompromised patient suppression genital herpes hiv-infected patient 
Carbenicillin,broad-spectrum semisynthetic penicillin derivative used parenterally susceptible gastric juice penicillinase may damage platelet function , treatment acute chronic infection upper lower urinary tract asymptomatic bacteriuria due susceptible strain bacteria 
Mazindol,mazindol tricyclic anorexigenic agent unrelated le toxic amphetamine similar side effect inhibits uptake catecholamine block binding cocaine dopamine uptake transporter mazindol approved united state treatment duchenne muscular dystrophy marketed available united state use treatment obesity ,used short-term week treatment exogenous obesity conjunction regimen weight reduction based caloric restriction exercise behavior modification patient body mass index 30 kg body weight per height meter squared kg/m sup 2 /sup patient body mass index 27 kg/m sup 2 /sup presence risk factor hypertension diabetes hyperlipidemia 
Valdecoxib,valdecoxib removed canadian u.s. e.u market 2005 due concern possible increased risk heart attack stroke , treatment osteoarthritis dysmenorrhoea
Lactulose,lactulose synthetic disaccharide derivative lactose commonly used laxative agent despite also formally indicated serve adjunct therapy treating portal-systemic encephalopathy pse fda label l6199 l6202 despite first synthesized 1929 a178081 investigation regarding possible use laxative treatment chronic constipation occur 1960s first clinical use treating pse 1966 l6202 nevertheless although lactulose received formal fda approval 1977 since become readily available generic brand-name non-prescription medication listed world health organization 's list essential medicine one effective safe medicine employed health system l6205 data regarding optimal place therapy often ambiguous l6202 especially considering use lactulose laxative typically considered lifestyle dietary modification fail fact lactulose therapy ethically withheld patient diagnosed pse placebo study substance may one many option available treating constipation efficacy managing pse may never formally confirmed refuted via clinical investigation l6202 ,lactulose indicated use laxative treatment chronic constipation adult geriatric patient fda label l6199 l6202 additionally lactulose also employed adjunct protein restriction supportive therapy prevention treatment portal-systemic encephalopathy pse including hepatic pre-coma coma variation fda label l6199 l6202 particular lactulose solution effective managing pse resulting surgical portacaval shunt chronic hepatic disease like cirrhosis l6199 moreover also study demonstrating capacity lactulose minimize formation gallstone even investigation regarding experimental use agent developing novel anticancer agent owing ability bind galactin carbohydrate involved various tumor progression l6202 
Voriconazole,voriconazole vfend pfizer triazole antifungal medication used treat serious fungal infection l15571 used treat invasive fungal infection generally seen patient immunocompromised include invasive candidiasis invasive aspergillosis emerging fungal infection increased affinity voriconazole 14-alpha sterol demethylase make useful fluconazole -resistant organism a236050 voriconazole approved fda trade name vfend may 24 2002 l34660 , treatment esophageal candidiasis cadidemia invasive pulmonary aspergillosis serious fungal infection caused scedosporium apiospermum /i fusarium /i spp l9821 l15571 
Levocarnitine,constituent striated muscle liver used therapeutically stimulate gastric pancreatic secretion treatment hyperlipoproteinemia , treatment primary systemic carnitine deficiency genetic impairment normal biosynthesis utilization levocarnitine dietary source treatment secondary carnitine deficiency resulting inborn error metabolism glutaric aciduria ii methyl malonic aciduria propionic acidemia medium chain fatty acylcoa dehydrogenase deficiency used therapeutically stimulate gastric pancreatic secretion treatment hyperlipoproteinemia parenteral levocarnitine indicated prevention treatment carnitine deficiency patient end-stage renal disease 
Enalapril,enalapril prodrug belonging angiotensin-converting enzyme ace inhibitor drug class work renin-angiotensin-aldosterone system responsible regulation blood pressure fluid electrolyte homeostasis enalapril orally-active long-acting nonsulphydryl antihypertensive agent suppresses renin-angiotensin-aldosterone system lower blood pressure developed targeted research programmed using molecular modelling a18459 prodrug enalapril rapidly biotransformed active metabolite enalaprilat responsible pharmacological action enalapril active metabolite enalapril competitively inhibits ace hinder production angiotensin ii key component renin-angiotensin-aldosterone system promotes vasoconstriction renal reabsorption sodium ion kidney ultimately enalaprilat work reduce blood pressure blood fluid volume commonly marketed trade name vasotec enalapril first approved fda 1985 management hypertension heart failure asymptomatic left ventricular dysfunction also found combination product containing hydrochlorothiazide used management hypertension active metabolite enalaprilat also available oral tablet intravenous formulation injection ,indicated management essential renovascular hypertension l6586 monotherapy combination antihypertensive agent thiazide diuretic additive effect label indicated treatment symptomatic congestive heart failure usually combination diuretic digitalis label indicated management asymptomatic left ventricular dysfunction patient ejection fraction ≤ 35 percent decrease rate development overt heart failure incidence hospitalization heart failure label 
Nizatidine, histamine h2 receptor antagonist low toxicity inhibits gastric acid secretion drug used treatment duodenal ulcer , treatment acid-reflux disorder gerd peptic ulcer disease active benign gastric ulcer active duodenal ulcer 
Diclofenac,diclofenac phenylacetic acid derivative non-steroidal anti-inflammatory drug nsaid label nsaid inhibit cyclooxygenase cox -1 and-2 enzyme responsible producing prostaglandin pgs pgs contribute inflammation pain signalling diclofenac like nsaid often used first line therapy acute chronic pain inflammation variety cause diclofenac product rational drug design based structure phenylbutazone mefenamic acid indomethacin a180796 addition two chlorine group ortho position phenyl ring lock ring maximal torsion appears related increased potency often used combination misoprostol prevent nsaid-induced gastric ulcer diclofenac first approved fda july 1988 trade name voltaren marketed novartis previously ciba-geigy l7360 ,diclofenac indicated use treatment pain inflammation varying source including inflammatory condition osteoarthritis rheumatoid arthritis ankylosing spondylitis well injury-related inflammation due surgery physical trauma often used combination misoprostol gastro-protective agent patient high risk developing nsaid-induced ulcer 
Cinalukast,used treatment asthma cinalukast selectively antagonizes leukotriene d4 ltd4 cysteinyl leukotriene receptor cyslt1 human airway cinalukast inhibits action ltd4 cyslt1 receptor preventing airway edema smooth muscle contraction enhanced secretion thick viscous mucus , protection second- phase inflamation exercise-induced bronchoconstriction asthma 
Fluticasone propionate,fluticasone propionate synthetic glucocorticoid f4355 f4358 fda label drug available inhaler nasal spray topical treatment various inflammatory indication f4355 f4358 fda label fluticasone propionate first approved 1990 l5962 ,fluticasone propionate indicated inhaler treatment management asthma prophylaxis fda label well inflammatory pruritic dermatosis f4355 fluticasone propionate nasal spray indicated managing allergic nonallergic rhinitis l8309 f4358 
Lisuride, ergot derivative act agonist dopamine d2 receptor dopamine agonist may also act antagonist dopamine d1 receptor agonist serotonin receptor serotonin agonist , management parkinson 's disease
Doxazosin,doxazosin alpha-1 antagonist used treatment benign prostatic hypertrophy bph symptom hypertension member drug class include prazosin terazosin tamsulosin alfuzosin a180661 long-lasting effect doxazosin administered day a180649 marketed pfizer initially approved fda 1990 l7285 ,doxazosin indicated treat symptom benign prostatic hypertrophy may include urinary frequency urgency nocturia among symptom addition doxazosin indicated alone combination various antihypertensive agent management hypertension l7282 off-label us doxazosin include treatment pediatric hypertension a180634 treatment ureteric calculus a180637 
Fluocinolone acetonide,fluocinolone acetonide formula 6-alpha 9-alpha-difluoro-16-alpha 17 alpha-acetonide corticosteroid present high lipophilicity t357 used extensively dermatological preparation also investigated thoroughly use implantable corticosteroid device t358 type device containing fluocinolone acetonide developed taro pharmaceutical approved fda may 2016 l4676 ,fluocinolone acetonide used extensively different medical area -in dermatology extensively used relief inflammatory dermatosis dermatitis psoriasis hypertrophic tissue keloid tissue atopic dermatitis f1955 -it used shampoo product low medium potency corticosteroid treatment seborrheic dermatitis scalp l4682 -in ear drop used low medium potency corticosteroid treatment chronic eczematous external otitis adult pediatric patient 2 year older l4683 -as intravitreal implant indicated treatment diabetic macular edema patient previously treated course corticosteroid clinically significant rise intraocular pressure l4684 -fluocinolone acetonide announced october 15 2018 fda approved treatment chronic non-infectious uveitis affecting posterior segment eye l4685 -some report indicated use fluocinolone acetonide vasoprotective agent use treatment first-degree hemorrhoid a39532 
Piperazine,piperazine organic compound consists six-membered ring containing two opposing nitrogen atom first used solvent uric acid use piperazine anthelmintic agent first introduced 1953 upon entry systemic circulation drug partly oxidized partly eliminated unchanged compound outside body piperazine remarkable power dissolve uric acid producing soluble urate clinical experience proved equally successful piperazine first introduced anthelmintic 1953 piperazine compound mediate anthelmintic action generally paralyzing parasite allowing host body easily remove expel invading organism ,used alternative treatment ascariasis caused ascaris lumbricoides /i roundworm enterobiasis oxyuriasis caused enterobius vermicularis /i pinworm also used treat partial intestinal obstruction common roundworm condition primarily occurring child 
Ethosuximide, anticonvulsant especially useful treatment absence seizure unaccompanied type seizure , treatment petit mal epilepsy 
Amiloride, pyrazine compound inhibiting sodium reabsorption sodium channel renal epithelial cell inhibition creates negative potential luminal membrane principal cell located distal convoluted tubule collecting duct negative potential reduces secretion potassium hydrogen ion amiloride used conjunction diuretic spare potassium loss gilman et al. goodman gilman 's pharmacological basis therapeutic 9th ed p705 , use adjunctive treatment thiazide diuretic kaliuretic-diuretic agent congestive heart failure hypertension 
Oxytetracycline, tetracycline analog isolated actinomycete streptomyces rimosus used wide variety clinical condition ,oxytetracycline indicated treatment infection caused variety gram positive gram negative microorganism including mycoplasma pneumoniae pasteurella pestis escherichia coli haemophilus influenzae /i respiratory infection diplococcus pneumoniae /i 
Ulobetasol,ulobetasol highly potent corticosteroid a215597 structurally related clobetasol a215597 due high potency mainly prescribed treatment severe plaque psoriasis corticosteroid responsive dermatosis l15047 l15052 l15102 ulobetasol granted fda approval 17 december 1990 l15047 ,ulobetasol cream ointment indicated treatment inflammatory pruritic corticosteroid responsive dermatosis l15047 ulobetasol lotion indicated treatment plaque psoriasis l15052 
Gadoteridol,gadoteridol provides contrast enhancement brain spine surrounding tissue resulting improved visualization compared unenhanced mri lesion abnormal vascularity thought cause disruption normal blood brain barrier gadoteridol also used whole body contrast enhanced mri including head neck liver breast musculoskeletal system soft tissue pathology n mri visualization normal pathological brain tissue depends part variation radiofrequency signal intensity occur change proton density alteration t1 variation t2 placed magnetic field gadoteridol shortens t1 relaxation time tissue accumulates abnormal vascularity disruption blood-brain barrier allows accumulation gadoteridol lesion neoplasm abscess subacute infarct ,gadoteridol indicated use magnetic resonance imaging mri order visualize lesion disrupted blood-brain barrier and/or abnormal vascularity brain spine associated tissue adult pediatric patient including term neonate l40898 also indicated visualization lesion head neck adult patient l40898 
Labetalol,labetalol racemic mixture 2 diastereoisomers dilevalol r r stereoisomer make 25 mixture l7730 labetalol formulated injection tablet treat hypertension l7727 l7730 labetalol granted fda approval 1 august 1984 l7724 ,labetalol injection indicated control blood pressure severe hypertension l7727 labetalol tablet indicated alone combination antihypertensive like thiazide loop diuretic manage hypertension l7730 
Thiopental, barbiturate administered intravenously induction general anesthesia production complete anesthesia short duration also used hypnosis control convulsive state used neurosurgical patient reduce increased intracranial pressure produce excitation poor analgesic muscle relaxant property small dos shown anti-analgesic lower pain threshold martindale extra pharmacopoeia 30th ed p920 , use sole anesthetic agent brief 15 minute procedure induction anesthesia prior administration anesthetic agent supplement regional anesthesia provide hypnosis balanced anesthesia agent analgesia muscle relaxation control convulsive state following inhalation anesthesia local anesthesia neurosurgical patient increased intracranial pressure narcoanalysis narcosynthesis psychiatric disorder 
Monobenzone,monobenzone monobenzyl ether hydroquinone used medically depigmentation monobenzone occurs white almost tasteless crystalline powder soluble alcohol practically insoluble water exerts depigmenting effect skin mammal increasing excretion melanin melanocyte may also cause destruction melanocyte permanent depigmentation ,used topically treat loss skin color vitiligo 
Linezolid,linezolid synthetic antibiotic used treatment infection caused aerobic gram-positive bacteria effect bacteriostatic enterococci staphylococci bactericidal isolates streptococci l32965 linezolid exerts antibacterial activity inhibiting initiation bacterial protein synthesis specifically bind 23 ribosomal rna 50 subunit a11227 a199050 prevents formation 70 initiation complex essential bacterial reproduction linezolid initially approved 2000 first member oxazolidinone antibiotic class a233425 second member class tedizolid approved fda 2014 considered generally effective tolerable predecessor ,linezolid indicated adult child treatment infection caused susceptible gram-positive bacteria including nosocomial pneumonia community-acquired pneumonia skin skin structure infection vancomycin-resistant _enterococcus faecium_ infection l32965 example susceptible bacteria include _staphylococcus aureus_ _streptococcus pneumoniae_ _streptococcus pyogenes_ _streptococcus agalactiae_ l32965 linezolid indicated treatment gram-negative infection evaluated use longer 28 day l32965 
Ivermectin,"ivermectin semi-synthetic antiparasitic medication derived avermectins class highly-active broad-spectrum antiparasitic agent isolated fermentation product _streptomyces avermitilis_ l31453 ivermectin mixture two avermectins comprising roughly 90 5-o-demethyl-22,23-dihydroavermectin sub 1a /sub 22,23-dihydroavermectin b sub 1a /sub 10 5-o-demethyl-25-de 1-methylpropyl -22,23-dihydro­-25- 1-methylethyl avermectin sub 1a /sub 22,23-dihydroavermectin b sub 1b /sub l31453 ivermectin mainly used human treatment onchocerciasis may also effective worm infestation strongyloidiasis ascariasis trichuriasis enterobiasis applied topically may used treatment head louse infestation advent 2020 covid-19 pandemic ivermectin began garnering notoriety due off-label use prophylaxis treatment covid-19 study still ongoing much evidence ivermectin covid-19 relies pre-print _in vitro_ data clinical utility data remains unclear due number factor example relatively low number patient per trial speed trial conducted study use ivermectin covid-19 fraught statistical error accusation plagiarism l36763 a238929 addition use aggregate patient data large-scale meta-analyses opposed individual patient data ipd shown disguise otherwise blatant data error extreme terminal digit bias duplication block patient record a238929 high-quality peer-reviewed data regarding safety efficacy ivermectin covid-19 human becomes available use ivermectin purpose avoided favour thoroughly-vetted therapy e.g covid-19 vaccine like comirnaty http //go.drugbank.com/drugs/db15696 ",administered topically ivermectin cream indicated treatment inflammatory lesion associated rosacea l36753 over-the-counter ivermection lotion commercially available indicated topical treatment head louse infestation patient ≥6 month age l36748 orally administered ivermectin indicated broad-spectrum anti-parasitic treatment intestinal strongyloidiasis caused _strongyloides stercoralis_ onchocerciasis caused _onchocerca volvulus_ l31453 systemic ivermectin therapy used internationally treatment various tropical disease including filariasis cutaneous larva migrans _loa loa_ infection amongst others a238298 
Medroxyprogesterone acetate,medroxyprogesterone acetate mpa progesterone derivative resistant metabolism improved pharmacokinetic property a14848 mpa use treat secondary amenorrhea endometrial hyperplasia abnormal uterine bleeding osteoporosis vasomotor symptom menopause vulvar vaginal atrophy prevent pregnancy manage pain endometriosis prevent pregnancy also used palliative care endometrial renal carcinoma l8657 l8660 l8663 l8666 l8669 medroxyprogesterone acetate granted fda approval 18 june 1959 l8657 ,medroxyprogesterone acetate mpa oral tablet indicated treat secondary amenorrhea reduce incidence endometrial hyperplasia postmenopausal woman treat abnormal uterine bleeding due hormonal imbalance organic pathology l8657 oral tablet containing mpa conjugated estrogen indicated prevent postmenopausal osteoporosis treat moderate severe menopausal symptom vasomotor symptom vulvar atrophy vaginal atrophy l8660 subcutaneous mpa indicated prevent pregnancy manage pain associated endometriosis l8663 intramuscular mpa indicated prevent pregnancy l8666 higher concentration palliative treatment endometrial renal carcinoma l8669 
Cisapride, many country including canada cisapride either withdrawn indication limited due report long qt syndrome due cisapride predisposes arrhythmia fda issued warning letter regarding risk health care professional patient , symptomatic treatment adult patient nocturnal heartburn due gastroesophageal reflux disease 
Sulindac,sulindac nonsteroidal anti-inflammatory drug nsaid arylalkanoic acid class marketed merck brand name clinoril like nsaid may used treatment acute chronic inflammatory condition sulindac prodrug derived sulfinylindene converted _in vivo_ active sulfide compound liver enzyme evidence study sulindac may associated fewer gastrointestinal side effect nsaid except cyclooxygenase-2 cox-2 inhibitor drug class may due sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood level compound without inducing gastrointestinal effect drug excreted bile reabsorbed intestine full mechanism action fully understood sulindac thought primarily mediate action inhibiting prostaglandin synthesis inhibiting cox-1 cox-2 , acute long-term use relief sign symptom osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitis/supraspinatus tendinitis acute gouty arthritis 
Cyclothiazide, diuretic cyclothiazide inhibits active chloride reabsorption early distal tubule via na-cl cotransporter resulting increase excretion sodium chloride water thiazide like cyclothiazide also inhibit sodium ion transport across renal tubular epithelium binding thiazide sensitive sodium-chloride transporter result increase potassium excretion via sodium-potassium exchange mechanism antihypertensive mechanism cyclothiazide le well understood although may mediated action carbonic anhydrases smooth muscle action large-conductance calcium-activated potassium kca channel also found smooth muscle cyclothiazide indicated adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy also indicated management hypertension either sole therapeutic agent enhance effectiveness antihypertensive drug severe form hypertension ,cyclothiazide indicated adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy also indicated management hypertension either sole therapeutic agent enhance effectiveness antihypertensive drug severe form hypertension 
Nafcillin, semi-synthetic antibiotic related penicillin naficillin narrow-spectrum beta-lactam antibiotic drug beta-lactamase-resistant penicillin indicated treatment staphylococcal infection caused strain resistant penicillin except caused mrsa may used first-line therapy methicillin-sensitive staphylococcus aureus infection a20360 ,indicated treatment infection caused penicillinase-producing staphylococci demonstrated susceptibility drug 
Chloroquine,chloroquine aminoquinolone derivative first developed 1940s treatment malaria a191655 drug choice treat malaria development newer antimalarial pyrimethamine artemisinin mefloquine a191787 chloroquine derivative hydroxychloroquine since repurposed treatment number condition including hiv systemic lupus erythematosus rheumatoid arthritis a192432 fda emergency use authorization hydroxychloroquine chloroquine treatment covid-19 revoked 15 june 2020 l14312 chloroquine granted fda approval 31 october 1949 l12054 ,chloroquine indicated treat infection _p vivax_ _p malariae_ _p ovale_ susceptible strain _p falciparum_ l12051 also used treat extraintestinal amebiasis l12051 chloroquine also used label treatment rheumatic disease a191655 well treatment prophylaxis zika virus a191649 a191652 chloroquine currently undergoing clinical trial treatment covid-19 a191631 
Ethionamide, second-line antitubercular agent inhibits mycolic acid synthesis also may used treatment leprosy smith reynard textbook pharmacology 1992 p868 , use treatment pulmonary extrapulmonary tuberculosis antitubercular drug failed 
Metaraminol, adrenergic agonist act predominantly alpha adrenergic receptor also stimulates release norepinephrine used primarily vasoconstrictor treatment hypotension , treatment prevention hypotension due hemorrhage spinal anesthesia shock associated brain damage
Butorphanol, synthetic morphinan analgesic narcotic antagonist action used management severe pain , relief moderate severe pain 
Bisoprolol,bisoprolol cardioselective β1-adrenergic blocking agent used treat high blood pressure a180472 l7219 considered potent drug long-half life used daily reduce need multiple dos antihypertensive drug a180472 bisoprolol generally well tolerated likely due β1-adrenergic receptor selectivity useful alternative non-selective β-blocker drug treatment hypertension carvedilol labetalol may used alone combination drug manage hypertension l7219 useful patient chronic obstructive pulmonary disease copd due receptor selectivity a180562 ,bisoprolol indicated treatment mild moderate hypertension l7219 may used off-label treat heart failure atrial fibrillation angina pectoris a180460 a180463 
Amodiaquine, 4-aminoquinoquinoline compound anti-inflammatory property , treatment acute malarial attack non-immune subject 
Furazolidone, nitrofuran derivative antiprotozoal antibacterial activity furazolidone bind bacterial dna lead gradual inhibition monoamine oxidase martindale extra pharmacopoeia 30th ed p514 , specific symptomatic treatment bacterial protozoal diarrhea enteritis caused susceptible organism 
Rifabutin, broad-spectrum antibiotic used prophylaxis disseminated mycobacterium avium complex infection hiv-positive patient , prevention disseminated mycobacterium avium /i complex mac disease patient advanced hiv infection 
Candoxatril,candoxatril orally-active prodrug candoxatrilat uk-73967 potent neutral endopeptidase nep inhibitor ,
Paramethadione,paramethadione anticonvulsant oxazolidinedione class associated fetal trimethadione syndrome also known paramethadione syndrome ,used control absence petit mal seizure refractory treatment medication 
Demeclocycline, tetracycline analog 7-chloro 6-methyl excreted slowly tetracycline maintains effective blood level longer period time ,used primarily treat lyme disease acne bronchitis also indicated rarely used treat urinary tract infection gum disease malaria bacterial infection gonorrhea chlamydia one registered us treatment hyponatremia low blood sodium concentration due syndrome inappropriate antidiuretic hormone siadh fluid restriction alone ineffective 
Imatinib,imatinib small molecule kinase inhibitor revolutionized treatment cancer particularly chronic myeloid leukemia 2001 a249305 deemed `` miracle drug '' due clinical success oncologist dr. brian noted `` complete hematologic response observed 53 54 patient cml treated daily dosage 300 mg typically occurred first four week therapy '' a249315 discovery imatinib also established new group therapy called `` targeted therapy '' since treatment tailored specifically unique cancer genetics patient l42220 ,imatinib indicated treatment adult pediatric chronic myeloid leukemia philadelphia chromosome mutation ph+ blast crisis accelerated phase chronic phase ifn-alpha therapy failure l42080 additionally imatinib also indicated treat adult pediatric ph+ acute lymphoblastic leukemia adult myelodysplastic/myeloproliferative disease adult aggressive systemic mastocytosis adult hypereosinophilic syndrome and/or chronic eosinophilic leukemia cel adult dermatofibrosarcoma protuberans malignant gastrointestinal stromal tumor gist l42080 
Triamcinolone,triamcinolone corticosteroid used treat various inflammatory condition body allergic rhinitis acute exacerbation multiple sclerosis l8255 triamcinolone used one time adjunct treatment osteoarthritic knee pain l8264 first line topical treatment corticosteroid responsive dermatosis l8249 triamcinolone commonly seen form triamcinolone hexacetonide triamcinolone acetonide triamcinolone diacetate l8246 l8249 l8252 l8255 l8258 l8261 l8264 triamcinolone granted fda approval 3 december 1957 l8243 october 2021 suspension triamcinolone acetonide approved suprachoroidal injection first suprachoroidal injection receive fda approval l38973 treatment patient macular edema associated uveitis l38963 ,triamcinolone hexacetonide injection indicated intralesional administration alopecia areata discoid lupus erythematosus keloid necrobiosis lipoidica diabeticorum l8246 formulation also used localized hypertrophic infiltrated inflammatory lesion granuloma annulare lichen planus lichen simplex chronicus psoriatic plaque l8246 triamcinolone acetonide spray cream indicated treatment inflammatory pruritic manifestation corticosteroid responsive dermatosis l8249 l8258 triamcinolone acetonide 10mg/ml 40mg/ml injection indicated intra-articularly acute gouty arthritis acute subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis l8252 l8255 10mg/ml injection indicated intralesional route treatment alopecia areata discoid lupus erythematosus keloid necrobiosis lipoidica diabeticorum tumor aponeurosis tendon l8252 formulation also used localized hypertrophic infiltrated inflammatory lesion granuloma annulare lichen planus lichen simplex chronicus psoriatic plaque l8252 40mg/ml injection indicated intramuscularly controlling severe allergic condition asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial seasonal allergic rhinitis serum sickness transfusion reaction treatment bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevens-johnson syndrome congenital adrenal hyperplasia hypercalcemia cancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamond-blackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbation multiple sclerosis cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonia symptomatic sarcoidosis dermatomyositis polymyositis systemic lupus erythematosus adjunct treatment adrenocortical insufficiency regional enteritis ulcerative colitis fulminating disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management leukemia lymphoma induction diuresis remission proteinuria idiopathic nephrotic syndrome lupus erythematosus l8255 triamcinolone intravitreal injection indicated treatment sympathetic ophthalmia temporal arteritis uveitis ocular inflammatory condition l8261 intravitreal injection also used visualization vitrectomy l8261 extended release suspension indicated intra-articularly management pain osteoarthritis knee l8264 triamcinolone acetonide suspension injection suprachoroidal space indicated treatment macular edema associated uveitis l38963 
Oxandrolone, synthetic hormone anabolic androgenic property ,use promote weight gain weight loss following extensive surgery 
Nicardipine, potent calcium channel blockader marked vasodilator action antihypertensive property effective treatment angina coronary spasm without showing cardiodepressant effect also used treatment asthma enhances action specific antineoplastic agent pubchem ,used management patient chronic stable angina treatment hypertension 
Fluphenazine, phenothiazine used treatment psychosis property us generally similar chlorpromazine , management manifestation psychotic disorder 
Testosterone,testosterone steroid sex hormone indicated treat primary hypogonadism hypogonadotropic hypogonadism l8983 l8935 l8938 l8986 l8989 l8992 l8995 testosterone antagonizes androgen receptor induce gene expression cause growth development masculine sex organ secondary sexual characteristic a187114 l8983 l8935 l8938 l8986 l8989 l8992 l8995 testosterone isolated sample also synthesized 1935 a186943 ,testosterone indicated treat primary hypogonadism hypogonadotropic hypogonadism l8983 l8935 l8938 l8986 l8989 l8992 l8995 
Efavirenz,efavirenz brand name sustiva® stocrin® non-nucleoside reverse transcriptase inhibitor nnrti used part highly active antiretroviral therapy haart treatment human immunodeficiency virus hiv type 1 hiv infection previously treated efavirenz lamivudine combination zidovudine tenofovir preferred nnrti-based regimen efavirenz also used combination antiretroviral agent part expanded postexposure prophylaxis regimen prevent hiv transmission exposed material associated high risk hiv transmission , use combination treatment hiv infection aid 
Bacitracin,bacitracin combination least 9 bacitracin a955 a181952 60-80 commercially prepared bacitracin bacitracin a181952 bacillus produce bacitracin first isolated knee scrape 1945 knee wound child named margaret tracy a181952 bacitracin granted fda approval 29 july 1948 a181997 l7748 ,bacitracin indicated topical formulation acute chronic localized skin infection a181997 occasionally also used intramuscularly infantile streptococcal pneumonia empyema a181997 bacitracin also formulated ointment neomycin polymyxin b counter use a181997 l7769 bacitracin ointment formulated neomycin polymyxin b along hydrocortisone indicated treatment corticosteroid responsive dermatosis secondary infection l7772 
Niacin,niacin b vitamin used treat vitamin deficiency well hyperlipidemia dyslipidemia hypertriglyceridemia reduce risk myocardial infarction l7550 l7553 l7556 l7559 l7562 l7565 ,niacin indicated prevent vitamin deficiency pediatric adult patient receiving parenteral nutrition part multivitamin intravenous injection l7550 l7553 l7556 l7559 niacin oral tablet indicated monotherapy combination simvastatin lovastatin treat primary hyperlipidemia mixed dyslipidemia l7562 l7565 also used reduce risk nonfatal myocardial infarction patient history myocardial infarction hyperlipidemia l7562 l7565 niacin also indicated bile acid binding resin treat atherosclerosis patient coronary artery disease hyperlipidemia treat primary hyperlipidemia l7562 l7565 finally niacin indicated treat severe hypertriglyceridemia l7562 l7565 
Clorazepic acid, water-soluble benzodiazepine derivative effective treatment anxiety also muscle relaxant anticonvulsant action , management anxiety disorder short-term relief symptom anxiety also used adjunctive therapy management partial seizure symptomatic relief acute alcohol withdrawal 
Guanabenz, alpha-2 selective adrenergic agonist used antihypertensive agent pubchem , management high blood pressure
Alendronic acid,alendronic acid second generation bisphosphonate used treatment form osteoperosis paget 's disease fda label a959 a203111 function preventing resorption bone fda label a959 ,alendronic acid indicated treatment prevention osteoporosis men postmenopausal woman treatment glucocorticoid-induced osteoporosis paget 's disease bone fda label a959 a176750 however alendronic acid indicated use pediatric population patient creatinine clearance 35ml/min fda label 
Clofarabine,clofarabine purine nucleoside antimetabolite studied treatment cancer marketed clolar u.s. canada evoltra europe australia new zealand clofarabine used paediatrics treat type leukaemia called relapsed refractory acute lymphoblastic leukaemia least two type treatment failed known drug extends life expectancy potential use acute myeloid leukaemia aml juvenile myelomonocytic leukaemia jmml investigated , treatment pediatric patient 1 21 year old relapsed refractory acute lymphocytic lymphoblastic leukemia least two prior regimen designated orphan drug fda use 
Docosanol,docosanol drug used topical treatment recurrent herpes simplex labialis episode episode cold sore fever blister saturated 22-carbon aliphatic alcohol docosanol exhibit antiviral activity many lipid enveloped virus including herpes simplex virus hsv docosanol inhibits fusion plasma membrane herpes simplex virus hsv envelope thereby preventing viral entry cell subsequent viral replication , topical treatment recurrent oral-facial herpes simplex episode cold sore fever blister 
Dexmedetomidine, agonist receptor adrenergic alpha-2 used veterinary medicine analgesic sedative property racemate dexmedetomidine ,administered intravenously dexmedetomidine indicated sedation initially intubated mechanically ventilated patient treatment intensive care setting sedation non-intubated patient prior and/or surgery procedure l41374 also available buccally- sublingually-administered dissolvable film acute treatment agitation associated schizophrenia bipolar ii disorder l41379 
Sulfacetamide, anti-infective agent used topically treat skin infection orally urinary tract infection , treatment bacterial vaginitis keratitis acute conjunctivitis blepharitis 
Prednisone, synthetic anti-inflammatory glucocorticoid derived cortisone a187463 biologically inert converted prednisolone liver l10502 prednisone granted fda approval 21 february 1955 l10496 ,prednisone indicated anti-inflammatory immunosuppressive drug allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious endocrine neoplastic condition well organ transplant l10502 
Clofibrate, fibric acid derivative used treatment hyperlipoproteinemia type iii severe hypertriglyceridemia martindale extra pharmacopoeia 30th ed p986 , primary dysbetalipoproteinemia type iii hyperlipidemia respond adequately diet help control high cholesterol high triglyceride level 
Astemizole,astemizole long-acting non-sedating second generation antihistamine used treatment allergy symptom withdrawn market manufacturer 1999 due potential cause arrhythmia high dos especially taken cyp inhibitor grapefruit juice ,astemizole indicated use relieving allergy symptom particularly rhinitis conjunctivitis withdrawn market however due concern arrhythmia 
Inulin, starch found tuber root many plant since hydrolyzable fructose classified fructosan used physiologic investigation determination rate glomerular function ,historically used important medical test renal function specifically measure glomerular filtration rate sometimes used help relieve symptom diabetes mellitus condition characterised hyperglycemia and/or hyperinsulinemia 
Butoconazole,butoconazole imidazole antifungal used gynecology , local treatment vulvovaginal candidiasis infection caused candida 
Adenosine, structure adenosine first described 1931 a229823 though vasodilating effect described literature 1940s a229828 adenosine indicated adjunct thallium-201 myocardial perfusion scintigraphy l31983 though rarely used indication largely replaced dipyridamole regadenson a229833 a229838 adenosine also indicated treatment supraventricular tachycardia l31998 adenosine granted fda approval 30 october 1989 l31978 ,adenosine indicated adjunct thallium-201 myocardial perfusion scintigraphy patient unable adequately exercise l31983 also indicated convert sinus rhythm paroxysmal supraventricular tachycardia l31998 
Simvastatin,simvastatin also known brand name product zocor lipid-lowering drug derived synthetically fermentation product _aspergillus terreus_ belongs statin class medication used lower risk cardiovascular disease manage abnormal lipid level inhibiting endogenous production cholesterol liver specifically statin medication competitively inhibit enzyme hydroxymethylglutaryl-coenzyme hmg-coa reductase a181421 catalyzes conversion hmg-coa mevalonic acid third step sequence metabolic reaction involved production several compound involved lipid metabolism transport including cholesterol low-density lipoprotein ldl sometimes referred `` bad cholesterol '' low-density lipoprotein vldl prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd type 2 diabetes clear evidence benefit statin use coupled minimal side effect long term effect resulted class becoming one widely prescribed medication north america a181087 a181406 simvastatin drug statin class medication including atorvastatin pravastatin rosuvastatin fluvastatin lovastatin considered first-line option treatment dyslipidemia a181087 a181406 increasing use statin class drug largely due fact cardiovascular disease cvd includes heart attack atherosclerosis angina peripheral artery disease stroke become leading cause death high-income country major cause morbidity around world a181084 elevated cholesterol level particular elevated low-density lipoprotein ldl level important risk factor development cvd a181087 a181553 use statin target reduce ldl level shown number landmark study significantly reduce risk development cvd all-cause mortality a181090 a181093 a181096 a181427 a181475 a181538 statin considered cost-effective treatment option cvd due evidence reducing all-cause mortality including fatal non-fatal cvd well need surgical revascularization angioplasty following heart attack a181087 a181406 evidence shown even low-risk individual 10 risk major vascular event occurring within 5 year statin cause 20 -22 relative reduction major cardiovascular event heart attack stroke coronary revascularization coronary death every 1 mmol/l reduction ldl without significant side effect risk a181397 a181403 statin medication considered equally effective clinical standpoint rosuvastatin considered potent dos 10 40mg rosuvastatin per day found clinical study result 45.8 54.6 decrease ldl cholesterol level simvastatin found average decrease ldl-c ~35 a181409 a181535 a181538 a1793 potency thought correlate tissue permeability lipophilic statin simvastatin thought enter endothelial cell passive diffusion opposed hydrophilic statin pravastatin rosuvastatin taken hepatocytes oatp1b1 organic anion transporter protein 1b1 -mediated transport a181424 a181460 despite difference potency several trial demonstrated minimal difference term clinical outcome statin a181427 ,simvastatin indicated treatment hyperlipidemia reduce elevated total cholesterol total-c low-density lipoprotein cholesterol ldl‑c apolipoprotein b apo b triglyceride tg increase high-density lipoprotein cholesterol hdl-c f4655 f4658 includes treatment primary hyperlipidemia fredrickson type iia heterozygous familial nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh adjunct lipid-lowering treatment well adolescent patient heterozygous familial hypercholesterolemia hefh f4655 f4658 simvastatin also indicated reduce risk cardiovascular morbidity mortality including myocardial infarction stroke need revascularization procedure primarily used patient high risk coronary event existing coronary heart disease diabetes peripheral vessel disease history stroke cerebrovascular disease f4655 f4658 prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd statin-indicated condition include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl-c level a181087 a181406 
Pemetrexed,pemetrexed chemotherapy drug manufactured marketed eli lilly company brand name alimta indicated use combination cisplatin treatment patient malignant pleural mesothelioma whose disease either unresectable otherwise candidate curative surgery use non-small cell lung cancer also investigated pemetrexed first approved fda february 4 2004 a253907 ,pemetrexed indicated use patient non-squamous non-small cell lung cancer nsclc either combination pembrolizumab platinum-based chemotherapy initial treatment metastatic disease egfr alk genomic tumour aberration exist combination cisplatin initial treatment locally advanced metastatic disease maintenance treatment locally advanced metastatic disease progressed following four cycle platinum-based chemotherapy treatment recurrent metastatic disease following prior chemotherapy l40943 pemetrexed also indicated combination cisplatin initial treatment patient malignant pleural mesothelioma whose disease unresectable otherwise candidate curative surgery l40943 
Mebendazole, benzimidazole act interfering carbohydrate metabolism inhibiting polymerization microtubule pubchem , treatment enterobius vermicularis /i pinworm trichuris trichiura /i whipworm ascaris lumbricoides /i common roundworm ancylostoma duodenale /i common hookworm necator americanus /i american hookworm single mixed infection 
Gonadorelin,gonadorelin another name gonadotropin-releasing hormone gnrh synthetic decapeptide prepared using solid phase peptide synthesis gnrh responsible release follicle stimulating hormone leutinizing hormone anterior pituitary , evaluating functional capacity response gonadotropes anterior pituitary also evaluating residual gonadotropic function pituitary following removal pituitary tumor surgery and/or irradiation 
Dyclonine,dyclonine oral anaesthetic found sucrets counter throat lozenge may also found cepacol sore throat spray product ,used provide topical anesthesia accessible mucous membrane prior examination endoscopy instrumentation procedure involving esophagus larynx mouth pharynx throat respiratory tract trachea urinary tract vagina also used suppress gag reflex and/or laryngeal esophageal reflex facilitate dental examination procedure including oral surgery endoscopy intubation also used relief canker sore cold sore fever blister 
Nystatin,nystatin polyene antifungal drug broad-spectrum fungicidal fungistatic activity number yeast fungi notably _candida_ specie l10686 one effective antifungal agent synthesized bacteria case strain _streptomyces noursei_ l10776 closely related amphotericin b differing slightly structure a188562 nystatin greater antifungal activity amphotericin b parenterally administered nystatin however associated significant toxicity available formulation appropriate systemic use a188562 undergoes little absorption following oral topical administration nystatin 's efficacy limited treatment/prevention cutaneous mucocutaneous gastrointestinal fungal infection l10686 l10728 ,nystatin available oral formulation treatment and/or prevention oral candidiasis a.k.a thrush intestinal candidiasis anal candidiasis l10686 l10728 indicated topically treatment vulvovaginal candidiasis cutaneous candida infection l10728 combination product containing nystatin alongside neomycin gramicidin triamcinolone viaderm k.c.® indicated treatment corticosteroid-responsive dermatosis caused bacterial candidal infection pruritus ani/vulvae l10731 also available combination metronidazole treatment mixed infection due _trichomonas vaginalis_ _candida albicans_ l10776 nystatin also sometimes used off-label prevention invasive candidiasis low birth weight neonate a188565 though generally reserved second-line option fluconazole 
Dextropropoxyphene,dextropropoxyphene opioid analgesic manufactured eli lilly company used symptomatic treatment mild pain display antitussive local anaesthetic action due risk cardiac arrhythmia overdose possibly leading death dextropropoxyphene withdrawn market europe united state drug often referred general form `` propoxyphene '' however dextro-isomer dextropropoxyphene analgesic effect levo-isomer appears exhibit limited antitussive effect , relief mild moderate pain 
Mitotane, derivative insecticide dichlorodiphenyldichloroethane specifically inhibits cell adrenal cortex production hormone used treat adrenocortical tumor cause cns damage bone marrow depression , treatment inoperable adrenocortical tumour cushing 's syndrome
Stavudine, dideoxynucleoside analog inhibits reverse transcriptase vitro activity hiv , treatment human immunovirus hiv infection 
Leucovorin,folinic acid also known 5-formyl tetrahydrofolic acid leucovorin 5-formyl derivative tetrahydrofolic acid necessary co-factor body commercially available leucovorin composed 1:1 racemic mixture dextrorotary levorotary isomer levoleucovorin contains pharmacologically active levo-isomer vitro levo-isomer shown rapidly converted biologically available methyl-tetrahydrofolate form dextro form slowly excreted kidney despite difference activity two commercially available form shown pharmacokinetically identical may used interchangeably limited difference efficacy side effect kovoor et al 2009 folate analog leucovorin levoleucovorin used counteract toxic effect folic acid antagonist methotrexate act inhibiting enzyme dihydrofolate reductase dhfr indicated use rescue therapy following use high-dose methotrexate treatment osteosarcoma diminishing toxicity associated inadvertent overdosage folic acid antagonist injectable form also indicated use treatment megaloblastic anemia due folic acid deficiency oral therapy feasible use combination 5-fluorouracil prolong survival palliative treatment patient advanced colorectal cancer folic acid essential b vitamin required body synthesis purine pyrimidine methionine incorporation dna protein however order function role must first reduced enzyme dihydrofolate reductase dhfr cofactor dihydrofolate dhf tetrahydrofolate thf important pathway required de novo synthesis nucleic acid amino acid disrupted high-dose methotrexate used cancer therapy methotrexate function dhfr inhibitor prevent dna synthesis rapidly dividing cell also prevents formation dhf thf result deficiency coenzyme resultant buildup toxic substance responsible numerous adverse side effect associated methotrexate therapy levoleucovorin leucovorin analog tetrahydrofolate thf able bypass dhfr reduction act cellular replacement co-factor thf thereby preventing toxic side effect , treatment osteosarcoma high dose methotrexate therapy used diminish toxicity counteract effect impaired methotrexate elimination inadvertent overdosages folic acid antagonist treat megaloblastic anemia due folic acid deficiency also used combination 5-fluorouracil prolong survival palliative treatment patient advanced colorectal cancer 
Dyphylline,dyphylline theophylline derivative broncho- vasodilator property typically used management asthma cardiac dyspnea bronchitis , relief acute bronchial asthma reversible bronchospasm associated chronic bronchitis emphysema 
Pentazocine, first mixed agonist-antagonist analgesic marketed agonist kappa sigma opioid receptor weak antagonist action mu receptor ama drug evaluation annual 1991 p97 , relief moderate severe pain 
Magnesium sulfate, small colorless crystal used anticonvulsant cathartic electrolyte replenisher treatment pre-eclampsia eclampsia cause direct inhibition action potential myometrial muscle cell excitation contraction uncoupled decrease frequency force contraction ama drug evaluation annual 1992 p1083 ,used immediate control life-threatening convulsion treatment severe toxemia pre-eclampsia eclampsia pregnancy treatment acute nephritis child also indicated replacement therapy magnesium deficiency especially acute hypomagnesemia accompanied sign tetany similar hypocalcemia also used uterine tetany myometriat relaxant 
Latanoprost,latanoprost prodrug analog prostaglandin f2 alpha used treat elevated intraocular pressure iop initially approved fda 1998 latanoprost first topical prostaglandin f2 alpha analog used glaucoma treatment a184493 found well-tolerated use normally result systemic adverse effect like drug used treat elevated intraocular pressure timolol another benefit latanoprost administered day a184490 ,latanoprost indicated reduction elevated intraocular pressure patient diagnosed open-angle glaucoma ocular hypertension l8357 l8402 l44401 available monotherapy combination product netarsudil l8369 timolol l15217 canada latanoprost also indicated treat elevated intraocular pressure due angle-closure glaucoma treated peripheral iridotomy laser iridoplasty l8402 
Estrone,estrone one major mammalian estrogen aromatized c18 steroid 3-hydroxyl group 17-ketone produced vivo androstenedione testosterone via estradiol produced primarily ovary placenta peripheral tissue especially adipose tissue conversion adrostenedione estrone may metabolized 16-alpha-hydroxyestrone may reduced estriol estradiol dehydrogenase , management perimenopausal postmenopausal symptom 
Trazodone,trazodone triazolopyridine derivative serotonin receptor antagonist reuptake inhibitor sari class antidepressant a181180 used adult shown comparable efficacy drug tricyclic antidepressant tcas selective serotonin reuptake inhibitor ssri serotonin-norepinephrine receptor inhibitor snris treatment depression t646 unique feature drug promote anxiety symptom sexual symptom insomnia commonly associated ssri snri therapy t646 trazodone act various receptor including certain histamine serotonin adrenergic receptor distinguishing antidepressant cover narrow range neurotransmitter t646 initially granted fda approval 1981 l3484 ,trazodone indicated treatment major depressive disorder mdd l3484 used off-label adjunct therapy alcohol dependence off-label treat anxiety insomnia l3484 may also used off-label treat symptom dementia alzheimer ’ disease schizophrenia eating disorder fibromyalgia due effect various neurotransmitter receptor a31634 
Mecamylamine, nicotinic antagonist well absorbed gastrointestinal tract cross blood-brain barrier mecamylamine used ganglionic blocker treating hypertension like ganglionic blocker often used research tool , treatment moderately severe severe essential hypertension uncomplicated case malignant hypertension
Sevelamer,sevelamer phosphate binding drug used prevent hyperphosphataemia patient chronic renal failure marketed genzyme trade name renagel , control serum phosphorus patient chronic kidney disease ckd hemodialysis 
Acamprosate,alcohol use disorder responsible large worldwide burden morbidity premature mortality economic consequence resulting accident violence incarceration decreased productivity increased healthcare spending a229073 acamprosate also known brand name campral drug used maintenance alcohol abstinence structural analogue neurotransmitter γ-aminobutyric acid gaba l31758 acamprosate first medication specifically formulated maintenance alcohol abstinence ethanol-dependent patient alcohol detoxification a997 unlike naltrexone disulfiram first approved fda 2004 initially marketed forest laboratory l31783 ,acamprosate indicated maintenance abstinence alcohol patient alcohol dependence abstinent treatment initiation also indicated maintenance alcohol abstinence patient undergone alcohol detoxification drug used psychosocial support program providing adequate support l31738 
Metaxalone,metaxalone moderate strong muscle relaxant used symptomatic treatment musculoskeletal pain caused strain sprain musculoskeletal condition marketed king pharmaceutical brand name skelaxin® main mechanism action thought involve general central nervous system depression metaxalone associated side effect available 800 mg scored tablet , treatment painful peripheral musculoskeletal condition spasticity upper motor neuron syndrome 
Verapamil,verapamil phenylalkylamine calcium channel blocker used treatment high blood pressure heart arrhythmia angina l8791 first calcium channel antagonist introduced therapy early 1960s a188514 member non-dihydropyridine class calcium channel blocker includes drug like diltiazem flunarizine chemically unrelated cardioactive medication l8791 verapamil administered racemic mixture containing equal amount s- r-enantiomer pharmacologically distinct s-enantiomer carry approximately 20-fold greater potency r-enantiomer metabolized higher rate a188435 ,verapamil indicated treatment vasopastic i.e prinzmetal 's angina unstable angina chronic stable angina also indicated treat hypertension prophylaxis repetitive paroxysmal supraventricular tachycardia combination digoxin control ventricular rate patient atrial fibrillation atrial flutter l8791 given intravenously indicated treatment various supraventricular tachyarrhythmias including rapid conversion sinus rhythm patient supraventricular tachycardia temporary control ventricular rate patient atrial fibrillation atrial flutter l10481 verapamil commonly used off-label prophylaxis cluster headache a13983 
Trimethobenzamide,trimethobenzamide novel antiemetic prevents nausea vomiting human action unclear likely involves chemoreceptor trigger zone ctz dog pretreated trimethobenzamide hcl emetic response apomorphine inhibited little protection afforded emesis induced intragastric copper sulfate , treatment postoperative nausea vomiting nausea associated gastroenteritis 
Flumethasone,flumethasone moderately potent difluorinated corticosteroid ester anti-inflammatory antipruritic vasoconstrictive property privalate salt anti-inflammatory action concentrated site application local effect diseased area result prompt decrease inflammation exudation itching , treatment contact dermatitis atopic dermatitis exczema psoriasis diaper rash skin condition
Sulfametopyrazine,long-acting plasma-bound sulfonamide used respiratory urinary tract infection also malaria , treatment urinary tract infection chronic bronchitis 
Nilutamide,nilutamide antineoplastic hormonal agent primarily used treatment prostate cancer nilutamide pure nonsteroidal anti-androgen affinity androgen receptor progestogen estrogen glucocorticoid receptor consequently nilutamide block action androgen adrenal testicular origin stimulate growth normal malignant prostatic tissue prostate cancer mostly androgen-dependent treated surgical chemical castration date antiandrogen monotherapy consistently shown equivalent castration , use combination surgical castration treatment metastatic prostate cancer involving distant lymph node bone visceral organ stage d2 
Nafarelin,nafarelin potent synthetic agonist gonadotropin-releasing hormone 3- 2-naphthyl -d-alanine substitution residue 6 nafarelin used treatment central precocious puberty endometriosis , treatment central precocious puberty true precocious puberty gnrh-dependent precocious precocity complete isosexual precocity child sex treatment endometriosis 
Epinephrine,epinephrine also known _adrenaline_ hormone neurotransmitter produced adrenal gland also used drug due various important function though long used treatment hypersensitivity reaction epinephrine auto-injector form epipen available since 1987 usa many new products/biosimilars dosage route approved various name last several decade l4355 l4356 l4358 august 16 2018 teva pharmaceutical usa gained approval market generic epinephrine auto-injector 0.3 mg 0.15 mg strength l4353 dosage delivery route epinephrine include intravenous inhalation nebulization intramuscular injection subcutaneous injection general common us parenteral epinephrine relieve respiratory distress due bronchospasm provide rapid relief hypersensitivity anaphylactic anaphylactoid reaction drug animal serum allergen prolong action infiltration anesthetic f2136 addition function epinephrine primary drug administered cardiopulmonary resuscitation cpr reverse cardiac arrest a37697 a37699 used severe case croup l4824 ,epinephrine injection indicated emergency treatment type allergic reaction including anaphylaxis also used increase mean arterial blood pressure adult patient hypotension associated septic shock l41260 epinephrine 's cardiac effect may use restoring cardiac rhythm cardiac arrest due various cause used cardiac failure hemorrhagic traumatic cardiogenic shock f1247 epinephrine used hemostatic agent also used treating mucosal congestion hay fever rhinitis acute sinusitis relieve bronchial asthmatic paroxysm syncope due complete heart block carotid sinus hypersensitivity symptomatic relief serum sickness urticaria angioneurotic edema resuscitation cardiac arrest following anesthetic accident simple open angle glaucoma relaxation uterine musculature inhibit uterine contraction epinephrine injection utilized prolong action local anesthetic f1247 addition epinephrine used counter otc agent intermittent symptom asthma wheezing tightness chest shortness breath f2131 also used maintenance mydriasis intraocular surgery l4825 
Sumatriptan,sumatriptan serotonin receptor agonist commonly used treat migraine sometimes cluster headache l6793 l6796 l6799 l6805 l6808 l6811 sumatriptan first triptans made available europe 1991 treat migraine a179761 sumatriptan granted fda approval 28 december 1992 l6805 , combination sumatriptan naproxen tablet indicated treatment migraine without aura patient 12 year age older l6793 sumatriptan nasal powder nasal spray subcutaneous injection tablet indicated treat migraine without aura adult l6796 l6799 l6805 l6808 l6811 one subcutaneous formulation sumatriptan also indicated treat cluster headache adult l6805 subcutaneous formulation l6808 
Pirenzepine, antimuscarinic agent inhibits gastric secretion lower dos required affect gastrointestinal motility salivary central nervous system cardiovascular ocular urinary function promotes healing duodenal ulcer due cytoprotective action beneficial prevention duodenal ulcer recurrence also potentiates effect antiulcer agent cimetidine ranitidine generally well tolerated patient , treatment peptic ulcer gastric ulcer duodenal ulcer 
Cefixime,cefixime antibiotic third-generation cephalosporin like ceftriaxone cefotaxime cefixime highly stable presence beta-lactamase enzyme result many organism resistant penicillin cephalosporin due presence beta-lactamase may susceptible cefixime antibacterial effect cefixime result inhibition mucopeptide synthesis bacterial cell wall , use treatment following infection caused susceptible strain designated microorganism 1 uncomplicated urinary tract infection caused escherichia coli /i proteus mirabilis /i 2 otitis medium caused haemophilus influenzae /i beta-lactamase positive negative strain moraxella catarrhalis /i beta-lactamase positive pyogenes /i 3 pharyngitis tonsillitis caused pyogenes /i 4 acute bronchitis acute exacerbation chronic bronchitis caused streptococcus pneumoniae /i haemophilus influenzae /i beta-lactamase positive negative strain 5 uncomplicated gonorrhea cervical/urethral caused neisseria gonorrhoeae /i penicillinase- non-penicillinase-producing strain 
Chlorpropamide,chlorpropamide oral antihyperglycemic agent used treatment non-insulin-dependent diabetes mellitus niddm belongs sulfonylurea class insulin secretagogues act stimulating β cell pancreas release insulin sulfonylurea increase basal insulin secretion meal-stimulated insulin release medication class differ dose rate absorption duration action route elimination binding site target pancreatic β cell receptor sulfonylurea also increase peripheral glucose utilization decrease hepatic gluconeogenesis may increase number sensitivity insulin receptor sulfonylurea associated weight gain though le insulin due mechanism action sulfonylurea may cause hypoglycemia require consistent food intake decrease risk risk hypoglycemia increased elderly debilitated malnourished individual chlorpropamide recommended treatment niddm increase blood pressure risk retinopathy ukpds-33 80 single oral dose chlorpropramide metabolized likely liver 80-90 dose excreted urine unchanged drug metabolite renal hepatic dysfunction may increase risk hypoglycemia , treatment niddm conjunction diet exercise 
Aprepitant,aprepitant antiemetic substance p/neurokinin 1 nk1 receptor antagonist combination antiemetic agent indicated prevention acute delayed nausea vomiting associated initial repeat course highly emetogenic cancer chemotherapy aprepitant selective high-affinity antagonist human substance p/neurokinin 1 nk1 receptor aprepitant little affinity serotonin 5-ht3 dopamine corticosteroid receptor target existing therapy chemotherapy-induced nausea vomiting ci nv , prevention nausea vomiting associated highly emetogenic cancer chemotherapy including high-dose cisplatin combination antiemetic agent 
Galantamine,galantamine tertiary alkaloid reversible competitive inhibitor acetylcholinesterase ache enzyme widely studied therapeutic target used treatment alzheimer 's disease a1018 first characterized early 1950s galantamine tertiary alkaloid extracted botanical source _galanthus nivalis_ a201968 galantamine first studied paralytic neuropathic condition myopathy postpolio paralytic condition reversal neuromuscular blockade a182993 a201968 following discovery ache-inhibiting property cognitive effect galantamine studied wide variety psychiatric disorder mild cognitive impairment cognitive impairment schizophrenia bipolar disorder autism however re-development drug alzheimer ’ disease commence early 1990s due difficulty extraction synthesis a201968 galantamine block breakdown acetylcholine synaptic cleft thereby increasing acetylcholine neurotransmission also act allosteric modulator nicotinic receptor giving dual mechanism action clinical significance a182993 drug approved fda 2001 treatment mild moderate dementia alzheimer 's type alzheimer 's disease progressive neurodegenerative disorder galantamine known alter course underlying dementing process galantamine work block enzyme responsible breakdown acetylcholine synaptic cleft thereby enhancing cholinergic neuron function signalling hypothesized mechanism action therapeutic effect galantamine may decrease disease progression advance fewer cholinergic neuron remain functionally intact l13571 therefore considered disease-modifying drug a203558 galantamine marketed brand name razadyne available oral immediate- extended-release tablet solution l13571 ,galantamine indicated treatment mild moderate dementia alzheimer ’ type l13571 
Tamoxifen,tamoxifen non-steroidal antiestrogen used treat estrogen receptor positive breast cancer well prevent incidence breast cancer high risk population a1025 l7799 l7802 tamoxifen used alone adjuvant treatment l7799 l7802 tamoxifen may longer preferred treatment type cancer patient generally better survival side effect profile compliance anastrozole a1026 tamoxifen granted fda approval 30 december 1977 l7799 ,tamoxifen indicated treat estrogen receptor positive metastatic breast cancer adult adjuvant treatment early stage estrogen receptor positive breast cancer adult reduce risk invasive breast cancer surgery radiation adult woman ductal carcinoma situ l7802 
Benzyl benzoate,benzyl benzoate one older preparation used treat scabies scabies skin infection caused mite sarcoptes scabiei characterised severe itching particularly night red spot may lead secondary infection benzyl benzoate lethal mite useful treatment scabies also used treat louse infestation head body benzyl benzoate treatment choice scabies due irritant property ,used kill louse mite responsible skin condition scabies 
Isoflurophate, irreversible cholinesterase inhibitor action similar echothiophate powerful miotic used mainly treatment glaucoma vapor highly toxic recommended solution arachis oil used therapeutically martindale extra pharmacopoeia 29th ed p1330 , use eye treat certain type glaucoma eye condition accommodative esotropia 
Losartan,losartan angiotensin ii receptor blocker arb used treat hypertension l7423 angiotensin-converting enzyme ace inhibitor used similar indication associated cough l7423 patient ace inhibitor associated cough switched arb like losartan incidence cough similar placebo hydrochlorothiazide l7423 losartan available losartan potassium oral tablet well combination tablet losartan potassium hydrochlorothiazide l7423 l7426 patient taking losartan renal function potassium level monitored l7423 losartan granted fda approval 14 april 1995 l7423 ,losartan indicated treat hypertension patient older 6 year reduce risk stroke patient hypertension left ventricular hypertrophy though benefit may extend patient african heritage treat diabetic nephropathy elevated serum creatinine proteinuria patient type 2 diabetes hypertension l7423 losartan hydrochlorothiazide indicated treat hypertension reduce risk stroke patient hypertension left ventricular hypertrophy though benefit may extend patient african heritage l7426 
Thioridazine, phenothiazine antipsychotic used management psychosis including schizophrenia control severely disturbed agitated behavior little antiemetic activity thioridazine higher incidence antimuscarinic effect lower incidence extrapyramidal symptom chlorpromazine martindale extra pharmacopoeia 30th ed p618 thioridazine withdrawn worldwide 2005 due association cardiac arrythmias , treatment schizophrenia generalized anxiety disorder 
Moricizine, antiarrhythmia agent used primarily ventricular rhythm disturbance ,used treat irregular heartbeat arrhythmia maintain normal heart rate 
Amphotericin B,amphotericin b show high order vitro activity many specie fungi histoplasma capsulatum coccidioides immitis candida specie blastomyces dermatitidis rhodotorula cryptococcus neoformans sporothrix schenckii mucor mucedo aspergillus fumigatus inhibited concentration amphotericin b ranging 0.03 1.0 mcg/ml vitro candida albicans generally quite susceptible amphotericin b non-albicans specie may le susceptible pseudallescheria boydii fusarium sp often resistant amphotericin b antibiotic without effect bacteria rickettsia virus ,used treat potentially life threatening fungal infection 
Warfarin,warfarin anticoagulant drug normally used prevent blood clot formation well migration although originally marketed pesticide d-con rodex among others warfarin since become frequently prescribed oral anticoagulant north america warfarin several property noted used medicinally including ability cross placental barrier pregnancy result fetal bleeding spontaneous abortion preterm birth stillbirth neonatal death additional adverse effect necrosis purple toe syndrome osteoporosis valve artery calcification drug interaction also documented warfarin use warfarin actually affect blood viscosity rather inhibits vitamin-k dependent synthesis biologically active form various clotting factor addition several regulatory factor , indicated label l6616 1 prophylaxis treatment venous thromboembolism related pulmonary embolism 2 prophylaxis treatment thromboembolism associated atrial fibrillation 3 prophylaxis treatment thromboembolism associated cardiac valve replacement 4 use adjunct therapy reduce mortality recurrent myocardial infarction thromboembolic event post myocardial infarction off-label us include 1 secondary prevention stroke transient ischemic attack patient rheumatic mitral valve disease without atrial fibrillation a179182 
Midazolam,midazolam short-acting hypnotic-sedative drug anxiolytic muscle relaxant anticonvulsant sedative hypnotic amnesic property a173842 belongs class drug called _benzodiazepines_ drug unique others class due rapid onset effect short duration action a173842 midazolam available oral rectal intranasal intramuscular im intravenous iv route used various biomedical application including dentistry cardiac surgery endoscopic procedure pre-anesthetic medication adjunct local anesthesia f2977 drug initially approved u fda 1985 approved various indication since fda label late 2018 intramuscular preparation approved fda treatment status epilepticus adult fda label may 2019 nasal spray midazolam approved acute treatment distinctive intermittent stereotypic seizure episode patient 12 year age older midazolam considered schedule iv drug united state due low potential abuse low risk dependence l5074 , intravenous indicated promoting preoperative sedation anxiolysis anesthesia induction amnesia f2434 intramuscular indicated treatment status epilepticus adult fda label nasal indicated acute treatment intermittent stereotypic episode frequent seizure activity i.e. seizure cluster acute repetitive seizure distinct patient ’ usual seizure pattern patient epilepsy 12 year age older l6559 
Tobramycin,aminoglycosides many derived directly _streptomyces_ spp. concentration-dependent bactericidal antibiotic broad spectrum activity gram-positive gram-negative organism a232294 inhaled tobramycin notable use treating chronic _pseudomonas aeruginosa_ infection cystic fibrosis patient _p aeruginosa_ notoriously inherently resistant many antibiotic a232294 a232299 l32739 however tobramycin also administered intravenously topically treat variety infection caused susceptible bacteria l32744 l32749 use limited case characteristic toxicity nephrotoxicity ototoxicity yet remains valuable option face growing resistance front-line antibiotic β-lactams cephalosporin a232294 a232349 l32739 l32749 tobramycin approved fda 1975 currently available variety form administration inhalation injection external application eye ophthalmic l32739 l32744 l32749 ,inhaled tobramycin indicated management cystic fibrosis patient _pseudomonas aeruginosa_ recommended patient six year age forced expiratory volume 1 second fev sub 1 /sub 25 80 predicted _burkholderia cepacia_ l32739 tobramycin applied topically eye indicated treatment external eye adjoining structure infection susceptible bacteria l32744 tobramycin injection indicated adult pediatric patient treatment serious bacterial infection including septicemia caused _p aeruginosa_ _escherichia coli_ _klebsiella_ spp lower respiratory tract infection caused _p aeruginosa_ _klebsiella_ spp. _enterobacter_ spp. _serratia_ spp. _e coli_ _staphylococcus aureus_ penicillinase non-penicillinase-producing strain serious central-nervous-system infection meningitis caused susceptible organism intra-abdominal infection including peritonitis caused _e coli_ _klebsiella_ spp. _enterobacter_ spp skin bone skin structure infection caused _p aeruginosa_ _proteus_ spp. _e coli_ _klebsiella_ spp. _enterobacter_ spp. _serratia_ spp _s aureus_ complicated recurrent urinary tract infection caused _p aeruginosa_ _proteus_ spp. _e coli_ _klebsiella_ spp. _enterobacter_ spp. _serratia_ spp. _s aureus_ _providencia_ spp. _citrobacter_ spp. l32749 aminoglycosides including tobramycin generally used uncomplicated urinary tract infection staphylococcal infection unless le toxic antibiotic used bacteria question known sensitive aminoglycosides l32749 antibiotic tobramycin use limited case bacterial infection known strongly suspected caused sensitive organism possible emergence resistance monitored closely l32739 l32744 l32749 
Trovafloxacin,trovafloxacin broad spectrum antibiotic commonly marketed brand name trovan pfizer exerts antibacterial activity inhibiting uncoiling supercoiled dna various bacteria blocking activity dna gyrase topoisomerase iv shown effective gram-positive bacteria gram-negative bacteria compared previous fluoroquinolones due hepatotoxic potential trovafloxacin withdrawn market , treatment infection caused susceptible strain designated microorganism uncomplicated urethral gonorrhea male endocervical rectal gonorrhea female caused neisseria gonorrhoeae /i well non gonoccocal urethritis cervicitis due chlamydia trachomatis /i 
Pentosan polysulfate,pentosan polysulfate sulfated pentosyl polysaccharide heparin-like property , relief bladder pain discomfort associated interstitial cystitis 
Fludrocortisone,fludrocortisone synthetic mineralocorticoid used conjunction hydrocortisone replace missing endogenous corticosteroid patient adrenal insufficiency a187169 a187187 functionally similar aldosterone body 's primary endogenous mineralocorticoid structurally analogous cortisol differing fluorine atom 9-position steroid structure fluorination thought crucial fludrocortisone 's significant mineralocorticoid potency a5423 ,fludrocortisone indicated partial replacement therapy primary secondary adrenocortical insufficiency addison 's disease also indicated treatment salt-losing androgenital syndrome l8971 
Mycophenolate mofetil,mycophenolate mofetil also known mmf cellcept prodrug mycophenolic acid classified reversible inhibitor inosine monophosphate dehydrogenase impdh a180805 drug immunosuppressant combined drug cyclosporine corticosteroid prevent organ rejection hepatic renal cardiac transplant l7363 marketed roche pharmaceutical granted fda approval prophylaxis transplant rejection 1995 a180826 addition us mycophenolate mofetil also studied treatment nephritis complication autoimmune disease unlike another immunosuppressant class calcineurin inhibitor mmf generally cause nephrotoxicity fibrosis a180799 a180805 previously mycophenolic acid mpa administered individual autoimmune disease beginning 1970s discontinued due gastrointestinal effect concern carcinogenicity a180826 new semi-synthetic 2-morpholinoethyl ester mpa synthesized avoid gastrointestinal effect associated administration mpa demonstrates increased bioavailability higher efficacy reduced gastrointestinal effect compared mpa a180826 ,mycophenolate mofetil indicated combination immunosuppressant prevent rejection kidney heart liver transplant adult pediatric patient ≥3 month old l42020 mycophenolate mofetil may also used off-label second-line treatment autoimmune hepatitis responded adequately first-line therapy a180814 off-label us drug include lupus-associated nephritis dermatitis child a180817 
Cephaloglycin, cephalorsporin antibiotic longer commonly used , treatment severe infection caused susceptible bacteria 
Flurazepam, benzodiazepine derivative used mainly hypnotic , short-term intermittent use patient recurring insomnia poor sleeping habit
Moexipril,moexipril non-sulfhydryl containing precursor active angiotensin-converting enzyme ace inhibitor moexiprilat used treat high blood pressure hypertension work relaxing blood vessel causing widen lowering high blood pressure help prevent stroke heart attack kidney problem , treatment hypertension 
Phentolamine, nonselective alpha-adrenergic antagonist used treatment hypertension hypertensive emergency pheochromocytoma vasospasm raynaud disease frostbite clonidine withdrawal syndrome impotence peripheral vascular disease ,used aid diagnosis pheochromocytoma may administered immediately prior pheochromocytomectomy prevent control paroxysmal hypertension resulting anesthesia stress operative manipulation tumor phentolamine also used treat hypertensive crisis caused sympathomimetic amine catecholamine excess certain food drug patient taking mao inhibitor clonidine withdrawal syndrome indication include prevention dermal necrosis sloughing following iv administration extravasation norepinephrine decrease impedance left ventricular ejection infarct size patient mi associated left ventricular failure treatment erectile dysfunction self-injection small dos combined papaverine hydrochloride corpus cavernosum adjunct management cocaine overdose reverse coronary vasoconstriction following use oxygen benzodiazepine nitroglycerin 
Fluorescein, phthalic indicator dye appears yellow-green normal tear film bright green alkaline medium aqueous humor used therapeutically diagnostic aid corneal injury corneal trauma approved fda use externally applied drug cosmetic merck index 12th ed american medical association drug evaluation 1995 p2275 , diagnostic imaging primarily indicated diagnostic fluorescein angiography angioscopy fundus iris vasculature 
Daunorubicin, toxic anthracycline aminoglycoside antineoplastic isolated streptomyces peucetius others used treatment leukemia neoplasm , remission induction acute nonlymphocytic leukemia myelogenous monocytic erythroid adult remission induction acute lymphocytic leukemia child adult daunorubicin indicated combination cytarabine treatment newly-diagnosed therapy-related acute myeloid leukemia t-aml aml myelodysplasia-related change aml-mrc adult pediatric patient 1 year older l32843 
Furosemide,furosemide potent loop diuretic act kidney ultimately increase water loss body anthranilic acid derivative l7958 furosemide used edema secondary various clinical condition congestive heart failure exacerbation liver failure renal failure high blood pressure l7961 mainly work inhibiting electrolyte reabsorption kidney enhancing excretion water body furosemide fast onset short duration action used safely effectively pediatric adult patient a182495 use furosemide particularly beneficial clinical setting require drug higher diuretic potential addition oral formulation solution intravenous intramuscular administration also available typically limited patient unable take oral medication patient emergency clinical situation l7958 ,furosemide indicated treatment edema associated congestive heart failure cirrhosis liver renal disease including nephrotic syndrome adult pediatric patient l7958 oral furosemide indicated alone management mild moderate hypertension severe hypertension combination antihypertensive medication l9659 intravenous furosemide indicated adjunctive therapy acute pulmonary edema rapid onset diuresis desired l7958 subcutaneous furosemide indicated treatment congestion due fluid overload adult nyha class ii/iii chronic heart failure drug formulation indicated emergency situation patient acute pulmonary edema l43408 
Ergotamine, vasoconstrictor found ergot central europe alpha-1 selective adrenergic agonist commonly used treatment migraine disorder , use therapy abort prevent vascular headache e.g. migraine migraine variant called `` histaminic cephalalgia '' 
Tizanidine,tizanidine fast-acting drug used management muscle spasm may result effect multiple sclerosis stroke acquired brain injury spinal cord injury t574 may also caused musculoskeletal injury a177583 regardless cause muscle spasticity extremely painful debilitating condition initially approved fda 1996 tizanidine alpha-2 adrenergic receptor agonist reducing spasticity presynaptic inhibition excitatory neurotransmitter cause firing neuron promoting muscle spasm fda label ,tizanidine indicated relief muscle spasticity interfere daily activity general recommendation reserve tizanidine use period time particular need relief short duration action fda label f4471 
Nitrofurantoin,nitrofurantoin nitrofuran antibiotic used treat uncomplicated urinary tract infection l6856 l6859 l6862 nitrofurantoin converted bacterial nitroreductases electrophilic intermediate inhibit citric acid cycle well synthesis dna rna protein a179824 drug resistant development bacterial resistance act many target a179824 nitrofurantoin second line treatment trimethoprim sulfamethoxazole a179830 nitrofurantoin granted fda approval 6 february 1953 l6895 ,nitrofurantoin indicated treat acute uncomplicated urinary tract infection l6856 l6859 l6862 
Nicergoline, ergot derivative used cerebral vasodilator peripheral vascular disease suggested ameliorate cognitive deficit cerebrovascular disease , treatment senile dementia migraine vascular origin transient ischemia platelet hyper-aggregability macular degeneration 
Eplerenone,eplerenone aldosterone receptor antagonist similar spironolactone shown produce sustained increase plasma renin serum aldosterone consistent inhibition negative regulatory feedback aldosterone renin secretion resulting increased plasma renin activity aldosterone circulating level overcome effect eplerenone eplerenone selectively bind recombinant human mineralocorticoid receptor relative binding recombinant human glucocorticoid progesterone androgen receptor , improvement survival stable patient left ventricular systolic dysfunction ejection fraction 40 clinical evidence congestive heart failure acute myocardial infarction 
Amprenavir,amprenavir protease inhibitor used treat hiv infection , treatment hiv-1 infection combination antiretroviral agent 
Icodextrin,icodextrin iso-osmotic peritoneal dialysis solution containing glucose polymer used primarily ambulatory peritoneal dialysis capd diabetic patient automated peritoneal dialysis apd patient end-stage renal disease injected solution peritoneal cavity drug absorbed via convective transport via peritoneal lymphatic pathway ,used continuous ambulatory peritoneal dialysis capd diabetic patient automated peritoneal dialysis apd management end-stage renal disease 
Methazolamide, carbonic anhydrase inhibitor used diuretic treatment glaucoma , treatment chronic open-angle glaucoma acute angle-closure glaucoma
Naltrexone,derivative noroxymorphone n-cyclopropylmethyl congener naloxone narcotic antagonist effective orally longer lasting potent naloxone proposed treatment heroin addiction fda approved naltrexone treatment alcohol dependence ,used adjunct medically supervised behaviour modification program maintenance opiate cessation individual formerly physically dependent opiate successfully undergone detoxification also used management alcohol dependence conjunction behavioural modification program 
Delavirdine, potent non-nucleoside reverse transcriptase inhibitor activity specific hiv-1 , treatment hiv-1 infection combination appropriate antiretroviral agent therapy warranted
Tamsulosin,tamsulosin selective alpha-1a alpha-1b adrenoceptor antagonist exerts greatest effect prostate bladder receptor common label indicated treatment sign symptom benign prostatic hypertrophy label antagonism receptor lead relaxation smooth muscle prostate detrusor muscle bladder allowing better urinary flow label alpha-1 adrenoceptor antagonist developed 1980s le selective likely act smooth muscle blood vessel resulting hypotension a178351 tamsulosin first approved fda april 15 1997 l6238 ,tamsulosin indicated treatment sign symptom benign prostatic hyperplasia label tamsulosin also used label treatment ureteral stone prostatitis female voiding dysfunction a178339 l6259 
Porfimer sodium, purified component hematoporphyrin derivative consists mixture oligomeric porphyrin used photodynamic therapy hematoporphyrin photoradiation treat malignant lesion visible light experimentally antiviral agent first drug approved use photodynamic therapy united state ,indicated treatment esophageal cancer 
Sufentanil,sufentanil opioid analgesic used adjunct anesthesia balanced anesthesia primary anesthetic agent administered intravenous epidural sublingual route also known _dsuvia_ sublingual form used management acute pain adult severe warrant use opioid analgesic certified medically supervised healthcare setting including hospital surgical center emergency department l4717 consideration may made future use sublingual form u military case analgesia required immediately l4718 sublingual form manufactured acelrx pharmaceutical inc. acelrx approved november 2 2018 l4717 route administration intended simple effective non-invasive analgesic option enable healthcare professional rapidly manage acute pain without difficult intravenous epidural administration l4717 a39633 , indication drug follows 1 analgesic adjunct maintenance balanced general anesthesia patient intubated ventilated 2 primary anesthetic agent induction maintenance anesthesia 100 oxygen patient undergoing major surgical procedure patient intubated ventilated cardiovascular surgery neurosurgical procedure sitting position provide favorable myocardial cerebral oxygen balance extended postoperative ventilation anticipated 3 epidural administration analgesic combined low dose usually 12.5 mg per administration bupivacaine usually labor vaginal delivery 4 sublingual form indicated management acute pain adult severe warrant use opioid analgesic certified medically supervised healthcare setting including hospital surgical center emergency department fda label 
Lamivudine, reverse transcriptase inhibitor zalcitabine analog sulfur atom replaces 3 39 carbon pentose ring used treat human immunodeficiency virus type 1 hiv-1 hepatitis b hbv , treatment hiv infection chronic hepatitis b hbv 
Ibandronate,ibandronate bm 21.0955 third generation nitrogen containing bisphosphonate similar zoledronic acid minodronic acid risedronic acid a203111 a203138 used prevent treat postmenopausal osteoporosis l13805 l13808 ibandronate first described literature 1993 treatment bone loss dog a203138 ibandronate granted fda approval 16 may 2003 l13805 , treatment prevention osteoporosis postmenopausal woman l13805 l13808 
Diethylcarbamazine, anthelmintic used primarily citrate treatment filariasis particularly infestation wucheria bancrofti loa loa ,used treatment certain filarial disease including tropical pulmonary eosinophilia loiasis lymphatic filariasis caused infection wuchereria bancrofti /i brugia malayi /i brugia timori /i 
Flurbiprofen,flurbiprofen propionic acid derivative nonsteroidal anti-inflammatory agent nsaia antipyretic analgesic activity oral formulation flurbiprofen may used symptomatic treatment rheumatoid arthritis osteoarthritis anklylosing spondylitis flurbiprofen may also used topically prior ocular surgery prevent reduce intraoperative miosis flurbiprofen structurally pharmacologically related fenoprofen ibuprofen ketoprofen ,flurbiprofen tablet indicated acute long-term symptomatic treatment rheumatoid arthritis osteorarthritis anklosing spondylitis may also used treat pain associated dysmenorrhea mild moderate pain accompanied inflammation e.g bursitis tendonitis soft tissue trauma topical ophthalmic formulation may used pre-operatively prevent intraoperative miosis 
Oxacillin, antibiotic similar flucloxacillin used resistant staphylococci infection ,used treatment resistant staphylococci infection 
Apomorphine,apomorphine non-ergoline dopamine d2 agonist indicated treat hypomobility associated parkinson 's first synthesized 1845 first used parkinson 's disease 1884 a203618 apomorphine also investigated emetic sedative treatment alcoholism treatment movement disorder a203597 a203618 apomorphine granted fda approval 20 april 2004 l13919 ,apomorphine indicated treat acute intermittent treatment hypomobility episode associated advanced parkinson 's disease l13919 l13922 
Paroxetine,paroxetine selective serotonin reuptake inhibitor ssri drug commonly known paxil variety us including treatment anxiety disorder major depression posttraumatic stress disorder symptom menopause among others t653 approved fda early 1990s marketed smithkline beecham l7712 l7715 unique feature drug highly potent selective inhibition serotonin reuptake little effect neurotransmitter a31914 potent inhibition serotonin reuptake paroxetine likely cause withdrawal effect upon cessation paroxetine well tolerated patient similar adverse effect profile member drug class a31914 controlled release formulation designed decrease likelihood nausea sometimes associated paroxetine l7700 l7742 ,paroxetine indicated management depression obsessive-compulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorder l3358 one form paroxetine commercially known brisdelle used manage mild moderate vasomotor symptom menopause l7703 off-label paroxetine may used treatment premature ejaculation irritable bowel syndrome ibs a1093 a181754 a181904 
Nedocromil, pyranoquinolone derivative inhibits activation inflammatory cell associated asthma including eosinophil neutrophil macrophage mast cell monocyte platelet , treatment mild moderate asthma
Norethisterone,norethisterone also known norethindrone synthetic progestational hormone belonging 19-nortestosterone-derived class progestin a10367 classified second-generation progestin along levonorgestrel derivative active form several progestin including norethynodrel lynestrenol a10367 norethisterone mimic action endogenous progesterone albeit greater potency a188075 used combination estrogen derivative variety application including contraception hormone replacement therapy l9527 l10301 l10304 l10307 first derived 1951 mexico city norethisterone originally intended use remedy irregular menstruation endometriosis marketed use oral contraceptive 1962 l10439 ,norethisterone indicated oral contraceptive given monotherapy l9527 combination estrogen component ethinylestradiol estradiol l10313 l10307 combination estrogen component oral norethisterone also indicated hormone replacement therapy treatment postmenopausal osteoporosis moderate-to-severe vasomotor symptom arising menopause l10304 applied via transdermal patch combination norethisterone estradiol indicated treatment hypoestrogenism vulvovaginal atrophy moderate-severe vasomotor symptom l10301 norethisterone taken combination intramuscular leuprolide also indicated symptomatic treatment endometriosis-related pain l10310 
Adefovir dipivoxil,adefovir dipivoxil previously called bis-pom pmea trade name preveon hepsera orally-administered acyclic nucleotide analog reverse transcriptase inhibitor ntrti used treatment hepatitis b ineffective hiv-1 adefovir dipivoxil diester prodrug adefovir ,indicated treatment chronic hepatitis b adult patient evidence active viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease based histological virological biochemical serological response adult patient hbeag+ hbeag- chronic hepatitis b compensated liver function adult patient clinical evidence lamivudine-resistant hepatitis b virus either compensated decompensated liver function 
Azatadine,antihistamine azatadine appear compete histamine histamine h1- receptor site effector cell antihistamine antagonize pharmacological effect histamine mediated activation h1- receptor site thereby reduce intensity allergic reaction tissue injury response involving histamine release , relief symptom upper respiratory mucosal congestion perennial allergic rhinitis relief nasal congestion eustachian t.b congestion 
Clodronic acid,clodronic acid first generation bisphosphonate similar etidronic acid tiludronic acid a203111 drug developed mimic action pyrophosphate regulator calcification decalcification a1923 clodronate ’ use decreased year favor third generation nitrogen containing bisphosphonate zoledronic acid ibandronic acid minodronic acid risedronic acid a203111 clodronic acid fda approved approved canada l13910 ,clodronic acid indicated adjunct management osteolysis bone metastasis malignant tumor management hypercalcemia malignancy l13910 
Procaine, local anesthetic ester type slow onset short duration action mainly used infiltration anesthesia peripheral nerve block spinal block martindale extra pharmacopoeia 30th ed p1016 procaine also investigated oral entry inhibitor treatment-experienced hiv patient l1215 ,used local anesthetic primarily oral surgery
Lisinopril,lisinopril angiotensin converting enzyme inhibitor acei used treat hypertension heart failure myocardial infarction l8384 l8387 l8390 lisinopril captopril aceis prodrugs a184853 function inhibition angiotensin converting enzyme well renin angiotensin aldosterone system a184781 a184808 a184817 aceis commonly used first line therapy treatment hypertension along thiazide diuretic beta blocker a184844 lisinopril granted fda approval 29 december 1987 l8384 ,lisinopril indicated treatment acute myocardial infarction hypertension patient ≥6 year adjunct therapy heart failure l8384 l8387 combination product hydrochlorothiazide indicated treatment hypertension l8390 
Methoxamine, alpha-adrenergic agonist cause prolonged peripheral vasoconstriction little direct effect central nervous system ,indicated treatment management hypotension 
Imiquimod,imiquimod immune response modifier act toll-like receptor 7 agonist imiquimod commonly used topically treat wart skin genital anal area imiquimod cure wart new wart may appear treatment imiquimod fight virus cause wart directly however help relieve control wart production miquimod also used treat skin condition face scalp called actinic keratoses certain type skin cancer called superficial basal cell carcinoma , topical treatment clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses face scalp immunocompetent adult also indicated treatment external genital perianal warts/condyloma acuminata individual 12 year old 
Homatropine methylbromide,homatropine methylbromide quaternary ammonium muscarinic acetylcholine receptor antagonist belonging group medicine called anti-muscarinics homatropine used treat duodenal stomach ulcer intestine problem used together antacid medicine treatment peptic ulcer may also used prevent nausea vomiting motion sickness ,used conjunction antacid histamine h2-receptor antagonist treatment peptic ulcer gastric ulcer duodenal ulcer reduce gastric acid secretion delay gastric emptying 
Trimipramine,tricyclic antidepressant similar imipramine antihistaminic sedative property , treatment depression depression accompanied anxiety agitation sleep disturbance
Nitroglycerin,nitroglycerin also known glyceryl trinitrate a180169 organic nitrate vasodilating agent l38369 first discovered 1847 a249965 originally used dynamite antianginal effect identified late 1860s produced headache factory worker worker angina pectoris heart failure experienced relief chest pain a180166 a180172 use treatment angina date back 1879 still used treat prevent angina a249970 nitroglycerin cause vasodilation artery vein a180172 nitroglycerin used variety different condition including angina pectoris due coronary artery disease l7102 l7141 l38369 l42320 peri-operative hypertension congestive heart failure l7099 chronic anal fissure l42445 also used induce intraoperative hypotension l7099 ,sublingual nitroglycerin indicated acute relief attack acute prophylaxis angina pectoris due coronary artery disease l7102 l38369 l42320 transdermal nitroglycerin indicated prevention angina pectoris due coronary artery disease l7141 intravenous nitroglycerin indicated treatment peri-operative hypertension control congestive heart failure setting acute myocardial infarction treatment angina pectoris patient responded sublingual nitroglycerin beta β -blockers induction intraoperative hypotension l7099 topical nitroglycerin ointment used treat moderate severe pain associated chronic anal fissure l42445 
Rocuronium,rocuronium rapid onset-curonium desacetoxy analogue vecuronium rapid onset action aminosteroid non-depolarizing neuromuscular blocker muscle relaxant used modern anaesthesia facilitate endotracheal intubation provide skeletal muscle relaxation surgery mechanical ventilation introduced 1994 rocuronium rapid onset intermediate duration action commonly marketed trade name zemuron esmeron drug associated risk developing allergic reaction high-risk patient asthma however similar incidence allergic reaction associated non-depolarizing neuromuscular blocking agent sugammadex γ-cyclodextrin derivative introduced novel agent reverse action rocuronium , inpatient outpatient adjunct general anesthesia facilitate rapid sequence routine tracheal intubation provide skeletal muscle relaxation surgery mechanical ventilation 
Thiabendazole,2-substituted benzimidazole first introduced 1962 active variety nematode drug choice strongyloidiasis cns side effect hepatototoxic potential smith reynard textbook pharmacology 1992 p919 , treatment strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans trichinosis 
Nateglinide,nateglinide oral antihyperglycemic agent used treatment non-insulin-dependent diabetes mellitus niddm belongs meglitinide class short-acting insulin secretagogues act binding β cell pancreas stimulate insulin release nateglinide amino acid derivative induces early insulin response meal decreasing postprandial blood glucose level taken meal meal-time dos skipped skipped meal approximately one month therapy required decrease fasting blood glucose seen meglitnides may neutral effect weight cause slight increase weight average weight gain caused meglitinides appears lower caused sulfonylurea insulin appears occur naïve oral antidiabetic agent due mechanism action meglitinides may cause hypoglycemia although risk thought lower sulfonylurea since action dependent presence glucose addition reducing postprandial fasting blood glucose meglitnides shown decrease glycosylated hemoglobin hba1c level reflective last 8-10 week glucose control meglitinides appear effective lowering postprandial blood glucose metformin sulfonylurea thiazolidinediones nateglinide extensively metabolized liver excreted urine 83 feces 10 major metabolite posse le activity parent compound one minor metabolite isoprene potency parent compound , treatment non-insulin dependent-diabetes mellitus conjunction diet exercise 
Atracurium besylate, non-depolarizing neuromuscular blocking agent short duration action lack significant cardiovascular effect lack dependence good kidney function elimination provide clinical advantage alternate non-depolarizing neuromuscular blocking agent , use adjunct general anesthesia facilitate endotracheal intubation provide skeletal muscle relaxation surgery mechanical ventilation 
Pralidoxime,pralidoxime antidote organophosphate pesticide chemical organophosphate bind esteratic site acetylcholinesterase result initially reversible inactivation enzyme given within 24 hour organophosphate exposure pralidoxime reactivates enzyme cholinesterase cleaving phosphate-ester bond formed organophosphate acetylcholinesterase , treatment poisoning due pesticide chemical organophosphate class anticholinesterase activity control overdosage anticholinesterase drug used treatment myasthenia gravis 
Risperidone,risperidone second-generation antipsychotic sga medication used treatment number mood mental health condition including schizophrenia bipolar disorder l12885 one widely used sgas paliperidone another commonly used sga primary active metabolite risperidone i.e 9-hydroxyrisperidone l12885 schizophrenia various mood disorder thought caused excess dopaminergic d2 serotonergic 5-ht2a activity resulting overactivity central mesolimbic pathway mesocortical pathway respectively risperidone thought reduce overactivity inhibition dopaminergic d2 receptor serotonergic 5-ht2a receptor brain l12885 risperidone bind high affinity 5-ht2a receptor approximately 10-20 fold greater drug 's binding affinity d2 receptor carry lesser activity several off-targets may responsible undesirable effect l12885 ,risperidone indicated treatment schizophrenia irritability associated autistic disorder l12885 also indicated monotherapy adjunctly lithium valproic acid treatment acute mania mixed episode associated bipolar disorder l12885 risperidone additionally indicated canada short-term symptomatic management aggression psychotic symptom patient severe dementia alzheimer type unresponsive nonpharmacological approach l12906 risperidone also used off-label number condition including adjunct antidepressant treatment-resistant depression a177226 
Naftifine,naftifine synthetic broad spectrum antifungal agent allylamine derivative topical treatment tinea pedis tinea cruris tinea corporis caused organism trichophyton rubrum trichophyton mentagrophytes trichophyton tonsurans epidermophyton floccosum , topical treatment tinea pedis tinea cruris tinea corporis caused organism trichophyton rubrum /i trichophyton mentagrophytes /i trichophyton tonsurans /i epidermophyton floccosum /i 
Esomeprazole,esomeprazole sold brand name nexium proton pump inhibitor ppi medication used management gastroesophageal reflux disease gerd gastric protection prevent recurrence stomach ulcer gastric damage chronic use nsaid treatment pathological hypersecretory condition including zollinger-ellison ze syndrome also found quadruple regimen treatment _h pylori_ infection along antibiotic including db01060 db01211 db00916 example a177271 f4498 efficacy considered similar medication within ppi class including db00338 db00213 db00448 db05351 db01129 esomeprazole s-isomer db00338 racemate s- r-enantiomer esomeprazole shown inhibit acid secretion similar extent db00338 without significant difference two compound _in vitro_ esomeprazole exerts stomach acid-suppressing effect preventing final step gastric acid production covalently binding sulfhydryl group cysteine found h+ k+ -atpase enzyme secretory surface gastric parietal cell effect lead inhibition basal stimulated gastric acid secretion irrespective stimulus binding esomeprazole h+ k+ -atpase enzyme irreversible new enzyme need expressed order resume acid secretion esomeprazole 's duration antisecretory effect persists longer 24 hour fda label ppis esomeprazole also shown inhibit activity dimethylarginine dimethylaminohydrolase ddah enzyme necessary cardiovascular health ddah inhibition cause consequent accumulation nitric oxide synthase inhibitor asymmetric dimethylarginie adma thought cause association ppis increased risk cardiovascular event patient unstable coronary syndrome a177577 a177580 due good safety profile several ppis available counter without prescription current use north america widespread long term use ppis esomeprazole associated possible adverse effect however including increased susceptibility bacterial infection including gastrointestinal _c difficile_ reduced absorption micronutrient iron b12 increased risk developing hypomagnesemia hypocalcemia may contribute osteoporosis bone fracture later life a177571 rapid discontinuation ppis esomeprazole may cause rebound effect short term increase hypersecretion a177574 esomeprazole dos slowly lowered tapered discontinuing prevent rebound effect ,esomeprazole indicated treatment acid-reflux disorder including healing maintenance erosive esophagitis symptomatic gastroesophageal reflux disease gerd peptic ulcer disease h. pylorus eradication prevention gastrointestinal bleeds nsaid use long-term treatment pathological hypersecretory condition including zollinger-ellison syndrome 
Meclizine,meclizine histamine h1 antagonist antiemetic antivertigo property used symptomatic treatment motion sickness control vertigo associated vestibular system disease also exhibit anticholinergic central nervous system depressant local anesthetic effect l6760 commonly marketed brand name antivert u.s. meclizine available oral tablet ,indicated symptomatic treatment nausea vomiting dizziness associated motion sickness l6772 management vertigo due various cause including radiation sickness meniere ’ syndrome labyrinthitis vestibular disturbance l6766 
Pentamidine,antiprotozoal agent effective trypanosomiasis leishmaniasis fungal infection used treatment pneumocystis pneumonia hiv-infected patient may cause diabetes mellitus central nervous system damage toxic effect , treatment pneumonia due pneumocystis carinii /i 
Hetacillin,hetacillin penicillin beta-lactam antibiotic used treatment bacterial infection caused susceptible usually gram-positive organism name `` penicillin '' either refer several variant penicillin available group antibiotic derived penicillin hetacillin vitro activity gram-positive gram-negative aerobic anaerobic bacteria bactericidal activity hetacillin result inhibition cell wall synthesis mediated hetacillin binding penicillin binding protein pbps hetacillin withdrawn market since discovered therapeutic advantage compared non-ester derivative like ampicillin ,hetacillin beta-lactam antibiotic prodrug used treat bacterial infection body get converted ampicillin 
Riluzole, glutamate antagonist receptor glutamate used anticonvulsant anticonvulsant prolong survival patient amyotrophic lateral sclerosis riluzole marketed rilutek sanofi , treatment amyotrophic lateral sclerosis al lou gehrig 's disease 
Hydrocortisone,hydrocortisone cortisol glucocorticoid secreted adrenal cortex a188387 hydrocortisone used treat immune inflammatory neoplastic condition l10529 l10532 l10535 l10538 l7772 l7321 discovered 1930s edward kendall named compound f 17-hydroxycorticosterone a188420 hydrocortisone granted fda approval 5 august 1952 l10574 ,otic solution indicated infection external auditory canal caused susceptible organism inflammation l10529 l10532 hydrocortisone tablet indicated certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal condition l10535 hydrocortisone enema indicated ulcerative colitis l10538 topical ointment antibiotic indicated corticosteroid responsive dermatosis infection l7772 topical cream acyclovir indicated treat cold sore l7321 oral granule hydrocortisone used replacement therapy adrenocortical insufficiency ai child 17 year age l16533 
Mannitol,mannitol osmotic diuretic metabolically inert human occurs naturally sugar sugar alcohol fruit vegetable mannitol elevates blood plasma osmolality resulting enhanced flow water tissue including brain cerebrospinal fluid interstitial fluid plasma result cerebral edema elevated intracranial pressure cerebrospinal fluid volume pressure may reduced mannitol may also used promotion diuresis irreversible renal failure becomes established promotion urinary excretion toxic substance antiglaucoma agent renal function diagnostic aid october 30 2020 mannitol approved fda add-on maintenance therapy control pulmonary symptom associated cystic fibrosis adult patient currently marketed indication name bronchitol® chiesi usa inc. l20024 ,used promotion diuresis irreversible renal failure becomes established reduction intracranial pressure treatment cerebral edema promotion urinary excretion toxic substance mannitol also indicated add-on maintenance therapy improving pulmonary function cystic fibrosis patient aged 18 passed bronchitol tolerance test btt recommended patient take orally inhaled short-acting bronchodilator 5-15 minute prior every inhaled mannitol dose l20024 
Gadobenic acid,gadobenic acid form gadobenate dimeglumine mri contrast agent used primarily mr imaging liver also used visualizing cns heart contrast conventional extracellular fluid contrast agent gadobenate dimeglumine characterized weak transient binding capacity serum protein binding lead increased relaxivity gadobenate dimeglumine consequently considerably increased signal intensity agent ,gadobenate dimeglumine indicated use magnetic resonance imaging mri central nervous system adult pediatric patient order visualize lesion abnormal blood-brain barrier abnormal vascularity brain spine associated tissue l40888 also indicated use magnetic resonance angiography mra evaluate adult known suspected renal aorto-ilio-femoral occlusive vascular disease l40888 
Zileuton,leukotrienes substance induce numerous biological effect including augmentation neutrophil eosinophil migration neutrophil monocyte aggregation leukocyte adhesion increased capillary permeability smooth muscle contraction effect contribute inflammation edema mucus secretion bronchoconstriction airway asthmatic patient zileuton relief symptom selective inhibition 5-lipoxygenase enzyme catalyzes formation leukotrienes arachidonic acid specifically inhibits leukotriene ltb4 ltc4 ltd4 lte4 formation r enantiomer pharmacologically active 5-lipoxygenase inhibitor vitro system immediate release tablet zileuton withdrawn u market , prophylaxis chronic treatment asthma adult child 12 year age older 
Modafinil,modafinil stimulant drug marketed 'wakefulness promoting agent one stimulant used treatment narcolepsy narcolepsy caused dysfunction family wakefulness-promoting sleep-suppressing peptide orexins whose neuron activated modafinil prexin neuron activation associated psychoactivation euphoria exact mechanism action unclear although vitro study shown inhibit reuptake dopamine binding dopamine reuptake pump lead increase extracellular dopamine modafinil activates glutamatergic circuit inhibiting gaba , improve wakefulness patient excessive daytime sleepiness ed associated narcolepsy 
Deferoxamine,natural product isolated streptomyces pilosus form iron complex used chelating agent particularly mesylate form ,used treat acute iron aluminum toxicity excess aluminum body certain patient also used certain patient anemia must receive many blood transfusion 
Scopolamine,scopolamine tropane alkaloid isolated member _solanaceae_ family plant similar atropine hyoscyamine structurally mimic natural neurotransmitter acetylcholine a228423 a228763 scopolamine first synthesized 1959 date synthesis remains le efficient extracting scopolamine plant a228763 acetylcholine analogue scopolamine antagonize muscarinic acetylcholine receptor machrs central nervous system throughout body inducing several therapeutic adverse effect related alteration parasympathetic nervous system cholinergic signalling a228758 l31578 due dose-dependent adverse effect scopolamine first drug offered commercially transdermal delivery system scopoderm tts® 1981 a228423 a228758 result anticholinergic effect scopolamine investigated diverse therapeutic application currently approved prevention nausea vomiting associated motion sickness surgical procedure a228773 l31578 scopolamine first approved fda december 31 1979 currently available oral tablet transdermal delivery system l31578 ,scopolamine indicated adult patient prevention nausea vomiting associated motion sickness prevention postoperative nausea vomiting ponv associated anesthesia opiate analgesia l31578 
Carbinoxamine,carbinoxamine first generation antihistamine competes free histamine binding ha-receptor site antagonizes effect histamine ha-receptors leading reduction negative symptom brought histamine ha-receptor binding product label carbinoxamine counter cough cold medicine modified state `` use '' child 4 year age order prevent reduce misuse many unapproved carbinoxamine-containing preparation contained inappropriate labeling promoted unapproved us including management congestion cough common cold use child 2 year age potentially cause serious health risk , symptomatic relief seasonal perennial allergic rhinitis vasomotor rhinitis well allergic conjunctivitis caused food inhaled allergen also relief allergic reaction blood plasma symptomatic management mild uncomplicated allergic skin manifestation urticaria angioedema 
Etodolac,etodolac non-steroidal anti-inflammatory drug nsaid anti-inflammatory analgesic antipyretic property therapeutic effect due ability inhibit prostaglandin synthesis indicated relief sign symptom rheumatoid arthritis osteoarthritis , acute long-term management sign symptom osteoarthritis rheumatoid arthritis well management pain 
Prilocaine, local anesthetic similar pharmacologically lidocaine currently used often infiltration anesthesia dentistry ama drug evaluation annual 1992 p165 ,used local anaesthetic often used dentistry 
Epinastine,epinastine used prevention itching associated allergic conjunctivitis multi-action effect inhibits allergic response 3 way 1. stabilizes mast cell preventing mast cell degranulation control allergic response 2. prevents histamine binding h1- h2-receptors stop itching provide lasting protection 3. prevents release proinflammatory chemical mediator blood vessel halt progression allergic response , prevention itching associated allergic conjunctivitis 
Tranylcypromine," propylamine formed cyclization side chain amphetamine monoamine oxidase inhibitor effective treatment major depression dysthymic disorder atypical depression also useful panic phobic disorder ama drug evaluation annual 1994 p311 tranylcypromine racemate comprising equal amount 1r,2s 1s,2r -2-phenylcyclopropan-1-amine chiral center located cylopropane ring irreversible monoamine oxidase inhibitor used antidepressant inn tranylcypromine ", treatment major depressive episode without melancholia 
Isoflurane, stable non-explosive inhalation anesthetic relatively free significant side effect , induction maintenance general anesthesia 
Ethotoin,ethotoin hydantoin derivative anticonvulsant ethotoin exerts antiepileptic effect without causing general central nervous system depression mechanism action probably similar phenytoin latter drug appears stabilize rather raise normal seizure threshold prevent spread seizure activity rather abolish primary focus seizure discharge ethotoin longer commonly used , control tonic-clonic grand mal complex partial psychomotor seizure 
Tretinoin,tretinoin also known all-trans-retinoic acid atra naturally occurring derivative vitamin retinol retinoids tretinoin important regulator cell reproduction proliferation differentiation used treat acne photodamaged skin manage keratinization disorder ichthyosis keratosis follicularis tretinoin also represents class anticancer drug called differentiating agent used treatment acute promyelocytic leukemia apl , induction remission patient acute promyelocytic leukemia apl french-american-british fab classification m3 including m3 variant topical treatment acne vulgaris flat wart skin condition psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedo senile keratosis keratosis follicularis darier 's disease basal cell carcinoma palliative therapy improve fine wrinkling mottled hyperpigmentation roughness associated photodamage tretinoin also indicated combination benzoyl peroxide treatment acne vulgaris patient aged nine year older l34869 
Hexachlorophene, chlorinated bisphenol antiseptic bacteriostatic action gram-positive organism much le effective gram-negative organism mainly used soap cream ingredient various preparation used skin disorder martindale extra pharmacopoeia 30th ed p797 , use surgical scrub bacteriostatic skin cleanser may also used control outbreak gram-positive infection infection control procedure unsuccessful 
Dolasetron,dolasetron antinauseant antiemetic agent indicated prevention nausea vomiting associated moderately-emetogenic cancer chemotherapy prevention postoperative nausea vomiting dolasetron highly specific selective serotonin 5-ht3 receptor antagonist drug shown activity known serotonin receptor low affinity dopamine receptor , prevention nausea vomiting associated emetogenic cancer chemotherapy including initial repeat course chemotherapy also used prevention postoperative nausea vomiting drug used intravenously treatment postoperative nausea vomiting 
Clopidogrel,clopidogrel prodrug platelet inhibitor used reduce risk myocardial infarction stroke a180508 l7213 clopidogrel indicated reduce risk myocardial infarction patient non-st elevated acute coronary syndrome ac patient st-elevated myocardial infarction recent mi stroke established peripheral arterial disease l7213 shown superior aspirin reducing cardiovascular outcome patient cardiovascular disease provides additional benefit patient acute coronary syndrome already taking aspirin a180547 clopidogrel granted fda approval 17 november 1997 l7213 ,clopidogrel indicated reduce risk myocardial infarction patient non-st elevated acute coronary syndrome ac patient st-elevated myocardial infarction recent mi stroke established peripheral arterial disease l7213 
Tetracycline,tetracycline broad spectrum polyketide antibiotic produced streptomyces genus actinobacteria exerts bacteriostatic effect bacteria binding reversible bacterial 30 ribosomal subunit blocking incoming aminoacyl trna binding ribosome acceptor site also bind extent bacterial 50 ribosomal subunit may alter cytoplasmic membrane causing intracellular component leak bacterial cell fda withdrew approval use liquid oral drug product formulated pediatric use containing tetracycline concentration greater 25 mg/ml l43942 formulation tetracycline continue used ,used treat bacterial infection rocky mountain spotted fever typhus fever tick fever q fever rickettsialpox brill-zinsser disease may used treat infection caused chlamydiae spp. b. burgdorferi lyme disease upper respiratory infection caused typical s. pneumoniae h. influenzae m. catarrhalis atypical organism c. pneumoniae m. pneumoniae l. pneumophila may also used treat acne tetracycline may alternative drug people allergic penicillin 
Meropenem,meropenem broad-spectrum carbapenem antibiotic active gram-positive gram-negative bacteria meropenem exerts action penetrating bacterial cell readily interfering synthesis vital cell wall component lead cell death august 2017 combination antibacterial therapy market name vabomere approved treatment adult patient complicated urinary tract infection cuti vabomere consists meropenem db12107 intravenously admininstered treatment aim resolve infection-related symptom achieve negative urine culture infection proven strongly suspected caused susceptible bacteria , use single agent therapy treatment following infection caused susceptible isolates designated microorganism b complicated skin skin structure infection /b due staphylococcus aureus /i b-lactamase non-b-lactamase producing methicillin-susceptible isolates streptococcus pyogenes /i streptococcus agalactiae /i viridans group streptococci enterococcus faecalis /i excluding vancomycin-resistant isolates pseudomonas aeruginosa /i escherichia coli /i proteus mirabilis /i bacteroides fragilis /i peptostreptococcus /i specie b complicated appendicitis peritonitis /b caused viridans group streptococci escherichia coli /i klebsiella pneumoniae /i pseudomonas aeruginosa /i bacteroides fragilis /i b thetaiotaomicron /i peptostreptococcus /i specie also use treatment bacterial meningitis caused streptococcus pneumoniae /i haemophilus influenzae /i b-lactamase non-b-lactamase-producing isolates neisseria meningitidis /i 
Potassium chloride, white crystal crystalline powder used electrolyte replenisher treatment hypokalemia buffer solution fertilizer explosive fda withdrew approval use solid oral dosage form drug product containing potassium chloride supply 100 mg potassium per dosage unit except controlled-release dosage form product formulated preparation solution prior ingestion l43942 , use electrolyte replenisher treatment hypokalemia 
Irinotecan,irinotecan antineoplastic enzyme inhibitor primarily used treatment colorectal cancer derivative camptothecin inhibits action topoisomerase i. irinotecan prevents religation dna strand binding topoisomerase i-dna complex cause double-strand dna breakage cell death derivative camptothecin irinotecan approved treatment advanced pancreatic cancer october 2015 irinotecan liposome injection trade name onivyde , treatment metastatic colorectal cancer first-line therapy administered 5-fluorouracil leucovorin also used combination cisplatin treatment extensive small cell lung cancer irinotecan currently investigation treatment metastatic recurrent cervical cancer also used combination fluorouracil leucovorin treatment patient metastatic adenocarcinoma pancreas disease progression following gemcitabine-based therapy 
Methimazole,methimazole thionamide antithyroid agent inhibits synthesis thyroid hormone a184559 a184733 a184694 first introduced antithyroid agent 1949 a184502 commonly used management hyperthyroidism particularly aggressive option surgery radioactive iodine therapy inappropriate l8336 l8339 weight basis methimazole 10 time potent major antithyroid thionamide used north america propylthiouracil l8339 active metabolite pro-drug carbimazole antithyroid medication used united kingdom part former british commonwealth a184733 traditionally methimazole preferentially used propylthiouracil due risk fulminant hepatotoxicity carried latter a184757 propylthiouracil preferred pregnancy due perceived lower risk teratogenic effect despite documented teratogenic effect published label l8336 l8339 true teratogenicity methimazole appears unclear a184643 a184757 a184763 place therapy may change future , united state methimazole indicated treatment hyperthyroidism patient graf disease toxic multinodular goiter thyroidectomy radioactive iodine therapy appropriate treatment option methimazole also indicated amelioration hyperthyroid symptom preparation thyroidectomy radioactive iodine therapy l8336 canada methimazole carry indication also indicated medical treatment hyperthyroidism regardless available treatment option l8339 
Mometasone,mometasone corticosteroid currently used medical product mometasone furoate however still use , inhaler indicated maintenance treatment asthma prophylactic therapy nasal spray indicated treatment nasal symptom seasonal allergic perennial allergic rhinitis 
Metyrosine, inhibitor enzyme tyrosine 3-monooxygenase consequently synthesis catecholamine used control symptom excessive sympathetic stimulation patient pheochromocytoma martindale extra pharmacopoeia 30th ed , use treatment patient pheochromocytoma preoperative preparation patient surgery management patient surgery contraindicated chronic treatment patient malignant pheochromocytoma 
Clavulanic acid,clavulanic acid beta-lactamase inhibitor frequently combined amoxicillin ticarcillin fight antibiotic resistance preventing degradation beta-lactamase enzyme broadening spectrum susceptible bacterial infection t665 clavulanic acid derived organism streptomyces clavuligerus a182228 combined amoxicillin clavulanic acid frequently known augmentin co-amoxiclav clavulin l7880 l7904 l7910 ,clavulanic acid combined antibiotic indicated prevent development drug-resistant strain bacteria promotes therapeutic antibacterial effect l7880 l7904 following condition produced beta-lactamase treated combination amoxicillin clavulanic acid ticarcillin clavulanic acid l7880 l7904 acute otitis medium caused h. influenzae m. catarrhalis sinusitis due h. influenzae m. catarrhalis lower respiratory tract infection due haemophilus influenzae s.aureus klebsiella specie moraxella catarrhalis skin skin structure infection caused staphylococcus aureus escherichia coli klebsiella specie urinary tract infection due e. coli klebsiella specie bacteria enterobacter specie bacteria s.marcescens s.aureus gynecologic infection due variety bacteria including p.melaninogenicus enterobacter specie e.coli specie klebsiella specie s. aureus s.epidermidis septicemia due variety bacteria including klebsiella specie e.coli specie s.aureus pseudomonas specie bone joint infection due s.aureus intraabdominal infection due e.coli k.pnemoniae b.fragilis group note susceptibility noted administered infection confirmed highly likely caused susceptible bacteria culture susceptibility test performed possible used selecting whether antibiotic prescribed beta-lactamase enzyme production detected microbiological testing clavulanic acid used test available pattern local infection susceptibility may used determine appropriateness using clavulanic acid l7880 ticarcillin clavulanate shown particular efficacy mixed infection addition empiric therapy determining susceptibility causative organism ticarcillin-clavulanic acid combination may prove effective single-agent antibiotic therapy treat infection regimen several drug may normally used l7904 
Benzquinamide,benzquinamide discontinued antiemetic compound antihistaminic mild anticholinergic sedative property mechanism action known presumably benzquinamide work via antagonism muscarinic acetycholine receptor histamine h1 receptor ,used prevent treat nausea vomiting associated anesthesia surgery administered intramuscularly intravenously 
Olopatadine,olopatadine selective histamine h1 antagonist mast cell stabilizer work attenuating inflammatory allergic reaction structural analog doxepin minimal anti-allergic activity l6790 olopatadine work blocking effect histamine primary inflammatory mediator cause inflammatory allergic reaction ophthalmic solution olopatadine approved fda european union treatment seasonal perennial allergic conjunctivitis 1996 2002 respectively a1172 comparison anti-allergenic ophthalmic medication olopatadine display good comfort tolerability profile since cause perturbation cell membrane a179809 olopatadine used symptomatic treatment ocular itching associated allergic conjunctivitis ophthalmic formulation seasonal allergic rhinitis intranasal formulation currently marketed several brand name including pazeo patanase opatanol ,olopatadine indicated symptomatic treatment ocular itching associated allergic conjunctivitis ophthalmic solution l6781 nasal spray monotherapy combination mometasone furoate olopatadine indicated symptomatic relief seasonal allergic rhinitis patient 12 year age older l6784 l39845 
Hydrocortamate,hydrocortamate synthetic glucocorticoid used anti-inflammatory immunosuppressive property treat inflammation due corticosteroid-responsive dermatosis glucocorticoid class steroid hormone characterised ability bind cortisol receptor trigger variety important cardiovascular metabolic immunologic homeostatic effect ,used topically antiinflammatory treatment steroid-responsive dermatosis
Alprostadil,alprostadil produced endogenously cause vasodilation mean direct effect vascular ductus arteriosus da smooth muscle preventing reversing functional closure da occurs shortly birth result increased pulmonary systemic blood flow infant infant used palliative definitive therapy temporarily maintain patency ductus arteriosus corrective palliative surgery performed neonate congenital heart defect depend upon patent ductus survival adult used treatment erectile dysfunction due neurogenic vasculogenic psychogenic mixed etiology , palliative definitive therapy temporarily maintain patency ductus arteriosus corrective palliative surgery performed neonate congenital heart defect depend upon patent ductus survival also treatment erectile dysfunction due neurogenic vasculogenic psychogenic mixed etiology 
Clidinium,clidinium synthetic anticholinergic agent shown experimental clinical study pronounced antispasmodic antisecretory effect gastrointestinal tract inhibits muscarinic action acetylcholine postganglionic parasympathetic neuroeffector site used treatment peptic ulcer disease also help relieve abdominal stomach spasm cramp due colicky abdominal pain diverticulitis irritable bowel syndrome , treatment peptic ulcer disease also help relieve abdominal stomach spasm cramp due colicky abdominal pain diverticulitis irritable bowel syndrome 
Malathion,malathion parasympathomimetic organophosphate compound used insecticide treatment head louse malathion irreversible cholinesterase inhibitor low human toxicity , patient infected pediculus humanus capitis head louse ovum scalp hair 
Etoposide, semisynthetic derivative podophyllotoxin exhibit antitumor activity etoposide inhibits dna synthesis forming complex topoisomerase ii dna complex induces break double stranded dna prevents repair topoisomerase ii binding accumulated break dna prevent entry mitotic phase cell division lead cell death etoposide act primarily g2 phase cell cycle , use combination chemotherapeutic agent treatment refractory testicular tumor first line treatment patient small cell lung cancer also used treat malignancy lymphoma non-lymphocytic leukemia glioblastoma multiforme 
Hydroflumethiazide, thiazide diuretic action us similar hydrochlorothiazide martindale extra pharmacopoeia 30th ed p822 ,used adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy also used management hypertension either sole therapeutic agent enhance effect antihypertensive drug severe form hypertension 
Tirofiban,tirofiban prevents blood clotting episode chest pain heart attack patient undergoing procedure treat blocked coronary artery non-peptide reversible antagonist platelet glycoprotein gp iib/iiia receptor inhibits platelet aggregation , treatment combination heparin acute coronary syndrome including patient managed medically undergoing ptca atherectomy 
Oxcarbazepine,oxcarbazepine anti-epileptic medication used treatment partial onset seizure first approved use united state 2000 l8627 l8630 l8633 structural derivative carbamazepine a186101 exerts majority activity via pharmacologically active metabolite mhd exists racemate blood pro-drug active -enantiomer also marketed separate anti-epileptic name eslicarbazepine a186011 compared anti-epileptic drug generally metabolized via cytochrome p450 system oxcarbazepine reduced propensity involvement drug-drug interaction owing primarily reductive metabolism a186032 , united state oxcarbazepine indicated use monotherapy adjunctive therapy treatment partial-onset seizure adult monotherapy treatment partial-onset seizure pediatric patient aged 4 year adjunctive therapy pediatric patient aged 2 year partial-onset seizure l8627 canada oxcarbazepine indicated use monotherapy adjunctive therapy treatment partial-onset seizure patient 6 year age older l8630 
Propiomazine,propiomazine atypical antipsychotic agent used treat negative positive symptom schizophrenia acute mania bipolar disorder agitation psychotic symptom dementia future us may include treatment obsessive-compulsive disorder severe behavioral disorder autism structurally pharmacologically similar clozapine propiomazine bind alpha 1 dopamine histamine h1 muscarinic serotonin type 2 5-ht2 receptor ,propiomazine largely used antihistamininc sleep inducing effect treating insomnia 
Roxithromycin,roxithromycin semi-synthethic macrolide antibiotic structurally pharmacologically similar erythromycin azithromycin clarithromycin shown effective certain gram-negative bacteria particularly _legionella pneumophila_ roxithromycin exerts antibacterial action binding bacterial ribosome interfering bacterial protein synthesis marketed australia treatment respiratory tract urinary soft tissue infection ,used treat respiratory tract urinary soft tissue infection 
Nalidixic acid,"nalidixic acid synthetic 1,8-naphthyridine antimicrobial agent limited bacteriocidal spectrum inhibitor subunit bacterial dna gyrase ", treatment urinary tract infection caused susceptible gram-negative microorganism including majority e coli /i enterobacter /i specie klebsiella /i specie proteus /i specie 
Phenelzine,phenelzine formula β-phenylethylhydrazine monoamine oxidase inhibiting antidepressant effective treatment panic disorder social anxiety disorder a15753 developed parke davis originally fda approved june 9th 1961 currently approved prescription name nardil ,phenelzine indicated treatment nonendogenous neurotic atypical depression patient tolerate form therapy l1356 atypical depression high prevalence rate start early life tends last longer likely occur people bipolar disorder high comorbidity anxiety disorder carry risk suicidal behavior important specify atypical feature predict clinical course depression hence generate best treatment service featuring symptom atypical feature include mood reactivity two symptom 1 increased appetite 2 increased sleep 3 leaden paralysis 4 interpersonal rejection sensitivity melancholic catatonic feature depression a31917 neurotic depression depression emotionally unstable person secondary condition major personality disorder neurosis drug use disorder likewise primary depression family history depression spectrum disease would fit category a31922 nonendogenous depression characterized disturbance mood general outlook physical symptom tend le severe often occurs response stressful life event keep occurring large period time generating continuous stress daily living a31924 
Propantheline, muscarinic antagonist used antispasmodic rhinitis urinary incontinence treatment ulcer high dos nicotinic effect resulting neuromuscular blocking , treatment enuresis also used hyperhidrosis cramp spasm stomach intestine bladder 
Estradiol,estradiol naturally occurring hormone circulating endogenously female commercially available several hormone therapy product managing condition associated reduced estrogen vulvovaginal atrophy hot flash available form estradiol include oral tablet injection vaginal ring transdermal patch spray gel cream l11485 l11488 l11491 l11494 l11497 l11500 l11503 used oral im administration estradiol commonly synthesized pro-drug ester db13952 db13953 db13954 db13955 db13956 low oral bioavailability estradiol commonly formulated ester side-chain db00977 ee synthetic form estradiol commonly used estrogenic component combination oral contraceptive pill ocps ethinyl estradiol different estradiol due higher biovailability increased resistance metabolism rendering suitable oral administration ,estradiol indicated various preparation treatment moderate severe vasomotor symptom vulvar vaginal atrophy due menopause treatment hypoestrogenism due hypogonadism castration primary ovarian failure prevention postmenopausal osteoporosis also used treatment breast cancer palliation therapy certain men woman metastatic disease treatment androgen-dependent prostate cancer palliation therapy l11485 l11494 l11497 also used combination hormone component oral contraceptive pill preventing pregnancy commonly db00977 synthetic form estradiol note duration treatment recommendation treatment menopausal symptom changed drastically following release result early termination woman 's health initiative whi study 2002 concern raised regarding estrogen use a31626 specifically combined estrogen–progestin group discontinued 5 year follow due statistically significant increase invasive breast cancer cardiovascular event a31627 following extensive critique whi result hormone replacement therapy hrt recommended used short period 3-5 year postmenopause low dos woman without history breast cancer increased risk cardiovascular thromboembolic disease a31628 estrogen postmenopausal symptom always given progestin component due estrogen 's stimulatory effect endometrium woman intact uterus unopposed estrogen shown promote growth endometrium lead endometrial hyperplasia possibly cancer long-term 
Mefenamic acid, non-steroidal anti-inflammatory agent analgesic anti-inflammatory antipyretic property inhibitor cyclooxygenase , treatment rheumatoid arthritis osteoarthritis dysmenorrhea mild moderate pain inflammation fever 
Cryptenamine,cryptenamine mixture closely related hypotensive alkaloid veratrum album liliaceae used treatment hypertension largely replaced drug fewer adverse effect cryptenamine marked re-producible depressor effect given intravenously hypertensive patient however mechanism action known , treatment hypertension 
Marimastat,used treatment cancer marmiastat angiogenesis metastasis inhibitor angiogenesis inhibitor limit growth production blood vessel antimetatstatic agent prevents malignant cell breaching basement membrane , treatment various cancer
Acyclovir,acyclovir nucleotide analog antiviral used treat herpes simplex _varicella zoster_ herpes zoster herpes labialis acute herpetic keratitis l7303 l7315 l7318 l7321 l7324 l7327 acyclovir generally used first line treatment virus product indicated patient young 6 year old l7321 acyclovir granted fda approval 29 march 1982 l7318 , acyclovir topical cream indicated treat recurrent herpes labialis immunocompetent patient 12 year older l7303 acyclovir oral tablet capsule suspension indicated treat herpes zoster genital herpes chickenpox l7315 acyclovir topical ointment indicated treat initial genital herpes limited non-life-threatening mucocutaneous herpes simplex immunocompromised patient l7318 acyclovir cream hydrocortisone indicated treat recurrent herpes labialis shortening lesion healing time patient 6 year older l7321 acyclovir buccal tablet indicated treatment recurrent herpes labialis l7324 acyclovir ophthalmic ointment indicated treat acute herpetic keratitis l7327 
Naproxen,naproxen classified nonsteroidal anti-inflammatory dug nsaid initially approved prescription use 1976 over-the-counter otc use 1994 a178975 effectively manage acute pain well pain related rheumatic disease well studied adverse effect profile a179098 given overall tolerability effectiveness naproxen considered first line treatment variety clinical situation requiring analgesia a179098 naproxen available immediate delayed release formulation combination sumatriptan treat migraine combination esomeprazole lower risk developing gastric ulcer l6582 l6583 l7309 l7312 ,naproxen indicated management rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea relief mild moderate pain l6582 l6583 a178975 first-line therapy osteoarthritis acute gouty arthritis dysmenorrhea musculoskeletal inflammation pain a178975 
Gadopentetic acid, complex gadolinium chelating agent diethylenetriamine penta-acetic acid dtpa see pentetic acid given enhance image cranial spinal mri martindale extra pharmacopoeia 30th ed p706 , use magnetic resonance imaging mri adult pediatric patient 2 year age older visualize lesion abnormal vascularity brain intracranial lesion spine associated tissue well lesion abnormal vascularity head neck also used facilitate visualization lesion abnormal vascularity body excluding heart 
Perindopril,perindopril nonsulfhydryl prodrug belongs angiotensin-converting enzyme ace inhibitor class medication rapidly metabolized liver perindoprilat active metabolite following oral administration perindoprilat potent competitive inhibitor ace enzyme responsible conversion angiotensin ati angiotensin ii atii atii regulates blood pressure key component renin-angiotensin-aldosterone system raas perindopril may used treat mild moderate essential hypertension mild moderate congestive heart failure reduce cardiovascular risk individual hypertension post-myocardial infarction stable coronary disease , treatment mild moderate essential hypertension mild moderate congestive heart failure reduce cardiovascular risk individual hypertension post-myocardial infarction stable coronary disease 
Uracil mustard,nitrogen mustard derivative uracil alkylating antineoplastic agent used lymphatic malignancy cause mainly gastrointestinal bone marrow damage ,used antineoplastic property 
Tripelennamine, histamine h1 antagonist low sedative action frequent gastrointestinal irritation used treat asthma hay fever urticaria rhinitis also veterinary application tripelennamine administered various route including topically ,used symptomatic relief hypersensitivity reaction cough common cold 
Haloprogin,haloprogin used topical ointment cream treatment tinea infection tinea infection superficial fungal infection caused three specie fungi collectively known dermatophytes trichophyton microsporum epidermophyton commonly infection named body part affected including tinea corporis general skin tinea cruris groin tinea pedis foot haloprogin halogenated phenolic ether administered topically dermotaphytic infection mechanism action unknown thought via inhibition oxygen uptake disruption yeast membrane structure function haloprogin longer available united state discontinued ,used treat fungal tinea skin infection athlete 's foot jock itch ringworm tinea versicolor 
Primidone,primidone anticonvulsant used treat essential tremor well grand mal psychomotor focal epileptic seizure l11112 primidone developed j yule bogue h c carrington 1949 a189522 primidone granted fda approval 8 march 1954 l11112 ,primidone commonly indicated management grand mal psychomotor focal epileptic seizure l4645 l11112 addition also studied utilized effective management essential tremor a39414 a39415 l4645 
Sulfasalazine, drug used management inflammatory bowel disease activity generally considered lie metabolic breakdown product 5-aminosalicylic acid see mesalamine released colon martindale extra pharmacopoeia 30th ed p907 , u sulfasalazine indicated treat mild moderate ulcerative colitis prolong remission period acute attack ulcerative colitis l39065 sulfasalazine also indicated adjunct therapy severe ulcerative colitis l39065 delayed-release tablet formulation sulfasalazine also indicated treat rheumatoid arthritis pediatric patient responded inadequately salicylate nonsteroidal anti-inflammatory drug polyarticular-course juvenile rheumatoid arthritis patient characteristic l39065 
Candesartan cilexetil,candesartan angiotensin-receptor blocker arb may used alone agent treat hypertension administered orally prodrug candesartan cilexetil rapidly converted active metabolite candesartan absorption gastrointestinal tract candesartan lower blood pressure antagonizing renin-angiotensin-aldosterone system raas competes angiotensin ii binding type-1 angiotensin ii receptor at1 subtype prevents blood pressure increasing effect angiotensin ii unlike angiotensin-converting enzyme ace inhibitor arb adverse effect dry cough candesartan may used treat hypertension isolated systolic hypertension left ventricular hypertrophy diabetic nephropathy may also used alternative agent treatment heart failure systolic dysfunction myocardial infarction coronary artery disease ,may used first line agent treat uncomplicated hypertension isolated systolic hypertension left ventricular hypertrophy may used first line agent delay progression diabetic nephropathy candesartan may also used second line agent treatment congestive heart failure systolic dysfunction myocardial infarction coronary artery disease intolerant ace inhibitor 
Tolazoline, vasodilator apparently direct action blood vessel also increase cardiac output tolazoline interact degree histamine adrenergic cholinergic receptor mechanism therapeutic effect clear used treatment persistent pulmonary hypertension newborn , treatment pulmonary artery anomaly
Gentamicin,gentamicin bactericidal aminoglycoside discovered isolated _micromonospora purpurea_ 1963 a234349 one frequently prescribed aminoglycosides due spectrum activity low cost availability a234339 a234354 gentamicin effective gram-positive gram-negative organism particularly useful treatment severe gram-negative infection including caused _pseudomonas aeruginosa_ a233325 a234359 a234364 added benefit synergy gentamicin co-administered antibacterial beta-lactams a234364 synergistic activity important treatment complex infection also contribute dose optimization reduced adverse effect a234359 a234364 although gentamicin well-established may used variety clinical application also associated severe adverse effect including nephrotoxicity ototoxicity may limit use a234369 ,
Tazarotene,tazarotene commonly marketed tazorac® avage® zorac® member acetylenic class retinoids prodrug found topical formulation used treatment various conditons psoriasis acne sun damaged skin photodamage ,used treat psoriasis acne sun damaged skin photodamage 
Fenoldopam, dopamine d1 receptor agonist used antihypertensive agent lower blood pressure arteriolar vasodilation , in-hospital short-term 48 hour management severe hypertension rapid quickly reversible emergency reduction blood pressure clinically indicated including malignant hypertension deteriorating end-organ function 
Halazepam,halazepam _benzodiazepine_ derivative drug exerting anxiolytic anticonvulsant sedative muscle relaxing effect a1212 a178114 shown le toxic chlordiazepoxide diazepam a1212 drug longer marketed united state withdrawn _schering_ manufacturer 2009 l6226 l6229 ,used relieve anxiety nervousness tension associated anxiety disorder 
Alfentanil, short-acting opioid anesthetic analgesic derivative fentanyl produce early peak analgesic effect fast recovery consciousness alfentanil effective anesthetic surgery supplementation analgesia surgical procedure analgesic critically ill patient , management postoperative pain maintenance general anesthesia 
Colistin,cyclic polypeptide antibiotic bacillus colistinus composed polymyxin e1 e2 colistins b c act detergent cell membrane colistin le toxic polymyxin b otherwise similar methanesulfonate used orally , treatment acute chronic infection due sensitive strain certain gram-negative bacillus particularly pseudomonas aeruginosa /i 
Dicyclomine,dicyclomine muscarinic m1 m3 m2 receptor antagonist well non-competitive inhibitor histamine bradykinin used treat spasm intestine seen functional bowel disorder irritable bowel syndrome a6556 a182555 a234659 l7967 though commonly prescribed recommendation may based small amount evidence prescription becoming le favourable l7982 dicyclomine granted fda approval 11 may 1950 l7967 ,dicyclomine indicated treatment functional bowel disorder irritable bowel syndrome l7967 
Minaprine,minaprine psychotropic drug proved effective treatment various depressive state like antidepressant minaprine antagonizes behavioral despair minaprine amino-phenylpyridazine antidepressant reported relatively free cardiotoxicity drowsiness weight gain , treatment depression
Pentoxifylline,pentoxifylline ptx synthetic dimethylxanthine derivative modulates rheological property blood also anti-oxidant anti-inflammatory property a226415 l30300 although originally developed treat intermittent claudication form exertion-induced leg pain common patient peripheral arterial disease ptx investigated possible use diverse condition including osteoradionecrosis diabetic kidney disease generally condition associated fibrosis a226410 a226415 a226455 recently ptx suggested possible treatment covid-19-induced pulmonary complication due ability regulate production inflammatory cytokine a226608 pentoxifylline marketed europe since 1972 ptx extended-release tablet sold trade name trental u pharm holding first approved fda aug 30 1984 since discontinued branded product pentoxil marketed upsher-smith laboratory generic form marketed valeant pharmaceutical apotex available since late 1990s l30300 ,pentoxifylline indicated treatment intermittent claudication patient chronic occlusive arterial disease pentoxifylline may improve limb function reduce symptom replace therapy surgical bypass removal vascular obstruction l30300 
Proparacaine,proparacaine topical anesthetic drug amino ester group found ophthalmic solution concentration 0.5 hydrochloride salt ,used local ophthalmic anesthetic 
Indapamide, significant modifiable risk factor cardiovascular disease prominent contributor all-cause mortality hypertension a204155 characterized office blood pressure ≥140/90 hypertension pervasive impact estimated 25 adult globally a204155 treatment hypertension include number lifestyle change ie reduced sodium intake along pharmacotherapy noted treatment several antihypertensive agent may required order achieve blood pressure target a204155 thiazide-like diuretic indapamide valuable tool treatment hypertension continue grow popularity falling behind ace inhibitor term prescription frequency a204134 compared hydrochlorothiazide another commonly prescribed diuretic indapamide shown superior lowering systolic blood pressure reducing left ventricular mass index lowering oxidative stress inhibiting platelet aggregation reducing microalbuminuria associated diabetes a204134 interestingly unlike thiazide diuretic several source suggest indapamide associated glucose lipid disturbance a204134 a204161 indapamide characterized methylindoline sulfamoyl chlorobenzamide functional group former largely responsible molecule ’ lipid solubility a204158 ,indapamide diuretic indicated use monotherapy combination blood pressure-lowering agent treat hypertension l13982 may also used treat fluid salt retention associated congestive heart failure l13982 
Tropicamide,tropicamide alkaloid atropine‐derived anticholinergic drug non‐selective antagonist muscarinic acetylcholine mach receptor a230103 usually available ophthalmic formulation tropicamide used cause mydriasis cycloplegia eye exam ocular procedure a229958 also used combination hydroxyamphetamine indication l32178 oral tropicamide investigated potential drug relieve sialorrhea patient parkinson 's disease a229958 ,tropicamide indicated induce mydriasis dilation pupil cycloplegia paralysis ciliary muscle eye diagnostic procedure l32103 used combination hydroxyamphetamine indication l32178 
Biperiden, muscarinic antagonist effect central peripheral nervous system used treatment arteriosclerotic idiopathic postencephalitic parkinsonism also used alleviate extrapyramidal symptom induced phenothiazine derivative reserpine , use adjunct therapy form parkinsonism control extrapyramidal disorder secondary neuroleptic drug therapy 
Ribavirin,producing broad-spectrum activity several rna dna virus ribavirin synthetic guanosine nucleoside antiviral agent interferes synthesis viral mrna primarily indicated use treating hepatitis c viral hemorrhagic fever hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 reported ribavirin might effective early stage viral hemorrhagic fever including lasser fever crimean-congo hemorrhagic fever venezuelan hemorrhagic fever hantavirus infection ribavirin prodrug metabolized nucleoside analog block viral rna synthesis viral mrna capping development newer drug ribavirin db00008 db00022 dual therapy considered first-generation standard antiviral treatment a19626 dual therapy administered 48 week patient genotype 1 4 5 6 24 week patient genotype 2 3 a19626 newer drug developed hepatitis c viral infection treatment used reduce eliminate use ribavirin associated serious adverse effect also improve therapeutic efficacy patient failed db00008 db00022 ribavirin-based therapy potential use ribavirin treatment acute myeloid leukemia currently investigation according 2017 american association study liver disease aasld 2015 consensus guideline canadian association study liver casl ribavirin typically used adjunct therapy various first-line second-line combination therapy recommended genotype ribavirin added decrease relapse rate accelerating viral clearance early treatment course a19645 used treat hepatitis c virus hcv infection always used part combination therapy ribavirin monotherapy efficacious treatment chronic hepatitis c infection a19644 additionally including ribavirin regimen increase risk anemia hcv genotye 1/2/3/4/5/6 patient ribavirin used combination therapy involving db09102 db08934 eplusa db08934 db11613 harvoni db08934 db09027 db06290 db08934 viekira pak db09296 db09297 db00503 db09183 technivie db00503 db09296 db09297 zepatier db11574 db11575 addition weight-based ribavirin technivie therapy increased sustained virologic response 12 week daily therapy svr12 90 97 patient hcv genotype 1a 90.9 100 hcv genotype 4 patient l852 zepatier therapy along ribavirin improved svr hcv genotype 5 patient combination therapy ribavirin db00008 result svr 44 patient genotype 1 infection 70 patient genotype 2-6 inclusion ribavirin combination therapy depend individual patient 's profile example hcv genotype 3 patient y93h genetic variant compensated cirrhosis ,indicated treatment chronic hepatitis c virus hcv infection combination antiviral agent intent cure achieve sustained virologic response svr typically added improve svr reduce relapse rate a19644 addition ribavirin technivie therapy indicated treating hcv genotype 1a 4 infection recommended patient without cirrhosis resistance viral genetic determinant resulting variable response ribavirin therapy yet determined 
Phenylbutazone, drug anti-inflammatory antipyretic analgesic activity especially effective treatment ankylosing spondylitis also useful rheumatoid arthritis reiter 39 syndrome investigational indication although phenylbutazone effective gouty arthritis risk/benefit consideration indicate drug employed disease ama drug evaluation annual 1994 p1822 , treatment backache ankylosing spondylitis
Fentanyl,fentanyl potent opioid agonist developed 1950s fill need strong rapid analgesia a179542 characteristic fentanyl commonly used treat chronic cancer pain anesthesia label l6598 l6601 l6604 l6607 l922 l6610 l6613 fentanyl related opioids like morphine oxycodone fentanyl 's high potency also made common adulterant illicit drug especially heroin a179542 2017 47600 overdose death united state involved opioid 2/3 overdose death l6748 opioid overdoses kill average 11 canadian daily l6751 fentanyl fda approved 1968 label l6598 l6601 l6604 l6607 l922 l6610 l6613 ,fentanyl intravenous intramuscular injection indicated short term analgesia induction maintenance recovery general regional anesthesia label injection also used neuroleptic premedication induction adjunct maintenance anesthesia label finally fentanyl intravenous intramuscular injection used oxygen anesthesia high risk patient label fentanyl sublingual tablet transmucosal lozenge buccal tablet sublingual spray transdermal system nasal spray indicated management breakthrough pain opioid tolerant cancer patient require around clock pain management l6598 l6601 l6604 l6607 l922 l6610 
Meloxicam,meloxicam nonsteroidal anti-inflammatory drug nsaid used relieve various type pain including pain caused musculoskeletal condition osteoarthritis rheumatoid arthritis a190189 longer half-life nsaid favorable option require once-daily dosing meloxicam available oral transdermal intravenous formulation preferential cox-2 inhibitor purportedly reducing risk adverse gastrointestinal tract effect however topic controversy a190198 a190201 ,meloxicam indicated symptomatic treatment arthritis osteoarthritis addition indicated pauciarticular polyarticular course juvenile rheumatoid arthritis jra patient aged 2 year old l11398 off-label us include treatment dental post-surgical pain addition meloxicam also studied treatment neuropathic pain a190189 meloxicam combination bupivacaine indicated postsurgical analgesia adult patient 72 hour following foot ankle small-to-medium open abdominal lower extremity total joint arthroplasty surgical procedure l34100 
Sodium lauryl sulfate,sodium lauryl sulfate sl anionic surfactant naturally derived coconut and/or palm kernel oil usually consists mixture sodium alkyl sulfate mainly lauryl sl lower surface tension aqueous solution used fat emulsifier wetting agent detergent cosmetic pharmaceutical toothpaste also used cream paste properly disperse ingredient research tool protein biochemistry sl also microbicidal activity ,sl used surfactant shampoo toothpaste sl also microbicidal activity enveloped herpes simplex virus hiv-1 semliki forest virus nonenveloped papillomaviruses reovirus rotavirus poliovirus virus although approved use 
Orciprenaline, beta-adrenergic agonist used treatment asthma bronchospasm pubchem , treatment bronchospasm chronic bronchitis asthma emphysema 
Rosoxacin,rosoxacin quinolone derivative antibiotic treatment bacterial infection respiratory tract urinary tract gi cns immuno compromised patient rosoxacin known effective penicillin resistant strain single dose orally administered drug avoids complication parenteral administration seen penicillin especially anaphylactic shock , treatment bacterial infection respiratory tract urinary tract gi cns immuno compromised patient 
Propofol,propofol intravenous anaesthetic agent used induction maintenance general anaesthesia iv administration propfol used induce unconsciousness anaesthesia may maintained using combination medication recovery propofol-induced anaesthesia generally rapid associated le frequent side effect e.g drowsiness nausea vomiting thiopental methohexital etomidate propofol may used prior diagnostic procedure requiring anaesthesia management refractory status epilepticus induction and/or maintenance anaesthesia prior surgery ,used induction and/or maintenance anaesthesia management refractory status epilepticus 
Acetazolamide,one carbonic anhydrase inhibitor sometimes effective absence seizure sometimes useful also adjunct treatment tonic-clonic myoclonic atonic seizure particularly woman whose seizure occur exacerbated specific time menstrual cycle however usefulness transient often rapid development tolerance antiepileptic effect may due inhibitory effect brain carbonic anhydrase lead increased transneuronal chloride gradient increased chloride current increased inhibition smith reynard textbook pharmacology 1991 p337 , adjunctive treatment edema due congestive heart failure drug-induced edema centrencephalic epilepsy chronic simple open-angle glaucoma
Tadalafil,tadalafil selective phosphodiesterase-5 inhibitor used treatment erectile dysfunction ed pulmonary arterial hypertension pah benign prostatic hypertrophy l39100 l39105 first approved 2003 fda use ed later 2009 pah contrast pde5 inhibitor like sildenafil tadalafil greater selectivity pde5 longer half-life made suitable option chronic once-daily dosing treatment pah a242287 ,tadalafil indicated treatment erectile dysfunction ed either alone combination finasteride treatment benign prostatic hypertrophy bph l39095 l39439 also indicated treatment pulmonary arterial hypertension pah alone combination macitentan endothelin-1 antagonist l39100 l39105 
Carprofen,carprofen non-steroidal anti-inflammatory drug nsaid used veterinarian supportive treatment relief arthritic symptom geriatric dog carprofen previously used human medicine 10 year 1985-1995 generally well tolerated majority adverse effect mild gastro-intestinal pain nausea similar recorded aspirin non-steroidal anti-inflammatory drug longer marketed human usage withdrawn commercial ground , use pain reliever treatment joint pain post-surgical pain 
Disulfiram, carbamate derivative used alcohol deterrent relatively nontoxic substance administered alone markedly alters intermediary metabolism alcohol alcohol ingested administration disulfiram blood acetaldehyde concentration increased followed flushing systemic vasodilation respiratory difficulty nausea hypotension symptom acetaldehyde syndrome act inhibiting aldehyde dehydrogenase , treatment management chronic alcoholism
Ethynodiol diacetate, synthetic progestational hormone used alone combination estrogen oral contraceptive although etynodiol ethynodiol sometimes used synonym ethynodiol diacetate usually referred actually ethynodiol diacetate ethynodiol separate drug never marketed see db13866 , prevention pregnancy woman elect use product method contraception 
Enprofylline,enprofylline derivative theophylline share bronchodilator property enprofylline used asthma chronic obstructive pulmonary disease management cerebrovascular insufficiency sickle cell disease diabetic neuropathy long-term enprofylline administration may associated elevation liver enzyme level unpredictable blood level ,used management symptom asthma also used treatment peripheral vascular disease management cerebrovascular insufficiency sickle cell disease diabetic neuropathy 
Levomenthol,"menthol covalent organic compound made synthetically obtained peppermint mint oil forming clear white waxy crystalline substance menthol typically solid room temperature -menthol naturally-occurring main form menthol assigned 1r,2s,5r configuration menthol mediates anesthetic property anti-irritating property locally thus widely used relieve minor throat irritation ",used treat occasional minor irritation pain sore mouth sore throat well cough associated cold inhaled irritant 
Natamycin,amphoteric macrolide antifungal antibiotic streptomyces natalensis s. chattanoogensis used variety fungal infection mainly topically pubchem , treatment fungal blepharitis conjunctivitis keratitis caused susceptible organism including fusarium solani /i keratitis 
Cinoxacin,synthetic antimicrobial related oxolinic acid nalidixic acid used urinary tract infection , treatment initial recurrent urinary tract infection adult caused following susceptible microorganism escherichia coli /i proteus mirabilis /i proteus vulgaris /i klebsiella /i specie including k pneumoniae /i enterobacter /i specie 
Fosfomycin,fosfomycin discovered 1969 scientist spanish penicillin antibiotic company produced _streptomyces fradiae_ a229338 a230348 may also produced synthetically commercially available disodium salt intravenous administration calcium trometamol salt oral administration a230348 term chemical structure fosfomycin phosphoenolpyruvate analog contains phosphonic group epoxide ring a230348 due ease administration single 3-gram oral dose desirable safety profile fosfomycin largely become first-line therapeutic option treatment uncomplicated urinary tract infection utis female a230378 despite fda approved urinary tract infection fosfomycin actually broad spectrum activity active gram-positive gram-negative bacteria a230348 great interest exploring usefulness fosfomycin indication beyond treatment utis a230353 a230358 ,fosfomycin indicated treatment uncomplicated case cystitis caused susceptible strain _escherichia coli_ _enterococcus faecalis_ l31818 fosfomycin officially indicated treatment pyelonephritis perinephric abscess although reported case off-label usage situation l31818 
Diazepam, benzodiazepine anticonvulsant anxiolytic sedative muscle relaxant amnesic property long duration action action mediated enhancement gamma-aminobutyric acid activity used treatment severe anxiety disorder hypnotic short-term management insomnia sedative premedicant anticonvulsant management alcohol withdrawal syndrome martindale extra pharmacopoeia 30th ed p589 given diazepam 's storied history commonly used effective medication variety indication contemporary advancement formulation administration agent include development u fda approval auto-injectable formulation rapid treatment uncontrolled seizure 2015-2016 l5200 combining diazepam proven effective therapy acute repetitive seizure auto-injector designed subcutaneous administration quickly easily administered offer potential complete consistent drug absorption rapid onset effect l5200 current development subsequently important addition rescue therapy tool chest patient epilepsy l5200 , general diazepam useful symptomatic management mild moderate degree anxiety condition dominated tension excitation agitation fear aggressiveness may occur psychoneurosis anxiety reaction due stress condition anxiety state somatic expression f3160 moreover acute alcoholic withdrawal diazepam may useful symptomatic relief acute agitation tremor impending acute delirium tremens f3160 furthermore diazepam useful adjunct relief skeletal muscle spasm due reflex spasm local pathology inflammation muscle joint secondary trauma spasticity caused upper motor neuron disorder cerebral palsy paraplegia athetosis rare `` stiff man syndrome '' f3160 particular label information united kingdom also list particular age-specific indication including adult 1 short-term relief 2-4 week anxiety severe disabling subjecting individual unacceptable distress occurring alone association insomnia short-term psychosomatic organic psychotic illness 2 cerebral palsy 3 muscle spasm 4 adjunct certain type epilepsy eg myoclonus 5 symptomatic treatment acute alcohol withdrawal 6 oral premedication nervous dental patient 7 premedication surgery l5188 uk label information diazepam indicated child 1 control tension irritability cerebral spasticity selected case 2 adjunct control muscle spasm tetanus 3 oral premedication l5188 diazepam nasal spray indicated patient 6 year older treat intermittent stereotypic episode frequent seizure activity different patient 's usual seizure pattern l11247 
Phenmetrazine, sympathomimetic drug used primarily appetite depressant action mechanism similar dextroamphetamine ,used anorectic treatment obesity 
Trifluoperazine, phenothiazine action similar chlorpromazine used antipsychotic antiemetic , treatment anxiety disorder depressive symptom secondary anxiety agitation 
Phensuximide,phensuximide member succinimide class anticonvulsant property suppresses paroxysmal three cycle per second spike wave eeg pattern associated lapse consciousness petit mal seizure frequency attack reduced depression nerve transmission motor cortex , treatment epilepsy 
Cefaclor,semisynthetic broad-spectrum antibiotic derivative cephalexin , treatment certain infection caused bacteria pneumonia ear lung skin throat urinary tract infection 
Mifepristone,mifepristone progestational glucocorticoid hormone antagonist inhibition progesterone induces bleeding luteal phase early pregnancy releasing endogenous prostaglandin endometrium decidua glucocorticoid receptor antagonist drug used treat hypercortisolism patient nonpituitary cushing syndrome two marketed form mifepristone mifeprex® mifepristone 200mg korlym™ mifepristone 300mg currently investigation use psychotic depression phase 3 trial , medical termination intrauterine pregnancy 49 day pregnancy also indicated control hyperglycemia secondary hypercortisolism adult patient endogenous cushing 's syndrome type 2 diabetes mellitus glucose intolerance candidate surgery unsuccessful surgery 
Brompheniramine,histamine h1 antagonist used treatment allergy rhinitis urticaria , treatment symptom common cold allergic rhinitis runny nose itchy eye watery eye sneezing 
Loperamide,loperamide anti-diarrheal agent available various over-the-counter product treating diarrhea l42785 drug first synthesized 1969 used medically 1976 a251610 highly lipophilic synthetic phenylpiperidine opioid a251610 structurally similar opiate receptor agonist diphenoxylate haloperidol a6249 due pharmacological property loperamide misused abused self-manage opioid withdrawal symptom induce euphoria a251610 a251625 however loperamide associated risk experiencing range adverse effect often life-threatening taking non-therapeutic reason dos higher recommended dose l42790 ,loperamide indicated relief diarrhea including traveler ’ diarrhea l42785 off-label use often used manage chemotherapy-related diarrhea a251610 
Progabide,progabide analog prodrug gamma-aminobutyric acid commonly used treatment epilepsy agonistic activity gabaa gabab receptor clinical trial progabide investigated parkinson 's disease schizophrenia clinical depression anxiety disorder therapeutic effectiveness condition fully elucidated ,indicated treatment epilepsy 
Clocortolone,clocortolone medium potency corticosteroid often used topical cream relief inflammatory oand pruritic itching arising steroid-responsive dermatosis scalp , short-term topical treatment inflammatory pruritic manifestation moderate severe corticosteroid-responsive dermatosis scalp 
Tolazamide, sulphonylurea hypoglycemic agent action us similar chlorpropamide , use adjunct diet lower blood glucose patient non-insulin dependent diabetes mellitus type ii whose hyperglycemia satisfactorily controlled diet alone 
Hydroxypropyl cellulose,hydroxypropyl cellulose ether cellulose hydroxyl group cellulose hydroxypropylated forming -och2ch oh ch3 group lacrisertis formulation hydroxypropyl cellulose used artificial tear used treat syndrome characterized insufficient tear production keratoconjunctivitis sicca recurrent corneal erosion decreased corneal sensitivity exposure neuroparalytic keratitis lubricant artificial eye food additive hydroxypropyl cellulose used thickener emulsion stabilizer ,used relieve dryness irritation caused reduced tear flow occurs certain eye disease keratoconjunctivitis sicca recurrent corneal erosion decreased corneal sensitivity exposure neuroparalytic keratitis lubricant artificial eye 
Dobutamine, beta-1 agonist catecholamine cardiac stimulant action without evoking vasoconstriction tachycardia proposed cardiotonic myocardial infarction open heart surgery ,indicated parenteral therapy necessary inotropic support short-term treatment patient cardiac decompensation due depressed contractility resulting either organic heart disease cardiac surgical procedure 
Oxazepam,oxazepam intermediate-acting 3-hydroxybenzodiazepine used treatment alcohol withdrawal anxiety disorder oxazepam like related 3-hydroxybenzodiazepine lorazepam considered le susceptible pharmacokinetic variability based patient-specific factor e.g age liver disease feature advantageous compared benzodiazepine likely owing part oxazepam 's relatively simple metabolism a203516 active metabolite diazepam temazepam a39486 undergoes little biotransformation following absorption making unlikely participate pharmacokinetic interaction l13895 ,oxazepam indicated management anxiety disorder short-term relief symptom anxiety l13895 may also used management alcohol withdrawal symptom l13895 
Donepezil, 2016 global burden dementia estimated 43.8 million demonstrating significant increase global prevalence 20.2 million 1990 a182411 donepezil also known aricept piperidine derivative acetylcholinesterase inhibitor used management dementia alzheimer 's disease case used manage type dementia donepezil first approved fda 1996 extended-release form approved combination memantine 2014 manage moderate severe form alzheimer 's dementia l7916 l7937 donepezil transdermal delivery system adlarity approved fda march 2022 treatment alzheimer 's dementia l41125 though alter progression alzheimer 's disease donepezil effective managing symptom associated dementia t668 ,donepezil administered orally l7916 via transdermal delivery system l41125 indicated treatment dementia alzheimer 's type also available extended-release capsule combination memantine treatment moderate-to-severe dementia alzheimer 's type patient previously stabilized 10mg donepezil hydrochloride daily l7937 off-label us include management vascular dementia parkinson 's disease-associated dementia lewy body dementia amongst others a182333 t668 
Nalbuphine, narcotic used pain medication appears agonist kappa opioid receptor antagonist partial agonist mu opioid receptor nalbuphine opioid analgesic controlled substance united state , relief moderate severe pain 
Clofazimine,clofazimine highly lipophilic antimicrobial riminophenazine dye used combination agent dapsone treatment leprosy originally described 1957 prototypical riminophenazine dye bright-red dye clinical use result long-lasting discoloration skin bodily fluid a203144 although carry _in vitro_ activity mycobacterium _mycobacterium tuberculosis_ generally considered ineffective treatment comparison classic tuberculosis treatment rifampicin isoniazid a203144 ,clofazimine indicated treatment lepromatous leprosy including dapsone-resistant lepromatous leprosy lepromatous leprosy complicated erythema nodosum leprosum l13802 prevent development drug resistance used combination antimycobacterial leprosy treatment 
Flurandrenolide, corticosteroid used topically treatment various skin disorder usually employed cream ointment also used polyethylene tape adhesive martindale extra pharmacopoeia 30th ed p733 , relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis particularly dry scaling localized lesion
Cysteamine,cystinosis rare disease caused mutation ctns gene encodes cystinosin protein responsible transporting cystine cell lysosome defect cystinosin function followed cystine accumulation throughout body especially eye kidney a218721 several preparation cysteamine exist treatment cystinosis manifestation capsule form others ophthalmic solution form l15606 l15616 particular cystine deposit eye cause significant discomfort throughout day require frequent treatment eye drop typically every waking hour l15611 august 25th 2020 first ophthalmic solution cystinosis requiring 4 daily treatment granted fda approval l15606 cysteamine eye drop practical effective option affected ocular cystinosis marketed recordati rare disease inc. cystadrops® reduce burden multiple frequent medication normally administered cystinosis l15601 , bitartrate salt cysteamine used oral treatment nephropathic cystinosis cystinuria adult child ≥6 year old l15616 hydrochloride salt used eye drop preparation indicated treatment corneal cystine crystal accumulation patient cystinosis l15601 l15606 
Levamisole,levamisole antihelminthic drug commonly used treatment parasitic viral bacterial infection a178117 manufactured _janssen_ first used 1969 agent treat worm infestation a178123 levamisole approved fda 1990 adjuvant treatment colon cancer l6232 prior levamisole used antirheumatic therapy 1970s 1980s patient rheumatoid arthritis a178123 immunomodulatory effect drug studied treatment various immune-mediated disease study showing positive result a178117 drug also used combination drug treatment various cancer a178117 a178123 levamisole withdrawn american market 2000 due ability cause serious adverse effect including agranulocytosis a178123 interestingly levamisole found adulterant cocaine lead variety adverse effect individual using drug a178120 , adjuvant treatment combination fluorouracil surgical resection patient duke stage c colon cancer also used treat malignant melanoma head/neck cancer 
Methylphenobarbital, barbiturate metabolized phenobarbital used similar purpose especially epilepsy evidence mephobarbital offer advantage phenobarbital , relief anxiety tension apprehension also used anticonvulsant treatment epilepsy 
Perphenazine, antipsychotic phenothiazine derivative action us similar chlorpromazine , use management manifestation psychotic disorder control severe nausea vomiting adult 
Dacarbazine, antineoplastic agent significant activity melanoma martindale extra pharmacopoeia 31st ed p564 dacarbazine oblimersen clinical trial treatment malignant melanoma , treatment metastatic malignant melanoma addition dacarbazine also indicated hodgkin 's disease secondary-line therapy used combination antineoplastic agent 
Pseudoephedrine,pseudoephedrine structurally related ephedrine exerts weaker effect sympathetic nervous system a188820 a188823 drug naturally occur ephedra plant history use traditional eastern medicine first researched west 1889 a188823 decongestant effect pseudoephedrine described dog 1927 a188823 ,pseudoephedrine sympathomimetic amine used decongestant activity l11031 l11037 l11040 l11046 l11052 l11058 l11061 
Temozolomide,refractory anaplastic astrocytoma grade iii glioblastoma multiforme grade iv primary malignant brain tumour poor prognosis limited treatment option despite considerable genetic heterogeneity tumour often impaired dna repair system rendering initially sensitive alkylating agent although invariably develop resistance agent time a229848 a229858 l32033 temozolomide imidazotetrazine prodrug stable acidic ph undergoes spontaneous nonenzymatic hydrolysis neutral slightly basic ph property allow oral intravenous administration a229853 a229888 a229923 l32033 following initial hydrolysis reaction liberate highly reactive methyl diazonium cation capable methylating various residue adenosine guanine base leading dna lesion eventual apoptosis a229853 a229923 temozomolide adjunct radiotherapy followed maintenance dosing remains standard care glioblastoma refractory anaplastic astrocytoma l32033 temozolomide granted fda approval august 11 1999 oral capsule subsequently february 27 2009 intravenous injection currently marketed trademark temodar® merck l32033 ,temozolomide indicated adult patient treatment newly diagnosed glioblastoma concomitantly radiotherapy use maintenance treatment thereafter also indicated treatment refractory anaplastic astrocytoma adult patient experienced disease progression drug regimen containing nitrosourea procarbazine l32033 
Levorphanol, narcotic analgesic may habit-forming nearly effective orally injection , management moderate severe pain preoperative medication opioid analgesic appropriate 
Aminolevulinic acid, compound produced succinyl-coa glycine intermediate heme synthesis used photochemotherapy actinic keratosis pubchem ,aminolevulinic acid plus blue light illumination using blue light photodynamic therapy illuminator indicated treatment minimally moderately thick actinic keratoses face scalp 
Chlorphenesin,,used along rest physical therapy treat injury painful muscular condition investigated use trigeminal neuralgia tic douloureux neuropathic disorder characterized severe facial pain investigated modulator histamine release 
Terbinafine,terbinafine hydrochloride lamisil synthetic allylamine antifungal l9065 l9068 highly lipophilic nature tends accumulate skin nail fatty tissue a1279 like allylamines terbinafine inhibits ergosterol synthesis inhibiting fungal squalene monooxygenase also called squalene epoxidase enzyme part fungal cell wall synthesis pathway a1279 a1281 l9068 terbinafine hydrochloride granted fda approval 30 december 1992 l9064 ,terbinafine hydrochloride indicated treat fungal skin nail infection caused _trichophyton_ specie _microsporum canis_ _epidermophyton floccosum_ l9068 _tinea_ specie l9065 terbinafine hydrochloride also treat yeast infection skin caused _candida_ specie _malassezia furfur_ l9068 
Drostanolone,drostanolone also known dromostanolone potent synthetic androgenic anabolic steroid similar testosterone drostanolone indicated postmenopausal woman recurrent breast cancer combined hormone therapy ,
Penicillamine,penicillamine pharmaceutical chelator class pharmaceutical form d-penicillamine l-penicillamine toxic inhibits action pyridoxine α-amino acid metabolite penicillin although antibiotic property , treatment wilson 's disease cystinuria active rheumatoid arthritis 
Prednisolone,prednisolone glucocorticoid similar cortisol used anti-inflammatory immunosuppressive anti-neoplastic vasoconstrictive effect a187463 prednisolone granted fda approval 21 june 1955 l9431 ,prednisolone indicated treat endocrine rheumatic hematologic disorder collagen dermatologic ophthalmic respiratory gastrointestinal disease allergic edematous state condition like tuberculous meningitis l9542 
Diflunisal,diflunisal salicylate derivative nonsteroidal anti-inflammatory agent nsaia pharmacologic action similar prototypical nsaias diflunisal posse anti-inflammatory analgesic antipyretic activity though mechanism action clearly established action appear associated inhibition prostaglandin synthesis via arachidonic acid pathway diflunisal used relieve pain accompanied inflammation symptomatic treatment rheumatoid arthritis osteoarthritis , symptomatic treatment mild moderate pain accompanied inflammation e.g musculoskeletal trauma post-dental extraction post-episiotomy osteoarthritis rheumatoid arthritis 
Vardenafil,vardenafil levitra oral therapy treatment erectile dysfunction selective inhibitor cyclic guanosine monophosphate cgmp -specific phosphodiesterase type 5 pde5 penile erection hemodynamic process initiated relaxation smooth muscle corpus cavernosum associated arteriole sexual stimulation nitric oxide released nerve ending endothelial cell corpus cavernosum nitric oxide activates enzyme guanylate cyclase resulting increased synthesis cyclic guanosine monophosphate cgmp smooth muscle cell corpus cavernosum cgmp turn trigger smooth muscle relaxation allowing increased blood flow penis resulting erection tissue concentration cgmp regulated rate synthesis degradation via phosphodiesterases pdes abundant pde human corpus cavernosum cgmpspecific phosphodiesterase type 5 pde5 therefore inhibition pde5 enhances erectile function increasing amount cgmp ,used treatment erectile dysfunction
Ranitidine,ranitidine commonly used drug classified histamine h2-receptor antagonist belongs drug class cimetidine famotidine drug help prevent treat gastric-acid associated condition including ulcer ability decrease gastric acid secretion a176759 l10818 ranitidine often referred zantac available various form including tablet injection effervescent tablet preparation l10818 f4253 prevalence gerd thought 10-20 western country a176843 ranitidine proven effective treatment relieving uncomfortable symptom gastric acid associated condition therefore widely used gerd gastric-acid related condition a176849 l10818 , drug used alone concomitant antacid following condition short-term treatment active duodenal ulcer treating gastric acid hypersecretion due zollinger-ellison syndrome systemic mastocytosis condition may pathologically raise gastric acid level also used short term treatment active benign gastric ulcer maintenance therapy gastric ulcer reduced dose addition ranitidine used treatment gerd symptom treatment erosive esophagitis endoscopically diagnosed maintenance gastric duodenal ulcer healing l10818 l10821 
Tacrolimus,tacrolimus also fk-506 fujimycin immunosuppressive drug whose main use organ transplant reduce activity patient 's immune system risk organ rejection also used topical preparation treatment severe atopic dermatitis severe refractory uveitis bone marrow transplant skin condition vitiligo discovered 1984 fermentation broth japanese soil sample contained bacteria streptomyces tsukubaensis tacrolimus chemically known macrolide reduces peptidyl-prolyl isomerase activity binding immunophilin fkbp-12 fk506 binding protein creating new complex fkbp12-fk506 complex inhibits calcineurin inhibits t-lymphocyte signal transduction il-2 transcription ,immediate-release formulation tacrolimus indicated prophylaxis organ rejection adult pediatric patient receiving allogeneic liver kidney heart lung transplant combination immunosuppressant l8162 extended-release formulation tacrolimus indicated prophylaxis organ rejection adult pediatric patient receiving kidney transplant combination immunosuppressant l20034 l41005 may used patient converted immediate-release formulation l41005 topical tacrolimus ointment indicated second-line therapy short-term non-continuous treatment moderate-to-severe atopic dermatitis non-immunocompromised adult child failed respond adequately topical treatment alternative treatment advisable l3935 available strength indicated adult patient lower strength 0.03 formulation indicated pediatric patient 2 15 year age l3935 
Benzphetamine, sympathomimetic agent property similar dextroamphetamine used treatment obesity martindale extra pharmacopoeia 30th ed p1222 , management exogenous obesity short term adjunct week regimen weight reduction based caloric restriction
Alprenolol,one adrenergic beta-antagonists used antihypertensive anti-anginal anti-arrhythmic agent alprenolol longer marketed astrazeneca may still available generic variety , treatment hypertension angina arrhythmia
Ritodrine,adrenergic beta-agonist used control premature labor , treatment prophylaxis premature labour
Benzonatate,benzonatate oral antitussive drug used relief suppression cough patient older ten year age a5790 currently benzonatate non-narcotic antitussive available prescription drug a189519 work reduce activity cough reflex desensitizing tissue lung pleura involved cough reflex benzonatate approved fda 1958 market name tessalon perles a5790 chemical structure resembles anesthetic agent para-amino-benzoic acid class procaine tetracaine benzonatate exhibit anesthetic numbing action l11193 although prone drug misuse abuse benzonatate associated risk severe toxicity overdose especially child a189513 ,benzonatate indicated symptomatic relief cough l11193 
Dorzolamide,dorzolamide non-bacteriostatic sulfonamide derivative a1304 topical carbonic anhydrase ca inhibitor treat elevated intraocular pressure iop associated open-angle glaucoma ocular hypertension l11377 work blocking enzyme ciliary process regulates ion balance fluid pressure eye a1303 unlike oral ca inhibitor dorzolamide negligible effect acid-base electrolyte disturbance systemic adverse effect a1304 first marketed 1995 a190624 dorzolamide available ophthalmic solution monotherapy marketed trusopt l11377 combination timolol cosopt pf l11380 ,dorzolamide indicated management elevated intraocular pressure patient ocular hypertension open-angle glaucoma l11377 also used combination timolol indication patient insufficiently responsive ophthalmic beta-blockers l11380 pre-operative use also investigated prevent elevated intraocular pressure neodynium yttrium aluminum garnet laser posterior capsulotomy a190183 
Suprofen, ibuprofen-type anti-inflammatory analgesic antipyretic inhibits prostaglandin synthesis proposed anti-arthritic longer approved use united state ,used eye drop inhibit miosis pupil constriction may occur ocular surgery 
Terbutaline,terbutaline first synthesized 1966 a230333 described literature late 1960s early 1970s a230328 selective beta-2 adrenergic agonist used bronchodilator asthmatic patient a230333 l32093 l32098 terbutaline granted fda approval 25 march 1974 l32088 ,terbutaline indicated prevention reversal bronchospasm patient least 12 year old asthma reversible bronchospasm associated bronchitis emphysema l32093 l32098 
Conivaptan,conivaptan non-peptide inhibitor antidiuretic hormone vasopressin approved 2004 hyponatremia low blood sodium level caused syndrome inappropriate antidiuretic hormone siadh conivaptan inhibits isotypes vasopressin receptor v1a v2 , treatment euvolemic hypervolemic hyponatremia e.g syndrome inappropriate secretion antidiuretic hormone setting hypothyroidism adrenal insufficiency pulmonary disorder etc hospitalized patient 
Loteprednol etabonate,loteprednol etabonate le topical corticoid anti-inflammatory used ophthalmic solution treatment steroid responsive inflammatory condition eye allergic conjunctivitis uveitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides nasal spray used treatment management seasonal allergic rhinitis prescription le product however tend indicated treatment post-operative inflammation pain following ocular surgery fda label number new formulation approved include kala pharmaceutical 's inveltys first twice-daily bid ocular corticosteroid approved indication designed specifically enhance patient compliance simplified dosing compared similar ocular steroid dosed four time daily l4545 moreover le purposefully engineered 'soft drug one designed active locally site administration rapidly metabolized inactive component eliciting action desired location thereby subsequently minimizing chance adverse effect a38693 , number prescription loteprednol etabonate ophthalmic product specifically indicated treatment post-operative inflammation pain following ocular surgery fda label 
Guaifenesin,guaifenesin posse storied history originally formally approved u fda 1952 continues one perhaps drug readily available used expectorant f4525 since time agent combination component various prescription non-prescription over-the-counter cough cold product currently widely available over-the-counter generic medication f4525 although principally believed guaifenesin elicits action facilitate productive cough manage chest congestion a177661 l6100 f4516 f4522 f4525 known whether agent reliably mitigate coughing regardless march 1 2007 fda received petition asking fda notify public antitussive expectorant decongestant antihistamine cough/cold combination known safe effective child age 6 year f4525 negotiation fda major manufacturer voluntary transition label using guaifenesin child age 4 year endorsed fda 2008 f4525 furthermore also contemporary research suggest guaifenesin posse capable demonstrating anticonvulsant muscle relaxant effect degree possibly acting nmda receptor antagonist a177652 ,guaifenesin expectorant indicated providing temporary symptomatic relief congested chest cough may due cold bronchitis and/or breathing illness fda label f4510 l6079 
Flupentixol,flupentixol antipsychotic drug thioxanthene group exists two geometric isomer trans e pharmacologically active ci z form flupentixol decanoate one active ingredient found injectable drug formulation produced esterification ci z ‐flupentixol decanoic acid a229083 flupentixol antagonist d1 d2 dopamine receptor a229083 available oral tablet long-acting intramuscular injection flupentixol marketed brand name depixol fluanxol approved use canada country around world u used management chronic schizophrenia patient whose main manifestation include excitement agitation hyperactivity l31808 marketed manage symptom depression patient may may exhibit sign anxiety l31928 combination melitracen flupentixol used manage symptom anxiety depression asthenia l31923 ,flupentixol indicated maintenance therapy chronic schizophrenic patient whose main manifestation include excitement agitation hyperactivity l31808 indicated management depression adult patient may may also showing sign anxiety l31928 flupentixol combination melitracen indicated manage symptom anxiety depression asthenia adult l31923 
Eprosartan,eprosartan angiotensin ii receptor antagonist used treat hypertension performs 2 action renin angiotensin system preventing binding angiotensin ii at1 vascular smooth muscle relaxes vasodilation occurs inhibiting norepinephrine production blood pressure reduced , management hypertension alone combination class antihypertensive agent also used first-line agent treatment diabetic nephropathy well second-line agent treatment congestive heart failure intolerant ace inhibitor 
Sirolimus,sirolimus also known rapamycin macrocyclic lactone antibiotic produced bacteria _streptomyces hygroscopicus_ isolated soil vai atari region rapa nui easter island a242412 first isolated identified antifungal agent potent anticandida activity however potent antitumor immunosuppressive activity later discovered extensively investigated immunosuppressive antitumour agent a13448 primary mechanism action inhibition mammalian target rapamycin mtor serine/threonine-specific protein kinase regulates cell growth proliferation survival mtor important therapeutic target various disease shown regulate longevity maintain normal glucose homeostasis a242417 targeting mtor received attention especially cancer mtor signalling pathway constitutively activated many type human cancer a1320 sirolimus first approved fda 1999 prophylaxis organ rejection patient aged 13 year older receiving renal transplant a242372 november 2000 drug recognized european agency alternative calcineurin antagonist maintenance therapy corticosteroid a242412 may 2015 fda approved sirolimus treatment patient lymphangioleiomyomatosis l39292 november 2021 albumin-bound sirolimus intravenous injection approved fda treatment adult locally advanced unresectable metastatic malignant perivascular epithelioid cell tumour pecoma l39267 sirolimus also investigated cancer skin cancer kaposi ’ sarcoma cutaneous t-cell lymphoma tuberous sclerosis a242372 topical formulation sirolimus marketed hyftor approved fda april 2022 mark first topical treatment approved u facial angiofibroma associated tuberous sclerosis complex l41494 ,sirolimus indicated prophylaxis organ rejection patient aged 13 year older receiving renal transplant patient low-to moderate-immunologic risk recommended sirolimus used initially regimen cyclosporine corticosteroid cyclosporine withdrawn two four month transplantation patient high-immunologic risk defined black recipient and/or repeat renal transplant recipient lost previous allograft immunologic reason and/or patient high panel-reactive antibody pra peak pra level 80 recommended sirolimus used combination cyclosporine corticosteroid first year following transplantation l19809 also used treat lymphangioleiomyomatosis l19809 u albumin-bound sirolimus intravenous injection indicated treatment adult patient locally advanced unresectable metastatic malignant perivascular epithelioid cell tumour pecoma l39267 europe recommended sirolimus prophylaxis organ rejection renal transplant used combination cyclosporin microemulsion corticosteroid two three month sirolimus may continued maintenance therapy corticosteroid cyclosporin microemulsion progressively discontinued l7021 topical sirolimus indicated treatment facial angiofibroma associated tuberous sclerosis adult pediatric patient six year age older l41489 
Chlorhexidine,chlorhexidine broad-spectrum antimicrobial biguanide used topical antiseptic dental practice treatment inflammatory dental condition caused microorganism l11512 one common skin mucous membrane antiseptic agent use today a190417 molecule cationic bis-guanide consisting two 4-chlorophenyl ring two biguanide group joined central hexamethylene chain a190453 topical chlorhexidine disinfection well oral rinse dental use carry activity broad range pathogen including bacteria yeast virus l11518 l11512 a190453 chlorhexidine developed uk imperial chemical industry early 1950s a190474 introduced u 1970s l11572 fda withdrew approval use chlorhexidine gluconate topical tincture 0.5 due significant number report concerning chemical thermal burn associated use product l43942 l44027 formulation chlorhexidine continue available ,chlorhexidine available over-the-counter various formulation e.g solution sponge cloth swab topical antiseptic sanitize prior surgery and/or medical procedure l11518 l11521 l11527 l11533 dental formulation available prescription include oral rinse indicated treatment gingivitis l11512 slow-release `` chip '' inserted periodontal pocket indicated reduction pocket depth adult patient periodontitis adjunct therapy dental scaling root planing procedure l11536 
Emtricitabine,emtricitabine nucleoside reverse transcriptase inhibitor nrti indicated treatment hiv infection adult l9019 combined tenofovir alafenamide prevention hiv-1 infection high risk adolescent adult l9010 emtricitabine cytidine analogue l9019 drug work inhibiting hiv reverse transcriptase preventing transcription hiv rna dna l9019 emtricitabine granted fda approval 2 july 2003 l9019 ,emtricitabine indicated combination medication treatment hiv-1 infection l9019 l9836 l44226 treatment hiv-1 infection pediatric patient 25-35kg treatment hiv-1 infection adult patient ≥35kg pre exposure prophylaxis hiv-1 adolescent adult patient excluding receptive vaginal sex l4388 l9010 treatment hiv-1 infection pediatric adult patient ≥17kg pre exposure prophylaxis adolescent adult ≥35kg l9833 treatment hiv-1 patient ≥12 year ≥35kg l9587 treatment hiv-1 patient weighing ≥35kg l9839 l9842 treatment hiv-1 patient weighing ≥25kg l9647 l9845 treatment hiv-1 patient weighing ≥40kg l9848 
Chlorothiazide, thiazide diuretic action us similar hydrochlorothiazide martindale extra pharmacopoeia 30th ed p812 ,chlorothiazide indicated adjunctive therapy edema associated congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy also indicated management hypertension either sole therapeutic agent enhance effectiveness antihypertensive drug severe form hypertension 
Quinapril,quinapril ethyl ester prodrug non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat l8420 l8423 used treat hypertension heart failure l8420 l8423 ace inhibitor commonly used first line therapy treatment hypertension along thiazide diuretic beta blocker a184844 quinapril granted fda approval 19 november 1991 l8420 combination tablet hydrochlorothiazide also approved 28 december 1999 l8423 ,quinapril indicated treatment hypertension adjunct therapy treatment heart failure l8420 quinapril combination hydrochlorothiazide indicated treatment hypertension l8423 
Clomifene, triphenyl ethylene stilbene derivative estrogen agonist antagonist depending target tissue ,used mainly female infertility due anovulation e.g due polycystic ovary syndrome induce ovulation 
Isosorbide dinitrate, vasodilator used treatment angina pectoris action similar nitroglycerin slower onset action , prevention angina pectoris due coronary artery disease 
Risedronic acid,risedronic acid third generation bisphosphonate used treatment form osteoperosis paget 's disease fda label a959 a203111 function preventing resorption bone fda label a959 ,risedronic acid indicated treatment osteoperosis men treatment paget 's disease treatment prevention osteoperosis postmenopausal woman treatment prevention glucocorticoid-induced osteoperosis fda label 
Pemirolast,pemirolast potassium slightly yellow powder soluble water mast cell stabilizer act antiallergic agent ophthalmic aqueous sterile solution pemirolast used prevention itching eye caused allergy hay fever allergic conjunctivitis pemirolast potentially useful prophylaxis pulmonary hypersensitivity reaction drug paclitaxel , prevention itching eye caused allergy hay fever allergic conjunctivitis
Omapatrilat,omapatrilat investigational drug inhibits neutral endopeptidase nep angiotensin converting enzyme ace inhibition nep elevates natriuretic peptide level increasing excretion sodium urine dilating blood vessel reducing preload ventricular remodeling drug bm approved fda due angioedema safety concern , treatment hypertension 
Bumetanide,bumetanide sulfamyl diuretic , treatment edema associated congestive heart failure hepatic renal disease including nephrotic syndrome 
Mechlorethamine, vesicant necrotizing irritant destructive mucous membrane mechlorethamine alkylating drug formerly used war gas hydrochloride used antineoplastic hodgkin 's disease lymphoma cause severe gastrointestinal bone marrow damage fda granted marketing approval orphan drug valchlor mechlorethamine gel august 23 2013 topical treatment stage ia ib mycosis fungoides-type cutaneous t-cell lymphoma ctcl patient received prior skin-directed therapy tube valchlor contains 0.016 mechlorethamine equivalent 0.02 mechlorethamine hcl , palliative treatment hodgkin 's disease stage iii iv lymphosarcoma chronic myelocytic chronic lymphocytic leukemia polycythemia vera mycosis fungoides bronchogenic carcinoma also palliative treatment metastatic carcinoma resulting effusion 
Granisetron, serotonin receptor 5ht-3 selective antagonist used antiemetic antinauseant cancer chemotherapy patient , prevention nausea vomiting associated initial repeat course emetogenic cancer therapy including high dose cisplatin postoperation radiation including total body irradiation daily fractionated abdominal radiation 
Dienestrol,dienestrol synthetic non-steroidal estrogen estrogen receptor agonist estrogen work partly increasing normal clear discharge vagina making vulva urethra healthy using applying estrogen relief lessens dryness soreness vagina itching redness soreness vulva condition treated vaginal estrogen include genital skin condition vulvar atrophy inflammation vagina atrophic vaginitis inflammation urethra atrophic urethritis , use treatment atrophic vaginitis kraurosis vulva 
Sulfapyridine,antibacterial potentially toxic previously used treat certain skin disease longer prescribed , treatment dermatitis herpetiformis benign mucous membrane pemphigoid pyoderma gangrenosum
Oxybuprocaine,oxybuprocaine also known benoxinate local anesthetic used especially ophthalmology otolaryngology oxybuprocaine bind sodium channel reversibly stabilizes neuronal membrane decrease permeability sodium ion ,used temporarily numb front surface eye eye pressure measured foreign body removed 
Iron Dextran,iron dextran dark brown slightly viscous liquid complex ferric hydroxide dextran intravenous intramuscular use iron dextran used treatment patient documented iron deficiency oral administration unsatisfactory impossible , treatment patient documented iron deficiency oral administration unsatisfactory impossible also used replenish body iron store non-dialysis dependent-chronic kidney disease ndd-ckd patient receiving receiving erythropoietin hemodialysis dependent hdd-ckd peritoneal dialysis dependent pdd-ckd chronic kidney disease patient receiving erythropoietin 
Testolactone, antineoplastic agent derivative progesterone used treat advanced breast cancer , palliative treatment advanced breast cancer postmenopausal woman 
Benzylpenicilloyl polylysine,benzylpenicilloyl polylysine used skin-testing reagent detect immunoglobulin e antibody people history penicillin allergy quantitation vitro ige antibody benzylpenicilloyl determinant useful tool evaluating allergic subject , use adjunct assessing risk administering penicillin benzylpenicillin penicillin g 
Rimexolone,rimexolone 1 eye drop solution glucocorticoid steroid used treat inflammation eye marketed vexol , treatment postoperative inflammation following ocular surgery treatment anterior uveitis 
Triazolam,withdrawn united kingdom due risk psychiatric adverse drug reaction drug continues available u.s internationally triazolam schedule iv drug convention psychotropic substance , short-term treatment insomnia 
Ethanol, clear colorless liquid rapidly absorbed gastrointestinal tract distributed throughout body bactericidal activity used often topical disinfectant widely used solvent preservative pharmaceutical preparation well serving primary ingredient alcoholic beverage , therapeutic neurolysis nerve ganglion relief intractable chronic pain condition inoperable cancer trigeminal neuralgia tic douloureux patient neurosurgical procedure contraindicated 
Remifentanil,remifentanil marketed abbott ultiva potent ultra short-acting synthetic opioid given patient surgery pain relief adjunctive anaesthetic remifentanil specific mu-type-opioid receptor agonist mean reduces sympathetic nervous system tone cause respiratory depression analgesia , use induction maintenance general anesthesia 
Didanosine, dideoxynucleoside compound 3 39 -hydroxy group sugar moiety replaced hydrogen modification prevents formation phosphodiester linkage needed completion nucleic acid chain didanosine potent inhibitor hiv replication acting chain-terminator viral dna binding reverse transcriptase ddi metabolized dideoxyadenosine triphosphate putative active metabolite , use combination antiretroviral agent treatment hiv-1 infection adult 
Bitolterol,bitolterol mesylate used treat bronchospasm asthma copd beta-2-adrenergic receptor agonist bitolterol withdrawn market elan pharmaceutical 2001 ,used dilate air passage lung become narrowed result disease inflammation used treatment asthma chronic obstructive pulmonary disease copd 
Methdilazine,methdilazine phenothiazine compound antihistaminic activity used treatment various dermatosis relieve pruritus ,used symptomatic relief hypersensitivity reaction particularly control pruritic skin disorder
Etacrynic acid, compound inhibits symport sodium potassium chloride primarily ascending limb henle also proximal distal tubule pharmacological action result excretion ion increased urinary output reduction extracellular fluid compound classified loop high ceiling diuretic , treatment high blood pressure edema caused disease like congestive heart failure liver failure kidney failure 
Ondansetron, competitive serotonin type 3 receptor antagonist effective treatment nausea vomiting caused cytotoxic chemotherapy drug including cisplatin reported anxiolytic neuroleptic property developed 1980s glaxosmithkline approved u fda since january 1991 ondansetron demonstrated long history use efficacy commonly formulated oral tablet orally disintegrating tablet odt injection available generic product well ondansetron continues see contemporary innovation formulation use including development orally soluble film discreet administration le burden comparison patient attempt swallow pill emesis l5221 fda withdrew approval use intravenous drug product containing 16 mg ondansetron hydrochloride single dose due high risk qt prolongation l44067 l43942 , adult patient population orally administered ondansetron tablet orally disintegrating tablet odt indicated prevention nausea vomiting associated emetogenic cancer chemotherapy including high dose ie greater equal 50 mg/m2 cisplatin therapy radiotherapy prevention treatment postoperative nausea vomiting ii intravenously administered ondansetron injection formulation indicated prevention nausea vomiting associated emetogenic cancer chemotherapy including high dose ie greater equal 50 mg/m2 cisplatin therapy prevention treatment postoperative nausea vomiting pediatric 4-18 year age patient population ondansetron effective well tolerated given child 4-12 year age treatment post-chemotherapy induced nausea vomiting ii ondansetron tablet ondansetron odt ondansetron injection indicated treatment child 3 year age younger iii ondansetron tablet ondansetron odt ondansetron injection indicated use age group pediatric population treatment post-radiotherapy induced nausea vomiting iv ondansetron tablet ondansetron odt ondansetron injection indicated use age group pediatric population treatment postoperative nausea vomiting geriatric 65 year age patient population efficacy tolerance ondansetron similar observed younger adult treatment post-chemotherapy radiotherapy-induced nausea vomiting ii clinical experience use ondansetron prevention treatment postoperative nausea vomiting limited indicated use geriatric patient population
Bimatoprost,bimatoprost also known latisse lumigan belongs group drug called prostamides synthetic structural analog prostaglandin bimatoprost marketed allergan administered ophthalmic solution implant form ability reduce ocular hypotension proving effective condition ocular hypertension glaucoma l6877 l6892 l6898 l12069 bimatoprost also used treat eyelash hypotrichosis sparse eyelash growth l6910 initially approved fda 2001 ocular hypertension later approved hypothrichosis 2008 eyelash growth became desirable adverse effect patient using drug l4894 ,bimatoprost used reduction elevated intraocular pressure patient open-angle glaucoma ocular hypertension patient must intolerant intraocular pressure lowering medication inadequately responsive treatment l6877 bimatoprost also indicated treat eyelash hypotrichosis l6910 
Tiagabine,tiagabine anti-convulsive medication also used treatment panic disorder anticonvulsant though exact mechanism tiagabine exerts effect human body unknown appear operate selective gaba reuptake inhibitor , treatment partial seizure
Cocaine, alkaloid ester extracted leaf plant including coca local anesthetic vasoconstrictor clinically used purpose particularly eye ear nose throat also powerful central nervous system effect similar amphetamine drug abuse cocaine like amphetamine act multiple mechanism brain catecholaminergic neuron mechanism reinforcing effect thought involve inhibition dopamine uptake , introduction local topical anesthesia accessible mucous membrane oral laryngeal nasal cavity 
Quinidine,quinidine d-isomer quinine present bark cinchona tree similar plant specie alkaloid first described 1848 long history antiarrhythmic medication a38016 a250050 quinidine considered first antiarrhythmic drug class ia moderately efficacious acute conversion atrial fibrillation normal sinus rhythm a38016 prolongs cellular action potential blocking sodium potassium current phenomenon known “ quinidine syncope ” first described 1950s characterized syncopal attack ventricular fibrillation patient treated drug a38016 due side effect increased risk mortality use quinidine reduced next decade however continues used treatment brugada syndrome short qt syndrome idiopathic ventricular fibrillation a250050 ,quinidine indicated management prophylactic therapy atrial fibrillation/flutter well suppression recurrent documented ventricular arrhythmia l42420 l3719 also used treatment brugada syndrome short qt syndrome idiopathic ventricular fibrillation a250050 a250055 
Zonisamide,zonisamide sulfonamide anticonvulsant used adjunctive therapy adult partial-onset seizure l42530 l42535 zonisamide may act blocking repetitive firing voltage-gated sodium channel leading reduction t-type calcium channel current binding allosterically gaba receptor latter action may inhibit uptake inhibitory neurotransmitter gaba enhancing uptake excitatory neurotransmitter glutamate l42530 l42535 zonisamide represents alternative patient remain refractory established antiepileptic drug 1989 approved commercial use japan u europe approved 2000 2005 respectively a1379 a1383 ,zonisamide capsule indicated adjunctive therapy treatment partial seizure adult epilepsy l42530 zonisamide oral suspension indicated adjunctive therapy treatment partial-onset seizure adult pediatric patient 16 year age older l42535 
Paricalcitol,paricalcitol synthetic vitamin analog paricalcitol used reduce parathyroid hormone level paricalcitol indicated prevention treatment secondary hyperparathyroidism associated chronic renal failure , treatment secondary hyperparathyroidism associated chronic kidney disease ckd stage 3 4
Tinidazole, nitroimidazole antitrichomonal agent effective _trichomonas vaginalis_ _entamoeba histolytica_ _giardia lamblia_ infection , treatment trichomoniasis caused vaginalis /i female male patient also treatment giardiasis caused g duodenalis /i adult pediatric patient older three year age treatment intestinal amebiasis amebic liver abscess caused e histolytica /i adult pediatric patient older three year age 
Repaglinide,repaglinide oral antihyperglycemic agent used treatment non-insulin-dependent diabetes mellitus niddm belongs meglitinide class short-acting insulin secretagogues act binding β cell pancreas stimulate insulin release repaglinide induces early insulin response meal decreasing postprandial blood glucose level taken meal meal-time dos skipped skipped meal approximately one month therapy required decrease fasting blood glucose seen meglitnides may neutral effect weight cause slight increase weight average weight gain caused meglitinides appears lower caused sulfonylurea insulin appears occur naïve oral antidiabetic agent due mechanism action meglitinides may cause hypoglycemia although risk thought lower sulfonylurea since action dependent presence glucose addition reducing postprandial fasting blood glucose meglitnides shown decrease glycosylated hemoglobin hba1c level reflective last 8-10 week glucose control meglitinides appear effective lowering postprandial blood glucose metformin sulfonylurea thiazolidinediones repaglinide extensively metabolized liver excreted bile repaglinide metabolite posse appreciable hypoglycemic activity approximately 90 single orally administered dose eliminated feces 8 urine , adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus 
Anileridine,anileridine synthetic opioid strong analgesic medication narcotic pain reliever used treat moderate severe pain narcotic analgesic act central nervous system cns relieve pain side effect also caused action cns , treatment management pain systemic use anesthesia adjunct 
Phenformin, biguanide hypoglycemic agent action us similar metformin although generally considered associated unacceptably high incidence lactic acidosis often fatal still available country martindale extra pharmacopoeia 30th ed p290 , reatment type ii diabetes mellitus 
Amantadine, antiviral used prophylactic symptomatic treatment influenza also used antiparkinsonian agent treat extrapyramidal reaction postherpetic neuralgia mechanism effect movement disorder well understood probably reflect increase synthesis release dopamine perhaps inhibition dopamine uptake , chemoprophylaxis prophylaxis treatment sign symptom infection caused various strain influenza virus also treatment parkinsonism drug-induced extrapyramidal reaction 
Metronidazole,metronidazole commonly used antibiotic belonging nitroimidazole class antibiotic l3754 frequently used treat gastrointestinal infection well trichomoniasis giardiasis amebiasis parasitic infection a181036 a181039 metronidazole used antibiotic several decade l7429 added antiparasitic property set apart many antibacterial drug allowing treat wide variety infection available capsule form tablet form topical form suppository preparation treatment various infection ,metronidazole indicated treatment confirmed trichomoniasis caused trichomonas vaginalis except first trimester pregnancy patient 's sexual partner bacterial vaginosis l7432 certain type amebiasis various anaerobic infection a181057 anaerobic infection may occur skin skin structure abdomen heart reproductive organ central nervous system respiratory system may also present bloodstream case septicemia common infection treated metronidazole bacteroides specie infection clostridium infection fusobacterium infection well peptococcus peptostreptococcus infection l3754 also used off-label treatment crohn 's disease rosacea prophylactic agent surgery a181039 treatment helicobacter pylorus infection a181045 also studied prevention preterm birth treat periodontal disease a1391 a181078 
Dinoprostone,dinoprostone naturally occurring prostaglandin e2 pge2 important effect labour also stimulates osteoblast release factor stimualtes bone resorption osteoclast prescription drug used vaginal suppository prepare cervix labour induce labour , termination pregnancy second trimester 12th 20th gestational week calculated first day last normal menstrual period well evacuation uterine content management missed abortion intrauterine fetal death 28 week gestational age calculated first day last normal menstrual period also used management nonmetastatic gestational trophoblastic disease benign hydatidiform mole indication include improving cervical inducibility cervical `` ripening '' pregnant woman near term medical obstetrical need labor induction management postpartum hemorrhage 
Almotriptan,almotriptan triptan drug treatment migraine headache almotriptan class medication called selective serotonin receptor agonist work narrowing blood vessel brain stopping pain signal sent brain stopping release certain natural substance cause pain nausea symptom migraine almotriptan prevent migraine attack , treatment acute migraine headache adult
Spectinomycin, antibiotic produced streptomyces spectabilis active gram-negative bacteria used treatment gonorrhea , use treatment acute gonorrheal urethritis proctitis male acute gonorrheal cervicitis proctitis female due susceptible strain neisseria gonorrhoeae /i 
Ketotifen,ketotifen benzocycloheptathiophene derivative a231204 potent antihistaminic mast cell stabilizing property similar structure first-generation antihistamine cyproheptadine azatadine a231204 ketotifen first developed switzerland 1970 sandoz pharmaceutical initially marketed treatment anaphylaxis a231204 u used over-the-counter ophthalmic formulation treatment itchy eye associated allergy l32278 canada prescription-only oral formulation available indicated add-on therapy child atopic asthma l32283 addition oral ketotifen used mexico across europe treatment various allergic symptom disorder a231204 including urticaria mastocytosis food allergy ,administered orally ketotifen indicated add-on medication chronic treatment mild atopic asthma child l32283 also available over-the-counter ophthalmic solution indicated temporary prevention itching eye due allergic conjunctivitis l32278 
Buprenorphine,buprenorphine weak partial mu-opioid receptor agonist weak kappa-opioid receptor antagonist used treatment severe pain a186283 a186292 also commonly used alternative methadone treatment severe opioid addiction f4715 f4718 buprenorphine commercially available brand name product suboxone formulated 4:1 fixed-dose combination product along naloxone non-selective competitive opioid receptor antagonist combination naloxone intended reduce abuse potential suboxone naloxone poorly absorbed oral route effect taken orally would reverse opioid agonist effect buprenorphine injected intravenously a186289 f4715 f4718 buprenorphine poor gastrointestinal absorption therefore formulated sublingual tablet buprenorphine number unique pharmacokinetic pharmacodynamic property make preferred agent treatment condition requiring high dos strong opioids a186286 example buprenorphine dissociates opioid receptor slowly resulting long duration action relief pain withdrawal symptom upwards 24-36 hour use once-daily buprenorphine may benefit individual developed tolerance potent opioids require larger frequent dos buprenorphine may also preferred agent methadone also commonly used treat severe pain opioid use disorder le effect qtc interval prolongation a186271 a186274 fewer drug interaction reduced risk sexual side effect a186298 improved safety profile lower risk overdose respiratory depression a186263 a186266 a186269 buprenorphine act partial mu-opioid receptor agonist high affinity receptor lower intrinsic activity compared full mu-opioid agonist heroin oxycodone methadone a186292 mean buprenorphine preferentially bind opioid receptor displaces lower affinity opioids without activating receptor comparable degree clinically result slow onset action clinical phenomenon known `` ceiling effect '' certain dose reached buprenorphine 's effect plateau effect beneficial however dose-related side effect respiratory depression sedation intoxication also plateau around 32mg resulting lower risk overdose compared methadone full agonist opioids a186215 a186218 also mean opioid-dependent patient experience sedation euphoria rate might experience potent opioids improving quality life patient severe pain reducing reinforcing effect opioids lead drug-seeking behaviour a186280 treatment opioid addiction buprenorphine methadone slow-release oral morphine srom termed opioid agonist treatment oat opioid substitution therapy ost intention substitution illicit opioids long-acting opioids used oat prevent withdrawal symptomns 24-36 hour following dosing ultimately reduce craving drug-seeking behaviour use oat also intended improved social stabilization including reduction crime rate marginalization incarceration use illicit substance heroin fentanyl illegally purchased opioids often injected may laced substance increase risk harm overdose provision oat often combined education harm reduction including use clean needle injection supply effort reduce risk associated injection drug use includes contraction hiv hepatitis c complication including skin infection abscess endocarditis a186295 ,buprenorphine indicated management pain severe enough require opioid analgesic alternative treatment inadequate buprenorphine also used combination naloxone fixed-dose combination product treatment moderate severe opioid use disorder f4715 f4718 
Levosimendan,levosimendan increase calcium sensitivity myocytes binding troponin c calcium dependent manner increase contractility without raising calcium level also relaxes vascular smooth muscle opening adenosine triphosphate sensitive potassium channel levosimendan used manage acutely decompensated congestive heart failure , short term treatment acutely decompensated severe chronic heart failure chf also investigated use/treatment heart disease 
Ceforanide,ceforanide administered parenterally longer elimination half-life currently available cephalosporin activity similar cefamandole another second-generation cephalosporin antibiotic except ceforanide le active gram-positive organism many coliforms including escherichia coli klebsiella enterobacter proteus susceptible ceforanide strain salmonella shigella hemophilus citrobacter arizona specie , treatment infection caused susceptible organism 
Cyclobenzaprine,cyclobenzaprine centrally-acting muscle relaxant first synthesized 1961 a185039 available human use since 1977 a184982 initially studied use antidepressant given structural similarity tricyclic antidepressant differs amitriptyline single double bond a185039 a184982 since approval remained relatively popular adjunctive short-term treatment acute skeletal muscle spasm secondary musculoskeletal injury ,cyclobenzaprine indicated short-term 2-3 week adjunct therapy along rest physical therapy relief muscle spasm associated acute painful musculoskeletal condition found effective treatment spasticity originating cerebral spinal cord disease spasticity child cerebral palsy l8408 l8411 cyclobenzaprine also occasionally used off-label reducing pain sleep disturbance patient fibromyalgia a184946 
Phenoxybenzamine, alpha-adrenergic antagonist long duration action used treat hypertension peripheral vasodilator , treatment phaeochromocytoma malignant benign prostatic hypertrophy malignant essential hypertension 
Etretinate,etretinate medication used treat severe psoriasis synthetic aromatic retinoid mechanism action etretinate still incompletely understood although like retinoic acid thought interfere terminal differentiation keratinocytes thought bind retinoic acid receptor etretinate also believed enhance binding camp regulatory ri subunit camp dependent protein kinase etretinate taken market canada 1996 america 1998 due risk birth defect etretinate used treat t-cell lymphoma also appears inhibit nadh oxidase activity , treatment severe psoriasis adult 
Famotidine,famotidine competitive histamine-2 h sub 2 /sub receptor antagonist work inhibit gastric acid secretion commonly used gastrointestinal condition related acid secretion gastric ulcer gastroesophageal reflux disease gerd adult child l11166 compared h sub 2 /sub receptor antagonist famotidine display high selectivity towards receptor study consisting healthy volunteer patient acid hypersecretory disease famotidine 20 50 time potent inhibiting gastric acid secretion cimetidine eight time potent ranitidine weight basis a189462 famotidine used various over-the-counter off-label us l11166 oral formulation famotidine commonly used intravenous solution drug available use hospital setting l11142 ,famotidine indicated pediatric adult patient bodyweight 40 kg management active duodenal ulcer du active gastric ulcer symptomatic non-erosive gastroesophageal reflux disease gerd erosive esophagitis due gerd diagnosed biopsy l11139 also indicated adult patient treatment pathological hypersecretory condition e.g. zollinger-ellison syndrome multiple endocrine neoplasia reduction risk du recurrence l11139 intravenous formulation famotidine available hospitalized patient pathological hypersecretory condition intractable ulcer alternative oral dosage form short-term use patient unable take oral medication l11142 over-the-counter famotidine used management prevention heartburn caused gastroesophageal reflux child adult off-label us famotidine include reduction nsaids-associated gastrointestinal effect treatment refractory urticarial prevention stress ulcer critically-ill patient symptomatic relief gastritis l11166 l11172 
Azacitidine, pyrimidine nucleoside analogue inhibits dna methyltransferase impairing dna methylation also antimetabolite cytidine incorporated primarily rna azacytidine used antineoplastic agent , treatment patient following french-american-british myelodysplastic syndrome subtypes refractory anemia refractory anemia ringed sideroblast accompanied neutropenia thrombocytopenia requiring transfusion refractory anemia excess blast refractory anemia excess blast transformation classified acute myelogenous leukemia multilineage dysplasia chronic myelomonocytic leukemia 
Misoprostol,misoprostol prostaglandin analog used reduce risk nsaid related ulcer manage miscarriage prevent post partum hemorrhage also first trimester abortion l7616 l7619 a181589 a181583 a181697 stimulation prostaglandin receptor stomach reduces gastric acid secretion stimulating receptor uterus cervix increase strength frequency contraction decrease cervical tone a181586 misoprostol granted fda approval 27 december 1988 l7616 ,misoprostol indicated tablet reduce risk nsaid induced gastric ulcer duodenal ulcer high risk patient l7616 misoprostol also formulated combination diclofenac treat symptom osteoarthritis rheumatoid arthritis patient high risk developing gastric ulcer l7619 misoprostol used label management miscarriage prevention post partum hemorrhage also used alone combination mifepristone country first trimester abortion a181589 a181583 a181697 
Colesevelam,colesevelam bile acid sequestrant colesevelam used exercise diet change restriction cholesterol fat intake reduce amount cholesterol certain fatty substance blood work binding bile acid intestine bile acid made cholesterol broken body removing bile acid help lower blood cholesterol , use alone combination hmg-coa reductase inhibitor adjunctive therapy diet exercise reduction elevated ldl cholesterol patient primary hypercholesterolemia fredrickson type iia 
Metacycline, broad-spectrum semisynthetic antibiotic related tetracycline excreted slowly maintaining effective blood level extended period , treatment acute bacterial exacerbation chronic bronchitis
Tipranavir,tipranavir sulfonamide-containing dyhydropyrone nonpeptidic protease inhibitor target hiv protease tipranavir ritonavir coadministered treat hiv , combination antiretroviral treatment hiv-1 infected adult patient evidence viral replication highly treatment-experienced hiv-1 strain resistant multiple protease inhibitor 
Mesoridazine, phenothiazine antipsychotic effect similar chlorpromazine ,used treatment schizophrenia organic brain disorder alcoholism psychoneurosis 
Maprotiline,maprotiline tetracyclic antidepressant similar pharmacological property tricyclic antidepressant tcas similar tcas maprotiline inhibits neuronal norepinephrine reuptake posse anticholinergic activity affect monoamine oxidase activity differs tcas appear block serotonin reuptake maprotiline may used treat depressive affective disorder including dysthymic disorder depressive neurosis major depressive disorder maprotiline effective reducing symptom anxiety associated depression , treatment depression including depressed phase bipolar depression psychotic depression involutional melancholia may also helpful treating certain patient suffering severe depressive neurosis 
Oxymetazoline,oxymetazoline imidazole derivative potent direct-acting alpha α -adrenergic agonist affinity α sub 1 /sub α sub 2 /sub -adrenoceptors a215542 oxymetazoline available various formulation wide variety clinical implication topical formulation drug used treat persistent facial redness adult l15062 effective decongestant oxymetazoline available over-the-counter intranasal spray used relieve nasal sinus congestion caused wide variety condition common cold hay fever upper respiratory allergy a215587 l15092 dentistry oxymetazoline tetracaine combination intranasal spray kovanaze used regional anesthesia dental procedure child adult l15057 july 2020 fda approved use ophthalmic formulation oxymetazoline upneeq adult acquired blepharoptosis ptosis making first fda-approved medical treatment medical condition l15042 l15067 ,oxymetazoline indicated topical treatment persistent facial erythema associated rosacea adult l15062 ophthalmic oxymetazoline indicated treatment acquired blepharoptosis adult l15067 used combination tetracaine intranasally oxymetazoline indicated regional anesthesia performing restorative procedure teeth 4-13 a-j adult child weigh 40 kg l15057 oxymetazoline found over-the-counter nasal product nasal decongestant l15092 off-label us oxymetazoline used nasal intubation ear nose throat surgery improve visualization airway minimize post-operative bleeding a215542 
Salicylic acid, compound obtained bark white willow wintergreen leaf also prepared synthetically bacteriostatic fungicidal keratolytic action salt salicylate used analgesic ,key additive many skin-care product treatment acne psoriasis callouses corn keratosis pilaris wart 
Diethylpropion, appetite depressant considered produce le central nervous system disturbance drug therapeutic category also considered among safest patient hypertension ama drug evaluation annual 1994 p2290 ,used management exogenous obesity short-term adjunct week regimen weight reduction based caloric restriction 
Salmeterol,salmeterol long-acting beta-2 adrenergic receptor agonist drug currently prescribed treatment asthma chronic obstructive pulmonary disease copd l11545 l11548 l11551 l11554 l11557 longer duration action short-acting beta-2 adrenergic receptor agonist salbutamol a190459 salmeterol first described literature 1988 a190477 salmeterol 's structure similar salbutamol 's aralkyloxy-alkyl substitution amine a183737 salmeterol granted fda approval 4 february 1994 l11542 ,salmeterol indicated treatment asthma inhaled corticosteroid prevention exercise induced bronchospasm maintenance airflow obstruction prevention exacerbation chronic obstructive pulmonary disease l11545 l11548 l11551 l11554 l11557 
Meclofenamic acid, non-steroidal anti-inflammatory agent antipyretic antigranulation activity also inhibits prostaglandin biosynthesis , relief mild moderate pain treatment primary dysmenorrhea treatment idiopathic heavy menstrual blood loss also relief sign symptom acute chronic rheumatoid arthritis osteoarthritis 
Methantheline,methantheline synthetic antispasmodic antispasmodic used relieve cramp spasm stomach intestine bladder methantheline used treat intestine stomach ulcer peptic ulcer disease intestine problem irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm urinary problem reflex neurogenic bladder child , treatment peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm reflex neurogenic bladder child 
Hexafluronium,hexafluronium bromide neuromuscular blocking agent used anesthesiology prolong potentiate skeletal muscle relaxing action suxamethonium surgery known bind block activity plasma cholinesterase ,used adjunct succinylcholine suxamethonium chloride prolong muscle relaxation prevent succinylcholine-induced muscle fasciculation 
Cycrimine,cycrimine drug used reduce level acetylcholine return balance dopamine treatment management parkinson 's disease , treatment management parkinson 's disease 
Zalcitabine, dideoxynucleoside compound 3'-hydroxyl group sugar moiety replaced hydrogen modification prevents formation 5 3 phosphodiester linkage needed elongation dna chain thus resulting termination viral dna growth compound potent inhibitor hiv replication low concentration acting chain-terminator viral dna binding reverse transcriptase principal toxic side effect axonal degeneration resulting peripheral neuropathy , treatment human immunovirus hiv infection conjunction antiviral 
Demecarium,demecarium indirect-acting parasympathomimetic agent used treat glaucoma cholinesterase inhibitor anticholinesterase cholinesterase inhibitor prolong effect acetylcholine released neuroeffector junction parasympathetic postganglion nerve inactivating cholinesterase break demecarium inactivates pseudocholinesterase acetylcholinesterase eye cause constriction iris sphincter muscle causing miosis ciliary muscle outflow aqueous humor facilitated lead reduction intraocular pressure , topical treatment chronic open-angle glaucoma 
Acetylsalicylic acid,also known _aspirin_ acetylsalicylic acid asa commonly used drug treatment pain fever due various cause acetylsalicylic acid anti-inflammatory antipyretic effect drug also inhibits platelet aggregation used prevention blood clot stroke myocardial infarction mi fda label interestingly result various study demonstrated long-term use acetylsalicylic acid may decrease risk various cancer including colorectal esophageal breast lung prostate liver skin cancer a177325 aspirin classified _non-selective cyclooxygenase cox inhibitor_ a32682 a177268 available many dos form including chewable tablet suppository extended release formulation others l5968 acetylsalicylic acid common cause accidental poisoning young child kept reach young child toddler infant fda label , pain fever inflammation acetylsalicylic acid asa regular tablet form immediate-release indicated relieve pain fever inflammation associated many condition including flu common cold neck back pain dysmenorrhea headache tooth pain sprain fracture myositis neuralgia synovitis arthritis bursitis burn various injury also used symptomatic pain relief surgical dental procedure fda label _extra strength_ formulation acetylsalicylic acid also indicated management migraine pain photophobia sensitivity light phonophobia sensitivity sound fda label indication asa also indicated various purpose due ability inhibit platelet aggregation include reducing risk cardiovascular death suspected case myocardial infarction mi fda label reducing risk first non-fatal myocardial infarction patient reducing risk morbidity mortality case unstable angina prior myocardial infarction fda label reducing risk transient ischemic attack tia prevent atherothrombotic cerebral infarction conjunction treatment fda label prevention thromboembolism hip replacement surgery fda label decreasing platelet platelet adhesion following carotid endarterectomy aiding prevention transient ischemic attack tia fda label used patient undergoing hemodialysis silicone rubber arteriovenous cannula inserted prevent thrombosis insertion site fda label important note regarding use extended-release formulation f4405 setting acute myocardial infarction percutaneous intervention extended-release form acetylsalicylic acid used use immediate-release formulation scenario requiring rapid onset action label f4405 extended-release form taken decrease incidence mortality myocardial infarction mi individual diagnosed chronic coronary artery disease cad including patient previous myocardial infarction mi unstable angina chronic stable angina additionally extended-release form used decrease risk death recurrent episode stroke patient history stroke tia f4405 
Phenprocoumon,coumarin derivative act long-acting oral anticoagulant ,used prevention treatment thromboembolic disease including venous thrombosis thromboembolism pulmonary embolism well prevention ischemic stroke patient atrial fibrillation af 
Fulvestrant,fulvestrant drug treatment hormone receptor hr -positive metastatic breast cancer post-menopausal woman disease progression following anti-estrogen therapy estrogen receptor antagonist agonist effect work down-regulating degrading estrogen receptor used monotherapy treatment breast cancer also used combination alpelisib treatment hr-positive human epidermal growth factor receptor 2 her2 -negative pik3ca-mutated advanced metastatic breast cancer, treatment hormone receptor positive metastatic breast cancer postmenopausal woman disease progression following anti-estrogen therapy monotherapy combination antineoplastic agent 
Mezlocillin,semisynthetic ampicillin-derived acylureido penicillin proposed infection certain anaerobe may useful inner ear bile cns infection ,used treat serious gram ndash negative infection lung urinary tract skin 
Felbamate,felbamate anticonvulsant drug used treatment epilepsy particular adult patient population employed treat partial seizure without generalization alternatively used treat partial generalized seizure associated lennox-gastaut syndrome child weak inhibitory effect gaba receptor binding site , use patient respond inadequately alternative treatment whose epilepsy severe substantial risk aplastic anemia and/or liver failure deemed acceptable light benefit conferred use 
Fexofenadine,fexofenadine over-the-counter second-generation antihistamine used treatment various allergic symptom l4269 selective h sub 1 /sub receptor carry little-to-no activity off-targets cross blood-brain barrier l10779 contrast previous first-generation antihistamine diphenhydramine readily bind off-targets contribute side effect sedation a1452 fexofenadine major active metabolite terfenadine a1495 administered racemic mixture enantiomer display approximately equivalent antihistamine activity l10779 , united state fexofenadine indicated symptomatic treatment allergic rhinitis patient ≥2 year old chronic idiopathic urticaria patient ≥6 month old l4269 canada fexofenadine carry indication approved patient ≥12 year old l10779 fexofenadine also available combination pseudoephedrine symptomatic treatment season allergic rhinitis patient ≥12 year old l10800 
Isoniazid,antibacterial agent used primarily tuberculostatic remains treatment choice tuberculosis , treatment form tuberculosis organism susceptible 
Naratriptan,naratriptan triptan drug selective 5-hydroxytryptamine1 receptor subtype typically used treatment migraine headache , acute treatment migraine attack without aura adult 
Rizatriptan,rizatriptan triptan drug used treatment migraine headache selective 5-hydroxytryptamine1 receptor subtype agonist , treatment acute migraine attack without aura 
Dirithromycin,dirithromycin macrolide glycopeptide antibiotic used treat many different type bacterial infection bronchitis pneumonia tonsillitis even skin infection , treatment following mild-to-moderate infection caused susceptible strain microorganism acute bacterial exacerbation chronic bronchitis secondary bacterial infection acute bronchitis community-acquired pneumonia pharyngitis/tonsilitis uncomplicated skin skin structure infection 
Netilmicin,netilmicin semisynthetic 1-n-ethyl derivative sisomycin aminoglycoside antibiotic action similar gentamicin le ear kidney toxicity netilmicin inhibits protein synthesis susceptible organism binding bacterial 30 ribosomal subunit interfering mrna binding acceptor trna site bactericidal effect netilmiicin fully understood , treatment bacteremia septicaemia respiratory tract infection skin soft-tissue infection burn wound peri-operative infection caused susceptible strain 
Hydrocodone,hydrocodone synthetic opioid derivative codeine t116 commonly used combination acetaminophen control moderate severe pain historically hydrocodone used cough suppressant although largely replaced dextromethorphan current cough cold formulation hydrocodone 's potent metabolite hydromorphone also found wide use analgesic frequently used case severe pain fda first approved hydrocodone use part cough suppressant syrup hycodan march 1943 l9025 ,hydrocodone indicated management acute pain sometimes combination acetaminophen ibuprofen well symptomatic treatment common cold allergic rhinitis combination decongestant antihistamine expectorant label l7991 
Norgestimate,norgestimate first described literature 1977 a191068 developed ortho pharmaceutical corporation part effort develop new hormonal contraceptive reduced adverse effect a191068 commonly formulated ethinylestradiol combined oral contraceptive also used treat moderate acne vulgaris l11845 l11848 norgestimate granted fda approval 29 december 1989 l11842 ,norgestimate formulated ethinylestradiol combined oral contraceptive l11845 l11848 also given low dose ethinylestradiol contraception well treatment moderate acne vulgaris woman ≥15 year old l11848 
Carboplatin,carboplatin organoplatinum antineoplastic alkylating agent used treatment advanced ovarian carcinoma l32253 early clinical study carboplatin performed 1982 a230523 carboplatin developed analog cisplatin reduced nephrotoxicity vomiting a230463 a230523 carboplatin granted fda approval 3 march 1989 l32248 ,carboplatin indicated combination established combination chemotherapeutic agent initial treatment advanced ovarian carcinoma l32253 carboplatin also indicated palliative treatment ovarian carcinoma recurrent prior chemotherapy l32253 
Methylprednisolone,methylprednisolone prednisolone derivative glucocorticoid higher potency prednisone a188811 first described literature late 1950s a188811 a188814 methylprednisolone granted fda approval 24 october 1957 l10785 outbreak covid-19 low dose methylprednisolone-based therapy successful treating covid-19-associated pneumonia one patient long-term immunosuppression a192813 efficacy methylprednisolone novel coronavirus pneumonia investigated clinical trial l12666 ,oral intramuscular methylprednisolone indicated number endocrine rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system disorder l10785 l10788 intra-articular soft tissue injection indicated short term treatment acute gouty arthritis acute subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis l10788 intralesional injection indicated alopecia areata discoid lupus erythematosus keloid lichen planus lichen simplex chronicus psoriatic plaque necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesion granuloma annulare l10788 
Pindolol,pindolol first generation non-selective beta blocker used treatment hypertension l32353 early research use pindolol found chronotropic effect investigation focused treatment arrhythmia a231059 research pindolol 's use treatment hypertension began early 1970s a231064 pindolol granted fda approval 3 september 1982 l32348 ,pindolol indicated management hypertension l32353 canada also indicated prophylaxis angina l32388 
Mepivacaine, local anesthetic chemically related bupivacaine pharmacologically related lidocaine indicated infiltration nerve block epidural anesthesia mepivacaine effective topically large dos therefore used route ama drug evaluation 1994 p168 , production local regional analgesia anesthesia local infiltration peripheral nerve block technique central neural technique including epidural caudal block 
Zaleplon,zaleplon sedative/hypnotic mainly used insomnia known nonbenzodiazepine hypnotic zaleplon interacts gaba receptor complex share pharmacological property benzodiazepine zaleplon schedule iv drug united state , treatment short-term treatment insomnia adult 
Bromfenac,bromfenac nonsteroidal anti-inflammatory drug nsaid ophthalmic use ophthalmic nsaid becoming cornerstone management ocular pain inflammation well-characterized anti-inflammatory activity analgesic property established safety record also made nsaid important tool optimizing surgical outcome non-ophthalmic formulation bromfenac withdrawn u 1998 due case severe liver toxicity l43942 t239 , treatment postoperative inflammation patient undergone cataract extraction 
Apraclonidine,apraclonidine also known iopidine sympathomimetic used glaucoma therapy alpha2-adrenergic agonist , prevention reduction intraoperative postoperative increase intraocular pressure iop ocular laser surgery used prophylactically also used short-term adjunctive therapy patient open-angle glaucoma maximally tolerated medical therapy requiring additional iop reduction 
Ethiodized oil,ethiodized oil used injection radio-opaque contrast agent composition oil comprised iodine combined ethyl ester fatty acid poppyseed oil although ester primarily ethyl monoiodostearate ethyl diiodostearate actual specific structure unknown , use radio-opaque medium hysterosalpingography lymphography antineoplastic agent part iodine 131-i also used follow-up imaging chemoembolization 
Telmisartan,telmisartan angiotensin ii receptor antagonist arb used management hypertension generally angiotensin ii receptor blocker arb telmisartan bind angiotensin ii type 1 at1 receptor high affinity causing inhibition action angiotensin ii vascular smooth muscle ultimately leading reduction arterial blood pressure recent study suggest telmisartan may also ppar-gamma agonistic property could potentially confer beneficial metabolic effect ,used alone combination class antihypertensive treatment hypertension also used treatment diabetic nephropathy hypertensive patient type 2 diabetes mellitus well treatment congestive heart failure patient tolerate ace inhibitor 
Desloratadine,desloratadine second generation tricyclic antihistamine selective peripheral h1-antagonist action active descarboethoxy metabolite loratidine second generation histamine desloratidine long-lasting effect cause drowsiness readily enter central nervous system , relief symptom seasonal allergic rhinitis perennial non-seasonal allergic rhinitis desloratidine also used sympomatic treatment pruritus urticaria hive associated chronic idiopathic urticaria 
Methyldopa,"methyldopa α-methyldopa centrally acting sympatholytic agent antihypertensive agent a231784 analog dopa 3,4‐hydroxyphenylanine prodrug meaning drug requires biotransformation active metabolite therapeutic effect methyldopa work binding alpha α -2 adrenergic receptor agonist leading inhibition adrenergic neuronal outflow reduction vasoconstrictor adrenergic signal a1499 methyldopa exists two isomer d-α-methyldopa l-α-methyldopa active form a232224 first introduced 1960 antihypertensive agent methyldopa considered useful certain patient population pregnant woman patient renal insufficiency since methyldopa largely replaced newer better-tolerated antihypertensive agent a231784 however still used monotherapy l32614 combination hydrochlorothiazide l32619 methyldopa also available intravenous injection used manage hypertension oral therapy unfeasible treat hypertensive crisis l32624 ",methyldopa indicated management hypertension monotherapy l32614 combination hydrochlorothiazide l32619 methyldopa injection used manage hypertensive crisis l32624 
Alosetron,alosetron 5-ht3 antagonist used management severe diarrhoea-predominant irritable bowel syndrome ibs woman alosetron antagonist action 5-ht3 receptor thus may modulate serotonin-sensitive gastrointestinal gi process alosetron voluntarily withdrawn u market november 2000 manufacturer due numerous report severe adverse effect including ischemic colitis severely obstructed ruptured bowel death june 2002 fda approved supplemental new drug application allowing remarketing drug restricted condition use , treatment symptom severe diarrhea-predominant irritable bowel syndrome ibs woman chronic symptom generally lasting greater 6 month present anatomic biochemical gi abnormality responded conventional therapy 
Dactinomycin, compound composed two cyclic peptide attached phenoxazine derived streptomyces parvullus bind dna inhibits rna synthesis transcription chain elongation sensitive initiation termination release result impaired mrna production protein synthesis also decline dactinomycin therapy ama drug evaluation annual 1993 p2015 , treatment wilms tumor childhood rhabdomyosarcoma ewing 's sarcoma metastatic nonseminomatous testicular cancer part combination chemotherapy and/or multi-modality treatment regimen
Selenium Sulfide,selenium sulfide antifungal agent well cytostatic agent slowing growth hyperproliferative cell seborrhea selenium sulfide active ingredient often used shampoo treatment dandruff seborrheic dermatitis tinea capitis fungal infection primarily disease preadolescent child , treatment tinea versicolor tinea capitis dandruff seborrheic dermatitis scalp 
Azelastine,azelastine phthalazine derivative antihistamine available intranasal spray treatment allergic vasomotor rhinitis ophthalmic solution treatment allergic conjunctivitis l8240 l8270 racemic mixture though noted difference pharmacologic activity enantiomer first granted fda approval 1996 l8240 l8270 azelastine also available combination fluticasone propionate nasal spray marketed trade name dymista™ indicated symptomatic treatment seasonal allergic rhinitis patient 6 year age older l8309 ,intranasal azelastine indicated symptomatic treatment seasonal allergic rhinitis patient 5 year older symptomatic treatment vasomotor rhinitis patient 12 year older l8240 ophthalmic azelastine solution indicated treatment itchy eye associated allergic conjunctivitis l8270 0.15 nasal spray azelastine hydrochloride also indicated over-the-counter treatment allergy patient aged six year older l34640 
Ezetimibe,ezetimibe lipid-lowering compound inhibits intestinal cholesterol phytosterol absorption discovery research drug began early 1990s intravenous administration radiolabelled ezetimibe rat revealed localized within enterocytes intestinal villus prompted study investigating effect ezetimibe intestinal cholesterol absorption a15202 ezetimibe used adjunctive therapy healthy diet lower cholesterol level primary hyperlipidemia mixed hyperlipidemia homozygous familial hypercholesterolemia hofh homozygous sitosterolemia phytosterolemia l11347 unlike class cholesterol-reducing compound including statin bile acid sequestrants ezetimibe distinct mechanism action involving sterol transporter niemann-pick c1-like 1 npc1l1 unique affect absorption fat-soluble nutrient fat-soluble vitamin triglyceride bile acid a33313 genetically npc1l1-deficient mouse 70 reduction intestinal cholesterol absorption seen mouse insensitive ezetimibe treatment determined based finding npc1l1 play essential role promoting intestinal cholesterol uptake via ezetimibe-sensitive pathway a15202 interfering intestinal uptake cholesterol phytosterols ezetimibe reduces delivery intestinal cholesterol liver l11347 ,ezetimibe indicated reduce elevated total-c ldl-c apo b non-hdl-c patient primary hyperlipidemia alone combination hmg-coa reductase inhibitor statin l11347 l11401 l11404 also indicated reduce elevated total-c ldl-c apo b non-hdl-c patient mixed hyperlipidemia combination fenofibrate reduce elevated total-c ldl-c patient homozygous familial hypercholesterolemia hofh combination atorvastatin simvastatin l11347 ezetimibe may also used reduce elevated sitosterol campesterol patient homozygous sitosterolemia phytosterolemia l11347 
Edetic acid, chelating agent chelating agent sequesters variety polyvalent cation used pharmaceutical manufacturing food additive , reduction blood level depot store lead lead poisoning acute chronic lead encephalopathy pediatric population adult 
Dipyridamole, phosphodiesterase inhibitor block uptake metabolism adenosine erythrocyte vascular endothelial cell dipyridamole also potentiates antiaggregating action prostacyclin ama drug evaluation annual 1994 p752 , adjunct coumarin anticoagulant prevention postoperative thromboembolic complication cardiac valve replacement also used prevention angina 
Telithromycin,telithromycin semi-synthetic erythromycin derivative belongs new chemical class antibiotic called ketolides ketolides recently added macrolide-lincosamide-streptogramin class antibiotic similar macrolide antibiotic telithromycin prevents bacterial growth interfering bacterial protein synthesis telithromycin bind 50 subunit 70 bacterial ribosome block peptide elongation binding occurs simultaneously two domain 23 rna 50 ribosomal subunit domain ii v older macrolides bind one used treat mild moderate respiratory infection , treatment pneumococcal /i infection acute sinusitis acute bacterial tonsillitis acute bronchitis bronchiolitis lower respiratory tract infection lobar pneumococcal pneumonia 
Ethinylestradiol,ethinylestradiol first synthesized 1938 han herloff inhoffen walter hohlweg schering a191107 developed effort create estrogen greater oral bioavailability a191107 property achieved substitution ethinyl group carbon 17 estradiol a191107 ethinylestradiol soon replaced mestranol contraceptive pill a191107 ethinylestradiol granted fda approval 25 june 1943 l11884 ,ethinylestradiol combined drug use contraceptive premenstrual dysphoric disorder moderate acne moderate severe vasomotor symptom menopause prevention postmenopausal osteoporosis l11944 l11965 l11947 l11950 l11845 l9806 l11953 l10304 l11956 l11959 l11962 
Lomefloxacin,lomefloxacin fluoroquinolone antibiotic used treat bacterial infection including bronchitis urinary tract infection utis additionally employed prophylaxis utis prior surgery well , treatment bacterial infection respiratory tract chronic bronchitis urinary tract pre-operative prophylactic prevent urinary tract infection caused s.pneumoniae /i h.influenzae /i s.aureus /i p.aeruginosa /i e cloaca /i p mirabilis /i c civersus /i asprphyticus /i e.coli /i k.pneumoniae /i 
Cyclopentolate, parasympatholytic anticholinergic used solely obtain mydriasis cycloplegia ,used mainly produce mydriasis cycloplegia diagnostic purpose 
Ramelteon,ramelteon first new class sleep agent selectively bind melatonin receptor suprachiasmatic nucleus scn used insomnia particularly delayed sleep onset ramelteon shown produce dependence shown potential abuse , treatment insomnia characterized difficulty sleep onset 
Physostigmine, cholinesterase inhibitor rapidly absorbed membrane applied topically conjunctiva also cross blood-brain barrier used central nervous system effect desired treatment severe anticholinergic toxicity , treatment glaucoma treatment severe anticholinergic toxicity 
Isotretinoin,isotretinoin retinoid derivative vitamin used treatment severe recalcitrant acne label widely marketed brand name accutane since discontinued l6574 isotretinoin associated major risk pregnancy therefore available ipledge program united state l6579 first isotretinoin-containing product fda approved 7 may 1982 l6574 ,isotretinoin indicated treat severe recalcitrant nodular acne patient ≥12 year enrolled ipledge program label l6579 
Formoterol,formoterol inhaled beta sub 2 /sub -agonist used management copd asthma first approved use united state 2001 l10986 act bronchial smooth muscle dilate relax airway administered racemic mixture active r r inactive -enantiomers a189528 major clinical advantage formoterol inhaled beta-agonists rapid onset action 2-3 minute least fast salbutamol combined long duration action 12 hour reason treatment guideline asthma recommend use reliever maintenance medication l11256 available single-entity product l10986 l11223 several formulation combination inhaled corticosteroid l10995 l10619 long-acting muscarinic antagonist l10992 l10989 ,formoterol indicated various formulation treatment asthma copd treatment copd formoterol available single-entity inhalation solution l10986 combination long-acting muscarinic antagonist lama aclidinium l10992 glycopyrronium l10989 combination corticosteroid budesonide l10619 treatment asthma formoterol available combination mometasone furoate patient 5 year older l10995 budesonide patient 6 year older l10619 formoterol may also used as-needed basis prophylaxis exercise-induced bronchospasm l10998 
Nandrolone phenpropionate,c18 steroid androgenic anabolic property generally prepared alkyl ether estradiol resemble testosterone le one carbon 19 position schedule iii drug u.s , treatment refractory deficient red cell production anemia breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure turner 's syndrome also indicated prophylaxis hereditary angioedema 
Dimenhydrinate,dimehydrinate first described literature 1949 a233120 patented 1950 l32995 early research dimenhydrinate focused role antihistamine urticaria treatment motion sickness accidental discovery a233130 dimenhydrinate also known b-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate indicated prevent nausea vomiting dizziness caused motion sickness l32980 l32985 l32995 dimenhydrinate combination diphenhydramine 8-chlorotheophylline salt form 53 -55.5 dried diphenhydramine 44 -47 died 8-chlorotheophylline l32985 antiemetic property dimenhydrinate primarily thought produced diphenhydramine 's antagonism h1 histamine receptor vestibular system a1540 excitatory effect thought produced 8-chlorotheophylline 's adenosine receptor blockade a33889 used large dos dimenhydrinate shown cause `` high '' characterized hallucination excitement incoordination disorientation a1539 dimenhydrinate granted fda approval 31 may 1972 l32975 ,dimenhydrinate indicated prevention treatment nausea vomiting vertigo motion sickness l32980 l32985 
Glycopyrronium,glycopyrronium also known nva237 glycopyrrolate racemic mixture two enantiomer l33110 quaternary ammonium compound long acting muscarinic antagonist l33110 one commonly prescribed anticholinergic medication a233535 a233540 early research glycopyrronium use indication adjunct therapy treatment peptic ulcer a233570 l33090 later research taking advantage systemic distribution muscarinic receptor body found glycopyrronium could also used reducing sweat gland l4755 oral l33140 airway gastric secretion l33120 well reducing cardiac inhibitory reflex l33120 reducing bronchoconstriction copd l33105 glycopyrronium commonly prescribed first line treatment wide variety indication considered wider therapeutic window tiotropium a233565 glycopyrronium originally granted fda approval 11 august 1961 l33090 ,glycopyrronium formulated topical cloth indicated treat primary axillary hyperhidrosis patient ≥9 year l4755 inhalational solution indicated long term maintenance airflow obstruction copd l33105 glycopyrronium intravenous intramuscular injection indicated adult pediatric patient reduce volume acidity gastric secretion reduce airway secretion block cardiac inhibitory reflex induction anesthesia intubation treat surgically-induced drug-induced vagal reflex associated arrhythmia intraoperatively prevent peripheral muscarinic effect cholinergic drug l33120 injection indicated adult adjunct therapy treatment peptic ulcer orally disintegrating tablet formulation l33120 l39615 oral solution indicated treat excessive drooling associated neurologic condition patient aged 3-16 year l33140 glycopyrronium budesonide l33145 formulated formoterol fumarate maintenance copd l33150 
Cytarabine, pyrimidine nucleoside analog used mainly treatment leukemia especially acute non-lymphoblastic leukemia cytarabine antimetabolite antineoplastic agent inhibits synthesis dna action specific phase cell cycle also antiviral immunosuppressant property martindale extra pharmacopoeia 30th ed p472 , treatment acute non-lymphocytic leukemia acute lymphocytic leukemia blast phase chronic myelocytic leukemia cytarabine indicated combination daunorubicin treatment newly-diagnosed therapy-related acute myeloid leukemia t-aml aml myelodysplasia-related change aml-mrc adult pediatric patient 1 year older l32843 
Dopamine,one catecholamine neurotransmitter brain derived tyrosine precursor norepinephrine epinephrine dopamine major transmitter extrapyramidal system brain important regulating movement family receptor receptor dopamine mediate action , correction hemodynamic imbalance present shock syndrome due myocardial infarction trauma endotoxic septicemia open-heart surgery renal failure chronic cardiac decompensation congestive failure
Rivastigmine,rivastigmine parasympathomimetic cholinergic agent treatment mild moderate dementia alzheimer 's type rivastigmine cholinesterase inhibitor inhibits butyrylcholinesterase acetylcholinesterase , treatment mild moderate dementia associated parkinson 's disease alzheimer 's type 
Exemestane,exemestane oral steroidal aromatase inhibitor used adjuvant treatment hormonally-responsive also called hormone-receptor-positive estrogen-responsive breast cancer postmenopausal woman irreversibly bind active site enzyme resulting permanent inhibition , treatment advanced breast cancer postmenopausal woman whose disease progressed following tamoxifen therapy 
Oxaprozin,oxaprozin non-narcotic non-steroidal anti-inflammatory drug nsaid used relieve inflammation swelling stiffness joint pain associated osteoarthritis rheumatoid arthritis ,used relieve inflammation swelling stiffness joint pain associated rheumatoid arthritis osteoarthritis 
Methyl aminolevulinate,methyl aminolevulinate prodrug metabolised protoporphyrin ix photosensitizer used photodynamic therapy , topical use combination 570 670 nm wavelength red light illumination treatment non-hyperkeratotic actinic keratoses face scalp immunocompetent patient used conjunction lesion preparation debridement using sharp dermal curette 
Azathioprine,azathioprine prodrug 6-mercaptopurine first synthesized 1956 gertrude elion william lange george hitchings attempt produce derivative 6-mercaptopurine better therapeutic index a189678 a189687 a189690 azathioprine used treat inflammatory condition like rheumatoid arthritis immunosuppressant prevention renal transplant rejection l11214 azathiprine granted fda approval 20 march 1968 l11214 ,azathioprine indicated treat rheumatoid arthritis prevent renal transplant rejection l11214 
Neomycin,neomycin broad-spectrum aminoglycoside antibiotic drug derived metabolic product _streptomyces fradiae_ l11979 neomycin complex comprised three component neomycin b c. a191529 neomycin b also known framycetin active component complex neomycin c isomer neomycin b making two stereoisomers active component neomycin a175042 a191529 neomycin neamine moiety conjoins two molecule neomycin b c together a175042 neomycin active gram-positive gram-negative organism mediates pharmacological action binding bacterial ribosome inhibiting protein synthesis crucial survival bacteria l11985 neomycin sulfate common form pharmaceutical preparation compound complex amount neomycin product measured unit a191529 neomycin sulfate monotherapy available oral solution adjunct use treatment hepatic coma l11979 also used combination polymyxin b sulfate hydrocortisone otic suspension use treatment bacterial infection external auditory canal including infection caused medical procedure ear l10532 neomycin also used combination polymyxin b sulfate dexamethasone ophthalmic preparation use treatment inflammatory condition infection eye l10716 neomycin also available over-the-counter topical product prevent minor skin infection ,oral neomycin sulfate indicated adjunctive therapy hepatic coma portal-system encephalopathy reducing ammonia-forming bacteria intestinal tract strongly recommended oral neomycin used infection proven strongly suspected caused susceptible bacteria reduce risk development drug-resistant bacteria l11979 neomycin combination polymyxin b sulfate hydrocortisone otic suspension used treatment superficial bacterial infection external auditory canal caused organism susceptible antibiotic otic formulation also used treatment infection mastoidectomy fenestration cavity caused organism susceptible antibiotic l10532 ophthalmic solution containing neomycin combination polymyxin b sulfate dexamethasone used treat steroid-responsive inflammatory ocular condition corticosteroid indicated bacterial infection risk bacterial infection exists l10716 
Auranofin,auranofin gold salt capable eliciting pharmacologic action suppress inflammation stimulate cell-mediated immunity subsequently listed world health organization member antirheumatic agent category auranofin appears induce heme oxygenase 1 ho-1 mrna heme oxygenase 1 inducible heme-degrading enzyme anti-inflammatory property ,used treatment active progressive destructive form inflammatory arthritis adult rheumatoid arthritis 
Gabapentin,gabapentin structural analogue inhibitory neurotransmitter gamma-aminobutyric acid gaba first approved use united state 1993 l8717 originally developed novel anti-epileptic treatment certain type seizure a186277 a186143 today also widely used treat neuropathic pain a14097 a186179 gabapentin stark advantage compared anti-epileptics relatively benign adverse effect profile wide therapeutic index lack appreciable metabolism making unlikely participate pharmacokinetic drug interactions. a186143 a185981 l8717 structurally functionally related another gaba derivative pregabalin , united state gabapentin officially indicated treatment postherpetic neuralgia adult adjunctive treatment partial-onset seizure without secondary generalization patient 3 year age older l8717 europe gabapentin indicated adjunctive therapy treatment partial-onset seizure without secondary generalization patient 6 year age older monotherapy patient 12 year age older also used adult treatment various type peripheral neuropathic pain painful diabetic neuropathy l8732 
Doxorubicin,doxorubicin cytotoxic anthracycline antibiotic isolated culture streptomyces peucetius var caesius doxorubicin bind nucleic acid presumably specific intercalation planar anthracycline nucleus dna double helix ,doxorubicin used produce regression disseminated neoplastic condition like acute lymphoblastic leukemia acute myeloblastic leukemia wilms ’ tumor neuroblastoma soft tissue bone sarcoma breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin ’ disease malignant lymphoma bronchogenic carcinoma small cell histologic type responsive compared cell type doxorubicin also indicated use component adjuvant therapy woman evidence axillary lymph node involvement following resection primary breast cancer 
Frovatriptan,frovatriptan triptan drug developed vernalis treatment migraine headache particular associated menstruation frovatriptan cause vasoconstriction artery vein supply blood head , acute treatment migraine attack without aura adult 
Hydrochlorothiazide,hydrochlorothiazide commonly prescribed thiazide diuretic a185138 indicated treat edema hypertension a185138 l8447 l8450 hydrochlorothiazide use common declining favour angiotensin converting enzyme inhibitor a185138 many combination product available containing hydrochlorothiazide angiotensin converting enzyme inhibitor l8390 l8423 angiotensin ii receptor blocker l7426 l7459 hydrochlorothiazide granted fda approval 12 february 1959 l8444 ,hydrochlorothiazide indicated alone combination management edema associated congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure corticosteroid estrogen therapy l8447 l8450 hydrochlorothiazide also indicated alone combination management hypertension a185138 l8447 l8450 
Cyclacillin, cyclohexylamido analog penicillanic acid , treatment bacterial infection caused susceptible organism 
Salbutamol,salbutamol short-acting selective beta2-adrenergic receptor agonist used treatment asthma copd 29 time selective beta2 receptor beta1 receptor giving higher specificity pulmonary beta receptor versus beta1-adrenergic receptor located heart salbutamol formulated racemic mixture r- s-isomers r-isomer 150 time greater affinity beta2-receptor s-isomer s-isomer associated toxicity lead development levalbuterol single r-isomer salbutamol however high cost levalbuterol compared salbutamol deterred wide-spread use enantiomerically pure version drug salbutamol generally used acute episode bronchospasm caused bronchial asthma chronic bronchitis chronic bronchopulmonary disorder chronic obstructive pulmonary disorder copd also used prophylactically exercise-induced asthma label a174379 a174400 ,salbutamol indicated symptomatic relief prevention bronchospasm due bronchial asthma chronic bronchitis reversible obstructive airway disease chronic bronchopulmonary disorder bronchospasm complicating factor and/or ii acute prophylaxis exercise-induced bronchospasm stimulus known induce bronchospasm label f3265 f3268 
Levobupivacaine,levobupivacaine amino-amide local anaesthetic drug belonging family n-alkylsubstituted pipecoloxylidide s-enantiomer bupivacaine levobupivacaine hydrochloride commonly marketed astrazeneca trade name chirocaine particular specific levobupivacaine enantiomer worthwhile pursuit demonstrates le vasodilation posse greater length action comparison bupivacaine approximately 13 per cent le potent molarity racemic bupivacaine.levobupivacaine indicated local anaesthesia including infiltration nerve block ophthalmic epidural intrathecal anaesthesia adult infiltration analgesia child administered appropriately occurrence adverse effect anticipated much general majority potential adverse effect predominantly associated inappropriate administration method may cause systemic exposure and/or toxicity associated overexposure anesthetic regardless allergic reaction may also occur although rarely , production local regional anesthesia surgery obstetrics post-operative pain management
Cromoglicic acid, chromone complex act inhibiting release chemical mediator sensitized mast cell used prophylactic treatment allergic exercise-induced asthma affect established asthmatic attack , management patient bronchial asthma also used treatment vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis 
Ganciclovir, acyclovir analog potent inhibitor herpesvirus family including cytomegalovirus ganciclovir used treat complication aids-associated cytomegalovirus infection , induction maintenance treatment cytomegalovirus cmv retinitis immunocompromised patient including patient acquired immunodeficiency syndrome aid also used treatment severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease disseminated cmv infection immunocompromised patient 
Hydroxyurea, antineoplastic agent inhibits dna synthesis inhibition ribonucleoside diphosphate reductase ,hydroxyurea indicated reduce frequency painful crisis reduce need blood transfusion adult pediatric patient 2 year age older sickle cell anemia recurrent moderate severe painful crisis l41150 
Letrozole,letrozole cgs 20267 oral non-steroidal type ii aromatase inhibitor first described literature 1990 a190543 a1559 l11623 l11626 third generation aromatase inhibitor like exemestane anastrozole meaning significantly affect cortisol aldosterone thyroxine a190546 letrozole granted fda approval 25 july 1997 l11623 ,letrozole indicated treat postmenopausal woman hormone receptor hr positive early breast cancer postmenopausal woman early breast cancer periviously treated tamoxifen postmenopausal woman hr+ unknown advanced breast cancer l11623 letrozole given ribociclib indicated treat pre peri postmenopausal woman hr+ human epidermal growth factor 2 her2 negative advanced metastatic breast cancer l11626 
Tioconazole,tioconazole imidazole antifungal used treat fungal yeast infection topical formulation used ringworm jock itch athlete 's foot tinea versicolor `` sun fungus '' tioconazole interacts 14-alpha demethylase cytochrome p-450 enzyme convert lanosterol ergosterol essential component yeast membrane way tioconazole inhibits ergosterol synthesis resulting increased cellular permeability , local treatment vulvovaginal candidiasis moniliasis 
Busulfan,busulfan bifunctional alkylating agent selective immunosuppressive effect bone marrow structural analog nitrogen mustard used palliative treatment chronic myeloid leukemia myeloid leukemia chronic although symptomatic relief provided permanent remission brought according fourth annual report carcinogen ntp 85-002 1985 busulfan listed known carcinogen , use combination cyclophosphamide conditioning regimen prior allogeneic hematopoietic progenitor cell transplantation chronic myelogenous myeloid myelocytic granulocytic leukemia fda designated busulfan orphan drug use also used component pretransplant conditioning regimen patient undergoing bone marrow transplantation acute myeloid leukemia nonmalignant disease 
Ketoprofen,ketoprofen propionic acid derivative nonsteroidal anti-inflammatory agent nsaia analgesic antipyretic property , symptomatic treatment acute chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea mild moderate pain associated musculotendinous trauma sprain strain postoperative including dental surgery postpartum pain 
Edrophonium, rapid-onset short-acting cholinesterase inhibitor used cardiac arrhythmia diagnosis myasthenia gravis also used antidote curare principle , differential diagnosis myasthenia gravis adjunct evaluation treatment requirement disease may also used evaluating emergency treatment myasthenic crisis 
Metyrapone, inhibitor enzyme steroid 11-beta-monooxygenase used test feedback hypothalamic-pituitary mechanism diagnosis cushing syndrome ,used diagnostic drug testing hypothalamic-pituitary acth function occasionally used cushing 's syndrome 
Cinacalcet,cinacalcet calcimimetic sold amgen trade name sensipar® north america australia mimpara® europe used treat hyperparathyroidism due parathyroid tumour renal failure , treatment secondary hyperparathyroidism patient chronic kidney disease hemodialysis peritoneal dialysis also treatment hypercalcemia patient parathyroid carcinoma 
Clobetasol propionate,clobetasol propionate prednisolone derivative higher specificity glucocorticoid receptor mineralocorticoid receptor l11815 demonstrated superior activity compared fluocinonide a190963 first described literature 1974 a190936 clobetasol propionate granted fda approval 27 december 1985 l11809 ,clobetasol propionate indicated treat moderate severe plaque psoriasis l11818 l11821 l11824 well inflammatory pruritic manifestation corticosteroid responsive dermatosis l11815 l11827 
Balsalazide,balsalazide anti-inflammatory drug used treatment inflammatory bowel disease sold name `` colazal '' u `` colazide '' uk chemical name e -5- -4- 2-carboxyethyl aminocarbonyl phenyl azo -2-hydroxybenzoic acid usually administered disodium salt balsalazide work deliverying mesalazine large intestine act directly ulcerative colitis mesalazine also known 5-aminosalicylic acid 5-asa , treatment mildly moderately active ulcerative colitis 
Sulfamethoxazole,sulfamethoxazole bacteriostatic sulfonamide antibiotic interferes folic acid synthesis susceptible bacteria l11830 generally given combination trimethoprim inhibits sequential step bacterial folic acid synthesis agent work synergistically block two consecutive step biosynthesis nucleic acid protein necessary bacterial growth division using conjunction help slow development bacterial resistance l11830 combination sulfamethoxazole useful treatment variety bacterial infection including urinary respiratory gastrointestinal tract ,sulfamethoxazole indicated combination trimethoprim various formulation following infection caused bacteria documented susceptibility urinary tract infection acute otitis medium pediatric patient clinically indicated acute exacerbation chronic bronchitis adult enteritis caused susceptible _shigella_ prophylaxis treatment _pneumocystis jiroveci_ pneumonia traveler diarrhea caused enterotoxigenic _e coli_ l11830 l11863 canada additional indication include adjunctive treatment cholera treatment bacillary dysentery nocardiosis second-line treatment brucellosis combination gentamicin rifampicin l11851 
Glyburide,glyburide second generation sulfonylurea used treat patient diabetes mellitus type ii l8123 typically given patient managed standard first line therapy metformin l8123 glyburide stimulates insulin secretion closure atp-sensitive potassium channel beta cell raising intracellular potassium calcium ion concentration a183617 glyburide granted fda approval 1 may 1984 l8117 formulation metformin granted fda approval 31 july 2000 l8120 ,glyburide indicated alone part combination product metformin adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus l8120 l8123 
Minocycline,minocycline first described literacture 1966 a190681 second generation tetracycline antibiotic active gram-negative gram-positive bacteria a190723 like semisynthetic tetracycline minocycline modification carbon 7-9 ring generate higher efficacy previous tetracycline a190723 minocycline granted fda approval 30 june 1971 l11695 ,oral topical minocycline indicated treat inflammatory lesion acne vulgaris l11701 l11704 l11719 subgingival microspheres indicated adjunct treatment reduction pocket depth adult periodontitis l11716 oral intravenous formulation indicated treat infection susceptible microorganism l11707 l11710 l11713 include rickettsia _mycoplasma pneumoniae_ _chlamydia trachomatis_ _chlamydophila psittaci_ _chlamydia trachomatis_ _ureaplasma urealyticum_ _borrelia recurrentis_ _haemophilus ducreyi_ _yersinia pestis_ _francisella tularensis_ _vibrio cholerae_ _campylobacter fetus_ _brucella_ specie _bartonella bacilliformis_ _klebsiella granulomatis_ _escherichia coli_ _enterobacter aerogenes_ _shigella_ specie _acinetobacter_ specie _haemophilus influenzae_ _kelbsiella_ specie l11710 
Guanfacine,guanfacine b 100-141 a189838 a189841 selective alpha-a2 adrenergic receptor agonist initially indicated treatment hypertension l11274 indicated extended release tablet treatment adhd l11277 guanfacine first described literature 1974 a189841 guanfacine granted fda approval 27 october 1986 l11274 ,guanfacine indicated alone adjunct stimulant treat adhd l11277 
Bethanechol,bethanechol synthetic ester initially synthesized 1935 a232905 l32539 cholinergic agent bethanechol similar structure pharmacological function acetylcholine used specific case stimulation parasympathetic nervous system necessary a232905 l32539 example bethanechol readily used treat postoperative postpartum urinary retention advantage bethanechol contrast acetylcholine bethanechol degraded cholinesterase allowing effect longer-lasting l32539 ,bethanechol indicated treatment acute functional postpartum postoperative urinary retention also indicated treatment neurogenic atony bladder retention a226320 l32539 
Isosorbide mononitrate,isosorbide mononitrate organic nitrate vasodilating property anti-anginal agent work relaxing smooth muscle artery vein predominantly vein reduce cardiac preload l11698 l11743 isosorbide mononitrate active metabolite isosorbide dinitrate like organic nitrate isosorbide mononitrate act prodrug active metabolite nitric oxide mediates therapeutic action isosorbide mononitrate l11743 isosorbide mononitrate longer duration action nitroglycerin due slow onset absorption metabolism t28 first approved fda 1991 l11743 isosorbide mononitrate used prevention management angina pectoris caused coronary artery disease however onset action orally-administered isosorbide mononitrate rapid enough offset acute anginal episode l11698 available oral tablet generically brand name ismo monoket extended-release form drug also available generically brand name imdur l11743 ,isosorbide mononitrate indicated prevention management angina pectoris due coronary artery disease onset action oral isosorbide mononitrate sufficiently rapid useful aborting acute anginal episode l11698 
Trichlormethiazide, thiazide diuretic property similar hydrochlorothiazide martindale extra pharmacopoeia 30th ed p830 ,used treatment oedema including associated heart failure hypertension 
Phylloquinone,vitamin k1 also called phylloquinone phytonadione fat soluble vitamin l33319 l33345 phylloquinone cofactor enzyme γ-carboxylase modifies activates precursor coagulation factor ii vii ix x a234264 a234195 a234259 indicated treatment coagulation disorder due faulty formation coagulation factor ii vii ix x caused deficiency interference activity vitamin k. l33319 phylloquinone synthesized since least 1939 a234384 approved fda prior 1955 l33389 ,oral phylloquinone indicated treat prothrombin deficiency caused coumarin indanedione derivative hypoprothrombinemia secondary antibacterial therapy salicylate obstructive jaundice biliary fistula concomitant bile salt administration l33345 parenteral intravenous intramuscular subcutaneous phylloquinone indicated treat coagulation disorder due faulty formation coagulation factor ii vii ix x caused vitamin k deficiency interference vitamin k activity l33319 indication include indication well hypoprothrombinemia secondary sprue ulcerative colitis celiac disease intestinal resection pancreatic cystic fibrosis regional enteritis hypoprothrombinemia caused interference vitamin k metabolism l33319 
Felodipine,"felodipine long-acting 1,4-dihydropyridine calcium channel blocker ccb b act primarily vascular smooth muscle cell stabilizing voltage-gated l-type calcium channel inactive conformation inhibiting influx calcium smooth muscle cell felodipine prevents calcium-dependent myocyte contraction vasoconstriction felodipine potent ccb use unique exhibit fluorescent activity addition binding l-type calcium channel felodipine bind number calcium-binding protein exhibit competitive antagonism mineralcorticoid receptor inhibits activity calmodulin-dependent cyclic nucleotide phosphodiesterase block calcium influx voltage-gated t-type calcium channel felodipine used treat mild moderate essential hypertension ", treatment mild moderate essential hypertension 
Mycophenolic acid,mycophenolic acid potent immunosuppressant agent inhibits _de novo_ purine biosynthesis l42165 derived _penicillium stoloniferum_ also shown antibacterial antifungal antiviral properties. a249170 mycophenolic acid used immunosuppressive regimen part triple therapy includes calcineurin inhibitor ciclosporin tacrolimus prednisolone a249175 regimen used place older anti-proliferative azathioprine due stronger immunosuppressive potency a249180 however mycophenolic acid treatment expensive requires therapeutic drug monitoring optimize efficacy minimize toxicity a249180 a249185 mycophenolic acid available enteric-coated tablet delayed-release effort improve upper gastrointestinal adverse event delaying mycophenolic acid release reach small intestine a249190 mycophenolate mofetil prodrug mycophenolic acid also prescribed transplant recipient prevent organ rejection l42020 ,mycophenolic acid antimetabolite immunosuppressant indicated prophylaxis organ rejection adult patient receiving kidney transplant pediatric patient least 5 year age older least 6 month post kidney transplant mycophenolic acid used combination cyclosporine corticosteroid l42165 
Amlexanox,amlexanox antiallergic drug clinically effective atopic disease especially allergic asthma rhinitis amlexanox topical paste well tolerated treatment recurrent aphthous ulcer recurrent aphthous ulcer rau prevalent oral mucosal disease human estimated affect 5 50 general population ,used paste mouth treat aphthous ulcer canker sore 
Ketoconazole,ketoconazole imidazole antifungal agent used prevention treatment variety fungal infection fda label function preventing synthesis ergosterol fungal equivalent cholesterol thereby increasing membrane fluidity preventing growth fungus a181802 t116 ketoconazole first approved oral formulation systemic use fda 1981 a188054 time considered significant improvement previous antifungal miconazole clotrimazole due broad spectrum good absorption however discovered ketoconazole produce frequent gastrointestinal side effect dose-related hepatitis a188054 a188057 effect combined waning efficacy led eventual replacement triazole agent fluconazole itraconazole voriconazole posaconazole ketoconazole predecessor clotrimazole continue used topical formulation ,ketoconazole used treatment prevention fungal infection including blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis paracoccidioidomycosis fda label europe also used treatment endogenous cushing 's syndrome l7736 
Methoxyflurane, inhalation anesthetic currently methoxyflurane rarely used surgical obstetric dental anesthesia employed administered nitrous oxide achieve relatively light level anesthesia neuromuscular blocking agent given concurrently obtain desired degree muscular relaxation ama drug evaluation annual 1994 p180 u methoxyflurane one product withdrawn removed market reason safety effectiveness l43942 , use induction maintenance general anesthesia
Irbesartan,irbesartan angiotensin receptor blocker arb indicated treat hypertension diabetic nephropathy l7456 l7459 also used part combination product hydrochlorothiazide patient well controlled expected well controlled monotherapy l7459 unlike angiotensin converting enzyme inhibitor arb associated dry cough l7456 l7459 irbesartan granted fda approval 30 september 1997 l7456 l7459 ,irbesartan indicated treat hypertension diabetic nephropathy hypertensive patient type 2 diabetes elevated serum creatinine proteinuria l7456 combination product hydrochlorothiazide indicated hypertension patient uncontrolled hypertension monotherapy first line patient expected well controlled monotherapy l7459 
Topotecan, antineoplastic agent used treat ovarian cancer work inhibiting dna topoisomerases type , treatment advanced ovarian cancer patient disease recurred progressed following therapy platinum-based regimen also used second-line therapy treatment-sensitive small cell lung cancer well combination cisplatin treatment stage iv-b recurrent persistent cervical cancer amenable curative treatment surgery and/or radiation therapy 
Ethinamate,ethinamate short-acting sedative-hypnotic medication used treat insomnia like many similar medication regular use ethinamate result development drug tolerance patient nevertheless medication generally longer effective using greater 7 day structurally resemble barbituates share many effect class drug depressant effect ethinamate however generally milder barbiturate ,used short-term treatment insomnia however generally replaced sedative-hypnotic agent 
Probenecid, prototypical uricosuric agent inhibits renal excretion organic anion reduces tubular reabsorption urate probenecid also used treat patient renal impairment reduces renal tubular excretion drug used adjunct antibacterial therapy , reduction serum uric acid concentration chronic gouty arthritis tophaceous gout patient frequent disabling gout attack also effectively used promote uric acid excretion hyperuricemia secondary administration thiazide related diuretic 
Mercaptopurine, antimetabolite antineoplastic agent immunosuppressant property interferes nucleic acid synthesis inhibiting purine metabolism used usually combination drug treatment remission maintenance program leukemia , remission induction maintenance therapy acute lymphatic leukemia 
Cerulenin,cerulenin antifungal agent whose activity interferes otherwise act prevent formation fatty acid sterol fatty acid synthesis reported bind equimolar ratio b-keto-acyl-acp synthase sterol synthesis inhibits hmg-coa synthetase activity also shown inhibit feeding induce dramatic weight loss mouse found naturally cephalosporium caerulensfungus , use biochemical tool cerulenin shown cause dramatic weight loss animal
Procainamide, derivative procaine le cns action , treatment life-threatening ventricular arrhythmia 
Tolterodine,tolterodine antimuscarinic drug used treat urinary incontinence tolterodine act m2 m3 subtypes muscarinic receptor , treatment overactive bladder symptom urinary frequency urgency urge incontinence 
Selegiline, selective irreversible inhibitor type b monoamine oxidase used newly diagnosed patient parkinson 's disease may slow progression clinical disease delay requirement levodopa therapy also may given levodopa upon onset disability ama drug evaluation annual 1994 p385 compound without isomeric designation deprenyl ,monotherapy initial treatment parkinson 's disease well adjunct therapy patient decreased response levodopa/carbadopa also used palliative treatment mild moderate alzheimer 's disease higher dos treatment depression 
Carphenazine,carphenazine antipsychotic drug used hospitalized patient management chronic schizophrenic psychosis ,used treatment acute chronic schizophrenic reaction hospitalized patient 
Fenofibrate,fenofibrate fibric acid derivative like clofibrate gemfibrozil a185954 fenofibrate used treat primary hypercholesterolemia mixed dyslipidemia severe hypertriglyceridemia l8588 l8591 fenofibrate granted fda approval 31 december 1993 l8585 ,fenofibrate indicated adjunctive therapy diet reduce elevated ldl-c total-c triglyceride apo b increase hdl-c adult primary hypercholesterolemia mixed dyslipidemia l8588 l8591 fenofibrate also indicated treat adult severe hypertriglyceridemia l8588 l8591 
Thalidomide, piperidinyl isoindole originally introduced non-barbiturate hypnotic thalidomide withdrawn market due teratogenic effect reintroduced used number inflammatory disorder cancer thalidomide display immunosuppressive anti-angiogenic activity modulating release inflammatory mediator like tumor necrosis factor-alpha tnf-a cytokine action due severe teratogenicity pregnancy must excluded start treatment patient must enrol thalidomid risk evaluation mitigation strategy rem program ensure contraception adherence l41235 ,thalidomide primarily used acute treatment maintenance therapy prevent suppress cutaneous manifestation moderate severe erythema nodosum leprosum enl l41235 
Melphalan, alkylating nitrogen mustard used antineoplastic form levo isomer melphalan racemic mixture merphalan dextro isomer medphalan toxic bone marrow little vesicant action potential carcinogen ,melphalan indicated use high-dose conditioning treatment prior hematopoietic stem cell transplantation patient multiple myeloma l40025 also indicated palliative treatment multiple myeloma palliation non-resectable epithelial carcinoma ovary l40928 
Memantine,initially approved fda 2013 memantine n-methyl-d-aspartate nmda receptor antagonist used management alzheimer 's disease ad different many alzheimer 's disease medication work different mechanism cholinesterase enzyme inhibitor normally employed management alzheimer 's disease a1639 memantine block effect glutamate neurotransmitter brain lead neuronal excitability excessive stimulation alzheimer 's disease t556 2010 estimated 36 million people worldwide live alzheimer 's disease 2013 number increased 44 million almost doubling every 20 year prevalence alzheimer 's disease predicted reach 66 million 2030 115 million 2050 f4366 december 2013 g8 dementia summit concluded dementia considered global priority objective developing cure disease-modifying therapy year 2025 l5953 f4366 ,memantine used manage moderate severe alzheimer 's dementia fda label recent systemic review meta-analysis a177106 indicates memantine beneficial first line drug treatment alzheimer 's dementia cholinesterase inhibitor may added memantine beneficial effect behavioral symptom symptom dementia a177106 
Gatifloxacin,gatifloxacin antibiotic agent member fourth-generation fluoroquinolone family work inhibiting bacterial enzyme dna gyrase topoisomerase iv first introduced bristol-myers squibb 1999 brand name tequin® treatment respiratory tract infection gatifloxacin available tablet various aqueous solution intravenous therapy also available eye drop brand name zymar® marketed allergan fda withdrew approval use non-ophthalmic drug product containing gatifloxacin due high prevalence gatifloxacin-associated dysglycemia adverse event report high incidence hyperglycemic hypoglycemic episode patient taking gatifloxacin compared macrolide antibiotic l43942 l44037 , treatment bronchitis sinusitis community-acquired pneumonia skin infection abscess wound caused s. pneumoniae h. influenzae s. aureus m. pneumoniae c. pneumoniae l. pneumophila s. pyogenes
Rifampicin, semisynthetic antibiotic produced streptomyces mediterranei broad antibacterial spectrum including activity several form mycobacterium susceptible organism inhibits dna-dependent rna polymerase activity forming stable complex enzyme thus suppresses initiation rna synthesis rifampin bactericidal act intracellular extracellular organism gilman et al. goodman gilman 's pharmacological basis therapeutic 9th ed p1160 , treatment tuberculosis tuberculosis-related mycobacterial infection 
Lubiprostone,lubiprostone medication used management idiopathic chronic constipation prostaglandin e1 derivative lubiprostone bicyclic fatty acid activates clc-2 chloride channel located apical side gastrointestinal epithelial cell activation channel promotes secretion chloride-rich fluid soften stool increase gastrointestinal motility induce spontaneous bowel movement sbm ,lubiprostone indicated treatment adult patient chronic idiopathic constipation opioid-induced constipation patient chronic non-cancer pain l4421 also indicated treatment irritable bowel syndrome constipation ibs-c female patient ≥18 year old l4421 
Fluocinonide, topical glucocorticoid used treatment eczema , topical anti-inflammatory product relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Abacavir,abacavir abc powerful nucleoside analog reverse transcriptase inhibitor nrti used treat hiv aid chemically synthetic carbocyclic nucleoside enantiomer 1 4r absolute configuration cyclopentene ring vivo abacavir sulfate dissociates free base abacavir ,abacavir indicated combination anti-retroviral agent treatment hiv-1 infection l30400 available combination product alongside dolutegravir lamivudine treatment adult pediatric patient hiv-1 weigh ≥10 kg l41365 
Ergoloid mesylate,ergoloid mesylate equiproportional preparation three different ergotamantriones dihydroergocornine dihydroergocristine dihydroergocryptine a32912 component produced fungus _claviceps purpurea_ derivative tetracyclic compound 6-methylergonovine t90 derivative fungus identified 350 different substance component ergoloid mesylate mixture composed dihydrogenated ergot alkaloid derivative a32914 mixture ergoloid mesylate first developed novartis fda approved november 5 1953 specific formulation discontinued l2639 later 1991 mixture ergoloid mesylates retaken sun pharmaceutical industry approved fda l2640 know individual component ergoloid mixture please visit db11275 db11274 db11273 db13345 , labeled fda treatment symptom idiopathic decline mental capacity related potentially reversible condition a32913 well age-related cognitive impairment a32926 prescription drug conditioned corroboration patient suffering potentially reversible treatable condition especially delirium dementiform illness secondary systemic disease primary neurological disease primary mood disturbance l2637 know individual component ergoloid mixture please visit db13345 db11274 
Ibuprofen,ibuprofen non-steroidal anti-inflammatory drug nsaid derived propionic acid considered first propionics a39074 formula ibuprofen 2- 4-isobutylphenyl propionic acid initial development 1960 researching safer alternative aspirin a39075 ibuprofen finally patented 1961 drug first launched rheumatoid arthritis uk 1969 usa 1974 first available over-the-counter nsaid a39076 available product ibuprofen administered racemic mixture administered r-enantiomer undergoes extensive interconversion s-enantiomer _in vivo_ activity alpha-methylacyl-coa racemase particular generally proposed s-enantiomer capable eliciting stronger pharmacological activity r-enantiomer a39194 ,ibuprofen commonly used prescribed nsaid common over-the-counter medication widely used analgesic anti-inflammatory antipyretic a39096 use ibuprofen enantiomer db09213 racemic mix common management mild moderate pain related dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis soft tissue disorder a39097 due activity prostaglandin thromboxane synthesis ibuprofen attributed alteration platelet function prolongation gestation labour a39092 ibuprofen widely used medication main therapeutic indication patent ductus arteriosus neonatal condition wherein ductus arteriosus blood vessel connects main pulmonary artery proximal descending aorta fails close birth causing severe risk heart failure prostaglandin inhibition ibuprofen studied treatment condition known prostaglandin e2 responsible keeping ductus arteriosus open a39100 rheumatoid- osteo-arthritis ibuprofen commonly used symptomatic treatment inflammatory musculoskeletal rheumatic disorder a39176 cystic fibrosis use high dosage ibuprofen proven decrease inflammation decreasing polymorphonuclear cell influx lung a39177 orthostatic hypotension ibuprofen induce sodium retention antagonize effect diuretic reported beneficial patient severe orthostatic hypotension a1651 dental pain ibuprofen used manage acute chronic orofacial pain a10901 pain ibuprofen widely used reduce minor ache pain well reduce fever manage dysmenorrhea commonly used relief acute indication fever tension headache a39092 also used manage mild moderate pain moderate severe pain adjunct opioid analgesic l40208 investigational us effort put developing ibuprofen prophylaxis alzheimer 's disease parkinson disease breast cancer a39092 
Novobiocin,novobiocin antibiotic compound derived _streptomyces niveus_ chemical structure similar coumarin novobiocin bind dna gyrase block adenosine triphosphatase atpase activity reynolds martindale extra pharmacopoeia 30th ed p189 novobiocin sodium salt form novobiocin initially approved september 1964 indicated treatment serious infection due susceptible strain _staphylococcus aureus_ le toxic antibiotic used 2009 fda determined novobiocin sodium withdrawn sale reason safety effectiveness l44062 l43942 , treatment infection due staphylococci susceptible organism
Benzylpenicillin,benzylpenicillin penicillin g narrow spectrum antibiotic used treat infection caused susceptible bacteria natural penicillin antibiotic administered intravenously intramuscularly due poor oral absorption penicillin g may also used case prophylaxis susceptible organism natural penicillin considered drug choice several infection caused susceptible gram positive aerobic organism streptococcus pneumoniae group b c g streptococci nonenterococcal group streptococci viridans group streptococci non-penicillinase producing staphylococcus aminoglycosides may added synergy group b streptococcus s. agalactiae s. viridans enterococcus faecalis natural penicillin may also used first second line agent susceptible gram positive aerobic bacillus bacillus anthracis corynebacterium diphtheriae erysipelothrix rhusiopathiae natural penicillin limited activity gram negative organism however may used case treat infection caused neisseria meningitidis pasteurella generally used treat anaerobic infection resistance pattern susceptibility treatment guideline vary across region , use treatment severe infection caused penicillin g-susceptible microorganism rapid high penicillin level required treatment septicemia meningitis pericarditis endocarditis severe pneumonia 
Nitrendipine,nitrendipine calcium channel blocker marked vasodilator action effective antihypertensive agent differs calcium channel blocker reduce glomerular filtration rate mildly natriuretic rather sodium retentive , treatment mild moderate hypertension
Mimosine,mimosine antineoplastic alanine-substituted pyridine derivative isolated _leucena glauca_ ,
Tocainide, antiarrhythmic agent exerts potential- frequency-dependent block sodium channel , treatment documented ventricular arrhythmia sustained ventricular tachycardia judgment physician life-threatening 
Echothiophate, potent long-acting irreversible cholinesterase inhibitor used ocular hypertensive treatment glaucoma occasionally used accomodative esotropia , use treatment subacute chronic angle-closure glaucoma iridectomy surgery refused contraindicated 
Praziquantel, anthelmintic used schistosome many cestode infestation , treatment infection due specie schistosoma 
Norfloxacin, synthetic fluoroquinolone fluoroquinolones broad-spectrum antibacterial activity gram-negative gram-positive bacteria norfloxacin inhibits bacterial dna gyrase , treatment urinary tract infection
Amoxicillin,amoxicillin brl-2333 penicillin g derivative first described literature 1972 a190648 amoxicillin similar activity penicillin ampicillin lead higher serum concentration ampicillin a190648 amoxicillin granted fda approval 18 january 1974 l11644 ,amoxicillin alone indicated treat susceptible bacterial infection ear nose throat genitourinary tract skin skin structure lower respiratory tract l11656 l11659 amoxicillin given calvulanic acid treat acute bacterial sinusitis community acquired pneumonia lower respiratory tract infection acute bacterial otitis medium skin skin structure infection urinary tract infection l11650 l7880 l11653 amoxicillin given omeprazole treatment _helicobacter pylori_ _h pylori_ infection l9743 l11647 amoxicillin used combination vonoprazan clarithromycin co-packaged triple therapy combination vonoprazan co-packaged dual therapy treat _h pylori_ infection adult l41695 
Azlocillin,azlocillin semisynthetic ampicillin-derived acylureido penicillin , treatment infection caused pseudomonas aeruginosa /i escherichia coli /i haemophilus influenzae /i 
Oxybutynin,overactive bladder oab common condition negatively impacting life million patient worldwide due urinary symptom include nocturia urgency frequency condition cause social embarrassment poor quality life a185996 a185999 oxybutynin also marketed ditropan xl anticholinergic medication used relief overactive bladder symptom optimized high level safety efficacy since initial fda approval 1975 a183782 l8648 drug relief undesirable urinary symptom increasing quality life patient affected oab often used first-line therapy oab a185990 ,oxybutynin indicated symptomatic treatment overactive bladder cause urge urinary incontinence frequency urgency oxybutynin may also used child aged 6 symptomatic management detrusor muscle overactivity found related neurological condition spina bifida example neurological condition oxybutynin may used control urinary symptom l8648 occasion oxybutynin may used off-label relieve bladder spasm associated ureteral stent urinary catheter t689 
Acetophenazine,acetophenazine antipsychotic drug moderate-potency used treatment disorganized psychotic thinking also used help treat false perception e.g hallucination delusion primarily target dopamine d2 receptor , treatment disorganized psychotic thinking also used help treat false perception e.g hallucination delusion 
Isoprenaline,isoprenaline non-selective beta adrenergic receptor agonist indicated treat heart block adams-stokes attack bronchospasm anesthesia cadiac arrest hypovolemic shock septic shock hypoperfusion congestive hear failure cardiogenic shock a15638 l33160 isoprenaline research 1940s found isopropyl analog epinephrine dilated bronchus well raising heart rate cardiac output without vasoconstriction a233724 a233729 u patent 1943 state compound wider therapeutic index stronger action adrenaline l33204 isoprenaline granted fda approval 19 february 1948 l33155 ,isoprenaline indicated treat mild transient episode heart block requiring electric shock pacemaker serious episode heart block adams-stokes attack caused ventricular tachycardia fibrillation bronchospasm anesthesia l33160 isoprenaline also indicated case cardiac arrest preferable treatment like electric shock pacemaker available l33160 isoprenaline also indicated adjunct therapy fluid electrolyte replacement therapy hypovolemic shock septic shock hypoperfusion congestive heart failure cardiogenic shock l33160 
Melatonin,melatonin biogenic amine found animal plant microbe aaron b. lerner yale university credited naming hormone defining chemical structure 1958 mammal melatonin produced pineal gland pineal gland small endocrine gland size rice grain shaped like pine cone hence name located center brain rostro-dorsal superior colliculus outside blood-brain barrier secretion melatonin increase darkness decrease exposure light thereby regulating circadian rhythm several biological function including sleep-wake cycle particular melatonin regulates sleep-wake cycle chemically causing drowsiness lowering body temperature melatonin also implicated regulation mood learning memory immune activity dreaming fertility reproduction melatonin also effective antioxidant action melatonin mediated binding activation melatonin receptor individual autism spectrum disorder asd may lower normal level melatonin 2008 study found unaffected parent individual asd also lower melatonin level deficit associated low activity asmt gene encodes last enzyme melatonin synthesis reduced melatonin production also proposed likely factor significantly higher cancer rate night worker ,used orally jet lag insomnia shift-work disorder circadian rhythm disorder blind evidence efficacy benzodiazepine nicotine withdrawal evidence indicates melatonin likely effective treating circadian rhythm sleep disorder blind child adult received fda orphan drug status oral medication use number study shown melatonin may effective treating sleep-wake cycle disturbance child adolescent mental retardation autism central nervous system disorder appears decrease time fall asleep child developmental disability cerebral palsy autism mental retardation may also improve secondary insomnia associated various sleep-wake cycle disturbance possible us evidence include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety sedation prostate cancer solid tumor combined il-2 therapy certain cancer sunburn prevention topical use tardive dyskinesia thrombocytopenia associated cancer chemotherapy disorder 
Cefditoren,cefditoren oral third-generation cephalosporin commonly marketed trade name spectracef cornerstone biopharma , treatment mild moderate infection adult adolescent 12 year age older caused susceptible strain microorganism acute bacterial exacerbation chronic bronchitis community-acquired pneumonia pharyngitis/tonsillitis uncomplicated skin skin-structure infection 
Glipizide,glipizide oral hypoglycemic agent second-generation sulfonylurea drug class used control blood sugar level patient type 2 diabetes mellitus first introduced 1984 a179491 available various country including canada u.s according 2018 clinical practice guideline diabetes canada sulfonylurea drug considered second-line glucose-lowering therapy following metformin l6712 sulfonylurea require functional pancreatic beta cell therapeutic effectiveness sulfonylurea commonly used early-stage type 2 diabetes progressed pancreatic failure t28 compared first-generation sulfonylurea tolbutamide chlorpropamide second-generation sulfonylurea contain non-polar side chain chemical structure enhances hypoglycemic potency a179488 compared member sulfonylurea drug group glipizide display rapid absorption onset action shortest half-life duration action reducing risk long-lasting hypoglycemia often observed blood glucose-lowering agent a179485 glipizide first approved fda 1994 available extended-release tablet brand name glucotrol® well combination metformin brand name metaglip® ,indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus label 
Clonazepam, benzodiazepine used treat various seizure including myotonic atonic seizure photosensitive epilepsy absence seizure although tolerance may develop fda label l5572 f3763 f3787 f3796 agent also indicated treating panic disorder fda label a175438 l5572 f3763 f3787 f3796 mechanism action appears involve enhancement gamma-aminobutyric acid receptor response fda label a175438 a175441 l5572 f3763 f3787 f3796 since first patented 1960 released sale roche u 1975 t469 t472 clonazepam experienced storied history treatment aforementioned medical condition available generic medication agent continues see exceptionally high use million prescription written medication internationally every year unfortunately however like benzodiazepine clonazepam use also associated recreational use drug abuse fda label l5572 f3763 f3787 f3796 ,clonazepam indicated monotherapy adjunct treatment lennox-gastaut syndrome petit mal variant akinetic myoclonic seizure fda label f3787 furthermore clonazepam may also value patient absence spell petit mal failed respond succinimides fda label f3787 additionally clonazepam also indicated treatment panic disorder without agoraphobia defined dsm-v fda label alternatively regional prescribing information note clonazepam indicated clinical form epileptic disease seizure adult especially absence seizure petit mal including atypical absence primary secondarily generalised tonic-clonic grand mal tonic clonic seizure partial focal seizure elementary complex symptomatology various form myoclonic seizure myoclonus associated abnormal movement l5572 f3796 regional label data also clonazepam indicated type epilepsy infant child especially absence petit mal myoclonic seizure tonic-clonic fit whether due primary generalized epilepsy secondary generalization partial epilepsy f3796 
Promethazine,"promethazine originally known 3,277 r.p. n-dimethylaminopropyl derivative phenothiazine developed france 1946 a189901 promethazine antagonizes variety receptor allowing used number indication including allergic reaction pain sedation nausea vomiting a189907 a190153 a190159 a190150 a190171 promethazine granted fda approval 29 march 1951 a190177 l4000 ",promethazine tablet suppository indicated treat rhinitis allergic conjunctivitis allergic reaction blood plasma dermographism anaphylactic reaction sedation nausea vomiting pain motion sickness allergic skin reaction a189907 l4000 promethazine cough syrup phenylephrine codeine indicated relieve cough upper respiratory symptom nasal congestion associated allergy common cold l11326 
Dihydrotachysterol, vitamin regarded reduction product vitamin d2 ,used prevention treatment rickets osteomalacia manage hypocalcemia associated hypoparathyroidism pseudohypoparathyroidism also used treatment vitamin dependent rickets rickets osteomalacia secondary long-term high dose anticonvulsant therapy early renal osteodystrophy osteoporosis conjunction calcium hypophosphatemia associated fanconi syndrome treatment acidosis 
Mequitazine,mequitazine histamine h1 antagonist antihistamine competes histamine normal h1-receptor site effector cell gastrointestinal tract blood vessel respiratory tract provides effective temporary relief sneezing watery itchy eye runny nose due hay fever upper respiratory allergy , treatment hay fever urticaria hive allergic rhinitis
Atazanavir,atazanavir formerly known bms-232632 antiretroviral drug protease inhibitor pi class like antiretrovirals used treat infection human immunodeficiency virus hiv atazanavir distinguished pi given once-daily rather requiring multiple dos per day lesser effect patient 's lipid profile amount cholesterol fatty substance blood like protease inhibitor used combination hiv medication u.s. food drug administration fda approved atazanavir june 20 2003 ,atazanavir indicated combination antiretroviral agent treatment hiv-1 infection adult pediatric patient 3 month age older weighing least 5kg l37604 atazanavir also indicated combination cobicistat antiretrovirals treatment hiv-1 infection adult pediatric patient weighing least 35kg l37599 
Fludarabine,fludarabine chemotherapeutic agent used treatment hematological malignancy commonly marketed brand name fludara , treatment adult patient b-cell chronic lymphocytic leukemia cll responded whose disease progressed treatment least one standard alkylating-agent containing regimen
Perhexiline,perhexiline coronary vasodilator used especially angina effort may cause neuropathy hepatitis , management severe angina pectoris 
Diphenhydramine,diphenhydramine perhaps known commonly brand name formulation benadryl first-generation h1 receptor antihistamine used extensively treatment seasonal allergy insect bite sting rash l5263 l5266 l5269 f3379 however also antiemetic antitussive hypnotic antiparkinson property l5269 f3352 histamine receptor exist peripherally central nervous system diphenhydramine shown cause sedation due competitive antagonism histamine h1 receptor within central nervous system l5263 l5266 l5269 f3379 a174541 use allergy therapy sometimes fall favor due sedative effect diphenhydramine repurposed use within many non-prescription over-the-counter sleep aid cough-and-cold medication marketed `` night time '' use l5263 l5281 l5287 diphenhydramine also used combination db14132 anti-nausea drug db00985 utilized primarily antagonism h1 histamine receptor within vestibular system a1540 diphenhydramine also shown implicated number neurotransmitter system affect behaviour including dopamine norepinephrine serotonin acetylcholine opioid a1539 result diphenhydramine investigated anxiolytic anti-depressant property ,diphenhydramine first-generation histamine h1 receptor antagonist h1 antihistamine widely available non-prescription over-the-counter otc medication otc medication diphenhydramine typically formulated tablet cream indicated use treating sneezing runny nose itchy/watery eye itching nose throat insomnia pruritis urticaria insect bites/stings allergic rash nausea l5263 l5266 l5269 f3379 a174541 additionally use oral diphenhydramine impractical also prescription-only formulation diphenhydramine injection product effective adult pediatric patient premature infant neonate amelioration allergic reaction blood plasma anaphylaxis adjunct epinephrine standard measure acute allergic reaction symptom controlled uncomplicated allergic condition immediate type oral therapy impossible contraindicated f3352 ii active treatment motion sickness f3352 iii use parkinsonism oral therapy impossible contraindicated follows parkinsonism elderly unable tolerate potent agent mild case parkinsonism age group case parkinsonism combination centrally acting anticholinergic agent f3352 
Atorvastatin,"atorvastatin lipitor® lipid-lowering drug included statin class medication inhibiting endogenous production cholesterol liver statin lower abnormal cholesterol lipid level ultimately reduce risk cardiovascular disease specifically statin medication competitively inhibit enzyme hydroxymethylglutaryl-coenzyme hmg-coa reductase a181421 catalyzes conversion hmg-coa mevalonic acid conversion critical metabolic reaction involved production several compound involved lipid metabolism transport including cholesterol low-density lipoprotein ldl sometimes referred `` bad cholesterol '' very-low-density lipoprotein vldl prescribing statin considered standard practice patient following cardiovascular event people moderate high risk developing cardiovascular disease evidence supporting statin use coupled minimal side effect long term benefit resulted wide use medication north america a181087 a181406 atorvastatin statin including lovastatin pravastatin rosuvastatin fluvastatin simvastatin considered first-line treatment option dyslipidemia a181087 a181406 increasing use class drug largely attributed rise cardiovascular disease cvd heart attack atherosclerosis angina peripheral artery disease stroke many country a181084 elevated cholesterol level elevated low-density lipoprotein ldl level particular significant risk factor development cvd a181087 a181553 several landmark study demonstrate use statin associated reduction ldl level cvd risk a181090 a181093 a181096 a181427 a181475 a181538 statin shown reduce incidence all-cause mortality including fatal non-fatal cvd well need surgical revascularization angioplasty following heart attack a181087 a181406 evidence shown even low-risk individual 10 risk major vascular event occurring within five year statin use lead 20 -22 relative reduction number major cardiovascular event heart attack stroke coronary revascularization coronary death every 1 mmol/l reduction ldl without significant side effect risk a181397 a181403 atorvastatin first synthesized 1985 dr. bruce roth approved fda 1996 t568 pentasubstituted pyrrole a177415 formed two contrasting moiety achiral heterocyclic core unit 3,5-dihydroxypentanoyl side chain identical parent compound t571 unlike member statin group atorvastatin active compound therefore require activation a177436 ",atorvastatin indicated treatment several type dyslipidemias including primary hyperlipidemia mixed dyslipidemia adult hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia adolescent patient failed dietary modification a177397 dyslipidemia describes elevation plasma cholesterol triglyceride well presence low level high-density lipoprotein condition represents increased risk development atherosclerosis l6025 atorvastatin indicated combination dietary modification prevent cardiovascular event patient cardiac risk factor and/or abnormal lipid profile a177397 atorvastatin used preventive agent myocardial infarction stroke revascularization angina patient without coronary heart disease multiple risk factor patient type 2 diabetes without coronary heart disease multiple risk factor a177397 atorvastatin may used preventive agent non-fatal myocardial infarction fatal non-fatal stroke revascularization procedure hospitalization congestive heart failure angina patient coronary heart disease a177397 prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd statin-indicated condition include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl-c level a181087 a181406 
Etidronic acid,etidronic acid first generation bisphosphonate similar clodronic acid tiludronic acid a203111 drug developed mimic action pyrophosphate regulator calcification decalcification a1923 etidronate ’ use decreased year favor third generation nitrogen containing bisphosphonate zoledronic acid ibandronic acid minodronic acid risedronic acid a203111 etidronic acid granted fda approval 1 september 1977 l13901 ,etidronate indicated treat paget 's disease bone well treatment prevention heterotropic ossification total hip replacement spinal cord injury l13901 
Deslanoside,deacetyllanatoside c. cardiotonic glycoside leaf digitalis lanata , treatment management congestive cardiac insufficiency arrhythmia heart failure 
Tegaserod,novartis brand name zelnorm tegaserod originally received approval u fda 2002 treatment irritable bowel syndrome constipation ibs-c l5918 f4229 however voluntarily withdrawn widespread use u market 2007 concern arose possibility tegaserod could potentially cause dangerous cardiovascular event patient l5918 f4229 since closer evaluation original data suggesting cardiovascular risk resulted limited reintroduction 're-approval tegaserod treatment ibs-c specifically female patient le 65 year age considered lower risk cardiovascular event broader population l5918 f4229 zelnorm tegaserod sloan pharma subsequently gained re-approval april 2019 l5918 nevertheless tegaserod remains un-approved certain region f4226 despite relative complication involved history regulatory approval ever since first introduction 2002 tegaserod remains therapy ibs-c posse unique mechanism action acting serotonin-4 5-ht 4 receptor smooth muscle cell gastrointestinal wall facilitate action like esophageal relaxation peristaltic gut movement natural secretion gut among others l5918 a11044 a176762 f4229 f4223 ,tegaserod serotonin-4 5-ht4 receptor agonist indicated treatment adult woman le 65 year age irritable bowel syndrome constipation ibs-c f4223 f4229 safety effectiveness tegaserod men ibs-c established f4223 f4229 
Vigabatrin,vigabatrin analog gamma-aminobutyric acid gaba main inhibitory neurotransmitter central nervous system used treatment refractory seizure infantile spasm l13616 irreversibly inhibits enzyme responsible gaba metabolism thereby increasing level circulating gaba although administered racemic mixture enantiomer pharmacologically active a202037 first introduced antiepileptic agent united kingdom 1989 used extensively 1997 association vision loss became apparent a202124 use generally reserved patient failed alternative therapy u approval fda 2009 mandated creation drug registry monitor patient visual deficit l13661 a202124 ,vigabatrin indicated adjunctive therapy treatment refractory complex partial seizure patient 2 year age older inadequate response multiple previous treatment i.e used first-line therapy l13616 also indicated monotherapy treatment infantile spasm patient 1 month 2 year age potential benefit outweigh risk vision loss l13616 
Diphenoxylate, meperidine congener used antidiarrheal usually combination atropine high dos act like morphine unesterified metabolite difenoxin similar property used similarly little analgesic activity medication classified schedule v controlled substance act food drug administration fda dea united state used preparation diphenoxylate used alone classified schedule ii , adjunctive therapy management diarrhea
Streptomycin,streptomycin antibiotic derived _streptomyces griseus_ first aminoglycoside discovered used practice 1940s a233325 a233390 selman waksman eventually albert schatz recognized nobel prize medicine discovery streptomycin antibacterial activity a233325 a232294 although streptomycin first antibiotic determined effective mycobacterium tuberculosis fallen favor due resistance primarily used adjunctive treatment case multi-drug resistant tuberculosis a233325 ,although streptomycin first antibiotic available treatment mycobacterium tuberculosis largely second line option due resistance toxicity a233320 streptomycin may also used treat variety infection caused susceptible strain aerobic bacteria le toxic agent ineffective example include _yersinia pestis_ _francisella tularensis_ _brucella_ _calymmatobacterium granulomatis_ donovanosis granuloma inguinale _h ducreyi_ chancroid _h influenzae_ respiratory endocardial meningeal infection concomitantly another antibacterial agent _k pneumoniae_ pneumonia concomitantly another antibacterial agent _e.coli_ _proteus_ _a.aerogenes_ _k pneumoniae_ _enterococcus faecalis_ urinary tract infection _streptococcus viridans_ _enterococcus faecalis_ endocardial infection concomitantly penicillin gram-negative bacillary bacteremia concomitantly another antibacterial agent 
Orlistat, global prevalence obesity increasing rapidly obesity-related complication lead significant personal economic burden reducing quality life increasing cost healthcare individual diet exercise insufficient maintain weight loss pharmacological surgical intervention required a229928 orlistat lipase inhibitor used treatment obesity work inhibiting fat-metabolizing enzyme approved fda use combination reduced-calorie diet 1999 l11130 drug generally well-tolerated effective weight-loss aid available over-the-counter l31963 prescription preparation depending dosage quantity l11130 ,orlistat indicated obesity management including weight loss weight maintenance used combination calorie reduction overweight obese adult indication applies prescription formulation 120 mg l11130 over-the-counter formulation 60 mg. l31963 orlistat 120 mg prescription formulation also indicated reduce risk weight regain following weight loss l11130 
Emedastine,emedastine antihistamine used eye drop treat allergic conjunctivitis , temporary relief sign symptom allergic conjunctivitis 
Pilocarpine, slowly hydrolyzed muscarinic agonist nicotinic effect pilocarpine used miotic treatment glaucoma , treatment radiation-induced dry mouth xerostomia symptom dry mouth patient sj ouml grens syndrome pilocarpine ophthalmic solution indicated treatment presbyopia adult l39015 
Benzocaine,benzocaine ester local anesthetic act preventing transmission impulse along nerve fiber nerve ending a231219 commonly used local anesthesia many counter product l32454 l32459 l32464 benzocaine first used local anesthesia dentistry a231259 ,benzocaine indicated local anesthesia dentistry minor trauma preparation infiltrative anesthesia a231219 benzocaine product indicated topical anesthesia wide variety condition including skin irritation l32454 oral pain l32459 hemorrhoid l32464 
Primaquine, aminoquinoline given mouth produce radical cure prevent relapse vivax ovale malaria following treatment blood schizontocide also used prevent transmission falciparum malaria returning area potential re-introduction malaria adverse effect include anemia gi disturbance martindale extra pharmacopeia 30th ed p404 , treatment malaria 
Iloprost,iloprost synthetic analogue prostacyclin pgi2 dilates systemic pulmonary arterial vascular bed used treat pulmonary arterial hypertension pah ,used treatment pulmonary arterial hypertension 
Deserpidine,deserpidine ester alkaloid drug isolated rauwolfia canescens family apocynaceae antipsychotic antihypertensive property used control high blood pressure relief psychotic behavior , treatment hypertension 
Pentolinium,pentolinium nicotinic antagonist used ganglionic blocking agent hypertension ,used produce controlled hypotension surgical procedure hypertensive crisis 
Butenafine,butenafine hydrochloride synthetic benzylamine antifungal agent butenafine 's mechanism action believed involve synthesis inhibition sterol particular butenafine act inhibit activity squalene epoxidase enzyme essential formation sterol necessary fungal cell membrane , topical treatment following dermatologic infection tinea pityriasis versicolor due furfur /i interdigital tinea pedis athlete rsquo foot tinea corporis ringworm tinea cruris jock itch due e floccosum /i mentagrophytes /i rubrum /i tonsurans /i 
Ouabain, cardioactive glycoside consisting rhamnose ouabagenin obtained seed strophanthus gratus plant apocynaceae used like digitalis commonly used cell biological study inhibitor na -k -exchanging atpase , treatment atrial fibrillation flutter heart failure
Dimethyl sulfoxide, highly polar organic liquid used widely chemical solvent ability penetrate biological membrane used vehicle topical application pharmaceutical also used protect tissue cryopreservation dimethyl sulfoxide show range pharmacological activity including analgesia anti-inflammation , symptomatic relief patient interstitial cystitis 
Hesperetin,hesperetin belongs flavanone class flavonoid hesperetin form glycoside hesperidin predominant flavonoid lemon orange , lowering cholesterol possibly otherwise favorably affecting lipid vitro /i research also suggests possibility hesperetin might anticancer effect might anti-aromatase activity well activity 
Fluvastatin,"fluvastatin antilipemic agent competitively inhibits hydroxymethylglutaryl-coenzyme hmg-coa reductase hmg-coa reductase catalyzes conversion hmg-coa mevalonic acid rate-limiting step cholesterol biosynthesis fluvastatin belongs class medication called statin used reduce plasma cholesterol level prevent cardiovascular disease also first entirely synthetic hmg-coa reductase inhibitor structurally distinct fungal derivative therapeutic class fluvastatin racemate comprising equimolar amount 3r,5s 3s,5r -fluvastatin ", used adjunct dietary therapy prevent cardiovascular event may used secondary prevention patient coronary heart disease chd reduce risk requiring coronary revascularization procedure reducing progression coronary atherosclerosis hypercholesterolemic patient chd treatment primary hypercholesterolemia mixed dyslidipidemia 
Oxamniquine, anthelmintic schistosomicidal activity schistosoma mansoni schistosoma spp oxamniquine cause worm shift mesenteric vein liver male worm retained female worm return mesentery longer release egg martidale extra pharmacopoeia 31st ed p121 , treatment schistosomiasis caused schistosoma mansoni /i 
Leflunomide,leflunomide pyrimidine synthesis inhibitor belonging dmard disease-modifying antirheumatic drug class drug chemically pharmacologically heterogeneous leflunomide approved fda many country e.g. canada europe 1999 , management sign symptom active rheumatoid arthritis ra improve physical function slow progression structural damage associated disease also used prevention acute chronic rejection recipient solid organ trasnplants designated fda orphan drug use 
Rosuvastatin,rosuvastatin also known brand name product crestor lipid-lowering drug belongs statin class medication used lower risk cardiovascular disease manage elevated lipid level inhibiting endogenous production cholesterol liver specifically statin medication competitively inhibit enzyme hydroxymethylglutaryl-coenzyme hmg-coa reductase a181421 catalyzes conversion hmg-coa mevalonic acid third step sequence metabolic reaction involved production several compound involved lipid metabolism transport including cholesterol low-density lipoprotein ldl sometimes referred `` bad cholesterol '' low-density lipoprotein vldl prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd type 2 diabetes clear evidence benefit statin use coupled minimal side effect long term effect resulted class becoming one widely prescribed medication north america a181087 a181406 rosuvastatin drug statin class medication including atorvastatin pravastatin simvastatin fluvastatin lovastatin considered first-line option treatment dyslipidemia a181087 a181406 largely due fact cardiovascular disease cvd includes heart attack atherosclerosis angina peripheral artery disease stroke become leading cause death high-income country major cause morbidity around world a181084 elevated cholesterol level particular elevated low-density lipoprotein ldl level important risk factor development cvd a181087 a181553 use statin target reduce ldl level shown number landmark study significantly reduce risk development cvd all-cause mortality a181090 a181093 a181096 a181427 a181475 a181538 statin considered cost-effective treatment option cvd due evidence reducing all-cause mortality including fatal non-fatal cvd well need surgical revascularization angioplasty following heart attack a181087 a181406 evidence shown even low-risk individual 10 risk major vascular event occurring within 5 year statin cause 20 -22 relative reduction major cardiovascular event heart attack stroke coronary revascularization coronary death every 1 mmol/l reduction ldl without significant side effect risk a181397 a181403 statin medication considered equally effective clinical standpoint rosuvastatin considered potent dos 10 40mg rosuvastatin per day found clinical study result 45.8 54.6 decrease ldl cholesterol level three-fold potent atorvastatin 's effect ldl cholesterol a181409 a1793 however result saturn trial a181427 concluded despite difference potency difference effect progression coronary atherosclerosis rosuvastatin also unique member class statin due high hydrophilicity increase hepatic uptake site action low bioavailability minimal metabolism via cytochrome p450 system a181523 last point result le risk drug-drug interaction compared atorvastatin lovastatin simvastatin extensively metabolized cytochrome p450 cyp 3a4 enzyme involved metabolism many commonly used drug a181460 drug ciclosporin gemfibrozil antiretrovirals likely interact statin antagonism oatp1b1 organic anion transporter protein 1b1-mediated hepatic uptake rosuvastatin f4649 f4652 , fda monograph state rosuvastatin indicated adjunct diet treatment triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia homozygous familial hypercholesterolemia f4649 health canada monograph rosuvastatin specifies rosuvastatin indicated reduction elevated total cholesterol total-c ldl-c apob total-c/hdl-c ratio triglyceride tg increasing hdl-c hyperlipidemic dyslipidemic condition response diet exercise alone inadequate also indicated prevention major cardiovascular event including risk myocardial infarction nonfatal stroke coronary artery revascularization adult patient without documented history cardiovascular cerebrovascular event least two conventional risk factor cardiovascular disease f4652 prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd statin-indicated condition include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl-c level a181087 a181406 
Flucytosine, fluorinated cytosine analog used antifungal agent , treatment combination amphotericin b serious infection caused susceptible strain candida septicemia endocarditis urinary system infection and/or cryptococcus meningitis pulmonary infection 
Pimozide, diphenylbutylpiperidine effective antipsychotic agent alternative haloperidol suppression vocal motor tic patient tourette syndrome although precise mechanism action unknown blockade postsynaptic dopamine receptor postulated ama drug evaluation annual 1994 p403 ,used suppression motor phonic tic patient tourette 's disorder failed respond satisfactorily standard treatment 
Capecitabine,capecitabine orally-administered chemotherapeutic agent used treatment metastatic breast colorectal cancer capecitabine prodrug enzymatically converted fluorouracil antimetabolite tumor inhibits dna synthesis slows growth tumor tissue , treatment patient metastatic breast cancer resistant paclitaxel anthracycline-containing chemotherapy regimen may also used combination docetaxel treatment metastatic breast cancer patient failed respond recurred relasped following anthracycline-containing chemotherapy capecitabine used alone adjuvant therapy following complete resection primary tumor patient stage iii colon cancer monotherapy fluroprymidine preferred use capecitabine combination regimen advanced gastric cancer currently investigated 
Arbutamine,arbutamine administered closed-loop computer-controlled drug-delivery system indicated elicit acute cardiovascular response similar produced exercise order aid diagnosing presence absence coronary artery disease patient exercise adequately ,used elicit acute cardiovascular response cardiac stumulant similar produced exercise order aid diagnosing presence absence coronary artery disease cad patient exercise adequately 
Quinacrine, acridine derivative formerly widely used antimalarial superseded chloroquine recent year also used anthelmintic treatment giardiasis malignant effusion used cell biological experiment inhibitor phospholipase a2 , treatment giardiasis cutaneous leishmaniasis management malignant effusion 
Sertraline,sertraline popular antidepressant medication commonly known selective serotonin reuptake inhibitor ssri similar drug citalopram fluoxetine despite marked structural difference compound drug class ssri exert similar pharmacological effect several week therapy sertraline may required beneficial effect noticed sertraline display enhanced safety tolerability class antidepressant frequently cause high level drowsiness dizziness blurred vision undesirable effect a1846 a187075 t28 ,sertraline indicated management major depressive disorder mdd post-traumatic stress disorder ptsd obsessive-compulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd social anxiety disorder sad l9016 common off-label us sertraline include prevention post stroke depression a187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy neurocardiogenic syncope l5227 
Sibutramine,sibutramine trade name meridia usa reductil europe country usually sibutramide hydrochloride monohydrate orally administered agent treatment obesity centrally acting stimulant chemically related amphetamine thus classified schedule iv controlled substance united state october 2010 sibutramine withdrawn canadian u.s. market due concern drug increase risk heart attack stroke patient history heart disease , treatment obesity 
Levocabastine,levocabastine selective second-generation h1-receptor antagonist used allergic conjunctivitis levocabastine discovered janssen pharmaceutica 1979 , ophthalmic temporary relief sign symptom seasonal allergic conjunctivitis also used nasal spray allergic rhinitis 
Methyprylon,methyprylon sedative piperidinedione derivative family previously used treatment insomnia however introduction newer drug fewer side effect benzodiazepine clinical use methyprylon limited methyprylon withdrawn u.s. market june 1965 canadian market september 1990 due adverse event , treatment insomnia 
Trilostane,trilostane inhibitor 3 beta-hydroxysteroid dehydrogenase used treatment cushing 's syndrome withdrawn united state market april 1994 ,used treatment cushing 's syndrome normally used short-term treatment permanent therapy possible 
Heparin,"unfractionated heparin uh heterogenous preparation anionic sulfated glycosaminoglycan polymer weight ranging 3000 30,000 da naturally occurring anticoagulant released mast cell bind reversibly antithrombin iii atiii greatly accelerates rate atiii inactivates coagulation enzyme thrombin factor iia factor xa uh different low molecular weight heparin lmwh following way average molecular weight lmwh 4.5 kda whereas 15 kda uh uh requires continuous infusion activated partial prothrombin time aptt monitoring required using uh uh higher risk bleeding higher risk osteoporosis long term use unfractionated heparin specific lmwh thrombin furthermore effect uh typically reversed using protamine sulfate ",unfractionated heparin indicated prophylaxis treatment venous thrombosis extension prevention post-operative deep venous thrombosis pulmonary embolism prevention clotting arterial cardiac surgery cardiology used prevent embolism patient atrial fibrillation adjunct antithrombin therapy patient unstable angina and/or non-q wave myocardial infarction i.e non-st elevated acute coronary artery syndrome platelet glycoprotein iib/iiia receptor inhibitor additionally used prevent clotting dialysis surgical procedure maintain patency intravenous injection device prevent vitro coagulation blood transfusion blood sample drawn laboratory value 
Miconazole,miconazole broad-spectrum azole antifungal activity gram-positive bacteria well a203636 widely used treat mucosal yeast infection including oral vaginal infection although intravenous miconazole longer available wide variety suppository cream gel tablet-based product available l14021 l14024 l14027 l14033 l14396 miconazole thought act primarily inhibition fungal cyp450 14α-lanosterol demethylase activity a203636 a203639 miconazole first synthesized 1969 first granted fda approval january 8 1974 sale insight pharmaceutical topical cream a214523 l14021 currently available variety prescription counter product despite clinical use extended period resistance miconazole among susceptible organism relatively low a203636 ,miconazole indicated local treatment oropharyngeal candidiasis adult patient adjunctive treatment diaper dermatitis complicated candidiasis immunocompetent patient aged four week older l14021 l14024 miconazole available suppository cream treatment vaginal yeast infection relief associated vulvar itching irritation l14027 lastly miconazole cream effective treating athlete 's foot tinea pedis jock itch tinea cruris ringworm infection tinea corporis l14033 pityriasis formerly tinea versicolor a203633 cutaneous candidiasis a203630 
Colistimethate,colistimethate antibiotic shown bactericidal activity aerobic gram-negative microorganism colistimethate particularly indicated infection caused sensitive strain pseudomonas aeruginosa , treatment acute chronic infection due sensitive strain certain gram-negative bacillus particularly _pseudomonas aeruginosa_ 
Cefuroxime,broad-spectrum cephalosporin antibiotic resistant beta-lactamase proposed infection gram-negative gram-positive organism gonorrhea haemophilus , treatment many different type bacterial infection bronchitis sinusitis tonsillitis ear infection skin infection gonorrhea urinary tract infection 
Papaverine, alkaloid found opium closely related opium alkaloid structure pharmacological action direct-acting smooth muscle relaxant used treatment impotence vasodilator especially cerebral vasodilation mechanism pharmacological action clear apparently inhibit phosphodiesterases may direct action calcium channel , treatment impotence vasospasms 
Chlorpheniramine, histamine h1 antagonist used allergic reaction hay fever rhinitis urticaria asthma also used veterinary application one widely used classical antihistaminics generally cause le drowsiness sedation promethazine , treatment rhinitis urticaria allergy common cold asthma hay fever 
Nifedipine,nifedipine bay 1040 first generation dihydropyridine l-type calcium channel blocker similar nicardipine a190210 a190273 a175390 l11383 nifedipine developed bayer first described literature along dihydropyridines 1972 a175390 a190276 since nifedipine 's development second third generation dihydropyridines developed slower onset longer duration action a190273 popular third generation dihydropyridines amlodipine a190273 nifedipine granted fda approval 31 december 1981 l11383 ,nifedipine capsule indicated treat vasospastic angina chronic stable angina l11383 extended release tablet indicated treat vasospastic angina chronic stable angina hypertension l11389 l1245 
Trimethaphan, nicotinic antagonist used ganglionic blocker hypertension adjunct anesthesia induce hypotension surgery , controlled reduction blood pressure surgery treatment hypertensive emergency 
Atovaquone,atovaquone hydroxynaphthoquinone analog ubiquinone antimicrobial antipneumocystis activity used antimalarial protocol , treatment prevention pneumocystis carinii /i pneumonia patient intolerant trimethoprim-sulfamethoxazole tmp-smx also indicated acute oral treatment mild moderate pcp patient intolerant tmp-smx 
Amiodarone,amiodarone benzofuran derivative anti-arrhythmic drug used commonly variety setting a36817 known approved indication life-threatening ventricular arrhythmia also used off-label outpatient inpatient setting atrial fibrillation ability cause serious toxicity possibly death amiodarone use reserved approved indication according prescribing information l3561 l11265 l11286 , fda approved indication amiodarone recurrent ventricular fibrillation vf recurrent hemodynamically unstable ventricular tachycardia vt fda emphasizes drug given condition clinically documented responded normal therapeutic dos antiarrhythmic agent drug tolerated patient l3561 off-label indication include atrial fibrillation supraventricular tachycardia a189666 a189720 a189723 l11286 
Diazoxide, benzothiadiazine derivative peripheral vasodilator used hypertensive emergency lack diuretic effect apparently lack sulfonamide group ,used parentally treat hypertensive emergency also used treat hypoglycemia secondary insulinoma 
Gliclazide,gliclazide oral antihyperglycemic agent used treatment non-insulin-dependent diabetes mellitus niddm classified differently according drug property based chemical structure gliclazide considered first-generation sulfonylurea due structural presence sulfonamide group able release proton presence one aromatic group a39546 hand based pharmacological efficacy gliclazide considered second-generation sulfonylurea present higher potency shorter half-life t238 t360 gliclazide belongs sulfonylurea class insulin secretagogues act stimulating beta cell pancreas release insulin sulfonylurea increase basal insulin secretion meal-stimulated insulin release medication class differ dose rate absorption duration action route elimination binding site target pancreatic beta cell receptor sulfonylurea also increase peripheral glucose utilization decrease hepatic gluconeogenesis may increase number sensitivity insulin receptor sulfonylurea associated weight gain though le insulin due mechanism action sulfonylurea may cause hypoglycemia require consistent food intake decrease risk risk hypoglycemia increased elderly debilitated malnourished individual gliclazide shown decrease fasting plasma glucose postprandial blood glucose glycosolated hemoglobin hba1c level reflective last 8-10 week glucose control gliclazide extensively metabolized liver metabolite excreted urine 60-70 feces 10-20 , treatment niddm conjunction diet exercise 
Phenacemide,phenacemide used control certain seizure treatment epilepsy medicine act central nervous system cns reduce number severity seizure ,used control certain seizure treatment epilepsy 
Ambenonium,ambenonium cholinesterase inhibitor used management myasthenia gravis ,ambenonium used treat muscle weakness due muscle disease myasthenia gravis 
Proflavine,"3,6-diaminoacridine topical antiseptic used mainly wound dressing ",topical antiseptic used mainly wound dressing 
Tolbutamide,tolbutamide oral antihyperglycemic agent used treatment non-insulin-dependent diabetes mellitus niddm structurally similar acetohexamide chlorpropamide tolazamide belongs sulfonylurea class insulin secretagogues act stimulating β cell pancreas release insulin sulfonylurea increase basal insulin secretion meal-stimulated insulin release medication class differ dose rate absorption duration action route elimination binding site target pancreatic β cell receptor sulfonylurea also increase peripheral glucose utilization decrease hepatic gluconeogenesis may increase number sensitivity insulin receptor sulfonylurea associated weight gain though le insulin due mechanism action sulfonylurea may cause hypoglycemia require consistent food intake decrease risk risk hypoglycemia increased elderly debilitated malnourished individual tolbutamide appears metabolized liver tolbutamide metabolite excreted urine 75-85 feces , treatment niddm non-insulin-dependent diabetes mellitus conjunction diet exercise 
Anisindione,anisindione synthetic anticoagulant indanedione derivative anticoagulant action mediated inhibition vitamin k-mediated gamma-carboxylation precursor protein critical forming formation active procoagulation factor ii vii ix x well anticoagulant protein c liver , prophylaxis treatment venous thrombosis extension treatment atrial fibrillation embolization prophylaxis treatment pulmonary embolism adjunct treatment coronary occlusion 
Dutasteride,dutasteride oral synthetic 4-azasteroid commonly marketed trade name avodart novel dual 5α-reductase inhibitor work blocking isoforms 5α-reductase enzyme potent selective irreversible manner a1909 type ii 5α-reductase enzyme convert testosterone dihydrotestosterone dht primary hormonal mediator play role development enlargement prostate gland dutasteride approved fda 2001 treatment symptomatic benign prostatic hyperplasia bph men monotherapy combination α-adrenergic antagonist tamsulosin enhance therapeutic response clinical efficacy benign prostate hyperplasia male patient comparable finasteride specific type ii 5α-reductase inhibitor however unlike finasteride dutasteride yet indicated treatment androgenic alopecia although demonstrated effective several randomized double-blind placebo-controlled trial androgenetic alopecia a178333 a178336 ,indicated treatment symptomatic benign prostatic hyperplasia bph men enlarged prostate gland improve symptom reduce risk acute urinary retention need bph-related surgery alone combination tamsulosin l10568 
Econazole, broad spectrum antimycotic action gram positive bacteria used topically dermatomycoses also orally parenterally , topical application treatment tinea pedis tinea cruris tinea corporis caused trichophyton rubrum /i trichophyton mentagrophytes /i trichophyton tonsurans /i microsporum canis /i microsporum audouini /i microsporum gypseum /i epidermophyton floccosum /i treatment cutaneous candidiasis treatment tinea versicolor 
Bicalutamide,bicalutamide oral non-steroidal anti-androgen prostate cancer comprised racemic mixture 50:50 composition r -bicalutamide -bicalutamide enantionmers bicalutamide bind androgen receptor ,bicalutamide indicated combination luteinizing hormone-releasing hormone lhrh agonist treatment stage d2 metastatic carcinoma prostate l40478 
Rabeprazole,rabeprazole antiulcer drug class proton pump inhibitor prodrug acid environment parietal cell turn active sulphenamide form rabeprazole inhibits h+ k+atpase coating gastric cell dose-dependent oppresses basal stimulated gastric acid secretion , treatment acid-reflux disorder gerd peptic ulcer disease h. pylorus eradication prevention gastroinetestinal bleeds nsaid use 
Prednicarbate,prednicarbate relatively new topical corticosteroid drug display similar potency hydrocortisone used treatment inflammatory skin disease atopic dermatitis favorable benefit-risk ratio inflammatory action similar medium potency corticosteroid low potential cause skin atrophy anti-inflammation action corticosteroid associated inhibition interleukin 1-alpha cytokine within keratinocytes il-1a also found fibroblast responsible proliferation collagenase induction il-6 synthesis related skin thickness , relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Proguanil,proguanil prophylactic antimalarial drug work stopping malaria parasite _plasmodium falciparum_ _plasmodium vivax_ reproducing red blood cell inhibiting enzyme dihydrofolate reductase involved reproduction parasite , causal prevention suppression malaria caused susceptible strain p falciparum /i specie plasmodium found geographical area world 
Pioglitazone,pioglitazone antihyperglycemic used adjunct diet exercise antidiabetic medication manage type 2 diabetes mellitus l11416 l11419 l11422 l11425 administered racemic mixture though pharmacologic difference enantiomer appear interconvert _in vivo_ little consequence l11416 thiazolidinedione class medication also includes rosiglitazone troglitazone exerts pharmacological effect primarily promoting insulin sensitivity improved uptake blood glucose l11416 via agonism peroxisome proliferator-activated receptor-gamma pparγ a19757 ppars ligand-activated transcription factor involved expression 100 gene affect numerous metabolic process notably lipid glucose homeostasis a19759 thiazolidinediones including pioglitazone fallen favor recent year due presence multiple adverse effect warning regarding use e.g congestive heart failure bladder cancer availability safer effective alternative patient type 2 diabetes mellitus l11461 ,pioglitazone indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus l11416 also available combination metformin l11419 glimepiride l11422 alogliptin l11425 indication 
Tiludronic acid,"tiludronate 4-chlorophenyl thio-methylene-1,1-bisphosphonate first generation bisphosphonate similar etidronic acid clodronic acid a1923 a203111 drug developed mimic action pyrophosphate regulator calcification decalcification a1923 tiludronic acid first described literature 1988 potential treatment paget 's disease bone a202235 tiludronic acid granted fda approval 7 march 1997 l4763 ",tiludronic acid indicated treat paget 's disease bone patient serum alkaline phosphatase level ≥2 time upper limit normal symptom risk future complication l4763 
Desoxycorticosterone pivalate,desoxycorticosterone pivalate mineralocorticoid hormone analog desoxycorticosterone white odorless stable air practically insoluble water sparingly soluble acetone slightly soluble methanol ether vegetable oil federal u.s.a. law restricts drug use order licensed veterinarian ,examined treatment adrenocortical insufficiency especially multiple sclerosis congenital cerebral palsy polyarteritis nodosa rheumatoid arthritis currently approved treating cat dog treatment addison 's disease 
Doxacurium,doxacurium chloride long-acting nondepolarizing skeletal muscle relaxant intravenous administration ,used provide skeletal muscle relaxation adjunct general anesthesia endotracheal intubation facilitate mechanical ventilation 
Carvedilol,carvedilol racemic mixture enantiomer beta adrenoceptor blocker r enantiomer beta alpha-1 adrenoceptor blocker l7889 l7892 currently used treat heart failure left ventricular dysfunction hypertension l7889 l7892 dual action carvedilol advantageous combination therapy moderate dos 2 drug decreased incidence adverse effect compared high dose monotherapy treatment moderate hypertension a182306 carvedilol granted fda approval 14 september 1995 l7889 ,carvedilol indicated treat mild severe heart failure left ventricular dysfunction myocardial infarction ventricular ejection fraction ≤40 hypertension l7889 l7892 
Levofloxacin,levofloxacin fluoroquinolone antibiotic optical s- isomer racemic ofloxacin a190663 reportedly carry 8 128-fold activity gram-negative gram-positive bacteria compared r- -ofloxacin a190663 remains stereochemically stable following administration i.e invert inactive isomer l11638 levofloxacin along quinolones gatifloxacin moxifloxacin member third generation fluoroquinolones colloquially referred `` respiratory quinolones '' due improved activity gram-positive bacteria commonly implicated respiratory infection a31453 a190756 levofloxacin first approved fda 1996 approved canada several south american country soon a190663 , oral intravenous formulation levofloxacin indicated adult treatment various infection caused susceptible bacteria including infection upper respiratory tract lower respiratory tract skin skin structure urinary tract prostate l11638 l11692 oral formulation also indicated adult child 6 month age older post-exposure management inhalational anthrax caused _bacillus anthracis_ treatment and/or prophylaxis plague caused _yersinia pestis_ l11638 ophthalmic formulation levofloxacin indicated treatment bacterial conjunctivitis caused susceptible organism l11641 inhalational solution available canada indicated management cystic fibrosis patient aged 18 year older chronic pulmonary _pseudomonas aeruginosa_ infection l11689 
Sulfinpyrazone, uricosuric drug used reduce serum urate level gout therapy lack anti-inflammatory analgesic diuretic property , treatment gout gouty arthritis 
Cefapirin,cefapirin inn also spelled cephapirin commonly marketed trade name cefadyl first-generation cephalosporin antibiotic available injectable formulation production use human discontinued united state cefapirin partly plasma-bound effective gram-negative gram-positive organism , treatment infection caused susceptible bacteria 
Cefadroxil,long-acting broad-spectrum water-soluble cephalexin derivative , treatment following infection skin uti ent caused pneumoniae h. influenzae staphylococci s. pyogenes /i group beta-hemolytic streptococci e coli p. mirabilis klebsiella /i sp coagulase-negative staphylococci streptococcus pyogenes /i 
Micafungin,"micafungin antifungal drug belongs antifungal class compound known echinocandins exerts effect inhibiting synthesis 1,3-beta-d-glucan integral component fungal cell wall ",indicated treatment candidemia acute disseminated candidiasis certain invasive candida /i infection well esophageal candidiasis prophylaxis candida /i infection patient undergoing hematopoietic stem cell transplantation micafungin also used alternative treatment oropharyngeal candidiases used success primary salvage therapy alone combination antifungal treatment invasive aspergillosis indicated prophylaxis candida infection patient undergoing hematopoietic stem cell transplantation 
Doxepin,doxepin psychotropic agent antidepressant anxiolytic property t559 tertiary amine presented e z stereoisomers z stereoisomer corresponding cidoxepin doxepin commonly produce 5:1 e z racemic mixture t83 strict sense doxepin tricyclic antidepressant commonly associated class since share lot property member drug family including amitriptyline clomipramine desipramine imipramine nortriptyline protriptyline trimipramine l5977 doxepin developed pfizer fda approved 1969 antidepressant l5971 however 2010 approved treatment insomnia latter indication presented pernix therapeutic l5974 ,oral doxepin approved following indication treatment depression and/or anxiety a177163 treatment depression and/or anxiety associated different condition including alcoholism organic disease manic-depressive disorder t249 treatment psychotic depressive disorder associated anxiety t249 treatment involutional depression t249 treatment manic-depressive disorder t249 treatment insomnia characterized difficulty sleep maintenance a177163 topical doxepin also approved short-term 8 day management moderate pruritus adult patient atopic dermatitis pruritus lichen simplex chronicus t249 off-label doxepin used topically management neuropathic pain a177172 depression common medical illness cause feeling sadness loss interest prior enjoyable activity condition lead emotional physical disturbance decrease ability person function regular environment l5980 anxiety normal reaction body towards normal danger anxious state exacerbated appears situation without danger defined anxiety disorder disorder appear different form phobia panic obsessive-compulsive disorder post-traumatic stress disorder l5983 insomnia sleep disorder directly affect quality life individual characterized complication either fall asleep stay asleep condition occasional chronic l5986 pruritus defined unpleasant skin reaction provokes urge scratch localized generalized appear acute chronic manner l5989 neuropathic pain occurs due damage dysfunction peripheral central nervous system rather stimulation pain receptor l5992 
Amifostine, phosphorothioate proposed radiation-protective agent cause splenic vasodilation may block autonomic ganglion , reduction cumulative renal toxicity patient ovarian cancer using cisplatin moderate severe xerostomia patient undergoing post-operative radiation treatment head neck cancer 
Diclofenamide, carbonic anhydrase inhibitor used treatment glaucoma , adjunctive treatment chronic simple open-angle glaucoma secondary glaucoma preoperatively acute angle-closure glaucoma delay surgery desired order lower intraocular pressure
Sulfoxone,sulfoxone water-soluble sulfone used antileprosy drug used limited success treatment dermatitis herpetiformis , treatment leprosy dermatitis herpetiformis
Diphenylpyraline,diphenylpyraline antihistamine antihistamine used treatment allergy act competing histamine h 1-receptor site effector cell antihistamine prevent reverse response mediated histamine alone antihistamine antagonize varying degree pharmacological effect histamine including urticaria pruritus , use treatment allergic rhinitis hay fever allergic skin disorder 
Cloxacillin, semi-synthetic penicillin antibiotic chlorinated derivative oxacillin ,cloxacillin indicated treatment beta-hemolytic streptococcal pneumococcal staphylococcal infection including beta-lactamase producing organism l33170 
Flavoxate, drug used various urinary syndrome antispasmodic therapeutic usefulness mechanism action clear may local anesthetic activity direct relaxing effect smooth muscle well activity muscarinic antagonist pubchem , symptomatic relief dysuria urgency nocturia suprapubic pain frequency incontinence may occur cystitis prostatitis urethritis urethrocystitis/urethrotrigonitis 
Nefazodone,"nefazodone hydrochloride trade name serzone antidepressant drug marketed bristol-myers squibb sale discontinued 2003 country due small possibility hepatic liver injury drug-induced hepatic injury associated risk elevated need liver transplant even death incidence severe liver damage shown approximately 1 250,000 300,000 patient-years may 20 2004 bristol-myers squibb discontinued sale serzone united state ", treatment depression 
Cefprozil,cefprozil cephalosporin antibiotic commonly employed treat variety bacterial infection including ear skin bronchitis others , treatment following infection respiratory skin soft tissue uti ent caused s. pneumoniae h. influenzae staphylococci s. pyogenes group beta-hemolytic streptococci e. coli p. mirabilis klebsiella sp coagulase-negative staph
Desipramine,desipramine hydrochloride dibenzazepine-derivative tricyclic antidepressant tca tcas structurally similar phenothiazine contain tricyclic ring system alkyl amine substituent central ring non-depressed individual desipramine affect mood arousal may cause sedation depressed individual desipramine exerts positive effect mood tcas potent inhibitor serotonin norepinephrine reuptake secondary amine tcas desipramine nortriptyline potent inhibitor norepinephrine reuptake tertiary amine tcas amitriptyline doxepine tcas also down-regulate cerebral cortical beta -adrenergic receptor sensitize post-synaptic serotonergic receptor chronic use antidepressant effect tcas thought due overall increase serotonergic neurotransmission tcas also block histamine-h sub 1 /sub receptor alpha sub 1 /sub -adrenergic receptor muscarinic receptor account sedative hypotensive anticholinergic effect e.g blurred vision dry mouth constipation urinary retention respectively see toxicity section complete listing side effect desipramine exerts le anticholinergic sedative side effect compared tertiary amine tcas amitriptyline clomipramine desipramine may used treat depression neuropathic pain unlabeled use agitation insomnia unlabeled use attention-deficit hyperactivity disorder unlabeled use , relief symptom various depressive syndrome especially endogenous depression also used manage chronic peripheral neuropathic pain second line agent management anxiety disorder e.g panic disorder generalized anxiety disorder second third line agent adhd management 
Candicidin,candicidin antibiotic obtained streptomyces streptomyces griseus active fungi genus candida c. albicans candicidin administered intravaginally treatment vulvovaginal candidiasis ,used topical treatment vulvovaginal candidiasis 
Sertaconazole,sertaconazole nitrate antifungal medication imidazole class available topical formulation treatment skin infection athlete 's foot , topical treatment interdigital tinea pedis immunocompetent patient 12 year age older caused trichophyton rubrum /i trichophyton mentagrophytes /i epidermophyton floccosum /i 
Thiamylal, barbiturate administered intravenously production complete anesthesia short duration induction general anesthesia inducing hypnotic state martindale extra pharmacopoeia 30th ed p919 ,used production complete anaesthesia short duration induction general anaesthesia inducing hypnotic state 
Gemifloxacin,gemifloxacin quinolone antibacterial agent broad-spectrum activity used treatment acute bacterial exacerbation chronic bronchitis mild-to-moderate pneumonia available oral formulation gemifloxacin act inhibiting dna synthesis inhibition dna gyrase topoisomerase iv essential bacterial growth , treatment bacterial infection caused susceptible strain pneumoniae /i h influenzae /i h parainfluenzae /i catarrhalis /i pneumoniae /i including multi-drug resistant strain mdrsp pneumoniae /i c pneumoniae /i k pneumoniae /i 
Bupropion,bupropion also known brand name product wellbutrin® norepinephrine/dopamine-reuptake inhibitor ndri used commonly management major depressive disorder mdd seasonal affective disorder sad aid smoking cessation bupropion exerts pharmacological effect weakly inhibiting enzyme involved uptake neurotransmitter norepinephrine dopamine synaptic cleft therefore prolonging duration action within neuronal synapse downstream effect neurotransmitter specifically bupropion bind norepinephrine transporter net dopamine transporter dat a6399 a178810 bupropion originally classified `` atypical '' antidepressant exert effect classical antidepressant monoamine oxidase inhibitor maoi tricyclic antidepressant tcas selective serotonin reuptake inhibitor ssri comparable effectiveness typical first-line option treatment depression ssri a178798 a178804 bupropion unique option treatment mdd lack clinically relevant serotonergic effect typical mood medication effect histamine adrenaline receptor a6399 a178840 lack activity receptor result tolerable side effect profile bupropion le likely cause sexual side effect sedation weight gain compared ssri tcas example a178804 a178807 used aid smoking cessation bupropion thought confer anti-craving anti-withdrawal effect inhibiting dopamine reuptake thought involved reward pathway associated nicotine antagonism nicotinic acetylcholinergic receptor a178825 a1966 a16508 cochrane review meta-analyses available treatment modality smoking cessation found abstinence rate approximately doubled bupropion used compared placebo found similar rate smoking cessation nicotine replacement therapy nrt a178816 bupropion sometimes used add-on agent first-line treatment depression selective serotonin reuptake inhibitor ssri medication treatment-failure partial response a178789 bupropion also used off-label management attention/deficit-hyperactivity disorder adhd adult comorbid bipolar depression avoid mood destabilization caused typical stimulant medication used treatment adhd f4624 used combination naltrexone marketed product contraveⓡ chronic weight management two component thought effect area brain involved regulation food intake includes hypothalamus involved appetite regulation mesolimbic dopamine circuit involved reward pathway l6562 study shown combined activity bupropion naltrexone increase firing rate hypothalamic pro-opiomelanocortin pomc neuron blockade opioid receptor-mediated pomc auto-inhibition associated reduction food intake increased energy expenditure l6562 a179038 a179050 combination naltrexone bupropion shown result statistically significant weight loss mean change body weight -6.3 compared -1.3 placebo a179047 ,bupropion indicated treatment major depressive disorder mdd seasonal affective disorder sad aid smoking cessation used combination naltrexone marketed product contraveⓡ bupropion indicated adjunct reduced-calorie diet increased physical activity chronic weight management adult initial body mass index bmi 30 kg/m^2 greater obese 27 kg/m^2 greater overweight presence least one weight-related comorbid condition e.g. hypertension type 2 diabetes mellitus dyslipidemia bupropion also used off-label first-line treatment patient adhd comorbid bipolar disorder used adjunct mood stabilizer f4624 
Trimetrexate, nonclassical folic acid inhibitor inhibition enzyme dihydrofolate reductase tested efficacy antineoplastic agent antiparasitic agent pneumocystis pneumonia aid patient myelosuppression dose-limiting toxic effect , use concurrent leucovorin administration leucovorin protection alternative therapy treatment moderate-to-severe pneumocystis carinii /i pneumonia pcp immunocompromised patient including patient acquired immunodeficiency syndrome aid also used treat several type cancer including colon cancer 
Bretylium,bretylium block release noradrenaline peripheral sympathetic nervous system used emergency medicine cardiology specialty acute management ventricular tachycardia ventricular fibrillation primary mode action bretylium thought inhibition voltage-gated k channel recent evidence shown bretylium may also inhibit na k-atpase binding extracellular k-site , use prophylaxis therapy ventricular fibrillation also used treatment life-threatening ventricular arrhythmia ventricular tachycardia failed respond adequate dos first-line antiarrhythmic agent lidocaine 
Halothane, nonflammable halogenated hydrocarbon anesthetic provides relatively rapid induction little excitement analgesia may adequate nitrous oxide often given concomitantly halothane may produce sufficient muscle relaxation supplemental neuromuscular blocking agent may required ama drug evaluation annual 1994 p178 , induction maintenance general anesthesia
Dinoprost tromethamine, tromethamine tham salt naturally occurring prostaglandin f2 alpha dinoprost tromethamine occurs white off-white hygroscopic crystalline powder dinoprost tromethamine may also known dinoprost trometamol pgf2 alpha tham prostaglandin f2 alpha tromethamine ,used aborting second-trimester pregnancy twelfth eighteenth week gestation incomplete abortion therapeutic abortion case intrauterine fetal death congenital abnormality incompatible life also used low-doses medically indicated induction labor term also injected intra-arterially use vasodilator assist angiography 
Chloroprocaine,chloroprocaine ester local anesthetic commonly available salt form chloroprocaine hydrochloride similar local anesthetic increase threshold electrical excitation nerve slowing propagation nerve impulse reducing rate rise action potential l43402 pharmacological profile chloroprocaine characterized short latency duration similar one observed lidocaine a252952 chloroprocaine given injection available formulation without methylparaben preservative given intrathecal injection peripheral central nerve block preservative-free formulation used lumbar caudal epidural block a252952 l43382 topical chloroprocaine ophthalmic use approved fda september 2022 ocular surface anesthesia l43387 ,chloroprocaine intrathecal injection indicated production subarachnoid block spinal anesthesia adult l43377 also indicated production local anesthesia infiltration peripheral central nerve block preservative-free form also used lumbar caudal epidural block l43382 topical chloroprocaine ophthalmic use indicated ocular surface anesthesia l43387 
Terazosin,terazosin quinazoline derivative alpha-1-selective adrenergic blocking agent indicated benign prostatic hyperplasia hypertension fda label a176831 terazosin block adrenaline 's action alpha-1 adrenergic receptor causing relaxation smooth muscle blood vessel prostate a176837 ,terazosin indicated use treating symptomatic benign prostatic hyperplasia hypertension fda label 
Amdinocillin,amidinopenicillanic acid derivative broad spectrum antibacterial action poorly absorbed given orally used urinary infection typhus amdinocillin available united state ,used treatment urinary tract infection caused strain e. coli klebsiella enterobacter specie used mainly gram negative organism 
Calcium chloride,calcium chloride ionic compound calcium chlorine highly soluble water deliquescent salt solid room temperature behaves typical ionic halide several common application brine refrigeration plant ice dust control road cement produced directly limestone large amount also produced by-product solvay process hygroscopic nature must kept tightly-sealed container , treatment hypocalcemia condition requiring prompt increase blood plasma calcium level treatment magnesium intoxication due overdosage magnesium sulfate used combat deleterious effect hyperkalemia measured electrocardiographic ecg pending correction increased potassium level extracellular fluid 
Ofloxacin, synthetic fluoroquinolone fluoroquinolones antibacterial agent inhibits supercoiling activity bacterial dna gyrase halting dna replication , treatment infection respiratory tract kidney skin soft tissue uti urethral cervical gonorrhoea 
Cilostazol,cilostazol quinolinone derivative antiplatelet agent vasodilating property used symptomatic treatment intermittent claudication patient peripheral ischaemia marketed brand name pletal otsuka pharmaceutical co .. cilostazol work inhibiting primary secondary aggregation reducing calcium-induced contraction ,indicated alleviation symptom intermittent claudication pain leg occurs walking disappears rest 
Itraconazole,one triazole antifungal agent inhibits cytochrome p-450-dependent enzyme resulting impairment ergosterol synthesis used histoplasmosis blastomycosis cryptococcal meningitis aspergillosis , treatment following fungal infection immunocompromised non-immunocompromised patient pulmonary extrapulmonary blastomycosis histoplasmosis aspergillosis onychomycosis 
Procarbazine, antineoplastic agent used primarily combination mechlorethamine vincristine prednisone mopp protocol treatment hodgkin 's disease , use anticancer drug treatment stage iii stage iv hodgkin 's disease 
Arsenic trioxide,arsenic trioxide chemotherapeutic agent idiopathic function used treat leukemia unresponsive first line agent suspected arsenic trisulfide induces cancer cell undergo apoptosis general arsenic known naturally toxic substance capable eliciting variety dangerous adverse effect enzyme thioredoxin reductase recently identified target arsenic trioxide , induction remission consolidation patient acute promyelocytic leukemia apl whose apl characterized presence 15 17 translocation pml/rar-alpha gene expression
Guanethidine, antihypertensive agent act inhibiting selectively transmission post-ganglionic adrenergic nerve believed act mainly preventing release norepinephrine nerve ending cause depletion norepinephrine peripheral sympathetic nerve terminal well tissue pubchem , treatment moderate severe hypertension either alone adjunct treatment renal hypertension 
Moclobemide, reversible monoamine oxidase inhibitor maoi selective isoform rima used treat major depressive disorder meta-analyses study indicate acute management depression moclobemide efficacious placebo medication similarly efficacious tricyclic antidepressant tca selective serotonin reuptake inhibitor ssri due negligible anticholinergic antihistaminic action moclobemide better tolerated tri- heterocyclic antidepressant a31901 , treatment major depressive disorder bipolar disorder a31901 
Kanamycin,kanamycin also known kanamycin aminoglycoside bacteriocidal antibiotic available oral intravenous intramuscular form used treat wide variety infection kanamycin isolated bacterium streptomyces kanamyceticus commonly used form kanamycin sulfate , treatment infection one following known suspected pathogen e coli /i proteus /i specie indole-positive indole-negative e aerogenes k. pneumoniae s. marcescens /i acinetobacter /i specie 
Orphenadrine, muscarinic antagonist used treat drug-induced parkinsonism relieve pain muscle spasm ,indicated adjunct rest physical therapy measure relief discomfort associated acute painful musculo skeletal condition 
Phenobarbital, barbituric acid derivative act nonselective central nervous system depressant promotes binding inhibitory gamma-aminobutyric acid subtype receptor modulates chloride current receptor channel also inhibits glutamate induced depolarization , treatment type seizure except absence seizure 
Escitalopram,escitalopram selective serotonin re-uptake inhibitor ssri s-enantiomer racemic citalopram a185420 used restore serotonergic function treatment depression anxiety l8513 l8516 l8522 escitalopram approximately 150 time potent citalopram ’ r-enantiomer responsible vast majority citalopram ’ clinical activity evidence suggesting r-enantiomer racemic citalopram actively dampens activity escitalopram rather existing simply inactive enantiomer a39738 a185819 amongst ssri escitalopram exerts highest degree selectivity serotonin transporter sert relative off-targets may explain lower rate adverse effect compared agent class a185726 escitalopram also differentiates ssri via allosteric action target may mechanism responsible observed superior efficacy faster onset compared ssri a185825 a185726 a185822 ,escitalopram indicated acute maintenance treatment major depressive disorder mdd acute treatment generalized anxiety disorder gad l8513 additionally indicated symptomatic relief obsessive-compulsive disorder ocd canada l8516 
Cyclizine, histamine h1 antagonist given mouth parenterally control postoperative drug-induced vomiting motion sickness martindale extra pharmacopoeia 30th ed p935 , prevention treatment nausea vomiting dizziness associated motion sickness vertigo dizziness caused medical problem 
Idarubicin, orally administered anthracycline antineoplastic compound shown activity breast cancer lymphoma leukemia together potential reduced cardiac toxicity , treatment acute myeloid leukemia aml adult includes french-american-british fab classification m1 m7 
Chlormezanone, non-benzodiazepine used management anxiety suggested use treatment muscle spasm ,used management anxiety treatment muscle spasm 
Podofilox, lignan found podophyllin resin root podophyllum plant potent spindle poison toxic taken internally used cathartic irritating skin mucous membrane keratolytic action used treat wart keratoses may antineoplastic property congener derivative , treatment external genital wart condyloma acuminatum /i 
Rescinnamine,rescinnamine angiotensin-converting enzyme inhibitor used antihypertensive drug alkaloid obtained _rauwolfia serpentina_ specie _rauwolfia_ , treatment hypertension 
Ifosfamide,ifosfamide chemotherapeutic agent chemically related nitrogen mustard synthetic analog cyclophosphamide active alkylating agent immunosuppressive agent ,used component various chemotherapeutic regimen third-line therapy recurrent refractory germ cell testicular cancer also used component various chemotherapeutic regimen treatment cervical cancer well conjunction surgery and/or radiation therapy treatment various soft tissue sarcoma indication include treatment osteosarcoma bladder cancer ovarian cancer small cell lung cancer non-hodgkin 's lymphoma 
Propafenone, antiarrhythmia agent particularly effective ventricular arrhythmia also weak beta-blocking activity drug generally well tolerated ,used prolong time recurrence paroxysmal atrial fibrillation/flutter paf associated disabling symptom patient without structural heart disease also used treatment life-threatening documented ventricular arrhythmia sustained ventricular tachycardia 
Naloxone,naloxone opioid antagonist medication used block reverse effect opioid drug particularly within setting drug overdoses rapidly becoming leading cause death worldwide a234594 specifically naloxone high affinity μ-opioid receptor act inverse agonist causing rapid removal drug bound receptor a234594 taken large quantity opioid medication morphine hydromorphone methadone heroin fentanyl capable causing life-threatening symptom respiratory depression reduced heart rate slurred speech drowsiness constricted pupil a234594 l33724 untreated progress vomiting absent pulse breathing loss consciousness even death l33724 naloxone indicated rapid reversal symptom central nervous system depression opioid overdose a234589 's important note naloxone work opioid receptor within body therefore capable reversing effect non-opioid medication stimulant like methamphetamine cocaine benzodiazepine like lorazepam diazepam also known brand name product narcan naloxone currently available intramuscular im subcutaneous subq injection nasal spray intravenous iv infusion l33729 l33739 naloxone im injection commonly available form `` kit '' ideal making overdose treatment accessible readily available administration minimally trained individual within community l33734 kit commonly include supply necessary treat overdose non-medical setting alcohol swab syrinx rescue breathing mask instruction use frequently also carried medical emergency personnel event known associated heavy drug use like music festival naloxone kit considered key component harm reduction strategy injected intramuscularly im naloxone act within three five minute administration naloxone associated side effect notably injected person currently using opioid medication would noticeable effect however individual using opioid medication experiencing overdose im injection naloxone rapidly revers opioid effect cause injected individual immediately experience withdrawal symptom a234589 common symptom opioid withdrawal include nausea vomiting sweating runny nose ache diarrhea a234589 although certainly physically uncomfortable opioid withdrawal symptom life-threatening administration naloxone therefore appropriate person appearing symptom opioid overdose due short duration action person injected naloxone monitored responsiveness potentially injected second time taken hospital a234589 naloxone also available within combination product suboxone opioid medication buprenorphine l33714 l33719 suboxone used maintenance treatment opioid dependence addiction l33714 l33719 taken orally naloxone pharmacological effect reduce effectiveness opioid effect buprenorphine l33714 l33719 primary purpose including naloxone within suboxone act deterrent injection injected naloxone would rapidly reverse effect buprenorphine l33714 l33719 naloxone granted fda approval 13 april 1971 l33709 ,naloxone nasal spray indicated emergency treatment opioid overdose suspected opioid overdose l33694 intramuscular intravenous subcutaneous injection indicated complete partial reversal opioid depression diagnosis known suspected opioid overdose adjunct therapy treatment septic shock l33739 sublingual tablet film formulated buprenorphine treatment opioid dependence l33714 l33719 naloxone also formulated pentazocine oral tablet severe pain l33744 intramuscular subcutaneous naloxone autoinjector used emergency treatment people 12 year age older use high-potency opioids fentanyl analogue chemical weapon suspected l40758 l40763 naloxone used off-label treatment neuraxial opioid-induced pruritus a234604 
Domperidone, specific blocker dopamine receptor speed gastrointestinal peristalsis cause prolactin release used antiemetic tool study dopaminergic mechanism , management dyspepsia heartburn epigastric pain nausea vomiting 
Fluoxymesterone, anabolic steroid used treatment male hypogonadism delayed puberty male treatment breast neoplasm woman , male used replacement therapy condition associated symptom deficiency absence endogenous testosterone female palliation androgenresponsive recurrent mammary cancer woman one year le five year postmenopausal 
Pergolide,pergolide long-acting dopamine agonist approved 1982 treatment parkinson ’ disease ergot derivative act dopamine d2 d3 alpha2- alpha1-adrenergic 5-hydroxytryptamine 5-ht receptor indicated adjunct therapy levodopa/carbidopa symptomatic treatment parkinsonian syndrome later found pergolide increased risk cardiac valvulopathy drug withdrawn u market march 2007 canadian market august 2007 use pergolide human still approved country pergolide mainly used veterinary purpose ,indicated adjunctive treatment levodopa/carbidopa management sign symptom parkinson 's disease withdrawn u canadian market 2007 due increased risk cardiac valvulopathy 
Iophendylate,"iophendylate mixture isomer used contrast medium mainly brain spinal cord visualization iophendylate myelographic oil-ester u.s. patent 2,348,231 iophendylate never shown safe initially introduced use small amount 1-2cc locating spinal tumor next appeared world scene high volume 12-15cc routine use diagnosing disc herniation number clinician published danger oil myelography 1942 van wagenen neurosurgical colleague warren university rochester identified iophendylate causing chemical meningitis 30 patient `` space-displacing mass within spinal canal suspected '' ",iophendylate used contrast agent locate spinal tumor 
Ciclopirox,ciclopirox olamine used preparation called batrafen loprox mycoster penlac stieprox synthetic antifungal agent topical dermatologic treatment superficial mycoses particular agent especially effective treating tinea versicolor ,used topical treatment immunocompetent patient mild moderate onychomycosis fingernail toenail without lunula involvement due trichophyton rubrum /i 
Desflurane,desflurane i-653 volatile anesthetic rapidly cleared le metabolized previous inhaled anesthetic methoxyflurane sevoflurane enflurane isoflurane a226390 a39015 a226893 developed late 1980s need rapidly acting rapidly cleared inhaled anesthetic a226883 a226888 desflurane granted fda approval 18 september 1992 l30285 ,desflurane indicated induction maintenance anesthesia adult well maintenance anesthesia pediatric patient l30285 
Clindamycin,clindamycin semi-synthetic lincosamide antibiotic used treatment variety serious infection due susceptible microorganism l11599 l11596 well topically acne vulgaris l11593 relatively narrow spectrum activity includes anaerobic bacteria well gram-positive cocci bacillus gram-negative bacillus a190621 interestingly clindamycin appears carry activity protozoan used off-label treatment toxoplasmosis malaria babesiosis a190657 clindamycin derived largely replaced lincomycin naturally occurring lincosamide eponymous member antibiotic class due improved property parent compound name lincomycin derived lincoln nebraska first isolated _streptomyces lincolnensis_ found soil sample a190621 , oral parenteral formulation clindamycin indicated treatment serious infection caused susceptible anaerobic bacteria well susceptible staphylococci streptococci pneumococcus l11599 l11602 used topically indicated treatment acne vulgaris l11593 l11611 l11605 available combination benzoyl peroxide l11584 tretinoin l11590 purpose clindamycin also indicated vaginal cream l11596 suppository l11608 gel l39416 treatment bacterial vaginosis non-pregnant female clindamycin used antimicrobial prophylaxis _viridans_ group streptococcal infection susceptible patient undergoing oral dental upper respiratory surgery may used prophylaxis bacterial endocarditis penicillin-allergic patient high risk infection l11629 
Dexfenfluramine,dexfenfluramine also marketed name redux serotoninergic anorectic drug fairly limited time middle ninety u fda approved use managing weight loss however following multiple concern cardiovascular side-effects drug approval withdrawn , management obesity including weight loss maintenance weight loss patient reduced calorie diet
Oxymorphone, opioid analgesic action us similar morphine apart absence cough suppressant activity used treatment moderate severe pain including pain obstetrics may also used adjunct anesthesia martindale extra pharmacopoeia 30th ed p1092 june 8 2017 fda requested endo pharmaceutical remove medication market due opioid misuse abuse risk associated product 's injectable reformulation , treatment moderate-to-severe pain 
Acebutolol, cardioselective beta-adrenergic antagonist little effect bronchial receptor drug stabilizing quinidine-like effect cardiac rhythm well weak inherent sympathomimetic action , management hypertension ventricular premature beat adult 
Brinzolamide,brinzolamide highly specific non-competitive reversible carbonic anhydrase inhibitor carbonic anhydrase ca enzyme found many tissue body including eye catalyzes reversible reaction involving hydration carbon dioxide dehydration carbonic acid human carbonic anhydrase exists number isoenzymes active carbonic anhydrase ii ca-ii inhibition carbonic anhydrase ciliary process eye decrease aqueous humor secretion presumably slowing formation bicarbonate ion subsequent reduction sodium fluid transport result reduction intraocular pressure brinzolamide indicated treatment elevated intraocular pressure patient ocular hypertension open-angle glaucoma , treatment elevated intraocular pressure patient ocular hypertension open-angle glaucoma 
Flecainide,flecainide class anti-arrhythmic agent like encainide propafenone a186880 flecainide ’ development began 1966 first synthesized 1972 attempt generate new anesthetic a186931 used prevent supraventricular ventricular arrhythmia well paroxysmal atrial fibrillation flutter l8878 l5056 flecainide granted fda approval 31 october 1985 l8875 , new zealand america flecainide indicated prevent supraventricular arrhythmia ventricular arrhythmia l8878 united state also indicated prevent paroxysmal atrial fibrillation flutter a186886 l5056 
Estramustine, nitrogen mustard linked estradiol usually phosphate used treat prostatic neoplasm also radiation protective property , palliative treatment patient metastatic and/or progressive carcinoma prostate
Captopril,captopril potent competitive inhibitor angiotensin-converting enzyme ace enzyme responsible conversion angiotensin ati angiotensin ii atii atii regulates blood pressure key component renin-angiotensin-aldosterone system raas captopril may used treatment hypertension , treatment essential renovascular hypertension usually administered drug particularly thiazide diuretic may used treat congestive heart failure combination drug e.g cardiac glycoside diuretic beta -adrenergic blocker may improve survival patient left ventricular dysfunction following myocardial infarction may used treat nephropathy including diabetic nephropathy 
Zopiclone,zopiclone novel hypnotic agent used treatment insomnia mechanism action based modulating benzodiazepine receptor addition zopiclone 's benzodiazepine pharmacological property also barbiturate-like property , short-term treatment insomnia 
Tubocurarine,tubocurarine non-depolarizing neuromuscular blocking agent first identified curare alkaloid a216008 curare one name used describe plant-derived poison used indigenous south american coat tip hunting arrow dart typically derived plant genus _chondrodendron_ _strychnos_ a216008 tubocurarine benzylisoquinoline derivative share structural backbone number plant-derived alkaloid including morphine papaverine a216028 first isolated harold king 1935 used clinically induce neuromuscular blockade surgery particularly involving abdomen a216038 tubocurarine 's clinical use limited relatively long duration action 30-60 minute a216038 number significant side effect a216048 safer pharmacokinetically favorable non-depolarizing neuromuscular blocker rocuronium largely replaced use tubocurarine clinical setting a216048 ,
Bromocriptine,bromocriptine mesylate semisynthetic ergot alkaloid derivative potent dopaminergic activity inhibits prolactin secretion may used treat dysfunction associated hyperprolactinemia bromocriptine also indicated management sign symptom parkinsonian syndrome well treatment acromegaly bromocriptine associated pulmonary fibrosis also cause sustained suppression somatotropin growth hormone secretion patient acromegaly 1995 fda withdrew approval bromocriptine mesylate prevention physiological lactation finding bromocriptine shown safe use l43942 l43947 continues used indication mentioned , treatment galactorrhea due hyperprolactinemia prolactin-dependent menstrual disorder infertility prolactin-secreting adenoma prolactin-dependent male hypogonadism adjunct therapy surgery radiotherapy acromegaly monotherapy special case monotherapy early parksinsonian syndrome adjunct levodopa advanced case motor complication bromocriptine also used off-label treat restless leg syndrome neuroleptic malignant syndrome 
Rifapentine,rifapentine antibiotic drug used treatment tuberculosis inhibits dna-dependent rna polymerase activity susceptible cell specifically interacts bacterial rna polymerase inhibit mammalian enzyme , treatment pulmonary tuberculosis 
Levetiracetam,levetiracetam drug within pyrrolidine class used treat various type seizure stemming epileptic disorder first approved use united state 1999 structurally mechanistically unrelated anti-epileptic drug aeds l8606 l8600 l8615 levetiracetam posse wide therapeutic index l8615 a185918 little-to-no potential produce subject pharmacokinetic interaction l8606 l8600 l8615 characteristic make desirable choice aeds class drug notorious generally narrow therapeutic index propensity involvement drug interaction a185927 ,levetiracetam indicated adjunctive therapy treatment partial onset seizure epileptic patient one month age older additionally indicated adjunct treatment myoclonic seizure patient juvenile myoclonic epilepsy 12 year age older primary generalized tonic-clonic seizure patient idiopathic generalized epilepsy 6 year age older l8606 levetiracetam also available orally dissolvable tablet indicated adjunct treatment partial onset seizure patient epilepsy 4 year age older weigh 20kg l8609 
Nadolol,nadolol nonselective beta adrenal receptor blocker used lower blood pressure l7922 l7925 nonselective beta adrenal receptor blocker may longer first line treatment hypertension newer generation beta adrenal receptor blocker higher selectivity offer better rate adverse effect a34177 nadolol granted fda approval 10 december 1979 l7922 ,nadolol indicated treat angina pectoris hypertension l7922 another product formulated bendroflumethiazide indicated treat hypertension l7925 
Mitoxantrone, anthracenedione-derived antineoplastic agent , treatment secondary chronic progressive progressive relapsing worsening relapsing-remitting multiple sclerosis
Flumazenil,fumazenil imidazobenzodiazepine derivative potent benzodiazepine receptor antagonist competitively inhibits activity benzodiazepine recognition site gaba/benzodiazepine receptor complex thereby reversing effect benzodiazepine central nervous system , complete partial reversal sedative effect benzodiazepine case general anesthesia induced and/or maintained benzodiazepine sedation produced benzodiazepine diagnostic therapeutic procedure also management benzodiazepine overdose adjunct appropriate supportive symptomatic measure 
Lomustine, alkylating agent value hematologic malignancy solid tumor , treatment primary metastatic brain tumor component combination chemotherapy addition appropriate surgical and/or radiotherapeutic procedure also used combination agent secondary therapy treatment refractory relapsed hodgkin 's disease 
Ridogrel,ridogrel dual action drug useful prevention systemic thrombo-embolism adjunctive agent thrombolytic therapy acute myocardial infarction however currently clinical indication preferential use ridogrel aspirin ,used adjunctive therapy induce thrombolysis patient suffering acute myocardial infarction 
Sparfloxacin,sparfloxacin fluoroquinolone antibiotic indicated bacterial infection sparfloxacin exerts antibacterial activity inhibiting dna gyrase bacterial topoisomerase dna gyrase essential enzyme control dna topology assist dna replication repair deactivation transcription , treatment adult following infection caused susceptible strain microorganism community-acquired pneumonia caused chlamydia pneumoniae /i haemophilus influenzae /i haemophilus parainfluenzae /i moraxella catarrhalis /i mycoplasma pneumoniae /i streptococcus pneumoniae /i acute bacterial exacerbation chronic bronchitis caused chlamydia pneumoniae /i enterobacter cloaca /i haemophilus influenzae /i haemophilus parainfluenzae /i klebsiella pneumoniae /i moraxella catarrhalis /i staphylococcus aureus /i streptococcus pneumoniae /i 
Dezocine,dezocine partial opiate drug used pain management dezocine effective alternative fentanyl administered outpatient laparoscopy although associated increased incidence postoperative nausea ,indicated treatment moderate severe pain 
Levobunolol, nonselective beta-adrenoceptor antagonist used treatment glaucoma , lowering intraocular pressure iop may used patient chronic open-angle glaucoma ocular hypertension 
Clarithromycin,clarithromycin semisynthetic macrolide antibiotic derived erythromycin inhibits bacterial protein synthesis binding bacterial 50 ribosomal subunit binding inhibits peptidyl transferase activity interferes amino acid translocation translation protein assembly process clarithromycin may bacteriostatic bactericidal depending organism drug concentration , alternative medication treatment acute otitis medium caused h influenzae m. catarrhalis s. pneumoniae /i patient history type penicillin hypersensitivity also treatment pharyngitis tonsillitis caused susceptible streptococcus pyogenes /i well respiratory tract infection including acute maxillary sinusitis acute bacterial exacerbation chronic bronchitis mild moderate community-acquired pneuomia legionnaire disease pertussis indication include treatment uncomplicated skin skin structure infection helicobacter pylorus infection duodenal ulcer disease bartonella infection early lyme disease encephalitis caused toxoplasma gondii /i hiv infected patient conjunction pyrimethamine clarithromycin may also decrease incidence cryptosporidiosis prevent occurence α-hemolytic viridans group streptococcal endocarditis well serve primary prevention mycobacterium avium /i complex mac bacteremia disseminated infection adult adolescent child advanced hiv infection clarithromycin indicated combination vonoprazan amoxicillin co-packaged triple therapy treat _helicobacter pylori_ _h pylori_ infection adult l41695 
Ceftriaxone,ceftriaxone broad-spectrum third-generation cephalosporin antibiotic a215582 long half-life compared cephalosporin high penetrable meninges a215582 eye a215647 inner ear a215627 ceftriaxone broader stronger gram-negative coverage first second-generation cephalosporin worse activity methicillin-susceptible s.aureus ceftriaxone commonly used antimicrobial due good activity multi-drug resistant enterobacteriaceae relatively safe adverse effect profile long half-life allows convenience daily twice-daily dosing a215582 ,ceftriaxone used treatment infection respiratory skin soft tissue uti ent caused susceptible organism l15082 organism generally susceptible ceftriaxone include s. pneumoniae s. pyogenes group beta-hemolytic streptococci coagulase-negative staphylococci enterobacter spp h. influenzae n. gonorrhoeae p. mirabilis e. coli klebsiella spp m. catarrhalis b. burgdorferi oral anaerobe a215582 
Fomepizole,fomepizole used antidote confirmed suspected methanol ethylene glycol poisoning fomepizole competitive inhibitor alcohol dehydrogenase enzyme catalyzes initial step metabolism ethylene glycol methanol toxic metabolite ,antizol indicated antidote ethylene glycol antifreeze methanol poisoning use suspected ethylene glycol methanol ingestion either alone combination hemodialysis
Metipranolol, beta-adrenergic antagonist effective beta-1 beta-2 receptor used antiarrhythmic antihypertensive antiglaucoma agent ,indicated treatment elevated intraocular pressure patient ocular hypertension open angle glaucoma 
Estazolam, benzodiazepine anticonvulsant hypnotic muscle relaxant property shown case potent diazepam nitrazepam , short-term management insomnia characterized difficulty falling asleep frequent nocturnal awakening and/or early morning awakening 
Finasteride,finasteride synthetic 4-azasteroid compound l10565 specific inhibitor steroid type ii 5α-reductase intracellular enzyme convert androgen testosterone 5α-dihydrotestosterone dht work similar fashion dutasteride another 5-alpha-reductase inhibitor exerting antiandrogenic effect finasteride orally active drug first approved fda 1992 treatment benign prostatic hyperplasia improve symptom reduce risk acute urinary retention need surgical procedure l6244 l10565 1998 approved fda treat male pattern hair loss l6244 finasteride commonly marketed brand name propecia proscar used aloneo combination doxazosin alpha-blocker benign prostatic hyperplasia androgenic alopecia androgen-dependent disorder characterized _in situ_ high level dht a178159 treatment benign prostate hyperplasia alpha-blocker tamsulosin terazosin also used compared alpha-blocker focus providing rapid relief symptom 5α-reductase inhibitor aim target underlying disease blocking effect primary androgen involved benign prostate hyperplasia androgenic alopecia thus reducing risk secondary complication providing symptom control a2132 ,finasteride indicated treatment symptomatic benign prostatic hyperplasia bph men enlarged prostate improve symptom reduce risk acute urinary retention reduce risk need surgery including transurethral resection prostate turp prostatectomy l10565 combination product tadalafil also used symptomatic treatment bph 26 week l39439 finasteride also indicated treatment male pattern hair loss androgenetic alopecia hereditary alopecia common male baldness male patient l6235 
Anastrozole,anastrozole non-steroidal aromatase inhibitor ai similar letrozole used decrease circulating estrogen level treatment postmenopausal woman estrogen-responsive breast cancer l8863 anastrozole also related exemestane steroidal ai non-steroidal nature provides stark advantage including lack steroid-associated adverse effect weight gain acne a186865 aromatase inhibitor including anastrozole become endocrine drug choice treatment postmenopausal breast cancer due favourable efficacy adverse effect profile compared earlier estrogen receptor modulators tamoxifen a186877 a186955 anastrozole first approved use united state 1995 l8863 ,anastrozole indicated adjunct therapy treatment hormone receptor-positive early breast cancer postmenopausal woman first-line treatment hormone receptor-positive hormone receptor-unknown locally advanced metastatic breast cancer postmenopausal woman l8863 may also used treatment advanced breast cancer postmenopausal woman experience disease progression despite treatment tamoxifen l8866 l8863 
Halofantrine,halofantrine antimalarial belongs phenanthrene class compound includes quinine lumefantrine appears inhibit polymerisation heme molecule parasite enzyme `` heme polymerase '' resulting parasite poisoned waste halofantrine shown preferentially block open inactivated herg channel leading degree cardiotoxicity , treatment severe malaria
Dantrolene,chemically dantrolene hydantoin derivative exhibit antiepileptic activity like hydantoin derivates phenytoin , use along appropriate supportive measure management fulminant hypermetabolism skeletal muscle characteristic malignant hyperthermia crisis patient age also used preoperatively sometimes postoperatively prevent attenuate development clinical laboratory sign malignant hyperthermia individual judged malignant hyperthermia susceptible 
Rifaximin,rifaximin semisynthetic rifamycin-based non-systemic antibiotic meaning drug pas gastrointestinal wall circulation common type orally administered antibiotic multiple indication used treatment traveller 's diarrhea caused e. coli reduction risk overt hepatic encephalopathy recurrence well diarrhea-predominant irritable bowel syndrome ibs-d adult woman men marketed brand name xifaxan salix pharmaceutical ,rifaximin multiple indication fda treatment patient ≥12 year age traveller 's diarrhea caused noninvasive strain escherichia coli reduction overt hepatic encephalopathy recurrence patient ≥18 year age may 2015 approved irritable bowel syndrome diarrhea ibs-d treatment adult men woman 
Ketamine,ketamine nmda receptor antagonist potent anesthetic effect a31869 developed 1963 replacement phencyclidine pcp calvin stevens parke davis laboratory started used veterinary purpose belgium 1964 proven compared pcp produced minor hallucinogenic effect shorter psychotomimetic effect fda approved 1970 used anesthetic child patient undergoing minor surgery mainly veterinary purpose l1332 ,ketamine indicated anesthetic agent recommended diagnostic surgical procedure skeletal muscle relaxation needed combined muscle relaxant surgical procedure involves visceral pain supplemented agent obtunds visceral pain ketamine used induction anesthesia prior general anesthetic agent supplement low potency agent l1336 fda label report indicated potential use ketamine therapeutic tool management depression administered lower dos a31873 report increased interest ketamine area several clinical trial launched indication l1337 a31874 
Budesonide,budesonide glucocorticoid mix 22r 22 epimer used treat inflammatory condition lung intestine asthma copd crohn 's disease ulcerative colitis a188529 a188532 budesonide granted fda approval 14 february 1994 l10598 also available combination product formoterol l10619 ,budesonide extended release capsule indicated treatment maintenance mild moderate crohn ’ disease l10601 l10604 various inhaled budesonide product indicated prophylactic therapy asthma l10607 l10613 l10619 reduce exacerbation copd l10619 budesonide nasal spray available counter symptom hay fever upper respiratory allergy l10616 extended-release capsule indicated induce remission mild moderate ulcerative colitis l10622 rectal foam used mild moderate distal ulcerative colitis l10625 addition delayed-release capsule formulation budesonide indicated reduce proteinuria adult iga nephropathy risk rapid disease progression l39479 l42515 europe budesonide indicated treat eosinophilic esophagitis eoe adult l42525 
Aminophylline,aminophylline drug combination contains theophylline ethylenediamine 2:1 ratio body theophylline released act phosphodiesterase inhibitor adenosine receptor blocker histone deacetylase activator similar theophylline aminophylline indicated treatment lung disease asthma chronic bronchitis copd majority aminophylline medication discontinued remaining medication market short supply , treatment bronchospasm due asthma emphysema chronic bronchitis 
Quetiapine,initially approved fda 1997 quetiapine second-generation atypical antipsychotic used schizophrenia major depression bipolar disorder l8546 quetiapine demonstrates high level therapeutic efficacy low risk adverse effect long-term treatment well-tolerated suitable option patient high sensitivity drug clozapine olanzapine a2189 ,quetiapine used symptomatic treatment schizophrenia addition may used management acute manic mixed episode patient bipolar disorder monotherapy combined drug may used manage depressive episode bipolar disorder addition indication quetiapine used combination antidepressant drug treatment major depression l8546 off-label us drug include management post-traumatic stress disorder ptsd generalized anxiety disorder psychosis associated parkinson 's disease a185438 a185447 t685 
Enoxaparin,enoxaparin common low-molecular-weight heparin lmwh used prevention management various thromboembolic disorder initially approved fda 1993 administered subcutaneous intravenous injection marketed several pharmaceutical company l31393 enoxaparin markedly reduces incidence venous thromboembolism hospitalized patient compared unfractionated heparin without increasing risk serious bleeding a228178 a228313 ,enoxaparin indicated prevention ischemic complication unstable angina non q-wave myocardial infarction indicated conjunction percutaneous intervention and/or treatment management acute st elevation myocardial infarction l31393 enoxaparin also indicated prophylaxis dvt abdominal surgery hip replacement knee replacement medical patient severely restricted mobility acute illness additionally enoxaparin indicated inpatient treatment dvt without pulmonary embolism treatment outpatient dvt without pulmonary embolism l31393 
Mivacurium,mivacurium bisbenzylisoquinolinium based neuromuscular blocker muscle relaxant bind competitively cholinergic receptor motor end-plate antagonize action acetylcholine resulting block neuromuscular transmission , inpatient outpatient adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation surgery mechanical ventilation 
Levacetylmethadol,levacetylmethadol narcotic analgesic long onset duration action used mainly treatment narcotic dependence levacetylmethadol withdrawn use european union due high risk qt interval prolongation production levacetylmethadol u ceased well l44052 t862 , treatment management opiate dependence sometimes used treat severe pain terminal patient 
Encainide, drug product containing encainide hydrochloride encainide hydrochloride formerly marketed enkaid capsule associated increased death rate patient asymptomatic heart rhythm abnormality recent heart attack manufacturer enkaid capsule voluntarily withdrew product u market december 16 1991 ,encainide class ic antiarrhythmic agent used management irregular heartbeat atrial fibrillation atrial flutter ventricular tachycardia ventricular fibrillation 
Paclitaxel,paclitaxel chemotherapeutic agent marketed brand name taxol among others used treatment various cancer paclitaxel mitotic inhibitor first isolated 1971 bark pacific yew tree contains endophytic fungi synthesize paclitaxel available intravenous solution injection newer formulation contains albumin-bound paclitaxel marketed brand name abraxane ,used treatment kaposi 's sarcoma cancer lung ovarian breast abraxane® specfically indicated treatment metastatic breast cancer locally advanced metastatic non-small cell lung cancer 
Pemoline, 2005 food drug administration fda withdrew approval pemoline march 2005 abbott laboratory cylert marketer discontinued production cylert arguing economic reason , treatment attention deficit hyperactivity disorder adhd 
Diphenidol,diphenidol antiemetic agent used treatment vomiting vertigo diphenidol overdose may result serious toxicity child , use prevention symptomatic treatment peripheral labyrinthine vertigo associated nausea vomiting occur condition meniere 's disease surgery middle inner ear also control nausea vomiting associated postoperative state malignant neoplasm labyrinthine disturbance antineoplastic agent therapy radiation sickness infectious disease 
Saquinavir,saquinavir hiv-1 protease inhibitor used combination ritonavir antiretrovirals treatment human immunodeficiency virus-1 hiv-1 infection 1995 became first protease inhibitor approved fda followed shortly ritonavir 1996 remains clinical use today due relatively benign adverse effect profile compared antiretroviral therapy a214382 efficacy initially limited exceptionally poor oral bioavailability approximately 4 l3450 current indication require co-administration ritonavir potent enzyme inhibitor increase bioavailability subsequent serum concentration saquinavir thus dramatically improving antiviral activity a214382 l3450 l14351 ,saquinavir indicated combination ritonavir antiretroviral agent treatment hiv-1 infection patient 16 year age older l3450 
Metoclopramide,diabetic gastroparesis condition cause frequent nausea vomiting negative impact quality life pose significant burden healthcare system a184934 metoclopramide dopamine antagonist used treat nausea vomiting may associated diabetic gastroparesis addition gastroesophageal reflux disease gerd also used prevent nausea vomiting associated chemotherapy certain surgical diagnostic procedure l8417 one unique property drug increase gastric acid secretion available oral tablet form solution also administered intravenous route t683 metoclopramide initially approved fda 1980 a184922 ,metoclopramide oral tablet form used symptomatic treatment acute recurrent diabetic gastroparesis addition treatment gastroesophageal reflux disease gerd patient failed respond traditional therapy l8414 nasal spray formulation also indicated treat adult acute recurrent diabetic gastroparesis l14381 intravenous injection form indicated condition well prevention vomiting may follow emetogenic chemotherapy nausea vomiting surgery intravenous metoclopramide facilitates intubation small bowel stimulates gastric emptying barium flow patient require radiological examination stomach small intestine case delay gastrointestinal emptying interferes radiographic visualization gastrointestinal tract metoclopramide used facilitate emptying case allowing adequate diagnostic visualization l8417 off-label us metoclopramide include management radiation-induced nausea vomiting gastric bezoars intractable hiccup migraine pain a184961 a184964 a184967 a40105 
Dexamethasone,dexamethasone mk-125 corticosteroid fluorinated position 9 used treat endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous condition l10701 developed 1957 structurally similar corticosteroid like hydrocortisone prednisolone a188724 dexamethasone granted fda approval 30 october 1958 l10695 press release randomized evaluation covid-19 therapy recovery trial 16 june 2020 dexamethasone recommended use covid-19 patient severe respiratory symptom dexamethasone reduced death approximately one third patient requiring ventilation one fifth requiring oxygen l14318 ,dexamethasone ciprofloxacin otic suspension indicated bacterial infection inflammation acute otitis medium acute otitis externa l10698 intramuscular intravenous injection indicated number endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous condition l10701 oral tablet indicated treatment multiple myeloma l10710 intravitreal implant indicated form macular edema non-infectious posterior uveitis affecting posterior eye l10719 various ophthalmic formulation indicated inflammatory condition eye l10704 l10707 l10713 l10716 l10722 l10725 
Levodopa,levodopa prodrug dopamine administered patient parkinson 's due ability cross blood-brain barrier label levodopa metabolised dopamine either side blood-brain barrier generally administered dopa decarboxylase inhibitor like carbidopa prevent metabolism crossed blood-brain barrier label a177781 past blood-brain barrier levodopa metabolized dopamine supplement low endogenous level dopamine treat symptom parkinson 's label first developed drug product approved fda levodopa carbidopa combined product called sinemet approved may 2 1975 a177781 l6133 ,levodopa formulated oral inhalation powder indicated intermittent treatment episode parkinson 's patient already treated carbidopa levodopa fda label levodopa commonly formulated oral tablet peripheral dopa decarboxylase inhibitor indicated treatment parkinson 's disease post-encephalitic parkinsonism symptomatic parkinsonism following carbon monoxide intoxication manganese intoxication f4579 
Sevoflurane,sevoflurane ether inhalation anesthetic agent used induce maintain general anesthesia l42340 volatile non-flammable compound low solubility profile blood/gas partition coefficient l42340 sevoflurane patented 1972 approved clinical use japan 1990 approved fda 1996 a249885 sevoflurane three time potent desflurane lower potency compared halothane isoflurane unlike volatile anesthetic sevoflurane pleasant odor irritate airway hemodynamic respiratory depressive effect sevoflurane well tolerated patient receiving anesthetic agent present little toxicity a249910 therefore used inhalational induction adult child wide variety anesthetic procedure a249885 ,sevoflurane used induction maintenance general anesthesia adult pediatric patient inpatient outpatient surgery l42340 
Bromodiphenhydramine,bromodiphenhydramine ethanolamine antihistamine antimicrobial property bromodiphenhydramine used control cutaneous allergy ethanolamine antihistamine produce marked sedation patient , management symptom related hay fever type allergy used help bring phlegm thin secretion make cough productive 
Aripiprazole,aripiprazole atypical antipsychotic orally indicated treatment schizophrenia bipolar major depressive disorder irritability associated autism tourette 's label also indicated injection agitation associated schizophrenia bipolar mania label aripiprazole exerts effect agonism dopaminic 5-ht1a receptor antagonism alpha adrenergic 5-ht2a receptor label a4393 aripiprazole given fda approval november 15 2002 l6136 ,aripiprazole indicated manic mixed episode associated bipolar disorder irritability associated autism spectrum disorder treatment schizophrenia treatment tourette 's disorder adjunctive treatment major depressive disorder label injectable formulation aripiprazole indicated agitation associated schizophrenia bipolar mania label 
Chlorprothixene,chlorprothixene typical antipsychotic drug thioxanthene tricyclic class chlorprothixene exerts strong blocking effect blocking 5-ht2 d1 d2 d3 histamine h1 muscarinic alpha1 adrenergic receptor , treatment psychotic disorder e.g schizophrenia acute mania occuring part bipolar disorder 
Epoprostenol, prostaglandin powerful vasodilator inhibits platelet aggregation biosynthesized enzymatically prostaglandin endoperoxides human vascular tissue sodium salt also used treat primary pulmonary hypertension , long-term intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease nyha class iii class iv patient respond adequately conventional therapy 
Gemfibrozil,gemfibrozil fibric acid agent similar clofibrate used treat type iib iv v hyperlipidemia a185777 l8525 gemfibrozil first line treatment prescribed patient responded adequately weight loss diet exercise medication l8525 gemfibrozil granted fda approval 21 december 1981 l8525 ,gemfibrozil indicated treat patient type iv v hyperlipidemia elevated serum triglyceride usually 2000mg/dl elevated vldl cholesterol fasting chylomicron risk developing pancreatitis adequately respond dietary restriction l8525 gemfibrozil also indicated reduce risk developing coronary heart disease patient type iib hyperlipidemia without history symptom coronary heart disease adequately respond weight loss diet exercise medication low hdl raised ldl raised triglyceride l8525 
Clomipramine,clomipramine 3-chloro analog imipramine dibenzazepine-derivative tricyclic antidepressant tca tcas structurally similar phenothiazine contain tricyclic ring system alkyl amine substituent central ring non-depressed individual clomipramine affect mood arousal may cause sedation depressed individual clomipramine exerts positive effect mood tcas potent inhibitor serotonin norepinephrine reuptake tertiary amine tcas clomipramine potent inhibitor serotonin reuptake secondary amine tcas nortriptyline desipramine tcas also down-regulate cerebral cortical beta -adrenergic receptor sensitize post-synaptic serotonergic receptor chronic use antidepressant effect tcas thought due overall increase serotonergic neurotransmission tcas also block histamine-h sub 1 /sub receptor alpha sub 1 /sub -adrenergic receptor muscarinic receptor account sedative hypotensive anticholinergic effect e.g blurred vision dry mouth constipation urinary retention respectively see toxicity section complete listing side effect clomipramine may used treat obsessive-compulsive disorder disorder obsessive-compulsive component e.g depression schizophrenia tourette ’ disorder unlabeled indication include panic disorder chronic pain e.g central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy associated narcolepsy autistic disorder trichotillomania onchophagia stuttering premature ejaculation premenstrual syndrome clomipramine rapidly absorbed gastrointestinal tract demethylated liver primary active metabolite desmethylclomipramine ,may used treat obsessive-compulsive disorder disorder obsessive-compulsive component e.g depression schizophrenia tourette ’ disorder unlabeled indication include depression panic disorder chronic pain e.g central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation premenstrual syndrome 
Chloroxine,chloroxine synthetic antibacterial compound chloroxine compound used shampoo treatment dandruff seborrheic dermatitis scalp ,used treatment dandruff mild moderately severe seborrheic dermatitis scalp 
Bepridil, long-acting non selective calcium channel blocker significant anti-anginal activity drug produce significant coronary vasodilation modest peripheral effect antihypertensive selective anti-arrhythmia activity act calmodulin antagonist longer marketed united state implicated causing ventricular arrhythmia ie torsade de pointes , treatment hypertension chronic stable angina classic effort-associated angina 
Decamethonium,decamethonium used anesthesia cause paralysis short acting depolarizing muscle relaxant similar acetylcholine act partial agonist nicotinic acetylcholine receptor , use skeletal muscle relaxant
Alimemazine, phenothiazine derivative used antipruritic ,used prevent relieve allergic condition cause pruritus itching urticaria allergic skin reaction 
Isocarboxazid,isocarboxazid formula 1-benzyl-2- 5-methyl-3-isoxazolylcarbonyl hydrazine-isocarboxazid monoamine oxidase inhibitor a31930 used treatment major depression dysthymic disorder atypical disorder panic disorder phobic disorder t115 first introduced roche pharmaceutical developed validus pharms inc first fda approved prescription drug july 1st 1959 ,isocarboxazid indicated treatment enduring debilitating symptom depression responded antidepressant drug l1372 depression common serious mood disorder patient present change feeling thought ability handle everyday activity mood disorder considered depression symptom present least two week l1375 
Docetaxel,docetaxel clinically well established anti-mitotic chemotherapy medication used mainly treatment breast ovarian non-small cell lung cancer docetaxel reversibly bind tubulin high affinity 1:1 stoichiometric ratio, treatment patient locally advanced metastatic breast cancer failure prior chemotherapy also used single agent treatment patient locally advanced metastatic non-small cell lung cancer failure prior platinum-based chemotherapy also used combination prednisone treatment patient androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel us treatment gastric adenocarinoma head neck cancer 
Iodixanol,iodixanol nonionic hydrophilic compound commonly used contrast agent coronary angiography particularly individual renal dysfunction believed le toxic kidney intravascular contrast agent ,iodixanol contrast agent coronary angiography 
Olsalazine,olsalazine anti-inflammatory drug used treatment inflammatory bowel disease ulcerative colitis olsalazine derivative salicylic acid inactive prodrug converted bacteria colon mesalamine mesalamine work anti-inflammatory agent treating inflammatory disease intestine , treatment inflammatory bowel disease ulcerative colitis 
Gliquidone,gliquidone sulfonylurea drug used treat diabetes mellitus type 2 atp-dependent k+ katp channel blocker block cause depolarization lead activation voltage-dependent ca channel ca2+ influx eventually increase insulin release ,used treatment diabetes mellitus type 2 
Mitiglinide,mitiglinide drug treatment type 2 diabetes may stimulate insulin secretion beta-cells closing atp dependant potassium ion channel , treatment type 2 diabetes 
Ergometrine, ergot alkaloid uterine vascular smooth muscle contractile property ,used treat postpartum haemorrhage postabortion haemorrhage patient uterine atony 
Dasatinib,dasatinib oral dual bcr/abl src family tyrosine kinase inhibitor approved use patient chronic myelogenous leukemia cml main target dasatinib bcrabl src ephrins gfr , treatment adult chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy also indicated treatment adult philadelphia chromosome-positive acute lymphoblastic leukemia resistance intolerance prior therapy 
Lisdexamfetamine,also known _vyvanse_ lisdexamfetamine l-lysine-d-amphetamine prodrug psychostimulant d-amphetamine a40246 paired essential amino acid _l-lysine_ lisdexamfetamine dimesylate increase attention span decrease restlessness child adult overactive/hyperactive concentrate long period easily distracted impulsive a2230 central nervous system stimulant lisdexamfetamine utilized adjunct therapy treatment attention deficit hyperactivity disorder adhd prodrug lisdexamfetamine specifically engineered abuse-resistant product f2368 mechanism occurs delayed release ingestion unlike psychostimulant drug may abused oral administration absorption enzyme hydrolysis contact red blood cell metabolize lisdexamfetamine l- lysine naturally occurring essential amino acid active _d-amphetamine_ responsible drug ’ pharmacological effect gastrointestinal ph affect conversion addition l-lysine slows amount d-amphetamine available circulation central nervous system f2368 , treatment attention-deficit/hyperactivity disorder adhd moderate severe binge eating disorder adult fda label a40246 drug indicated weight loss use sympathomimetic drug weight loss associated serious cardiovascular effect safety effectiveness drug treatment obesity yet determined fda label 
Retapamulin,retapamulin marketed glaxosmithkline ointment altabax antibiotic skin infection like impetigo approved fda april 2007 , use adult pediatric patient aged 9 month older topical treatment impetigo 100 cm sup 2 /sup total area adult 2 total body surface area pediatric patient aged 9 month older due staphylococcus aureus methicillin-susceptible isolates streptococcus pyogenes 
Eculizumab,eculizumab monoclonal antibody target complement protein c5 l6919 a2245 binding protein prevents activation complement terminal complex used treat number autoimmune condition l6919 a2245 a2246 eculizumab granted fda approval 16 march 2007 l6919 ,eculizumab indicated treat paroxysmal nocturnal hemoglobinuria pnh reduce hemolysis atypical hemolytic uremic syndrome inhibit complement-mediated thrombotic microangiopathy l6919 a2246 neuromyelitis optica spectrum disorder nmosd l6916 
Lapatinib,lapatinib anti-cancer drug developed glaxosmithkline gsk treatment solid tumour breast lung cancer approved fda march 13 2007 use patient advanced metastatic breast cancer conjunction chemotherapy drug capecitabine lapatinib human epidermal growth factor receptor type 2 her2/erbb2 epidermal growth factor receptor her1/egfr/erbb1 tyrosine kinase inhibitor bind intracellular phosphorylation domain prevent receptor autophosphorylation upon ligand binding ,indicated combination capecitabine treatment patient advanced metastatic breast cancer whose tumor overexpress human epidermal receptor type 2 her2 protein received prior therapy including anthracycline taxane trastuzumab 
Desonide, nonfluorinated corticosteroid anti-inflammatory agent used topically dermatosis , relief inflammatory pruritic manifestation corticosteroid responsive dermatose 
Sitagliptin,sitagliptin oral dipeptidyl peptidase-4 dpp-4 inhibitor used conjunction diet exercise improve glycemic control patient type 2 diabetes mellitus label a2260 a2255 a2256 effect medication lead glucose dependent increase insulin decrease glucagon improve control blood sugar label a2255 sitagliptin granted fda approval october 16 2006 l6061 ,sitagliptin indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus used treat type 1 diabetes patient history pancreatitis l41220 also used combination metformin l41215 ertugliflozin l41225 
Decitabine,myelodysplastic syndrome md heterogeneous group hematopoietic neoplasm variable underlying etiology presentation including neutropenia thrombocytopenia mutation leading increased proliferation cancerous cell eventually lead secondary acute myeloid leukemia poor prognosis a215082 a215092 among treatment option nucleoside analogue decitabine azacitidine integrate cellular dna inhibit action dna methyltransferases leading global hypomethylation related downstream therapeutic benefit a2263 a2264 a2265 a215317 l14962 decitabine developed mgi pharma/supergen inc. approved fda treatment md february 5 2006 first marketed name dacogen® l14962 also available oral combination product together cytidine deaminase inhibitor cedazuridine ,decitabine indicated treatment patient myelodysplastic syndrome md including french-american-british subtypes refractory anemia refractory anemia ringed sideroblast refractory anemia excess blast refractory anemia excess blast transformation chronic myelomonocytic leukemia well md scored belonging intermediate-1 intermediate-2 high-risk group international prognostic scoring system l14962 
Posaconazole,posaconazole triazole antifungal drug used treat invasive infection candida specie aspergillus specie severely immunocompromised patient , prophylaxis invasive em aspergillus /em em candida /em infection patient 13 year age older high risk developing infection due severely immunocompromised result procedure hematopoietic stem cell transplant hsct recipient graft-versus-host disease gvhd due hematologic malignancy prolonged neutropenia chemotherapy also treatment oropharyngeal candidiasis including oropharyngeal candidiasis refractory itraconazole and/or fluconazole posaconazole used alternative treatment invasive aspergillosis em fusarium /em infection zygomycosis patient intolerant whose disease refractory antifungal 
Darunavir,darunavir protease inhibitor used hiv protease inhibitor drug well ritonavir effective management hiv-1 infection l9227 second-generation protease inhibitor darunavir designed combat resistance standard hiv therapy a2278 a2281 initially approved fda 2006 l9227 darunavir studied possible treatment sars-cov-2 coronavirus responsible covid-19 due vitro evidence supporting ability combat infection a191682 clinical trial underway expected conclude august 2020 l12066 ,darunavir co-administered ritonavir antiretroviral agent indicated treatment human immunodeficiency virus hiv child age 3 adult hiv-1 infection l9227 
Telbivudine,telbivudine synthetic thymidine nucleoside analog specific activity hepatitis b virus telbivudine orally administered good tolerance lack toxicity dose-limiting side effect , treatment chronic hepatitis b adult adolescent patient ≥16 year age evidence viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease 
Sinecatechins,sinecatechins botanical drug product topical use partially purified fraction water extract green tea leaf camellia sinensis mixture catechin green tea component catechin constitute 85 95 weight total drug substance includes 55 epigallocatechin gallate egcg catechin derivative epicatechin ec epigallocatechin egc epicatechin gallate ecg additional minor catechin derivative i.e gallocatechin gallate gcg gallocatechin gc catechin gallate cg catechin c addition known catechin component also contains gallic acid caffeine theobromine together constitute 2.5 drug substance remaining amount drug substance contains undefined botanical constituent derived green tea leaf , topical treatment external genital perianal wart condylomata acuminata immunocompetent patient 18 year older 
Paliperidone,paliperidone primary active metabolite risperidone mechanism action unknown likely act via similar pathway risperidone proposed drug 's therapeutic activity schizophrenia mediated combination central dopamine type 2 d2 serotonin type 2 5ht2a receptor antagonism paliperidone also active antagonist alpha 1 alpha 2 adrenergic receptor h1 histaminergic receptor may explain effect drug paliperidone approved fda treatment schizophrenia december 20 2006 available extended-release tablet once-monthly intramuscular injection every-three-month intramuscular injection twice-yearly gluteal injection l16168 l37744 l4137 l37749 , oral extended-release tablet once-monthly extended-release suspension intramuscular injection paliperidone indicated treatment adult adolescent schizophrenia treatment schizoaffective disorder combination antidepressant mood stabilizer l16168 l37744 paliperidone also available every-three-month twice-yearly extended-release suspension intramuscular injection treatment schizophrenia l4137 l37749 
Sunitinib,sunitinib small-molecule multi-targeted receptor tyrosine kinase rtk inhibitor january 26 2006 agent formally approved u fda indication treating renal cell carcinoma rcc imatinib-resistant gastrointestinal stromal tumor gist purpose sunitinib generally available orally administered formulation sunitinib inhibits cellular signaling targeting multiple rtks include platelet-derived growth factor receptor pdgf-r vascular endothelial growth factor receptor vegf-r sunitinib also inhibits kit cd117 rtk drive majority gist addition sunitinib inhibits rtks including ret csf-1r flt3 ,sunitinib indicated following condition l4135 treatment adult patient gastrointestinal stromal tumor gist following disease progression intolerance imatinib mesylate treatment adult patient advanced renal cell carcinoma rcc adjuvant treatment adult patient high risk recurrent rcc following nephrectomy treatment progressive well-differentiated pancreatic neuroendocrine tumor pnet adult patient unresectable locally advanced metastatic disease
Panitumumab,panitumumab abx-egf recombinant human igg2 monoclonal antibody bind specifically human epidermal growth factor receptor egfr drug antineoplastic agent panitumumab granted fda approval 27 september 2006 l17663 , treatment egfr-expressing metastatic colorectal carcinoma refractory fluoropyrimidine- oxaliplatin- irinotecan- containing chemotherapy regimen 
Ranibizumab,ranibizumab recombinant humanized igg1 kappa isotype monoclonal antibody fragment directed human vascular endothelial growth factor vegf-a glycoprotein implicated pathophysiology age-related macular degeneration a2301 l38978 ranibizumab used treat various ocular disorder abnormal growth blood vessel neovascular wet age-related macular degeneration development ranibizumab first began bevacizumab another anti-vegf anticancer drug discovered inhibit neovascularization used off-label treatment neovascular age-related macular degeneration intravenous injection order improve drug delivery target organ ranibizumab available intravitreal use a246399 ranibizumab initially approved fda 2006 a2301 european commission ec 2007 l41429 marketed brand name lucentis susvimo byooviz biosimilar lucentis approved health canada march 2022 making first biosimilar drug ranibizumab available canada l41399 august 2022 biosimilars cimerli raivisio approved fda l42625 ec respectively l43513 ,ranibizumab injection intravitreal use indicated treat neovascular wet age-related macular degeneration amd macular edema following retinal vein occlusion diabetic macular edema diabetic retinopathy myopic choroidal neovascularization l38978 l41434 ranibizumab injection intravitreal use via ocular implant used treat neovascular wet age-related macular degeneration amd patient responded least two intravitreal injection vegf inhibitor l38983 
Idursulfase,idursulfase purified form human iduronate-2-sulfatase lysosomal enzyme idursulfase produced recombinant dna technology human cell line idursulfase enzyme hydrolyzes 2-sulfate ester terminal iduronate sulfate residue glycosaminoglycans dermatan sulfate heparan sulfate lysosome various cell type idursulfase 525-amino acid glycoprotein molecular weight approximately 76 kilodaltons enzyme contains eight asparagine-linked glycosylation site occupied complex oligosaccharide structure enzyme activity idursulfase dependent post-translational modification specific cysteine formylglycine , treatment hunter syndrome adult child age 5 older 
Alglucosidase alfa,"aglucosidase alfa consists human enzyme acid alpha-glucosidase gaa essential degradation glygogen glucose lysosome encoded predominant nine observed haplotype gene aglucosidase alfa produced recombinant dna technology chinese hamster ovary cell line alglucosidase alfa degrades glycogen catalyzing hydrolysis a-1,4- a-1,6- glycosidic linkage lysosomal glycogen structurally alglucosidase alfa glycoprotein calculated mass 98,008 dalton 883 residue mature polypeptide chain total mass approximately 109,000 dalton including carbohydrate used treatment pompe disease gaa deficiency infant pediatric patient ", treatment pompe disease gaa deficiency infant pediatric patient 
Varenicline,varenicline prescription medication used treat smoking addiction medication first approved nicotinic receptor partial agonist specifically varenicline partial agonist alpha4/beta2 subtype nicotinic acetylcholine receptor addition act alpha3/beta4 weakly alpha3beta2 alpha6-containing receptor full agonism displayed alpha7-receptors march 9 2015 u.s. food drug administration warned varenicline form pfizer inc 's quit-smoking drug chantix associated seizure patient drink taking drug may become aggressive black pfizer conducting additional safety study drug result expected late 2015 fda said keeping black box place least result trial announced , use aid smoking cessation varenicline nasal spray indicated symptomatic treatment dry eye disease l38954 
Arformoterol,arformoterol bronchodilator work relaxing muscle airway improve breathing arformoterol inhalation used prevent bronchoconstriction people chronic obstructive pulmonary disease including chronic bronchitis emphysema use arformoterol pending revision due safety concern regard increased risk severe exacerbation asthma symptom leading hospitalization well death patient using long-acting beta agonist treatment asthma ,arformoterol indicated maintenance treatment bronchoconstriction patient chronic obstructive pulmonary disease copd including chronic bronchitis emphysema l43732 
Hydralazine,originally developed 1950s malaria treatment hydralazine showed antihypertensive ability soon repurposed a186841 hydralazine hydrazine derivative vasodilator used alone adjunct therapy treatment hypertension adjunct therapy treatment heart failure a186820 l8782 l8785 hydralazine longer first line therapy indication since development newer antihypertensive medication t691 hydralazine hydrochloride fda approved 15 january 1953 l8779 ,hydralazine indicated alone adjunct standard therapy treat essential hypertension l8782 combination product isosorbide dinitrate indicated adjunct therapy treatment heart failure l8785 
Exenatide,exenatide glucagon-like peptide-1 glp-1 analog l42690 activates glp-1 receptor increase insulin secretion decrease glucagon secretion slows gastric emptying improve glycemic control l42690 exenatide given fda approval april 28 2005 l6106 available immediate- extended-release formulation l42685 l42690 bydureon brand name product extended-release exenatide injectable suspension discontinued 2021 bydureon bcise auto-injector extended-release formulation remains available l42700 ,exenatide indicated adjunct diet exercise improve glycemic control patient type 2 diabetes extended-release formulation available indicated patient ≥10 year old l40828 immediate-acting formulation approved adult patient l42690 
Mecasermin,mecasermin contains recombinant-dna-engineered human insulin-like growth factor-1 rhigf-1 fda label igf-1 consists 70 amino acid single chain three intramolecular disulfide bridge molecular weight 7649 dalton amino acid sequence product identical endogenous human igf-1 rhigf-1 protein synthesized bacteria e. coli modified addition gene human igf-1 , long-term treatment growth failure pediatric patient primary igfd gh gene deletion developed neutralizing antibody gh a2322 indicated treat secondary igfd resulting gh deficiency malnutrition hypothyroidism cause substitute gh therapy 
Pramlintide,pramlintide relatively new adjunct treatment diabetes type 1 2 developed amylin pharmaceutical derived amylin hormone released bloodstream similar pattern insulin meal like insulin amylin deficient individual diabetes , treatment type 1 type 2 diabetes mellitus adjunct preprandial insulin therapy patient without adequate glycemic control insulin therapy 
Galsulfase,galsufase variant form polymorphic human enzyme n-acetylgalactosamine 4-sulfatase recombinant dna origin galsulfase glycoprotein molecular weight approximately 56 kd recombinant protein comprised 495 amino acid contains six asparagine-linked glycosylation site four carry bi mannose-6-phosphate manose7 oligosaccharide specific cellular recognition post-translational modification cys53 produce catalytic amino acid residue ca-formylglycine required enzyme activity conserved member sulfatase enzyme family , treatment adult child mucopolysaccharidosis vi 
Nelarabine,nelarabine antineoplastic agent typically employed treat acute t-cell lymphoblastic leukemia nelarabine purine nucleoside analog converted corresponding arabinosylguanine nucleotide triphosphate aragtp resulting inhibition dna synthesis cytotoxicity , treatment pediatric adult patient acute t-cell lymphoblastic leukemia t-cell lymphoblastic lymphoma whose disease responded relapsed following treatment least two chemotherapy regimen 
Abatacept,"abatacept soluble fusion protein link extracellular domain human cytotoxic t-lymphocyte-associated antigen 4 ctla-4 modified fc hinge ch2 ch3 domain portion human immunoglobulin g1 igg1 l20504 l42715 structurally abatacept glycosylated fusion protein maldi-ms molecular weight 92,300 da homodimer two homologous polypeptide chain 357 amino acid produced recombinant dna technology mammalian cho cell drug activity selective co-stimulation modulator inhibitory activity lymphocyte although approved treatment rheumatoid arthritis repligen entered slightly different formulation ctla4-ig clinical trial rg2077 ",abatacept indicated adult patient treatment moderately-to-severely active rheumatoid arthritis treatment active psoriatic arthritis l20504 patient two year age older abatacept also indicated treatment moderately-to-severely active juvenile idiopathic arthritis l20504 abatacept also indicated prophylaxis acute graft-versus-host disease combination methotrexate calcineurin inhibitor tacrolimus patient two year age older undergoing hematopoietic stem cell transplantation matched 1 allele-mismatched unrelated donor l20504 
Carbetocin,carbetocin drug used control postpartum hemorrhage bleeding giving birth analogue oxytocin action similar oxytocin -- cause contraction uterus ,used control postpartum hemorrhage bleeding giving birth 
Lumiracoxib,lumiracoxib cox-2 selective non-steroidal anti-inflammatory drug nsaid august 11 2007 australia 's therapeutic good administration tga australian equivalent fda cancelled registration lumiracoxib australia due concern may cause liver failure new zealand canada also followed suit recalling drug , acute chronic treatment sign symptom osteoarthritis knee adult 
Tetracosactide,tetracosactide also known cosyntropin synthetic peptide identical 24-amino acid segment sequence sysmehfrwgkpvgkkrrpvkvyp n-terminal adrenocorticotropic hormone acth 1-24 segment similar specie contains biological activity stimulates production corticosteroid adrenal cortex tetracosactide exhibit activity natural acth regard biological activity complex result product whose absorption man effected longer period time compared corticotropin therefore therapy may maintained le frequent administration , use diagnostic agent screening patient presumed adrenocortical insufficiency 
Corticotropin,corticotropin acth adrenocorticotropic hormone polypeptide hormone produced secreted pituitary gland important player hypothalamic-pituitary-adrenal axis , use diagnostic agent screening patient presumed adrenocortical insufficiency purified corticotropin injection indicated variety allergic autoimmune condition l39150 
Fenoterol,fenoterol adrenergic beta-2 agonist used bronchodilator tocolytic ,fenoterol used treatment asthma 
Glisoxepide,"glisoxepide one sulphonamide-derived oral antidiabetic drug inhibits uptake bile acid isolated rat hepatocytes however inhibits taurocholate uptake absence sodium ion glisoxepide uptake could inhibited blocker hepatocellular monocarboxylate transporter loop diuretic bumetanide 4,4'-diisothiocyano-2,2'-stilbenedisulfonate dids sulphate result consistent transport glisoxepide via transport system unconjugated bile acid cholate a31819 a31820 ", treatment diabetes mellitus type 2 
Pirbuterol,"pirbuterol beta-2 adrenergic bronchodilator vitro study vivo pharmacologic study demonstrated pirbuterol preferential effect beta-2 adrenergic receptor compared isoproterenol recognized beta-2 adrenergic receptor predominant receptor bronchial smooth muscle data indicate population beta-2 receptor human heart existing concentration 10-50 precise function receptor established pharmacologic effect beta adrenergic agonist drug including pirbuterol least proof attributable stimulation beta adrenergic receptor intracellular adenyl cyclase enzyme catalyzes conversion adenosine triphosphate alp cyclic-3† ,5†-adenosine monophosphate c-amp increased c-amp level associated relaxation bronchial smooth muscle inhibition release mediator immediate hypersensitivity cell especially mast cell ", prevention reversal bronchospasm patient 12 year age older reversible bronchospasm including asthma 
Bismuth subsalicylate,bismuth subsalicylate antacid anti-diarrheal agent exhibiting antibacterial gastroprotective property bismuth subsalicylate insoluble salt salicylic acid linked trivalent bismuth cation molecule bismuth subsalicylate contains 58 bismuth 42 salicylate weight a230733 bismuth subsalicylate around 100 year originally developed 1901 hygienic use sanitation cholera infection a230728 a230773 bismuth subsalicylate first approved fda 1939 mainly used relieve nausea diarrhea gastrointestinal discomfort a230728 active ingredient found pepto-bismol common over-the-counter medication used temporarily treat discomfort stomach gastrointestinal tract l32318 bismuth subsalicylate component helidac therapy bismuth subsalicylate metronidazole tetracycline treatment regimen indicated eradication _h pylori_ treatment patient _h pylori_ infection duodenal ulcer disease l32363 ,bismuth subsalicylate indicated temporarily relieve diarrhea traveler diarrhea upset stomach due overindulgence food drink including heartburn indigestion nausea gas belching fullness l32318 bismuth subsalicylate component helidac therapy bismuth subsalicylate metronidazole tetracycline treatment regimen indicated eradication _h pylori_ treatment patient _h pylori_ infection duodenal ulcer disease l32363 
Bevantolol,bevantolol beta-1 adrenoceptor antagonist shown effective beta blocker treatment angina pectoris hypertension mechanism action animal experiment confirm agonist antagonist effect alpha-receptors addition antagonist activity beta-1 receptor , treatment angina pectoris hypertension 
Glucosamine,osteoarthritis oa progressive degenerative joint disease marked loss cartilage bone change synovial membrane inflammation a232289 treatment chondroprotective drug glucosamine sulfate may offer additional benefit nonsteroidal anti-inflammatory drug treating painful symptom oa glucosamine commonly used counter treatment arthritic joint pain although acceptance medical therapy varies due contradictory finding unclear clinical significance clinical trial a231894 a232289 currently approved prescription product fda widely available counter ,glucosamine generally used counter symptomatic treatment osteoarthritis joint pain a2352 frequently combined chondroitin sulfate and/or ibuprofen l32699 
Practolol, beta-adrenergic antagonist used emergency treatment cardiac arrhythmia ,used emergency treatment cardiac arrhythmia 
Sulfacytine,sulfacytine short-acting sulfonamide sulfonamide synthetic bacteriostatic antibiotic wide spectrum gram-positive many gram-negative organism however many strain individual specie may resistant sulfonamide inhibit multiplication bacteria acting competitive inhibitor p-aminobenzoic acid folic acid metabolism cycle bacterial sensitivity various sulfonamide resistance one sulfonamide indicates resistance sulfonamide readily absorbed orally however parenteral administration difficult since soluble sulfonamide salt highly alkaline irritating tissue sulfonamide widely distributed throughout tissue high level achieved pleural peritoneal synovial ocular fluid although drug longer used treat meningitis csf level high meningeal infection sulfacytine competitive inhibitor enzyme dihydropteroate synthetase inhibits bacterial synthesis dihydrofolic acid preventing condensation pteridine para-aminobenzoic acid paba substrate enzyme dihydropteroate synthetase inhibited reaction necessary organism synthesis folic acid ,used orally treatment acute urinary tract infection 
Sulfadoxine, long acting sulfonamide used usually combination drug respiratory urinary tract malarial infection ,sulfadoxine used combination pyrimethamine treatment prevention malaria also used treat various infection livestock well sulfadoxine pyrimethamine indicated treatment plasmodium falciparum malaria patient chloroquine resistance suspected 
Rolitetracycline, pyrrolidinylmethyl tetracycline ,rolitetracycline broad-spectrum antibiotic used case needing high concentration oral administration impractical 
Oxtriphylline,oxtriphylline choline salt form theophylline body theophylline released act phosphodiesterase inhibitor adenosine receptor blocker histone deacetylase activator main physiological reponse dilate bronchiole oxytriphylline indicated mainly asthma bronchospasm copd i.e indication theophylline marketed name choledyl sa several form oxytriphylline discontinued u oxtriphylline longer available ,used treat symptom asthma bronchitis copd emphysema 
Insulin aspart,insulin aspart rapid-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes insulin typically prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle absorption glucose cell allows transformation glycogen fat storage insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level result people t1d rely primarily exogenous form insulin insulin aspart lower glucose level blood insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell insulin typically prescribed later course t2d trying several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin marketed brand name product novorapid insulin aspart begin exert effect within 15 minute subcutaneous administration peak level occur 30 90 minute administration due duration action around 5 hour novorapid considered `` bolus insulin '' provides high level insulin short period time mimic release endogenous insulin pancreas meal bolus insulin often combined daily long-acting `` basal insulin '' db01307 db09564 db00047 provide low concentration background insulin keep blood sugar stable meal overnight use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia insulin aspart recombinant biosynthetic fast-acting insulin analogue compared human insulin single amino acid substitution position b28 proline replaced aspartic acid substitution decrease propensity form hexamers give higher rate absorption following subcutaneous administration compared native insulin insulin aspart produced genetically modified strain _saccharomyces cerevisiae_ baker 's yeast without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy ,insulin aspart indicated improve glycemic control adult child diabetes mellitus l12273 l42550 
Insulin detemir,insulin detemir long-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes a2358 a2359 a2360 a44 insulin typically prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism a2358 a2359 a2360 a44 insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle a2358 a2359 a2360 a44 absorption glucose cell allows transformation glycogen fat storage a2358 a2359 a2360 a44 insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function a2358 a2359 a2360 a44 insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level a2358 a2359 a2360 a44 result people t1d rely primarily exogenous form insulin insulin detemir lower glucose level blood a2358 a2359 a2360 a44 insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level a2358 a2359 a2360 a44 without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell a2358 a2359 a2360 a44 insulin typically prescribed later course t2d several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin a2358 a2359 a2360 a44 marketed brand name product levemir insulin detemir duration action 16-24 hour allowing once-daily dosing typically bedtime a2358 a2359 a2360 a44 due duration action levemir considered `` basal insulin '' provides low concentration background insulin keep blood sugar stable meal overnight a2358 a2359 a2360 a44 basal insulin often combined short-acting `` bolus insulin '' db00046 db01309 db01306 provide higher dos insulin required following meal a2358 a2359 a2360 a44 use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia a2358 a2359 a2360 a44 insulin detemir produced using recombinant dna technology yeast cell a2358 a2359 a2360 a44 insulin analogue 14-c fatty acid myristic acid bound lysine amino acid position b29 myristoyl side chain increase self-association albumin binding a2358 a2359 a2360 a44 along slow systemic absorption injection site prolongs distribution hormone tissue result long duration action a2358 a2359 a2360 a44 without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst a2358 a2359 a2360 a44 left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy a2358 a2359 a2360 a44 ,insulin detemir indicated improve glycemic control adult child diabetes mellitus l42375 
Insulin glulisine,insulin glulisine short-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes insulin typically prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle absorption glucose cell allows transformation glycogen fat storage insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function insulin important treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level result people t1d rely primarily exogenous form insulin insulin glulisine lower glucose level blood insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell insulin typically prescribed later course t2d trying several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin marketed brand name product apidra insulin glulisine begin exert effect within 15 minute subcutaneous administration peak level occur 30 90 minute administration due duration action around 5 hour apidra considered `` bolus insulin '' provides high level insulin short period time mimic release endogenous insulin pancreas meal bolus insulin often combined daily long-acting `` basal insulin '' db01307 db09564 db00047 provide low concentration background insulin keep blood sugar stable meal overnight use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia insulin glulisine biosynthetic rapid-acting human insulin analogue produced non-pathogenic laboratory strain _escherichia coli_ k12 recombinant hormone differs native human insulin amino acid asparagine position b3 replaced lysine lysine position b29 replaced glutamic acid l12519 structural modification decrease hexamer formation stabilize insulin glulisine monomer increase rate absorption onset action compared human insulin without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy ,insulin glulisine indicated improve glycemic control adult pediatric patient diabetes mellitus 
Fosamprenavir,fosamprenavir prodrug amprenavir inhibitor human immunodeficiency virus hiv protease ,indicated combination antiretroviral agent treatment human immunodeficiency virus hiv-1 infection well postexposure prophylaxis hiv infection individual occupational nonoccupational exposure potentially infectious body fluid person known infected hiv exposure represents substantial risk hiv transmission use fosamprenavir pending revision due potential association drug myocardial infarction dyslipidemia hiv infected adult 
Fosphenytoin,fosphenytoin water-soluble phenytoin prodrug used hospital treatment epileptic seizure work slowing impulse brain cause seizure main mechanism block frequency-dependent use-dependent voltage-dependent neuronal sodium channel therefore limit repetitive firing action potential ,fosphenytoin indicated treatment generalized tonic-clonic status epilepticus prevention treatment seizure occurring neurosurgery adult patient also substituted short-term oral phenytoin patient aged two year older oral phenytoin administration possible l20619 
Josamycin, macrolide antibiotic streptomyces narbonensis drug antimicrobial activity wide spectrum pathogen , treatment bacterial infection 
Polythiazide, thiazide diuretic action us similar hydrochlorothiazide martindale extra pharmacopoeia 30th ed p826 ,polythiazide thiazide diuretic used decrease edema decrease blood pressure 
Quinethazone,quinethazone marketed hydromox thiazide diuretic indicated hypertension patient may experience adverse reaction dizziness dry mouth nausea hypokalemia ,used treat hypertension 
Cefamandole,cefamandole also known cephamandole parenterally administered broad-spectrum cephalosporin antibiotic generally formulated formate ester cefamandole nafate longer marketed united state , treatment serious infection caused susceptible strain microorganism 
Cefazolin, semisynthetic cephalosporin analog broad-spectrum antibiotic action due inhibition bacterial cell wall synthesis attains high serum level excreted quickly via urine ,mainly used treat bacterial infection skin also used treat moderately severe bacterial infection involving lung bone joint stomach blood heart valve urinary tract clinically effective infection caused staphylococci streptococci specie gram positive bacteria may used surgical prophylaxis required metronidazole may added cover b. fragilis 
Cefonicid, second-generation cephalosporin administered intravenously intramuscularly bactericidal action result inhibition cell wall synthesis used urinary tract infection lower respiratory tract infection soft tissue bone infection , treatment bacterial infection caused susceptible microorganism 
Cefoperazone,cefoperazone semisynthetic broad-spectrum cephalosporin proposed effective pseudomonas /i infection third-generation antiobiotic agent used treatment various bacterial infection caused susceptible organism body including respiratory tract infection peritonitis skin infection endometritis bacterial septicemia clinical use discontinued u.s. cefoperazone available several european country commonly product name sulperazon ,indicated treatment following infection caused susceptible bacteria label 1 respiratory tract infection caused _s pneumoniae_ _h influenzae_ _s aureus_ penicillinase non-penicillinase producing strain _s pyogenes_ group beta-hemolytic streptococci _p aeruginosa_ _klebsiella pneumoniae_ _e coli_ _proteus mirabilis_ enterobacter specie 2 peritonitis intra-abdominal infection caused _e coli_ _p aeruginosa_ anaerobic gram-negative bacillus including _bacteroides fragilis_ 3 bacterial septicemia caused _s pneumoniae_ _s agalactiae_ _s aureus_ _pseudomonas aeruginosa_ _e coli_ _klebsiella_ spp. _klebsiella pneumoniae_ proteus specie indole-positive indole-negative _clostridium_ spp anaerobic gram-positive cocci 4 infection skin skin structure caused s. aureus penicillinase non-penicillinase producing strain s. pyogenes p. aeruginosa 5 pelvic inflammatory disease endometritis infection female genital tract caused n. gonorrhoeae s. epidermidis s. agalactiae e. coli clostridium spp. bacteroides specie including bacteroides fragilis anaerobic gram-positive cocci 6 urinary tract infection caused escherichia coli pseudomonas aeruginosa 7 enterococcal infection although cefoperazone shown clinically effective treatment infection caused enterococci case peritonitis intra-abdominal infection infection skin skin structure pelvic inflammatory disease endometritis infection female genital tract urinary tract infection majority clinical isolates enterococci tested susceptible cefoperazone fall intermediate zone susceptibility moderately resistant cefoperazone however _in vitro_ susceptibility testing may correlate directly _in vivo_ result despite cefoperazone therapy resulted clinical cure enterococcal infection chiefly polymicrobial infection cefoperazone used enterococcal infection care dos achieve satisfactory serum level cefoperazone 
Cefotetan, semisynthetic cephamycin antibiotic administered intravenously intramuscularly drug highly resistant broad spectrum beta-lactamase active wide range aerobic anaerobic gram-positive gram-negative microorganism , prophylaxis treatment bacterial infection 
Cefoxitin,cefoxitin semi-synthetic broad-spectrum cepha antibiotic intravenous administration derived cephamycin c produced streptomyces lactamdurans /i , treatment serious infection caused susceptible strain microorganism 
Ceftizoxime, semisynthetic cephalosporin antibiotic administered intravenously suppository drug highly resistant broad spectrum beta-lactamase active wide range aerobic anaerobic gram-positive gram-negative organism side effect reported safe effective aged patient patient hematologic disorder ,cetizoxime previously indicated treatment infection due susceptible strain bacteria 
Cefradine, semi-synthetic cephalosporin antibiotic ,
Metocurine,dimethyltubocurarinium inn metocurine usan also known dimethyltubocurarine non-depolarizing muscle relaxant patient chronic anticonvulsant drug relatively resistant metocurine a2393 ,metocurine muscle relaxant 
Pancuronium, bis-quaternary steroid competitive nicotinic antagonist neuromuscular blocking agent potent curare le effect circulatory system histamine release ,used muscle relaxant anesthesia surgical procedure 
Pipecuronium,pipecuronium piperazinyl androstane derivative non-depolarizing neuromuscular blocking agent ,used muscle relaxant anesthesia surgical procedure 
Vecuronium,monoquaternary homolog pancuronium non-depolarizing neuromuscular blocking agent shorter duration action pancuronium lack significant cardiovascular effect lack dependence good kidney function elimination well short duration action easy reversibility provide advantage alternative established neuromuscular blocking agent ,vecuronium muscle relaxing agent used adjunct general anesthesia 
Cilazapril,cilazapril ace inhibtor class drug used treatment hypertension heart failure belongs angiotensin-converting enzyme inhibitor ace inhibitor class drug prodrug hydrolyzed absorption main metabolite cilazaprilat branded inhibace canada country vascace dynorm number european country among many name none variety available united state ,cilazapril ace inhibtor class drug used treatment hypertension heart failure 
Forasartan,forasartan specific angiotensin ii antagonist used alone antihypertensive agent treat hypertension forasartan competes angiotensin ii binding at1 receptor subtype angiotensin ii vasoconstrictor also stimulates synthesis release aldosterone blockage effect result decrease systemic vascular resistance , treatment hypertension 
Tolevamer,sodium polystyrene sulfonate medication used treat abnormally high potassium level may taken orally rectum enema function potassium-binding resin intestine also effective topical microbicide spermicide inhibiting genital transfection among others hiv ,used treat abnormally high potassium level 
Potassium cation,potassium major cation positive ion inside animal cell sodium major cation outside animal cell concentration difference charged particle cause difference electric potential inside outside cell known membrane potential balance potassium sodium maintained ion pump cell membrane cell membrane potential created potassium sodium ion allows cell generate action potential—a `` spike '' electrical discharge ability cell produce electrical discharge critical body function neurotransmission muscle contraction heart function potassium also essential mineral needed regulate water balance blood pressure level acidity ,potassium used regulate hypokalemia primary condition secondary medical condition 
Quinidine barbiturate, administration quinidine derivative help observe various skin mucosal reaction papulopurpuric eruption patient without thrombopenia developed taking quinidine phenylethyl barbiturate intermittently reintroduction pmid 9739909 ,
Saprisartan,saprisartan at1 receptor antagonist based medication losartan 's prototypical chemical structure mode functional at1 receptor antagonism characterized insurmountable/noncompetitive saprisartan likely slow dissociation kinetics at1 receptor underlie insurmountable antagonism a14009 ,saprisartan used treatment hypertension heart failure 
Spirapril,spirapril ace inhibitor antihypertensive drug used treat hypertension spirapril converted active spiraprilat administration ace inhibitor used primarily treatment hypertension congestive heart failure ,spirapril ace inhibitor class drug used treat hypertension 
Tasosartan,tasosartan long-acting angiotensin ii angii receptor blocker long duration action attributed active metabolite enoltasosartan used treat patient essential hypertension ,tasosartan infrequently treatment hypertension heart failure 
Amobarbital, barbiturate hypnotic sedative property antianxiety adverse effect mainly consequence dose-related cns depression risk dependence continued use high martindale extra pharmacopoeia 30th ed p565 ,
Aprobarbital,aprobarbital barbiturate derivative synthesized 1920s ernst preiswerk determined substance capable demonstrating sedative hypnotic anticonvulsant effect primary treatment indicated use aprobarbital subsequently insomnia aprobarbital never widely used common barbiturate derivative phenobarbital rarely prescribed ,
Butobarbital,butobarbital sedative hypnotic drug , treatment insomnia 
Heptabarbital,heptabarbital intermediate short term barbiturate used mainly sedation hypnosis ,used mainly sedation hypnosis 
Hexobarbital, barbiturate effective hypnotic sedative , induction anesthesia prior use general anesthetic agent induction anesthesia short surgical diagnostic therapeutic procedure associated minimal painful stimulus 
Lithium cation,lithium used 19th century treat gout lithium salt lithium carbonate li2co3 lithium citrate lithium orotate mood stabilizer used treatment bipolar disorder since unlike mood altering drug counteract mania depression lithium also used augment antidepressant drug also sometimes prescribed preventive treatment migraine disease cluster headache active principle salt lithium ion li+ smaller diameter easily displace k+ na+ even ca+2 spite greater charge occupying site several critical neuronal enzyme neurotransmitter receptor ,lithium salt form used mood stabilizer treatment depression mania frequently prescribed treatment bipolar disorder 
Mestranol, 3-methyl ether ethinyl estradiol must demethylated biologically active used estrogen component many combination oral contraceptive ,mestranol used one first oral contraceptive 
Penbutolol,penbutolol drug beta-blocker class used treat hypertension penbutolol bind beta-1 beta-2 adrenergic receptor rendering non-selective beta-blocker penbutolol act partial agonist beta adrenergic receptor since sympathomimetric drug penbutolol also demonstrates high binding affinity 5-hydroxytryptamine receptor 1a antagonistic effect binding characteristic penbutolol investigated implication antidepressant therapy penbutolol contraindicated patient cardiogenic shock sinus bradycardia second third degree atrioventricular conduction block bronchial asthma known hypersensitivity ,penbutolol indicated treatment mild moderate arterial hypertension may used alone combination antihypertensive agent especially thiazide-type diuretics.penbutolol contraindicated patient cardiogenic shock sinus bradycardia second third degree atrioventricular conduction block bronchial asthma known hypersensitivity 
Iohexol,iohexol effective non-ionic water-soluble contrast agent used myelography arthrography nephroangiography arteriography radiographic procedure low systemic toxicity combined result low chemotoxicity low osmolality ,iohexol ia used myelography arthrography nephroangiography arteriography radiographic procedure 
Ephedra sinica root,ephedra alkaloid chemical compound traditionally obtained plant _ephedra sinica_ sale ephedra-containing supplement intended increase muscle weight promote weight loss banned united state 2004 due risk adverse effect lack evidence clinical effectiveness drug still sold canada otc formulation respiratory condition associated bronchial asthma ,ephedra indicated temporary relief shortness breath tightness chest wheezing due bronchial asthma temporary relief bronchial asthma over-the-counter formulation 
Ephedrine,ephedrine first described western literature 1888 naturally occurring component ephedra plant along pseudoephedrine a193698 ephedrine act direct indirect sympathomimetic alpha- beta-adrenergic receptor agonist however also cause indirect release norepinephrine sympathetic neuron inhibiting norepinephrine reuptake displacing norepinephrine storage vesicle a193650 l12972 ephedrine used vasoconstrictive positive chronotropic positive inotropic effect l12972 ephedrine phenylephrine still used treat hypotension use indication decreased due development selective adrenergic agonist a193701 a193704 l12975 ephedrine granted type 7 fda approval 29 april 2016 l12975 ,ephedrine intravenous injection indicated treat hypotension anesthesia l12972 l34645 ephedrine injection multiple route indicated treat allergic condition bronchial asthma l12996 ephedrine nasal spray otc medication used decongestant l12993 
Mephentermine, sympathomimetic agent mainly indirect effect adrenergic receptor used maintain blood pressure hypotensive state example following spinal anesthesia although central stimulant effect mephentermine much le amphetamine use may lead amphetamine-type dependence martindale extra pharmacopoeia 30th ed p1248 ,used maintain blood pressure hypotensive state 
Procaterol, long-acting beta-2-adrenergic receptor agonist potent bronchodilator may administered orally aerosol inhalation , treatment asthma chronic obstructive pulmonary disease copd 
Rasagiline,rasagiline irreversible inhibitor monoamine oxidase used monotherapy early parkinson 's disease adjunct therapy advanced case , treatment sign symptom idiopathic parkinson disease initial monotherapy adjunct therapy levodopa 
Quinupristin,quinupristin/dalfopristin combination two antibiotic used treat infection staphylococci vancomycin-resistant enterococcus faecium dalfopristin inhibits early phase protein synthesis bacterial ribosome quinupristin inhibits late phase protein synthesis combination two component act synergistically effective vitro component alone , treatment bacterial infection usually combination dalfopristin 
Aluminium, metallic element atomic number 13 atomic symbol al atomic weight 26.98 ,
Calcium,calcium play vital role anatomy physiology biochemistry organism cell particularly signal transduction pathway skeleton act major mineral storage site element release ca2+ ion bloodstream controlled condition circulating calcium either free ionized form bound blood protein serum albumin although calcium flow bone neutral 5 mmol turned day bone serf important storage point calcium contains 99 total body calcium low calcium intake may also risk factor development osteoporosis best-absorbed form calcium pill calcium salt like carbonate phosphate calcium gluconate calcium lactate absorbed well pregnant woman senior absorb calcium lactate gluconate citrate better unless take calcium supplement full breakfast ,calcium play vital role anatomy physiology biochemistry organism cell particularly signal transduction pathway vital cell signaling muscular contraction bone health signalling cascade 
Aluminium monostearate,aluminium monostearate salt stearic acid aluminium molecular formula al oh 2c18h35o2 also known dihydroxyaluminium dihydroxy stearato aluminium used form gel packaging pharmaceutical preparation color cosmetic considered safe use extensive usage may result aluminum accumulation ,
Magnesium oxide,magnesium oxide inorganic compound occurs nature mineral periclase aqueous medium combine quickly water form magnesium hydroxide used antacid mild laxative many nonmedicinal us ,indicated over-the-counter use supplement cardiovascular neuromuscular health antacid relief acid indigestion upset stomach magnesium oxide combination sodium picosulfate anhydrous citric acid indicated cleansing colon preparation colonoscopy adult pediatric patient age 9 year older l43832 
Magnesium cation,magnesium hydroxide used primarily `` milk magnesia '' white aqueous mildly alkaline suspension magnesium hydroxide formulated 8 w/v milk magnesia primarily used alleviate constipation also used relieve indigestion heartburn taken internally mouth laxative osmotic force magnesia suspension act draw fluid body retain already within lumen intestine serving distend bowel thus stimulating nerve within colon wall inducing peristalsis resulting evacuation colonic content ,
Cortisone acetate,cortisone acetate first isolate 1935 became widely researched 1949 a226295 since glucocorticoid cortisone acetate used treat number inflammatory condition endocrine rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal disease disorder a226300 l13203 cortisone acetate granted fda approval 13 june 1950 l15107 ,cortisone acetate indicated treat wide variety endocrine rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal disease disorder a226300 l13203 
Ginkgo biloba,_ginkgo biloba_ extract contains group terpene lactones notably ginkgolides diterpenes ginkgo flavone glycoside notably ginkgetin bilobetin sciadopitysin antioxidant vasoactive property a232389 study investigate effect _ginkgo biloba_ use standardized extract _ginkgo biloba_ egb 761 egb761 developed german pharmaceutical company 1964 a232404 egb761 contains 6 terpene lactones 24 flavonoid glycoside a232379 flavonoid include quercetin rutin kaempferol isorhamnetin lactones include ginkgolide ginkgolide b ginkgolide c bilobalide ginkgotoxin lactone structurally related pyridoxine l32789 _ginkgo biloba_ herbal plant cultivated worldwide originally native china _ginkgo biloba_ extract used traditional chinese medicine century a232389 nootropic property discovered _ginkgo biloba_ gained attention therapeutic ingredient memory concentration enhancement cognitive impairment neurogenerative disease dementia a232384 _ginkgo biloba_ investigated preliminary study variety therapeutic purpose improving cardiovascular health sexual dysfunction psychiatric disorder skin disorder glaucoma _ginkgo biloba_ found number homeopathic over-the-counter herbal product dietary supplement approved therapeutic indication regulatory body fda ema health canada a232379 _ginkgo folium_ leaf extract _ginkgo biloba_ considered anti-dementia drug world health organization a232389 ,_ginkgo biloba_ currently approved therapeutic indication insufficient evidence support unapproved use a232379 available over-the-counter herbal product mostly oral use improve memory cognitive problem 
Glymidine,glycodiazine used diet lower blood glucose increasing secretion insulin pancreas increasing sensitivity peripheral tissue insulin mechanism action glycodiazine lowering blood glucose appears dependent stimulating release insulin functioning pancreatic beta cell increasing sensitivity peripheral tissue insulin glycodiazine likely bind atp-sensitive potassium channel receptor pancreatic cell surface reducing potassium conductance causing depolarization membrane membrane depolarization stimulates calcium ion influx voltage-sensitive calcium channel increase intracellular calcium ion concentration induces secretion insulin used concomitant use insulin treatment noninsulin-dependent type 2 diabetes mellitus ,glycodiazine used concomitantly insulin treatment noninsulin-dependent type 2 diabetes mellitus 
Paramethasone, glucocorticoid general property corticosteroid used mouth treatment condition corticosteroid therapy indicated except adrenal-deficiency state lack sodium-retaining property make le suitable hydrocortisone supplementary fludrocortisone martindale extra pharmacopoeia 30th ed p737 , treatment condition corticosteroid therapy indicated except adrenal-deficiency state lack sodium-retaining property make le suitable hydrocortisone supplementary fludrocortisone 
Mibefradil,mibefradil withdrawn market 1998 potentially harmful interaction drug , treatment angina high blood pressure 
Sodium bicarbonate,sodium bicarbonate white crystalline powder commonly used ph buffering agent electrolyte replenisher systemic alkalizer topical cleansing solution ,sodium bicarbonate used treatment metabolic acidosis may occur severe renal disease uncontrolled diabetes circulatory insufficiency due shock severe dehydration extracorporeal circulation blood cardiac arrest severe primary lactic acidosis also indicated severe diarrhea often accompanied significant loss bicarbonate indicated treatment certain drug intoxication including barbiturate dissociation barbiturateprotein complex desired poisoning salicylate methyl alcohol hemolytic reaction requiring alkalinization urine diminish nephrotoxicity blood pigment 
Yohimbine, plant alkaloid alpha-2-adrenergic blocking activity yohimbine used mydriatic treatment impotence also alleged aphrodisiac ,indicated sympatholytic mydriatic impotence successfully treated yohimbine male patient vascular diabetic origin psychogenic origin 
Bezafibrate,antilipemic agent lower cholesterol triglyceride decrease low density lipoprotein increase high density lipoprotein , treatment primary hyperlipidaemia type iia iib iii iv v fredrickson classification corresponding group ii iii european atherosclerosis society guideline diet alone improvement lifestyle increased exercise weight reduction lead adequate response also treatment secondary hyperlipidaemia e.g severe hypertriglyceridemias sufficient improvement occur correction underlying disorder e.g diabetes mellitus 
Colchicine,first approved fda 1961 colchicine alkaloid drug commonly used management gout condition associated painful deposition urate crystal joint a183614 l8138 derived plant belonging lily family known colchicum autumnale `` autumn crocus '' a183611 use gout colchicine approved managing exacerbation familial mediterranean fever fmf hereditary autoinflammatory condition a183620 l8141 ,colchicine indicated prophylaxis treatment gout flare also indicated familial mediterranean fever fmf child adult 4 year age older important note medication pain reliever used painful condition consider analgesic purpose l8138 off-label us colchicine include treatment manifestation behcet 's syndrome pericarditis postpericardiotomy syndrome a183932 a183935 
Drospirenone,drospirenone synthetic progestin commonly found popular oral contraceptive yaz combination ethinyl estradiol l7973 recently approved health canada fda combination estetrol oral contraceptive therapy l33199 l33174 aside contraceptive effect drospirenone used estrogen control acne premenstrual dysphoric disorder pmdd drospirenone subject widespread safety concern due possibility increased risk venous thromboembolism associated use a182543 a182552 2012 however safety statement fda concluded increase risk thromboembolism resulting use drospirenone remains unclear study regarding risk conflicting study demonstrated significantly increased risk demonstrating risk thromboembolic event statement fda mentioned increased risk venous thromboembolism oral contraceptive drospirenone exists remains lower risk condition pregnancy postpartum period considered assessing potential risk hormonal contraceptive use l7979 ,drospirenone combination ethinyl estradiol estetrol indicated oral contraceptive prevention pregnancy l7973 l33174 addition use contraceptive effect combination used treat moderate acne vulgaris symptom premenstrual dysphoric disorder l7973 l7976 drug approved indication combination estrogen treatment menopause-associated symptom vasomotor symptom vulvovaginal atrophy drospirenone combined estrogen may also may aid prevention osteoporosis woman post-menopausal least year candidate therapy l7997 l8075 sometimes found preparation containing estrogen folic acid folic acid replenishment oral contraception l8078 used treatment acne vulgaris drospirenone-containing contraceptive used woman ≥14 year age experienced menarche desire oral contraception contraindication oral contraceptive l7976 off-label us drug include treatment menstrual irregularity dysmenorrhea hirsutism endometriosis a2439 a182576 
Digitoxin, cardiac glycoside sometimes used place digoxin longer half-life digoxin toxic effect similar digoxin longer lasting martindale extra pharmacopoeia 30th ed p665 , treatment management congestive cardiac insufficiency arrhythmia heart failure 
Magnesium salicylate,magnesium salicylate non-steroidal anti-inflammatory drug nsaid used treat mild moderate pain available several over-the-counter otc formulation though recommended doseage 1160 mg every six hour per package direction doan 's otc brand 580 mg magnesium salicylate tetrahydrate equivalent 934.4 mg anhydrous magnesium salicylate effective pain relief often found half dosage reduced anti-inflammatory result ,magnesium salicylate common analgesic non-steroidal anti-inflammatory drug nsaid used treat mild moderate muscular pain
Salsalate,salsalate nonsteroidal anti-inflammatory agent oral administration salsalate 's mode action anti-inflammatory antirheumatic agent may due inhibition synthesis release prostaglandin usefulness salicylic acid active vivo product salsalate treatment arthritic disorder established contrast aspirin salsalate cause greater fecal gastrointestinal blood loss placebo salsalate readily soluble small intestine partially hydrolyzed two molecule salicylic acid significant portion parent compound absorbed unchanged undergoes rapid esterase hydrolysis body parent compound elimination half-life 1 hour salicylic acid active metabolite biotransformation saturated anti-inflammatory dos salsalate capacity limited biotransformation result increase half-life salicylic acid 3.5 16 hour , relief sign symptom rheumatoid arthritis osteoarthritis related rheumatic disorder 
Neostigmine, cholinesterase inhibitor used treatment myasthenia gravis reverse effect muscle relaxant gallamine tubocurarine neostigmine unlike physostigmine cross blood-brain barrier ,neostigmine used symptomatic treatment myasthenia gravis improving muscle tone 
Choline magnesium trisalicylate,choline magnesium trisalicylate non-acetylated salicylate used widely nonsteroidal anti-inflammatory drug trisalicylate significantly reduces methotrexate renal clearance displacing methotrexate protein increasing fraction unbound 28 a19653 a19654 ,choline magnesium trisalicylate used reduce pain inflammation caused condition arthritis medication also used treat fever adult 
Methotrimeprazine, phenothiazine pharmacological activity similar chlorpromazine promethazine histamine-antagonist property antihistamine together central nervous system effect resembling chlorpromazine martindale extra pharmacopoeia 30th ed p604 , treatment psychosis particular schizophrenia manic phase bipolar disorder 
Ginseng,ginseng promoted adaptogen product increase body 's resistance stress one certain extent supported reference anticarcinogenic antioxidant property ginseng also known contain phytoestrogens ,
Temafloxacin,temafloxacin antibiotic agent belonging fluoroquinolone drug class first approved use u.s. market 1992 withdrawn shortly due report serious adverse reaction allergic reaction hemolyric anemia resulting three death , treatment lower respiratory tract infection genital urinary infection like prostatitis skin infection 
Danazol, synthetic steroid antigonadotropic anti-estrogenic activity act anterior pituitary suppressant inhibiting pituitary output gonadotropin posse androgenic property danazol used treatment endometriosis benign breast disorder , treatment endometriosis fibrocystic breast disease patient unresponsive simple measure also used prophylactic treatment type hereditary angioedema male female 
Clenbuterol, substituted phenylaminoethanol beta-2 adrenomimetic property low dos used bronchodilator asthma ,used bronchodilator treatment asthma patient 
Bambuterol,bambuterol long acting beta-adrenoceptor agonist used treatment asthma prodrug terbutaline , prevention reversal bronchospasm patient 12 year age older asthma reversible bronchospasm associated bronchitis emphysema 
Tiotropium,tiotropium long-acting antimuscarinic bronchodilator used management chronic obstructive pulmonary disease copd asthma a180163 l7084 l7087 l7090 l7093 tiotropium act mainly m3 muscarinic receptor located airway produce smooth muscle relaxation bronchodilation a180163 l7084 l7087 l7090 l7093 tiotropium specific subset muscarinic receptor commonly found lung ipratropium a180163 tiotropium granted fda approval 30 january 2004 l7084 ,tiotropium powder inhalation indicated maintenance bronchospasm copd prevent exacerbation copd l7084 combination tiotropium olodaterol metered inhalation spray indicated maintenance copd l7087 tiotropium inhalation spray indicated maintenance bronchospasm copd prevent exacerbation copd treat asthma patient 12 year old l7090 tiotropium metered inhalation spray indicated maintenance bronchospasm copd prevent exacerbation copd treat asthma patient 6 year old l7093 
Ciclesonide,ciclesonide glucocorticoid used treat obstructive airway disease marketed brand name alvesco , treatment nasal symptom associated seasonal perennial allergic rhinitis adult adolescent 12 year age older 
Pranlukast,pranlukast cysteinyl leukotriene receptor-1 antagonist antagonizes reduces bronchospasm caused principally asthmatic allergic reaction accidentally inadvertently encountered allergen ,used adjunct standard therapy inhaled steroid inhaled long- and/or short-acting beta-agonists 
Theobromine,"theobromine 3,7-dimethylxanthine principle alkaloid theobroma cacao cacao bean plant xanthine alkaloid used bronchodilator vasodilator weaker diuretic activity theophylline also le powerful stimulant smooth muscle practically stimulant effect central nervous system formerly used diuretic treatment angina pectoris hypertension martindale extra pharmacopoeia 30th ed pp1318-9 ",theobromine used vasodilator diuretic heart stimulant similar caffeine may useful management fatigue orthostatic hypotension 
Cefepime,cefepime fourth-generation cephalosporin antibiotic developed 1994 cefepime active gram-positive gram-negative bacteria greater activity compared third-generation antibiotic a2457 a249050 cefepime normally used treat severe nosocomial pneumonia infection caused multi-resistant microorganism _pseudomonas aeruginosa_ also indicated empirical treatment febrile neutropenia a249050 popularity third-generation predecessor clinical efficacy high prevalence multidrug-resistant bacteria might factor leading increase use cefepime activity cefepime enterobacteriaceae _pseudomonas aeruginosa_ _staphylococcus aureus_ due high stability toward beta-lactamase a249050 general cefepime seems well tolerated however patient treated antibiotic especially renal impairment may develop neurotoxicity a249050 l42095 l42100 ,cefepime indicated treatment pneumonia caused susceptible bacteria empiric therapy febrile neutropenic patient cefepime also indicated treatment uncomplicated complicated urinary tract infection including pyelonephritis uncomplicated skin skin structure infection complicated intra-abdominal infection used combination metronidazole adult caused susceptible bacteria l42095 l42100 
Cefacetrile, derivative 7-aminocephalosporanic acid ,cefacetrile broad-spectrum first generation cephalosporin antibiotic effective gram-positive gram-negative bacterial infection 
Ceftibuten,ceftibuten third-generation cephalosporin antibiotic orally-administered typically used treat acute bacterial exacerbation chronic bronchitis abecb acute bacterial otitis medium pharyngitis tonsilitis ,indicated treatment acute bacterial exacerbation chronic bronchitis abecb acute bacterial otitis medium pharyngitis tonsilitis 
Cefpodoxime,cefpodoxime oral third generation cephalosporin antibiotic effectiveness gram positive gram negative bacteria commonly used treat acute otitis medium pharyngitis sinusitis cefpodoxime proxetil prodrug absorbed de-esterified intestinal mucosa cefpodoxime ,indicated treatment patient mild moderate infection caused susceptible strain designated microorganism 
Acenocoumarol,acenocoumarol coumarin derivative used anticoagulant coumarin derivative inhibit reduction vitamin k vitamin k reductase prevents carboxylation vitamin k-dependent clotting factor ii vii ix x interferes coagulation a188739 hematocrit hemoglobin international normalized ratio liver panel monitored patient acenocoumarol prohibited giving blood , treatment prevention thromboembolic disease specifically indicated prevention cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism infarction transient ischemic attack used treatment deep vein thrombosis myocardial infarction 
Antrafenine,antrafenine piperazine derivative drug act analgesic anti-inflammatory drug similar efficacy naproxen widely used largely replaced newer drug ,antrafenine used anti-inflammatory analgesic agent relief mild moderate pain 
Testosterone propionate,testosterone propionate slower-releasing anabolic steroid short half-life synthetic androstane steroid derivative testosterone form 17β propionate ester testosterone t83 testosterone propionate developed initially watson lab fda approved february 5 1974 currently drug discontinued human vet application still available otc l1160 ,testosterone propionate used veterinary practice heifer order stimulate maximal growth l1160 
Paromomycin, oligosaccharide antibiotic produced various streptomyces pubchem , treatment acute chronic intestinal amebiasis effective extraintestinal amebiasis also management hepatic coma adjunctive therapy 
Nitroxoline,nitroxoline urinary antibacterial agent active susceptible gram-positive gram-negative organism commonly found urinary tract infection hydroxyquinoline derivative unrelated class drug a179251 nitroxoline active bacterial gyrases ,nitroxoline antibiotic agent 
Stepronin,strepronin mucolytic drug mucolytic agent agent dissolve thick mucus usually used help relieve respiratory difficulty viscosity mucous secretion lung dependent upon concentration mucoprotein well presence disulfide bond macromolecule dna ,strepronin mucolytic expectorant drug 
Aminophenazone,aminophenazone pyrazolone analgesic anti-inflammatory antipyretic property carry risk agranulocytosis biomedical application radiolabelled 13c-labeled aminophenazone used breath test measure cytochrome p-450 metabolic activity liver function test fda suspended use aminophenazone due association agranulocytosis life-threatening side effect a254242 l43942 ,formerly widely used antipyretic analgesic rheumatism neuritis common cold currently used measure total body water 
Alizapride,alizapride dopamine antagonist capable demonstrating prokinetic antiemetic effect kind pharmacological activity make effective use treatment various kind nausea vomiting including may occur postoperatively ,alizapride used treatment nausea vomiting including postoperative nausea vomiting 
Ajmaline, alkaloid found root rauwolfia serpentina among plant source class ia antiarrhythmic agent apparently act changing shape threshold cardiac action potential ajmaline produce potent sodium channel blocking effect short half-life make useful drug acute intravenous treatment drug popular country treatment atrial fibrillation patient wolff–parkinson–white syndrome well tolerated monomorphic ventricular tachycardia also used many year drug challenge conduction system heart case bundle branch block syncope case abnormal prolongation hv interval taken proof infrahisian conduction defect tributary permanent pacemaker implantation , use antiarrhythmic agent 
Amrinone,amrinone inamrinone type 3 pyridine phosphodiesterase inhibitor used treatment congestive heart failure ,used treatment congestive heart failure 
Oxybenzone,oxybenzone organic compound used sunscreen derivative benzophenone form colorless crystal readily soluble organic solvent used ingredient sunscreen cosmetic absorbs uv-a ultraviolet ray ,used ingredient sunscreen cosmetic 
Aprindine,aprindine cardiac depressant used arrhythmia ,
Almitrine,almitrine respiratory stimulant enhances respiration acting agonist peripheral chemoreceptor located carotid body used treatment chronic obstructive pulmonary disease also reported potentially beneficial effect treating noctural oxygen desaturation without impairing quality sleep , treatment chronic obstructive pulmonary disease 
Allylestrenol, synthetic steroid progestational activity widely marketed throughout europe including russia many european country also available japan hong kong india bangladesh indonesia much southeast asia though notably united state canada ,allylestrenol designed used miscarriage prevention prevention premature labour investigated possible use men treatment benign prostatic hyperplasia 
Cholestyramine,cholestyramine colestyramine bile acid sequestrant bile acid sequestrants polymeric compound serve ion exchange resin cholestyramine resin quite hydrophilic insoluble water ,indicated adjunctive therapy diet reduction elevated serum cholesterol patient primary hypercholesterolemia elevated low density lipoprotein ldl cholesterol respond adequately diet also relief pruritus associated partial biliary obstruction 
Methadyl acetate, narcotic analgesic long onset duration action used mainly treatment narcotic dependence ,used mainly treatment narcotic dependence 
19-norandrostenedione,19-norandrostenedione refers two steroid isomer marketed dietary supplement mainly used body builder 2005 19-norandrostenedione regulated united state schedule iii controlled substance well banned use competitive sport world anti-doping agency body 19-norandrostenedione rapidly metabolized nandrolone also known nortestosterone , claim supplemental 19-norandrostenedione anabolic effect unsubstantiated 
Antipyrine, analgesic antipyretic given mouth ear drop antipyrine often used testing effect drug disease drug-metabolizing enzyme liver martindale extra pharmacopoeia 30th ed p29 ,antipyrine analgesic often used test effect drug liver enzyme combination benzocaine otic solution antipyrine indicated symptomatic relief acute otitis medium arising various etiology 
Alfacalcidol,alfacalcidol 1-alpha-hydroxycholecalciferol 1-alpha-hydroxyvitamin d3 non-endogenous analogue vitamin a234044 play essential function calcium homeostasis bone metabolism alfacaldisol activated enzyme 25-hydroxylase liver mediate effect body importantly kidney bone pharmacological action alfacalcidol prolonged vitamin negative feedback mechanism regulates final activation step vitamin kidney a175348 a175351 alfacalcidol available oral intravenous formulation canada marketed one-alpha manages hypocalcemia secondary hyperparathyroidism osteodystrophy adult chronic renal failure l33284 approving european country alfacalcidol also indicated managing nutritional malabsorptive rickets osteomalacia vitamin d-dependent rickets osteomalacia hypophosphataemic vitamin resistant rickets osteomalacia l33364 l33369 ,alfacalcidol indicated adult patient chronic renal failure management hypocalcemia secondary hyperparathyroidism osteodystrophy l33284 alfacalcidol indicated management nutritional malabsorptive rickets osteomalacia vitamin d-dependent rickets osteomalacia hypophosphataemic vitamin resistant rickets osteomalacia l33364 l33369 
Glutethimide,glutethimide hypnotic sedative use largely superseded drug , treatment insomnia 
Phenazopyridine,phenazopyridine also known pyridium urinary tract analgesic used short-term management urinary tract irritation associated unpleasant symptom burning pain urination usa drug previously marked roche discontinued fda l7832 still used various part world ingestion phenazopyridine found change appearance urine imparting orange red color considered azo dye l7829 ,phenazopyridine hydrochloride indicated relieve uncomfortable symptom occur consequence mucosal irritation lower urinary tract adult irritation may result trauma surgery endoscopic procedure infection insertion instrument urinary catheter l7826 phenazopyridine may used combination antimicrobial therapy used antimicrobial agent contributes relief discomfort pain antimicrobial therapy begin take effect important note duration treatment drug last maximum 2 day l7826 phenazopyridine available many country counter drug a182147 
3-Methylthiofentanyl,3-methyl-thiofentanyl fentanyl analog opioid analgesic work inducing central nervous system cns depression ,
gamma-Hydroxybutyric acid,gamma hydroxybutyric acid commonly abbreviated ghb therapeutic drug illegal multiple country currently regulated u sold jazz pharmaceutical name xyrem however important note ghb designated orphan drug 1985 today xyrem schedule iii drug however ghb remains schedule drug illicit use xyrem fall penalty schedule i. ghb naturally occurring substance found central nervous system wine beef small citrus fruit almost living creature small amount used illegally street name juice liquid ecstasy simply g either intoxicant date rape drug xyrem central nervous system depressant reduces excessive daytime sleepiness cataplexy patient narcolepsy ,used general anesthetic treat condition insomnia clinical depression narcolepsy alcoholism improve athletic performance 
"5-Methoxy-N,N-diisopropyltryptamine",5-methoxy-n n-diisopropyltryptamine 5-meo-dipt tryptamine derivative share many similarity schedule tryptamine hallucinogen alpha-ethyltryptamine n n-dimethyltryptamine n n-diethyltryptamine bufotenine psilocybin psilocin since 1999 growing popularity 5-meo-dipt among drug abuser substance abused hallucinogenic effect ,
MMDA,"mmda 3-methoxy-4,5-methylenedioxyamphetamine member amphetamine drug class stimulant psychedelic property also act entheogen entactogen mmda bear resemblance psychopharmacologically active essential oil elemicin myristicin found nutmeg effect mmda includes feeling euphoria warmth well realistic closed-eye visuals ",mmda recreational drug current medical us schedule controlled substance usa present 
19-Nor-5-androstenedione,19-nor-5-andorstenedione prohormone potential affect bodily level testosterone metabolized vivo regulated united state schedule iii controlled substance prohibited world anti-doping agency use competitive sport ,
Dimethylthiambutene,"dimethylthiambutene n n-dimethyl-1-methyl-3,3-di-2-thienylallylamine dimethibutin ohton opioid analgesic drug international control schedule un single convention narcotic drug 1961 presumably due high abuse potential although little information available ",dimethylthiambutene opioid analgesic previously used moderate pain relief 
Bufotenine, hallucinogenic serotonin analog found frog toad skin mushroom higher plant mammal especially brain plasma urine schizophrenic bufotenin used tool cns study misused psychedelic ,
Indopan,"indopan alpha-methyltryptamine stimulant psychoactive drug produce effect similar 3,4-methylenedioxy-n-methylamphetamine mdma despite structurally dissimilar developed 1960 's upjohn intention use antidepressant 1990 's indopan became regulated schedule controlled substance united state ",
Diamorphine,diamorphine heroin narcotic analgesic may habit-forming controlled substance opium derivative listed u.s. code federal regulation title 21 part 329.1 1308.11 1987 sale forbidden united state federal statute merck index 11th ed internationally diamorphine controlled schedule iv single convention narcotic drug heroin illegal manufacture posse sell united state uk however name diamorphine heroin legal prescription drug united kingdom ,diamorphine prescription medication united kingdom indicated use treatment severe pain associated surgical procedure myocardial infarction pain terminally ill relief dyspnoea acute pulmonary edema l4999 
Midomafetamine, n-substituted amphetamine analog widely abused drug classified hallucinogen cause marked long-lasting change brain serotonergic system commonly referred mdma ecstasy widely abused drug classified hallucinogen cause marked long-lasting change brain serotonergic system ,clinical trial testing therapeutic potential mdma post-traumatic stress disorder ptsd anxiety associated terminal cancer mdma one four widely used illicit drug u.s 
5-androstenedione,5-androstenedione prohormone testosterone united state controlled substance act inclusive anabolic steroid precursor thus 5-androstenedione controlled substance use athlete prohibited world anti-doping agency apart positioning carbon-carbon double bond structure similar 4-androstenedione prohormone naturally produced body adrenal gland gonad act precursor testosterone well estrone estradiol ,
Bezitramide,bezitramide narcotic analgesic discovered 1961 clinically tested around 1970 's a14383 marketed name burgodin case fatal overdose netherlands 2004 drug withdrawn market bezitramide never fda approved currently schedule ii drug , narcotic analgesic used treatment severe chronic pain a14383 
Diethyltryptamine,diethyltryptamine det orally active hallucinogenic agent substituted form tryptamine ,
Dimenoxadol,dimenoxadol opioid analgesic produce typical opioid effect analgesia sedation structurally similar methadone benzilic acid derivative united state classified schedule controlled drug ,
Fencamfamin,fencamfamin glucoenergan reactivan stimulant developed 1960s appetite suppressant later withdrawn application due problem dependence abuse around half potency dexamphetamine prescribed dose 10-60mg although abuser drug tend rapidly develop tolerance escalate dose fencamfamin used treating depressive day-time fatigue lack concentration lethargy especially useful patient chronic condition due favourable safety profile , treatment depressive fatigue convalescence debilitated state well treatment depressive day-time fatigue lack concentration lethargy 
Ethylmorphine, narcotic analgesic antitussive metabolized liver ethylmorphine-n-demethylase used indicator liver function marketed u approved use various country around world u schedule ii drug single-entity schedule iii drug combination product ,ethylmorphine analgesic used pain relief 
alpha-methylthiofentanyl,alpha-methylthiofentanyl opioid analgesic analog fentanyl ,
Betaprodine, opioid analgesic chemically related action resembling meperidine rapid onset shorter duration used obstetrics pre-operative medication minor surgical procedure dental procedure martindale extra pharmacopoeia 30th ed p1067 ,
Desmethylprodine,desmethylprodine derivative meperidine opioid analgesic potency morphine listed schedule controlled drug united state thus used clinically known designer drug synthesized 1977 purpose recreational use illicit manufacturing occurred ,
1-Testosterone,"1-testosterone anabolic steroid differs testosterone 1,2-double bond instead 4,5-double bond ring ",
Barbital, long-acting barbiturate depresses metabolic process high dos used hypnotic sedative may induce dependence barbital also used veterinary practice central nervous system depression barbital schedule iv controlled drug ,
4-Hydroxytestosterone,4-hydroxytestosterone testosterone substituted hydroxy group fourth carbon atom anabolic steroid therapeutic indication prohibited use sport world anti-doping agency formestane lentaron act prohormone 4-hydroxytestosterone 4-hydroxytestosterone one many byproduct formestane metabolism specifically 17-hydroxylated analog formestane a14385 like formestane 4-hydroxytesterone patented use decreasing estrogen production body indication currently exists 4-hydroxytestosterone first patented 1955 g.d searle company ,
Cathine,cathine also known d-norpseudoephedrine -norpseudoephedrine psychoactive drug stimulant property belongs phenethylamine amphetamine chemical class united state classified schedule iv controlled substance ,used decrease appetite 
Dimethyltryptamine, n-methylated indoleamine derivative serotonergic hallucinogen found several plant especially prestonia amazonica apocynaceae mammalian brain blood urine apparently act agonist type serotonin receptor antagonist others , people use compound psychedelic inducing agent 
Camazepam,camazepam benzodiazepine dimethyl carbamate ester tamzepam metabolite diazepam similarly drug class antxiolytic anticonvulsant hypnotic skeletal muscle relaxant property however unlike benzodiapeines camazepam predominantly anxiolytic relatively weak anticonvulsant hypnotic skeletal muscle relaxant camazepam also le side effect impaired cognition reaction time compared benzodiazepine however impairment cognition disrupted sleep pattern occur dos higher 40mg carazepam camazepam also believed increase attention associated skin disorder united state camazepam regulated schedule iv controlled substance ,camazepam used placebo controlled study treatment patient suffering anxiety depression 
Aminorex,aminorex amphetamine-like anorectic agent may cause pulmonary hypertension ,
Ethylestrenol, anabolic steroid progestational activity little androgenic effect pubchem ,
Dichloralphenazone,dichloralphenazone sedative composed chloral hydrate phenazone typically found combination product nodolor midrin containing isometheptene acetaminophen used relief tension vascular headache u schedule iv drug clinical use limited ,
Etorphine, narcotic analgesic morphinan used sedative veterinary practice certain country etorphine classified schedule 1 drug hence country used legally health professional research purpose etorphine available patient official prescription u etorphine listed schedule drug although etorphine hydrochloride classified schedule ii ,etorphine available use veterinary main usage related immobilization large mammal 
Alphameprodine,alphameprodine opioid analgesic classified united state drug enforcement administration schedule illegal substance stereoisomer betameprodine similarly classified however alphameprodine widely used referred meprodine alphameprodine structural analogue meperidine exerts physiological effect characteristic opioids analgesia euphoria sedation well itching nausea respiratory depression ,
Difenoxin,difenoxin 4-phenylpiperidine closely related opioid analgesic meperidine difenoxin alone usa schedule controlled drug may habit forming however listed schedule iv controlled drug combined atropine added decrease deliberate misuse motofen r brand mixture combine atropine sulfate difenoxin hydrochloride approved fda treat acute chronic diarrhea difenoxin active metabolite anti-diarrheal drug diphenoxylate also used combination atropine brand mixture lomotil r work mostly periphery activates opioid receptor intestine rather central nervous system cns 3 difenoxin also closely related loperamide unlike loperamide still capable crossing blood brain barrier produce weak sedative analgesic effect however antidiarrheal potency difenoxin much greater cns effect make attractive alternative opioids ,motofen r combination atropine anticholinergic drug difenoxin antidiarrheal drug used many country many year second line opioid-agonist antidiarrheal exists intermediate loperamide paragoric 2 diarrhea result cyclic diarrhea predominant inflammatory bowel syndrome may treated effectively difenoxin diphenoxylate loperamide diarrhea cramping respond non-centrally acting derivative belladonna derivative atropine often treated conservative dos codeine patient acute ulcerative colitis induction toxic megacolon possible thus use motofen r cautioned motofen r assigned pregnancy category c fda used potential benefit outweigh potential risk fetus safety use lactation unknown thus recommended 
Tenamfetamine, amphetamine derivative inhibits uptake catecholamine neurotransmitter hallucinogen le toxic methylated derivative sufficient dos may still destroy serotonergic neuron used purpose experimentally pubchem ,
Delorazepam,delorazepam benzodiazepine like drug class posse anxiolytic skeletal muscle relaxant hypnotic anticonvulsant property may adverse effect drowsiness cognitive impairment short term memory impairment delorazepam active metabolite benzodiazepine known cloxazolam long acting benzodiazepine make superior sense lorazepam short acting lorazepam also major active metabolite delorazepam addition long acting delorazepam relatively potent 1 mg delorazepam equivalent 10 mg diazepam approved marketing italy ,mainly used anti-anxiety agent study found delorazepam effective first 4 week use antidepressant however 4 week antidepressant showed superior anti-anxiety effect anti-anxiety effect also appear weaker elderly patient effectiveness also observed treatment alcohol withdrawal delorazapam reported manageable drug exhibit severe side effect require therapy control symptom withdrawal 
Benzoylecgonine,benzoylecgonine major metabolite cocaine formed hydrolysis cocaine liver catalysed carboxylesterases excreted urine cocaine user processing liver main pharmaceutical ingredient investigational drug esterom topical solution used relief muscle pain fda approved market united state a18735 ,
Tenocyclidine,tenocyclidine tcp thienyl cyclohexylpiperidine dissociative anesthetic drug stimulant hallucinogenic effect potent phencyclidine hence drug classified schedule 1 1970 , high affinity phencyclidine binding site nmda receptor 3h radiolabelled form tenocyclidine widely used research nmda receptor 
Betacetylmethadol, narcotic analgesic long onset duration action used mainly treatment narcotic dependence pubchem ,
Androstenediol,androstenediol intermediate testosterone biosynthesis found testis adrenal gland androstenediol derived dehydroepiandrosterone reduction 17-keto group 17-hydroxysteroid dehydrogenases converted testosterone oxidation 3-beta hydroxyl group 3-keto group 3-hydroxysteroid dehydrogenases ,
"4-Methyl-2,5-dimethoxyamphetamine", psychedelic phenyl isopropylamine derivative commonly called dom whose mood-altering effect mechanism action may similar lsd ,
Dextromoramide, opioid analgesic structurally related methadone used treatment severe pain martindale extra pharmacopoeia 30th ed p1070 ,
α-Methylacetylfentanyl,α-methylacetylfentanyl analog fentanyl opioid analgesic property categorized schedule u illegally sold early 1980. α-methylacetylfentanyl synthesis process similar α-methylfentanyl substitution acetic anhydride production chemical propionic anhydride synthesis ,
Chlorhexadol,chlorhexadol sedative hypnotic regulated united state schedule iii controlled substance derivative chloral hydrate ,
Carfentanil,"carfentanil carfentanyl wildnil analogue popular synthetic opioid analgesic fentanyl one potent opioids known also potent opioid used commercially carfentanil first synthesized 1974 team chemist janssen pharmaceutica included paul janssen quantitative potency approximately 10,000 time morphine 100 time fentanyl activity human starting 1 microgram marketed trade name wildnil general anaesthetic agent large animal carfentanil intended large-animal use extreme potency make inappropriate use human currently sufentanil approximately 10–20 time le potent 500 1000 time efficacy morphine per weight carfentanil maximum strength fentanyl analog use human ",carfentanil similar potent opioid analgesic fentanyl used tranquilizer large animal 
Androstenedione, delta-4 c19 steroid produced testis also ovary adrenal cortex depending tissue type androstenedione serve precursor testosterone well estrone estradiol ,
17alpha-methyl-4-hydroxynandrolone,17alpha-methyl-4-hydroxynandrolone schedule 3 anabolic steroid ,
Boldenone,boldenone anabolic steroid developed veterinary use mostly treatment horse indicated use human u available veterinary clinic ,
Flunitrazepam,flunitrazepam benzodiazepine pharmacologic action similar diazepam cause anterograde amnesia report indicate used date rape drug suggest may precipitate violent behavior united state government banned importation drug , short-term treatment severe insomnia responsive hypnotic 
Etryptamine," 1960 's alpha-ethyltryptamine αet non hydrazine reversible monoamine oxidase inhibitor developed united state upjohn chemical company use antidepressant αet fda approved antidepressant name monase however 1962 discovery unacceptable incidence agranulocytosis development monase halted drug withdrawn potential market use 1993 u drug enforcement administration added αet schedule schedule controlled substance increasing incidence use recreational drug 1980 's currently αet illegal substance however 's activity still scientific investigation αet stimulant hallucinogen le stimulating hallucinogenic alpha-methyltryptamine closely related compound instead effect αet tryptamine derivative closely resemble amphetamine derived drug 3,4-methylenedioxy-n-methylamphetamine mdma similarly mdma αet shown release serotonin pre-synaptically well lesser amount norepinephrine dopamine like mdma increase locomotor activity mood elevation seen post administration ",developed 1960 's use antidepressant market withdrawal 1962 
Diprenorphine, narcotic antagonist similar action naloxone used remobilize animal etorphine neuroleptanalgesia considered specific antagonist etorphine pubchem ,diprenorphine indicated reverse effect powerful opioids including etorphine carfentanil often used tranquilizing large animal drug approved use human 
Rolicyclidine,rolicyclidine pcpy classified dissociative anesthetic agent also hallucinogenic sedative property pharmacodynamic similarity drug phencyclidine pcp rolicyclidine added schedule list illegal drug usa 1970s ,rolicyclidine anesthetic property induce sedative effect 
Fenproporex,fenproporex orally active stimulant drug developed 1960s used appetite suppressant treatment obesity listed illicit substance many country due addiction issue listed prohibited substance world anti-doping agency structurally fenproporex n-2-cyanoethylamphetamine fall within phenylethamine amphetamine chemical class drug n-2-cyanoethyl substituent believed resistant cleavage fenproporex -- recommended obesity treatment patient cardiovascular disease -- originally claimed lack stimulant property contrary claim research demonstrated easy vivo cleavage n-2-cyanothyl substituent yield amphetamine metabolite 5 however clinical practice central nervous system stimulative effect le notorious agent diethylpropion mazindol 7 united state fenproporex never approved fda clinical use due lack efficacy safety data listed drug schedule iv controlled substance act 2006 2009 fda issued warning detected diet pill sold online imported foreign manufacturer despite banned united state fenproporex described second commonly consumed appetite suppressant worldwide 6 fenproporex containing anorectic still commonly prescribed south america little known specific hazard amphetamine based diet pill however case report noted side effect chest pain palpitation headache insomnia addition placebo controlled study shown participant using fenproporex experience joint pain sweating blurred vision tremor 2 ,fenproporex used appetite suppressant anti-obesity agent 2 however due substance abuse potential illicit substance many country country brazil still prescribed -- often form diet pill ie brazilian diet pill combine amphetamine benzodiazepine antidepressant diuretic laxative united state sale diet pill banned due concern side effect risk potentially fatal overdose however internet sale illicit market lead international availability found primary care physician brazilian immigrant woman utilized imported diet pill particularly high rate sometimes suffered side effect requiring hospitalization experienced loss employment 3 
Dihydrocodeine,dihydrocodeine opioid analgesic used alternative adjunct codeine treat moderate severe pain severe dyspnea cough semi-synthetic developed germany 1908 international search find effective antitussive agent help reduce spread airborne infectious disease tuburculosis marketed 1911 ,dihydrocodeine used treatment moderate severe pain including post-operative dental pain 2 also used treat chronic pain 1 breathlessness coughing heroin addict dihydrocodeine used substitute drug dos 2500mg/day treat addiction http //www.ncbi.nlm.nih.gov/pmc/articles/pmc2014322/ 
Betameprodine,betameprodine opioid analgesic classified united state drug enforcement administration schedule illegal substance stereoisomer alphameprodine similarly classified widely used referred meprodine betameprodine structural analogue meperidine exerts physiological effect characteristic opioids analgesia euphoria sedation well itching nausea respiratory depression ,
Cloxazolam,cloxazolam benzodiazepine anxiolytic sedative/hypnotic muscle relaxant antiepileptic effect marketed argentina australia portugal belgium switzerland luxembourg germany taiwan japan -- mainly anti-anxiety usual dose cloxazolam adult 3-12mg/day anti-anxiety although le commonly noted also reported clinically effective treatment depression schizophrenia neurosis well also studied japan dos 15-30mg/day adjunct treatment intractable epilepsy demonstrated effectiveness ,used primarily anti-anxiety agent typically used short term may given single dose 100mcg/kg reduce anxiety tension experienced prior surgery 
Alphacetylmethadol, narcotic analgesic long onset duration action used mainly treatment narcotic dependence pubchem ,
Chlorphentermine, sympathomimetic agent formerly used anorectic property similar dextroamphetamine implicated lipid storage disorder pulmonary hypertension martindale extra pharmacopoeia 30th ed p1223 ,used appetite suppressant 
α-Methylfentanyl,α-methylfentanyl analog fentanyl opioid analgesic property ,
Bromazepam,one benzodiazepine used treatment anxiety disorder schedule iv drug u.s. canada convention psychotropic substance intermediate-acting benzodiazepine , short-term treatment insomnia short-term treatment anxiety panic attack benzodiazepine required alleviation symptom alcohol- opiate-withdrawal 
Clotiazepam,clotiazepam thienodiazepine approved sale u.s. canada approved u.k schedule iv drug canada , treatment anxiety disorder 
Cathinone,cathinone monoamine alkaloid found shrub catha edulis khat closely related ephedrine cathine amphetamine probably main contributor stimulant effect catha edulis cathinone differs many amphetamine structure ketone amphetamine share structure include antidepressant bupropion stimulant methcathinone among others internationally cathinone categorized schedule drug cathinone added controlled substance act 's schedule 1993 compliance international law ,
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine,1- 2-phenylethyl -4-phenyl-4-acetoxypiperidine pepap synthetic analogue meperidine sold `` synthetic heroin '',
Chloral hydrate, hypnotic sedative used treatment insomnia safety margin narrow chloral hydrate used general anesthetic human commonly used purpose animal experiment longer considered useful anti-anxiety medication ,mainly used hypnotic treatment insomnia however effective hypnotic short-term use may used routine sedative preoperatively decrease anxiety cause sedation and/or sleep respiration depression cough reflex 
Calusterone, 17-alkylated orally active androgenic steroid schedule iv drug canada , anabolic steroid theoretically aid restauration buildup certain tissue especially muscle similar synthetic testosterone still early investigation also investigated use treatment metastatic breast cancer 
Dihydromorphine, semisynthetic analgesic used study narcotic receptor abuse potential pubchem ,dihydromorphine opioid analgesic used moderate severe pain relief 
Fludiazepam,fludiazepam drug benzodiazepine derivative posse anxiolytic anticonvulsant sedative skeletal muscle relaxant property scheduled drug u.s. approved use japan ,used short-term treatment anxiety disorder 
Formebolone,formebolone derivative androstane anabolic androgenic steroid list substance prohibited word anti-doping agency regularly screened athlete a14416 also classified u drug enforcement administration schedule iii drug controlled substance act used experimentally treatment growth retardation noted increase bone mass a14416 additionally patented use development novel transdermal delivery system enhanced drug delivery , approved indication studied experimentally treatment non-pituitary growth retardation a14416 
Ohmefentanyl,"ohmefentanyl extremely potent opioid analgesic drug selectively bind µ-opioid receptor chinese recorded ohmefentanyl potency 6,300 time morphine ohmefentanyl one potent μ -receptor agonist known comparable super-potent opioids carfentanil etorphine used tranquilizing large animal elephant veterinary medicine mouse ohmefentanyl 28 time powerful fentanyl 6300 time effective morphine ohmefentanyl three stereogenic center hence derive eight stereoisomers currently named f9201–f9208 researcher studying different pharmaceutical property isomer ",
3-Methylfentanyl,3-methylfentanyl opioid analgesic analog potent opioid fentanyl 3-methylfentanyl one powerful opioid drug sold illegally estimated 400-6000 time potent morphine certain case 3-methylfentanyl initially discovered 1974 widespread illegal use drug occurred since time ,
Methyl-1-testosterone,methyl-1-testosterone synthetic orally active anabolic–androgenic steroid aa never marketed medical use derivative 1-testosterone methyl group carbon 17 methyl-1-testosterone considered prohibited doping substance ,
Attapulgite,attapulgite magnesium aluminium phyllosilicate occurs type clay soil common southeastern united state used medicine physically bind acid toxic substance stomach digestive tract reason often used antidiarrheal medication 2003 active ingredient used kaopectate product reformulated bismuth subsalicylate , used medicine physically bind acid toxic substance stomach digestive tract reason often used antidiarrheal medication attapulgite adsorbent 
Kaolin,kaolin layered silicate mineral kaolin used ceramic medicine coated paper food additive toothpaste light diffusing material white incandescent light bulb cosmetic early 1990s active substance anti-diarrhoea medicine kaopectate ,used upset stomach diarrhea traditional medicine used china south america africa kaolin also used treat aids-related diarrhea kaolin based bandage also investigation 
Dextroamphetamine,dextroamphetamine dextrorotary enantiomer amphetamine a2505 dextroamphetamine approved fda 2001 treatment attention deficit hyperactivity disorder l6010 label ,dextroamphetamine indicated treatment attention deficit hyperactivity disorder adhd label 
Metamfetamine,metamfetamine methamphetamine psychostimulant sympathomimetic drug member amphetamine group sympathomimetic amine methamphetamine induce effect euphoria increased alertness energy enhanced self-esteem scheduled drug country due high potential addiction abuse fda withdrew approval use parenteral drug product containing methamphetamine hydrochloride metamfetamine salt l43942 , treatment attention deficit disorder hyperactivity adhd exogenous obesity 
Metrizamide,metrizamide solute density gradient centrifugation offering higher maximum solution density without problem increased viscosity also used resorbable non-ionic contrast medium ,metrizamide used lumbar thoracic cervical total columnar myelography determine presence abnormality spinal column spinal canal central nervous system cns well cisternography direct injection using standard radiologic technique visualize basal cistern brain computerized tomography ct intracranial subarachnoid space ventriculography direct injection using standard radiologic technique visualize cerebral ventricle also used pediatric angiocardiography visualize lesion malformation heart obstruction anomaly major thoracic vessel also used adult peripheral arteriography visualize specific region vascular system blood flow area help diagnosis evaluation neoplasm known suspected vascular disease congenital acquired may cause change normal vascular anatomy physiology metrizamide also indicated adult intravenous digital arteriography head neck 
Phendimetrazine,phendimetrazine weight loss medication phendimetrazine chemically related amphetamine schedule iii drug convention psychotropic substance u since 1970 ,used management exogenous obesity short term adjunct week regimen weight reduction based caloric restriction 
Oxprenolol, beta-adrenergic antagonist used treatment hypertension angina pectoris arrhythmia anxiety ,used treatment hypertension angina pectoris arrhythmia anxiety 
Sulfamerazine, sulfanilamide used antibacterial agent , sulfanilamide used antibacterial agent used treat bronchitis prostatitis urinary tract infection 
Sulfamethazine, sulfanilamide anti-infective agent spectrum antimicrobial action similar sulfonamide , treatment bacterial infection causing bronchitis prostatitis urinary tract infection 
Liotrix,liotrix synthetically derived thyroid hormone replacement preparation consists levothyroxine sodium thyroxine t4 liothyronine sodium triiodothyronine t3 4 1 ratio weight liotrix developed believed serum level t4 t3 maintained direct thyroidal secretion known thyroid gland secretes approximately ten time t4 t3 80 serum t3 derived deiodination t4 peripheral tissue administration levothyroxine alone sufficient maintaining serum t4 t3 level patient combination hormone replacement therapy generally offer therapeutic advantage fact administration t3 may result supratherapeutic level t3 ,may used treat primary secondary tertiary hypothyroidism may also used suppress thyroid stimulating hormone tsh secretion patient simple nontoxic goiter subacute chronic lymphocytic thyroiditis multinodular goiter management thyroid cancer may used conjunction antithyroid agent treat thyrotoxicosis prevent goitrogenesis hypothyroidism may also used differential diagnosis suspected mild hyperthyroidism thyroid gland autonomy 
Thyroglobulin,thyroglobulin also known tg enzyme thyroid hormone used thyroid gland produce thyroid hormone thyroxine t4 triiodothyronine t3 active form thyroxine triiodothyronine produced within thyroid gland periphery 5'-deiodinase patient hashimoto 's thyroiditis graf disease frequently develop antibody thyroglobulin thyroglobulin used treat hypothyroidism , treatment hypothyroidism deficiency production thyroid hormone 
Ursodeoxycholic acid,ursodeoxycholic acid epimer chenodeoxycholic acid mammalian bile acid found first bear apparently either precursor product chenodeoxycholate administration change composition bile may dissolve gallstone used cholagogue choleretic , drug decrease absorption cholesterol used dissolve cholesterol gallstone patient alternative surgical procedure remove gallstone 
Ketazolam,ketazolam benzodiazepine derivative anxiolytic anticonvulsant sedative skeletal muscle relaxant activity ketazolam approved canada america ,ketazolam could used treatment anxiety approved country indicated treatment anxiety tension irritability similar stress related symptom 
Prazepam,prazepam benzodiazepine used treatment anxiety disorder schedule iv drug u.s , treatment anxiety disorder 
Quazepam,quazepam drug benzodiazepine derivative induces impairment motor function hypnotic property quazepam used treat insomnia ,used treat insomnia 
Everolimus,everolimus derivative rapamycin sirolimus work similarly rapamycin mtor mammalian target rapamycin inhibitor currently used immunosuppressant prevent rejection organ transplant similar fashion mtor inhibitor everolimus effect solely mtorc1 protein mtorc2 protein ,everolimus indicated treatment postmenopausal woman advanced hormone receptor-positive her2-negative breast cancer advanced hr+ bc combination exemestane failure treatment letrozole anastrozole indicated treatment adult patient progressive neuroendocrine tumor pancreatic origin pnet unresectable locally advanced metastatic disease indicated treatment adult patient advanced renal cell carcinoma rcc failure treatment sunitinib sorafenib indicated treatment adult patient renal angiomyolipoma tuberous sclerosis complex tsc requiring immediate surgery indicated pediatric adult patient tuberous sclerosis complex tsc treatment subependymal giant cell astrocytoma sega requires therapeutic intervention curatively resected 
Solifenacin,solifenacin competitive muscarinic receptor antagonist indicated treat overactive bladder urinary incontinence urgency frequency l7511 long duration action usually taken daily l7511 solifenacin granted fda approval 19 november 2004 l7511 ,solifenacin tablet indicated treat overactive bladder urinary incontinence urgency frequency l7511 
Iron, metallic element found certain mineral nearly soil mineral water essential constituent hemoglobin cytochrome component respiratory enzyme system chief function transport oxygen tissue hemoglobin cellular oxidation mechanism depletion iron store may result iron-deficiency anemia iron used build blood anemia ,used preventing treating iron-deficiency anemia 
Zinc, metallic element atomic number 30 atomic weight 65.38 necessary trace element diet forming essential part many enzyme playing important role protein synthesis cell division zinc deficiency associated anemia short stature hypogonadism impaired wound healing geophagia identified symbol _zn_ l2098 newer study suggests implies imbalance zinc associated neuronal damage associated traumatic brain injury stroke seizure a32465 understanding mechanism control brain zinc homeostasis therefore imperative development preventive treatment regimen neurological disorder a32465 addition recent review article already demonstrated important role zinc pathophysiology treatment affective disorder plus discussed potential value zinc marker disease l2097 recently research shown polymorphism common polymorphism zinc transporter _slc30a8/znt8_ may increase susceptibility type 2 diabetes provided novel insight role zinc diabetes a32416 ,zinc used treatment prevention zinc deficiency/its consequence including stunted growth acute diarrhea child slowed wound healing also utilized boosting immune system treating common cold recurrent ear infection well preventing lower respiratory tract infection l2172 
Cinolazepam,cinolazepam benzodiazepine derivative anxiolytic anticonvulsant sedative skeletal muscle relaxant activity approved canada america , management anxiety disorder short-term relief symptom anxiety anxiety associated depressive symptom 
Nitrazepam, benzodiazepine derivative used anticonvulsant hypnotic ,used treat short-term sleeping problem insomnia difficulty falling asleep frequent awakening night early-morning awakening 
Cilastatin,cilastatin inhibitor renal dehydropeptidase enzyme responsible metabolism thienamycin beta-lactam antibiotic well conversion leukotriene d4 leukotriene e4 since antibiotic imipenem one antibiotic hydrolyzed dehydropeptidase cilastatin used combination imipenem prevent metabolism first combination product containing drug approved fda november 1985 trade name primaxin marketed merck co. l7628 newer triple-drug product approved july 2019 trade name recarbrio also contains relebactam l4894 ,cilastatin indicated combination imipenem without relebactam treatment bacterial infection including respiratory skin bone gynecologic urinary tract intra-abdominal well septicemia endocarditis l7526 l7568 
Imipenem,imipenem semisynthetic thienamycin wide spectrum antibacterial activity gram-negative gram-positive aerobic anaerobic bacteria including many multiresistant strain label stable many beta-lactamase similar compound include meropenem known greater activity gram negative bacteria newer ertapenem exhibit longer half-life due increased binding plasma protein a15389 imipenem commonly used combination cilastatin available triple-drug product cilastatin relebactam recently approved fda imipenem first approved fda november 1985 combination product primaxin marketed merck co. l7628 ,imipenem indicated combination cilastatin without relebactam treatment bacterial infection including respiratory skin bone gynecologic urinary tract intra-abdominal well septicemia endocarditis l7526 l7568 
Probucol, drug used lower ldl hdl cholesterol yet little effect serum-triglyceride vldl cholesterol martindale extra pharmacopoeia 30th ed p993 ,used lower ldl hdl cholesterol 
Tiaprofenic acid,tiaprofenic acid non-steroidal anti-inflammatory drug employed treatment pain particularly arthritis pain belongs _arylpropionic acid_ profen group nonsteroidal anti-inflammatory drug nsaid ,tiaprofenic acid used treat pain especially arthritic pain 
Lopinavir,lopinavir antiretroviral protease inhibitor used combination antiretrovirals treatment hiv-1 infection l11163 lopinavir marketed administered exclusively combination ritonavir combination first marketed abbott brand name kaletra 2000 necessary due lopinavir 's poor oral bioavailability extensive biotransformation ritonavir potent inhibitor enzyme responsible lopinavir metabolism co-administration `` boost '' lopinavir exposure improves antiviral activity l11163 like many protease inhibitor e.g saquinavir nelfinavir lopinavir peptidomimetic molecule contains hydroxyethylene scaffold mimic peptide linkage typically targeted hiv-1 protease enzyme cleaved thus preventing activity hiv-1 protease a191757 lopinavir previously investigation combination ritonavir treatment covid-19 caused sars-cov-2 l12012 , combination product lopinavir/ritonavir marketed brand name kaletra indicated combination antiretrovirals treatment hiv-1 infection adult pediatric patient ≥14 day old l11163 
Bacampicillin,bacampicillin prodrug ampicillin microbiologically inactive absorbed following oral administration absorption gastrointestinal tract bacampicillin hydrolyzed esterases present intestinal wall microbiologically active ampicillin exerts bactericidal action inhibition biosynthesis cell wall mucopeptides used cure infection upper lower respiratory tract skin soft tissue urinary tract acute uncomplicated gonococcal urethritis etc , infection following site upper lower respiratory tract skin soft tissue urinary tract acute uncomplicated gonococcal urethritis due sensitive strain following organism gram-positive streptococci including faecalis /i pneumoniae /i nonpenicillinase-producing staphylococci gram-negative h influenzae /i n gonorrhoeae /i e coli /i p mirabilis /i salmonella /i shigellae /i 
Meticillin,one penicillin resistant penicillinase susceptible penicillin-binding protein inactivated gastric acid administered injection ,used treat infection caused susceptible gram-positive bacteria particularly beta-lactamase-producing organism staphylococcus aureus /i would otherwise resistant penicillin 
Pivampicillin,pivalate ester analog ampicillin , treatment respiratory tract infection including acute bronchitis acute exacerbation chronic bronchitis pneumonia ear nose throat infection gynecological infection urinary tract infection including acute uncomplicated gonococcal urethritis caused non penicillinase-producing susceptible strain following organism gram-positive organism e.g. streptococci pneumococcus staphylococci gram-negative organism e.g. h. influenzae n. gonorrhoeae e. coli p. mirabilis 
Pivmecillinam,pivmecillinam mecillinam prodrug pivaloyloxymethyl ester amdinocillin well absorbed orally broken amdinocillin intestinal mucosa active gram-negative organism used amdinocillin pubchem ,used treat infection due mecillinam-sensitive organism urinary tract infection salmonellosis typhoid fever 
Tazobactam,tazobactam antibiotic beta-lactamase inhibitor class prevents breakdown antibiotic beta-lactamase enzyme producing organism combined piperacillin ceftolozane treatment variety bacterial infection piperacillin-tazobactam initially approved fda 1994 ceftolozane-tazobactam approved fda 2014 fda label providing wider antibacterial coverage gram-negative infection june 2019 ceftolozane-tazobactam approved fda treating hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia significant cause morbidity mortality hospitalized patient l6673 ,tazobactam used combination piperacillin ceftolozane broaden spectrum piperacillin antibacterial action treating susceptible infection antibiotic tazobactam used infection either proven strongly suspected susceptible tazobactam containing drug tazobactam-piperacillin combined piperacillin used treat variety infection including caused aerobic facultative gram-positive gram-negative bacteria addition gram-positive gram-negative anaerobe example infection treated piperacillin-tazobactam include cellulitis diabetic foot infection appendicitis postpartum endometritis infection l4417 certain gram-negative bacillus infection beta-lactamase producing organism treated piperacillin-tazobactam due gene mutation conferring antibiotic resistance a179266 tazobactam-ceftolozane tazobactam used combination ceftolozane treatment infection caused designated susceptible microorganism adult pediatric patient l41618 complicated intra-abdominal infection ciai used combination metronidazole complicated urinary tract infection cuti including pyelonephritis hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia habp/vabp 
Ticarcillin, antibiotic derived penicillin similar carbenicillin action , treatment bacterial infection 
Periciazine,periciazine phenothiazine piperidine group shown reduce pathologic arousal affective tension psychotic patient symptom abnormal mental integration relatively unaffected sedative phenothiazine weak antipsychotic property also adrenolytic anticholinergic metabolic endocrine effect action extrapyramidal system used adjunctive medication psychotic patient control residual prevailing hostility impulsiveness aggressiveness pericyazine like phenothiazine presumed act principally subcortical area producing described central adrenergic blockade , use adjunctive medication psychotic patient propericiazine pericyazine used control residual prevailing hostility impulsiveness aggressiveness 
Deferasirox,deferasirox iron chelator first oral medication fda approved chronic iron overload patient receiving long term blood transfusion , treatment chronic iron overload due blood transfusion transfusional hemosiderosis patient 2 year age older 
Valganciclovir,valganciclovir hydrochloride valcyte manufactured roche antiviral medication used treat cytomegalovirus infection l-valyl ester ganciclovir actually prodrug ganciclovir oral administration rapidly converted ganciclovir intestinal hepatic esterases ,valganciclovir antiviral medication used treatment cytomegalovirus infection 
Hydroxychloroquine,hydroxychloroquine racemic mixture consisting r enantiomer a183047 hydroxychloroquine aminoquinoline like chloroquine l8072 commonly prescribed medication treatment uncomplicated malaria rheumatoid arthritis chronic discoid lupus erythematosus systemic lupus erythematosus l8072 hydroxychloroquine also used prophylaxis malaria region chloroquine resistance unlikely l8072 developed world war ii derivative quinacrine le severe side effect a183092 chloroquine hydroxychloroquine investigated treatment sars-cov-2 a192132 fda emergency use authorization hydroxychloroquine chloroquine treatment covid-19 revoked 15 june 2020 l14312 hydroxychloroquine granted fda approval 18 april 1955 l8072 recent study reported fatality group treated hydroxychloroquine covid-19 a192546 ,hydroxychloroquine indicated prophylaxis malaria chloroquine resistance reported treatment uncomplicated malaria caused _p falciparum_ _p malariae_ _p ovale_ _p vivax_ chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis chronic rheumatoid arthritis l8072 
Amyl Nitrite,amyl nitrite antihypertensive medicine amyl nitrite employed medically treat heart disease angina treat cyanide poisoning use prescription medicine come ability lower blood pressure inhalant also psychoactive effect led illegal drug use , rapid relief angina pectoris 
Erythrityl tetranitrate, vasodilator general property similar nitroglycerin martindale extra pharmacopoeia 30th ed p1020 , prevention angina 
Acepromazine,acepromazine one phenothiazine derivative psychotropic drug used little human however frequently animal sedative antiemetic ,acepromazine first used human 1950s antipsychotic agent rarely used human acepromazine frequently used animal sedative antiemetic principal value quietening calming anxious animal 
Aceprometazine,aceprometazine drug neuroleptic anti-histamine property although widely prescribed used combination meprobamate treatment sleep disorder france trade name mepronizine ,aceprometazine often used combination meprobamate treatment sleep disorder 
Alverine,alverine smooth muscle relaxant used relieve cramp spasm stomach intestine therefore useful treating irritable bowel syndrome ibs similar condition also used help relieve period pain ,used relieve cramp spasm stomach intestine also useful treating irritable bowel syndrome ibs similar condition also used help relieve period pain alverine citrate also investigation increase cytotoxic effect proteasome inhibitor mg132 breast cancer cell 
Molindone, indole derivative effective schizophrenia psychosis possibly useful treatment aggressive type undersocialized conduct disorder molindone much lower affinity d2 receptor antipsychotic agent relatively low affinity d1 receptor low moderate affinity cholinergic alpha-adrenergic receptor electrophysiologic data animal indicate molindone certain characteristic resemble clozapine ama drug evaluation annual 1994 p283 ,molindone used management manifestation psychotic disorder 
Phenindamine,phenindamine antihistamine phenindamine block effect naturally occurring chemical histamine body antihistamine phenindamine appear compete histamine histamine h1- receptor site effector cell antihistamine antagonize pharmacological effect histamine mediated activation h1- receptor site thereby reduce intensity allergic reaction tissue injury response involving histamine release used treat sneezing runny nose itching watery eye hive rash itching symptom allergy common cold symptom phenindamine overdose include extreme sleepiness confusion weakness ringing ear blurred vision large pupil dry mouth flushing fever shaking insomnia hallucination possibly seizure ,used treat sneezing runny nose itching watery eye hive rash itching symptom allergy common cold 
Pheniramine,pheniramine first-generation antihistamine alkylamine class similar brompheniramine chlorpheniramine a181628 used over-the-counter allergy well cold flu product combination drug pheniramine 's use anti-allergy medication largely supplanted second-generation antihistamine cetirizine loratadine ,pheniramine commonly used over-the-counter product treat seasonal allergy cold flu symptom l7649 l7652 
Pipotiazine,pipotiazine action similar phenothiazine among different phenothiazine derivative appears le sedating weak propensity causing hypotension potentiating effect cns depressant anesthetic however produce high incidence extra pyramidal reaction used maintenance treatment chronic non-agitated schizophrenic patient symptom overdose include severe extrapyramidal manifestation hypotension lethargy sedation , maintenance treatment chronic non-agitated schizophrenic patient 
Thioproperazine,thioproperazine potent neuroleptic antipsychotic property thioproperazine marked cataleptic antiapomorphine activity associated relatively slight sedative hypothermic spasmolytic effect virtually without antiserotonin hypotensive action antihistaminic property used treatment type acute chronic schizophrenia including respond usual neuroleptic manic syndrome , treatment type acute chronic schizophrenia including respond usual neuroleptic manic syndrome 
Thiothixene, thioxanthine used antipsychotic agent effect similar phenothiazine antipsychotic , management schizophrenia 
Zuclopenthixol,zuclopenthixol also known zuclopentixol zuclopenthixolum antipsychotic agent zuclopenthixol thioxanthene-based neuroleptic therapeutic action similar phenothiazine antipsychotic antagonist d1 d2 dopamine receptor major brand zuclopenthixol cisordinol acuphase clopixol drug liquid compound belongs thioxanthenes organic polycyclic compound containing thioxanthene moiety aromatic tricycle derived xanthene replacing oxygen atom sulfur atom known drug target zuclopenthixol include 5-hydroxytryptamine receptor 2a 1b dopamine receptor 2 dopamine receptor 1a dopamine receptor alpha-1a adrenergic receptor known zuclopenthixol metabolized cytochrome p450 2d6 zuclopenthixol approved use canada 2011 approved use united state ,used management acute psychosis mania schizophrenia however use zuclopenthixol acetate psychiatric emergency alternative standard treatment haloperidol clotiapine etc cautioned since well executed documented trial zuclopenthixol acetate use yet conducted zuclopenthixol acetate intended long-term use 
Isopropamide,isopropamide iodide long-acting quaternary anticholinergic drug used treatment peptic ulcer gastrointestinal disorder marked hyperacidity hypermotility , treatment wide range gastrointestinal disorder including condition peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia chronic cholelithiasis duodenitis gastrointestinal spasm may also used treat genitourinary spasm 
Pargyline,pargyline monoamine oxidase inhibitor antihypertensive property , treatment moderate severe hypertension 
Lincomycin,lincomycin lincosamide antibiotic first isolated soil bacterium _streptomyces lincolnensis_ lincoln nebraska a190621 clinical use lincomycin largely superseded semisynthetic derivative clindamycin due higher efficacy wider range susceptible organism though lincomycin remains use a190657 a190621 lincomycin approved fda december 29 1964 l33214 ,lincomycin indicated treatment serious bacterial infection susceptible strain streptococci pneumococcus staphylococci patient allergic penicillin situation penicillin deemed inappropriate antibacterial agent lincomycin used treat infection proven strongly suspected caused susceptible bacteria l33214 
Etoricoxib,etoricoxib new cox-2 selective inhibitor current therapeutic indication treatment rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain gout like cox-2 selective inhibitor etoricoxib selectively inhibits isoform 2 cyclo-oxigenase enzyme cox-2 reduce generation prostaglandin pgs arachidonic acid approved 60 country worldwide u , treatment rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain gout 
5-fluorouridine,5-fluorouridine also known furd 5-fluorouracil 1-beta-d-ribofuranoside 5-fur 5-fluoro-uridine 5-fluorouridine solid compound belongs pyrimidine nucleoside analogue compound comprising pyrimidine base attached sugar 5-fluorouridine known target uridine phosphorylase furd often used chemical biochemical comparison study fluorouracil thymine analog ,
5-O-phosphono-alpha-D-ribofuranosyl diphosphate, key substance biosynthesis histidine tryptophan purine pyrimidine nucleotide ,
Sorbitol, polyhydric alcohol half sweetness sucrose sorbitol occurs naturally also produced synthetically glucose formerly used diuretic may still used laxative irrigating solution surgical procedure ,used non-stimulant laxative via oral suspension enema 
Thymidine monophosphate,5-thymidylic acid thymine nucleotide containing one phosphate group esterified deoxyribose moiety ,
Genistein, isoflavonoid derived soy product inhibits protein-tyrosine kinase topoisomerase-ii dna topoisomerases type ii activity used antineoplastic antitumor agent experimentally shown induce g2 phase arrest human murine cell line additionally genistein antihelmintic activity determined active ingredient felmingia vestita /i plant traditionally used worm shown effective treatment common liver fluke pork trematode poultry cestode genistein phytoestrogen selective estrogen receptor modulator property investigated clinical trial alternative classical hormone therapy help prevent cardiovascular disease postmenopausal woman a14417 natural source genistein include tofu fava bean soybean kudzu lupin ,currently genistein studied clinical trial treatment prostate cancer 
Roflumilast,"roflumilast highly selective phosphodiesterase-4 pde4 inhibitor first approved eu april 2010 management chronic obstructive pulmonary disease a251385 pde4 major cyclic-3',5′-adenosinemonophosphate cyclic amp camp -metabolizing enzyme l37564 expressed nearly immune pro-inflammatory cell addition structural cell like smooth muscle epithelium a251385 resultant increase intracellular camp induced roflumilast 's inhibition pde4 thought mediate disease-modifying effect although precise mechanism action yet elucidated l37564 a251385 ",administered orally roflumilast indicated reduce risk copd exacerbation patient severe copd associated chronic bronchitis history exacerbation l37564 administered topically indicated treatment plaque psoriasis patient ≥12 year old l42580 
8-azaguanine,8-azaguanine one early purine analog showing antineoplastic activity function antimetabolite easily incorporated ribonucleic acid ,
Virginiamycin M1,pristinamycin iia macrolide antibiotic member streptogramin group antibiotic one component pristinamycin produced streptomyces graminofaciens bacteria , treatment bacterial infection 
Trinitrotoluene,trinitrotoluene explosive chemical cause skin irritation toxic consequence ,
RU84687,ru84687 subnanomolar src sh2 selective binder ,
Topiroxostat,topiroxostat selective xanthine oxidase inhibitor developed treatment management hyperuricemia gout xanthine oxidase xanthine oxidoreductase xor regulates purine metabolism inhibition enzyme result efficacious reduction serum urate level xanthine oxidase inhibitor classified two group purine analog db00437 db05262 non-purine agent includes topiroxostat db00437 considered first-line therapy treating hyperuricemic condition often associated side effect ineffective reducing uric acid level recommended dosing regimen renal complication major comorbidities limit db00437 therapy dose reduction recommended topiroxostat metabolite shown unaffected renal complication thus may effective patient chronic kidney disease a19657 approved therapeutic use japan since 2013 topiroxostat marketed name topiloric uriadec orally administered twice daily ,indicated treatment gout hyperurcemia japan 
"N,N-dimethylarginine",asymmetric dimethylarginine adma naturally occurring chemical found blood plasma metabolic by-product continual protein modification process cytoplasm human cell closely related l-arginine conditionally-essential amino acid adma interferes l-arginine production nitric oxide key chemical endothelial hence cardiovascular health ,
Dithioerythritol, compound along isomer cleland 's reagent dithiothreitol used protection sulfhydryl group oxidation disulfides reduction disulfides sulfhydryl group pubchem ,
Rutin, flavonol glycoside found many plant including buckwheat tobacco forsythia hydrangea viola etc used therapeutically decrease capillary fragility ,
AICA ribonucleotide,5-aminoimidazole-4-carboxamide ribonucleotide aicar intermediate generation inosine monophosphate analog adenosine monophosphate amp capable stimulating amp-dependent protein kinase ampk activity aicar used clinically treat protect cardiac ischemic injury drug first used 1980s method preserve blood flow heart surgery currently interest potential treatment diabetes increasing metabolic activity tissue changing physical composition muscle ,
"2-(3,4-Dihydroxyphenyl)Acetic Acid", deaminated metabolite levodopa pubchem ,
Prasterone,prasterone also known dehydroepiandrosterone dhea major c19 steroid produced adrenal cortex also produced small quantity testis ovary dehydroepiandrosterone dhea converted testosterone androstenedione estradiol estrone dhea sulfated dehydroepiandrosterone sulfate secretion united state dhea dheas advertised claim may beneficial wide variety ailment dhea dheas readily available united state marketed over-the-counter dietary supplement november 2016 dhea approved intrarosa treat woman experiencing moderate severe pain sexual intercourse dyspareunia symptom vulvar vaginal atrophy vva due menopause canada prescription required buy dhea ,dhea taken supplement variety unsubstantiated indication following indication shown promise backed scientific evidence schizophrenia dhea may effective woman men improving appearance older people ’ skin taking dhea mouth seems increase skin thickness moisture decrease facial “ age spot ” elderly men woman improving ability achieve erection men sexual dysfunction additionally dhea shown promise improving symptom lupus sle taking dhea mouth along conventional treatment may help reduce number time symptom flare may allow reduction dose prescription drug needed dhea may also help sle symptom muscle ache mouth ulcer dhea also seems strengthen bone sle patient treated high-dose steroid corticosteroid dhea also show promise treatment osteoporosis taking dhea mouth daily seems improve bone mineral density bmd older woman men osteoporosis osteopenia pre-osteoporosis dhea may also increase bmd young woman eating disorder called anorexia nervosa dhea often prescribed india induction ovulation improve chance pregnancy 
2-phospho-D-glyceric acid, 2-phosphoglyceric acid glyceric acid moiety r configuration ,
UDP-alpha-D-xylose, decarboxylation product udpglucuronic acid used formation xylosides seryl hydroxyl group mucoprotein synthesis also form plant xylans ,
Cetrimonium,cetrimonium quaternary ammonium cation whose salt used antiseptic ,
Camphor,camphor bicyclic monoterpene ketone found widely plant especially _cinnamomum camphora_ used topically skin antipruritic anti-infective agent ingested camphor rapid onset toxic effect camphorated oil product often responsible toxicity fda ruled camphorated oil could marketed united state product could contain concentration higher 11 appears list drug product withdrawn removed market safety effectiveness a254252 l43942 however camphor found several nonprescription medication lower concentration a254252 ,
D-Leucine, essential branched-chain amino acid important hemoglobin formation pubchem ,
S-adenosyl-L-homocysteine,5'-s- 3-amino-3-carboxypropyl -5'-thioadenosine formed s-adenosylmethionine transmethylation reaction ,
Dalfopristin,dalfopristin combination two antibiotic dalfopristin quinupristin used treat infection staphylococci vancomycin-resistant enterococcus faecium effective enterococcus faecalis infection dalfopristin inhibits early phase protein synthesis bacterial ribosome quinupristin inhibits late phase protein synthesis , treatment bacterial infection usually combination quinupristin 
Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester,serf glycosyl donor formation bacterial glycogen amylose green algae amylopectin higher plant pubchem ,
Dihydroxyacetone," ketotriose compound addition blood preservation solution result better maintenance 2,3-diphosphoglycerate level storage readily phosphorylated dihydroxyacetone phosphate triokinase erythrocyte combination naphthoquinone act sunscreening agent pubchem ",
Pantothenic acid,pantothenic acid also called pantothenate vitamin b5 b vitamin water-soluble vitamin discovered roger j. williams 1919 many animal pantothenic acid essential nutrient required synthesize coenzyme-a coa well synthesize metabolize protein carbohydrate fat pantothenic acid amide pantoic acid β-alanine commonly found alcohol analog provitamin panthenol calcium pantothenate small quantity pantothenic acid found nearly every food high amount whole-grain cereal legume egg meat royal jelly avocado yogurt pantothenic acid ingredient hair skin care product dextrorotatory isomer pantothenic acid posse biological activity levorotatory l form may antagonize effect dextrorotatory isomer ,studied treatment many us treatment testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy also investigated hypolipidemic effect cholesterol lowering agent 
D-Alanine, d-enantiomer alanine ,
Piclamilast,"piclamilast rp-73,401 selective pde4 inhibitor comparable pde4 inhibitor anti-inflammatory effect investigated application treatment condition chronic obstructive pulmonary disease bronchopulmonary dysplasia asthma structure piclamilast first elucidated 1995 european patent application exhibit structural functionality cilomilast roflumilast ",
Quinolinic Acid, metabolite tryptophan possible role neurodegenerative disorder elevated csf level quinolinic acid correlated severity neuropsychological deficit patient aid pubchem ,
Propylene glycol, clear colorless viscous organic solvent diluent used pharmaceutical preparation ,
Bacteriochlorophyll A, specific bacteriochlorophyll similar structure chlorophyll ,
Pimelic Acid, group compound derivative heptanedioic acid general formula r-c7h11o4 pubchem ,
Uridine diphosphate glucose, key intermediate carbohydrate metabolism serf precursor glycogen metabolized udpgalactose udpglucuronic acid incorporated polysaccharide galactose glucuronic acid also serf precursor sucrose lipopolysaccharides glycosphingolipids ,
Isopropyl beta-D-thiogalactopyranoside, non-metabolizable galactose analog induces expression lac operon ,
5'-Guanosine-Diphosphate-Monothiophosphate,guanosine 5 39 trihydrogen diphosphate monoanhydride phosphorothioic acid stable gtp analog enjoys variety physiological action stimulation guanine nucleotide-binding protein phosphoinositide hydrolysis cyclic amp accumulation activation specific proto-oncogene ,
Epothilone D,,investigated use/treatment colorectal cancer lung cancer breast cancer solid tumor prostate cancer 
Benzophenone,benzophenone organic compound substituted benzophenones oxybenzone dioxybenzone used sunscreen ,
Hyperforin,hyperforin phytochemical generated plant hypericum family one important member family due medical property _hypericum perforatum_ also known st john 's wort ,
Sinefungin,sinefungin solid compound belongs purine nucleoside analogue compound comprising purine base attached sugar protein adenosyl-ornithine target include rdmb modification methylase taqi rrna adenine-n6- -methyltransferase modification methylase rsri ,
N-Methylmesoporphyrin,n-methylmesoporphyrin solid compound belongs porphyrin compound containing fundamental skeleton four pyrrole nucleus united alpha-positions four methine group form macrocyclic structure medication known target ferrochelatase ,
"2,2':6',2''-Terpyridine Platinum(Ii)","2,2':6',2 '' -terpyridine platinum ii solid known drug target 2,2':6',2 '' -terpyridine platinum ii include truncated transposase autolysin ",
D-glucose,glucose simple sugar monosaccharide generated phosynthesis involving water carbon sunlight plant produced human via hepatic gluconeogenesis breakdown polymeric glucose form glycogenolysis circulates human circulation blood glucose act essential energy source many organism aerobic anaerobic respiration fermentation a19399 primarily stored starch plant glycogen animal used various metabolic process cellular level aldohexose stereoisomer dextrose d-glucose commonly occurring isomer glucose nature l-glucose synthesized enantiomer used low-calorie sweetener laxative t28 unspecified form glucose commonly supplied injection nutritional supplementation metabolic disorder glucose level improperly regulated l786 glucose listed world health organization 's list essential medicine important medication needed basic health system ,glucose pharmaceutical formulation oral tablet injection indicated caloric supply carbohydrate supplementation case nutrient deprivation also used metabolic disorder hypoglycemia l787 
S-Hydroxycysteine,s-hydroxycysteine solid compound belongs alpha amino acid derivative amino acid amino group attached carbon atom immediately adjacent carboxylate group alpha carbon derivative thereof target protein subtilisin bpn glutathione s-transferase a1 glutathione s-transferase p myelin p2 protein complement c3 ,
Putrescine,putrescine toxic diamine formed putrefaction decarboxylation arginine ornithine putrescine solid compound belongs polyamines compound containing one amine group known drug target putrescine include putrescine-binding periplasmic protein ornithine decarboxylase s-adenosylmethionine decarboxylase proenzyme ,
[Methyltelluro]Acetate, methyltelluro acetate solid compound belongs organic oxoanionic compound organic compound containing oxoanion medication target protein monomeric sarcosine oxidase ,
Pentanal,pentanal solid compound belongs polyamines compound containing one amine group drug target protein camp-dependent protein kinase catalytic subunit alpha ,
1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose,includes ortho- meta- para-nitrophenylgalactosides pubchem ,
LG-100268,lg-100268 retinoid x receptor rxr selective compound ,
Formic acid,formic acid systematically called methanoic acid simplest carboxylic acid important intermediate chemical synthesis occurs naturally famously venom bee ant sting commonly used preservative antibacterial agent livestock feed ,
Inhibitor of P38 Kinase,"inhibitor p38 kinase solid compound belongs indoles compound containing indole moiety consists pyrrole ring fused benzene form 2,3-benzopyrrole drug known target mitogen-activated protein kinase 14 ",
Rolipram, phosphodiesterase inhibitor antidepressant property ,
Taurine,taurine whose chemical name 2-aminoethanesulfonic acid one abundant amino acid several organ play important role essential biological process a31396 conditional amino acid either manufactured body obtained diet mainly consumption fish meat l1058 supplement containing taurine fda approved 1984 hypertonic injection composed cristalline amino acid fda label , use diet supplement containing taurine indicated nutritional support infant young pediatric patient requiring total parenteral nutrition via central peripheral route usage diet supplement containing taurine prevents nitrogen weight loss treat negative nitrogen balance pediatric patient alimentary tract done oral gastrostomy jejunostomy administration impaired gastrointestinal absorption protein requirement substantially increased fda label 
Phosphonotyrosine, amino acid occurs endogenous protein tyrosine phosphorylation dephosphorylation play role cellular signal transduction possibly cell growth control carcinogenesis pubchem ,
Guanosine-5'-Monophosphate,guanosine 5 39 -monophosphate guanine nucleotide containing one phosphate group esterified sugar moiety found widely nature pubchem ,
Cocarboxylase, coenzyme form vitamin b1 present many animal tissue required intermediate pyruvate dehydrogenase complex ketoglutarate dehydrogenase complex ,
Cholesterol sulfate,component human seminal plasma spermatozoon ,
Coenzyme A,coenzyme coa coash hscoa coenzyme well known 's role synthesis oxidation fatty acid oxidation pyruvate citric acid cycle genome sequenced date encode enzyme use coenzyme substrate around 4 cellular enzyme use thioester form substrate used supplement hypothetical treatment acne ,
Staurosporine, indolocarbazole potent protein kinase c inhibitor enhances camp-mediated response human neuroblastoma cell biochem biophys re commun 1995 214 3 :1114-20 ,
Tridolgosir, indolizidine alkaloid plant swainsona canescens potent alpha-mannosidase inhibitor swainsonine also exhibit antimetastatic antiproliferative immunomodulatory activity ,
Prostaglandin D2, principal cyclooxygenase metabolite arachidonic acid released upon activation mast cell also synthesized alveolar macrophage among many biological action important bronchoconstrictor platelet-activating-factor-inhibitory cytotoxic effect ,
(S)-AMPA,ampa specific agonist ampa receptor ,
Cyclohexanone,cyclohexanone also known oxocyclohexane pimelic ketone ketohexamethylene cyclohexyl ketone ketocyclohexane six-carbon cyclic molecule ketone functional group colorless oily liquid acetone-like smell ,
Cellobiose, disaccharide consisting two glucose unit beta 1-4 glycosidic linkage obtained partial hydrolysis cellulose pubchem ,
Triglyme,triethylene glycol dimethyl ether also called triglyme glycol ether used solvent ,
Aminooxyacetic acid, compound inhibits aminobutyrate aminotransferase activity vivo thereby raising level gamma-aminobutyric acid tissue pubchem ,
Phosphoaminophosphonic acid guanylate ester, non-hydrolyzable analog gtp oxygen atom bridging beta gamma phosphate replaced nitrogen atom bind tightly g-protein presence mg2+ nucleotide potent stimulator adenylate cyclase ,
Isatin,isatin indole derivative first obtained erdman laurent 1841 oxidation product indigo dye nitric acid chromic acid compound found many plant schiff base isatin investigated pharmaceutical application ,
Glycochenodeoxycholic Acid, bile salt formed liver chenodeoxycholate glycine usually sodium salt act detergent solubilize fat absorption absorbed cholagogue choleretic pubchem ,
Vanillic acid, flavoring agent intermediate product two-step bioconversion ferulic acid vanillin j biotechnol 1996 50 2-3 :107-13 ,
Zenarestat,,investigated use/treatment neuropathy diabetic 
Xanthine, purine base found body tissue fluid certain plant urinary calculus intermediate degradation adenosine monophosphate uric acid formed oxidation hypoxanthine methylated xanthine compound caffeine theobromine theophylline derivative used medicine bronchodilator effect dorland 28th ed ,
Molybdenum cofactor,absence molybdenum cofactor lead accumulation toxic level sulphite neurological damage usually leading death within month birth due lack active sulfite oxidase ,
(R)-Propylene glycol, clear colorless viscous organic solvent diluent used pharmaceutical preparation ,
Propidium,quaternary ammonium analog ethidium intercalating dye specific affinity certain form dna used diiodide separate density gradient also form fluorescent complex cholinesterase inhibits pubchem ,
"9,10-Deepithio-9,10-Didehydroacanthifolicin", specific inhibitor phosphoserine/threonine protein phosphatase 1 2a also potent tumor promoter thromb re 1992 67 4 :345-54 cancer re 1993 53 2 :239-41 ,
D-Glutamine, non-essential amino acid present abundantly throughout body involved many metabolic process synthesized glutamic acid ammonia principal carrier nitrogen body important energy source many cell ,
"D-1,4-dithiothreitol", reagent commonly used biochemical study protective agent prevent oxidation sh thiol group reducing disulphides dithiols pubchem ,
Equilin, estrogenic steroid produced horse total four double bond a- b-ring high concentration equilin found urine pregnant mare , treatment moderate severe vasomotor symptom associated menopause atrophic vaginitis osteoporosis hypoestrogenism due hypogonadism castration primary ovarian failure breast cancer palliation advanced androgen-dependent carcinoma prostate palliation 
Phenylethyl alcohol, antimicrobial antiseptic disinfectant used also aromatic essence preservative pharmaceutic perfumery ,
S-Ethylisothiourea,s-ethylisothiourea nitric oxide synthase inhibitor ,
2'-Deoxyuridine,2 39 -deoxyuridine antimetabolite converted deoxyuridine triphosphate dna synthesis laboratory suppression deoxyuridine used diagnose megaloblastic anemia due vitamin b12 folate deficiency pubchem ,
D-glyceraldehyde 3-phosphate, aldotriose important intermediate glycolysis tryptophan biosynthesis ,
Flufenamic acid, anthranilic acid derivative analgesic anti-inflammatory antipyretic property used musculoskeletal joint disorder administered mouth topically martindale extra pharmacopoeia 30th ed p16 ,
Porphobilinogen,porphobilinogen pyrrole involved porphyrin metabolism generated enzyme ala dehydratase converted hydroxymethyl bilane enzyme porphobilinogen deaminase ,
Irosustat,irosustat investigated treatment metastatic breast cancer locally advanced breast cancer ,
Calcipotriol,calcipotriol inn calcipotriene usan sythetic derivative calcitriol vitamin , treatment moderate plaque psoriasis adult 
Cyclic GMP,cyclic guanosine monophosphate cyclic gmp guanine nucleotide containing one phosphate group esterified sugar moiety 3 39 5 39 -positions cellular regulatory agent described second messenger level increase response variety hormone including acetylcholine insulin oxytocin found activate specific protein kinase merck index 11th ed ,
Isopropyl alcohol, isomer 1-propanol colorless liquid disinfectant property used manufacture acetone derivative solvent topically used antiseptic ,
Carbenoxolone, agent derived licorice root used treatment digestive tract ulcer especially stomach antidiuretic side effect frequent otherwise drug low toxicity pubchem ,
2-Methoxyestradiol,2-methoxyestradiol 2me2 drug prevents formation new blood vessel tumor need order grow angiogenesis undergone phase 1 clinical trial breast cancer preclinical study suggest 2me2 could also effective inflammatory disease rheumatoid arthritis , treatment breast cancer inflammatory disease rheumatoid arthritis 
Selenocysteine, naturally occurring amino acid eukaryotic prokaryotic organism found trna catalytic site enzyme gene glutathione peroxidase formate dehydrogenase contain tga codon code amino acid pubchem ,
Aminobenzoic acid, member vitamin b complex used common sunscreening agent found also sensitizer potassium salt used therapeutically fibrotic skin disorder ,
Beta-D-Glucose, primary source energy living organism naturally occurring found fruit part plant free state used therapeutically fluid nutrient replacement ,
nor-NOHA,n-hydroxy-nor-l-arginine nor-noha investigation clinical trial nct02009527 arginase inhibition ischemia-reperfusion injury ,
Tolrestat,tolrestat inn ay-27773 aldose reductase inhibitor approved control certain diabetic complication approved marketed several country failed phase iii trial u.s. due toxicity never received fda approval sold tradename alredase discontinued wyeth 1997 risk severe liver toxicity death , pharmacological control certain diabetic complication 
D-threo-neopterin, pteridine derivative present body fluid elevated level result immune system activation malignant disease allograft rejection viral infection stedman 26th ed neopterin also serf precursor biosynthesis biopterin ,
Cytidine-5'-Triphosphate,cytidine 5 39 tetrahydrogen triphosphate cytosine nucleotide containing three phosphate group esterified sugar moiety pubchem ,
Methoxy arachidonyl fluorophosphonate,methoxy arachidonyl fluorophosphonate commonly referred mafp irreversible active site-directed enzyme inhibitor inhibits nearly serine hydrolases serine protease inhibits phospholipase a2 fatty acid amide hydrolase special potency displaying ic50 value low-nanomolar range ,
Phosphonothreonine, phosphoric acid ester threonine used identifier analysis peptide protein enzyme pubchem ,
Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid, nucleoside monophosphate sugar donates n-acetylneuraminic acid terminal sugar ganglioside glycoprotein pubchem ,
9-(4-hydroxybutyl)-N2-phenylguanine,9- 4-hydroxybutyl -n2-phenylguanine solid compound belongs hypoxanthines compound containing purine derivative 1h-purin-6 9h -one 9- 4-hydroxybutyl -n2-phenylguanine known target thymidine kinase ,
1-Deoxy-D-xylulose 5-phosphate,1-deoxy-d-xylulose 5-phosphate solid compound belongs pentose phosphate carbohydrate derivative containing pentose substituted one phosphate group protein 1-deoxy-d-xylulose 5-phosphate target include 1-deoxy-d-xylulose 5-phosphate reductoisomerase pyridoxine 5'-phosphate synthase 1-deoxy-d-xylulose 5-phosphate intermediate non-mevalonate pathway ,
Farnesol, colorless liquid extracted oil plant citronella neroli cyclamen tuberose intermediate step biological synthesis cholesterol mevalonic acid vertebrate delicate odor used perfumery mcgraw-hill dictionary scientific technical term 5th ed ,
Thymol, phenol obtained thyme oil volatile oil used stabilizer pharmaceutic preparation used antiseptic antibacterial antifungal action formerly used vermifuge dorland 28th ed ,
D-Glutamic Acid,glutamic acid common excitatory neurotransmitter central nervous system ,
Ditiocarb, chelating agent used mobilize toxic metal tissue man experimental animal main metabolite disulfiram ,
Cyclic adenosine monophosphate,cyclic adenosine monophosphate camp cyclic amp 3'-5'-cyclic adenosine monophosphate molecule important many biological process derived adenosine triphosphate atp ,
gamma-Aminobutyric acid, common inhibitory neurotransmitter central nervous system ,
Vorinostat,vorinostat rinn suberoylanilide hydroxamic acid saha drug currently investigation treatment cutaneous cell lymphoma ctcl type skin cancer used disease persists get worse come back treatment medicine first new class agent known histone deacetylase inhibitor recent study suggested vorinostat also posse activity recurrent glioblastoma multiforme resulting median overall survival 5.7 month compared 4 4.4 month earlier study brain tumor trial planned using combination vorinostat drug , treatment cutaneous manifestation patient cutaneous t-cell lymphoma progressive persistent recurrent disease following two systemic therapy 
D-Phenylalanine, essential aromatic amino acid precursor melanin dopamine noradrenalin norepinephrine thyroxine pubchem ,
Peldesine,peldesine potent inhibitor human ccrf-cem t-cell proliferation undergone phase trial treatment human immunodeficiency virus hiv infection ,
Mesoheme, color-furnishing portion hemoglobin found free tissue prosthetic group many hemeproteins ,
Acrylic Acid, α β-unsaturated monocarboxylic acid ethene substituted carboxy group ,
Colforsin,potent activator adenylate cyclase system biosynthesis cyclic amp plant coleus forskohlii antihypertensive positive inotropic platelet aggregation inhibitory smooth muscle relaxant activity also lower intraocular pressure promotes release hormone pituitary gland ,
Latrunculin A,latrunculin actin binding macrolide purified red sea sponge latrunculia magnifica investigation treatment cancer disrupts actin polymerization prevents mitotic spindle formation thus cell replication ,
Terlipressin,terlipressin synthetic analogue vasopressin endogenous neurohormone act vasoconstrictor a2601 prodrug lypressin lysine vasopressin compared endogenous vasopressin terlipressin longer half life increased selectivity v1 receptor l43217 potent vasopressor terlipressin investigated various shock state condition diminished vasomotor tone a2601 a2602 a2603 a2604 a2605 also studied hepatorenal syndrome hr variceal bleeding a252672 drug first approved fda september 2022 l43217 ,terlipressin vasopressin receptor agonist indicated improve kidney function adult hepatorenal syndrome rapid reduction kidney function u prescribing information state patient serum creatinine 5 mg/dl unlikely experience benefit terlipressin l43217 
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium,constituent striated muscle liver used therapeutically stimulate gastric pancreatic secretion treatment hyperlipoproteinemia pubchem ,
D-Aspartic Acid, d-isomer aspartic acid pubchem ,
LY-294002,specific inhibitor phosphatidylinositol 3-kinase ,
Cholic Acid, major primary bile acid produced liver usually conjugated glycine taurine facilitates fat absorption cholesterol excretion pubchem cholic acid formulated cholbam capsule approved united state food drug administration treatment child adult bile acid synthesis disorder due single enzyme defect peroxisomal disorder zellweger syndrome ,oral cholic acid indicated treatment bile acid synthesis disorder due single enzyme defect adjunctive treatment peroxisomal disorder including zellweger spectrum disorder patient exhibit manifestation liver disease steatorrhea complication decreased fat soluble vitamin absorption 
Filaminast,filaminast phosphodiesterase 4 inhibitor pde4 inhibitor potential treatment asthma chronic obstructive pulmonary disease copd ,
"(1R,2S)-2-Phenylcyclopropanaminium", propylamine formed cyclization side chain amphetamine monoamine oxidase inhibitor effective treatment major depression dysthymic disorder atypical depression also useful panic phobic disorder ama drug evaluation annual 1994 p311 ,
Cyanamide, cyanide compound used fertilizer defoliant many manufacturing process often occurs calcium salt sometimes also referred cyanamide citrated calcium salt used treatment alcoholism pubchem ,
Glycocholic acid, glycine conjugate cholic acid act detergent solubilize fat absorption absorbed ,
Nicotinamide, important compound functioning component coenzyme nad primary significance prevention and/or cure blacktongue pellagra animal manufacture compound amount sufficient prevent nutritional deficiency therefore must supplemented dietary intake ,
Fusidic acid, antibiotic isolated fermentation broth fusidium coccineum merck index 11th ed act inhibiting translocation protein synthesis often used topically cream eyedrop available systemic formulation including tablet injection , treatment bacterial infection 
Resveratrol,"resveratrol 3,5,4'-trihydroxystilbene polyphenolic phytoalexin stilbenoid derivate stilbene produced plant help enzyme stilbene synthase exists cis- z trans- e isomer trans- form undergo isomerisation cis- form heated exposed ultraviolet irradiation 2004 issue science dr. sinclair harvard university said resveratrol easy molecule protect oxidation claimed readily degraded exposure light heat oxygen however study find trans-resveratrol undergoes negligible oxidation normal atmosphere room temperature ", investigated treatment herpes labialis infection cold sore 
Ethylmercurithiosalicylic acid,ethylmercurithiosalicylic acid topical antiseptic used skin mucous membrane also used preservative pharmaceutical ,
Pyroquilon,pyroquilon commercial blasticide bind naphthol pocket fungal trihydroxynaphthalene reductase active site ,
Sucrose, nonreducing disaccharide composed glucose fructose linked via anomeric carbon obtained commercially sugarcane sugar beet beta vulgaris plant used extensively food sweetener ,
(S)-acetoin, product fermentation component butanediol cycle microorganism mammal oxidized carbon dioxide ,
Pregnenolone, 21-carbon steroid derived cholesterol found steroid hormone-producing tissue pregnenolone precursor gonadal steroid hormone adrenal corticosteroid ,
"Brodimoprim-4,6-Dicarboxylate","brodimoprim-4,6-dicarboxylate solid compound belongs anisoles organic compound contaiing methoxybenzene derivative thereof medication known target protein dihydrofolate reductase ",
Phosphonoacetic Acid, simple organophosphorus compound inhibits dna polymerase especially virus used antiviral agent pubchem ,
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide,9-amino-n- 3- dimethylamino propyl acridine-4-carboxamide inactive derivative antitumour agent n- 2- dimethylamino ethyl acridine-4-carboxamide daca 9-amino-daca ,
D-Proline,d-proline isomer naturally occurring amino acid l-proline d-amino acid found relatively high abundance human plasma saliva a19262 amino acid may bacterial origin also evidence endogenously produced amino acid racemase activity a19263 ,
Aetiocholanolone, 5-beta-reduced isomer androsterone etiocholanolone major metabolite testosterone androstenedione many mammalian specie including human excreted urine pubchem ,
Guanosine,guanosine nucleoside comprising guanine attached ribose ribofuranose ring via β-n9-glycosidic bond guanosine phosphorylated become gmp guanosine monophosphate cgmp cyclic guanosine monophosphate gdp guanosine diphosphate gtp guanosine triphosphate factor signal transduction pathway ,
3-amino-5-phenylpentane,3-amino-5-phenylpentane solid compound belongs phenylpropylamines compound containing phenylpropylamine moiety consists phenyl group substituted third carbon propan-1-amine 3-amino-5-phenylpentane target protein cathepsin k cathepsin l2 ,
Arotinoid acid,arotinoid acid retinoic acid analog act selective rar agonist ,
Methylthioinosine, analog inosine methylthio group replacing hydroxyl group 6-position ,
Stanolone, potent androgenic metabolite testosterone dihydrotestosterone dht generated 5-alpha reduction testosterone unlike testosterone dht aromatized estradiol therefore dht considered pure androgenic steroid ,
3'-phospho-5'-adenylyl sulfate,3'-phospho-5'-adenylyl sulfate key intermediate formation living cell sulfate ester phenol alcohol steroid sulfated polysaccharide simple ester choline sulfate formed sulfate ion atp two-step process compound also important step process sulfur fixation plant microorganism ,
Piretanide,piretanide inn trade name arelix eurelix tauliz synthesized 1973 hoechst ag germany loop diuretic compound using then-new method introducing cyclic amine residue aromatic nucleus presence aromatically bonded functional group ,
Adenosine 5'-[gamma-thio]triphosphate, nucleoside triphosphate analogue atp one oxygen attached 3-phosphate group replaced sulfur ,
"Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate",adenylic acid adenine nucleotide containing one phosphate group esterified sugar moiety 2 39 3 39 5 39 -position pubchem ,
Oxitriptan,5-hydroxytryptophan 5-htp also known oxitriptan inn naturally occurring amino acid metabolic intermediate synthesis serotonin melatonin 5-htp sold over-the-counter united kingdom united state canada dietary supplement use antidepressant appetite suppressant sleep aid also marketed many european country indication major depression trade name like cincofarm levothym levotonine oxyfan telesol tript-oh triptum several double-blind placebo-controlled clinical trial demonstrated effectiveness 5-htp treatment depression though lack high quality study noted study needed determine efficacy treating depression , use antidepressant appetite suppressant sleep aid 
Rhamnose, methylpentose whose l- isomer found naturally many plant glycoside gram-negative bacterial lipopolysaccharides pubchem ,
N-Ethylmaleimide, sulfhydryl reagent widely used experimental biochemical study pubchem ,
Metribolone, synthetic non-aromatizable androgen anabolic steroid bind strongly androgen receptor therefore also used affinity label receptor prostate prostatic tumor ,
Quisqualic acid,quisqualic acid agonist two subset excitatory amino acid receptor ionotropic receptor directly control membrane channel metabotropic receptor indirectly mediate calcium mobilization intracellular store compound obtained seed fruit _quisqualis chinensis_ ,
Arsanilic acid, arsenical used feed additive enteric condition pig poultry cause blindness ototoxic nephrotoxic animal pubchem ,
Patupilone,epothilone b 16-membered macrolide mimic biological effect taxol ,investigated use/treatment ovarian cancer lung cancer brain cancer breast cancer gastric cancer 
Lauric acid,lauric acid inexpensive non-toxic safe handle compound often used laboratory investigation melting-point depression lauric acid solid room temperature melt easily boiling water liquid lauric acid treated various solute used determine molecular mass ,
D-Levofloxacin, synthetic fluoroquinolone fluoroquinolones antibacterial agent inhibits supercoiling activity bacterial dna gyrase halting dna replication ,
Nitrilotriacetic acid,nitrilotriacetic acid derivative acetic acid n ch2cooh 3 complexing sequestering agent form stable complex zn2+ miall 's dictionary chemistry 5th ed ,
UDP-alpha-D-glucuronic acid, nucleoside diphosphate sugar serf source glucuronic acid polysaccharide biosynthesis may also epimerized udp iduronic acid donates iduronic acid polysaccharide animal udp glucuronic acid used formation many glucosiduronides various aglycones pubchem ,
Doramapimod,doramapimod p38 map kinase inhibitor ,
Malonaldehyde,malonaldehyde dialdehyde malonic acid ,
D-Lactic acid, normal intermediate fermentation oxidation metabolism sugar concentrated form used internally prevent gastrointestinal fermentation stedman 26th ed ,
Zebularine, chemically stable cytidine analog display anti-tumor property act transition state analog inhibitor cytidine deaminase binding active site covalent hydrate also shown inhibit dna methylation tumor growth vitro vivo ,
Pidolic acid,pidolic acid naturally occurring little-studied amino acid derivative formed enzymatically non-enzymatically participates biological intermediate unique pharmacodynamics various chemical pathway a32991 l2729 elevation acid blood level may associated problem glutamine glutathione metabolism l2729 pidolic acid general found large quantity brain tissue tissue bound form like skin l2729 currently little medicine available clinically approved marketed employing pidolic acid active ingredient particular formal indication although pidolic acid included over-the-counter non-prescription dietary supplement proposed purpose facilitating cognitive memory enhancement available research suggest exercising caution recommendation much research necessary a32981 a32982 , currently clinically approved and/or marketed medicine relies upon pidolic acid active ingredient formal therapeutic indication although pidolic acid may sold variety non-prescription over-the-counter dietary supplement product cognitive memory enhancement many study suggest product supplementation elicit kind cognitive benefit user a32981 a32982 fact general suggestion pidolic acid product exercise caution recommendation much research necessary a32981 pidolic acid sodium pidolic acid however used extent skin hair conditioning agent owing humectant characteristic f53 
scyllo-inositol, isomer glucose traditionally considered b vitamin although uncertain status vitamin deficiency syndrome identified man martindale extra pharmacopoeia 30th ed p1379 inositol phospholipid important signal transduction scyllitol investigated treatment alzheimer disease ,
beta-Alanine,beta-alanine amino acid formed vivo degradation dihydrouracil carnosine since neuronal uptake neuronal receptor sensitivity beta-alanine demonstrated compound may false transmitter replacing gamma-aminobutyric acid rare genetic disorder hyper-beta-alaninemia reported ,
Acetylcholine, neurotransmitter acetylcholine vertebrate major transmitter neuromuscular junction autonomic ganglion parasympathetic effector junction subset sympathetic effector junction many site central nervous system generally used administered drug broken rapidly cholinesterase useful ophthalmological application ,used obtain miosis iris second delivery lens cataract surgery penetrating keratoplasty iridectomy anterior segment surgery rapid miosis may required 
Flavin adenine dinucleotide, condensation product riboflavin adenosine diphosphate coenzyme various aerobic dehydrogenases e.g. d-amino acid oxidase l-amino acid oxidase lehninger principle biochemistry 1982 p972 flavin adenine dinucleotide approved use japan trade name adeflavin ophthalmic treatment vitamin b2 deficiency ,used treat eye disease caused vitamin b2 deficiency keratitis blepharitis 
Acetic acid,acetic acid product oxidation ethanol destructive distillation wood used locally occasionally internally counterirritant also reagent stedman 26th ed acetic acid otic ear antibiotic treat infection caused bacteria fungus ,used treat infection ear canal 
Tubercidin, antibiotic purine ribonucleoside readily substitute adenosine biological system incorporation dna rna inhibitory effect metabolism nucleic acid ,
Propyl alcohol, colorless liquid made oxidation aliphatic hydrocarbon used solvent chemical intermediate ,
KB-141, anticholesteremic agent ,
Stearic acid,stearic acid iupac systematic name octadecanoic acid one useful type saturated fatty acid come many animal vegetable fat oil waxy solid ,
D-Cysteine, thiol-containing non-essential amino acid oxidized form cystine ,
Sphingosine, amino alcohol long unsaturated hydrocarbon chain sphingosine derivative sphinganine major base sphingolipids mammal dorland 28th ed ,
Pyrroloquinoline Quinone, pyrrolo-quinoline two adjacent keto-groups 4 5 position three acidic carboxyl group coenzyme dehydrogenases pubchem ,
Duvoglustat, alpha-glucosidase inhibitor antiviral action derivative deoxynojirimycin may anti-hiv activity ,
Oteracil,oteracil adjunct antineoplastic therapy used reduce toxic side effect associated chemotherapy approved european medicine agency ema march 2011 oteracil available combination db09257 db09256 within commercially available product `` teysuno '' main active ingredient teysuno db09256 pro-drug db00544 5-fu cytotoxic anti-metabolite drug act rapidly dividing cancer cell mimicking class compound called `` pyrimidine '' essential component rna dna 5-fu able insert strand dna rna thereby halting replication process necessary continued cancer growth oteracil 's main role within teysuno reduce activity 5-fu within normal gastrointestinal mucosa therefore reduce 's gastrointestinal toxicity l933 function blocking enzyme orotate phosphoribosyltransferase oprt involved production 5-fu ,oteracil used adjunct antineoplastic therapy used within product teysuno oteracil indicated treatment adult advanced gastric stomach cancer given combination cisplatin 
Vinylglycine,vinylglycine irreversible inhibitor aspartate aminotransferase ,
D-Tryptophan,tryptophan one 20 standard amino acid well essential amino acid human diet encoded standard genetic code codon ugg d-stereoisomer occasionally found naturally produced peptide example marine venom peptide contryphan distinguishing structural characteristic tryptophan contains indole functional group essential amino acid defined growth effect rat ,
Trifluoroethanol, non-aqueous co-solvent serf tool study protein folding also used various pharmaceutical chemical engineering application ,
Nicotinamide Mononucleotide,3-carbamoyl-1-beta-d-ribofuranosyl pyridinium hydroxide-5 39 phosphate inner salt nucleotide nitrogenous base nicotinamide beta-n-glycosidic linkage c-1 position d-ribose synonym nicotinamide ribonucleotide nmn pubchem ,
Flavin mononucleotide, coenzyme number oxidative enzyme including nadh dehydrogenase principal form riboflavin found cell tissue ,
D-Lysine, essential amino acid often added animal feed pubchem ,
Phenol,phenol antiseptic disinfectant active wide range micro-organism including fungi virus slowly effective spore phenol used disinfect skin relieve itching phenol also used oral analgesic anesthetic product chloraseptic treat pharyngitis additionally phenol related compound used surgical ingrown toenail treatment process termed phenolization research indicates parental exposure phenol related compound positively associated spontaneous abortion second world war phenol injection used mean execution nazi phenol toxic compound whose vapour corrosive skin eye respiratory tract ,phenol primarily indicated minor sore throat pain sore mouth minor mouth irritation pain associated canker sore additionally phenol indicated treatment focal spasticity 
Glutaral,one protein cross-linking reagent used disinfectant sterilization heat-sensitive equipment laboratory reagent especially fixative ,
D-Treitol, four-carbon sugar found algae fungi lichen twice sweet sucrose used coronary vasodilator pubchem ,
Isoliquiritigenin,isoliquiritigenin precursor several flavonones many plant ,
Glutathione disulfide, glutathione dimer formed disulfide bond cysteine sulfhydryl side chain course oxidized ,
Brivudine,brivudine used treatment herpes zoster although approved u.s. canada approved several european country ,
5-fluorotryptophan,5-fluorotryptophan used substrate analogue study enzyme mechanism nmr spectroscopy ,
Maltose, dextrodisaccharide malt starch used sweetening agent fermentable intermediate brewing grant hackh 39 chemical dictionary 5th ed ,
Huperzine B,huperzine b novel acetylcholinesterase inhibitor , investigation treatment alzheimer 's disease 
3-Acetylpyridine Adenine Dinucleotide, coenzyme composed ribosylnicotinamide 5 39 -diphosphate coupled adenosine 5 39 -phosphate pyrophosphate linkage found widely nature involved numerous enzymatic reaction serf electron carrier alternately oxidized nad+ reduced nadh dorland 27th ed ,
"3,5-Diiodotyrosine", product iodination monoiodotyrosine biosynthesis thyroid hormone diiodotyrosine residue coupled monoiodotyrosine diiodotyrosine residue form t4 t3 thyroid hormone thyroxine triiodothyronine pubchem ,
"1D-myo-inositol 1,4,5-trisphosphate","intracellular messenger formed action phospholipase c phosphatidylinositol 4,5-bisphosphate one phospholipid make cell membrane inositol 1,4,5-trisphosphate released cytoplasm release calcium ion internal store within cell 39 endoplasmic reticulum calcium ion stimulate activity b kinase calmodulin ",
Cytidine-5'-Monophosphate, pyrimidine ribonucleoside 5'-monophosphate cytosine nucleobase ,
Hemin,hemin trade name panhematin iron-containing porphyrin specifically protoporphyrin ix containing ferric iron ion heme b chloride ligand ,used management porphyria attack particularly acute intermittent porphyria 
Ubenimex,ubenimex also known bestatin competitive protease inhibitor inhibitor aminopeptidase b leukotriene a4 hydrolase aminopeptidase n. studied use treatment acute myelocytic leukemia , adjuvant therapy used acute chronic myelonous leukemia lung cancer nasopharyngeal cancer also used treat hypercholesterolaemia 
Uridine-5'-Diphosphate, uracil nucleotide containing pyrophosphate group esterified c5 sugar moiety pubchem ,
Cephalothin Group,"cephalothin group solid compound belongs 1,3-thiazines organic compound containing 1,3-thiazine six-member ring nitrogen sulfur atom ring position 1 3 respectively well two double bond substance known target beta-lactamase toho-1 d-alanyl-d-alanine carboxypeptidase ",
Lexacalcitol,lexacalcitol solid compound belongs vitamin derivative class chemical compound containing secosteroid backbone usually secoergostane secocholestane known target vitamin d3 receptor ,
Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate," solid compound belongs stilbenes organic compound containing 1,2-diphenylethylene moiety stilbenes c6-c2-c6 derived common phenylpropene c6-c3 skeleton building block introduction one hydroxyl group phenyl ring lead stilbenoids substance target protein interleukin-2 ",
"3-methyl-benzene-1,2-diol","3-methyl-benzene-1,2-diol solid compound belongs catechols compound containing 1,2-benzenediol moeity 3-methyl-benzene-1,2-diol target protein biphenyl-2,3-diol 1,2-dioxygenase ",
(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid, 1h-indol-3-yl 2-mercapto-ethoxyimino -acetic acid solid compound belongs indole-3-acetic acid derivative compound containing acetic acid derivative linked c3 carbon atom indole 1h-indol-3-yl 2-mercapto-ethoxyimino -acetic acid known target interleukin-2 ,
N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide,n2- benzyloxy carbonyl -n1- 3 -1-cyanopyrrolidin-3-yl -l-leucinamide solid compound belongs n-acyl-alpha amino acid derivative compound containing alpha amino acid derivative thereof bear acyl group terminal nitrogen atom known target cathepsin k ,
"N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid","n 4 -adenosyl-n 4 -methyl-2,4-diaminobutanoic acid solid compound belongs purine nucleoside analogue compound comprising purine base attached sugar ",
Sparfosic acid,sparfosic acid solid compound belongs n-acyl-alpha amino acid compound containing alpha amino acid bear acyl group terminal nitrogen atom substance known target aspartate carbamoyltransferase catalytic chain cad protein ,
Nicotinamide adenine dinucleotide phosphate,"nicotinamide adenine dinucleotide phosphate coenzyme composed ribosylnicotinamide 5 39 -phosphate nmn coupled pyrophosphate linkage 5 39 -phosphate adenosine 2 39 ,5 39 -bisphosphate serf electron carrier number reaction alternately oxidized nadp+ reduced nadph dorland 27th ed ",
Alvocidib,alvocidib synthetic flavonoid based extract indian plant potential treatment cancer work inhibiting cyclin-dependent kinase arresting cell division causing apoptosis non-small lung cancer cell ,investigated use/treatment esophageal cancer leukemia lymphoid lung cancer liver cancer lymphoma unspecified 
Galactose-uridine-5'-diphosphate, nucleoside diphosphate sugar epimerized udpglucose entry mainstream carbohydrate metabolism serf source galactose synthesis lipopolysaccharides cerebrosides lactose ,
alpha-D-galacturonic acid, α-anomer d-galacturonic acid ,
Equilenin,equilenin estrogenic steroid produced horse total five double bond a- b-ring high concentration equilenin found urine pregnant mare ,
Eniluracil,eniluracil previously development glaxosmithkline gsk developed adherex enhance therapeutic value effectiveness 5-fluorouracil 5-fu one world ’ widely-used oncology agent 5-fu widely used u.s. often first second line therapy variety cancer including colorectal breast gastric head neck ovarian basal cell cancer skin eniluracil could improve 5-fu increasing effectiveness reducing side effect and/or making orally available eniluracil received orphan drug status fda treatment hepatocellular cancer combination fluoropyrimidines including 5-fu , treatment cancer combination 5-fluorouracil 
Spermidine,spermidine polyamine formed putrescine found almost tissue association nucleic acid found cation ph value thought help stabilize membrane nucleic acid structure precursor spermine ,
alpha-N-Acetyl-D-galactosamine, n-acetyl derivative galactosamine pubchem ,
Butyric Acid, four carbon acid ch3ch2ch2cooh unpleasant odor occurs butter animal fat glycerol ester ,
Phencyclidine, hallucinogen formerly used veterinary anesthetic briefly general anesthetic human phencyclidine similar ketamine structure many effect like ketamine produce dissociative state exerts pharmacological action inhibition nmda receptor receptor n-methyl-d-aspartate drug abuse known pcp angel dust ,
Glucose-6-Phosphate, ester glucose phosphoric acid made course glucose metabolism mammalian cell normal constituent resting muscle probably constant equilibrium fructose-6-phosphate stedman 26th ed ,
Oxyphenbutazone,oxyphenbutazone withdrawn canadian market march 1985 due concern regarding bone marrow suppression ,
Pyruvaldehyde, organic compound used often reagent organic synthesis flavoring agent tanning demonstrated intermediate metabolism acetone derivative isolated cell preparation various culture medium vivo certain animal pubchem ,
Capric acid,decanoic acid solid compound belongs straight chain fatty acid fatty acid straight aliphatic chain protein decanoic acid target include furin octanoyltransferase 3-oxoacyl- acyl-carrier-protein synthase 1 peptostreptococcal albumin-binding protein putative uncharacterized protein tcp14 ,
5-deoxyflavanone,"5-deoxyflavanone solid compound belongs flavanones compound containing flavan-3-one moiety whose structure characterized 2-phenyl-3,4-dihydro-2h-1-benzopyran bearing ketone carbon c3 ",
Tiratricol, metabolite t3 t4 thyroid hormone promoted hyperlipidemia localized lipodystrophy obesity tiratricol used trial studying treatment allan-herndon-dudley syndrome ,
(S)-Rolipram, phosphodiesterase inhibitor antidepressant property pubchem ,
Diminazene,"diminazene also known diminazine 4,4'- diazoamino benzamidine 4,4'- 1-triazene-1,3-diyl bis-benzenecarboximidamide diminazine aceturate diminazene aceturate trypanocidal agent major brand diminazene berenil pirocide ganasag azidin substance solid compound belongs phenylhydrazines compound containing phenylhydrazide moiety consists hydrazide substituent attached phenyl group known drug target diminazene include hth-type transcriptional regulator qacr trypsin-1 amiloride-sensitive amine oxidase copper-containing mitochondrial peroxiredoxin-5 ",
3'-deoxyguanosine,3'-deoxyguanosine solid compound belongs purine nucleoside analogue compound comprising purine base attached sugar medication target protein purine nucleoside phosphorylase ,
Ribostamycin,ribostamycin aminoglycoside antibiotic a187166 isolated _streptomyces ribosidificus_ a187178 listed one world health organization 's critically important antimicrobial l9071 ,
Deoxycholic acid,deoxycholic acid bile acid emulsifies solubilizes dietary fat intestine injected subcutaneously disrupts cell membrane adipocytes destroys fat cell tissue april 2015 deoxycholic acid approved fda treatment submental fat improve aesthetic appearance reduce facial fullness convexity marketed brand name kybella kythera biopharma first pharmacological agent available submental fat reduction allowing safer le invasive alternative surgical procedure , improvement appearance moderate severe fullness associated submental fat adult 
Adamantane, tricyclo bridged hydrocarbon pubchem ,
3-hydroxyanthranilic acid, oxidation product tryptophan metabolism may free radical scavenger carcinogen ,
Picric acid,used antiseptic astringent stimulant epitheliazation ,
Butylamine,butylamine colourless liquid acquires yellow colour upon storage air one four isomeric amine butane known fishy ammonia-like odor common amine ,
L-cysteic acid,l-cysteic acid beta-sulfoalanine amino acid c-terminal sulfonic acid group isolated human hair oxidized permanganate occurs normally outer part sheep 's fleece wool exposed light weather ,
Digoxigenin,digoxigenin cardenolide aglycon digoxin obtained hydrolysis digoxin digitalis orientalis l. digitalis lanata ehrh ,
Uridine monophosphate,5'-uridylic acid uracil nucleotide containing one phosphate group esterified sugar moiety 2 3 5 position ,
Piritrexim,piritrexim used trial studying treatment bladder cancer urethral cancer transitional cell cancer renal pelvis ureter ,
Vanoxerine,vanoxerine highly selective dopamine transporter antagonist synthesized late 1970s developed potential treatment depression a19824 vanoxerine later evaluated potential treatment cocaine addiction due ability block dopamine reuptake slower dissociation rate cocaine a37914 although several study suggested profile vanoxerine safer cocaine a19824 a248550 study found vanoxerine least moderate potential abused human a248585 recently vanoxerine tested potential anti-arrhythmic anti-atrial fibrillatory agent due ability block hkv11.1 herg cardiac potassium channel a248555 vanoxerine investigational drug approved therapeutic use ,vanoxerine approved therapeutic use 
Cyclohexanol,monohydroxy derivative cyclohexanes contain general formula r-c6h11o camphorlike odor used making soap insecticide germicide dry cleaning plasticizer pubchem ,
Adenosine 5'-phosphosulfate,5'-adenylic acid monoanhydride sulfuric acid initial compound formed action atp sulfurylase sulfate ion sulfate uptake synonym adenosine sulfatophosphate aps ,
N-Ethyl-5'-Carboxamido Adenosine, stable adenosine a1 a2 receptor agonist experimentally inhibits camp cgmp phosphodiesterase activity pubchem ,
N-acetyl-alpha-neuraminic acid, n-acyl derivative neuraminic acid n-acetylneuraminic acid occurs many polysaccharide glycoprotein glycolipids animal bacteria dorland 28th ed p1518 ,
N-acetyl-alpha-D-glucosamine, n-acetyl derivative glucosamine ,
N-Acetyl-glucosamine thiazoline,"n-acetyl-glucosamine thiazoline nag-thiazoline analog oxazolinium bicyclic intermediate leading n-acetylglucosamine 1,6-anhydro-n-acetylmuramic acid ",
Tromethamine, organic amine proton acceptor used synthesis surface-active agent pharmaceutical emulsifying agent cosmetic cream lotion mineral oil paraffin wax emulsion biological buffer used alkalizer merck 11th ed martindale extra pharmacopoeia 30th ed p1424 , prevention correction metabolic acidosis 
Doconexent, mixture fish oil primrose oil doconexent used high-docosahexaenoic acid dha supplement dha 22 carbon chain 6 ci double bond anti-inflammatory effect biosythesized alpha-linolenic acid commercially manufactured microalgae omega-3 fatty acid primary structural component human brain cerebral cortex skin retina thus play important role development function amino-phospholipid dha found high concentration across several brain subcellular fraction including nerve terminal microsome synaptic vesicle synaptosomal plasma membrane a19436 ,used high-docosahexaenoic acid dha oral supplement 
Propanoic acid,sodium propionate sodium salt propionic acid exists colorless transparent crystal granular crystalline powder considered generally recognized safe gras food ingredient fda act antimicrobial agent food preservation flavoring agent use food additive also approved europe sodium propionate prepared neutralizing propionic acid sodium hydroxide sodium propionate previously approved canada active ingredient amino-cerv used treat inflammation injury cervix ,propanoic acid various direct sodium calcium salt formulation acid currently commonly approved indicated organization like fda ema use antibacterial food additive preservative animal feed food human consumption l2715 l2716 similarly although use propanoic acid direct sodium calcium salt formulation excipient ingredient pharmaceutical necessarily major role compound today sodium propionate used vaginal cream preparation indicated cervicitis cervical tear and/or postcauterization postcryosurgery postconization cervix t193 product sodium propionate primarily used elicit preservative bacteriostatic l2710 f50 effect active ingredient combined formulation like urea benzalkonium chloride inositol methionine cystine amino acid facilitated debridement enhanced medication spread epithelialization promotion wound healing respectively l2710 a32973 nevertheless great variety propionic acid derivative exist separate pharmaceutical unique therapeutic category pharmacodynamics pharmacokinetics 
alpha-D-quinovopyranose, pyranose form d-quinovose α-configuration anomeric position ,
Phenacetin,phenacetin withdrawn canadian market june 1973 due concern regarding nephropathy damage disease kidney ,used principally analgesic 
GW-3965,gw-3965 liver x receptor ligand ,
Benzoic acid, fungistatic compound widely used food preservative conjugated glycine liver excreted hippuric acid sodium salt form sodium benzoate used treatment urea cycle disorder due ability bind amino acid lead excretion amino acid decrease ammonia level recent research show sodium benzoate may beneficial add-on therapy 1 gram/day schizophrenia total positive negative syndrome scale score dropped 21 compared placebo ,
Palmitic Acid, common saturated fatty acid found fat wax including olive oil palm oil body lipid ,
2'-Deoxycytidine-5'-Monophosphate,"deoxycytidine dihydrogen phosphate deoxycytosine nucleotide containing one phosphate group esterified deoxyribose moiety 2 39 -,3 39 5- position pubchem ",
D-Tyrosine, non-essential amino acid animal synthesized phenylalanine also precursor epinephrine thyroid hormone melanin ,
Formaldehyde, highly reactive aldehyde gas formed oxidation incomplete combustion hydrocarbon solution wide range us manufacture resin textile disinfectant laboratory fixative preservative formaldehyde solution formalin considered hazardous compound vapor toxic reynolds martindale extra pharmacopoeia 30th ed p717 ,use drying skin surgical removal wart dryness required 
Cilomilast,"cilomilast ariflo sb-207,499 drug developed treatment respiratory disorder asthma chronic obstructive pulmonary disease copd orally active act selective phosphodiesterase-4 inhibitor following four clinical trial drug proved effective treating copd however never marketed due poor side effect profile ",investigated use/treatment chronic obstructive pulmonary disease copd 
Eucalyptol,eucalyptol naturally produced cyclic ether monoterpenoid eucalyptol ingredient many brand mouthwash cough suppressant control airway mucus hypersecretion asthma via anti-inflammatory cytokine inhibition eucalyptol effective treatment nonpurulent rhinosinusitis eucalyptol reduces inflammation pain applied topically kill leukaemia cell vitro ,
Cadaverine,cadaverine foul-smelling diamine formed bacterial decarboxylation lysine ,
Prostaglandin G2, cyclic endoperoxide intermediate produced action cyclooxygenase arachidonic acid converted series specific enzyme series 2 prostaglandin pubchem ,
Biopterin, natural product considered growth factor insect pubchem ,
Triphosphoric acid,used water softener peptizing agent emulsifier dispersing agent ingredient cleanser meat preservative ,
Oxalic Acid, strong dicarboxylic acid occurring many plant vegetable produced body metabolism glyoxylic acid ascorbic acid metabolized excreted urine used analytical reagent general reducing agent pubchem ,
Urea, compound formed liver ammonia produced deamination amino acid principal end product protein catabolism constitutes one half total urinary solid ,urea used topically debridement promotion normal healing hyperkeratotic surface lesion particularly healing retarded local infection necrotic tissue fibrinous purulent debris eschar urea useful treatment hyperkeratotic condition dry rough skin dermatitis psoriasis xerosis ichthyosis eczema keratosis keratoderma corn callus well damaged devitalized ingrown nail l41484 
N-Ethylretinamide,n-ethylretinamide ethylamide all-trans b-retinoic acid ,
Freselestat,,investigated use/treatment chronic obstructive pulmonary disease copd 
"5alpha-androstane-3beta,17alpha-diol","5alpha-androstane-3beta,17alpha-diol unspecified form steroid normally major metabolite testosterone androgenic activity implicated regulator gonadotropin secretion ",
D-Serine, non-essential amino acid occurring natural form l-isomer synthesized glycine threonine involved biosynthesis purine pyrimidine amino acid pubchem ,
Oxamic Acid,amino-substituted glyoxylic acid derivative pubchem ,
D-Asparagine, non-essential amino acid involved metabolic control cell function nerve brain tissue biosynthesized aspartic acid ammonia asparagine synthetase concise encyclopedia biochemistry molecular biology 3rd ed ,
"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium",calcium magnesium salt used therapeutically hepatobiliary dysfunction ,
1-deoxymannojirimycin, alpha-glucosidase inhibitor antiviral action derivative deoxynojirimycin may anti-hiv activity pubchem ,
Clorobiocin,clorobiocin aminocoumarin antibiotic similar novobiocin coumermycin a1 ,
Ethanolamine, viscous hygroscopic amino alcohol ammoniacal odor widely distributed biological tissue component lecithin used surfactant fluorimetric reagent remove co2 h2s natural gas gas ,
Uridine 5'-triphosphate,uridine 5 39 tetrahydrogen triphosphate uracil nucleotide containing three phosphate group esterified sugar moiety ,
Clorgiline, antidepressive agent monoamine oxidase inhibitor related pargyline ,
Guanosine tetraphosphate,guanosine tetraphosphate guanine nucleotide containing four phosphate group two phosphate group esterified sugar moiety 5 position two 2 3 position nucleotide serf messenger turn synthesis ribosomal rna amino acid available protein synthesis ,
D-arginine, d-α-amino acid d-isomer arginine l-form physiologically active ,
Coenzyme A persulfide,coenzyme persulfide possible vivo inhibitor mammalian short chain acyl-coa dehydrogenase ,
Ergosterol, steroid interest biosynthesis fungi target antifungal agent notably azoles present skin animal ultraviolet ray break bond result ergocalciferol ,
Hypoxanthine,hypoxanthine purine reaction intermediate metabolism adenosine formation nucleic acid salvage pathway ,
RH-1,rh-1 used trial studying treatment advanced solid tumor non-hodgkin 's lymphoma ,
Balhimycin,balhimycin novel glycopeptide antibiotic ,
Berberine, alkaloid hydrastis canadensis l. berberidaceae also found many plant relatively toxic parenterally used orally various parasitic fungal infection antidiarrheal ,
Aurodox,aurodox antibiotic obtained streptomyces variant considered possibly effective streptococcus pyogenes infection may promote growth poultry ,
Willardiine,willardiine compound isolated seed _acacia willariana_ ,
Guanosine-5'-Triphosphate,guanosine 5 39 tetrahydrogen triphosphate guanine nucleotide containing three phosphate group esterified sugar moiety pubchem ,
Nicotinyl alcohol, direct-acting peripheral vasodilator cause flushing may decrease blood pressure used vasospasm threatened gangrene pubchem ,
(R)-Rolipram, r -enantiomer rolipram phosphodiesterase inhibitor antidepressant property ,
Digitoxigenin,digitoxigenin cardenolide aglycon digitoxin ,
Methylmalonic Acid, malonic acid derivative vital intermediate metabolism fat protein abnormality methylmalonic acid metabolism lead methylmalonic aciduria metabolic disease attributed block enzymatic conversion methylmalonyl coa succinyl coa pubchem ,
Norvaline,norvaline isomer common amino acid valine ,
Dequalinium,dequalinium antibacterial agent multi-targeted action also posse antifungal antiparasitic antiviral anticancer neuroprotective property a249255 quaternary ammonium compound l42190 consists amphipathic cation two aminoquinaldinium ring end long hydrophobic hydrocarbon chain due flexible structure dequalinium investigated build drug gene delivery system a249255 first used antiseptic disinfectant 1950s dequalinium still found various otc product treat condition oral infection inflammation a249255 also used vaginal tablet treat bacterial vaginosis l42190 ,dequalinium used several otc product treat mouth infection inflammation tonsillitis pharyngitis gingivitis a249255 vaginal tablet dequalinium indicated treatment bacterial vaginosis adult woman 55 year age l42190 
Quercetin,quercetin flavonol widely distributed plant antioxidant like many phenolic heterocyclic compound glycosylated form include rutin quercetrin ,
Sparsomycin, antitumor antibiotic produced streptomyces sparsogenes inhibits protein synthesis 70 80 ribosomal system pubchem ,
Nitroarginine, inhibitor nitric oxide synthetase shown prevent glutamate toxicity nitroarginine experimentally tested ability prevent ammonia toxicity ammonia-induced alteration brain energy ammonia metabolite neurochem re 1995:200 4 :451-6 ,
Oleic Acid, unsaturated fatty acid widely distributed abundant fatty acid nature used commercially preparation oleates lotion pharmaceutical solvent stedman 26th ed ,
Butyrylthiocholine, sulfur-containing analog butyrylcholine hydrolyzed butyrylcholinesterase butyrate thiocholine used reagent determination butyrylcholinesterase activity pubchem ,
Tretazicar,tretazicar investigation clinical trial nct00746590 study anti-tumour effect safety prolarix™ hepatocellular carcinoma ,
Geneticin,geneticin also known g418 aminoglycoside antibiotic similar structure gentamicin b1 produced micromonospora rhodorangea geneticin block polypeptide synthesis inhibiting elongation step prokaryotic eukaryotic cell commonly used laboratory research select genetically engineered cell resistance geneticin conferred neo gene tn5 encoding aminoglycoside 3 ‘ -phosphotransferase aph 3 ‘ ii ,
N-acetyl-beta-neuraminic acid, n-acyl derivative neuraminic acid n-acetylneuraminic acid occurs many polysaccharide glycoprotein glycolipids animal bacteria dorland 28th ed p1518 ,
Cyclotheonamide A,cyclotheonamide cyclic peptide isolated marine sponge theonella ,
Citric acid, key intermediate metabolism acid compound found citrus fruit salt citric acid citrate used anticoagulant due calcium-chelating ability citric acid one active ingredient phexxi non-hormonal contraceptive agent approved fda may 2020 l14120 also used combination magnesium oxide form magnesium citrate osmotic laxative l43832 ,
Oxfenicine,oxfenicine inhibitor myocardial metabolism nonesterified fatty acid nefa ,
Guanosine-5'-Diphosphate, guanine nucleotide containing two phosphate group esterified sugar moiety pubchem ,
Dihydroxyacetone phosphate,dihydroxyacetone phosphate important intermediate lipid biosynthesis glycolysis dihydroxyacetone phosphate investigated treatment lymphoma large-cell diffuse ,
Inosine, purine nucleoside hypoxanthine linked n9 nitrogen c1 carbon ribose intermediate degradation purine purine nucleoside uric acid pathway purine salvage also occurs anticodon certain transfer rna molecule dorland 28th ed , primary popular claim made inosine enhances exercise athletic performance refuted available research data preliminary evidence inosine may neurorestorative anti-inflammatory immunomodulatory cardioprotective effect 
Carbocisteine,dyspnea cough common symptom chronic obstructive pulmonary disease copd a231169 respiratory condition characterized increased mucus production individual copd greater risk pulmonary infection due growth accumulation virus bacteria thick bronchial mucus carbocisteine mucolytic drug alleviates respiratory symptom infection reducing viscosity mucus allowing expelled l32383 several license drug withdrawn following serious fatal paradoxical effect carbocisteine therapy child respiratory dress dyspnea cough aggravation reported physician france italy a230993 carbocisteine currently fda health canada approved approved use asia europe south america ,carbocisteine indicated counter prescription formula clear airway secretion condition associated increased mucus l24484 l24984 l20019 
Taurocholic acid, product conjugation cholic acid taurine sodium salt chief ingredient bile carnivorous animal act detergent solubilize fat absorption absorbed used cholagogue cholerectic ,
"(S)-propane-1,2-diol"," -propane-1,2-diol clear colorless viscous organic solvent diluent used pharmaceutical preparation ",
(R)-acetoin, product fermentation component butanediol cycle microorganism mammal oxidized carbon dioxide ,
Arecoline, alkaloid obtained betel nut areca catechu fruit palm tree agonist muscarinic nicotinic acetylcholine receptor used form various salt ganglionic stimulant parasympathomimetic vermifuge especially veterinary practice used euphoriant pacific island ,
Meglutol, antilipemic agent lower cholesterol triglyceride serum beta-lipoprotein phospholipid act interfering enzymatic step involved conversion acetate hydroxymethylglutaryl coenzyme well inhibiting activity hydroxymethylglutaryl coa reductase rate limiting enzyme biosynthesis cholesterol ,
Phosphoaminophosphonic Acid-Adenylate Ester,5 39 -adenylic acid monoanhydride imidodiphosphoric acid analog atp oxygen atom bridging beta gamma phosphate replaced nitrogen atom potent competitive inhibitor soluble membrane-bound mitochondrial atpase also inhibits atp-dependent reaction oxidative phosphorylation pubchem ,
Thiodigalactoside,thiodigalactoside solid compound belongs dihexoses disaccharide containing two hexose carbohydrate medication known target galectin-1 heat-labile enterotoxin b chain neurocan core protein lactose permease ,
Lactic acid, normal intermediate fermentation oxidation metabolism sugar concentrated form used internally prevent gastrointestinal fermentation stedman 26th ed sodium lactate sodium salt lactic acid mild saline taste produced fermentation sugar source corn beet neutralizing resulting lactic acid create compound formula nac3h5o3 lactic acid one active ingredient phexxi non-hormonal contraceptive agent approved fda may 2020 l14120 , use alkalinizing agent 
"L-erythro-7,8-dihydrobiopterin","7,8-dihydrobiopterin inhibitor enzyme dihydroneopterin aldolase dhna catalyzes conversion 7,8-dihydrobiopterin 6-hydroxymethyl-7,8-dihydropterin glycolaldehyde ",
D-norleucine, unnatural amino acid used experimentally study protein structure function structurally similar methionine however contain sulfur ,
Homocysteine,homocysteine thiol-containing amino acid formed demethylation methionine ,
3-Fluoro-L-tyrosine,3-fluoro-l-tyrosine solid compound belongs phenylpropanoic acid compound whose structure contain benzene ring conjugated propanoic acid 3-fluoro-l-tyrosine target protein superoxide dismutase mn mitochondrial ,
"1,4-Dithiothreitol", reagent commonly used biochemical study protective agent prevent oxidation sh thiol group reducing disulphides dithiols pubchem ,
"N,N,N-trimethylglycinium", naturally occurring compound interest role osmoregulation drug betaine hydrochloride used source hydrochloric acid treatment hypochlorhydria betaine also used treatment liver disorder hyperkalemia homocystinuria gastrointestinal disturbance martindale extra pharmacopoeia 30th ed p1341 ,
N-Formylmethionine,n-formylmethionine effective initiation protein synthesis initiating methionine residue enters ribosome n-formylmethionyl trna process occurs escherichia coli bacteria well mitochondrion eucaryotic cell ,
Lactose, disaccharide glucose galactose human cow milk used pharmacy tablet medicine nutrient industry ,
Afimoxifene,afimoxifene 4-hydroxytamoxifen trade name tamogel new estrogen inhibitor investigation variety estrogen-dependent condition including cyclic breast pain gynecomastia tamogel formulated using enhanced hydroalcoholic gel ehg technology technology enables percutaneous delivery drug delivered orally developed ascent therapeutic , potential treatment menstrual-cycle related mastalgia fibrocystic breast disease breast disease gynecomastia keloid scarring 
Erythritol,erythritol four-carbon sugar found algae fungi lichen twice sweet sucrose used coronary vasodilator ,
Thymidine,thymidine pyrimidine deoxynucleoside thymidine dna nucleoside pair deoxyadenosine double-stranded dna cell biology used synchronize cell phase ,
Chlorophyll B, light silvery metallic element atomic symbol mg atomic number 12 atomic weight 24.31 salt essential nutrition required activity many enzyme especially concerned oxidative phosphorylation component intra- extracellular fluid excreted urine feces deficiency cause irritability nervous system tetany vasodilation convulsion tremor depression psychotic behavior dorland 27th ed ,
Caprylic acid,caprylic acid eight-carbon chain fatty acid also known systematically octanoic acid found naturally coconut breast milk oily liquid slightly unpleasant rancid-like smell minimally soluble water ,
Dexfosfoserine, phosphoric acid ester serine ,
Malonyl-CoA, coenzyme derivative play key role fatty acid synthesis cytoplasmic microsomal system ,
"2,4-Dinitrophenol", toxic dye chemically related trinitrophenol picric acid used biochemical study oxidative process uncouples oxidative phosphorylation also used metabolic stimulant stedman 26th ed ,
Cholesterol, principal sterol higher animal distributed body tissue especially brain spinal cord animal fat oil ,
Niflumic acid,niflumic acid analgesic anti-inflammatory agent used treatment rheumatoid arthritis ,used treatment rheumatoid arthritis 
Cytidine-5'-Diphosphate,cytidine 5 39 trihydrogen diphosphate cytosine nucleotide containing two phosphate group esterified sugar moiety synonym crpp cytidine pyrophosphate pubchem ,
Arachidonic Acid, unsaturated essential fatty acid found animal human fat well liver brain glandular organ constituent animal phosphatides formed synthesis dietary linoleic acid precursor biosynthesis prostaglandin thromboxanes leukotrienes pubchem ,
Gluconolactone,gluconolactone naturally-occurring food additive used sequestrant acidifier curing pickling leavening agent cyclic ester d-gluconic acid pure gluconolactone white odorless crystalline powder ,
Inosinic Acid,inosine 5'-monophosphate purine nucleotide hypoxanthine base one phosphate group esterified sugar moiety ,
Latamoxef,latamoxef broad- spectrum beta-lactam antibiotic similar structure cephalosporin except substitution oxaazabicyclo moiety thiaazabicyclo moiety certain cephalosporin proposed especially meningitides pass blood-brain barrier anaerobic infection ,latamoxef oxacephem antibiotic usually grouped cephalosporin used treat bacterial infection latamoxef primarily indicated condition like bone joint infection gi infection gynecological infection meningitis respiratory tract infection septicaemia skin infection soft tissue infection uti 
Trioxsalen,trioxsalen trimethylpsoralen trioxysalen trisoralen furanocoumarin psoralen derivative obtained several plant mainly psoralea corylifolia like psoralens cause photosensitization skin administered either topically orally conjunction uv-a least damaging form ultraviolet light phototherapy treatment vitiligo hand eczema photoactivated form produce interstrand linkage dna resulting cell apoptosis research conjugated dye confocal microscopy used visualize site dna damage 3 compound explored development antisense oligonucleotides cross-linked specifically mutant mrna sequence without affecting normal transcript differing even single base pair ,trioxsalen pigmenting photosensitizing agent used conjunction ultraviolet light treatment vitiligo 
Thiotepa,n n'n'-triethylenethiophosphoramide thiotepa cancer chemotherapeutic member alkylating agent group use 50 year stable derivative n n n '' triethylenephosphoramide tepa mostly used treat breast cancer ovarian cancer bladder cancer also used conditioning bone marrow transplantation main toxicity myelosuppression ,thiotepa used conditioning treatment prior allogeneic autologous haematopoietic progenitor cell transplantation hpct haematological disease adult paediatric patient also high dose chemotherapy hpct support appropriate treatment solid tumour adult paediatric patient 
Estriol, hydroxylated metabolite estradiol estrone hydroxyl group c3-beta 16-alpha 17-beta position estriol major urinary estrogen pregnancy large amount estriol produced placenta isomer inversion hydroxyl group group called epiestriol though estriol used part primarily north american phenomenon bioidentical hormone replacement therapy approved use fda health canada however available united state prescription filled compounding pharmacy also approved marketed throughout europe asia approximately 40 year treatment post-menopausal hot flash ,used test determine general health unborn fetus 
Estrone sulfate,estrone sulfate estropipate form estrogen several us alleviate symptom menopause hormone replacement therapy treatment type infertility treatment condition leading underdevelopment female sexual characteristic treatment vaginal atrophy treatment type breast cancer particularly men postmenopausal woman treatment prostate cancer prevention osteoporosis ,estropipate used treatment moderate severe vasomotor symptom associated monopause moderate severe symptom vulval vaginal atrophy associated menopause also used treat hypoestrogenism due hypogonadism castration primary ovarian failure prevent postmenopausal osteoporosis 
Quinestrol, 3-cyclopentyl ether ethinyl estradiol ,used hormone replacement therapy treating symptom menopause hot flash also used treat breast prostate cancer 
Fleroxacin,fleroxacin broad-spectrum antimicrobial fluoroquinolone strongly inhibits dna-supercoiling activity dna gyrase fleroxacin inhibitor cyp1a2 a39048 ,fleroxacin broad-spectrum antimicrobial fluoroquinolone 
1-benzylimidazole,1-benzylimidazole n-imidazole derivative shown strong cardiotonic activity ,
Aniracetam,compound anti-depressive property used mental performance enhancer ,
Cycloleucine,cycloleucine non-metabolisable amino acid formed cyclization leucine also specific reversible inhibitor nucleic acid methylation widely used biochemical experiment ,
Apramycin,apramycin aminoglycoside antibiotic bactericidal action many gram-negative bacteria apramycin structurally unique antibiotic contains bicyclic sugar moiety monosubstituted deoxystreptamine approved use human , treatment bacterial infection animal 
Allosamidin,allosamidin exhibit extremely potent inhibitory activity chitinases number source particularly candida albicans /i utilized potent antifungal agent ,
Aldosterone, hormone secreted adrenal cortex regulates electrolyte water balance increasing renal retention sodium excretion potassium ,
Dibromothymoquinone, low concentration compound inhibits reduction conventional hydrophilic electron acceptor probably acting plastoquinone antagonist higher concentration act electron acceptor intercepting electron either site inhibitory activity pubchem ,
Corticosterone, adrenocortical steroid modest significant activity mineralocorticoid glucocorticoid goodman gilman 39 pharmacological basis therapeutic 8th ed p1437 ,
Carboxin, systemic agricultural fungicide seed treatment agent ,
Choline alfoscerate, component phosphatidylcholines lecithin two hydroxy group glycerol esterified fatty acid stedman 26th ed counteracts effect urea enzyme macromolecule pubchem ,
Camptothecin,camptothecin alkaloid isolated stem wood chinese tree camptotheca acuminata /i compound selectively inhibits nuclear enzyme dna topoisomerase type several semisynthetic analog camptothecin demonstrated antitumor activity ,investigated treatment cancer 
"Estrane-3,17-dione","estrane-3,17-dione potent inhibitor isomerase ",
gamma-Butyrolactone,one furan carbonyl thereby forming cyclic lactone endogenous compound made gamma-aminobutyrate precursor gamma-hydroxybutyrate also used pharmacological agent solvent ,
Hesperidin,hesperidin flavan-on glycoside found citrus fruit ,
Iodipamide,iodipamide water-soluble radiographic contrast medium cholecystography intravenous cholangiography ,iodipamide used contrast agent cholecystography intravenous cholangiography 
Licofelone,developed german pharmaceutical company merckle gmbh together euroalliance partner alfa wassermann lacer licofelone ml3000 dual cox/lox inhibitor first member new class analgesic anti-inflammatory drug currently evaluation treatment osteoarthritis oa common form arthritis although phase iii trial successfully completed oa patient date regulatory submission yet given , management osteoarthritis 
Citraconic acid,citraconic acid one isomeric dicarboxylic acid produced distillation citric acid metabolite microorganism cis-ch3-c co2h =chco2h trans-isomer mesaconic acid ,
Motuporin,motuporin toxin isolated marine sponge thenonella swinhoie grey ,
Nimesulide,nimesulide relatively cox-2 selective non-steroidal anti-inflammatory drug nsaid analgesic antipyretic property approved indication treatment acute pain symptomatic treatment osteoarthritis primary dysmenorrhoea adolescent adult 12 year old due concern risk hepatotoxicity nimesulide withdrawn market many country , treatment acute pain symptomatic treatment osteoarthritis primary dysmenorrhoea adolescent adult 12 year old 
Sulfatide, class cerebroside sulfuric ester found largely medullated nerve fiber may accumulate metachromatic leukodystrophy ,
Streptolydigin,streptolydigin antibiotic isolated culture filtrate streptomyces lydicus active gram-postive bacteria except micrococcus ,
Suramin, polyanionic compound unknown mechanism action used parenterally treatment african trypanosomiasis used clinically diethylcarbamazine kill adult onchocerca ama drug evaluation annual 1992 p1643 also shown potent antineoplastic property suramin manufactured bayer germany germanin® , treatment human sleeping sickness onchocerciasis disease caused trypanosomes worm 
Tanaproget,tanaproget nsp-989 investigational non-steroidal progestin high affinity high efficacy agonist progesterone receptor pr much selective binding profile relative conventional progestin tanaproget may prove produce fewer side effect comparison currently process developed clinical use contraceptive ligand pharmaceutical analog tanaproget 4-fluoropropyltanaproget 18f developed radiotracer imaging pr positron emission tomography ,
Tagetitoxin,tagetitoxin bacterial phytotoxin preferentially inhibits eukaryotic rna polymerase ,
5-methyltetrahydrofolic acid,"5-methyltetrahydrofolic acid methylated derivate tetrahydrofolate generated methylenetetrahydrofolate reductase 5,10-methylenetetrahydrofolate used recycle homocysteine back methionine 5-methyltetrahydrofolate-homocysteine methyltransferases also called methionine synthases ",
Bifonazole,bifonazole azole antifungal drug ,used treatment various topical fungal infection including athlete 's foot tinea pedis 
Thenoyltrifluoroacetone,thenoyltrifluoroacetone chelating agent inhibitor cellular respiration ,
Inecalcitol,,investigated use/treatment prostate cancer psoriasis hyperparathyroidism 
Virginiamycin S1,one component virginiamycin cyclic polypeptide antibiotic complex streptomyces virginiae s. loidensis s. mitakaensis s. pristina-spiralis s. ostreogriseus others used treat infection gram-positive organism growth promoter cattle swine poultry ,
Benoxaprofen, use benoxaprofen formerly marketed oraflex tablet associated fatal cholestatic jaundice among serious adverse reaction holder approved application voluntarily withdrew oraflex tablet market august 5 1982 ,
Bithionol,bithionol formerly marketed active ingredient various topical drug product shown potent photosensitizer potential cause serious skin disorder approval nda 's bithionol drug product withdrawn october 24 1967 see federal register october 31 1967 32 fr 15046 ,
Bunamiodyl,withdrawn canadian u uk market 1963 due nephropathy ,
Clioquinol,clioquinol withdrawn 1983 due neurotoxicity ,used topical antifungal treatment 
Dantron,withdrawn canadian u uk market 1998 due genotoxicity ,
Metamizole,metamizole dipyrone pyrazolone derivative belongs group nonacid nonopioids considered potent analgesic antipyretic favourable gastrointestinal tolerability a251885 metamizole formerly marketed u dimethone tablet injection protemp oral liquid drug product withdrawn due association potentially fatal agranulocytosis approval nda 's metamizole drug product withdrawn june 27 1977 see federal register june 17 1977 42 fr 30893 l42975 1963 metamizole withdrawn canadian market banned uk france sweden norway australia a251805 metamizole still used certain country europe asia south america a251805 ,metamizole banned several country previously used powerful analgesic fever reducer country still available metamizole indicated acute severe pain injury surgery colic tumor pain acute severe pain symptom well high fever treatment unsuccessful a251805 
Iproniazid,withdrawn canadian market july 1964 due interaction food product containing tyrosine , treatment depression originally intended treat tuberculosis 
Methapyrilene,methapyrilene formerly marketed many drug product shown potent carcinogen manufacturer voluntarily withdrew methapyriline drug product market may june 1979 ,
Nialamide,withdrawn canadian u uk market 1963 due interaction food product containing tyrosine ,
Nomifensine,nomifensine formerly marketed merital capsule associated increased incidence hemolytic anemia approved application holder removed merital capsule market january 23 1986 fda published notice determination merital capsule removed market safety reason see federal register june 17 1986 51 fr 21981 approval nda merital capsule withdrawn march 20 1992 see federal register march 20 1992 57 fr 9729 also withdrawn canadian uk market ,
Oxeladin,withdrawn canadian u uk market 1976 due carcinogenicity ,
Oxyphenisatin, laxative undergoes enterohepatic circulation may cause jaundice ,
Phenolphthalein,phenolphthalein withdrawn canada due concern carcinogenicity 1997 ,used century laxative 
Prenylamine,prenylamine withdrawn canadian u uk market 1988 due concern regarding cardiac arrhythmia ,
Thenalidine,withdrawn canadian u uk market 1963 due concern involving neutropenia ,
Urethane,urethane formerly marketed inactive ingredient profenil injection determined carcinogenic removed canadian u uk market 1963 ,
Zomepirac,zomepirac formerly marketed zomax tablet associated fatal near-fatal anaphylactoid reaction manufacturer voluntarily removed zomax tablet canadian u uk market march 1983 ,zomepirac indicated management mild severe pain 
Lysergic acid diethylamide,debate continues nature cause chronic flashback explanation term lsd physically remaining body month year consumption discounted experimental evidence say hppd manifestation post-traumatic stress disorder related direct action lsd brain chemistry varies according susceptibility individual disorder many emotionally intense experience lead flashback person reminded acutely original experience however published case report chronic flashback appear describe anxious hyper-vigilant state reminiscent post-traumatic stress disorder ,
Buformin,buformin anti-diabetic drug biguanide class chemically related metformin phenformin withdrawn market country due high risk causing lactic acidosis ,
Tienilic acid,tienilic acid ticrynafen diuretic drug uric acid-lowering action marketed treatment hypertension withdrawn 1982 case report united state suggested link ticrynafen hepatitis manier et al. 1982 , treatment hypertension 
Zimelidine,zimelidine banned worldwide due serious sometimes fatal case central and/or peripheral neuropathy known guillain-barré syndrome due peculiar hypersensitivity reaction involving many organ including skin exanthema flu-like symptom arthralgia sometimes eosinophilia additionally zimelidine charged cause increase suicidal ideation and/or attempt among depressive patient , treatment depression 
Methaqualone,methaqualone sedative-hypnotic drug similar effect barbiturate general central nervous system depressant sedative-hypnotic activity first noted indian researcher 1950s 1962 methaqualone patented u wallace tiernan use peaked early 1970s hypnotic sedative muscle relaxant commonly used insomnia also used illegally recreational drug commonly known quaalude sopor ludes mandrax particularly 1970s north america depending manufacturer since least 2001 widely used south africa commonly referred `` smarties '' `` geluk-tablette '' meaning happy tablet clandestinely produced methaqualone still seized government agency police force around world , treatment insomnia sedative muscle relaxant 
Rapacuronium,rapacuronium withdrawn 2001 many country due risk fatal bronchospasm ,used anaesthesia aid enable endotracheal intubation 
Maraviroc,maraviroc brand-named selzentry celsentri outside u.s. chemokine receptor antagonist drug developed drug company pfizer designed act hiv interfering interaction hiv ccr5 originally labelled uk-427857 development assigned maraviroc name entered trial approved use fda august 2007 ,maraviroc indicated combination antiretroviral agent treatment ccr5-tropic hiv-1 infection adult pediatric patient weighing least 2kg l4109 recommended patient dual/mixed- cxcr4-tropic hiv-1 
Amineptine, food drug administration suspended marketing authorisation survector 1999 france withdrew market however several developing country continued produce 2005 , treatment depression 
Clofedanol,clofedanol centrally-acting cough suppressant available canada trade name ulone available united state ,used treatment dry cough 
Cyclandelate, direct-acting smooth muscle relaxant used dilate blood vessel may cause gastrointestinal distress tachycardia cyclandelate approved use u.s. canada approved various european country ,used treatment various blood vessel disease e.g. claudication arteriosclerosis raynaud 's disease nighttime leg cramp 
Cyproterone acetate, anti-androgen form acetate cyproterone acetate also progestational property used treatment hypersexuality male palliative prostatic carcinoma combination estrogen therapy severe acne hirsutism female , palliative treatment patient advanced prostatic carcinoma 
Debrisoquine, adrenergic neuron-blocking drug similar effect guanethidine also noteworthy substrate polymorphic cytochrome p-450 enzyme person certain isoforms enzyme unable properly metabolize many clinically important drug commonly referred debrisoquin 4-hydroxylase polymorphism , treatment moderate severe hypertension either alone adjunct treatment renal hypertension 
Flunarizine,flunarizine selective calcium entry blocker calmodulin binding property histamine h1 blocking activity effective prophylaxis migraine occlusive peripheral vascular disease vertigo central peripheral origin adjuvant therapy epilepsy ,used prophylaxis migraine occlusive peripheral vascular disease vertigo central peripheral origin adjuvant therapy epilepsy 
Fluspirilene, long-acting injectable antipsychotic agent used chronic schizophrenia ,used treatment schizophrenia 
Mepenzolate,mepenzolate post-ganglionic parasympathetic inhibitor decrease gastric acid pepsin secretion suppresses spontaneous contraction colon mepenzolate diminishes gastric acid pepsin secretion mepenzolate also suppresses spontaneous contraction colon pharmacologically post-ganglionic parasympathetic inhibitor shown effective contributing healing peptic ulcer decreasing rate recurrence preventing complication , use adjunctive therapy treatment peptic ulcer shown effective contributing healing peptic ulcer decreasing rate recurrence preventing complication 
Tetrabenazine, drug formerly used antipsychotic used primarily symptomatic treatment various hyperkinetic disorder monoamine depletor used symptomatic treatment chorea associated huntington 's disease fda approved august 15 2008 ,treatment hyperkinetic movement disorder like chorea huntington 's disease hemiballismus senile chorea tourette syndrome tic disorder tardive dyskinesia
Ixabepilone,ixabepilone epothilone b analog developed bristol-myers squibb cancer drug fda approved october 16 2007 treatment unresponsive aggressive metastatic locally advanced breast cancer ixabepilone administered injection marketed trade name ixempra ixabepilone semisynthetic analogue epothilone b lactone–lactam modification minimizes susceptibility esterase degradation ,investigated use/treatment breast cancer head neck cancer melanoma lung cancer lymphoma non-hodgkin 's prostate cancer renal cell carcinoma cancer/tumors unspecified 
Celiprolol,celiprolol indicated management mild moderate hypertension effort-induced angina pectoris simultaneously selective β1 receptor antagonist β2 receptor partial agonist weak α2 receptor antagonist 2010 clinical trial suggested use medication prevention vascular complication rare inherited disease called vascular ehlers–danlos syndrome study demonstrated decreased incidence arterial rupture dissection specific type arterial rupture layer vessel separate prior complete failure artery wall celiprolol approved use fda treatment vascular ehlers–danlos syndrome ,celiprolol indicated management mild moderate hypertension effort-induced angina pectoris 
Roxadustat,roxadustat first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used treat anemia associated chronic kidney disease work reducing breakdown hypoxia-inducible factor hif transcription factor stimulates red blood cell production response low oxygen level a245393 roxadustat first approved european commission august 2021 l40323 ,roxadustat indicated treatment adult patient symptomatic anemia associated chronic kidney disease ckd l40318 
AZD0947,azd0947 k+ channel opener investigation astrazeneca treatment overactive bladder march 2003 drug phase ii trial however october 2004 longer appeared company ’ development pipeline ,intended treatment urinary incontinence 
Cediranib, novel indole-ether quinazoline cediranib highly potent ic sub 50 /sub lt 1 nmol/l atp-competitive inhibitor recombinant kdr tyrosine kinase vitro developed clinically once-daily oral therapy treatment cancer , treatment liver cancer advanced non-small cell lung cancer nsclc advanced colorectal cancer crc solid tumor 
Posizolid,posizolid azd2563 oxazolidinone antibiotic july 2002 completion phase trial december 2001 astrazeneca announced longer pursuing development posizolid presumably due negative trial result though result reported , treatment gram-positive infection including multiresistant strain 
Biricodar, pipecolinate derivative biricodar vx-710 clinically applicable modulator p-glycoprotein pgp multidrug resistance protein mrp-1 ,administered intravenously biricodar dicitrate used combination cancer chemotherapy agent 
Implitapide,implitapide microsomal triglyceride transfer protein mtp -inhibitor , treatment atherosclerosis 
Binodenoson,binodenoson pharmacologic stress agent specific adenosine receptor necessary increased cardiac blood flow sub 2a /sub receptor specificity allows binodenoson deliver single injection effective dose medication fewer side effect current treatment typically require 15-20 minute infusion , cardiac pharmacologic stress spect imaging used diagnose coronary artery disease 
Febuxostat,febuxostat non-purine xanthine oxidase xo inhibitor a39743 early 2008 febuxostat granted marketing authorization european commission treatment chronic hyperuricemia gout a230548 following year fda approved febuxostat use chronic management hyperuricemia adult patient gout inadequate response intolerance allopurinol l32238 gout form arthritis caused accumulation uric acid crystal around joint leading inflammation deposition uric acid crystal deposition bone joint tissue organ long term gout closely associated hyperuricemia febuxostat work inhibiting activity enzyme responsible synthesis uric acid thereby reducing serum uric acid level a230548 february 2019 black box warning febuxostat added based finding post-market clinical study care trial increased risk cardiovascular cv fatal outcome patient gout known cardiovascular disease treated febuxostat compared treated allopurinol manufacturer fda advise health professional limit use febuxostat second-line therapy patient inadequate response intolerance allopurinol avoid use febuxostat patient cardiovascular disease a2742 l13056 ,febuxostat indicated chronic management hyperuricemia adult patient gout inadequate response maximally titrated dose allopurinol intolerant allopurinol treatment allopurinol advisable recommended treatment asymptomatic hyperuricemia l32238 secondary hyperuricemia a230583 
Dronedarone,dronedarone class iii antiarrhythmic drug work restore normal sinus rhythm patient paroxysmal persistent atrial fibrillation atrial fibrillation common sustained arrhythmia treatment primarily focus stroke prevention symptom management managed rate control rhythm control prevention thromboembolic event treatment underlying disease a34604 similar amiodarone dronedarone multichannel blocker work control rhythm rate atrial fibrillation a186071 meet criterion four vaughan williams antiarrhythmic drug class blocking sodium potassium calcium ion channel inhibiting β-adrenergic receptor a34604 l8699 dronedarone related benzofuran compound amiodarone chemical structure lack iodine moiety associated amiodarone-induced thyroid problem a34604 t28 additionally methyl sulfonyl group structure render dronedarone lipophilic shorter half-life amiodarone a34604 ultimately lead reduced tissue accumulation drug decreased risk organ toxicity thyroid pulmonary toxicity t28 commonly marketed multaq® dronedarone approved fda july 2009 health canada august 2009 safety concern risk drug-induced hepatocellular injury issued following marketing dronedarone l8800 ,dronedarone indicated management atrial fibrillation af patient sinus rhythm history paroxysmal persistent af reduce risk hospitalization l8699 
Dexloxiglumide,dexloxiglumide selective cholecystokinin type ccka receptor antagonist phase iii testing rottapharm europe u.s. trial discontinued d-isomer loxiglumide retains pharmacological property loxiglumide potent , treatment irritable bowel syndrome ibs gastroesophageal reflux disease gerd 
Brasofensine,brasofensine orally administered dopamine reuptake inhibitor developed treatment parkinson 's disease phase i/ii trial brasofensine completed u.k november 2001 neurosearch confirmed drug 's development discontinued favor n 2230 , treatment parkinson 's disease 
Tirapazamine,tirapazamine also known sr-4233 experimental anticancer drug activated hypoxic condition activation useful hypoxic state found human solid tumor common phenomenon known tumor hypoxia hence tirapazamine solely activated hypoxic area solid tumor important take consideration normally cell hypoxic region resistant radiotherapy anticancer drug reason combination tirapazamine anticancer treatment highly recommended tirapazamine entered phase iii testing 2006 patient head neck cancer gynecological cancer well solid tumor cancer type , treatment head neck cancer 
Zanapezil,zanapezil tak-147 selective acetylcholine ach esterase inhibitor investigation drug alzheimer 's disease ad treatment , treatment dementia subject alzheimer ’ disease 
Isatoribine,isatoribine selective agonist tlr7 , treatment hepatitis c 
Nebivolol,nebivolol racemic mixture 2 enantiomer one beta adrenergic antagonist act cardiac stimulant without beta adrenergic activity a182579 treatment nebivolol lead greater decrease systolic diastolic blood pressure atenolol propranolol pindolol a182579 nebivolol beta blocker generally first line therapy many patient first treated thiazide diuretic a182594 nebivolol granted fda approval 17 december 2007 l7985 ,nebivolol indicated treat hypertension a2762 a182579 l7985 l7988 
Merimepodib,merimepodib vx-497 novel noncompetitive inhibitor impdh merimepodib orally bioavailable inhibits proliferation primary human mouse rat dog lymphocyte concentration approximately 100 nm , treatment hepatitis c virus hcv infection 
Lefradafiban,lefradafiban oral platelet glycoprotein iib/iiia receptor antagonist investigated treatment angina , treatment unstable angina 
Huperzine A,huperzine naturally occurring sesquiterpene alkaloid found extract firmoss _huperzia serrata_ botanical used china century treatment swelling fever blood disorder recently clinical trial china demonstrated neuroprotective effect currently investigated possible treatment disease characterized neurodegeneration – particularly alzheimer ’ disease ,investigated use/treatment alzheimer 's disease 
Omacetaxine mepesuccinate,omacetaxine mepesuccinate formerly known hht homoharringtonine cephalotaxine ester protein synthesis inhibitor established clinical activity single agent hematological malignancy omacetaxine mepesuccinate synthesized cephalotaxine extract leaf plant cephalotaxus specie october 2005 omacetaxine mepesuccinate received orphan drug designation emea treatment chronic myeloid leukemia cml march 2006 received orphan drug status fda treatment cml november 2006 omacetaxine mepesuccinate treatment cml granted fast track designation fda recently october 2012 omacetaxine mepesuccinate marketed brand name synribo fda approved patient intolerant and/or resistant two tyrosine kinase inhibitor used treat accelerated chronic phase cml ,used patient intolerant and/or resistant two tyrosine kinase inhibitor used treat accelerated chronic phase cml 
Halofuginone,halofuginone low molecular weight quinazolinone alkaloid potent inhibitor collagen alpha1 matrix metalloproteinase 2 mmp-2 gene expression halofuginone also effectively suppresses tumor progression metastasis mouse collgard biopharmaceuticals developing halofuginone treatment scleroderma received orphan drug designation u.s. food drug administration march 2000 , treatment scleroderma cancer restenosis 
Lintitript,lintitript new highly specific potent cck-a receptor antagonist , treatment pancreatic cancer appetite disorder 
Nilotinib,nilotinib also known amn107 tyrosine kinase inhibitor investigation possible treatment chronic myelogenous leukemia cml phase clinical trial 2006 showed drug relatively safe offered significant therapeutic benefit case cml found resistant treatment imatinib gleevec another tyrosine kinase inhibitor used first-line treatment cml , potential treatment various leukemia including chronic myeloid leukemia cml 
Olcegepant,boehringer ingelheim pharmaceutical ’ olcegepant bibn 4096 selective calcitonin gene-related peptide cgrp antagonist new class drug development treatment acute migraine attack olcegepant undergoing phase ii trial europe u preliminary result suggesting cgrp antagonist may represent potential new approach treatment migraine , treatment migraine headache 
Oleoyl-estrone,oleoyl-estrone oe fatty acid ester estrone hormone occurs naturally found circulating various animal specie human shown animal study promote loss body fat maintaining body protein storage maintaining nitrogen balance body protein loss unpleasant effect fat loss restriction calorie study show drug appears avoid effect , treatment obesity 
Lorcaserin,lorcaserin previously apd-356 highly selective 5ht2c receptor agonist used treatment obesity shown reduce body weight food intake animal model obesity thought targeting 5ht2c receptor may alter body weight regulating satiety lorcaserin marketed salt form called belviq lorcaserin hydrochloride february 2020 fda issued drug safety communication requesting manufacturer belviq lorcaserin hydrochloride tablet 10 mg belviq xr lorcaserin hydrochloride extended-release tablet 20 mg voluntarily withdraw product u.s. market company submitted request voluntarily withdraw drug decision based result clinical trial assessing risk heart-related problem found patient treated lorcaserin may higher risk cancer l44042 l44047 , treatment obesity adjunct reduced-calorie diet increased physical activity 
Osanetant,developed sanofi-aventis formerly sanofi-synthelabo osanetant sr-142801 nk3 receptor antagonist development treatment schizophrenia central nervous system cns disorder review r portfolio company announced august 2005 would cease development osanetant follows earlier decision discontinue development eplivanserin schizophrenia ,potential therapy schizophrenia depression visceral pain 
Piboserod,piboserod sb 207266 selective 5-ht 4 receptor antagonist , treatment atrial fibrillation irritable bowel syndrome ibs 
Picoplatin,picoplatin cytotoxic platinum compound clinical development treatment patient solid tumor cause apoptosis cell death binding dna interfering dna replication transcription , treatment patient solid tumor 
Pralnacasan,pralnacasan orally bioavailable pro-drug potent non-peptide inhibitor interleukin-1beta converting enzyme ice , treatment rheumatoid arthritis ra 
Vildagliptin,vildagliptin laf237 orally active antihyperglycemic agent selectively inhibits dipeptidyl peptidase-4 dpp-4 enzyme used manage type ii diabetes mellitus glp-1 secretion insulinotropic effect impaired a232488 inhibiting dpp-4 vildagliptin prevents degradation glucagon-like peptide 1 glp-1 glucose-dependent insulinotropic polypeptide gip incretin hormone promote insulin secretion regulate blood glucose level elevated level glp-1 gip consequently result improved glycemic control l32803 clinical trial vildagliptin relatively low risk hypoglycemia a232488 oral vildagliptin approved european medicine agency 2008 treatment type ii diabetes mellitus adult monotherapy combination metformin sulfonylurea thiazolidinedione patient inadequate glycemic control following monotherapy marketed galvus l32803 vildagliptin also available eucreas fixed-dose formulation metformin adult adequately glycemic control monotherapy l32813 vildagliptin currently investigation u ,vildagliptin indicated treatment type ii diabetes mellitus adult monotherapy vildagliptin indicated adult inadequately controlled diet exercise alone metformin inappropriate due contraindication intolerance l32803 also indicated dual therapy combination metformin sulphonylurea thiazolidinedione adult patient insufficient glycemic control despite maximal tolerated dose monotherapy l32803 vildagliptin also marketed combination product metformin treatment adult type ii diabetes mellitus inadequately respond either monotherapy vildagliptin metformin fixed-dose formulation used combination sulphonylurea insulin i.e. triple therapy adjunct diet exercise adult achieve adequate glycemic control monotherapy dual therapy l32813 
Voacamine,voacamine alkaloid isolated bark _pescheria fuchsiae folia_ tree antimalarial drug approved use several african country voacamine also investigation use modulating multidrug-resistance tumor cell , treatment malaria also investigation modulation multidrug resistance cancer cell 
Voglibose,voglibose alpha-glucosidase inhibitor used lowering post-prandial blood glucose level people diabetes mellitus made india ranbaxy lab sold trade name volix , treatment diabetes specifically used lowering post-prandial blood glucose level thereby reducing risk macrovascular complication 
Vatalanib,vatalanib ptk787/zk-222584 new oral antiangiogenic molecule inhibits known vascular endothelial growth factor receptor vatalanib investigation treatment solid tumor ,used combination first- second-line chemotherapy treatment metastatic colorectal cancer non-small cell lung cancer nsclc 
Enoximone,enoximone selective phosphodiesterase inhibitor vasodilating positive inotropic activity cause change myocardial oxygen consumption used patient congestive heart failure trial halted u.s. drug used various country , treatment congestive heart failure 
Elacridar,elacridar gw120918 oral bioenhancer target multiple drug resistance tumor many case appearance multidrug resistance cancer due change expression protein inhibitor august 2007 elacridar listed gsk 's product pipeline development assumed discontinued , treatment solid tumor 
Edotecarin,edotecarin novel non-camptothecin dna topoisomerase inhibitor member class compound called indolocarbazoles ,clinical study edotecarin shown activity subject colorectal cancer esophageal cancer solid tumor 
Darusentan,darusentan selective endothelin eta receptor antagonist evaluated treatment congestive heart failure hypertension , treatment congestive heart failure hypertension 
Dapoxetine,dapoxetine selective serotonin reuptake inhibitor treatment premature ejaculation phase ii proof-of-concept study conducted ppd dapoxetine demonstrated statistically significant increase ejaculatory latency compared placebo alza submitted nda fda dapoxetine treatment premature ejaculation december 2004 october 2005 company received fda non-approvable letter fda time planned work regulator address outstanding question , treatment premature ejaculation 
Cilansetron,cilansetron 5ht-3 antagonist made solvay pharmaceutical currently trial phase eu u , treatment symptom associated irritable bowel syndrome 
Calanolide A,calanolide new non-nucleoside reverse transcriptase inhibitor nnrti derived plant found malaysian rain forest related compound calanolide b also anti-hiv activity drug developed sarawak pharmaceutical preliminary dosing study among hiv-infected individual showed significant antiviral effect compared placebo , use combination treatment hiv infection aid 
Brecanavir,brecanavir vx-385 orally active aspartic protease inhibitor pi investigation vertex glaxosmithkline treatment hiv july 2006 vertex indicated expected gsk initiate phase iii trial drug 2007 december 2006 gsk announced decision discontinue development brecanavir treatment hiv decision based issue regarding formulation drug , treatment hiv-1 infection combination antiretroviral agent 
Bifeprunox,bifeprunox novel atypical antipsychotic agent along slv313 aripiprazole ssr-181507 combine minimal d2 receptor agonism 5-ht receptor agonism ,bifeprunox evaluated treatment schizophrenia psychosis parkinson 's disease 
Bicifadine,bicifadine dov-220075 nonopioid analgesic inhibitor norepinephrine serotonin transporter nmda antagonist non-narcotic profile bicifadine shown potent analgesic activity vivo chosen development treatment pain , treatment pain 
Bepotastine,bepotastine non-sedating selective antagonist histamine 1 h1 receptor bepotastine approved japan use treatment allergic rhinitis uriticaria/puritus july 2000 january 2002 respectively marketed tanabe seiyaku co. ltd. brand name talion available oral opthalmic dosage form japan opthalmic solution fda approved since sept 8 2009 brand name bepreve , symptomatic treatment itchy eye caused ige-induced mast cell degranulation due allergic conjunctivitis 
Becocalcidiol,becocalcidiol vitamin 3 analogue caused hypercalcaemia significant irritation preclinical trial , topical treatment psoriasis psoriatic disorder 
Phenserine,phenserine development axonyx u biopharmaceutical company focus treatment dementia phenserine next generation acetylcholinesterase ache inhibitor indicated treatment ad unlike currently marketed ache inhibitor dual mechanism action also includes anti-amyloid activity may confer disease-modifying effect patient ad substantiated ongoing clinical trial phenserine may open door entirely new type treatment ad axonyx announced 20 september 2005 phenserine ineffective two curtailed phase 3 trial , treatment alzheimer 's disease ad 
AZD3409,azd3409 farnesyl-transferase inhibitor far indicated treatment solid tumor phase trial initiated january 2003 ongoing february 2004 february 2007 development azd3409 discontinued , treatment solid tumor 
Vapreotide,vapreotide synthetic octapeptide somatostatin analog studied treatment cancer , treatment esophageal variceal bleeding patient cirrhotic liver disease also shown efficacy treatment patient aids-related diarrhea 
Pegaptanib,pegaptanib polynucleotide aptamer pegatinib aid neovascular age-related macular degeneration binding vegf order reduces angiogenesis vessel permeability pegaptanib granted fda approval 17 september 2004 l17903 , treatment neovascular wet age-related macular degeneration 
Milnacipran,milnacipran selective serotonin norepinephrine reuptake inhibitor snri like many agent category originally developed continues approved indicated treatment depression f3928 f3934 a175786 a175951 furthermore 2009 u fda approved milnacipran additional indication treating fibromyalgia f3925 although regional regulatory authority like ema among others yet approved agent treatment citing lack robust evidence efficacy insufficient demonstration maintenance effect concern f3928 f3934 nevertheless milnacipran demonstrates somewhat unique characteristic among snris elicit relatively balanced reuptake inhibition serotonin noradrenaline somewhat increased preference noradrenaline reuptake inhibition potentially point interest given plausible proposal noradrenaline play important role mitigation pain signal descending inhibitory pain pathway brain spinal cord a175759 a175843 a175846 moreover recent research shown levorotatory enantiomer milnacipran levomilnacipran may capacity inhibit activity beta-site amyloid precursor protein cleaving enzyme-1 bace-1 investigationally associated β-amyloid plaque formation making agent possible course treatment alzheimer 's disease a175957 ,milnacipran selective serotonin norepinephrine reuptake inhibitor snri indicated management fibromyalgia patient 18 year old f3925 milnacipran may used treatment major depressive disorder mdd recommended adult patient 18 year old f3922 due increased risk suicidal ideation thinking behavior child adolescent young adult taking antidepressant major depressive disorder mdd psychiatric disorder regional prescribing information note use medication specifically short-term symptomatic relief mdd f3919 nevertheless important note regulatory approval and/or indication listed milnacipran may may exist and/or vary greatly region nation f3928 f3934 
Lucinactant,lucinactant new synthetic peptide-containing surfactant intratracheal use contains sinapultide novel hydrophobic 21-amino acid peptide leucine lysine repeating unit kl4 peptide designed mimic human surfactant protein-b sb-p specifically mimic c-terminal amphipathic helical domain protein also consists phospholipid dipalmitoylphosphatidylcholine dppc palmitoyloleoyl phosphatidylglycerol popg fatty acid palmitic acid completely devoid animal-derived component fda approved march 6 2012 ,intended prevention respiratory distress syndrome rds premature infant high risk rds 
Ximelagatran,ximelagatran anticoagulant intended become replacement warfarin overcoming dietary restriction drug interaction monitoring issue associated former 2006 manufacturer astrazeneca announced would attempt market ximelagatran report hepatotoxicity liver damage trial discontinue distribution country drug approved , treatment acute deep vein thrombosis 
Nesiritide,nesiritide medication used treat acutely decompensated congestive heart failure dyspnea rest minimal exertion talk eating bathing nesiritide 32 amino acid recombinant human b-type natriuretic peptide , intravenous treatment patient acutely decompensated congestive heart failure dyspnea rest minimal activity 
Thymalfasin,thymalfasin chemically synthesized version thymosin alpha 1 identical human thymosin alpha 1 thymosin alpha 1 acetylated polypeptide thymosin alpha 1 approved 35 developing country treatment hepatitis b c. also used boost immune response treatment disease ,indicated adjuvant influenza vaccine elderly patient adjuvant influenza hepatitis b vaccine chronic hemodialysis patient failed achieve adequate antibody titer previous immunization 
Galiximab,galiximab chimeric monoclonal antibody used immunosuppressive drug ,investigated use/treatment lymphoma non-hodgkin 's psoriasis psoriatic disorder bone metastasis multiple myeloma prostate cancer rheumatoid arthritis 
Pagoclone,pagoclone anxiolytic drug cyclopyrrolone family related well known drug sleeping medication zopiclone one relatively recently developed class medicine known nonbenzodiazepines similar effect older benzodiazepine group quite different chemical structure , potential treatment panic anxiety disorder 
Amolimogene,amolimogene investigational therapeutic designed specifically augment body 's defensive response human papillomavirus hpv amolimogene biologically engineered targeted therapy treatment cervical dysplasia ,intended treatment cervical dysplasia associated human papillomavirus hpv 
Tesmilifene,tesmilifene novel potentiator chemotherapy added doxorubicin achieved unexpected large survival advantage doxorubicin alone randomized trial advanced breast cancer ,intended treatment various form cancer 
Sitimagene ceradenovec,sitimagene ceradenovec novel gene-based product treatment patient operable high grade glioma type malignant brain tumour given addition standard surgery radiotherapy/chemotherapy developed ark therapeutic ,intended treatment brain cancer 
Flibanserin,flibanserin first drug approved hypoactive sexual desire disorder hsdd premenopausal woman fda august 2015 originally developed antidepressant medication boehringer ingelheim showed lack efficacy trial developed hypoactive sexual disorder drug sprout pharmaceutical flibanserin 's mechanism action attributed high affinity 5-hta1 5-hta2 receptor displaying agonist activity 5-hta1 antagonist 5-hta2 resulting lowering serotonin brain well effect increasing norepinephrine dopamine neurotransmitter , treatment hypoactive sexual desire disorder hsdd premenopausal woman 
Sitamaquine,sitamaquine wr-6026 orally active 8-aminoquinoline analog development walter reed army institute collaboration glaxosmithkline formerly smithkline beecham potential treatment visceral leishmaniasis ,investigated use/treatment infectious parasitic disease unspecified 
Oxibendazole,oxibendazole polymerase inhibitor phase iii trial treatment helminth intestinal infection ,investigated use/treatment infectious parasitic disease unspecified pediatric indication 
Oritavancin,oritavancin glycopeptide antibiotic used treatment skin infection developed medicine company acquired novartis l12858 oritavancin initially approved fda 2014 formulated combat susceptible gram-positive bacteria cause skin skin structure infection boast option single-dose administration proven non-inferior full course vancomycin therapy a39384 a193482 l8492 march 12 2021 fda approved kimyrsa complete course therapy single 1 hour 1200 mg infusion l32634 orbactiv fda approved oritavancin product administered 3 hour infusion contains lower dose 400 mg marketed melinta therapeutic kimyrsa offer effective time-efficient treatment skin skin structure infection l32629 ,oritavancin indicated treatment adult patient acute bacterial skin skin structure including subcutaneous infection used confirmed/suspected infection designated susceptible gram-positive organism l8492 two preparation oritavancin 400 mg dose administered 3 hour 1200 mg dose administered 1 hour indicated susceptible gram-positive skin skin structure infection adult l8492 l32629 antimicrobial susceptibility pattern geographically distinct local antibiograms consulted ensure adequate coverage relevant pathogen prior use 
Stannsoporfin,stannsoporfin competitive heme oxygenase ho inhibitor developed infacare subsidiary wellspring pharmaceutical prevention hyperbilirubinemia infant risk developing jaundice ,investigated use/treatment liver disease metabolic disease pediatric indication 
G17DT,g17dt vaccine neutralises gastrin-17 hormone required growth number cancer gastrointestinal tract phase iii trial advanced pancreatic cancer monotherapy combination gemcitabine also phase ii/iii trial advanced stomach cancer combination 5-fluorouracil cisplatin late phase ii trial advanced colorectal cancer combination irinotecan ,intended treatment various form cancer 
Idronoxil,idronoxil substance studied treatment cancer belongs family drug called signal transduction inhibitor ,intended treatment various form cancer 
Renzapride,renzapride currently phase iii clinical development united state treatment constipation-predominant irritable bowel syndrome ibs-c suggested renzapride effective treatment irritable bowel syndrome alternating stool pattern developed alizyme uk , treatment constipation-predominant irritable bowel syndrome ibs-c 
Ceftobiprole,ceftobiprole cephalosporin antibiotic activity methicillin-resistant staphylococcus aureus /i discovered basilea pharmaceutica developed johnson johnson pharmaceutical research development ceftobiprole first cephalosporin demonstrate clinical efficacy patient infection due methicillin-resistant staphylococci approved regulatory authority expected useful addition armamentarium agent treatment complicated skin infection pneumonia , treatment serious bacterial infection hospitalised patient 
Alfimeprase,alfimeprase recombinant analog fibrolase fibrolase zinc-containing metalloproteinase isolated venom southern copperhead snake agkistrodon contortrix contortrix /i small protein contains 203 residue randolph et al 1992 alfimeprase developed nuvelo ,alfimeprase evaluated potential treatment acute ischemic stroke catheter occlusion co acute peripheral arterial occlusion pao 
Clevidipine,clevidipine dihydropyridine l-type calcium channel blocker selective vascular smooth muscle indicated blood pressure reduction oral therapy option , reduction blood pressure oral antihypertensive therapy feasible desirable 
Dirucotide,dirucotide synthetically prepared peptide particular sequence prepared 17 amino acid chain identical section myelin basic protein mbp found human dirucotide developed treatment multiple sclerosis m developed university alberta dirucotide investigated bioms medical corp , treatment multiple sclerosis m 
rhThrombin,rhthrombin recombinant human thrombin developed zymogenetics inc. general aid achieving hemostasis surgery zymogenetics developing rhthrombin recombinant form human thrombin derived animal human blood aid controlling bleeding surgery thrombin used 1 million surgery year united state currently thrombin derived bovine blood available u.s. stand-alone thrombin product bovine-derived thrombin associated development antibody may cross-react human blood protein case antibody appear related serious bleeding complication production recombinant protein dependent availability blood animal human donor scaled-up meet market demand ,investigated use/treatment blood blood forming organ disorder unspecified hemorrhage 
Itopride,itopride dopamine d2 antagonist acetylcholinesterase inhibitory action ,investigated use/treatment gastrointestinal disease disorder miscellaneous 
Desmoteplase,desmoteplase chemical saliva vampire bat activates plasminogen serine protease plasmin plasmin act breaking fibrin blood clot vampire bat bite victim secretes enzyme prevents blood clotting enzyme called dspa desmodus rotundus salivary plasminogen activator scientist using dspa stroke heart attack medication desmoteplase recombinant form vampire bat dspa salivary plasminogen activator alpha 1 ,investigated use/treatment cerebral ischemia stroke 
Neramexane,neramexane low-to-moderate affinity uncompetitive nmda receptor antagonist ,investigated use/treatment alzheimer 's disease hearing loss pain acute chronic 
XP12B,xp12b developed xanodyne pharmaceutical treatment menorrhagia heavy menstrual bleeding granted fast track status indication fda november 2004 ,investigated use/treatment menstrual disorder 
DG031,dg031 decode genetics 's lead compound developed prevention myocardial infarction heart attack ,investigated use/treatment heart disease myocardial infarction 
Permethrin, pyrethroid insecticide commonly used treatment louse infestation scabies yellow light orange-brown low melt-ing solid viscous liquid , treatment infestation sarcoptes scabiei /i scabies 
Afamelanotide,afamelanotide first-in-class synthetic 13-amino acid peptide analogue endogenous alpha melanocyte-stimulating hormone α-msh l9086 differs structurally endogenous counterpart two amino acid structural difference improve biological efficacy imparting greater affinity target longer biological half-life a187202 a187205 afamelanotide currently approved drug therapy used management erythropoietic protoporphyria received approval eu december 2014 l9119 subsequent fda approval october 2019 l9092 despite relatively recent approval afamelanotide available use orphan drug u eu since 2008 l9122 l9125 ,afamelanotide indicated prevention phototoxicity adult patient erythropoietic protoporphyria epp l9086 
Defibrotide,defibrotide sodium salt mixture single-stranded oligodeoxyribonucleotides derived porcine mucosal dna shown antithrombotic anti-inflammatory anti-ischemic property without associated significant systemic anticoagulant effect marketed brand name dasovas fm noravid prociclide variety country usa approved march 2016 defitelio ,indicated treatment severe hepatic veno-occlusive disease vod also known sinusoidal obstruction syndrome so renal pulmonary dysfunction following hematopoietic stem-cell transplantation hsct label 
Eritoran,eritoran structural analogue lipid portion lipopolysaccharide lp developed eisai research institute boston treatment severe sepsis ,investigated use/treatment sepsis septicemia 
Rifalazil,rifalazil derivative antibiotic rifamycin investigated activbiotics treatment various bacterial infection ,investigated use/treatment atherosclerosis bacterial infection peripheral vascular disease 
Tagatose,tagatose functional sweetener naturally occurring monosaccharide specifically hexose commonly found dairy similar texture sweetened capacity sucrose third calorie approved food additive low calorie sweetener additionally investigation spherix treatment obesity type ii diabetes ,intended use therapeutic adjunct treatment type ii diabetes 
Ospemifene,ospemifene new selective non-hormonal estrogen receptor modulator serm used treatment moderate severe dyspareunia symptom vulvar vaginal atrophy due menopause fda approved february 26 2013 ,ospemifene indicated treatment moderate severe dyspareunia vaginal dryness associated menopause l35265 
Crofelemer,crofelemer previously known investigational drug sp-303 novel proanthocyanidin purified bark latex amazonian croton tree croton lechleri /i marketed brand name fulyzaq indicated symptomatic treatment non-infectious diarrhea adult patient hiv/aids taking antiretroviral therapy , symptomatic treatment non-infectious diarrhea adult patient hiv/aids taking antiretroviral therapy 
Tamibarotene,tamibarotene novel synthetic retinoid acute promyelocytic leukaemia apl tamibarotene currently approved japan treatment recurrent apl undergoing clinical trial united state ,investigated use/treatment leukemia unspecified 
LX201,lx201 silicone matrix ocular implant provides sustained release cyclosporine csa locally eye course one year lx201 implanted subconjunctivally beneath transparent membrane covering white eye minimally invasive procedure implant developed clinically prevention rejection corneal transplantation developed lux bioscience inc ,investigated use/treatment eye disorders/infections transplant rejection 
Acadesine,acadesine aica-riboside purine nucleoside analog anti-ischemic property currently studied phase 3 prevention adverse cardiovascular outcome patient undergoing coronary artery bypass graft cabg surgery developed jointly pericor schering-plough acadesine granted orphan drug designation b-cll eu ,investigated use/treatment cardiac reperfusion injury cardiovascular disorder coronary artery disease 
Hemoglobin, respiratory protein red blood cell consists primarily globin heme ,investigated use/treatment blood blood forming organ disorder unspecified hemorrhage 
Iloperidone,iloperidone atypical antipsychotic treatment schizophrenia symptom hoechst marion roussel inc. researched drug may 1996 june 1997 gave research right titan pharmaceutical gave worldwide development manufacturing marketing right novartis august 1998 june 9 2004 titan pharmaceutical gave phase iii development right vanda pharmaceutical fda approved may 9 2009 ,treatment acute schizophrenia 
Altropane,boston life science bls developing altropane potential radio-imaging agent used single photon emission tomography spect early diagnosis parkinson 's disease pd attention deficit hyperactivity disorder adhd ,investigated use/treatment attention deficit/hyperactivity disorder adhd parkinson 's disease pediatric indication 
Lofexidine,lofexidine non-opioid centrally acting alpha2-adrenergic receptor agonist first approved treatment opioid withdrawal united kingdom 1992 a33084 first studied use antihypertensive 1980 researched stopped found le effective treatment hypertension clonidine t210 lofexidine repurposed treatment opioid withdrawal seen economical fewer side effect clonidine t209 lofexidine developed u woldmeds llc approved fda may 16 2018 l2794 ,lofexidine indicated mitigation symptom associated acute withdrawal opioids facilitation completion opioid discontinuation treatment first non-opioid medication symptomatic management opioid discontinuation l2801 opioid withdrawal syndrome debilitating manifestation opioid dependence a33085 condition extremely unpleasant lasting several day main feature abdominal pain nausea diarrhea mydriasis lacrimation piloerection symptom often observed abrupt reduction opioid dose resolved re-administration opioid a33088 
Pexelizumab,pexelizumab humanized monoclonal antibody used immunosuppressive drug investigated alexion pharmaceutical , treatment inflammation cardiac surgery 
Ranpirnase,ranpirnase ribonuclease enzyme found rana pipiens /i oocyte studied treatment cancer manufactured alfacell corporation first ribonuclease enter cancer clinical trial , treatment various form cancer 
Pirfenidone,pirfenidone synthetic pyridone drug a251370 antifibrotic agent anti-inflammatory antioxidant property a251370 used treat idiopathic pulmonary fibrosis ipf l26801 chronic progressive form interstitial pneumonia a251370 mechanism action yet fully understood pirfenidone proposed primarily regulate tumor necrosis factor tnf pathway modulate cellular oxidation a251365 fda first approved pirfenidone alongside nintedanib one first drug treat ipf a251165 ,pirfenidone indicated treatment idiopathic pulmonary fibrosis ipf l26801 l26816 l42555 canada europe approved adult l26816 l42555 
Ramoplanin,ramoplanin novel glycolipodepsipeptide antibiotic development treatment cdad , treatment bacterial infection 
Ezogabine,ezogabine d23129 close structural analog centrally acting analgesic flupitrine neuronal potassium channel opener developed first-in-class antiepileptic drug aed currently studied phase 3 trial adjunctive treatment partial-onset seizure adult patient refractory epilepsy fda approved june 10 2011 name ezogabine ,adjuvant treatment partial-onset seizure 
Tecadenoson,tecadenoson novel selective a1 adenosine receptor agonist currently evaluated conversion paroxysmal supraventricular tachycardia psvt sinus rhythm developed cv therapeutic inc ,investigated use/treatment arrhythmia atrial fibrillation 
Pumactant,pumactant synthetic surfactant used treating respiratory distress syndrome neonate unique formulation naturally occurring phospholipid dipalmitoylphosphatidycholine dppc phosphatidyl glycerol pg ,investigated use/treatment asthma lung injury surgical adhesion 
Afelimomab,afelimomab also known fab 2 mak 195f anti-tnf-α monoclonal antibody administration 195f reduces concentration interleukin-6 patient sepsis ,investigated use/treatment sepsis septicemia 
Azimilide,azimilide investigational class iii anti-arrhythmic drug block fast slow component delayed rectifier cardiac potassium channel approved use country currently clinical trial united state ,investigated use/treatment arrhythmia atrial fibrillation 
Epratuzumab,epratuzumab humanized monoclonal antibody derived murine ig2a monoclonal antibody ll2 epb-2 agent may subsequently well matched use oncology treatment inflammatory autoimmune disorder lupus ,investigated use/treatment leukemia lymphoid lymphoma non-hodgkin 's systemic lupus erythematosus 
Verpasep caltespen,hspe7 recombinant chimeric protein composed heat shock protein 65 hsp65 _mycobacterium bovis_ human papilloma viral hpv protein e7 hsp65 similar member family protein elicits strong immune response may used design vaccine number different cancer e7 protein involved carcinogenesis anal cervical tumor represents tumor antigen may specifically targeted lymphocyte developed stressgen biotechnology corp ,investigated use/treatment anal dysplasia cervical dysplasia/cancer genital wart hiv infection infectious parasitic disease unspecified pediatric indication wart viral infection 
Tipifarnib,tipifarnib r-115777 substance studied treatment acute myeloid leukemia aml type cancer belongs family drug called farnesyltransferase inhibitor also called zarnestra june 2005 fda issued approvable letter zarnestra ,investigated use/treatment colorectal cancer leukemia myeloid pancreatic cancer solid tumor 
Troxacitabine,troxacitabine nucleoside analog antineoplastic activity growing interest development treatment patient refractory lymphoproliferative condition ,investigated use/treatment leukemia myeloid 
Bectumomab,bectumomab marketed trade name lymphoscan® mouse monoclonal antibody 's used treat non-hodgkin 's lymphoma radioisotope technetium 99m tc 's added ,investigated use/treatment lymphoma non-hodgkin 's 
rhGAD65,rhgad65 recombinant human glutamic acid decarboxylase vaccine developed treat insulin dependent type 1 diabetes ,investigated use/treatment diabetes mellitus type 1 
Oregovomab,oregovomab murine monoclonal antibody attache tumor-associated antigen ca125 ,investigated use/treatment ovarian cancer 
Lucanthone,one schistosomicides replaced largely hycanthone recently praziquantel martindale extrapharmacopoeia 30th ed. p46 currently tested radiation sensitizer ,intended use radiation sensitizer treatment brain cancer 
PH94B,ph94b developed pherin pharmaceutical inc. treatment social phobia generalized anxiety disorder member new family pharmaceutical compound called vomeropherins ,intended acute treatment social phobia 
NV1020,nv1020 genetically engineered herpes simplex virus novel anticancer therapeutic ,intended treatment various form cancer 
Lesopitron,lesopitron anxiolytic pre- post-synaptic 5-ht1a agonist activity development esteve ,intended treatment anxiety disorder 
Reglitazar,"reglitazar isoxazolidine-3,5-dione derivative developed pfizer treatment diabetes first non-thiazolidenedione enter clinical trial ", treatment diabetes mellitus type 1 2 
Canfosfamide,canfosfamide active agent chemotherapy-resistant ovarian cancer ,intended treatment various form cancer 
LErafAON,neopharm developing liposome-encapsulated c-raf antisense oligodeoxynucleotides lerafaon potential treatment various solid tumor including become resistant radiation chemotherapy phase i/ii trial commenced march 2001 ongoing june 2003 ,intended treatment various form cancer 
Rimiducid,rimiducid lipid-permeable tacrolimus analogue protein dimerizer designed overcome limitation current cellular immunotherapy used cancer blood disorder enhancing control immune cell activity function administered via chemically-inducible dimerization cid technology rimiducid bind switch protein dimerizes triggering downstream signaling cascade a187496 l9521 combination use rimiducid immunotherapy enhanced therapeutic effectiveness currently investigation ,investigated use/treatment bone marrow transplant graft versus host disease 
Banoxantrone,banoxantrone highly selective bioreductive drug activated preferentially toxic hypoxic cell tumour shown work synergistically fractionated radiation significantly delay growth tumour compared administration either banoxantrone radiation alone banoxantrone also efficacious tumour model administered combination either cisplatin chemoradiation a3115 , treatment various form cancer 
M40403,m40403 low molecular weight synthetic manganese containing superoxide dismutase mimetic sodm selectively remove superoxide anion ,intended treatment pain possibly various form cancer 
Plitidepsin,aplidine peptide found tunicate show promise shrinking tumor pancreatic stomach bladder prostate cancer specific marine organism _aplidium albicans_ aplidine also interest potential treatment leukemia ,intended treatment various form cancer 
SP1049C,sp1049c novel anthracycline chemotherapeutic agent designed overcome drug resistance number cancer successfully completed phase 1 trial phase 2 result currently final review preliminary data first clinically tested indication show sp1049c active stage iv non-resectable adenocarcinoma oesophagus median survival encouraging correlate strongly dose level ,intended treatment carcinoma oesophagus 
AVR118,avr118 represents new type biopolymer chemistry also posse novel immunomodulator activity non-toxic peptide-nucleic acid date shown indication human toxicity appears stimulate proinflammatory response required combat viral infection aid human papilloma virus dampen aberrant autoimmune-type inflammatory response avr118 studied promise shown ability mitigate toxic side effect drug including used treat hiv infection chemotherapeutic drug employed treatment cancer ability stimulate immune system attack tumor cell especially cancer cell damaged chemotherapeutic agent ability treat cachexia wasting patient aid cancer ,
Lemuteporfin,lemuteporfin development qlt incorporated benzoporphyrin-derived chlorin-like photosensitizer intended treatment beign prostatic hyperplasia ,intended treatment benign prostatic hyperplasia prostrate disorder 
CG7870,cg7870 oncolytic virus therapy prostate cancer replication-selective prostate-specific antigen-targeted oncolytic adenovirus treatment hormone-refractory metastatic prostate cancer ,intended treatment various form cancer 
Talampanel,talampanel substance studied treatment brain tumor brain disorder epilepsy parkinson disease type ampa receptor antagonist , treatment epilepsy 
Denufosol,denufosol inhaled drug used treatment cystic fibrosis cf showing various improvement lung function phase iii clinical trial new drug application nda filed fda 2011 however second phase iii clinical trial showed lack improvement lung function cystic fibrosis patient taking denufosol drug also evaluated treatment retinal detachment disease retina denufosol gained fda approval clinical trial drug ceased since 2011 , use inhaled treatment cystic fibrosis 
Tigapotide,tigapotide synthetic 15-mer peptide derived natural sequence amino acid prostate secretory protein psp94 one three predominant protein found human seminal fluid , treatment late stage hormone refractory prostate cancer hrpc effective therapy currently exists 
ZYC300,zyc300 plasmid dna cyp1b1 encapsulated biodegradable poly-dl-lactide-coglycolide microparticles designed vaccine intended increase immune system sensitivity cyp1b1 enzyme highly prevalent tumor cell , treatment various form cancer 
P113D,p113d novel 12 amino-acid antimicrobial peptide drug derived histatins compound found naturally human saliva pursued potential treatment cystic fibrosis demegen inc , potential treatment cystic fibrosis bacterial infection 
IGN311,ign311 humanized monoclonal antibody mab lewis carbohydrate antigen blood-group-related oligosaccharide ,intended treatment various form cancer 
Ty800,ty800 vaccine designed offer rapid oral single-dose protection salmonella typhi /i cause typhoid fever ty800 vaccine developed using genetic technique delete specific gene known essential virulence typhi /i developed avant immunotherapeutics inc , production immunity salmonella typhi /i cause typhoid fever 
XL784,xl784 potent inhibitor adam-10 metalloprotease enzyme target significant interest important role blood vessel formation cell proliferation xl784 specifically optimized mmp-1 sparing thus potentially enhancing safety profile enabling higher dosing compared previously studied metalloprotease inhibitor result single dose phase clinical trial xl784 administered orally 96 healthy volunteer demonstrated xl784 attractive safety pharmacokinetic profile developed exelixis inc , treatment patient diabetes clinically significant proteinuria 
AP5346,ap5346 designed target diaminocyclohexane platinum pt moiety tumor ph-sensitive linkage 25 kda hydroxypropylmethacrylamide polymer pursued access pharmaceutical inc , treatment various form cancer 
AT1022,at1022 hydromorphone skin patch designed provide rapid sustained delivery potent opiate management severe pain at1022 incorporates passport tm system developed deliver protein peptide drug small-molecule drug gene vaccine across skin local systemic effect ,investigated use/treatment pain acute chronic 
Satraplatin,satraplatin platinum compound currently investigation one treatment patient advanced prostate cancer failed previous chemotherapy investigation drug yet received u.s. food drug administration fda approval available retail pharmacy ,investigated use/treatment lung cancer prostate cancer solid tumor 
ATL1102,atl1102 second-generation antisense inhibitor cd49d immunesystem protein known vla-4 immune cell molecule work entering cell targeting gene ,investigated use/treatment asthma multiple sclerosis 
AGRO100,agro100 oligonucleotide function aptamer bind nucleolin protein found intranuclear cell uniquely expressed surface tumor cell binding lead internalization complex strong anti-proliferative response tumor cell pre-clinical testing demonstrates agro100 inhibition nucleolin function produce anti-cancer effect multiple type disease including lung prostate breast cervical colon cancer well malignant melanoma leukemia ,investigated use/treatment cancer/tumors unspecified kidney cancer leukemia myeloid pancreatic cancer 
MBO7133,mb07133 hepdirect prodrug activated form cytarabine arac anti-cancer drug used treat leukemia ineffective primary liver cancer arac 's anti-cancer activity associated ability converted biologically active form aractp however arac slowly converted aractp liver primary liver tumor due low level enzyme liver required conversion arac aracmp first step activation pathway drug higher dos arac used overcome limitation due bone marrow toxicity resulting rapid activation tissue mb07133 us hepdirect technology target prodrug form aracmp specifically liver liver cell prodrug rapidly cleaved producing aracmp bypassing rate-limiting enzyme generated target tissue aracmp rapidly converted aractp cancer-killing active form ,investigated use/treatment liver cancer 
AeroLEF,aerolef™ aerosolized liposome-encapsulated fentanyl novel proprietary inhalation formulation free liposome-encapsulated fentanyl intended provide rapid extended personalized analgesia patient experiencing acute pain episode aerolef™ development treatment moderate severe pain including cancer pain ,investigated use/treatment pain acute chronic 
PSN9301,psn9301 oral small molecule inhibitor dipeptidyl peptidase iv dp-iv developed treatment type 2 diabetes psn9301 rapid onset relatively short duration action available pre-clinical clinical data indicate may ideal product candidate meal-related dosing ,investigated use/treatment diabetes mellitus type 1 2 
Imexon,imexon currently studied treatment pancreatic lung breast prostate melanoma multiple myeloma cancer belongs family drug called cyanoaziridine derivative also called amplimexon imexon cyanoaziridine derivative imexon thiol-binding small molecule induces mitochondrial oxidation loss membrane potential cytochrome c leading apoptosis ,investigated use/treatment melanoma multiple myeloma ovarian cancer pancreatic cancer solid tumor 
Peptide YY (3-36),peptide yy 3-36 synthetic human pyy 3-36 compound evaluated treatment obesity reduces appetite increase satiety obese patient ,investigated use/treatment metabolic disease obesity 
Adecatumumab,adecatumumab recombinant human monoclonal antibody igg1 subclass binding specificity epithelial cell adhesion molecule epcam epcam cd326 cell surface protein frequently expressed high level solid tumor type including prostate breast colon gastric ovarian pancreatic lung cancer ,investigated use/treatment breast cancer prostate cancer 
Apadenoson,apadenoson selective a2a adenosine receptor agonist designed use pharmacologic stress agent cardiac perfusion imaging study developed bristol-myers squibb phase ii clinical trial ,investigated use/treatment cardiovascular disorder inflammatory disorder unspecified 
SGS-742,sgs-742 used trial studying treatment seizure metabolic disease ,investigated use/treatment alzheimer 's disease attention deficit/hyperactivity disorder adhd memory loss schizophrenia schizoaffective disorder 
Taberminogene vadenovec,taberminogene vadenovec eg004 novel product consisting local delivery device gene-based medicine developed prevent blocking vein artery frequently occurs vascular surgery initial target market haemodialysis graft access surgery procedure patient whose kidney failed plastic tube grafted blood vessel generally forearm blood regularly filtered using dialysis machine eg004 completed phase ii trial first part phase ii/iii study received approval u recombinant dna advisory committee rac ,investigated use/treatment cardiovascular disorder kidney disease 
XEN-2174,xen-2174 synthetic drug modeled peptide venom cone shell found australia 's great barrier reef xen-2174 represents new class molecule called chi conopeptides selectively inhibit norepinephrine transporter net net primary mechanism regulating biological effect norepinephrine ne body episode pain inhibition net xen-2174 elevates level ne leading activation inhibitory pathway preventing pain signal reaching brain , treatment chronic cancer pain 
Ingenol mebutate,ingenol mebutate approved fda january 2012 marketed name picato® picato gel indicated topical treatment actinic keratosis approval ingenol mebutate called pep005 investigational drug pep005 selective small molecule activator protein kinase c pkc extracted plant euphorbia peplus whose sap used traditional medicine treatment skin condition including wart cancer pep005 also potent anti-leukemic effect inducing apoptosis myeloid leukemia cell line primary aml cell nanomolar concentration , topical treatment actinic keratosis 
XL999,xl999 potential provide benefit patient lung cancer acute myelogenous leukemia xl999 new chemical entity inhibits spectrum receptor tyrosine kinase rtks growth promoting angiogenic property including fgfr 1/3 pdgfrα/β vegfr2/kdr kit flt3 xl999 also inhibits flt4 src xl999 potential prevent tumor growth — directly novel effect tumor cell proliferation indirectly inhibition host angiogenic response xl999 induces cell-cycle block mechanism distinct previously identified exhibit broad antitumor activity xenograft model ,investigated use/treatment cancer/tumors unspecified lung cancer solid tumor 
Belinostat,belinostat novel agent inhibits enzyme histone deacetylase hdac sulfonamide-hydroxamide structure developed orphan drug target hematological malignancy solid tumor topotarget safety efficacy belinostat currently evaluated use combination traditional front-line therapy treatment ptcl intravenous administration agent available beleodaq monotherapy dosing regimen involves 21-day cycle us-approved july 2014 therapeutic agent relapsed refractory peripheral t-cell lymphoma ,belinostat indicated treatment patient relapsed refractory peripheral t-cell lymphoma ptcl manageable safety profile potential alternative therapy patient experience adequate response first-line drug ptcl used patient baseline thrombocytopenia a19161 
Ataluren,ataluren novel orally administered drug target nonsense mutation ataluren approved use european medicine agency treat duchenne muscular dystrophy patient aged 5 year older able walk specifically ataluren used small group patient whose disease caused specific genetic defect called ‘ nonsense mutation ’ dystrophin gene drug yet approval u food drug administration health canada indication ,ataluren approved use european medicine agency treat duchenne muscular dystrophy patient aged 5 year older able walk specifically ataluren used small group patient whose disease caused specific genetic defect called ‘ nonsense mutation ’ dystrophin gene 
YSIL6,ysil6 small-molecule drug development treatment inflammatory disease including rheumatoid arthritis psoriasis molecule work inhibiting tnf-alpha il-6 production t-cells macrophage inhibiting t-cell proliferation migration ,investigated use/treatment crohn 's disease psoriasis psoriatic disorder rheumatoid arthritis 
Migalastat,"fabry disease rare progressive genetic disorder characterized defective gla gene cause deficiency enzyme alpha-galactosidase alpha-gal fda label f1107 l4274 l4263 enzyme responsible breaking glycosphingolipid substrate deficient patient fabry disease build blood vessel kidney nerve heart organ fda label f1107 l4274 l4278 u.s. estimated 3,000 people living fabry disease estimated 50 percent diagnosed patient currently untreated l4274 migalastat approved sold amicus therapeutic brand name galafold subsequently oral pharmacological chaperone alpha-gal treatment fabry disease adult amenable gla variant fda label f1107 l4274 l4278 patient migalastat work stabilizing body ’ dysfunctional alpha-gal enzyme clear accumulation glycosphingolipid disease substrate fda label f1107 l4274 l4278 globally estimated approximately 35 50 percent fabry patient may amenable gla variant treatable migalastat l4274 given rarity fabry disease proportion fabry disease patient could benefit migalastat therapy amicus therapeutic brand name galafold approved using accelerated approval pathway fda may approve drug serious condition unmet medical need drug shown certain effect reasonably likely predict clinical benefit patient fda label f1107 l4274 l4278 study required verify describe clinical benefit galafold sponsor conducting confirmatory clinical trial galafold adult fabry disease fda label f1107 l4274 l4278 additionally galafold alzo granted priority review designation fda ’ goal take action application within six month application filing agency determines drug approved would provide significant improvement treating diagnosing preventing serious condition available therapy fda label f1107 galafold also received orphan drug designation provides incentive assist encourage development drug rare disease fda label f1107 august 2018 migalastat amicus therapeutic brand name galafold currently approved australia canada european union israel japan south korea switzerland united state ",migalastat alpha-galactosidase alpha-gal pharmacological chaperone indicated long-term treatment adult adolescent aged 16 year older confirmed diagnosis fabry disease alpha-galactosidase deficiency amenable galactosidase alpha gene gla mutation/variant based upon vitro assay data fda label f1107 indication approved u fda accelerated approval based reduction kidney interstitial capillary cell globotriaosylceramide kic gl-3 substrate fda label continued approval u fda indication may contingent upon verification description clinical benefit ongoing confirmatory trial fda label 
LC16M8,lc16m8 next-generation attenuated smallpox vaccine designed better safety profile yet equally effective compared conventional smallpox vaccine attenuated vaccine licensed use human prevent smallpox infection ,investigated use/treatment viral infection 
Besifovir dipivoxil,besifovir dipivoxil small-molecule orally available inhibitor hbv polymerase hbv polymerase enzyme catalyzes production new rna existing strand rna besifovir dipivoxil believed inhibit viral proliferation interrupting replicating machinery virus ,investigated use/treatment hepatitis viral b 
EMZ702,emz702 non-toxic agent strong anti-viral synergy interferon ideal candidate combination current standard hepatitis c treatment emz702 excellent safety profile combination emz702 interferon ribavirin surrogate model hepatitis c demonstrated two three fold increase anti-viral potency compared interferon ribavirin alone ,investigated use/treatment hepatitis viral c 
Amonafide,amonafide substance studied treatment cancer belongs family drug called topoisomerase inhibitor intercalating agent ,investigated use/treatment breast cancer ovarian cancer prostate cancer 
ATL1101,atl1101 second-generation antisense drug designed block synthesis igf-1 receptor protein involved regulation cell overgrowth psoriasis atl1101 developed cream topical treatment mild moderate case psoriasis ,investigated use/treatment psoriasis psoriatic disorder 
CTA018,cta018 member new class vitamin analogue dual mechanism action called vitamin signal amplifier proprietary new drug potent inhibitor cyp24 enzyme responsible breakdown vitamin potent activator vitamin signaling pathway cta018 first drug novel dual mechanism action enter clinical development preclinical study shown cta018 inhibits proliferation rapidly dividing cell human epidermal keratinocytes skin cell also effective inhibiting pro-inflammatory cytokine secretion may involved etiology psoriasis cytochroma anticipates cta018 potent currently marketed vitamin analogue calcitriol calcipotriol expected greater safety index ,investigated use/treatment kidney disease psoriasis psoriatic disorder 
Arimoclomol,arimoclomol experimental drug compound developed cytrx corporation biopharmaceutical company based los angeles california orally administered drug intended treat amyotrophic lateral sclerosis al also known lou gehrig 's disease neurodegenerative disease effective treatment ,investigated use/treatment amyotrophic lateral sclerosis al diabetes mellitus type 2 neurologic disorder neuropathy diabetic 
DG041,dg041 novel first-in-class orally-administered small molecule developmented prevention arterial thrombosis complication dg041 anti-platelet compound shown selective potent antagonist ep3 receptor prostaglandin e2 ep3 target associate increased risk various vascular disease block formation blood clot mediated inflammation atherosclerotic plaque without increasing bleeding risk ,investigated use/treatment peripheral vascular disease 
Lancovutide,lancovutide peptide antibiotic clinical development treatment cystic fibrosis lancovutide 19-amino-acid tetracyclic peptide produced streptoverticillium cinnamoneus closely related cinnamycin ro09-0198 belongs lantibiotics lantibiotics bacteriocins characterized presence high proportion unusual amino acid ,investigated use/treatment cystic fibrosis eye disorders/infections 
REV131,rev131 development allergic rhinitis asthma several inflammatory eye disease topically delivered small protein act anti-inflammatory agent ,investigated use/treatment allergic reaction allergic rhinitis cataract 
INCB7839,incb7839 novel orally available adam metalloprotease inhibitor designed block activation epidermal growth factor egfr pathway represents potentially important new class targeted breast cancer therapy shown promising clinical activity heavily pretreated refractory breast cancer patient ,investigated use/treatment breast cancer 
Ularitide,ularitide synthetic form urodilatin naturally occurring human natriuretic peptide involved regulating blood pressure excretion water sodium kidney urodilatin produced kidney excreted urine thus exists low level naturally systemic blood circulation injected blood ularitide appears cause diuresis urine output natriuresis sodium excretion well vasodilation ularitide currently phase 2 development potential treatment patient acute decompensated heart failure adhf ,investigated use/treatment congestive heart failure 
Eprotirome,eprotirome compound promising property treatment obesity dyslipidemia eprotirome increase body ’ energy consumption reduces body weight markedly reduces blood lipid blood glucose ,investigated use/treatment hyperlipidemia metabolic disease obesity 
Grn163l,grn163l novel anti-cancer drug characterized preclinically shown inhibit telomerase human tumor cell many cancer type including lung breast prostate liver early stage human breast cancer cell culture system animal model study drug show potential utility treatment patient hematologic solid tumor malignancy ,investigated use/treatment leukemia lymphoid solid tumor 
Anatibant,anatibant selective potent small-molecule bradykinin b2 receptor antagonist developed treatment traumatic brain injury tbi ,investigated use/treatment traumatic brain injury 
Indacaterol,indacaterol novel ultra-long-acting rapid onset β 2 -adrenoceptor agonist developed novartis once-daily management asthma chronic obstructive pulmonary disease approved european medicine agency ema 30 november 2009 fda 1 july 2011 marketed europe onbrez america arcapta neohaler indacaterol provided maleate salt form indacaterol also chiral molecule pure r-enantiomer dispensed , long term once-daily-dosing maintenance airflow obstruction patient chronic obstructive pulmonary disease copd including chronic bronchitis and/or emphysema 
MVA3000,mva3000 attenuated smallpox vaccine developed use people traditional smallpox vaccine contraindicated patient disorder immune system skin condition eczema ,investigated use/treatment viral infection 
SGS518,sgs518 novel antagonist 5ht6 subtype serotonin receptor developed treatment cognitive impairment associated schizophrenia cia ,investigated use/treatment neurologic disorder schizophrenia schizoaffective disorder 
GSK159797,gsk159797 '797 inhaled longer-acting beta2 agonist developed treatment respiratory disease asthma copd ,investigated use/treatment asthma chronic obstructive pulmonary disease copd 
PSN357,psn357 glycogen phosphorylase inhibitor gpi designed rapidly lower blood glucose level preventing glycogen breakdown glucose liver ,investigated use/treatment diabetes mellitus type 2 
Obinepitide,obinepitide synthetic analogue two natural human hormone pyy pancreatic polypeptide normally released meal hormone known play role regulation food intake appetite man satiety signal gi-tract cns obinepitide property hormone implanted single molecule ,investigated use/treatment obesity 
V1003,v1003 intranasal formulation buprenorphine opiate analgesic management post-operative pain hospital home setting buprenorphine well-known analgesic intranasal formulation potential provide convenient alternative treatment allowing patient manage post-operative pain prior discharge hospital home recovery period ,investigated use/treatment pain acute chronic 
CX-717,cx-717 ampakine compound previously investigated treatment attention-deficit/hyperactivity disorder adhd alzheimer 's disease ,investigated treatment attention-deficit/hyperactivity disorder adhd alzheimer 's disease 
Cannabinor,cannabinor synthetic cb2-selective agonist phase 2 clinical testing analgesic ,investigated use/treatment pain acute chronic 
DDP733,ddp733 oral prokinetic drug dynogen developing treatment irritable bowel syndrome constipation ibs-c nocturnal gastroesophageal reflux disease ngerd partial agonist serotonin type 3 receptor 5-ht3 serotonin neurotransmitter known involved control gastrointestinal gi system preclinical study ddp733 established compound ’ prokinetic property ability promote motility gi tract ,investigated use/treatment constipation gastroesophageal reflux disease gerd gastrointestinal disease disorder miscellaneous irritable bowel syndrome ibs 
ADL5859,adl5859 novel oral compound target delta opioid receptor delta receptor agonist thought offer benefit approach management pain ,investigated use/treatment pain acute chronic 
BZL101,bzl101 oral drug designed treatment advanced breast cancer novel mechanism action bzl101 target diseased cell leaving normal cell healthy intact ,investigated use/treatment breast cancer 
MF101,mf101 novel estrogen receptor beta erβ selective agonist unlike currently available hormone therapy activate estrogen receptor alpha erα known implicated tumor formation mf101 oral drug designed treatment hot flash night sweat peri-menopausal menopausal woman ,investigated use/treatment hormone replacement therapy menopause menopause 
MB-07803,mb07803 second generation gluconeogenesis inhibitor treatment type 2 diabetes designed block metabolic pathway liver responsible producing glucose ,investigated use/treatment diabetes mellitus type 2 
AN0128,an0128 novel compound contains boron atom within borinic acid complex an0128 broad spectrum activity wide variety gram positive bacteria including many known skin colonizer particular importance p. acne causal role acne vulgaris rise antibiotic resistance p. acne standard antibiotic necessitates development new treatment agent an0128 good candidate topical antibiotic currently developed anacor novel therapeutic acne atopic dermatitis ,investigated use/treatment acne atopic dermatitis pediatric indication psoriasis psoriatic disorder 
RG2417,rg2417 proprietary formulation uridine biological compound essential synthesis dna rna basic hereditary material found cell numerous factor essential cell metabolism uridine synthesized mitochondrion power plant human cell responsible energy metabolism rationale uridine therapy neuropsychiatric disorder supported preclinical clinical research recent report indicate certain gene encode mitochondrial protein significantly regulated brain bipolar patient new insight suggests symptom bipolar disorder may linked dysregulation energy metabolism brain ,investigated use/treatment bipolar disorder manic disorder 
EGS21,egs21 tm beta-d-glucosylceramide gc compound potential therapeutic treating immune mediated disorder gc glycolipid shown enzo scientist collaborator act anti-inflammatory agent animal model system therefore evaluated important candidate drug treatment various immune mediated disease crohn 's disease hepatitis non-alcoholic steatohepatitis nash fatty liver hiv ,investigated use/treatment crohn 's disease hepatitis unspecified liver disease 
Erdosteine,erdosteine drug cause breakdown mucus also known _mucolytic_ agent _thiol_ derivative produced clinical management chronic obstructive bronchitis addition infective exacerbation chronic bronchitis drug contains sulfhydryl group released erdosteine undergoes hepatic first pas metabolism three active metabolite result posse mucolytic activity addition free radical scavenging activity erdosteine act control mucus production control viscosity increasing mucociliary transport also combat effect free radical resulting cigarette smoke erdosteine shown safe well tolerated clinical trial erdosteine 300mg twice daily reduced cough frequency severity sputum viscosity quickly effectively placebo reduced adhesivity sputum effectively ambroxol 30mg twice daily co-administration erdosteine amoxicillin patient acute infective exacerbation chronic bronchitis resulted higher concentration antibiotic sputum leading earlier pronounced amelioration clinical symptom compared placebo erdosteine associated low incidence adverse event gastrointestinal generally mild ,fro treatment chronic bronchitis adult 
ILY101,ily101 metal-free non-absorbed polymeric drug designed selective binding removal phosphate anion gastrointestinal tract ily101 developed treatment hyperphosphatemia ckd patient dialysis work reducing systemic absorption dietary phosphate ily101 designed allow lower daily dos improved patient acceptance tolerability comparison product class drug ,investigated use/treatment kidney disease 
R1626,r1626 one new class hepatitis c therapy called polymerase inhibitor achieves significant reduction viral load chronic hepatitis c patient infected difficult treat genotype 1 virus r1626 effective inhibiting viral replication,investigated use/treatment hepatitis viral c 
GFT14,gft14 new class medicaction treatment cardiometabolic disease gft14 aim target mixed dyslipidemia type iib high level triglyceride ldl-c one major indication cardiometabolic disease gft14 destined improve condition patient risk cardiovascular disease simultaneous favorable action plasmatic lipid rise hdl- cholesterol et lowering triglyceride risk factor hypertension diabetes orally absorbed gft14 absolutely structural link current treatment dyslipidemia statin fibrate based risk medical interaction weak gft14 may easily combined statin antidiabetic molecule glitazones ,investigated use/treatment cardiovascular disorder hyperlipidemia 
Mitoquinone,mitoquinone based novel technology targeted lipophilic cation transport concentrate antioxidant mitochondrion -- organelle inside cell provide energy life process -- accumulate thousand fold 2004 genomic study hereditary early-onset parkinson 's disease demonstrated direct molecular link mitochondrial dysfunction pathogenesis parkinson 's disease mitochondrial dysfunction also shown represent early critical event pathogenesis sporadic form parkinson 's disease clinical study parkinson 's study group show high dos antioxidant called coenzyme q mitoquinone effectively target mitochondrion appear slow progression parkinson 's disease symptom ,investigated use/treatment hepatitis viral c parkinson 's disease 
INCB13739,incb13739 developed new treatment type 2 diabetes orally available small molecule inhibitor 11beta-hsd1 11-beta hydroxysteroid dehydrogenase type 1 11beta-hsd1 enzyme appears critical development type 2 diabetes ,investigated use/treatment diabetes mellitus type 2 diabetes prevention 
ATG002,atg002 completely new approach treating chronic wound diabetic foot ulcer based upon stimulation angiogenesis wound bed help drive wound-healing process unlike protein-derived growth factor atg002 small molecule applied topically effectively penetrates wound surrounding tissue ,investigated use/treatment diabetic foot ulcer wound 
ATG003,atg003 novel anti-angiogenic drug candidate formulation mecamylamine currently clinical development neovascular age-related macular degeneration ,investigated use/treatment macular degeneration 
ADX10059,adx10059 metabotropic glutamate receptor 5 mglur5 negative allosteric modulator nam orally available small molecule drug candidate highly specific mglur5 discovered addex 2003 developed treatment gerd migraine anxiety ,investigated use/treatment anxiety disorder gastroesophageal reflux disease gerd migraine cluster headache 
ACE393,ace393 injectable vaccine designed combat bacterium campylobacter jejuni one greatest cause bacterial diarrhoeal infection developed world ,investigated use/treatment diarrhea infectious parasitic disease unspecified 
AV608,av608 nk-1 antagonist developed treatment social anxiety disorder sad irritable bowel syndrome ibs overactive bladder oab ,investigated use/treatment anxiety disorder irritable bowel syndrome ibs urinary incontinence 
TG-100801,tg100801 topically applied kinase inhibitor macular degeneration patient administered noninvasively eye drop designed suppress vegf mediated leakage additional kinase target associated inflammation edema angiogenesis pathological hallmark amd back eye disease including diabetic macular edema proliferative diabetic retinopathy ,investigated use/treatment macular degeneration 
Fenretinide, synthetic retinoid used orally chemopreventive prostate cancer woman risk developing contralateral breast cancer also effective antineoplastic agent ,investigated use/treatment macular degeneration 
SLV319,slv319 belongs novel class agent called cb1 antagonist work blocking cannabinoid type 1 cb1 receptor developed treatment obesity metabolic disorder ,investigated use/treatment obesity 
AER001,aer001 il4/13 receptor antagonist severe asthma eczema currently phase 2 study ,investigated use/treatment asthma 
HY10275,hy10275 novel compound specifically designed modulate two key neurobiological mechanism interfere sleeping process hy10275 highly selective histamine h1 serotonin 5ht2a two chemical receptor known impact ability fall asleep stay asleep hy10275 rationally designed `` let sleep '' rather depress entire brain `` make sleep '' dual-acting receptor activity lack affinity undesired off- target receptor thought account compound excellent efficacy tolerability profile ,investigated use/treatment insomnia 
OBE101,obe101 new weight loss drug developed obecure ltd new formulation based vertigo medication betahistine obecure repurposing betahistine h1 receptor agonist partial h3 receptor antagonist treatment obese individual weight management indication ,investigated use/treatment adverse effect drug hyperlipidemia obesity 
JB991,jb991 cyclopentenone prostaglandin analogue intended treatment psoriasis drug exerts marked antiproliferative pro-apoptotic effect human keratinocytes fibroblast vitro addition closely related cyclopentenone prostaglandin analogue shown exert marked anti-inflammatory effect vivo animal model drug applied topically skin ,investigated use/treatment psoriasis psoriatic disorder skin infections/disorders 
ARX201,arx201 peg-ahgh recombinant form human growth hormone modified using ambrx ’ patented recode™ technology achieve precise spatial positioning site polyethylene glycol peg attachment human growth hormone biosynthetic incorporation chemically unique amino acid ahgh arx201 improved pharmacological property allow le frequent administration daily dosing regimen currently available growth hormone ,investigated use/treatment growth hormone deficiencies/abnormalities 
Abaloparatide,abaloparatide analog pthrp parathyroid hormone-related protein approved april 28 2017 fda tymlos treatment postmenopausal woman osteoporosis high risk fracture abaloparatide synthetic peptide related hpthrp demonstrated preclinical testing potential widen anabolic window bone therapeutic stimulating bone formation limited effect bone resorption mineral mobilization could enable improved convenience currently available anabolic therapy resulting greater compliance ultimately greater benefit patient october 2022 ema 's committee medicinal product human use chmp recommended abaloparatide granted marketing authorization europe treatment osteoporosis postmenopausal woman increased risk fracture l43552 december 2022 fda indication abaloparatide expanded include male patient addition postmenopausal woman l740 ,abaloparatide indicated treatment osteoporosis men postmenopausal woman high risk fracture l740 also indicated patient osteoporosis treatment ineffective intolerable l740 
TM30339,tm30339 analogue natural hormone pancreatic polypeptide pp released connection meal tm30339 work receptor natural satiety hormone pancreatic polypeptide pp tm30339 improved property compared pp tm30339 thus imitates natural mechanism satiety signal gastrointestinal system involved regulation food intake human tm30339 developed treatment obesity ,investigated use/treatment schizophrenia schizoaffective disorder 
Ganaxolone,ganaxolone 3β-methylated synthetic analog allopregnanolone l41130 metabolite progesterone a3197 ganaxolone belongs class compound referred neurosteroids a3197 endogenous neurosteroids comprise certain metabolite progesterone deoxycorticosterone bind potently specifically gaba sub /sub receptor enhance inhibitory effect thus known anxiolytic analgesic anticonvulsant sedative hypnotic anesthetic property a245995 ganaxolone similar endogenous counterpart positive allosteric modulator gaba sub /sub receptor l41130 approved u fda march 2022 treatment seizure associated cdkl5 deficiency disorder cdd becoming first fda-approved treatment indicated specifically cdd l41135 ,ganaxolone indicated treatment seizure associated cyclin-dependent kinase-like 5 cdkl5 deficiency disorder cdd patient ≥2 year old l41130 
Tetrathiomolybdate,tetrathiomolybdate oral small-molecule anticopper agent highly specific lowering level free copper serum coprexa completed pivotal clinical trial treatment neurologic wilson 's disease also developed fibrotic disorder based upon rationale fibrotic disease process dependent upon availability free copper body ,investigated use/treatment liver disease pulmonary fibrosis 
VPM4001,vpm4001 allogeneic vaccine treatment prostate carcinoma consists irradiated human lncap cell genetically modified permanently secrete interferon-γ interleukin-2 lncap/il-2/ifn-γ interferon-γ enhances presentation tumour antigen whereas interleukin-2 stimulates cell ,investigated use/treatment prostate cancer 
FP0011,fp0011 small molecule antiglutamatergic compound symptomatic disease modifying effect variety neurological disorder amyotrophic lateral sclerosis parkinson 's disease act presynaptic regulation glutamate show strong neuroprotective property ,investigated use/treatment amyotrophic lateral sclerosis al parkinson 's disease 
M0002,m0002 orally-active selective vasopressin antagonist inhibits water re-absorption kidney vasopressin 2 antagonist represents new class compound – aquaretics – produce profound diuresis without loss electrolyte major benefit patient responding satisfactorily diuretic alone ,vasopressin regulates renal water resorption v2 receptor inhibition vasopressin ’ effect v2 receptor enhances water excretion increase urinary output m0002 vasopressin 2 antagonis electrolyte-sparing aquaretic cause much lower level salt excretion 
CDP323,cdp323 antagonist _vascular cell adhesion molecule 1_ vcam-1 binding alpha4-integrins adhesion molecule process thought implicated pathophysiology multiple sclerosis m considered small-molecule prodrug cdp323 originally developed british biopharmaceutical company celltech plc ucb s.a. putative new drug oral treatment multiple sclerosis ,investigated use/treatment multiple sclerosis 
AX200,ax200 developed treatment stroke advanced drug candidate halfway process gaining clinical approval expression endogenous ax200 protein brain increased brain damage thus drug administered acute phase stroke brain ’ protective action supported double neurotherapeutic approach beneficial ax200 stop neuronal cell death acute phase stroke stimulating simultaneously regeneration nervous tissue induction neuro- arteriogenesis supporting reorganisation nervous system ,investigated use/treatment cardiovascular disorder stroke 
Cimicoxib,cimicoxib selective cox-2 inhibitor developed affectis treatment depression schizophrenia approved cimicoxib would first drug decade treat depression new mechanism action ,investigated use/treatment depression 
LY2140023,ly2140023 investigational drug lilly developed new treatment option schizophrenia ly2140023 oral `` prodrug '' meaning devoid intrinsic biological activity administered metabolized provide active mglu2/3 receptor agonist called ly404039 currently approved antipsychotic medication work affecting neurotransmitter dopamine serotonin ly2140023 active substance ly404039 thought work reducing presynaptic release another neurotransmitter glutamate brain region mglu2/3 receptor expressed study planned ongoing learn safety effectiveness including determining optimal therapeutic dose ly2140023 ,investigated use/treatment psychosis schizophrenia schizoaffective disorder 
Labetuzumab,labetuzumab humanized monoclonal antibody carcinoembryonic antigen inhibits tumor growth used radioimmunotherapy ,labetuzumab humanized monoclonal antibody used treat cancer retrieved `` http //en.wikipedia.org/wiki/labetuzumab ''
Leptin,although leptin circulating signal reduces appetite general obese people unusually high circulating concentration leptin people said resistant effect leptin much way people type 2 diabetes resistant effect insulin thus obesity develops people take energy use prolonged period time excess food intake driven hunger signal occurring spite anti-appetite signal circulating leptin high sustained concentration leptin enlarged fat store result cell respond leptin becoming desensitized ,investigated use/treatment lipodystrophy obesity 
Ancrod,ancrod marketed viprinex defibrinogenating agent derived malayan pit viper venom defribrinogenation blood result anticoagulant effect currently viprinex®/ancrod approved marketed country investigated stroke treatment worldwide clinical trial january 2005 u.s. fda granted 'fast-track status investigation ancrod use patient suffering acute ischemic stroke life threatening condition caused blockage blood vessel supplying blood oxygen portion brain phase iii trial currently conducted ,ancrod indicated treatment deep vein thrombosis dvt central retinal branch vein thrombosis pripaism pulmonary hypertension embolic origin embolism insertion prosthetic cardiac valve rethrombosis thrombolytic therapy rethrombosis vascular surgery prevention dvt repair fractured neck femur 
Prinomastat,prinomastat synthetic hydroxamic acid derivative potential antineoplastic activity prinomastat inhibits matrix metalloproteinases mmps specifically mmp-2 9 13 14 thereby inducing extracellular matrix degradation inhibiting angiogenesis tumor growth invasion metastasis lipophilic agent prinomastat cross blood-brain barrier ,investigated use/treatment brain cancer lung cancer prostate cancer 
Matuzumab,matuzumab formerly known experimental drug emd 72000 humanized monoclonal antibody used cancer treatment high affinity egfr epithelial growth factor receptor frequently associated growth blood vessel malignancy facilitating tumor growth survival ,investigated use/treatment cervical dysplasia/cancer colorectal cancer gastric cancer lung cancer 
Rupintrivir,rupintrivir rhinovirus 3c protease inhibitor development use human rhinoviral hrv infection rupintrivir active 48 hrv serotypes tested cell protection assay h1-hela cell designed combat cold caused rhinovirus ,investigated use/treatment viral infection 
AN-9,pivaloyloxymethyl butyrate an-9 acyloxyalkyl ester prodrug butyric acid ba exhibited low toxicity significant anticancer activity vitro vivo show greater potency ba inducing malignant cell differentiation tumor growth inhibition demonstrated favorable toxicological pharmacological pharmaceutical property ba preclinical study ,investigated use/treatment liver cancer lung cancer melanoma leukemia lymphoid 
Asimadoline,asimadoline proprietary small molecule therapeutic originally discovered merck kgaa darmstadt germany asimadoline originally developed treat peripheral pain arthritis asimadoline orally administered agent act kappa opioid receptor agonist shown encouraging clinical efficacy treatment ibs barostat study ibs patient potential treating gastrointestinal disease ,investigated use/treatment irritable bowel syndrome ibs 
Pleconaril,pleconaril antiviral drug _viral capsid inhibitor_ class manufactured _schering-plough_ intended prevention acute asthma exacerbation common cold symptom asthmatic patient exposure _picornavirus_ act inhibiting viral replication use pleconaril gained approval u.s. food drug administration fda due fact found induce cyp3a enzyme activity therefore increasing risk serious drug interaction ,investigated use/treatment upper respiratory infection 
IR208,ir208 synthetic t-cell receptor peptide vaccine developed immune response corporation contains three peptide bv5s2 bv6s5 bv13s1 expressed t-cells 90 m patient ir208 currently undergoing phase ii study 200-patient trial ,investigated use/treatment multiple sclerosis 
16-Bromoepiandrosterone,16-bromoepiandrosterone injectable formulation compound called alpha-epi-bromide chemical relative dhea selected development showed antiretroviral activity laboratory test ,investigated use/treatment cystic fibrosis hiv infection hepatitis viral b malaria 
EHT899,eht899 proprietary formulation hbv viral protein designed eliminate undesirable immune response elicited hbv infection also apparently enhances secondary immune response clear viral infection resulting reduction liver damage decrease viral load ,investigated use/treatment hepatitis viral b 
Trabectedin,trabectedin also referred et-743 development marine-derived antitumor agent discovered carribean tunicate _ecteinascidia turbinata_ produced synthetically trabectedin unique mechanism action bind minor groove dna interfering cell division genetic transcription process dna repair machinery approved use europe russia south korea treatment advanced soft tissue sarcoma currently evaluation treatment breast cancer prostate cancer addition pediatric sarcoma european commission u.s. food drug administration fda approved trabectedin orphan drug soft tissue sarcoma ovarian cancer october 23 2015 fda approved trabectedin yondelis treatment specific soft tissue sarcoma ,indicated treatment advanced soft tissue sarcoma patient refractory unsuitable receive anthracycline ifosfamide chemotherapy europe russia south korea approved orphan drug status u.s. fda treatment soft tissue sarcoma ovarian cancer investigated use/treatment cancer/tumors unspecified gastric cancer ovarian cancer pediatric indication sarcoma solid tumor 
VIR201, experimental therapeutic vaccine currently clinical trial aim therapeutic vaccine augment body 's immune response hiv delay prevent progression aid ,investigated use/treatment hiv infection 
Fontolizumab,fontolizumab marketed trade name huzaf™ humanized monoclonal antibody used immunosuppressive drug treat crohn 's disease ,investigated use/treatment crohn 's disease psoriasis psoriatic disorder 
AP5280,ap5280 novel n- 2-hydroxypropyl methacrylamide hpma copolymer-bound platinum pt therapeutic designed increase therapeutic index relative conventional small-molecule platinum agent ,investigated use/treatment solid tumor 
105AD7,105ad7 human monoclonal antibody mimic complement regulatory protein cd55 overexpressed many solid tumour including osteosarcoma 105ad7 induced antitumour inflammatory response metastatic colorectal cancer patient 105ad7 may suitable vaccine treatment disease ,investigated use/treatment colorectal cancer 
EHC18,ehc18 immune regulation medicine broad spectrum specific hcv protein ,investigated use/treatment hepatitis viral c hepatocellular carcinoma 
NN344,nn344 neutral soluble long-acting human insulin analogue 24 hour coverage daily injection nn344 flat predictable action profile product intended basal insulin treatment diabetes mellitus ,investigated use/treatment diabetes mellitus type 1 2 
Thymectacin,thymectacin phosphoramidate derivative e -5- 2-bromovinyl -2'-deoxyuridine novel small molecule anticancer agent thymectacin selectively active tumor cell expressing high level thymidylate synthase t critical enzyme dna biosynthesis thymectacin efficacious irinotecan drug recently approved treatment 5-fluorouracil-resistant colon cancer ,investigated use/treatment colorectal cancer 
IGN301,ign301 cancer vaccine based anti-idiotypic antibody provokes immune response lewis y. lewis carbohydrate molecule expressed surface tumor cell epithelial origin e.g lung intestinal breast prostate ovarian cancer ,investigated use/treatment cancer/tumors unspecified 
R1204,r1204 g-protein-coupled receptor modulator developed treatment depression ,investigated use/treatment depression 
Rilapladib,rilapladib third genomics-derived small molecule drug arising human genome sciences-glaxosmithkline collaboration enter clinical development lipoprotein-associated phospholipase a2 lp-pla2 inhibitor lp-pla2 enzyme associated formation atherosclerotic plaque ,investigated use/treatment atherosclerosis cardiovascular disorder 
AT1391,at1391 daily insulin skin patch designed provide continuous basal level insulin patient diabetes ,investigated use/treatment diabetes mellitus type 1 2 
1D09C3,1d09c3 monoclonal antibody lymphoid cancer anti-mhc major histocompatibility complex class ii monoclonal antibody antibody isolated collaboration morphosys hucal r library human antibody 1d09c3 bind certain cell surface receptor selectively killing activated proliferating mhc class ii-positive tumor cell include b-cell t-cell lymphoma 1d09c3 shown induce programmed cell death require functioning immune system cell-killing effect ,intended treatment various form cancer 
R1295,r1295 integrin antagonist currently clinical trial treatment rheumatoid arthritis integrins associated pathology seen autoimmune disease rheumatoid arthritis ,investigated use/treatment rheumatoid arthritis 
Gemcabene,gemcabene new drug lower low-density lipoprotein cholesterol ldl-c decrease triglyceride raise high-density lipoprotein cholesterol hdl-c ,investigated use/treatment atherosclerosis cardiovascular disorder hyperlipidemia 
ARC183,arc183 dna aptamer single-stranded dna molecule consisting 15 deoxynucleotides form well-defined three-dimensional configuration allowing bind thrombin high affinity specificity key advantage arc183 compared thrombin inhibitor rapid onset action short half-life giving potential ideal agent medical procedure require rapid resolution anticoagulation require reversal anticoagulation shortly procedure completed ,investigated use/treatment blood blood forming organ disorder unspecified cardiac surgery coronary artery disease 
SC12267,sc12267 novel small molecule agent class dmards disease modifying anti-rheumatic drug therapy autoimmune disease rheumatoid arthritis multiple sclerosis highly selective inhibition pyrimidine biosynthesis control growth rapidly proliferating cell especially lymphocyte important immune response ,investigated use/treatment multiple sclerosis rheumatoid arthritis 
PYM50018,pym50018 patented orally active neuroprotective neuroregenerative compound developed treatment amyotrophic lateral sclerosis al also known lou gehrig 's disease pre-clinical model pym50018 observed protect neuronal damage increase neurite outgrowth reverse oxidative damage reverse neuronal apoptosis vitro administered orally transgenic pre-clinical model al pym50018 delay loss muscle strength extends survival time ,investigated use/treatment amyotrophic lateral sclerosis al 
ANA971,ana971 orally administered prodrug isatoribine isatoribine nucleoside analog development treatment chronic hepatitis c virus hcv infection ana971 prodrug designed improve oral bioavailability isatoribine ana971 resulted higher level isatoribine blood present oral administration isatoribine ,investigated use/treatment hepatitis viral c 
Aminocandin,aminocandin new representative echinocandins could potentially affect cellular morphology metabolic status candida albicans cell within biofilms ,investigated use/treatment fungal infection 
Elsamitrucin, cytostatic agent elsamitrucin new fermentation product active variety vivo tumor model murine human origin pmid 8150873 ,investigated use/treatment lymphoma non-hodgkin 's 
INCB3284,incb3284 ccr2 antagonist inflammation-driven disease ,investigated use/treatment inflammatory disorder unspecified 
TTP889,ttp889 orally bioavailable selective inhibitor intrinsic coagulation pathway developed anticoagulant treatment thromboembolic disorder ttp889 known selective small molecule inhibitor factor ix key enzyme intrinsic pathway blood coagulation system ttp889 proven effective preventing clot formation several animal model human disease without sign bleeding associated traditional anticoagulant ,investigated use/treatment blood blood forming organ disorder unspecified cardiac surgery venous thromboembolism 
ND1251,nd1251 orally active phosphodiesterase-4 pde4 inhibitor mechanism clinically proven play role alleviating symptom depression nd1251 potent compound large safety margin nd1251 may also application disorder alzheimer 's disease mild cognitive impairment multiple sclerosis certain respiratory disease ,investigated use/treatment depression 
VP025,vp025 novel drug formulation based phospholipid microparticles incorporating phosphatidylglycerol inhibit neuroinflammation vp025 may inhibit immune system activation protect motoneuron injury also show ability reduce inflammation across blood-brain barrier improve correlate memory learning function developed target chronic inflammation within central nervous system associated number neurological disease including alzheimer ’ disease parkinson ’ disease amyotrophic lateral sclerosis lou gehrig ’ disease considered systemic anti-inflammatory neuroprotective agent ,investigated use/treatment alzheimer 's disease inflammatory disorder unspecified 
Tanespimycin,tanespimycin manufactured conforma therapeutic development small molecule inhibitor heat shock protein 90 hsp90 developed treatment several type cancer solid tumor chronic myelogenous leukemia ,investigated use/treatment leukemia myeloid solid tumor 
Vibriolysin,vibriolysin proteolytic enzyme secreted marine microorganism vibrio proteolyticus new agent enzymatic debridement shown rapidly thoroughly hydrolyze burn wound eschar within full-thickness wound ,investigated use/treatment burn burn infection 
Bavituximab,bavituximab chimeric anti-ps monoclonal antibody analog used potentially treat cancer viral infection bind phosphatidylserine exposed host cell lipid induced cellular stress additional analog class include 3g4 2ag4 9d2 hu3g4 ,investigated use/treatment breast cancer cancer/tumors unspecified hiv infection hepatitis viral c solid tumor 
Lobeline, alkaloid action similar nicotine nicotinic cholinergic receptor le potent proposed variety therapeutic us including respiratory disorder peripheral vascular disorder insomnia smoking cessation pubchem ,investigated use/treatment addiction 
AdPEDF,adpedf development treatment wet age-related macular degeneration amd shown rapidly elevate intraocular adpedf protein level eye inhibit abnormal blood vessel growth cause abnormal blood vessel regress protecting eye ’ photoreceptors ,investigated use/treatment macular degeneration 
CR002,cr002 novel investigational fully human monoclonal antibody block activity excess platelet-derived growth factor-d pdgf-d target shown play role kidney inflammation novel therapeutic approach treat kidney inflammation ,investigated use/treatment nephropathy 
RAV12,rav12 investigated use/treatment solid tumor rav12 solid rav12 chimeric antibody recognizes raag12 n-linked carbohydrate antigen found gastric colon pancreatic prostate ovarian breast kidney cancer cell ,investigated use/treatment solid tumor 
LY2181308,ly2181308 investigated clinical trial treating solid tumor ly2181308 solid ly2181308 directed molecular target called survivin ly2181308 known target baculoviral iap repeat-containing protein 5 ly2181308 anti-sense oligonucleotide potently downregulated survivin expression human cancer cell derived lung colon breast prostate ovary cervix skin brain ,investigated use/treatment cancer/tumors unspecified solid tumor 
ND7001,"nd7001 selective pde2 inhibitor clinical trial treatment depression nd7001 solid known drug target nd7001 including phosphodiesterase 2a cgmp-stimulated cgmp-dependent 3',5'-cyclic phosphodiesterase new type antidepressant drug anxiolytic activity first representative new generation psycho-active compound potentially devoid several problem seen existing treatment ",investigated use/treatment anxiety disorder depression 
OXI-4503,oxi-4503 investigated clinical trial treating cancer/tumors oxi-4503 solid oxi-4503 block destroys tumor vasculature resulting extensive tumor cell death necrosis oxi-4503 combretastatin a1 di-phosphate ca1p unique highly potent dual-mechanism vascular disrupting agent vda addition however preclinical data demonstrates oxi-4503 metabolized oxidative enzyme e.g. tyrosinase peroxidase elevated many solid tumor tumor infiltrates orthoquinone chemical specie direct cytotoxic effect tumor cell preclinical study demonstrated oxi-4503 single-agent activity range xenograft tumor model ii synergistic additive effect incorporated various combination regimen chemotherapy molecularly-targeted therapy including tumor-angiogenesis inhibitor radiation therapy ,investigated use/treatment cancer/tumors unspecified 
PEV3A,pev3a prophylactic malaria vaccine act various stage disease two-component vaccine contains virosome formulated peptide mimetics pev301 pev302 two synthetic peptide vaccine component mimic native structure important antigen malaria parasite elicited antibody highly specific able inhibit parasite ’ ability invade liver tissue _in vitro_ ,investigated use/treatment malaria 
TH0318,th0318 stabilized analogue human glp-1 glucagon-like peptide-1 investigation treatment type 2 diabetes ,investigated use/treatment diabetes mellitus type 1 2 
XL820,xl820 investigated use/treatment solid tumor xl820 solid protein xl820 inhibit include platelet-derived growth factor receptor beta pdgfr mast/stem cell growth factor receptor kit vascular endothelial growth factor receptor 2 platelet-derived growth factor receptor alpha clinically validated target implicated variety human cancer xl820 exhibit dose-dependent growth inhibition model breast carcinoma glioma leukemia ,investigated use/treatment solid tumor 
CYT997,cyt997 orally available vascular argeting cytotoxic agent proven effective animal model wide range tumour type including breast prostate colon well leukemia ,investigated use/treatment solid tumor 
CG0070,cg0070 investigated clinical trial treating bladder cancer cg0070 solid cg0070 potentially destroy cancer cell two different mechanism direct cell killing virus immune-mediated cell killing stimulated gm-csf cg0070 oncolytic virus therapy specificity multiple cancer evaluated numerous preclinical study engineered secrete gm-csf immune stimulating hormone also serf adjuvant cancer immunotherapy ,investigated use/treatment bladder cancer 
XL844,xl844 investigated use treatment solid tumor xl844 solid xl844 potent inhibitor checkpoint kinase chk1 chk2 induce cell cycle arrest response variety dna damaging agent known drug target xl844 including serine/threonine-protein kinase chk1 serine/threonine-protein kinase chk2 ,investigated use/treatment cancer/tumors unspecified solid tumor 
CAD106,cad106 immunotherapeutic product development treatment alzheimer 's disease designed induce antibody beta-amyloid-protein inhibit formation plaque brain alzheimer 's disease patient ,investigated use/treatment alzheimer 's disease 
TST10088,tst10088 recombinant variant plant toxin belonging family class ii ribosome inactivating protein molecule efficiently kill cell activating preprogrammed death pathway known apoptosis tst10088 designed engineered twinstrand contain peptide switch specifically cleaved matrix metalloproteinases known involved tumor growth metastasis cleavage peptide switch activates prodrug causing ribosomal inactivation death cancerous cell ,investigated use/treatment solid tumor 
NGX267,ngx267 muscarinic agonist developed treatment alzheimer ’ disease shown potential reduce symptom slow disease progression ,investigated use/treatment alzheimer 's disease schizophrenia schizoaffective disorder 
Pretomanid,persistent form tuberculosis tb proven major cause global morbidity mortality cause significant concern research recent year geared toward development novel therapy target persistent form disease shown resistance standard therapy regimen a182915 pretomanid antimycobacterial agent administered bedaquiline linezolid treat resistant form pulmonary tb first tb drug developed nonprofit organization known tb alliance granted fda approval august 14 2019 l8048 l8066 unlike therapeutic regimen treatment resistant tb may take 18 month longer may effective pretomanid-containing regimen allows efficacious shorter duration treatment fewer drug l8066 ,pretomanid indicated adult combination bedaquiline linezolid treatment pulmonary form nonresponsive multidrug-resistant mdr extensively drug-resistant xdr treatment-intolerant form pulmonary tuberculosis tb l8048 important note following condition approved indication pretomanid therapy according fda l8048 drug-sensitive d tuberculosis latent tuberculosis caused m.tuberculosis extra-pulmonary tuberculosis caused m.tuberculosis multidrug-resistant tb treatment-intolerant nonresponsive conventional tb therapy 
CR665,cr665 lead clinical development candidate series highly selective peripheral kappa opioid receptor agonist preclinical study cr665 highly selective peripheral kappa opioid receptor preclinical animal study suggest cr665 potent analgesic compound addition unlike currently marketed opioids cr665 produce inhibition intestinal transit ileus induce respiratory depression elicit sign euphoria addiction animal model preclinical study also indicate cr665 posse anti-inflammatory activity ,investigated use/treatment pain acute chronic 
SL017,sl017 formulated topical gel combined widely available light source permanent removal unwanted hair treatment actinic keratosis,investigated use/treatment acne actinic keratosis cancer/tumors unspecified keratoses skin infections/disorders 
KC706,kc706 novel anti-inflammatory drug work inhibiting activity p38 map kinase kc706 hold potential treat inflammatory condition rheumatoid arthritis psoriasis inflammatory bowel disease cardiovascular disease ,investigated use/treatment cardiovascular disorder inflammatory bowel disease inflammatory disorder unspecified psoriasis psoriatic disorder rheumatoid arthritis 
PM02734,pm02734 marine derived compound pm02734 new antiproliferative drug demonstrating activity broad spectrum tumor type breast colon pancreas lung prostate among others ,investigated use/treatment cancer/tumors unspecified solid tumor 
CCX915,ccx915 developed chemocentryx target chemokine receptor ccr2 phase 1 clinical trial treatment multiple sclerosis neurologic disorder ccr2 receptor thought central importance inflammatory disease multiple sclerosis m type ii diabetes atherosclerosis ,investigated use/treatment multiple sclerosis neurologic disorder 
Topsalysin,topsalysin developed treatment localized prostate cancer also benign prostatic hyperplasia topsalysin delivered locally prostate ultrasound guidance ,investigated use/treatment benign prostatic hyperplasia cancer/tumors unspecified prostate cancer prostate disorder solid tumor 
Elafin,elafin human protein produced naturally skin lung breast protecting respective tissue destruction immune system elafin ’ ability block activity destructive enzyme involved inflammatory reaction make highly promising active compound treatment inflammatory lung disease severe reperfusion injury occurring heart attack serious injury organ transplantation excellent tolerability elafin human subject demonstrated phase clinical single dose escalating study ,investigated use/treatment inflammatory disorder unspecified 
PV903,pv903 self administered vaginally delivered recombinant protein treatment recurrent miscarriage resulting intolerant immune response developing foetus ,investigated use/treatment infertility 
CMLVAX100,cmlvax100 vaccine targeting bcr-abl-derived p210 fusion protein reduces residual disease patient chronic myeloid leukemia developed breakthrough therapeutic completed phase clinical trial ,investigated use/treatment leukemia myeloid 
LY2275796,ly2275796 second-generation antisense anti-cancer drug candidate clinical development ly2275796 target eukaryotic initiation factor- 4e eif-4e protein involved translation key growth survival factor drive tumor progression angiogenesis metastasis ,investigated use/treatment cancer/tumors unspecified solid tumor 
APD668,apd668 novel highly potent orally active glucose-dependent insulinotropic receptor gdir agonist intended efficiently stimulate insulin release beta cell response elevated blood glucose level also avoid hypoglycemia ,investigated use/treatment diabetes mellitus type 2 
PDPSC18,pdpsc18 therapeutic dna vaccine designed fight chronic infection hepatitis b virus entering phase clinical trial ,investigated use/treatment hepatitis viral b 
Vintafolide,vintafolide folate-targeted chemotherapeutic conjugate folate vitamin vinca alkaloid clinical stage development treatment folate-receptor positive cancer ,investigated use/treatment solid tumor 
AT9283,at9283 aurora kinase inhibitor developed astex therapeutic treatment cancer discovered developed internally using astex ’ fragment-based drug discovery platform pyramid ,investigated use/treatment cancer/tumors unspecified leukemia myeloid solid tumor 
Benzimate,benzimate lead compound selected series compound known benzimidazoles anti-cancer anti-viral activity benzimidazoles originally investigated proctor gamble company beginning 1990 's currently investigation amplimed phase clinical trial ,investigated use/treatment cancer/tumors unspecified 
E-2012,e-2012 gamma secretase modulator evaluated potential new treatment alzheimer 's disease ,investigated use/treatment alzheimer 's disease 
AT3022,at3022 altea therapeutic ’ fentanyl citrate transdermal patch designed provide safe rapid management moderate severe chronic pain ,investigated use/treatment pain acute chronic 
PTC299,ptc299 novel orally administered small-molecule designed inhibit production vascular endothelial growth factor vegf tumor overexpression vegf play key role multiple disease including cancer macular degeneration ptc299 discovered ptc 's gem technology targeting post-transcriptional process regulate vegf formation currently developed treatment cancer ,investigated use/treatment cancer/tumors unspecified solid tumor 
CX501,cx501 used treat epidermolysis bullosa eb rare genetic condition lead contraction joint fusion finger toe contraction mouth membrane narrowing oesophagus developed cellerix phase clinical trial ,investigated use/treatment skin infections/disorders 
DG051,dg051 novel small-molecule inhibitor leukotriene a4 hydrolase lta4h protein made one gene leukotriene pathway shown link risk heart attack dg051 designed decrease risk heart attack decreasing production leukotriene b4 ltb4 end product leukotriene pathway potent promoter inflammation ,investigated use/treatment myocardial infarction 
DLO6001,dl6001 developed daniolabs using proprietary zebrafish technology treat parkinson ’ disease symptom including sialorrhoea hyperhidrosis ,investigated use/treatment parkinson 's disease 
DLO6002,dlo6002 developed summit corporation phase clinical trial treatment parkinson 's disease ,investigated use/treatment parkinson 's disease 
LX6171,lx6171 oral drug candidate generated lexicon medicinal chemist developed treat disorder characterized cognitive impairment alzheimer 's disease schizophrenia vascular dementia ,investigated use/treatment alzheimer 's disease attention deficit/hyperactivity disorder adhd dementia neurologic disorder schizophrenia schizoaffective disorder 
BTA798,bta798 antiviral treatment hrv common cold virus known cause significant clinical complication sufferer asthma chronic obstructive pulmonary disease ,investigated use/treatment viral infection 
AS1409,as1409 genetically engineered fusion protein made two distinct component one cytokine il12 anti-cancer activity antibody target tumour developed antisoma phase clinical trial treatment renal cancer melanoma ,investigated use/treatment kidney cancer melanoma 
MLN0415,mln0415 novel small molecule ikk2 inhibitor discovered millennium scientist preclinical study mln0415 shown decrease nf-kb activation down-regulate expression number inflammatory protein inflammatory protein play critical role inflammation drive inflammatory response disease controlling protein may prevent slow disease progression ,investigated use/treatment inflammatory disorder unspecified 
XL228,xl228 novel anticancer compound designed inhibit insulin-like growth factor type-1 receptor igf1r src abl tyrosine kinase – target play crucial role cancer cell proliferation survival metastasis ,investigated use/treatment leukemia lymphoid leukemia myeloid 
Olesoxime,olesoxime cholesterol-like small molecule demonstrated remarkable neuroprotective profile battery vitro vivo preclinical model example demonstrated ability prevent neurodegeneration enhance nerve function accelerate neuroregeneration following nerve trauma a3282 a253233 ,investigated use/treatment neurologic disorder 
SQ-109,sq-109 orally active small molecule antibiotic treatment pulmonary tb currently phase clinical trial sq-109 could replace one drug current first-line tb drug regimen simplify therapy shorten tb treatment regimen ,investigated use/treatment bacterial infection infectious parasitic disease unspecified tuberculosis 
Elafibranor,elafibranor code name gft505 multimodal pluripotent medication treatment atherogenic dyslipidemia overweight patient without diabetes oral treatment act 3 sub-types ppar ppara pparg ppard preferential action ppara february 2016 elafibranor completed 8 clinical trial phase iii progress ,investigated use/treatment atherosclerosis diabetes mellitus type 2 
KD3010,kd3010 small molecule peroxisome proliferator-activator receptor delta ppar delta agonist treatment metabolic disorder including obesity ,investigated use/treatment metabolic disease obesity 
EPC2407,epc2407 novel small molecule vascular disruption agent apoptosis inducer treatment patient advanced solid tumor lymphoma intended treatment advanced cancer patient solid tumor well vascularized tumor include frequently occurring cancer lung gastrointestinal tract ovary breast ,investigated use/treatment cancer/tumors unspecified 
XL281,xl281 novel anticancer compound designed potently inhibit ras/raf/mek/erk signaling pathway mutational activation ra occurs 30 percent human tumor including non-small cell lung pancreatic colon cancer xl281 specific inhibitor raf kinase including mutant form b-raf activated 60 percent melanoma 24-44 percent thyroid cancer 9 percent colon cancer ,investigated use/treatment solid tumor 
Atl146e,atl146e anti-inflammatory compound agonist a2a adenosine receptor ,investigated use/treatment inflammatory disorder unspecified 
MB07811,mb07811 first novel class product candidate discovered metabasis designed lower serum cholesterol triglyceride mb07811 small molecule administered orally extensively studied preclinically currently undergoing clinical testing mb07811 combine novel thyroid hormone receptor agonist company 's novel hepdirect liver targeting prodrug technology combination selectivity beta form receptor liver targeting structural characteristic limit extra-hepatic activity designed provide significant efficacy avoiding side effect associated activation thyroid hormone receptor outside liver ,investigated use/treatment hyperlipidemia 
KB002,kb002 engineered human igg1k antibody engineered human developed treatment autoimmune disease initially rheumatoid arthritis ,investigated use/treatment rheumatoid arthritis 
ADC4022,adc4022 investigational medicine treatment chronic obstructive pulmonary disease copd severe asthma ,investigated use/treatment asthma chronic obstructive pulmonary disease copd 
ACR325,acr325 developed treatment parkinson ’ disease psychosis including bipolar disorder disease existing therapy limited effect considerable adverse side effect acr325 dopaminergic stabiliser demonstrated promising result disease model motor function psychosis ,investigated use/treatment affective disorder bipolar disorder psychosis 
Sofalcone,sofalcone mucosal protective agent reported inhibit growth helicobacter pylorus adherence production vacuolating toxin vt induction interleukin-8 il-8 secretion h. pylorus ,investigated use/treatment gastroenteritis ulcer 
CYC116,cyc116 novel anticancer compound unique target profile involving cell cycle angiogenesis inhibition mechanism preclinical study cyc116 demonstrated antitumor activity solid tumor hematological cancer cyclacel 's small molecule investigational drug cyc116 third orally-available cyclacel drug enter development demonstrated anticancer activity mechanism consistent inhibition aurora kinase ,advanced solid tumor
LX1031,lx1031 orally-dosed drug candidate irritable bowel syndrome gastrointestinal disorder lx1031 generated lexicon medicinal chemist target internally identified key control point regulation peripheral serotonin level lx1031 designed act locally gastrointestinal tract reducing serotonin available receptor activation without affecting serotonin level brain central nervous system function ,irritable bowel syndrome ibs gastrointestinal disorder
AT2220,at2220 experimental oral therapy treatment pompe disease belongs class molecule known pharmacological chaperone small molecule designed act pharmacological chaperone specifically bind stabilizes facilitates proper folding trafficking α-glucosidase gaa gaa lysosome perform normal function at2220 shown increase gaa activity cell line derived pompe patient transfected cell expressing misfolded form gaa ,pompe disease also known glycogen storage disease type ii acid maltase deficiency relatively rare neuromuscular lysosomal storage disorder caused inherited genetic mutation key enzyme called α-glucosidase gaa 
V24343, anti-obesity drug v24343 act targeting cb1 receptor brain suppressing person 's appetite ,obesity related disorder cardiovascular disease type ii diabetes
Egaptivon pegol,arc1779 therapeutic aptamer antagonist a1 domain von willebrand factor vwf ligand receptor glycoprotein 1b platelet arc1779 developed novel antithrombotic agent use patient acute coronary syndrome arc1779 therapeutic oligonucleotide `` aptamer '' block binding a1 domain vwf platelet gpib receptor thereby modulates platelet adhesion activation aggregation high shear condition coronary arterial stenosis plaque rupture ,platelet aggregation thrombosis acute coronary syndrome
SPP1148,spp1148 promising compound new series renin inhibitor treatment hypertension related end-organ disease ,investigated use/treatment hypertension 
XL418,xl418 novel anticancer compound ,
CX157,"cx157,3-fluoro-7- 2,2,2 -trifluoroethoxy phenoxathiin-10,10-dioxide reversible selective inhibitor mao-a designed improved oral bioavailability reduced clearance compared previous mao-a inhibitor class ",anxiety disorder depression 
SD118,sd118 previously investigation japan different indication following re-profiling evaluation experimental animal model demonstrated potential new oral therapy neuropathic pain ,central nervous system neuropathic pain
Rozrolimupab,rozrolimupab recombinant polyclonal antibody consisting 25 different anti-rhesus rhd antibody replace existing anti-rhd hyperimmune immunoglobulin treatment idiopathic thrombocytopenic purpura itp prevention hemolytic disease newborn hdn ,investigated use/treatment thrombocytopenia 
SF1126,sf1126 integrin-targeted pi3 kinase inhibitor , treatment various form cancer 
PS386113,ps386113 small molecule drug candidate investigation treatment inflammatory disorder developed schering-plough pharmacopeia little information released ps386113 , treatment inflammatory disease 
HE3286,, treatment rheumatoid arthritis type 2 diabetes 
KD7040,kd7040 topically-delivered inducible nitric oxide synthase inos inhibitor treatment neuropathic pain kd7040 ind filed 4q06 phase ib clinical trial began 2q07 developed kalypsys , treatment pain 
GMX1777,gmx1777 water-soluble prodrug cyanoguanidine compound gmx1778 potential antineoplastic activity vivo apoptosis inducer gmx1777 rapidly converted gmx1778 hydrolytic cleavage carbonate ester bond although exact mechanism action yet fully elucidated gmx1778 appears antagonize nuclear factor-kappa b nf-kb transcription resulting induction tumor cell apoptosis ,intended treatment solid tumor lymphoma 
PN0621,pn0621 anti-tnf domain antibody dab based therapeutic target tumour necrosis factor tnf treat auto-immune inflammatory disease rheumatoid arthritis developed peptech ,intended treatment auto-immune disease rheumatoid arthritis psoriasis crohn 's disease 
Crisaborole,crisaborole novel oxaborole approved fda december 14 2016 eucrisa topical treatment mild moderate atopic dermatitis non-steroidal agent efficacious improving disease severity reducing risk infection reducing sign symptom patient 2 year old older reduces local inflammation skin prevents exacerbation disease good safety profile structure contains boron atom facilitates skin penetration binding bimetal center phosphodiesterase 4 enzyme currently development topical treatment psoriasis ,intended topical treatment mild moderate atopic dermatitis patient 2 year age older 
Alisertib,alisertib novel aurora kinase inhibitor investigation treatment various form cancer , treatment various form cancer 
KB001,kb001 humaneered trade pegylated monoclonal antibody fragment treatment life-threatening pseudomonas aeruginosa infection common problem cystic fibrosis mechanically ventilated patient , treatment infection caused multi-drug resistant em pseudomonas aeruginosa /em 
Pracinostat,pracinostat novel hdac inhibitor improved vivo property compared hdac inhibitor currently clinical trial allowing oral dosing data demonstrate pracinostat potent effective anti-tumor drug potential oral therapy variety human hematological solid tumor , treatment various form cancer 
REP8839,rep8839 novel methionyl-trna synthetase mets inhibitor developed replidyne glaxosmithkline licensed rep8839 replidyne june 2003 , treatment bacterial infection caused susceptible microorganism staphylococcus aureus /i including methicillin-resistant aureus /i mrsa streptococcus pyogenes /i 
AM103,am103 novel inhibitor 5-lipoxygenase-activiting protein flap demonstrated potential treat asthma cardiovascular disease preventing synthesis lt trigger inflammation developed amira , treatment asthma cardiovascular disease 
BTA9881,bta9881 respiratory syncytial virus rsv antiviral drug developed australian company biota holding currently phase trial , treatment respiratory syncytial virus infection 
APD791,apd791 oral anti-thrombotic drug candidate evaluated phase 1 clinical trial arena apd791 intended lower risk arterial thrombosis reducing amplification platelet aggregation arterial constriction intimal hyperplasia mediated serotonin , treatment prophylaxis arterial thrombosis 
RDEA806,rdea806 new hiv non-nucleoside reverse transcriptase inhibitor nnrti high genetic barrier resistance broad spectrum activity , treatment hiv-1 infection combination appropriate antiretroviral agent therapy warranted 
Beraprost,beraprost synthetic analogue prostacyclin clinical trial treatment pulmonary hypertension also studied use avoiding reperfusion injury , treatment pulmonary hypertension 
AC3056,ac3056 non-peptide antioxidant act inhibitor vascular cell adhesion molecule expression originally developed aventis pharmaceutical since acquired amylin pharmaceutical completed phase trial , treatment atherosclerosis condition related obstruction blood vessel 
Tetrodotoxin, aminoperhydroquinazoline poison found mainly liver ovary fish order tetraodontiformes eaten toxin cause paresthesia paralysis interference neuromuscular conduction tetrodotoxin investigated wex pharmaceutical treatment chronic breakthrough pain advanced cancer patient well treatment opioid dependence , treatment chronic breakthrough pain advanced cancer patient well treatment opioid dependence 
AP1081, transdermal gel containing ethinyl estradiol norelgestromin investigated antares pharma use female contraceptive , use female contraceptive 
LGD2941,lgd2941 non-steroidal selective androgen receptor modulator sarm developed jointly ligand tap , treatment prevention osteoporosis 
NRP409,nrp409 triiodothyronine t3 hormone investigated new river pharmaceutical treatment patient primary hypothyroidism , use treatment hypothyroidism 
ReN001,ren001 clonal human neural stem cell line developed clinical use treatment stable disability stroke ren001 strong candidate one first cell-based ind application submitted food drug administration united state consideration treatment stroke human , treatment stroke 
rhMBL,rhmbl protein therapeutic developed enzon prevention treatment severe infection individual low level mannose-binding lectin mbl 10 percent general population estimated mbl-deficient natural mbl 400-700kda oligomer made 3 identical 32kda peptide chain mbl form different oligomers must form least tetramer active ,investigated use/treatment immunodeficiency infectious parasitic disease unspecified 
Cobimetinib,cobimetinib orally active potent highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 map2k1 mek1 central component ras/raf/mek/erk signal transduction pathway approved switzerland u combination vemurafenib treatment patient unresectable metastatic braf v600 mutation-positive melanoma ,cobimetinib indicated combination vemurafenib treatment unresectable metastatic melanoma braf v600e v600k mutation single agent cobimetinib also indicated treatment adult patient histiocytic neoplasm l43717 
XL765,xl765 orally available small molecule shown preclinical study selectively inhibit activity phosphoinositide-3 kinase pi3k mammalian target rapamycin mtor developed exelixis inc , treatment various form cancer 
NUC B1000,nuc b1000 expressed interfering rna eirna based product consisting plasmid dna construct designed produce four short interfering rna sirna molecule formulated proprietary cationic-lipid delivery system f3910 eirna approach rnai therapeutic whereby plasmid dna coding desired dsrna delivered diseased cell enabling cell carry dsrna production internally thereby invoking rnai response targeted disease causing gene january 11 2008 announced nuc b1000 entering phase 1 human safety study experimental treatment chronic hepatitis b virus hbv infection ,investigated use/treatment hepatitis viral b 
XL019,xl019 selective inhibitor cytoplasmic tyrosine kinase jak2 ind xl019 filed exelixis may 2007 , treatment various form cancer 
G4544,g4544 oral gallium compound enables oral absorption active ingredient contained ganite trade gallium nitrate injection target bone tissue actively incorporated bone mineral site bone metabolically active , treatment non-hodgkin 's lymphoma bone metastasis paget 's disease osteoporosis
Silver sulfadiazine,silver sulfadiazine sulfa derivative topical antibacterial used primarily second- third-degree burn ,indicated adjunct prevention treatment wound sepsis patient second- third-degree burn 
Methsuximide,mesuximide methsuximide anticonvulsant medication sold pfizer name petinutin , control absence petit mal seizure refractory drug 
FavId,favid active immunotherapy based upon unique genetic information extracted patient 's tumor ,b-cell non-hodgkin 's lymphoma
Fenoxaprop-ethyl,fenoxaprop-ethyl organic nitrate combined l-arginine oral proprietary nitrate therapeutic shown induce coronary vasodilation overcoming significant problem drug tolerance fenoxaprop-ethyl investigated treat chronic angina chest pain occurs inadequate blood flow coronary artery around heart ,chronic angina coronary artery disease
Telapristone acetate,telapristone acetate orally-available selective progesterone receptor modulator development alleviate symptom associated uterine fibroid endometriosis , treatment uterine fibroid endometriosis 
Fibrinolysin,"fibrinolysin consists two polypeptide chain one light one heavy linked disulfide bond light chain molecular weight approximately 27,000 da contains active center fibrinolysin heavy chain molecular weight approximately 57,000 da fibrinolysin used local healing ointment combined together enzyme deoxyribonuclease extracted bovine pancreas fibrinolysin deoxyribonuclease act lytic enzyme combination available ointment containing 1 bu biological unit fibrinolysin 666 bus desoxyribonuclease per gram ointment marketed pfizer brand name fibrolan variety country e.g switzerland currently approved usa ",fibrinolysin assist healing minor burn superficial wound ulcer surgical wound superficial hematoma 
Ronacaleret,ronacaleret calcium-sensing receptor antagonist ,post-menopausal woman osteoporosis
Neocartilage,neocartilage novel cartilage regeneration treatment neocartilage generated juvenile rather adult chondrocytes neocartilage scaffold-free living cartilage graft market ,investigated use/treatment pain acute chronic 
Interferon alfa,natural interferon alpha multiferon obtained leukocyte fraction human blood following induction sendai virus interferon alfa contains several naturally occurring ifn-α subtypes purified affinity chromatography interferon alpha protein mainly involved innate immune response viral infection come 13 subtypes called ifna1 ifna2 ifna4 ifna5 ifna6 ifna7 ifna8 ifna10 ifna13 ifna14 ifna16 ifna17 ifna21 multiferon consists 6 major subtypes ifn-α1 ifn-α2 ifn-α8 ifn-α10 ifn-α14 ifn-α21 ifn-α2 ifn-α14 glycosylated ,investigated use/treatment hepatitis viral c leukemia lymphoid leukemia myeloid leukemia unspecified melanoma 
Glatiramer,glatiramer acetate mix synthetic polypeptide includes l-glutamic acid l-alanine l-tyrosine l-lysine average molar fraction 0.141 0.427 0.095 0.338 respectively l41940 since glatiramer acetate heterogeneous drug limited information physicochemical property a248870 originally glatiramer acetate designed stimulant myelin basic protein mbp myelin antigen involved development multiple sclerosis m induce experimental autoimmune encephalitis m animal model a248870 however opposite observed glatiramer acetate exhibit several immunomodulatory effect reduces relapse rate relapsing-remitting multiple sclerosis rrms 30 a248870 along human interferon beta teriflunomide dimethyl fumarate glatiramer acetate first-line drug patient ms. a248880 approved fda 1996 generic version became available 2017 ,glatiramer acetate indicated treatment relapsing form multiple sclerosis m adult including clinically isolated syndrome relapsing-remitting disease active secondary progressive disease l41940 
Gallium nitrate,gallium nitrate drug used treat hypercalcemia much calcium blood condition may occur secondary certain type cancer gallium nitrate also known common brand name ganite , treatment hypercalcemia also intended treatment non-hodgkin 's lymphoma 
Oxypurinol,oxypurinol inhibitor xanthine oxidase metabolite allopurinol ,intended treatment congestive heart failure hyperuricemia 
Caprospinol,caprospinol sp-233 first drug ever demonstrate correlation clearing beta-amyloid brain also improves brain histopathology recovers memory function ,alzheimer 's disease
NPI 32101,npi 32101 posse anti-inflammatory broad spectrum antimicrobial activity combination pharmacological property may additional therapeutic us beyond dermatology ,atopic dermatitis
Ecabet,ecabet prescription eye drop treatment dry eye syndrome ecabet represents new class molecule increase quantity quality mucin produced conjunctival goblet cell corneal epithelium mucin glycoprotein component tear film lubricates retarding moisture loss tear evaporation ecabet currently marketed japan oral agent treatment gastric ulcer gastritis , treatment reflux oesophagitis peptic ulcer disease 
Ibudilast,ibudilast anti-inflammatory neuroprotective oral agent show excellent safety profile 60 mg/day provides significantly prolonged time-to-first relapse attenuated brain volume shrinkage patient relapsing-remitting rr and/or secondary progressive sp multiple sclerosis m ibudilast currently development u.s. code av-411 mn-166 approved use antiinflammatory japan , treatment multiple sclerosis asthma cerebrovascular disease 
iCo-007,ico-007 formerly known isi 13650 second generation antisense compound developed ico treatment various eye disease caused formation new blood vessel angiogenesis age-related macular degeneration amd diabetic retinopathy dr ,various eye disease
Rotigotine,rotigotine neupro non-ergoline dopamine agonist indicated treatment parkinson 's disease pd restless leg syndrome rls europe united state formulated once-daily transdermal patch provides slow constant supply drug course 24 hour like dopamine agonist rotigotine shown posse antidepressant effect may useful treatment depression well rotigotine developed aderis pharmaceutical 1998 aderis licensed worldwide development commercialization right schwarz pharma germany approved european medicine agency 2006 fda 2007 however neupro patch united state europe recalled 2008 due delivery mechanism issue rotigotine authorized treatment rls since august 2008 , use/treatment neurologic disorder parkinson 's disease well moderate-to-severe primary restless leg syndrome 
Samarium (153Sm) lexidronam,samarium sm 153 lexidronam radioactive medication used treat pain caused cancer spread bone radiopharmaceutical radiopharmaceutical radioactive agent may used diagnose disease studying function body 's organ treat certain diseases.samarium sm 153 lexidronam used help relieve bone pain may occur certain kind cancer radioactive samarium taken bone cancer area give radiation help provide relief pain ,investigated use/treatment bone metastasis multiple myeloma prostate cancer rheumatoid arthritis 
Hepatitis B immune globulin,long-term hepatitis b immune globulin hbig shown reduce hepatitis b virus hbv reinfection patient transplanted hepatitis b infection hepatitis b may lead hepatocellular carcinoma type liver cancer therefore hepatitis-b vaccine cancer-preventing vaccine according center disease control prevention cdc hepatitis b vaccine first anti-cancer vaccine hbig prepared plasma donor high antibody level hepatitis b surface antigen extracted cohn fraction ii process virus deactivated final step solvent used preparation removed preparation tested absence hiv hcv herpes virus reovirus ,investigated use/treatment hepatitis viral b liver transplant surgery pediatric indication 
MCC,mycobacterial cell wall-dna complex mcc formulated mycobacterium phlei non-pathogenic strain mycobacteria mcc shown immune stimulatory apoptosis programmed cell death activity cancer cell product sterile biological composition sub-micron suspension produced bioniche manufacturing facility pointe-claire quebec ,bladder cancer
CA4P,ca4p combretastatin shown laboratory shut blood supply tumour one first vascular targeting drug tested patient drug originally isolated african bush willow first study patient drug aimed finding whether safely given patient side effect produce whether actually shut blood supply human tumour ,
SB-249553,sb-249553 vaccine mage-3 cancer antigen adjuvant sbas-2 also glaxosmithkline treat melanoma lung cancer ,lung cancer/melanoma
Anecortave acetate,anecortave acetate retaane analog cortisol acetate among modification steroid removal 11ß hydroxyl oh group addition 21-acetate group result modification anecortave acetate lack typical antiinflammatory immunosuppressive property glucocorticoids.alcon inc. developing marketing retaane ,investigated use/treatment glaucoma macular degeneration 
Tarenflurbil,tarenflurbil investigational drug studied patient mild alzheimer 's disease selective amyloid lowering agent sala reduces level toxic peptide amyloid beta 42 aβ42 cultured human cell animal model aβ42 primary initiator neurotoxicity amyloid plaque development brain alzheimer 's disease patient june 2008 development drug alzheimer 's disease discontinued tarenflurbil also used trial studying treatment prostate cancer ,investigated use/treatment alzheimer 's disease prostate cancer 
SPP 301,spp301 avosentan potent highly selective et receptor blocker clinically investigated diabetic nephropathy study designed evaluate whether avosentan influence pharmacokinetics steroid oral contraceptive ,investigated use/treatment cardiovascular disorder neuropathy diabetic 
IDM-1,idm-1 idm ’ advanced antibody-based cell drug treatment cancer comprised mak monocytes-derived activated killer cell associated mdx-210 bispecific anti-her-2/neu antibody developed medarex inc ,ovarian cancer
IDM-2,idm-2 composed monocyte-derived activated killer mak cell idm produce mak cell patient 's white blood cell activating cell ex vivo allow recognize destroy tumor cell ,investigated use/treatment bladder cancer 
Vandetanib,vandetanib oral once-daily kinase inhibitor tumour angiogenesis tumour cell proliferation potential use broad range tumour type april 6 2011 vandetanib approved fda treat nonresectable locally advanced metastatic medullary thyroid cancer adult patient ,vandetanib currently approved alternative local therapy unresectable disseminated disease vandetanib prolong q-t interval contraindicated use patient serious cardiac complication congenital long qt syndrome uncompensated heart failure 
Eldecalcitol,eldecalcitol ed-71 vitamin analog potent inhibitor bone resorption alfacalcidol estrogen-deficient rat model osteoporosis eldecalcitol effectively safely increased lumbar hip bone mineral density bmd osteoporotic patient also received vitamin d3 supplementation ,investigated use/treatment osteoporosis 
Motexafin lutetium,motexafin lutetium mlu second-generation photosensitizer photodynamic therapy pdt cancer belongs family drug called metallotexaphyrins also called lutetium texaphyrin motexafin lutetium pentadentate aromatic metallotexaphyrin photosensitizing property ,investigated use/treatment brain cancer breast cancer cervical dysplasia/cancer prostate cancer cancer/tumors unspecified coronary artery disease macular degeneration peripheral vascular disease 
Paclitaxel docosahexaenoic acid, combination dha natural fatty acid paclitaxel anticancer drug studied treatment cancer type mitotic inhibitor ,investigated use/treatment breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer skin cancer 
Tetomilast,tetomilast used trial studying treatment crohn disease colitis ulcerative chronic obstructive pulmonary disease ,investigated use/treatment ulcerative colitis 
Keyhole limpet hemocyanin,keyhole limpet hemocyanin immune modulator given vaccine help body respond cancer natural protein isolated marine mollusc keyhole limpet keyhole limpet hemocyanin immunogenic carrier protein vivo increase antigenic immune response haptens weak antigen idiotype protein ,investigated use/treatment bladder cancer solid tumor 
PTI-801,pti-801 represents new class drug treat pain pti-801 minimize opioid tolerance dependence addiction often associated repeat use oxycodone combination oxycodone ultralow-dose naltrexone opioid antagonist ,investigated use/treatment addiction osteoarthritis pain acute chronic 
LAX-101,lax-101 treat hungtington ’ disease symptom disease active molecule lax-101 eicosapentaenoic acid epa molecule epa identical molecule epa found lax-101 identical molecule epa found fish oil food supplement ,investigated use/treatment depression huntington 's disease 
OMS-103HP,oms103hp first drug developed improve joint function following arthroscopic surgery one common procedure performed today orthopedic surgeon ,investigated use/treatment inflammatory disorder unspecified knee replacement orthopedic surgery pain acute chronic 
Girentuximab,girentuximab monoclonal chimeric mouse/human antibody directed carbonic anhydrase ix antigen expressed 95 clear cell renal cell carcinoma rcc ,investigated use/treatment gall bladder cancer renal cell carcinoma 
Cintredekin besudotox,cintredekin besudotox developed specific tumor-targeting agent administered positive-pressure convection-enhanced delivery ced directly brain tissue risk residual infiltrating glioblastoma multiforme gbm tumor resection cintredekin besudotox made human protein interleukin 13 il13 linked bacterial toxin _pseudomonas exotoxin_ pe il13 portion bind receptor tumor ,investigated use/treatment brain cancer 
Alferminogene tadenovec,alferminogene tadenovec cardium ’ lead product candidate developed potential treatment myocardial ischemia give rise angina symptom associated coronary heart disease alferminogene tadenovec represents new therapeutic class biologics designed promote angiogenesis thereby improve blood flow following one-time intracoronary administration standard cardiac infusion catheter ,investigated use/treatment angina coronary artery disease heart disease 
ANX-510,anx-510 cofactor folate-based biomodulator drug developed enhance activity reduce associated toxicity widely used cancer chemotherapy 5-fluorouracil 5-fu cofactor use 5-fu evaluated clinical trial first line treatment metastatic colorectal cancer ,investigated use/treatment breast cancer colorectal cancer gall bladder cancer pancreatic cancer 
TP-508,tp508 non-proteolytic synthetic peptide representing portion human thrombin originally identified fibroblast high-affinity receptor binding domain ,investigated use/treatment bone fracture diabetic foot ulcer wound 
FP-1096,fp1096 reduced painful symptom endometriosis trial subject minimal side effect ,investigated use/treatment endometriosis 
Ecallantide,ecallantide potent selective human plasma kallikrein inhibitor indicated symptomatic treatment hereditary angioedema ecallantide recombinant 60-amino-acid protein produced _pichia pastoris_ yeast cell contains three intramolecular disulfide bond fda label discovered phage display technology a32017 share sequence similarity naturally occurring human protein tissue-factor pathway inhibitor tfpi also known lipoprotein-associated coagulation inhibitor laci l1458 amino acid sequence two compound differ seven amino acid l1458 ecallantide work blocking kallikrein participate kallikrein-kinin system complex proteolytic cascade initiate inflammatory coagulation pathway fda label protease plasma kallikerin facilitates conversion kininogen bradykinin pro-inflammatory vasodilator increase vascular permeability induces pain a3362 hereditary angioedema rare autosomal dominant disorder mutation c1-esterase-inhibitor c1-inh located chromosome 11q resulting substantially lower level c4 c1-inh activity fda label disorder associated recurrent attack severe swelling thought caused unregulated activity kallikrein excessive bradykinin production fda label reversibly binding plasma kallikrein ecallantide display rapid on-rate slow off-rate result high affinity inhibition picomolar range l1458 ecallantide marketed fda ema trade name kalbitor subcutaneous injection apart fda ema indication ecallantide used label management nonhistaminergic angioedema due hae a32017 ,indicated symptomatic treatment acute attack hereditary angioedema hae patient 12 year age older fda label 
NVS antibody, drug developed using medarex 's ultimab human antibody development system treat autoimmune disease ,investigated use/treatment autoimmune disease rheumatoid arthritis 
MP4,mp4 hemoglobin-based oxygen carrier designed serve alternative blood transfusion free harmful vasoactivity provides targeted oxygen delivery tissue risk oxygen deprivation ,investigated use/treatment hemorrhage transfusion 
MC-1,medicure 's mc-1 drug cardio-protectant designed reduce damage heart artery blocked subsequently reopened bypass surgery ,investigated use/treatment coronary artery disease 
Pimavanserin,psychotic symptom associated parkinson 's disease pd relatively common reducing quality life prognosis individual pd a232783 pimavanserin acp-103 marketed trade name nuplazid drug developed acadia pharmaceutical treatment psychosis related parkinson 's disease due action serotonin receptor lack effect dopamine receptor pimavanserin treat hallucination delusion without causing extrapyramidal symptom a232613 initially approved fda 2016 review potential treatment dementia related psychosis april 2021 fda approval granted indication despite previous breakthrough designation l32913 ,pimavanserin indicated treatment hallucination delusion associated parkinson ’ disease psychosis l32883 
TAK-475,tak-475 `` squalene synthase inhibitor '' type cholesterol-lowering drug yet brought market ,investigated use/treatment hyperlipidemia 
Oportuzumab monatox,vb4-845 studied treatment certain type head neck cancer vb4-845 made linking monoclonal antibody fragment toxic protein may kill cancer cell vb4-845 fusion protein containing humanized scfv specific epithelial cell adhesion molecule ep-cam tumor cell-associated target highly expressed carcinoma cell epithelial origin truncated portion pseudomonas exotoxin ,investigated use/treatment bladder cancer head neck cancer 
ATG-Fresenius S,atg-fresenius concentrated anti-human t-lymphocyte immunoglobulin preparation derived rabbit immunization t-lympoblast cell line atg-fresenius immunosuppressive product prevention treatment acute rejection following organ transplantation ,investigated use/treatment immunosuppressive transplant rejection 
PEG-uricase,peg-uricase polyethylene glycol `` peg '' conjugate recombinant porcine uricase urate oxidase break uric acid deposit studied phase iii clinical trial treatment severe treatment-refractory gout united state 2006 ,investigated use/treatment hyperuricemia 
INGN 201,ingn 201 advexin replication-impaired adenoviral vector carry p53 gene evaluated preclinical clinical trial advexin well-tolerated efficacious treatment numerous cancer monotherapy combination radiation and/or chemotherapy agent ,investigated use/treatment bladder cancer brain cancer breast cancer esophageal cancer head neck cancer lung cancer oral cavity cancer ovarian cancer prostate cancer 
INGN 225,ingn 225 therapeutic consisting cancer patient 's immune cell treated adenovector carrying human p53 gene ad-p53 ingn 225 currently phase 1/2 trial patient small cell lung cancer breast cancer ,investigated use/treatment breast cancer head neck cancer lung cancer 
INKP-102,inkp-102 next generation sodium phosphate tablet designed aid bowl preparation colonoscopy ,investigated use/treatment gastrointestinal disease disorder miscellaneous 
Ranirestat,ranirestat structurally novel stereospecifically potent aldose reductase akr1b ec 1.1.1.21 inhibitor contains succinimide ring undergoes ring-opening physiological ph level used trial studying treatment mild moderate diabetic sensorimotor polyneuropathy ,investigated use/treatment neuropathy diabetic 
VGV-1,vgv-1 potential salvage therapy treatment hiv infected people failed anti-retroviral therapy ,investigated use/treatment hiv infection 
MDX-1379,mdx-1379 vaccine consists two gp100 melanoma peptide drug underinvestigation treat malignant melanoma ,investigated use/treatment melanoma 
ALTU-135,altu-135 company 's orally administered enzyme replacement therapy patient pancreatic insufficiency manufactured blending three drug substance enzyme lipase protease amylase consistent pure enzyme combination designed improve fat protein carbohydrate absorption pancreatic insufficient individual altu-135 granted orphan drug fast-track designation well cma pilot 2 program status food drug administration fda ,investigated use/treatment cystic fibrosis pancreatic disorder 
Romiplostim,romiplostim thrombopoiesis stimulating dimer fc-peptide fusion protein peptibody increase platelet production activation thrombopoietin receptor peptibody molecule two identical single-chain subunit one made 269 amino acid residue subunit consists igg1 fc carrier domain covalently attached polypeptide sequence contains two binding domain interact thrombopoietin receptor c-mpl domain consists 14 amino acid interestingly romiplostim 's amino acid sequence similar endogenous thrombopoietin romiplostim produced recombinant dna technology escherichia coli fda approved august 22 2008 ,treatment chronic immune thrombocytopenic purpura 
TC-5231,tc-5231 small molecule investigation oral treatment adhd attention deficit/hyperactivity disorder tc-5231 mecamylamine hydrochloride active ingredient fda-approved product inversine lower dose inversine ,investigated use/treatment attention deficit/hyperactivity disorder adhd neurologic disorder tourette 's syndrome 
Obiltoxaximab,obiltoxaximab affinity-enhanced monoclonal antibody mab used prevention treatment infection death caused anthrax toxin obiltoxaximab chimeric igg1 kappa monoclonal antibody mab bind pa component b. anthracis toxin approximate molecular weight 148 kda ,investigated use/treatment anthrax exposure bacterial infection crohn 's disease graft versus host disease 
SOT-107,sot-107 drug combination protein called transferrin poison called diphtheria toxin drug treat type brain cancer called high grade glioma brain tumour half brain tumour glioma ,investigated use/treatment brain cancer 
MN-305,mn-305 novel potent highly selective serotonin 5-ht1a receptor agonist development medicinova treatment anxiety disorder beginning generalized anxiety disorder gad ,investigated use/treatment anxiety disorder depression insomnia neurologic disorder 
ATL-2502,atl-2502 colal-pred old drug prednisolone metasulphobenzoate steroid new delivery system release medication colon releasing drug directly colon reduces potential significant side effect often experienced steroid drug colal-pred studied use ulcerative colitis ,investigated use/treatment inflammatory bowel disease ulcerative colitis 
Arundic acid,arundic acid investigated treatment amyotrophic lateral sclerosis al ,investigated use/treatment cerebral ischemia 
Ciliary neurotrophic factor,ciliary neurotrophic factor nt-501 neurotech 's lead product two phase ii/iii clinical trial treatment visual loss associated retinitis pigmentosa phase ii trial treatment dry form age-related macular degeneration neurotech also evaluating factor used proprietary delivery technology encapsulated cell technology ect treat additional retinal disease ,investigated use/treatment eye disorders/infections macular degeneration retinal disorder unspecified 
SO-101,so-101 silenor low-dose oral tablet formulation doxepin hydrochloride patent protected use insomnia doxepin prescribed 40 year treatment depression anxiety dosage typically ranging 75 mg 300 mg per day ,investigated use/treatment insomnia 
WL-1002,wl-1002 developed winston laboratory topical cream formulation 075 zucapaicin also known civamide treatment pain due osteoarthritis ,investigated use/treatment osteoarthritis pain acute chronic 
Dexlansoprazole,dexlansoprazole new generation proton pump inhibitor ppi used management symptom associated gastroesophageal reflux disease gerd erosive esophagitis dexlansoprazole r-enantiomer db00448 composed racemic mixture r- s-enantiomers compared older generation ppis includes db00213 db00338 db00448 a178084 dexlansoprazole mr unique pharmacokinetic profile due delayed-release dual-delivery release system active ingredient released two phase different ph value different time point resulting two peak concentration blood 25 dose released ph 5.5 proximal duodenum remaining 75 released ph 6.75 distal small intestine a19567 result dexlansoprazole peak concentration within 1-2 hour dosing another within 4-5 hour fda label dexlansoprazole 's unique pharmacokinetics address limitation older generation ppis including short plasma half-life break-through symptom need meal-associated dosing a19568 characteristic make dexlansoprazole good option people struggle adherence strict dosage timing meal a178087 a19566 dexlansoprazole exerts stomach acid-suppressing effect way drug ppi family inhibiting final step gastric acid production dexlansoprazole target h+ k+ -atpase enzyme involved secretion hydrochloric acid exchange h+ ion cytoplasm k+ ion normally functioning h+ k+ -atpase stimulates hydrochloric acid secretion gastric lumen thereby increasing stomach acidity lowering ph absorbed circulation dexlansoprazole covalently bind sulfhydryl group cysteine found h+ k+ -atpase enzyme secretory surface gastric parietal cell lead inhibition basal stimulated gastric acid secretion despite dexlansoprazole 's unique pharmacokinetic profile efficacy management gerd symptom considered similar medication within ppi class including db00338 db00736 db00448 db00213 db01129 due good safety profile several ppis available counter without prescription current use north america widespread long term use ppis dexlansoprazole associated possible adverse effect however including increased susceptibility bacterial infection including gastrointestinal _c difficile_ reduced absorption micronutrient including iron b12 increased risk developing hypomagnesemia hypocalcemia may contribute osteoporosis bone fracture later life a177571 ppis dexlansoprazole also shown inhibit activity dimethylarginine dimethylaminohydrolase ddah enzyme necessary cardiovascular health ddah inhibition cause consequent accumulation nitric oxide synthase inhibitor asymmetric dimethylarginine adma thought cause association ppis increased risk cardiovascular event patient unstable coronary syndrome a177577 a177580 dexlansoprazole dos slowly lowered tapered discontinuing rapid discontinuation ppis dexlansoprazole may cause rebound effect short term increase hypersecretion a177574 ,dexlansoprazole indicated healing grade erosive esophagitis ee maintaining healing ee relief heartburn treating heartburn associated symptomatic non-erosive gastroesophageal reflux disease gerd 
Fx-1006A,fx-1006a small molecule compound potential treat genetic disorder familial amyloid cardiomyopathy fac familial amyloid polyneuropathy fap ,investigated use/treatment amyloidosis 
CMC 001,cmc 001 orally administered mri contrast agent development enhancement liver bile duct gastrointestinal tract ,investigated use/treatment liver cancer 
SR-123781A,sr-123781a synthetic hexadecasaccharide factor iia xa antagonist investigation sanofi-aventis organon treatment thrombosis acute coronary syndrome ac ,investigated use/treatment cardiovascular disorder thrombosis venous thromboembolism 
SSR-126517E,ssr-126517e second generation synthetic pentasaccharide bind antithrombin high affinity assumes plasma half-life 80 hour ,investigated use/treatment thrombosis venous thromboembolism 
LIC-477,lic-477is indicated suitable treatment psychosomatic disturbance epilepsy trigeminal neuralgia cerebral spasticity ,investigated use/treatment bipolar disorder 
ROX-888,rox-888 roxro 's lead compound currently phase 3 trial treatment acute pain including post-operative pain ,investigated use/treatment pain acute chronic 
Actelion-1,actelion-1 tissue-targeting endothelin receptor antagonist discovered actelion pharmaceutical ,investigated use/treatment cardiovascular disorder hypertension pulmonary hypertension 
Ragweed pollen extract,ragweed pollen extract developed curalogic company initiated phase iii trial product oral immunotherapy ragweed allergy traditional disease-modifying immunotherapeutics administered subcutaneous injection curalogic developed convenient orally administered drug ,investigated use/treatment allergic reaction 
HZT-501,hzt-501 investigation horizon therapeutic inc. privately held biopharmaceutical company entered phase 3 clinical trial march 2007 reduction risk development ibuprofen-associated upper gastrointestinal i.e. gastric and/or duodenal ulcer hzt-501 combination product including ibuprofen acid reducing agent famotidine ,investigated use/treatment pain acute chronic 
ACR-16,acr-16 investigation neurosearch acr16 successfully investigated phase ii multi-centre randomised placebo-controlled trial patient huntington ’ disease well three phase ib study within huntington ’ disease parkinson ’ disease schizophrenia respectively acr-16 dopamine stabilizer acr-16 also studied psychiatric neurologic disease ,investigated use/treatment huntington 's disease schizophrenia schizoaffective disorder 
Rindopepimut,rindopepimut cdx-110 injectable peptide cancer vaccine target mutant protein called egfrviii present 25 30 glioblastoma case vaccine consists egfrv3-specific peptide 13-amino acid mutant viii epitope conjugated non-specific immunomodulator keyhole limpet hemocyanin klh u fda granted breakthrough therapy designation glioblastoma feb 2015 ,investigated use/treatment brain cancer 
Chlorfenson,chlorfenson developed moberg derma treatment onychomycosis nail fungus primary indication ,investigated use/treatment fungal infection 
DOTMP HO-166,dotmp ho-166 used skeletal targeted radiotherapy str srt designed used combination high-dose chemotherapy producing direct therapeutic effect tumor site bone plus general bone-marrow effect destroy myeloma cell bone marrow experimental therapy developed neorx corporation ,investigated use/treatment multiple myeloma 
Histamine, depressor amine derived enzymatic decarboxylation histidine powerful stimulant gastric secretion constrictor bronchial smooth muscle vasodilator also centrally acting neurotransmitter ,histamine phosphate indicated diagnostic aid evaluation gastric acid secretory function 
Iodine,iodine commonly used antiseptic minor cut abrasion preventing infection may result contaminated wound additionally iodine studied treatment fibrocystic disease breast cancer a3413 a192153 a192156 a192159 ,investigated use/treatment breast disorder unspecified pain acute chronic 
Pimagedine,pimagedine developed synvista therapeutic inc treatment diabetic kidney disease advanced glycation end product inhibitor manages diabetic nephropathy either alone combination therapy beneficial treating patient diabetic nephropathy ,investigated use/treatment diabetic kidney disease 
Carbopol 974P,carbopol 974p highly carboxylated polymer composed lightly cross-linked polyacrylic acid broad-spectrum mechanism based acidification pathogen development reprotect llc gel may help block spread sexually transmitted disease reduce unwanted pregnancy compound known buffergel advanced clinical trial ability prevent pregnancy discontinued ,investigated use/treatment contraception hiv prevention 
PRO 2000,pro 2000 investigational medicine yet approved fda use outside clinical trial studied prevention hiv infection sexually transmitted disease medicine cure hiv infection aid studied reduce risk passing virus people ,investigated use/treatment hiv prevention prevention stdis vaginal infection 
Regramostim,regramostim gm-csf differentially glycosylated factor produced mainly activated cell macrophage endothelial cell fibroblast also produce gm-csf exposure tnf-α il-1 il-2 ifn-γ gm-csf found associated extracellular matrix membrane-bound format gm-csf stimulates proliferation activation differentiation macrophage granulocyte progenitor ,investigated use/treatment adverse effect chemotherapy bone marrow transplant 
AE-941,ae-941 naturally occurring anti-angiogenic compound extracted cartilage multiple anti-angiogenic mechanism action provide broad therapeutic potential number disease currently international phase iii trial renal cell carcinoma non-small-cell lung cancer ,investigated use/treatment kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer psoriasis psoriatic disorder 
Tetrachlorodecaoxide,wf10 chlorite-based immunomodulating drug developed nuvo research inc. certain preclinical evidence clinical pilot data suggest wf10 may effective treating certain cancer corporation belief research to-date demonstrates wf10 act macrophage type white blood cell modulating balance inflammation phagocytosis state body digest foreign potentially harmful substance corporation commenced phase ii clinical trial effort demonstrate efficacy wf10 combination xeloda capecitabine treatment pancreatic cancer trial conducted germany university heidelberg national centre tumor disease ,investigated use/treatment acquired immune deficiency syndrome aid aids-related infection cancer/tumors unspecified hiv infection inflammatory disorder unspecified 
INS 316,ins316 belongs family drug called nucleoside triphosphates.it studied diagnosis lung disease including lung cancer selective p2y2 receptor antagonist claimed useful anti-inflammatory agent ,investigated use/treatment lung cancer 
liposomal prostaglandin E1,liposome-encapsulated form prostaglandin e1 liprostin known potent vasodilator platelet inhibitor well anti-inflammatory anti-thrombotic agent liposomal formulation pge-1 change drug ’ dynamic improve therapeutic index way pge-1 alone could achieve ,investigated use/treatment neuropathy diabetic peripheral vascular disease 
NOV-002,"nov-002 lead compound act chemoprotectant immunomodulator combination chemotherapy nov-002 approved marketed russian fereration pharma bam trade name glutoxim administered 10,000 patient demonstrating clinical efficacy excellent safety data ",investigated use/treatment breast cancer lung cancer ovarian cancer 
Corticorelin,corticotropin-releasing factor studied treatment brain cancer made naturally hypothalamus part brain also made laboratory human corticotropin-releasing factor may help reduce symptom caused edema swelling brain type neurohormone also called hcrf ,investigated use/treatment brain cancer neurologic disorder 
Amibegron,amibegron agonist atypical beta3-adrenoceptors inhibits intestinal motility ,investigated use/treatment depression irritable bowel syndrome ibs obesity 
Albinterferon Alfa-2B,albumin-interferon alpha albuferon novel long-acting form interferon alpha recombinant interferon alpha approved treatment hepatitis c hepatitis b broad range cancer human genome science modified interferon alpha improve pharmacological property using company 's proprietary albumin fusion technology human genome science developing albuferon potential treatment chronic hepatitis c. drug investigation alternative pegylated ifn-α-2a treatment hepatitis c. response fda ruling novartis human genome science announced october 5 2010 ceased development drug ,investigated use/treatment hepatitis viral c 
C31G,c31g potent broad spectrum antimicrobial agent effective gram positive gram negative bacteria yeast fungi.c31g vaginal gel developed biosyn inc. commenced enrollment phase iii pivotal clinical trial reduction sexual transmission human immunodeficiency virus hiv ,investigated use/treatment contraception hiv infection prevention stdis 
Succinobucol,agi-1067 novel small molecule anti-oxidant anti-inflammatory property discovered atherogenics designed treat atherosclerosis blood vessel heart coronary artery disease ,investigated use/treatment atherosclerosis coronary artery disease diabetes mellitus type 2 in-stent restenosis 
QS-21,qs-21 investigational adjuvant substance added vaccine immunotherapy designed enhance body ’ immune response antigen contained within treatment leading member stimulon family adjuvant vaccine additive currently evaluated clinical trial variety disease area antigenics ,investigated use/treatment genital herpes hiv infection hepatitis viral b influenza malaria melanoma viral infection 
CEP-1347,cep-1347 semi-synthetic compound shown protect multiple nerve cell type variety insult leading programmed cell death apoptosis could improve survival dopamine neuron prior transplantation ,investigated use/treatment asthma parkinson 's disease 
AZD 3355,azd 3355 reflux inhibitor used treatment gastroesophageal reflux disease developed astrazeneca currently phase i/ii trial ,investigated use/treatment gastroesophageal reflux disease gerd 
XTL-001,xtl001 investigational monoclonal antibody mab product developed xtl biopharmaceuticals evaluate safety profile antiviral activity compound patient chronically infected hepatitis b virus hbv ,investigated use/treatment hepatitis viral b 
GTI-2501,gti-2501 novel antisense drug shown favorable safety profile preclinical study phase clinical trial drug phase ii clinical trial combination docetaxel treatment hormone refractory prostate cancer initial testing demonstrated strong antitumor activity preclinical study prostate cancer variety tumor type ,investigated use/treatment prostate cancer solid tumor 
TBC-3711,tbc3711 next-generation endothelin antagonist studied oral intravenous formulation encysive pharmaceutical ,investigated use/treatment congestive heart failure hypertension pulmonary hypertension 
Emricasan,emricasan first caspase inhibitor tested human received orphan drug status fda developed pfizer made way protects liver cell excessive apoptosis ,investigated use/treatment hepatitis viral c liver disease transplantation organ tissue 
NCX 701,nitroparacetamol ncx-701 newly synthesized nitric oxide-releasing derivative paracetamol ,investigated use/treatment pain acute chronic 
NCX 1022,ncx no-releasing derivative hydrocortisone ,investigated use/treatment atopic dermatitis 
VB2-011,vb2-011 antibody developed anti-cancer treatment according preclinical study potential inhibit tumour growth various cancer including lymphoma melanoma drug includes parent igm h11 igm recombinant igg version h11 igg ,investigated use/treatment cancer/tumors unspecified 
Talmapimod,talmapimod first-generation oral p38 map kinase inhibitor developed scios shown effective cure inflammatory disease rheumatoid arthritis ,investigated use/treatment pain acute chronic rheumatoid arthritis 
Tifuvirtide,tifuvirtide first member new class anti-hiv drug also called fusion inhibitor received fast-track designation fda phase i/ii clinical testing ,investigated use/treatment acquired immune deficiency syndrome aid aids-related infection hiv infection 
Pipendoxifene,er modulator era-923 pipendoxifene estrogen receptor modulator evaluated treatment breast cancer pipendoxifene new 2-phenyl indole selective estrogen receptor modulators serm exhibit excellent preclinical pharmacological profile selected development treatment metastatic breast cancer ,investigated use/treatment breast cancer 
OSI-461,osi-461 second-generation molecule belonging new class drug termed selective apoptotic anti-neoplastic drug saands ,investigated use/treatment crohn 's disease inflammatory bowel disease kidney cancer leukemia lymphoid prostate cancer 
Cardarine,cardarine gw-501516 peroxisome proliferator-activator receptor-delta agonist potential treatment dyslipidemia cardarine investigated treatment obesity lipid disorder cardiovascular disease ,investigated use/treatment hyperlipidemia 
GW 468816,gw 468816 glycine receptor antagonist designed aid abstinence people quit smoking delaying time relapse undergoing phase ii trial since december 2003 ,investigated use/treatment tobacco dependence 
GW 597599,gw 597599 neurokinin-1 nk1 receptor antagonist currently phase ii trial chemotherapy-induced vomiting functional dyspepsia depression anxiety ,investigated use/treatment adverse effect chemotherapy anxiety disorder depression gastrointestinal disease disorder miscellaneous 
ADX-10061,adx10061 potent selective antagonist dopamine d1 receptor developed addex pharmaceutical treatment nicotine dependence ,investigated use/treatment sleep disorder smoking cessation substance abuse 
Gallium maltolate,gallium maltolate titan ’ novel oral agent development potential treatment chronic bacterial infection bone disease cancer ,investigated use/treatment bladder cancer lymphoma unspecified multiple myeloma paget 's disease prostate cancer 
CP-122721,cp-122721 neurokinin 1 nk1 antagonist developed pfizer treat depression emesis inflammatory disease including asthma irritable bowel syndrome ,investigated use/treatment asthma depression irritable bowel syndrome ibs 
OPC-14523,opc-14523 antidepressant drug developed otsuka america pharmaceutical ,investigated use/treatment bulimia depression obsessive-compulsive disorder 
ORG-34517,org-34517 currently investigation organon treatment depression potential treat number disease cushing ’ disease hypertension diabetes glaucoma etc activity metabolite corticosterone cortisol high ,investigated use/treatment depression 
Canertinib,canertinib pan-erbb tyrosine kinase inhibitor work esophageal squamous cell carcinoma vitro vivo canertinib treatment significantly affect tumour metabolism proliferation hypoxia determined pet ,investigated use/treatment breast cancer lung cancer 
Talactoferrin alfa,talactoferrin alfa novel immunomodulatory 80 kd protein demonstrated oral anti-tumor property lactoferrin protein found breast milk developed agennix increase body ’ immune power also work natural antioxidant helping control cell tissue damage caused oxidation ,investigated use/treatment adverse effect chemotherapy cancer/tumors unspecified diabetic foot ulcer lung cancer solid tumor ulcer 
IDD-3,idd-3 therapeutic specific immunostimulant developed idm pharma partnership sanofi-aventis consists mature dendritic cell loaded lysates melanoma tumor cell line includes dendritophages dendritic cell type specialized immune cell derived patient 's white blood cell ,investigated use/treatment melanoma 
Motexafin gadolinium,motexafin gadolinium studied treatment cancer pharmacyclics may make tumor cell sensitive radiation therapy improve tumor image using magnetic resonance imaging mri kill cancer cell belongs family drug called metalloporphyrin complex also called gadolinium texaphyrin ,investigated use/treatment brain cancer cancer/tumors unspecified lung cancer lymphoma non-hodgkin 's 
CAT-213,cat-213 fully human anti-eotaxin monoclonal antibody potential treatment allergic disorder moved pre-clinical development developed medimmune treatment allergic rhinitis ,investigated use/treatment allergic rhinitis 
VLTS-589,vlts-589 consists plasmid encoding angiomatrix protein del-1 conjunction poloxamer 188 treatment peripheral vascular disease ,investigated use/treatment peripheral vascular disease 
MLN-977,mln-977 small molecule compound inhibits production leukotrienes especially 5-lipoxygenase developed pharmaengine treat asthma chronic obstructive pulmonary disease ,investigated use/treatment asthma chronic obstructive pulmonary disease copd 
DAS-431 IV,das-431 iv dopamine d1 receptor agonist developed drugabuse science treatment addiction schizophrenia schizoaffective disorder dementia parkinson 's disease stroke etc ,investigated use/treatment addiction dementia parkinson 's disease schizophrenia schizoaffective disorder stroke 
rGLP-1,rglp-1 continuous infusion glucagon-like peptide 1 glp-1 targeted treatment congestive heart failure chf patient ineligible transplant glp-1 naturally occurring hormone produced intestine response food intake ,investigated use/treatment congestive heart failure diabetes mellitus type 2 
ABT-510,abt-510 peptide mimetics thrombospondin-1 tsp-1 block angiogenesis vitro vivo slow tumor growth developed abbott laboratory treatment solid tumor lymphoma melanoma ,investigated use/treatment lymphoma unspecified melanoma solid tumor 
NAV 1800,rigscan cr49 125i-labelled cr monoclonal antibody directed tumour-associated antigen tag-72 undergoing development neoprobe intraoperative detection metastatic colorectal cancer ,investigated use/treatment colorectal cancer solid tumor 
IDM-4,idm-4 immuno-designed molecule completed phase i/ii investigation treatment leukemia monoclonal antibody-specific antigen selectively target cancer-affected cell coupling tumor cell-killing mak cell derived patient 's monocyte trial drug likely discontinued manufacturer ,investigated use/treatment leukemia lymphoid 
IDD-1,lipid promote fusion liposome cell eladem idd-1 therapeutic vaccine consisting dendritophages loaded vitro tumor antigen reinjected subject monoclonal antibody process stimulates immune response particular disease-related antigen ,investigated use/treatment prostate cancer 
SRP 299,srp 299 preparation killed mycobacterium vaccae tested us related inhibiting periodontal disease treating asthma treating eczema itching inflammation mycobacterium vaccae non-pathogenic saprophytic bacteria whose antigen used induce peripheral immune activation activity regulatory t-cells surpress inappropriate th2 activity specific subset serotonergic neuron interfascicular part dorsal raphe nucleus dri believed involved based study mouse ,investigated use/treatment asthma atopic dermatitis pediatric atopic dermatitis indication 
AVAC,avac derived m. vaccae tested us related asthma treating eczema atopic dermatitis.mycobacterium vaccae non-pathogenic saprophytic bacteria whose antigen used induce peripheral immune activation activity regulatory t-cells surpress inappropriate th2 activity ,investigated use/treatment asthma atopic dermatitis 
Etiprednol dicloacetate,etiprednol dicloacetate bnp-166 soft corticosteroid anti-inflammatory property indicated treatment asthma chron 's disease anti-asthmatic effect associated decreased cytokine production lipopolysaccharide-stimulated lymphocyte attenuated lectin-induced proliferation blood mononuclear cell tissue culture ,investigated use/treatment asthma crohn 's disease 
ADL 10-0101,adl 10-0101 peripheral kappa opioid agonist analgesic product candidate preclinical trial adl 10-0101 suggested compound may effective treatment inflammatory pain itch visceral pain adl 10-0101 cross blood-brain barrier enter brain administered therapeutic dos expected avoid central nervous system side effect ,investigated use/treatment pain acute chronic rheumatoid arthritis trial also conducted relieving burn pain dermal itch 
Iroxanadine,brx-235 iroxanadine novel small molecule synthesized biorex hungary act cardioprotective agent induces phosphorylation p38 sapk play important role ec homeostasis endothelial cell ec ec function play central role vascular disease e.g atherosclerosis restenosis diabetic angiopathy microvascular angina peripheral arterial disease brx-235 also cause translocation calcium-dependent protein kinase c isoform membrane ,investigated use/treatment atherosclerosis vascular disease cardioprotective agent use also suggested prevention early restenosis following vascular surgery balloon angioplasty 
TA-NIC,ta-nic novel proprietary vaccine development aid quitting smoking motivated patient designed raise anti-nicotine antibody bind nicotine molecule patient 's blood stream reducing rate quantity nicotine entry brain reduce addictive reward associated smoking ,investigated use/treatment tobacco dependence 
LJP 1082,ljp 1082 toleragen designed shut b cell produce antibody ß2 gp1 ljp 1082 undergoing trial treatment stroke deep-vein thrombosis condition associated antibody-mediated thrombosis antibody-mediated thrombosis also called antiphospholipid syndrome aps blood clotting disorder patient high level anticardiolipin antibody aca increased risk stroke heart attack deep vein thrombosis recurrent fetal loss target ljp 1082 's clot-promoting antibody small region key blood protein called beta 2-glycoprotein date scientist shown approximately 90 patient studied antibody-mediated thrombosis antibody bind region ,investigated use/treatment autoimmune disease stroke thrombosis 
AVI-4557,avi-4557 oral antisense compound selectively inhibits metabolic enzyme cytochrome p450 3a4 cyp liver enzyme responsible metabolism breakdown approximately half currently marketed drug study indicate avi-4557 successfully reduce rate metabolism certain drug therefore allowing greater longer availability drug patient 's system decrease clearance increase maximal blood concentration cmax avi-4557 therefore indicated limit toxicity patient receiving highly-toxic therapeutic drug treatment anxiety cancer number serious condition ,investigated use/treatment adverse effect chemotherapy adverse effect drug 
PX-12,px-12 1-methylpropyl 2-imidazolyl disulfide small-molecule inhibitor trx-1 thioredoxin-1 stimulates apoptosis down-regulates hif-1α vascular endothelial growth factor vegf inhibits tumor growth animal model since high level trx-1 associated colorectal gastric lung cancer px-12 indicated potential cancer treatment combination chemotherapy patient advanced metastatic cancer initial trial correlated dos px-12 increased patient survival ,investigated use/treatment cancer/tumors unspecified gastric cancer pancreatic cancer 
FM-VP4,fm-vp4 novel hydrophilic phytostanol analogue representing new class cholesterol-lowering drug called cholesterol absorption inhibitor fm-vp4 shown inhibit cholesterol absorption lower plasma ldl-cholesterol total cholesterol broad range animal specie additional experiment suggest fm-vp4 reduce plasma ldl cholesterol level triglyceride level reduce weight gain exert anti-atherosclerosis effect ,investigated use/treatment hyperlipidemia cancer/tumors unspecified monotherapy recommended people marginally high ldl-cholesterol prescribed statin due drug interaction safety concern combination therapy recommended statin therapy alone either insufficient achieve guideline set ncep concern side effect statin dos lowered combination treatment without losing efficacy 
Smilagenin,smilagenin novel non-peptide orally bioavailable neurotrophic factor inducer readily revers free radical neurotoxicity produced 1-ethyl-4- phenylpyridium mpp+ dopaminergic neurones revers decrease neuronal growth factor dopamine receptor brain pre-clinical work smilagenin showed neuroprotective betya-amyloid glutamate damage contributes alzheimer 's disease revers change area brain involved parkinson ’ disease p58 protein synthesis stimulant act restoring level protein altered ageing brain reversing loss nerve receptor ageing brain potentially allowing regrowth neural connection p58 therefore provides totally novel mode action potential importance disease associated ageing brain p58 one family phytochemical isolated traditional treatment elderly previously shown offer significant benefit treatment senile dementia ,investigated use/treatment alzheimer 's disease parkinson 's disease neurodegenerative disease 
P54,p54 reduces inflammation associated cancer/tumors crohn 's disease inflammatory bowel disease osteoarthritis ulcerative colitis inhibits induction enzyme nfkb thereby inhibiting downstream inflammatory gene cox ii inos ,investigated use/treatment cancer/tumors unspecified crohn 's disease inflammatory bowel disease osteoarthritis ulcerative colitis 
PH-284,ph-284 belongs new family new chemical entity called vomeropherins vomeropherins self-administered patient metered nasal spray nasal aerosol device bind peripheral chemosensory receptor nasal passage binding produce neural impulse transmitted specific pathway hypothalamic centre directly rapidly affect brain function ph-284 investigation pherin organon treatment anorexia nervosa loss appetite cachexia cancer aid patient ,investigated use/treatment anorexia condition causing harmful weight loss manufacturer suggests could relevant treatment weight loss associated symptom -- i.e. lack energy decrease appetite physical wasting vulnerability toxicity sometimes reduced life expectancy -- patient eating disorder patient advanced cancer patient aid patient experiencing loss appetite due aging acute illness pregnancy 
Paliroden,paliroden orally active neurotrophic non-peptidic compound activates synthesis endogenous neurotrophines study show use paliroden increased rate formation neural progenitor mature neuron indicated use alzheimer 's disease parkinson ’ ,investigated use/treatment alzheimer 's disease parkinson 's disease 
SR 121463,sr 121463 nonpeptide aquaretic compound potent selective antagonism vasopressin v2 v1b receptor subtype candidate control hyponatremia treatment syndrome inappropriate secretion anti-diuretic hormone siadh ,investigated use/treatment cardiovascular disorder treatment syndrome inappropriate secretion anti-diuretic hormone siadh hyponatremia 
ETC-588,etc-588 luv large unilamellar vesicle made naturally occurring lipid circulate artery facilitate role high-density lipoprotein hdl removing accumulated cholesterol lipid cell including arterial wall luv capable transporting excess cholesterol vasculature liver eventual elimination part reverse lipid transport rlt pathway believed removal cholesterol etc-588 pathway may result reversal atherosclerosis esperion currently developing etc-588 treatment patient acute coronary syndrome ,investigated use/treatment atherosclerosis coronary artery disease vascular disease 
OSI-7904L,osi-7904l liposome encapsulated thymidylate synthase inhibitor indicated use advanced gastric and/or gastroesophageal adenocarcinoma a-g/geja current treatment also inhibit thymidylate synthase innovative lipid coating osi-7904l allows enduring result administration t inhibitor ,investigated use/treatment gastric cancer 
Pozanicline,abt-089 neuronal nicotinic acetylcholine receptor agonist may therapeutic utility treatment several neurological disorder including alzheimer attention deficit hyperactivity disorder schizophrenia/schizoaffective disorder radioligand binding study abt-089 shown selectivity toward alpha4beta2 nachr subtype compared alpha7 alpha1beta1deltagamma nachr subtypes neuronal nicotinic acetylcholine receptor nachrs modulate release several important neurotransmitter acetylcholine dopamine ,investigated use/treatment alzheimer 's disease attention deficit/hyperactivity disorder adhd schizophrenia schizoaffective disorder 
Briakinumab,briakinumab human anti-il-12 monoclonal antibody developed treatment number t-cell driven autoimmune disease target neutralize interleukin-12 interleukin-23 two protein associated inflammation pro-inflammatory interleukin tumor necrosis factor- alpha briakinumab represents novel approach treating psoriasis multiple sclerosis crohn ’ disease autoimmune inflammatory disorder 2011 drug development psoriasis discontinued u.s. europe ,investigated use/treatment autoimmune disease crohn 's disease multiple sclerosis psoriasis psoriatic disorder rheumatoid arthritis 
Ezatiostat,ezatiostat investigated clinical trial treating myelodysplastic syndrome compound belongs peptide compound containing amide derived two amino carboxylic acid molecule different formation covalent bond carbonyl carbon one nitrogen atom another medication known target glutathione s-transferase p. ezatiostat small molecule drug analog inhibitor glutathione s-transferase p1-1 act intracellularly mapk signaling pathway activating erk2 ezatiostat myelostimulant activity preclinical rodent model human bone marrow culture differentiates granulocyte monocyte hl60 cell ezatiostat candidate designed stimulate formation bone marrow cell precursor granulocyte monocyte white blood cell erythrocyte red blood cell platelet many condition characterized depleted bone marrow including myelodysplastic syndrome md form pre-leukemia bone marrow produce insufficient level one 3 major blood element white blood cell red blood cell platelet might also relevant adjunct therapy since reduction blood cell level also common toxic effect many standard chemotherapeutic drug ,investigated use/treatment myelodysplastic syndrome 
OPC-28326, low dos opc 28326 selectively vasodilates femoral arterial bed due inhibitory action alpha-2-adrenoceptors minimal action systemic blood pressure heart rate coronary carotid vertebral renal mesenteric blood flow clinical compound profile currently investigated treatment peripheral vascular disease raynaud 's syndrome ,investigated use/treatment peripheral vascular disease raynaud 's disease 
Chlorotoxin I-131,chlorotoxin i-131 investigated clinical trial treating brain cancer chlorotoxin i-131 bind reduces activity matrix metalloproteinase mmp regulates functioning chloride channel cell membrane chlorotoxin small 36-amino-acid peptide selectively bind glioma cell normal brain parenchyma synthetic version neurotoxin isolated venom giant yellow israeli scorpion leiurus quinquestriatus synthetic version peptide manufactured covalently linked iodine 131 mean targeting radiation tumor cell treatment brain cancer selective effect chlorotoxin i-131 regulated action mmp2 receptor ,investigated use/treatment various form brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma oligo-astrocytoma gliosarcoma
ISS-1018,i 1018 short synthetic unmethylated cpg oligodeoxynucleotide cpg odn immunostimulatory activity i 1018 signal toll-like receptor 9 tlr9 induce production immunoglobulin b cell interferon ifn -alpha ifn-beta interleukin-12 il-12 tumor necrosis factor alpha tnf-alpha plasmacytoid dendritic cell pdc i 1018 cpg odn promotes antigen presentation co-stimulatory molecule expression i 1018 currently investigated combination hbsag vaccine prophylactic treatment prevent hepatitis b adult also investigated combination rituximab treatment b-cell non-hodgkin 's lymphoma ,investigated use/treatment colorectal cancer hepatitis viral b lymphoma non-hodgkin 's i 1018 currently investigated combination hbsag vaccine prophylactic treatment prevent hepatitis b adult also investigated combination rituximab treatment b-cell non-hodgkin 's lymphoma 
NOX-700,nox-700 new orally active dithiocarbamate-based nitric oxide blocking agent development treatment diabetes mellitus type 2 diabetes animal study nox-700 lowered serum glucose improved glucose tolerance reduced percentage total glycated hemoglobin immunohistochemical study pancreatic tissue also showed nox-700 therapy effectively preserved islet structure increased insulin immunoreactivity since found oxidative signaling redox-sensitive transcription factor nf-κb inhibiting protein glycation responsible drug 's therapeutic effect ,investigated use/treatment diabetes mellitus type 2 
Tandutinib,mln518 novel oral small molecule designed inhibit type iii receptor tyrosine kinase including flt3 platelet-derived growth-factor receptor pdgfr c-kit tyrosine kinase enzyme involved several cellular process known activated cancer cell drive tumor growth aml patient flt3 mutation experience earlier disease relapse shorter survival rate compared patient without mutation approximately 25 30 percent adult aml patient mutation flt3 gene use mln518 treat aml granted fast-track status u.s. food drug administration phase i/ii trial underway ,investigated use/treatment leukemia myeloid 
R673,r673 novel nk1 antagonist penetrates blood-brain barrier excellent safety tolerability show low p450-based drug interaction potential phase ii program treatment depression anxiety ongoing u eu.it clear tachykinin antagonist exert effect sp level commonly linked functioning limbic system respect anxiety depression ,investigated use/treatment depression anxiety 
Palovarotene,fibrodysplasia ossificans progressiva fop estimated worldwide prevalence one 2 million individual a244920 exceptionally rare genetic disorder fop caused gain-of-function mutation acvr1/alk2 gene result progressive heterotopic ossification process wherein connective tissue e.g skeletal muscle ligament tendon replaced bone a244920 ossification occurring result fop insidious cumulative provoked flare-up response injury treatment option patient fop extremely limited although substantial recent interest novel treatment disease a244920 palovarotene selective agonist retinoic acid receptor gamma rarγ belonging class medication known retinoids similar mechanism drug like tazarotene trifarotene derivative vitamin first garnered interest potential treatment emphysema a3568 a3570 eventually recognized potential novel therapy patient fop a244920 agonist retinoic acid receptor shown inhibit chondrogenesis heterotopic ossification transgenic mouse model fop selective rarγ agonist e.g palovarotene demonstrating greatest efficacy a244920 palovarotene approved use canada january 2022 management heterotopic ossification patient fop l39990 representing first global approval fop therapy l40020 granted rare pediatric disease breakthrough therapy designation u fda although previously submitted nda withdrawn august 2021 pending resubmission additional data analysis l40010 ,palovarotene indicated canada reduce formation heterotopic ossification adult child ≥8 year old female ≥10 year old male fibrodysplasia ossificans progressiva fop l39990 
R411,r411 non-steroid oral medicine treatment asthma immunosuppressive block activation recruitment cell involved respiratory inflammation dual-acting competitive integrin antagonist compared previously developed single integrin antagonist sias prevents binding v-cam1 either a4b1 a4b7 ,investigated use/treatment asthma 
R450,r450 alpha 1 antagonist act tighten muscle tone bladder considered treatment stress-related urinary incontinence phase iia data drug show reduced number incontinent episode compared placebo minimal cardiovascular effect ,investigated use/treatment urinary incontinence 
VX-702,vx-702 small molecule investigational oral anti-cytokine therapy treatment inflammatory disease specifically rheumatoid arthritis ra act p38 map kinase inhibitor future vx-702 may investigated combination methotrexate commonly used therapy ra ,investigated use/treatment coronary artery disease inflammatory disorder unspecified rheumatoid arthritis 
SGN-30,sgn-30 engineered monoclonal antibody mab reacts significant affinity cd30 antigen highly expressed variety hematologic malignancy compared normal cell sgn-30 shown induce direct anti-cancer activity towards tumor cell expressing cd30 undergoing phase ii trial cancer therapy sgn-30 demonstrated objective antitumor response single agent phase ii clinical trial collaborating national cancer institute nci three clinical trial sgn-30 combination chemotherapy treatment relapsed hodgkin lymphoma front-line alcl pediatric alcl sgn-30 received orphan drug designation fda july 2003 hodgkin lymphoma february 2004 t-cell lymphoma ,investigated use/treatment autoimmune disease cancer/tumors unspecified lymphoma non-hodgkin 's lymphoma unspecified 
Human interferon omega-1,human interferon omega 1 ifn-omega 1 ifn-alpha ii1 recently discovered protein structurally related ifn-alpha -beta occurs naturally human body currently manufactured intarcia genetic engineering multiple route administration omega interferon injection implantable subcutaneous drug delivery system oral formulation investigated single combination treatment biological activity ifn-omega 1 physiological role known date ,investigated use/treatment hepatitis viral c 
QR-334,qr-334 investigation treatment sialorrhea sialorrhea excess secretion saliva produced salivary gland resulting drooling pharmaceutical intervention currently exist treat sialorrhea symptom associated many disease including amyotrophic lateral sclerosis al also known lou gehrig ’ disease cerebral palsy parkinson 's disease muscular dystrophy ,investigated use/treatment saliva salivary gland dysfunction sialorrhea 
T487,t487 small molecule chemokine receptor antagonist correct modify immune system response bind selectively potently cxcr3 formulation administered orally anti-inflammatory effect condition rheumatoid arthritis inflammatory bowel disease psoriasis ,investigated use/treatment inflammatory disorder rheumatoid arthritis inflammatory bowel disease psoriasis 
Golotimod,scv-07 g -d-glutamyl-l-tryptophan novel synthetic dipeptide act broadly toll-like receptor pathway shown stimulate t-lymphocyte differentiation macrocytic phagocytosis specific immune response enhance il-2 inf-g production due preferential activation th1 cytokine production scv-07 may show utility treatment tuberculosis administered orally subcutaneously independent study treatment tuberculosis scv-07 improved clearance mycobacteria improved cavity healing improvement immune parameter reduced symptom fever weakness sweating dry cough productive cough dyspnea chest pain tachycardia without adverse local general effect scv-07 shown efficacy treating various viral bacterial infection ,investigated use/treatment hepatitis viral c infectious parasitic disease unspecified tuberculosis 
WX-UK1,wx-uk1 3-amidinophenylalanine-based non-cytotoxic small molecule belongs new class drug animal model wx-uk1 block tumor cell invasion metastasis primary tumor growth inhibiting serine protease urokinase plasminogen activator upa system shown play key role metastasis primary tumor growth breast gastric colon cancer various solid tumor independent study show administration wx-uk1 resulted decrease tumor cell invasion suggesting efficacy adjuvant antimetastatic therapy carcinoma ,investigated use/treatment solid tumor 
MUC1 Dendritic Cell Vaccine,dendritic cell dc therapy newly emerging potent form immune therapy amplifies action body 's immune system help fight cancer aid serious condition dendritic cell immune cell whose role recognition processing presentation foreign antigen t-cells initiate primary response effector arm immune system dendritic cell activate lymphocyte induce immune response also minimize autoimmune reaction downplaying self-antigens stimulated t-cells dendritic cell therapy involves harvesting blood cell ie monocyte macrophage patient processing laboratory produce greater typical dendritic cell concentration cell given back patient vaccine order allow potent immune response cancer ,investigated use/treatment cancer/tumors unspecified ovarian cancer 
Pradefovir mesylate,pradefovir mesilate previously known mb-06886 hepavir b remofovir mesylate orally administered small molecule compound belongs novel series phosphate phosphonate prodrugs adefovir adefovir hepsera acyclic phosphonate analogue adenine used treat hepatitis b virus adefovir poorly absorbed associated high level nephrotoxicity pradefovir mesilate designed specifically target liver reduce risk external tissue especially kidney improving result adefovir pradefovir activated oxidation mediated cytochrome p-450 cyp 3a4 predominantly expressed liver novel prodrug highly stable plasma tissue demonstrated potent preclinical clinical anti-hbv activity pradefovir undergoing phase ii development treatment chronic hepatitis b ,investigated use prodrug hepsera treating hepatitis viral b 
CZEN 002,czen-002 novel non-azole anti-fungal synthetic octapeptide derived alpha-melanocyte-stimulating hormone a-msh czen-002 modulates inflammatory immune response also shown kill candida albicans c. albicans single-celled fungal organism cause variety infection including vaginitis organism invade tissue produce fatal infection individual compromised immune system suffering hiv/aids undergoing organ bone transplant antimicrobial activity czen-002 unique depend direct damage microbial membrane appears czen-002 work receptor yeast yet identified study attempting understand candidacidal activity derivative alpha-msh focused alpha-msh amino acid sequence 6-13 contains invariant core sequence his-phe-arg-trp 6-9 important binding known melanocortin receptor second focus sequence lys-pro-val 11-13 known important antimicrobial activity ,investigated use/treatment candidiasis vaginitis 
PBI-1402,pbi-1402 small molecule synthetic compound oral bioavailability compound activates neutrophil enhancing survival activation comparable efficacy gm-csf g-csf epo currently used treat anemia however shown co-administered compound effect additive making pbi-1402 excellent candidate combination therapy asserting independent mechanism action pbi-1402 appears work pmn pathway specific binding property known pbi-1402 dual therapeutic action chemoprotectant hematopoietic progenitor stimulator since stimulates immune activity considered candidate cancer treatment well anemia ,investigated use/treatment adverse effect chemotherapy anemia chemotherapy 
Recombinant alpha 1-antitrypsin,alpha 1-antitrypsin glycoprotein primarily produced hepatocytes lesser extent immune system cell recombinant alpha 1-antitrypsin raat produced yeast unlike commercially available form plasma-derived aat eliminates risk associated blood-borne infectious agent allows increased manufacturing raat belongs family structurally-related protein classified serine protease inhibitor serpins known inhibit several protease including trypsin cathepsin g thrombin tissue kallikrein well neutrophil elastase proteinase/antiproteinase balance believed important maintaining healthy skin raat topical gel dermolastin™ indicated patient atopic dermatitis psoriasis company indicated formulation gastroenterological urological indication also developed ,investigated use/treatment alpha 1 antitrypsin deficiency atopic dermatitis chronic obstructive pulmonary disease copd 
7-ethyl-10-hydroxycamptothecin,7-ethyl-10-hydroxycamptothecin sn 38 liposomal formulation active metabolite irinotecan db00762 chemotherapeutic pro-drug approved treatment advanced colorectal cancer sn 38 used trial studying treatment cancer advanced solid tumor small cell lung cancer metastatic colorectal cancer triple negative breast cancer among others ,investigated use/treatment colorectal cancer 
Picolinic acid,pcl-016 picolinic acid drug substance pyridine carboxylate metabolite tryptophan act anti-infective immunomodulator produced approximately 25-50 mg quantity body daily basis breakdown tryptophan pcl-016 play key role zinc transport therapeutic agent molecule work binding zinc finger protein zfps way change structure disrupts zinc binding inhibiting function zfps involved viral replication packaging well normal cell homeostatic function picolinic acid shown anti-viral vitro vivo sometimes work conjunction cytokine interferon gamma affect immune response acne vulgaris herpes viral infection therefore pose potential therapeutic target pcl-016 ,investigated use/treatment acne herpes labialis infection cold sore venereal disease 
MDX-018,mdx-018 also known humax-inflam fully human antibody directed il-8 interleukin-8 may potential application oncology inflammation trial initially focus study treat glioblastoma cancer central nervous system possible indication include chronic obstructive pulmonary disease copd pustular dermatosis pre-clinical study humax-inflam shown inhibit tumor growth tumor model using primary human tumor immunodeficient mouse humax-inflam also effective reducing disease activity palmoplantar pustulosis patient clinical study ,investigated use/treatment autoimmune disease inflammatory disorder unspecified 
ADH-1,adherex 's biotechnology compound adh-1 target n-cadherin protein present certain tumor cell established tumor blood vessel adh-1 currently clinical development combination program range chemotherapeutic agent investigate synergistic effect noted preclinical model end 2006 company also completed patient enrollment single-agent phase ib/ii phase ii trial adh-1 cadherins cell adhesion cell signaling molecule crucial development tissue organ organism agent target inhibit cadherin function potential attack progression cancer two distinct point direct targeting cadherins expressed cancer cell may disturb cadherin-mediated signaling leading apoptosis death cancer cell cadherin inhibitor may exploit inherent structural weakness tumor vasculature causing angiolysis disruption blood vessel tumor damage many tumor become aggressive invasive malignant researcher found n-cadherin expressed greater amount making important target developing anti-cancer treatment poorly differentiated highly invasive carcinoma characterized over-expression n-cadherin opposed e-cadherin change primary cadherin expression cause epithelial cell lose tightly adherent polarized well-defined shape become loosely adherent flattened migratory cadherin switching promotes property dedifferentiation local invasion metastasis leading poor prognosis adh-1 may utility wide variety cancer n-cadherin overexpressed variety tumor tumor progress become higher grade invasive metastatic frequency n-cadherin expression generally rise ,investigated use/treatment breast cancer cancer/tumors unspecified melanoma ovarian cancer solid tumor 
Custirsen,custirsen benzopyran potential antineoplastic activity custirsen act selective estrogen receptor modulator serm inhibiting proliferation estrogen-sensitive breast cancer cell agent also inhibits growth induces apoptosis glioblastoma cell via mechanism independent estrogen receptor-related mechanism custirsen also investigated treatment primary brain tumor ,investigated use/treatment brain cancer breast cancer 
Technetium Tc-99m ciprofloxacin,99mtc-ciprofloxacin new formulation ciprofloxacin infecton investigated radioimaging agent potential diagnosis infection including fever unknown origin osteomyelitis wound infection abdominal abscess pneumonia appendicitis tuberculosis infecton combine widely used antibiotic ciprofloxacin technetium 99m tc commonly used radioisotope nuclear medical imaging currently controversy around drug 's ability discriminate sterile inflammation bacterial versus nonbacterial infection ,investigated use/treatment infectious parasitic disease unspecified 
ACA 125, igg1 murine monoclonal anti-idiotype antibody ab2 aca-125 developed bind anti-ca 125 antibody aca-125 mimic tumor-associated antigen ca-125 detected 80 ovarian carcinoma new concept oncological immunotherapy consists attempt trigger immune system host respond tumor cell antiidiotypic antibody bearing internal image antigen expressed surface tumor suited approach create aca-125 hybridoma cell adapted serum-free medium antibody produced hollow fiber cell culture system positive clinical result reported ,investigated use/treatment ovarian cancer 
AMG-131,amg-131 t131 orally-administered therapy expected lower blood glucose type ii diabetic patient improving body ’ ability respond insulin t131 selective modulator pparg peroxisome proliferator activated receptor gamma receptor involved regulating body ’ ability respond insulin t131 structurally related thiazolidinedione class pparg agonist includes actos avandia ,investigated use/treatment diabetes mellitus type 2 
ATN-161,atn-161 non-rgd based integrin binding peptide targeting alpha-5 beta-1 alpha-v beta-3 inhibits migration adhesion particular integrins activated endothelial cell play critical role tumor angiogenesis approach targeting tumor vasculature cancer cell may effective single therapy well combination therapy since expression alpha 5 beta 1 integrin cancer cell role molecule tumor angiogenesis similar across range different cancer therapeutic benefit atn-161 expected extend variety cancer ,investigated use/treatment brain cancer cancer/tumors unspecified 
Epicept NP-1,epicept np-1 prescription topical analgesic cream designed provide effective long-term relief pain peripheral neuropathy peripheral neuropathy medical condition caused damage nerve peripheral nervous system peripheral nervous system includes nerve run brain spinal cord rest body epicept np-1 cream patented formulation containing two fda-approved drug amitriptyline widely-used antidepressant ketamine nmda antagonist used anesthetic ,investigated use/treatment neuropathy diabetic pain acute chronic 
NX-1207,nx-1207 investigational new drug bph whose chemical entity mechanism action remain undisclosed nymox pharmaceutical corporation recently completed study nx-1207 treatment benign prostatic hyperplasia bph ,investigated use/treatment benign prostatic hyperplasia 
Elacytarabine,elacytarabine fatty acid derivative cytarabine approved cytotoxic cancer drug cytarabine limitation minimal uptake solid tumour used treat leukaemia elacytarabine designed overcome limitation shown considerable uptake solid tumour cell elacytarabine patented new chemical entity nucleoside analog class improved biological property potential treat solid tumour non-small cell lung cancer malignant melanoma ovarian cancer ,investigated use/treatment leukemia unspecified melanoma 
PG-530742,pg-530742 selectively inhibits certain matrix metalloproteinases implicated cartilage degradation occurs osteoarthritis inhibiting mmps potentially limit cartilage degradation disease progression study currently assessing efficacy safety pg-530742 treatment mild moderate knee osteoarthritis ,investigated use/treatment osteoarthritis 
Otelixizumab,otelixizumab monoclonal antibody bind receptor found cell called cd3 involved normal cell signaling otelixizumab believed inhibit function autoreactive cell important propagating autoimmune disease inducing regulatory cell pathway promote immunological tolerance inhibit autoreactive disease activity tolerx developing otelixizumab treat patient type 1 diabetes psoriasis autoimmune disease rheumatoid arthritis ,investigated use/treatment diabetes mellitus type 1 pediatric indication psoriasis psoriatic disorder 
KW-7158,kw-7158 tricyclic compound non-cholingergic mechanism action treatment `` urinary urgency '' `` frequent urination '' `` urinary incontinence '' associated bladder overactivity involuntary abnormal contraction bladder therapeutic effect kw-7158 overactive bladder may due activation a-type k channel regulate afferent neuron excitability firing property dorsal root ganglion neuron ,investigated use/treatment urinary incontinence 
TAK-428,tak-428 drug treating diabetic neuropathy based novel concept peripheral nervous tissue damaged diabetes repaired regenerated stimulating increase neurotrophic factor ,investigated use/treatment neuropathy diabetic 
AVN-944,avn944 biotech drug demonstrated statistically meaningful impact impdh protein critical activity cancer cell including nucleotide biosynthesis energy metabolism dna replication apoptosis cell cycle control avn944 associated cancer cell death clinical trial investigated treatment patient advanced hematologic malignancy ,investigated use/treatment cancer/tumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma pancreatic cancer 
AMD-070,amd-070 small molecule drug candidate belongs new investigational class anti-hiv drug known entry fusion inhibitor currently one fda-approved entry inhibitor enfuvirtide fuzeon available treatment hiv infection several experimental entry inhibitor early stage testing including amd-070 target cxcr4 receptor hiv prevents virus entering infecting healthy cell entry inhibitor target ccr5 receptor hiv.these new agent widely viewed next generation anti-hiv drug potential significantly advance hiv therapeutic ,investigated use/treatment hiv infection 
AG-858,ag-858 autologous heat-shock protein 70 peptide vaccine recombinant cancer vaccine made tumor-derived heat shock protein 70 hsp70 peptide complex hsp70 associate antigenic peptide transporting antigen presenting cell apc processing tumor-derived hsp70-peptide complex used vaccine preparation shown prime tumor immunity tumor-specific cell animal model ,investigated use/treatment leukemia myeloid 
NM-702,nissan chemical taisho jointly developing nm-702 drug treatment arteriosclerosis obliterans m-702 orally active inhibitor phosphodiesterase thromboxane synthetase japan phase 2 study conducted intermittent claudication caused arteriosclerosis obliterans intermittent claudication caused spinal canal stenosis asthma usa phase 2 study intermittent claudication caused arteriosclerosis obliterans successfully completed intermittent claudication major symptom arteriosclerosis obliterans caused insufficient oxygen supply exercising muscle lower extremity due decreased blood flow result sclerosis peripheral artery estimated 6 million people suffer intermittent claudication usa 10 percent people currently receiving treatment patient claudication experience significant disability owing exercise limitation therapeutic option improve exercise performance patient limited,investigated use/treatment peripheral vascular disease 
ISIS 113715,isi 113715 second-generation antisense inhibitor protein tyrosine phosphatase 1b ptp‑1b treatment type 2 diabetes early trial isi 113715 induced statistically significant improvement multiple measure glucose control along statistically significant reduction ldl-cholesterol ,investigated use/treatment diabetes mellitus type 2 
VX-765,vx-765 orally available prodrug potent selective competitive inhibitor ice/caspase-1 vrt-043198 vx-765 currently clinical development treatment inflammatory autoimmune condition block hypersensitive response inflammatory stimulus ,investigated use/treatment inflammatory disorder unspecified psoriasis psoriatic disorder 
LI-301,li 301 orally bio-available compound delivered fast melt mechanism taste masking enabling taken anytime without water novel mode action combining light effect selective serotonin reuptake inhibitor `` ssri '' likely antagonistic 5ht1a receptor antagonism mu-opioid receptor result slight dulling sensation used treat premature ejaculation without interfering normal sexual pleasure orgasm ,investigated use/treatment premature ejaculation 
Piclidenoson,cf 101 known generically ib-meca anti-inflammatory drug rheumatoid arthritis patient novel mechanism action relies antagonism adenoside a3 receptor cf101 supplied oral drug excellent safety profile also considered treatment autoimmune-inflammatory disorder crohn 's disease psorasis dry eye syndrome ,investigated use/treatment cancer/tumors unspecified eye disorders/infections psoriasis psoriatic disorder rheumatoid arthritis can-fite biopharma reported targeting adenosine a3-receptor cf101 may also used treat crohn 's disease serious gastrointestinal disorder 
MM-093,mm-093 recombinant version human alpha-fetoprotein hafp immunomodulatory serum protein normally produced high level fetus present low level blood adult child research afp suggests may play role modulating immune system mother order protect developing fetus pregnancy presence hafp pregnant mother ’ blood long associated remission many autoimmune disease including rheumatoid arthritis psoriasis multiple sclerosis third trimester pregnancy current study assessing mm-093 ’ potential improve treatment autoimmune disease ,investigated use/treatment autoimmune disease psoriasis psoriatic disorder rheumatoid arthritis 
Atiprimod,,investigated use/treatment cancer/tumors unspecified multiple myeloma rheumatoid arthritis 
Cobiprostone,,investigated use/treatment cystic fibrosis 
PI-0824,"pemphigus vulgaris pv autoimmune disease affecting approximately 40,000 people worldwide people pv produce antibody attack cell skin resulting blister left untreated lead devastating infection discomfort currently doctor treat patient pv prescribe high-dose steroid drug suppress immune system effort decrease production antibody unfortunately medication associated serious difficult side effect often result discontinuation use peptimmune inc. developed new therapy treatment pv pi-0824 goal therapy reduce production antibody cause pv blister acting disease causing component immune system hoped use pi-0824 reduce potentially eliminate need high dose steroid drug suppress immune system ",investigated use/treatment autoimmune disease skin infections/disorders 
Managlinat dialanetil,"cs-917 novel inhibitor fructose 1,6-bisphphosphatase fbpase one rate-limiting enzyme gluconeogenesis ",investigated use/treatment diabetes mellitus type 2 
Budiodarone,budiodarone ati-2042 antiarrhythmic related amiodarone currently studied clinical trial ,investigated use/treatment arrhythmia atrial fibrillation 
Mimopezil,mimopezil acetylcholinesterase ache inhibitor demonstrated potential use treatment alzheimer 's disease mimopezil pro-drug rapidly absorbed converted huperzine ,investigated use/treatment alzheimer 's disease 
Telaprevir,telaprevir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas telaprevir telaprevir inhibitor ns3/4a serine protease enzyme encoded hcv genotype 1 fda label enzyme essential viral replication serve cleave virally encoded polyprotein mature protein like ns4a ns4b ns5a ns5b barrier develoment resistance ns3/4a inhibitor lower ns5b inhibitor another class daas a19593 subtitutions amino acid position 155 156 168 known confer resistance substitution enzyme 's catalytic triad consisting h58 d82 s139 also likely alter affinity drug ns3/4a activity enzyme despite disadvantage telaprevir still effective hcv paired db00811 db00008 db00022 telaprevir db00811 db00008 db00022 used intent cure achieve sustained virologic response svr 12 week daily administration combination therapy followed 12 36 week therapy db00811 db00008 db00022 svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 telaprevir available fixed dose product tradename incivek used treatment chronic hepatitis c. approved may 2011 fda incivek indicated treatment hcv genotype 1 combination db00811 db00008 db00022 fda label incivek since withdrawn market ,telaprevir used combination db00811 db00008 db00022 indicated use treatment chronic hcv genotype 1 infection adult fda label 
Pelitinib,pelitinib ekb-569 potent low molecular weight selective irreversible inhibitor epidermal growth factor receptor egfr developed anticancer agent ,investigated use/treatment colorectal cancer lung cancer 
EW-A-401,ew-a-401 circle genetic material plasmid dna instructs body produce genetically-engineered transcription factor protein regulates expression gene specific transcription factor shown animal study increase expression vegf-a gene promote growth new blood vessel ,investigated use/treatment peripheral vascular disease 
Mipomersen,mipomersen sodium known investigational drug isis-301012 salt form synthetic phosphorothioate oligonucleotide mipomersen sodium prevents formation apo b-100 resulting decrease level apolipoprotein b apo b low density lipoprotein ldl total cholesterol mipomersen indicated patient homozygous familial hypercholesterolemia adjunct diet lipid-lowering medication marketed brand name kynamro united state fda label includes black box warning hepatoxicity specifically elevation liver enzyme i.e transaminase liver fat hepatic steatosis reported due serious risk liver toxicity mipomersen sodium available patient restricted program called kynamro risk evaluation mitigation strategy program ,used patient homozygous familial hypercholesterolemia adjunct diet lipid-lowering medication 
CPG 10101,cpg 10101 synthetic oligodeoxynucleotide odn clinical trial toll-like receptor 9 tlr9 agonist antiviral immunomodulatory property could potentially influence chronic infection hcv ,investigated use/treatment hepatitis viral c viral infection 
alpha-Pyrrolidinononanophenone,,investigated use/treatment actinic keratosis breast cancer liver cancer melanoma psoriasis psoriatic disorder solid tumor 
BMS-488043,bms-488043 investigated anti-hiv agent ,investigated use/treatment hiv infection 
QR-333,qr-333 investigated treatment diabetic peripheral neuropathy qr-333 concentrated standardized nutrient based active compound dosed topical cream designed reduce oxidative stress treat symptom diabetic peripheral neuropathy nerve disorder lead numbness skin ulcer constant pain extreme sensitivity stimulus ,investigated use/treatment neuropathy diabetic 
Alanosine, amino acid analogue antibiotic derived bacterium streptomyces alanosinicus antimetabolite potential antineoplastic activity ,investigated use/treatment brain cancer cancer/tumors unspecified 
Brivaracetam,brivaracetam racetam derivative levetiracetam used treatment partial-onset seizure brivaracetam bind sv2a 20 time higher affinity levetiracetam a19184 available brand name briviact made ucb briviact received fda approval february 19 2016 l760 ,used adjunctive therapy partial-onset seizure patient 16 year age older 
Naronapride,,investigated use/treatment gastroesophageal reflux disease gerd gastroparesis 
AMG 108,amg 108 investigated use antirheumatic agent ,investigated use/treatment osteoarthritis rheumatoid arthritis 
SB-743921,,investigated use/treatment cancer/tumors unspecified lymphoma non-hodgkin 's 
INO-1001,,investigated use/treatment brain cancer cardiovascular disorder myocardial infarction 
Iratumumab,"immunoglobulin g1 anti- human cd30 antigen human monoclonal mdx-060 heavy chain disulfide human monoclonal mdx-060 light chain dimer molecular weight approximately 170,000 dalton phase i/ii clinical trial treatment cd30+ lymphoma ",investigated use/treatment lymphoma unspecified 
TG100-115, nsaid inhibits pi-3k gamma delta ,investigated use/treatment angioedema myocardial infarction 
Regrelor,,investigated use/treatment cardiac surgery coronary artery disease thrombosis transfusion 
Enokizumab, humanized immunoglobulin g1k anti-interleukin-9 mab ,investigated use/treatment asthma 
NF-kappaB Decoy,,investigated use/treatment atopic dermatitis inflammatory disorder unspecified skin infections/disorders 
Delcasertib,,investigated use/treatment myocardial infarction 
Naluzotan,,investigated use/treatment anxiety disorder depression 
PBT-1033,,investigated use/treatment alzheimer 's disease 
Motesanib,,investigated use/treatment solid tumor 
Ramucirumab,ramucirumab human monoclonal antibody igg1 vascular endothelial growth factor receptor 2 vegfr2 type ii trans-membrane tyrosine kinase receptor expressed endothelial cell binding vegfr2 ramucirumab prevents binding ligand vegf-a vegf-c vegf-d thereby preventing vegf-stimulated receptor phosphorylation downstream ligand-induced proliferation permeability migration human endothelial cell vegfr stimulation also mediates downstream signalling required angiogenesis postulated heavily involved cancer progression making highly likely drug target contrast agent directed vegfr-2 ramucirumab bind specific epitope extracellular domain vegfr-2 thereby blocking vegf ligand binding ramucirumab indicated u advanced gastric gastro-esophageal junction adenocarcinoma single agent combination paclitaxel prior fluoropyrimidine- platinum-containing chemotherapy ,ramucirumab indicated treatment advanced metastatic gastric gastro-esophageal junction adenocarcinoma single agent combination paclitaxel patient progress prior fluoropyrimidine- platinum-containing chemotherapy indicated combination erlotinib first-line treatment metastatic non-small cell lung cancer epidermal growth factor exon 19 deletion exon 21 l858r point mutation also indicated combination docetaxel treatment metastatic non-small cell lung cancer patient progressed following prior platinum-based chemotherapy patient egfr alk genomic aberration also disease progression following fda-approved therapy aberration ramucirumab combination folfiri folinic acid fluorouracil irinotecan indicated treatment metastatic colorectal cancer patient progressed following therapy bevacizumab oxaliplatin fluoropyrimidine lastly ramucirumab indicated treatment hepatocellular carcinoma patient alpha-fetoprotein level ≥400 ng/ml previously treated sorafenib l40938 
TRU-015,,investigated use/treatment lymphoma unspecified rheumatoid arthritis 
Praconase,,investigated use/treatment spinal cord injury 
Verubulin,antineoplastic small-molecule inhibitor microtubule formation substrate multidrug resistance pump ,investigated use/treatment brain cancer lung cancer melanoma solid tumor 
Facinicline,,investigated use/treatment alzheimer 's disease neurologic disorder schizophrenia schizoaffective disorder 
Bedoradrine,,investigated use/treatment asthma labor delivery 
Blarcamesine,,investigated use/treatment breast cancer 
Cantuzumab ravtansine,,investigated use/treatment gastric cancer 
Farletuzumab,farletuzumab morab-003 fully humanized monoclonal antibody folate receptor alpha potential treatment epithelial ovarian cancer ,investigated use/treatment ovarian cancer 
PRX-03140,,investigated use/treatment alzheimer 's disease memory loss 
Fibroblast growth factor-1,,investigated use/treatment coronary artery disease peripheral vascular disease 
Beclanorsen,,investigated use/treatment leukemia lymphoid 
PRX-08066,,investigated use/treatment chronic obstructive pulmonary disease copd pulmonary hypertension 
MKC-1,,investigated use/treatment breast cancer leukemia unspecified lung cancer solid tumor 
Apilimod,,investigated use/treatment crohn 's disease psoriasis psoriatic disorder 
"4'-Methylene-5,8,10-trideazaaminopterin",ch-1504 antirheumatic agent shown vitro nonpolyglutamylatable nonhydroxylatable antifolate efficiently taken cell reduced folate carrier rfc system methotrexate investigated treatment rheumatoid arthritis phase ii ,investigated use/treatment inflammatory disorder unspecified psoriasis psoriatic disorder rheumatoid arthritis 
AVI-4065,avi-4065 phosphorodiamidate morpholino oligomer pmo investigational antisense hcv drug developed sarepta therapeutic inc. phase ii trial cancelled due lack potency l2917 ,investigated use/treatment hepatitis viral c 
Teverelix, synthetic decapeptide water-soluble gonadotropin-releasing hormone antagonist reached phase ii clinical trial ,investigated use/treatment benign prostatic hyperplasia endometriosis prostate cancer 
CTCE-9908,,investigated use/treatment cancer/tumors unspecified lung cancer sarcoma 
Retaspimycin,,investigated use/treatment gastric cancer lung cancer multiple myeloma 
Sodium stibogluconate,sodium stibogluconate medicine used treat leishmaniasis available administration injection belongs class medicine known pentavalent antimonials sodium stibogluconate sold uk pentostam manufactured glaxosmithkline widespread resistance limited utility sodium stibogluconate many part world amphotericin miltefosine used instead also investigated anti-tumor agent , treatment various type protozoal infection called leishmaniasis may result sandfly bite tropical temperate part world also investigated use/treatment cancer/tumors unspecified solid tumor 
ALT-2074, organoselenium drug previously studied oxis international phase-ii clinical trial ulcerative colitis patient indication efficacy demonstrated bxt-51072 enthusiastic endorsement treatment cardiovascular indication primarily ability mimic function glutathione peroxidase ,investigated use/treatment cardiovascular disorder diabetes mellitus type 1 2 
Glypromate,neuren pharmaceutical developing glypromate glycine-proline glutamate naturally occurring small-molecule neuroprotectant derived igf-1 inhibits caspase iii dependent apoptosis potential treatment neurodegenerative disease iv infusion december 2008 company discontinued development drug failed show observable effect ,investigated use/treatment neurologic disorder 
Asvasiran,asvasiran sirna target respiratory syncytial virus rsv n gene inhibits viral replication potential treat prevent rsv infection ,investigated use/treatment infectious parasitic disease unspecified viral infection 
DDP-225,ddp225 noradrenaline reuptake inhibitor serotonin type 3 receptor 5-ht3 antagonist noradrenaline serotonin neurotransmitter known involved control gastrointestinal system unique combination noradrenaline reuptake inhibition 5-ht3 antagonism one orally delivered compound represents novel approach treating ibs-d functional gi disease dynogen licensed preclinical clinical data related ddp225 mitsubishi pharma october 2003 ,investigated use/treatment alzheimer 's disease depression diarrhea gastrointestinal disease disorder miscellaneous irritable bowel syndrome ibs 
IRX-2,irx-2 contains multiple human cytokine investigated promote enhance anti-cancer immune response ,investigated use/treatment cancer/tumors unspecified head neck cancer solid tumor 
KP-1461,kp-1461 potent non-chain-terminating mutagenic deoxyribonucleoside analogue designated dna covert nucleoside drug consists modified base incorporates randomly hiv pair multiple base ,investigated use/treatment hiv infection 
Larazotide, octapeptide inhibitor paracellular permeability whose structure derived protein zonula occludens toxin secreted vibrio cholerae treatment coeliac disease ,investigated use/treatment autoimmune disease diabetes mellitus type 1 gastrointestinal disease disorder miscellaneous 
NTx-265,ntx-265 combination two currently marketed large molecule designed stimulate growth differentiation neural stem cell adult suffered stroke – second leading cause death worldwide may 2006 biotechnology company stem cell therapeutic started phase iia study ntx-265 also investigating use compound neurodegenerative disorder huntington ’ disease alzheimer ’ disease ,investigated use/treatment stroke 
OT-551,ot-551 novel small molecule topically dosed eye drop unique ability penetrate cell membrane reach front back eye intended treat age-related macular degeneration amd preclinical research result indicate additional us ot-551 including treatment early stage advanced dry age-related macular degeneration amd protecting retina photoreceptor cell death inhibiting angiogenesis growth small blood vessel leading wet-form amd leading cause vision loss amd affect approximately 10 million american ,investigated use/treatment cataract eye disorders/infections glaucoma macular degeneration 
VTP-201227,vtp-201227 novel mechanism action developed topical agent treatment psoriasis potential extension dermatological indication developed vitae pharmaceutical ,investigated use/treatment psoriasis psoriatic disorder 
IRX-5183,,investigated use/treatment adverse effect chemotherapy blood blood forming organ disorder unspecified 
Veltuzumab,veltuzumab monoclonal antibody october 2009 undergoing phase i/ii clinical trial treatment non-hodgkin 's lymphoma ,investigated use/treatment lymphoma non-hodgkin 's 
Faropenem medoxomil,faropenem medoxomil ester prodrug derivative beta-lactam antibiotic faropenem prodrug form faropenem offer dramatically improved oral bioavailability lead higher systemic concentration drug faropenem medoxomil broad-spectrum antibiotic highly resistant beta-lactamase degradation developed jointly replidyne inc. forest laboratory inc ,investigated use/treatment bacterial infection bronchitis otitis medium pediatric indication 
D-JNKI-1, synthetic cell permeable peptide block mapk-jnk signal pathway potential therapeutic value long-term protection morphological integrity physiological function organ corti time oxidative stress ,investigated use/treatment hearing loss 
NP-50301,np-50301 ophthalmic therapeutic eye drop treating post-menopausal dry eye syndrome de developed nascent pharmaceutical estimated 30 postmenopausal woman suffer symptom de account 12 million woman u.s majority sufferer de postmenopausal woman clinical research around world suggested benefit topical systemic estrogen therapy treatment de population ,investigated use/treatment eye disorders/infections 
Levoketoconazole,cushing 's syndrome c underpinned chronic hypercortisolism leading multisystem morbidity including effect cardiovascular endocrine system metabolic syndrome accompanying change body composition neuropsychiatric effect change blood pressure chemistry opportunistic infection a244078 a244083 ketoconazole used on- off-label treat c due ability inhibit cortisol production still toxicity limited use notably hepatic toxicity tendency prolong qt interval a244083 levoketoconazole one two enantiomer present racemic ketoconazole posse inhibitory effect towards steroidogenic enzyme making attractive candidate c treatment potentially lower toxicity profile racemate a244083 a29319 l39573 levoketoconazole approved fda december 30 2021 currently marketed registered trademark recorlev xeris pharmaceutical inc. l39563 ,levoketoconazole indicated treatment endogenous hypercortisolemia adult patient cushing ’ syndrome surgery option curative levoketoconazole indicated treatment fungal infection l39563 
Palifosfamide,palifosfamide zio-201 proprietary stabilized metabolite ifosfamide ifosfamide shown effective high dos treating testicular cancer sarcoma lymphoma ,investigated use/treatment cancer/tumors unspecified lymphoma unspecified sarcoma 
ATL-104,atl-104 potent mitogen epithelial cell gastrointestinal tract animal model atl-104 aid regeneration gastrointestinal tract treatment chemotherapeutic agent ,investigated use/treatment adverse effect chemotherapy 
AC-100,ac-100 novel synthetic peptide derived endogenous human protein produced bone dental cell fragment matrix extracellular phosphoglycoprotein developed acologix inc ,investigated use/treatment periodontal disease 
EP-2104R,ep-2104r imaging pharmaceutical development detection blood clot first targeted high-resolution technique designed visualize blood clot directly developed epix pharmaceutical inc ,investigated use/treatment cardiovascular disorder thrombosis 
Apremilast,apremilast also known otezla phosphodiesterase 4 pde4 inhibitor used treat various type symptom resulting certain inflammatory autoimmune disease belongs drug class roflumilast crisaborole a181244 l7495 initially approved 2014 marketed celgene l7501 july 2019 apremilast granted new fda approval treatment oral ulcer associated behcet 's disease autoimmune condition cause recurrent skin blood vessel central nervous system inflammation a181216 ,apremilast indicated treatment adult active psoriatic arthritis adult oral ulcer associated behcet 's disease addition apremilast indicated treatment plaque psoriasis severity adult patient candidate phototherapy systemic therapy l7501 
SLx-4090,slx-4090 microsomal triglyceride transfer protein mttp inhibitor potentially treatment type 2 diabetes a33218 ,investigated use/treatment hyperlipidemia 
Ustekinumab,ustekinumab human immunoglobulin ig g1 kappa monoclonal antibody directed interleukin il -12 il-23 cytokine involved immune inflammatory response a187349 generated via recombinant human il-12 immunization human ig hu-ig transgenic mouse a187349 targeted biologic disease-modifying anti-rheumatic drug bdmards used management various inflammatory condition involve activation il-12 il-23 signalling pathway a187346 therapeutic use drug started canada u europe since 2009 first approved treatment adult patient moderate severe plaque psoriasis active psoriatic arthritis alone combination methotrexate september 2016 ustekinumab additionally approved management moderate severe crohn 's disease selected adult patient october 2019 also approved fda use manage moderately severely active ulcerative colitis adult ustekinumab currently first approved biologic therapy ulcerative colitis target interleukin il -12 il-23 cytokine l9392 dosing regimen ustekinumab based patient 's weight intravenous subcutaneous formulation drug based dosing schedule condition treated ustekinumab commonly marketed trade name stelara ,ustekinumab indicated management moderate severe plaque psoriasis patient 6 year age older candidate phototherapy systemic therapy l9386 indicated management active psoriatic arthritis patient 6 year age older l42575 also indicated management moderately severely active ulcerative colitis crohn 's disease adult l9386 
Sotirimod,,investigated use/treatment actinic keratosis skin infections/disorders 
Iodofiltic acid I-123,,investigated use/treatment cardiac ischemia 
FX06,fx06 naturally occurring peptide derived neo-n-terminus fibrin bbeta 15-42 prevents leukocyte migration gap junction endothelial cell fx06 proven safe acute subchronic toxicological study recently entered clinical development developed fibrex medical inc ,investigated use/treatment cardiac reperfusion injury myocardial infarction 
Sivifene,,investigated use/treatment cervical dysplasia/cancer genital wart skin cancer 
BL-1020,bl-1020 first class novel compound treatment schizophrenia developed biolinerx bioline ,investigated use/treatment schizophrenia schizoaffective disorder 
CRx-119,crx-119 novel synergistic combination drug candidate discovered using combinatorx combination high throughput screening chts tm technology potential therapeutic use broad range immuno-inflammatory condition crx-119 combination low dose steroid prednisolone 3mg amoxapine ,investigated use/treatment periodontal disease rheumatoid arthritis 
NPS-2143,,investigated use/treatment osteoporosis 
Trabedersen,,investigated use/treatment brain cancer colorectal cancer melanoma pancreatic cancer 
GI-4000, vaccine containing heat-killed recombinant em saccharomyces cerevisiae /em yeast transfected mutated form ra oncogene frequently found solid tumor potential immunostimulant antitumor activity l112 ,investigated use/treatment pancreatic cancer 
ALS-08,als-08 proprietary creatine-derivative developed potential therapeutic amyotrophic lateral sclerosis al developed avicena group inc ,investigated use/treatment amyotrophic lateral sclerosis al 
13-deoxydoxorubicin,gpx-100 anthracycline anticancer drug belongs family drug called antitumor antibiotic ,investigated use/treatment breast cancer cancer/tumors unspecified 
GTS-21,gts-21 also known dmbx-a novel small-molecule orally active selective alpha-7 nicotinic acetylcholine nach receptor agonist demonstrated memory cognition enhancement activity human clinical trial athenagen licensed exclusive right compound related library analog part acquisition osprey pharmaceutical company april 2006 gts-21 studied multiple phase study healthy volunteer one phase i/ii study schizophrenic patient study compound well tolerated phase multi-dose double-blind placebo controlled study healthy adult gts-21 also demonstrated cognitive enhancement across dos statistically significant improvement attention related memory related task kitagawa et al neuropsychopharmacology 2003 28 542-551 ,investigated use/treatment alzheimer 's disease schizophrenia schizoaffective disorder 
Gantacurium,gantacurium chloride new investigational non-depolarizing ultra-short acting neuromuscular blocker developed avera pharmaceutical ,investigated use/treatment anesthesia unspecified 
AZD-9684,azd-9684 first member new anti-thrombotic class cpu inhibitor developed astrazeneca ,investigated use/treatment thrombosis 
LY-517717,ly517717 investigational oral direct inhibitor activated factor xa believed lilly 's pmd-3112 licensed amgen ,investigated use/treatment thrombosis venous thromboembolism 
Flovagatran,,investigated use/treatment thrombosis 
Maxy-G34,maxy-g34 pegylated variant human granulocyte-colony stimulating factor g-csf variant contains multiple non-naturally occurring lysine introduced alpha helix wild type human g-csf pegylation site multiple undesired naturally occurring lysine removed compared wild type human g-csf avoid pegylation site specifically amino acid sequence maxy-g34 differs human wild type g-csf residue 16 34 40 105 159 accomplished removing three lysine residue position 16 34 40 replacing arginine substituting two new lysine residue position 105 159 maxy-g34 pegylated 5 kd mpeg spa succinimidyl propionate group 3 amino acid residue including peg group attached amino terminal end protein two internal lysine residue neulasta single 20 kd peg group attached n terminal end wild type g-csf protein developed maxygen inc. treatment chemotherapy-induced neutropenia ,investigated use/treatment adverse effect chemotherapy neutropenics 
Elesclomol,elesclomol novel injectable drug candidate kill cancer cell elevating oxidative stress level beyond breaking point triggering programmed cell death preclinical model elesclomol showed potent killing broad range cancer cell type high dos ability strongly enhance efficacy certain chemotherapy agent minimal additional toxicity moderate dos developed synta pharmaceutical ,investigated use/treatment melanoma 
EVT 201,evt 201 novel partial positive allosteric modulator gabaa receptor complex developed treatment insomnia developed evotec inc ,investigated use/treatment insomnia 
CGC-11047,cgc-11047 polyamine analog designed halt cell growth induce apoptosis ,investigated use/treatment lymphoma unspecified macular degeneration prostate cancer solid tumor 
ALKS 29,alks 29 new product candidate treatment alcohol dependence developed alkermes inc ,investigated use/treatment addiction alcohol dependence 
alpha-Conotoxin VC 1.1,,investigated use/treatment pain acute chronic 
PMI-001,pmi-001 stand-alone disease-modifying anti-rheumatic drug dmard developed phytomedics inc extract root undisclosed perennial shrub interferes production il-2 cox-2 protein potential treatment autoimmune disease rheumatoid arthritis lupus erythematosus psoriasis ,investigated use/treatment rheumatoid arthritis 
Strontium malonate,strontium malonate developed novel orally available pharmaceutical treatment prevention osteoporosis developed osteologix inc ,investigated use/treatment osteoporosis 
Cefilavancin,cefilavancin covalently-linked glycopeptide-cephalosporin beta-lactam heterodimer antibiotic exhibit substantially greater activity component part gram-positive bacteria ,investigated use/treatment bacterial infection skin infections/disorders staph bacterial infection 
MIV-701,miv-701 selective potent inhibitor protease cathepsin k. developed treatment osteoporosis ,investigated use/treatment osteoporosis 
Varespladib methyl,varespladib methyl investigated treatment acute coronary syndrome study showed varespladib methyl treatment resulted significant positive change lipoprotein inflammation ,investigated use/treatment atherosclerosis coronary artery disease 
Vapitadine,vapitadine antihistamine barrier therapeutic developing treatment allergic reaction skin associated hive itch associated atopic dermatitis advantage vapitadine antihistamine may absence sedation even high dos ,investigated use/treatment atopic dermatitis 
CYT006-AngQb,cyt006-angqb therapeutic vaccine development treatment hypertension designed instruct patient ’ immune system produce antibody response angiotensin ii small peptide cause blood vessel narrow result increased blood pressure unique treatment modality aim address issue patient compliance offering convenient dosing schedule due long-lasting effect induced vaccination ,investigated use/treatment hypertension 
RPI-78M,rpi-78m developed treatment multiple sclerosis m neurological disorder may served rpi-78m include myasthenia gravis mg muscular dystrophy md amyotrophic lateral sclerosis al ,investigated use/treatment multiple sclerosis neurologic disorder pain acute chronic 
AGS-005,ags-005 personalized dendritic cell-based immunotherapy optimized immune response characteristic designed stimulate patient 's immune system target destroy patient 's cancer cell ,investigated use/treatment leukemia lymphoid 
AGS-004,ags-004 personalized rna-loaded dendritic cellbased immunotherapy designed stimulate patient ’ immune system target destroy patient ’ unique viral burden non-personalized hiv immunotherapy unable raise cytotoxic lymphocyte hiv antigen fail induce cell memory importantly provide antiviral protection patient 's particular virus personalized immunotherapy address issue able capture private viral mutation providing matched complete immune response individual hiv patient approach may overcome weakness available therapy therefore could result better chance success hiv treatment ,investigated use/treatment hiv infection 
CRx-139,crx-139 oral synergistic combination drug candidate novel mechanism action targeting multiple biological pathway simultaneously dissociated steroid designed enhance immuno-modulatory activity low-dose glucocorticoid steroid without comparable increase steroid-related side effect synergistic combination containing low dos glucocorticoid steroid prednisolone antidepressant paroxetine novel synergistic combination developed treatment immuno-inflammatory disease ,investigated use/treatment rheumatoid arthritis 
PF-03187207,pf-03187207 nitric oxide-donating prostaglandin f2-alpha analog potential treatment glaucoma based promising preclinical result well-known activity nitric oxide pf-03187207 expected increased capacity reduce high iop development abnormally high iop due blockage malfunction system controlling amount fluid eye believed one principal cause glaucoma ,investigated use/treatment glaucoma ocular hypertension 
R-851,r-851 part family immune response modifier irm act novel way stimulate human body 's immnune system attack virus-infected cell tumor cell expected topical treatment cervical displasia cervical high-risk human papillomavirus hpv sexually transmitted virus cause case cervical cancer ,investigated use/treatment cervical dysplasia/cancer viral infection 
MPI-674,mpi-674 aromatase inhibitor ai well-established multi-year chronic safety tolerability profile ai class drug reduce amount estrogen circulating body binding inhibiting enzyme aromatase responsible converting certain hormone estrogen developed treatment several serious woman ’ health condition including endometrial thinning prior endometrial ablation premenopausal woman abnormal uterine bleeding aub ,investigated use/treatment menstrual disorder 
AVE-1625,ave-1625 oral selective potent antagonist cannabinoid 1 cb1 receptor mechanism action rimonabant currently developed obesity associated comorbidities ave-1625 also developed treatment alzheimer disease ,investigated use/treatment alzheimer 's disease obesity schizophrenia schizoaffective disorder 
RP01,rp01 novel anti-ige immunotherapy allergic individual designed induce immune system produce antibody block immunoglobulin e ige key mediator allergic response could offer benefit million asthma allergy patient ,investigated use/treatment allergic reaction asthma 
ALKS 27,alks 27 inhaled formulation trospium chloride treatment chronic obstructive pulmonary disease copd study showed alks 27 well-tolerated wide dose range dose-limited effect observed ,investigated use/treatment chronic obstructive pulmonary disease copd 
VSF-173,vsf-173 oral small molecule oral compound demonstrated effect animal sleep/wake pattern gene expression pattern suggestive stimulant effect developed treatment excessive sleepiness study show vsf-173 posse novel mechanism address disorder excessive sleepiness ,investigated use/treatment sleep disorder 
IPH 1101,iph 1101 chemically-synthesized structural analog non-conventional bacterial phosphoantigens specifically activate vγ9vδ2 cell subset iph 1101 advanced drug candidate γδ cell platform,investigated use/treatment hepatitis viral c leukemia myeloid lymphoma non-hodgkin 's 
BF-37,bf-37 treatment atopic dermatitis and/or psoriasis active ingredient bf-37 riluzole applied topical formulation believed correct imbalance immune system cause atopic dermatitis psoriasis ,investigated use/treatment atopic dermatitis 
PAC-113,pac-113 anti-fungal treatment oral candidiasis infection 12 amino-acid antimicrobial peptide derived naturally occurring histatin protein found saliva vitro study demonstrate potent anti-fungal activity candida albicans including drug-resistant hiv patient isolates pac-113 targeting oral candida infection immunocompromised patient patient salivary dysfunction ,investigated use/treatment candidiasis fungal infection saliva salivary gland dysfunction 
DNB-001,dnb-001 first-in-class oral therapy dual mechanism action initially developed treatment glaucoma preclinical animal model dnb-001 demonstrated potent iop- lowering effect well neuroprotective effect optic nerve ,investigated use/treatment ocular hypertension 
CYT007-TNFQb,cyt007-tnfqb active immunization therapy aim providing novel treatment people suffering ra psoriasis vaccine allow administration low amount drug individual patient microgram range convenient dosing schedule ,investigated use/treatment psoriasis psoriatic disorder 
ATX-201,atx-201 one family novel compound inhibits microtubule polymerization developed kythera biopharmaceuticals inc. treatment actinic keratosis company announced decision discontinue atx-201 clinical program actinic keratosis company determined program meeting expected primary exploratory objective ,investigated use/treatment actinic keratosis 
Norclozapine,acp-104 n-desmethylclozapine major metabolite clozapine developed acadia novel stand-alone therapy schizophrenia combine atypical antipsychotic efficacy profile added potential benefit enhanced cognition thereby addressing one major challenge treating schizophrenia today ,investigated use/treatment schizophrenia schizoaffective disorder 
Andrographolide,andrographolide hmpl-004 botanical product extracted herb occurs naturally china herb extensive history use tcm treatment upper respiratory tract infection inflammatory infectious disease ,investigated use/treatment ulcerative colitis 
Alkaline Phosphatase,alkaline phosphatase ap oral treatment favorable side-effect profile ap act locally colon reduce continuous inflammation colon endotoxin gram-negative bacteria extracellular atp uc patient ,investigated use/treatment ulcerative colitis 
LCP-AtorFen,lcp-atorfen fixed-dose combination therapy treatment high cholesterol level combining atorvastatin active ingredient lipitor® lowest dose fenofibrate without food effect lcp-atorfen designed daily tablet offering powerful safe treatment high cholesterol level addressing three primary cardiovascular risk factor low density lipoprotein cholesterol ldl-c high density lipoprotein cholesterol hdl-c triglyceride tg ,investigated use/treatment hyperlipidemia 
LLL-3348, botanical drug product lll-3348 once-daily oral formulation treatment chronic stable plaque type psoriasis ,investigated use/treatment psoriasis psoriatic disorder 
Rabeximod,rabeximod orally administered compound treatment moderate severe active rheumatoid arthritis currently undergoing phase ii clinical testing eight european country ,investigated use/treatment rheumatoid arthritis 
Trastuzumab emtansine,trastuzumab emtansine formerly called trastuzumab-dm1 t-dm1 first-in-class her2 antibody drug conjugate adc comprised genentech 's trastuzumab antibody linked immunogen 's cell-killing agent dm1 t-dm1 combine two strategy -- anti-her2 activity targeted intracellular delivery potent anti-microtubule agent dm1 maytansine derivative -- produce cell cycle arrest apoptosis trastuzumab emtansine marketed brand name kadcyla indicated use her2-positive metastatic breast cancer patient already used taxane and/or trastuzumab metastatic disease cancer recur within 6 month adjuvant treatment fda label two precaution first trastuzumab emtansine trastuzumab interchanged second black box warning serious side effect hepatotoxicity embryo-fetal toxicity cardiac toxicity ,used her2-positive metastatic breast cancer patient already used taxane and/or trastuzumab metastatic disease cancer recur within 6 month adjuvant treatment 
CRx-401,crx-401 novel insulin sensitizer designed provide anti-diabetic activity without promoting weight gain consists low dose analgesic diflunisal conjunction modified-release therapeutic dose bezafibrate anti-cholesterol agent third-party clinical study dose bezafibrate contained crx-401 observed positive impact cellular pathway influence glycemic lipid profile dose proven well tolerated clinical trial unlike nsaid non-steroidal anti-inflammatory drug dose diflunisal crx-401 demonstrated preclinical study ability synergistically enhance anti-diabetic effect bezafibrate novel disease-targeted mechanism ,investigated use/treatment diabetes mellitus type 2 
IC41,"ic41 therapeutic peptide vaccine devloped intercell ag treatment hepatitis c. vaccine consists five synthetic peptide ipep83 84 87 89,1426 harboring hcv cd4 cd8 t-cell epitope synthetic adjuvant poly-l-arginine ",investigated use/treatment hepatitis viral c 
Thrombomodulin Alfa,thrombomodulin alfa novel recombinant soluble thrombomodulin art-123 human protein thrombin inhibiting protein c stimulating activity potential treatment thromboembolism blood clotting disorder disseminated intravascular thromboembolism a18701 ,investigated use/treatment blood preservative blood blood forming organ disorder unspecified sepsis septicemia thrombosis 
Col-118,col-118 topical compound based sansrosa technology treatment redness associated rosacea skin disorder believed reduce erythema constricting enlarged blood vessel facial tissue col-118 unique formulation presentation brimonidine selective alpha-2 adrenergic receptor agonist ,investigated use/treatment skin infections/disorders 
Oglufanide,oglufanide synthetic dipeptide immunomodulator development treatment chronic hepatitis c viral infection oglufanide originally developed treat severe infectious disease russia registered pharmaceutical extensively studied cancer clinical trial united state acquired implicit bioscience 2005 oglufanide work regulator body 's immune response given intranasal administration patient chronic hepatitis c viral infection ,investigated use/treatment hepatitis viral c 
ATX-101,atx-101 medical sodium deoxycholate subcutaneous injection evaluated treatment reduction localized fat deposit includes treatment superficial lipoma benign tumor soft tissue composed mature fat cell fat deposit submental region face/neck localized fat deposit part body deoxycholic acid naturally occurring bile acid produced liver one several end product cholesterol metabolism naturally occurring component human body deoxycholate considered ‘ biocompatible ’ detergent solubilizes fat small intestine atx-101 demonstrates relative selectivity fat tissue ,investigated use/treatment solid tumor 
LGD-1550,lgd-1550 orally-active synthetic aromatic retinoic acid agent potential antineoplastic chemopreventive activity ,investigated use/treatment cancer/tumors unspecified 
Irofulven, novel anti-cancer compound synthesized scientist university california san diego decade ago toxin poisonous jack-o-lantern mushroom granted “ fast track ” status u.s. food drug administration fda demonstrating promise one deadly cancer mgi-114 irofulven currently developed mgi pharma inc. emerging oncology-focused pharmaceutical company based minneapolis phase iii clinical trial involving drug underway since early 2001 site u.s. europe ,investigated use/treatment brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indication prostate cancer sarcoma 
LM-609,lm-609 vitaxin artificial antibody target protein surface newly forming blood vessel well certain tumor addition cancer protein implicated bone destruction rheumatoid arthritis inflammatory process psoriasis ,investigated use/treatment colorectal cancer melanoma prostate cancer psoriasis psoriatic disorder rheumatoid arthritis solid tumor 
MX6,"mx6 adamantyl group derivative containing retinoid-related compound induce apoptosis cancer cell therefore may used treatment cancer including advanced cancer specifically shown adamantyl compound e.g. 6- 3- 1-adamantyl -4-methoxyphenyl -2-naphthoic acid 2- 3- 1-adamantyl -4-methoxyphenyl -5-benzimidazole carboxylic acid 6- 3- 1-adamantyl -4,5-methylenedioxyphenyl -2-naphthoic acid used treat prevent cervical cancer precancers cervical dysplasia including high grade low grade dysplasia ",investigated use/treatment cervical dysplasia/cancer 
SR 140333,sr 140333 tachykinin antagonist potential treat diarrhoea due food allergy inflammatory bowel disease ,investigated use/treatment asthma inflammatory bowel disease 
Perflubron,perflubron oxygent developed intravascular oxygen carrier designed augment oxygen delivery surgical patient ,investigated use/treatment cardiac surgery hemorrhage ileus 
Arylacenamide,arylacenamide sr31747 peripheral sigma ligand bind four protein human cell i.e srbp-1 sigma -2 hsi relative srbp-2 dual agent immunomodulatory antiproliferative activity ,investigated use/treatment cancer/tumors unspecified immunosuppressive prostate cancer 
PRO-542,pro 542 belongs new class drug viral-entry inhibitor intended prevent hiv entering infecting cell pro 542 cd4-immunoglobulin g2 tetravalent cd4-immunoglobulin fusion protein broadly neutralizes primary hiv-1 isolates ,investigated use/treatment acquired immune deficiency syndrome aid aids-related infection hiv infection pediatric indication 
Serelaxin,recombinant human relaxin hormone produced pregnancy facilitates birth process causing softening lengthening cervix pubic symphysis place pubic bone come together .it heterodimer protein secreted corpus luteum placenta pregnancy ,investigated use/treatment cardiovascular disorder congestive heart failure infertility peripheral vascular disease scleroderma 
Daglutril,daglutril orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor development treatment essential hypertension congestive heart failure ,investigated use/treatment congestive heart failure hypertension 
TNX-901,tnx-901 therapeutic monoclonal antibody designed address significant unmet medical need area asthma allergy inflammation disease affecting human immune system ,investigated use/treatment allergic reaction 
GEM-231,gem231 second-generation antisense oligonucleotide targeting mrna r1alpha regulatory subunit camp dependent protein kinase monoclonal antibody combined toxic substance used treat certain type acute myeloid leukemia older patient studied treatment type cancer monoclonal antibody made laboratory locate bind cancer cell ,investigated use/treatment solid tumor 
NOX-100,nox-100 new nitric oxide neutralizing agent developed san diego-based medinox -- demonstrated effectiveness potential therapeutic treat hemorrhagic shock nox-100 first series proprietary neutralizing compound medinox developing bind inactivate simple gas molecule key biological messenger body ,investigated use/treatment sepsis septicemia 
Alethine,alethine studied treatment cancer belongs family chemical called disulfides low molecular weight disulfide shown exhibit vivo antitumor activity murine myeloma melanoma model ,investigated use/treatment blood blood forming organ disorder unspecified lymphoma unspecified multiple myeloma 
GTI 2040,gti-2040 substance studied treatment cancer belongs family drug called antisense oligonucleotides ,investigated use/treatment breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma solid tumor 
ISIS 14803,isi 14803 20-unit antisense phosphorothioate oligodeoxynucleotide bind hepatitis c virus hcv rna translation initiation region internal ribosome entry site ire inhibits protein expression cell culture ,investigated use/treatment hepatitis viral c 
Prasterone sulfate,dhea sulfate major steroid fetal adrenal dhea-s principal adrenal androgen secreted together cortisol control acth prolactin dhea-s elevated hyperprolactinemia ,investigated use/treatment asthma burn burn infection 
NS-2359,ns2359 triple monoamine re-uptake inhibitor new unique drug profile expected yield important benefit compared existing treatment depression enhancing function three neurotransmitter serotonin noradrenalin dopamine ns2359 desired `` triple-mode-of-action '' mode action expected produce optimal reduction disease symptom possibility earlier onset action compared antidepressant already market ,investigated use/treatment addiction attention deficit/hyperactivity disorder adhd depression 
Cositecan,cositecan novel camptothecin derivative also known karenitecin developed superior oral bioavailability increased lactone stability used treat cancer ,investigated use/treatment brain cancer lung cancer melanoma 
HGTV-43,hgtv43 anti-sense treatment designed produce cell genetically resistant hiv infection hgtv43 one number so-called 'gene transfer vector developed biotechnology company enzo biochem inc ,investigated use/treatment hiv infection 
Muparfostat,muparfostat pi-88 mixture highly sulfated monophosphorylated mannose oligosaccharide derived extracellular phosphomannan yeast pichia hansenula holstii potential antiangiogenic activity ,investigated use/treatment hepatocellular carcinoma liver cancer melanoma multiple myeloma 
TA-CIN,ta-cin subunit vaccine comprising l2/e6/e7 protein human papillomavirus hpv16 designed generate strong cellular immune response hpv-infected cell ,investigated use/treatment cervical dysplasia/cancer 
99mTc-glucarate,99mtc-glucarate gla agent non-invasive detection breast tumour ,investigated use/treatment myocardial infarction 
HSV-2 theracine,hsv-2 theracine attenuated recombinant vaccine developed aurx treatment genital herpes ,investigated use/treatment genital herpes 
Abiraterone,abiraterone derivative steroidal progesterone innovative drug offer clinical benefit patient hormone refractory prostate cancer abiraterone administered acetate salt prodrug higher bioavailability le susceptible hydrolysis abiraterone fda approved april 28 2011 ,abiraterone acetate indicated combination methylprednisolone treatment metastatic castration-resistant prostate cancer crpc l40968 prednisone treatment metastatic crpc metastatic high-risk castration-sensitive prostate cancer cspc l40193 
GPI-1485,gpi 1485 product candidate belongs class small molecule compound called neuroimmunophilin ligand preclinical experiment neuroimmunophilin ligand shown repair regenerate damaged nerve without affecting normal healthy nerve gpi 1485 studied phase 2 clinical trial treatment parkinson 's disease post-prostatectomy erectile dysfunction pre-clinical development hiv related dementia neuropathy ,investigated use/treatment erectile dysfunction parkinson 's disease 
GnRH pharmaccine, gnrh pharmaccine consists synthetic peptide constructed `` look like '' gnrh bound chemically carrier suspended proprietary `` delivery vehicle '' pharmaccine administered intramuscularly patient injection induces immune response production antibody patient neutralize gnrh thus removing circulation ,investigated use/treatment prostate cancer 
Laromustine,vnp40101m novel alkylating agent used trial studying treatment leukemia lymphoma lung cancer small intestine cancer myelodysplastic syndrome among others ,investigated use/treatment brain cancer cancer/tumors unspecified colorectal cancer leukemia lymphoid leukemia myeloid lung cancer myelodysplastic syndrome pediatric indication solid tumor 
SGN-15,sgn-15 studied treatment cancer combine monoclonal antibody anticancer drug doxorubicin monoclonal antibody substance made laboratory locate bind cancer cell doxorubicin type anthracycline antitumor antibiotic combined monoclonal antibody form type drug conjugate also called cbr96-doxorubicin immunoconjugate ,investigated use/treatment breast cancer colorectal cancer lung cancer 
NBI-6024,nbi-6024 altered peptide ligand designed cause immune response result preservation beta-cell function endogenous insulin production ,investigated use/treatment diabetes mellitus type 1 pediatric indication 
DP-b99,"dp-b99 newly developed lipophilic cell permeable derivative bapta 1,2-bis 2-aminophenoxy ethane-n n n n'-tetraacetic acid development neuroprotectant potential treatment stroke head trauma neurological damage associated coronary artery bypass graft ",investigated use/treatment stroke traumatic brain injury 
DP-VPA,dp-vpa d-pharm 's proprietary lipid modified version valproic acid vpa demonstrate dp-vpa well-tolerated patient resistant epilepsy marked effect reducing seizure frequency ,investigated use/treatment bipolar disorder epilepsy migraine cluster headache 
CNS-5161,cns 5161 blocker nmda ion channel completed phase iia proof concept clinical trial novel compound treatment neuropathic pain ,investigated use/treatment migraine cluster headache neuropathy diabetic pain acute chronic 
NCX 1015,ncx 1015 nitric oxide-releasing derivative prednisolone developed treatment inflammatory bowel disease ibd nicox sa ,investigated use/treatment arthritis arthritic pain inflammatory bowel disease 
Prolease-r-hFSH,prolease-r-hfsh recombinant human follicle stimulating hormone r-hfsh alkermes prolease injectable sustained release drug delivery technology provides patient long term therapeutic benefit single administration rather multiple injection ,investigated use/treatment infertility 
G207,g207 cancer-killing virus so-called oncolytic virus treatment various form cancer developed medigene ag virus specific herpes simplex virus hsvs generally known cause cold sore medigene us virus however modified `` disarmed '' form order make utilizable therapeutic agent human ,investigated use/treatment brain cancer 
LU-31130,lu-31130 rapid acting therapy developed h. lundbeck a/s treat psychosis schizophrenia schizoaffective disorder act dopamine d4 receptor cortex low affinity d2 receptor adrenoceptors muscarinic histaminergic receptor provides anti-psychotic characteristic low incidence extrapyramidal cardiovascular side effect ,investigated use/treatment psychosis schizophrenia schizoaffective disorder 
Parathyroid hormone,parathyroid hormone pth single-chain polypeptide composed 84 amino acid available preotact identical form human recombinant hormome produced fusion protein undergoeing post-translational processing involving cleavage ompa leader sequence leaving mature protein single-chain 84 amino-acids polypeptide 9.4 kda preotact used treatment osteoporosis postmenopausal woman high risk osteoporotic fracture marketed europe nycomed preos registered trade mark owned np pharmaceutical inc name preos new drug application pending approval u.s. food drug administration fda , use/treatment osteoporosis 
Trestolone,trestolone 7α-methyl-19-nortestosterone synthetic androgen developed population council potential candidate drug use hormonal male contraceptive method male regular administration sufficient quantity trestolone induces state temporary infertility ,investigated use/treatment contraception male hormonal deficiencies/abnormalities 
ING-1,ing-1 high-affinity human engineered trade mark monoclonal antibody recognizes 40 kilodalton epithelial cell adhesion molecule epcam glycoprotein expressed high level adenocarcinoma attractive target immunotherapy ,investigated use/treatment cancer/tumors unspecified 
PPI-1019,apan ppi-1019 developed praecis pharmaceutical treat alzheimer 's disease ,investigated use/treatment alzheimer 's disease 
OC-1012,oc-1012 compound emerged promising therapeutic agent treatment prevention mucositis serious side effect chemotherapy head neck radiation therapy ,investigated use/treatment adverse effect chemotherapy head neck cancer 
NS-3728,ns3728 orally active chloride channel blocker treatment cancer ,investigated use/treatment anemia sickle cell cancer/tumors unspecified 
AG-702,ag-702 recombinant human heat shock protein also known stress protein also known hsps group protein induced cell undergoes various type environmental stress like heat cold oxygen deprivation hsps present cell life form bacteria mammal structure function similar across diverse life form drug developed antigenics treatment genital herpes infection phase clinical trial ,investigated use/treatment genital herpes 
OSI-7836,osi-7836 member nucleoside class cytotoxic drug gemcitabine market leader osi pharmaceutical develops osi-7836 next-generation gemcitabine anti-tumor activity osi-7836 appeares le schedule dependent gemcitabine also active ara-c another clinically used nucleoside analog nine model active either paclitaxel cisplatin two lung xenograft model tested drug show unexpected toxicity observed appeared similar nucleoside agent ,investigated use/treatment solid tumor 
OPC-51803,opc-51803 first nonpeptide vasopressin avp v 2 -receptor-selective agonist v 2 -selective agonist produce significant antidiuretic action single multiple oral dosing avp-deficient normal avp state useful therapeutic drug treatment hypothalamic diabetes insipidus nocturnal enuresis kind urinary incontinence ,investigated use/treatment nocturia frequent nighttime urination urinary incontinence 
BG-777,bg-777 immunomodulator proven efficacy viral bacterial infection preclinical study ,investigated use/treatment cytomegalovirus cmv retinitis hiv infection influenza pneumonia 
AGI-1096,agi-1096 novel oral antioxidant selective anti-inflammatory agent developed address accelerated inflammation grafted blood vessel known transplant arteritis common chronic organ transplant rejection ,investigated use/treatment transplant rejection 
AI-128,ai-128 first human demonstration sustained release drug administration lung ai-128 consists slowly dissolving microspheres designed control drug particle go lung quickly release drug ,investigated use/treatment asthma 
AI-850,ai-850 cremophor r -free formulation paclitaxel active ingredient taxol r product used treat variety solid tumor ,investigated use/treatment breast cancer solid tumor 
trans NV-04,trans nv-04 cardiovascular drug show significant reduction blood pressure arterial stiffness ,investigated use/treatment cardiovascular disorder hypertension 
NV-07a,nv-07a topical skin repair compound protecting skin sun-induced immunosuppression uv-induced damage ,investigated use/treatment skin cancer skin infections/disorders 
Mito-4509,mito-4509 non-feminizing estrogen analog could affect mitochondrial metabolic pathway used treat parkinson 's disease alzheimer 's disease retinal disorder neurologic disorder ,investigated use/treatment alzheimer 's disease neurologic disorder parkinson 's disease retinal disorder unspecified 
humanized SMART Anti-IL-12 Antibody, humanized anti-il-12 antibody important addition pdl 's already strong pipeline humanized antibody developed treatment autoimmune disease smart anti-il-12 antibody humanized pdl murine anti-il-12 antibody licensed together certain intellectual property related anti-il-12 therapy hoffmann-la roche inc. il-12 cytokine may considerable potential target therapy autoimmune disease ,investigated use/treatment autoimmune disease inflammatory disorder unspecified 
NCX 950,ncx 950 beta2-adrenoceptor agonist widely used treatment pulmonary disease ,investigated use/treatment asthma chronic obstructive pulmonary disease copd 
Biomed 101,biomed 101 investigated use/treatment adverse effect chemotherapy renal cell carcinoma biomed 101 solid biomed 101 bind leukotriene b4 receptor affect interleukin-2 antitumor activity ,investigated use/treatment adverse effect chemotherapy renal cell carcinoma 
cryopreserved human liver cells,vesta therapeutic privately held company developing cell therapeutic liver repair regeneration company 's technology centered isolation expansion cryopreservation liver cell human hepatocytes obtained organ donor liver suitable whole organ transplantation ,investigated use/treatment liver disease 
CLX-0921,clx-0921 investigated use/treatment diabetes mellitus type 2 clx-0921 solid clx-0921 spectrum activity differs commercially available thiazolidinediones substance target protein peroxisome proliferator-activated receptor gamma pharmacologically active antihyperglycemic agent act increasing peripheral tissue sensitivity insulin ,investigated use/treatment diabetes mellitus type 2 
Rivanicline,rivanicline tc-2403 rjr-2403 e -metanicotine partial agonist neuronal nicotinic acetylcholine receptor binding primarily α4β2 subtype originally developed potential treatment alzheimer 's disease nootropic effect also found inhibit production interleukin-8 subsequently developed potential anti-inflammatory treatment ulcerative colitis rivanicline also stimulant analgesic action thought due increased noradrenaline release ,investigated use/treatment ulcerative colitis 
CPD 923,cpd 923 n-butylgalactonorjirimycin iminosugar analogue zavescatm show efficacy vivo study well favourable pre-clinical tolerability profile ,investigated use/treatment metabolic disease 
Q-Derp1,q-derp1 developed cytos biotechnology immunodrug antigen prevention various major chronic disease derp1 dominant allergic protein found dust mite feces ,
BI-K0376,bi-k0376 investigated use/treatment acne bi-k0376 solid investigation pfizer gone phase clinical trail ,investigated use/treatment acne 
PI-166,pi-166 small organic compound specific avidity liver cancer cell demonstrated ability reduce growth rat hepatoma like human hepatoma resistant established anti-cancer agent ,investigated use/treatment liver cancer 
Peginterferon alfacon-1,pegylation technology chemical attachment polyethylene glycol peg polymer chain broad range drug substance peptide protein including antibody fragment small molecule drug infergen bio-engineered type interferon alpha fda-approved treatment patient chronic hepatitis c infection ,investigated use/treatment hepatitis viral c 
Tasquinimod, quinoline-3-carboxamide anti-angiogenic agent tasquinimod enhances anti-prostate cancer efficacy androgen ablation taxotere without effecting serum psa directly human xenograft,investigated use/treatment prostate cancer 
TRX1,trx1 humanized antibody bind cd4 receptor found subset cell trx1 developed potential treatment autoimmune disease collaboration genentech inc. tolerrx currently conducting phase clinical study trx1 united kingdom ,investigated use/treatment autoimmune disease 
PPI-2458,ppi-2458 represents potentially new important addition growing list therapeutic aimed specific molecular oncology target ppi-2458 novel proprietary molecule belonging fumagillin class compound specifically target metap-2 enzyme class compound shown prevent abnormal cell growth formation new blood vessel known angiogenesis contribute growth aberrant tissue disease cancer rheumatoid arthritis clinical development previous fumagillin derivative limited toxicity profile preclinical study date ppi-2458 demonstrated potent pharmacologic activity class compound displaying improved pharmacokinetic toxicity profile ,investigated use/treatment lymphoma non-hodgkin 's solid tumor 
VIT-100,vit-100 developed itherx pharmaceutical san diego preclinical study companyl shown vit-100 inhibits growth cell taken multiple keloid biopsy compared keloidal cell treated control believed similar effect would seen cell isolated hypertrophic scar ,investigated use/treatment diabetic retinopathy scar tissue vitreous hemorrhage 
ETC-1001,etc-1001 pfizer ’ lead oral small molecule product candidate intended chronic treatment individual lipid disorder ,investigated use/treatment hyperlipidemia 
99mTc-14 F7 Mab,99mtc 14f7 mab strong anti tumor activity myeloma cell vivo growth inhibition prolonged survival myeloma tumor obtained evidence anti tumor effect treatment 99mtc 14f7 mab ,investigated use/treatment breast cancer 
Ciluprevir, compound named biln 2061 orally active inhibitor hcv ns3 protease first member new drug class tested human ,investigated use/treatment hepatitis viral c 
Ethyl pyruvate,cti-01 ethyl pyruvate novel anti-inflammatory agent treatment critical inflammatory condition cti-01 show potent anti-inflammatory tissue protection activity multiple animal model disease including pancreatitis ischemia-reperfusion injury sepsis renal injury endotoxemia ,investigated use/treatment burn burn infection cardiac surgery inflammatory disorder unspecified ischemic reperfusion injury sepsis septicemia 
anti-alpha5Beta1-integrin antibody,integrins important adhesion molecule regulate tumor endothelial cell survival proliferation migration integrin alpha5beta1 shown play critical role angiogenesis anti-alpha5beta1 integrin antibody inhibits angiogenesis including vessel formation induced vascular endothelial growth factor vegf basic fibroblast growth factor bfgf well pro-angiogenic growth factor ,investigated use/treatment colorectal cancer pancreatic cancer solid tumor 
UC-781,uc-781 thiocarboxanilide non-nucleoside reverse transcriptase inhibitor nnrti topical microbicide targeted aid virus ,investigated use/treatment hiv infection 
AVI-4020,avi-4020 neugene antisense drug candidate treatment patient acute west nile virus disease serious neurological impairment wnv neuroinvasive disease ,investigated use/treatment infectious parasitic disease unspecified viral infection 
AEOL-10150,aeol 10150 developed aeolus therapeutic agent based proprietary small molecule catalytic antioxidant ,investigated use/treatment amyotrophic lateral sclerosis al 
"Sar9, Met (O2)11-Substance P",sar9 met o2 11-substance p neurokinin-1 receptor agonist analog naturally occurring human neuropeptide substance p found throughout body including airway human many specie ,investigated use/treatment acute respiratory distress syndrome ards viral infection 
AME-527,ame-527 humanized monoclonal antibody recognizes human tnf-alpha htnf-alpha high affinity specificity ame-527 generated protein engineering identified library antibody variant based improved binding property ,investigated use/treatment rheumatoid arthritis 
MBT-0312,medigene 's newly acquired drug candidate mbt-0312 aim novel method cancer therapy `` starving '' tumor ,investigated use/treatment solid tumor 
EHT 0202,eht 0202 developed treat neurodegenerative disorder exonhit therapeutic ,investigated use/treatment alzheimer 's disease neurologic disorder 
CHF 4227,chf 4227 new selective estrogen receptor modulator serm compound high receptor affinity shown promising efficacy prevention bone loss animal model osteoporosis additionally compound shown uterotrophic activity suggesting potential therapeutic advantage drug normally used postmenopausal therapy ,investigated use/treatment osteoporosis 
ABX-PTH,abx-pth fully human monoclonal antibody generated abgenix 's technology platform drug target neutralizes action parathyroid hormone pth treatment secondary hyperparathyroidism ,investigated use/treatment chronic renal failure parathyroid disorder 
HCV-086,hcv-086 small molecule antiviral designed block enzyme required replication hepatitis c virus ,investigated use/treatment hepatitis viral c 
Seletracetam,seletracetam pyrrolidone derivative structural similarity newer generation antiepileptic drug levetiracetam bind target levetiracetam higher affinity shown potent seizure suppression model acquired genetic epilepsy high cns tolerability predicted low drug-drug interaction inhibition induction major human metabolizing enzyme seletracetam phase ii clinical trial supervision u.s. food drug administration fda investigated treatment epilepsy partial epilepsy however development put hold july 2007 2010 production halted due investigation newer antiepileptic agent brivaracetam ,investigated use/treatment epilepsy 
NV-18,nv-18 product novogen diphenolic synthetic analogue program creating drug diverse activity specific type cancer like phenoxodiol nv-18 broadly effective laboratory almost human cancer type nv-18 distinctive showing particular potency melanoma cholangiocarcinoma cancer gall bladder ,investigated use/treatment solid tumor 
TAFA-93,tafa93 novel prodrug mtor inhibitor rapamycin successfully completed phase 1 clinical development mtor inhibitor currently used prevention organ rejection transplantation treatment autoimmune oncological disease component coated stent treatment coronary artery disease ,investigated use/treatment transplant rejection 
MEM 1414,mem 1414 pde4 inhibitor evaluated treatment alzheimer ’ disease drug candidate completed phase 1 clinical trial mem 1414 work blocking phosphodiesterase enzyme break important brain chemical cyclic amp appears work area brain new memory formed ,investigated use/treatment alzheimer 's disease depression memory loss neurologic disorder 
Inotuzumab ozogamicin,inotuzumab ozogamicin antibody-drug conjugate using linker cytotoxic drug technology similar developed ground-breaking treatment mylotarg db00056 approved u fda 2000 treatment acute myeloid leukaemia inotuzumab ozogamicin consists recombinant humanised igg4 kappa cd22-targeting monoclonal antibody covalently attached calicheamicin derivative n-acetyl-gamma-calicheamicin dimethylhydrazide potent dna-binding cytotoxic agent a20352 developed pfizer ucb inotuzumab ozogamicin granted approval eu june 2017 followed fda august 17th 2017 treatment adult relapsed refractory b-cell precursor acute lymphoblastic leukemia rapidly progressing cancer bone marrow associated high mortality rate low therapeutic response standard chemotherapy relasping condition randomized trial inotuzumab ozogamicin displayed higher percentage patient undergoing longer period complete remission evidence disease comparison patient receiving alternative chemotherapy a20353 ,indicated monotherapy treatment adult relapsed refractory cd22-positive b cell precursor acute lymphoblastic leukaemia 
Veglin,vegf-as veglin anti-angiogenesis non-chemotherapy drug angiogenesis inhibitor developed vasgene therapeutic inc. treatment variety malignancy including mesothelioma veglin one several newly developed non-chemotherapy drug tested possible utilization ongoing struggle combat malignant mesothelioma ,investigated use/treatment cancer/tumors unspecified solid tumor 
RI 624,ri 624 novel humanized monoclonal antibody block nerve growth factor ngf key mediator acute chronic pain ri 624 developed rinat currently phase clinical trial ,investigated use/treatment pain acute chronic 
GT 389-255,peptimmune ’ lead product gt 389-255 novel lipase inhibitor fat binding hydrogel polymer conjugate treatment obesity completed single multiple ascending dose sad mad phase trial expected block fat absorption fewer side effect currently marketed lipase inhibitor ,investigated use/treatment obesity 
HGS-TR2J,hgs-tr2j novel agonistic human monoclonal antibody trail receptor 2 patient advanced solid malignancy developed human genome science inc phase clinical trial ,investigated use/treatment solid tumor 
Sirna-027,sirna-027 chemically modified short interfering rna sirna targeting vascular endothelial growth factor receptor-1 vegfr-1 vegfr-1 key component clinically validated vascular endothelial growth factor vegf pathway sirna-027 developed sirna therapeutic phase clinical trail used treat macular degeneration ,investigated use/treatment macular degeneration 
rhIGFBP-3,rhigfbp-3 recombinant human insulin-like growth factor binding protein-3 insmed ’ proprietary anti-cancer compound demonstrated significant decrease cancerous growth several model human developed insmed currently phase clinical trial ,investigated use/treatment cancer/tumors unspecified 
CERE-110,cere-110 gene-therapy product involves vivo delivery nerve growth factor ngf gene adeno-associated viral vector aav delivery system drug developed ceregene currently phase clinical trial ,investigated use/treatment alzheimer 's disease gene therapy 
CRLX101,it-101 conjugate insert 's proprietary drug delivery molecule cyclosert potent anti-cancer compound camptothecin ,investigated use/treatment cancer/tumors unspecified solid tumor 
KOS-1584,kos-1584 second-generation epothilone epothilones anticancer agent taxane-like mechanism action demonstrated activity taxane-resistant tumor kos-1584 second-generation compound increased potency favorable tissue distribution ease formulation ,investigated use/treatment solid tumor 
BLX-883,blx-883 form alfa interferon developed biolex treatment hepatitis viral c. alfa interferon used treatment hepatitis c hepatitis b multiple cancer worldwide sale currently exceed 3 billion ,investigated use/treatment hepatitis viral c 
TD-2749,td-2749 selective 5-ht4 agonist discovered theravance application multivalent drug design drug discovery program dedicated finding new medicine gi motility disorder chronic constipation constipation-predominant irritable bowel syndrome c-ibs opioid-induced constipation functional dyspepsia diabetic gastroparesis ,investigated use/treatment constipation gastrointestinal disease disorder miscellaneous gastroparesis irritable bowel syndrome ibs 
CCR5 mAb,ccr5 mab fully human monoclonal antibody specifically recognizes bind chemokine receptor ccr5 known key facilitator infection human immunodeficiency virus hiv-1 generated hg using abgenix xenomouse technology ,investigated use/treatment hiv infection 
RUS 3108,ru 3108 developed treatment atherosclerosis major cause cardiovascular disorder heart attack stroke dr. reddy ’ laboratory drug ’ phase clinical trial initiated europe ass safety drug compound healthy volunteer ,investigated use/treatment atherosclerosis 
REN-850,ren-850 oral drug multiple sclerosis phase clinical trial ,investigated use/treatment multiple sclerosis 
OSI-930,osi-930 orally active inhibitor two clinically validated target c-kit vascular endothelial growth factor receptor-2 vegfr-2 osi-930 designed target cancer cell proliferation blood vessel growth angiogenesis selected tumor preclinical study osi-930 show broad efficacy tumor model representative small cell lung cancer glioblastoma colorectal renal head neck non-small cell lung cancer gastric cancer ,investigated use/treatment solid tumor 
Stamulumab,myo-029 human anti-gdf-8 monoclonal antibody developed treat muscle-wasting disease including muscular dystrophy age-related sarcopenia ,investigated use/treatment muscular dystrophy 
CT-011,ct-011 humanized monoclonal antibody directed b7 family-associated protein patient advanced haematological malignancy directed human pd-1 programmed cell death 1 pdcd1 immunomodulating antitumor activity ,investigated use/treatment cancer/tumors unspecified 
LS11,ls11 talaporfin sodium agent consisting chlorin e6 derived chlorophyll l-aspartic acid photosensitizing activity intratumoral activation light emitting diode taporfin sodium form extended high energy conformational state generates singlet oxygen resulting free radical-mediated cell death used treat many kind cancer ,investigated use/treatment macular degeneration 
DDP-200,ddp200 developed dynogen treatment non-incontinent form overactive bladder oab particular focus male female patient urinary frequency urinary urgency nocturia ,investigated use/treatment urinary incontinence 
RTA 744,rta 744 novel anthracycline derivative cross blood-brain barrier show significant potential treatment primary metastatic brain cancer anthracyclines one broadly used effective class cancer therapy however used treat brain cancer current therapy cross blood-brain barrier ,investigated use/treatment brain cancer 
NLX-P101,nlx-p101 gene therapy developed neurologix treat parkinson ’ disease gene glutamic acid decarboxylase gad whose product synthesizes major inhibitory neurotransmitter brain gamma -aminobutyric acid gaba target subthalamic nucleus stn overactive patient parkinson ’ disease nlx-p101 evaluated therapeutic drug injected deep brain structure known function abnormally parkinson ’ patient ,investigated use/treatment parkinson 's disease 
Dovitinib,dovitinib orally active small molecule exhibit potent inhibitory activity multiple rtks involved tumor growth angiogenesis preclinical data show dovitinib work inhibit multiple kinase associated different cancer including acute myeloid leukemia aml multiple myeloma chiron currently three ongoing phase clinical trial dovitinib ,investigated use/treatment multiple myeloma solid tumor 
GPI-0100,gpi-0100 avantogen ’ lead adjuvanat-immunopotentiator key component vaccine boosting immune response gpi-0100 adjuvant shown significantly enhance immune response variety vaccine shown good overall performance characteristic safety efficacy ,investigated use/treatment breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer prostate cancer 
SB-559448,sb-559448 small-molecule drug mimic activity thrombopoietin tpo protein factor promotes growth production blood platelet drug developed glaxosmithkline used treat thrombocytopenia.thrombocytopenia decreased platelet count common side effect many chemotherapy lead uncontrolled bleeding thus representing significant problem treatment cancer patient ,investigated use/treatment thrombocytopenia 
Pegdinetanib,ct-322 proprietary adnectin tm protein therapeutic preclinical study specifically bind vascular endothelial growth factor receptor 2 vegfr-2 regulates primary tumor angiogenesis pathway result ct-322 block known ligand vegfr-2 ,investigated use/treatment cancer/tumors unspecified macular degeneration 
Denibulin,denibulin novel small molecule vascular disrupting agent development medicinova treatment solid tumor cancer ,investigated use/treatment solid tumor 
CTCE-0214,ctce-0214 stable peptide agonist stromal cell-derived factor-1 sdf-1 key signaling molecule proliferation homing engraftment expansion hematopoietic stem cell white blood cell ,investigated use/treatment adverse effect chemotherapy blood blood forming organ disorder unspecified cancer/tumors unspecified neutropenics vascular disease 
CVT-6883,cvt-6883 selective potent orally available a2b-adenosine receptor antagonist cv therapeutic investigating potential treatment asthma condition related inflammation fibrosis ,investigated use/treatment asthma 
Edonerpic,edonerpic neurotrophic agent intended treatment alzheimer 's disease phase clinical trial ,investigated use/treatment alzheimer 's disease 
MK-0354,mk-0354 orally administered drug candidate development merck treatment atherosclerosis related disorder target g protein-coupled receptor gpcr potential regulate plasma lipid profile including hdl good cholesterol similar therapeutic action niacin ,investigated use/treatment atherosclerosis 
Leronlimab,leronlimab pro-140 human monoclonal antibody developed cytodyn l12684 first described literature 2001 a3922 antibody bind ccr5 may useful treating hiv cancer severely ill covid-19 patient a192846 a192858 l12684 ,leronlimab currently investigated treatment number cancer a192858 hiv a3922 recently leronlimab begun phase ii clinical trial severely ill covid-19 patient l12684 preliminary data show reduction 'cytokine storm particularly il-6 well normalization cd4/cd8 t-cell ratio l12684 result may mitigate immune mediate injury seen severely ill covid-19 patient l12684 
GI-5005,gi-5005 globeimmune 's lead infectious disease product proprietary tarmogen active immunotherapy platform treatment chronic hepatitis c infection gi-5005 whole heat-killed recombinant yeast genetically modified express hcv-specific protein target tarmogens believed activate innate immune response via toll-like receptor tlrs well adaptive antigen specific cellular immune response ,investigated use/treatment hepatitis viral c 
Resatorvid,resatorvid investigational compound designed treatment severe sepsis ,investigated use/treatment sepsis septicemia 
Varlitinib,varlitinib oral selective reversible small molecule tyrosine kinase inhibitor erbb-2 her-2/neu egfr over-expression erbb-2 egfr receptor tumor predictive poor prognosis cancer patient varlitinib shown significant anti-tumor activity preclinical model human breast lung epidermal carcinoma tumor ,investigated use/treatment cancer/tumors unspecified 
MDX-1303,mdx-1303 fully human antibody inhalation anthrax lethal form illness human caused bacillus anthracis bacterium target protein component lethal toxin known anthrax protective antigen ,investigated use/treatment anthrax exposure bacterial infection 
Contulakin-G,contulakin-g broad spectrum non-opioid analgesic synthetic form natural peptide extracted venom conus geographus sea snail ,investigated use/treatment pain acute chronic 
EVT-101,,investigated use/treatment alzheimer 's disease neurologic disorder pain acute chronic parkinson 's disease 
ENMD-1198,,investigated use/treatment cancer/tumors unspecified solid tumor 
PPL-100,,investigated use/treatment hiv infection 
Amitifadine,,investigated use/treatment depression 
TAS-108,,investigated use/treatment breast cancer 
ANZ-100,,investigated use/treatment cancer/tumors unspecified liver cancer 
PR-104,,investigated use/treatment cancer/tumors unspecified solid tumor 
SNS-032,,investigated use/treatment cancer/tumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma solid tumor 
Archexin,,investigated use/treatment solid tumor 
Inosine 5'-sulfate,,investigated use/treatment gastrointestinal disease disorder miscellaneous inflammatory bowel disease ulcerative colitis 
Transcrocetinate,vitamin a-analog increase diffusivity oxygen aqueous solution including plasma ,investigated use/treatment cancer/tumors unspecified hemorrhage hypoxia respiratory failure stroke 
Bardoxolone methyl,,investigated use/treatment lymphoma unspecified multiple myeloma solid tumor 
RAF-265,,investigated use/treatment melanoma 
Obeticholic acid,primary biliary cirrhosis pbc progressive chronic condition lead hepatic injury often resulting end-stage liver failure requires liver transplantation a192786 obeticholic acid farnesoid-x receptor fxr agonist used treat condition possibly allowing increased survival a18696 2016 granted approval treat primary biliary cholangitis combination ursodeoxycholic acid previously mainstay treatment condition a18696 l12633 may 2021 fda updated prescribing information contraindicate use obeticholic acid patient pbc advanced cirrhosis e.g portal hypertension hepatic decompensation due risk liver failure case requiring liver transplantation l34650 obeticholic acid currently considered fda approval treat fibrosis caused non-alcoholic liver steatohepatitis nash nda intercept pharmaceutical approved november 2019 obeticholic acid expected granted full approval indication 2020 l12636 ,obeticholic acid indicated treatment primary biliary cholangitis combination ursodeoxycholic acid udca adult inadequate response udca also used monotherapy adult pbc unable tolerate udca l12633 obeticholic acid currently considered fda approval treat fibrosis caused non-alcoholic liver steatohepatitis nash likely approved indication 2020 l12636 
Plinabulin,,investigated use/treatment cancer/tumors unspecified 
PRX-07034,,investigated use/treatment alzheimer 's disease obesity schizophrenia schizoaffective disorder 
Glembatumumab vedotin, conjugate anti-glycoprotein non-metastatic melanoma protein b mab monomethyl auristatin e treatment melanoma breast cancer ,investigated use/treatment melanoma 
Adomiparin,,investigated use/treatment cardiovascular disorder coronary artery disease 
AMG-222,,investigated use/treatment diabetes mellitus type 2 
Aldoxorubicin,aldoxorubicin antineoplastic agent albumin-binding prodrug doxorubicin ,investigated use/treatment solid tumor 
Eteplirsen,eteplirsen synthetic antisense oligonucleotide phosphorodiamidate morpholino oligomer consists six-membered morpholino ring replacing five-membered ribofuranosyl ring found natural dna rna l40015 duchenne muscular dystrophy rare genetic disorder characterized progressive muscle deterioration premature death commonly due respiratory cardiac complication a244930 caused loss-of-function mutation dmd gene coding dystrophin essential protein involved maintaining structural integrity function muscle fibre eteplirsen first approved fda september 2016 treatment duchenne muscular dystrophy dmd patient confirmed mutation dmd gene code dystrophin amenable exon 51 skipping eteplirsen directly work dmd gene promote dystrophin production eteplirsen first treatment dmd approved fda a244925 ,eteplirsen indicated treatment duchenne muscular dystrophy dmd patient confirmed mutation dmd gene amenable exon 51 skipping indication approved accelerated approval based increase dystrophin skeletal muscle observed patient treated eteplirsen l40015 
Cariprazine,cariprazine atypical antipsychotic agent piperazine derivative first developed hungary a247100 work partial agonist central dopamine d2 dopamine d3 serotonin 5-ht sub 1a /sub receptor antagonist serotonin 5-ht sub 2a /sub receptor l40198 cariprazine investigated variety psychiatric disorder including schizophrenia bipolar disorder major depressive disorder cariprazine gained first global approval u september 2015 a3941 later approved health canada april 2022 l41670 currently used treat schizophrenia manic mixed episode depressive episode associated bipolar disorder l41655 l40198 ,cariprazine indicated treatment schizophrenia adult manage positive negative symptom also indicated monotherapy acute management manic mixed episode associated bipolar disorder bipolar mania adult acute management depressive episode associated bipolar disorder bipolar depression adult l43307 l40198 
AV-412,,investigated use/treatment cancer/tumors unspecified 
GlycoPEG-GCSF,glycopeg-gcsf long-acting glycopegylated granulocyte colony stimulating factor treatment chemotherapy-induced neutropenia ,investigated use/treatment adverse effect chemotherapy neutropenics 
PA-1050040,pa1050040 second generation hiv-1 maturation inhibitor chemical analog bevirimat bvm inhibits virus replication mechanism action bvm ,investigated use/treatment hiv infection 
Filanesib,filanesib potent kinesin spindle protein ksp inhibitor caused marked tumor regression preclinical model human solid tumor human leukemia often leading durable response ,investigated use/treatment cancer/tumors unspecified 
ZEN-012,zen-012 novel small molecule first anti-cancer drug development involving two mechanism action tubulin topoisomerase ii inhibition zen-012 also express additional mode action pro-apoptotic anti-angiogenic property developed treatment solid tumor ,investigated use/treatment cancer/tumors unspecified 
Olaratumab,olaratumab imc-3g3 fully human igg1 monoclonal antibody antitumor activity selectively bind external domain human platelet-derived growth factor receptor pdgfr -α high affinity block ligand binding composed two heavy chain molecule fragment 2 light chain fragment study show treatment olaratumab combination doxorubicin resulted significant reduction cancer cell proliferation tumor growth olaratumab granted accelerated approval lartruvo initial therapy treat adult certain type soft tissue sarcoma sts october 2016 ,olaratumab indicated combination doxorubicin treatment adult patient advanced mestastatic soft tissue sarcoma sts histologic subtype anthracycline-containing regimen appropriate amenable curative treatment radiotherapy surgery 
Trofinetide,trofinetide nnz-2566 neuroprotective analogue glypromate novel molecule profile suitable intravenous infusion chronic oral delivery currently development treat traumatic brain injury ,investigated use/treatment traumatic brain injury 
IPH 2101,iph-2101 nn-1975 fully human monoclonal antibody developed patient acute myeloid leukemia ,investigated use/treatment leukemia myeloid multiple myeloma 
TB-402,tb-402 human antibody binding factor viii play crucial role coagulation blood expected developed potential treatment prevent blood clot formation connection certain type heart arrhythmia atrial fibrillation ,investigated use/treatment atrial fibrillation thrombosis 
XTL-6865,xtl-6865 combination two fully human monoclonal antibody ab68 ab65 hepatitis c virus e2 envelope protein developed prevent hcv re-infection following liver transplant treatment chronic hcv disease ,investigated use/treatment hepatitis viral c 
AZD-8330,azd-8330 potent selective orally active mek inhibitor block signal transduction pathway implicated cancer cell proliferation survival azd-8330 shown tumor suppressive activity multiple preclinical model human cancer including melanoma pancreatic colon lung breast cancer ,investigated use/treatment cancer/tumors unspecified 
CAM-2029,cam2029 new ready-to-use long-acting octreotide formulation developed long-term treatment acromegaly carcinoid syndrome vasoactive intestinal peptide vip -producing tumour cam2029 found provide long-acting release octreotide resulting statistically significant suppression clinical biomarker insulin-like growth factor 1 igf-1 target one-month therapeutic period ,investigated use/treatment acromegaly cancer/tumors unspecified 
KAI-1455,kai-1455 selective epsilon protein kinase c εpkc activator designed reduce ischemic organ injury procedure blood supply may compromised coronary artery bypass grafting cabg congenital cardiac defect repair hip replacement may protect renal injury associated contrast medium several study demonstrated epsilon pkc play key role cytoprotection period ischemia preclinical study kai-1455 showed dramatic reduction infarct size delivered prior ischemic insult ,investigated use/treatment ischemic reperfusion injury 
XMT-1001,xmt-1001 polymer-based prodrug camptothecin cpt well-characterized topoisomerase inhibitor potent anti-tumor activity water-soluble macromolecular conjugate camptothecin cpt novel cpt pro-drug cpt conjugated 70 kda biodegradable hydrophilic polyacetal poly 1-hydroxymethylene hydroxylmethylformal xmt-1001 demonstrated improved therapeutic window compared cpt irinotecan human tumor xenograft model,investigated use/treatment solid tumor 
SNX-5422,snx-5422 synthetic novel small molecule hsp90 inhibitor oral formulation demonstrates strong efficacy tolerability snx-5422 positioned breakthrough therapy broad applicability across wide range cancer ,investigated use/treatment cancer/tumors unspecified 
DTS-201,dts-201 prodrug doxorubicin widely used anti-cancer drug diatos intends develop treatment various solid tumor activated tumor environment dts-201 may suitable treatment many type solid tumor including tumor sensitive doxorubicin potentially tumor currently treated doxorubicin express high level cd-10 top peptidase prostate cancer colorectal cancer melanoma pancreatic cancer type renal cancer ,investigated use/treatment cancer/tumors unspecified 
CTS-21166,cts-21166 small-molecule beta-secretase inhibitor developed disease-modifying treatment alzheimer 's disease cts-21166 bace1 inhibitor passed phase clinical trial thus far 2008 comentis revealed small compound transition-state analog inhibitor structure currently undisclosed excellent property brain penetration selectivity metabolic stability oral availability met requirement ideal oral drug candidate ,investigated use/treatment alzheimer 's disease 
Linsitinib, orally bioavailable small molecule inhibitor insulin-like growth factor 1 receptor igf-1r potential antineoplastic activity igf-1r inhibitor osi-906 selectively inhibits igf-1r may result inhibition tumor cell proliferation induction tumor cell apoptosis ,investigated use/treatment cancer/tumors unspecified solid tumor 
Lumateperone,schizophrenia complex mental illness impact approximately 1 population l10902 although several antipsychotic including aripiprazole paliperidone clozapine available clinical use generally accompanied significant metabolic and/or neurological adverse effect a189093 lumateperone newly approved 2nd generation antipsychotic currently indicated treatment schizophrenia a189093 unique receptor binding profile differs antipsychotic modulates glutamate serotonin dopamine neurotransmitter contribute pathophysiology schizophrenia a189093 a189174 data far indicates lumateperone alleviate positive negative symptom schizophrenia a189093 new antipsychotic selective dopamine d2 receptor mesolimbic mesocortical brain region also minimal off-target activity a189093 characteristic lend favourable adverse effect profile ultimately safer drug a189093 l10908 ,lumateperone approved treatment schizophrenia adult l10860 also approved treatment depressive episode associated bipolar disorder i.e bipolar depression adult monotherapy and/or adjunctive therapy lithium valproate l10860 
Linifanib,linifanib abt-869 small molecule vascular endothelial growth factor vegf receptor-based kinase inhibitor designed suppress tumor growth preventing formation new blood vessel supply tumor oxygen nutrient inhibiting key angiogenic signaling pathway linifanib intended treatment hematologic malignancy solid tumor ,investigated use/treatment leukemia myeloid myelodysplastic syndrome solid tumor 
Caplacizumab,caplacizumab firstly called alx-0081 humanized single-variable-domain immunoglobulin consisting two identical humanized building block genetically linked three-alanine linker caplacizumab developed ablynx sanofi company fda approved february 6 2019 l5302 approved previously eu october 2018 combination therapy plasma exchange immunosuppression a174634 ,capacizumab approved treatment adult experiencing episode acquired thrombotic thrombocytopenic purpura attp conjunction plasma exchange immunosuppression patient 18 year older a174634 l5302 attp rare autoimmune condition presented disruption blood clotting order translated systemic microvascular thrombosis leading profound thrombocytopenia hemolytic anemia organ ischemia caused production autoantibody adamts-13 protein charge cleaving von-wilebrand factor lack process produce generation ultra large von wilebrand multimers bind platelet form microthrombi causing thromboembolic complication a174649 previously capacizumab review prevention thrombosis high-risk patient acute coronary syndrome undergoing percutaneous coronary intervention indication withdrawn a174634 
PX-478,px-478 small molecule inhibitor hypoxia inducible factor hif -1 alpha currently clinical trial patient advanced metastatic cancer lymphoma px-478 effective model non-small cell lung cancer small cell lung cancer express hif-1 alpha ,investigated use/treatment cancer/tumors unspecified 
Tapinarof,"tapinarof novel first-in-class small-molecule ahr agonist indicated treatment adult psoriasis available topical cream applied affected area daily l41845 a248790 tapiranof first discovered metabolite 3,5-dihydroxy-4-isopropylstilbene produced _photorhabdus luminescens_ gram-negative bacillus life symbiotically _heterorhabditis_ nematode a248790 1959 noticed _heterorhabditis_ high amount 3,5-dihydroxy-4-isopropylstilbene putrefy dead thus suggesting potential anti-inflammatory activity a248790 tapinarof received initial approval fda 2022 l41845 ",tapinarof indicated topical treatment plaque psoriasis adult l41845 
Friulimicin B,friulimicin b naturally occurring antibiotic produced micro-organism actinoplanes friuliensis show strong cidal activity number gram-positive pathogen commonly cause serious infection hospital patient becoming routinely acquired community ,investigated use/treatment bacterial infection 
ICA-105665,ica-105665 novel small molecule compound treatment epilepsy novel opener kcnq ion channel preclinical study demonstrated broad spectrum activity model epilepsy addition ica-105665 also demonstrated activity certain model neuropathic pain ,investigated use/treatment epilepsy 
Bradanicline,bradanicline novel small molecule modulates activity neuronal nicotinic receptor nnr subtype known alpha7 α7 bradanicline belongs new class drug treatment central nervous system disease disorder ,investigated use/treatment neurologic disorder 
Evofosfamide,th-302 novel cancer therapeutic specifically activated low oxygen `` hypoxic '' condition typical solid tumor cancer cell th-302 nitroimidazole-linked prodrug brominated derivative isophosphoramide mustard previously used cancer drug ifosfamide cyclophosphamide glufosfamide th-302 shown preclinical study efficacious well tolerated ,investigated use/treatment solid tumor 
ABT-560,abt-560 neuronal nicotinic receptor nnr modulator shown promise preclinical model relevant treatment cognitive deficit ,investigated use/treatment neurologic disorder 
Apatorsen,apatorsen second generation antisense drug preclinical experiment inhibits production heat shock protein 27 hsp27 cell survival protein found elevated level many human cancer including prostate lung breast ovarian bladder renal pancreatic multiple myeloma liver cancer ,investigated use/treatment cancer/tumors unspecified 
NXN-188,nxn-188 first-in-class dual-action small molecule incorporating neuronal nitric oxide synthase nnos inhibition 5-ht agonism developed treatment acute migraine ,investigated use/treatment migraine cluster headache 
GSK-923295,gsk-923295 small-molecule inhibitor mitotic kinesin centromere-associated protein e cenp-e third novel drug candidate arise cytokinetics broad strategic alliance glaxosmithkline gsk gsk-923295 demonstrated broad spectrum activity range human tumor xenograft grown nude mouse including model colon breast ovarian lung tumor gsk-923295 first drug candidate enter human clinical trial specifically target cenp-e currently phase human clinical trial conducted gsk ,investigated use/treatment cancer/tumors unspecified solid tumor 
PRLX 93936,prlx 93936 selectively toxic cancer cell ,investigated use/treatment solid tumor 
IMC-1C11,imc-1c11 anti-angiogenesis agent chimeric anti-kinase insert domain-containing receptor kdr antibody block vegfr-kdr interaction inhibits vegfr-induced endothelial cell proliferation imc-1c11 used treatment patient liver metastasis colorectal carcinoma ,investigated use/treatment cancer/tumors unspecified 
VX-148,vx-148 second-generation orally administered inhibitor inosine monophosphate dehydrogenase impdh impdh enzyme play key role regulating immune response proliferation specific cell type including lymphocyte vx-148 developed treatment autoimmune disease ,investigated use/treatment autoimmune disease psoriasis psoriatic disorder viral infection 
AIT-034,ait-034 distinct chemical analog hypoxanthine pyrollidone demonstrated animal study enhance memory reverse memory deficit severely impaired animal respond neotrofin ait-034 induce production ngf mechanism action therefore believed different neotrofin evidence ait-034 could complement neotrofin treatment alzheimer 's disease dementia ,investigated use/treatment dementia 
YKP-1358,ykp1358 novel serotonin 5-ht2a dopamine d2 antagonist demonstrated potent activity animal relates positive negative symptom schizophrenia addition ykp1358 pharmacological profile suggests low potential extrapyramidal side effect ,investigated use/treatment schizophrenia schizoaffective disorder 
AB192,ab192 dpp iv enzymatic activity inhibitor ,investigated use/treatment diabetes mellitus type 2 
"3,4-Methylenedioxy-N-isopropylamphetamine",mdi-p demonstrated potent anti-hiv activity mdi-p shown effective killing hiv cell culture hiv virus cause acquired immune deficiency syndrome aid mdi-p also potential therapeutic agent treatment symptom cystic fibrosis `` cf '' ,investigated use/treatment asthma cystic fibrosis hiv infection 
Eldelumab,mdx-1100 fully human antibody target ip10 also known cxcl10 chemokine expressed association multiple inflammatory disease indication rheumatoid arthritis inflammatory bowel disease multiple sclerosis ,investigated use/treatment ulcerative colitis 
"1alpha,24S-Dihydroxyvitamin D2",lr-103 naturally occurring d-hormone produced kidney vitamin d. lr-103 one d-hormones produced hectorol developed treatment secondary hyperparathyroidism patient chronic kidney disease ckd study shown lr-103 potency calcitriol much lower toxicity ,investigated use/treatment parathyroid disorder 
Cenobamate,cenobamate ykp-3089 antiepileptic drug developed sk pharmaceutical used treat partial onset seizure a188442 l10653 exact mechanism action described literature though positively modulates gaba sub /sub inhibits voltage gated sodium channel l10653 cenobamate granted fda approval 21 november 2019 l10653 ,cenobamate indicated treatment partial onset seizure adult l10653 
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,c-101 also called myodur developed treatment duchenne ’ muscular dystrophy dmd morbid genetic disease lead death late adolescence due accelerated skeletal muscle breakdown c-101 includes carnitine carrier molecule leupeptin analogue known calpain inhibitor calpain primary protease degrades skeletal muscle ,investigated use/treatment muscular dystrophy 
Bisegliptin,bisegliptin compound treatment type 2 diabetes orally active dipeptidyl peptidase-iv dppiv inhibitor lower blood glucose level blocking degradation hormone glp-1 thereby stimulating glucose-dependent insulin secretion lowering blood glucose level without hypoglycemic effect ,investigated use/treatment diabetes mellitus type 2 
SVV-001,"svv-001 investigated use/treatment cancer/tumors lung cancer svv-001 solid svv-001 seneca valley virus novel native picornavirus developed systemically deliverable oncolytic virus treatment human cancer neuroendocrine feature svv-001 also demonstrated cancer-killing specificity 10,000 time higher traditional chemotherapeutics overt toxicity dos one million time higher effective dos mouse ",investigated use/treatment cancer/tumors unspecified lung cancer 
FAV-201,fav-201 patient-specific immunotherapy treatment t-cell lymphoma ,investigated use/treatment lymphoma non-hodgkin 's 
Dimethylcurcumin,dimethylcurcumin synthetic chemical compound loosely based compound found curcumin novel anti-androgen enhances androgen receptor degradation ,investigated use/treatment acne alopecia 
SNS-314,sns-314 potent selective inhibitor aurora kinase b c. proliferating cell treated sns-314 bypass mitotic spindle checkpoint fail undergo cytokinesis leading multiple round endoreduplication eventually cell death sns-314 inhibits tumor growth variety preclinical model tested single agent phase 1 study patient advanced solid tumour ,investigated use/treatment solid tumor 
Tirbanibulin,tirbanibulin kx-o1 kx2–391 dual inhibitor src kinase tubulin a225726 december 14 2020 tirbanibulin approved fda topical treatment actinic keratosis face scalp marketed brand name klisyri l27806 actinic keratosis chronic condition characterized lesion potentially transform invasive squamous cell carcinoma risk 1 10 year a225721 a225741 tirbanibulin block molecular pathway promote proliferation survival metastasis malignant cell tirbanibulin exhibit antitumour effect vitro vivo a225791 investigated antitumor efficacy management various cancer prostate cancer breast cancer a225726 a225731 a225736 ,tirbanibulin indicated topical treatment actinic keratosis face scalp l27786 
IRL-1620,spi-1620 endothelin b receptor agonist animal model spi-1620 selectively transiently increase tumor blood flow allowing increased delivery anticancer agent tumor developed adjunct chemotherapy ,investigated use/treatment cancer/tumors unspecified 
SUVN-502,suvn-502 novel potent safe highly selective orally active antagonist central nervous system serotonin receptor site 5-ht6 intended treatment cognitive disorder alzheimer ’ schizophrenia unmet medical need ,investigated use/treatment neurologic disorder 
Aminoimidazole carboxamide,,investigated use/treatment allergic rhinitis pediatric indication 
Sertindole,sertindole neuroleptic one newer antipsychotic medication available serdolect developed danish pharmaceutical company h. lundbeck phenylindole derivative used treatment schizophrenia first marketed 1996 several european country withdrawn two year later numerous cardiac adverse effect approved soon available french australian market ,used treatment schizophrenia 
Spiramycin,spiramycin primarily bacteriostatic macrolide antimicrobial agent activity gram-positive cocci rod gram-negative cocci also legionellae mycoplasma chlamydiae type spirochete toxoplasma gondii cryptosporidium spiramycin 16-membered ring macrolide discovered 1952 product streptomyces ambofaciens available oral formulation since 1955 parenteral formulation since 1987 resistant organism include enterobacteria pseudomonad mould ,macrolide antibiotic treatment various infection 
Sulfathiazole,sulfathiazole short-acting sulfa drug used common oral topical antimicrobial le toxic alternative discovered still occasionally used sometimes combination sulfabenzamide sulfacetamide except formulated vaginal use fda withdrew approval use drug product containing sulfathiazole l43942 ,sulfathiazole effective wide range gram positive gram negative pathogenic microorganism although longer used human used cattle 
Mianserin, tetracyclic compound antidepressant effect mianserin previously available internationally however market phased favour mirtazapine , treatment depression 
Teicoplanin,teicoplanin glycopeptide antibiotic consisting mixture several compound five major named teicoplanin a2-1 a2-5 four minor named teicoplanin rs-1 rs-4 teicoplanins share glycopeptide core teicoplanin a3-1 differ length conformation side chain attached β-d-glucosamine moiety , treatment bacterial infection caused susceptible microorganism 
Sulfadimethoxine,sulfadimethoxine sulfonamide antibiotic sulfadimethoxine used treat many infection including treatment respiratory urinary tract enteric soft tissue infection frequently used veterinary medicine although approved country use human sulfadimethoxine inhibits bacterial synthesis folic acid pteroylglutamic acid para-aminobenzoic acid sulfadimethoxine approved russia use human including child successfully used 35 year widely available russia over-the-counter drug manufactured number russian pharmaceutical company u sulfadimethoxine one product withdrawn removed market found unsafe effective l43942 , use treatment infection 
Acetylcysteine,acetylcysteine antioxidant glutathione inducer indicated mucolytic therapy treatment acetaminophen overdose l31378 l31383 l31388 l31478 acetylcysteine also studied wide variety off-label indication mixed result a228158 a228163 a228168 acetylcysteine granted fda approval 14 september 1963 l31488 ,acetylcysteine indicated mucolytic therapy management acetaminophen overdose l31378 l31383 l31388 l31478 
Nylidrin,nylidrin also known _buphenine_ belongs category drug called _vasodilators_ relax blood vessel increase blood flow nylidrin peripheral vasodilator study show evidence improving cognitive impairment selected individual geriatric patient mild moderate symptom cognitive emotional physical impairment l2279 nylidrin utilized treat several disorder may benefit increased blood flow example certain mental disorder blood vessel disease due diabetes frostbite night leg cramp certain type ulcer medication work dilating widening blood vessel help increase blood flow improving circulation throughout body including extremity central nervous system effect may help improve memory/judgment improve walking ability support healing frostbite/ulcers l2283 fda considered nylidrin `` lacking substantial evidence effectiveness '' cerebral ischemia cerebral arteriosclerosis cerebral circulatory insufficiency therefore fda withdrawn nylidrin u.s. market l2286 ,nylidrin mainly indicated condition like arteriosclerosis cerebrovascular disease peripheral vascular disease raynaud 's disease thrombo-angitis obliterans thrombophlebitis l2285 may sometimes used treatment peripheral vascular disorder addition premature labor however drug approved premature labor a32531 
Pizotifen,pizotifen belongs class antamines related cyproheptadine a32532 potent serotonin tryptamine antagonist used migraine prevention many year exhibit weak anticholinergic antihistamine antikinin action addition sedative appetite-stimulating property l2292 patient receiving pizotifen treatment developed tolerance prolonged use drug l2292 numerous study revealed potential antidepressant effect pizotifen independent antimigraine action a32538 suggested pizotifen may act similarly classic tricyclic antidepressant a32538 full mechanism antidepressant action fully elucidated pizotifen hydrochloride active ingredient sandomigran used prophylactic management migraine sandomigran available number country approved fda ema ,indicated prophylactic management migraine l2292 
Pentaerythritol tetranitrate,pentaerythritol tetranitrate nitrate ester pentaerythritol posse explosive property mixed plasticizer chemical form plastic explosive recognized fda coronary vasodilator treatment heart condition angina l2395 pentaerythritol nitrate four hydroxy group pentaerythritol converted corresponding nitrate ester vasodilator property quite similar glyceryl trinitrate however prolonged duration action also one powerful high explosive known component plastic explosive known semtex l2393 petn chemical formula c5h8n4o12 formed reacting pentaerythritol c5h12o4 alcohol commonly used paint varnish nitric acid hno2 reacting solution chilled precipitate petn filtered washed dried recrystallized produce colorless crystalline material stored shipped mixture water alcohol l2394 interestingly drug studied potential benefit chronic ischemic heart failure patient petn targeting reactive oxygen specie generation halted change mitochondrial antioxidant enzyme progressive fibrotic remodeling leading amelioration cardiac functional performance rat ischemic heart failure a32649 ,used treatment angina pectoris l2393 
Rimonabant,rimonabant anorectic anti-obesity drug produced marketed sanofi-aventis inverse agonist cannabinoid receptor cb1 main avenue effect reduction appetite rimonabant first selective cb1 receptor blocker approved use anywhere world rimonabant approved 38 country including e.u. mexico brazil rejected approval use united state decision made u.s. advisory panel recommended medicine approved may increase suicidal thinking depression , use conjunction diet exercise patient body mass index greater 30 kg/m sup 2 /sup patient wih bmi greater 27 kg/m sup 2 /sup associated risk factor type 2 diabetes dyslipidaemia 
Tesofensine,,investigated use/treatment alzheimer 's disease parkinson 's disease obesity 
Istaroxime,,investigated use/treatment heart disease 
Rubitecan,,investigated use/treatment pancreatic cancer leukemia unspecified melanoma ovarian cancer cancer/tumors unspecified 
Garenoxacin,garenoxacin quinolone antibiotic investigated treatment gram-positive gram-negative bacterial infection ,investigated use/treatment bacterial infection 
Opebacan,,investigated use/treatment crohn 's disease congenital anomaly unspecified cardiovascular disorder pediatric indication burn burn infection 
Lumiliximab,lumiliximab chimeric monoclonal antibody used immunosuppressive drug primatized anti-cd23 macaque/human chimeric antibody inhibits production ige antibody potential treatment allergic condition lumiliximab developed idec pharmaceutical acquired biogen clinical trial cll terminated 2010 allergic asthma 2007 result published cll clinical trial failed meet primary endpoint ,investigated use/treatment asthma leukemia lymphoid 
Plevitrexed,,investigated use/treatment pancreatic cancer solid tumor gastric cancer lung cancer colorectal cancer 
Fosdevirine,,investigated use/treatment hiv infection acquired immune deficiency syndrome aid aids-related infection 
Canakinumab,canakinumab recombinant human anti-human-il-1β monoclonal antibody belongs igg1/κ isotype subclass expressed murine sp2/0-ag14 cell line comprised two 447- 448- residue heavy chain two 214-residue light chain molecular mass 145157 dalton deglycosylated heavy chain canakinumab contain oligosaccharide chain linked protein backbone asparagine 298 asn 298 canakinumab bind human il-1β neutralizes inflammatory activity blocking interaction il-1 receptor bind il-1alpha il-1 receptor antagonist il-1ra canakinumab marketed brand name ilaris indicated patient 4 year age older treat familial cold autoinflammatory syndrome fcas muckle-wells syndrome mws part cryopyrin-associated periodic syndrome cap well patient 2 year age older treat systemic juvenile idiopathic arthritis sjia clinical trial established administration canakinumab every 2 week safe effective offering considerable advantage existing treatment human il-1 receptor antagonist anakinra must injected daily often poorly tolerated patient ,used patient 4 year age older treat familial cold autoinflammatory syndrome fcas muckle-wells syndrome mws part cryopyrin-associated periodic syndrome cap well patient 2 year age older treat systemic juvenile idiopathic arthritis sjia 
Indibulin,,investigated use/treatment solid tumor 
Paclitaxel trevatide,three paclitaxel molecule linked cleavable succinyl ester linkage brain peptide vector angiopep-2 conjugate named ang1005 ,investigated use/treatment brain cancer 
Noscapine,,investigated use/treatment lymphoma non-hodgkin 's leukemia lymphoid cancer/tumors unspecified multiple myeloma 
Romidepsin,romidepsin selective inhibitor histone deacetylase approved u 2009 treatment cutaneous t-cell lymphoma ctcl patient received least one prior systemic therapy ,romidepsin indicated treatment cutaneous t-cell lymphoma ctcl adult patient received least one prior systemic therapy l39925 
Glufosfamide,,investigated use/treatment pancreatic cancer solid tumor breast cancer colorectal cancer brain cancer lung cancer ovarian cancer sarcoma 
Talotrexin,,investigated use/treatment solid tumor lung cancer leukemia unspecified leukemia lymphoid 
Darinaparsin,,investigated use/treatment blood blood forming organ disorder unspecified cancer/tumors unspecified solid tumor multiple myeloma liver cancer 
TG1024,,investigated use/treatment solid tumor melanoma 
IMO-2055,,investigated use/treatment renal cell carcinoma solid tumor lung cancer 
Talabostat,,investigated use/treatment lymphoma non-hodgkin 's leukemia lymphoid lung cancer melanoma pancreatic cancer 
AEG35156, second-generation synthetic antisense oligonucleotide potential antineoplastic activity aeg35156 selectively block cellular expression x-linked inhibitor apoptosis protein xiap pivotal inhibitor apoptosis overexpressed many tumor agent reduces total level xiap tumor cell working synergistically cytotoxic drug overcome tumor cell resistance apoptosis xiap interferes intrinsic extrinsic program-death signaling pathway may render tumor cell resistant apoptosis ,investigated use/treatment cancer/tumors unspecified leukemia myeloid 
Forodesine,forodesine highly potent orally active rationally designed pnp inhibitor shown activity preclinical study malignant cell clinical utility t-cell acute lymphoblastic leukemia cutaneous t-cell lymphoma additional preliminary finding support use management b-cell malignancy ,investigated use/treatment lymphoma non-hodgkin 's leukemia lymphoid 
Ipilimumab,ipilimumab fully humanized igg1 monoclonal antibody block cytotoxic lymphocyte antigen-4 ctla-4 l12126 blocking ctla-4 remove inhibitory signal reducing activity lymphocyte a35065 a35080 l12126 ipilimumab developed bristol-myers squibb medarex l12126 ipilimumab granted fda approval 25 march 2011 l12126 ,ipilimumab indicated following cancerous condition l42050 melanoma treatment unresectable metastatic melanoma patient ≥12 year old treatment unresectable metastatic melanoma combination nivolumab adult patient adjuvant treatment patient cutaneous melanoma pathologic involvement regional lymph node 1 mm undergone complete resection including total lymphadenectomy renal cell carcinoma rcc first-line treatment patient intermediate- poor-risk advanced renal cell carcinoma combination nivolumab colorectal cancer combination nivolumab treatment patient ≥12 year old microsatellite instability-high msi-h mismatch repair deficient dmmr metastatic colorectal cancer progressed following previous treatment fluoropyrimidine oxaliplatin irinotecan hepatocellular carcinoma combination nivolumab treatment patient hepatocellular carcinoma previously treated sorafenib non-small cell lung cancer nsclc treatment adult patient metastatic non-small cell lung cancer expressing pd-l1 efgr alk genomic tumor aberration first-line treatment combination nivolumab treatment adult patient metastatic recurrent non-small cell lung cancer egfr alk genomic tumor aberration first-line treatment combination nivolumab 2 cycle platinum-doublet chemotherapy malignant pleural mesothelioma treatment adult patient unresectable malignant pleural mesothelioma first-line treatment combination nivolumab esophageal cancer treatment adult patient unresectable advanced metastatic esophageal squamous cell carcinoma first line treatment combination nivolumab
Valtorcitabine,,investigated use/treatment hepatitis viral b 
Ispinesib,,investigated use/treatment breast cancer lung cancer solid tumor renal cell carcinoma pediatric indication ovarian cancer head neck cancer 
Solabegron,"solabegron gw-427,353 selective β3 adrenoceptor agonist developed treatment overactive bladder irritable bowel syndrome ",investigated use/treatment diabetes mellitus type 2 irritable bowel syndrome ibs urinary incontinence 
Zosuquidar,zosuquidar compound antineoplastic drug candidate currently development `` phase 3 '' clinical test united state action mechanism consists inhibition p-glycoproteins drug mechanism include tariquidar laniquidar ,investigated use/treatment leukemia myeloid myelodysplastic syndrome 
Nimotuzumab,,investigated use/treatment head neck cancer brain cancer pediatric indication pancreatic cancer lung cancer colorectal cancer 
Pixantrone,pixantrone aza-anthracenedione dna intercalator inhibits topoisomerase ii similar structure anthracyclines mitoxantrone exerts fewer toxic effect cardiac tissue 2 lower cardio-toxic effect pixantrone may explained part redox inactivity 3 pixantrone bind iron promotes formation reactive oxygen specie lesser degree anthracyclines also inhibits doxorubicinol formation human myocardium 3 result believed le cardiotoxic still exerting efficacy pixantrone designed treat relapsed refractory aggressive non-hodgkin 's lymphoma nhl patient failed two prior line therapy 2 patient suffering nhl first line therapy consist anthracycline containing multi-drug treatment unfortunately known cause irreversible myocardial tissue damage patient refractory treatment relapse discouraged anthracycline use due cumulative cardiotoxicity pixantrone dimaleate administered intravenously designed cell therapeutic incorporated alternative second line therapy refractory relapsed nhl currently tested phase iii trial 2 although pixantrone yet received fda approval united state granted conditional marketing approval european union conditional approval granted european medicine agency phase iii extend trial patient nhl showed pixantrone tolerable resulted significantly higher complete response rate progression free survival comparison single chemotherapy agent however notable extend trial stopped early leaving statistical significance result question based uncertainty 2009 fda ultimately rejected cell therapeutic 's initial application accelerated approval pixantrone use relapsed refractory nhl another phase iii trial pix-r ongoing clarify pixantrones place therapy compare pixantrone efficacy gemcitabine 2 ,currently phase iii investigation treatment relapsed refractory aggressive non-hodgkin 's lymphoma patient failed two prior line therapy presently standard therapy exists patient relapsed refractory nhl 2 first line therapy initiated patient received lifetime limit doxorubicin use anthracyclines may potentially lead anthracycline-induced congestive heart failure chf pixantrone attractive alternative second line agent due lack cardiac toxicity 2 phase iii trial pix-r ongoing compare pixantrone multidrug therapy equivalent regimen patient diffuse large b-cell lymphoma common type nhl previous study result also suggested possibility pixantrone may safe effective doxorubicin naive patient myocardial strip doxorubicin naive pixantrone taken higher degree myocardial strip doxorubicin exposed absorbed exhibit redox inactivity 3 pixantrone dimaleate also investigated treatment acute myelogenous leukemia diffuse large b-cell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphoma general metastatic cancer 
Elocalcitol,elocalcitol calcitriol analog inhibition prostate cell growth phase ii clinical trial patient benign prostate hyperplasia 4/2004 ,investigated use/treatment benign prostatic hyperplasia urinary incontinence prostate disorder infertility 
Seliciclib,r-roscovitine seliciclib cyc202 cyclin-dependent kinase cdk inhibitor preferentially inhibits multiple enzyme target including cdk2 cdk7 cdk9 alter growth phase treated cell developed cyclacel seliciclib researched treatment non-small cell lung cancer nsclc leukemia hiv infection herpes simplex infection mechanism chronic inflammation disorder ,investigated use/treatment breast cancer lung cancer lymphoma unspecified multiple myeloma leukemia lymphoid cancer/tumors unspecified 
Icatibant,icatibant firazyr synthetic peptidomimetic drug consisting ten amino acid act effective specific antagonist bradykinin b2 receptor approved eu use hereditary angioedema investigation number condition bradykinin thought play significant role icatibant currently orphan drug status united state fda approved august 25 2011 ,approved use acute attack hereditary angioedema hae investigated use/treatment angioedema liver disease burn burn infection 
Bimosiamose,,investigated use/treatment asthma psoriasis psoriatic disorder atopic dermatitis inflammatory disorder unspecified chronic obstructive pulmonary disease copd 
Alovudine,,investigated use/treatment hiv infection 
Atrasentan,atrasentan substance studied treatment cancer belongs family drug called endothelin-1 protein receptor antagonist novel selective endothelin receptor antagonist serum ,investigated use/treatment prostate cancer cancer/tumors unspecified 
Tedisamil,tedisamil planned trade name pulzium investigational drug atrial fibrillation atrial flutter currently developed solvay currently regulatory review united state food drug administration ,investigated use/treatment arrhythmia atrial fibrillation angina 
Rufinamide,rufinamide triazole derivative anticonvulsant medication treat seizure disorder like lennox-gastuat syndrome form childhood epilepsy clinical trial suggest efficacy treatment partial seizure ,adjunct therapy treatment seizure associated lennox-gastaut syndrome 
Lasofoxifene,lasofoxifene non-steroidal 3rd generation selective estrogen receptor modulator serm selectively bind erα erβ high affinity naphthalene derivative marketed prevention treatment osteoporosis treatment vaginal atrophy initially developed oporia pfizer treatment postmenopausal osteoporosis vaginal atrophy rejected approval fda later fablyn developed result research collaboration pfizer ligand pharmaceutical newly submitted new drug application 2008 gained approval european commission march 2009 ligand pharmaceutical signed license agreement sermonix pharmaceutical development commercialization oral lasofoxifene usa ,investigated use/treatment postmenopausal osteoporosis reduce risk vertebral novertebral fracture well address postmenopausal condition including reduction risk breast cancer treatment vulvar vaginal atrophy vva 
Alogliptin,alogliptin selective orally-bioavailable inhibitor enzymatic activity dipeptidyl peptidase-4 dpp-4 chemically alogliptin prepared benzoate salt exists predominantly r-enantiomer 99 undergoes little chiral conversion vivo -enantiomer fda approved january 25 2013 ,indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus 
Tapentadol,opioid analgesic treatment moderate severe pain fda approved nov 20 2008 , immediate-release formulation tapentadol indicated relief moderate severe acute pain long-acting formulation serf continuous around-the-clock analgesic indicated relief moderate severe chronic pain neuropathic pain associated diabetic peripheral neuropathy 
Hyaluronidase (human recombinant), purified preparation enzyme recombinant human hyaluronidase hyaluronidase human recombinant inn vorhyaluronidase alfa produced genetically engineered chinese hamster ovary cho cell containing dna plasmid encoding soluble fragment human hyaluronidase ph20 a4033 hyaluronidase enzyme used improve absorption dispersion parenterally administered fluid drug contrast agent l13338 action hyaluronidase first described 1936 named 1939 a199026 early research hyaluronidase identified `` spreading factor '' allowed increased permeability connective tissue a199026 hyaluronidase used surgical setting least past 60 year improve diffusion local anesthetic a199047 hyaluronidase first used prescription product united state 5 may 2004 l13338 ,hyaluronidase indicated subcutaneous fluid administration hydration increasing resorption radiopaque agent subcutaneous urography l13338 hyaluronidase also indicated multiple route increase dispersion injectable drug l13338 
Sugammadex,sugammadex selective relaxant binding agent indicated reversal neuromuscular blockade induced rocuronium bromide vecuronium bromide surgery rocuronium bromide vecuronium bromide neuromuscular blocking medication cause temporary paralysis especially useful general anesthesia ventilation tracheal intubation patient may require surgery sugammadex provides new treatment option reverse effect medication possibly help patient recover sooner post-surgery sugammadex brand name bridion marketed merck sharp dohme approved united state fda december 15 2015 ,sugammadex indicated reversal neuromuscular blockade induced rocuronium bromide vecuronium bromide adult pediatric patient ≥2 year old undergoing surgery l15766 
Silodosin,silodosin selective antagonist alpha α -1 adrenergic receptor bind α sub 1a /sub subtype highest affinity α1-adrenergic receptor regulate smooth muscle tone bladder neck prostate prostatic urethra α sub 1a /sub subtype account approximately 75 α1-adrenoceptors prostate a231159 silodosin first approved fda october 2008 a231159 also approved europe canada silodosin available oral capsule common trade name rapaflo urorec indicated symptomatic treatment benign prostatic hyperplasia adult l32368 commonly affecting male age 40 year benign prostatic hyperplasia non-malignant enlargement prostate gland associated lower urinary tract symptom negative impact quality life patient a231159 silodosin work binding α sub 1a /sub -adrenoceptors high affinity relaxing lower urinary tract thereby improving urinary symptom alleviating bladder outlet obstruction a231229 ,silodosin indicated treatment sign symptom benign prostatic hyperplasia bph indicated treatment hypertension l32368 
Prasugrel,prasugrel thienopyridine derivative platelet activation aggregation inhibitor structurally pharmacologically related clopidogrel ticlopidine similar clopidogrel prasugrel prodrug requires enzymatic transformation liver active metabolite r-138727 r-138727 irreversibly bind p2y12 type adp receptor platelet thus preventing activation gpiib/iiia receptor complex result inhibition adp-mediated platelet activation aggregation occurs prasugrel developed daiichi sankyo co. currently marketed united state canada cooperation eli lilly company acute coronary syndrome planned percutaneous coronary intervention pci fda approved 2009 ,indicated combination acetylsalicylic acid asa prevent atherothrombotic event patient acute coronary syndrome ac managed percutaneous coronary intervention pci may used patient unstable angina ua non-st elevation myocardial infarction nstemi st-elevation myocardial infarction stemi managed pci prasugrel recommended patient 75 year age greater weigh 60kg patient history stroke transient ischemic attack due increased risk fatal intracranial bleeding 
Eltrombopag,eltrombopag used treat low blood platelet count adult chronic immune idiopathic thrombocytopenia itp certain medicine surgery remove spleen worked well enough itp condition may cause unusual bruising bleeding due abnormally low number platelet blood eltrombopag also recently approved late 2012 treatment thrombocytopenia low blood platelet count patient chronic hepatitis c allow initiate maintain interferon-based therapy ,thrombopoietin receptor agonist pharmaceutical agent stimulate platelet production bone marrow differ previously discussed agent act attempting curtail platelet destruction 
Doripenem,doripenem broad-spectrum carbapenem antibiotic marketed brand name doribax janssen doripenem injection approved fda 2007 treat complicated urinary tract intra-abdominal infection clinical trial doripenem treatment ventilator associated pneumonia vs. imipenem cilastatin found doripenem carried increased risk death lower clinical cure rate resulting premature termination trial fda revised doripenem label 2014 include warning use ventilator-associated pneumonia reiterate safety efficacy approved indication ,doripenem indicated treatment complicated intra-abdominal infection complicated urinary tract infection including pyelonephritis caused designated susceptible bacteria 
Tolvaptan,tolvaptan used treat low blood sodium level hyponatremia associated various condition like congestive heart failure cirrhosis syndrome inappropriate antidiuretic hormone siadh fda approved may 19 2009 ,treatment symptomatic resistant fluid restriction euvolemic hypervolemic hyponatremia associated congestive heart failure siadh cirrhosis 
Regadenoson,regadenoson a2a adenosine receptor agonist cause coronary vasodilation used myocardial perfusion imagining manufactured astellas fda approved april 10 2008 ,diagnostic agent radionuclide myocardial perfusion imaging mpi 
Ferumoxytol,ferumoxytol intravenously administered iron preparation indicated eu u treatment iron deficiency anemia adult patient chronic kidney disease ckd a32478 comprised superparamagnetic iron oxide nanoparticles coated semi-synthetic carbohydrate shell isotonic neutral ph solution may administered relatively high dose rapid intravenous injection l2181 , drug indicated treatment iron deficiency anemia adult patient experienced intolerance oral iron experienced unsatisfactory response oral iron chronic kidney disease ckd fda label 
Asenapine,developed schering-plough merger organon international asenapine sublingually administered atypical antipsychotic treatment schizophrenia acute mania associated bipolar disorder asenapine also belongs dibenzo-oxepino pyrrole class also severe post-traumatic stress disorder nightmare soldier off-label use fda approved august 13 2009 ,used treatment psychosis schizophrenia schizoaffective disorder manic disorder bipolar disorder monotherapy combination 
Vernakalant,vernakalant developed cardiome pharma antiarrhythmic drug intended rapid conversion atrial fibrillation sinus rhythm act atypical class iii antiarrhythmic drug potentiates effect higher heart rate intravenous formulation approved europe september 2010 brinavess canada april 2017 investigational drug regulatory review fda ,indicated rapid conversion recent onset atrial fibrillation sinus rhythm adult non-surgery patient last le 7 day duration post-cardiac surgery patient atrial fibrillation lasting le 3 day duration 
Lacosamide,lacosamide functionalized amino acid activity maximal electroshock seizure test indicated adjunctive treatment partial-onset seizure diabetic neuropathic pain recent study indicate lacosamide affect neuron depolarized active long period time typical neuron focus epileptic seizure opposed antiepileptic drug carbamazepine lamotrigine slow recovery inactivation reduce ability neuron fire action potential ,lacosamide indicated treatment partial-onset seizure patient aged one month older adjunctive therapy treatment primary generalized tonic-clonic seizure patient aged four year older l40958 
Dalbavancin,dalbavancin second-generation lipoglycopeptide antibiotic designed improve natural glycopeptides currently available vancomycin teicoplanin a4072 a4073 modification older glycoprotein class facilitated similar mechanism action dalbavancin increased activity once-weekly dosing fda label f2356 a4072 a4073 use indicated treatment acute bacterial skin skin structure infection absssi caused following gram-positive microorganism staphylococcus aureus including methicillin-susceptible methicillin-resistant strain s. pyogenes s. agalactiae s. dysgalactiae s. anginosus group including s. anginosus s. intermedius s. constellatus enterococcus faecalis vancomycin susceptible strain fda label f2356 dalbavancin act interfering bacterial cell wall synthesis binding d-alanyl-d-alanine terminus nascent cell wall peptidoglycan preventing cross-linking fda label f2356 a4072 a4073 ,dalbavancin injection indicated treatment adult patient acute bacterial skin skin structure infection absssi caused susceptible isolates following gram-positive microorganism staphylococcus aureus including methicillin-susceptible methicillin-resistant strain streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius streptococcus constellatus enterococcus faecalis vancomycin susceptible strain fda label f2356 dalbavancin active gram-negative bacteria therefore combination therapy may clinically indicated absssi polymicrobial includes suspected documented gram-negative pathogen f2356 reduce development drug-resistant bacteria maintain effectiveness dalbavancin antibacterial drug dalbavancin used treat infection proven strongly suspected caused susceptible bacteria fda label f2356 culture susceptibility information available considered selecting modifying antibacterial therapy fda label f2356 absence data local epidemiology susceptibility pattern may contribute empiric selection therapy fda label f2356 
Alicaforsen,,investigated use/treatment crohn 's disease ulcerative colitis 
HMR4011,"hmr4011 ipl 576,092 novel steroidal anti-inflammatory compound mechanism action distinct glucocorticoid ipl 576,092 previously investigated treatment asthma ",investigated use/treatment asthma 
Nelipepimut-S,,investigated use/treatment prostate cancer breast cancer 
Rivaroxaban,rivaroxaban anticoagulant first orally active direct factor xa inhibitor unlike warfarin routine lab monitoring inr necessary however antidote available event major bleed 10 mg tablet taken without regard food 15 mg 20 mg tablet taken food fda approved july 1 2011 ,rivaroxaban indicated prevention venous thromboembolic event vte patient undergone total hip replacement total knee replacement surgery prevention stroke systemic embolism patient nonvalvular atrial fibrillation treatment deep vein thrombosis dvt pulmonary embolism pe reduce risk recurrent dvt and/or pe rivaroxaban also indicated combination aspirin reducing risk major cardiovascular event patient chronic coronary artery disease peripheral artery disease use also recommended severe renal impairment 30ml/min l12819 rivaroxaban also indicated treatment prevention vte pediatric patient birth 18 year age thromboprophylaxis pediatric patient ≥2 year old congenital heart disease following fontan procedure l12819 
Ocaperidone,,investigated use/treatment schizophrenia schizoaffective disorder 
Nalmefene,nalmefene 6-methylene analogue naltrexone opioid receptor antagonist l40684 act antagonist mu μ -opioid delta δ -opioid receptor partial agonist kappa κ -opioid receptor l1024 europe nalmefene oral tablet used reduce alcohol consumption adult alcohol dependence l1024 nalmefene approved use united state 1995 antidote opioid overdose a245839 nalmefene injection used manage known suspected opioid overdose used complete partial reversal opioid drug effect including respiratory depression induced either natural synthetic opioids l40684 ,nalmefene oral tablet indicated reduction alcohol consumption adult patient alcohol dependence high drinking risk level drl without physical withdrawal symptom require immediate detoxification nalmefene prescribed conjunction continuous psychosocial support focused treatment adherence reducing alcohol consumption nalmefene initiated patient continue high drl two week initial assessment l1024 nalmefene injection indicated complete partial reversal opioid drug effect including respiratory depression induced either natural synthetic opioids nalmefene injection indicated management known suspected opioid overdose used postoperative opioid overdose reversal l40684 
Caldaret,,investigated use/treatment heart disease myocardial infarction 
Ridaforolimus,,investigated use/treatment solid tumor sarcoma cancer/tumors unspecified endometrial cancer prostate cancer bone metastasis 
Maribavir,maribavir inhibitor cytomegalovirus cmv hhv5 pul97 kinase used treat cmv infection patient post-transplantation l39322 standard cmv therapy ganciclovir foscarnet target cmv dna polymerase generally effective medication tend promote development cmv resistance dna polymerase-based therapy use often limited toxicity like myelosuppression renal injury a242557 maribavir novel instead target cmv pul97 kinase thereby providing effective alternative treatment option case resistant infection maribavir approved fda november 2021 name livtencity takeda treatment resistant cmv infection post-transplant patient l39327 drug also approved health canada september 2022 l43262 european commission november 2022 l44411 ,maribavir indicated treatment post-transplant cytomegalovirus cmv infection following hematopoietic stem cell transplant solid organ transplant refractory standard treatment ganciclovir valganciclovir cidofovir foscarnet l39322 l43262 l44406 u patient receiving treatment weigh 35 kg least 12 year old l39322 canada europe maribavir approved adult l43262 l44406 
Vadimezan,,investigated use/treatment solid tumor lung cancer ovarian cancer prostate cancer 
Elvucitabine,,investigated use/treatment hepatitis viral b hiv infection 
Avanafil,avanafil phosphodiesterase-5 pde5 inhibitor used treatment erectile dysfunction comparison drug class show greater selectivity pde5 pde6 sildenafil vardenafil le selectivity tadalafil suggesting relatively lower risk visual disturbance associated off-target pde6 inhibition l32113 first received fda approval april 27 2012 l32058 subsequent ema approval june 2013 l32113 ,avanafil indicated treatment erectile dysfunction l32058 
Tipapkinogene sovacivec,,investigated use/treatment cervical dysplasia/cancer viral infection vulvar dysplasia carcinoma 
Tariquidar,,investigated use/treatment ovarian cancer lung cancer breast cancer 
Clenoliximab,clenoliximab chimeric monoclonal antibody _macaca irus_ cd4 act immunomodulator investigated treatment rheumatoid arthritis ,investigated use/treatment rheumatoid arthritis 
Eflornithine,eflornithine prescription drug indicated treatment facial hirsutism excessive hair growth eflornithine hydrochloride cream topical application intended use woman suffering facial hirsutism sold allergan inc. brand name vaniqa eflornithine injection sleeping sickness manufactured sanofi aventis sold brand name ornidyl usa discontinued eflornithine world health organization 's list essential medicine ,eflornithine indicated treatment facial hirsutism excessive hair growth 
Trafermin,,investigated use/treatment coronary artery disease peripheral vascular disease periodontal disease bone fracture entero-related fistula diabetic foot ulcer 
Lanoteplase,,investigated use/treatment myocardial infarction 
Exisulind,,investigated use/treatment adenomatous polyposis coli lung cancer prostate cancer colon polyp barrett 's esophagus disease pediatric indication 
CX516,,investigated use/treatment alzheimer 's disease memory loss autism neurologic disorder dementia schizophrenia schizoaffective disorder attention deficit/hyperactivity disorder adhd sleep disorder 
Amelubant,,investigated use/treatment asthma chronic obstructive pulmonary disease copd cystic fibrosis rheumatoid arthritis 
Arzoxifene,,investigated use/treatment breast cancer osteoporosis endometrial cancer 
Fluasterone, antiproliferative effect hiv-1 reduces hiv-1 replication ,investigated use/treatment psoriasis psoriatic disorder hyperlipidemia metabolic disease cancer/tumors unspecified obesity 
Dersalazine,,investigated use/treatment inflammatory bowel disease 
Thioctic acid tromethamine, salt alpha-lipoic acid tromethamine may useful treating vascular stress patient diabetes ,investigated use/treatment diabetes mellitus type 2 neuropathy diabetic vascular disease 
Incadronic acid,incadronate ym-175 a202769 nitrogen containing bisphosphonate along investigated treat hypercalcemia malignancy a202862 also investigated treatment myeloma leukemia cancer a14426 a14431 a14427 a202769 incadronic acid first described literature 1991 a202289 ,incadronate investigated treatment myeloma a14426 a14431 leukemia a14427 cancer a202769 also investigated patient hypercalcemia malignancy a202862 
rPSGL-Ig,recombinant p-selectin glycoprotein ligand igg fusion protein rpsgl-ig fusion protein human p-selectin ligand igg1-fc ,investigated use/treatment myocardial infarction red blood cell disorder anemia kidney transplant surgery transplant rejection liver transplant surgery ischemic reperfusion injury 
HE-2200,,investigated use/treatment adverse effect chemotherapy hyperlipidemia autoimmune disease hepatitis viral b 
Bimoclomol,bimoclomol investigational drug induces stress protein cytoprotective effect ,investigated use/treatment neuropathy diabetic wound 
Hexaminolevulinate,hexaminolevulinate optical imaging drug solution form instilled intravesically use photodynamic blue light cystoscopy adjunct white light cystoscopy may 28 2010 u.s. food drug administration fda granted approval hexaminolevulinate hydrochloride cysview intravesical solution photocure asa optical imaging agent use combination karl storz photodynamic diagnostic d-light c pdd system cystoscopic detection non-muscle invasive papillary cancer bladder patient suspected known lesion basis prior cystoscopy hexaminolevulinate manufactured brand cysview® photocure asa europe hexaminolevulinate marketed brand hexvix® ,hexaminolevulinate indicated use cystoscopic detection non-muscle invasive papillary cancer bladder among patient suspected known lesion basis prior cystoscopy 
Droxidopa,"droxidopa precursor noradrenaline used treatment parkinsonism approved use japan currently trial u.s racaemic form dl-threo-3,4-dihydroxyphenylserine also used investigated treatment orthostatic hypotension deficit noradrenaline well dopamine parkinson 's disease proposed underlies sudden transient freezing seen usually advanced disease though l-dops used japan southeast asia already time also currently clinical trial phase iii point united state u.s. canada australia throughout europe provided l-dops successfully completes clinical trial could approved treatment neurogenic orthostatic hypotension noh early 2011 additionally phase ii clinical trial intradialytic hypotension also underway chelsea therapeutic obtained orphan drug status od l-dops u.s. noh associated parkinson 's disease pure autonomic failure multiple system atrophy pharmaceutical company developing country ", treatment neurogenic orthostatic hypotension noh associated various disorder including multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension parkinson 's disease also investigated use/treatment neurologic disorder nephropathy blood blood forming organ disorder unspecified dizzy/fainting spell 
Amrubicin,amrubicin third-generation synthetic anthracycline currently development treatment small cell lung cancer pharmion licensed right amrubicin november 2006 2002 amrubicin approved launched sale japan based phase 2 efficacy data sclc nsclc since january 2005 amrubicin marketed nippon kayaku japanese pharmaceutical firm focused oncology licensed japanese marketing right dainippon sumitomo original developer amrubicin l1714 l1716 ,investigated use/treatment lung cancer a4138 
Tolperisone,tolperisone oral centrally acting muscle relaxant precise mechanism completely understood though block sodium calcium channel posse high affinity nervous system tissue reaching highest concentration brain stem spinal cord peripheral nerve based existing clinical data tolperisone sedating interact alcohol ,investigated use/treatment neurologic disorder spinal cord injury muscle spasm back pain multiple sclerosis 
Lonidamine,lonidamine lnd drug interferes energy metabolism cancer cell principally inhibiting aerobic glycolytic activity effect mitochondrially-bound hexokinase hk way lnd could impair energy-requiring process recovery potentially lethal damage induced radiation treatment cytotoxic drug ,investigated use/treatment benign prostatic hyperplasia prostate disorder cancer/tumors unspecified 
Udenafil,udenafil new phosphodiesterase type 5 pde5 inhibitor used treat erectile dysfunction ed approved south korea marketed brand name zydena yet approved use u.s. e.u. canada ,investigated use/treatment erectile dysfunction hypertension 
Sitaxentan,sitaxentan marketed trade name thelin treatment pulmonary arterial hypertension pah encysive pharmaceutical pfizer purchased encysive february 2008 2010 pfizer voluntarily removed sitaxentan market concern hepatotoxicity ,investigated use/treatment pulmonary hypertension connective tissue disease hypertension congestive heart failure 
MAHDL01,mahdl01 pharmaceutical combination whole plant used increase hdl/ldl ratio improves overall cardiovascular health ,investigated use/treatment hyperlipidemia 
Sulodexide,sulodexide mixture glycosaminoglycans gag composed dermatan sulfate d fast moving heparin fmh ,sulodexide used clinically prophylaxis treatment vascular disease increased risk thrombosis including intermittent claudication peripheral arterial occlusive disease post-myocardial infarc-tion also investigated treatment diabetic kidney disease diabetic neuropathy new anti-inflammatory property also extended use venous disease 
Tocilizumab,tocilizumab recombinant humanized monoclonal antibody il-6 receptor inhibitor used treat inflammatory autoimmune condition l12789 first described literature 2003 chugai subsidiary roche began developing il-6 inhibiting monoclonal antibody a193281 tocilizumab granted fda approval 8 january 2010 treat number inflammatory autoimmune disorder different type arthritis cytokine release syndrome l12789 later approved health canada 30 april 2010 l43697 investigated treat severely ill patient covid-19 a193278 l12837 l12843 tocilizumab approved european commission december 2021 treat covid-19 adult receiving systemic corticosteroid supplemental oxygen mechanical ventilation l40164 subsequently granted approval health canada fda october l43697 december 2022 respectively l44483 ,tocilizumab indicated treat moderate severe rheumatoid arthritis giant cell arteritis systemic sclerosis-associated interstitial lung disease polyarticular juvenile idiopathic arthritis systemic juvenile idiopathic arthritis cytokine release syndrome l12789 l43697 tocilizumab also used treat coronavirus disease 2019 covid-19 adult receiving systemic corticosteroid require supplemental oxygen mechanical ventilation extracorporeal membrane oxygenation ecmo l40169 l43697 l44483 
Alvimopan,alvimopan peripherally acting μ opioid antagonist used avoid postoperative ileus following small large bowel resection accelerates gastrointestinal recovery period ,used accelerate time upper lower gastrointestinal recovery following partial large small bowel resection surgery primary anastomosis also investigated use treatment pain acute chronic 
Tanomastat,,investigated use/treatment pancreatic cancer lung cancer ovarian cancer osteoarthritis 
Senicapoc,,investigated use/treatment anemia sickle cell asthma 
Torcetrapib,torcetrapib cp-529414 pfizer developed treat hypercholesterolemia development halted 2006 phase iii study showed excessive mortality treatment group receiving combination atorvastatin study drug ,investigated use/treatment peripheral vascular disease hyperlipidemia 
Levocetirizine,levocetirizine selective histamine h sub 1 /sub antagonist used treat variety allergic symptom a181748 a181790 l7694 r enantiomer cetirizine l7694 levocetirizine greater affinity histamine h sub 1 /sub receptor cetirizine l7694 levocetirizine granted fda approval 1995 l7694 ,levocetirizine indicated treat symptom perennial allergic rhinitis uncomplicated skin manifestation chronic idiopathic urticaria l7694 also used counter variety mild allergy symptom a181748 
Ziconotide,ziconotide also known snx-111 neurotoxic peptide derived cone snail _conus magus_ comprising 25 amino acid three disulphide bond a202835 l13389 peptide collectively termed conotoxins exist shown efficacy binding specific subset calcium channel ziconotide used part synthesized without loss proper bond formation structural element a202829 a202832 ziconotide used manage severe chronic pain refractory method ability inhibit n-type calcium channel involved nociceptive signalling a202829 a202835 a202838 a202841 a202850 a202859 l13389 ziconotide granted fda approval december 28 2004 marketing tersera therapeutic llc name prialt l13389 date ziconotide calcium channel blocking peptide approved use fda a202835 ,ziconotide indicated management severe chronic pain patient refractory treatment intrathecal therapy warranted l13389 
Teriparatide,teriparatide recombinant parathyroid hormone pth analog potent osteoanabolic agent a251395 made first amino n -terminal 34 amino acid human pth a251395 first approved united state november 2002 europe april 2003 a251400 teriparatide make first approved drug new category osteoporosis therapy called anabolic therapy a251395 teriparatide used treatment osteoporosis men woman l42590 l42595 ,teriparatide indicated treatment postmenopausal woman osteoporosis high risk fracture defined herein history osteoporotic fracture multiple risk factor fracture failed intolerant available osteoporosis therapy postmenopausal woman osteoporosis teriparatide reduces risk vertebral nonvertebral fracture l42590 l42595 increase bone mass men primary hypogonadal osteoporosis high risk fracture failed intolerant available osteoporosis therapy l42590 l42595 treatment men woman osteoporosis associated sustained systemic glucocorticoid therapy daily dosage equivalent 5 mg greater prednisone high risk fracture failed intolerant available osteoporosis therapy l42590 l42595 
Temsirolimus,temsirolimus derivative sirolimus used treatment renal cell carcinoma rcc developed wyeth pharmaceutical trade name torisel temsirolimus approved fda late may 2007 well european medicine agency emea november 2007 , treatment renal cell carcinoma rcc also investigated use/treatment breast cancer lymphoma unspecified rheumatoid arthritis multiple myeloma 
Amisulpride,amisulpride benzamide derivative dopamine receptor antagonist selectively work dopamine d2 d3 receptor antipsychotic agent amisulpride alleviates positive negative symptom schizophrenia exhibit antidepressant property patient psychiatric disorder dysthymia major depression a6755 amisulpride predominantly work limbic system explains relatively lower risk extrapyramidal adverse effect compared atypical antipsychotic agent a6752 l32764 oral tablet amisulpride used european country treatment acute chronic schizophrenic disorder well secondary negative symptom mental health disorder affective disorder depressive mood mental retardation l32764 amisulpride also used antiemetic agent u intravenous formulation amisulpride used treat prevent postoperative nausea vomiting adult either monotherapy combination another antiemetic agent different drug class l32759 marketed brand name barhemsys ,intravenous amisulpride indicated adult prevention postoperative nausea vomiting either alone combination antiemetic different class also indicated treatment postoperative nausea vomiting patient received anti-emetic prophylaxis agent different class received prophylaxis l32759 oral amisulpride indicated treatment acute chronic schizophrenic disorder characterized positive symptom delusion hallucination thought disorder hostility suspicious behavior primarily negative symptom deficit syndrome blunted affect emotional social withdrawal amisulpride also control secondary negative symptom productive condition well affective disorder depressive mood retardation l32764 
Simeprevir,simeprevir hepatitis c virus hcv ns3/4a protease inhibitor indicated patient 's hcv genotype 1 treatment chronic hepatitis c virus hcv infection hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 like ns3/4a inhibitor simeprevir serine protease inhibitor similarity db08873 db05521 classified second generation protease inhibitor class antiviral drug first direct acting antiviral approved associated lower cure rate newer drug broad use simeprevir occurred used combination newer drug db08934 inhibiting hcv ns3/4a protease potent highly specific manner simeprevir direct-acting antiviral agent hepatitis c virus since viral protease ns3/4a complex essential cleaving hcv encoded polyprotein individual viral protein facilitating replication a19632 drug block viral replication process shown display synergistic effect interferon-α hcv ns5b inhibitor additive effect ribavirin hcv replicon cell a19629 unlike first generation serine protease inhibitor simprevir sightly different resistance profile limited therapeutic efficacy drug observed ns3 q80k polymorphic variant simeprevir-specific amino acid position 168 also result higher treatment failure rate a19630 observed prevalence n3 q80k polymorphism 30 subject infected hcv genotype 1a 0.5 subject infected hcv genotype 1b a19630 according 2017 american association study liver disease aasld 2015 consensus guideline canadian association study liver casl simeprevir used first-line second-line threapies treatment-naïve patient adjunct sofosbuvir treatment genotype 1 peg-interferon/ribavirin combination therapy genotype 1 4 combination therapy simeprevir antiviral agent initiated hcv-positive patient intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 simeprevir approved fda november 2014 marketed brand name olysio oral tablet administered daily food 150mg simeprevir capsule used combination db08934 patient hcv genotype 1 without cirrhosis 12 week duration patient hcv genotype 1 compensated cirrhosis treatment directed 24 week duration sustained virologic response 12 week planned end treatment svr12 achieved 170/176 97 subject without cirrhosis treated 12 week simeprevir combination sofosbuvir fda label overall svr12 88 44/50 treatment-naïve patient cirrhosis l852 simeprevir also used treatment hcv genotype 4 patient without cirrhosis taken db00008 db00811 triple therapy allows shortening treatment duration 48 week longer 12 24 week a19630 depending prior response status presence hiv-1 co-infection prior initiation treatment db00008 db00811 screening presence virus ns3 q80k polymorphism strongly recommended detected alternative treatment considered instead prevent therapeutic failure svr12 83 29/35 treatment-naïve patient 86 19/22 relapsing patient ,indicated treatment adult chronic hepatitis c virus hcv infection typically combination sofosbuvir patient hcv genotype 1 without cirrhosis compensated cirrhosis combination peginterferon alfa peg-ifn-alfa ribavirin rbv patient hcv genotype 1 4 without cirrhosis compensated cirrhosis resistance reduced susceptibility simeprevir commonly associated viral ns3 q80k polymorphism amino acid substitution ns3 position s122 r155 and/or d168 also shown reduce susceptibility simeprevir genotype 1a/b patient 
Dapagliflozin,dapagliflozin sodium-glucose cotransporter 2 inhibitor indicated managing diabetes mellitus type 2 a6757 combined diet exercise adult dapagliflozin help improve glycemic control inhibiting glucose reabsorption proximal tubule nephron causing glycosuria a6757 dapagliflozin approved fda jan 08 2014 l6034 ,dapagliflozin indicated improve glycemic control adult patient type 2 diabetes mellitus along diet exercise label a6757 a6758 
Pegnivacogin,,investigated use/treatment thrombosis coronary artery disease vascular disease 
Semuloparin,,investigated use/treatment thrombosis 
Pramiconazole,,investigated use/treatment seborrhea fungal infection skin infections/disorders onychomycosis 
LX-2931,,investigated use/treatment rheumatoid arthritis inflammatory disorder unspecified autoimmune disease 
Hydronidone,hydronidone antifibrotic activity ,investigated use/treatment liver disease 
Glesatinib,,investigated use/treatment cancer/tumors unspecified 
Otilimab,investigated treatment osteoarthritis rheumatoid arthritis ra ,investigated use/treatment inflammatory disorder unspecified 
BIIB015,biib015 humanized igg1 immunoglobulin g 1 dm4-conjugated anti-cripto monoclonal antibody investigated treatment subject relapsed refractory solid tumour ,investigated use/treatment solid tumor 
Sonepcizumab, humanized monoclonal antibody directed sphingosine 1-phosphate s1p potential antiangiogenic antineoplastic activity upon administration sonepcizumab bind s1p may result inhibition tumor angiogenesis s1p extracellular ligand g protein-coupled lysophospholipid receptor edg-1 endothelial differentiation gene-1 ,investigated use/treatment solid tumor 
Onalespib,,investigated use/treatment cancer/tumors unspecified 
Apoptone,,investigated use/treatment cancer/tumors unspecified 
Refametinib,,investigated use/treatment cancer/tumors unspecified 
Motavizumab,,investigated use/treatment viral infection pediatric indication 
Darapladib,,investigated use/treatment atherosclerosis 
BNC105,,investigated use/treatment cancer/tumors unspecified 
SGX-523, met receptor tyrosine kinase inhibitor ,investigated use/treatment solid tumor cancer/tumors unspecified 
Elotuzumab,elotuzumab humanized igg1 immunoglobulin g monoclonal antibody indicated combination lenalidomide dexamethasone treatment patient multiple myeloma received one three prior therapy elotuzumab target slamf7 also known signaling lymphocytic activation molecule family member 7 cell surface glycoprotein elotuzumab consists complementary determining region cdr mouse antibody muluc63 grafted onto human igg1 heavy kappa light chain framework elotuzumab produced ns0 cell recombinant dna technology elotuzumab theoretical mass 148.1 kda intact antibody elotuzumab approved november 30 2015 u.s. food drug administration elotuzumab marketed brand empliciti™ bristol-myers squibb ,indicated combination lenalidomide dexamethasone treatment patient multiple myeloma received one three prior therapy 
AVE9633,ave9633 anti-cd33 monoclonal antibody-dm4 conjugate ,investigated use/treatment leukemia myeloid 
R-348,,investigated use/treatment autoimmune disease 
Carotuximab,,investigated use/treatment solid tumor 
AZX-100,,investigated use/treatment scar tissue 
XmAb 2513,xmab 2513 humanized monoclonal antibody target antigen cd30 molecule expressed surface number tumor cell type investigated treatment hodgkin ’ lymphoma ,investigated use/treatment lymphoma unspecified lymphoma non-hodgkin 's 
Pegpleranib,,investigated use/treatment macular degeneration eye disorders/infections 
Latiglutenase,,investigated use/treatment gastrointestinal disease disorder miscellaneous autoimmune disease celiac disease 
Methoxyamine,,investigated use/treatment cancer/tumors unspecified 
RG-7795,,investigated use/treatment solid tumor 
4-O-Demethylpenclomedine,,investigated use/treatment solid tumor 
Trodusquemine,trodusquemine spermine metabolite cholesterol naturally occurring aminosterol inhibits protein tyrosine phosphatase 1b demonstrated ability stimulate regeneration heart multiple tissue animal model a176600 ,investigated use/treatment obesity diabetes mellitus type 2 
Tucidinostat,,investigated use/treatment cancer/tumors unspecified 
Saxagliptin,saxagliptin rinn orally active hypoglycemic anti-diabetic drug new dipeptidyl peptidase-4 dpp-4 inhibitor class drug fda approved july 31 2009 ,treatment type 2 diabetes mellitus improve glycemic control combination agent monotherapy 
Elsiglutide,,investigated use/treatment diarrhea adverse effect chemotherapy 
Coltuximab ravtansine,coltuximab ravtansine sar3419 target cd19 investigated treatment acute lymphoblastic leukemia ,investigated use/treatment lymphoma non-hodgkin 's 
Teprotumumab,teprotumumab fully human igg1 monoclonal antibody directed human insulin-like growth factor-1 receptor l11359 following clinical trial efficacy treatment thyroid eye disease ted assessed received `` breakthrough therapy '' designation fda 2016 a190129 approved fda january 2020 treatment ted l11350 thyroid eye disease potentially debilitating complication graf disease involving inflammation tissue remodeling behind eye previous treatment option typically involved multiple invasive surgery teprotumumab first drug ever approved treatment ted therefore represents significant step forward treatment disease l11350 ,teprotumumab indicated treatment thyroid eye disease l44451 
AR-9281,ar-9281 inhibits soluble epoxide hydrolase ,investigated use/treatment hypertension 
Fiboflapon,,investigated use/treatment inflammatory disorder unspecified 
Cenisertib,cenisertib aurora kinase inhibitor ,investigated use/treatment solid tumor leukemia myeloid myelodysplastic syndrome cancer/tumors unspecified 
Elinogrel, p2y12 inhibitor platelet aggregation inhibitor ,investigated use/treatment cardiovascular disorder myocardial infarction 
Tezampanel,tezampanel ampa receptor antagonist ,investigated use/treatment pain acute chronic migraine cluster headache 
ACY001,,investigated use/treatment cardiac ischemia cardiovascular disorder 
TRC093,trc093 recombinant humanized igg1k monoclonal antibody ,investigated use/treatment solid tumor cancer/tumors unspecified 
Iclaprim,,investigated use/treatment bacterial infection skin infections/disorders obesity liver disease kidney disease pneumonia 
Lucatumumab,,investigated use/treatment leukemia lymphoid multiple myeloma lymphoma unspecified 
rsPSMA Vaccine,prostate-specific membrane antigen psma ∼100 kda transmembrane glycoprotein abundantly preferentially expressed prostate cancer including recurrent hormone-refractory case rspsma vaccine subunit vaccine based novel rspsma protein represents entire extracellular domain psma schulke et al. pnas 100:12590 2003 vaccine comprises purified rspsma protein formulated alhydrogel® adjuvant preclinical study rspsma elicited high-titer antibody strongly cross-reacted prostate cancer cell l1039 ,investigated use/treatment prostate cancer 
Becatecarin,becatecarin derivative rebeccamycin ,investigated use/treatment cancer/tumors unspecified liver cancer gastric cancer leukemia unspecified 
XR5944,xr5944 dna bis-intercalating anticancer drug intercalating antineoplastic activity ,investigated use/treatment solid tumor 
Sapacitabine,,investigated use/treatment solid tumor cutaneous t-cell lymphoma myelodysplastic syndrome leukemia lymphoid 
Pertuzumab,pertuzumab recombinant humanized monoclonal antibody target extracellular dimerization domain subdomain ii human epidermal growth factor receptor 2 protein her2 consists two heavy chain two light chain 448 214 residue respectively first approved fda 2012 use docetaxel another her2-targeted monoclonal antibody trastuzumab treatment metastatic her2-positive breast cancer indicated condition since expanded include use neoadjuvant therapy adjuvant therapy treatment her2-positive breast cancer high risk recurrence l14642 l14772 ,pertuzumab indicated intravenous administration combination trastuzumab docetaxel treatment patient her2-positive metastatic breast cancer received prior anti-her2 therapy chemotherapy metastatic disease l14747 also indicated combination trastuzumab chemotherapy neoadjuvant treatment her2-positive locally advanced inflammatory early-stage breast cancer part complete treatment regimen l14747 adjuvant treatment patient her2-positive early-stage breast cancer high risk recurrence l14747 pertuzumab also indicated subcutaneous injection combination trastuzumab hyaluronidase treatment her2-positive breast cancer adult l14510 
Relacatib,,investigated use/treatment osteoporosis bone metastasis 
Alamifovir,alamifovir antiviral agent specific hbv ,investigated use/treatment hepatitis viral b 
Indisulam,,investigated use/treatment lung cancer 
Siplizumab,,investigated use/treatment psoriasis psoriatic disorder transplant rejection graft versus host disease lymphoma unspecified leukemia unspecified 
Rilonacept,rilonacept dimeric fusion protein consisting portion il-1r il-1r accessory protein linked fc portion immunoglobulin g1 rilonacept function interleukin 1 inhibitor used treatment cap also known cryopyrin-associated periodic syndrome including familial cold auto-inflammatory syndrome fcas muckle-wells syndrome mws adult child greater 12 year old ,rilonacept indicated treatment cryopyrin-associated periodic syndrome cap including familial cold auto-inflammatory syndrome fcas muckle-wells syndrome mws patient aged 12 older rilonacept also indicated maintenance remission deficiency interleukin-1 receptor antagonist dira adult pediatric patient weighing least 10 kg finally rilonacept indicated treatment recurrent pericarditis rp reduce risk rp recurrence patient aged 12 older l40483 
Elacestrant,,investigated use/treatment menopause female hormonal deficiencies/abnormalities 
CHGN111,chgn111 inhibitor mitochondrial enzyme clk-1 demethoxyubiquinone hydroxylase numerous parameter mitochondrial function altered activity clk-1 reduced result decrease ro critical cellular site well decrease systemic oxidative stress investigation approximately 2007 ,investigated use/treatment skin infections/disorders 
Calcitonin gene-related peptide, 37-amino acid peptide derived calcitonin gene occurs result alternative processing mrna calcitonin gene neuropeptide widely distributed brain gut perivascular nerve tissue peptide produce multiple biological effect circulatory neurotransmitter mode action particular potent endogenous vasodilator potential drug demonstrated preclinical study profile could make ideal anti-asthmatic drug candidate bronchodilatory bronchoprotecting anti-inflammatory property ,investigated use/treatment myocardial infarction heart disease asthma 
Xaliproden,,investigated use/treatment amyotrophic lateral sclerosis al alzheimer 's disease 
Riferminogene pecaplasmid,riferminogene pecaplasmid non-viral fibroblast growth factor 1 nv1fgf recombinant dna plasmid pcor backbone allowing expression human fgf1 ,investigated use/treatment amputation limb peripheral vascular disease 
Abafungin,,investigated use/treatment fungal infection bacterial infection skin infections/disorders onychomycosis 
Nicaraven,,investigated use/treatment cerebrovascular disease unspecified 
Atacicept,atacicept recombinant fusion protein combined extracellular ligand binding portion taci ,investigated use/treatment autoimmune disease systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma non-hodgkin 's leukemia lymphoid 
Vitespen,,investigated use/treatment kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer brain cancer 
Bazedoxifene,bazedoxifene third generation selective estrogen receptor modulator serm developed pfizer following completion takeover wyeth pharmaceutical late 2013 pfizer received approval bazedoxifene part combination drug duavee prevention treatment postmenopausal osteoporosis approved european union marketed italy spain japan monotherapy 2013 combination product containing conjugated estrogen bazedoxifene approved fda treatment moderate severe vasomotor symptom associated menopause well prevention postmenopausal osteoporosis woman ,indicated following condition alone combination conjugated estrogen woman uterus treatment moderate severe vasomotor symptom associated menopause prevention postmenopausal osteoporosis
Telavancin,telavancin semi-synthetic derivative vanocymycin bactericidal activity methicillin-resistant staphylococcus aureus mrsa gram-positive bacteria mrsa important pathogen capable causing hospital-acquired pneumonia hap ventilator-associated pneumonia vap skin subcutaneous tissue infection among others , treatment complicated skin skin structure infection csssi caused gram-positive bacteria like methicillin-susceptible -resistant staphylococcus aureus vancomycin-susceptible enterococcus faecalis streptococcus pyogenes streptococcus agalactiae streptococcus anginosus group also treatment adult patient hospital-acquired bacterial pneumonia hap ventilator-associated bacterial pneumonia vap known suspected caused susceptible isolates staphylococcus aureus including methicillin-susceptible methicillin-resistant s. aureus 
Ambrisentan,ambrisentan orally active selective type endothelin receptor antagonist indicated treatment pulmonary arterial hypertension approved europe canada united state use single agent improve exercise ability delay clinical worsening addition approved united state use combination tadalafil reduce risk disease progression hospitalization improve exercise ability study establishing efficacy ambrisentan included patient idiopathic heritable pulmonary arterial hypertension pulmonary arterial hypertension associated connective tissue disease patient studied displayed symptom etiology predominantly functional class ii-iii endothelin receptor antagonist ambrisentan prevents endogenous endothelin peptide constricting muscle blood vessel allowing relax permit reduction blood pressure ,ambrisentan indicated treatment idiopathic ‘ primary ’ pulmonary arterial hypertension ipah pulmonary arterial hypertension pah associated connective tissue disease patient functional class ii iii symptom united state america ambrisentan also indicated combination tadalafil reduce risk disease progression hospitalization worsening pah improve exercise ability 
Human C1-esterase inhibitor,c1 esterase inhibitor human composed purified endogenous complement component-1 esterase inhibitor hc1inh isolated human plasma primary function endogenous c1inh regulate activation complement contact system pathway l16586 l16606 drug indicated prophylaxis treatment hereditary angioedema hae human genetic disorder caused shortage c1 inhibitor activity result overreaction immune system disease characterized acute attack painful case fatal swelling several soft tissue edema may last five day untreated l16586 l16606 ,intravenous subcutaneous formulation human c1-esterase inhibitor indicated routine prophylaxis acute attack hereditary angioedema patient six year age older l16586 l16606 also used treat adult adolescent patient hereditary angioedema l40995 
Eprodisate,eprodisate slows decline renal function aa amyloidosis ,investigated use/treatment amyloidosis 
Idraparinux,idraparinux synthetic pentasaccharide antithrombin-dependent inhibitor activated factor x developed treatment prevention thromboembolic event however clinical trial revealed idraparinux lead bleeding result sanofi stopped development drug ,investigated use/treatment thrombosis venous thromboembolism stroke heart disease atrial fibrillation 
Taribavirin,,investigated use/treatment hepatitis viral c 
Morphine glucuronide,,investigated use/treatment pain acute chronic 
Doxercalciferol,"doxercalciferol synthetic vitamin d2 analog undergoes metabolic activation vivo form 1α,25-dihydroxyvitamin d2 1α,25- oh 2d2 naturally occurring biologically active form vitamin d2 doxercalciferol indicated treatment secondary hyperparathyroidism patient chronic kidney disease dialysis well treatment secondary hyperparathyroidism patient stage 3 stage 4 chronic kidney disease doxercalciferol marketed brand name hectoral genzyme corporation manufactured catalent pharma solution inc ",doxercalciferol indicated treatment secondary hyperparathyroidism patient chronic kidney disease dialysis well treatment secondary hyperparathyroidism patient stage 3 stage 4 chronic kidney disease 
Oxymetholone,oxymetholone synthetic anabolic steroid marketed brand name anapolon hoffmann la roche limitedand used treatment osteoporosis anaemia agent stimulate muscle growth malnourished underdeveloped patient anabolic-androgenic steroid aa oxymetholone abused bodybuilder athlete uncontrolled misuse oxymetholone lead large variety detrimental effect often reported cardiovascular event 2009 producer oxymetholone identified worldwide sri 2009 available 14 supplier including 8 u.s. supplier chemsources 2009 ,indicated treatment anemia caused deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis hypoplastic anemia due administration myelotoxic drug often respond oxymetholone replace supportive measure transfusion correction iron folic acid vitamin b12 pyridoxine deficiency antibacterial therapy appropriate use corticosteroid 
Armodafinil,armodafinil enantiopure wakefulness-promoting agent modafinil provigil indicated improve wakefulness adult patient excessive sleepiness associated obstructive sleep apnea osa narcolepsy shift work disorder swd research shown armodafinil significantly improves driving simulator performance patient swd armodafinil consists − -r-enantiomer racemic modafinil armodafinil produced pharmaceutical company cephalon inc. wholly owned subsidiary teva pharmaceutical industry ltd. approved u.s. food drug administration fda june 2007 ,investigated use/treatment sleep disorder obstructive sleep apnea schizophrenia schizoaffective disorder depression bipolar disorder 
Etravirine,etravirine antiretroviral agent specifically classified non-nucleoside reverse transcriptase inhibitor nnrti etraverine used clinically treatment human immunodeficiency virus type 1 hiv-1 infection january 18 2007 fda granted accelerated approved use etravirine 100mg tablet treatment adult hiv-1 infection documented resistant therapy nnrti antiretroviral agent march 26 2012 approval extended use treatment-experienced pediatric patient 6 18 year age weighing least 16 kg etravarine must always used combination antiretroviral drug etravirine exerts effect via direct inhibition reverse transcriptase enzyme human immunodeficiency virus type 1 hiv-1 consequently block dna-dependent rna-dependent polymerase activity etravirine inhibit human dna polymerase alpha beta gamma common side effect use include mild moderate rash within first 6 week therapy nausea diarrhea peripheral neuropathy patient advised immediately contact healthcare provider rash develops 2009 postmarketing case report stevens-johnson syndrome toxic epidermal necrolysis erythema multiforme hypersensitivity reaction lead revision etravirine 's `` warning precaution '' well notification health care provider 2013 report autoimmune disorder graf ’ disease polymyositis guillain-barré syndrome setting immune reconstitution well depth information development rash patient taking etravirine lead modification etravirine 's monograph ,etravirine indicated combination antiretroviral agent treatment hiv-1 infection treatment-experienced patient ≥2 year age l9320 
Calfactant,calfactant sterile non-pyrogenic lung surfactant intended intratracheal instillation off-white suspension extract natural surfactant calf lung suspended 0.9 saline milliliter calfactant contains 35mg phospholipid including 26 mg phosphatidylcholine 16 mg disaturated phosphatidylcholine 0.65mg protein including surfactant-associated protein b c. calfactant approved use united state america used prevent treat respiratory distress syndrome premature infant lung surfactant deficiency calfactant shown decrease incidence respiratory distress syndrome mortality due respiratory distress syndrome air leak associated respiratory distress syndrome clinical trial adsorbs air fluid interface lung work reduce surface tension manner similar endogenous pulmonary surfactant ,calfactant indicated prophylaxis therapy prevent respiratory distress syndrome rds premature infant 29 week gestational age low lung surfactant high risk rds calfactant therapy also indicated treatment respiratory distress syndrome infant 72 hour le age rds confirmed clinical radiologic finding requiring endotracheal intubation 
Cethromycin,"cethromycin 3-keto ketolide derivative erythromycin 11,12-carbamate group o-6-linked aromatic ring system a203369 cethromycin represents joint development effort abbott laboratory taisho pharmaceutical advanced life science intended marketed trade name restanza treatment community-acquired pneumonia l14006 a203369 however completing phase iii clinical trial deemed safe sufficiently efficacious fda a203369 since time cethromycin received fda orphan drug designation prophylactic treatment anthrax inhalation plague due _yersinia pestis_ tularemia due _francisella tularensis_ l13988 also investigated together zoliflodacin treatment gonorrhea a203432 a203495 recently suggested possible treatment liver-stage _plasmodium_ sporozoite infection a203441 ",cethromycin currently fda-approved indication granted orphan drug designation prophylactic treatment inhalation anthrax 2007 prophylactic treatment plague due _yersinia pestis_ tularemia due _francisella tularensis_ 2009 l13988 
Annamycin,,investigated use/treatment breast cancer leukemia unspecified 
Declopramide,,investigated use/treatment colorectal cancer inflammatory bowel disease 
Ticalopride,,investigated use/treatment gastroesophageal reflux disease gerd gastroparesis 
Endostatin,,investigated use/treatment cancer/tumors unspecified macular degeneration diabetic retinopathy 
Talnetant,"talnetant sb-223,412 neurokinin 3 receptor antagonist developed glaxosmithkline researched several different function primarily irritable bowel syndrome potential antipsychotic drug treatment schizophrenia ",investigated use/treatment schizophrenia schizoaffective disorder irritable bowel syndrome ibs chronic obstructive pulmonary disease copd 
Evernimicin,,investigated use/treatment bacterial infection 
Tezacitabine, synthetic purine nucleoside analogue potential antineoplastic activity ,investigated use/treatment colorectal cancer lung cancer leukemia unspecified gastric cancer 
Repifermin,,investigated use/treatment bone marrow transplant ulcer inflammatory bowel disease 
Tarazepide,,investigated use/treatment gastrointestinal disease disorder miscellaneous 
Semaxanib,,investigated use/treatment colorectal cancer lung cancer 
Tifacogin,,investigated use/treatment sepsis septicemia pneumonia 
Tyloxapol,tyloxapol non-ionic detergent often used surfactant ,tyloxapol inhaled surfactant assist removing liquefying removing bronchopulmonary secretion mucus pu tyloxapol administered either nebulized solution stream oxygen also investigated use/treatment cystic fibrosis pediatric indication 
Ravuconazole,,investigated use/treatment fungal infection aspergillosis candidiasis onychomycosis 
Cangrelor,cangrelor intravenous direct-acting reversible p2y12 inhibitor patient undergoing percutaneous coronary intervention pci yet treated oral p2y12 inhibitor advantage cangrelor provides oral p2y12 inhibitor prasugrel ticagrelor clopidogrel active drug requiring metabolic conversion therefore providing rapid onset offset action cangrelor approved fda june 2015 intravenous application , use adjunct percutaneous coronary intervention pci reducing risk periprocedural myocardial infarction mi repeat coronary revascularization stent thrombosis st patient treated p2y12 platelet inhibitor given glycoprotein iib/iiia inhibitor 
Avasimibe,,investigated use/treatment peripheral vascular disease 
Dexanabinol,,investigated use/treatment traumatic brain injury neurologic disorder 
"N1,N11-Diethylnorspermine",,investigated use/treatment renal cell carcinoma pancreatic cancer melanoma lung cancer 
Dotarizine,,investigated use/treatment migraine cluster headache 
E5531,e5531 endotoxin antagonist ,investigated use/treatment sepsis septicemia 
Lonafarnib,hutchinson-gilford progeria syndrome hgps rare autosomal dominant disorder estimated affect approximately one 20 million individual resulting adverse symptom associated premature ageing skeletal dysplasia joint contracture atherosclerosis myocardial fibrosis/dysfunction scleroderma-like cutaneous effect lipoatrophy alopecia severe failure thrive hgps uniformly fatal a224379 a224384 a224389 a224394 a224399 mechanistically hgps underpinned single heterozygous c-to-t mutation position 1824 _lmna_ gene result accumulation aberrant farnesylated form lamin called progerin inner nuclear membrane a224379 a224394 lonafarnib farnesyl transferase ftase inhibitor fti reduces farnesylation numerous cellular protein including progerin progerin farnesylation important localization nuclear membrane lonafarnib inhibits progerin accumulation improves symptom hgps patient a224379 a224414 a224419 l23414 merck originally developed lonafarnib subsequently licensed eiger biopharmaceuticals inc. currently market trademark zokinvy™ l23414 l23544 lonafarnib granted fda approval november 20 2020 first fda-approved treatment hgps related progeroid laminopathies l23414 l23549 ,lonafarnib farnesyltransferase inhibitor indicated patient aged 12 month older body surface area least 0.39 sup 2 /sup reduce risk mortality associated hutchinson-gilford progeria syndrome hgps also indicated population treatment processing-deficient progeroid laminopathies either involve heterozygous _lmna_ mutation resulting accumulation progerin-like protein homozygous/compound heterozygous mutation _zmpste24_ l23414 
Ilodecakin,,investigated use/treatment inflammatory disorder unspecified crohn 's disease rheumatoid arthritis 
Aprinocarsen,aprinocarsen specific antisense oligonucleotide inhibitor protein kinase c-alpha ,investigated use/treatment lung cancer 
Mirostipen,,investigated use/treatment breast cancer lung cancer ovarian cancer 
Sarizotan,,investigated use/treatment schizophrenia schizoaffective disorder parkinson 's disease 
Meclinertant,,investigated use/treatment colorectal cancer prostate cancer schizophrenia schizoaffective disorder psychosis depression lung cancer 
Tecastemizole,,investigated use/treatment allergic rhinitis 
Remacemide,,investigated use/treatment epilepsy huntington 's disease parkinson 's disease 
Enrasentan,,investigated use/treatment congestive heart failure chronic obstructive pulmonary disease copd benign prostatic hyperplasia 
Squalamine,,investigated use/treatment ovarian cancer lung cancer macular degeneration 
Mitumomab,mitumomab anti-bec-2 monoclonal antibody derived mouse previously studied treat small cell lung carcinoma combination bcg vaccination ,investigated use/treatment lung cancer melanoma 
IR502,ir502 zorcell potential treatment psoriasis ,investigated use/treatment psoriasis psoriatic disorder 
IR501,ir501 ravax potential first-in-class vaccine treatment rheumatoid arthritis specifically target autoreactive t-cells reducing activity last known phase iii clinical trial ,investigated use/treatment rheumatoid arthritis 
FK-960,,investigated use/treatment dementia alzheimer 's disease schizophrenia schizoaffective disorder memory loss 
Apolizumab,apolizumab humanized monoclonal antibody studied treatment hematologic cancer ,investigated use/treatment lymphoma non-hodgkin 's leukemia lymphoid solid tumor 
Cariporide,,investigated use/treatment cardiac surgery 
Lestaurtinib,,investigated use/treatment pancreatic cancer prostate cancer leukemia myeloid 
Clomethiazole,clomethiazole well-established γ-aminobutyric acid gabaa -mimetic drug sedative hypnotic widely used treating preventing symptom acute alcohol withdrawal drug structurally related thiamine vitamin b1 act like sedative hypnotic muscle relaxant anticonvulsant also used management agitation restlessness short-term insomnia parkinson 's disease elderly ,investigated use/treatment stroke 
Naxifylline,,investigated use/treatment congestive heart failure 
Fradafiban,,investigated use/treatment angina 
Sibrotuzumab,sibrotuzumab humanized monoclonal antibody directed fibroblast activation protein fap used treat cancer ,investigated use/treatment cancer/tumors unspecified colorectal cancer lung cancer 
Ruplizumab,ruplizumab humanized monoclonal antibody used immunosuppressive drug component antova ,investigated use/treatment thrombocytopenia systemic lupus erythematosus transplant rejection blood blood forming organ disorder unspecified multiple sclerosis 
Sumanirole,,investigated use/treatment parkinson 's disease 
Porfiromycin,porfiromycin substance studied treatment cancer belongs family drug called anticancer antibiotic ,investigated use/treatment head neck cancer 
Propentofylline,,investigated use/treatment alzheimer 's disease 
Prucalopride,prucalopride dihydrobenzofurancarboxamide derivative benzofurane family selectively stimulates 5-ht4 receptor thus present enterokinetic property a37348 high selectivity prucalopride allowed development prevented cardiac adverse reaction observed due non-target effect precedent therapy a40254 prucalopride developed shire development llc approved use europe 2009 a40250 canada december 7 2011 fda december 17 2018 l4880 ,prucalopride indicated treatment chronic idiopathic constipation cic adult l4882 cic one common chronic functional gastrointestinal disorder worldwide diagnosis agent hard confirmed patient experience least two following -straining 25 bowel movement -lumpy hard stool 25 bowel movement -sensation incomplete evacuation 25 bowel movement -sensation anorectal blockage obstruction 25 bowel movement -manual maneuver required 25 bowel movement -fewer 3 bowel movement per week l4883 
Manitimus,fk778 novel compound multiple mechanism action efficacious well tolerated safe kidney transplant patient potentially offering breakthrough immunosuppressive therapy ,investigated use/treatment immunosuppressive transplant rejection 
ALGRX 1207,algrx 1207 topical local anesthetic act binding fast sodium channel algrx 1207 entered clinical trial cutaneous neuropathic pain chemotherapy-induced neuropathy 2006 developed anesiva trial halted ,investigated use/treatment pain acute chronic 
Ropidoxuridine,ropidoxuridine novel orally available thymidine analogue prodrug iudr demonstrated survival advantage phase ii study anaplastic astrocytoma type brain tumor ,investigated use/treatment cancer/tumors unspecified 
Enzastaurin,enzastaurin investigational targeted oral agent evaluated 100 site worldwide treatment relapsed glioblastoma multiforme gbm aggressive malignant form brain cancer ,investigated use/treatment brain cancer lymphoma non-hodgkin 's lung cancer 
Liatermin,,investigated use/treatment parkinson 's disease 
Mirococept,mirococept apt070 complement inhibitor currently development treatment rheumatoid arthritis i/ri truncated form human complement receptor 1 cr1 linked unique prodaptin™ construct regulates over-production complement cell surface occurs inflammation consists first three short consensus domain human complement receptor 1 cr1 manufactured recombinant bacteria modified membrane-targeting amphiphilic peptide based naturally occurring membrane-bound myristoyl-electrostatic switch peptide ,investigated use/treatment transplant rejection kidney disease rheumatoid arthritis 
Velafermin,velafermin novel investigational protein therapeutic also known fibroblast growth factor-20 fgf-20 promotes epithelial mesenchymal cell proliferation vitro demonstrated activity multiple animal model velafermin investigated potential therapy prevention treatment oral mucositis fostering regeneration repair cell lining gastrointestinal tract ,investigated use/treatment adverse effect chemotherapy 
Sufugolix,,investigated use/treatment endometriosis uterine fibroid 
Onercept,,investigated use/treatment psoriasis psoriatic disorder crohn 's disease 
Dextrin 2-sulfate,,investigated use/treatment hiv prevention 
Aplaviroc, spiro-diketo-piperazine potent noncompetitive allosteric antagonist ccr5 receptor concomitantly potent antiviral effect hiv-1 ,investigated use/treatment hiv infection 
L523S,according nemunaitis j. et al `` l523s immunogenic lung cancer antigen demonstrated preclinical safety gene injected intramuscularly expressive plasmid pvax/l523s delivered following incorporation e1b-deleted adenovirus ad/l523s '' a175909 investigated lung cancer vaccine ,investigated use/treatment lung cancer 
Furaprofen,,investigated use/treatment hepatitis viral c 
MLN2222,mln2222 novel proprietary recombinant protein block c3 c5 convertases essential component complement activation pathway ,investigated use/treatment coronary artery disease 
S-8510,s-8510 sb-737552 bzd inverse agonist investigated treatment alzheimer ’ disease mild moderate senile dementia codeveloped shionogi glaxosmithkline ,investigated use/treatment alzheimer 's disease dementia 
Repinotan,repinotan high-affinity selective full agonist 5ht1a-receptor subtype neuroprotective property ,investigated use/treatment stroke cerebral ischemia depression 
GW-559090,,investigated use/treatment asthma allergic rhinitis 
Muraglitazar,muraglitazar bristol-myers squibb/merck new agent investigation treatment patient type 2 diabetes belongs novel class drug target peroxisome proliferator-activated receptor alpha gamma subtypes addition improvement blood glucose hemoglobin a1c hba1c muraglitazar treatment associated substantial reduction triglyceride tgs increase hdl-c modest decrease ldl-c level ,investigated use/treatment diabetes mellitus type 2 
AMGN-0007,recombinant osteoprotegerin amgn-0007 recombinant opg construct developed potential therapeutic agent treatment bone disease ,investigated use/treatment osteoporosis bone metastasis 
Deramciclane,deramciclane egis-3886 used treatment number anxiety disorder deramciclane differs anti anxiety medication benzodiazepine different structure target antagonizes 5-ht2a receptor agonizes 5-ht2c receptor function gaba reuptake inhibitor ,investigated use/treatment anxiety disorder 
Resiniferatoxin,resiniferatoxin rtx naturally occurring ultrapotent capsaicin analog activates vanilloid receptor subpopulation primary afferent sensory neuron involved nociception transmission physiological pain ,investigated use/treatment interstitial cystitis urinary incontinence 
MLN576,xr11576 mln576 novel monophenazine mechanism action includes interaction topoisomerase topo ii a234609 ,investigated use/treatment solid tumor 
R-1487,,investigated use/treatment rheumatoid arthritis 
Edaglitazone,,investigated use/treatment diabetes mellitus type 2 
Ertiprotafib,ertiprotafib belongs novel class insulin sensitizer developed treatment type 2 diabetes insulin-resistant rodent model ertiprotafib close analog lowered fasting blood glucose insulin level improved glycemic excursion oral glucose tolerance test ,investigated use/treatment diabetes mellitus type 2 
Levovirin,,investigated use/treatment hepatitis viral c 
Ganstigmine,ganstigmine orally active geneserine derived carbamate-based acetylcholinesterase inhibitor developed treatment alzheimer 's disease ,investigated use/treatment alzheimer 's disease 
Tramiprosate,,investigated use/treatment stroke alzheimer 's disease 
Ocinaplon,,investigated use/treatment anxiety disorder 
Resiquimod, substance studied treatment type skin cancer put skin resiquimod cause immune cell make certain chemical may help kill tumor cell also studied find adding tumor vaccine improves antitumor immune response type imidazoquinoline type immunomodulator ,investigated use/treatment genital herpes 
Pafuramidine,pafuramidine prodrug furamidine currently orphan status _pneumocystis jiroveci_ pneumonia ,investigated use/treatment pneumonia trypanosomiasis malaria hiv infection infectious parasitic disease unspecified 
Ragaglitazar,,investigated use/treatment diabetes mellitus type 2 
Thrombopoietin,,investigated use/treatment thrombocytopenia 
Etilevodopa,,investigated use/treatment parkinson 's disease 
Tesaglitazar,tesaglitazar dual peroxisome proliferator-activated receptor alpha/gamma agonist improves apolipoprotein level non-diabetic subject insulin resistance tesaglitazar proposed treatment type 2 diabetes completed several phase iii clinical trial however may 2006 astrazeneca announced discontinued development ,investigated use/treatment diabetes mellitus type 2 
Robalzotan,,investigated use/treatment anxiety disorder depression 
Astaxanthin,astaxanthin keto-carotenoid terpene class chemical compound classified xanthophyll carotenoid vitamin activity found majority aquatic organism red pigment astaxanthin shown mediate anti-oxidant anti-inflammatory action may found fish feed animal food color additive ,investigated use/treatment eye disorders/infections cancer/tumors unspecified asthma 
Gavilimomab,,investigated use/treatment graft versus host disease 
Atibuclimab,atibuclimab ic14 chimeric cd14 antibody investigated treatment patient severe sepsis ,investigated use/treatment sepsis septicemia pneumonia 
Minodronic acid,,investigated use/treatment multiple myeloma breast cancer osteoporosis lung cancer 
Labradimil,,investigated use/treatment brain cancer pediatric indication 
Bivatuzumab,bivatuzumab previously biwa 4 humanized monoclonal antibody cd44 v6 a31688 a31689 ,investigated use/treatment cancer/tumors unspecified head neck cancer 
rNAPc2,recombinant nematode anticoagulant protein c2 rnapc2 specific inhibitor tissue factor tf /factor viia complex novel antithrombotic activity a175642 ,investigated use/treatment thrombosis deep vein angina coronary artery disease colorectal cancer 
Gaboxadol,"gaboxadol also known 4,5,6,7-tetrahydroisoxazolo 5,4-c pyridin-3-ol thip experimental sleep aid drug developed lundbeck merck reported increased deep sleep without reinforcing effect benzodiazepine development gaboxadol stopped march 2007 concern regarding safety efficacy act gaba system seemingly different way benzodiazepine sedative ",investigated use/treatment sleep disorder insomnia 
Siramesine,,investigated use/treatment anxiety disorder 
Edifoligide,,investigated use/treatment cardiac surgery peripheral vascular disease kidney disease 
Lerdelimumab,,investigated use/treatment glaucoma cataract 
Tezosentan,tezosentan intravenous endothelin receptor a/b antagonist tezosentan initially developed vasodilation patient acute heart failure study shown assist treatment dyspnea prevent cardiovascular event ,investigated use/treatment congestive heart failure liver disease heart disease 
Lanimostim,,investigated use/treatment fungal infection 
Pascolizumab,pascolizumab sb 240683 humanized anti-interleukin-4 antibody therapeutic potential asthma ,investigated use/treatment asthma 
Emfilermin,,investigated use/treatment adverse effect chemotherapy reproductive health infertility 
alpha-Hydroxy glycineamide,alpha-hydroxy glycineamide αhga active antiviral metabolite tri-peptide glycyl-prolyl-glycine-amide gpg-nh2 αhga inhibits replication hiv-1 vitro interfering capsid formation also effect viral gp160 envelope protein a31692 ,investigated use/treatment hiv infection 
P-57AS3,,investigated use/treatment obesity 
Rebimastat,,investigated use/treatment lung cancer prostate cancer 
Valomaciclovir,,investigated use/treatment herpes zoster infection viral infection 
Baminercept,,investigated use/treatment rheumatoid arthritis 
Tonabersat,,investigated use/treatment migraine cluster headache 
Adipiplon,adipiplon nonbenzodiazepine anxiolytic developed neurogen corporation known standardized identifier ng2-73 ,investigated use/treatment insomnia sleep disorder 
Celgosivir,,investigated use/treatment hepatitis viral c 
Bevirimat,bevirimat also known pa-457 yk-fh312 investigated clinical trial treating hiv infection bevirimat solid compound belongs androgen derivative hydroxylated c19 steroid hormone known favour development masculine characteristic also show profound effect scalp body hair human bevirimat target protein gag-pol polyprotein bevirimat derived betulinic acid-like compound first isolated syzygium claviflorum /i chinese herb currently fda-approved undergoing clinical trial conducted pharmaceutical company panacos ,investigated use/treatment hiv infection 
Dextofisopam,,investigated use/treatment irritable bowel syndrome ibs 
TG4010, bivalent cancer vaccine comprised modified vaccinia virus ankara mva strain encoding human mucin 1 muc1 interleukin-2 il-2 potential immunostimulating antineoplastic activity originally developed eradication smallpox mva highly attenuated replication-defective strain incapable virion assembly exerts potent immunostimulatory activity antigen vaccination mva-muc1-il2 vaccine may stimulate host immune system mount humoral cytotoxic lymphocyte ctl response tumor cell expressing muc1 tumor associated antigen resulting tumor cell lysis expression il-2 augments specific ctl response muc1 expressing cell l5191 ,investigated use/treatment breast cancer renal cell carcinoma prostate cancer lung cancer 
Fipamezole,,investigated use/treatment parkinson 's disease neurologic disorder 
Cetilistat,cetilistat novel inhibitor pancreatic lipase developed alizyme treatment obesity associated co-morbidities including type 2 diabetes ,investigated use/treatment obesity 
Mitemcinal,mitemcinal gm-611 novel erythromycin-derived prokinetic agent act agonist motilin receptor ,investigated use/treatment gastroparesis irritable bowel syndrome ibs 
Triphendiol,,investigated use/treatment cancer/tumors unspecified 
Pazopanib,pazopanib small molecule inhibitor multiple protein tyrosine kinase potential antineoplastic activity developed glaxosmithkline fda approved october 19 2009 ,treatment advanced renal cell cancer advanced soft tissue sarcoma patient previously treated chemotherapy 
Ceftaroline fosamil,ceftaroline fosamil cephalosporin antibacterial indicated treatment following infection caused designated susceptible bacteria acute bacterial skin skin structure infection community-acquired bacterial pneumonia ,ceftaroline fosamil indicated treatment patient following infection caused susceptible isolates designated microorganism 
Pegargiminase,pegargiminase anticancer agent ,investigated use/treatment melanoma hepatocellular carcinoma 
Agomelatine,agomelatine structurally closely related melatonin agomelatine potent agonist melatonin receptor antagonist serotonin-2c 5-ht2c receptor tested animal model depression agomelatine developed europe servier laboratory ltd. submitted european medicine agency ema 2005 committee medical product human use chmp recommended refusal marketing authorization 27 july 2006 major concern efficacy sufficiently shown 2006 servier sold right develop agomelatine u novartis development u market discontinued october 2011 currently sold australia valdoxan trade name ,agomelatine indicated treat major depressive episode adult 
Midostaurin,midostaurin rydapt multitarget kinase inhibitor treatment adult patient newly diagnosed acute myeloid leukemia aml specific genetic mutation called flt3 initially characterized potential broad-spectrum antineoplastic agent activity toward diverse solid hematopoietic tumor a19108 approved april 28 2017 shown increase overall survival rate patient aml adjunct therapy along chemotherapeutic agent ,investigated use/treatment adult patient high-risk acute myeloid leukemia aml flt3 mutation-positive agressive systemic mastocytosis asm systemic mastocytosis associated hematological neoplasm sm-ahn mast cell leukemia mcl 
Estradiol sulfamate,,investigated use/treatment endometriosis 
Brostallicin,,investigated use/treatment solid tumor 
Lexatumumab,lexatumumab fully humanized high-affinity immunoglobulin g 1 lambda monoclonal antibody mab ,investigated use/treatment cancer/tumors unspecified 
Nemonoxacin,,investigated use/treatment bacterial infection pneumonia 
Reslizumab,reslizumab humanized interleukin-5 il-5 antagonist monoclonal antibody igg4 kappa produced recombinant dna technology murine myeloma non-secreting 0 ns0 cell il-5 pro-inflammatory cytokine responsible growth differentiation recruitment activation survival eosinophil fda label elevated level eosinophil increase risk asthma exacerbation including allergic form nonallergic form asthma eosinophilia prominent targeting il-5 disrupting signalling pathway reslizumab aim inhibit eosinophil maturation promote programmed cell death a31578 asthma chronic respiratory disease cause inflammation lung asthma attack lead severe breathing difficulty patient often experience persistent exacerbating symptom overtime despite conventional first-line therapy available inflammation-predominant asthma chatacterized eosinophilic infiltration airway mucosa elevated level eosinophil blood sputum bal fluid associated increased risk recurrent exacerbation asthma-related hospitalization a31579 four double-blind randomized placebo‑controlled trial patient severe asthma currently available therapy patient receiving reslizumab fewer asthma attack longer time first attack compared patient receiving placebo fda label a31579 addition significant improvement lung function seen measured volume air exhaled patient one second l1133 study demonstrated reslizumab effective various asthma outcome patient without eosinophilia a31577 reslizumab developed teva pharmaceutical approved fda march 2016 reslizumab marketed brand name cinqair intravenous injection injected every four week via intravenous infusion cinqair indicated add-on maintenance therapy adult severe asthma eosinophilic phenotype approved patient history severe asthma attack exacerbation despite receiving current asthma medicine reslizumab marketed cinqaero europe ,indicated add-on maintenance treatment patient severe asthma aged 18 year older eosinophilic phenotype 
Panobinostat,panobinostat oral deacetylace dac inhibitor approved february 23 2015 fda treatment multiple myeloma approval accelerated based progression-free survival therefore confirmatory trial sponsor demonstrate clinical efficacy multiple myeloma treatment progress conducted panobinostat marketed novartis brand name farydak panobinostat act non-selective histone deacetylase inhibitor pan-hdac inhibitor potent dac inhibiting agent available market ,panobinostat indicated treatment multiple myeloma combination dexamethasone bortezomib patient received 2 previous treatment regimen including bortezomib immunomodulatory agent indication approved accelerated approval based progression free survival february 23 2015 
Ilepatril,,investigated use/treatment hypertension 
Apixaban,apixaban oral direct highly selective factor xa fxa inhibitor free bound fxa well prothrombinase independent antithrombin iii prevention treatment thromboembolic disease label a6897 marketed name eliquis label l6043 apixaban approved fda december 28 2012 l6043 ,apixaban indicated reducing risk stroke systemic embolism patient nonvalvular atrial fibrillation prophylaxis deep vein thrombosis dvt leading pulmonary embolism pe patient hip knee replacement surgery treatment dvt pe reduce risk recurrence label a177565 a6897 
Teplizumab,teplizumab teplizumab-mzwv humanized igg1 kappa cd3-directed monoclonal antibody used delay onset type 1 diabetes t1d a241480 a241045 a241475 l44091 t1d autoimmune condition cell-mediated destruction pancreatic β cell lead loss insulin production impaired glycemic control reliance exogenous insulin a241490 anti-cd3 therapy traditionally used prevent graft-versus-host-disease organ transplantation recently explored prolong onset t1d high-risk patient a241480 a241500 targeting cell achieved antibody cell receptor tcr component cd3 although mechanism action teplizumab fully elucidated may involve partial agonistic signaling deactivation pancreatic beta cell autoreactive lymphocyte l44091 fc-receptors bind `` tail-end '' anti-cd3 antibody antigen-non-specific manner lead severe adverse effect related cytokine release syndrome cr teplizumab designed fc-non-binding antibody order reduce incidence cr a241480 november 2022 teplizumab approved fda first drug delay onset type 1 diabetes l44096 ,teplizumab indicated delay onset stage 3 type 1 diabetes t1d adult pediatric patient aged 8 year older stage 2 t1d l44091 
Catumaxomab,catumaxumab trifunctional monoclonal antibody developed use cancer treatment affinity t-cells accessory immune cell cancer cell catumaxumab initially authorized market european medicine agency april 2009 treatment malignant ascites l1122 market authorization withdrawn eu june 2017 manufacturer 's request due company 's insolvency catumaxumab approved market canada may 2012 condition fda label currently available brand name removab , use management malignant ascites tumour via intraperitoneal infusion standard therapy available feasible fda label 
Tafenoquine,tafenoquine 8-aminoquinoline analogue primaquine varies presence 5-phenoxy group a35671 a35690 discovered scientist walter reed army institute research 1978 substitute primaquine would effective relapsing vivax malaria a35690 tafenoquine developed collaboratively glaxosmithkline medicine malaria venture a35677 fda approved july 20 2018 l3770 ,tafenoquine used treatment prevention relapse vivax malaria patient 16 year older tafenoquine indicated treat acute vivax malaria a35671 malaria disease remains occur many tropical country vivax malaria caused _plasmodium vivax_ known le virulent seldom cause death however cause substantive illness-related burden endemic area known present dormant form hepatocytes named hypnozoites remain dormant week even month dormant form produce ongoing relapse a35671 
Odiparcil,,investigated use/treatment atrial fibrillation cardiovascular disorder thrombosis venous thromboembolism 
Omiganan,omiganan investigated treatment mupirocin-resistant mrsa skin infection ,investigated use/treatment bacterial infection rosacea 
Pegsunercept,pegsunercept used treating rheumatoid arthritis phase ii clinical trial completed january 2010 ,investigated use/treatment rheumatoid arthritis 
Mepolizumab,eosinophil involved inflammatory immune response prolonged hypereosinophilia typically defined absolute eosinophil level 1500/mm sup 3 /sup associated spectrum disease including severe asthma eosinophilic granulomatosis polyangiitis egpa hypereosinophilic syndrome he pathogenesis eosinophilia complex il-5 recognized key cytokine involved differentiation recruitment activation prolonged survival eosinophil peripheral tissue activated eosinophil stimulate inflammatory response also induce tissue lesion promote fibrosis contribute multifactorial symptomatology hypereosinophilic disease a221048 a221053 a221058 a221063 a221068 l16518 mepolizumab fully-humanized recombinant igg1 kappa monoclonal antibody directed il-5 produced chinese hamster ovary cell mepolizumab first approved fda november 4 2015 add-on therapy severe asthma marketed brand name nucala glaxosmithkline indication subsequently expanded cover egpa december 12 2017 he september 25 2020 l16518 ,mepolizumab anti-il-5 igg1 kappa monoclonal antibody indicated add-on maintenance treatment patient aged six year older severe eosinophilic asthma treatment adult patient eosinophilic granulomatosis polyangiitis egpa mepolizumab also indicated treatment hypereosinophilic syndrome he patient aged 12 older eosinophilia present least six month without identifiable non-hematologic secondary cause l16518 mepolizumab additionally indicated add-on maintenance treatment chronic rhinosinusitis nasal polyp crswnp patient ≥18 year old inadequate response nasal corticosteroid l16518 
Peramivir,peramivir antiviral agent developed biocryst pharmaceutical treat influenza a/b development peramivir supported u department health human service part government 's effort prepare flu pandemic influenza virus neuraminidase inhibitor peramivir work preventing new virus emerging infected cell due poor oral bioavailability oral formulation drug previously abandoned johnson johnson company injectable intravenous formulation peramivir approved fda september 2017 treatment acute uncomplicated influenza pediatric patient 2 year older symptomatic two day ,peramivir indicated treatment acute uncomplicated influenza patient six month older symptomatic two day l36768 
Bosutinib,bosutinib bcr-abl kinase inhibitor treatment philadelphia chromosome-positive ph+ chronic myelogenous leukemia cml compared tyrosine kinase inhibitor favourable hematologic toxicity profile fda approved september 4 2012 ,treatment chronic accelerated blast phase philadelphia chromosome-positive ph+ chronic myelogenous leukemia cml resistance intolerance prior therapy adult patient 
Cutamesine,,investigated use/treatment stroke depression 
Amdoxovir,,investigated use/treatment hiv infection acquired immune deficiency syndrome aid aids-related infection 
Aplindore,,investigated use/treatment parkinson 's disease neurologic disorder 
7-beta-Hydroxyepiandrosterone,,investigated use/treatment alzheimer 's disease 
Flupirtine,flupirtine pyridine derivative clinical use nonopioid analgesic approved treatment pain 1984 europe approved use u.s. canada currently phase ii trial treatment fibromyalgia ,investigated use/treatment fibromyalgia 
Taranabant,,investigated use/treatment obesity 
Vipadenant,,investigated use/treatment parkinson 's disease 
Axitinib,axitinib second generation tyrosine kinase inhibitor work selectively inhibiting vascular endothelial growth factor receptor vegfr-1 vegfr-2 vegfr-3 l6676 mechanism action axitinib block angiogenesis tumour growth metastasis reported exhibit potency 50-450 time higher first generation vegfr inhibitor l6676 axitinib indazole derivative a179398 commonly marketed name inlyta® available oral formulation ,used kidney cell cancer investigated use/treatment pancreatic thyroid cancer 
Zibotentan,,investigated use/treatment prostate cancer 
Anacetrapib,,investigated use/treatment hyperlipidemia 
N-chlorotaurine,n-chlorotaurine inhibitor inducible nitric oxide synthase ikappab kinase ,investigated use/treatment eye disorders/infections 
Casopitant,,investigated use/treatment urinary incontinence adverse effect chemotherapy 
Otamixaban,otamixaban novel direct factor xa fxa inhibitor currently developed french pharmaceutical company sanofi-aventis treatment acute coronary syndrome ,investigated use/treatment thrombosis 
Isavuconazonium,isavuconazonium second-generation triazole antifungal approved march 6 2015 fda treatment invasive aspergillosis invasive mucormycosis marketed astellas brand cresemba prodrug form isavuconazole active moiety available oral parenteral formulation due low solubility water isavuconazole isovuconazonium formulation favorable high solubility water allows intravenous administration formulation also avoids use cyclodextrin vehicle solubilization required intravenous administration antifungal voriconazole posaconazole eliminating concern nephrotoxicity associated cyclodextrin isovuconazonium excellent oral bioavailability predictable pharmacokinetics good safety profile making reasonable alternative competitor market ,indicated treatment invasive aspergillosis invasive mucormycosis 
Dalfampridine,dalfampridine potassium channel blocker used help multiple sclerosis patient walk first drug specifically approved help mobility patient fda approved january 22 2010 ,dalfampridine neurofunctional modifier help improve walking speed patient multiple sclerosis m 
Quarfloxin,,investigated use/treatment leukemia lymphoid 
Fispemifene,,investigated use/treatment male hormonal deficiencies/abnormalities 
Perifosine,perifosine novel alkylphospholipid antiproliferative property attributed protein kinase b inhibition ,investigated use/treatment solid tumor multiple myeloma leukemia unspecified lung cancer brain cancer 
Bevasiranib,bevasiranib small interfering rna sirna targeting vascular endothelial growth factor vegf-a ,investigated use/treatment macular degeneration diabetic retinopathy 
Denosumab,denosumab novel fully human igg2 monoclonal antibody specific receptor activator nuclear factor kappa-b ligand rankl suppresses bone resorption marker patient variety metastatic tumor investigated multiple clinical trial prevention treatment bone metastasis chemically consists 2 heavy 2 light chain light chain consists 215 amino acid heavy chain consists 448 amino acid 4 intramolecular disulfides fda approved june 1 2010 ,prolia indicated treatment postmenopausal woman osteoporosis high risk fracture reduces incidence vertebral nonvertebral hip fracture prolia also indicated treatment increase bone mass woman high risk fracture receiving adjuvant aromatase inhibitor therapy breast cancer also used men osteoporosis high risk fracture men receiving androgen deprivation therapy nonmetastatic prostate cancer increase bone mass xgeva indicated prevention skeletal-related event patient bone metastasis solid tumor 
Anamorelin,,investigated use/treatment cachexia anorexia 
Volociximab,,investigated use/treatment solid tumor renal cell carcinoma melanoma pancreatic cancer lung cancer ovarian cancer 
Priralfinamide,,investigated use/treatment pain acute chronic 
Ofatumumab,ofatumumab novel anti-cd20 monoclonal antibody target b-cells igg1κ human monoclonal antibody produced recombinant murine cell line ns0 via transgenic mouse hybridoma technology l12612 ofatumumab work recognizing antigen expressed tumour cell certain cancer however antigen tumour-specific also found normal b-cells a6921 ofatumumab first approved fda 2009 l12771 used treatment recurrent progressive recurrent chronic lymphocytic leukemia cll cll treatment-naive patient fludarabine-based therapy considered inappropriate ofatumumab used monotherapy combination medication depending patient profile previous treatment history l12612 although similar molecular mechanism action rituximab another cd-20 monoclonal antibody used treatment rheumatoid arthritis b-cell non-hodgkin 's lymphoma ofatumumab higher affinity towards cd20 a6921 ofatumumab available intravenous administration marketed arzerra phase iii clinical trial consisting subject relapsing form multiple sclerosis rms subcutaneous administration ofatumumab reduced number relapse delayed disease progression february 2020 fda ema approved supplemental biologics license application sbla marketing authorization application maa respectively ofatumumab treatment rms adult l12753 fda subsequently approved ofatumumab treatment rms august 20 2020 l15581 potential therapeutic use ofatumumab various lymphoma rheumatoid arthritis also investigated a193053 ,ofatumumab indicated combination chlorambucil treatment previously untreated patient chronic lymphocytic leukemia cll fludarabine-based therapy considered inappropriate l12612 patient recurrent progressive cll ofatumumab indicated extended treatment patient complete partial response least two line therapy recurrent progressive cll l12612 ofatumumab indicated treatment patient cll refractory fludarabine alemtuzumab l12612 ofatumumab also indicated treatment adult patient relapsing form multiple sclerosis including active secondary progressive disease clinically isolated syndrome relapsing-remitting disease l15581 
DiaPep 277,diapep 277 24-mer laboratory-made peptide derived hsp60 437-460 ,investigated use/treatment diabetes mellitus type 1 autoimmune disease diabetes mellitus type 2 
Vicriviroc,vicriviroc also known sch 417690 sch-d currently clinical trial management hiv-1 pyrimidine based drug inhibits interaction hiv-1 ccr5 preventing viral entry cell drug developed schering-plough ,investigated use/treatment hiv infection viral infection 
Safinamide,safinamide treatment parkinson 's disease approved europe february 2015 united state march 21 2017 ,safinamide indicated add-on treatment levodopa without medicine parkinson ’ disease
Liraglutide,victoza contains liraglutide synthetic analog human glucagon-like peptide-1 glp-1 act glp-1 receptor agonist label a6932 liraglutide 97 similar native human glp-1 differing primarily substituting arginine lysine position 34 a6932 liraglutide made attaching c-16 fatty acid palmitic acid glutamic acid spacer remaining lysine residue position 26 peptide precursor a6932 liraglutide granted fda approval january 25 2010 l6070 ,saxenda formulation liraglutide intended weight loss indicated adjunct diet exercise chronic weight management adult patient obese bmi≥30 kg/m sup 2 /sup overweight bmi≥27 kg/m sup 2 /sup least one weight-related comorbidity also indicated chronic weight management pediatric patient ≥12 year old weigh ≥60 kg initial bmi corresponding obesity based international cut-offs l38839 victoza formulation liraglutide used diabetes indicated adjunct diet exercise improve glycemic control patient ≥10 year old type 2 diabetes mellitus also indicated reduce risk major adverse cardiovascular event adult patient type 2 diabetes established cardiovascular disease l38839 liraglutide also available combination insulin degludec adjunct diet exercise improve glycemic control adult patient type 2 diabetes mellitus l38844 
TAS-106,tas-106 new nucleoside antimetabolite tas-106 demonstrated strong antitumor activity without serious toxicity nude rat model bearing human tumour a31693 ,investigated use/treatment solid tumor cancer/tumors unspecified 
Valrocemide,,investigated use/treatment epilepsy 
Rostaporfin,,investigated use/treatment macular degeneration 
Saredutant,saredutant sr 48968 neurokinin-2 antagonist drug developed antidepressant anxiolytic sanofi-aventis ,investigated use/treatment depression anxiety disorder 
Abetimus,abetimus developed la jolla pharmaceutical immunosuppressant never marketed american europe despite application marketing authorization mid-2000s ,investigated use/treatment kidney disease systemic lupus erythematosus 
Pasireotide,pasireotide synthetic long-acting cyclic hexapeptide somatostatin-like activity marketed diaspartate salt called signifor used treatment cushing 's disease , treatment cushing ’ disease specifically patient pituitary surgery curative option 
Lixivaptan,,investigated use/treatment hyponatremia congestive heart failure 
Arverapamil,,investigated use/treatment irritable bowel syndrome ibs diarrhea 
Odanacatib,odanacatib inhibiter cathepsin k originally developed merck co new treatment osteoporosis a19388 drug made phase iii trial abandoned due increased stroke ,investigated use/treatment osteoporosis a19388 
Almorexant,,investigated use/treatment sleep disorder insomnia 
Golimumab,golimumab human igg1қ monoclonal antibody derived immunizing genetically engineered mouse human tnfα golimumab bind inhibits soluble transmembrane human tnfα increased tnfα associated chronic inflammation thus golimumab indicated use adult adjunct methotrexate treatment patient moderate severe active rheumatoid arthritis ra ii alone adjunct methotrexate treatment patient active psoriatic arthritis psa iii single agent patient active ankylosing spondylitis iv single agent patient moderate severe ulcerative colitis uc require chronic steroid experienced intolerance partial response previous medication u.s. canada golimumab marketed brand name simponi® fda label includes black box warning serious infection malignancy additionally child adolescent taking golimumab lymphoma malignancy observed ,used adult adjunct methotrexate treatment patient moderate severe active rheumatoid arthritis ra l16626 ii patient 2 year old active psoriatic arthritis psa l16626 iii single agent patient active ankylosing spondylitis combination methotrexate l16631 iv single agent patient moderate severe ulcerative colitis uc require chronic steroid experienced intolerance partial response previous medication l16631 also indicated v treatment active polyarticular juvenile idiopathic arthritis pjia patient 2 year age older l16626 
Clazosentan,,investigated use/treatment stroke 
Esmirtazapine,esmirtazapine known standardized identifier sch 900265 development organon treat insomnia vasomotor symptom associated menopause esmirtazapine -enantiomer mirtazapine posse similar overall pharmacology includes inverse agonist activity h1 5-ht2 receptor antagonism α2-adrenergic receptor merck terminated internal clinical development program esmirtazapine march 2010 ,investigated use/treatment insomnia sleep disorder 
Amediplase,amediplase recombinant chimeric plasminogen activator consisting kringle 2 domain a-chain tissue plasminogen activator t-pa carboxy terminal region pro-urokinase mesh ,investigated use/treatment myocardial infarction thrombosis 
Asoprisnil,asoprisnil j867 selective progesterone receptor modulator used treat progesterone sensitive myoma ,investigated use/treatment uterine fibroid 
Belatacept,"belatacept soluble fusion protein link extracellular domain human cytotoxic t-lymphocyte-associated antigen 4 ctla-4 modified fc hinge ch2 ch3 domain portion human immunoglobulin g1 igg1 structurally abatacept glycosylated fusion protein maldi-ms molecular weight 92,300 da homodimer two homologous polypeptide chain 357 amino acid produced recombinant dna technology mammalian cho cell drug activity selective co-stimulation modulator inhibitory activity lymphocyte approved treatment rheumatoid arthritis belatacept selectively block process t-cell activation developed bristol-myers-squibb belatacept 2 amino acid different abatacept orencia fda approved june 15 2011 ", prophylaxis organ rejection also used concomitantly basiliximumab induction therapy mycophenolate corticosteriods kidney transplant recepients seropositive epstein-barr virus 
Naproxcinod,,investigated use/treatment pain acute chronic inflammatory disorder unspecified osteoarthritis arthritis arthritic pain 
Clevudine,,investigated use/treatment hepatitis viral b 
Vilazodone,vilazodone novel compound combined high affinity selectivity 5-hydroxytryptamine 5-ht transporter 5-ht 1a receptor label a177622 vilazodone may also associated le sexual dysfunction weight gain a6947 vilazodone given fda approval january 21 2011 l6046 a177622 ,vilazodone approved treatment major depressive disorder label a38477 a177622 
Laquinimod,laquinimod immunomodulator developed active biotech produced teva pharmaceutical industry currently development phase iii trial treatment multiple sclerosis oral therapy like fingolimod shown reduce disease activity magnetic resonance imaging well tolerated orally ,investigated use/treatment multiple sclerosis 
Sipuleucel-T,"sipuleucel-t personalized autologous cellular immunotherapy sipuleucel-t therapeutic cancer vaccine prostate cancer sipuleucel-t selectively target prostate-specific antigen psa known prostatic acid phosphatase pap expressed around 95 prostate cancer must prepared specifically patient metastatic prostate cancer extended survival median 4.1 month impact phase iii trial data sipuleucel-t marketed brand name provenge dendreon corporation sipuleucel-t approved u.s. food drug administration fda april 29 2010 treat asymptomatic minimally symptomatic metastatic hormone-refractory prostate cancer hrpc treatment initially cost 93,000 time fda approval rose 100,000 2014 ",sipuleucel-t autologous cellular immunotherapy indicated treatment asymptomatic minimally symptomatic metastatic castrate resistant hormone refractory prostate cancer 
Ethanolamine oleate,ethanolamine oleate mild sclerosing agent composed ethanolamine basic substance combined oleic acid form clear straw pale yellow colored deliquescent oleate , treatment patient esophageal varix recently bled prevent rebleeding 
Nitrous oxide,nitrous oxide commonly known `` laughing gas '' chemical compound chemical formula n2o room temperature colorless non-flammable gas pleasant slightly sweet odor taste used surgery dentistry anesthetic analgesic effect known `` laughing gas '' due euphoric effect inhaling property led recreational use inhalant drug ,
Mepyramine,mepyramine pyrilamine target h1 receptor first generation antihistamine however rapidly permeates brain often cause drowsiness side effect found over-the-counter combination product cold menstrual symptom considered unapproved prescription medication used cough cold allergic condition ,indicated treatment allergic condition symptomatic relief hypersensitivity reaction treatment pruritic skin disorder 
Aprotinin,aprotinin protein-based drug also known bovine pancreatic trypsin inhibitor bpti since demonstrates capacity slow fibrinolysis employed reduce bleeding complex surgery heart liver surgery use typically administered injection goal using aprotinin subsequently minimize end-organ damage resulting hypotension due blood loss surgery reduce necessity blood transfusion surgery nevertheless drug formally withdrawn worldwide may 2008 study confirmed use enhanced risk complication death substance consequently made available restricted research use , prophylactic use reduce perioperative blood loss need blood transfusion patient undergoing cardiopulmonary bypass course coronary artery bypass graft surgery increased risk blood loss blood transfusion 
Mevastatin,"mevastatin compactin cholesterol-lowering agent isolated penicillium citinium /i first discovered agent belonging class cholesterol-lowering medication known statin search antibiotic compound produced fungi 1971 akira endo sankyo co. japan discovered class compound appeared lower plasma cholesterol level two year later research group isolated compound structurally similar hydroxymethylglutarate hmg inhibited incorporation acetate compound proposed bind reductase enzyme named compactin mevastatin competitive inhibitor hmg-coenzyme hmg-coa reductase binding affinity 10,000 time greater hmg-coa substrate mevastatin pro-drug activated vivo /i hydrolysis lactone ring served one lead compound development synthetic compound used today ", used therapeutically due many side effect 
Xylometazoline,xylometazoline imidazoline derivative a228523 sympathomimetic nasal decongestant activity xylometazoline work binding alpha α -adrenergic receptor cause vasoconstriction nasal blood vessel a228508 xylometazoline available over-the-counter otc nasal spray drop temporarily relieve nasal congestion due cold hay fever respiratory allergy country available combination product ipratropium domiphen dexpanthenol ,xylometazoline indicated temporary relief nasal congestion due cold hay fever respiratory allergy l31598 
Dabigatran etexilate,dabigatran etexilate oral prodrug hydrolyzed competitive reversible direct thrombin inhibitor dabigatran a177463 a6970 l34675 l34680 dabigatran etexilate may used decrease risk venous thromboembolic event patient anticoagulation therapy indicated a177463 contrast warfarin anticoagulant effect predictable lab monitoring necessary a177463 dabigatran etexilate approved fda 2010 l6022 ,dabigatran etexilate available oral pellet capsule form dabigatran etexilate pellet indicated treatment venous thromboembolic event vte pediatric patient three month 12 year age treated parenteral anticoagulant least 5 day also indicated age group reduce risk recurrence vte patient previously treated l34675 capsule form dabigatran etexilate indicated adult reduce risk stroke systemic embolism associated non-valvular atrial fibrillation treatment deep venous thrombosis dvt pulmonary embolism pe patient treated parenteral anticoagulant 5-10 day also indicated adult reduce risk recurrence dvt pe patient previously treated prophylaxis dvt pe patient undergone hip replacement surgery lastly indicated pediatric patient eight 18 year age treatment venous thromboembolic event vte patient treated parenteral anticoagulant least 5 day reduce risk recurrence vte patient previously treated l34680 
Arbekacin, semisynthetic aminoglycoside antibiotic often used treatment multi-resistant bacterial infection methicillin-resistant _staphylococcus aureus_ mrsa ,arbekacin used short term treatment multi-resistant bacterial infection methicillin-resistant staphylococcus aureus /i mrsa 
Artemether,artemether antimalarial agent used treat acute uncomplicated malaria administered combination lumefantrine improved efficacy combination therapy exerts effect erythrocytic stage plasmodium spp. /i may used treat infection caused p falciparum /i unidentified plasmodium /i specie including infection acquired chloroquine-resistant area ,artemether lumefantrine combination therapy indicated treatment acute uncomplicated malaria caused plasmodium falciparum /i including malaria acquired chloroquine-resistant area may also used treat uncomplicated malaria plasmodium /i specie identified indicated use adult child greater 5 kg 
Betahistine,ménière 's disease progressive disease inner ear characterized vertigo tinnitus hearing loss significant impact physical social functioning affected individual a220318 l16408 betahistine histamine-like antivertigo drug used treating symptom associated ménière 's disease thought reduce symptom action histamine receptor a220333 l16403 betahistine first approved fda 1970s withdrawn within approximately 5 year due lack evidence supporting efficacy currently marketed canada various company including teva pharmaceutical ,betahistine indicated reduction recurrent vertigo episode associated ménière 's disease patient 18 year old l16388 
Degarelix,degarelix used treatment advanced prostate cancer degarelix synthetic peptide derivative drug bind gonadotropin-releasing hormone gnrh receptor pituitary gland block interaction gnrh antagonism reduces luteinising hormone lh follicle-stimulating hormone fsh ultimately cause testosterone suppression reduction testosterone important treating men advanced prostate cancer chemically synthetic linear decapeptide amide seven unnatural amino acid five d-amino acid fda approved december 24 2008 ,degaralix used management advanced prostate cancer 
Desvenlafaxine,desvenlafaxine o-desmethylvenlafaxine major active metabolite venlafaxine antidepressant serotonin norepinephrine reuptake inhibitor snri class label desvenlafaxine may used treat major depressive disorder label formulated extended release tablet label desvenlafaxine approved fda 2008 l6016 ,desvenlafaxine indicated treatment major depressive disorder adult a6990 a6991 label 
Dexmethylphenidate,dexmethylphenidate dextrorotary form methylphenidate introduced 2002 a177181 norepinephrine-dopamine reuptake inhibitor ndri thus psychostimulant a177193 used treatment attention deficit hyperactivity disorder adhd label a177181 d-isomer thought greater effect fewer side effect l-isomer racemic mixture a177181 ,dexmethylphenidate used treatment adhd ideally conjunction psychological educational behavioral form treatment a177187 label 
Fesoterodine,fesoterodine antimuscarinic prodrug treatment overactive bladder syndrome ,fesoterodine indicated treatment overactive bladder adult patient symptom urge urinary incontinence urgency frequency l37624 also indicated treatment neurogenic detrusor overactivity pediatric patient ≥6 year old weighing 25 kg l37624 
Gadobutrol,intravenous gadobutrol second-generation extracellular non-ionic macrocyclic gbca gadolinium-based contrast agent used magnetic resonance imaging mri adult child older 2 year age may help visualize detect vascular abnormality blood brain barrier bbb central nervous system cns patient impaired renal function gadolinium based contrast agent increase risk nephrogenic systemic fibrosis nsf physician contacted symptom nsf encountered dark red patch skin stiffness joint trouble moving bending straightening arm hand leg foot burning itching swelling scaling hardening tightening skin pain hip bone rib muscle weakness common adverse reaction may experienced include headache nausea feeling hot abnormal taste warmth burning pain local injection site general precaution taken patient pregnant breastfeeding history allergic reaction contrast medium bronchial asthma allergic respiratory disorder ,gadobutrol indicated use magnetic resonance imaging following diagnostic process l40893 detect visualize area disrupted blood-brain barrier and/or abnormal vascularity central nervous system adult pediatric patient including term neonate ass presence extent malignant breast disease adult patient evaluate known suspected supra-aortic renal artery disease adult pediatric patient including term neonate ass myocardial perfusion stress rest late gadolinium enhancement adult patient known suspected coronary artery disease
Iobenguane,synthetic guanethidine derivative locates phaeochromocytoma neuroblastoma radioisotope used either iodine-123 imaging iodine-131 destruction tissue metabolize noradrenaline iodine 123 cyclotron-produced radionuclide decay te 123 electron capture image produced i123 mibg scintigraphy fda approved september 19 2008 ,detection primary metastatic pheochromocytoma neuroblastoma
Gadofosveset trisodium,gadofosveset trisodium intravenous contrast agent used magnetic resonance angiography mra non-invasive way imaging blood vessel agent allows vascular system imaged clearly mra way gadofosveset trisodium used help diagnose certain disorder heart blood vessel ,gadofosveset trisodium indicated use contrast agent magnetic resonance angiography mra evaluate aortoiliac occlusive disease aiod adult known suspected peripheral vascular disease 
Isometheptene,isometheptene sympathomimetic drug cause vasoconstriction used treating migraine tension headache ,isometheptene sympathomimetic drug cause vasoconstriction used treating migraine tension headache 
Levonordefrin,levonordefrin act topical nasal decongestant vasoconstrictor often used dentistry ,used topical nasal decongestant vasoconstrictor dentistry 
Lumefantrine,lumefantrine antimalarial agent used treat acute uncomplicated malaria administered combination artemether improved efficacy combination therapy exerts effect erythrocytic stage plasmodium spp. /i may used treat infection caused p falciparum /i unidentified plasmodium /i specie including infection acquired chloroquine-resistant area ,lumefantrine artemether combination therapy indicated treatment acute uncomplicated malaria caused plasmodium falciparum /i including malaria acquired chloroquine-resistant area may also used treat uncomplicated malaria plasmodium /i specie identified indicated use adult child greater 5 kg 
Methacholine,asthma complex condition associated phenomenon airway hyperresponsiveness ahr smooth muscle airway asm excessively contract response stimulus reducing pulmonary function causing symptom difficulty breathing a229598 a229603 although underlying pathology ahr complex asm contraction stimulated cholinergic agonist activate sub 3 /sub muscarinic receptor stimulate asm contraction a229603 a229618 a229643 methacholine non-specific cholinergic agonist parasympathomimetic act muscarinic receptor lung induce bronchoconstriction l31763 patient ahr lower dose methacholine required induce bronchoconstriction form basis methacholine challenge test diagnose ahr a229648 l31763 methacholine granted fda approval october 31 1986 marketed trademark provocholine® methapharm inc. l31763 ,methacholine indicated adult pediatric patient aged five year older without clinically apparent asthma diagnosis bronchial airway hyperactivity via methacholine challenge test l31763 
Methyltestosterone, synthetic anabolic steroid used treating men testosterone deficiency similar androgen replacement therapy also antineoplastic property used secondarily woman advanced breast cancer methyltestosterone schedule iii drug u ,methyltestosterone anabolic steroid hormone used treat men testosterone deficiency also used woman treat breast cancer breast pain swelling due pregnancy addition estrogen treat symptom menopause 
Naphazoline,naphazoline rapid acting imidazoline sympathomimetic vasoconstrictor ocular nasal artierioles l5804 l5807 act decrease congestion found many counter otc eye drop nasal preparation l5804 l5807 naphazoline first developed 1942 nasal formulation congestion a176609 ,naphazoline indicated use otc eyedrop ocular vasoconstriction nasal preparation nasal congestion a176558 l5804 l5807 
Nilvadipine,nilvadipine calcium channel blocker ccb treatment hypertension , management vasospastic angina chronic stable angina hypertension 
Norelgestromin,norelgestromin drug used contraception norelgestromin active progestin responsible progestational activity occurs woman application ortho evra patch ,norelgestromin used contraception menopausal hormonal therapy norelgestromin may potentially used breast cancer treatment due inhibitory effect estrone sulfatase convert sulfated steroid precursor estrogen pregnancy 
Propylhexedrine,propylhexedrine alpha-adrenergic agonist often used nasal decongestant inhaler used give temporary relief nasal congestion cold allergic rhinitis allergy , used provide temporary symptomatic relief nasal congestion due cold allergy allergic rhinitis 
Potassium Iodide,saturated solution potassium iodide sski used pharmaceutically emergency use patient experiencing acute symptom severe hyperthyroidism also known thyroid storm thyrotoxic crisis sski also used radioiodine-contamination emergency preparation thyrotoxic patient thyroidectomy ,potassium iodide oral antithyroid agent used prevention radioactive iodine uptake thyroid gland nuclear radiation emergency potassium iodide may used adjunct antithyroid agent treatment hyperthyroidism thyrotoxicosis preoperatively induce thyroid involution 
Fospropofol,fospropofol water soluble prodrug converted propofol liver fospropofol short acting hypnotic/sedative/anesthetic agent unlike propofol cause injection-site pain unable activate trpa1 fda approved december 2008 fospropofol schedule iv controlled substance united state controlled substance act , monitored anaesthesia care sedation patient undergoing diagnostic procedure like bronchoscopy colonscopy minor surgical procedure like arthroscopy bunionectomy 
Fosaprepitant,fosaprepitant intravenously administered antiemetic drug prodrug aprepitant aid prevention acute delayed nausea vomiting associated chemotherapy treatment ,fosaprepitant indicated adult pediatric patient ≥6 month age combination antiemetic agent prevention acute delayed nausea vomiting associated initial repeat course highly emetogenic cancer chemotherapy including high-dose cisplatin l40338 also indicated treatment delayed nausea vomiting initial repeat course moderately emetogenic cancer chemotherapy l40338 
Stanozolol,stanozolol synthetic anabolic steroid therapeutic us treating hereditary angioedema stanozolol derived testosterone abused several high profile professional athlete ,stanozolol synthetic anabolic steroid therapeutic us treating c1-inhibitor deficient hereditary angioedema c1-inhibitor protease inhibits complement system part innate immune system biochemical chain reaction assist body removing pathogen body stanozolol may help control attack hereditary angioedema stanozolol administered orally intramuscularly 
Buserelin,buserelin synthetic peptide analog luteinizing hormone-releasing hormone lhrh agonist stimulates pituitary gland 's gonadotrophin-releasing hormone receptor gnrhr used prostate cancer treatment ,buserelin may used treatment hormone-responsive cancer prostate cancer breast cancer estrogen-dependent condition endometriosis uterine fibroid assisted reproduction 
Velaglucerase alfa,velaglucerase alfa gene-activated human recombinant glucocerebrosidase used treatment type 1 gaucher disease caused deficiency lysosomal enzyme glucocerebrosidase additionally velaglucerase alfa also investigated use type 3 gaucher disease ,velaglucerase alfa hydrolytic lysosomal glucocerebroside-specific enzyme indicated long-term enzyme replacement therapy pediatric adult patient type 1 gaucher disease 
Gimatecan,gimatecan orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative ,
Aluminum hydroxide,aluminum hydroxide inorganic salt used antacid basic compound act neutralizing hydrochloric acid gastric secretion subsequent increase ph may inhibit action pepsin increase bicarbonate ion prostaglandin may also confer cytoprotective effect , relief heartburn acid indigestion 
Calcium carbonate,calcium carbonate inorganic salt used antacid basic compound act neutralizing hydrochloric acid gastric secretion subsequent increase ph may inhibit action pepsin increase bicarbonate ion prostaglandin may also confer cytoprotective effect calcium carbonate may also used nutritional supplement treat hypocalcemia , relief heartburn acid indigestion may also used nutritional supplement treat hypocalcemia 
Lornoxicam,lornoxicam chlortenoxicam new nonsteroidal anti-inflammatory drug nsaid oxicam class analgesic anti-inflammatory antipyretic property lornoxicam differs oxicam compound potent inhibition prostaglandin biosynthesis property explains particularly pronounced efficacy drug lornoxicam approved use japan , treatment acute mild moderate pain well pain inflammation joint caused certain type rheumatic disease 
Bufuralol,bufuralol new non-selective -adrenoceptor blocking agent ,
Sparteine,sparteine plant alkaloid derived _cytisus scoparius_ _lupinus mutabilis_ may chelate calcium magnesium sodium channel blocker fall category class 1a antiarrhythmic agent sparteine currently fda-approved human use salt sparteine sulfate one product withdrawn removed market reason safety effectiveness l43942 ,
Aniline,aniline phenylamine aminobenzene organic compound formula c6h5nh2 consisting amine attached benzene ring aniline prototypical aromatic amine precursor many industrial chemical main use manufacture precursor polyurethane like volatile amine posse somewhat unpleasant odour rotten fish aniline colorless slowly oxidizes resinifies air giving red-brown tint aged sample ,
Sulfaphenazole,sulfaphenazole sulfonamide antibacterial , treatment bacterial infection 
Gestodene,gestodene progestogen hormonal contraceptive product containing gestoden include meliane contains 20 mcg ethinylestradiol 75 mcg gestodene gynera contains 30 mcg ethinylestradiol 75 mcg gestodene ,
Seproxetine,seproxetine also known -norfluoxetine selective serotonin reuptake inhibitor ssri active metabolite fluoxetine seproxetine investigated eli lilly antidepressant development never completed drug never marketed ,
beta-Naphthoflavone,"β-naphthoflavone also known 5,6-benzoflavone potent agonist aryl hydrocarbon receptor induces cytochrome p450 cyps uridine 5'-diphospho-glucuronosyltransferases ugts may chemopreventive agent ",
Bafilomycin A1, bafilomycins refer category toxic macrolide antibiotic derivative streptomyces griseus compound appear fermentation similar biological activity bafilomycins specific inhibitor vacuolar-type h+-atpase v-atpase commonly utilized bafilomycin bafilomycin a1 useful tool prevent re-acidification synaptic vesicle undergone exocytosis ,
Aceclofenac,aceclofenac oral non-steroidal anti-inflammatory drug nsaid marked anti-inflammatory analgesic property used treat osteoarthritis rheumatoid arthritis ankylosing spondylitis reported higher anti-inflammatory action least comparable effect conventional nsaid double-blind study a19667 a19668 a19670 aceclofenac potently inhibits cyclo-oxygenase enzyme cox involved synthesis prostaglandin inflammatory mediator cause pain swelling inflammation fever aceclofenac belongs bcs class ii posse poor aqueous solubility a19667 display high permeability penetrate synovial joint patient osteoarthritis related condition loss articular cartilage area cause joint pain tenderness stiffness crepitus local inflammation a19666 aceclofenac also reported effective painful condition dental gynaecological condition a19672 1991 aceclofenac developed analog commonly prescribed nsaid db00586 via chemical modification effort improve gastrointestinal tolerability drug commonly prescribed drug europe ,aceclofenac indicated relief pain inflammation osteoarthritis rheumatoid arthritis ankylosing spondylitis 
Zaltoprofen, non-steroidal anti-inflammatory drug approved use japan 1993 ,
Ketobemidone,ketobemidone powerful opioid analgesic also nmda-antagonist property make useful type pain n't respond well opioids commonly cited equalisation ratio analgesic dos 25 mg ketobemidone hydrobromide 60 mg morphine hydrochloride sulfate circa 8 mg ketobemidone injection , treatment type severe pain postoperative cancer kidney stone fracture 
Seratrodast,seratrodast inn thromboxane receptor antagonist used primarily treatment asthma ,
BW-A 58C,"bw-a 58c also known 2- 4-tert-butylcyclohexyl -3-hydroxy-1,4-naphthoquinone experimental naphthoquinone antimalarial drug undergoes extensive alkyl hydroxylation single t-butylhydroxy metabolite man vivo also human liver microsome catalysed primarily 54 kda cyp2c9 form cytochrome p450 p450hb20-27 ",
Gavestinel,highly potent selective non-competitive antagonist acting strychnine-insensitive glycine binding site nmda receptor-channel complex kd 0.8 nm gavestinel display 1000-fold selectivity nmda ampa kainate binding site orally bioavailable active vivo ,
Ambroxol,ambroxol secretolytic agent used treatment respiratory disease associated viscid excessive mucus active ingredient mucosolvan lasolvan mucoangin substance mucoactive drug several property including secretolytic secretomotoric action restore physiological clearance mechanism respiratory tract play important role body ’ natural defence mechanism stimulates synthesis release surfactant type ii pneumocytes surfactant act anti-glue factor reducing adhesion mucus bronchial wall improving transport providing protection infection irritating agent ,ambroxol indicated secretolytic therapy bronchoplmonary disease abnormal mucus secretion transport allows mucus easily cleared ease patient 's breathing 
Ginkgolide A,ginkgolide highly active paf antagonist cage molecule isolated leaf ginkgo biloba tree show potential wide variety inflammatory immunological disorder ,
Ginsenoside Rb1,ginsenosides class steroid glycoside triterpene saponin found exclusively plant genus panax ginseng ginsenosides target research viewed active compound behind claim ginseng 's efficacy ginsenosides appear affect multiple pathway effect complex difficult isolate rb1 appears abundant panax quinquefolius american ginseng rb1 seems affect reproductive system animal testicle recent research show rb1 affect rat embryo development teratogenic effect causing birth defect another study show rb1 may increase testosterone production male rat indirectly stimulation luteinizing hormone ,
Ginsenoside Rg1,ginsenosides class steroid glycoside triterpene saponin found exclusively plant genus panax ginseng ginsenosides target research viewed active compound behind claim ginseng 's efficacy ginsenosides appear affect multiple pathway effect complex difficult isolate rg1 appears abundant panax ginseng chinese/korean ginseng improves spatial learning increase hippocampal synaptophysin level mouse plus demonstrates estrogen-like activity ,
Drotaverine,drotaverine antispasmodic drug work inhibiting phosphodiesterase-4 pde4 a231619 benzylisoquinoline derivative structurally related papaverine although display potent antispasmodic activity papaverine drotaverine used symptomatic treatment various spastic condition gastrointestinal disease biliary dyskinesia vasomotor disease associated smooth muscle spasm a7036 also investigated dysmenorrhea abortion a231609 augmentation labour a231614 recently drotaverine gained attention treatment benign prostatic hyperplasia parainfluenza avian influenza virus a231619 drotaverine approved fda european medicine agency health canada approved use thailand oral tablet intramuscular injection l22689 ,drotaverine used alleviate gastrointestinal genitourinary smooth muscle spasm cholecystitis gallbladder disorder l22689 
Chymopapain,chymopapain first isolated 1941 crude latex derived fruit carica papaya squeezing green papaya plant prior harvest l2482 extracellular plant cysteine proteinase similar papain specificity a32688 chymopapain developed chart medcl fda approved november 10 1982 currently discontinued l2487 ,chymopapain indicated development chemonucleolysis used digestion nucleus pulposus patient disc herniation confirmed myelography a32687 disc herniation occurs outer portion spinal disc break inner portion nucleus pulposus leak pressing surrounding nerve leading irradiating pain l2496 chemonucleolysis non-surgical treatment involves injection enzyme dissolve nucleus pulposus l2482 
Danaparoid,danaparoid low-molecular-weight heparinoid average molecular weight 5500 dalton consisting mixture glycosaminoglycans a32565 active constituent heparan dermatan db09301 t28 isolated porcine intestinal mucosa fda label danaparoid posse potent antithrombic activity work inhibiting activated factor x factor xa activated factor ii factor iia chemically distinct heparin containing different protein binding property thus lower cross-reactivity heparin-intolerant patient danaproid used treatment heparin-induced thrombocytopenia hit off-label indication prevention post-operative deep venous thrombosis dvt initially approved fda orgaran™ danaparoid withdrawn organon international august 14 2002 due shortage drug substance manufacturer use orgaran™ discontinued united state however available several country including european country japan danaparoid sodium common salt form therapeutic preparation typically administered subcutaneously ,indicated prophylaxis post-operative deep venous thrombosis dvt may lead pulmonary embolism pe patient undergoing elective hip replacement surgery fda label 
Beta carotene,beta-carotene molecular formula c40h56 belongs group carotenoid consisting isoprene unit presence long chain conjugated double bond donates beta-carotene specific color t162 abundant form carotenoid precursor vitamin a. beta-carotene composed two retinyl group antioxidant found yellow orange green leafy vegetable fruit t158 fda beta-carotene considered generally recognized safe substance gras l2191 ,beta-carotene fda approved used nutrient supplement even added infant formula source vitamin l2191 also approved used color additive food product l2192 drug label `` color additive '' l2193 cosmetic l2194 used commonly reduction photosensitivity patient erythropoietic protoporphyria photosensitivity disease a32485 
Betaine,betaine methyl group donor function normal metabolic cycle methionine naturally occurring choline derivative commonly ingested diet role regulating cellular hydration maintaining cell function a252235 a252240 homocystinuria inherited disorder lead accumulation homocysteine plasma urine currently treatment available correct genetic cause homocystinuria however order normalize homocysteine level patient treated vitamin b6 pyridoxine vitamin b12 cobalamin folate specific diet l43115 betaine reduces plasma homocysteine level patient homocystinuria l43105 although present many food product level found insufficient treat condition fda ema approved product cystadane betaine anhydrous oral solution treatment homocystinuria l43105 l43115 ema approved use amversio betaine anhydrous oral powder l43110 ,"betaine indicated treatment homocystinuria pediatric adult patient decrease elevated homocysteine blood level l43105 included within category homocystinuria deficiency defect cystathionine beta-synthase cbs 5,10-methylenetetrahydrofolate reductase mthfr cobalamin cofactor metabolism cbl l43105 "
Manganese,manganese transition metal molar mass 54.94g/mol manganese considered critical human health play important role development metabolism antioxidant system said excessive manganese intake associated manganism neurodegenerative disorder cause dopaminergic neuronal death parkinsonian-like symptom ,indicated use supplement intravenous solution given total parenteral nutrition tpn administration help maintain plasma level prevent depletion endogenous store subsequent deficiency symptom 
Fomivirsen,fomivirsen antisense 21 mer phosphorothioate oligonucleotide antiviral agent used treatment cytomegalovirus retinitis cmv immunocompromised patient including aid complementary nucleotide messenger rna major immediate-early region protein human cytomegalovirus disrupts replication virus antisense mechanism l1428 discovered scientist national institute health nih first developed _isis pharmaceuticals_ subsequently licensed _novartis_ a31990 drug withdrawn fda high unmet need drug treat cmv drug initially discovered developed due cmv arising people aid development haart dramatically reduced number case cmv fomivirsen marketed trade name vitravene intravitreal injection first antisense drug approved food drug administration fda ,indicated local treatment cytomegalovirus cmv retinitis patient acquired immunodeficiency syndrome aid therapy ineffective considered unsuitable fda label l1428 
Sacrosidase,sacrosidase liquid enzyme preparation s.cerevisiae used treatment congenital sucrose-isomaltase deficiency csid people csid variable amount sucrose-isomaltase enzyme activity therefore issue metabolizing dietary disaccharide sucrose causing chronic intermittent watery diarrhea infant child treatment option patient limited usually consists lifelong sucrose-free diet therefore sacrosidase offer potential alternative symptom relief , treatment congenital sucrose-isomaltase deficiency csid 
Beractant,beractant pulmonary surfactant used treatment respiratory distress syndrome rds premature infant considered natural source surfactant made bovine lung extract beractant contains mixture phospholipid neutral lipid fatty acid surfactant-associated protein sp-b sp-c final composition provides 25 mg/ml phospholipid including 11.0-15.5 mg/ml disaturated phosphatidylcholine 0.5-1.75 mg/ml triglyceride 1.4-3.5 mg/ml free fatty acid le 1.0 mg/ml protein suspended 0.9 sodium chloride solution heat-sterilized anticipation birth endogenous lung surfactant produced lower surface tension alveolar surface stabilize alveolus collapse resting transpulmonary pressure however respiratory distress syndrome developmental deficiency surfactant result collapse alveolus causing fast breathing increased heart rate apoxia sometimes death administration lung surfactant remains cornerstone therapy condition currently leading cause death preterm infant comparison synthetic form surfacant natural form beractant found reduced incidence pneumothorax reduced mortality ,beractant indicated prevention treatment respiratory distress syndrome rds premature infant 
Pinacidil,pinacidil cyanoguanidine drug act opening atp-sensitive potassium channel leading peripheral vasodilatation arteriole decreasing peripheral vascular resistance process result reduced blood pressure drug discontinued fda ,
Tetryzoline,tetryzoline also known tetrahydrozoline derivative imidazoline central peripheral alpha α -adrenergic property a231769 available since 1950s tetryzoline selective α sub 1 /sub -receptor agonist a231774 used ocular nasal decongestant tetryzoline found wide array over-the-counter eye drop including common brand visine l32579 tetryzoline also found combination product lubricant anti-irritants povidone polyethylene glycol 400 dextran zinc sulfate l32584 l32589 l32594 also used combination drug class antihistamine corticosteroid glucocorticoid country tetryzoline also found nasal spray trade name tyzine used decongestion nasal nasopharyngeal mucosa l32599 cause profound sedation child adult tetryzoline increasingly becoming scrutinized possible drug overdose toxicity accidental ingestion a7045 a231769 also misused non-therapeutic purpose causative drug several case drug-facilitated sexual assault a231764 ,tetryzoline indicated temporary relief discomfort redness eye due minor eye irritation monotherapy l32579 combination eye lubricant anti-irritants l32584 l32589 l32594 tetryzoline also indicated decongestion nasal nasopharyngeal mucosa l32599 
Alcaftadine,alcaftadine h1 histamine receptor antagonist indicated prevention itching associated allergic conjunctivitis drug approved july 2010 , prevention itching associated allergic conjunctivitis 
Ammonium chloride,ammonium chloride inorganic compound formula nh4cl highly soluble water producing mildly acidic solution ,1 expectorant cough syrup 2 ammonium ion nh4+ body play important role maintenance acid-base balance kidney us ammonium nh4+ place sodium na+ combine fixed anion maintaining acid-base balance especially homeostatic compensatory mechanism metabolic acidosis therapeutic effect ammonium chloride depend upon ability kidney utilize ammonia excretion excess fixed anion conversion ammonia urea liver thereby liberating hydrogen h+ chloride cl– ion extracellular fluid ammonium chloride injection usp dilution isotonic sodium chloride injection may indicated treatment patient 1 hypochloremic state 2 metabolic alkalosis 
Ammonium lactate,ammonium lactate ammonium salt lactic acid , treatment dry scaly skin xerosis ichthyosis vulgaris temporary relief itching associated condition 
Bendamustine,bendamustine nitrogen mustard drug indicated use treatment chronic lymphocytic leukemia cll indolent b-cell non-hodgkin lymphoma nhl progressed within six month treatment rituximab rituximab-containing regimen bendamustine bifunctional mechlorethamine derivative capable forming electrophilic alkyl group covalently bond molecule function alkylating agent bendamustine cause intra- inter-strand crosslinks dna base resulting cell death active active quiescent cell although exact mechanism action unknown ,bendamustine indicated use treatment chronic lymphocytic leukemia cll indolent b-cell non-hodgkin lymphoma nhl progressed within six month treatment rituximab rituximab-containing regimen 
Benzyl alcohol,,ulesfia benzyl alcohol lotion indicated topical treatment head louse infestation patient 6 month age older ulesfia lotion ovicidal activity 
Besifloxacin,besifloxacin fourth generation fluoroquinolone-type opthalmic antibiotic treatment bacterial conjunctivitis fda approved may 28 2009 ,treatment bacterial conjunctivitis bacterial isolates susceptible besifloxacin include cdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius 
Cabazitaxel,cabazitaxel anti-neoplastic used steroid medicine prednisone cabazitaxel used treat people prostate cancer progressed despite treatment docetaxel cabazitaxel prepared semi-synthesis precursor extracted yew needle 10-deacetylbaccatin iii approved u.s. food drug administration fda june 17 2010 , treatment patient hormone-refractory metastatic prostate cancer previously treated docetaxel-containing treatment regimen 
Human calcitonin,calcitonin first discovered isolated parathyroid tissue substance serum-calcium-lowering effect a32099 constituted 32-amino acid single chain polypeptide structure get secreted regulatory agent calcium-phosphorus metabolism a32098 used alternative people developing antibody salmon calcitonin a32100 ,human calcitonin indicated treatment paget 's disease case use salmon calcitonin may provoke generation high-titer antibody a32100 paget 's disease metabolic bone disorder characterized focal area increased disorganized bone turnover coupled increased bone formation majority case asymptomatic clinical manifestation include pain bone deformity complication pathological fracture deafness a32105 increased activity bone associated rise serum level alkaline phosphatase increased urinary excretion hydroxyproline product bone breakdown a32099 
Capsaicin,capsaicin often used topical analgesic exists many formulation cream liquid patch preparation various strength however may also found dietary supplement capsaicin naturally-occurring botanical irritant chili pepper synthetically derived pharmaceutical formulation recent capsaicin fda approval qutenza 8 capsaicin patch dermal-delivery system indicated neuropathic pain associated post-herpetic neuralgia , capsaicin 8 patch indicated treatment neuropathic pain associated post-herpetic neuralgia multiple topical capsaicin formulation available including cream solution indicated temporary analgesia muscle join pain well neuropathic pain 
Carglumic acid,carglumic acid drug used treatment hyperammonemia patient deficiency n-acetyl glutamate synthase rare genetic disorder result elevated blood level ammonia eventually cross blood–brain barrier cause neurologic problem cerebral edema coma death carglumic acid approved u.s. food drug administration fda 18 march 2010 , treatment acute chronic hyperammonaemia patient n-acetylglutamate synthase nag deficiency enzyme important component urea cycle prevent build neurotoxic ammonium blood 
Sodium cellulose phosphate,sodium cellulose phosphate used treat hypercalcemia hypercalciuria used prevent kidney stone a31694 compound ion-exchange resin absorbed body however used restore normal intestinal calcium absorption ,
Chenodeoxycholic acid,chenodeoxycholic acid chenodiol epimer ursodeoxycholic acid db01586 chenodeoxycholic acid bile acid naturally found body work dissolving cholesterol make gallstone inhibiting production cholesterol liver absorption intestine help decrease formation gallstone also reduce amount bile acid harmful liver cell level elevated ,chenodiol indicated patient radiolucent stone well-opacifying gallbladder selective surgery would undertaken except presence increased surgical risk due systemic disease age chenodiol dissolve calcified radiopaque radiolucent bile pigment stone 
Cupric sulfate,cupric sulfate salt created treating cupric oxide sulfuric acid form large bright blue crystal containing five molecule water cuso4∙5h2o also known _blue vitriol_ anhydrous salt created heating hydrate 150 °c 300 °f cupric sulfate used primarily agricultural purpose pesticide germicide feed additive soil additive secondary us raw material preparation copper compound reagent analytic chemistry electrolyte battery electroplating bath medical practice locally applied fungicide bactericide astringent l1820 copper essential trace element important catalyst heme synthesis iron absorption zinc iron copper third abundant trace element found human body copper noble metal property include high thermal electrical conductivity low corrosion alloying ability malleability copper component intrauterine contraceptive device iud release copper necessary important contraceptive effect average daily intake copper usa approximately 1 mg cu diet primary source a32221 interestingly dysregulation copper studied focus neurodegenerative disease wilson ’ disease alzheimer ’ disease parkinson ’ disease data clinical observation neurotoxic effect copper may provide basis future treatment affecting copper homeostasis l1830 ,elemental use copper deficiency l1823 copper copper containing compound broadly used medical practice metallic copper used already many year dental filling copper intrauterine device iud reversible contraception ointment containing copper release copper ion absorbed skin management cramp disturbance renal function peripheral venous hypostatic circulatory disturbance rheumatic disease swelling associated trauma also cosmetic facial cream containing copper main active ingredient l1828 
Dalteparin,dalteparin low molecular weight heparin lmwh prepared nitrous acid degradation unfractionated heparin porcine intestinal mucosa origin anticoagulant composed strongly acidic sulphated polysaccharide chain average molecular weight 5000 90 material within range 2000-9000 lmwhs predictable response greater bioavailability longer anti-xa half life unfractionated heparin dalteparin also safely used pregnant woman low molecular weight heparin le effective inactivating factor iia due shorter length compared unfractionated heparin ,dalteparin used prophylaxis deep-vein thrombosis pulmonary embolism patient undergoing general surgery e.g. abdominal gynecologic urologic patient acute medical condition e.g cancer bed rest heart failure severe lung disease also used patient severely restricted mobility pose risk thromboembolic complication dalteparin also used concomitantly aspirin and/or therapy e.g. nitrate β-adrenergic blocker clopidogrel platelet glycoprotein gp iib/iiia-receptor inhibitor reduce risk acute cardiac ischemic event patient undergo treatment combination unstable angina non-st-segment elevation/non-q-wave myocardial infarction i.e. non-st-segment elevation acute coronary syndrome also used prevention clotting hemodialysis hemofiltration connection acute renal failure chronic renal insufficiency 
Difluprednate,difluprednate topical corticosteroid indicated treatment infammation pain associated ocular surgery butyrate ester 6 α 9 α -difluoro prednisolone acetate difluprednate abbreviated dfba difluoroprednisolone butyrate acetate indicated treatment endogenous anterior uveiti , treatment inflammation pain associated ocular surgery 
Dimercaprol,dimercaprol traditional chelating agent developed british biochemist oxford university world war ii developed experimental antidote arsenic-based poison gas lewisite used clinically since 1949 arsenic cadmium mercury poisoning addition past used treatment wilson 's disease genetic disorder body tends retain copper dimercaprol toxic potential use may followed variety adverse effect , treatment arsenic gold mercury poisoning indicated acute lead poisoning used concomitantly edetate calcium disodium db00974 
Prussian blue,prussian blue described deep blue pigment produced oxidation ferrous ferrocyanide salt occurs contains ferric hexacyanoferrate ii cubic lattice crystal structure insoluble water also tends form colloid thus exist either colloidal water-soluble form insoluble form orally administered clinical purpose used antidote certain kind heavy metal poisoning thallium radioactive isotope caesium prussian blue included world health organization model list essential medicine specific antidote used poisoning provide symptomatic supportive treatment also administered individual exposed 137-cs+ goiânia accident one worst radioactive contamination incident occured brazil 1983 ,indicated treatment patient known suspected internal contamination radioactive cesium and/or radioactive non-radioactive thallium increase rate elimination 
Gallium citrate Ga-67,gallium citrate ga 67 citrate salt radioisotope gallium ga 67 although mechanism unknown gallium ga 67 concentrate lysosome bound soluble intracellular protein certain viable primary metastatic tumor focal site inflammation allowing scintigraphic localization ga-67 scintigraphy g differentiate tumor acute inflammation nci thesaurus ,gallium citrate ga 67 injection may useful demonstrate presence extent hodgkin 's disease lymphoma bronchogenic carcinoma positive gallium ga-67 uptake absence prior symptom warrant follow-up indication potential disease state gallium citrate ga 67 injection may useful aid detecting acute inflammatory lesion 
Ganirelix,ganirelix synthetic decapeptide competitive gonadotropin-releasing hormone gnrh antagonist derived endogenous gnrh ganirelix amino acid substitution ganirelix indicated controlled ovarian hyperstimulation assisted reproduction technique l43045 first case pregnancy achieved use ganirelix assisted reproduction program reported 1998 a252195 ganirelix first approved fda july 29 1999 l43070 ,ganirelix indicated inhibition premature luteinizing hormone lh surge woman undergoing controlled ovarian hyperstimulation assisted reproduction technique art l43040 l43045 
Halcinonide,halcinonide corticosteroid indicated relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis distributed cream ointment halcinonide marketed brand name halog® ranbaxy laboratory inc. research suggests clobetasol propionate demonstrates superior pharmacologic efficacy treatment psoriasis compared halcinonide ,indicated relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis 
Hexocyclium,hexocyclium muscarinic acetylcholine receptor antagonist presumably used treatment gastric ulcer diarrhea available tradename tral marketed abbvie inc. discontinued proton pump inhibitor like db00338 opiate anti-diarrheal agent like db00836 largely replaced use anti-muscarinics treatment gastric ulcer diarrhea due favorable side effect profile , world health organization classifies hexocyclium drug functional gastrointestinal disorder l876 like anti-muscarinic agent hexocyclium likely used treat peptic ulcer diarrhea 
Histrelin,histrelin gonadotropin-releasing hormone gnrh agonist act potent inhibitor gonadotropin administered implant delivering continuous therapeutic dos drug synthetic analog naturally occurring gnrh higher potency histrelin implant non-biodegradable diffusion-controlled hydrogel polymer reservoir containing histrelin acetate need replaced every 52 week l41700 l41715 l41755 initially histrelin implant developed reduce testosterone castration level patient advanced prostate cancer l41715 vantas product approved fda october 2004 palliative treatment condition l41715 vantas later discontinued endo pharmaceutical inc. september 21 2021 l41710 gnrh agonist first line treatment child central precocious puberty cpp due capacity reduce lh level concentration sex steroid product supprelin la histrelin indicated treatment cpp child approved fda may 2007 l41700 , product supprelin la fda histrelin indicated treatment child central precocious puberty cpp l41700 product vantas fda histrelin indicated palliative treatment advanced prostate cancer l41715 
Hydroxyprogesterone caproate,hydroxyprogesterone caproate synthetic steroid hormone similar medroxyprogesterone acetate megestrol acetate ester derivative 17α-hydroxyprogesterone formed caproic acid hexanoic acid hydroxyprogesterone caproate previously marketed trade name delalutin squibb approved u.s. food drug administration fda 1956 withdrawn marketing 1999 u.s. fda approved makena kv pharmaceutical previously named gestiva february 4 2011 prevention preterm delivery woman history preterm delivery sparking pricing controversy ,hydroxyprogesterone caproate indicated prevention spontaneous preterm birth singleton pregnancy woman previously spontaneous preterm birth 1 
Lanreotide,lanreotide drug employed management acromegaly hormonal condition caused excess growth hormone addition symptom caused neuroendocrine tumor especially carcinoid syndrome drug long-acting analog drug somatostatin growth hormone inhibitor lanreotide manufactured company _ipsen pharmaceuticals_ lanreotide acetate marketed _somatuline_ approved several country worldwide including united kingdom australia canada lanreotide first approved use united state fda august 30 2007 ,lanreotide indicated long-term treatment patient acromegaly inadequate response treated surgery and/or radiotherapy l41115 also indicated treatment adult patient unresectable well- moderately-differentiated locally advanced metastatic gastroenteropancreatic neuroendocrine tumor gep-nets improve progression-free survival l41115 lanreotide additionally indicated treatment adult carcinoid syndrome used reduces frequency short-acting somatostatin analog rescue therapy l41115 
Lanthanum carbonate,lanthanum carbonate phosphate binder commonly used clinical practice marketed trade name _fosrenol_ shire pharmaceutical largest pill filled community pharmacy sometimes patient forget fosrenol swallowed whole instead chewed led severe choking prescribed treating high phosphate level mainly found patient chronic kidney disease lanthanum taken meal bind phosphate diet preventing phosphate absorption intestine ,used reduce serum phosphate patient end stage renal disease esrd 
Levopropoxyphene,levopropoxyphene stereoisomer propoxyphene form 2 3r enantiomer sold antitussive removed market 70 t133 levopropoxyphene developed lilly fda approved march 21st 1962 drug presented different dosage administered capsule suspension ,levopropoxyphene used antitussive antitussive medication often recommended treatment cough associated respiratory tract disorder a32160 enantiomer dextropropoxyphene present analgesic effect a32161 
Lodoxamide,lodoxamide mast-cell stabilizer topical administration eye mast-cell stabilizer first one approved cromolyn sodium used treatment ocular hypersensitivity reaction vernal conjunctivitis condition often require treatment anti-inflammatory medication ophthalmic nsaid topical steroid may cause systemic toxic effect long-term although le effective topical steroid decreasing inflammation mast-cell stabilizer offer another treatment option exhibit minimal adverse effect lodoxamide marketed brand name alomide alcon ,indicated treatment ocular disorder referred term vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis 
Mafenide,mafenide sulfonamide-type antimicrobial agent used treat severe burn act reducing bacterial population present burn tissue promotes healing deep burn l36773 1998 mafenide acetate approved fda ’ accelerated approval regulation november 2022 use mafenide acetate powder 5 topical solution withdrawn fda due unresolved confirmatory study required fulfill accelerated approval requirement l44251 ,indicated use adjunctive topical antimicrobial agent control bacterial infection used moist dressing meshed autograft excised burn wound label 
Mangafodipir,mangafodipir contrast agent used diagnostic tool administered intravenously enhance contrast magnetic resonance imaging mri liver pancreas drug made paramagnetic manganese ii ion combined chelating agent _fodipir_ dipyridoxyl diphosphate dpdp manganese absorption tissue make normal tissue appear brighter mri limited abnormal cancerous tissue enhanced contrast mangafodipir improves visualization detection lesion liver formed metastatic disease hepatocellular carcinoma contrast agent present mangafodipir trisodium marketed name teslascan teslascan removed drug product list fda 2003 withdrawn european market 2012 ,indicated use organ-specific paramagnetic contrast agent developed imaging hepatobiliary system detecting lesion liver pancreas 
Mebutamate,mebutamate sedative anxiolytic drug anti-hypertensive blood pressure lowering effect comparable barbiturate around 1/3rd potency secobarbital sedative side effect include dizziness headache ,
Methenamine,methenamine heterocyclic organic compound cage-like structure similar adamantane salt form used treatment urinary tract infection example methenamine hippurate hippuric acid salt methenamine , prophylactic suppressive treatment frequently recurring urinary tract infection long-term therapy considered necessary drug used treat infection used appropriate eradication infection antimicrobial agent 
Methylnaltrexone,methylnaltrexone pheriphally-acting μ-opioid antagonist act gastrointestinal tract decrease opioid-induced constipation without producing analgesic effect withdrawal symptom also weak cyp2d6 inhibitor fda approved 2008 ,treatment opioids induced constipation palliative patient inadequately responding laxative therapy 
Monoctanoin,monoctanoin used dissolve cholesterol gallstone ,
Nepafenac,nepafenac non-steroidal anti-inflammatory prodrug nsaid usually sold prescription eye drop used treat pain inflammation associated cataract surgery , treatment pain inflammation associated cataract surgery 
Niclosamide,niclosamide antihelminthic used treatment tapeworm infection helminth worm multicellular organism infect large number human cause broad range disease 1 billion people infected intestinal nematode many million infected filarial nematode fluke tapeworm even greater problem domestic animal niclosamide marketed u brand name niclocide voluntarily withdrawn market bayer 1996 l11860 , treatment tapeworm intestinal fluke infection taenia saginata beef tapeworm taenia solium pork tapeworm diphyllobothrium latum fish tapeworm fasciolopsis buski large intestinal fluke niclosamide also used molluscicide control schistosomiasis 
Nonoxynol-9,nonoxynol-9 n-9 typical surfactant used vaginal spermicide spermicide locally acting non-hormonal contraceptive present vagina intercourse immobilize/inactivate/damage and/or kill sperm without eliciting systemic effect n-9 use 30 year over-the-counter otc drug cream gel foam condom lubricant commonly used spermicidal contraceptive uk usa several european country spermicide longer market ,nonoxynol 9 surfactant spermicide used contraception spermicidal cream jelly foam gel lubricant also used conjuction method contraception including condom cervical cap diaphragm 
Plerixafor,plerixafor hematopoietic stem cell mobilizer used stimulate release stem cell bone marrow blood patient non-hodgkin lymphoma multiple myeloma purpose stimulating immune system stem cell collected used autologous stem cell transplantation replace blood-forming cell destroyed chemotherapy plerixafor orphan drug status united state european union approved u.s. food drug administration december 15 2008 ,used combination granulocyte-colony stimulating factor g-csf filgrastim mobilize hematopoietic stem cell peripheral blood collection subsequent autologous transplantation patient non-hodgkin ’ lymphoma nhl multiple myeloma mm 
Plicamycin,plicamycin antineoplastic antibiotic produced streptomyces plicatus used treatment testicular cancer paget 's disease bone rarely management hypercalcemia manufacturer discontinued plicamycin 2000 , treatment testicular cancer well hypercalcemia hypercalciuria associated variety advanced form cancer 
Polidocanol,polidocanol sclerosing agent indicated treat uncomplicated spider vein varicose vein ≤1 mm diameter uncomplicated reticular vein varicose vein 1 3 mm diameter lower extremity marketed brand name asclera varithena formula polidocanol structural formula c12h25 och2ch2 noh mean extent polymerization n approximately 9 mean molecular weight approximately 600 ,polidocanol sclerosing agent indicated treat uncomplicated spider vein uncomplicated reticular vein lower extremity 
Povidone-iodine,povidone-iodine stable chemical complex polyvinylpyrrolidone povidone pvp elemental iodine contains 9.0 12.0 available iodine calculated dry basis unique complex discovered 1955 industrial toxicology laboratory philadelphia h. a. shelanski m. v. shelanski vitro testing demonstrate anti-bacterial activity found complex le toxic mouse tincture iodine human clinical trial showed product superior iodine formulation povidone-iodine immediately marketed since become universally preferred iodine antiseptic , topical application treatment prevention infection wound 
Pralatrexate,pralatrexate antifolate treatment relapsed refractory peripheral t-cell lymphoma l37674 pralatrexate developed response due inferior response patient using standard therapy b-cells counterpart a246693 compared methotrexate pralatrexate better accumulation cancer cell a246693 pralatrexate designed higher affinity reduced folate carrier protein overexpressed malignant cell upregulated oncogene a246703 pralatrexate thought better therapeutic window compared antifolate analog due novel target rfc a246703 pralatrexate approved fda september 24 2009 l37674 also studied type lymphoma solid malignancy non-small-cell lung cancer breast cancer bladder cancer a246678 ,pralatrexate indicated treatment relapsed refractory peripheral t-cell lymphoma l37674 
Protokylol,protokylol β-adrenergic receptor agonist used bronchodilator europe united state ,
Pyrithione,pyrithione zinc zinc pyrithione zinc pyridinethione coordination complex consisted pyrithione ligand chelated zinc 2+ ion via oxygen sulfur center crystalline state exists centrosymmetric dimer due dynamic fungistatic bacteriostatic property pyrithione zinc used treat dandruff seborrheic dermatitis dandruff common scalp disease affecting 40 world 's adult population may caused fungi _malassezia globosa_ _m restricta_ a32162 pyrithione zinc commonly found active ingredient otc antidandruff topical treatment shampoo mediates action increasing cellular level copper damaging iron-sulfur cluster protein essential fungal metabolism growth a27132 due low solubility pyrithione zinc released topical formulation deposited retained relatively well onto target skin surface a27133 us pyrithione zinc include additive antifouling outdoor paint algaecide use approved early 1960 's fda a32163 safety effectiveness pyrithione zinc reported decade shown significant estrogenic activity according _in vivo_ _in vitro_ assay a32163 ,indicated treatment dandruff seborrheic dermatitis a27133 
Pyrvinium,pyrvinium anthelmintic effective pinworm several form pyrvinium prepared variable counter anion halide tosylate triflate pamoate pyrvinum 's anti-cancer property currently investigation ,pyrvinium used treatment pinworm infestation t39 
Raltegravir,raltegravir antiretroviral drug produced merck co. used treat hiv infection received approval u.s. food drug administration fda 12 october 2007 first new class hiv drug integrase inhibitor receive approval , treatment hiv-1 infection conjunction antiretrovirals 
Phenylbutyric acid,phenylbutyric acid fatty acid derivative butyric acid naturally produced colonic bacteria fermentation demonstrates number cellular biological effect relieving inflammation acting chemical chaperone a249035 used treat genetic metabolic syndrome neuropathy urea cycle disorder l386 l42105 ,phenylbutyric acid used treatment various condition including urea cycle disorder neonatal-onset deficiency late-onset deficiency disease patient history hyperammonemic encephalopathy phenylbutyric acid must combined dietary protein restriction case essential amino acid supplementation l386 phenylbutyric acid sodium phenylbutyrate used combination tauroursodeoxycholic acid treat amyotrophic lateral sclerosis al adult l42105 l43473 
Sulconazole,sulconazole brand name exelderm broad-spectrum anti-fungal agent available topical cream solution sulconazole nitrate active ingredient imidazole derivative inhibits growth common pathogenic dermatophytes making effective treatment tinea cruris tinea corporis infection ,sulconazole solution 1.0 indicated treatment tinea cruris tinea corporis caused trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum microsporum canis treatment tinea versicolor effectiveness proven tinea pedis athlete ’ foot 
Sulfameter,long acting sulfonamide used leprosy urinary respiratory tract infection ,
Tinzaparin,tinzaparin low molecular weight heparin lmwh produced enzymatic depolymerization unfractionated heparin porcine intestinal mucosa heterogeneous mixture average molecular weight 5500 7500 dalton tinzaparin composed molecule without special site high affinity binding antithrombin iii atiii complex greatly accelerates inhibition factor xa anticoagulant considered antithrombotic tinzaparin must given either subcutaneously parenterally lmwhs le effective inactivating factor iia due shorter length compared unfractionated heparin ,tinzaparin used prevention postoperative venous thromboembolism patient undergoing orthopedic surgery patient undergoing general surgery high risk developing postoperative venous thromboembolism also used treatment deep vein thrombosis and/or pulmonary embolism indicated use preventing clot formation indwelling intravenous line hemodialysis 
Tiopronin,tiopronin prescription thiol drug used primarily treatment severe homozygous cystinuria patient cystinuria excrete high level cystine urine risk kidney stone formation tiopronin used second-line therapy control rate cystine precipitation excretion prevent kidney stone formation used failure non-pharmacological first line treatment consisting increased fluid intake restriction sodium protein urinary alkalinization cystinuria relatively rare disease tiopronin classified orphan drug patented united state similar d-penicillamine use efficacy offer advantage far le adverse effect tiopronin dosed individual basis using close monitoring urinary cystine concentration urinary output tiopronin may also used bind metal nanoparticles wilson 's disease overload copper body investigated use treatment arthritis neuroprotective agent aneurysmal subarachnoid hemorrhage ,tiopronin indicated prevention kidney stone formation patient severe homozygous cystinuria consisting urinary cystine concentration greater 500 mg/day failed treatment non-pharmacological measure increased fluid intake decreased sodium protein intake urine alkalinization 
Triethylenetetramine,triethylenetatramine teta also known trientine potent selective copper ii -selective chelator structural analog linear polyamine compound spermidine spermine teta first developed germany 1861 chelating property first recognized 1925 a19333 initially approved fda 1985 second-line treatment wilson 's disease a19334 teta currently indicated treat adult stable wilson ’ disease de-coppered tolerant penicillamine l41730 teta investigated clinical trial treatment heart failure patient diabetes a18804 a19332 a19333 a19334 a19335 ,triethylenetetramine copper chelator indicated treatment adult patient stable wilson ’ disease de-coppered tolerant penicillamine l41730 
Triptorelin,triptorelin synthetic decapeptide agonist analog luteinizing hormone releasing hormone lhrh possessing greater potency endogenous lhrh triptorelin reversibly represses gonadotropin secretion chronic continuous administration agent effect sustained decrease lh fsh production testicular ovarian steroidogenesis serum testosterone concentration may fall level typically observed surgically castrated men ,triptorelin indicated palliative treatment advanced prostate cancer 
Unoprostone,"unoprostone isopropyl prostaglandin analogue ophthalmic solution 0.15 synthetic docosanoid unoprostone isopropyl chemical name isopropyl z -7- 1r,2r,3r,5s -3,5 dihydroxy-2- 3-oxodecyl cyclopentyl -5-heptenoate main indication unoprostane treatment glucoma ", lowering intraocular pressure patient open-angle glaucoma ocular hypertension intolerant intraocular pressure lowering medication insufficiently responsive failed achieve target iop determined multiple measurement time another intraocular pressure lowering medication 
Viomycin,viomycin tuberactinomycin antibiotic used treat mycobacterium tuberculosis replaced le toxic capreomycin drug bind rna bacterial ribosome inhibit protein synthesis viomycin derived actinomycete _streptomyces puniceus_ ,viomycin essential component drug cocktail currently used fight infection mycobacterium tuberculosis 
Prinaberel,prinaberel estrogen receptor beta agonist ,
CHIR-124,chir-124 potent inhibitor chk1 potentiates cytotoxicity topoisomerase poison vitro vivo ,
1-Dodecanol,1-dodecanol saturated 12-carbon fatty alcohol obtained coconut oil fatty acid floral odor used detergent lubricating oil pharmaceutical mcgraw-hill dictionary scientific technical term 5th ed ,
"N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide","n-ethyl-4- 5- methoxycarbamoyl -2-methylphenyl amino -5-methylpyrrolo 2,1-f 1,2,4 triazine-6-carboxamide solid compound belongs pyrrolotriazines compound containing pyrrolotriazine moiety consists pyrrole ring fused triazine ring n-ethyl-4- 5- methoxycarbamoyl -2-methylphenyl amino -5-methylpyrrolo 2,1-f 1,2,4 triazine-6-carboxamide known target mitogen-activated protein kinase 14 ",
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide, z -2- 2- 4-methylpiperazin-1-yl benzyl diazenecarbothioamide solid compound belongs phenylpiperazines compound containing phenylpiperazine skeleton consists piperazine bound phenyl group drug target protein s100b ,
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide,n- 4-carbamimidoylbenzyl -1- 3-phenylpropanoyl -l-prolinamide solid compound belongs alpha amino acid amide amide derivative alpha amino acid medication target protein prothrombin ,
(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol, 3 -1- 4- but-2-yn-1-yloxy phenyl sulfonyl pyrrolidine-3-thiol solid compound belongs benzenesulfonamides organic compound containing sulfonamide group s-linked benzene ring substance known target disintegrin metalloproteinase domain-containing protein 17 ,
N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide,n- 3-cyclopropyl-1h-pyrazol-5-yl -2- 2-naphthyl acetamide solid compound belongs naphthalene compound containing naphthalene moiety consists two fused benzene ring protein n- 3-cyclopropyl-1h-pyrazol-5-yl -2- 2-naphthyl acetamide target include cyclin-a2 cyclin-dependent kinase 2 ,
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide,n-hydroxy-4- 4- 4- trifluoromethyl phenoxy phenyl sulfonyl tetrahydro-2h-pyran-4-carboxamide solid compound belongs diarylethers organic compound containing dialkyl ether functional group formula ror r r aryl group substance known target disintegrin metalloproteinase thrombospondin motif 5 ,
JNJ-27390467,jnj-27390467 potent nonpeptide inhibitor human mast cell tryptase ,
TO-901317,to-901317 lxralpha lxrbeta agonist ,
Mirdametinib,pd-0325901 used trial studying treatment basic science melanoma solid tumour solid tumor advanced cancer breast neoplasm among others ,
Neflamapimod,neflamapimod used trial studying treatment alzheimer 's disease mild cognitive impairment ,
Nesbuvir,nesbuvir investigated treatment hepatitis c ,
AKI-001,aki-001 aurora kinase inhibitor ,
BMS-564929,bms-564929 investigational therapeutic agent built selective androgen receptor modulator sarm far developed bristol-myers squibb symptomatic treatment andropause ,
R-95845,r-95845 inhibitor hiv-1 reverse transcriptase ,
Acifluorfen,acifluorfen protoporphyrinogen oxidase inhibitor ,
Brefeldin A, metabolite penicillium brefeldianum exhibit wide range antibiotic activity ,
Anisomycin,anisomycin sometimes known flagecidin antibiotic retrieved bacteria _streptomyces griseolus_ drug act inhibit bacterial protein dna synthesis ,
Atrazine,atrazine selective triazine herbicide inhalation hazard low apparent skin manifestation toxicity human acutely poisoned sheep cattle may show muscular spasm fasciculation stiff gait increased respiratory rate adrenal degeneration congestion lung liver kidney merck index 11th ed ,
Azoxystrobin,azoxystrobin methoxyacrylate analog strobilurin fungicide ,
S-23, androgen receptor modulator ,
Andarine,andarine non-steroidal selective androgen receptor modulator ,
Chloramphenicol succinate,chloramphenicol succinate ester prodrug chloramphenicol a192987 chloramphenicol bacteriostatic antibiotic a204065 use chloramphenicol succinate chloramphenicol decreased due risk potentially fatal blood dyscrasia l14174 chloramphenicol succinate granted fda approval 20 february 1959 l12711 ,chloramphenicol succinate indicated treat serious susceptible bacterial infection le dangerous drug ineffective contraindicated l12711 
Tranilast,tranilast antiallergic drug developed kissei pharmaceutical 1982 approved japan south korea management bronchial asthma indication keloid hypertrophic scar added 1993 used treatment allergic disorder asthma allergic rhinitis atopic dermatitis , treatment bronchial asthma keloid hypertrophic scar allergic disorder asthma allergic rhinitis atopic dermatitis 
PD-168393,pd-168393 epidermal growth factor receptor inhibitor ,
2-Hydroxyestradiol,2-hydroxyestradiol classified endogenous steroid catechol estrogen metabolite estradiol also positional isomer estriol a31630 ,
Emodin,emodin investigated treatment polycystic kidney ,
Z-Val-Ala-Asp fluoromethyl ketone,"non-methylated competitive irreversible inhibitor caspase 1 well caspases,1 used directly purified enzyme require esterase hydrolyze o-methyl ester like cell-permeable form z-val-ala-asp o-me fluoromethyl ketone ",
Epitestosterone,"epitestosterone 17-alpha isomer testosterone derived pregnenolone via delta5-steroid pathway via 5-androstene-3-beta,17-alpha-diol epitestosterone act antiandrogen various target tissue ratio testosterone/epitestosterone used monitor anabolic drug abuse ",
Phloretin,phloretin natural dihydrochalcone found apple many fruit ,
Talviraline,talviraline used trial studying treatment hiv infection ,
"2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",metabolic product biphenyl pseudomonas putida ,
Hexestrol, synthetic estrogen used hormonal antineoplastic agent ,
Erteberel,erteberel estrogen receptor beta agonist used trial studying treatment benign prostatic hyperplasia ,
PH-797804,ph-797804 investigated treatment osteoarthritis ,
SU-11652,su-11652 tyrosine kinase inhibitor ,
Pirodavir,pirodavir antipicornavirus agent ,
MK-0731,mk-0731 kinesin spindle protein inhibitor antineoplastic agent ,
ABT-341,abt-341 potent selective dpp-4 inhibitor structure similar sitagliptin 2d 3d structure significantly different a39406 ,
Wortmannin,wortmannin steroid metabolite _penicillium funiculosum_ _talaromyces wortmannii_ fungi drug act nonspecific covalent inhibitor phosphoinositide 3-kinase enzyme pi3ks ,
AMG-208,amg-208 used trial studying treatment cancer tumor oncology prostate cancer oncology patient among others ,
Latrunculin B,latrunculin b 14-membered macrolide attached 2-thiazolidinone moiety isolated red sea sponge _latrunculia magnifica_ ,
LGD-2226, androgen receptor modulator ,
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide,3-fluoro-n-1h-indol-5-yl-5-morpholin-4-ylbenzamide solid compound belongs phenylmorpholines aromatic compound containing morpholine ring benzene ring linked cc cn bond drug target mitogen-activated protein kinase 14 ,
"{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid", compound belongs nitrofuran compound containing furan ring bear nitro group target protein aldose reductase ,
"6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine","6-ethyl-5- 2 -1- 3-methoxypropyl -2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl pyrimidine-2,4-diamine solid compound belongs phenylquinolines heterocyclic compound containing quinoline moiety substituted phenyl group substance target protein renin ",
AT-7519,at7519 selective inhibitor certain cyclin dependent kinase cdks leading tumour regression developed astex treatment solid tumour haematological malignancy ,investigated use/treatment leukemia unspecified lymphoma unspecified myelodysplastic syndrome solid tumor 
Fasudil,fasudil investigated carotid stenosis ,
Emivirine,emivirine used trial studying treatment hiv infection ,
"(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide"," 1s,2r,3s,4r,5r -2,3,4-trihydroxy-n-octyl-6-oxa-8-azabicyclo 3.2.1 octane-8-carbothioamide solid compound belongs oxepanes compound containing oxepane ring seven-member saturated aliphatic heterocycle one oxygen six carbon atom drug target protein beta-glucosidase ",
"2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester","2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester solid compound belongs naphthalenecarboxylic acid derivative compound containing napthalene moiety ring carbon bear carboxylic acid group derivative drug target protein neocarzinostatin ",
"2,6-dicarboxynaphthalene","2,6-dicarboxynaphthalene solid compound belongs naphthalenecarboxylic acid compound containing napthalene moiety ring carbon bear carboxylic acid group drug target protein hemoglobin subunit alpha hemoglobin subunit beta ",
N-(carboxycarbonyl)-D-phenylalanine,n- carboxycarbonyl -d-phenylalanine solid compound belongs n-acyl-alpha amino acid compound containing alpha amino acid bear acyl group terminal nitrogen atom target protein hypoxia-inducible factor 1-alpha inhibitor ,
"(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene"," 1r 2 -cis 1,2 dihydroxy-1,2-dihydronaphthalene solid compound belongs naphthalene compound containing naphthalene moiety consists two fused benzene ring known drug target 1r 2 -cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta naphthalene 1,2-dioxygenase subunit alpha ",
"6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one","6-amino-4- 2-phenylethyl -1,7-dihydro-8h-imidazo 4,5-g quinazolin-8-one solid compound belongs stilbenes organic compound containing 1,2-diphenylethylene moiety stilbenes c6-c2-c6 derived common phenylpropene c6-c3 skeleton building block introduction one hydroxyl group phenyl ring lead stilbenoids known target queuine trna-ribosyltransferase ",
Nocodazole,nocodazole antineoplastic agent exerts effect depolymerizing microtubule ,
Gosogliptin,gosogliptin used trial studying treatment renal insufficiency chronic ,
"2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","phip 2-amino-1-methyl-6-phenylimidazo 4,5-b pyridine used trial studying basic science pancreas cancer ",
Puromycin,puromycin antibiotic prevents bacterial protein translation utilized selective agent laboratory cell culture puromycin toxic prokaryotic eukaryotic cell resulting significant cell death appropriate dos ,
Parecoxib,parecoxib water-soluble injectable prodrug valdecoxib marketed dynastat european union parecoxib cox2 selective inhibitor category celecoxib celebrex rofecoxib vioxx injectable used perioperatively patient unable take oral medication approved much europe short term perioperative pain control much way ketorolac toradol used united state letter non-approval parecoxib issued fda 2005 ,used short term perioperative pain control 
MK-4965,mk-4965 hiv-1 reverse transcriptase inhibitor ,
(R)-Fluoxetine, n-methyl-3-phenyl-3- 4- trifluoromethyl phenoxy propan-1-amine r configuration antidepressant drug fluoxetine racemate comprising equimolar amount r -fluoxetine ,
CTS-1027,cts-1027 used trial studying treatment hepatitis c chronic hepatitis c virus infection ,
(R)-warfarin,warfarin consists racemic mixture two active enantiomers—r- s- forms—each cleared different pathway s-warfarin 2-5 time potent r-isomer producing anticoagulant response a1038 ,
Capravirine,,investigated use/treatment acquired immune deficiency syndrome aid aids-related infection hiv infection 
(S)-Fluoxetine, n-methyl-3-phenyl-3- 4- trifluoromethyl phenoxy propan-1-amine configuration antidepressant drug fluoxetine racemate comprising equimolar amount r -fluoxetine ,
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",potent reversible inhibitor phenylethanolamine n-methyltransferase ,
(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid, 1r -1- 2-thienylacetylamino -1-phenylmethylboronic acid solid compound belongs benzene substituted derivative aromatic compound containing least one benzene ring medication target protein beta-lactamase ,
"(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime"," 1e -5- 1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl -2,3-dihydro-1h-inden-1-one oxime solid compound belongs phenylpyrazoles compound containing phenylpyrazole skeleton consists pyrazole bound phenyl group target protein serine/threonine-protein kinase b-raf ",
N-(3-carboxypropanoyl)-L-norvaline,n- 3-carboxypropanoyl -l-norvaline solid compound belongs n-acyl-alpha amino acid compound containing alpha amino acid bear acyl group terminal nitrogen atom medication known target n-acetylornithine carbamoyltransferase putative ornithine carbamoyltransferase ,
"1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline","1- 3-bromophenyl -7-chloro-6-methoxy-3,4-dihydroisoquinoline solid compound belongs isoquinolines derivative aromatic polycyclic compound containing isoquinoline moiety consists benzene ring fused pyridine ring forming benzo c pyridine medication known target mitogen-activated protein kinase 10 ",
"N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide","n- 2s,4s,6r -2- dihydroxymethyl -4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo 3.2.0 hept-6-yl -2-phenylacetamide solid compound belongs penicillin organic compound containing penicillin core structure structurally characterized penam ring bearing two methyl group position 2 amide group position 6 starting sulfur atom position 1 drug known target penicillin g acylase ",
Sinapic acid,sinapic acid matrix matrix-assisted laser desorption technique protein mw determination also constituent propolis ,
Triclosan," aromatic ether phenol substituted c-5 chloro group c-2 2,4-dichlorophenoxy group widely used preservative antimicrobial agent personal care product soap skin cream toothpaste deodorant well household item plastic chopping board sport equipment shoe ",triclosan used variety common household product including soap mouthwash dish detergent toothpaste deodorant hand sanitizers also used health care setting surgical scrub personnel hand wash 
Thiorphan, potent inhibitor membrane metalloendopeptidase enkephalinase thiorphan potentiates morphine-induced analgesia attenuates naloxone-precipitated withdrawal symptom ,
TNP-470,o- chloroacetylcarbamoyl fumagillol tnp-470 used trial studying treatment hiv infection sarcoma kaposi pancreatic neoplasm ,
Dapivirine,dapivirine investigated prevention hiv-1 infection topical penile exposure ,
5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine,5-imino-4- 3-trifluoromethyl-phenylazo -5h-pyrazol-3-ylamine solid compound belongs benzene substituted derivative aromatic compound containing least one benzene ring drug target protein methionine aminopeptidase ,
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine,4- 4-fluoro-phenylazo -5-imino-5h-pyrazol-3-ylamine solid compound belongs fluorobenzenes compound containing one fluorine atom attached benzene ring substance target protein methionine aminopeptidase ,
3-(5-Amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid,3- 5-amino-3-imino-3h-pyrazol-4-ylazo -benzoic acid solid compound belongs aminobenzoic acid derivative benzoic acid derivative thereof containing amine group attached benzene moiety 3- 5-amino-3-imino-3h-pyrazol-4-ylazo -benzoic acid target protein methionine aminopeptidase ,
FG-2216, orally active prolyl-hydroxylase inhibitor stabilize hypoxia-inducible transcription factor independent oxygen availability a14422 ,investigated use/treatment anemia kidney disease 
"5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole","5- 5- 4- 4,5-dihydro-2-oxazoly phenoxy pentyl -3-methyl osoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring drug known target genome polyprotein ",
"5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole","5- 5- 2,6-dichloro-4- 4,5-dihydro-2-oxazolyl phenoxy pentyl -3- hydroxyethyl oxymethyleneoxymethyl isoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring 5- 5- 2,6-dichloro-4- 4,5-dihydro-2-oxazolyl phenoxy pentyl -3- hydroxyethyl oxymethyleneoxymethyl isoxazole target protein genome polyprotein ",
5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole,5- 7- 6-chloro-4- 5-hydro-4-methyl-2-oxazolyl phenoxy heptyl -3-methyl isoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring 5- 7- 6-chloro-4- 5-hydro-4-methyl-2-oxazolyl phenoxy heptyl -3-methyl isoxazole target protein genome polyprotein ,
WIN-54954,win-54954 broad-spectrum antipicornavirus drug ,
5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole,5- 5- 4- 5-hydro-4-methyl-2-oxazolyl phenoxy pentyl -3-methyl isoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring medication known target genome polyprotein ,
"(S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole"," -5- 7- 4- 4-ethyl-4,5-dihydro-2-oxazolyl phenoxy heptyl -3-methylisoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring substance target protein genome polyprotein ",
"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole","5- 7- 4- 4,5-dihydro-2-oxazolyl phenoxy heptyl -3-methyl isoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring known drug target 5- 7- 4- 4,5-dihydro-2-oxazolyl phenoxy heptyl -3-methyl isoxazole include genome polyprotein ",
"3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole","3-methyl-5- 7- 4- 4r -4-methyl-4,5-dihydro-1,3-oxazol-2-yl phenoxy heptyl -1,2-oxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring 3-methyl-5- 7- 4- 4r -4-methyl-4,5-dihydro-1,3-oxazol-2-yl phenoxy heptyl -1,2-oxazole known target genome polyprotein ",
"5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole","5- 3- 2,6-dichloro-4- 4,5-dihydro-2-oxazolyl phenoxy propyl -3-methyl isoxazole solid compound belongs phenol ether aromatic compound containing ether group substituted benzene ring known drug target 5- 3- 2,6-dichloro-4- 4,5-dihydro-2-oxazolyl phenoxy propyl -3-methyl isoxazole include genome polyprotein ",
Casimiroin,casimiroin quinone reductase 2 inhibitor isolated _casimiroa edulis_ ,
Y-27632,y-27632 inhibitor rho-associated protein kinase inhibits calcium sensitization affect smooth muscle relaxation ,
Diloxanide,"diloxanide diloxanide furoate anti-protozoal drug used treatment entamoeba histolytica protozoal infection although currently approved use united state approved cdc study treatment 4,371 case entamoeba histolytica 1977 1990 ",diloxanide used alone primary agent treatment asymptomatic cyst passer intestinal amebiasis caused entamoeba histolytica diloxanide may also used concurrently sequentially agent nitroimidazoles eg metronidazole treatment invasive extraintestinal form amebiasis 
Ethyl biscoumacetate,ethyl biscoumacetate courmarin used anticoagulant action similar warfarin martindale extra pharmacopoeia 30th ed p226 ,
Azidocillin,azidocillin penicillin antibiotic similir ampicillin , treatment infection respiratory gi uti meningitis due e. coli p. mirabilis enterococci shigella s. typhosa salmonella nonpenicillinase-producing n. gononhoeae h. influenzae staphylococci streptococci including streptoc
Pipazethate, non-narcotic oral antitussive agent , treatment cough 
Salicylamide,salicylamide common name substance o-hydroxybenzamide amide salicyl salicylamide non-prescription drug analgesic antipyretic property similar medicinal us aspirin salicylamide used combination aspirin caffeine over-the-counter pain remedy,
Sulfamoxole,sulfamoxole antibacterial sulfonamide class , treatment bacterial infection 
Antazoline,antazoline 1st generation antihistamine anticholinergic activity used relieve nasal congestion also formulated eye drop naphazoline relieve allergic conjunctivitis ,used relieve nasal congestion eye drop usually combination naphazoline relieve symptom allergic conjunctivitis 
Chloropyramine,chlorpyramine first generation antihistamine used eastern european country treat bronchial asthma well allergice rhinitis allergic conjunctivitis allergic reaction also indicated quincke 's edema allergic reaction insect bite food drug allergy anaphylactic shock , treatment allergic conjunctivitis allergic rhinitis bronchial asthma atopic allergic condition 
Dimetindene,dimetindene fenistil antihistamine/anticholinergic used orally locally antipruritic ,indicated symptomatic treatment allergic reaction urticaria allergy upper respiratory tract hey fever perennial rhinitis food drug allergy pruritus various origin except pruritus due cholestasis insect bite dimethindene also indicated pruritus eruptive skin disease chicken-pox dimethindene also used adjuvant eczema pruriginous dermatosis allergic origin 
Isothipendyl,isothipendyl antihistamine anticholinergic used antipruritic , topical treatment itching associated allergic reaction 
Tymazoline,tymazoline nasal preparation , treatment inflammation lining nose paranasal sinus allergic inflammation nasopharyngeal 
Nandrolone decanoate,nandrolone decanoate also known nandrolone caprinate alkylated anabolic steroid indicated management anemia renal insufficiency adjunct therapy treatment senile postmenopausal osteoporosis a233789 a233849 l32564 l9464 process creating ester nandrolone patented spain 1959 l33244 1960 described long duration action strong anabolic effect compared nandrolone ester a233849 nandrolone decanoate granted fda approval 5 october 1962 l32564 ,nandrolone decanoate indicated management anemia renal insufficiency l32564 canada also indicated adjunct therapy treatment senile postmenopausal osteoporosis l9464 
Metiamide,metiamide h-2 receptor antagonist derived burimamide intermediate product path developing cimetidine ,potential treatment management acid-reflux disorder gerd peptic ulcer disease heartburn acid indigestion 
Roxatidine acetate,roxatidine acetate specific competitive h2 receptor antagonist currently approved south africa tradename roxit , treatment disorder upper gastro-intestinal region due excess hydrochloric acid gastric juice i.e duodenal ulcer benign gastric ulcer also prophylaxis recurrent gastric duodenal ulcer
Bopindolol,bopindolol inn ester prodrug beta blocker pindolol , management hypertension edema ventricular tachycardia atrial fibrillation 
Bupranolol,bupranolol non-selective beta blocker potency similar propanolol intrinsic sympathomimetic activity isa strong membrane stabilizing activity ,used manage hypertension tachycardia also used treat glaucoma 
Dichloroacetic acid,dichloroacetic acid often abbreviated dca acid analogue acetic acid two three hydrogen atom methyl group replaced chlorine atom salt dca used drug since inhibit enzyme pyruvate dehydrogenase kinase early report activity brain cancer cell led patient treat dca commercially available non-pharmaceutical grade phase 1 study 5 patient concluded dca safe n't designed establish effectiveness dca approved use canada 1989 topical formulation treatment wart cauterization removal wide variety skin tissue lesion cancelled post market ,
Cinitapride,cinitapride gastroprokinetic agent antiulcer benzamide agonist activity 5-ht1 5-ht4 receptor antagonist activity 5-ht2 receptor marketed spain mexico , indicated treat gastrointestinal disorder associated motility disturbance like gastroesophageal reflux disease gerd non-ulcer dyspepsia delayed gastric emptying 
Tofisopam,"tofisopam marketed brand name emandaxin grandaxin 2,3-benzodiazepine drug benzodiazepine derivative contrast classical 1,4-benzodiazepines compound bind benzodiazepine binding site gamma-aminobutyric acid receptor psychopharmacological profile differs compound although tofisopam approved sale north america approved use various country worldwide including part europe d-enantiomer dextofisopam currently phase ii trial u.s. treatment irritable bowel syndrome ", treatment anxiety alcohol withdrawal 
Nadroparin,nadroparin low molecular weight heparin lmwh bound antithrombin iii atiii accelerates inactivation factor ii factor xa nadroparin halt coagulation pathway inhibiting activation thrombin factor iia factor xa amplification fibrin clotting cascade stopped factor xa iia inactivated derived porcine source mean molecular size 5000 dalton low molecular weight heparin le effective inactivating factor iia due shorter length compared unfractionated heparin ,nadroparin used prophylaxis thromboembolic disorder general surgery orthopedic surgery treatment deep vein thrombosis prevention clotting hemodialysis treatment unstable angina non-q wave myocardial infarction 
Triflusal,triflusal 2-acetoxy-4-trifluoromethylbenzoic acid aspirin chemically-related molecule derivative benefit agent lack action arachidonic acid pathway driven production nitric oxide increase cyclic nucleotide concentration endothelial cell latest translates expansion peripheral blood vessel a31675 important secondary prevention ischemic stroke offering lower risk bleeding a31676 developed j. uriach company even though commercialized different country approved fda ema healthcanada ,triflusal indicated prophylaxis thromboembolic disorder l1185 registered spain country europe south america south korea prevention stroke myocardial infarction t93 
Lurasidone,lurasidone atypical antipsychotic developed dainippon sumitomo pharma approved u.s. food drug administration fda treatment schizophrenia october 29 2010 currently pending approval treatment bipolar disorder united state ,lurasidone indicated treatment schizophrenia patient ≥13 year old l16103 also indicated monotherapy treatment bipolar depression patient ≥10 year old combination lithium valproate treatment bipolar depression adult l16103 
Ticagrelor,ticagrelor azd6140 first described literature 2003 a204170 a2903 ticagrelor adp derivative developed p2y sub 12 /sub receptor antagonism a2903 unlike clopidogrel ticagrelor prodrug a2903 marketed astra zeneca brilinta u l14201 brilique possia eu l14207 ticagrelor granted ema approval 3 december 2010 l14207 ticagrelor granted fda approval 20 july 2011 l14201 ,ticagrelor indicated reduce risk cardiovascular death myocardial infarction stroke patient acute coronary syndrome history myocardial infarction l14201 ticagrelor also indicated reduce risk first myocardial infarction stroke high risk patient coronary artery disease l14201 
Hyaluronic acid,hyaluronic acid ha anionic nonsulfated glycosaminoglycan found connective epithelial neural tissue first isolated 1934 karl meyer john palmer obtained glycosaminoglycan gag bovine eye giving name “ hyaluronic acid ” ha involved many important physiological process including limited wound healing tissue regeneration joint lubrication demonstrates unique viscoelasticity moisturizing anti-inflammatory quality important property prove beneficial various clinical application a230128 ha used drug delivery system treatment cancer ophthalmological condition joint condition aesthetic imperfection a230133 several preparation hyaluronic acid approved fda available oral topical injectable form popular use hyaluronic acid recent year cosmetic injection due ability minimize appearance wrinkle aging-related skin imperfection l32193 , intra-articular preparation hyaluronic acid indicated knee pain associated osteoarthritis l32228 hyaluronic acid used cosmetic application prevent reduce appearance wrinkle face dermal filler correct facial imperfection imperfection part body l32208 l32223 frequently ingredient topical application wound healing symptomatic treatment skin irritation various cause l32198 hyaluronic acid may also indicated ophthalmological preparation oral capsule treat discomfort caused dry eye conjunctivitis protective quality eye surgery a230128 l32213 finally hyaluronic acid used off-label coat bladder relief interstitial cystitis symptom a230533 
Tafluprost, prostaglandin analogue ester prodrug used topically eye drop control progression glaucoma management ocular hypertension chemically tafluprost fluorinated analog prostaglandin f2-alpha tafluprost approved use u.s. february 10 2012 ,tafluprost indicated reducing elevated intraocular pressure patient open-angle glaucoma ocular hypertension 
Ivacaftor,ivacaftor also known kalydeco vx-770 drug used management cystic fibrosis cf manufactured distributed vertex pharmaceutical approved food drug administration january 31 2012 l768 health canada late 2012 l6841 ivacaftor administered monotherapy also administered combination drug management cf l6814 l6979 l6847 cystic fibrosis autosomal recessive disorder caused one several different mutation gene cystic fibrosis transmembrane conductance regulator cftr protein ion channel involved transport chloride sodium ion across cell membrane cftr active epithelial cell organ lung pancreas liver digestive system reproductive tract alteration cftr gene result altered production misfolding function protein consequently abnormal fluid ion transport across cell membrane a20298 a20299 result cf patient produce thick sticky mucus clog duct organ produced making patient susceptible complication infection lung damage pancreatic insufficiency malnutrition a20302 prior development ivacaftor management cf primarily involved therapy control infection nutritional support clearance mucus management symptom rather improvement underlying disease process lung function fev1 notably ivacaftor first medication approved management underlying cause cf abnormality cftr protein function rather control symptom a20297 , used monotherapy product kalydeco ivacaftor indicated treatment cystic fibrosis cf patient aged four month older one mutation cftr gene responsive ivacaftor potentiation based clinical and/or _in vitro_ assay data l6979 l41320 used combination drug lumacaftor product orkambi ivacaftor indicated management cf patient aged one year older homozygous _f508del_ mutation cftr gene patient ’ genotype unknown fda-cleared cf mutation test used detect presence _f508del_ mutation allele cftr gene l43060 used combination tezacaftor product symdeko used manage cf patient 12 year older least one mutation cftr gene patient aged 12 older shown homozygous f508del mutation l6814 used combination tezacaftor elexacaftor product trikafta indicated treatment cystic fibrosis patient 12 year age older least one _f508del_ mutation cftr gene l9395 
Azilsartan medoxomil,azilsartan medoxomil prodrug broken azilsartan belongs angiotensin-receptor blocking arb drug class selective at1 subtype angiotensin ii receptor antagonist azilsartan medoxomil relatively recently-developed antihypertensive drug first approved fda february 2011 a7354 many guideline recommend use arb first-line therapy initiating antihypertensive therapy indicate clinical efficacy arb comparable angiotensin-converting enzyme ace inhibitor also used first-line treatment hypertension a232863 azilsartan medoxomil marketed brand name edarbi used treat hypertension monotherapy combination antihypertensive drug also available combination product chlorthalidone hypertension major risk factor cardiovascular disease a7354 early management hypertension several implication patient survival rate quality life future lowering blood pressure associated reduced risk fatal nonfatal cardiovascular event primarily stroke myocardial infarction l32918 azilsartan medoxomil thus speculated lower mortality rate onset cardiovascular disease although clinical significance yet determined azilsartan medoxomil may potential off-label us patient history myocardial infarction heart failure a232863 ,azilsartan medoxomil indicated treatment hypertension lower blood pressure patient 18 year age may used either alone combination antihypertensive agent antihypertensive drug lesser effect blood pressure black patient l32918 azilsartan medoxomil available fixed-dose combination product chlorthalidone indicated treatment hypertension patient whose hose blood pressure adequately controlled monotherapy may used initial therapy patient likely need multiple drug achieve blood pressure goal l32923 azilsartan medoxomil belongs angiotensin-receptor blocking arb class drug used decrease progression moderate-to-severe albuminuria prevent recurrence atrial fibrillation off-label us patient diabetes mellitus hypertension a232863 
Spinosad,spinosad pediculicide mixture spinosyn spinosyn approximately 5:1 ratio respectively used topical treatment head louse child four year old older adult spinosad insecticide based compound found s. spinosa bacterial specie spinosad also experimented use cat treatment flea infestation also experimented use ks1 ctenocephalides felis flea strain infesting dog addition many investigation use animal agricultural plant ,spinosad indicated topical treatment head louse infestation adult pediatric patient ≥6 month old l146 also indicated topical treatment scabies infestation adult pediatric patient ≥4 year old l146 
Ioflupane I-123,ioflupane i-123 radiopharmaceutical used image dopamine neuron diagnose parkinsonian syndrome ,ioflupane i-123 spect single photon emission computerized tomography agent used distinguish parkinson ’ syndrome tremor essential tremor 
Deferiprone,deferiprone oral iron chelator used second line agent thalassemia syndrome iron overload blood transfusion occurs thalassemia type hereditary anaemia due defect production hemoglobin result erythropoiesis production new red blood cell impaired fda approved october 14 2011 ,deferiprone indicated thalassemia syndrome first line chelation agent adequate treat transfusional iron overload 
Lomitapide,lomitapide microsomal triglyceride transfer protein mtp inhibitor used homozygous familial hypercholesterolemia hofh patient marketed name juxtapid r ,used homozygous familial hypercholesterolemia hofh patient reduce low-density lipoprotein cholesterol ldl-c total cholesterol tc apolipoprotein b apo b non-high-density lipoprotein cholesterol non-hdl-c 
Vismodegib,vismodegib inhibits hedgehog signalling pathway indicated treatment adult basal cell carcinoma fda approved jan 30 2012 ,vismodegib used treating locally advanced metastatic basal cell carcinoma patient whose carcinoma recurred surgery patient candidate surgery radiation 
Dehydroascorbic acid,"dehydroascorbic acid made oxidation ascorbic acid reaction reversible dehydroascorbic acid instead undergo irreversible hydrolysis 2,3-diketogulonic acid dehydroascorbic acid well ascorbic acid termed vitamin c latter main form found human body dehydroascorbic acid ascorbic acid similar biological activity antiviral dehydroascorbic acid also neuroprotective effect currently dehydroascorbic acid experimental drug known approved indication ", approved indication dehydroascorbic acid potential therapeutic use patient certain virus ischemic stroke 
2-deoxyglucose,2-deoxyglucose predominantly used diagnostic agent radiolabelled form fluorine-18 used radiolabel using positron emission tomography pet radiolabelled 2-deoxyglucose determine glucose metabolism altered disease cardiovascular disease tumor alzheimer 's disease therapeutically 2-deoxyglucose investigational drug studied anticancer antiviral agent concerning former 2- deoxyglucose used adjunct chemotherapy radiotherapy treatment solid tumor lung breast pancreas head neck gastric tumor exact mechanism action 2-deoxyglucose still investigated known hypoxic cancer cell 2-deoxyglucose glycolysis inhibitor prevents atp production ultimately cell survival respect antiviral therapy 2-deoxyglucose shown effective herpes simplex virus affecting virus ability penetrate cell experimental drug 2-deoxyglucose demonstrated work anticonvulsant temporal lobe epilepsy condition 2-deoxyglucose represses expression certain protein high level seizure although several possible therapeutic indication 2-deoxyglucose presently approved indication 2-deoxyglucose therapeutic agent , july 2013 approved therapeutic indication 2-deoxyglucose 2-deoxyglucose may several potential indication adjunct chemotherapy radiotherapy treatment solid tumor antiviral treatment herpes simplex patient antiepileptic temporal lobe epilepsy patient 
Taurochenodeoxycholic acid,taurochenodeoxycholic acid experimental drug normally produced liver physiologic function emulsify lipid cholesterol bile medication taurochenodeoxycholic acid reduces cholesterol formation liver likely used choleretic increase volume bile secretion liver cholagogue increase bile discharge duodenum also investigated role inflammation cancer therapy ,taurochenodeoxycholic acid likely indicated choleretic cholagogue also investigated role inflammation cancer therapy 
Tauroursodeoxycholic acid,tauroursodeoxycholic acid also known ursodoxicoltaurine highly hydrophilic tertiary bile acid a249070 produced human low concentration a249070 taurine conjugate ursodeoxycholic acid a249065 comparable therapeutic efficacy safety a249070 much higher hydrophilicity a249060 normally hydrophilic bile acid regulates hydrophobic bile acid cytotoxic effect tauroursodeoxycholic acid reduce absorption cholesterol small intestine thereby reducing body 's intake dietary cholesterol body cholesterol content a249080 tauroursodeoxycholic acid currently used europe treat prevent gallstone bile acid derivative l17040 due range molecular property namely anti-apoptotic effect tauroursodeoxycholic acid examined inflammatory metabolic disease neurodegenerative disease a249065 a249070 ,tauroursodeoxycholic acid used prevent treat gallstone formation l17040 tauroursodeoxycholic acid used combination phenylbutyric acid treat amyotrophic lateral sclerosis al adult l42105 l43473 
Spaglumic acid,spaglumic acid β-aspartyl isoform n-acetyl-l-aspartylglutamate isospaglumic acid n- n-acetyl-l-α-aspartyl -l-glutamic acid eye drop spaglumic acid either magnesium sodium salt n-acetyl-l-aspartylglutamate spaglumic acid mast cell stabilizer thus used allergic condition allergic conjunctivitis specifically spaglumic acid approved portugal brand name naabak greece brand name naaxia use patient allergic conjunctivitis ,used patient allergic conjunctivitis 
Temocapril,temocapril prodrug-type angiotensin-i converting enzyme ace inhibitor approved use united state approved japan south korea temocapril also used hemodialysis patient without risk serious accumulation ,temocapril ace inhibitor primarily indicated treatment hypertension congestive heart failure diabetic nephropathy improvement prognosis coronary artery disease including acute myocardial infarction 
Tetraethylammonium,tetraethylammonium experimental drug approved indication marketed formulation marketed drug containing tetraethylammonium combination drug called fosglutamina b6 drug discontinued experimental agent tetraethylammonium used salt form tetraethylammonium chloride tetraethylammonium bromide mechanism action still investigated known tetraethylammonium block autonomic ganglion calcium- voltage- activated potassium channel nicotinic acetylcholine receptor inhibitory action autonomic ganglion tetraethylammonium thought potential therapeutic vasodilator serious toxic effect found common use tetraethylammonium presently pharmacological research agent block selective potassium channel structurally tetraethylammonium positively charged due central quaternary ammonium ,tetraethylammonium experimental drug approved indication 
Agmatine,agmantine natural metabolite amino acid arginine formed arginine decarboxylated enzyme arginine decarboxylase found naturally ragweed pollen ergot fungi octopus muscle herring sperm sponge mammalian brain agmatine experimental investigational drug investigational drug studied non-blinded prospective case study united state looking patient diagnosed small fiber peripheral neuropathy age 18 75 year july 2013 result study yet published experimental drug agmatine studied several indication cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injury epilepsy glaucoma neuropathic pain psychiatric condition depression anxiety schizophrenia cognition exact mechanism action still investigated potential indication agmatine ,agmatine studied experimentally several indication cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injury epilepsy glaucoma neuropathic pain psychiatric condition depression anxiety schizophrenia cognition investigational drug agamatine studied non-blinded prospective case study united state looking patient diagnosed small fiber peripheral neuropathy 
Serotonin, temporary relief nervousness anxiety mood swing joint pain weakness drowsiness itching lethargy evaluated fda homeopathic product ,
N-methylnicotinamide,n-methylnicotinamide experimental drug approved indication marketed formulation metabolite niacinamide/nicotinamide niacin/nicotinic acid vitamin b3 n-methylnicotinamide used diagnose niacin deficiency measuring n-methylnicotinamide urine ,n-methylnicotinamide experimental drug approved indication 
Tyramine,tyramine 4-hydroxyphenethylamine para-tyramine mydrial uteramin naturally occurring monoamine compound trace amine derived amino acid tyrosine tyramine act inducing release catecholamine important characteristic product impediment cross blood-brain barrier restrains side effect nonpsychoactive peripheral sympathomimetic effect report hypertensive crisis patient ingesting tyramine-rich diet conjunction monoamine oxidase inhibitor maoi ,
Acetylcarnitine,acetylcarnitine investigational drug united state italy united kingdom china israel norway approved italy portugal argentina chile philippine australia india acetylcarnitine synthesized also naturally found adequate amount healthy human human plasma tissue acetylcarnitine predominant acylated ester carnitine amino acid derivative made kidney liver brain lysine methionine main role acetylcarnitine help transport fatty acid mitochondrial matrix fatty acid metabolism occurs ,acetylcarnitine approved indication united state canada approved indicated italy cerebrovascular disorder mental function disorder peripheral nerve disorder diabetic neuropathy nutritional supplementation portugal mental function disorder argentina cerebral vasculopathy nutritional supplementation peripheral neuropathy chile dementia philippine cerebrovascular disorder mental function disorder australia nutritional supplementation india nutritional supplementation increase sperm count acetylcarnitine also several potential therapeutic indication still investigated norway acetylcarnitine phase iv trial prophylactic treatment migraine italy acetylcarnitine phase ii trial use patient type 2 diabetes mellitus phase iii trial alleviating fatigue patient chronic hepatitis c use patient minimal hepatic encephalopathy united state acetylcarnitine phase ii trial neurodegenerative disorder progressive supranuclear palsy phase ii iii trial reducing peripheral neuropathy cancer patient adjunct chemotherapy phase ii trial treating patient septic shock phase ii trial bipolar depression phase ii trial reduce oxidative stress patient sickle cell disease phase ii trial chronic fatigue syndrome study preventing nerve damage hiv patient china acetylcarnitine phase iii trial reducing peripheral neuropathy cancer patient adjunct chemotherapy united kingdom acetylcarnitine investigated preventing nerve damage hiv patient israel acetylcarnitine studied treatment male infertility 
Uric acid,uric acid last product purine metabolism human formation uric acid enzyme xanthine oxidase oxidizes oxypurines normally small amount uric acid present body excess amount blood called hyperuricemia lead gout formation kidney stone therapeutic agent known uric acid increased response oxidative stress uric acid act antioxidant present august 2013 approved formulation indication uric acid one country spain uric acid investigational drug phase 3 trial studying effect adjunct alteplase acute ischemic stroke , present august 2013 approved indication uric acid potential therapeutic use uric acid adjunct acute ischemic stroke 
Oxogluric acid,oxogluric acid α-ketoglutarate approved indication world investigational drug united state united state phase clinical trial investigating whether oxogluric acid precursor found nutritional supplement benefit patient metabolic disorder propionic acidemia oxogluric acid sold dietary supplement athlete improve performance helping remove excess ammonia officially approved indication experimental study shown reduction ammonia oxogluric acid hemodialysis patient physiologically oxogluric acid act krebs cycle intermediate involved transamination reaction metabolism amino acid form glutamic acid combining ammonia reduces nitrogen combining well several experimental study also shown administration oxogluric acid helped attenuate decreased synthesis muscle protein often seen post-surgery ,α-α-ketoglutarate approved indication world investigational drug united state potential indication α-ketoglutarate patient metabolic disorder propionic acidemia trauma patient muscle loss 
Ellagic acid,ellagic acid present several fruit cranberry strawberry raspberry pomegranate pomegranate several therapeutic compound ellagic acid active abundant ellagic acid also present vegetable ellagic acid investigational drug studied treatment follicular lymphoma phase 2 trial protection brain injury intrauterine growth restricted baby phase 1 2 trial improvement cardiovascular function adolescent obese phase 2 trial topical treatment solar lentigo ellagic acid 's therapeutic action mostly involves antioxidant anti-proliferative effect ,ellagic acid investigated use follicular lymphoma brain injury intrauterine growth restricted baby obese adolescent solar lentigo 
Hydroxyproline,hydroxyproline neutral heterocyclic protein amino acid found collagen common many gelatin product hydroxyproline mostly used diagnostic marker bone turnover liver fibrosis therapeutically hydroxyproline studied experimental medicine approved france combination topical gel product called cicactive small superficial wound ,used france combination product treatment small superficial wound 
Guvacine,guvacine pyridine alkaloid found areca nut also known betel nut experimental drug approved indication experimental study still investigated determine physiological effect mechanism action guvacine currently determined guvacine specific gaba reuptake inhibitor significant affinity gaba receptor , approved indication guvacine 
Leukotriene C4, conjugation product leukotriene a4 glutathione major arachidonic acid metabolite macrophage human mast cell well antigen-sensitized lung tissue stimulates mucus secretion lung produce contraction nonvascular vascular smooth muscle dictionary prostaglandin related compound 1990 ,
DADLE, delta-selective opioid analgesic opioid cause transient depression mean arterial blood pressure heart rate ,
Bamet-UD2,bamet-ud2 novel bile acid-platinum derivative ,
Pitavastatin,pitavastatin also known brand name product livalo lipid-lowering drug belonging statin class medication inhibiting endogenous production cholesterol within liver statin lower abnormal cholesterol lipid level ultimately reduce risk cardiovascular disease specifically statin medication competitively inhibit enzyme hydroxymethylglutaryl-coenzyme hmg-coa reductase a181421 catalyzes conversion hmg-coa mevalonic acid third step sequence metabolic reaction involved production several compound involved lipid metabolism transport including cholesterol low-density lipoprotein ldl sometimes referred `` bad cholesterol '' low-density lipoprotein vldl prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd type 2 diabetes clear evidence benefit statin use coupled minimal side effect long term effect resulted class becoming one widely prescribed medication north america a181087 a181406 pitavastatin drug statin class medication including atorvastatin pravastatin rosuvastatin fluvastatin lovastatin considered first-line option treatment dyslipidemia a181087 a181406 increasing use statin class drug largely due fact cardiovascular disease cvd includes heart attack atherosclerosis angina peripheral artery disease stroke become leading cause death high-income country major cause morbidity around world a181084 elevated cholesterol level particular elevated low-density lipoprotein ldl level important risk factor development cvd a181087 a181553 use statin target reduce ldl level shown number landmark study significantly reduce risk development cvd all-cause mortality a181090 a181093 a181096 a181427 a181475 a181538 statin considered cost-effective treatment option cvd due evidence reducing all-cause mortality including fatal non-fatal cvd well need surgical revascularization angioplasty following heart attack a181087 a181406 evidence shown even low-risk individual 10 risk major vascular event occurring within 5 year statin cause 20 -22 relative reduction major cardiovascular event heart attack stroke coronary revascularization coronary death every 1 mmol/l reduction ldl without significant side effect risk a181397 a181403 statin medication considered equally effective clinical standpoint rosuvastatin considered potent dos 10 40mg rosuvastatin per day found clinical study result 45.8 54.6 decrease ldl cholesterol level a181409 a181535 a181538 a1793 study data confirmed pitavastatin 's potency lowering ldl-c comparable statin also increased efficacy increasing hdl-c also known `` good cholesterol '' a182000 a182003 a182006 despite difference potency several trial demonstrated minimal difference term clinical outcome statin a181538 a181427 ,pitavastatin indicated treatment adult patient primary hyperlipidemia mixed dyslipidemia reduce elevated total cholesterol tc low-density lipoprotein cholesterol ldl-c apolipoprotein b apo b triglyceride tg increase high-density lipoprotein cholesterol hdl-c also indicated treatment pediatric patient aged 8 year older heterozygous familial hypercholesterolemia hefh reduce elevated tc ldl-c apo b f4667 prescribing statin medication considered standard practice following cardiovascular event people moderate high risk development cvd statin-indicated condition include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl-c level a181087 a181406 
DPDPE, heterodetic cyclic peptide cyclic enkephalin analogue d-penicillaminyl residue located position 2 5 form heterocycle via disulfide bond ,
Cholecystokinin,cholecystokinin also known _cck cck-pz_ peptide hormone gastrointestinal system responsible stimulating digestion fat protein cholecystokinin previously called _pancreozymin_ synthesized secreted enteroendocrine cell duodenum first portion small intestine lead release bile digestive enzyme cck also act appetite suppressant studied weight management regimen l1637 normally endogenous hormone available commercially diagnostic process replacement pancreatic insufficiency l1646 l1647 l1648 octapeptide form cholecystokinin one first gastrointestinal hormone discovered identified 90 year ago due ability stimulate gallbladder contraction 1928 soon recognized identical factor responsible stimulating pancreatic exocrine secretion 1943 l1636 hormone also shown positive effect enteric smooth muscle contraction nerve activity multiple location peripheral central nervous system addition role promoting smooth muscle cell contraction/exocrine cell secretion cck promotes cell growth energy production gene expression protein synthesis process profound drug development l1636 drug also investigated possible antipsychotic property owing effect cck receptor brain l1638 recent study suggested cholecystokinin also play major role inducing drug tolerance opioids morphine heroin partially implicated experience pain hypersensitivity opioid withdrawal a32101 , use diagnostic aid evaluation gallbladder disorder also used conjunction secretin pancreatic insufficiency l1634 
Rilpivirine,rilpivirine non-nucleoside reverse transcriptase inhibitor nnrti used treatment hiv-1 infection treatment-naive patient a31328 diarylpyrimidine derivative a31329 internal conformational flexibility rilpivirine plasticity interacting binding site give high potency reduces chance resistance compared nnrti 's a31331 rilpivirine developed tilbotec inc. fda approved may 20 2011 l1030 november 21 2017 rilpivirine combination dolutegravir approved part first complete treatment regimen two drug treatment adult hiv-1 named juluca l1031 rilpivirine combination cabotegravir granted fda approval 21 january 2021 l31193 previously administered once-monthly combination product granted fda approval dosing every two month february 01 2022 l40084 without need oral lead-in period prior l31193 ,"rilpivirine combination agent indicated treatment hiv-1 infection antiretroviral treatment-naive patient hiv-1 rna ≤100,000 copies/ml cd4+ cell count 200 cells/mm sup 3 /sup l1030 fda combination therapy approval rilpivirine dolutegravir indicated adult adolescent 12 year age older weighing least 35 kg hiv-1 infection whose virus currently suppressed 50 copies/ml stable regimen least six month without history treatment failure known substitution associated resistance two component therapy l1031 rilpivirine combination cabotegravir indicated complete regimen treatment hiv-1 infection adult adolescent ≥12 year old weighing least 35kg replace current antiretroviral regimen virologically suppressed hiv-1 rna 50 copies/ml stable antiretroviral regimen history treatment failure known suspected resistance either cabotegravir rilpivirine l31193 "
Crizotinib,crizotinib tyrosine kinase receptor inhibitor used treatment anaplastic lymphoma kinase alk ros1-positive non-small cell lung cancer nsclc tumor well alk-positive anaplastic large cell lymphoma alcl inflammatory myofibroblastic tumor imt l42460 targeting echinoderm microtubule-associated protein-like 4 eml4 -alk fusion protein crizotinib offer robust effectiveness treating nsclc patient type rearrangement a250785 crizotinib first-in-class drug used treat alk-positive tumor second- third-generation alk-tyrosine kinase-inhibitors overcome many pharmacodynamic genetic resistance mechanism crizotinib prone a250785 crizotinib approved fda 2011 use accompanied fda-approved test used detect alk ros1 rearrangement l42460 ,crizotinib kinase inhibitor indicated treatment patient metastatic non-small cell lung cancer nsclc whose tumor anaplastic lymphoma kinase alk ros1-positive detected fda-approved test l42460 crizotinib also indicated treatment relapsed refractory systemic anaplastic large cell lymphoma alcl alk-positive pediatric patient 1 year age older young adult safety efficacy crizotinib established older adult relapsed refractory systemic alk-positive alcl l42460 additionally crizotinib indicated treatment adult pediatric patient 1 year age older unresectable recurrent refractory inflammatory myofibroblastic tumor imt alk-positive l42460 
Ulipristal,ulipristal selective progesterone receptor modulator used purpose emergency contraception ella treatment uterine fibroid fibristal derivative 19-norprogesterone antagonistic partial agonist activity progesterone receptor also bind glucocorticoid receptor however compared mifepristone progesterone receptor antagonist ulipristal tolerable lower glucocorticoid activity better binding affinity ulipristal currently recommended first line therapy emergency contraception due improved efficacy similar side effect profile compared traditional use levonorgestrel yuzpe regimen exact mechanism action ulipristal still currently debated though evidence function inhibiting ovulation recent systematic review proclaimed majority available evidence demonstrates inhibitory effect ovulation rather post-fertilization effect endometrium heavily debated due ethical concern related abortion rosato et al 2016 nevertheless current ongoing research agent 's mechanism action emergency contraceptive continue provide potentially plausible evidence ulipristal may fact elicit activity endometrium prevents embryo implantation a175372 a175375 a175378 , product ella available canada u ulipristal indicated use emergency contraception unprotected intercourse possible contraceptive failure administered within 120 hour 5 day unprotected intercourse known suspected contraceptive failure product fibristal available canada ulipristal indicated treatment sign symptom uterine fibroid adult woman 
Fingolimod,multiple sclerosis m devastating inflammatory disease often progress cause severe neurological physical cognitive effect a176474 fingolimod sphingosine 1-phosphate receptor modulator treatment relapsing-remitting multiple sclerosis developed novartis initially approved fda 2010 l12651 fingolimod also studied treatment covid-19 disease caused infection sars-cov-2 virus l12654 l12657 ,fingolimod indicated treatment patient aged 10 relapsing form multiple sclerosis may include clinically isolated syndrome relapsing-remitting disease well active secondary progressive disease l12651 l44346 
Tesamorelin,tesamorelin stabilized synthetic peptide analogue hypothalamic peptide growth hormone releasing hormone ghrh indicated reduction excess abdominal fat hiv-infected patient lipodystrophy lipodystrophy metabolic condition characterized insulin resistance fat redistribution hyperlipidemia associated antiretroviral therapy hiv infection ,tesamorelin acetate synthetic analogue human hypothalamic growth hormone releasing factor hgrf indicated induce maintain reduction excess abdominal fat hiv-infected patient lipodystrophy 
Brentuximab vedotin,brentuximab vedotin also known adcetris® antibody-drug conjugate combine anti-cd30 antibody drug monomethyl auristatin e mmae anti-neoplastic agent used treatment hodgkin 's lymphoma systemic anaplastic large cell lymphoma brentuximab vedotin initially approved 2011 january 2012 drug label revised boxed warning condition known progressive multifocal leukoencephalopathy death due opportunistic jc virus infection post treatment l1737 u.s. food drug administration approved adcetris march 2018 treat adult patient previously untreated stage iii iv classical hodgkin lymphoma chl combination chemotherapy l1737 adcetris also previously approved fda treat hodgkin 's lymphoma relapse hodgkin 's lymphoma stem cell transplantation patient high risk relapse progression systemic anaplastic large cell lymphoma alcl failure treatment regimen primary cutaneous alcl failure treatment regimen l1737 lymphoma malignancy begin lymphatic system help combat infection disease lymphoma may begin anywhere body spread nearby lymph node two main type lymphoma hodgkin lymphoma also called hodgkin disease non-hodgkin lymphoma individual hodgkin 's lymphoma classical type type lymphoma large abnormal lymphocyte type white blood cell found lymph node called reed-sternberg cell early diagnosis intervention patient hodgkin lymphoma normally experience long-term remission l1737 echelon-1 study result demonstrated superior efficacy drug combined chemotherapy regimen compared previous standard care importantly removing drug bleomycin highly toxic agent completely removed regimen demonstrates meaningful progress treatment patient affected disease l1739 ,brentuximab vedotin indicated adult patient treatment previously untreated stage iii iv classical hodgkin 's lymphoma chl combination doxorubicin vinblastine dacarbazine also indicated treatment chl post-autologous hematopoietic stem cell transplantation auto-hsct patient high risk relapse progression finally may used treatment adult patient chl previously failed either auto-hsct least two prior multi-agent chemotherapy regimen candidate auto-hsct l39789 brentuximab vedotin additionally indicated treatment previously untreated systemic anaplastic large cell lymphoma salcl cd30-expressing peripheral t-cell lymphoma ptcl combination cyclophosphamide doxorubicin prednisone may also used monotherapy salcl therapeutic failure least one prior multi-agent chemotherapy regimen l39789 brentuximab vedotin also indicated treatment primary cutaneous large anaplastic large cell lymphoma cd30-expressing mycosis fungoides received prior systemic therapy l39789 
Eribulin,eribulin microtubule inhibitor indicated treatment patient metastatic breast cancer previously received least two chemotherapeutic regimen treatment metastatic disease eribulin isolated marine sponge halichondria okadai eribulin also investigated use treatment advanced solid tumor a7439 , treatment patient metastatic breast cancer previously received least two chemotherapeutic regimen treatment metastatic cancer 
Gabapentin enacarbil,gabapentin enacarbil marketed name horizant prodrug gabapentin indicated adult treatment restless leg syndrome rls postherpetic neuralgia phn , treatment adult restless leg syndrome rls postherpetic neuralgia phn 
Boceprevir,boceprevir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas boceprevir boceprevir inhibitor ns3/4a serine protease enzyme encoded hcv genotype 1 4 synthesis enzyme essential viral replication serve cleave virally encoded polyprotein mature protein like ns4a ns4b ns5a ns5b fda label barrier develoment resistance ns3/4a inhibitor lower ns5b inhibitor another class daas a19593 subtitutions amino acid position 155 156 168 known confer resistance substitution enzyme 's catalytic triad consisting h58 d82 s139 also likely alter affinity drug ns3/4a activity enzyme despite disadvantage boceprevir still effective hcv paired db00811 db00008 db00022 joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa reccomend boceprevir combination db00811 db00008 db00022 first line therapy hepatitis c a19593 boceprevir db00811 db00008 db00022 used intent cure achieve sustained virologic response svr 48 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 boceprevir available fixed dose product tradename victrelis used treatment chronic hepatitis c. approved may 2011 fda victrelis indicated treatment hcv genotype 1 combination db00811 db00008 db00022 fda label victrelis longer widely used interferon-free therapy developed ,boceprevir used combination db00811 db00008 db00022 indicated use treatment chronic hcv genotype 1 infection adult fda label 
Fidaxomicin,fidaxomicin novel macrolide antibiotic used treatment diarrhea caused _clostridioides_ formerly _clostridium_ _difficile_ adult pediatric patient age 6 month l11575 fidaxomicin naturally-occurring 18-member macrocycle derived fermentation a190501 fidaxomicin contains 18-membered lactone ring structure referred macrocyclic lactone antibiotic drug a190492 antibacterial activity fidaxomicin distinct macrolides rifamycins bactericidal activity time-dependent concentration-dependent a190492 fidaxomicin first macrocyclic lactone antibiotic activity _c difficile_ a190486 display narrow spectrum activity gram-positive anaerobe a7445 mediates potent bactericidal action bacteria inhibiting bacterial rna synthase thereby disrupting bacterial transcription a190486 minimum inhibitory concentration mic sub 90 /sub fidaxomicin four time le vancomycin primary drug choice _c difficile_ infection approval fidaxomicin a190492 unlike vancomycin however fidaxomicin negligible effect normal colonic microflora a190516 fda initially approved fidaxomicin may 2011 treatment _c difficile_-associated diarrhea adult patient age 18 a190492 later year december drug also approved european medicine agency a190492 june 2012 fidaxomicin also granted approval health canada a190486 approved indication fidaxomicin expanded fda january 2020 include pediatric patient age 6 month treatment population l11575 ,fidaxomicin indicated treatment _clostridioides_ formerly _clostridium_ _difficile_-associated diarrhea adult pediatric patient 6 month age older l11575 fidaxomicin used patient proven strongly suspected _c difficile_ infection reduce risk development drug-resistant bacteria maximize therapeutic effectiveness fidaxomicin antimicrobial agent l11575 
Cabozantinib,cabozantinib first approved 2012 non-specific tyrosine kinase inhibitor initially approved u brand name cometriq indicated treatment metastatic medullary thyroid cancer l15123 2016 capsule formulation cabometyx approved treatment advanced renal cell carcinoma formulation gained additional approval u canada 2019 treatment hepatocellular carcinoma previously treated patient l15128 l15133 ,cabozantinib indicated treatment progressive metastatic medullary thyroid cancer l15123 also indicated treatment advanced renal cell carcinoma hepatocellular carcinoma patient previously treated sorafenib l15128 l15133 
Taliglucerase alfa,taliglucerase alfa recombinant active form human lysosomal enzyme β-glucocerebrosidase approved 2012 marketed name elelyso use patient type 1 gaucher 's disease , treatment adult type 1 gaucher disease 
Ruxolitinib,ruxolitinib formerly known incb018424 inc424 anticancer drug janus kinase jak inhibitor potent selective inhibitor jak1 jak2 a229698 tyrosine kinase involved cytokine signalling hematopoiesis a7450 myeloproliferative neoplasm myelofibrosis polycythemia vera often characterized aberrant activation jak-stat pathway leading abnormal blood cell count thrombotic complication inhibiting jak1 jak2 ruxolitinib work block dysregulated cell signalling pathway prevents abnormal blood cell proliferation a229708 due large number patient myeloproliferative neoplasm jak2 mutation ruxolitinib first atp-competitive inhibitor jak1 jak2 ever developed a229938 ruxolitinib first approved treatment adult patient myelofibrosis fda 2011 followed ema 's approval 2012 a229708 2014 approved treatment polycythemia vera adult inadequate response intolerant hydroxyurea 2019 ruxolitinib approved use steroid-refractory acute graft-versus-host disease adult child l31958 topical formulation ruxolitinib used treat atopic dermatitis vitiligo l39125 investigated inflammatory skin condition a229883 ruxolitinib investigated treat patient coronavirus disease 2019 covid-19 accompanied severe systemic hyperinflammation phase ii clinical trial ruxolitinib improved chest computed tomography improved recovery patient lymphopenia a229713 a229718 however phase iii clinical trial later determined ruxolitinib inadequate meeting primary endpoint reducing number hospitalized covid-19 patient experienced severe complication l31968 thus drug approved treatment covid-19 ,ruxolitinib indicated treatment following condition intermediate high-risk myelofibrosis mf including prima1y mf post-polycythemia vera mf post-essential thrombocythemia mf adult l31938 also used treat disease-related splenomegaly symptom adult patient condition l32073 polycythemia vera pv adult inadequate response intolerant hydroxyurea l31938 steroid-refracto1y acute graft-versus-host disease gvhd adult pediatric patient 12 year older l31938 chronic gvhd patient aged 12 year older failed one two line systemic therapy l31938 topical ruxolitinib indicated short-term non-continuous chronic treatment mild moderate atopic dermatitis non-immunocompromised patient patient 12 year age older whose disease adequately controlled topical prescription therapy therapy advisable l39125 treatment nonsegmental vitiligo adult pediatric patient 12 year age older l39125 
Aminopterin,aminopterin amino derivative folic acid used antineoplastic agent treatment pediatric leukemia 1950 's production discontinued favor methotrexate le potent le toxic label aminopterin also used treatment psoriasis clinician need aware characteristic teratologic effect aminopterin methotrexate ,prior withdrawal aminopterin initially used treatment childhood leukemia specifically induce remission later aminopterin used off-label united state treat psoriasis yielding dramatic lesion clearing aminopterin later supplanted methotrexate treating cancer better therapeutic index aminopterin well methotrexate also explored use abortifacient however association severe congenital malformation teratogenic effect become known fetal aminopterin syndrome 
Belimumab,belimumab fully human recombinant igg1λ monoclonal antibody inhibits soluble human b lymphocyte stimulator protein blys also referred baff tnfsf13b b cell survival factor l42630 blys level often elevated immunodeficient autoimmune disorder systemic lupus erythematosus sle a251495 l42705 binding blys blocking interaction b cell receptor belimumab inhibits survival b cell produced recombinant dna technology murine cell ns0 expression system l42630 belimumab first approved fda march 9 2011 a251495 making newest drug approved treatment sle 50 year a251520 currently used treat sle lupus nephritis l42630 , u belimumab indicated treat active systemic lupus erythematosus sle active lupus nephritis patient aged five year older receiving standard therapy l42630 europe belimumab also used treat sle lupus nephritis adult l42705 efficacy belimumab evaluated patient severe active central nervous system lupus use belimumab recommended situation l42630 
Teriflunomide,teriflunomide active metabolite leflunomide act immunomodulatory agent inhibiting pyrimidine synthesis marketed name aubagio® indicated treatment multiple sclerosis specifically relapsing form fda label state important warning risk hepatoxicity teratogenicity patient using teriflunomide ,used treatment relapsing form multiple sclerosis m 
Vemurafenib,vemurafenib competitive kinase inhibitor activity braf kinase mutation like v600e a31269 exerts function binding atp-binding domain mutant braf a31270 vemurafenib co-developed roche plexxikon obtained fda approval august 17 2011 company hoffmann la roche approval roche collaboration genentech launched broad development program l1012 ,vemurafenib approved since 2011 treatment metastatic melanoma mutation braf valine located exon 15 codon 600 mutation denominated v600e a31270 v600e mutation substitution glutamic acid valine account 54 case cutaneous melanoma a31271 vemurafenib approval extended 2017 use treatment adult patient erdheim-chester disease whose cancer cell present braf v600 mutation l1013 erdheim-chester disease extremely rare histiocyte cell disorder affect large bone large vessel central nervous system well skin lung reported association erdheim-chester disease v600e mutation a31272 
Linagliptin,linagliptin dpp-4 inhibitor developed boehringer ingelheim treatment type ii diabetes l9557 linagliptin differs dpp-4 inhibitor non-linear pharmacokinetic profile primarily eliminated renal system obeys concentration dependant protein binding a37050 linagliptin approved fda may 2 2011 l9557 ,linagliptin indicated treatment type ii diabetes addition diet exercise l9557 used treat type diabetes diabetic ketoacidosis l9557 extended-release combination product containing empagliflozin linagliptin metformin approved fda january 2020 improvement glycemic control adult type 2 diabetes mellitus used adjunctively diet exercise l11479 
Perampanel,perampanel noncompetitive ampa glutamate receptor antagonist marketed name fycompa™ indicated adjunct patient 12 year old treatment partial-onset seizure may may occur generalized seizure fda label includes important black-boxed warning serious life-threatening behavioral psychiatric reaction patient taking fycompa™ ,perampanel indicated treatment partial-onset seizure without secondarily generalized seizure epileptic patient four year age older also indicated adjunct treatment primary generalized tonic-clonic seizure epileptic patient aged 12 year older l40913 
Gadoxetic acid,gadoxetic acid gadoxetate paramagnetic gadolinium-containing contrast agent salt form gadoxetate disodium used intravenous injection ethoxybenzyl diethylenetriaminepentaacetic acid moiety chelate gadolinium ion form stable complex make drug marketed bayer healthcare pharmaceutical fda approved july 3 2008 ,gadoxetate used contrast medium magnetic resonance imaging mri detect characterize lesion liver 
Aflibercept,aflibercept recombinant protein composed binding domain two human vascular endothelial growth factor vegf receptor fused fc region human immunoglobulin gamma 1 igg1 structurally aflibercept dimeric glycoprotein protein molecular weight 96.9 kilo dalton kda contains approximately 15 glycosylation give total molecular weight 115 kda five putative n-glycosylation site polypeptide chain predicted primary sequence occupied carbohydrate exhibit degree chain heterogeneity including heterogeneity terminal sialic acid residue except single unsialylated site associated fc domain aflibercept ophthalmic agent used treatment macular edema following central retinal vein occlusion crvo neovascular age-related macular degeneration amd ziv-aflibercept brand name zaltrap developed injection treatment metastatic colorectal cancer fda approved november 18 2011 ema approved november 2012 , opthalmic agent used treatment neovascular wet age-related mascular degeneration amd macular edema following central retinal vein occulsion crvo systemic injection known ziv-aflibercept combination 5-fluorouracil leucovorin irinotecan- folfiri treatment metastatic colorectal cancer resistant progressed following treatment oxaliplatin 
Asparaginase Erwinia chrysanthemi,asparaginase _erwinia chrysanthemi_ asparaginase-specific enzyme derived _erwinia_ _chrysanthemi_ used anticancer agent work depleting store important amino acid called asparagine involved dna synthesis cell survival malignant cell leading cell death l1448 l-asparaginase first identified 1963 a236344 different formulation l-asparaginase including asparaginase escherichia coli pegylated form enzyme pegaspargase a7464 asparaginase _erwinia chrysanthemi_ asparaginase escherichia coli differ pharmacokinetic immunogenic profile l1452 thus allergic asparaginase escherichia coli cross-react asparaginase _erwinia chrysanthemi_ a236344 study show substitution _erwinia_ asparaginase _e coli_-derived asparaginase following allergic reaction safe effective a236359 asparaginase _erwinia chrysanthemi_ first approved fda november 2011 treat patient acute lymphoblastic leukemia allergic _e coli_-derived asparaginase used part multi-agent chemotherapy l149 june 2021 recombinant form asparaginase _erwinia chrysanthemi_ approved fda component chemotherapy regimen treat acute lymphoblastic leukemia lymphoblastic lymphoma adult pediatric patient allergic _e coli_-derived asparaginase l34714 ,asparaginase _erwinia chrysanthemi_ indicated component multi-agent chemotherapeutic regimen treatment patient acute lymphoblastic leukemia lymphoblastic lymphoma adult child developed hypersensitivity _e coli_-derived asparaginase l149 l34719 
Icosapent ethyl,icosapent ethyl ethyl eicosapentaenoic acid synthetic derivative omega-3 fatty acid eicosapentaenoic acid epa used adjunct therapy severe hypertriglyceridemia tg level 500 mg/dl reduce risk cardiovascular event certain patient elevated triglyceride fda approved july 26 2012 ,icosapent ethyl indicated adjunct maximally tolerated statin therapy reduce risk myocardial infarction stroke coronary revascularization unstable angina requiring hospitalizing adult patient elevated triglyceride ≥150 mg/dl established cardiovascular disease diabetes mellitus ≥2 risk factor cardiovascular disease l41105 also indicated adjunct diet reduce triglyceride level adult patient severe ≥500 mg/dl hypertriglyceridemia l41105 
Ocriplasmin,ocriplasmin recombinant truncated form human plasmin molecular weight 27.2 kda produced recombinant dna technology pichia pastoris expression system ocriplasmin protein made 249 amino acid two peptide chain agent pharmacologic vitreolysis thrombolytic agent fda approved october 17 2012 ,ocriplasmin proteolytic enzyme indicated treatment symptomatic vitreomacular adhesion 
Carfilzomib,carfilzomib injectable antineoplastic agent iv chemically modified tetrapeptidyl epoxide analog epoxomicin also selective proteasome inhibitor fda approved carfilzomib july 2012 treatment adult relapsed refractory multiple myeloma monotherapy combination therapy l39392 ,carfilzomib indicated treatment adult patient relapsed refractory multiple myeloma received one three line therapy combination lenalidomide dexamethasone dexamethasone daratumumab dexamethasone daratumumab hyaluronidase-fihj dexamethasone isatuximab dexamethasone also indicated single agent treatment patient relapsed refractory multiple myeloma received one line therapy l39392 l42350 
Linaclotide,linaclotide orally administered peptide agonist guanylate cyclase 2c treatment irritable bowel syndrome chemically heterodetic cyclic peptide consists fourteen amino acid protein sequence follows cys cys glu tyr cys cys asn pro ala cys thr gly cys tyr three disulfide bond located cys1 cys6 cys2 cys10 cys5 cys13 fda approved august 30 2012 ,treatment irritable bowel syndrome ibs constipation chronic idiopathic constipation 
Arbaclofen,arbaclofen stx209 r-enantiomer baclofen believed selective gamma-amino butyric acid type b receptor agonist investigated treatment autism spectrum disorder fragile x syndrome randomized double blind placebo controlled trial also investigated treatment spasticity due multiple sclerosis spinal cord injury arbaclofen investigated treatment gastroesophageal reflux disease gerd however disappointing result ,investigated clinical trial potential treatment spasticity multiple sclerosis autism spectrum disorder social withdrawal fragile x syndrome 
Arbaclofen Placarbil,arbaclofen placerbil prodrug arbaclofen selective gamma-amino-butyric acid type b receptor agonist r-enantiomer baclofen discovered patented xenoport new chemical entity improved pharmacokinetic profile compared baclofen allows sustained release property arbaclofen placerbil believed therapeutic potential treating gastroesophogeal reflux disease gerd plasticity however due discouraging clinical trial result drug abandoned xenoport 2011 treatment gerd may 20th 2013 xenoport announced plan terminate development arbaclofen placerbil treatment multiple sclerosis ,investigated treatment spasticity multiple sclerosis acute back spasm gerd 
Mirabegron,mirabegron sympathomimetic beta-3 adrenergic receptor agonist used relax smooth muscle bladder treatment urinary frequency incontinence unique amongst overactive bladder treatment option unlike treatment solifenacin darifenacin lack significant antimuscarinic activity a232553 responsible therapeutic effect medication broad range adverse effect mirabegron comparatively favorable adverse effect profile compared available treatment option complementary mechanism antimuscarinics came allows use alongside solifenacin refractory case l32853 mirabegron first received fda approval 2012 brand name myrbetriq treatment adult overactive bladder l32853 extended-release granule formulation subsequently granted approval march 2021 treatment pediatric patient neurogenic detrusor overactivity l32853 mirabegron also used jurisdiction across globe including canada l32925 eu l32945 japan a7469 ,mirabegron indicated treatment overactive bladder oab symptom urge urinary incontinence urgency urinary frequency either alone combination solifenacin l32853 also indicated treatment neurogenic detrusor overactivity ndo pediatric patient 3 year age older weighing 35kg l32853 
Peginesatide,peginesatide synthetic peptide attached polyethylene glycol treatment anemia polyethylene glycol moiety help make drug le immunogenic prolongs plasma half-life chemically peginesatide designed mimic pharmacological activity erythropoietin replica structure peginesatide consists two 21-amino acid chain covalently bonded linker derived iminodiacetic acid β-alanine fda approved march 27 2012 ,peginesatide used treatment anemia due chronic kidney disease ckd adult patient dialysis
Tofacitinib,tofacitinib inhibitor janus kinase group intracellular enzyme involved signalling pathway affect hematopoiesis immune cell function approved fda treatment moderate severe rheumatoid arthritis responds inadequately methotrexate intolerant methotrexate besides rheumatoid arthritis tofacitinib also studied clinical trial prevention organ transplant rejection currently investigation treatment psoriasis known adverse effect include nausea headache well serious immunologic hematological adverse effect tofacitinib marketed brand name xeljanz pfizer ,tofacitinib indicated treatment adult patient moderately-to-severely active rheumatoid arthritis ra active psoriatic arthritis active ankylosing spondylitis moderately-to-severely active ulcerative colitis inadequate response intolerance one tnf blocker l30395 also indicated oral solution patient ≥2 year age treatment polyarticular course juvenile idiopathic arthritis inadequate response intolerance one tnf blocker l30395 tofacitinib recommended used combination biologic disease-modifying anti-rheumatic drug dmards potent immunosuppressive agent azathioprine cyclosporine l30395 
Regorafenib,regorafenib orally-administered inhibitor multiple kinase used treatment metastatic colorectal cancer advanced gastrointestinal stromal tumour hepatocellular carcinoma fda approved september 27 2012 approved use regorafenib expanded treat hepatocellular carcinoma april 2017 ,regorafenib indicated treatment patient metastatic colorectal cancer crc previously treated fluoropyrimidine- oxaliplatin- irinotecan-based chemotherapy anti-vegf therapy kras wild type anti-egfr therapy regorafenib also indicated treatment patient locally advanced unresectable metastatic gastrointestinal stromal tumour gist previously treated imatinib mesylate sunitinib malate regorafenib also indicated treatment patient hepatocellular carcinoma hcc previously treated sorafenib l16835 
Aclidinium,aclidinium anticholinergic long-term management chronic obstructive pulmonary disease copd much higher propensity bind muscarinic receptor nicotinic receptor fda approved july 24 2012 ,aclidinium bromide inhalation powder indicated long-term maintenance treatment bronchospasm associated chronic obstructive pulmonary disease copd including chronic bronchitis emphysema 
Glucarpidase,glucarpidase recombinant carboxypeptidase g2 produced genetically modified _escherichia coli_ bacteria 390-amino acid homodimer protein l39855 high-dose methotrexate antifolate agent widely safely used many decade treating various cancer however even aggressive hydration urine alkalinization leucovorin rescue patient still develop high-dose methotrexate-induced nephrotoxicity lead delayed renal clearance methotrexate elevated drug plasma level increasing risk methotrexate toxicity a7476 a7477 discovery certain bacteria capacity inactivate folate analog methotrexate carboxypeptidase g identified carboxypeptidase g1 first isolated _pseudomonas stutzeri_ 1967 1983 gene carboxypeptidase g2 glucarpidase derived _pseudomonas_ sp strain rs-16 cloned _escherichia coli_ allowing enzyme produced sufficient quantity therapeutic purpose a244750 glucarpidase enzyme rapidly hydrolyze methotrexate nontoxic metabolite prevents methotrexate toxicity patient renal dysfunction undergoing high-dose methotrexate treatment provides alternative non-renal pathway methotrexate elimination l39855 glucarpidase first approved fda january 2012 a7476 followed european commission 's approval january 2022 l39865 marketed voraxaze ,glucarpidase indicated reduce toxic plasma methotrexate concentration greater 1 micromole per litre adult pediatric patient delayed methotrexate clearance plasma methotrexate concentration greater 2 standard deviation mean methotrexate excretion curve specific dose methotrexate administered due impaired renal function l39855 european prescribing information glucarpidase specified use adult child aged 28 day older l39895 glucarpidase recommended use patient exhibit expected clearance expected plasma methotrexate concentration reducing plasma methotrexate concentration patient may result subtherapeutic exposure methotrexate l39855 
Enzalutamide,enzalutamide androgen receptor ar inhibitor treatment castration-resistant prostate cancer crpc metastatic non-metastatic l40639 second-generation antiandrogen agent fda approved august 31 2012 l40639 a252667 although androgen deprivation therapy adt first-line treatment prostate cancer remission achieved arising resistance inevitable becoming castration-resistant prostate cancer a252667 recently docetaxel treatment available metastatic crpc however ar inhibitor developed targeted therapy although first-generation ar inhibitor like bicalutamide substantially increase survival rate a252667 second-generation enzalutamide efficacious due higher affinity ar partial agonist activity compared bicalutamide a252667 a252642 due favorable pharmacological profile phase 1 study enzalutamide initiated july 2007 compared average time 10 15 year drug go pre-clinical clinical study enzalutamide developed relatively rapidly a252667 ,enzalutamide indicated treatment castration-resistant prostate cancer metastatic castration-sensitive prostate cancer l40639 
Teduglutide,teduglutide glucagon-like peptide-2 glp-2 analogue made 33 amino acid manufactured using strain escherichia coli modified recombinant dna technology teduglutide differs glp-2 one amino acid alanine substituted glycine significance substitution teduglutide longer acting endogenous glp-2 resistant proteolysis dipeptidyl peptidase-4 fda approved december 21 2012 ,teduglutide indicated treatment adult pediatric patient 1 year age older short bowel syndrome sb dependent parenteral support l39870 
Ponatinib,ponatinib novel bcr-abl tyrosine kinase inhibitor especially effective t315i mutation treatment chronic myeloid leukemia fda approved december 14 2012 ,ponatinib indicated treatment adult patient chronic phase accelerated phase blast phase chronic myeloid leukemia cml resistant intolerant prior tyrosine kinase inhibitor therapy philadelphia chromosome positive acute lymphoblastic leukemia ph+all resistant intolerant prior tyrosine kinase inhibitor therapy 
Raxibacumab,raxibacumab human igg1λ monoclonal antibody bind protective antigen pa component b. anthracis toxin raxibacumab molecular weight approximately 146 kilodaltons raxibacumab produced recombinant dna technology murine cell expression system fda approved december 14 2012 ,raxibacumab indicated treatment adult pediatric patient inhalational anthrax due bacillus anthracis combination appropriate antibacterial drug prophylaxis inhalational anthrax alternative therapy available appropriate 
Bedaquiline,bedaquiline bactericidal antimycobacterial drug chemically diarylquinoline fda approved december 28 2012 ,bedaquiline indicated part combination therapy adult ≥ 18 year pulmonary multi-drug resistant tuberculosis mdr-tb 
Certolizumab pegol,certolizumab pegol pegylated monoclonal antibody tumor necrosis factor-alpha tnf-alpha a176585 formed humanized fab fragment 50 kda igg 1 isotype fused 40 kda polyethylene glycol moiety replacing fc antibody region absence fc region ideated prevent complement fixation antibody-mediated cytotoxicity well markedly increase half-life a176606 certolizumab require glycosylation active function hence production significantly affordable compared existing tnf-alpha therapy done directly bacterial host _e coli_ a176606 developed manufactured ucb pharma first fda approved 2008 l4894 updated new indication march 28 2019 l5819 ,certolizumab pegol approved several different condition listed symptomatic management chron 's disease patient maintenance clinical response patient moderate severe disease inadequate response conventional therapy treatment adult patient moderate severely active rheumatoid arthritis treatment adult patient active psoriatic arthritis treatment adult patient active ankylosing spondylitis treatment adult patient moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy fda label treatment adult patient active non-radiographic axial spondyloarthritis objective sign inflammation l5819 canada certolizumab pegol additionally approved combination methotrexate symptomatic treatment including major clinical response reduction joint damage adult patient moderately severely active rheumatoid arthritis psoriatic arthritis l5825 inflammation biological response potential threat response normal certain condition immune system attack body 's normal cell tissue cause abnormal inflammation l5840 tnf-alpha identified key regulator inflammatory response signaling cascade inflammatory mediator produce wide range reaction including cell death survival differentiation proliferation migration a176660 
Formestane,formestane first selective type steroidal aromatase inhibitor used treatment estrogen-receptor positive breast cancer post-menopausal woman formestane suppresses estrogen production anabolic steroid prohormones formestane also prohormone 4-hydroxytestosterone active steroid weak androgenic activity mild aromatase inhibitor activity listed prohibited substance world anti-doping agency use athlete formestane poor oral bioavailability thus must administered fortnightly bi-weekly intramuscular injection clinical data suggested clinically recommended dose 250mg low discovery newer non-steroidal steroidal aromatase inhibitor orally active le expensive formestane formestane lost popularity currently formestane categorized anti-estrogenic agent prohibited use sport accordance regulation world anti-doping agency u fda approved intramuscular injection form formestane lentaron approved europe withdrawn , treatment estrogen-receptor positive breast cancer post-menopausal woman 
Fluticasone furoate,fluticasone furoate synthetic glucocorticoid available inhaler nasal spray various inflammatory indication fda label f4364 fluticasone furoate first approved 2007 l5965 ,fluticasone furoate indicated once-daily maintenance i.e prophylactic treatment asthma patient ≥5 year old l40838 fluticasone furoate available two combination medication one combination vilanterol one combination vilanterol umeclidinium indicated management chronic obstructive pulmonary disease copd treatment asthma patient ≥18 year old l38689 l40853 l44456 fluticasone furoate available over-the-counter nasal spray symptomatic treatment hay fever upper respiratory allergy patient ≥2 year old l40843 
Canagliflozin,canagliflozin also known _invokana_ sodium-glucose cotransporter 2 sglt2 inhibitor used management type 2 diabetes mellitus along lifestyle change including diet exercise fda label initially approved fda 2013 management diabetes later approved 2018 second indication reducing risk cardiovascular event patient diagnosed type 2 diabetes mellitus l5897 fda label canagliflozin first oral antidiabetic drug approved prevention cardiovascular event patient type 2 diabetes l5897 cardiovascular disease common cause death patient a177083 , drug used conjunction diet exercise increase glycemic control adult diagnosed type 2 diabetes mellitus fda label another indication canagliflozin prevention major cardiovascular event myocardial infarction stroke death due cardiovascular cause patient type 2 diabetes well hospitalization heart failure patient type 2 diabetes l5897 l8917 addition canagliflozin used lower risk end-stage kidney disease major increase serum creatinine cardiovascular death patient combination type 2 diabetes mellitus diabetic nephropathy albuminuria l8917 important note drug indicated treatment type 1 diabetes mellitus diabetic ketoacidosis fda label 
Dimethyl fumarate,dimethyl fumarate agent indicated treatment relapsing form multiple sclerosis a253942 l43752 mechanism action dimethyl fumarate multiple sclerosis well understood thought involve dimethyl fumarate degradation active metabolite monomethyl fumarate mmf mmf up-regulates nuclear factor erythroid-derived 2 -like 2 nrf2 pathway activated response oxidative stress l43752 dimethyl fumarate marketed brand name tecfidera third oral disease-modifying agent multiple sclerosis approved fda following fingolimod teriflunomide a253917 prior fda approval dimethyl fumarate used germany treatment psoriasis a253917 ,dimethyl fumarate indicated treatment relapsing form multiple sclerosis m including clinically isolated syndrome relapsing-remitting disease active secondary progressive disease adult l43752 
Glycerol phenylbutyrate,glycerol phenylbutyrate nitrogen-binding agent chemically triglyceride three molecule phenylbutyrate linked glycerol backbone fda approved february 1 2013 ,glycerol phenylbutyrate nitrogen-binding agent chronic management adult pediatric patient ≥2 year age urea cycle disorder ucds managed dietary protein restriction and/or amino acid supplementation alone 
Pomalidomide,pomalidomide analogue thalidomide immunomodulatory antineoplastic agent fda approved february 8 2013 ,pomalidomide indicated patient multiple myeloma received least two prior therapy including lenalidomide demonstrated disease progression within 60 day completion last therapy also indicated treatment kaposi 's sarcoma k aid patient failed highly active antiretroviral therapy haart treatment k hiv-negative patient l40918 
Trametinib,"trametinib dimethyl sulfoxide kinase inhibitor 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent 1 mg trametinib non-solvated parent fda approved may 29 2013 l2727 u.s. food drug administration approved db08912 tafilnar mekinist trametinib administered together treatment anaplastic thyroid cancer atc removed surgery spread part body metastatic type abnormal gene braf v600e braf v600e mutation-positive l2726 thyroid cancer disease cancer cell form tissue thyroid anaplastic thyroid cancer rare aggressive type thyroid cancer national institute health nih estimate 53,990 new case thyroid cancer estimated 2,060 death disease united state 2018 anaplastic thyroid cancer account approximately 1 2 percent thyroid cancer l2726 ",trametinib indicated single agent treatment braf-inhibitor treatment-naïve patient unresectable metastatic melanoma braf v600e v600k mutation detected fd-aapproved test l2727 used combination dabrafenib l2727 treatment unresectable metastatic melanoma braf v600e v600k mutation adjuvant treatment patient melanoma braf v600e v600k mutation detected fda-approved test involvement lymph node following complete resection treatment patient metastatic non-small cell lung cancer nsclc braf v600e mutation detected fda-approved test treatment patient locally advanced metastatic anaplastic thyroid cancer atc braf v600e mutation satisfactory locoregional treatment option 
Dabrafenib,dabrafenib mesylate tafinlar reversible atp-competitive kinase inhibitor target mapk pathway approved may 29 2013 treatment melanoma v600e v6000k mutation l41955 also used metastatic non-small cell lung cancer mutation l41955 may 2018 tafinlar dabrafenib mekinist db08911 combination approved treat anaplastic thyroid cancer caused abnormal braf v600e gene l41955 ,dabrafenib initially indicated single agent treatment patient unresectable metastatic melanoma braf v600e mutation detected fda-approved test l41955 later used combination trametinib treatment unresectable metastatic melanoma v600e v600k mutation either primary treatment adjuvant treatment l41955 besides melanoma combination dabrafenib trametinib also indicated treatment metastatic non-small cell lung carcinoma locally advanced metastatic anaplastic thyroid cancer l41955 dabrafenib indicated treatment patient wild-type braf melanoma wild-type braf nsclc wild-type braf atc
Radium Ra 223 dichloride,radium ra 223 dichloride radiopharmaceutical containing radioisotope radium-223 emits short range high linear energy alpha particle cation radium mimic calicum bind hydroxyapatite bone mineral found area high bone turnover seen bone metastasis first approved fda may 2013 currently marketed brand name xofigo formerly called alpharadin xofigo indicated patient metastatic bone cancer symptomatic visceral metastasis patient prostate cancer castration resistant fda label includes warning radium ra 223 dichloride used woman pregnant may become pregnant due high risk fetal harm ,used patient metastatic bone cancer symptomatic visceral metastasis patient prostate cancer castration resistant 
Aleglitazar,aleglitazar investigational drug company hoffmann–la roche currently phase iii clinical trial called alecardio investigated use patient type ii diabetes reduce risk cardiovascular mortality morbidity aleglitazar agonist peroxisome proliferator-activated receptor ppar pparα pparγ receptor subtypes phase ii clinical trial called synchrony type ii diabetic patient aleglitazar able control lipid glucose level synergistic manner also limited side effect toxicity ,investigated use patient type ii diabetes reduce risk cardiovascular mortality morbidity 
Afatinib,afatinib 4-anilinoquinazoline tyrosine kinase inhibitor form dimaleate salt available boehringer ingelheim 's brand name gilotrif fda label oral use afatinib tablet first-line initial treatment patient metastatic non-small cell lung cancer nsclc common epidermal growth factor receptor egfr mutation detected fda-approved test l2939 gilotrif afatinib first fda-approved oncology product boehringer ingelheim l2939 ,afatinib kinase inhibitor indicated monotherapy l2937 first-line fda label treatment epidermal growth factor receptor egfr tki tyrosine kinase inhibitor -naive adult patient locally advanced metastatic non-small cell lung cancer nsclc whose tumour non-resistant egfr mutation detected fda-approved test fda label b adult patient locally advanced metastatic nsclc squamous histology progressing platinum-based chemotherapy fda label l2937 recently january 2018 u fda approved supplemental new drug application boehringer ingelheim 's gilotrif afatinib first line treatment patient metastatic non-small cell lung cancer nsclc whose tumor non-resistant epidermal growth factor receptor egfr mutation detected fda-approved test l2939 new label includes data three additional egfr mutation l861q g719x s768i l2939 
Ferric carboxymaltose,ferric carboxymaltose iron replacement product chemically iron carbohydrate complex fda approved july 25 2013 ,ferric carboxymaltose iron replacement product indicated treatment iron deficiency anemia patient ≥1 year age intolerance unsatisfactory response oral iron therapy l39630 also indicated adult patient non-dialysis-dependent chronic kidney disease l39630 
Levomilnacipran,"levomilnacipran selective serotonin norepinephrine reuptake inhibitor chemically levomilnacipran 1s,2r-enantiomer milnacipran fda approved july 25 2013 ",levomilnacipran serotonin norepinephrine reuptake inhibitor indicated treatment major depressive disorder mdd 
(4R)-limonene,limonene common cosmetic product main odor constituent citrus plant family rutaceae d-limonene used food manufacturing medicine e.g flavoring mask bitter taste alkaloid fragrant perfumery ,
Perospirone,perospirone atypical second-generation antipsychotic azapirone family antagonizes serotonin 5ht2a receptor dopamine d2 receptor also display affinity towards 5ht1a receptor partial agonist dainippon sumitomo pharma developed perospirone japan 2001 treatment acute schizophrenia bipolar mania well chronic schizophrenia commonly present hydrated hydrochloride salt form classified neuroleptic agent perospirone shown effective positive negative general symptom patient schizophrenia a19676 also shown le associated extrapyramidal symptom side effect compared db00502 , treatment schizophrenia acute case bipolar mania 
Amfecloral,amfecloral stimulant drug phenethylamine amphetamine chemical class short period time available brand acutran indicated appetite suppressant product longer exists act prodrug split form amphetamine chloral hydrate similarly clobenzorex related compound except n-substituent case yield compound active right chloral hydrate metabolite gabaminergic sedative/hypnotic would theory counteract stimulant effect amphetamine metabolite would produce effect similar amphetamine/barbiturate combination previously used psychiatric medication ,used appetite suppressant 
Adrafinil,adrafinil mild central nervous system stimulating drug typically employed relieve excessive sleepiness inattention geriatric patient also used off-label prevent fatigue falling asleep extended period time adrafinil currently fda approval thus unregulated united state marketed france elsewhere europe trade name olmifon september 2011 france 's fda equivalent reassessed drug withdrew marketing permission adrafinil metabolized modafinil ,used relieve excessive sleepiness inattention elderly patient 
Acediasulfone,acediasulfone inn antimicrobial antimalarial long-acting prodrug dapsone ,
Amperozide,amperozide diphenylbutylpiperazine atypical antipsychotic antagonizes 5-ht2a receptor inhibits dopamine release alters firing dopaminergic neuron investigation regarding use agent revolved primarily around capability treating schizophrenia human even though drug ultimately never clinically adopted indication alternatively amperozide 's main use lie veterinary medicine typically employed minimize aggression stress intensively farmed pig ,
Arsthinol,"arsthinol inn antiprotozoal agent first synthesized ernst a.h. friedheim 1949 via complexing acetarsol 2,3-dimercaptopropanol since demonstrated agent posse activity amoeba yaw considered well tolerated compared related trivalent organoarsenicals arsthinol even undergone recent study potential anticancer agent ",antiprotozoal agent effective amoebiasis yaw 
Dolutegravir,dolutegravir hiv-1 intergrase inhibitor block strand transfer step integration viral genome host cell insti a7514 effect drug homology human host cell give excellent tolerability minimal toxicity a31342 dolutegravir developed viiv healthcare fda approved august 12 2013 l1035 november 21 2017 dolutegravir combination rilpivirine approved part first complete treatment regimen two drug treatment adult hiv-1 named juluca l1031 ,dolutegravir indicated combination antiretroviral agent treatment patient hiv-1 infection comply characteristic adult child aged 12 year older present least weight 40 kg a7520 fda combination therapy approval dolutegravir rilpivirine indicated adult hiv-1 infection whose virus currently suppressed 50 copies/ml stable regimen least six month without history treatment failure known substitution associated resistance two component therapy l1031 dolutegravir also available combination lamivudine abacavir treatment adult pediatric patient hiv-1 weigh ≥10kg l41365 
Riociguat,"riociguat soluble guanylate cyclase sgc agonist approved usa europe several region patient group pah pulmonary arterial hypertension fc ii iii treatment patient inoperable cteph chronic thromboembolic pulmonary hypertension persistent/recurrent ph pulmonary hypertension pulmonary endarterectomy fc ii iii riociguat marketed brand adempas® bayer healthcare pharmaceutical treatment riociguat cost usd 7,500 30 day treatment ",riociguat indicated treatment adult persistent/recurrent chronic thromboembolic pulmonary hypertension cteph group 4 surgical treatment inoperable cteph improve exercise capacity functional class riociguat indicated treatment adult pulmonary arterial hypertension pah group 1 improve exercise capacity functional class delay clinical worsening efficacy shown patient riociguat monotherapy combination endothelin receptor antagonist prostanoids study establishing effectiveness included predominately patient functional class ii–iii etiology idiopathic heritable pah 61 pah associated connective tissue disease 25 
Macitentan,macitentan dual endothelin receptor antagonist used treatment pulmonary arterial hypertension l35890 first approved fda 2013 macitentan differs predecessor bosentan due lower risk hepatotoxicity ,macitentan indicated treatment group 1 pulmonary arterial hypertension pah alone combination tadalafil l35890 l39105 
Luliconazole,luliconazole topical antifungal agent act unknown mechanism postulated involve altering synthesis fungi cell membrane approved fda usa november 2013 marketed brand name luzu luliconazole also approved japan ,luliconazole indicated treatment interdigital tinea pedis tinea cruris tinea corporis infection caused trichophyton rubrum epidermophyton floccosum l39910 
Sofosbuvir,"sofosbuvir tradename sovaldi direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas sofosbuvir prodrug nucleotide analog sofosbuvir metabolized active form antiviral agent 2'-deoxy-2'-α-fluoro-β-c-methyluridine-5'-triphosphate also known gs-461203 act defective substrate ns5b non-structural protein 5b synthesis ns5b rna-dependent rna polymerase essential transcription hepatitis c viral rna high replicative rate genetic diversity a19594 sofosbuvir direct acting antiviral therefore potent option treatment hepatitis c exhibit high barrier development resistance a19593 important advantage relative hcv drug target viral enzyme protease rapid development resistance proven important cause therapeutic failure joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend sofosbuvir first line therapy combination antiviral six genotype hepatitis c l852 depending genotype sofosbuvir often used combination antiviral db09027 db11613 db09102 db06290 db11574 db11575 db00811 db00008 db00022 intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 treatment direct acting antiviral sofosbuvir associated minimal side effect common headache fatigue fda label lack significant side effect short duration therapy considerable advantage older interferon- ribavirin-based regimen limited infusion site reaction reduced blood count neuropsychiatric effect a19635 since 2014 sofosbuvir available fixed dose combination product db09027 tradename harvoni used treatment chronic hepatitis c. approved october 2014 fda harvoni indicated treatment hcv genotype 1 4 5 6 without db00811 depending level liver damage cirrhosis fda label combined together ledipasvir sofosbuvir combination product harvoni shown achieve svr 93 99 12 week treatment a7535 use also proven successful treatment hcv patient co-infected hiv a19627 sofosbuvir also available fixed dose combination product db11613 commercially available product epclusa first approved june 2016 epclusa first combination hcv product indicated treatment genotype hepatitis c without cirrhosis epclusa also currently potent hcv antiviral medication market sustained virologic response svr 12 week therapy 93-99 depending genotype level cirrhosis l852 canadian american guideline list epclusa first line recommendation genotype hcv l852 a19626 notably sofosbuvir come intense scrutiny since release market 2013 price per pill set 1000 12-week treatment cost upwards 84,000 per patient a19636 ",sofosbuvir used combination therapy antiviral medication treat chronic hepatitis c virus hcv infected patient hcv genoptypes 1-6 treat hcv hiv co-infected patient depending level cirrhosis decompensation combination therapy also include either ribavirin alone ribavirin peg-interferon alfa used combination db09027 sofosbuvir following indication treatment genotype 1 4 5 6 infection without cirrhosis compensated cirrhosis combination db00811 genotype 1 infection decompensated cirrhosis combination db00811 treatment genotype 1 4 infection liver transplant recipient without cirrhosis compensated cirrhosis used combination db11613 combination product epclusa sofosbuvir indicated treatment adult patient chronic hepatitis c virus hcv genotype 1 2 3 4 5 6 infection without cirrhosis compensated cirrhosis combination db00811 associated decompensated cirrhosis resistance reduced susceptibility sofosbuvir associated ns5b substitution mutation s282t a19634 
Obinutuzumab,obinutuzumab humanized monoclonal antibody used combination treatment chlorambucil treat patient untreated chronic lymphocytic leukemia approved fda november 2013 marketed brand name gazyva black box warning fatal hepatitis b virus hbv reactivation fatal progressive multifocal leukoencephalopathy pml ,obinutuzumab used combination treatment chlorambucil treat patient untreated chronic lymphocytic leukemia 
Chlorcyclizine,chlorcyclizine first generation phenylpiperazine class antihistamine used treat urticaria rhinitis pruritus allergy symptom chlorcyclizine also local anesthetic anticholinergic antiserotonergic property used antiemetic ,
TAS-102,tas-102 taiho pharma usa inc. anti-cancer drug development stage 3 clinical trial treatment colorectal cancer composed thymidine phosphorylase inhibitor tpi tipiracil cytotoxin trifluridine trifluridine inhibits tumor growth incorporated dna dna synthesis tipiracil prevents trifluridine broken taken orally ,
Magaldrate,magaldrate antacid drug used treatment esophagitis duodenal gastric ulcer gastroesophageal reflux magaldrate discontinued u market ,
Letosteine,letosteine mucolytic used treatment chronic bronchopneumopathies related condition ,
Kebuzone,kebuzone also known ketophenylbutazone non-steroidal anti-inflammatory drug ,
Isoxsuprine, beta-adrenergic agonist cause direct relaxation uterine vascular smooth muscle vasodilating action greater artery supplying skeletal muscle supplying skin used treatment peripheral vascular disease premature labor ,
Isoxicam,isoxicam non-steroidal anti-inflammatory drug marketed united state ,
Isoconazole,isoconazole azole antifungal drug similar effectiveness clotrimazole treatment foot vaginal infection ,
Isoaminile,isoaminile antitussive drug structure similar methadone also anticholinergic antimuscarinic antinicotinic property ,
Iotroxic acid,iotroxic acid contrast medium molecule ,
Iopanoic acid,iopanoic acid contains iodine useful contrast medium cholecystography ,
Iopamidol,iopamidol contrast agent developed bracco nonionic low-osmolar property ,
Iodamide,iodamide contrast medium molecule longer marketed united state ,
Inositol nicotinate,inositol nicotinate also known inositol hexaniacinate/hexanicotinate `` no-flush niacin '' niacin ester vasodilator used food supplement source niacin vitamin b3 hydrolysis 1 g 1.23 mmol inositol hexanicotinate yield 0.91 g nicotinic acid 0.22 g inositol niacin exists different form including nicotinic acid nicotinamide derivative inositol nicotinate associated reduced flushing compared vasodilator broken metabolite inositol slower rate nicotinic acid play essential role many important metabolic process used lipid-lowering agent inositol nicotinate prescribed europe name hexopal symptomatic treatment severe intermittent claudication raynaud ’ phenomenon ,indicated dietary supplement source niacin investigated potential beneficial effect serum lipid europe inositol hexanicotinate indicated patented drug known hexopal therapeutically indicated symptomatic relief severe intermittent claudication raynaud ’ phenomenon 
Indoramin,indoramin discontinued piperidine antiadrenergic drug trade name baratol doralese selective alpha-1 adrenergic antagonist reflex tachycardia direct myocardial depression action ,
Indoprofen, drug analgesic anti-inflammatory property following report adverse reaction including report carcinogenicity animal study withdrawn market worldwide ,
Indenolol,indenolol drug beta-adrenergic blocker class ,
Indalpine,indalpine one first selective serotonin reuptake inhibitor reach american market initially marketed pharmuka however emergence widespread concern regarding adverse effect caused ssri reported hematological effect caused indalpine abruptly withdrawn u market ,
Ifenprodil,n-methyl-d-aspartate nmda receptor nmdars member ionotropic glutamate receptor family key role brain development neurological function a220118 a220128 nmdars heterotetramers typically involve dimer dimer glun1 glun2a-d subunit subunit composed n-terminal domain ntd ligand-binding domain lbd transmembrane domain c-terminal cytoplasmic domain binding lbd agonist glycine d-serine glun1 subunit glutamate glun2 subunit regulatory mechanism channel activation addition allosteric modulators known bind ntds form another layer regulation a220118 a220128 one allosteric regulator ifenprodil first shown bind nmdars 1990s specifically nmdars containing glun2b subunit a220133 study elucidated ifenprodil bind strongly inter-subunit interface adjacent glun1 glun2b ntds act non-competitive antagonist a220118 a220128 although ifenprodil received considerable interest potential neuromodulatory activity psychiatric condition including dependency a220138 depression a220143 also shown immunomodulatory effect a220143 a196128 unbiased screen compound capable reducing cell death induced infection influenza strain h5n1 ifenprodil found protective effect h5n1-induced lung damage part ability alleviate h5n1-induced cytokine storm reduce pulmonary infiltration neutrophil natural killer cell cell a196128 ifenprodil investigated potential utility treating covid-19 ongoing phase 2b/3 clinical trial nct04382924 l16343 ,
Ibuproxam,ibuproxam non steroidal anti-inflammatory drug nsaid ,
Hydroxydione,hydroxydione viadril neuroactive steroid used general anesthetic ,
Hexoprenaline,hexoprenaline stimulant beta 2 adrenergic receptor used bronchodilator antiasthmatic tocolytic agent ,
Hexetidine, bactericidal fungicidal antiseptic used 0.1 mouthwash local infection oral hygiene ,
Hexamethonium, nicotinic cholinergic antagonist often referred prototypical ganglionic blocker poorly absorbed gastrointestinal tract cross blood-brain barrier used variety therapeutic purpose including hypertension like ganglionic blocker replaced specific drug purpose although widely used research tool ,
Azosemide,azosemide loop diuretic used treat hypertension edema ascites ,
Glibornuride,glibornuride sulfonylurea-type anti-diabetic drug ,
Glafenine, anthranilic acid derivative analgesic property used relief type pain glafenine withdrawn american market ,
Gemeprost,gemeprost prostaglandin e1 pge1 analog antiprogestogen used preoperative dilation cervix surgical abortion available vaginal suppository also used combination antiprogestin mifepristone termination 1st- 2nd-trimester pregnancy a19726 fda-approved available japan marketed preglandin ,indicated softening dilatation cervix uterus prior transcervical intrauterine operative procedure first trimester pregnancy facilitating therapeutic termination pregnancy patient second trimester gestation 
Fusafungine,fusafungine antibiotic fusarium lateririum used treatment respiratory infection ,
Fursultiamine,compound used therapy thiamine deficiency also suggested several non-deficiency disorder yet proven useful fursultiamine vitamin b1 derivative ,
Dimetotiazine,dimetotiazine considerable antiemetic serotonin antagonistic action used mainly allergic skin condition ,
Fominoben,fominoben antitussive agent ,
Flurothyl,flurothyl convulsant primarily used experimental animal formerly used induce convulsion alternative electroshock therapy ,
Fluprednidene,fluprednidene corticosteroid ,
Fluocortolone,fluocortolone glucocorticoid anti-inflammatory activity used topically various skin disorder ,
Flumequine,flumequine synthetic chemotherapeutic antibiotic fluoroquinolone drug class used treat bacterial infection ,
Fluclorolone acetonide,fluclorolone acetonide inn flucloronide usan topical corticosteroid marketed brand name cutanit topicon ,
Flubendazole,flubendazole anthelmintic used treat worm infection human available otc europe ,
Florantyrone,florantyrone used treatment biliary dyskinesia,
Floctafenine,floctafenine anti-inflammatory analgesic similar action aspirin floctafenine inhibits prostaglandin synthesis ,
Fentonium,fentonium atropine derivative ,
Fenspiride,fenspiride oxazolidinone spiro compound used drug treatment certain respiratory disease approved use russia treatment acute chronic inflammatory disease ent organ respiratory tract like rhinopharyngitis laryngitis tracheobronchitis otitis sinusitis well maintenance treatment asthma ,
Fendiline,fendiline coronary vasodilator inhibits calcium function muscle cell excitation-contraction coupling proposed antiarrhythmic antianginal agent fendiline non-selective ,
Fenbufen,fenbufen non-steroidal anti-inflammatory drug used primarily treat inflammation osteoarthritis ankylosing spondylitis tendinitis also used relieve backache sprain fracture fenbufen available capsule tablet sold brand name cepal cinopal cybufen lederfen reugast fenbufen act preventing cyclooxygenase producing prostaglandin cause inflammation ,
Etozoline,etozoline marketed europe name diulozin elkapin etopinil etozoline loop diuretic ,
Etofibrate,etofibrate fibrate produced combination clofibrate ester linked niacin component separate body slowly allowing pharmacokinetics similar controlled-release formulation ,
Etofenamate,etofenamate used treat muscle joint paint non-steroidal anti-inflammatory drug nsaid ,
Etilefrine,etilefrine adrenergic agonist appears interact beta-1 alpha-adrenergic receptor used vasoconstrictor agent ,
Etifoxine,etifoxine anxiolytic anticonvulsant drug developed hoechst 1960s used anxiety disorder promote peripheral nerve healing bind benzodiazepine receptor though effect similar benzodiazepine effective lorazepam anxiolytic fewer side effect etifoxine associated acute liver injury ,
Etidocaine,etidocaine marketed name duranest injectable local anesthetic surgery labor delivery etidocaine long duration activity main disadvantage increased bleeding oral surgery ,
Ethoheptazine,ethoheptazine marketed name zactane phenazepine based opioid analgesic invented 1950s related drug proheptazine ethoheptazine longer marketed united state ,
Etamivan,etamivan inn ethamivan usan marketed name analepticon etamvin respiratory stimulant drug similar nikethamide longer used united state ,
Eprazinone,eprazinone trade name eftapan mucolytic drug relief bronchospasm ,
Epirizole,epirizole oral nonsteroidal anti-inflammatory drug nsaid used muscle joint pain ,
Eperisone,eperisone antispasmodic drug relaxes skeletal muscle vascular smooth muscle demonstrates variety effect reduction myotonia improvement circulation suppression pain reflex approved use united state available country like india south korea bangladesh ,
Enviomycin,cyclic basic peptide related viomycin isolated induced mutant streptomyces griseoverticillatus var tuberacticus act antitubercular agent le ototoxicity tuberactinomycin ,
Ditazole,ditazole non-steroidal anti-inflammatory drug nsaid ditazole 's analgesic antipyretic effect similar phenylbutazone additionally ditazole platelet aggregation inhibitor marketed spain portugal trade name ageroplas ,
Diosmin,chronic venous insufficiency common condition western population compression pharmacotherapy frequently used manage chronic venous insufficiency improving circulation symptom venous disease a232885 diosmin bioflavonoid isolated various plant synthesized hesperidin used improvement capillary fragility venous insufficiency including chronic venous insufficiency cvi hemorrhoid diosmin widely available over-the-counter demonstrates favourable favorable safety profile a232890 t840 l33040 ,diosmin used over-the-counter alone ingredient hesperidin diosmetin support vein capillary function l32823 l32848 
Dimetacrine,dimetacrine also known dimethacrine acripamine marketed name istonil istonyl linostil miroistonil dimetacrine tricyclic antidepressant tca imipramine-like effect used europe treatment depression dimetacrine longer used japan ,
Dexetimide, muscarinic antagonist used treat neuroleptic-induced parkinsonism benzetimide -enantimorph dexetimide ,
Demexiptiline,demexiptiline marketed name deparon tinoran tricyclic antidepressant act primarily norepinephrine reuptake inhibitor ,
Cyclopentamine,cyclopentamine sympathomimetic alkylamine classified vasoconstrictor cyclopentamine counter treatment nasal congestion europe australia widely discontinued due safety effectiveness availability similar drug propylhexedrine ,
Cyamemazine,cyamemazine tercian also known cyamepromazine typical antipsychotic drug phenothiazine class used primarily treatment schizophrenia psychosis-associated anxiety cyamemazine actually behaves like atypical antipsychotic due potent anxiolytic effect 5-ht2c lack extrapyramidal side effect 5-ht2a ,
Barbexaclone,barbexaclone salt compound propylhexedrine phenobarbital potent antiepileptic weight barbexaclone 40 propylhexedrine 60 phenobarbital barbexaclone sedative property propylhexedrine psychostimulant property intended offset sedative effect pharmacokinetic study demonstrated pharmacokinetics phenobarbital given barbexaclone affected propylhexedrine several report spanish italian literature suggest barbexaclone least effective phenobarbital adult child better tolerated le sedative property report conducted small series patient 1970s 1980s yet confirmed larger controlled trial despite lack controlled trial barbexaclone used widely turkey discontinued 2009 barbexaclone exists 25mg 100mg tablet 100mg barbexaclone equivalent 60mg phenobarbital difference potency mind pharmacokinetic consideration dose titration daily dosing optimal plasma concentration considered equivalent amount phenobarbital case barbexaclone abuse due amphetamine like property propylhexedrine although comparative abuse potential much lower amphetamine ,created treatment epilepsy intent creating antiepileptic le sedative property phenobarbital 
Cloperastine,cloperastine cough suppressant act central nervous system ,
Clocapramine,clocapramine atypical antipsychotic imidobenzyl class introduced japan 1974 treatment schizophrenia addition psychosis clocapramine also used augment antidepressant treatment anxiety panic clocapramine implicated least one strange death including suicide ,
Clobutinol,clobutinol cough suppressant withdrawn u eu market clobutinol may prolong qt interval 2007 clobutinol determined cause cardiac arrhythmia patient ,
Batroxobin,"batroxobin defibrinogenating hemostatic agent derived venom pit viper bothrops atrox moojeni addition batroxobin venom bothrops atrox composition 10.2 neutral carbohydrate batroxobin serine protease cleaves 16 arginine 17 glycine bond fibrinogen mw batroxobin approximately 43,000 g/mol-1 contains 231 amino acid batroxobin inactivated alpha2-macroglobulin anti-thrombin compound batroxobin also bind fibrinogen manner different thrombin higher affinity bound fibrin cause fibrin accretion clot formation degree 18 fold greater thrombin currently use experimental trial conducted support certain clinical application recombinant batroxobin relatively affordable could accessed mass production ", approved indication batroxobin defibrongenating agent observed reduce fibrinogen level thus reduce clot risk used intravenously 
Clinofibrate,clinofibrate fibrate drug sold marketed japan ,
Chlorphenoxamine,chlorphenoxamine marketed name phenoxene antihistamine anticholinergic used treat itching well antiparkinsonian effect ,
Cefaloridine,cephaloridine cefaloridine first generation semisynthetic cephalosporin derived cephalosporin c zwitterion physiological ph ,
Articaine,articaine dental local anesthetic articaine widely used around world popular local anesthetic many european country ,
Carmofur,carmofur derivative fluorouracil antineoplastic agent used treatment breast colorectal cancer carmofur known induce leukoencephalopathy ,
Beclamide,beclamide n-benzyl-b-chloropropionamide longer used drug posse anticonvulsant sedative activity studied 1950s generalised tonic-clonic seizure effective absence seizure , used management epilepsy epilepsy related behavioural disorder used generalised tonic-clonic seizure effective absence seizure recently focus shifted use beclamide behavioural disorder mentally handicapped epileptic patient found decrease anxiety antisocial demanding behaviour impulsivity mood stabilizing effect also noted 2 additionally due effect monoamine beclamide may potential place treating condition tardive dyskinesia hyperkinetic syndrome 2 
Carbazochrome,carbazochrome hemostatic agent promotes clotting preventing blood loss open wound oxidation product adrenaline enhances microcirculatory tone a19747 future may prevent excessive blood flow surgical operation treatment hemorrhoid research effectiveness severity side effect remains inconclusive fda-approved available tablet im/sc injection treatment hemorrhage number country carbazochrome investigated use treatment non-surgical acute uncomplicated hemorrhoid mixture db13124 combination therapy demonstrated efficacy safe tolerability either local systemic level a19744 ,indicated capillary parenchymal hemorrhage trauma tonsillectomy surgery intestinal bleeding thrombocytopenic purpura 
Befunolol,befunolol beta blocker introduced 1983 kakenyaku kakko currently experimental status tested management open angle glaucoma ,used management open angle glaucoma pmid 12480285 
Captodiame,captodiame also known captodiamine antihistamine used sedative anxiolytic derivative diphenhydramine captodiame suggested use preventing benzodiazepine withdrawal syndrome ,captodiame indicated treatment anxiety 
Canrenoic acid,canrenoic acid salt potassium canrenoate aldosterone antagonist like spironolactone prodrug metabolized canrenone body ,
Butriptyline,butriptyline tricyclic antidepressant used europe since 1974 isobutyl side chain homologue amitriptyline ,
Brotizolam,brotizolam sedative-hypnotic thienodiazepine drug benzodiazepine analog demonstrates anxiolytic anticonvulsant hypnotic sedative skeletal muscle relaxant effect brotizolam similar effect short-acting benzodiazepine triazolam brotizolam indicated 2-4 week treatment severe debilitating insomnia brotizolam extremely potent drug rapidly eliminated average half-life 4.4 hour range 3.6 7.9 hour brotizolam approved sale uk united state canada sold netherlands germany spain belgium austria portugal israel italy japan ,brotizolam indicated 2-4 week treatment severe debilitating insomnia 
Bromopride,bromopride dopamine antagonist used antiemetic prokinetic property similar metoclopramide unavailable america united kingdom ,bromopride indicated treatment nausea vomiting including ponv post-operative nausea vomiting gastroesophageal reflux disease gerd/gord well endoscopy preparation radiographic study gi tract 
Bromhexine,bromhexine mucolytic agent used variety respiratory condition associated increased mucus secretion derived adhatoda vasica plant aid clearance excess mucus improving breathing reducing cough introduced market 1963 widely available over-the-counter drug many country a233240 recently bromhexine metabolite ambroxol garnered interest potential prevention treatment covid-19 due interaction cell receptor lung a233345 a233370 ,bromohexine used alone ingredient diphenhydramine dextromethorphan guaifenesin reduce mucus viscosity clear mucus condition associated mucus hypersecretion including common cold influenza respiratory tract infection condition l29975 l24819 l33060 
Bisacodyl,bisacodyl diphenylmethane derivative commonly used counter stimulant laxative occasional constipation a233300 l13362 bisacodyl picosulfate metabolized active metabolite bis- p-hydroxyphenyl -pyridyl-2-methane bhpm a233290 a233300 a207700 bisacodyl patented 25 september 1956 l33045 used laxative since 1952 a233300 ,bisacodyl indicated relieve occasional constipation irregularity l13362 
Benzoctamine,benzoctamine drug two main us used sedative depress respiratory system rather stimulates also used anxiolytic efficacy chlordiazepoxide treating anxiety neurosis ,
Benfluorex,benfluorex anorectic hypolipidemic agent structurally related fenfluramine patented manufactured french pharmaceutical company servier european medicine agency ema recommended withdrawing benfluorex containing medicine 18 december 2009 recommendation based risk especially fenfluramine-like cardiovascular side-effects outweighing benefit ,
Benactyzine,benactyzine anticholinergic drug used antidepressant treatment depression associated anxiety benactyzine longer widely used medicine although still useful drug scientific research posse antihistamine property ,
Aliskiren,aliskiren first drug renin inhibitor drug class used treatment hypertension a203624 developed speedel novartis initially approved fda early 2007 l14018 aliskiren proven efficacious reducing blood pressure used alone conjunction antihypertensive agent a203624 ,aliskiren used treatment hypertension child 6 year adult l13994 drug may also used conjunction antihypertensive calcium channel blocker thiazide product form provide additional blood pressure control l14168 l14171 
Ledipasvir,ledipasvir direct acting antiviral daa medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas ledipasvir specifically ledipasvir inhibitor hepatitis c virus hcv non-structural protein 5a ns5a required viral rna replication assembly hcv virion although exact mechanism action unknown postulated prevent hyperphosphorylation ns5a required viral protein production effective genotype 1a 1b 4a 5a lesser activity genotype 2a 3a hcv ledipasvir direct acting antiviral potent option treatment hepatitis c exhibit high barrier development resistance a19593 important advantage relative hcv drug target viral enzyme protease rapid development resistance proven important cause therapeutic failure joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend ledipasvir first line therapy option combination sofosbuvir treatment hcv genotype 1a 1b 4 5 6 l852 treatment ledipasvir used intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 treatment direct acting antiviral ledipasvir associated minimal side effect common headache fatigue fda label lack significant side effect short duration therapy considerable advantage older interferon- ribavirin-based regimen limited infusion site reaction reduced blood count neuropsychiatric effect a19635 since 2014 ledipasvir available fixed dose combination product sofosbuvir tradename harvoni used treatment chronic hepatitis c. approved october 2014 fda harvoni indicated treatment hcv genotype 1 4 5 6 without ribavirin depending level liver damage cirrhosis fda label combined together ledipasvir sofosbuvir combination product harvoni shown achieve svr 93 99 12 week treatment fda label use also proven successful treatment hcv patient co-infected hiv a19627 , used combination antiviral medication sofosbuvir ledipasvir indicated treatment treatment chronic hepatitis c virus hcv adult pediatric patient 3 year age older following condition l3547 genotype 1 4 5 6 infection without cirrhosis compensated cirrhosis genotype 1 infection decompensated cirrhosis combination ribavirin genotype 1 4 infection liver transplant recipient without cirrhosis compensated cirrhosis combination ribavirin use also proven successful treatment hcv patient co-infected hiv a19627 
Cytisine,cytisine alkaloid naturally derived fabaceae family plant including genus laburnum cytisus recent study shown effective significantly affordable smoking cessation treatment nicotine replacement therapy also known baptitoxine sophorine cytisine used smoking cessation treatment since 1964 relatively unknown region outside central eastern europe cytisine partial nicotinic acetylcholine agonist half-life 4.8 hour recent phase iii clinical trial using tabex brand cytisine marketed sopharma ad shown similar efficacy varenicline fraction cost ,indicated use smoking cessation 
Secukinumab,secukinumab fully human monoclonal igg1/κ antibody interleukin-17a il-17a proinflammatory cytokine implicated various chronic immune-mediated inflammatory disorder plaque psoriasis l39600 blocking action il-17a secukinumab work inhibit pro-inflammatory pathway drive immune-mediated inflammatory disorder a249840 following first global approval japan december 2014 secukinumab approved european commission january 15 2015 fda day january 21 2015 a249805 currently approved treat number chronic inflammatory condition plaque psoriasis psoriatic arthritis ankylosing spondylitis l39600 l42280 ,secukinumab indicated treatment moderate severe plaque psoriasis patient six year older candidate systemic therapy phototherapy l39600 europe drug used child adolescent six 18 year age indication l42280 also indicated treatment active psoriatic arthritis psa u approved patient two year age older l39600 europe used alone combination methotrexate patient six year older whose disease responded inadequately tolerate conventional therapy l42280 secukinumab also indicated treatment active enthesitis-related arthritis era u approved patient four year age older l39600 europe used alone combination methotrexate patient six year older whose disease responded inadequately tolerate conventional therapy l42280 u secukinumab indicated treatment adult active ankylosing spondylitis non-radiographic axial spondyloarthritis objective sign inflammation l39600 
Vorapaxar,vorapaxar tricyclic himbacine-derived selective inhibitor protease activated receptor par-1 indicated reducing incidence thrombotic cardiovascular event patient history myocardial infarction mi peripheral arterial disease pad inhibiting par-1 thrombin receptor expressed platelet vorapaxar prevents thrombin-related platelet aggregation ,vorapaxar indicated reduction thrombotic cardiovascular event patient history myocardial infarction mi peripheral arterial disease pad usually co-administered acetylsalicylic acid asa and/or clopidogrel therefore administered addition medication studied alone 
Miltefosine,miltefosine broad spectrum antimicrobial anti-leishmanial phospholipid drug originally developed 1980s anti-cancer agent currently recognized oral agent used treat visceral cutaneous mucosal form leishmaniasis neglected tropical disease administered topically orally indicated patient aged 12 year older cdc also recommended first line treatment free-living ameba fla infection primary amebic meningoencephalitis granulomatous amebic encephalitis , treatment mucosal caused leishmania braziliensis cutaneous caused l. braziliensis l. guyanensis l. panamensis visceral leishmaniasis caused l. donovani comparing leishmania drug susceptibility found l. donovani susceptible miltefosine l. major least susceptible off-label use includes treatment free-living ameba fla infection unlabeled use cdc 2013 
Vedolizumab,vedolizumab recombinant humanized igg1 monoclonal antibody directed human lymphocyte α4β7 integrin key mediator gastrointestinal inflammation used treatment moderate severe active ulcerative colitis crohn 's disease patient inadequate response lost response intolerant inhibitor tumor necrosis factor-alpha tnf-alpha conventional therapy blocking primary target α4β7 integrin vedolizumab reduces inflammation gut vedolizumab administered iv infusion period 30 minute first dose given two six week every 8 week thereafter ,vedolizumab indicated adult patient moderately severely active uc cd inadequate response lost response intolerant tumor necrosis factor tnf blocker immunomodulator inadequate response intolerant demonstrated dependence corticosteroid 
Suvorexant,suvorexant selective dual antagonist orexin receptor ox1r ox2r promotes sleep reducing wakefulness arousal approved treatment insomnia ,suvorexant indicated treatment insomnia characterized difficulty sleep onset and/or sleep maintenance 
Nivolumab,nivolumab fully human igg4 antibody targeting immune checkpoint programmed death receptor-1 pd-1 l12129 antibody produced entirely mouse grafted onto human kappa igg4 fc region mutation _s228p_ additional stability reduced variability a35203 developed bristol myers squibb l12129 nivolumab granted fda approval 22 december 2014 l12129 ,nivolumab indicated treat unresectable metastatic melanoma melanoma adjuvant treatment resectable metastatic non-small cell lung cancer small cell lung cancer advanced renal cell carcinoma classical hodgkin lymphoma squamous cell carcinoma head neck urothelial carcinoma microsatellite instability-high mismatch repair deficient metastatic colorectal cancer hepatocellular carcinoma esophageal cancer l12129 l42970 nivolumab also approved treatment her2-negative advanced metastatic gastric gastroesophageal junction esophageal adenocarcinoma used combination fluoropyrimidine- platinum-containing chemotherapy regimen l39040 combination relatlimab nivolumab indicated treatment patient ≥12 year old unresectable metastatic melanoma l41265 
Siltuximab,siltuximab chimeric human-mouse monoclonal immunoglobulin g1-kappa antibody produced chinese hamster ovary cho cell line recombinant dna technology siltuximab prevents binding il-6 soluble membrane-bound il-6 receptor forming high affinity complex human interleukin-6 il-6 use indicated treatment adult patient multicentric castleman 's disease mcd human immunodeficiency virus hiv negative human herpesvirus-8 hhv-8 negative mcd rare blood disorder caused dysregulated il-6 production proliferation lymphocyte subsequent enlargement lymph node administered 1 hour intravenous infusion every 3 week ,siltuximab indicated treatment patient multicentric castleman 's disease mcd human immunodeficiency virus hiv negative human herpesvirus-8 hhv-8 negative siltuximab bind virally produced il-6 nonclinical study therefore studied patient mcd hiv hhv-8 positive 
Pembrolizumab,pembrolizumab highly selective igg4-kappa humanized monoclonal antibody pd-1 receptor generated grafting variable sequence high-affinity mouse antihuman pd-1 antibody onto human igg4-kappa isotype containing stabilizing s228p fc mutation a18829 contains 32 cysteine residue complete folded molecule includes 4 disulfide linkage interchain bond 23 interchain bond f136 developed merck co first approved treatment metastatic malignant melanoma fda september 4 2014 l2954 becoming first approved therapy pd-1 a7624 time since initial approval pembrolizumab granted approval treatment wide variety cancer l38934 l43257 ,pembrolizumab indicated following condition l38934 melanoma treatment patient unresectable metastatic melanoma adult patient u l38934 patient ≥12 year old eu l43488 adjuvant treatment adult pediatric patient 12 year age older stage iib iic iii melanoma following complete resection non-small cell lung cancer nsclc combination pemetrexed platinum-based chemotherapy first-line treatment patient metastatic nonsquamous nsclc egfr alk mutation combination carboplatin paclitaxel first-line treatment patient metastatic squamous nsclc monotherapy first-line treatment nsclc expressing pd-l1 egfr alk mutation patient metastatic disease stage iii disease candidate surgery chemoradiation monotherapy treatment nsclc expressing pd-l1 disease progression platinum-based chemotherapy includes patient egfr alk mutation providing experienced disease progression prior fda-approved therapy aberration head neck squamous cell cancer hnscc combination fluorouracil platinum-based chemotherapy first-line treatment patient metastatic recurrent unresectable hnscc monotherapy first-line treatment patient metastatic recurrent unresectable hnscc expressing pd-l1 monotherapy treatment patient metastatic recurrent hnscc disease progression platinum-based chemotherapy classical hodgkin lymphoma chl treatment adult patient relapsed refractory chl treatment pediatric patient refractory chl chl relapsed following ≥2 line therapy primary mediastinal large b-cell lymphoma pmbcl treatment adult pediatric patient refractory pmbcl pmbcl relapsed following ≥2 line therapy urothelial carcinoma treatment locally advanced metastatic urothelial carcinoma patient ineligible platinum-based chemotherapy treatment locally advanced metastatic urothelial carcinoma patient disease progression following platinum-based chemotherapy within 12 month adjuvant/neoadjuvant platinum-based chemotherapy treatment bcg vaccine -unresponsive high-risk non-muscle invasive bladder cancer carcinoma situ without papillary tumor candidate cystectomy microsatellite instability-high msi-h mismatch repair deficient cancer dmmr last-line therapy treatment adult pediatric patient unresectable metastatic msi-h dmmr solid tumor progressed following prior treatment treatment patient unresectable metastatic msi-h dmmr colorectal cancer gastric cancer combination trastuzumab fluoropyrimidine- platinum-containing chemotherapy first-line treatment patient locally advanced unresectable metastatic her2-positive gastric gastroesophageal junction gej adenocarcinoma esophageal cancer combination fluoropyrimidine- platinum-based chemotherapy treatment patient locally advanced metastatic esophageal gej carcinoma candidate surgery definitive chemoradiation monotherapy treatment locally advanced metastatic esophageal gej carcinoma expressing pd-l1 patient candidate surgery definitive chemoradiation cervical cancer combination chemotherapy without bevacizumab treatment persistent recurrent metastatic cervical cancer expressing pd-l1 monotherapy treatment recurrent metastatic cervical cancer expressing pd-l1 patient experienced disease progression previous chemotherapy hepatocellular carcinoma hcc monotherapy treatment hcc patient previously treated sorafenib merkel cell carcinoma mcc treatment adult pediatric patient recurrent locally advanced metastatic mcc renal cell carcinoma rcc combination either axitinib lenvatinib first-line treatment adult patient advanced rcc adjuvant treatment patient rcc intermediate-high high risk recurrence following nephrectomy following nephrectomy resection metastatic lesion endometrial carcinoma combination lenvatinib treatment patient advanced endometrial carcinoma msi-h dmmr experience disease progression following prior systemic therapy candidate surgery radiation therapy monotherapy treatment patient advanced endometrial carcinoma msi-h dmmr disease progression following prior systemic therapy candidate curative surgery radiation tumor mutational burden-high tmb-h cancer last-line therapy treatment adult pediatric patient unresectable metastatic tmb-h solid tumor progressed following prior treatment cutaneous squamous cell carcinoma cscc treatment patient recurrent metastatic scc locally advanced scc curable surgery radiation therapy triple-negative breast cancer tnbc treatment patient high-risk early-stage tnbc combination chemotherapy neoadjuvant treatment followed continued use single adjuvant agent following surgery combination chemotherapy treatment locally recurrent unresectable metastatic tnbc expressing pd-l1 approved adult indication pembrolizumab may used additional 6 week 400mg weekly l38934 
Empagliflozin,empagliflozin inhibitor sodium-glucose co-transporter-2 sglt2 transporter primarily responsible reabsorption glucose kidney a203453 used clinically adjunct diet exercise often combination drug therapy l13673 l13679 l11479 management type 2 diabetes mellitus l13688 first known inhibitor sglts phlorizin isolated bark apple tree 1835 researched extensively 20th century ultimately deemed inappropriate clinical use given lack specificity significant gastrointestinal side effect a203501 attempt overcoming limitation first saw development o-glucoside analog phlorizin e.g remogliflozin etabonate molecule proved relatively pharmacokinetically unstable development c-glucoside phlorizin analog remedied issue observed previous generation led fda approval canagliflozin 2013 dapagliflozin empagliflozin 2014 a203501 recently approved `` flozin '' drug empagliflozin carry highest selectivity sglt2 sglt1 approximately 2700-fold empagliflozin approved ema march 2022 health canada april 2022 making first approved treatment europe canada adult symptomatic chronic heart failure regardless ejection fraction l40783 l13916 ,empagliflozin indicated adjunct diet exercise improve glycemic control adult patient type 2 diabetes also indicated reduce risk cardiovascular death adult patient type 2 diabetes mellitus established cardiovascular disease l13688 l40778 empagliflozin also available combination product either metformin l13679 linagliptin l13673 adjunct diet exercise management type 2 diabetes mellitus adult extended-release combination product containing empagliflozin metformin linagliptin approved fda january 2020 improvement glycemic control adult type 2 diabetes mellitus used adjunctively diet exercise l11479 empagliflozin also approved reduce risk cardiovascular mortality hospitalization due heart failure adult patient heart failure l13688 europe empagliflozin indicated adult treatment symptomatic chronic heart failure reduced ejection fraction l40778 empagliflozin approved use patient type 1 diabetes 
Eliglustat,eliglustat glucosylceramide synthase inhibitor used long-term treatment type 1 gaucher disease a3752 l41404 gaucher disease rare genetic disorder characterized deficiency acid β-glucosidase enzyme convert glucosylceramide glucose ceramide patient gaucher disease accumulation glucosylceramide lead formation gaucher cell infiltrate liver spleen bone marrow organ lead complication anemia thrombocytopenia l41404 a246384 inhibiting glucosylceramide synthase eliglustat reduces accumulation glucosylceramide l41404 eliglustat mainly metabolized cyp2d6 l41404 patient selected eliglustat treatment undergo fda-cleared genotyping test establish cyp2d6 extensive metabolizers em intermediate metabolizers ims poor metabolizers pm result test dictate eliglustat dosing recommendation type patient dosing recommendation cyp2d6 ultra-rapid indeterminate metabolizers l41404 a7634 eliglustat approved fda august 2014 oral substrate reduction therapy first-line treatment type 1 gaucher disease l41404 a7634 enzyme replacement continues standard care treatment type 1 gaucher disease imiglucerase velaglucerase alfa taliglucerase alfa however oral substrate reduction therapy favourable safety profile eliglustat represent treatment alternative a246389 a7634 ,eliglustat glucosylceramide synthase inhibitor indicated long-term treatment type 1 gaucher disease adult patient cyp2d6 extensive metabolizers em intermediate metabolizers ims poor metabolizers pm detected fda-cleared test l41404 cyp2d6 ultra-rapid metabolizers may achieve adequate eliglustat concentration achieve therapeutic effect specific dosage recommended cyp2d6 indeterminate metabolizers l41404 
Efinaconazole,efinaconazole 14 alpha-demethylase inhibitor indicated treatment fungal infection nail known onychomycosis approved use canada usa 2014 marketed valeant pharmaceutical north america llc name jublia ,indicated treatment fungal infection nail known onychomycosis 
Tavaborole,tavaborale novel boron-based topical antifungal medication treatment onychomycosis fungal infection nail nail bed due trichophyton rubrum trichophyton mentagrophytes infection tavaborole function inhibiting leucyl-trna synthetase leurs essential fungal enzyme required protein synthesis catalysis atp-dependent ligation l-leucine trna leu ,indicated treatment onychomycosis fungal infection toenail due trichophyton rubrum /i trichophyton mentagrophytes /i l34989 
Tedizolid phosphate,drug-resistant bacteria methicillin-resistant _staphylococcus aureus_ vancomycin-resistant _enterococcus faecium_ penicillin-resistant _streptococcus penumoniae_ represent massive public health threat a199086 a199131 tedizolid member oxazolidinone class antibiotic includes previously approved linezolid generally effective multidrug-resistant gram-positive bacteria tedizolid indicated treatment acute bacterial skin skin structure infection absssi generally effective tolerable linezolid l11232 a199086 a199050 tedizolid approved fda june 20 2014 sale cubist pharmaceutical tedizolid phosphate sivextro® product currently available oral tablet powder intravenous injection l11232 ,tedizolid indicated treatment acute bacterial infection skin skin structure absssi prevent drug resistance tedizolid used infection caused susceptible bacteria l11232 
Albiglutide,albiglutide glucagon-like peptide-1 agonist glp-1 biologic drug indicated treatment type 2 diabetes marketed brand eperzan tanzeum gsk glaxosmithkline dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused human albumin albiglutide approved april 15 2014 fda ,indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus 
Dulaglutide,dulaglutide marketed eli lilly trulicity once-weekly subcutaneous glucagon-like peptide-1 glp-1 receptor agonist designed using recombinant dna technology approved adjunct therapy diet exercise management 2 diabetes t2dm a236070 dulaglutide initially approved fda 2014 february 2020 approved use patient t2dm multiple cardiovascular risk factor prevention cardiovascular event first t2dm drug approved reduce major adverse cardiovascular event mace risk primary secondary prevention population l34665 ,dulaglutide indicated adjunct diet exercise improve glycemic control adult pediatric patient ≥10 year age type 2 diabetes mellitus l30380 also indicated reduce risk major adverse cardiovascular event adult type 2 diabetes mellitus established cardiovascular disease multiple cardiovascular risk factor l30380 
Metreleptin,metreleptin recombinant analog human hormone leptin orphan drug used treat complication leptin deficiency people congenital acquired lipodystrophy affecting le 500 people worldwide lipodystrophy characterized lack adipose tissue fat deposition muscle liver metabolic complication hypertriglyceridemia insulin resistance diabetes mellitus fatty liver disease metabolic abnormality often aggravated excessive food intake aggravated leptin deficiency protein secreted adipose tissue administration metreleptin result improvement metabolic symptom including improvement insulin resistance reduced hba1c fasting glucose reduced triglyceride reduction food intake metreleptin produced e. coli differs native human leptin addition methionine residue amino terminus administered daily subcutaneous injection feb. 24 2014 metreleptin approved fda treatment complication leptin deficiency addition diet patient congenital generalized acquired generalized lipodystrophy metreleptin marketed brand myalept® aegerion pharmaceutical inc ,metreleptin indicated adjunct diet replacement therapy treat complication leptin deficiency patient congenital acquired generalized lipodystrophy l41315 
Finafloxacin,finafloxacin fluoroquinolone antibiotic indicated treatment acute otitis externa swimmer 's ear caused bacteria pseudomonas aeruginosa staphylococcus aureus finafloxacin marketed novartis brand xtoro™ approved fda december 2014 ,finafloxacin indicated treatment acute otitis externa aoe without otowick caused susceptible strain pseudomonas aeruginosa /i staphylococcus aureus /i patient age 1 year older 
Netupitant,netupitant antiemitic drug approved fda october 2014 use combination palonosetron prevention acute delayed vomiting nausea associated cancer chemotherapy including highly emetogenic chemotherapy netupitant neurokinin 1 receptor antagonist combination drug marketed eisai inc. helsinn therapeutic u.s. inc. brand akynzeo ,netupitant antiemitic drug approved fda october 2014 use combination palonosetron prevention acute delayed vomiting nausea associated cancer chemotherapy including highly emetogenic chemotherapy 
Naloxegol,naloxegol `` pegylated naloxol '' peripherally-selective opioid antagonist developed astrazeneca approved fda september 2014 indicated treatment opioid-induced constipation oic adult patient chronic non‑cancer pain advantage naloxegol opioid antagonist naloxone pegylated structure allows high selectivity peripheral opioid receptor lack entry central nervous system blood-brain barrier ,indicated treatment opioid-induced constipation oic adult patient chronic non-cancer pain 
Ceftolozane,ceftolozane semi-synthetic broad-spectrum fifth generation cephalosporin l6685 approved fda 2014 use combination tazobactam treatment serious infection intra-abdominal infection complicated urinary tract infection manufacturer drug cubist pharmaceutical a179422 recently june 2019 ceftolozane-tazobactam approved treatment hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia l41618 hospital-acquired pneumonia ventilator-associated pneumonia major cause morbidity mortality hospitalized patient use ceftolozane-tazobactam offer effective activity various organism causing infection pseudomonas aeruginosa l6691 ,ceftolozane used combination tazobactam treatment infection caused designated susceptible microorganism adult pediatric patient l41618 complicated intra-abdominal infection ciai used combination metronidazole complicated urinary tract infection cuti including pyelonephritis hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia habp/vabp 
Elosulfase alfa,elosulfase alfa synthetic version enzyme n-acetylgalactosamine-6-sulfatase approved fda 2014 treatment morquio syndrome elosulfase alfa developed biomarin pharmaceutical inc. marketed brand vimizim™ recommended dose 2 mg per kg given intravenously minimum range 3.5 4.5 hour based infusion volume every week ,vimizim hydrolytic lysosomal glycosaminoglycan gag -specific enzyme indicated patient mucopolysaccharidosis type iva mp iva morquio syndrome 
Blinatumomab,blinatumomab bite-class bi-specific t-cell engager constructed monoclonal antibody formed recombinant fusion anti-cd3 single-chain variable fragment scfv anti-cd19 scfv short peptide linker a254836 l44311 cd3 antigen expressed surface t-cells cd19 mostly expressed surface malignant b-cells since blinatumomab affinity antigen redirects t-cells tumor cell expressing cd19 promotes tumor cell lysis apoptosis a7659 a7660 a254831 blinatumomab manufactured amgen inc. marketed brand blincyto approved december 2014 fda ’ accelerated approval program treatment cd19-positive b-cell precursor acute lymphoblastic leukemia first second complete remission minimal residual disease mrd greater equal 0.1 adult child later approved treatment cd19-positive b-cell precursor relapsed refractory patient l44311 blinatumomab short half-life requiring patient receive continuous infusion 4-week cycle using portable mini-pump optimum delivery a254826 ,blinatumomab indicated treatment adult child relapsed refractory cd19-positive b-cell precursor acute lymphoblastic leukemia also indicated adult child treatment cd19-positive b-cell precursor first second complete remission minimal residual disease mrd greater equal 0.1 last indication approved accelerated approval based mrd response rate hematological relapse-free survival continued approval indication may contingent upon verification description clinical benefit confirmatory trial l44311 
Ibrutinib,ibrutinib small molecule act irreversible potent inhibitor burton 's tyrosine kinase designated targeted covalent drug present promising activity b cell malignancy a32299 ibrutinib developed pharmacyclics inc november 2013 fda-approved treatment mantle cell lymphoma later february 2014 ibrutinib approved treatment chronic lymphocytic leukemia also indicated treatment patient waldenström 's macroglobulinemia l12228 ibrutinib also approved ema treatment chronic lymphocytic leukemia mantle cell lymphoma a32299 ibrutinib approved use chronic graft versus host disease cgvhd august 2017 l12228 later approved used child making first fda-approved cgvhd treatment kid 1 year older failure one line systemic therapy l43020 ,ibrutinib indicated adult patient treatment following condition l42980 mantle cell lymphoma patient received least one prior therapy chronic lymphocytic leukemia small lymphocytic lymphoma 17p deletion waldenström 's macroglobulinemia marginal zone lymphoma mzl patient require systemic therapy received least one prior anti-cd20-based therapy chronic graft-versus-host disease prior failure one line systemic therapy oral suspension formulation drug indicated treatment chronic graft-versus-host disease patient aged one year older prior failure one line systemic therapy l42980 
Idelalisib,"idelalisib phosphoinositide 3-kinase inhibitor indicated treatment chronic lymphocytic leukemia cll relapsed follicular b-cell non-hodgkin lymphoma fl relapsed small lymphocytic lymphoma sll treatment relapsed cll currently indicated second-line agent combination rituximab patient rituximab alone would considered appropriate therapy due co-morbidities treatment fl sll intended used patient received least two prior systemic therapy specifically idelalisib target p110δ delta isoform enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase also known pi-3k pi-3ks family enzyme involved cellular function cell growth proliferation differentiation motility survival intracellular trafficking turn involved cancer contrast class ia pi3ks p110α p110β p110δ principally expressed leukocyte white blood cell important function cell b cell mast cell neutrophil inhibiting enzyme idelalisib induces apoptosis malignant cell inhibits several cell signaling pathway including b-cell receptor bcr signaling c-x-c chemokine receptor type 5 type 4 signalling involved trafficking homing b-cells lymph node bone marrow treatment lymphoma cell idelalisib shown result inhibition chemotaxis adhesion reduced cell viability ",idelalisib indicated treatment chronic lymphocytic leukemia cll relapsed follicular b-cell non-hodgkin lymphoma fl relapsed small lymphocytic lymphoma sll treatment relapsed cll currently indicated second-line agent combination rituximab patient rituximab alone would considered appropriate therapy due co-morbidities treatment fl sll intended used patient received least two prior systemic therapy 
Acipimox,acipimox niacin derivative used hypolipidemic agent used low dos may le marked adverse effect although unclear whether recommended dose effective standard dos nicotinic acid acipimox inhibits production triglyceride liver secretion vldl lead indirectly modest reduction ldl increase hdl long-term administration associated reduced mortality unwanted effect limit clinical use adverse effect include flushing associated prostaglandin d2 palpitation gi disturbance flushing reduced taking aspirin 20-30 min taking acipimox high dos cause disorder liver function impair glucose tolerance precipitate gout ,used treatment hyperlipidemia abnormally elevated level lipid and/or lipoprotein blood 
Amorolfine,amorolfine amorolfin morpholine antifungal drug inhibits fungal enzyme d14 reductase d7-d8 isomerase inhibition affect fungal sterol synthesis pathway depleting ergosterol causing ignosterol accumulate fungal cytoplasmic cell membrane amorolfine marketed curanail loceryl locetar odenil available form 5 amorolfine nail lacquer used treat onychomycosis fungal infection toe- fingernail amorolfine 5 nail lacquer twice weekly application 60-71 effective treating toenail onychomycosis complete cure rate three month stopping treatment six month treatment 38-46 however full experimental detail trial available since first reported 1992 subsequent trial topical solution treatment toenail infection systemic treatment may considered effective approved sale counter australia uk recently re-classified counter status approved treatment toenail fungus prescription country approved treatment onychomycosis united state canada ,
Anthrax immune globulin human,anthrax immune globulin human antibody given antibiotic treatment anthrax derived plasma human immunized biothrax adsorbed anthrax vaccine purified available product anthrasil fda result solution slow iv infusion containing polyclonal antibody bind protective antigen pa component bacillus anthracis lethal edema toxin binding antibody pa prevents pa-mediated cellular entry toxic factor administered combination appropriate antibiotic therapy immunoglobulin known direct antibacterial activity anthrax bacteria otherwise may continue grow produce anthrax toxin ,anthrax immune globulin indicated treatment inhalational anthrax adult pediatric patient combination appropriate antibacterial drug 
Atosiban,atosiban inhibitor hormone oxytocin vasopressin used intravenously halt premature labor although initial study suggested could used nasal spray hence would require hospital admission used form atobisan developed swedish company ferring pharmaceutical first reported literature 1985 atosiban licensed proprietary generic form delay imminent pre-term birth pregnant adult woman ,atosiban indicated use delaying imminent pre-term birth pregnant adult woman regular uterine contraction least 30 duration rate least 4 per 30 min cervical dilation 1-3cm 0-3cm nullipara effacement least 50 gestational age 24-33 week normal fetal heart rate
Avibactam,avibactam non-β-lactam β-lactamase inhibitor available combination ceftazidime avycaz combination approved fda february 25 2015 treatment complicated intra-abdominal infection combination metronidazole treatment complicated urinary tract infection including pyelonephritis caused antibiotic resistant-pathogens including caused multi-drug resistant gram-negative bacterial pathogen limited clinical safety efficacy data avycaz reserved patient 18 year old limited alternative treatment option ,avycaz ceftazidime-avibactam combination metronidazole indicated treatment complicated intra-abdominal infection caused following susceptible microorganism escherichia coli klebsiella pneumoniae proteus mirabilis providencia stuartii enterobacter cloaca klebsiella oxytoca pseudomonas aeruginosa patient 18 year older avycaz also indicated treatment complicated urinary tract infection including pyelonephritis caused following susceptible microorganism escherichia coli klebsiella pneumoniae citrobacter koseri enterobacter aerogenes enterobacter cloaca citrobacter freundii proteus spp. pseudomonas aeruginosa patient 18 year older 
Cannabidiol,cannabidiol cbd one least 85 active cannabinoids identified within cannabis plant major phytocannabinoid accounting 40 cannabis plant 's extract bind wide variety physiological target endocannabinoid system within body although exact medical implication currently investigated cbd shown promise therapeutic pharmaceutical drug target particular cbd shown promise analgesic anticonvulsant muscle relaxant anxiolytic antipsychotic shown neuroprotective anti-inflammatory antioxidant activity among currently investigated us a32477 a32469 cbd 's exact place within medical practice still currently hotly debated however body evidence grows legislation change reflect wide-spread use public medical opinion changed significantly regard usefulness number medical condition ranging anxiety epilepsy pharmacological perspective cannabis cbd 's diverse receptor profile explains potential application wide variety medical condition cannabis contains 400 different chemical compound 61 considered cannabinoids class compound act upon endogenous cannabinoid receptor body a32584 cannabinoid receptor utilized endogenously body endocannabinoid system includes group lipid protein enzyme receptor involved many physiological process modulation neurotransmitter release endocannabinoid system regulates cognition pain sensation appetite memory sleep immune function mood among many bodily system effect largely mediated two member g-protein coupled receptor family cannabinoid receptor 1 2 cb1 cb2 a32585 a32824 cb1 receptor found central peripheral nervous system majority receptor localized hippocampus amygdala brain physiological effect using cannabis make sense context receptor activity hippocampus amygdala primarily involved regulation memory fear emotion contrast cb2 receptor mainly found peripherally immune cell lymphoid tissue peripheral nerve terminal a32676 tetrahydrocannabinol thc cannabidiol cbd two type cannabinoids found naturally resin marijuana plant interact cannabinoid receptor found throughout body although thc cbd studied cannabinoids many others identified date including cannabinol cbn cannabigerol cbg db14050 cbdv db11755 thcv found within medical cannabis a32830 cbd thc used medicinal purpose different receptor activity function physiological effect provided activated form synthetic form thc like db00470 db00486 thc cbd obtained conversion precursor tetrahydrocannabinolic acid-a thca-a cannabidiolic acid cbda decarboxylation reaction achieved heating smoking vaporization baking dried unfertilized female cannabis flower primary psychoactive component cannabis delta 9-tetrahydrocannabinol δ9-thc demonstrates effect weak partial agonist activity cannabinoid-1 cb1r cannabinoid-2 cb2r receptor activity result well-known effect smoking cannabis increased appetite reduced pain change emotional cognitive process contrast thc 's weak agonist activity cbd shown act negative allosteric modulator cannabinoid cb1 receptor abundant g-protein coupled receptor gpcr body a32469 allosteric regulation achieved modulation receptor activity functionally distinct site agonist antagonist binding site clinically significant direct agonist thc limited psychomimetic effect change mood memory anxiety a32469 addition well-known activity cb1 cb2 receptor evidence cbd also activates 5-ht1a/2a/3a serotonergic trpv1–2 vanilloid receptor antagonizes alpha-1 adrenergic µ-opioid receptor inhibits synaptosomal uptake noradrenaline dopamine serotonin gamma-aminobutyric acid gaba cellular uptake anandamide act mitochondrion ca2+ store block low-voltage-activated t-type ca2+ channel stimulates activity inhibitory glycine-receptor inhibits activity fatty amide hydrolase faah a31555 a31574 cbd currently available canada within 1:1 formulation tetrahydrocannbinol thc formulation known `` nabiximols '' brand name product sativex approved use adjunctive treatment symptomatic relief spasticity adult patient multiple sclerosis m sativex also given conditional notice compliance noc/c use adjunctive treatment symptomatic relief neuropathic pain adult patient multiple sclerosis adjunctive analgesic treatment moderate severe pain adult patient advanced cancer l886 april 2018 food drug administration advisory panel unanimously recommended approval epidiolex cannabidiol oral solution treatment two rare form epilepsy lennox-gastaut syndrome dravet syndrome among two difficult type epilepsy treat l2721 l2719 epidiolex granted orphan drug designation well fast track approval fda study hard treat condition notably phase 3 clinical trial epidiolex demonstrated clinically significant improvement lennox-gastaut syndrome dravet syndrome l2720 june 25th 2018 epidiolex approved fda first cbd-based product available u market , used combination delta-9-tetrahydrocannabinol product sativex cannabidiol given standard marketing authorization ie notice compliance noc health canada following indication 1 adjunctive treatment symptomatic relief spasticity adult patient multiple sclerosis m responded adequately therapy demonstrate meaningful improvement initial trial therapy l886 due need confirmatory study verify clinical benefit coupled promising nature clinical evidence sativex also given notice compliance condition noc/c health canada following indication 1 adjunctive treatment symptomatic relief neuropathic pain adult patient multiple sclerosis 2 adjunctive analgesic treatment adult patient advanced cancer experience moderate severe pain highest tolerated dose strong opioid therapy persistent background pain l886 
Cefminox,cefminox inn second generation cephalosporin antibiotic approved use japan ,
Ceritinib,ceritinib used treatment adult anaplastic lymphoma kinase alk -positive metastatic non-small cell lung cancer nsclc following failure secondary resistance intolerance prior crizotinib therapy 4 patient nsclc chromosomal rearrangement generates fusion gene eml4 echinoderm microtubule-associated protein-like 4 alk anaplastic lymphoma kinase result constitutive kinase activity contributes carcinogenesis seems drive malignant phenotype ceritinib exerts therapeutic effect inhibiting autophosphorylation alk alk-mediated phosphorylation downstream signaling protein stat3 proliferation alk-dependent cancer cell following treatment crizotinib first-generation alk inhibitor tumour develop drug resistance due mutation key `` gatekeeper '' residue enzyme occurrence led development novel second-generation alk inhibitor ceritinib overcome crizotinib resistance fda approved ceritinib april 2014 due surprisingly high response rate 56 towards crizotinib-resistant tumour designated orphan drug status ,ceritinib kinase inhibitor indicated treatment patient anaplastic lymphoma kinase alk -positive metastatic non-small cell lung cancer nsclc progressed intolerant crizotinib indication approved accelerated approval based tumor response rate duration response improvement survival disease-related symptom established continued approval indication may contingent upon verification description clinical benefit confirmatory trial 
Cobicistat,cobicistat marketed name tybost formerly gs-9350 indicated treating infection human immunodeficiency virus hiv although anti-hiv activity cobicistat act pharmacokinetic enhancer inhibiting cytochrome p450 3a isoforms cyp3a therefore increase systemic exposure coadministered agent metabolized cyp3a enzyme specifically cobicistat indicated increase systemic exposure atazanavir darunavir daily dosing regimen combination antiretroviral agent treatment hiv-1 infection increasing systemic exposure anti-retrovirals arvs without increasing dosage allows better treatment outcome decreased side effect profile ,cobicistat cyp3a inhibitor indicated increase systemic exposure atazanavir darunavir daily dosing regimen combination antiretroviral agent treatment hiv-1 infection interchangeable ritonavir increase systemic exposure darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir due lack exposure data use cobicistat recommended darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir complex unknown mechanism drug interaction preclude extrapolation ritonavir drug interaction certain cobicistat interaction cobicistat ritonavir administered either atazanavir darunavir may result different drug interaction used concomitant medication 
Corifollitropin alfa,corifollitropin alfa also known _elonva_ used woman undergoing fertility treatment stimulate development one mature egg oocyte time ovary drug used together _a gonadotropin-releasing hormone gnrh antagonist_ type medicine also used fertility treatment elonva available prescription l2270 july 2014 merck announced receipt complete response letter crl u.s. fda new drug application drug corifollitropin alfa marketed elonva 75 country l2272 corifollitropin alfa produced method known ‘ recombinant dna technology ’ mean made cell dna introduced make able produce corifollitropin alfa l2270 multiple study meta-analysis suggest corifollitropin alfa efficacious recombinant fsh term live birth rate ongoing pregnancy rate well clinical pregnancy rate increased number egg retrieved corifollitropin alfa regimen represents elevated effectiveness drug however warns time possibility increased risk ovarian hyperstimulation high responder study group woman l2276 a32526 ,controlled ovarian stimulation l2273 case woman undergoing fertility treatment stimulate development one mature egg simultaneously ovary combination gonadotrophin-releasing hormone gnrh antagonist type medicine also used fertility treatment l2270 
Corticorelin ovine triflutate,corticorelin available commercially corticorelin ovine triflutate tradename acthrel synthetic form peptide human corticotropin-releasing hormone hcrh potent stimulator adrenocorticotropic hormone acth release anterior pituitary endogenous form hcrh involved stress response main function stimulation pituitary release acth used diagnostic agent evaluate status pituitary-adrenal axis differentiation pituitary source ectopic source excessive acth secretion provides differential diagnosis cushing 's disease pituitary source acth excess ectopic acth syndrome ectopic source acth excess corticorelin injection result increase plasma acth cortisol patient diagnosed cushing 's disease however corticorelin injection result increase plasma acth cortisol patient diagnosed ectopic acth syndrome ,corticorelin indicated use differentiating pituitary ectopic production acth patient acth-dependent cushing 's syndrome 
Vortioxetine,vortioxetine antidepressant medication indicated treatment major depressive disorder mdd classified serotonin modulator stimulator sm multimodal mechanism action towards serotonin neurotransmitter system whereby simultaneously modulates one serotonin receptor inhibits reuptake serotonin specifically vortioxetine act via following biological mechanism serotonin reuptake inhibitor sri inhibition serotonin transporter partial agonist 5-ht1b receptor agonist 5-ht1a antagonist 5-ht3 5-ht1d 5-ht7 receptor sm developed many different subtypes serotonin receptor however receptor appear involved antidepressant effect sris serotonin receptor seem play relatively neutral insignificant role regulation mood others 5-ht1a autoreceptors 5-ht7 receptor appear play oppositional role efficacy sris treating depression ,vortioxetine indicated treatment major depressive disorder mdd 
Trimetazidine,trimetazidine piperazine derivative indicated symptomatic treatment stable angina pectoris patient inadequately controlled intolerant first line therapy l33015 trimetazidine studied treatment angina pectoris since late 1960s a233255 a233260 acidic condition caused anaerobic metabolism fatty acid oxidation response myocardial ischemia activate sodium-hydrogen sodium-calcium antiport system a233215 increased intracellular calcium decrease contractility a233215 hypothesized trimetazidine inhibits 3-ketoacyl coenzyme thiolase decrease fatty acid oxidation glucose metabolism preventing acidic condition exacerbate ischemic injury a7688 l33020 however evidence mechanism controversial a233215 trimetazidine fda approved however approved france since 1978 l33020 ,trimetazidine indicated symptomatic treatment stable angina pectoris patient inadequately controlled intolerant first line therapy l33015 
Tibolone,tibolone synthetic steroid hormone drug mainly non-selective binding profile acting agonist primarily estrogen receptor er preference er alpha l1874 tibolone livial org od 14 produced organon west orange nj synthetic steroid posse estrogenic androgenic progestogenic property used europe almost 2 decade primarily prevention postmenopausal osteoporosis treatment post-menopausal symptom l1720 tibolone approved 90 country manage menopausal symptom 45 country prevent development osteoporosis l1876 june 2006 organon pharmaceutical announced receipt approvable letter u.s. food drug administration fda advising company new drug application nda tibolone approved l1722 interestingly use tibolone treatment cardiovascular disease studied inconclusive result a32164 tibolone anti-resorptive effect bone l1874 , relief post-menopausal symptom prevention osteoporosis l1724 
Tasimelteon,tasimelteon selective dual melatonin receptor agonist indicated treatment non-24-hour sleep-wake disorder n24hswd occurring commonly blind individual without light perception condition often characterized period night-time insomnia day-time sleepiness blind individual lack light stimulation cause extension 24-hour circadian cycle lead progressively delayed sleep onset activating melatonin receptor mt1 mt2 suprachiasmatic nucleus brain tasimelteon shown improve sleep resynchronizing circadian rhythm `` non-photic '' mechanism tasimelteon currently drug available treatment n24hswd granted orphan drug status fda 2010 ,tasimelteon oral capsule indicated treatment non-24 hour sleep-wake disorder adult patient treatment nighttime sleep disturbance smith-magenis syndrome patient ≥16 year old l40963 tasimelteon oral suspension indicated treatment nighttime sleep disturbance smith-magenis syndrome patient 3 15 year age l40963 
Sodium oxybate,sodium oxybate xyrem central nervous system cns depressant used treat cataplexy excessive daytime sleepiness associated narcolepsy l30598 sodium salt gamma-hydroxybutyric acid endogenous cerebral inhibitory neurotransmitter a251445 metabolite inhibitory neurotransmitter gaba a251430 due physiological effect sodium oxybate associated risk substance misuse abuse sodium oxybate misused stimulate body growth induce euphoria disinhibition sexual arousal `` party drug '' `` club drug `` a18723 safety reason sodium oxybate controlled substance available restricted program approved country l30598 extended-release oral suspension formulation sodium oxybate narcolepsy marketed brand name lumryz gained tentative fda approval july 2022 final approval subject june 2023 patent expiry l42645 country sodium oxybate investigated used alcohol withdrawal syndrome aws aid abstinence maintenance alcohol use disorder a251440 a251445 ,sodium oxybate central nervous system depressant indicated treatment cataplexy l30598 l42655 l42665 excessive daytime sleepiness ed patient narcolepsy l30598 u europe drug approved use patient 7 year age older l30598 l42665 canada recommended child age 18 unless clearly needed l42655 
Palbociclib,palbociclib piperazine pyridopyrimidine a176792 act cell cycle machinery second generation cyclin-dependent kinase inhibitor a176798 selected group pyridopyrimidine compound due favorable physical pharmaceutical property a176810 palbociclib developed pfizer inc discovery identified cyclin-dependent kinase key regulator cell growth l5867 originally fda approved march 2015 treatment hr-positive her2-negative advanced metastatic breast cancer indication updated april 2019 include male patient based finding postmarketing report electronic health record demonstrating safety clinical efficacy l4894 ,palbociclib indicated combination letrozole initial endocrine-based therapy treatment human epidermal growth factor receptor type 2 her2 -negative hormone receptor hr -positive tumor adult patient advanced/metastatic breast cancer well approved combination fulvestrant patient disease progression prior endocrine therapy a176783 official labeling use palbociclib accompanied either aromatase inhibition restricted letrozole initial endocrine-based therapy postmenopausal woman man fda label breast cancer start group cancer cell grow destroy nearby breast tissue growth spread part body called metastasis according location cancer cell categorized ductal carcinoma lobular carcinoma however type breast cancer include inflammatory breast cancer paget disease breast triple negative breast cancer non-hodgkin lymphoma soft tissue sarcoma l5870 male breast cancer usually treated case postmenopausal woman almost case ductal carcinoma l5873 
Olaparib,olaparib selective potent inhibitor poly adp-ribose polymerase parp enzyme parp1 parp2 l41100 l40908 l43792 parp inhibitor represent novel class anti-cancer therapy work taking advantage defect dna repair cancer cell brca mutation inducing cell death a246015 olaparib used treat number brca-associated tumour including ovarian cancer breast cancer pancreatic cancer prostate cancer l41100 l40908 l43792 first approved fda eu december 2014 a246020 health canada april 2016 l42820 , ovarian cancer olaparib indicated maintenance treatment adult deleterious suspected deleterious germline somatic brca-mutated advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response first-line platinum-based chemotherapy l41100 l42695 olaparib indicated combination bevacizumab maintenance treatment adult advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response first-line platinum-based chemotherapy whose cancer associated homologous recombination deficiency hrd -positive status defined either deleterious suspected deleterious brca mutation and/or genomic instability l41100 l42695 olaparib indicated maintenance treatment adult patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum-based chemotherapy l41100 l42695 breast cancer olaparib indicated adjuvant treatment adult patient deleterious suspected deleterious g_brca_m human epidermal growth factor receptor 2 her2 -negative high risk early breast cancer treated neoadjuvant adjuvant chemotherapy l41100 l42695 l42820 olaparib indicated treatment adult patient deleterious suspected deleterious g_brca_m her2-negative metastatic breast cancer treated chemotherapy neoadjuvant adjuvant metastatic setting patient hormone receptor hr positive breast cancer treated prior endocrine therapy considered inappropriate endocrine therapy l41100 l42695 pancreatic cancer olaparib indicated maintenance treatment adult patient deleterious suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease progressed least 16 week first-line platinum-based chemotherapy regimen l41100 l42695 prostate cancer olaparib indicated treatment adult patient deleterious suspected deleterious germline somatic homologous recombination repair hrr gene-mutated metastatic castration-resistant prostate cancer mcrpc progressed following prior treatment hormone agent l42695 enzalutamide abiraterone l41100 
Edoxaban,edoxaban member novel oral anti-coagulants noacs class drug rapidly acting oral selective factor xa inhibitor inhibiting factor xa key protein coagulation cascade edoxaban prevents stepwise amplification protein factor needed form blood clot indicated reduce risk stroke systemic embolism se patient nonvalvular atrial fibrillation nvaf treatment deep vein thrombosis dvt pulmonary embolism pe following 5-10 day initial therapy parenteral anticoagulant traditionally warfarin vitamin k antagonist used stroke prevention individual effective use drug limited 's delayed onset narrow therapeutic window need regular monitoring inr testing numerous drug-drug drug-food interaction prompted enthusiasm newer agent dabigatran apixaban rivaroxaban effective clot prevention addition daily dosing benefit warfarin also include significant reduction hemorrhagic stroke gi bleeding improved compliance beneficial many patient lifelong therapy ,edoxaban indicated reducing risk stroke systemic embolism se patient nonvalvular atrial fibrillation nvaf however used patient creatinine clearance crcl 95 ml/min increased risk ischemic stroke compared warfarin highest dose studied 60 mg also indicated treatment deep vein thrombosis dvt pulmonary embolism pe following 5-10 day initial therapy parenteral anticoagulant 
Umeclidinium,umeclidinium long-acting muscarinic antagonist lama used maintenance treatment symptom chronic obstructive pulmonary disease copd available once-daily inhalation monotherapy fixed-dose combination product long-acting beta2-agonist vilanterol copd progressive obstructive lung disease characterized shortness breath cough sputum production chronically poor airflow forced expiratory volume 1 second fev1 le 80 blocking m3 muscarinic receptor highly expressed airway smooth muscle lung umeclidinium inhibits binding acetylcholine thereby open airway preventing bronchoconstriction use shown provide clinically significant sustained improvement lung function ,indicated long-term once-daily maintenance treatment airflow obstruction patient chronic obstructive pulmonary disease copd l44466 
Dinutuximab,dinutuximab igg1 monoclonal human/mouse chimeric antibody gd2 disialoganglioside expressed tumor neuroectodermal origin including human neuroblastoma melanoma highly restricted expression normal tissue composed variable heavy- light-chain region murine anti-gd2 mab 14.18 constant region human igg1 heavy-chain kappa light-chain binding gd2 dinutiximab induces antibody-dependent cell-mediated cytotoxicity complement-dependent cytotoxicity tumor cell thereby leading apoptosis inhibiting proliferation tumour indicated combination granulocyte-macrophage colony-stimulating factor gm-csf interleukin-2 il-2 13-cis-retinoic acid ra treatment pediatric patient high-risk neuroblastoma achieve least partial response prior first-line multiagent multimodality therapy despite high clinical response seen first-line treatment complete eradication neuroblastoma rarely achieved majority patient advanced disease suffer relapse current strategy treatment include immunotherapy drug dinutuximab target surviving neuroblastoma cell prevent relapse ,dinutuximab indicated combination granulocyte-macrophage colony-stimulating factor gm-csf interleukin-2 il-2 13-cis-retinoic acid ra treatment pediatric patient high-risk neuroblastoma achieve least partial response prior first-line multiagent multimodality therapy despite high clinical response seen first-line treatment complete eradication neuroblastoma rarely achieved majority patient advanced disease suffer relapse current strategy treatment include immunotherapy drug dinutuximab target surviving neuroblastoma cell prevent relapse 
Lenvatinib,lenvatinib receptor tyrosine kinase rtk inhibitor inhibits kinase activity vascular endothelial growth factor vegf receptor vegfr1 flt1 vegfr2 kdr vegfr3 flt4 lenvatinib also inhibits rtks implicated pathogenic angiogenesis tumor growth cancer progression addition normal cellular function including fibroblast growth factor fgf receptor fgfr1 2 3 4 platelet derived growth factor receptor alpha pdgfrα kit ret receptor tyrosine kinase rtks located cell membrane play central role activation signal transduction pathway involved normal regulation cellular process cell proliferation migration apoptosis differentiation pathogenic angiogenesis lymphogenesis tumour growth cancer progression particular vegf identified crucial regulator physiologic pathologic angiogenesis increased expression vegf associated poor prognosis many type cancer lenvatinib indicated treatment patient locally recurrent metastatic progressive radioactive iodine rai -refractory differentiated thyroid cancer patient thyroid cancer good prognosis treatment 98 5 year survival rate involving surgery hormone therapy however patient rai-refractory thyroid cancer treatment option limited prognosis poor leading push development targeted therapy lenvatinib ,lenvatinib indicated treatment following cancerous condition l41120 differentiated thyroid cancer dtc treatment locally recurrent metastatic progressive radioactive iodine-refractory differentiated thyroid cancer renal cell carcinoma rcc first-line treatment combination pembrolizumab adult patient advanced renal cell carcinoma rcc treatment advanced renal cell carcinoma combination everolimus adult patient previously tried ≥1 anti-angiogenic therapy hepatocellular carcinoma hcc first-line treatment patient unresectable hepatocellular carcinoma endometrial carcinoma treatment advanced endometrial carcinoma microsatellite instability-high msi-h mismatch repair deficient dmmr combination pembrolizumab patient experienced disease progression following prior systemic therapy candidate curative surgery radiation
Nintedanib,nintedanib small molecule kinase inhibitor used treatment pulmonary fibrosis systemic sclerosis-associated interstitial lung disease non-small cell lung cancer nsclc l8453 l8459 first approved use united state 2014 l8453 within spectrum idiopathic pulmonary fibrosis treatment option nintedanib currently one two disease-modifying therapy available indicated condition pirfenidone used first-line treatment following diagnosis slow progressive loss lung function a185237 chemotherapeutic agent nsclc nintedanib combination docetaxel reserved patient tried failed first-line chemotherapeutic option l8459 ,nintedanib indicated treatment idiopathic pulmonary fibrosis ipf l8453 slow declining pulmonary function patient systemic sclerosis-associated interstitial lung disease l8462 also indicated treatment chronic fibrosing interstitial lung disease progressive phenotype l8462 eu brand name vargatef nintedanib indicated combination docetaxel treatment adult patient metastatic locally advanced locally recurrent non-small cell lung cancer adenocarcinoma histology already tried first-line therapy l8459 
Olodaterol,olodaterol novel long-acting beta2-adrenergic agonist laba exerts pharmacological effect binding activating beta2-adrenergic receptor located primarily lung beta2-adrenergic receptor membrane-bound receptor normally activated endogenous epinephrine whose signalling via downstream l-type calcium channel interaction mediates smooth muscle relaxation bronchodilation activation receptor stimulates associated g protein activates adenylate cyclase catalyzing formation cyclic adenosine monophosphate camp protein kinase pka elevation two molecule induces bronchodilation relaxation airway smooth muscle mechanism olodaterol used treatment chronic obstructive pulmonary disease copd progressive airflow obstruction characteristic treatment bronchodilator help mitigate associated symptom shortness breath cough sputum production single dos olodaterol shown improve forced expiratory volume 1 sec fev1 24 h patient copd allowing daily dosing once-a-day treatment laba several advantage short-acting bronchodilator twice-daily labas including improved convenience compliance improved airflow 24-hour period despite similarity symptom olodaterol indicated treatment acute exacerbation copd treatment asthma ,olodaterol indicated use chronic obstructive pulmonary disease copd including chronic bronchitis and/or emphysema indicated treatment acute exacerbation copd treatment asthma 
Idebenone,idebenone synthetic analogue ubiquinone also known coenzyme q10 vital cell antioxidant essential component electron transport chain etc proposed interacting etc idebenone increase atp production required mitochondrial function reduces free radical inhibits lipid peroxidation consequently protects lipid membrane mitochondrion oxidative damage a19768 specifically idebenone thought transfer electron directly complex iii mitochondrial etc thereby circumventing complex restoring cellular energy atp generation l885 due ability reduce oxidative damage improve atp production idebenone originally investigated potential use alzheimer 's disease cognitivie disorder a19769 lack improvement cognitive function halted production condition however continues investigated use condition associated mitochondrial damage idebenone currently indicated use european medicine agency ema treatment visual impairment adolescent adult patient leber ’ hereditary optic neuropathy lhon lhon mitochondrially inherited degeneration retinal ganglion cell resulting acute central vision loss due biochemical mode action 's thought idebenone may re-activate viable-but-inactive retinal ganglion cell rgcs lhon patient l885 currently approved use either food drug administration usa health canada ,idebenone indicated use european medicine agency ema treatment visual impairment adolescent adult patient leber ’ hereditary optic neuropathy lhon currently approved use either food drug administration usa health canada l885 
Vilanterol,"vilanterol selective long-acting beta2-adrenergic agonist laba inherent 24-hour activity daily treatment copd asthma pharmacological effect attributable stimulation intracellular adenylyl cyclase catalyzes conversion adenosine triphosphate atp cyclic-3',5'-adenosine monophosphate camp increase cyclic amp associated relaxation bronchial smooth muscle inhibition release hypersensitivity mediator mast cell lung vilanterol approved use several combination product fluticasone furoate tradename breo ellipta combination umeclidinium bromide anoro ellipta approved fda 2013 use breo ellipta indicated long-term once-daily maintenance treatment airflow obstruction patient copd including chronic bronchitis emphysema also indicated once-daily maintenance treatment asthma patient aged 18 older reversible obstructive airway disease ",vilanterol approved use several combination product fluticasone furoate tradename breo ellipta l38689 combination umeclidinium bromide anoro ellipta l44461 combination fluticasone furoate umeclidinium tradename trelegy ellipta l44456 approved fda 2013 use breo ellipta indicated long-term once-daily maintenance treatment airflow obstruction patient copd including chronic bronchitis emphysema well once-daily maintenance treatment asthma patient aged 18 older reversible obstructive airway disease anoro ellipta indicated maintenance treatment patient copd l44461 trelegy ellipta indicated maintenance treatment patient copd well maintenance treatment asthma patient aged 18 year older l44456 
Ivabradine,ivabradine novel heart rate lowering medicine symptomatic management stable angina pectoralis symptomatic chronic heart failure ivabradine brand name corlanor approved fda april 2015 treatment chronic heart failure patient ejection fraction ≤35 sinus rhythm resting heart rate ≥70 beat per minute beta-blockers due contraindication already receiving maximum beta-blocker dose recently new indication added treat symptomatic heart failure dilated cardiomyopathy patient 6 month age label ivabradine act selectively inhibiting `` funny '' channel pacemaker current sinoatrial node dose-dependent fashion resulting lower heart rate thus blood flow myocardium although non-dihydropyridine calcium channel blocker beta blocker also effectively lower heart rate exhibit adverse event due negative ionotropic effect therefore ivabradine designed `` pure '' heart rate-lowering drug selectively acting channel may offer favorable side effect profile due lower likelihood causing serious adverse effect ,ivabradine indicated fda reduce risk hospitalization worsening heart failure adult patient stable symptomatic chronic heart failure left ventricular ejection fraction ≤35 sinus rhythm resting heart rate ≥70 beat per minute either maximally tolerated dos beta-blockers contraindication beta-blocker use also indicated treatment stable symptomatic heart failure result dilated cardiomyopathy pediatric patient 6 month age fda label 
Benzydamine,benzydamine also known tantum verde difflam available hydrochloride salt locally-acting nonsteroidal anti-inflammatory drug nsaid local anaesthetic analgesic property used topically pain relief anti-inflammatory treatment mouth throat muscoskeletal system although indazole analogue benzydamine non-steroidal anti-inflammatory drug nsaid various physicochemical property pharmacologic activity different traditional aspirin-like nsaid facilitate benzydamine 's mechanism action effective locally-acting nsaid local anaesthetic analgesic property moreover unlike aspirin-like nsaid acid metabolised acid benzydamine fact weak base ,available predominantly liquid mouthwash oromucosal spray topical cream benzydamine frequently employed locally acting analgesic anti-inflammatory treatment relief painful inflammatory condition formulated mouthwash spray benzydamine may used treat traumatic condition like pharyngitis following tonsillectomy use naso-gastric tube inflammatory condition like pharyngitis aphthous ulcer oral ulceration due radiation therapy dentistry operation procedure general condition like sore throat sore tongue sore gum mouth ulcer discomfort caused denture l1121 used topical cream benzydamine may employed relieve symptom associated painful inflammatory condition muscolo-skeletal system including acute inflammatory disorder myalgia bursitis traumatic condition like sprain strain bruise sore muscle stiff joint even after-effects fracture l1123 
Tetracaine,tetracaine ester local anaesthetic currently available combination lidocaine cream patch ,ophthalmic tetracaine indicated procedure requiring rapid short- acting topical ophthalmic anesthetic combination lidocaine tetracaine patch indicated local dermal analgesia superficial dermatological procedure superficial venous access combination lidocaine tetracaine cream intended provide topical local analgesia superficial dermatological procedure 
Eugenol,eugenol naturally occurring phenolic molecule found several plant cinnamon clove bay leaf used topical antiseptic counter-irritant dental preparation zinc oxide root canal sealing pain control although currently available fda-approved product including otc eugenol found anti-inflammatory neuroprotective antipyretic antioxidant antifungal analgesic property exact mechanism action unknown however shown interfere action potential conduction number unapproved otc product available containing eugenol advertise use treatment toothache ,eugenol currently available fda-approved drug product number unapproved otc product advertise use toothache eugenol also commonly used combination zinc oxide dental procedure cementation temporary prosthesis temporary restoration teeth cavity 
Potassium alum,potassium alum considered fda generally recognized safe gras substance l1070 inorganic salt also called potassium aluminum sulfate formula alk so4 2 predominantly produced dodecahydrate form alk so4 2 12h2o potassium alum formed large transparent crystal used different product like food drug buffer neutralizing forming agent t60 ,potassium alum considered safe fda use homepathic otc product due presence several different drug main indication use potassium alum -constipation l1071 -cosmetic drug astringent helping shrinkage tissue dry secretion l1072 -oral health care drug l1072 -part formulation cleansing product skin-care product mosturizers face powder deodorant l1073 -antiperspirant l1074 -antifungal l1074 
Amylocaine,despite introduction using cocaine injection regional anesthesia 1884 non-addictive substitute sought immediately l1882 finally 1903 world 's first synthetic non-addictive local anesthetic amylocaine synthesized patented name forneaucaine ernest fourneau pasteur institute l1882 elsewhere english speaking country referred stovaine given meaning french word 'fourneau 'stove english l1882 although amylocaine could administered topically injected widely used spinal anesthesia l1882 even though certainly possessed le severe side effect cocaine l1882 eventual development clinical use newer effective even safer local anesthetic like lidocaine bupivicaine prilocaine 1940s 1950s superseded made use amylocaine obsolete , common indication usage amylocaine spinal anesthesia a32277 
Trimebutine,trimebutine spasmolytic agent regulates intestinal colonic motility relief abdominal pain antimuscarinic weak mu opioid agonist effect marketed treatment irritable bowel syndrome ibs lower gastrointestinal tract motility disorder ibs one common multifactorial gi disorder a19691 used restore normal bowel function commonly present pharmaceutical mixture trimebutine maleate salt form trimebutine fda-approved drug available canada several international country ,indicated symptomatic treatment irritable bowel syndrome ibs treatment postoperative paralytic ileus following abdominal surgery 
Pinaverium,pinaverium spasmolytic agent used functional gastrointestinal disorder quaternary ammonium compound act atypical calcium antagonist restore normal bowel function shown relieve gi spasm pain transit disturbance symptom related motility disorder a19697 may considered effective first-lline therapy patient irritable bowel syndrome ibs a19702 pinaverium bromide common ingredient formulation mostly oral tablet although currently approved drug fda pinaverium available 60 country including canada ,pinaverium indicated symptomatic treatment irritable bowel syndrome ibs functional disorder biliary tract 
Tixocortol,tixocortol 21-thiol derivative hydrocortisone classified class corticosteroid synthetic steroid topical anti-inflammatory property without systemic glucocorticoid mineralocorticoid activity toxicity l1078 ,tixocortol indicated treatment rhinitis nasal suspension aerosol also used form lozenge treatment pharyngitis form enema rectal solution treatment ulcerative colitis tixocortol used orally suspension powder treatment inflammatory condition l1077 also substance used screening contact allergy class steroid a31435 
Xanthinol,xanthinol potent water-soluble derivative niacin found diet supplement also known xanthinol nicotinate l1079 xaninthol known potent vasodilator easily pas cell membrane inside cell cause increase glucose metabolism resulting increased energy l1080 approved drug 1998 canada nowadays status cancelled post marketing ,xanthinol primarily used diet supplement increase brain metabolism glucose obtain atp xanthinol also used agent reduced cholesterol vasodilator l1080 action allows elevated rate blood flow brain help improve memory function concentration awareness l1079 thus due action xanthinol indicated improve cerebrovascular peripheral vascular disorder well hyperlipidaemia l1081 
Chlortetracycline,chlortetracycline _tetracycline_ antibiotic historically first member class identified discovered 1945 scientist benjamin minge duggar working lederle laboratory supervision yellapragada subbarow discovered antibiotic product actinomycete strain cultured obtained soil sample field missouri organism named _streptomyces aureofaciens_ due gold-hued color ,used manufacuring medicated animal feed fda label 
Podophyllin,podophyllin resin extracted root _podophyllum peltatum_ american mandrake _podophyllum emodi_ contains numerous compound amongst podophyllin well drug podophyllotoxin podophyllin principal active component podophyllin arrest mitosis metaphase ,25 podophyllin benzoin tincture indicated removal soft genital venereal wart condylomata acuminata 
Difluocortolone,difluocortolone potent topical corticosteroid commonly used dermatology reduction inflammation itching submitted fda july 1984 pharmaceutical company schering ag l1082 ,difluocortolone used topical treatment symptom inflammatory skin disorder like eczema seborrheic eczema lichen planus psoriasis disorder present common characteristic occurrence symptom itching swelling redness scaling l1083 
Benzoyl peroxide,benzoyl peroxide commonly used drug topical treatment acne l33249 l33264 l33269 l33299 l33314 formulated product either single active ingredient l33249 l33299 erythromycin l33264 clindamycin l33269 adapalene l33314 administration peroxide bond cleaved allowing benzoyloxy radical nonspecifically interact protein a18903 a233859 treatment decrease keratin sebum around follicle well increasing turnover epithelial cell a234059 a234064 a234069 benzoyl peroxide combination erythromycin granted fda approval 26 october 1984 l33264 ,benzoyl peroxide formulated antibiotic erythromycin l33264 clindamycin l33269 treatment acne vulgaris benzoyl peroxide formulated number topical product treatment acne l33249 l33299 benzoyl peroxide also indicated combination tretinoin treatment acne vulgaris patient aged nine year older l34869 topical benzoyl peroxide also indicated treatment inflammatory lesion rosacea adult l41613 
Quinagolide,quinagolide non-ergot-derived selective dopamine d2 receptor agonist used treatment elevated level prolactin hyperprolactinaemia hyperprolalctinaemia associated gonadal dysfunction including infertility reduced libido well long-term complication osteoporosis a19684 newer dopamine receptor agonist quinagolide db00248 shown effectively inhibit prolactin secretion improved efficacy db01200 drug effective patient intolerant resistant db01200 quinagolide exists racemate relevant clinical activity mediated predominantly enantiomer typically present hydrochloride salt form marketed oral tablet brand name norprolac contained racemate quinagolide currently available several country including canada approved treatment united state ,indicated treatment hyperprolactinemia idiopathic originating prolactin-secreting pituitary microadenoma macroadenoma 
Somatrem,despite ability almost contemporary recombinant growth hormone cause definite demonstrable increase growth rate patient administered drug use agent continues mired persistent bioethical debate a32292 discussion revolves around whether patient natural disposition short stature considered medical condition justifying medical treatment hormone therapy especially hormone agent proven effective increasing height child without growth hormone deficiency a32292 ,somatrem recombinant human growth hormone indicated treatment paediatric patient growth failure due growth hormone deficiency ghd b treatment paediatric patient growth failure due idiopathic short stature i c treatment paediatric patient growth failure due turner syndrome t treatment paediatric patient growth failure due chronic kidney disease ckd time renal transplantation e treatment adult childhood-onset ghd f treatment adult adult-onset ghd fda label 
Somatostatin,somatostatin also known growth hormone-inhibiting hormone naturally-occurring peptide hormone 14 28 amino acid residue t28 regulates endocrine system secreted cell islet inhibit release insulin glucagon also generated hypothalamus inhibits release growth hormone thyroid-stimulating hormone anterior pituitary t28 somatostatin initially secreted 116 amino acid precursor preprosomatostatin undergoes endoproteolytic cleavage prosomastatin prosomastatin process two active form somatostatin-14 sst-14 somatostatin-28 sst-28 extended sst-14 sequence n-terminus a20384 action somatostatin mediated via signalling pathway g protein-coupled somatostatin receptor antineoplastic effect potential us somatostatin various tumour including pituitary adenoma gep-nets paragangliomas carcinoid breast cancer malignant lymphoma small-cell lung cancer extensively investigated a20384 somatostatin used clinical setting diagnosis acromegaly gastrointestinal tract tumour analogue developed achieve favourable kinetics efficiency use management acute condition esophageal varix db00104 long-acting analogue somatostatin inhibits release number hormone clinically used relieve symptom uncommon gastroenteropancreatic endocrine tumour well treat acromegaly t28 , symptomatic treatment acute bleeding esophageal varix treatment option long-term management condition may considered necessary initial control established 
"Thyroid, porcine",thyroid extract dried powdered thyroid gland pig containing tiiodothyronine t3 thyroxine t4 used supplement low absent thyroid activity a190831 l11755 thyroid extract described literature treat hypothyroidism since 1891 a190807 use date back far 6th century a190831 thyroid extract longer considered first line therapy delivers dose inconsistent stated strength tablet a190813 currently patient likely treated levothyroxine a190813 thyroid extract never fda approved use united state predates fda a190831 ,thyroid extract indicated replacement therapy decreased absent thyroid function l11755 
Elvitegravir,elvitegravir human immunodeficiency virus type 1 hiv-1 integrase strand transfer inhibitor insti used treatment hiv-1 infection antiretroviral treatment-experienced adult integrase necessary viral replication inhibition prevents integration hiv-1 dna host genome thereby block formation hiv-1 provirus resulting propagation viral infection although available single dose tablet elvitegravir must used combination hiv protease inhibitor coadministered ritonavir another antiretroviral drug elvitegravir first licensed japan tobacco 2008 developed gilead science fda approved august 27 2012 september 24 2014 fda approved single pill form elvitegravir ,elvitegravir combination hiv protease inhibitor coadministered ritonavir antiretroviral drug indicated treatment hiv-1 infection antiretroviral treatment-experienced adult 
Daclatasvir,daclatasvir direct-acting antiviral agent hepatitis c virus hcv used treatment chronic hcv genotype 1 3 infection marketed name daklinza contained daily oral tablet hydrochloride salt form hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 daclatasvir first drug demonstrated safety therapeutic efficacy treating hcv genotype 3 without need co-administration interferon db00811 exerts antiviral action preventing rna replication virion assembly via binding ns5a nonstructural phosphoprotein encoded hcv binding n-terminus d1 domain ns5a prevents interaction host cell protein membrane required virion replication complex assembly daclatasvir shown target cis- trans-acting function ns5a disrupts function new hcv replication complex modulating ns5a phosphorylation status a19640 common critical ns5a amino acid substitution led reduced susceptibility daclatasvir therapy occured position q30 q30h/k/r m28 genotype 1a patient y93h genotype 3 patient according 2017 american association study liver disease aasld 60mg daclatasvir recommended 400mg db08934 genotype 1a/b patient without cirrhosis second-line therapy dosing regimen used first-line therapy patient genotype 3 without cirrhosis second-line therapy genotype 3 patient compensated cirrhosis combination therapy include daclatasir used challenging-to-treat patient hiv-1 coinfection advanced cirrhosis post-liver transplant recurrence hcv l863 therapy intended cure achieve sustained virologic response svr12 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 daclatasvir fda-approved july 2015 use db08934 sovaldi without db00811 treat hcv genotype 1 3 infection svr12 hcv genotype 1a-infected treatment-naïve subject without cirrhosis undergoing daclatasvir db08934 therapy 88 99 respectively fda label dosing regimen treatment-naïve patient hcv genotype 3 infection without cirrhosis achieved svr12 rate 71 98 respectively fda label ,indicated use sofosbuvir without ribavirin treatment chronic hcv genotype 1a/b 3 infection dosing regimen 60mg daclatasvir 60 mg 400mg sofosbuvir day recommended genontypes resistance reduced susceptibility daclatasvir associated polymorphism ns5a amino acid position m28 q30 l31 y93 genotype 1a 1b 3a patient ns5a resistance testing recommended hcv genotype 1a-infected patient cirrhosis prior initiaition treatment risk resistance development higher genotype 1a patient 
Ancestim,ancestim non-glycosylated recombinant methionyl human stem cell factor 166 amino acid protein produced e. coli amino acid sequence identical natural sequence predicted human dna sequence analysis except addition n-terminal methionine l1088 ancestim developed amgen sold biovitrium december 2008 submitted fda status recommendation approval 10 1 vote t68 also approved health canada 1999 currently status canceled post-market l1087 ,ancestim combination filgrastim indicated setting autologous peripheral blood progenitor cell transplantation patient risk poor peripheral blood progenitor cell mobilisation l1090 use ancestim filgrastim generate sustained increase number peripheral blood progenitor cell capable engraftment used mobilization progenitor cell bone marrow peripheral blood withouth mobilizing chemotherapy harvested progenitor cell used transplant following myelosuppressive myeloablative therapy l1089 
Magnesium hydroxide,magnesium hydroxide inorganic compound naturally found mineral brucite magnesium hydroxide used antacid laxative either oral liquid suspension chewable tablet form additionally magnesium hydroxide smoke suppressing flame retardant property thus used commercially fire retardant also used topically deodorant relief canker sore aphthous ulcer ,magnesium hydroxide used antacid laxative depending administered dose antacid used temporary relief heartburn upset stomach sour stomach acid indigestion laxative used relief occasional constipation promoting bowel movement 30 minute 6 hour 
Asfotase alfa,"asfotase alfa first-in-class bone-targeted enzyme replacement therapy designed address underlying cause hypophosphatasia hpp —deficient alkaline phosphatase alp hypophosphatasia almost always fatal severe skeletal disease obvious birth replacing deficient alp treatment asfotase alfa aim improve elevated enzyme substrate level improve body 's ability mineralize bone thereby preventing serious skeletal systemic patient morbidity premature death asfotase alfa first approved pharmaceutical medical device agency japan pmda july 3 2015 approved european medicine agency ema august 28 2015 approved u.s. food drug administration fda october 23 2015 asfotase alfa marketed brand name strensiq® alexion pharmaceutical inc annual average price asfotase alfa treatment 285,000 ",indicated treatment patient perinatal/infantile juvenile onset hypophosphatasia hpp 
Hydroxyethyl Starch,hydroxyethyl starch hes/haes nonionic starch derivative hydroxyethyl starch he synthetic colloid commonly used fluid resuscitation replace intravascular volume he general term sub-classified according average molecular weight molar substitution concentration c2/c6 ratio maximum daily dose , intravenous solution hydroxyethyl starch used prevent shock following severe blood loss caused trauma surgery issue 
Methoxy polyethylene glycol-epoetin beta,methoxy polyethylene glycol-epoetin beta chemically synthesised erythropoiesis stimulating agent esa longer half-life erythropoietin esa used increase synthesis red blood cell treat chronic kidney disease associated anemia , treatment patient anaemia associated chronic kidney disease substitute rbc transfusion immediate correction anemia required 
Simoctocog alfa,simoctocog alfa recombinant b-domain deleted bdd rfviii produced genetically modified human embryonic kidney hek 293f cell harvested product concentrated purified series chromatography step antihemorrhagic agent used replacement therapy individual haemophilia lack factor viii intrinsic pathway blood coagulation system patient haemophilia predisposed episode recurrent bleeding l1115 simoctocog alfa administered treatment prevention bleeding prior surgical procedure simoctocog alfa glycoprotein consisting 1440 amino acid approximate molecular mass 170 kda comprising fviii domain a1-a2 a3-c1-c2 whereas b-domain present full-length plasma-derived fviii deleted replaced 16 amino acid linker simoctocog alfa fourth-generation bdd fviii product made human embryonic kidney hek cell line full human post-translational modification via elimination potentially immunogenic glycosylation pattern found non-human cell line led decreased immunogenicity longer half-life a31525 ,simoctocog alfa recombinant antihemophilic factor blood coagulation factor viii factor viii indicated adult child hemophilia on-demand treatment control bleeding episode perioperative management bleeding routine prophylaxis reduce frequency bleeding episode indicated treatment von willebrand disease l40985 l40990 
Turoctocog alfa,turoctocog alfa recombinant factor viii rfviii truncated b-domain made sequence coding 10 amino acid n-terminus 11 amino acid c-terminus naturally occurring b-domain turoctocog alfa produced chinese hamster ovary cho cell without addition human- animal-derived material secretion rfviii molecule cleaved c-terminal heavy chain hc amino acid 720 monoclonal antibody binding c-terminal position used purification process allowing isolation intact rfviii a31504 developped novo nordisk fda approved october 16 2013 l1104 ,turoctocog alfa indicated treatment prophylaxis bleeding patient presenting hemophilia l1105 treatment turoctocog alfa related use control bleeding episode perioperative management l1106 hemophilia hereditary hemorrhagic disorder generated congenital deficit coagulation factor viii disease manifested excessive spontaneous trauma-driven bleeding coagulation factor viii robust initiator thrombin later required generation fibrin form platelet plug gene expressed x chromosome a31505 
Coenzyme M,coenzyme commonly known salt form mesna synthetic sulfhydryl thiol compound used prophylaxis ifosfamide cyclophosphamide induced hemorrhagic cystitis a18572 ,mesna uroprotective agent used prophylactically reduce ifosfamide cyclophosphamide induced hemorrhagic cystitis a18572 
Pentastarch,pentastarch artificial colloid hydroxyethyl starch derivative pentastarch characterized presenting five hydroxyethyl group signifies approximate 50 hydroxyethylation sold name pentaspan bristol-myers squibb used fluid resuscitation administered pentastarch remains mainly circulatory system hence considered plasma expander , primary intended use pentastarch substitute older colloid albumin hetastarch use plasma volume expansion 
Nitrous acid,nitrous acid sodium nitrite used part intravenous mixture sodium thiosulfate treat cyanide poisoning world health organization 's list essential medicine list important medication needed basic health system also research investigate applicability towards treatment heart attack brain aneurysm pulmonary hypertension infant pseudomonas aeruginosa infection , sequential use sodium thiosulfate treatment acute cyanide poisoning judged life-threatening fda label 
Poractant alfa,poractant alfa pulmonary surfactant marketed curosurf united state canada used treat respiratory distress syndrome rds premature infant endogenous pulmonary surfactant deficiency poractant alfa extract natural porcine lung surfactant consisting 99 polar lipid mainly phospholipid 1 hydrophobic low molecular weight protein surfactant associated protein sp-b sp-c phospholipid content extract consists primarily phosphatidylcholine dipaimitoylphosphatidylcholine poractant alfa creamy white suspension extract 0.9 sodium chloride solution contains preservative ,poractant alfa indicated treatment respiratory distress syndrome rds premature infant 
Colfosceril palmitate,colfosceril palmitate synthetic pulmonary surfactant administered infant respiratory distress syndrome a31510 part first generation commercially available artificial surfactant t70 developed burroughs wellcome fda approved august 6 1990 l1109 nowadays colfosceril palmitate state canceled post-marketing ,colfosceril palmitate indicated treatment respiratory distress syndrome rds premature infant official label referred intratracheal suspension prophylactic treatment infant le 1350 gram birth weight risk developing rds infant birth weight greater 1350 gram pulmonary immaturity rescue treatment infant already developed rds l1109 central feature rds surfactant deficiency due lung immaturity lung condition frequently presented due risk factor like prematurity delayed lung maturation caused maternal diabetes male gender surfactant dysfuntion due perinatal asphyxia pulmonary infection delivery without labor t70 
Diiodohydroxyquinoline,diiodohydroxyquinoline also known uidoquinol iodoquinol quinoline derivative used treatment amoebiasis exact mechanism action unknown iodoquinol currently available fda-approved product ,used treatment amoebiasis 
Calcium carbimide,calcium carbimide sold citrate salt alcohol-sensitizing agent effect similar drug disulfiram antabuse interferes normal metabolism alcohol preventing breakdown metabolic product acetaldehyde calcium carbimide conceived alternative treatment alcoholism reduced side effect profile either consumed accompanied alcohol without a31516 drug developed lederle cyanamid canada inc approved marketing canada 1959 current status calcium carbimide cancelled post marketing l1113 ,calcium carbimide approved fda intended indication treatment alcoholism t74 medication marketed canada united kingdom europe trade name temposil sole use alcoholism treatment l1114 
Paraldehyde,paraldehyde initially introduced medical practice united kingdom 1882 italian physician vincenzo cervello classified central nervous system cns depressant also found effective anticonvulsant hypnotic sedative agent due cns depressant property paraldehyde used ingredient cough medicine expectorant efficacy indication confirmed use expectorant may possibly due placebo effect ,paraldehyde used historically sedative hypnotic a19735 used treatment seizure anticonvulsant a19736 
Stiripentol,stiripentol antiepileptic agent aromatic allylic alcohol drug make structurally unique antiepileptic drug a19740 a250825 clinical development marketing stiripentol first delayed due drug 's potent inhibitory effect hepatic cytochrome p450 cyp enzyme a250825 however clinical efficacy adjunctive therapy epilepsy stem inhibitory action cyp enzyme stiripentol reduces degradation cyp-sensitive antiepileptic drug hence boosting therapeutic efficacy stiripentol may also exhibit direct anticonvulsant property although exact mechanism action fully understood a19739 approved u canada europe stiripentol used treat seizure associated dravet syndrome l880 l42500 l42510 marketed brand name diacomit , u stiripentol indicated treatment seizure associated dravet syndrome patient taking clobazam 6 month age older weighing 7 kg clinical data support use stiripentol monotherapy dravet syndrome l42500 europe canada stiripentol indicated use adjunctive therapy clobazam valproate refractory generalized tonic-clonic seizure patient dravet syndrome infancy whose seizure adequately controlled clobazam valproate alone l880 l42510 
Eslicarbazepine acetate,eslicarbazepine acetate esl anticonvulsant medication approved use europe united state canada adjunctive therapy partial-onset seizure adequately controlled conventional therapy eslicarbazepine acetate prodrug rapidly converted eslicarbazepine primary active metabolite body eslicarbazepine 's mechanism action well understood known exert anticonvulsant activity inhibiting repeated neuronal firing stabilizing inactivated state voltage-gated sodium channel thus preventing return activated state seizure activity occur eslicarbazepine acetate marketed aptiom north america zebinix exalief europe available 200 400 600 800mg tablet taken daily without food eslicarbazepine acetate associated numerous side effect including dizziness drowsiness nausea vomiting diarrhea headache aphasia lack concentration psychomotor retardation speech disturbance ataxia depression hyponatremia recommended patient taking eslicarbazepine acetate monitored suicidality ,eslicarbazepine acetate indicated treatment partial-onset seizure patient 4 year age older l4565 
Zucapsaicin,zucapsaicin cis-isomer capsaicin topical analgesic used treat osteoarthritis knee neuropathic pain modulator transient receptor potential cation channel subfamily v member 1 trpv-1 also known vanilloid capsaicin receptor 1 reduces pain improves articular function zucapsaicin also evaluated management several condition manifested chronic nerve pain condition include herpes simplex hsv infection cluster headache migraine osteoarthritis knee zucapsaicin approved health canada 2010 topical cream marketed brand name zuacta currently fda-approved ,indicated used conjunction oral cox-2 inhibitor nsaid relief severe pain adult patient osteoarthritis knee controlled oral cox-2 inhibitor nsaid alone duration three month 
Aurothioglucose,aurothioglucose also known gold thioglucose formerly used treat rheumatoid arthritis contemporary research effect gold salt treatment began 1935 primarily reduce inflammation slow disease progression patient rheumatoid arthritis a32326 use gold compound decreased since 1980s owing numerous side effect limited efficacy slow onset action many gold compound indicated rheumatoid arthritis therapy since replaced use various current disease modifying anti-rheumatic drug dmards like methotrexate others far effective ,aurothioglucose indicated adjunctive treatment early active adult juvenile type rheumatoid arthritis adequately controlled anti-inflammatory agent conservative measure like salicylate glucocorticoid etc l1925 l1937 chronic advanced case rheumatoid arthritis gold therapy demonstrated valuable l1937 antirheumatic measure salicylate anti-inflammatory drug steroidal non steroidal may continued initiation gold therapy l1937 improvement commences measure may discontinued slowly symptom permit l1937 
Peginterferon beta-1a,multiple sclerosis m chronic inflammatory autoimmune disease central nervous system disrupting communication brain part body patient diagnosed illness experience initial disease symptom age 20 40 often productive year life symptom may include limited fatigue gait change bowel bladder dysfunction abnormal muscle twitching vision disturbance depressing mood swing l5801 m one common cause neurological disability young adult found occur frequently woman men a176474 l5792 peginterferon beta-1a interferon therapy used management relapsing form m originally approved fda 2014 subcutaneous use approved intramuscular use january 2021 l31428 currently approved pegylated interferon management m proven ability reduce relapse delay progression disability resulting m ,peginterferon beta-1a indicated treatment adult patient relapsing form m including relapsing-remitting disease clinically isolated syndrome active progressive secondary disease l31428 
Dienogest,dienogest orally-active semisynthetic progestogen also posse property 17α-hydroxyprogesterone derivative 19-nortestosterone antiandrogenic property primarily used contraceptive combination ethinylestradiol combination form pill approved united state europe however available u europe australia malaysia singapore japan dienogest single therapy approved treatment endometriosis alleviate painful symptom endometriosis reduce endometriotic lesion a20330 dienogest commonly marketed visanne natazia qlaira ,indicated use treatment endometriosis alone contraceptive combination ethinylestradiol 
Medrogestone,"medrogestone inn also known 6,17α-dimethyl-6-dehydroprogesterone progestational agent derived 17-methylprogesterone conceived alternative orally effective contraceptive option a31526 developed ayerst approved canada 1969 current status cancelled post-marketing l1118 never approved fda ",medrogestone indicated adjunct treat endometial shedding menopausal woman treat secondary amenorrhea induce menses treat dysfunctional uterine bleeding adult adolescent woman t76 
Potassium citrate,potassium citrate also known tripotassium citrate potassium salt citric acid white hygroscopic crystalline powder odorless saline taste contains 38.3 potassium mass monohydrate form highly hygroscopic deliquescent potassium citrate used treat kidney stone condition called renal tubular acidosis potassium citrate indicated also management hypocitraturic calcium oxalate nephrolithiasis , management renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis uric acid lithiasis without calcium stone 
Chorionic Gonadotropin (Human),human chorionic gonadotropin hcg polypeptide hormone produced human placenta endogenously produced hcg interacts lhcg receptor ovary promotes maintenance corpus luteum beginning pregnancy allows corpus luteum continuously secrete hormone progesterone first trimester required maintenance uterus prevents menstruation male hcg also stimulates production gonadal steroid hormone stimulating interstitial cell leydig cell testis produce androgen hcg composed alpha beta sub-unit alpha sub-unit essentially identical alpha sub­ unit human pituitary gonadotropin luteinizing hormone lh follicle-stimulating hormone fsh well alpha sub-unit human thyroid-stimulating hormone tsh beta sub­ unit hormone differ amino acid sequence drug product chorionic gonadotropin highly purified pyrogen-free preparation obtained urine pregnant female , treatment prepubertal cryptorchidism due anatomical obstruction treatment selected case hypogonadotropic hypogonadism hypogonadism secondary pituitary deficiency male induction ovulation pregnancy anovulatory infertile woman cause anovulation secondary due primary ovarian failure appropriately pretreated human menotropins 
Brexpiprazole,brexpiprazole novel d2 dopamine serotonin 1a partial agonist called serotonin-dopamine activity modulator sdam potent antagonist serotonin 2a receptor noradrenergic alpha 1b 2c receptor brexpiprazole approved treatment schizophrenia adjunctive treatment major depressive disorder mdd although failed phase ii clinical trial adhd designed provide improved efficacy tolerability e.g. le akathisia restlessness and/or insomnia established adjunctive treatment major depressive disorder mdd ,brexpiprazole indicated adjunctive therapy antidepressant treatment major depressive disorder adult l39568 also indicated treatment schizophrenia patient 13 year age older l39568 
Chromic chloride,chromic chloride injection sterile nonpyrogenic solution intended use additive solution total parenteral nutrition tpn , use supplement intravenous solution given total parenteral nutrition tpn 
Copper,copper transition metal trace element body important function many enzyme including cytochrome c oxidase monoamine oxidase superoxide dismutase fda label copper commonly used contraceptive intrauterine device iud l801 , use supplementation total parenteral nutrition contraception intrauterine device fda label l801 
Cupric Chloride,cupric chloride injection sterile nonpyrogenic solution intended use additive solution total parenteral nutrition tpn , use supplement intravenous solution given total parenteral nutrition tpn 
Gadoteric acid,"gadoteric acid macrocycle-structured gadolinium-based mri contrast agent composed organic acid dota 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid used chelating property gadolinium gd3+ paramagnetic molecule gadoterate develops magnetic moment placed magnetic field magnetic moment enhances relaxation rate water proton vicinity leading increase signal intensity brightness tissue specifically reduces t1 relaxation time extent t2 t2 relaxation time nmr source clinical utility increased signal brightness allows used imaging blood vessel inflamed diseased tissue blood vessel become 'leaky gadoteric acid fda approved product dotarem indicated intravenous use magnetic resonance imaging mri brain intracranial spine associated tissue adult pediatric patient 2 year age older detect visualize area disruption blood brain barrier bbb and/or abnormal vascularity ",gadoteric acid indicated intravenous use magnetic resonance imaging mri brain intracranial spine associated tissue adult pediatric patient 2 year age older detect visualize area disruption blood brain barrier bbb and/or abnormal vascularity 
Iothalamic acid,iothalamic acid iodine containing organic anion used diagnostic contrast agent ,conray indicated use excretory urography cerebral angiography peripheral arteriography venography arthrography direct cholangiography endoscopic retrograde cholangiopancreatography contrast enhancement computed tomographic brain image cranial computerized angiotomography intravenous digital subtraction angiography arterial digital subtraction angiography conray may also used enhancement computed tomographic scan performed detection evaluation lesion liver pancreas kidney abdominal aorta mediastinum abdominal cavity retroperitoneal space 
Ioversol,ioversol non-ionic compound tri-iodinated benzene ring used contrast dye diagnostic procedure visualize different type organ tissue l41780 iodine high atomic density give ability attenuate x-ray l41790 intravascular administration iodine compound ioversol enhances contrast vessel path flow contrast medium normal tissue allowing visualization internal structure l41780 ioversol highly hydrophilic agent considered generally safe l41790 however serious adverse reaction reported due inadvertent intrathecal administration ioversol indicated intra-arterial intravenous use l41780 ioversol approved fda 1989 currently indicated computed tomographic ct imaging contrast enhancement peripheral arteriography coronary arteriography left ventriculography l41780 l41790 , product optiray 300 intra-arterial use ioversol indicated cerebral arteriography peripheral arteriography adult intravenous use indicated ct imaging head body venography intravenous excretory urography adult l41780 product optiray 320 intra-arterial use ioversol indicated cerebral arteriography peripheral arteriography visceral renal arteriography aortography coronary arteriography left ventriculography adult angiocardiography pediatic patient l41780 intravenous use product indicated ct imaging head body venography intravenous excretory urography adult ct imaging head body intravenous excretory urography pediatric patient l41780 product optiray 350 intra-arterial use ioversol indicated peripheral arteriography coronary arteriography left ventriculography adult angiocardiography pediatic patient l41780 intravenous use product indicated ct imaging head body venography intravenous excretory urography intravenous digital subtraction angiography iv-dsa adult ct imaging head body intravenous excretory urography pediatric patient l41780 
Ioxilan,ioxilan tri-iodinated diagnostic contrast agent intravascular injection result opacification vessel path flow contrast medium permitting radiographic visualization internal structure human body significant hemodilution occurs , administered intra-arterially ioxilan indicated following diagnostic test cerebral arteriography 300 mgi/ml coronary arteriography left ventriculography 350 mgi/ml visceral angiography 350 mgi/ml aortography 350 mgi/ml peripheral arteriography 350 mgi/ml administered intravenously ioxilan indicated excretory urography contrast enhanced computed tomographic cect imaging head body 300 350 mgi/ml 
Isosulfan blue,,isosulfan blue synthetic visual lymphatic imaging agent isosulfan blue upon subcutaneous administration delineates lymphatic vessel draining region injection adjunct lymphography primary secondary lymphedema extremity chyluria chylous ascites chylothorax lymph node involvement primary secondary neoplasm lymph node response therapeutic modality 
Technetium Tc-99m mebrofenin,technetium tc 99m mebrofenin diagnostic radiopharmaceutical composed diisopropyl-iminodiacetic acid disida attached technetium-99m ion following intravenous injection single photon emission computer tomography spect imaging liver gallbladder performed using gamma camera detect gamma ray emitted technetium-99m decay possible technetium-99m decay isomeric transition technetium-99 release gamma ray liver gallbladder imaging enabled attachment mebrofenin molecule high hepatic uptake fast biliary excretion resulting improved hepatic imaging specifically mebrofenin taken hepatocytes action oatp1b1 oatp1b3 transporter currently available within sterile kit tc-99m mebrofenin indicated imaging liver gallbladder ,technetium tc 99m mebrofenin indicated hepatobiliary imaging agent 
Technetium Tc-99m medronate,technetium 99mtc medronic acid pharmaceutical product used nuclear medicine imaging composed technetium ion complexed medronic acid type bisphosphonate like bisphosphonates used treatment osteoporosis medronic acid bind hydroxyapatite crystal within bone way localizes drug bone delineation area altered osteogenesis following intravenous injection single photon emission computed tomography spect performed detect gamma ray emmitted decay technetium-99m technetium-99 ,technetium tc 99m medronate indicated use bone imaging agent delineate area altered osteogenesis 
Technetium Tc-99m oxidronate,technetium tc-99m oxidronate also known 99mtc-methylene diphosphonate radiopharmaceutical agent radiopharmaceutical defined medicinal formulation containing radioisotope used major clinical area diagnosis and/or therapy l1137 radiopharmaceutical based technetium-99m widely used diagnostic purpose 99mtc versatile chemistry allows produce extense variety complex specific characteristic l1138 complex formed binding 99mtc metal atom organic molecule group oxidronate fall category diphosphonates whose structure allows bind calcium l1139 thus technetium tc-99m oxidronate powerful detection tool abnormal osteogenesis skeletal scintigraphy l1140 developed mallinkrodt nuclear fda approved february 18 1981 ,technetium tc-99m oxidronate indicated adult pediatric patient used skeletal imaging diagnosis area present altered osteogenesis administered intravenously able generate clear image bone allows physician diagnose bone problem l1141 important point drug manipulated service nuclear specialist l1140 approved indication bone scan 1 visualization tumor metastasis bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis 7 prosthetic joint evaluation major indication detection metastatic disease common present 95 sensitivity lesion detection done 6 month earlier x-ray study l1139 
Oxygen,oxygen element displayed symbol atomic number 8 essential element human survival decreased oxygen level may treated medical oxygen therapy treatment oxygen serf increase blood oxygen level also exerts secondary effect decreasing blood flow resistance diseased lung leading decreased cardiovascular workload attempt oxygenate lung oxygen therapy used treat emphysema pneumonia heart disorder congestive heart failure disorder cause increased pulmonary artery pressure disease impairs body 's ability take use gaseous oxygen higher level oxygen ambient air hyperoxia introduced normobaric hyperbaric condition ,oxygen therapy clinical setting used across diverse specialty including various type anoxia hypoxia dyspnea disease state condition reduce efficiency gas exchange oxygen consumption respiratory illness trauma poisoning drug overdoses oxygen therapy try achieve hyperoxia l745 reduce extent hypoxia-induced tissue damage malfunction 
Protamine sulfate,since 's earliest discovery salmon rine sperm head late 1800 's formal introduction via u fda approval 1939 protamine sulfate occupied important therapeutic niche perhaps viable option reversing anticoagulant effect heparin use 77 year a174778 a174781 subsequently invasive surgical procedure involve routine use heparin prevent potentially surgery-complicating blood clotting case major bleeding frequent procedure managed use protamine sulfate a174778 agent elicits heparin reversal predominantly via formation inactive complex anionic nature heparin cationic state a174778 a174781 l5371 despite relative importance protamine sulfate 's medical indication medication notoriously cause variety potentially rare genuinely severe adverse effect include systemic hypotension pulmonary hypertension liver kidney tissue damage anaphylactic reaction amongst others a174778 l5371 consequence whenever protamine sulfate use clinically considered careful consideration must given whether use agent could decrease safety procedure worsen recovery patient procedure a174778 a174781 l5371 regardless protamine sulfate continues see contemporary use given genuine effectiveness reversing heparin effect although current date review study continue search new therapeutic alternative protamine sulfate substitute posse similar unacceptable adverse effect a174778 a174781 agent may considered potentially successful alternative including idarucizumab dabigatran reversal cost procurement potential range reversing parenteral anticoagulant sometimes considered high limited respectively a174778 a174781 ,protamine sulfate indicated counteracting reversing anticoagulant effect heparin necessary f3559 f3562 l5371 l5443 reversal may example required often surgery renal hemodialysis post open heart surgery whenever excessive bleeding result heparin use and/or treatment heparin overdosage among similar related circumstance f3559 f3562 l5371 l5443 
Sincalide,sincalide medication given injection assist diagnosis gallbladder pancreas disorder identified 8-amino acid c-terminal segment cholecystokinin also known _cck-8_ naturally occurring cholecystokinin gastrointestinal peptide hormone normally essential stimulating protein fat digestion body injected intravenously sincalide produce substantial reduction gallbladder size causing organ contract evacuation bile result similar occurs physiologically response endogenous cholecystokinin furthermore sincalide stimulates pancreatic secretion bicarbonate enzyme product kinevac fda sincalide used following indication 1 stimulate gallbladder contraction may assessed various method diagnostic imaging obtain duodenal aspiration sample concentrated bile analysis cholesterol bile salt phospholipid crystal 2 stimulate pancreatic secretion especially conjunction secretin prior obtaining duodenal aspirate analysis enzyme activity composition cytology 3 accelerate transit barium meal small bowel thereby decreasing time extent radiation associated fluoroscopy x-ray examination intestinal tract , product kinevac fda sincalide used following indication 1 stimulate gallbladder contraction may assessed various method diagnostic imaging obtain duodenal aspiration sample concentrated bile analysis cholesterol bile salt phospholipid crystal 2 stimulate pancreatic secretion especially conjunction secretin prior obtaining duodenal aspirate analysis enzyme activity composition cytology 3 accelerate transit barium meal small bowel thereby decreasing time extent radiation associated fluoroscopy x-ray examination intestinal tract 
Sonidegib,sonidegib hedgehog signaling pathway inhibitor via smoothened antagonism developed anticancer agent novartis fda approved 2015 treatment basal cell carcinoma ,sonidegib approved use u eu treatment adult locally advanced basal cell carcinoma bcc recurred post surgery radiation therapy also approved adult patient bcc eligible surgery radiation therapy 2 
Uridine triacetate,uridine triacetate formerly known vistonuridine orally active prodrug naturally occurring nucleoside uridine used treatment hereditary orotic aciduria xuriden emergency treatment fluorouracil capecitabine overdose toxicity vistogard provided prodrug form uridine triacetate form delivers 4- 6-fold uridine systemic circulation compared equimolar dos uridine used treatment prevention toxicity associated fluorouracil antimetabolite uridine triacetate utilized ability compete 5-fluorouracil 5-fu metabolite incorporation genetic material non-cancerous cell reduces toxicity cell-death associated two cytotoxic intermediate 5-fluoro-2'-deoxyuridine-5'-monophosphate fdump 5-fluorouridine triphosphate futp normally fdump inhibits thymidylate synthase required thymidine synthesis dna replication repair futp incorporates rna resulting defective strand result metabolite associated various unpleasant side effect neutropenia mucositis diarrhea hand–foot syndrome like many neoplastic agent side effect limit dos 5-fu administered also affect efficacy treatment pre-administering uridine prodrug uridine triacetate higher dos 5-fu given allowing improved efficacy reduction toxic side effect a18578 also used rescue therapy severe side effect present within 96 hour initiation therapy uridine triacetate also used treatment hereditary orotic aciduria also known uridine monophosphate synthase deficiency rare congenital autosomal recessive disorder pyrimidine metabolism caused defect uridine monophosphate synthase ump bifunctional enzyme catalyzes final two step de novo pyrimidine biosynthetic pathway result ump deficiency patient experience systemic deficiency pyrimidine nucleotide accounting symptom disease additionally orotic acid de novo pyrimidine pathway converted ump excreted urine accounting common name disorder orotic aciduria furthermore orotic acid crystal urine cause episode obstructive uropathy administered prodrug uridine triacetate uridine used essentially cell make uridine nucleotide compensates genetic deficiency synthesis patient hereditary orotic aciduria intracellular uridine nucleotide restored normal range overproduction orotic acid reduced feedback inhibition urinary excretion orotic acid also reduced ,marketed product xuriden fda uridine triacetate indicated treatment hereditary orotic aciduria marketed product vistogard fda uridine triacetate indicated emergency treatment adult pediatric patient following situation following fluorouracil capecitabine overdose regardless presence symptom exhibit early-onset severe life-threatening toxicity affecting cardiac central nervous system and/or early-onset unusually severe adverse reaction e.g. gastrointestinal toxicity and/or neutropenia within 96 hour following end fluorouracil capecitabine administration 
Water,water chemical formula h2o transparent fluid form world 's stream lake ocean rain major constituent fluid organism chemical compound water molecule contains one oxygen two hydrogen atom connected covalent bond water liquid standard ambient temperature pressure often co-exists earth solid state ice gaseous state steam water vapor , diluting dissolving drug intravenous intramuscular subcutaneous injection according instruction manufacturer drug administered fda label 
Iron sucrose,iron sucrose sucroferric oxyhydroxide iron saccharate used source iron patient iron deficiency anemia chronic kidney disease ckd including undergoing dialysis hemodialysis peritoneal require dialysis due le side effect iron dextran iron sucrose preferred chronic kidney disease patient ,iron sucrose elemental iron injection replenishes body iron store patient iron deficiency 
Ferric pyrophosphate,ferric pyrophosphate iron replacement product free iron present several side effect catalyze free radical formation lipid peroxidation well presence interaction iron plasma ferric ion strongly complexed pyrophosphate a31979 present increasing interest insoluble form milder gastrointestinal tract present higher bioavailability l1433 ,ferric pyrophosphate intended indicated treatment iron loss iron deficiency formulation milder gastrointestinal effect l1423 l1433 iron deficiency appears dietary intake meet body 's requirement chronic external blood loss acute blood loss body iron store sufficient accelerated erythropoiesis restoration iron homeostasis altered homeostasis remains week month supplement needed cause iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 
Florbetaben (18F),florbetaben fluorine-18 18f -labeled stilbene derivative used positron emission tomography pet imaging brain used non-invasive detection density ß-amyloid neuritic plaque brain adult patient cognitive impairment ,florbetaben radioactive diagnostic agent indicated positron emission tomography pet imaging brain estimate β-amyloid neuritic plaque density adult patient cognitive impairment evaluated alzheimer ’ disease ad cause cognitive decline 
Florbetapir (18F),florbetapir 18f radiopharmaceutical compound containing radionuclide fluorine-18 bound compound florbetapir molecule bind high affinity beta amyloid plaque peptide play key role alzheimer 's disease pathogenesis marketed product amyvid florbetapir 18f indicated positron emission tomography pet imaging brain estimate β-amyloid neuritic plaque density adult patient cognitive impairment evaluated alzheimer 's disease ad cause cognitive decline radionucleide fluorine-18 chosen half life 110 minute allowing accumulate sufficiently brain undergoing positon emission decay ,florbetapir 18f indicated positron emission tomography pet imaging brain estimate β-amyloid neuritic plaque density adult patient cognitive impairment evaluated alzheimer 's disease ad cause cognitive decline 
Flutemetamol (18F),flutemetamol 18f pet scanning radiopharmaceutical containing radionuclide fluorine-18 indicated positron emission tomography pet imaging brain estimate β amyloid neuritic plaque density adult patient cognitive impairment evaluated alzheimer 's disease ad cause cognitive decline ,flutemetamol f18 indicated positron emission tomography pet imaging brain estimate β amyloid neuritic plaque density adult patient cognitive impairment evaluated alzheimer 's disease ad cause cognitive decline 
Nitrogen,nitrogen chemical element symbol n atomic number 7 room temperature transparent odorless diatomic gas liquid nitrogen used principally cryotherapy removal diseased skin liquid nitrogen help removal skin lesion necrosis result freezing thawing cell cryotherapy usually done doctor office also nitrogen famous component fertilizer energy-stores ,liquid nitrogen used mainly cryogenic agent treatment various benign malignant skin lesion 
Sodium chloride,sodium chloride also known salt common salt table salt halite ionic compound chemical formula nacl representing 1:1 ratio sodium chloride ion sodium chloride primary salt seawater extracellular fluid many multicellular organism listed world health organization model list essential medicine , intravenous solution indicated use adult pediatric patient source electrolyte water hydration also designed use diluent delivery system intermittent intravenous administration compatible drug additive 
Sodium citrate,sodium citrate sodium salt citric acid white crystalline powder white granular crystal slightly deliquescent moist air freely soluble water practically insoluble alcohol like citric acid sour taste medical point view used alkalinizing agent work neutralizing excess acid blood urine indicated treatment metabolic acidosis ,used anticoagulant plasmophoresis well neutralizing agent treatment upset stomach acidic urine fda label l788 l789 
Helium,helium second abundant chemical element universe symbol atomic number 2 colorless odorless tasteless non-toxic inert monatomic gas located top noble gas periodic table boiling melting point lowest among element clinical benefit inhalation therapy arises advantageous physical property ambient air helium lower density air generates le resistance provide improved lung ventilation also used analytical reagent diagnostic/imaging test detect respiratory function patient , use patient getting enough oxygen blood due blockage lung pathological condition injury suggested potential benefit upper airway obstruction severe asthma exacerbation copd/cold helium may used place carbon monoxide laparoscopic surgery lower risk developing respiratory acidosis selected patient 
Iopromide,iopromide low osmolar non-ionic x-ray contrast agent intravascular administration function contrast agent opacifying blood vessel path flow contrast agent permitting radiographic visualization internal structure significant hemodilution occurs available fda-approved product ultravist iopromide used radiographic study intra-arterial digital subtraction angiography ia-dsa cerebral peripheral arteriography peripheral venography excretory urography brain computer tomography ct coronary arteriography left ventriculography visceral angiography aortography ,iopromide product iovist indicated use x-ray contrast agent following procedure intra-arterial digital subtraction angiography ia-dsa 150 mg i/ml cerebral arteriography peripheral arteriography 300 mg i/ml coronary arteriography left ventriculography visceral angiography aortography 370 mg i/ml peripheral venography 240 mg i/ml excretory urography 300 mg i/ml contrast computed tomography ct imaging head body 300 mg i/ml 370 mg i/ml 
Carbon dioxide,carbon dioxide colorless odorless gas vital life earth naturally occurring chemical compound composed carbon atom covalently double bonded two oxygen atom medical carbon dioxide liquefied medicinal gas supplied cylinder filled high pressure medical carbon dioxide may used different situation e.g bodily investigation inflate body cavity surgery key-hole surgery solid form dry ice freezing tissue removal wart ,carbon dioxide commonly used insufflation gas minimal invasive surgery laparoscopy endoscopy arthroscopy enlarge stabilize body cavity provide better visibility surgical area used also cryotherapy respiratory stimulant anesthesia could used also expansion blood vessel required increase carbon dioxide level rapid breathing stimulate breathing period nonbreathing 
Trypan blue free acid,trypan blue diazo dye used ophthalmic cataract surgery stain anterior capsule presence mature cataract done aid visualization creating continuous curvilinear capsulorhexis ,trypan blue indicated use aid ophthalmic surgery staining epiretinal membrane ophthalmic surgical vitrectomy procedure facilitating removal tissue 
Technetium Tc-99m tetrofosmin,"technetium tc-99m tetrofosmin drug used nuclear myocardial perfusion imaging radioisotope technetium-99m chelated two 1,2-bis di- 2-ethoxyethyl phosphino ethane ligand belong group diphosphines referred tetrofosmin lipophilic technetium phosphine dioxo cation formulated freeze-dried kit yield injection a31592 technetium tc-99m tetrofosmin developed ge healthcare fda approved february 9 1996 ",technetium-99m tetrofosmin indicated diagnosis heart abnormality exercise myocardial scintigraphy exercise myocardial scintigraphy established method diagnosis severity coronary artery disease a31592 method allows distinguishing region reversible myocardial ischemia presence absence infarcted myocardium following rest stress condition l1147 use technetium-99m tetrofosmin mainly used ass myocardial perfusion ischemia infarction l1146 
Technetium Tc-99m sestamibi,technetium tc-99m sestamibi commonly sestamibi pharmaceutical agent used nuclear medicine imaging drug coordination complex consisting radioisotope technetium-99m bound six methoxyisobutylisonitrile mibi ligand hence name sesta 6 mibi .. following intravenous injection drug technetium tc-99m sestamibi taken myocardium parathyroid and/or breast tissue mechanism sestamibi localizes tissue established single photon emission computed tomography spect performed detect gamma ray emmitted decay technetium-99m technetium-99 currently available within preparation kit injection technetium tc 99m sestamibi indicated 1 detecting coronary artery disease localizing myocardial ischemia reversible defect infarction non-reversible defect 2 evaluating myocardial function developing information use patient management decision ,technetium tc 99m sestamibi indicated 1 detecting coronary artery disease localizing myocardial ischemia reversible defect infarction non-reversible defect 2 evaluating myocardial function developing information use patient management decision 
Technetium Tc-99m exametazime,technetium tc-99m exametazime radiopharmaceutical sold trade name ceretec used detection altered regional cerebral perfusion stroke cerebrovascular disease also used labelling leukocyte localise intra-abdominal infection inflammatory bowel disease exametazime also known hexamethylpropyleneamine oxime hmpao act chelating agent tc-99m radioisotope ,technetium tc99m exametazime scintigraphy without methylene blue stabilization may useful adjunct detection altered regional cerebral perfusion stroke tc99m exametazime without methylene blue stabilization indicated leukocyte labeled scintigraphy adjunct localization intra-abdominal infection inflammatory bowel disease 
Technetium Tc-99m disofenin,technetium tc-99m disofenin radiopharmaceutical agent used hepatobiliary imaging diagnostic purpose well suited planar single photon tomographic scintigraphy quantitatively measure function liver gallbladder bile duct detect anatomical change hepatobliary system available intravenous injection preparation kit name hepatolite technetium tc-99m metastable nuclear isomer disofenin iminodiacetic acid derivative known pharmacologic action dos recommended however disofenin commonly used iminodiacetic acid since high liver renal extraction hepatic uptake highly dependent serum bilirubin level competitive inhibitor liver uptake tracer iminodiacetic acid ,technetium tc99m disofenin indicated hepatobiliary imaging agent hepatolite indicated diagnosis acute cholecystitis well rule occurrence acute cholecystitis suspected patient right upper quadrant pain fever jaundice right upper quadrant tenderness mass rebound tenderness limited sign symptom 
Technetium Tc-99m pyrophosphate, radionuclide imaging agent used primarily scintigraphy tomography heart evaluate extent necrotic myocardial process also used noninvasive test distribution organ involvement different type amyloidosis evaluation muscle necrosis extremity , use skeletal imaging agent used demonstrate area altered osteogenesis cardiac imaging agent used adjunct diagnosis acute myocardial infarction fda label may also used image gated blood pool detect gastrointetinal bleeding 
Etizolam,etizolam thienodiazepine chemically related benzodiazepine bdz drug class differs bdzs benzene ring replaced thiophene ring agonist gaba-a receptor posse amnesic anxiolytic anticonvulsant hypnotic sedative skeletal muscle relaxant property initially introduced 1983 japan treatment neurological condition anxiety sleep disorder etizolam marketed japan italy india approved use fda u however remains unscheduled several state legal research purpose ,indicated treatment generalized anxiety disorder depression panic disorder insomnia 
Dosulepin,dosulepin inn ban formerly known dothiepin usan tricyclic antidepressant anxiolytic property used several european south asian country well australia south africa new zealand fda-approved due low therpeutic index significant toxicity overdose dosulepin inhibits reuptake biogenic amine increasing available neurotransmitter level synaptic cleft use dosulepsin recommended patient intolerant unresponsive alternative antidepressant therapy dosulepsin thio derivative db00321 similar efficacy db00321 also exhibit anticholinergic antihistamine central sedative property l882 hydrochloride form common active ingredient different drug formulation ,indicated treatment symptom depressive illness especially anti-anxiety effect required 
4-Phenylfentanyl,4-phenylfentanyl sythetic opioid derived fentanyl 4-phenylfentanyl around 8x potency fentanyl analgesic test animal complex 4-heteroaryl derivative substituted thiophenes thiazoles potent still closer bioisosteres 4-carbomethoxy group carfentanil ,
3-Allylfentanyl,3-allyfentanyl fentanyl derivative opioid cause itching nausea serious respiratory depression fentanyl analog killed thousand people around world drug abuse ,
β-Hydroxythiofentanyl,β-hydroxythiofentanyl analgesic _opioid_ class drug analog fentanyl potent opioid ,
β-Methylfentanyl,β-methylfentanyl analgesic _opioid_ class analog potent opioid fentanyl ,
Brifentanil,brifentanil also known a-3331 analog fentanyl potent opioid drug classified opioid analgesic developed early 1990s effect brifentanil similar alfentanil strong short lasting analgesia sedation particularly notable itching respiratory depression ,
Butyrfentanyl,butyrfentanyl butyrylfentanyl confused 3-methylfentanyl potent short-acting synthetic opioid analgesic drug a182054 analog fentanyl roughly 1/30 potency l7811 butyrfentanyl first synthesized 1961 janssen pharmaceutical new opioid analgesic l7811 butyrfentanyl current legitimate clinical application anecdotal report indicate may occasionally surfacing grey-market recreational drug l7811 compound schedule controlled substance usa positional isomer 3-methylfentanyl l7814 dea united state confirmed least 40 fatality involving butyrfentanyl may 2016 l7811 ,butyrfentanyl investigated potential opioid analgesic longer used purpose a182060 often used recreational drug a182060 
Lofentanil,lofentanil analog fentanyl one potent opioids available today display similarity carfentanil 4-carbomethoxyfentanyl considered slightly potent drug ,
Mirfentanil,mirfentanil derivative fentanyl present high selectivity mu opioid receptor lower dos antagonizes analgesic effect alfentanil substitute naloxone morphine-treated monkey however also revers naloxone-precipitated withdrawal pigeon trained discriminate morphine naloxone high dos exhibit analgesic activity fully reversed opioid antagonist suggesting drug opioid non-opioid mechanism action ,
p-Fluorofentanyl,p-fluorofentanyl opioid analgesic analogue fentanyl developed janssen pharmaceutica 1960s p-fluorofentanyl sold briefly u black market early 1980s introduction federal analog act first time attempted control entire family drug based structural similarity rather scheduling drug individually appeared p-fluorofentanyl made synthetic route fentanyl substituting para-fluoroaniline aniline synthesis ,
Phenaridine,"phenaridine 2,5-dimethylfentanyl synthetic fentanyl derivative opioid developed 1972 used surgical anasthesia russia phenaridine similar effect fentanyl rat study le potent fentanyl side effect include itching nausea serious life threatening respiratory depression fentanyl analog killed hundred people throughout europe former soviet republic since recent resurgence use began estonia early 2000s novel derivative continue appear ",
R-30490,r-30490 opioid related carfentanil used animal tranquilizer first synthesized janssen pharmaceutica part structure-activity relationship study fentanly derivative r-30490 found selective agonist mu opioid receptor fentanyl analogue tested never introduced medical use human although closely related drug sufentanil widely used analgesia anesthesia major surgery ,
Thienylfentanyl,thienylfentanyl fentanyl analog analgesic sold black market 1980s federal analog act scheduled drug based structural similarity rather scheduling drug individually thienylfentanyl similar synthesis pathway fentanyl except 2- 2-bromoethyl thiophene substituted phenethyl bromide ,
Trefentanil,trefentanil a-3665 fentanyl analogue opioid developed 1992 potent shorter acting alfentanil trefentanil used clinic due severity respiratory depression though still used research ,
Benzylfentanyl,benzylfentanyl r-4129 fentanyl analog opioid list schedule drug america 1985 due structural similarity fentanyl 2010 removed list found minimal opioid activity benzylfentanyl ki 213nm mu opioid receptor binding around 200x le strongly fentanyl ,
Dasabuvir,dasabuvir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas dasabuvir dasabuvir non-nucleoside ns5b inhibitor bind palm domain ns5b induces conformational change render polymerase unable elongate viral rna fda label binding site non-nucleoside ns5b inhibitor poorly conserved across hcv genotype leading restriction dasabuvir 's use genotype 1 joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend dasabuvir first line therapy combination db09296 db09297 db00503 genotype 1b db00811 genotype 1a hepatitis c l852 dasabuvir db09296 db09297 db00503 db00811 used intent cure achieve sustained virologic response svr 12 week therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 dasabuvir available fixed dose combination product db09296 db09297 db00503 tradename viekira pak used treatment chronic hepatitis c. approved december 2014 fda viekira pak indicated treatment hcv genotype 1a db00811 genotype 1b without db00811 fda label combined together dasabuvir db09296 db09297 db00503 combination product viekira pak shown achieve svr 100 genotype 1b 89 95 genotype 1a 12 week 24 week treatment including db00811 ,dasabuvir combination db09296 db09297 db00503 viekira pak indicated treatment patient hcv genotype 1a db00811 genotype 1b without db00811 including compensated cirrhosis fda label 
Edivoxetine,edivoxetine drug act selective norepinephrine reuptake inhibitor currently development eli lilly attention-deficit hyperactivity disorder adhd antidepressant treatment edivoxetine failed approved major depressive disorder phase iii clinical trial 2012 ,
Viloxazine,viloxazine selective norepinephrine reuptake inhibitor l41685 decade immediate-release formulation viloxazine used europe antidepressant first approved uk 1974 however immediate-release formulation discontinued due business reason unrelated drug safety efficacy u viloxazine assigned orphan drug designation 1984 brand name catatrol product intended treat cataplexy narcolepsy drug never approved therapeutic indication april 2021 extended-release formulation viloxazine brand name qelbree approved fda treatment attention deficit hyperactivity disorder adhd a247985 ,viloxazine selective norepinephrine reuptake inhibitor indicated treatment attention deficit hyperactivity disorder adhd adult pediatric patient 6 year older l41685 
Nisoxetine,nisoxetine selective norepinephrine reuptake inhibitor snri developed 1970s originally investigated antidepressant current clinical application aside research standard snri used research obesity energy balance exerts local analgesia effect ,
Lortalamine,lortalamine lm-1404 selective norepinephrine reuptake inhibitor developed 1980s drug never made past clinical trial likely due ocular toxicity animal used positron emission tomography study label norepinephrine transporter ,
Amedalin,amedalin selective norepinephrine reuptake inhibitor developed 1970s significant effect reuptake serotonin dopamine antihistamine anticholinergic property drug never marketed ,
Daledalin,daledin uk-3557-15 selective norepinephrine reuptake inhibitor effect reuptake serotonin dopamine antihistamine anticholinergic property trial depression 1970s never marketed ,
Talopram,talopram selective norepinephrine reuptake inhibitor snri structurally similar citalopram melitracen researched 1960s 1970s never marketed ,
Talsupram,talsupram selective norepinephrine reuptake inhibitor nri research treatment depression 1960 1970 never marketed talsupram present similar structure citalopram ,
Tandamine,tandamine researched 1970s antidepressant never commercialized tandamine analog pirandamine act selective serotonin reuptake inhibitor ssri ,
"CP-39,332","cp-39,332 serotonin-norepinephrine reuptake inhibitor snri part group monoamine reuptake inhibitor stereoisomers including tametraline 1r,4s- cp-24,442 1s,4r- cp-22,185 cis- cp-22,186 show varying efficiency however none member stereoisomers marketed ",
Etoperidone,etoperidone atypical antidepressant introduced europe 1977 phenylpiperazine-substituted triazole derivative composition classifies analog tradozone present similar pharmacological profile t45 etoperidone developed angelini francesco acraf a4909 ,etoperidone studied treatment depression t47 tremor parkinson extrapyramidal symptom l1041 male impotence l1042 certain ever approved marketed current status withdrawn 
Lorpiprazole,lorpiprazole serotonin antagonist reuptake inhibitor used treatment major depressive disorder a31634 piperazinyl-triazole derivative t83 , 2016 lorpiprazole classified `` chemical structure-related drug-like criterion global approved drug '' antipsychotic anxiolytic l1167 antipsychotic medication used treat state delusion hallucination paranoia disordered thought hand anxiolytic medication used treatment severe chronic debilitating anxiety anxiety state defined unpleasant state tension apprehension uneasiness t77 
Lubazodone,"lubazodone ym-992 ym-35,995 arylpiperazine antidepressant developed treatment depression obsessive compulsive disorder reached phase ii clinical trial discontinued act serotonin reuptake inhibitor 5-ht2a receptor antagonist ",
Mepiprazole,mepiprazole minor tranquilizer phenylpiperazine structure pyrazolyl-alkyl-piperazine derivative mepiprazole mediates weak inhibitory action uptake 5-ht hypothalamic neuron a7816 mepiprazole marketed spain treatment anxiety neurosis act 5-ht2a α1-adrenergic receptor antagonist also shown inhibit reuptake induce release serotonin dopamine norepinephrine varying extent clinical study mepiprazole including patient irritable bowel syndrome ibs conducted result showed beneficial effect mepiprazole relieving ibs symptom certain patient like phenylpiperazine drug mepiprazole produce active metabolite m-chlorophenylpiperazine mcpp , treatment anxiety neurosis 
Lobeglitazone,lobeglitazone antidiabetic medication thiazolidinedione class drug primarily function insulin sensitizer binding activating peroxisome proliferator-activated receptor ppar gamma within fat cell activating ppar-gamma promoting binding insulin fat cell lobeglitazone thereby shown reduce blood sugar level lower hemoglobain a1c hba1c level improve lipid liver profile a19748 unlike db01132 dual ppar agonist ppar-alpha ppar-gamma lobeglitazone pure ppar-alpha agonist lobeglitazone approved ministry food drug safety south korea 2013 monitored postmarketing surveillance 2019 lobeglitazone approved use either food drug administration usa health canada european medicine agency use management diabetes ,lobeglitazone approved ministry food drug safety south korea 2013 monitored postmarketing surveillance 2019 lobeglitazone approved use either food drug administration usa health canada european medicine agency use management diabetes 
Netoglitazone,netoglitazone mcc-555 hypoglycemic agent ,
Rivoglitazone,rivoglitazone inn thiazolidinedione undergoing research use treatment type 2 diabetes developed daiichi sankyo co ,
Ciglitazone,developed takeda pharmaceutical early 1980s considered prototypical compound thiazolidinedione class ciglitazone never used medication sparked interest effect thiazolidinediones several analogue later developed which—such pioglitazone troglitazone—made market ciglitazone significantly decrease vegf production human granulosa cell vitro study may potentially used ovarian hyperstimulation syndrome ciglitazone potent selective pparγ ligand ec50 3.0 µm also anti-hyperglycemic agent ob/ob murine model vivo ciglitazone increase adipogenesis decrease differentiation angiogenesis human umbilical vein endothelial cell huvec osteoblastogenesis human mesenchymal stem cell ,
Cirazoline,cirazoline act number α adrenergic receptor agonist α1a partial agonist α1b α1d nonselective antagonist α2 believed combination property could make cirazoline effective vasoconstricting agent cirazoline also shown decrease food intake rat purportedly activation α1-adrenoceptors paraventricular nucleus hypothalamus brain ,
Synephrine,synephrine also referred p-synephrine naturally occurring alkaloid present approved drug product neo-synephrine m-substituted analog p-synephrine m-synephrine known longer acting adrenergic effect compared norepinephrine similarity naming m-synephrine unsubstituted form synephrine source confusion however m-synephrine refers related drug commonly known phenylephrine compound share chemical pharmacological similarity fact distinct chemical entity ,
Arotinolol,arotinolol alpha- beta-receptor blocker developed japan thiopropanolamine tertiary butyl moiety studied potential antihypertensive therapy t87 artinolol developed sumitomo pharmaceutical co. ltd. currently clinical trial l1168 ,artinolol introduced used antihypertensive agent since 1986 t88 studied function like tremor control patient parkinson disease currently clinical trial use control blood pressure heart rate l1168 
Moxisylyte,moxisylyte denominated thymoxamine uk specific orally active α1-adrenergic antagonist t45 according moxisylyte approved since 1987 t91 year acquired denomination orphan product fda l1172 drug developed japanese company fujirebio also american company iolab late 80 , moxisylyte indicated symptomatic management sequela cerebral infarction hemorrhage t91 cerebral infarction characterized blockage artery either formation thrombus embolus a31644 hand fda classified moxisylyte reversal phenylephrine-induced mydriasis patient narrow anterior angle risk developing acute attack angle-closure glaucoma l1172 closed-angle glaucoma caused contact iris trabecular meshwork contact damage aqueous outflow meshwork thus increasing eye pressure producing symptom glaucoma a31645 mydriasis referred dilatation pupil standard body function known trigger factor development acute closed-angle glaucoma.this risk explained generation pupillary block contact pupillary margin lens thus preventing flow aqueous humor anterior chamber followed increased pressure gradient l1173 moxisylyte also approved france first drug treatment impotence a31647 
Trimazosin,trimazosin sympatholytic alpha blocker ,
AS-8112,as-8112 synthetic compound act selective antagonist dopamine receptor subtypes d2 d3 serotonin receptor 5-ht3 shown exert potent antiemetic effect animal study investigated potential medical use ,
Pegloticase,pegloticase porcine recombinant pegylated uricase indicated treatment chronic gout adult patient respond type therapy l42425 pegloticase similar activity rasburicase enzyme metabolizes uric acid allantoin gout patient treated pegloticase conversion uric acid allantoin lead lower plasma uric acid concentration l42425 pegloticase longer terminal elimination half-life thanks addition polyethylene glycol peg group therefore therapeutic drug level maintained infrequent relatively low pegloticase dos a249980 peg group also give pegloticase lower potential induce immune response a249980 however case anaphylaxis infusion reaction reported patient treated drug l42425 pegloticase approved fda 2014 2022 drug label included co-administration pegloticase methotrexate l42425 ,pegloticase pegylated uric acid specific enzyme indicated treatment chronic gout adult patient refractory conventional therapy l42425 
Pholcodine,pholcodine formula 3-o-morpholinoethylmorphine classified antitussive defined opioid cough suppressant belongs opioid family compound widely used a31738 pholcodine activity suppression unproductive cough also mild sedative effect little analgesic effect a31742 pholcodine prescribed united state classed schedule drug categorized class b drug uk officially taken shelf 2008 pholcodine approved canada ,pholcodine indicated cough suppressant temporary relief non-productive dry cough stated present required label indication `` temporary relief dry cough `` l1200 cough respiratory movement occurs irritation signal transmitted central nervous system stimulates medulla oblongata stimulation cause motor output sent motoneuron respiratory muscle non-productive cough type cough characterized absence sputum large inspiration cause continuous coughing 
Piracetam,piracetam nootropic drug racetams group chemical name 2-oxo-1-pyrrolidine acetamide share 2-oxo-pyrrolidone base structure pyroglutamic acid cyclic derivative neurotransmitter γ-aminobutyric acid gaba however mechanism action differ endogenous gaba piracetam neuroprotective anticonvulsant property reported improve neural plasticity a31532 efficacy documented cognitive disorder dementia vertigo cortical myoclonus dyslexia sickle cell anemia although clinical application condition yet established piracetam effect vascular system reducing erythrocyte adhesion vascular endothelium hindering vasospasms facilitating microcirculation a31532 originally marketed ucb pharma 1971 piracetam first nootropic drug modulate cognitive function without causing sedation stimulation a31532 approved medical dietary use fda uk piracetam prescribed mainly myoclonus used off-label condition learning difficulty child memory loss cognitive defect elderly sickle-cell vaso-occlusive crisis l1124 evidence support use many condition unclear ,indicated adult patient suffering myoclonus cortical origin irrespective aetiology used combination anti-myoclonic therapy l1125 
Limaprost,limaprost limaprost alfadex ca number 88852-12-4 oral prostaglandin e1 analog prostaglandin act variety cell vascular smooth muscle cell causing constriction dilation platelet causing aggregation disaggregation spinal neuron causing pain prostaglandin wide variety action including limited muscular constriction mediation inflammation limaprost alfadex shown improve peripheral circulatory failure vasodilator action antithrombotic effect also improves poor blood flow nerve tissue cervical spondylosis normalizes nerve function limaprost alfadex discovered collaborative research ono pharmaceutical ono dainippon sumitomo pharma dsp approved treatment ischemic symptom skin ulcer pain coldness accompanying thromboangiitis obliterans 1988 treatment subjective symptom pain numbness lower leg walking disability associated acquired lumbar spinal canal stenosis additional indication 2001 drug sold trade name opalmon® tablet ono prorenal® tablet dsp 2011 ono dsp initiated phase ii clinical trial japan treatment carpal tunnel syndrome 2013 trial discontinued study failed demonstrate efficacy ono dsp also discontinued development limaprost alfadex additional indication cervical spondylosis 2008 due failure demonstrate anticipated efficacy phase ii study patient disease however verified seoul national university hospital november 2014 study efficacy oral limaprost alfadex surgery cervical myelopathy still ongoing ,limaprost used improvement various ischemic symptom ulcer pain feeling coldness associated thromboangiitis obliterans well improvement subjective symptom pain numbness lower leg gait ability associated acquired lumbar spinal canal stenosis patient bilateral intermittent claudication showing normal slr test result 
Loxoprofen,loxoprofen propionic acid derivative non-steroidal anti-inflammatory drug marketed trade name loxonin brazil mexico japan sankyo loxomac india oxeno argentina transdermal preparation approved use japan january 2006 ,loxoprofen non-steroidal anti-inflammatory medication nsaid indicated pain inflammation related musculoskeletal joint disorder l1226 addition effect pain antipyretic anti-inflammatory medication l1227 
Dexibuprofen,dexibuprofen -ibuprofen non-steroidal anti-inflammatory drug nsaid pharmacologically effective enantiomer racemic ibuprofen differs physicochemical property proposed pharmacologically active tolerable better safety profile ibuprofen due higher concentration active enantiomer dexibuprofen slower dissolution rate simulated gastric enteric juice compared racemic ibuprofen display improved oral bioavilability a19259 metabolism enzyme carrier transporter section refer ibuprofen , information refer ibuprofen 
Dexketoprofen,dexketoprofen non-steroidal anti-inflammatory drug available various country europe asia latin america analgesic antipyretic anti-inflammatory property l1298 , short-term treatment mild moderate pain including dysmenorrhoea musculoskeletal pain toothache l1302 
Droxicam,droxicam oxicam non-steroidal anti-inflammatory drug prodrug db00554 used reduce pain inflammation musculoskeletal disorder rheumatoid arthritis osteoarthritis ,droxicam nsaid previously used treatment inflammation rheumatoid arthritis l1119 
Tolfenamic acid,tolfenamic acid formula n- 2-methyl-3-chlorphenyl -anthranilic acid nonsteroidal anti-inflammatory agent a31824 discovered scientist medica pharmaceutical company finland used uk treatment migraine name clotam l1292 u present status class fda european medicine agency granted 2016 status orphan treatment supranuclear palsy l1291 , information tolfenamic acid stated drug nsaid effective treating pain associated acute attack migraine adult l1293 
Firocoxib,firocoxib cycooxygenase-2 cox-2 selective non-steroidal anti-inflammatory drug currently approved veterinary use dog horse brand name equioxx previcox firocoxib first cox-2 inhibitor approved u.s. food drug administration horse firocoxib intended approved use human medicine ,used treatment pain inflammation fever horse dog 
Clonixin,clonixin non-steroidal anti-inflammatory drug ,indicated use management chronic arthritic condition certain soft tissue disorder associated pain inflammation 
Bisoxatin,bisoxatin stimulant laxative increase peristalsis inhibits absorbtion water ion intestine l926 marketed belgium tradename wylaxine used treatment constipation preparation colon surgical procedure , use treatment constipation absence bowel obstruction surgical preparation colon l926 
Nicorandil,nicorandil orally efficacious vasodilatory drug antianginal agent marketed uk australia europe india philippine japan south korea taiwan approved drug fda niacinamide derivative induces vasodilation arteriole large coronary artery activating potassium channel often used patient angina remain symptomatic despite optimal treatment antianginal drug t28 nicorandil dual-action potassium channel opener relaxes vascular smooth muscle membrane hyperpolarization via increased transmembrane potassium conductance increased intracellular concentration cyclic gmp shown dilate normal stenotic coronary artery reduces ventricular preload afterload a20325 ,indicated prevention treatment chronic stable angina pectoris reduction risk acute coronary syndrome 
Polaprezinc,polaprezinc chelated form zinc l-carnosine zinc-related medicine approved first time japan clinically used treat gastric ulcer l1307 l1308 determined polaprezinc may effective pressure ulcer treatment a31856 study 2013 showed co-administration polaprezinc may effective small intestine mucosal injury associated long-term aspirin therapy a7840 ,peptic ulcer disease dyspepsia l1308 
Fibrinogen human,fibrinogen concentrate human hematological agent work replacing certain protein blood help blood clotting fibrinogen factor soluble plasma glycoprotein molecular weight 340 kda physiological substrate three enzyme plasmin factor xiiia thrombin indicated treatment acute bleeding episode patient congenital fibrinogen deficiency including afibrinogenemia hypofibrinogenemia ,human fibrinogen used treatment acute bleeding episode patient congenital fibrinogen deficiency including afibrinogenemia hypofibrinogenemia combination thrombin used indicated adjunct hemostasis mild moderate bleeding adult undergoing surgery control bleeding standard surgical technique suture ligature cautery ineffective impractical l12936 l12939 
Blonanserin,blonanserin atypical antipsychotic approved japan january 2008 offer improved tolerability lack side effect extrapyramidal symptom excessive sedation hypotension second-generation atypical antipsychotic significantly efficacious treatment negative symptom schizophrenia compared first-generation typical antipsychotic ,used treatment schizophrenia l1097 
Melperone,melperone atypical antipsychotic butyrophenone chemical class making structurally related typical antipsychotic haloperidol melperone used span greater 30 year european union l1316 well established treatment confusion anxiety restlessness particularly elderly schizophrenia known well-tolerated excellent safety profile recently studied treatment psychosis related parkinson 's disease l1316 , treatment schizophrenia sleep disorder agitation mentally confused state l1317 l1319 l1322 
Zotepine,zotepine formula 2-chloro-11- 2-dimethyl-amino-ethoxy -dibenzo thiepin neuroleptic drug designed synthesized fujisawa pharmaceutical co ltd. a31855 used antipsychotic japan india place europe like uk germany since 1980 's a31857 zotepine never approved fda 1993 classified inactive drug substance status type ii 1995 fda studied manufacturing procedure zotepine tablet germany status remained inactive l1082 analysis antipsychotic retaken 2016 fda zotepine reach threshold effect studied. l1313 ema 2015 pharmacovigilance study potential treatment acute renal failure l1314 ,zotepine like atypical antipsychotic considered first-line treatment newly diagnosed schizophrenia usually thought option choice managing acute schizophrenic episode discussion patient possible zotepine atypical antipsychotic used patient suffering unacceptable side effect conventional antipsychotic relapse patient inadequately controlled t108 important consider indication stated related atypical antipsychotic zotepine currently fda canada ema approved study shown additional benefit compared approved atypical antipsychotic a31857 schizophrenia chronic severe mental disorder affect person think feel behaves usually marked loose reality perspective delineated hallucination delusion thought movement disorder l1320 
Brilaroxazine,brilaroxazine rp5063 investigational atypical antipsychotic development reviva pharmaceutical treatment schizophrenia schizoaffective disorder reviva pharmaceutical also intends investigate rp5063 treatment bipolar disorder major depressive disorder psychosis/agitation associated alzheimer 's disease parkinson 's disease psychosis attention deficit hyperactivity disorder add/adhd autism may 2015 phase iii clinical trial schizophrenia ,investigated treatment schizophrenia schizoaffective disorder 
Barnidipine,barnidipine long-acting novel calcium antagonist belongs dihydropyridine dhp group calcium channel blocker used treatment hypertension barnidipine display high affinity calcium channel smooth muscle cell vascular wall l1131 selectivity cardiovascular l-type calcium channel a7842 barnidipine contains two chiral centre thus four possible enantiomer active component composed single optical isomer 3 's 4 configuration potent longest-acting four enantiomer a31567 compared several calcium antagonist racemates barnidipine compound consisting single enantiomer may offer high degree pharmacological selectivity a31567 according dose-ranging multicentre placebo-controlled double-blind study patient mild moderate hypertension antihypertensive response barnidipine treatment maintained 1-year 2-year follow-up period 91 patient initial response drug a7842 two european multicentre randomized double-blind trial barnidipine shown posse equivalent antihypertensive efficacy amlodipine nitrendipine produced fewer class-specific side-effects a31568 also demonstrated clinical efficacy similar atenolol enalapril hydrochlorothiazide a7842 available modified-release oral tablet brand name vasexten taken daily morning barnidipine gradual onset action shown well tolerated patient produce reflex tachycardia a7842 ,indicated treatment mild moderate essential hypertension management chronic stable angina 
Conestat alfa,c1 esterase inhibitor recombinant recombinant analogue endogenous complement component-1 esterase inhibitor rhc1inh purified milk transgenic rabbit primary function endogenous c1inh regulate activation complement contact system pathway inhibition several target protease within pathway including activated c1s kallikrein factor xiia factor xia c1 esterase inhibitor also shown inhibit action thrombin within coagulation pathway tpa plasmin within fibrinolytic pathway deficiency c1-inhibitor allows increased plasma kallikrein activation subsequent production bradykinin additionally c4 c2 cleavage occurs resulting auto-activation complement system down-stream effect lack enzyme inhibition c1 esterase inhibitor result swelling due leakage fluid blood vessel connective tissue consequently presentation hereditary angioedema hae marketed product ruconest fda drug indicated treatment acute attack hereditary angioedema hae due c1 esterase inhibitor deficiency adult intravenous replacement c1 esterase inhibitor result reversal acute symptom hae , treatment acute attack hereditary angioedema hae due c1 esterase inhibitor deficiency adult 
Aranidipine,"aranidipine novel dihydropyridine derivative give rise two active metabolite m-1α m-1β exhibit hypotensive activity calcium antagonist formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4- 2-nitrophenyl -3,5-pyridinedicarboxylate a31895 developed maruko seiyaku introduced taiho launched japan 1997 t88 ",aranidipine used many year treat angina pectoris hypertension a31895 
Azelnidipine,azelnidipine dihydropyridine calcium channel blocker marketed daiichi-sankyo pharmaceutical inc. japan gradual onset action produce long-lasting decrease blood pressure small increase heart rate unlike calcium channel blocker l1379 currently studied post-ischemic stroke management l1380 , treatment hypertension 
Benidipine,"benidipine formula 1,4-dihydro-2,6-dimethyl-4- 3-nitrophenyl -3,5-pyridine-dicarboxylic acid methyl 1- phenylmethyl -3-piperidinyl ester hydrochloride synthetic dihydropyridine derivative anti-hypertensive anti-anginal action a31948 originated japan kyowa hakko submitted fda approval currently available asian country like india japan l1385 l1386 ",benidipine potent long-lasting drug indicated treatment cardiovascular disease hypertension renoparenchymal hypertension angina pectoris a31950 
Cilnidipine,cilnidipine dihydropyridine calcium antagonist jointly developed fuji viscera pharmaceutical company japan ajinomoto japan approved 1995 compared calcium antagonist cilnidipine act n-type calcium channel existing sympathetic nerve end besides acting l-type calcium channel similar calcium antagonist drug approved china japan korea india several country european union a31970 ,cilnidipine indicated management hypertension end-organ protection l1436 reported useful elderly patient diabetes albuminuria cilnidipine increasingly used patient chronic kidney disease hypertension term used describe presence high blood pressure blood pressure generated force blood pumped heart blood vessel thus hypertension caused much pressure blood vessel effect damage blood vessel l1438 
Cronidipine,cronidipine calcium channel blocker ,
Darodipine,darodipine calcium channel blocker ,
Efonidipine,efonidipine calcium channel blocker _dihydropyridine class_ commercialized shionogi co. japan initially marketed 1995 trade name _landel_ drug shown block t-type addition l-type calcium channel a7844 a32001 also studied atherosclerosis acute renal failure a32001 drug also known nz-105 several study done pharmacokinetics animal l1456 , treatment hypertension 
Lacidipine,lacidipine lipophilic dihydropyridine calcium antagonist intrinsically slow onset activity due long duration action lacidipine lead reflex tachycardia a31536 display specificity vascular smooth muscle act antihypertensive agent dilate peripheral arteriole reduce blood pressure compared dihydropyridine calcium antagonist lacidipine exhibit greater antioxidant activity may confer potentially beneficial antiatherosclerotic effect a31540 lacidipine highly lipophilic molecule interacts biological membrane radiotracer analysis determined lacidipine display high membrane partition coefficient leading accumulation drug membrane slow rate membrane washout a31539 visualized small-angle x-ray diffraction angstrom resolution examine location within membrane lacidipine found deep within membrane 's hydrocarbon core a31539 result may explain long clinical half-life lacidipine a31539 randomised well-controlled trial administration daily single-dose lacidipine ranging 2-6 mg demonstrated comparable antihypertensive efficacy similar long-acting dihydropyridine calcium antagonist thiazide diuretic atenolol beta-blocker enalapril ace inhibitor a31536 available once-daily oral tablet containing 2 4 mg active compound commonly marketed lacipil motens currently fda-approved ,indicated treatment hypertension either alone combination antihypertensive agent including β-adrenoceptor antagonist diuretic ace-inhibitors l1126 
Levamlodipine,levamlodipine also known s-amlodipine pharmacologically active enantiomer amlodipine antihypertensive medication l10833 levamlodipine belongs dihydropyridine group calcium channel blocker l10833 medication first marketed russia india granted fda approval l1484 name s-amlodipine levamlodipine may used interchangeably substance however l10833 racemic mixture amlodipine contains r -amlodipine isomer -amlodipine active moiety posse therapeutic activity a188940 levamlodipine granted fda approval 19 december 2019 l10833 ,levamlodipine indicated alone combination treat hypertension adult child l10833 
Manidipine,manidipine inn calcium channel blocker dihydropyridine type used clinically antihypertensive selective vasculature produce effect heart clinically relevant dosage , treatment hypertension 
Niguldipine,niguldipine calcium channel blocker drug ccb a1-adrenergic antagonist property ,
Niludipine,niludipine calcium channel blocker ,
Methylene blue,methylene blue oxidation-reduction agent intravenous form methylene blue approved fda treatment pediatric adult patient acquired methemoglobinemia historically widely used africa treat malaria disappeared chloroquine cq drug entered market use urinary tract antiseptic also investigated methylthioninium chloride inn methylene blue proposed trade name rember investigational drug developed university aberdeen taurx therapeutic shown early clinical trial inhibitor tau protein aggregation drug potential interest treatment patient alzheimer 's disease ,indicated treatment pediatric adult patient acquired methemoglobinemia clinical application methylene blue include improvement hypotension associated various clinical state antiseptic urinary tract infection treatment hypoxia hyperdynamic circulation cirrhosis liver severe hepatopulmonary syndrome treatment ifofosamide induced neurotoxicity 
Moxonidine,moxonidine new-generation centrally acting antihypertensive drug approved treatment mild moderate essential hypertension suggested effective case agent thiazide beta-blockers ace inhibitor calcium channel blocker appropriate irresponsive well moxonidine shown present blood pressure-independent beneficial effect insulin resistance syndrome , treatment mild moderate essential primary hypertension l1025 effective first-line antihypertensive used monotherapy a27137 
Hydracarbazine,hydracarbazine pyridazine found use antihypertensive agent a19790 marketed france tradename normatensyl , used treatment hypertension a19790 
Pirlindole, drug classified reversible inhibitor monoamine oxidase enzyme also known rima drug developed currently used antidepressant russia chemical structure similar metralindole also share pharmacological property drug pirlindole selective reversible inhibitor monoamine oxidase mao subtype mao-a approved several european non-european country treatment major depression antidepressant efficacy safety pirlindole demonstrated numerous study supported many year clinical experience treatment depression pirlindole 's efficacy safety also shown treatment fibromyalgia , treatment major depression studied treatment fibromyalgia pain syndrome one study determined effect pirlindole sensorimotor performance driving motor vehicle show many similarity placebo drug appears stimulate central nervous system rather exhibit sedative effect like many antidepressant selective reversible inhibition monoamine oxidase mao-a short half-life unpleasant `` cheese effect '' avoided refers effect consuming tyramine-rich food cheese medicated monoamine oxidase inhibitor leading severe headache hypertension l1395 available evidence support pirlindole safe effective treatment option management depression fibromyalgia syndrome l1394 
Toloxatone,toloxatone antidepressant agent first ever use france 1984 act selective reversible inhibitor monoamine oxidase-a moa l1388 , treatment major depressive disorder 
Benmoxin,benmoxin irreversible nonselective monoamine oxidase inhibitor maoi hydrazine class first synthesized 1967 rapidly used europe antidepressant however agent longer marketed , treatment depression 
Iproclozide,iproclozide irreversible selective hydrazine class based monoamine oxidase inhibitor maoi although employed antidepressant time fact agent capable causing fulminant hepatitis use documented cause least three reported fatality resulted ultimately agent discontinued , treatment depression 
Mebanazine,mebanazine also known _actomol_ monoamine oxidase inhibitor maoi belonging _hydrazine_ class chemical used past antidepressant 1960s since discontinued hepatotoxic potential , treatment depression 
Octamoxin,octamoxin also known _2-octylhydrazine_ irreversible nonselective monoamine oxidase enzyme inhibitor maoi _hydrazine_ chemical class drug used past antidepressant agent 1960s however since discontinued , treatment depression 
Pheniprazine,pheniprazine irreversible nonselective monoamine oxidase inhibitor maoi hydrazine chemical class used antidepressant 1960s addition used treatment condition angina pectoris schizophrenia pheniprazine withdrawn manufacturer due ability cause toxicity liver ability cause optic neuritis , treatment depression schizophrenia angina pectoris 
Phenoxypropazine,phenoxypropazine non-selective irreversible monoamine oxidase enzyme inhibitor maoi belonging _hydrazine_ chemical class marketed antidepressant 1961 later withdrawn 1966 hepatotoxic potential , treatment depression 
Pivhydrazine,pivhydrazine also known pivazide member hydrazine family irreversible non-selective inhibitory activity monoamine oxidase 1960 widely used antidepressant agent discontinued , treatment depression 
Safrazine,safrazine member hydrazine family non-selective irreversible inhibitor effect monoamine oxidase 1960 used antidepressant discontinued , treatment depression 
Caroxazone,caroxazone antidepressant withdrawn market reversible monoamine oxidase inhibitor maoi b monoamine oxidase subtypes however present five-fold preference mao-b subtype , treatment depression 
Dextran,"dextran polysaccharide differs others glucose unit joined together 1:6 glucoside link main chain glucose short branch frequent interval probably joined 1:3 1:4 glucoside link chain composed 200,000 glucose unit a32011 many bacteria like _leuconostoc_ synthesize dextran sucrose activity used commercially obtain dextran t121 dextran 40 sterile nonpyrogenic preparation low molecular weight dextran average mol wt 40,000 5 dextrose injection 0.9 sodium chloride injection administered intravenous infusion dextran 75 complex branched glucan average molecular weight 75000 dalton produced certain bacteria α-1,6 glycosidic linkage glucose molecule α-1,3 linkage branch labelled technetium tc99m dextran 75 intravenously administered imaging agent detect diagnose condition vascular compartment pericardial effusion ventricular aneurysm ",dextran used restoration blood mass surgical intervention hypovolemia due trauma dehydration well used presence hemorrhage case blood loss level inferior 15 blood mass compatibility test completed blood lot need tested pathogen detection dextran also used prevention profound postoperative venous thrombosis l1455 dextran well present ophthalmic application solution ointment temporary relief xerophthalmia minor ocular irritation l1461 
Tegafur,tegafur inn ban usan prodrug db00544 5-fu antineoplastic agent used treatment various cancer advanced gastric colorectal cancer pyrimidine analogue used combination therapy active chemotherapeutic agent conjunction db09257 db03209 along db00544 db09327 tegafur usually given combination drug enhance bioavailability 5-fu blocking enzyme responsible degradation serf limit toxicity 5-fu ensuring high concentration 5-fu lower dose tegafur l933 converted bioactivated 5-fu drug mediates anticancer activity inhibiting thymidylate synthase t pyrimidine pathway involved dna synthesis 5-fu listed world health organization 's list essential medicine ,indicated treatment cancer usually combination biochemically modulating drug indicated adult treatment advanced gastric cancer given combination db00515 l933 indicated first-line treatment metastatic colorectal cancer db03419 calcium folinate l934 
Gimeracil,gimeracil adjunct antineoplastic therapy used increase concentration effect main active componets within chemotherapy regimen approved european medicine agency ema march 2011 gimeracil available combination db03209 db09256 within commercially available product `` teysuno '' main active ingredient teysuno db09256 pro-drug db00544 5-fu cytotoxic anti-metabolite drug act rapidly dividing cancer cell mimicking class compound called `` pyrimidine '' essential component rna dna 5-fu able insert strand dna rna thereby halting replication process necessary continued cancer growth gimeracil 's main role within teysuno prevent breakdown db00544 5-fu help maintin high enough concentration sustained effect cancer cell l933 function reversibly selectively blocking enzyme dihydropyrimidine dehydrogenase dpd involved degradation 5-fu a31408 allows higher concentration 5-fu achieved lower dose tegafur thereby also reducing toxic side effect ,gimeracil used adjunct antineoplastic therapy used within product teysuno gimeracil indicated treatment adult advanced gastric stomach cancer given combination cisplatin 
Bemiparin,bemiparin antithrombotic belongs group drug known low molecular weight heparin lmwh like semuloparin bemiparin classified ultra-lmh low mean molecular mass 3600 dalton unique property class a7866 heparin lower anti-thrombin activity traditional low molecular weight heparin act mainly factor-xa reducing risk bleeding due selectivity specific clotting factor interestingly current research underway potential benefit bemiparin treatment tumor diabetic foot ulcer l1468 a7866 ,bemiparin indicated following case prevent blood clot vein general abdominal surgery patient moderate risk venous thromboembolism prevention thromboembolic disease non-surgical patient prevention clotting extracorporeal circuit hemodialysis prevent blood clot vein major orthopedic surgery patient high risk venous thromboembolism secondary prevention venous thromboembolism recurrence patient deep vein thrombosis transient prevention treatment deep vein thrombosis dvt l1463 
Reviparin,reviparin low molecular weight heparin seems better safety profile unfractionated heparin a32019 prepared porcine intestinal mucosa nitrous acid depolymerization reviparin molecular weight 3.9 kda a32021 developed abbott laboratory 2009 reviparin presented orphan drug designation fda l1469 , fda reviparin indicated treatment deep vein may lead pulmonary embolism pediatric patient also indicated long-term treatment acute deep vein thrombosis without pulmonary embolism pregnant patient l1469 
Parnaparin,parnaparin heparin low molecular weight antithrombotic effect ,used prevention treatment venous thromboembolism deep vein thrombosis pulmonary embolism treatment myocardial infarction 
Certoparin,certoparin part heparin low molecular weight present high activity coagulation factor xa normally used prevent deep venous thrombosis ,used prevention treatment venous thromboembolism deep vein thrombosis pulmonary embolism treatment myocardial infarction 
Imidafenacin,imidafenacin antispasmodic agent anticholinergic effect antagonizes muscarinic receptor bladder reduce frequency urination treatment overactive bladder marketed japan tradenames staybla ono pharmaceutical uritos kyojin pharmaceutical ,used treatment overactive bladder fda label 
Patiromer,"patiromer powder suspension water oral administration approved u.s. veltassa october 2015 patiromer supplied patiromer sorbitex calcium consists active moiety patiromer non-absorbed potassium-binding polymer calcium-sorbitol counterion gram patiromer equivalent nominal amount 2 gram patiromer sorbitex calcium chemical name patiromer sorbitex calcium cross-linked polymer calcium 2-fluoroprop-2-enoate diethenylbenzene octa-1,7-diene combination d-glucitol patiromer sorbitex calcium amorphous free-flowing powder composed individual spherical bead ", treatment hyperkalemia 
Idarucizumab,idarucizumab humanized monoclonal antibody fragment fab derived immunoglobulin g1 isotype molecule bind inactivates oral anticoagulant dabigatran thereby reversing anticoagulant effect direct acting oral anticoagulant doac one risk associated use dabigatran includes bleeding espeically given patient increased risk elderly chronic kidney disease concomitant nsaid warfarin use etc approved tradename praxbind fda idarucizumab indicated emergency treatment dabigatran-associated bleeding life-threatening surgically induced situation use associated immediate complete sustained reversal anticoagulant effect dabigatran idarucizumab protein structure viewed disulfide bridge following point h22-h95 h149-h205 h225-l-219 l23-l93 l139-l199 , use patient treated dabigatran reversal anticoagulant effect dabigatran needed emergency surgery/urgent procedure life-threatening uncontrolled bleeding 
Lixisenatide,lixisenatide glucagon-like peptide-1 glp-1 receptor agonist used treatment type 2 diabetes mellitus t2dm sold brand name adlyxin sanofi-aventis adlyxin recieved fda approval july 28 2016 l763 , use antihyperglycemic agent treatment t2dm fda label 
Technetium Tc-99m tilmanocept,technetium tc-99m tilmanocept radiopharmaceutical diagnostic imaging agent approved u.s. food drug administration fda imaging lymph node without scintigraphic imaging macromolecule consisting multiple unit diethylenetriaminepentaacetic acid dtpa mannose covalently attached 10 kda dextran backbone fda label dtpa serf chelating agent technetium tc 99m bind fda label technetium tc-99m tilmanocept used lymphatic mapping lymph node localization breast cancer melanoma clinically node-negative squamous cell carcinoma oral cavity solid tumor a32169 a32170 detecting sentinel lymph node sln clinically useful prognosis management disease considered first lymph node receives afferent lymphatic drainage primary tumor may used predict tumour staging metastasis a32170 however nodal micrometastasis breast cancer may associated significant change survival also important identify clinically node-negative patient a32170 technetium tc-99m tilmanocept novel cd206 receptor-targeted molecule selectively bind mannose receptor expressed surface reticuloendothelial cell lymph node a32168 due relatively small molecular weight small molecular diameter 7 nm a32168 technetium tc-99m tilmanocept display rapid injection site clearance high sentinel node extraction low distal node accumulation compared conventional radiocolloids a32170 achieves high overall accuracy detecting sln a32169 reconstituted labelled technetium tc99m tilmanocept intended injected close proximity tumor diagnosed employed preoperative gamma detection imaging combination various technique including scintigraphy spect spect/ct l1157 may administered via subcutaneous intradermal subareolar peritumoral injection depending tutor location planned injection technique fda label marketed trade name lymphoseek potential application technetium tc-99m tilmanocept cancer investigated a32170 ,indicated without scintigraphic imaging lymphatic mapping using handheld gamma counter locate lymph node draining primary tumor site patient solid tumor procedure component intraoperative management fda label indicated without scintigraphic imaging guiding sentinel lymph node biopsy using handheld gamma counter patient clinically node negative squamous cell carcinoma oral cavity breast cancer melanoma fda label 
Strontium ranelate,strontium ranelate strontium ii salt ranelic acid medication osteoporosis report shown strontium ranelate slow progression osteoarthritis knee agent present atypical mechanism action increase deposition new bone osteoblast simultaneously reduces resorption bone osteoclast therefore promoted `` dual action bone agent '' daba indicated use treatment severe osteoporosis furthermore various clinical study demonstrate ability strontium ranelate improve strengthen intrinsic bone tissue quality microarchitecture osteoporosis way number cellular microstructural change anti-fracture efficacy enhanced available prescription use time part world protelos strontium ranelate 2 g granule oral suspension servier ultimately discontinued 2016-2017 owing increased adverse cardiac effect profile along increased risk venous thromboembolism vte various life threatening allergic reaction ,strontium ranelate therapeutically indicated treatment severe osteoperosis postmenopasual woman b adult men high risk fracture treatment medical product approved treatment osteoperosis possible due example contraindication intolerance l1127 postmenopausal woman strontium ranelate also reduce risk vertebral hip fracture l1127 
Picosulfuric acid,picosulfuric acid found laxative product sodium picosulfate used treat constipation induce colon cleansing prepare large bowel colonoscopy surgery combination product containing sodium picosulfate magnesium citrate introduced canadian market 2005 used european country many year a33322 ,sodium picosulfate combination magnesium oxide anhydrous citric acid indicated cleansing colon preparation colonoscopy adult pediatric patient age 9 year older l43832 
Phenylacetic acid,phenylacetic acid organic compound containing phenyl functional group carboxylic acid functional group white solid disagreeable odor used illicit production phenylacetone used manufacture substituted amphetamine subject control country including united state china , use adjunctive therapy treatment acute hyperammonemia associated encephalopathy patient deficiency enzyme urea cycle 
Ubidecarenone,"ubidecarenone also called coenzyme q10 1,4-benzoquinone name q10 q refers constitutive quinone group 10 related number isoprenyl subunit tail a7874 powerful antioxidant lipid-soluble essential cofactor mitochondrial oxidative phosphorylation a31413 ubidecarenone coenzyme destined mitochondrial enzyme complex involved oxidative phosphorylation production atp fundamental cell high metabolic demand l1062 ubidecarenone sold dietary supplement fda approved drug meant treat cure prevent disease fda approve dietary supplement sold regulate manufacturing process l1063 ", diet supplement containing ubidecarenone indicated stated product label assist individual cardiovascular complaint including congestive heart failure systolic hypertension product ubidecarenone used increase cardiac input well prevention several disease like parkinson fibromyalgia migraine periodontal disease diabetes based preclinical study l1064 important highlight product fda approved recommended use discretion 
Cimetropium,cimetropium semi-synthetic belladonna alkaloid derivative scopolamine potent antimuscarinic effective antispasmodic drug also endowed direct myolitic action partially account antispasmodic activity never approved use u.s. canada ,
Eluxadoline,eluxadoline mixed mu-opioid receptor agonist kappa-opioid receptor agonist a-delta opioid receptor antagonist indicated use diarrhea-predominant irritable bowel syndrome ibs-d mu- kappa- delta-opioid receptor mediate endogenous exogenous opioid response central nervous system peripherally gastrointestinal system agonism peripheral mu-opioid receptor result reduced colonic motility antagonism central delta-opioid receptor result improved analgesia making eluxadoline usable symptom pain diarrhea characteristic ibs-d marketed tradename viberzi fda eluxadoline antimotility agent decrease bowel contraction inhibits colonic transit reduces ﬂuid/ion secretion resulting improved symptom abdominal pain reduction bristol stool scale , treatment irritable bowel syndrome diarrhea ibs-d 
Doxofylline,doxofylline methylxanthine derivative presence dioxolane group position 7 drug used treatment asthma doxofylline shown similar efficacy theophylline significantly fewer side effect animal human study contrast xanthine derivative doxofylline significantly bind adenosine alpha-1 alpha-2 receptor lack stimulating effect decreased affinity adenosine receptor may account better safety profile doxofylline compared theophylline l1169 unlike theophylline doxofylline affect calcium influx antagonize action calcium channel blocker could explain reduced cardiac adverse reaction associated drug a7885 anti-asthmatic effect doxophylline mediated mechanism primarily inhibiting activity phosphodiesterase pde enzyme ,indicated treatment chronic obstructive pulmonary disease copd bronchial asthma pulmonary disease spastic bronchial component 
Artesunate,artesunate indicated initial treatment severe malaria l14099 world health organization recommends artesunate first line treatment severe malaria l890 artesunate developed need hydrophilic derivative artemisinin a203948 artesunate granted fda approval 26 may 2020 l14099 ,artesunate indicated initial treatment severe malaria adult pediatric patient l14099 
Bismuth subcitrate potassium, bismuth compound used peptic ulcer gastro-oesophageal reflux disease gord , treatment peptic ulcer gastro-oesophageal reflux disease gord treatment inflammatory erosive-ulcerous disease gastric duodenal mucosa gastritis ulcer disease stomach duodenum functional non-ulcerous dyspepsia erosive duodenitis post-operative inflammatory erosive change – anastomositis peptic ulcer anastomosis
Sodium aurothiomalate,sodium aurothiomalate gold compound used immunosuppressive anti-rheumatic effect gold sodium thiomalate supplied solution intramuscular injection containing 50 mg gold sodium thiomalate per ml effective active progressive rheumatoid arthritis little value presence extensive deformity treatment form arthritis , disease-modifying antirheumatic drug dmard indicated symptomatic treatment arthritis 
Choline C 11,choline c 11 marker cellular proliferation main molecule precursor biosynthesis phospholipid essential component cell membrane a32041 developed mcprf fda first approved september 2012 ,choline c11 indicated use positron emission tomography pet imaging patient suspected prostate cancer recurrence non-informative bone scintigraphy computerized tomography magnetic resonance imaging fda label a32037 
Activated charcoal,activated charcoal activated carbon amorphous form carbon prepared incomplete combustion carbonaceous organic matter activated oxidizing gas flow high temperature passed surface make fine network pore producing material large surface area high affinity various substance used gastric decontaminant emergency medication treat poisoning following excessive oral ingestion certain medication poison absorbing drug toxin however effect rendered poor compound including strong acid base methanol substance limited absorptive capacity including iron lithium arsenic work binding poison gastric content reversible fashion thus may adminstered together cathartic reduce small intestine transit time clinical application activated charcoal occured early 1800 's management acute poisoning considered fairly invasive world health organization 's list essential medicine includes important medication needed basic health system ,used antidote treat poisoning following excessive oral ingestion certain medication poison 
Fimasartan,fimasartan angiotensin ii receptor antagonist arb drug employed treatment hypertension heart failure found safe administered hydrochlorothiazide diuretic clinical trial fimasartan initially approved september 9th 2010 south korea marketed brand name _kanarb_ boryung pharmaceutical ,used treatment hypertension heart failure a20319 
Lumacaftor,"lumacaftor drug used combination db08820 fixed dose combination product orkambi management cystic fibrosis cf patient aged 6 year older cystic fibrosis autosomal recessive disorder caused one several different mutation gene cystic fibrosis transmembrane conductance regulator cftr protein transmembrane ion channel involved transport chloride sodium ion across cell membrane lung pancreas organ mutation cftr gene result altered production misfolding function cftr protein consequently abnormal fluid ion transport across cell membrane a20298 a20299 result cf patient produce thick sticky mucus clog duct organ produced making patient susceptible infection lung damage pancreatic insufficiency malnutrition a20302 lumacaftor improves cf symptom underlying disease pathology aiding conformational stability f508del-mutated cftr protein preventing misfolding resulting increased processing trafficking mature protein cell surface result clinical trial indicated treatment orkambi lumacaftor/ivacaftor result improved lung function reduced chance experiencing pulmonary exacerbation increased weight gain improvement cf symptom fda label data heavily scrutinized however clinical trial showing modest improvement despite hefty yearly cost 259,000 orkambi a20343 improvement lung function ppfev1 found statistically significant minimal 2.6-3.0 change baseline 70 patient failing achieve absolute improvement least 5 a20343 l936 wide variety cftr mutation correlate cystic fibrosis phenotype associated differing level disease severity common mutation affecting approximately 70 patient cf worldwide known f508del-cftr delta-f508 δf508 deletion amino acid phenylalanine position 508 result impaired production cftr protein thereby causing significant reduction amount ion transporter present cell membrane a20301 used combination db08820 fixed dose combination product orkambi lumacaftor specific management cf patient delta-f508 mutation act protein-folding chaperone aiding conformational stability mutated cftr protein consequently lumacaftor increase successful production cftr ion channel total number receptor available use cell membrane fluid ion transport a18395 next common mutation g551d affecting 4-5 cf patient worldwide characterized missense mutation whereby sufficient amount protein cell surface opening closing mechanism channel altered a17564 treatment patient g551d rarer missense mutation usually managed db08820 kalydeco aid altered gating mechanism potentiating channel opening probability cftr protein prior development lumacaftor db08820 kalydeco management cf primarily involved therapy control infection nutritional support clearance mucus management symptom rather improvement underlying disease process approved use food drug administration july 2015 health canada january 2016 orkambi first combination product approved management cystic fibrosis delta-f508 mutation ivacaftor manufactured distributed vertex pharmaceutical ", used combination drug lumacaftor product orkambi ivacaftor indicated management cf patient aged one year older homozygous _f508del_ mutation cftr gene patient ’ genotype unknown fda-cleared cf mutation test used detect presence _f508del_ mutation allele cftr gene l43060 
Magnesium trisilicate,magnesium trisilicate inorganic compound used antacid treatment peptic ulcer , treatment peptic ulcer relieving indigestion heartburn 
Molsidomine,molsidomine orally active long-acting vasodilator belongs class medication known syndnones interestingly studied preventive measure cerebral infarction a31932 , indication use molsidomine include ischemic heart disease angina chronic heart failure pulmonary hypertension l1370 l1371 
Trapidil,trapidil platelet-derived growth factor antagonist originally developed vasodilator anti-platelet agent used treat patient ischemic coronary heart liver kidney disease ,used treatment chronic stable angina a19770 
Imolamine,"imolamine compound molecular weight 260.33 g/mol formula diethyl 2- 5-imino-3-phenyl-4,5-dihydro-1,2,3-oxadiazol -4-yl ethyl amine developed brand name coremax novartis consumer health sa ",imolamine indicated treatment angina pectoris hydrochloride form used local anesthetic t83 
Morniflumate,morniflumate non-steroidal anti-inflammatory drug antipyretic property morpholinoethyl ester niflumic acid l1496 one study post morniflumate ingestion physical examination clinical symptom bronchitis showed improvement a7889 ,morniflumate indicated treatment inflammatory condition affecting airway ent system urogenital tract bone joint system adult italy morniflumate also indicated treatment pain associated ear nose throat ent gastrointestinal inflammatory condition child morniflumate well established nsaid use three decade italy particularly treatment upper respiratory tract infection child france belgium austria switzerland spain portugal generally favorable tolerability profile 
Pipamperone,pipamperone typical antipsychotic _butyrophenone_ family used treatment schizophrenia developed janssen pharmaceutica 1961 started first round clinical trial 1963 l1514 l1518 effort improve haloperidol 's pharmacological effect janssen discovered pipamperone agent whose pharmacological profile distinct haloperidol known antipsychotic drug time significant anti-tryptamine activity study suggest pipamperone first atypical antipsychotic interestingly risperidone created janssen suggested potent version pipamperone synthesized year 1984 risperidone ’ pharmacological property similar pipamperone ’ block serotonin potently dopamine l1518 ,treatment chronic psychosis state aggressiveness various origin l1515 
Polyethylene glycol,polyethylene glycol peg synthetic polymer produced via polymerization ethylene oxide molecule make joining unit ethylene glycol ether linkage a190975 a190978 peg water-soluble polymer form hydrogen bond ratio 100 water molecule per one peg molecule a190975 molecular weight peg vary time polymerization process molecular weight represents weighted average individual peg molecule peg differ physical chemical property depending molecular weight peg liquid molecular weight 1000 molecule turn waxy solid increasing molecular weight a190978 common preparation peg include peg 3350 peg 400 peg various application many field ranging medical industrial area peg long history gastroenterology peg 3350 common over-the-counter osmotic laxative used relieve occasional constipation l11812 peg 3350 also used cleansing colon preparation colonoscopy adult l6421 rationale using peg gastroenterology due physical property compound potent water-binding capacity negligible intestinal absorption increasing molecular mass lack significant toxicity limited intestinal enzymatic degradation bacterial metabolism make peg useful therapeutic agent treatment occasional constipation bowel cleansing preparation colonoscopy a18713 ,polyethylene glycol indicated use over-the-counter osmotic laxative relieve occasional constipation l11812 used combination sodium ascorbate sodium sulfate ascorbic acid sodium chloride potassium chloride used cleansing colon preparation colonoscopy adult l6421 
Propacetamol,"propacetamol non-opioid analgesic devoid major contraindication a32051 derivative acetaminophen paracetamol molecular formula glycine n n-diethyl-,4- acetylamino phenyl ester propacetamol parenteral formulation paracetamol thus prodrug completely hydrolyzed paracetamol a7892 available united state prodrug widely used country france since 1985 l1505 ",propacetamol paracetamol prodrug intravenous administration used control fever pain perioperative period multimodal analgesia therapy l1511 
Tianeptine,tianeptine drug used primarily treatment major depressive disorder studied treatment irritable bowel syndrome ibs a31983 structurally classified tricyclic antidepressant tca however posse different pharmacological property typical tricyclic antidepressant a31969 tianeptine discovered patented french society medical research 1960s l2946 currently tianeptine approved france manufactured marketed laboratory servier sa also marketed several european country trade name “ coaxil ” well asia including singapore latin america “ stablon ” “ tatinol ” available australia canada new zealand u.k. u.s ,used primarily treatment major depressive disorder anxiety a31969 currently studied fibromyalgia pain treatment l1426 
Ramosetron,ramosetron _serotonin 5-ht3 receptor antagonist_ commonly employed treat nausea vomiting addition certain diarrheal condition believed higher potency longer antiemetic action 1st generation 5-ht3 antagonist ondansetron currently ramosetron approved use japan certain southeast asian country , treatment nausea vomiting diarrhea-predominant irritable bowel syndrome male 
Rolapitant,rolapitant potent highly selective long-acting neurokinin-1 nk-1 receptor antagonist approved prevention delayed chemotherapy-induced nausea vomiting cinv adult delayed-phase cinv typically occurs 24 hour chemotherapy treatment principally mediated neurokinin-1 ligand substance p released gut following chemotherapy administration neurokinin-1 also known tachykinin receptor 1 tacr1 neurokinin 1 receptor nk1r substance p receptor spr blocking substance p interacting nk-1 receptor gut central nervous system rolapitant prevents late-phase cinv unlike available nk-1 receptor antagonist rolapitant inhibitor cytochrome p450 enzyme cyp3a4 long elimination half-life allowing single dose prevent acute late-phase cinv first 120 hour post-chemotherapy , drug indicated adult combination antiemetic prevention delayed nausea vomiting associated emetogenic chemotherapy 
Sacubitril,sacubitril prodrug neprilysin inhibitor used combination valsartan reduce risk cardiovascular event patient chronic heart failure nyha class ii-iv reduced ejection fraction approved fda given status priority review july 7 2015 sacubitril 's active metabolite lbq657 inhibits neprilysin neutral endopeptidase would typically cleave natiuretic peptide atrial natriuretic peptide anp brain natriuretic peptide bnp c-type natriuretic peptide cnp anp bnp released atrial ventricle stress activate downstream receptor leading vasodilation natriuresis diuresis normal condition neprilysin break vasodilating peptide also vasoconstrictor angiotensin ii endothelin-1 peptide amyloid beta-protein inhibition neprilysin therefore lead reduced breakdown increased concentration endogenous natriuretic peptide addition increased level vasoconstricting hormone angiotensin ii ,used combination valsartan reduce risk cardiovascular event patient chronic heart failure nyha class ii-iv reduced ejection fraction usually administered conjunction heart failure therapy place ace inhibitor arb also used combination valsartan l36445 
Iodide I-131,iodide i-131 sodium iodide i-131 radioisotopic drug used treatment palliation thyroid malignancy iodine-131 notable causing mutation death cell penetrates due mode beta decay result beta decay approximately 10 energy radiation dose via gamma radiation 90 beta radiation cause tissue damage without contributing ability see image isotope low level beta radiation also known causing cancer dose highly mutagenic reason le toxic iodine isotope i-123 frequently used nuclear imaging i-131 reserved tissue destroying effect thyroid gland naturally take iodine body therapeutic method using radioisotope take advantage mechanism localization drug site malignancy therapeutic solution sodium iodide-131 indicated treatment hyperthyroidism thyroid carcinoma take iodine palliative effect may observed patient advanced thyroid malignancy metastatic lesion take iodine also indicated use performance radioactive iodide rai uptake test evaluate thyroid function ,therapeutic solution sodium iodide-131 indicated treatment hyperthyroidism thyroid carcinoma take iodine palliative effect may observed patient advanced thyroid malignancy metastatic lesion take iodine also indicated use performance radioactive iodide rai uptake test evaluate thyroid function 
Talniflumate,talniflumate anti-inflammatory molecule studied used mucin regulator treatment cystic fibrosis chronic obstructive pulmonary disease copd asthma l1400 addition used inflammatory condition rheumatoid arthritis phase trial talniflumate treatment cystic fibrosis copd completed august 2001 phase ii trial performed ireland treatment cystic fibrosis research discontinued l1402 l1405 talniflumate approved approximately 20 year argentina country excluding united state europe japan l1405 ,talnifumate phthalidyl ester nifumic acid potent analgesic anti-inflammatory effect widely used treat inflammatory disorder rheumatoid arthritis osteoarthritis l1409 also studied management cystic fibrosis l1403 
Ombitasvir,ombitasvir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas ombitasvir ombitasvir inhibitor ns5a protein essential viral replication virion assembly fda label barrier develoment resistance ns5a inhibitor lower ns5b inhibitor another class daas a19593 joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend ombitasvir first line therapy option used combination antiviral genotype 1a 1b 4 l852 depending genotype ombitasvir often used combination antiviral db09183 db09297 db00503 db00811 intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 treatment direct acting antiviral ombitasvir associated minimal side effect common headache fatigue fda label lack significant side effect short duration therapy considerable advantage older interferon-based regimen limited infusion site reaction reduced blood count neuropsychiatric effect a19635 ombutasvir first came market fixed-dose combination product db09183 db09297 db00503 fda-approved product viekira pak first approved december 2014 viekira pak indicated treatment hcv genotype 1b without cirrhosis compensated cirrhosis combined ribavirin treatment hcv genotype 1a without cirrhosis compensated cirrhosis ombutasvir also available fixed-dose combination product db09297 db00503 fda- health canada-approved product technivie first approved july 2015 technivie indicated combination ribavirin treatment patient genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis canada ombutasvir also available fixed-dose combination product db09183 db09297 db00503 health canada-approved commercially available product holkira pak first approved january 2015 holkira pak indicated treatment hcv genotype 1b without cirrhosis combined db00811 treatment hcv genotype 1a without cirrhosis , used combination db09297 db00503 fixed dose product technivie ombitasvir indicated combination db00811 treatment patient genotype 4 chronic hepatitis c virus hcv infection without cirrhosis l866 used combination db09297 db00503 db09183 fixed dose product viekira pak ombitasvir indicated treatment hcv genotype 1b combined db00811 treatment hcv genotype 1a fda label 
Paritaprevir,paritaprevir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas paritaprevir newer generation directly acting hcv antiviral paritaprevir product better sustained virological response svr rate higher barrier resistance fewer side effect reduced pill burden compared older agent db08873 db05521 db00008 db00022 db00811 combining multiple antiretroviral medication fixed dose product viral lifecycle targeted multiple stage simultaneously reducing risk developing resistant viral strain a19593 within canada united state paritaprevir currently available three fixed dose product viekira pak fda technivie fda health canada holkira pak health canada specifically paritaprevir prevents viral replication inhibiting ns3/4a serine protease hepatitis c virus hcv fda label following viral replication hcv genetic material translation single polypeptide nonstructural protein 3 ns3 activating cofactor nonstructural protein 4a ns4a responsible cleaving genetic material following structural nonstructural protein required assembly mature virus ns3 ns4a ns4b ns5a ns5b a19643 inhibiting viral protease ns3/4a paritaprevir therefore prevents viral replication function joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend paritaprevir first line therapy option used combination antiviral genotype 1a 1b 4 l852 depending genotype paritaprevir often used combination antiviral db09296 db09183 db00503 db00811 intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 treatment direct acting antiviral paritaprevir associated minimal side effect common headache fatigue fda label lack significant side effect short duration therapy considerable advantage older interferon-based regimen limited infusion site reaction reduced blood count neuropsychiatric effect a19635 paritaprevir first came market fixed-dose combination product db09296 db09183 db00503 fda-approved product viekira pak first approved december 2014 viekira pak indicated treatment hcv genotype 1b without cirrhosis compensated cirrhosis combined db00811 treatment hcv genotype 1a without cirrhosis compensated cirrhosis paritaprevir also available fixed-dose combination product db09296 db00503 fda- health canada-approved product technivie first approved july 2015 technivie indicated combination db00811 treatment patient genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis canada paritaprevir also available fixed-dose combination product db09296 db09183 db00503 health canada-approved commercially available product holkira pak first approved january 2015 holkira pak indicated treatment hcv genotype 1b without cirrhosis combined db00811 treatment hcv genotype 1a without cirrhosis , used within fixed-dose combination product db09296 db09183 db00503 fda-approved product viekira pak paritaprevir indicated treatment hcv genotype 1b without cirrhosis compensated cirrhosis combined db00811 treatment hcv genotype 1a without cirrhosis compensated cirrhosis used within fixed-dose combination product db09296 db00503 fda- health canada-approved product technivie paritaprevir indicated combination db00811 treatment patient genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis used within fixed-dose combination product db09296 db09183 db00503 health canada-approved commercially available product holkira pak paritaprevir indicated treatment hcv genotype 1b without cirrhosis combined db00811 treatment hcv genotype 1a without cirrhosis 
Silibinin,silibinin major active constituent silymarin standardized extract milk thistle seed containing mixture flavonolignans consisting silibinin isosilibinin silicristin silidianin others silibinin presented mixture two diastereomers silybin silybin b found approximately equimolar ratio vitro animal research suggest silibinin hepatoprotective antihepatotoxic property protect liver cell toxin silibinin also demonstrated vitro anti-cancer effect human prostate adenocarcinoma cell estrogen-dependent -independent human breast carcinoma cell human ectocervical carcinoma cell human colon cancer cell small nonsmall human lung carcinoma cell ,currently tested treatment severe intoxication hepatotoxic substance death cap amanita phalloides poisoning 
Tenofovir alafenamide,tenofovir alafenamide novel tenofovir prodrug developed order improve renal safety compared counterpart tenofovir disoproxil a178060 prodrugs first created cover polar phosphonic acid group tenofovir using novel oxycarbonyloxymethyl linkers improve oral bioavailability intestinal diffusion t239 tenofovir alafenamide alanine ester form characterized presenting low systemic level high intracellular concentration a178219 reported produce large antiviral efficacy dos ten time lower tenofovir disoproxil a178327 tenofovir alafenamide indicated treat chronic hepatitis b l6241 treat hiv-1 l4388 l6277 l6280 l6283 prevent hiv-1 infection l4388 l9010 tenofovir alafenamide developed gilead science inc granted fda approval 5 november 2015 l6271 ,tenofovir alafenamide indicated treatment hepatitis b virus infection adult pediatric patient 12 year age older compensated liver disease l43582 combination emtricitabine antiretrovirals indicated treatment hiv-1 infection adolescent adult patient weight higher 35 kg l4388 combination also indicated prevent hiv-1 infection high risk adolescent adult patient excluding patient risk receptive vaginal sex l4388 l9010 combined antiretrovirals protease inhibitor require cyp3a inhibitor used treat pediatric patient weighing 25-35 kg l4388 combination product emtricitabine bictegravir tenofovir alafenamide considered complete treatment regimen hiv-1 infection treatment-naive patient patient virologically suppressed least three month history treatment failure l6277 l38944 l44226 additionally combination product including elvitegravir cobicistat emtricitabine tenofovir alafenamide combination product including emtricitabine rilpivirine tenofovir alafenamide used treatment hiv-1 infection patient older 12 year previous antiretroviral therapy history virologically suppressed least 6 month history treatment failure l6280 combination product including darunavir cobicistat emtricitabine tenofovir alafenamide indicated treatment hiv-1 infection adult without prior antiretroviral therapy patient virologically suppressed 6 month reported resistance darunavir tenofovir l6283 
Butylscopolamine,butylscopolamine peripherally acting antimuscarinic anticholinergic agent used treat pain discomfort caused abdominal cramp menstrual cramp spasmodic activity digestive system also effective preventing bladder spasm pain medication normal sense since directly affect pain rather work prevent painful cramp spasm occurring model list essential medicine important medication needed basic health system ,used treat abdmoninal cramping pain fda label 
Chondroitin sulfate,"chondroitin sulfate glycosaminoglycan considered symptomatic slow-acting drug osteoarthritis sysadoa a7906 sysadoa status suggested pain relief increased joint mobility relative long regular administration well long-lasting effect end treatment chondroitin sulfate composed alternating 1,3-n-acetyl-β-d-galactosamine 1,4-β-d-glucuronic acid unit bear 4-o- and/or 6-o-sulfations n-acetylgalactosamine unit disposed specific pattern depending predominating disaccharide unit present different biological activity a32063 chondroitin sulfate sold otc dietary supplement north america prescription drug ema europe a32066 ",chondroitin sulfate used glucosamine indicated alleviate pain inflammation primary osteoarthritis l1527 supplement reported improve joint function slow disease progression l1528 osteoarthritis characterized progressive structural metabolic change joint tissue mainly cartilage degradation subchondral bone sclerosis inflammation synovial membrane a32066 study proposed potential use chondroitin sulfate nutraceutical dietary supplement a32065 
Alirocumab,alirocumab biopharmaceutical obtained fda approval july 2015 second line treatment high cholesterol adult whose ldl-cholesterol ldl-c controlled combination diet statin treatment human monoclonal antibody part family pcsk9 inhibitor novel class anticholesterol therapeutic family first agent receive fda approval fda approval contingent completion clinical trial better determine efficacy safety pcsk9 inhibition facilitates ldl-c clearance blood ,alirocumab antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity indicated use reducing risk myocardial infarction stroke unstable angina requiring hospitalization adult established cardiovascular disease f4591 and/or ii use adjunct diet use alone combination lipid-lowering therapy statin ezetimibe example treatment adult primary hyperlipidemia including heterozygous familial hypercholesterolemia reduce low-density lipoprotein cholesterol ldl-c level body f4591 
Evolocumab,evolocumab monoclonal antibody designed treatment hyperlipidemia amgen subcutaneous injection approved fda individual maximum statin therapy still require additional ldl-cholesterol lowering approved homozygous heterozygous familial cholesterolemia adjunct first-line therapy evolocumab human igg2 monoclonal antibody target proprotein convertase subtilisin/kexin type 9 pcsk9 pcsk9 protein target ldl receptor degradation therefore reducing liver 's ability remove ldl-cholesterol ldl-c `` bad '' cholesterol blood evolocumab designed bind pcsk9 inhibit pcsk9 binding ldl receptor liver surface resulting ldl receptor surface liver remove ldl-c blood evolocumab second pcsk9 inhibitor market first alirocumab ,evolocumab indicated adult patient established cardiovascular disease reduce risk myocardial infarction stroke coronary revascularization l40644 also indicated adjunct diet alone combination hypolipidemic treatment adult primary hyperlipidemia pediatric patient ≥10 year old heterozygous familial hypercholesterolemia reduce ldl-c. l40644 addition indicated adjunctly hypolipidemic treatment patient ≥10 year old homozygous familiar hypercholesterolemia reduce ldl-c. l40644 
Setiptiline,setiptiline tetracyclic antidepressant teca act noradrenergic specific serotonergic antidepressant nassa japan company mochida started commercialization treatment depression started 1989 , treatment depression a19792 
Aptazapine,aptazapine cgs-7525a tetracyclic antidepressant developed 1980s aptazapine noradrenergic specific serotonergic activity antagonised α2 adrenergic receptor approximately 10 time effectively mianserin antagonised 5-ht2 receptor agonised h1 receptor affect reuptake serotonin norepinephrine although aptazapine reached clinical trial never marketed ,investigated treatment depression 
Metralindole,metralindole also known inkazan similar structure pharmacology pirlindole function reversible inhibitor monoamine oxidase russia drug investigated potential antidepressant activity ,investigated treatment depression 
Oxaprotiline,"oxaprotiline norepinephrine reuptake inhibitor tetracyclic antidepressant family related maprotiline drug never marketed oxaprotiline racemic mixture isomer levoprotiline dextroprotiline levoprotiline r levo isomer oxaprotiline cgp-12,103-a dextroprotiline dextro isomer oxaprotiline cgp-12,104-a enantiomer antidepressant effect levoprotiline also antihistamine dextroprotiline many pharmacological action ",investigated treatment depression 
Solithromycin,solithromycin ketolide antibiotic undergoing clinical development treatment community-acquired pneumonia cap infection ,investigated treatment community-acquired pneumonia cap 
Kitasamycin,kitasamycin macrolide antibiotic derived em streptomyces kitasatoensis /em ,
Catridecacog,coagulation factor xiii a-subunit recombinant also known catridecacog recombinant form factor xiii-a2 homodimer composed two factor xiii fxiii a-subunits fda label people congenital deficiency mutation factor xiii rare bleeding disorder exogenous replacement key coagulation factor essential management prevention bleeding episode also known fibrin stabilizing factor fsf factor xiii endogenously available coagulation factor final enzyme within blood coagulation cascade within body fxiii circulates heterotetramer composed 2 catalytic a-subunits 2 non-catalytic b-subunits fxiii-a2b2 a32363 activated thrombin site injury fxiii a2b2 pro-enzyme cleaved resulting activation catalytic a-subunit dissociation carrier b-subunit result active transglutaminase subunit cross-link fibrin protein resulting increased mechanical strength resistance fibrinolysis fibrin clot contributes enhanced platelet clot adhesion injured tissue thereby improving blood coagulation maintenance hemostasis a18581 supplied recombinant form coagulation factor xiii a-subunit recombinant bind free human fxiii b-subunit resulting heterotetramer ra2b2 similar activity profile half-life endogenously available form patient congenital factor xiii a-subunit deficiency product marketed tretten indicated routine prophylaxis bleeding patient activated rfxiii shown increase mechanical strength fibrin clot slow fibrinolysis enhance platelet adhesion site injury half-life endogenous factor xiii long 5-11 day prophylactic therapy replacement fxiii given every 4-6 maintain hemostasis a32363 drug product similar structure function coagulation factor xiii a-subunit recombinant include db12909 purified endogenous human form coagulation factor xiii compared coagulation factor xiii a-subunit recombinant produced recombinant dna technology target protein grown yeast isolated human form isolated pooled human plasma coagulation factor xiii a-subunit recombinant available u commmercially available product tretten eu novothirteen tretten manufactured intracellular soluble protein yeast saccharomyces cerevisiae production strain containing episomal expression vector pd16 subsequently isolated homogenization cell purification several chromatography step including hydrophobic interaction ion exchange chromatography fda label , routine prophylaxis bleeding patient congenital factor xiii a-subunit deficiency 
Polycarbophil,polycarbophil calcium synthetic polymer manufactured cross-linking polyacrylic acid divinyl glycol calcium counter-ion polycarbophil calcium stool stabilizer used treat constipation drug may also used help relieve symptom irritable bowel syndrome diarrhea le gas bloating compared psyllium laxative product cause heartburn belly cramp insoluble water dilute acid dilute alkali material posse exceptionally high water-binding capacity absorbed interfere activity digestive enzyme intestinal absorption posse satisfactory stability physiologically inert cause gastrointestinal irritation ,polycarbophil used treat constipation help maintain regular bowel movement 
Antilymphocyte immunoglobulin (horse),equine anti-thymocyte globulin composed purified gamma globulin containing primarily igg human thymus lymphocyte formed inoculating horse antigen human thymoyctes induces horse immune system 's b-lymphocytes produce igg immunoglobulin specific antigen result polyclonal igg purified horse 's serum produce usable drug product used immunosuppression although exact mechanism action unknown equine anti-thymocyte globulin target variety immune system protein including lymphocyte surface protein granulocyte platelet bone marrow cell cell type equine atg currently indicated suppression immune system prevent renal transplant rejection treatment aplastic anemia induction cell apoptosis resulting t-cell lymphopenia found vivo credited therapeutic effect condition currently various atg product available differ source inoculated animal rabbit horse pig type antigen product used produce immunoglobulin thymocytes peripheral cell etc , prevention renal transplant rejection treatment aplastic anemia 
Ioxaglic acid,ioxaglic acid marketed hexabrix drug ionic tri-iodinated benzoate used low-osmolality contrast agent diagnostic imaging procedure like organic iodine compound ioxaglic acid block x-ray opaque appearance x-ray film improving visualization important structure organ angiography arteriography arthrography cholangiography urography computed tomography l1889 ioxaglic acid low osmolarity associated fewer side effect compared older contrast agent l1883 , medicinal product diagnostic use adult child low-osmolality medium l1883 a7924 
Technetium Tc-99m pertechnetate,technetium tc-99m pertechnetate radiopharmaceutical diagnostic agent composed oxoanion chemical formula tco4- pertechnetate wide variety us within nuclear medicine distributes within body similar extent iodine also concentrate thyroid gland salivary gland gastric mucosa choroid plexus however contrast iodide ion pertechnetate ion released unchanged thyroid gland currently marketed product drytec technetium-99m pertechnetate indicated imaging following tissue thyroid salivary gland urinary bladder detection vesico-ureteral reflux nasolacrimal drainage system technetium-99m 's short half life 6 hour make storage impossible therefore supplied parent nuclide molybdenum-99 spontaneously decay technetium-99 beta decay normally supplied hospital setting use technetium-99m generator whereby technetium exit generator form pertechnetate ion tco4− extracted promptly used clinical diagnostics following intravenous injection single photon emission computed tomography spect performed detect gamma ray emmitted decay technetium-99m technetium-99 ,sodium pertechnetate tc99m injection indicated use adult imaging following tissue thyroid salivary gland urinary bladder detection vesico-ureteral reflux nasolacrimal drainage system dacryoscintigraphy indicated use child imaging following tissue thyroid urinary bladder 
Xenon-133,xenon-133 inhaled radionuclide used lung imaging imaging blood flow brain ass pulmonary function ,inhalation xenon xe 133 gas proved valuable evaluation pulmonary function imaging lung may also applied assessment cerebral flow 
Thallous chloride,thallous chloride also known thallium chloride colourless solid intermediate isolation thallium ore created treatment thallium sulfate hydrochloric acid solid crystallizes caesium chloride motif used diagnostic radiopharmaceutical used diagnosis heart parathyroid problem following among possible side effect blurred vision chest pain discomfort chill confusion cough difficulty breathing difficulty swallowing dizziness , use diagnostic radiopharmaceutical indicated help diagnose heart disease eg coronary artery disease heart attack also used diagnosis parathyroid problem 
"Synthetic Conjugated Estrogens, A",synthetic conjugated estrogen composed blend following nine synthetic estrogenic substance estrone sulfate sodium equilin sulfate sodium 17α-dihydroequilin sulfate sodium 17α-estradiol sulfate sodium 17β­ dihydroequilin sulfate sodium 17α-dihydroequilenin sulfate sodium 17β-dihydroequilenin sulfate sodium equilenin sulfate sodium 17β-estradiol sulfate blend nine estrogen derivative plant-derived form endogenous estrogen contain many compound conjugated equine estrogen cees although considered equivalent available product enjuvia fda combination plant-derived estrogenic compound indicated treatment moderate severe vasomotor symptom vulvovaginal atrophy associated menopause estrogen product mimic effect endogenous estrogen body responsible development maintenance female reproductive system secondary sexual characteristic estrogen act binding estrogen receptor wide variety tissue body modulating pituitary secretion gonadotropin luteinizing hormone lh follicle stimulating hormone fsh negative feedback mechanism prior menopause primary source estrogen ovarian follicle secretes 70-500 microgram estradiol daily depending phase menstrual cycle however woman stop ovulating sharp decline production progesterone estradiol ovary consequent fluctuation lh fsh due lack feedback control shift hormone production largely responsible many symptom experienced menopause includes hot flash vasomotor symptom painful intercourse vaginal dryness vulvovaginal atrophy symptom able reduced replacing many hormone lost following menopause synthetic naturally occurring form therapy known hormone replacement therapy hrt pharmacologic estrogen product available variety format although many contain several compound common estrogen derivative sodium estrone sulfate sodium equilin sulfate vary original source horse- human- plant-derived remaining mixture estrogenic derivative conjugated equine estrogen cees derived urine pregnant mare contain blend least 10 estrogen derivative marketed brand name premarin cees frequently used form conjugated estrogen currently generic form cees available detailed analytical characterization active ingredient estrogenic activity available time conjugated estrogen also available plant-derived synthetic form replicates naturally occurring horse-derived form available either `` synthetic conjugated estrogen '' containing 9 estrogen derivative available cenestin `` synthetic conjugated estrogen b '' containing 10 estrogen derivative available enjuvia product isolated precursor yam soy plant chemically modified mimic product available naturally occurring form , treatment moderate severe vasomotor symptom due menopause treatment moderate severe symptom vulvar vaginal atrophy due menopause 
"Synthetic Conjugated Estrogens, B","synthetic conjugated estrogen b tablet contain blend ten synthetic estrogenic substance estrogenic substance sodium estrone sulfate sodium equilin sulfate sodium 17α-dihydroequilin sulfate sodium 17α-estradiol sulfate sodium 17β­ dihydroequilin sulfate sodium 17α-dihydroequilenin sulfate sodium 17β-dihydroequilenin sulfate sodium equilenin sulfate sodium 17β-estradiol sulfate sodium δ8,9-dehydroestrone sulfate blend ten estrogen derivative plant-derived form endogenous estrogen contain many compound conjugated equine estrogen cees although considered equivalent available product cenestin fda combination plant-derived estrogenic compound indicated treatment moderate severe vasomotor symptom vulvovaginal atrophy vaginal dryness paint intercourse associated menopause estrogen product mimic effect endogenous estrogen body responsible development maintenance female reproductive system secondary sexual characteristic estrogen act binding estrogen receptor wide variety tissue body modulating pituitary secretion gonadotropin luteinizing hormone lh follicle stimulating hormone fsh negative feedback mechanism prior menopause primary source estrogen ovarian follicle secretes 70-500 microgram estradiol daily depending phase menstrual cycle however woman stop ovulating sharp decline production progesterone estradiol ovary consequent fluctuation lh fsh due lack feedback control shift hormone production largely responsible many symptom experienced menopause includes hot flash vasomotor symptom painful intercourse vaginal dryness vulvovaginal atrophy symptom able reduced replacing many hormone lost following menopause synthetic naturally occurring form therapy known hormone replacement therapy hrt pharmacologic estrogen product available variety format although many contain several compound common estrogen derivative sodium estrone sulfate sodium equilin sulfate vary original source horse- human- plant-derived remaining mixture estrogenic derivative conjugated equine estrogen cees derived urine pregnant mare contain blend least 10 estrogen derivative marketed brand name premarin cees frequently used form conjugated estrogen currently generic form cees available detailed analytical characterization active ingredient estrogenic activity available time conjugated estrogen also available plant-derived synthetic form replicates naturally occurring horse-derived form available either `` synthetic conjugated estrogen '' containing 9 estrogen derivative available cenestin `` synthetic conjugated estrogen b '' containing 10 estrogen derivative available enjuvia product isolated precursor yam soy plant chemically modified mimic product available naturally occurring form ", treatment moderate severe vasomotor symptom due menopause treatment moderate severe vaginal dryness pain intercourse symptom vulvar vaginal atrophy due menopause 
Carindacillin,carindacillin carbenicillin isdanyl oral penicillin prodrug carbenicillin marketed pfizer geocillin longer marketed united state , treatment acute chronic infection upper lower urinary tract asymptomatic bacteriuria due susceptible strain escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter enterococci. also indicated treatment prostatitis due susceptible strain escherichia coli enterococcus s. faecalis proteus mirabilis enterobacter sp 
Procaine benzylpenicillin,procaine benzylpenicillin inn also known procaine g penicillin injectable antiobiotic poorly soluble salt form penicillin combination naturally occuring benzylpenicillin penicillin g local anaesthetic agent procaine equimolar amount procaine benzylpenicillin administered deep intramuscular injection slowly absorbed hydrolyzed benzylpenicillin drug used prolonged exposure benzylpenicillin low concentration required combination aimed reducing pain discomfort associated large intramuscular injection penicillin widely used veterinary setting benzylpenicillin active wide range organism drug first choice many infection , treatment number bacterial infection syphilis anthrax mouth infection pneumonia diphtheria 
Zinc oxide,zinc oxide inorganic compound used number manufacturing process found rubber plastic ceramic glass cement lubricant paint ointment adhesive sealant pigment food battery ferrite fire retardant first-aid tape occurs naturally mineral zincite zinc oxide produced synthetically also widely used treat variety skin condition product baby powder barrier cream treat diaper rash calamine cream anti-dandruff shampoo antiseptic ointment , adjunctive treatment diaper dermatitis also used treat minor skin irritation eg cut burn scrape poison ivy zinc oxide used ointment cream lotion protect sunburn damage skin caused ultraviolet light 
Zinc sulfate,zinc sulfate inorganic compound formula znso4 historically known `` white vitriol '' world health organization 's list essential medicine list important medication needed basic health system , medication mineral used treat prevent low level zinc alone together oral rehydration therapy ort also used topical astringent zinc sulfate injection usp indicated use supplement intravenous solution given tpn 
Sulbactam,sulbactam β-lactamase inhibitor given combination β-lactam antibiotic inhibit β-lactamase enzyme produced bacteria destroys antibiotic activity ,sulbactam currently available combination product ampicillin within formulation indicated treatment infection due susceptible strain designated microorganism condition listed skin skin structure infection caused beta-lactamase producing strain staphylococcus aureus escherichia coli klebsiella spp including k. pneumoniae proteus mirabilis bacteroides fragilis enterobacter spp. acinetobacter calcoaceticus intra-abdominal infection caused beta-lactamase producing strain escherichia coli klebsiella spp including k. pneumoniae bacteroides spp including b. fragilis enterobacter spp gynecological infection caused beta-lactamase producing strain escherichia coli bacteroides spp including b. fragilis 
Sodium fluoride,sodium fluoride inorganic chemical compound source fluoride ion many application including dental care radiographic imaging used fluoride ion f-18 l4894 sodium fluoride 's benefit dental health first observed 1930s individual community fluoridated drinking water showed le tooth decay without fluoridated water use fluoride dental practice began 1940s sodium fluoride may found variety gel varnish rinse toothpaste product fluoride treatment provided dental care a181670 a181688 according american dental association ada thorough evidence review indicated use fluoride prevent control dental caries safe used correctly highly effective reducing prevalence caries l7691 ,sodium fluoride oral topical form indicated prevention control dental caries maintenance dental health a181652 l7670 fluoride supplement form tablet formula may prescribed prevent tooth decay high-risk child aged 6 month 16 year old whose drinking water source contains low fluoride concentration l7691 
Ammonia N-13,ammonia n 13 injection usp positron emitting radiopharmaceutical used diagnostic purpose conjunction positron emission tomography pet imaging active ingredient 13n ammonia molecular formula 13nh3 molecular weight 16.02 ammonia n 13 injection usp used imaging myocardium rest pharmacologic stress condition evaluate myocardial perfusion patient suspected existing coronary artery disease , diagnostic positron emission tomography pet imaging myocardium rest pharmacologic stress condition evaluate myocardial perfusion patient suspected existing coronary artery disease 
Tegafur-uracil,tegafur-uracil anti-tumor compound containing tegafur 1- 2-tetrahydrofuryl -5-fluorouracil uracil molar ratio 1:4 developed anti-cancer therapy taiho pharmaceutical co ltd. a32073 approved different country yet approved fda health canada ema ,tegafur-uracil indicated first line treatment metastatic colorectal cancer concomitant administration calcium folinate l934 colorectal cancer third diagnosed cancer 30 case present metastatic state a32077 
Vayarin,vayarin prescription medical food clinical dietary management certain lipid imbalance blamed associated attention deficit hyperactivity disorder adhd child vayarin contains _lipirinen_ proprietary composition containing phosphatidylserine-omega 3 epa eicosapentaenoic acid docosahexaenoic acid dha l1500 l1510 vayarin currently available prescription usa l1502 drug also used management hypertriglyceridemia l1503 vayarin orally administered prescription medical food clinical dietary management complex lipid imbalance thought associated adhd vayarin specially formulated designed address distinct previously determined lipid nutritional requirement child adhd dietary management achieved lifestyle modification l1502 vayarin novel therapy adhd appears effective several study l1501 l1502 l1503 approximately 60 user completed 12 week therapy reported subjective benefit treatment slow response time 12 week impediment successful management adhd 41.6 subject prescribed vayarin remained compliant duration study cost drug patient aversion taste vayarin significant reason therapy failure l1502 ,adhd child hypertriglyceridemia l1502 l1503 
"Antihemophilic factor (recombinant), PEGylated","antihemophilic factor recombinant pegylated approved fda december 2016 product _adynovate_ fda label antihemophilic factor recombinant pegylated recombinant full-length human coagulation factor viii 2,332 amino acid molecular weight mw approximately 280 kda covalently conjugated least one molecule polyethylene glycol mw 20 kda fda label created increase half-life factor viii decrease dose frequency decrease occurrence bleeding event a32067 a32069 fda label pegylation covalent attachment polyethylene glycol polymer called peg drug protein pegylation decrease factor viii clearance allowing increased duration drug circulation plasma l1529 ", management hemophilia congenital factor viii deficiency fda label a32064 medication human antihemophilic factor indicated adolescent adult patient 12 year older hemophilia congenital factor viii deficiency also used on-demand treatment control bleeding routine prophylaxis bleeding episode indicated treatment von willebrand disease fda label 
Osimertinib,osimertinib oral third-generation epidermal growth factor receptor egfr tyrosine kinase inhibitor tki drug developed astrazeneca pharmaceutical a7926 l43453 use indicated treatment metastatic non-small cell lung cancer nsclc case tumour egfr expression positive t790m mutation detected fda-approved testing progressed following therapy first-generation egfr tyrosine kinase inhibitor approximately 10 patient nsclc rapid clinically effective response egfr-tkis due presence specific activating egfr mutation within tumour cell a7927 specifically deletion around lrea motif exon 19 exon 21 l858r point mutation correlated response therapy a7928 development third-generation egfr-tkis osimertinib response altered tumour resistance pattern following treatment toxic side effect impact patient quality life treatment first-generation egfr-tkis gefitinib erlotinib associated development resistance activating mutation egfr gene second-generation egfr-tkis afatinib dacomitinib developed potent inhibitor although use associated increased toxicity nonspecific targeting wild-type egfr contrast third-generation inhibitor specific gate-keeper t790m mutation increase atp binding activity egfr result poor prognosis late-stage disease furthermore osimertinib shown spare wild-type egfr therapy thereby reducing non-specific binding limiting toxicity a7926 a7927 a7931 ,osimertinib indicated adjuvant therapy tumor resection adult patient non-small cell lung cancer nsclc whose tumor epidermal growth factor receptor egfr exon 19 deletion exon 21 l858r mutation detected fda-approved test first-line treatment adult patient metastatic nsclc whose tumor egfr exon 19 deletion exon 21 l858r mutation detected fda-approved test osimertinib also indicated treatment adult patient metastatic egfr t790m mutation-positive nsclc detected fda-approved test whose disease progressed egfr tki therapy l43453 
Daratumumab,daratumumab immunoglobulin g1 kappa monoclonal antibody developed janssen genmab a7935 first described literature 2010 monoclonal antibody target cd38+ multiple myeloma cell first kind a199002 daratumumab granted fda approval 16 november 2015 l13290 approved treatment multiple myeloma monotherapy combination therapy light chain al amyloidosis combination drug l13290 l13296 ,daratumumab indicated intravenous injection alone combination medication treatment multiple myeloma l13290 available combination product hyaluronidase treatment adult multiple myeloma monotherapy combination therapy light chain amyloidosis combination drug l13296 
Kappadione,kappadione vitamin k derivative chemically menadiol sodium diphosphate previously approved fda prior 1982 marketed lilly marketing drug discontinued available north america l1543 found carcinogenic potential mammalian cell well cytotoxic property l1544 study involving active metabolite formulation menadione showed oocyte toxicity study mouse l1544 ,anticoagulant-induced prothrombin deficiency caused coumadin indanedione derivative prophylaxis therapy hemorrhagic disease newborn hypoprothrombinemia due antibacterial therapy hypoprothrombinemia secondary factor limiting absorption synthesis vitamin k example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis pancreas regional enteritis drug-induced hypoprothrombinemia definitely shown result due interference vitamin k metabolism l1545 l1546 
Iopodic acid,iopodic acid also known name ipodate classified cholecystographic agent formed weak organic acid contains tri-iodinated benzene ring iodine position 2 4 6 a32080 due particular structure present high degree lipid solubility radiopaque property developed filed fda company bracco drug approved march 15 1962 nowadays discontinued fda health canada september 22 1981 ipodate submitted company schering ag currently inactive status l1082 ,iopodic acid available cholecystographic agent denomination indicates iopodic acid radiopaque substance used visualize gallbladder biliary channel abdominal x-ray l1587 a32087 abdominal x-ray us minimal amount ionizing radiation produce picture inside abdominal cavity commonly used evaluate stomach liver intestine spleen l1589 iopodic acid also indicated treatment hyperthyroidism graf disease a32085 a32086 hyperthyroidism refers condition much thyroid hormone produced body overactive thyroid overactivity involves entire thyroid gland known grave 's disease l1590 
Seractide acetate,seractide acetate acetate salt full length human corticotropin ,
Alatrofloxacin,alatrofloxacin fluoroquinolone antibiotic developed pfizer delivered mesylate salt withdrawn u.s. market 2001 ,
Technetium Tc-99m nofetumomab merpentan,technetium tc-99m nofetumomab merpentan tc-99m nm consists fab fragment igg2b pancarcinoma murine antibody nr-lu-10 a32115 nr-lu-10 antibody directed 40 kda glycoprotein antigen expressed variety cancer normal tissue fda label tc-99m nm developed boehringer ingelheim pharma kg fda approved september 14 1992 discontinued august 13 2013 2018 fda submission list found substance type ii drug substance active status l1650 l1082 ,tc-99m nm one technetium-labeled antibody indicated detection small-cell lung cancer l1146 small cell lung cancer syndrome characterized abnormal uncontrolled cell growth characterized shorter doubling time higher growth fraction earlier development metastasis l1651 
Medical air,medical air supplied special air compressor patient care area using clean outside air , use source clean air fda label 
Mersalyl,mersalyl sodium salt form mersalyl acid mercurial diuretic outdated drug approval discontinued fda mersalyl acid currently replaced le toxic non-mercury containing diuretic l1575 l1577 sodium salt mercury-containing derivative salicylamide formerly used often combination theophylline treat edema due powerful diuretic property l1577 interestingly found antiviral property mouse l1584 ,elevated blood pressure edema l1577 l1585 
Indium In-111 imciromab pentetate,indium in-111 imciromab pentetate mouse monoclonal antibody labelled radioisotope indium-111 used cardiac imaging trade name myoscint withdrawn 1993 ,
Tyropanoic acid,tyropanoic acid radiocontrast agent used cholecystography x-ray diagnosis gallstone trade name include bilopaque lumopaque tyropaque bilopac molecule contains three heavy iodine atom obstruct x-ray way calcium bone result visible image l1608 , use cholecystography x-ray diagnosis/imaging gallstone 
"Dextrose, unspecified form",glucose simple sugar monosaccharide generated phosynthesis involving water carbon sunlight plant produced human via hepatic gluconeogenesis breakdown polymeric glucose form glycogenolysis circulates human circulation blood glucose act essential energy source many organism aerobic anaerobic respiration fermentation primarily stored starch plant glycogen animal used various metabolic process cellular level aldohexose stereoisomer dextrose d-glucose commonly occurring isomer glucose nature l-glucose synthesized enantiomer used low-calorie sweetener laxative unspecified form glucose commonly supplied injection nutritional supplementation metabolic disorder glucose level improperly regulated glucose listed world health organization 's list essential medicine ,glucose pharmaceutical formulation oral tablet injection indicated caloric supply carbohydrate supplementation case nutrient deprivation also used metabolic disorder hypoglycemia 
Propoxycaine,propoxycaine local anesthetic ester type rapid onset action longer duration action procaine hydrochloride l1588 drug removed u market 1996 although longer available united state medication used combination procaine aid anesthesia dental procedure l1592 used combination procaine dental local anesthetic available cartridge form l1592 ,propoxycaine local anesthetic medication used beginning 1950s dental procedure l1591 combined procaine accelerate onset action provide longer-lasting anesthetic effect l1592 produced use amide local anesthetic contraindicated due allergy several amide anesthetic unsuccessful l1592 
Tipiracil,tipiracil thymidine phosphorylase inhibitor used combination trifluridine ratio 1:0.5 form tas-102 main function tipiracil tas-102 increase trifluridine bioavailability inhibiting catabolism a31255 tas-102 indicated treatment metastatic colorectal cancer previously treated fluoropyrimidine- oxaliplatin- irinotecan-based chemotherapy anti-vegf anti-egfr therapy a31254 ,tipiracil combination trifluridine indicated treatment adult patient metastatic colorectal cancer previously treated fluoropyrimidine- oxaliplatin- irinotecan-based chemotherapy anti-vegf biological therapy ra wild-type anti-egfr therapy combination use also used treat metastatic gastric gastroesophageal junction adenocarcinoma previously treated least two prior line chemotherapy included fluoropyrimidine platinum either taxane irinotecan appropriate her2/neu-targeted therapy l41250 
Invert sugar,invert sugar obtained sugar cane treated dilute acid invertase enzyme formed equal amount glucose fructose differentiates sugar cane rotation polarized light case invert sugar left levorotatory a32124 invert sugar fda approved since 1988 safe substance gras ,invert sugar present large variety us used therapeutically parenteral hyperalimentation t127 used excipient known effect l1691 invert sugar also approved use food product humectant crystallization modifier liquid nutritive sweetener t128 
Pramocaine,pramocaine also known pramoxine pramoxine hci topical anesthetic antipruritic used many dermatological anorectal/anogenital condition including minor cuts/burns insect bite hives/rashes due poison ivy exposure hemorrhoid anorectal/anogenital disorder pramocaine available combination medication various topical preparation work preventing ionic fluctuation needed neuron membrane depolarization action potential propagation , indicated temporary relief pain pruritus minor lip skin irritation well temporary relief pain burning itching discomfort associated hemorrhoid anorectal/anogenital disorder 
Metrizoic acid,"metrizoic acid molecule used contrast medium present higher risk allergic reaction due high osmolality approval discontinued fda one study 1976 demonstrated metrizoic acid used cardiac angiography well tolerated total 10 000 injection administered 2,028 patient undergoing angiocardiographic procedure three-year period two exception complication occurred injection right coronary artery seven case ventricular fibrillation 5 significant bradycardia/asystole associated metrizoic acid injection general drug well tolerated patient cardiac examination a32091 ", use contrast medium l1597 
Acetrizoic acid,"acetrizoic acid present molecular formula 3-acetamidol-2,4,6-triiodobenzoic acid l1702 first monomeric ionic compound used x-ray contrast agent a32135 first synthesized wallingford 1953 a32136 filled fda johnson johnson subsidiary cilag chemie ag february 8th 1978 l1704 acetrizoic acid present fda record category drug substance inactive status l1703 ",acetrizoic acid indication used contrast agent x-ray information indicates nephrotropic property one characteristic utilization acetrizoic acid a32135 x-ray imaging depends difference tissue density provided x-ray attenuation area interest surrounding tissue use contrast agent provoke contrast enhancement opacification improve differentiation pathological process normal tissue t125 
Propiolactone,propiolactone lactone compound four-membered ring colorless liquid pungent slightly sweet odor propiolactone disinfectant used sterilization blood plasma vaccine tissue graft surgical instrument enzyme used bacteria fungi virus a32144 currently fda approved use indirect additive used food contact substance propiolactone first commercially available united state 1958 a32144 ,propiolactone used vaccine tissue graft surgical instrument enzyme sterilant blood plasma water milk nutrient broth vapor-phase disinfectant enclosed space sporicidal action used vegetative bacteria pathologic fungi virus l1717 longer used medical procedure food a32144 
Gastric intrinsic factor,intrinsic factor also known gastric intrinsic factor gif glycoprotein produced parietal cell stomach necessary absorption vitamin b12 cobalamin later small intestine vitamin b12 provided combination intrinsic factor intrinsic factor reduces protease degradation increase absorption vitamin b12 intrinsic factor currently available fda health canada approved product however currently marketed unapproved product hematogen combination cyanocobalamin synthetic vitamin b12 ferrous fumarate ascorbic acid treatment anemia responsive oral iron therapy ,intrinsic factor currently available fda health canada approved product however currently marketed unapproved product hematogen combination cyanocobalamin synthetic vitamin b12 ferrous fumarate ascorbic acid treatment anemia responsive oral iron therapy 
Piperonyl butoxide,piperonyl butoxide pbo organic compound used component pesticide formulation used treatment head pubic crab body louse piperonyl butoxide synergist pesticidal activity act increase activity pesticide carbamate pyrethrins pyrethroids rotenone piperonyl butoxide semisynthetic derivative safrole , treatment head pubic crab body louse 
Levobetaxolol,levobetaxolol beta-blocker used lower pressure eye treat condition glaucoma marketed 0.5 ophthalmic solution levobetaxolol hydrochloride trade name betaxon discontinued ,used treatment open-angle glaucoma ocular hypertension fda label 
Hydroxyamphetamine,hydroxyamphetamine derivative amphetamine hydroxyamphetamine intended mainly local eye drop diagnostic purpose indirect sympathomimetic agent cause dilation eye pupil diagnostic test among minor side effect use change color vision difficulty seeing night dry mouth headache increased sensitivity eye sunlight muscle stiffness tightness temporary stinging eye main use hydroxyamphetamines eye drop diagnosis horner 's syndrome characterized nerve lesion ,mydriatic agent eye pupil dilatation diagnosis ophthalmic nerve lesion 
Octasulfur,sulfur chemical element present living tissue commonly used form pharmaceutical sulfur octasulfur s8 calcium phosphorus third abundant mineral human body sulfur also found garlic onion broccoli people take sulfur mouth shortness breath allergy swelling back throat pharyngitis high cholesterol clogged artery menopause upper respiratory tract infection like common cold sulfur seems antibacterial activity also used acne ,topically indicated dandruff acne hayfever common cold scaly red skin patch seborrheic dermatitis poison ivy sumac infection 
Sulfabenzamide,sulfabenzamide antimicrobial agent often used conjunction sulfathiazole sulfacetamide topical intravaginal antibacterial preparation ,
Dexpanthenol,dexpanthenol alcohol derivative pantothenic acid component b complex vitamin essential component normally functioning epithelium dexpanthenol enzymatically cleaved form pantothenic acid essential component coenzyme act cofactor many enzymatic reaction important protein metabolism epithelium a32373 due good penetration high local concentration dexpanthanol used many topical product ointment lotion treatment dermatological condition relieve itching promote healing dermatological effect topical use dexpanthenol include increased fibroblast proliferation accelerated re-epithelialization wound healing furthermore act topical protectant moisturizer demonstrated anti-inflammatory property a32377 dexpanthenol also available racemic mixture containing dextrorotatory form dexpanthenol levorotatory form levopanthenol db11204 pantothenic acid optically active dextrorotatory form dexpanthenol biologically active ,injection prophylactic use immediately major abdominal surgery minimize possibility paralytic ileus intestinal atony causing abdominal distention postoperative postpartum retention flatus postoperative delay resumption intestinal motility paralytic ileus topical medication used moisturizer treat prevent dry rough scaly itchy skin minor skin irritation e.g. diaper rash skin burn radiation therapy 
Rauwolfia serpentina root,rauwolfia rauwolfia serpentina also spelled _ravolphia_ medicinal plant milkweed family root plant ground powder sold tablet capsule compound commonly used asian medicine includes traditional ayurvedic medicine native india active ingredient drug alkaloid 50 identified various study although primary psychoactive component appear reserpine rescinnamine deserpidine l1618 product approved prior jan 1 1982 since discontinued due propensity leading depression l1616 l1630 reserpine derived rauwolfia serpentina commonly used antihypertensive agent 1950s l1621 rauwolfia serpentina also commonly referred _sarpaghanda_ a32097 interestingly hairy root component plant shown remarkable capacity regenerate complete rauwolfia plant show survival unaltered biosynthetic potential storage decreased temperature reason various study biotechnological application plant performed multiple study done biosynthetic potential numerous biotechnological method used study production pharmaceutically important alkaloid a32095 a32096 ,rauwolfia alkaloid indicated treatment hypertension l1614 rauwolfia alkaloid used relief symptom agitated psychotic state schizophrenia however use antipsychotic sedative replaced use effective safer agent l1614 
Propyliodone,radiopaque medium usually oil used bronchography ,
Polyestradiol phosphate,polymeric phosphoric acid ester estradiol ,
Norethynodrel, synthetic progestational hormone action us similar progesterone used treatment functional uterine bleeding endometriosis contraceptive usually administered combination mestranol ,
Tannic acid,tannic acid polyphenolic compound type commercially available tannin act weak acid tannic acid found nutgalls formed insect twig certain oak tree quercus infectoria quercus specie removed used medicine old day used antidote different poison nowadays tannic acid applied topically treatment cold sore diaper rash fever blister poison ivy tannic acid also taken mouth applied directly bleeding chronic diarrhea dysentery bloody urine painful joint persistent cough cancer ,tannic acid indicated cold sore fever blister diaper rash minor burn sunburn prickly heat vaginally tannic acid used douche leukorrhea also indicated sore throat inflamed tonsil spongy receding gum acute dermatitis 
Trolamine polypeptide oleate condensate,various ear disease infection treated eardrop containing triethanolamine polypeptide oleate-condensate cerumenex united state canada ,
Indocyanine green acid form,"indocyanine green water soluble tricarbocyanine dye peak spectral absorption 800 nm chemical name indocyanine green 1 h-benz e indolium 2- 7- 1,3-dihydro-1,1-dimethyl-3- 4-sulfobutyl -2h-benz e indol-2-ylidene -1,3,5-heptatrienyl -1,1-dimethyl-3- 4-sulfobutyl hydroxide inner salt sodium salt indocyanine green injection usp ph approximately 6.5 reconstituted vial indocyanine green injection usp contains 25 mg indocyanine green sterile lyophilized powder 5 sodium iodide ", determining cardiac output hepatic function liver blood flow ophthalmic angiography
Chymotrypsin,chymotrypsin ec 3.4.21.1 digestive enzyme promotes proteolysis breakdown protein polypeptide serine protease synthesized pancreas vital component pancreatic juice like proteolytic enzyme chymotrypsin activated inactive zymogen precursor chymotrypsinogen presence db11237 chymotrypsin abundant pancreatic protease represent 10-20 total protein synthesized exocrine pancreas a32637 chymotrypsin contains catalytic triad oxyanion hole tertiary structure chymotrypsin similar db11237 a32642 , therapeutic indication 
Lapyrium,lapyrium quaternary ammonium cation used surfactant antistatic agent biocide various cosmetic product a19426 commonly found formulated lapyrium chloride ,used surfactant antistatic agent biocide cosmetic product a19426 
Fluprednisolone, synthetic glucocorticoid anti-inflammatory property ,
Sutilain,"sutilain member keratase family includes agent papain able dissolve intercellular matrix help desquamation sutilain contains proteolytic enzyme derived _bacillus subtilis_ available cream-colored odorless powder one gram sutilain powder contains 250,000 casein unit proteolytic activity t169 sutilain developed abbott fda approved june 12 1969 currently discontinued l2368 ",sutilain indicated form ointment biochemical debridement second third-degree burn incisional traumatic pyrogenic wound ulcer occurring due peripheral vascular disease t169 
Esterified estrogens,esterified estrogen contain mixture estrogenic substance principle component estrone preparation contain 75 85 sodium estrone sulfate 6 15 sodium equilin sulfate total 90 esterified estrogen man-made mixture estrogen used treat symptom menopause hot flash vaginal dryness vaginal burning irritation hormonal change vagina also prevention treatment osteoporosis ,esterified estrogen indicated replace estrogen woman ovarian failure condition cause lack natural estrogen body also indicated treatment symptom breast cancer men woman men used treatment advanced prostate cancer also indicated treatment menopausal symptom 
Cyanocobalamin Co-60,cyanocobalamin co-60 analog vitamin b12 labeled co60 cyanocobalamin co-60 used diagnosis pernicious anemia withdrawn market u unknown reason ,
Norgestrel,norgestrel synthetic steroidal progestin used combination ethinyl estradiol oral contraception norgestrel composed racemic mixture two stereoisomers dextronorgestrel levonorgestrel however levorotary enantiomer levonorgestrel biologically active ,norgestrel combination ethinyl estradiol indicated prevention pregnancy woman elect use product method contraception 
Amino acids,mixture amino acid used parenteral nutrition infant ,
Phosphoric acid,phosphoric acid colorless odorless phosphorus-containing inorganic acid phosphoric acid sequestering agent bind many divalent cation including fe++ cu++ ca++ mg++ ,phosphoric acid used dentistry orthodontics etching solution clean roughen surface teeth dental appliance filling placed 
Sodium acetate,sodium acetate chemically designated ch3coona hygroscopic powder soluble water sodium acetate could used additive food industry concrete manufacture heating pad buffer solution medically sodium acetate important component electrolyte replenisher given intravenously mainly indicated correct sodium level hyponatremic patient used also metabolic acidosis urine alkalinization ,injection usp 40 meq indicated source sodium addition large volume intravenous fluid prevent correct hyponatremia patient restricted oral intake also useful additive preparing specific intravenous fluid formula need patient met standard electrolyte nutrient solution sodium acetate bicarbonate precursor alkalinising agent used correct metabolic acidosis alkalinisation urine 
Technetium Tc-99m sulfur colloid,technetium 99m sulfur colloid radiopharmaceutical diagnostic agent used evaluation various condition including lymph node metastasis breast cancer detection shunt patency imaging reticuloendothelial cell assessment liver function study esophageal transit gastroesophageal reflux following injection oral administration single photon emission computer tomography spect imaging performed using gamma camera detect technetium-99m decay possible technetium-99m decay isomeric transition technetium-99 release gamma ray depending site administration intended usage technetium 99m sulfur colloid enters capillary transported lymph node subcutaneous injection mix peritoneal fluid intraperitoneal injection taken reticulocyte intravenous injection enters gastroesphageal tract oral administration ,technetium 99m sulfur colloid indicated diagnostic agent adult following test localization lymph node draining primary tumor patient breast cancer malignant melanoma evaluation peritoneo-venous leveen shunt patency indicated adult pediatric patient imaging area functioning reticuloendothelial cell liver spleen bone marrow study esophageal transit gastroesophageal reflux detection pulmonary aspiration gastric content 
Fluoride ion F-18,sodium fluoride f 18 injection positron emitting radiopharmaceutical no-carrier added contains radioactive fluoride f 18 used diagnostic purpose conjunction positron emission tomography pet imaging administered intravenous injection primary indication bone imaging increased deposition around joint occur arthritis following trauma increased deposition bone noted around fracture site osteomyelitis fibrous dysplasia spondylitis tuberculosa paget 's disease adverse reaction reported ,18f used bone imaging agent define area altered osteogenic activity indicated back pain otherwise unexplained bone pain child abuse abnormal radiographic laboratory finding osteomyelitis trauma inflammatory degenerative arthritis avascular necrosis osteonecrosis mandible condylar hyperplasia metabolic bone disease also among indication fluoride imaging 
Isosorbide,isosorbide previously available oral formulation reduction intraocular pressure approved fda 1980 since discontinued currently isosorbide organic nitrate currently available isosorbide mononitrate isosorbide dinitrate form used prevention angina refer drug entry information ,isosorbide previously indicated temporary reduction intraocular pressure used interrupt acute glaucoma attack however currently approved indication l34064 refer isosorbide mononitrate isosorbide dinitrate drug entry isosorbide indication 
Iocetamic acid,iocetamic acid diagnostic aid radiopaque medium ,
Chlormerodrin Hg-197,chlormerodrin hg-197 radiolabelled form chlormerodrin organomercury compound previously used diuretic radiolabelled form used diagnostics brain scan ,
Magnesium chloride,magnesium chloride salt highly soluble water hydrated form magnesium chloride extracted brine sea water ,magnesium chloride used several medical topical skin related application magnesium chloride usp anhydrous us electrolyte replenisher pharmaceutic necessity hemodialysis peritoneal dialysis fluid 
Magnesium acetate tetrahydrate,magnesium acetate tetrahydrate hydrated form anhydrous magnesium acetate salt chemical formula mg ch3coo 2 • 4h2o salt form magnesium magnesium acetate one bioavailable form magnesium form water soluble compound magnesium essential element second abundant cation body play key role maintaining normal cellular function production atp efficient enzyme activity magnesium acetate tetrahydrate used electrolyte supplementation reagent molecular biology experiment ,used magnesium salf-containing laxative prevent constipation bring synergistic effect restore normal bowel function using combination aluminum salt induce bowel retention t28 magnesium acetate tetrahydrate used source water electrolyte combined dextrose salt form intravenous infusion injection used patient carbohydrate magnesium deficiency insulin hypoglycemia constipation hypertension pregnancy 
Monopotassium phosphate,monopotassium phosphate mkp also potassium dihydrogenphosphate kdp monobasic potassium phosphate kh2po4 soluble salt potassium dihydrogen phosphate ion source phosphorus potassium well buffering agent used fertilizer mixture reduce escape ammonia keeping ph low ,used buffer determination ph pharmaceutical production urinary acidifier paper processing baking powder food nutrient solution yeast food special liquid fertilizer sonar system electronic application used nutritional supplement food nonlinear optical material laser use wastewater treatment 
Dipotassium phosphate,dipotassium phosphate k2hpo4 highly water-soluble salt often used fertilizer food additive source phosphorus potassium well buffering agent ,dipotassium phosphate used imitation dairy creamer dry powder beverage mineral supplement starter culture additive used non-dairy creamer prevent coagulation dipotassium phosphate also used make buffer solution used production trypticase soy agar used make agar plate culturing bacteria 
Potassium perchlorate,potassium perchlorate inorganic salt chemical formula kclo4 strong oxidizer lowest solubility alkali metal perchlorate potassium commonly used flare automobile airbags a32609 use potassium perchlorate component sealing gasket food container revoked fda following use abandoned industry l2365 potassium perchlorate act competitive inhibitor iodine uptake thyroid gland attenuates production thyroid hormone thus use potassium perchlorate extensive hyperthyroidism last 50 year particularly late 1950s early 1960s a32609 therapeutic use potassium perchlorate thyroid disorder ceased due high risk developing aplastic anemia nephrotic syndrome l2364 , current fda- ema-approved therapeutic indication 
Xylose,xylose monosaccharide aldopentose type consisted five carbon atom aldehyde functional group xylose sugar isolated wood d-xylose sugar widely used diabetic sweetener food beverage xylose also used diagnostic agent observe malabsorption reduction xylose catalytic hydrogenation produce common food additive sweetener substitute xylitol db11195 dextrorotary form xylose d-xylose refers usually endogenously occurring form sugar living thing levorotary form l-xylose refer form synthesized nevertheless xylose may necessarily serve many purpose immediately metabolism result variety substrate serve important nutritional biological purpose , predominant everyday nutritional usage xylose parent sugar alcohol another sugar alcohol xylitol- derived used extremely common food additive sweetener used place regular sugar lower calorie alternative l2428 l2429 a32661 alternatively xylose also involved procedure known d-xylose absorption test used employed evaluate well individual capable absorbing simple sugar like d-xylose intestine l2432 measuring amount d-xylose urine blood sample individual ingested certain amount simple sugar dissolved water test sought determine nutrient properly absorbed patient 's gastrointestinal tract l2432 
Iodide I-123,iodide i-123 sodium iodide i-123 radioactive isotope iodine used nuclear medicine diagnostic study thyroid disease following oral administration i-123 absorbed gastrointestinal tract taken thyroid gland incorporation gamma camera used detect decay electron capture tellurium-123 iodine commonly used thyroid function diagnostic test gland normally absorbs iodine diet formation thyroid hormone triiodothyronine t3 prohormone thyroxine t4 radioactive i-123 particular effective use half-life approximately 13.13 h hour ideal 24-h hour iodine uptake test reduced radiation burden compared i-131 ,administration sodium iodide 123 capsule indicated diagnostic procedure used evaluating thyroid function and/or morphology 
Protirelin,protirelin pharmaceutically available synthetic analogue endogenous peptide thyrotropin-releasing hormone trh tri-peptide tropic hormone released hypothalamus stimulates release thyroid stimulating hormone tsh prolactin anterior pituitary although currently available fda-approved product protirelin component trh test used test response anterior pituitary gland condition secondary hypothyroidism acromegaly ,
Soybean oil,derived soybean soybean oil common vegetable oil source polyunsaturated saturated fatty acid complex mixture triglyceride per 100 g soybean oil 16 g saturated fat 23 g monounsaturated fat 58 g polyunsaturated fat major component fatty acid linoleic 48 58 oleic 17 30 palmitic 9 -13 linolenic 4 11 stearic 2.5 5.0 used cooking oil lipid emulsion parenteral nutrition clinical setting soybean oil-based lipid emulsion fda-approved lipid formulation clinical use ,indicated parenteral nutrition source calorie essential fatty acid oral enteral nutrition possible insufficient contraindicated 
Indium In-111 pentetate,indium in-111 pentetate disodium radioactive diagnostic indicated use radionuclide cisternography decay in-111 electron capture allows detection gamma camera visualization brain spinal column ,pentetate indium disodium 111 recommended use radionuclide cisternography 
Albumin iodinated I-125 serum,i-125 iodinated albumin radiolabeled albumin-based diagnostic agent used determination total blood plasma volume l12780 ,i-125 iodinated albumin used determination total blood plasma volume l12780 
Albumin iodinated I-131 serum,iodinated i-131 serum albumin radiopharmaceutical agent used several diagnostic purpose including determination body fluid volume imaging certain tissue l12783 ,iodinated i-131 albumin indicated use determination total blood plasma volume cardiac output cardiac pulmonary blood volume circulation time protein turnover study heart great vessel delineation localization placenta localization cerebral neoplasm l12783 
Technetium Tc-99m succimer,technetium tc-99m sup 99m /sup tc succimer also known technetium tc-99m dimercaptosuccinic acid dmsa a245643 radioactive diagnostic agent used evaluate functional renal tissue tubular function patient renal parenchymal disorder work binding cortical region kidney technetium tc-99m succimer used gamma scintigraphy single-photon emission computed tomography spect l40558 use technetium tc-99m succimer detection kidney cortical defect first approved fda february 23 2022 market name nephroscan l40573 ,technetium tc-99m succimer radioactive diagnostic agent indicated use aid scintigraphic evaluation renal parenchymal disorder adult pediatric patient including term neonate l40558 
Safflower oil,safflower _carthamus tinctorius_ l herbaceous plant asteraceae family extracted seed safflower safflower oil rich source various saturated fatty acid monounsaturated fatty acid oleic acid essential n-6 polyunsaturated fatty acid pufa linoleic acid a32677 a32679 depending flower type safflower oil higher content polyunsaturated fatty acid commonly used edible oil constituent safflower oil also include alpha-tocopherol gamma-tocopherol mixed db11251 a32692 safflower oil approved use indirect additive food contact substance readily available food ingredient gamma linolenic acid gla safflower oil marketed over-the-counter dietary supplement , approved therapeutic indication 
"Sodium phosphate, monobasic",sodium phosphate saline laxative thought work increasing fluid small intestine usually result bowel movement 30 minute 6 hour ,used treat constipation clean bowel colonoscopy fda label 
Insulin beef,insulin beef discontinued u canada since 2017 l10827 ,
L-tartaric acid,tartaric acid white crystalline organic acid occurs naturally many plant notably grapes.tartaric alpha-hydroxy-carboxylic acid diprotic aldaric acid characteristic dihydroxyl derivative succinic acid ,tartaric acid primarily indicated condition like antiscorbutic antiseptic 
Sodium carbonate,sodium carbonate disodium salt carbonic acid alkalinizing property dissolved water sodium carbonate form carbonic acid sodium hydroxide strong base sodium hydroxide neutralizes gastric acid thereby acting antacid ,used topically dermatitides mouthwash vaginal douche veterinary use emergency emetic.occasionally dermatitides topically lotion medication vet solution cleanse skin eczema soften scab ringworm 
Glycerin, trihydroxy sugar alcohol intermediate carbohydrate lipid metabolism , used solvent emollient pharmaceutical agent sweetening agent 
Sodium sulfate,sodium sulfate anhydrous anhydrous sodium salt form sulfuric acid sodium sulfate anhydrous disassociates water provide sodium ion sulfate ion sodium ion principal cation extracellular fluid play large part therapy fluid electrolyte disturbance sodium sulfate anhydrous electrolyte replenisher used isosmotic solution administration disturb normal electrolyte balance lead absorption excretion water ion ,indicated bowel cleansing prior colonoscopy barium enema x-ray examination 
Indium In-111 oxyquinoline,indium 111 oxyquinoline oxine diagnostic radiopharmaceutical intended radiolabeling autologous leukocyte composed 3:1 saturated complex in-111 isotope oxyquinoline indium-111 decay isomeric transition electron capture cadmium-111 emitting gamma ray detected gamma ray camera therefore useful nuclear medicine used labeling leukocyte localization process leukocyte migrate associated abscess infection degree accuracy may vary labeling technique size location nature inflammatory process following intravenous administration lipid-soluble complex able penetrate platelet cell membrane inside indium detaches oxyquinoline complex becomes attached cytoplasmic component ,indium 111 oxyquinoline indicated radiolabeling autologous leukocyte 
Enalaprilat,enalaprilat active metabolite orally available pro-drug enalapril used treatment hypertension enalapril ace inhibitor prevents angiotensin converting enzyme ace transforming angiotensin angiotensin ii angiotensin ii responsible vasoconstriction sodium reabsorption proximal tubule kidney down-regulation protein result reduced blood pressure blood fluid volume enalaprilat originally created overcome limitation first ace inhibitor captopril numerous side effect left metallic taste mouth removal problematic thiol group captopril resulted enalaprilat modified ester create orally available pro-drug enalapril enalaprilat poorly orally available therefore available intravenous injection treatment hypertension oral therapy possible ,enalaprilat injection indicated treatment hypertension oral therapy practical 
Rubidium Rb-82,rubidium chloride rb-82 injection sterile nonpyrogenic solution rubidium rb 82 chloride indicated positron emission tomography pet imaging myocardium rest pharmacologic stress condition evaluate regional myocardial perfusion adult patient suspected existing coronary artery disease ,rubidium rb 82 chloride injection indicated positron emission tomography pet imaging myocardium rest pharmacologic stress condition evaluate regional myocardial perfusion adult patient suspected existing coronary artery disease 
Magnesium carbonate,magnesium carbonate also known magnesite common counter remedy heartburn upset stomach caused overproduction acid stomach fda label ,used counter antacid l593 
Sodium fluorophosphate,sodium monofluorophosphate used otc dental preparation help protect cavity ,sodium monofluorophosphate indicated treatment cavity
Iotrolan,nonionic isotonic contrast medium designed intrathecal use ,
Acrivastine,acrivastine triprolidine analog antihistamine indicated treatment allergy hay fever h1 receptor antagonist function blocking action histamine receptor thereby preventing symptom associated histamine release pruritis vasodilation hypotension edema bronchoconstriction tachycardia acrivastine currently available combination pseudoephedrine fda-approved product semprex-d , relief symptom associated seasonal allergic rhinitis sneezing rhinorrhea pruritus lacrimation nasal congestion 
Indium In-111 chloride,indium in-111 chloride diagnostic radiopharmaceutical agent intended radiolabeling oncoscint satumomab pendetide prostascint capromab pendetide used _in vivo_ diagnostic imaging procedure radiolabeling zevalin ibritumomab tiuxetan preparation used radioimmunotherapy procedure supplied sterile pyrogen-free solution indium `` 'in chloride o.04m hci ,indium in-111 chloride indicated radio labeling monoclonal antibody preparation used vivo diagnostic imaging procedure indiclor also indicated radiolabeling zevalin preparation used radio immunotherapy procedure
Technetium Tc-99m red blood cells,technetium tc-99m red blood cell radiopharmaceutical diagnostic agent intravenously administered used blood pool imaging including cardiac first pas gated equilibrium imaging detection site gastrointestinal bleeding clinically useful early detection localization bleeding site preoperative diagnosis hemangioma a32178 a32179 autologous red blood cell radiolabeled sodium pertechnetate tc 99m reaction vial radiolabeled red blood cell re-injected intravenously patient gamma scintigraphic imaging fda label suggested _in vitro_ labelling improves heart-to-background ratio imaging a32181 ,indicated blood pool imaging including cardiac first pas gated equilibrium imaging detection site gastrointestinal bleeding fda label 
Cetyl alcohol,cetyl alcohol also known 1-hexadecanol n-hexadecyl alcohol 16-c fatty alcohol chemical formula ch3 ch2 15oh produced reduction palmitic acid cetyl alcohol present waxy white powder flake form room temperature insoluble water soluble alcohol oil a32209 discovered chevrenl 1913 cetyl alcohol one oldest known long-chain alcohol a32209 may contained cosmetic personal care product shampoo cream lotion mainly used opacifier emulsifier thickening agent alter thickness liquid increase stabilize foaming capacity due water-binding property cetyl alcohol commonly used emollient prevents drying chapping skin a32209 according fda code federal regulation cetyl alcohol safe synthetic fatty acid food synthesis food component condition contain le 98 percent total alcohol le 94 percent straight chain alcohol l1824 cetyl alcohol also listed otc ingredient list skin protectant skin irritation caused poison ivy oak sumac insect bite sting l1074 cetyl alcohol reported mild skin eye irritant , therapeutic indication medicinal product indicated used indirect additive food contact substance ingredient commercial cosmetic product 
Avobenzone,avobenzone dibenzoyl methane derivative oil soluble ingredient avobenzone ability absorb ultraviolet light wider range wavelength included many commercially available sunscreen used wide spectrum sunscreen avobenzone sensitive light increase stability duration action photostablizers added sunscreen product avobenzone absorption maximum 357 nm sunscreen containing avobenzone indicated providing protection sun addition limiting skin 's exposure sun using sunscreen agent may help reduce long-term sun damage premature aging skin skin cancer ,sun protection factor added sunscreen product wide spectrum ultraviolet absorption property 
Octinoxate,octinoxate cinnamate ester common ingredient sunscreen skin care product minimize dna photodamage originally developed 1950 's organic uv-b filter absorbs uv-b ray sun often combined nanoparticles water-resistant liposome formulation increase localization epidermis decrease risk percutaneous absorption use pharmaceutical cosmetic formulation approved fda , active ingredient sunscreen lip balm used protection damaging effect sun ray 
Strontium chloride Sr-89,strontium chloride sr-89 initially fda-approved 1993 used paliative therapeutic option help relieve pain bone metastasis strontium chloride mainly used case metastatic castrate-resistant prostate cancer a31264 bone metastasis common severe complication presented advanced stage disease usually presented mainly patient prostatic breast cancer well cancer lung bladder thyroid case apparent tumor regression given potential tumoricidal effect a31263 ,strontium-89 chloride injection indicated paliative relief bone pain patient skeletal metastasis impotant confirm presence bone metastasis prior beginning therapy a31264 
Thiosulfuric acid,thiosulfuric acid available salt form sodium thiosulfate sodium thiosulfate pentahydrate sodium thiosulfate part world health organization ’ list essential medicine variety industrial us including food preservative water de-chlorinator paper pulp bleaching agent a252827 sodium thiosulfate rapidly degraded stomach therefore normally administered route intravenous topical a252827 sodium thiosulfate approved treatment acute cyanide poisoning l310 l43332 a252832 frequently used conjunction sodium nitrite salt form nitrous acid sodium thiosulfate also used reduce risk ototoxicity associated cisplatin l43337 administered 6 hour cisplatin chemotherapy sodium thiosulfate lead lower incidence cisplatin-induced hearing loss among child without affecting effectiveness a252837 a252842 ,thiosulfuric acid sodium thiosulfate indicated sequential intravenous use sodium nitrite treatment acute cyanide poisoning judged life-threatening l43332 sodium thiosulfate also indicated reduce risk ototoxicity associated cisplatin pediatric patient 1 month age older localized non-metastatic solid tumor l43337 
Fludeoxyglucose (18F),fludeoxyglucose f 18 injection positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2- 18f fluoro-d-g1ucose used diagnostic purpose conjunction positron emission tomography pet administered intravenous injection , uptake 18f-fdg tissue marker tissue uptake glucose turn closely correlated certain type tissue metabolism fludeoxyglucose f 18 injection indicated positron emission tomography pet imaging assessment abnormal glucose metabolism assist evaluation malignancy patient known suspected abnormality found testing modality patient existing diagnosis cancer 
Urea C-13,urea 13c urea molecule radiolabelled non-radioactive element carbon-13 currently used urea breath test ubt available rapid diagnostic test marketed pranactin-citric detection helicobacter pylorus infection h pylorus common stomach bacteria linked variety upper gastrointestinal disorder gastritis gastric peptic ulcer stomach cancer gastric mucosa-associated lymphoid-tissue malt lymphoma ubt indicated confirm h. pylorus infection monitor post-treatment eradication radiolabelled urea available two form 13c 14c form used within urea breath test however may prefer 13c non-radioactive compared 14c may preferable pregnant woman child urea breath test based ability h. pylorus enzyme urease cleave urea ammonia carbon dioxide urease enzyme present mammalian cell presence urease product urea cleavage stomach evidence h. pylorus bacteria present detect h. pylorus urea labeled 13c swallowed patient gastric urease h. pylorus present urea split form co2 nh3 interface gastric epithelium lumen 13co2 absorbed blood exhaled breath exhaled breath sample collected measured presence radioactivity ,urea-13c indicated use qualitative detection urease associated helicobacter pylorus human stomach aid initial diagnosis post-treatment monitoring helicobacter pylorus infection adult patient test may used monitoring treatment used least four 4 week following completion therapy purpose system utilizes infrared spectrophotometer measurement ratio 13co2 12co2 breath sample 
Talc,talc mineral composed primarily magnesium silicon oxygen substance often found cosmetic personal hygiene product including baby powder adult body powder facial powder talc help absorb moisture freshen material reduce friction prevent rash although talc widely used decade lawsuit come surface claim serious health complication linked use fact recent study reported talc increase risk ovarian endometrial cancer approximately 30 percent ,indicated prevent recurrence malignant pleural effusion symptomatic patient thoracoscopy open thoracotomy 
Simethicone,simethicone silicon based surfactant decrease surface tension gastrointestinal gas bubble facilitate elimination a228308 favourable safety profile systemically absorbed a228308 simethicone use since 1940s a228303 granted fda approval 1952 a228308 ,simethicone indicated treatment bloating pressure cramp caused gas l31533 simethicone also used part bowel preparation colonoscopy a228343 
Urea C-14,urea 14c urea molecule radiolabelled radioactive carbon-14 currently used urea breath test ubt available rapid diagnostic test marketed pytest detection helicobacter pylorus infection h pylorus common stomach bacteria linked variety upper gastrointestinal disorder gastritis gastric peptic ulcer stomach cancer gastric mucosa-associated lymphoid-tissue malt lymphoma ubt indicated confirm h. pylorus infection monitor post-treatment eradication radiolabelled urea available two form 13c 14c form used within urea breath test however may prefer 13c non-radioactive compared 14c may preferable pregnant woman child urea breath test based ability h. pylorus enzyme urease cleave urea ammonia carbon dioxide urease enzyme present mammalian cell presence urease product urea cleavage stomach evidence h. pylorus bacteria present detect h. pylorus urea labeled 14c swallowed patient gastric urease h. pylorus present urea split form co2 nh3 interface gastric epithelium lumen 14co2 absorbed blood exhaled breath exhaled breath sample collected measured presence radioactivity ,14c-urea intended use detection gastric urease aid diagnosis helicobacter pylorus h. pylorus infection human stomach test utilizes liquid scintillation counter measurement 14co2 breath sample 
Mequinol,mequinol phenol used various application used inhibitor acrylic monomer acrylonitirles stabilizer chlorinated hydrocarbon ethyl cellulose ultraviolet inhibitor chemical intermediate manufacture antioxidant pharmaceutical plasticizer dyestuff l993 found active ingredient topical drug used skin depigmentation indicated treatment solar lentigo ,mequinol currently primarily available active ingredient combination product combined tretinoin indicated treatment solar lentigo related hyperpigmented lesion resulting chronic sun exposure fda label 
Sodium ferric gluconate complex,"sodium ferric gluconate complex iron replacement product treatment iron deficiency anemia stable macromolecular complex negatively charged alkaline ph apparent molecular weight 289,000 – 440,000 dalton gel chromatography composed iron iii oxide hydrate directly bonded sucrose chelating gluconate function molar ratio two iron molecule one gluconate used adult pediatric patient age 6 year chronic kidney disease ckd receiving hemodialysis receiving supplemental epoetin therapy ",sodium ferric gluconate complex sucrose injection used deplete total body content iron iron deficiency anemia patient aged 6 year older chronic kidney disease receiving hemodialysis receiving supplemental epoetin therapy l666 
Hydroquinone,hydroquinone topical lightening product found otc product used correct skin discoloration associated disorder hyperpigmentation including melasma post-inflammatory hyperpigmention sunspot freckle used alone frequently found combination agent alpha-hydroxy acid corticosteroid retinoids sunscreen hydroquinone come scrutiny due several complication associated use including dermal irritation exogenous onchronosis carginogenicity result concern hydroquinone banned eu uk ,hydroquinone used otc topical lightening agent disorder hyperpigmentation including melasma post-inflammatory hyperpigmention sunspot freckle 
Secretin porcine,secretin porcine stimulates pancreatic gastric secretion aid diagnosis pancreatic exocrine dysfunction diagnosis gastrinoma ,
Secretin human,human secretin gastrointestinal peptide hormone regulates secretion stomach pancreas liver hormone produced enterochromaffin cell duodenum response duodenal content ph le 4.5 l1875 main action secretin stimulate pancreas secrete pancreatic juice ph regulation small intestine secretin also responsible body fluid homeostasis a32276 bile production although gastrointestinal hormone secretin also considered neuropeptide hormone since also expressed central nervous system a32275 purified synthetic human secretin also referred rg1068 available intravenous injection market name chirhostim ® u.s .. contains amino acid sequence identical naturally occurring hormone consisting 27 amino acid fda label support α-helical formation a32275 carboxyl-terminal amino acid valine amidated synthetic human secretin display equivalent biological activity property naturally-occurring secretin a32265 indicated stimulation pancreatic gastric secretion aid diagnosis pancreatic exocrine dysfunction diagnosis gastrinoma facilitate identification ampulla vater accessory papilla endoscopic retrograde cholangiopancreatography ercp ,indicated stimulation pancreatic secretion including bicarbonate aid diagnosis pancreatic exocrine dysfunction fda label gastrin secretion aid diagnosis gastrinoma fda label pancreatic secretion facilitate identification ampulla vater accessory papilla endoscopic retrograde cholangiopancreatography ercp fda label 
Ecamsule,ecamsule organic compound added many sunscreen filter uva ray benzylidene camphor derivative many known excellent photostability ecamsule approved use u.s. since 2006 specific concentration product manufactured l'oreal company got approval product new drug application process ,applied topically filter uva ray 
Octocrylene,octocrylene compound often used additive sun screen thought skin moisturizing effect emollient property make chemical popular additive sun block ability neutralize uv radiation dissipated sunlight minimize skin damage prolonged sun exposure octocrylene also often combined avobenzone another common sunscreen ingredient often appearing ingredient label effectiveness chemical approved across globe use cosmetic skin care product concentration ingredient usually limited 10 12 percent however use chemical ’ stop sunscreen face arm extend variety product like hair spray tannin oil bb cream conditioner cc cream among others octocrylene may cause contact photocontact allergy , u octocrylene evaluated fda considered safe use 10 formula similarly eu allows use 10 formula health canada allows maximum use level 12 
Titanium dioxide,titanium dioxide also known titanium iv oxide titania naturally occurring oxide titanium used pigment name titanium white pigment white 6 pw6 ci 77891 typically extracted ilmenite rutile anatase ,titanium dioxide used sunscreen block uva uvb ray similar zinc oxide 
Iodine povacrylex,iodine povacrylex duraprep surgical solution film-forming iodophor complex provides fast acting persistent broad-spectrum antimicrobial activity duraprep solution indicated use patient preoperative skin preparation preparation skin prior surgery help reduce bacteria potentially cause skin infection broad spectrum antiseptic provide almost 99.9 antiseptic condition intended local use prolonged skin exposure could cause skin defatting manifested following signs/symptoms localized redness itching drying cracking skin ,antispetic germicidal agent indicated use patient preoperative skin preparation preparation skin prior surgery help reduce bacteria potentially cause skin infection 
Omega-3-acid ethyl esters,omega-3-acid ethyl ester prescription drug contain eicosapentaenoic acid-ethyl ester epa docosahexaenoic acid-ethyl ester dha used combination change diet lower triglyceride level adult severe ≥ 500 mg/dl hypertriglyceridemia fda label a176687 omega-3-acid ethyl ester currently marketed u eu many region brand name lovaza fda label l5849 ,omega-3-acid ethyl ester capsule usp indicated adjunct diet reduce triglyceride tg level adult patient severe ≥500 mg/dl hypertriglyceridemia htg fda label a176687 
Methyl salicylate,methyl salicylate oil wintergreen wintergreen oil organic ester naturally produced many specie plant particularly wintergreen compound first extracted isolated plant specie gaultheria procumbens 1843 manufactured synthetically used fragrance food beverage liniment form colorless yellow reddish liquid exhibit characteristic odor taste wintergreen acute joint muscular pain methyl salicylate used rubefacient analgesic deep heating liniment used flavoring agent chewing gum mint small concentration added antiseptic mouthwash solution ,ointment liniment containing methyl salicylate applied topically counter irritant relief acute pain associated lumbago sciatica rheumatic condition local analgesic human veterinary medicine 
Iobenguane sulfate I-123,iobenguane sulfate i-123 radiopharmaceutical used gamma-scintigraphy adrenergically inervated tissue fda label , use diagnostic imaging adrenergically inervated tissue purpose detecting metastatic pheochromocytoma neuroblastoma fda label also used ass sympathetic inervation myocardium via determination heart mediastinum ratio radioactivity patient new york heart association class ii iii heart failure 
Desoxyribonuclease,desoxyribonuclease crystalline enzyme aid digestion thymus nucleic acid mechanism action enzyme involves splitting thymus nucleic acid fragment approaching size tetranucleotides without release free phosphoric acid enzyme 's cofactor reported magnesium manganese ion although optimal concentration ion independent enzyme concentration a31251 ,
Thonzonium,thonzonium monocationic surface-active agent surfactant detergent property widely used additive ear nasal drop enhance dispersion penetration cellular debris exudate thereby promoting tissue contact administered medication common pharmaceutical formulation thonzonium bromide cortisporin-tc ear drop also reported thonzonium also confers antifungal property antiresorptive effect bone ,used monocationic surfactant detergent help penetration active ingredient cellular debris antibacterial action 
Dexchlorpheniramine maleate,dexchlorpheniramine s-enantiomer chlorpheniramine 1st generation anti-histamine dexchlorpheniramine pharmacological activity r potent racemic mixture ,dexchlorpheniramine used treatment perennial seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due inhalant allergen food mild uncomplicated allergic skin manifestation urticaria angioedema amelioration allergic reaction blood plasma dermographism 
Necitumumab,necitumumab intravenously administered recombinant monoclonal igg1 antibody used treatment non-small cell lung cancer nsclc egfr antagonist function binding epidermal growth factor receptor egfr prevents binding ligand process involved cell proliferation metastasis angiogenesis malignant progression binding necitumumab egfr induces receptor internalization degradation thereby preventing activation egfr beneficial nsclc many patient increased protein expression egfr necitumumab approved use combination cisplatin gemcitabine first-line treatment metastatic squamous non-small cell lung cancer nsclc ,necitumumab approved use combination cisplatin gemcitabine first-line treatment metastatic squamous non-small cell lung cancer nsclc indicated treatment non-squamous nsclc 
Sodium glycerophosphate,sodium glycerophosphate one several glycerophosphate salt used clinically treat prevent low phosphate level fda label glycerophosphate hydrolyzed inorganic phosphate glycerol body a32667 extent reaction dependent activity serum alkaline phosphatase ,sodium glycerophosphate indicated use source phosphate total parenteral nutrition fda label used combination amino acid dextrose lipid emulsion electrolyte 
Choline C-11,choline c 11 injection radioactive diagnostic agent positron emission tomography pet imaging pat ients suspected prostate cancer recurrence non-informative bone scintigraphy computerized tomography ct magnetic resonance imaging ,choline c 11 injection indicated positron emission tomography pet imaging patient suspected prostate cancer recurrence non-informative bone scintigraphy computerized tomography ct magnetic resonance imaging mri patient 11 c-choline pet imaging may help identify potential site prostate cancer recurrence subsequent histologic confirmation suspected prostate recurrence based upon elevated blood prostate specific antigen psa level following initial therapy clinical study imag e w ere produced pet/ct coregistration 
Insulin degludec,insulin degludec ultra-long-acting form insulin used treatment hyperglycemia caused type 1 type 2 diabetes a18561 a18562 a18563 a18564 a174934 insulin typically prescribed management diabetes mellitus mimic activity endogenously produced human insulin peptide hormone produced beta cell pancreas promotes glucose metabolism a18561 a18562 a18563 a18564 a174934 insulin released pancreas following meal promote uptake glucose blood internal organ tissue liver fat cell skeletal muscle a18561 a18562 a18563 a18564 a174934 absorption glucose cell allows transformation glycogen fat storage a18561 a18562 a18563 a18564 a174934 insulin also inhibits hepatic glucose production enhances protein synthesis inhibits lipolysis proteolysis among many function a18561 a18562 a18563 a18564 a174934 insulin essential treatment management type 1 diabetes t1d caused autoimmune reaction destroys beta cell pancreas resulting body able produce synthesize insulin needed manage circulating blood sugar level a18561 a18562 a18563 a18564 a174934 result people t1d rely primarily exogenous form insulin insulin degludec lower glucose level blood a18561 a18562 a18563 a18564 a174934 insulin also used treatment type 2 diabetes t2d another form diabetes mellitus slowly progressing metabolic disorder caused combination genetic lifestyle factor promote chronically elevated blood sugar level a18561 a18562 a18563 a18564 a174934 without treatment improvement non-pharmacological measure diet exercise lower blood glucose high blood sugar eventually cause cellular resistance endogenous insulin long term damage pancreatic islet cell a18561 a18562 a18563 a18564 a174934 insulin typically prescribed later course t2d several oral medication db00331 db01120 db01261 tried sufficient damage caused pancreatic cell body longer able produce insulin a18561 a18562 a18563 a18564 a174934 marketed brand name product tresiba insulin degludec duration action 42 hour allowing once-daily dosing typically bedtime a18561 a18562 a18563 a18564 a174934 due duration action tresiba considered `` basal insulin '' provides low concentration background insulin keep blood sugar stable meal overnight a18561 a18562 a18563 a18564 a174934 basal insulin often combined short-acting `` bolus insulin '' db00046 db01309 db01306 provide higher dos insulin required following meal use basal bolus insulin together intended mimic pancreas production endogenous insulin goal avoiding period hypoglycemia a18561 a18562 a18563 a18564 a174934 compared endogenous insulin insulin degludec added hexadecanedioic acid lysine b29 position allowing formation multi-hexamers a18561 a18562 a18563 a18564 a174934 injected subcutaneously multi-hexamers form drug depot store monomer slowly continuously absorbed circulation a18561 a18562 a18563 a18564 a174934 result insulin degludec protracted time action profile due delayed absorption subcutaneous tissue depot systemic circulation a18561 a18562 a18563 a18564 a174934 compared available long-acting analog db00047 db01307 duration action 20-24 hour insulin degludec provides consistent level basal insulin 42 hour low peak trough ratio a18561 a18562 a18563 a18564 a174934 limitation shorter-acting analog include frequent dosing le stable pharmacokinetics may negatively impact patient adherence glucose control particularly nocturnal control a18561 a18562 a18563 a18564 a174934 without adequate supply insulin promote absorption glucose bloodstream blood sugar level climb dangerously high level result symptom fatigue headache blurred vision increased thirst a18561 a18562 a18563 a18564 a174934 left untreated body start break fat instead glucose energy result build-up ketone acid blood syndrome called ketoacidosis life-threatening medical emergency long term elevated blood sugar level increase risk heart attack stroke diabetic neuropathy a18561 a18562 a18563 a18564 a174934 insulin degludec approved fda september 2015 product tresiba use providing glycemic control adult diabetes mellitus ,insulin degludec indicated improve glycemic control patient 1 year age older diabetes mellitus l42400 
Olive oil,oil extracted olive l857 consists primarily glyceride fatty acid linoleic oleic palmitic used source fatty acid total parenteral nutrition additive cosmetic product fda label , use adult source calorie fatty acid total parenteral nutrition fda label sometimes used additive cosmetic product 
Omega-3-carboxylic acids, omega-3 carboxylic acid om3-ca new formulation omega-3 fatty acid present enhanced bioavailability treatment dyslipidemia increased bioavailability explained om3-ca found form polyunsaturated free fatty acid opposed product whose form ethyl ester complex mixture free fatty acid form containing eicosapentaenoic acid docosahexaenoic acid abundant specie found proportion 55 20 respectively rest concentration represented docosapentaenoic acid trace component alpha-tocopherol gelatin glycerol sorbitol purified water a25808 developed astrazeneca pharmaceutical firstly approved fda may 05 2014 l2386 ,om3-ca indicated adjunct diet reduce triglyceride level adult patient severe hypertriglyceridemia 500 mg/dl patient involved treatment laced appropriate lipid-lowering diet l2387 hypertriglyceridemia defined elevated plasma triglyceride concentration usually correlated secondary condition poor diet alcohol use obesity metabolic syndrome type 2 diabetes a32630 
Ixazomib,ixazomib second generation proteasome inhibitor pi first oral pi approved fda november 2015 multiple myeloma treatment combination 2 therapy lenalidomide dexamethasone patient received least 1 prior therapy found similar efficacy bortezomib first pi approved multiple myeloma therapy control myeloma growth prevention bone loss ixazomib citrate marketed takeda pharmaceutical brand name ninlaro prodrug becomes quickly converted active metabolite ixazomib administration ,ixazomib indicated combination lenalidomide dexamethasone treatment patient multiple myeloma received least one prior therapy 
Levmetamfetamine,levomethamphetamine l-enantiomer methamphetamine sympathomimetic vasoconstrictor used over-the-counter otc nasal decongestant inhaler united state ,used over-the-counter nasal congestion 
Corynebacterium diphtheriae, corynebacterium diphtheriae toxin extracted pathogenic actinobacterium c. diphtheriae cause diphtheria bacteria culture grown medium purification diphtheria toxin detoxified formaldehyde diafiltered vaccine intramuscularly administered provide active immunization diphtheria infant child ,
"Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine",meningococcal group c w-135 oligosaccharide diphtheria crm197 conjugate vaccine used prevent invasive meningococcal disease caused bacteria _neisseria meningitidis_ entering bloodstream invading blood-brain barrier cause variety infection septicemia meningitis pneumonia a253277 several serogroups _n meningitidis_ b c w-135 known cause meningococcal infection identified a253277 meningococcal group c w-135 oligosaccharide diphtheria crm197 conjugate vaccine contains serogroup c w-135 oligosaccharide conjugated individually _corynebacterium diphtheriae_ crm197 protein carrier resulting four drug substance contained dose vaccine l43518 meningococcal group c w-135 oligosaccharide diphtheria crm197 conjugate vaccine marketed menveo first approved fda 2010 l43518 , vaccine indicated active immunization prevent invasive meningococcal disease caused _neisseria meningitidis_ serogroups c w-135 individual 2 month 55 year age meningococcal group c w-135 oligosaccharide diphtheria crm197 conjugate vaccine prevent _n meningitidis_ serogroup b infection l43518 
"Rabies virus inactivated antigen, B",inactivated rabies virus antigen b component rabies vaccine used pre- post-exposure prophylaxis rabies l12795 ,inactivated rabies virus antigen b indicated pre- post-exposure prophylaxis rabies l12795 
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen vaccine intramuscular injection used prevention invasive disease caused haemophilus influenzae type b h. influenzae gram-negative coccobacillus cause infection including sepsis meningitis vaccine contains haemophilus influenzae type b capsular polysaccharide polyribosyl-ribitol-phosphate prp high-molecular-weight polymer prepared h. influenzae type b strain 1482 grown semi-synthetic medium covalently bound tetanus toxoid l1007 toxoid antigen purified toxin-inactivated ,
Rotavirus vaccine,rotavirus commonly infects child infant causing severe diarrhea vomiting leading potentially fatal dehydration l1117 two rotavirus vaccine available prevention rotavirus gastroenteritis rotateq rotarix rotateq live vaccine consisting 5 reassorted human-bovine viral strain l1116 rotarix live attenuated vaccine containing 89-12 human strain label rotavirus vaccine 90 effective protecting severe rotavirus infection l1117 ,rotarix indicated prevention rotavirus gastroenteritis caused g1 g3 g4 g9 type infant aged 6-24 week fda label rotateq indicated prevention rotavirus gastroenteritis caused g1 g2 g3 g4 g9 type infant aged 6-32 week l1116 
"Rabies virus inactivated antigen, A",rabies virus inactivated antigen inactivated virus vacine intramuscular injection active immunization rabies administered pre- post-exposure rabies virus ,
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen,neisseria meningitidis serogroup b recombinant lp2086 a05 protein variant antigen sterile vaccine intramuscular injection indicated active immunization prevent invasive disease caused neisseria meningitidis serogroup b contained suspension trumenba vaccine composed two recombinant lipidated factor h binding protein fhbp variant n. meningitidis serogroup b one fhbp subfamily one subfamily b a05 b01 respectively ,
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen,neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen sterile vaccine intramuscular injection indicated active immunization prevent invasive disease caused neisseria meningitidis serogroup b contained suspension trumenba vaccine composed two recombinant lipidated factor h binding protein fhbp variant n. meningitidis serogroup b one fhbp subfamily one subfamily b a05 b01 respectively ,
Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 4 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 4 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 6b capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 6b individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 9v capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 9v individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 14 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 14 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 18c capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 18c individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 19f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 19f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 23f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 23f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 1 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 3 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 5 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 5 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 6a individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 7f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 7f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 19a capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 19a individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Human papillomavirus type 6 L1 capsid protein antigen,human papillomavirus type 6 l1 capsid protein antigen contained gardasil recombinant human papillomavirus quadrivalent type 6 11 16 18 vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 6 11 16 18 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 6 11 16 18 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 11 L1 capsid protein antigen,human papillomavirus type 11 l1 capsid protein antigen contained gardasil recombinant human papillomavirus quadrivalent type 6 11 16 18 vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 6 11 16 18 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 6 11 16 18 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 16 L1 capsid protein antigen,human papillomavirus type 16 l1 capsid protein antigen contained gardasil recombinant human papillomavirus quadrivalent type 6 11 16 18 vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 6 11 16 18 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 6 11 16 18 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 18 L1 capsid protein antigen,human papillomavirus type 18 l1 capsid protein antigen contained gardasil recombinant human papillomavirus quadrivalent type 6 11 16 18 vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 6 11 16 18 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 6 11 16 18 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 31 L1 capsid protein antigen,human papillomavirus type 31 l1 capsid protein antigen contained gardasil vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 31 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 31 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 33 L1 capsid protein antigen,human papillomavirus type 33 l1 capsid protein antigen contained gardasil vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 33 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 33 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 45 L1 capsid protein antigen,human papillomavirus type 45 l1 capsid protein antigen contained gardasil vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 45 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 45 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 52 L1 capsid protein antigen,human papillomavirus type 52l1 capsid protein antigen contained gardasil vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 52 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 52 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Human papillomavirus type 58 L1 capsid protein antigen,human papillomavirus type 58 l1 capsid protein antigen contained gardasil vaccine intramuscular injection immunization young men woman 9-26 year age prevention disease caused human papillomavirus hpv type 58 vaccine prepared purified virus-like particle vlps major capsid l1 protein hpv type 58 produced separate fermentation recombinant saccharomyces cerevisiae self-assembled vlps ,
Measles virus vaccine live attenuated,measles virus vaccine live attenuated live virus vaccine simultaneous vaccination measles common childhood disease vaccine prepared attenuated line measles virus derived enders attenuated edmonston strain propagated chick embryo cell culture ,measles virus vaccine used prevent measles combination virus vaccine rubella mumps virus vaccine l31298 l41970 
Mumps virus strain B level jeryl lynn live antigen,mumps virus strain b level jeryl lynn live antigen live attenuated virus vaccine subcutenous injection active immunization mumps common childhood disease ,mumps virus vaccine used prevent mumps combination virus vaccine rubella measles virus vaccine l31298 l41970 
Rubella virus vaccine,rubella virus vaccine live attenuated virus vaccine active immunization rubella german measles subcutaneously administered prepared ra 27/3 strain live attenuated rubella virus rubella common childhood disease caused rubella virus togavirus ,rubella virus vaccine used prevent rubella combination virus vaccine mumps measles virus vaccine l15696 l31298 l41970 
Varicella zoster vaccine (live/attenuated),live attenuated zoster vaccine available two product zostavax prevention shingle immunocompetent people age 50 varivax prevention chickenpox individual 12 month age older two vaccine contain immunological component provide protection virus zostavax contains higher dose used older adult prevent development shingle post-herpetic neuralgia first approved may 2006 food drug administration zostavax first vaccine available prevention shingle since october 2017 however replaced first line therapy shingrix db13924 effective longer lasting vaccine l1038 varivax zostavax composed lyophilized preparation live attenuated oka/merck strain varicella-zoster virus varicella zoster virus vzv virus commonly cause chickenpox also known varicella childhood l1040 following initial infection vzv resolution chickenpox child vzv lie dormant within dorsal root ganglion central nervous sytem decade later body 's immune system weakens age vzv able reactivate descend nerve cell surface skin cause painful blistering rash known shingle herpes zoster risk factor developing shingle include old age rate increasing substantially person 's age 50 low immune function immunosuppression psychological stress diabetes person 's living hiv cancer taking immunosuppressant transplant recipient particularly risk l1037 one common complication associated shingle development post-herpetic neuralgia phn persistant severe nerve pain develops result chronic pain shingle lesion phn last day month even year following resolution shingle complication also include bacterial infection spread shingle rash eye herpes zoster ophthalmicus ear nerve palsy spread vzv non-immune person via contact varicella lesion numerous advantage using shingrix zostavax clinical trial shingrix shown greater 90 efficacy adult aged 50 older 89 efficacy preventing postherpetic neuralgia patient 70 year older 91 efficacy patient 50-70 year age significant improvement predecessor zostavax reduces risk shingle 51 risk post-herpetic neuralgia 67 a31349 efficacy zostavax also wane time protection shingle phn lasting around 5 year efficacy prevention shingle highest patient 60-69 year old decrease increasing age furthermore shingrix inactivated vaccine also used prevent shingle phn individual suppressed immune system already increased risk developing shingle zostavax live attenuated vaccine contraindicated ,zostavax vaccine indicated prevention herpes zoster shingle immunocompetent adult aged 50 year older varivax vaccine indicated active immunization prevention varicella individual 12 month age older 
Streptococcus pneumoniae type 1 capsular polysaccharide antigen,streptococcus pneumoniae type 1 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 1 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 2 capsular polysaccharide antigen,streptococcus pneumoniae type 2 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 2 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 3 capsular polysaccharide antigen,streptococcus pneumoniae type 3 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 3 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 4 capsular polysaccharide antigen,streptococcus pneumoniae type 4 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 4 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 5 capsular polysaccharide antigen,streptococcus pneumoniae type 5 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 5 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 6b capsular polysaccharide antigen,streptococcus pneumoniae type 6b capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 6b streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 7f capsular polysaccharide antigen,streptococcus pneumoniae type 7f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 7f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 8 capsular polysaccharide antigen,streptococcus pneumoniae type 8 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 8 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 9n capsular polysaccharide antigen,streptococcus pneumoniae type 9n capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 9n streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 9v capsular polysaccharide antigen,streptococcus pneumoniae type 9v capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 9v streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 10a capsular polysaccharide antigen,streptococcus pneumoniae type 10a capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 10a streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 11a capsular polysaccharide antigen,streptococcus pneumoniae type 11a capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 11a streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 12f capsular polysaccharide antigen,streptococcus pneumoniae type 12f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 12f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 14 capsular polysaccharide antigen,streptococcus pneumoniae type 14 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 14 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 15b capsular polysaccharide antigen,streptococcus pneumoniae type 15b capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 15b streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 17f capsular polysaccharide antigen,streptococcus pneumoniae type 17f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 17f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 18c capsular polysaccharide antigen,streptococcus pneumoniae type 18c capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 18c streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 19f capsular polysaccharide antigen,streptococcus pneumoniae type 19f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 19f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 19a capsular polysaccharide antigen,streptococcus pneumoniae type 19a capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 19a streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 20 capsular polysaccharide antigen,streptococcus pneumoniae type 20 capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 20 streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 22f capsular polysaccharide antigen,streptococcus pneumoniae type 22f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 22f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 23f capsular polysaccharide antigen,streptococcus pneumoniae type 23f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 23f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Streptococcus pneumoniae type 33f capsular polysaccharide antigen,streptococcus pneumoniae type 33f capsular polysaccharide antigen vaccine contains highly purified capsular polysaccharide invasive pneumococcal type 33f streptococcus pneumoniae active immunization intramuscular subcutaneous injection pneumococcal disease pneumococcal pneumonia pneumococcal bacteremia ,
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen vaccine containing outer membrane antigen extracted haemophilus influenzae ,
Bacillus calmette-guerin substrain tice live antigen,bacillus calmette-guerin substrain tice live antigen vaccine containing attenuated live culture preparation bacillus calmette guerin bcg strain mycobacterium bovis percutaneous use administered prevent development tuberculosis ,
Ginger,ginger allergenic extract used allergenic testing ,
House dust,house dust allergenic extract used allergenic testing ,
Acacia longifolia pollen,acacia longifolia pollen pollen acacia longifolia plant acacia longifolia pollen mainly used allergenic testing ,
Fraxinus americana pollen,fraxinus americana pollen pollen fraxinus americana plant fraxinus americana pollen mainly used allergenic testing ,
Paspalum notatum pollen,paspalum notatum pollen pollen paspalum notatum plant paspalum notatum pollen mainly used allergenic testing ,
Fagus grandifolia pollen,fagus grandifolia pollen pollen fagus grandifolia plant fagus grandifolia pollen mainly used allergenic testing ,
Cynodon dactylon pollen,cynodon dactylon pollen also known bermuda grass pollen standardized grass pollen extract used diagnosis treatment allergic disease grass pollen cutaneously intradermally subcutaneously administered initiate immune response case allergic reaction diagnostic allergenic extract primarily indicated establishing clinical relevance specific allergen patient exposed degree sensitivity patient toward allergen ,
Betula lenta pollen,betula lenta pollen pollen betula lenta plant betula lenta pollen mainly used allergenic testing ,
Poa annua pollen,poa annua pollen pollen poa annua plant poa annua pollen mainly used allergenic testing ,
Acer negundo pollen,acer negundo pollen pollen acer negundo plant acer negundo pollen mainly used allergenic testing ,
Bromus inermis pollen,bromus inermis pollen pollen bromus inermis plant bromus inermis pollen mainly used allergenic testing ,
Xanthium strumarium pollen,xanthium strumarium pollen pollen xanthium strumarium plant xanthium strumarium pollen mainly used allergenic testing ,
Zea mays pollen,zea may pollen pollen zea may plant zea may pollen mainly used allergenic testing ,
Rumex acetosella pollen,rumex acetosella pollen pollen rumex acetosella plant rumex acetosella pollen mainly used allergenic testing ,
Rumex crispus pollen,rumex crispus pollen pollen rumex crispus plant rumex crispus pollen mainly used allergenic testing ,
Ulmus americana pollen,ulmus americana pollen pollen ulmus americana plant ulmus americana pollen mainly used allergenic testing ,
Ulmus pumila pollen,ulmus pumila pollen pollen ulmus pumila plant ulmus pumila pollen mainly used allergenic testing ,
Corylus americana pollen,corylus americana pollen pollen corylus americana plant corylus americana pollen mainly used allergenic testing ,
Carya ovata pollen,carya ovata pollen pollen carya ovata plant carya ovata pollen mainly used allergenic testing ,
Sorghum halepense pollen,sorghum halepense pollen pollen sorghum halepense plant sorghum halepense pollen mainly used allergenic testing ,
Poa pratensis pollen,poa pratensis pollen pollen poa pratensis plant poa pratensis pollen mainly used allergenic testing ,poa pratensis pollen allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Chenopodium album pollen,chenopodium album pollen pollen chenopodium album plant chenopodium album pollen mainly used allergenic testing ,
Acer saccharum pollen,acer saccharum pollen pollen acer saccharum plant acer saccharum pollen mainly used allergenic testing ,
Festuca pratensis pollen,festuca pratensis pollen pollen festuca pratensis plant festuca pratensis pollen mainly used allergenic testing ,
Prosopis juliflora pollen,prosopis juliflora pollen pollen prosopis juliflora plant prosopis juliflora pollen mainly used allergenic testing ,
Artemisia vulgaris pollen,artemisia vulgaris pollen pollen artemisia vulgaris plant artemisia vulgaris pollen mainly used allergenic testing ,
Morus rubra pollen,morus rubra pollen pollen morus rubra plant morus rubra pollen mainly used allergenic testing ,
Quercus agrifolia pollen,quercus agrifolia pollen pollen quercus agrifolia plant quercus agrifolia pollen mainly used allergenic testing ,
Quercus virginiana pollen,quercus virginiana pollen pollen quercus virginiana plant quercus virginiana pollen mainly used allergenic testing ,
Quercus alba pollen,quercus alba pollen oak white pollen non-standardized allergen extract used diagnosis treatment allergic disease grass pollen subcutaneously administered initiate immune response case allergic reaction diagnostic allergenic extract primarily indicated establishing clinical relevance specific allergen patient exposed degree sensitivity patient toward allergen ,
Avena sativa pollen,avena sativa pollen pollen avena sativa plant avena sativa pollen mainly used allergenic testing ,
Olea europaea pollen,olea europaea pollen pollen olea europaea plant olea europaea pollen mainly used allergenic testing ,
Dactylis glomerata pollen,dactylis glomerata pollen pollen dactylis glomerata plant dactylis glomerata pollen mainly used allergenic testing ,dactylis glomerata pollen allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Carya illinoinensis pollen,carya illinoinensis pollen allergenic extract used allergenic testing ,
Amaranthus retroflexus pollen,amaranthus retroflexus pollen pollen amaranthus retroflexus plant amaranthus retroflexus pollen mainly used allergenic testing ,
Plantago lanceolata pollen,plantago lanceolata pollen pollen plantago lanceolata plant plantago lanceolata pollen mainly used allergenic testing ,
Populus alba pollen,populus alba pollen pollen populus alba plant populus alba pollen mainly used allergenic testing ,
Ambrosia acanthicarpa pollen,ambrosia acanthicarpa pollen pollen ambrosia acanthicarpa plant ambrosia acanthicarpa pollen mainly used allergenic testing ,
Ambrosia artemisiifolia pollen,ambrosia artemisiifolia pollen pollen ambrosia artemisiifolia plant ambrosia artemisiifolia pollen mainly used allergenic testing ,ambrosia artemisiifolia pollen allergen extract indicated immunotherapy treatment short ragweed pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen-specific ige antibody short ragweed pollen approved use person five 65 year age allergen extract indicated immediate relief allergic symptom l41205 
Ambrosia trifida pollen,ambrosia trifida pollen pollen ambrosia trifida plant ambrosia trifida pollen mainly used allergenic testing ,
Ambrosia psilostachya pollen,ambrosia psilostachya pollen pollen ambrosia psilostachya plant ambrosia psilostachya pollen mainly used allergenic testing ,
Salsola kali pollen,salsola kali pollen pollen salsola kali plant salsola kali pollen mainly used allergenic testing ,
Lolium perenne pollen,lolium perenne pollen pollen lolium perenne plant lolium perenne pollen mainly used allergenic testing ,lolium perenne pollen allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Artemisia tridentata pollen,artemisia tridentata pollen pollen artemisia tridentata plant artemisia tridentata pollen mainly used allergenic testing ,
Atriplex wrightii pollen,atriplex wrightii pollen pollen atriplex wrightii plant atriplex wrightii pollen mainly used allergenic testing ,
Platanus occidentalis pollen,platanus occidentalis pollen pollen platanus occidentalis plant platanus occidentalis pollen mainly used allergenic testing ,
Platanus racemosa pollen,platanus racemosa pollen pollen platanus racemosa plant platanus racemosa pollen mainly used allergenic testing ,
Phleum pratense pollen,phleum pratense pollen allergenic extract used allergenic testing ,phleum pratense pollen allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Holcus lanatus pollen,holcus lanatus pollen pollen holcus lanatus plant holcus lanatus pollen mainly used allergenic testing ,
Juglans nigra pollen,juglans nigra pollen pollen juglans nigra plant juglans nigra pollen mainly used allergenic testing ,
Juglans californica pollen,juglans californica pollen pollen juglans californica plant juglans californica pollen mainly used allergenic testing ,
Salix nigra pollen,salix nigra pollen pollen salix nigra plant salix nigra pollen mainly used allergenic testing ,
Felis catus skin,felis catus skin pelt used allergenic testing ,
Dermatophagoides farinae,dermatophagoides farinae extract sterile solution used intradermal testing subcutaneous immunotherapy combination approved year-round once-a-day tablet 's dissolved tongue treatment dust mite allergy ,dermatophagoides farinae indicated immunotherapy house dust mite hdm -induced allergic rhinitis without conjunctivitis confirmed vitro testing ige antibody dermatophagoides farinae dermatophagoides pteronyssinus house dust mite skin testing licensed house dust mite allergen extract approved use adult 18 65 year age l41050 
Dermatophagoides pteronyssinus,dermatophagoides pteronyssinus extract sterile solution used intradermal testing subcutaneous immunotherapy combination approved year-round once-a-day tablet 's dissolved tongue treatment dust mite allergy ,dermatophagoides pteronyssinus indicated immunotherapy house dust mite hdm -induced allergic rhinitis without conjunctivitis confirmed vitro testing ige antibody dermatophagoides farinae dermatophagoides pteronyssinus house dust mite skin testing licensed house dust mite allergen extract approved use adult 18 65 year age l41050 
Agrostis gigantea pollen,agrostis gigantea pollen pollen agrostis gigantea plant agrostis gigantea pollen mainly used allergenic testing ,
Anthoxanthum odoratum pollen,anthoxanthum odoratum pollen pollen anthoxanthum odoratum plant anthoxanthum odoratum pollen mainly used allergenic testing ,anthoxanthum odoratum pollen allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Bos taurus skin,bos taurus skin pelt used allergenic testing ,
Cotton seed,cotton seed allergenic extract used allergenic testing ,
Canis lupus familiaris skin,canis lupus familiaris skin allergenic extract used allergenic testing ,
Equus caballus skin,equus caballus skin allergenic extract used allergenic testing ,
Ceiba pentandra fiber,ceiba pentandra fiber used allergenic testing ,
Mus musculus skin,mu musculus skin pelt used allergenic testing ,
Orris,orris allergenic extract used allergenic testing ,
Rabbit,rabbit allergenic extract used allergenic testing ,
Cavia porcellus skin,cavia porcellus skin pelt used allergenic testing ,
Periplaneta americana,american cockroach allergenic extract used allergenic testing ,
Blatella germanica,german cockroach allergenic extract used allergenic testing ,
Solenopsis invicta,solenopsis invicta allergenic extract used allergenic testing ,
Gallus gallus feather,gallus gallus feather used allergenic testing ,
Anas platyrhynchos feather,ana platyrhynchos feather used allergenic testing ,
Anser anser feather,anser anser feather used allergenic testing ,
Acremonium strictum,acremonium strictum fungus provoke allergic reaction acremonium strictum extract used allergenic testing ,
Alternaria alternata,alternaria alternata fungus provoke allergic reaction alternaria alternata extract used allergenic testing ,
Aspergillus fumigatus,aspergillus fumigatus fungus provoke allergic reaction aspergillus fumigatus extract used allergenic testing ,
Aspergillus niger var. niger,aspergillus niger var niger fungus provoke allergic reaction aspergillus niger var niger extract used allergenic testing ,
Aureobasidium pullulans var. pullutans,aureobasidium pullulans var pullutans fungus provoke allergic reaction aureobasidium pullulans var pullutans extract used allergenic testing ,
Botrytis cinerea,botrytis cinerea fungus provoke allergic reaction botrytis cinerea extract used allergenic testing ,
Candida albicans,candida albicans fungus provoke allergic reaction candida albicans used allergenic testing ,
Chaetomium globosum,chaetomium globosum fungus provoke allergic reaction chaetomium globosum extract used allergenic testing ,
Cladosporium cladosporioides,cladosporium cladosporioides fungus provoke allergic reaction cladosporium cladosporioides extract used allergenic testing ,
Cladosporium sphaerospermum,cladosporium sphaerospermum fungus provoke allergic reaction cladosporium sphaerospermum extract used allergenic testing ,
Cochliobolus sativus,cochliobolus sativus fungus provoke allergic reaction cochliobolus sativus extract used allergenic testing ,
Epicoccum nigrum,epicoccum nigrum fungus provoke allergic reaction epicoccum nigrum extract used allergenic testing ,
Fusarium oxysporum vasinfectum,fusarium oxysporum vasinfectum fungus provoke allergic reaction fusarium oxysporum vasinfectum extract used allergenic testing ,
Helminthosporium solani,helminthosporium solani fungus provoke allergic reaction helminthosporium solani extract used allergenic testing ,
Mucor plumbeus,mucor plumbeus fungus provoke allergic reaction mucor plumbeus extract used allergenic testing ,
Neurospora intermedia,neurospora intermedia fungus provoke allergic reaction neurospora intermedia extract used allergenic testing ,
Penicillium chrysogenum var. chrysogenum,penicillium chrysogenum var chrysogenum fungus provoke allergic reaction penicillium chrysogenum var chrysogenum extract used allergenic testing ,
Phoma exigua var. exigua,phoma exigua var exigua fungus provoke allergic reaction phoma exigua var exigua extract used allergenic testing ,
Rhizopus arrhizus var. arrhizus,rhizopus arrhizus var arrhizus fungus provoke allergic reaction rhizopus arrhizus var arrhizus extract used allergenic testing ,
Rhodotorula rubra,rhodotorula rubra fungus provoke allergic reaction rhodotorula rubra used allergenic testing ,
Ustilago maydis,ustilago maydis fungus provoke allergic reaction ustilago maydis extract used allergenic testing ,
Ustilago tritici,ustilago tritici fungus provoke allergic reaction ustilago tritici extract used allergenic testing ,
Stemphylium solani,stemphylium solani fungus provoke allergic reaction stemphylium solani extract used allergenic testing ,
Trichophyton mentagrophytes,trichophyton mentagrophytes fungus provoke allergic reaction trichophyton mentagrophytes extract used allergenic testing ,
Saccharomyces cerevisiae,saccharomyces cerevisiae fungus provoke allergic reaction saccharomyces cerevisiae used allergenic testing ,
Aspergillus oryzae,aspergillus oryzae allergenic extract used allergenic testing ,
Aspergillus repens,aspergillus repens fungus provoke allergic reaction aspergillus repens extract used allergenic testing ,
Aspergillus terreus,aspergillus terreus fungus provoke allergic reaction aspergillus terreus extract used allergenic testing ,
Acacia,acacia allergenic extract used allergenic testing ,
Ailanthus altissima pollen,ailanthus altissima pollen pollen ailanthus altissima plant ailanthus altissima pollen mainly used allergenic testing ,
Alnus incana subsp. rugosa pollen,alnus incana subsp rugosa pollen pollen alnus incana subsp rugosa plant alnus incana subsp rugosa pollen mainly used allergenic testing ,
Medicago sativa pollen,medicago sativa pollen pollen medicago sativa plant medicago sativa pollen mainly used allergenic testing ,
Fraxinus velutina pollen,fraxinus velutina pollen pollen fraxinus velutina plant fraxinus velutina pollen mainly used allergenic testing ,
Populus tremuloides pollen,populus tremuloides pollen pollen populus tremuloides plant populus tremuloides pollen mainly used allergenic testing ,
Morella cerifera pollen,morella cerifera pollen pollen morella cerifera plant morella cerifera pollen mainly used allergenic testing ,
Betula nigra pollen,betula nigra pollen pollen betula nigra plant betula nigra pollen mainly used allergenic testing ,
Amaranthus palmeri pollen,amaranthus palmeri pollen pollen amaranthus palmeri plant amaranthus palmeri pollen mainly used allergenic testing ,
Juniperus ashei pollen,juniperus ashei pollen pollen juniperus ashei plant juniperus ashei pollen mainly used allergenic testing ,
Juniperus virginiana pollen,juniperus virginiana pollen pollen juniperus virginiana plant juniperus virginiana pollen mainly used allergenic testing ,
Xanthium strumarium var. canadense pollen,xanthium strumarium var canadense pollen pollen xanthium strumarium var canadense plant xanthium strumarium var canadense pollen mainly used allergenic testing ,
Populus deltoides pollen,populus deltoides pollen pollen populus deltoides plant populus deltoides pollen mainly used allergenic testing ,
Populus fremontii pollen,populus fremontii pollen pollen populus fremontii plant populus fremontii pollen mainly used allergenic testing ,
Populus deltoides subsp. monilifera pollen,populus deltoides subsp monilifera pollen pollen populus deltoides subsp monilifera plant populus deltoides subsp monilifera pollen mainly used allergenic testing ,
Cupressus arizonica pollen,cupressus arizonica pollen pollen cupressus arizonica plant cupressus arizonica pollen mainly used allergenic testing ,
Taxodium distichum pollen,taxodium distichum pollen pollen taxodium distichum plant taxodium distichum pollen mainly used allergenic testing ,
Eupatorium capillifolium pollen,eupatorium capillifolium pollen pollen eupatorium capillifolium plant eupatorium capillifolium pollen mainly used allergenic testing ,
Ulmus crassifolia pollen,ulmus crassifolia pollen pollen ulmus crassifolia plant ulmus crassifolia pollen mainly used allergenic testing ,
Eucalyptus globulus pollen,eucalyptus globulus pollen pollen eucalyptus globulus plant eucalyptus globulus pollen mainly used allergenic testing ,
Solidago canadensis pollen,solidago canadensis pollen pollen solidago canadensis plant solidago canadensis pollen mainly used allergenic testing ,
Celtis occidentalis pollen,celtis occidentalis pollen pollen celtis occidentalis plant celtis occidentalis pollen mainly used allergenic testing ,
Juniperus californica pollen,juniperus californica pollen pollen juniperus californica plant juniperus californica pollen mainly used allergenic testing ,
Robinia pseudoacacia pollen,robinia pseudoacacia pollen pollen robinia pseudoacacia plant robinia pseudoacacia pollen mainly used allergenic testing ,
Acer rubrum pollen,acer rubrum pollen pollen acer rubrum plant acer rubrum pollen mainly used allergenic testing ,
Melaleuca quinquenervia pollen,melaleuca quinquenervia pollen pollen melaleuca quinquenervia plant melaleuca quinquenervia pollen mainly used allergenic testing ,
Chenopodium ambrosioides pollen,chenopodium ambrosioides pollen pollen chenopodium ambrosioides plant chenopodium ambrosioides pollen mainly used allergenic testing ,
Morus alba pollen,morus alba pollen pollen morus alba plant morus alba pollen mainly used allergenic testing ,
Quercus rubra pollen,quercus rubra pollen pollen quercus rubra plant quercus rubra pollen mainly used allergenic testing ,
Syagrus romanzoffiana pollen,syagrus romanzoffiana pollen pollen syagrus romanzoffiana plant syagrus romanzoffiana pollen mainly used allergenic testing ,
Schinus molle pollen,schinus molle pollen pollen schinus molle plant schinus molle pollen mainly used allergenic testing ,
Amaranthus spinosus pollen,amaranthus spinosus pollen pollen amaranthus spinosus plant amaranthus spinosus pollen mainly used allergenic testing ,
Casuarina equisetifolia pollen,casuarina equisetifolia pollen pollen casuarina equisetifolia plant casuarina equisetifolia pollen mainly used allergenic testing ,
Pinus strobus pollen,pinus strobus pollen pollen pinus strobus plant pinus strobus pollen mainly used allergenic testing ,
Pinus echinata pollen,pinus echinata pollen pollen pinus echinata plant pinus echinata pollen mainly used allergenic testing ,
Ligustrum vulgare pollen,ligustrum vulgare pollen pollen ligustrum vulgare plant ligustrum vulgare pollen mainly used allergenic testing ,
Elymus repens pollen,elymus repens pollen pollen elymus repens plant elymus repens pollen mainly used allergenic testing ,
Ambrosia tenuifolia pollen,ambrosia tenuifolia pollen pollen ambrosia tenuifolia plant ambrosia tenuifolia pollen mainly used allergenic testing ,
Ambrosia bidentata pollen,ambrosia bidentata pollen pollen ambrosia bidentata plant ambrosia bidentata pollen mainly used allergenic testing ,
Artemisia frigida pollen,artemisia frigida pollen pollen artemisia frigida plant artemisia frigida pollen mainly used allergenic testing ,
Distichlis spicata pollen,distichlis spicata pollen pollen distichlis spicata plant distichlis spicata pollen mainly used allergenic testing ,
Liquidambar styraciflua pollen,liquidambar styraciflua pollen pollen liquidambar styraciflua plant liquidambar styraciflua pollen mainly used allergenic testing ,
Juglans regia pollen,juglans regia pollen pollen juglans regia plant juglans regia pollen mainly used allergenic testing ,
Amaranthus tuberculatus pollen,amaranthus tuberculatus pollen allergenic extract used allergenic testing ,
Triticum aestivum pollen,triticum aestivum pollen pollen triticum aestivum plant triticum aestivum pollen mainly used allergenic testing ,
Felis catus hair,domestic cat hair used allergenic testing ,
Almond,almond allergenic extract used allergenic testing ,
Apple,apple allergenic extract used allergenic testing ,
Apricot,apricot allergenic extract used allergenic testing ,
Asparagus,asparagus allergenic extract used allergenic testing ,
Avocado,avocado allergenic extract used allergenic testing ,
Banana,banana allergenic extract used allergenic testing ,
Barley,barley allergenic extract used allergenic testing ,
String bean,string bean allergenic extract used allergenic testing ,
Beef,beef allergenic extract used allergenic testing ,
Brazil nut,brazil nut allergenic extract used allergenic testing ,
Broccoli,broccoli allergenic extract used allergenic testing ,
Buckwheat,buckwheat allergenic extract used allergenic testing ,
Cabbage,cabbage allergenic extract used allergenic testing ,
Cantaloupe,cantaloupe allergenic extract used allergenic testing ,
Carrot,carrot allergenic extract used allergenic testing ,
Casein,casein allergenic extract used allergenic testing ,
Celery,celery allergenic extract used allergenic testing ,
Cherry,cherry allergenic extract used allergenic testing ,
Chicken,chicken allergenic extract used allergenic testing ,
Cinnamon,cinnamon allergenic extract used allergenic testing ,
Coconut,coconut allergenic extract used allergenic testing ,
Coffee bean,coffee bean allergenic extract used allergenic testing ,
Red king crab,crab allergenic extract used allergenic testing ,
Cucumber,cucumber allergenic extract used allergenic testing ,
Egg white,egg white allergenic extract used allergenic testing ,
Egg,egg allergenic extract used allergenic testing ,
Egg yolk,egg yolk allergenic extract used allergenic testing ,
Flounder,flounder allergenic extract used allergenic testing ,
Garlic,garlic allergenic extract used allergenic testing ,
Grape,grape allergenic extract used allergenic testing ,
Grapefruit,grapefruit allergenic extract used allergenic testing ,
Karaya gum,karaya gum allergenic extract used allergenic testing ,
Honeydew melon,honeydew melon allergenic extract used allergenic testing ,
Lamb,lamb allergenic extract used allergenic testing ,
Lemon,lemon allergenic extract used allergenic testing ,
Lettuce,lettuce allergenic extract used allergenic testing ,
Lima bean,lima bean allergenic extract used allergenic testing ,
Lobster,lobster allergenic extract used allergenic testing ,
Goat milk,goat milk allergenic extract used allergenic testing ,
Cow milk,cow milk allergenic extract used allergenic testing ,
Cultivated mushroom,cultivated mushroom allergenic extract used allergenic testing ,
Mustard seed,mustard seed allergenic extract used allergenic testing ,
Oat,oat allergenic extract used allergenic testing ,
Black olive,black olive allergenic extract used allergenic testing ,
Onion,onion allergenic extract used allergenic testing ,
Orange,orange allergenic extract used allergenic testing ,
Oyster,oyster allergenic extract used allergenic testing ,
Pea,pea allergenic extract used allergenic testing ,
Peach,peach allergenic extract used allergenic testing , treatment pneumococcal pneumonia due susceptible strain group beta-hemolytic streptococcal infection upper respiratory tract 
Peanut,peanut allergenic extract used allergenic testing ,
Pear,pear allergenic extract used allergenic testing ,
Pecan,pecan allergenic extract used allergenic testing ,
Green bell pepper,green bell pepper allergenic extract used allergenic testing ,
Black pepper,black pepper allergenic extract used allergenic testing ,
Pineapple,pineapple allergenic extract used allergenic testing ,
Pistachio,pistachio allergenic extract used allergenic testing ,
Plum,plum allergenic extract used allergenic testing ,
Pork,pork allergenic extract used allergenic testing ,
Potato,potato allergenic extract used allergenic testing ,
Rice,rice allergenic extract used allergenic testing ,
Rye,rye allergenic extract used allergenic testing ,
Sesame seed,sesame seed allergenic extract used allergenic testing ,
Shrimp,shrimp allergenic extract used allergenic testing ,
Soybean,soybean allergenic extract used allergenic testing ,
Spinach,spinach allergenic extract used allergenic testing ,
Squash,squash allergenic extract used allergenic testing ,
Strawberry,strawberry allergenic extract used allergenic testing ,
Corn,corn allergenic extract used allergenic testing ,
Tomato,tomato allergenic extract used allergenic testing ,
Tuna,tuna allergenic extract used allergenic testing ,
Turkey,turkey allergenic extract used allergenic testing ,
Vanilla,vanilla allergenic extract used allergenic testing ,
English walnut,english walnut allergenic extract used allergenic testing ,
Watermelon,watermelon allergenic extract used allergenic testing ,
Wheat,wheat allergenic extract used allergenic testing ,
Tea leaf,tea leaf allergenic extract used allergenic testing ,
Khuskia oryzae,khuskia oryzae fungus provoke allergic reaction khuskia oryzae extract used allergenic testing ,
Artemisia annua pollen,artemisia annua pollen pollen artemisia annua plant artemisia annua pollen mainly used allergenic testing ,
Clostridium tetani toxoid antigen (formaldehyde inactivated),clostridium tetani toxoid antigen formaldehyde inactivated vaccine intramuscular injection used active immunization child 7 year age older adult prevention tetanus toxoid clostridium tetani culture grown detoxified followed purification via ammonium sulfate filtration precipation ,
"Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Meriones unguiculatus skin,meriones unguiculatus skin pelt used allergenic testing ,
Capra hircus skin,capra hircus skin pelt used allergenic testing ,
Mesocricetus auratus skin,mesocricetus auratus skin pelt used allergenic testing ,
Sus scrofa skin,sus scrofa skin pelt used allergenic testing ,
Oryctolagus cuniculus skin,oryctolagus cuniculus skin pelt used allergenic testing ,
Rattus norvegicus skin,rattus norvegicus skin pelt used allergenic testing ,
Bombyx mori fiber,bombyx mori fiber used allergenic testing ,
Duck,duck allergenic extract used allergenic testing ,
Allergenic extract- beef liver,beef liver allergenic extract used allergenic testing ,
Veal,veal allergenic extract used allergenic testing ,
Bluefish,bluefish allergenic extract used allergenic testing ,
Common carp,common carp allergenic extract used allergenic testing ,
Haddock,haddock allergenic extract used allergenic testing ,
Pacific halibut,pacific halibut allergenic extract used allergenic testing ,
Herring,herring allergenic extract used allergenic testing ,
Mackerel,mackerel allergenic extract used allergenic testing ,
Northern pike,northern pike allergenic extract used allergenic testing ,
Red snapper,red snapper allergenic extract used allergenic testing ,
Atlantic salmon,atlantic salmon allergenic extract used allergenic testing ,
European pilchard,european pilchard allergenic extract used allergenic testing ,
Scallop,scallop allergenic extract used allergenic testing ,
Smelt,smelt allergenic extract used allergenic testing ,
Swordfish,swordfish allergenic extract used allergenic testing ,
Trout,trout allergenic extract used allergenic testing ,
White fish,white fish allergenic extract used allergenic testing ,
Blackberry,blackberry allergenic extract used allergenic testing ,
Blueberry,blueberry allergenic extract used allergenic testing ,
Sour cherry,sour cherry allergenic extract used allergenic testing ,
Cranberry,cranberry allergenic extract used allergenic testing ,
Date,date allergenic extract used allergenic testing ,
Fig,fig allergenic extract used allergenic testing ,
Wine grape,wine grape allergenic extract used allergenic testing ,
Lime (citrus),lime citrus allergenic extract used allergenic testing ,
Raspberry,raspberry allergenic extract used allergenic testing ,
Tangerine,tangerine allergenic extract used allergenic testing ,
Artichoke,artichoke allergenic extract used allergenic testing ,
Kidney bean,kidney bean allergenic extract used allergenic testing ,
Beet,beet allergenic extract used allergenic testing ,
Kiwi fruit,kiwi fruit allergenic extract used allergenic testing ,
Brussels sprout,brussels sprout allergenic extract used allergenic testing ,
Cauliflower,cauliflower allergenic extract used allergenic testing ,
Eggplant,eggplant allergenic extract used allergenic testing ,
Lentil,lentil allergenic extract used allergenic testing ,
Green olive,green olive allergenic extract used allergenic testing ,
Parsley,parsley allergenic extract used allergenic testing ,
Sweet potato,sweet potato allergenic extract used allergenic testing ,
Raphanus sativus,radish allergenic extract used allergenic testing ,
Rhubarb,rhubarb allergenic extract used allergenic testing ,
Turnip,turnip allergenic extract used allergenic testing ,
Cashew,cashew allergenic extract used allergenic testing ,
Hazelnut,hazelnut allergenic extract used allergenic testing ,
Macadamia nut,macadamia nut allergenic extract used allergenic testing ,
Nectarine,nectarine allergenic extract used allergenic testing ,
Mango,mango allergenic extract used allergenic testing ,
Papaya,papaya allergenic extract used allergenic testing ,
Leek,leek allergenic extract used allergenic testing ,
Okra,okra allergenic extract used allergenic testing ,
Parsnip,parsnip allergenic extract used allergenic testing ,
Chickpea,chickpea allergenic extract used allergenic testing ,
Black-eyed pea,black-eyed pea allergenic extract used allergenic testing ,
Watercress,watercress allergenic extract used allergenic testing ,
Arabica coffee bean,arabica coffee bean allergenic extract used allergenic testing ,
Tragacanth,tragacanth allergenic extract used allergenic testing ,
Allspice,allspice allergenic extract used allergenic testing ,
Laurus nobilis,laurus nobilis allergenic extract used allergenic testing ,
Caraway seed,caraway seed allergenic extract used allergenic testing ,
Clove,clove allergenic extract used allergenic testing ,
Dill,dill allergenic extract used allergenic testing ,
Horseradish,horseradish allergenic extract used allergenic testing ,
Licorice,licorice allergenic extract used allergenic testing ,
Nutmeg,nutmeg allergenic extract used allergenic testing ,
Oregano,oregano allergenic extract used allergenic testing ,
Paprika,paprika allergenic extract used allergenic testing ,
White pepper,white pepper allergenic extract used allergenic testing ,
Poppy seed,poppy seed allergenic extract used allergenic testing ,
Spearmint,spearmint allergenic extract used allergenic testing ,
Wheat bran,wheat bran allergenic extract used allergenic testing ,
American chestnut,american chestnut allergenic extract used allergenic testing ,
Hops,hop allergenic extract used allergenic testing ,
Musca domestica,housefly allergenic extract used allergenic testing ,
Ctenocephalides canis,dog flea allergenic extract used allergenic testing ,
Aedes taeniorhynchus,aedes taeniorhynchus allergenic extract used allergenic testing ,
Ctenocephalides felis,cat flea allergenic extract used allergenic testing ,
Aspergillus flavus,aspergillus flavus fungus provoke allergic reaction aspergillus flavus extract used allergenic testing ,
Eurotium herbariorum,eurotium herbariorum fungus provoke allergic reaction eurotium herbariorum extract used allergenic testing ,
Trichothecium roseum,trichothecium roseum fungus provoke allergic reaction trichothecium roseum extract used allergenic testing ,
Curvularia inaequalis,curvularia inaequalis fungus provoke allergic reaction curvularia inaequalis extract used allergenic testing ,
Fusarium compactum,fusarium compactum fungus provoke allergic reaction fusarium compactum extract used allergenic testing ,
Geotrichum candidum,geotrichum candidum fungus provoke allergic reaction geotrichum candidum extract used allergenic testing ,
Phoma glomerata,phoma glomerata fungus provoke allergic reaction phoma glomerata extract used allergenic testing ,
Rhodotorula mucilaginosa,rhodotorula mucilaginosa fungus provoke allergic reaction rhodotorula mucilaginosa used allergenic testing ,
Stemphylium sarciniforme,stemphylium sarciniforme fungus provoke allergic reaction stemphylium sarciniforme extract used allergenic testing ,
Trichoderma harzianum,trichoderma harzianum fungus provoke allergic reaction trichoderma harzianum extract used allergenic testing ,
Ustilago avenae,ustilago avenae fungus provoke allergic reaction ustilago avenae extract used allergenic testing ,
Tilletia caries,tilletia caries allergenic extract used allergenic testing ,
Puccinia graminis,puccinia graminis fungus provoke allergic reaction puccinia graminis extract used allergenic testing ,
Cotton,cotton allergenic extract used allergenic testing ,
Flax seed,flax seed allergenic extract used allergenic testing ,
Tobacco leaf,tobacco leaf allergenic extract used allergenic testing ,
Corcorus capsularis fiber,corcorus capsularis fiber used allergenic testing ,
Agave sisalana fiber,agave sisalana fiber used allergenic testing ,
Poa compressa pollen,poa compressa pollen pollen poa compressa plant poa compressa pollen mainly used allergenic testing ,
Phalaris arundinacea pollen,phalaris arundinacea pollen pollen phalaris arundinacea plant phalaris arundinacea pollen mainly used allergenic testing ,
Bouteloua gracilis pollen,bouteloua gracilis pollen pollen bouteloua gracilis plant bouteloua gracilis pollen mainly used allergenic testing ,
Urochloa mutica pollen,urochloa mutica pollen pollen urochloa mutica plant urochloa mutica pollen mainly used allergenic testing ,
Secale cereale pollen,secale cereale pollen pollen secale cereale plant secale cereale pollen mainly used allergenic testing ,
Leymus condensatus pollen,leymus condensatus pollen pollen leymus condensatus plant leymus condensatus pollen mainly used allergenic testing ,
Pascopyrum smithii pollen,pascopyrum smithii pollen pollen pascopyrum smithii plant pascopyrum smithii pollen mainly used allergenic testing ,
Acacia baileyana pollen,acacia baileyana pollen pollen acacia baileyana plant acacia baileyana pollen mainly used allergenic testing ,
Alnus rubra pollen,alnus rubra pollen pollen alnus rubra plant alnus rubra pollen mainly used allergenic testing ,
Alnus rhombifolia pollen,alnus rhombifolia pollen pollen alnus rhombifolia plant alnus rhombifolia pollen mainly used allergenic testing ,
Fraxinus latifolia pollen,fraxinus latifolia pollen pollen fraxinus latifolia plant fraxinus latifolia pollen mainly used allergenic testing ,
Betula populifolia pollen,betula populifolia pollen pollen betula populifolia plant betula populifolia pollen mainly used allergenic testing ,
Tamarix gallica pollen,tamarix gallica pollen pollen tamarix gallica plant tamarix gallica pollen mainly used allergenic testing ,
Juniperus monosperma pollen,juniperus monosperma pollen pollen juniperus monosperma plant juniperus monosperma pollen mainly used allergenic testing ,
Juniperus pinchotii pollen,juniperus pinchotii pollen pollen juniperus pinchotii plant juniperus pinchotii pollen mainly used allergenic testing ,
Juniperus scopulorum pollen,juniperus scopulorum pollen pollen juniperus scopulorum plant juniperus scopulorum pollen mainly used allergenic testing ,
Juniperus osteosperma pollen,juniperus osteosperma pollen pollen juniperus osteosperma plant juniperus osteosperma pollen mainly used allergenic testing ,
Juniperus occidentalis pollen,juniperus occidentalis pollen pollen juniperus occidentalis plant juniperus occidentalis pollen mainly used allergenic testing ,
Tilia americana pollen,tilia americana pollen pollen tilia americana plant tilia americana pollen mainly used allergenic testing ,
Mangifera indica pollen,mangifera indica pollen pollen mangifera indica plant mangifera indica pollen mainly used allergenic testing ,
Acer macrophyllum pollen,acer macrophyllum pollen pollen acer macrophyllum plant acer macrophyllum pollen mainly used allergenic testing ,
Acer saccharinum pollen,acer saccharinum pollen pollen acer saccharinum plant acer saccharinum pollen mainly used allergenic testing ,
Broussonetia papyrifera pollen,broussonetia papyrifera pollen pollen broussonetia papyrifera plant broussonetia papyrifera pollen mainly used allergenic testing ,
Quercus velutina pollen,quercus velutina pollen pollen quercus velutina plant quercus velutina pollen mainly used allergenic testing ,
Quercus macrocarpa pollen,quercus macrocarpa pollen pollen quercus macrocarpa plant quercus macrocarpa pollen mainly used allergenic testing ,
Quercus kelloggii pollen,quercus kelloggii pollen pollen quercus kelloggii plant quercus kelloggii pollen mainly used allergenic testing ,
Quercus gambelii pollen,quercus gambelii pollen pollen quercus gambelii plant quercus gambelii pollen mainly used allergenic testing ,
Quercus lobata pollen,quercus lobata pollen pollen quercus lobata plant quercus lobata pollen mainly used allergenic testing ,
Quercus nigra pollen,quercus nigra pollen pollen quercus nigra plant quercus nigra pollen mainly used allergenic testing ,
Citrus sinensis pollen,citrus sinensis pollen pollen citrus sinensis plant citrus sinensis pollen mainly used allergenic testing ,
Pinus taeda pollen,pinus taeda pollen pollen pinus taeda plant pinus taeda pollen mainly used allergenic testing ,
Pinus palustris pollen,pinus palustris pollen pollen pinus palustris plant pinus palustris pollen mainly used allergenic testing ,
Pinus ponderosa pollen,pinus ponderosa pollen pollen pinus ponderosa plant pinus ponderosa pollen mainly used allergenic testing ,
Pinus elliottii pollen,pinus elliottii pollen pollen pinus elliottii plant pinus elliottii pollen mainly used allergenic testing ,
Pinus virginiana pollen,pinus virginiana pollen pollen pinus virginiana plant pinus virginiana pollen mainly used allergenic testing ,
Pinus monticola pollen,pinus monticola pollen pollen pinus monticola plant pinus monticola pollen mainly used allergenic testing ,
Populus nigra pollen,populus nigra pollen pollen populus nigra plant populus nigra pollen mainly used allergenic testing ,
Elaeagnus angustifolia pollen,elaeagnus angustifolia pollen pollen elaeagnus angustifolia plant elaeagnus angustifolia pollen mainly used allergenic testing ,
Salix lasiolepis pollen,salix lasiolepis pollen pollen salix lasiolepis plant salix lasiolepis pollen mainly used allergenic testing ,
Salix discolor pollen,salix discolor pollen pollen salix discolor plant salix discolor pollen mainly used allergenic testing ,
Populus balsamifera subsp. trichocarpa pollen,populus balsamifera subsp trichocarpa pollen pollen populus balsamifera subsp trichocarpa plant populus balsamifera subsp trichocarpa pollen mainly used allergenic testing ,
Taraxacum officinale pollen,taraxacum officinale pollen pollen taraxacum officinale plant taraxacum officinale pollen mainly used allergenic testing ,
Atriplex polycarpa pollen,atriplex polycarpa pollen pollen atriplex polycarpa plant atriplex polycarpa pollen mainly used allergenic testing ,
Baccharis halimifolia pollen,baccharis halimifolia pollen pollen baccharis halimifolia plant baccharis halimifolia pollen mainly used allergenic testing ,
Hymenoclea salsola pollen,hymenoclea salsola pollen pollen hymenoclea salsola plant hymenoclea salsola pollen mainly used allergenic testing ,
Allenrolfea occidentalis pollen,allenrolfea occidentalis pollen pollen allenrolfea occidentalis plant allenrolfea occidentalis pollen mainly used allergenic testing ,
Atriplex lentiformis pollen,atriplex lentiformis pollen pollen atriplex lentiformis plant atriplex lentiformis pollen mainly used allergenic testing ,
Artemisia douglasiana pollen,artemisia douglasiana pollen pollen artemisia douglasiana plant artemisia douglasiana pollen mainly used allergenic testing ,
Artemisia ludoviciana pollen,artemisia ludoviciana pollen pollen artemisia ludoviciana plant artemisia ludoviciana pollen mainly used allergenic testing ,
Urtica dioica pollen,urtica dioica pollen pollen urtica dioica plant urtica dioica pollen mainly used allergenic testing ,
Iva axillaris pollen,iva axillaris pollen pollen iva axillaris plant iva axillaris pollen mainly used allergenic testing ,
Ambrosia deltoidea pollen,ambrosia deltoidea pollen pollen ambrosia deltoidea plant ambrosia deltoidea pollen mainly used allergenic testing ,
Sarcobatus vermiculatus pollen,sarcobatus vermiculatus pollen pollen sarcobatus vermiculatus plant sarcobatus vermiculatus pollen mainly used allergenic testing ,
Atriplex canescens pollen,atriplex canescens pollen pollen atriplex canescens plant atriplex canescens pollen mainly used allergenic testing ,
Artemisia absinthium pollen,artemisia absinthium pollen pollen artemisia absinthium plant artemisia absinthium pollen mainly used allergenic testing ,
Foreskin fibroblast (neonatal),foreskin fibroblast-like stromal cell fdscs progenitor isolated human tissue differentiate various cell type a32660 also known dermagraft device cryopreserved human fibroblast-derived dermal substitute composed fibroblast extracellular matrix bioabsorbable scaffold effectively support wound healing l2418 dermagraft available united state investigational device ide dermagraft treatment diabetic foot ulcer approved sale canada 1997 dermagraft introduced united kingdom october 1997 several european country well new zealand australia device available commercial distribution australia canada finland france hong kong ireland netherlands new zealand singapore united kingdom l2418 impact diabetic foot ulcer dfu individual society devastating failure observe proper wound care condition often result amputation wound closure achieved likely delay need surgical intervention provide benefit improvement productivity mental outlook social interaction time work addition decreased mortality l2438 interestingly shown human foreskin cell posse immunosuppressive property mediated process reported bone marrow/stromal stem cell a32655 dermagraft combined db10772 create drug beneficial patient open burn wound l2427 , device indicated use treatment full-thickness diabetic foot ulcer greater six week duration extends dermis without tendon muscle joint capsule bone exposure drug used conjunction standard wound care regimen patient adequate blood supply involved foot l2418 
Bovine type I collagen,bovine collagen alpha-1 naturally occurring extracellular matrix protein found tendon connective tissue play vital role cell growth differentiation attachment migration l2481 often combined ingredient fibroblast keratinocytes allows accelerated effective wound healing l2427 l2450 excellagen topical gel bovine type collagen used management wound including partial full- thickness wound pressure ulcer venous ulcer diabetic ulcer chronic vascular ulcer tunneled/undermined wound surgical wound donor sites/graft post-moh ’ surgery post-laser surgery podiatric wound dehiscence trauma wound abrasion laceration second-degree burn skin tear draining wound l2500 bovine type collagen also used health supplement bone joint a32698 interestingly bovine type collagen studied possible endovascular stent material demonstrated promising result rabbit a32696 , management wound including partial full- thickness wound pressure ulcer venous ulcer diabetic ulcer chronic vascular ulcer tunneled/undermined wound surgical wound donor sites/graft post-moh ’ dermatological surgery post-laser surgery podiatric wound dehiscence trauma wound abrasion laceration second-degree burn skin tear draining wound l2500 gintuit allogeneic cultured keratinocytes fibroblast bovine collagen allogeneic cellularized scaffold product indicated topical non-submerged application surgically created vascular wound bed treatment mucogingival condition adult us bovine collagen matrix support growth keratinocytes fibroblast wound healing l2450 product using bovine type 1 collagen include primatrix integra orcel matriderm l2490 orcel bilayered cellular matrix normal human allogeneic skin cell epidermal keratinocytes dermal fibroblast cultured two separate layer type bovine collagen sponge indicated venous leg ulcer diabetic foot type bovine collagen act matrix growth proliferation fibroblast keratinocytes offering structure support l2427 laboratory bovine collagen type purified protein standard used control sds-page western blot elisa immunoprecipitation immunological assay l2488 
Foreskin keratinocyte (neonatal),skin largest organ human body play main role protecting body mechanical damage composed epidermal dermal hypodermal layer barrier function skin owed avascular epidermal layer made mainly keratinocytes keratinocytes form stratified epithelium growing basal cell innermost layer keratinized mostly impermeable outer stratum corneum layer surface l2452 foreskin keratinocytes form skin cell cultured skin cell replacement wound accelerate wound closure healing l2434 l2460 defining moment skin culture 1975 rheinwald green successfully grew human keratinocytes lethally irradiated murine fibroblast 1981 ’ conner group utilized cultured autologous epithelium coat burn defect first time construct `` living '' alternative dermal substitute based collagen gel created mesenchymal cell fibroblast epidermal layer added approach became known `` skin equivalent '' `` composite culture '' `` organotypical culture '' l2453 foreskin keratinocytes important ingredient several skin substitute l2460 used various indication keratinocytes derived neonatal foreskin used create drug called _apligraf_ mixture db10770 keratinocytes gel made bovine collagen used matrix cell growth differentiation apligraf useful treatment venous leg ulcer diabetic foot ulcer increasing rate wound healing decreasing time required closure wound l2452 orcel another skin substitute similar apligraf since contains fibroblast keratinocytes derived neonatal foreskin addition utilizes type collagen sponge matrix used grafting onto partial-thickness wound offer favorable matrix host cell migration l2452 , chronic leg ulcer diabetic foot l2439 orcel indicated use standard therapeutic compression treatment non-infected partial full-thickness skin ulcer due venous insufficiency greater 1 month duration effectively responded conventional ulcer therapy orcel also use standard diabetic foot ulcer care treatment full-thickness neuropathic diabetic foot ulcer greater 3 week duration effectively responded conventional ulcer therapy extend dermis without tendon muscle capsule bone involvement l2459 
Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated),bordetella pertussis filamentous hemagglutinin antigen formaldehyde inactivated vaccine contains inactivated acellular pertussis antigen isolated bordetella pertussis culture ,
Bordetella pertussis pertactin antigen,bordetella pertussis pertactin antigen vaccine prophylaxis whooping cough contains pertactin membrane-associated antigen bordetella pertussis a31248 ,
Bordetella pertussis fimbriae 2/3 antigen,bordetella pertussis fimbria 2/3 antigen vaccine prophylaxis disease caused bordetella pertussis gram-negative coccobacillus express two serologically distinct fimbria fim2 fim3 ,
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Poliovirus type 1 antigen (formaldehyde inactivated),poliovirus type 1 antigen suspension poliovirus type 1 mahoney used active immunization infant young 6 week age child adult prevention poliomyelitis caused poliovirus type 1 vaccine contains purified inactivated poliovirus type 1 grown continuous line monkey kidney cell ,
Poliovirus type 2 antigen (formaldehyde inactivated),poliovirus type 2 antigen suspension poliovirus type 2 mef-1 used active immunization infant young 6 week age child adult prevention poliomyelitis caused poliovirus type 2 vaccine contains purified inactivated poliovirus type 2 grown continuous line monkey kidney cell ,
Poliovirus type 3 antigen (formaldehyde inactivated),poliovirus type 3 antigen suspension poliovirus type 3 saukett used active immunization infant young 6 week age child adult prevention poliomyelitis caused poliovirus type 3 vaccine contains purified inactivated poliovirus type 3 grown continuous line monkey kidney cell ,
Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen,neisseria meningitidis group capsular polysaccharide diphtheria toxoid conjugate antigen active intramuscular immunization prophylaxis invasive meningococcal disease caused neisseria meningitidis serogroup vaccine contains n. meningitis serogroup capsular polysaccharide antigen purified individually conjugated diphtheria toxoid protein extracted corynebacterium diphtheriae grown another culture ,
Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen,neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen active intramuscular immunization prophylaxis invasive meningococcal disease caused neisseria meningitidis serogroup c. vaccine contains n. meningitis serogroup c capsular polysaccharide antigen purified individually conjugated diphtheria toxoid protein extracted corynebacterium diphtheriae grown another culture ,
Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen,neisseria meningitidis group capsular polysaccharide diphtheria toxoid conjugate antigen active intramuscular immunization prophylaxis invasive meningococcal disease caused neisseria meningitidis serogroup w-135 vaccine contains n. meningitis serogroup capsular polysaccharide antigen purified individually conjugated diphtheria toxoid protein extracted corynebacterium diphtheriae grown another culture ,
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen,neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen active intramuscular immunization prophylaxis invasive meningococcal disease caused neisseria meningitidis serogroup w-135 vaccine contains n. meningitis serogroup w-135 capsular polysaccharide antigen purified individually conjugated diphtheria toxoid protein extracted corynebacterium diphtheriae grown another culture ,
Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Typhoid Vi polysaccharide vaccine,typhoid vi polysaccharide vaccine vaccine administered intramuscularly active immunization prevention typhoid fever caused typhi approved use person two year age older vaccine contains purified cell surface vi polysaccharide extracted salmonella enterica serovar typhi typhi ty2 strain bacterial culture inactivated medium capsular polysaccharide precipated solution ,
Bacillus calmette-guerin substrain connaught live antigen,bacillus calmette-guerin substrain connaught live antigen intravesically administered treatment prophylaxis carcinoma situ ci urinary bladder prophylaxis primary recurrent stage ta and/or t1 papillary tumor following transurethral resection tur solution contains live attenuated strain mycobacterium bovis prepared connaught strain bacillus calmette guérin ,indicated intravesical use treatment prophylaxis carcinoma situ ci urinary bladder prophylaxis primary recurrent stage ta and/or t1 papillary tumor following transurethral resection tur 
Yellow fever vaccine,yellow fever vaccine prevents yellow fever viral hemorrhagic disease caused transmission _flavivirus_ bite infected mosquito symptom yellow fever range asymptomatic mild flu-like illness severe symptom shock jaundice internal bleeding organ failure l1655 interestingly yellow fever got name characteristic yellowing skin eye occurs development jaundice virus attack liver although supportive treatment available managing yellow fever currently antiviral developed specifically treat yellow fever vaccination yellow fever vaccine therefore considered important effective measure protect yellow fever protective immunity developing within 10 day vaccination two separate clinical trial yellow fever vaccine 90 subject seroconverted within 10 day vaccination 100 subject seroconverted within 14 day fda label world health organization longer recommends use 10-year booster dose following primary immunization single dose `` sufficient confer life-long immunity yellow fever disease '' l1654 yellow fever commonly found southern hemisphere tropical region africa central/south america l1653 world health organization recommends routine vaccination country yellow fever endemic traveller going endemic area proof vaccination often requirement border crossing prevent international spread disease l1653 l1657 yellow fever vaccine subcutaneously administered vaccination active immunization prophylaxis yellow fever pediatric patient 9 month age older composed two live attenuated strain yellow fever virus 17d-204 17dd shown elicit immune response identical induced wild-type infection fda label a32118 fda recommends vaccination yellow fever vaccine person living travelling endemic area laboratory personnel handle virulent yellow fever virus concentrated preparation yellow fever vaccine virus ,yellow fever vaccine indicated active immunization prevention yellow fever person 9 month age older following category 1 person living traveling endemic area actual risk contracting yellow fever travel probably low variability itinerary behavior seasonal incidence disease make difficult predict actual risk given individual living traveling known endemic epidemic area greater risk associated living traveling area south america africa yellow fever infection officially reported time travel traveling outside urban area country officially report disease lie yellow fever endemic zone 2 person travelling internationally country yellow fever country require individual valid international certificate vaccination prophylaxis icvp individual country either known thought harbor yellow fever virus certificate becomes valid 10 day vaccination yellow fever vaccine 3 laboratory personnel laboratory personnel handle virulent yellow fever virus concentrated preparation yellow fever vaccine virus strain may risk exposure direct indirect contact aerosol 
Fusarium oxysporum,fusarium oxysporum allergenic extract used allergenic testing ,
Candida tropicalis,candida tropicalis fungus provoke allergic reaction candida tropicalis used allergenic testing ,
Mucor racemosus,mucor racemosus fungus provoke allergic reaction mucor racemosus extract used allergenic testing ,
Penicillium camemberti,penicillium camemberti fungus provoke allergic reaction penicillium camemberti extract used allergenic testing ,
Penicillium expansum,penicillium expansum fungus provoke allergic reaction penicillium expansum extract used allergenic testing ,
Penicillium italicum,penicillium italicum fungus provoke allergic reaction penicillium italicum extract used allergenic testing ,
Penicillium roqueforti,penicillium roqueforti fungus provoke allergic reaction penicillium roqueforti extract used allergenic testing ,
Phoma destructiva,phoma destructiva fungus provoke allergic reaction phoma destructiva extract used allergenic testing ,
Rhizopus stolonifer,rhizopus stolonifer fungus provoke allergic reaction rhizopus stolonifer extract used allergenic testing ,
Fraxinus pennsylvanica pollen,fraxinus pennsylvanica pollen pollen fraxinus pennsylvanica plant fraxinus pennsylvanica pollen mainly used allergenic testing ,
Atriplex confertifolia pollen,atriplex confertifolia pollen pollen atriplex confertifolia plant atriplex confertifolia pollen mainly used allergenic testing ,
Passalora fulva,passalora fulva fungus provoke allergic reaction passalora fulva extract used allergenic testing ,
Cochliobolus spicifer,cochliobolus spicifer fungus provoke allergic reaction cochliobolus spicifer extract used allergenic testing ,
Myrothecium verrucaria,myrothecium verrucaria fungus provoke allergic reaction myrothecium verrucaria extract used allergenic testing ,
Hypomyces perniciosus,hypomyces perniciosus fungus provoke allergic reaction hypomyces perniciosus extract used allergenic testing ,
Neurospora crassa,neurospora crassa fungus provoke allergic reaction neurospora crassa extract used allergenic testing ,
Paecilomyces variotii,paecilomyces variotii fungus provoke allergic reaction paecilomyces variotii extract used allergenic testing ,
Microascus brevicaulis,microascus brevicaulis fungus provoke allergic reaction microascus brevicaulis extract used allergenic testing ,
Colletotrichum coccodes,colletotrichum coccodes fungus provoke allergic reaction colletotrichum coccodes extract used allergenic testing ,
Pleospora herbarum,pleospora herbarum fungus provoke allergic reaction pleospora herbarum extract used allergenic testing ,
Streptomyces griseus,streptomyces griseus allergenic extract used allergenic testing ,
Trichoderma viride,trichoderma viride fungus provoke allergic reaction trichoderma viride extract used allergenic testing ,
Trichophyton schoenleinii,trichophyton schoenleinii fungus provoke allergic reaction trichophyton schoenleinii extract used allergenic testing ,
Basil,basil allergenic extract used allergenic testing ,
Mung bean,mung bean allergenic extract used allergenic testing ,
Betula papyrifera pollen,betula papyrifera pollen pollen betula papyrifera plant betula papyrifera pollen mainly used allergenic testing ,
Betula occidentalis pollen,betula occidentalis pollen pollen betula occidentalis plant betula occidentalis pollen mainly used allergenic testing ,
Betula alleghaniensis pollen,betula alleghaniensis pollen pollen betula alleghaniensis plant betula alleghaniensis pollen mainly used allergenic testing ,
Ustilago cynodontis,ustilago cynodontis fungus provoke allergic reaction ustilago cynodontis extract used allergenic testing ,
Ustilago nuda hordei,ustilago nuda hordei fungus provoke allergic reaction ustilago nuda hordei extract used allergenic testing ,
Bromus secalinus pollen,bromus secalinus pollen pollen bromus secalinus plant bromus secalinus pollen mainly used allergenic testing ,
Beta vulgaris pollen,beta vulgaris pollen pollen beta vulgaris plant beta vulgaris pollen mainly used allergenic testing ,
Chenopodium botrys pollen,chenopodium botrys pollen pollen chenopodium botrys plant chenopodium botrys pollen mainly used allergenic testing ,
Mycocladus corymbiferus,mycocladus corymbiferus fungus provoke allergic reaction mycocladus corymbiferus extract used allergenic testing ,
Acrothecium robustum,acrothecium robustum fungus provoke allergic reaction acrothecium robustum extract used allergenic testing ,
Humicola grisea,humicola grisea allergenic extract used allergenic testing ,
Microsporum audouinii,microsporum audouinii fungus provoke allergic reaction microsporum audouinii extract used allergenic testing ,
Microsporum canis,microsporum canis fungus provoke allergic reaction microsporum canis extract used allergenic testing ,
Apiospora montagnei,apiospora montagnei fungus provoke allergic reaction apiospora montagnei extract used allergenic testing ,
Phycomyces blakesleeanus,phycomyces blakesleeanus fungus provoke allergic reaction phycomyces blakesleeanus extract used allergenic testing ,
Sporotrichum pruinosum,sporotrichum pruinosum fungus provoke allergic reaction sporotrichum pruinosum extract used allergenic testing ,
Stachybotrys chartarum,stachybotrys chartarum fungus provoke allergic reaction stachybotrys chartarum extract used allergenic testing ,
Syncephalastrum racemosum,syncephalastrum racemosum fungus provoke allergic reaction syncephalastrum racemosum extract used allergenic testing ,
Tetracoccosporium paxianum,tetracoccosporium paxianum fungus provoke allergic reaction tetracoccosporium paxianum extract used allergenic testing ,
Verticillium albo-atrum,verticillium albo-atrum fungus provoke allergic reaction verticillium albo-atrum extract used allergenic testing ,
White catfish,white catfish allergenic extract used allergenic testing ,
Carob,carob allergenic extract used allergenic testing ,
Sweet cherry,sweet cherry allergenic extract used allergenic testing ,
Opilio crab,opilio crab allergenic extract used allergenic testing ,
Bos taurus hair,bos taurus hair used allergenic testing ,
Serinus canaria feather,canary feather used allergenic testing ,
Melilotus albus pollen,melilotus albus pollen pollen melilotus albus plant melilotus albus pollen mainly used allergenic testing ,
Melilotus officinalis pollen,melilotus officinalis pollen pollen melilotus officinalis plant melilotus officinalis pollen mainly used allergenic testing ,
Typha latifolia pollen,typha latifolia pollen pollen typha latifolia plant typha latifolia pollen mainly used allergenic testing ,
Atlantic cod,atlantic cod allergenic extract used allergenic testing ,
Red currant,red currant allergenic extract used allergenic testing ,
Cumin,cumin allergenic extract used allergenic testing ,
Cladosporium herbarum,cladosporium herbarum fungus provoke allergic reaction cladosporium herbarum extract used allergenic testing ,
Acheta domesticus,house cricket allergenic extract used allergenic testing ,
Canis lupus familiaris hair,domestic dog hair used allergenic testing ,
Odocoileus virginianus hair,white-tailed deer hair used allergenic testing ,
Grain mill dust,grain mill dust allergenic extract used allergenic testing ,
Epidermophyton floccosum,epidermophyton floccosum fungus provoke allergic reaction epidermophyton floccosum extract used allergenic testing ,
Ambrosia dumosa pollen,ambrosia dumosa pollen pollen ambrosia dumosa plant ambrosia dumosa pollen mainly used allergenic testing ,
Ambrosia confertiflora pollen,ambrosia confertiflora pollen pollen ambrosia confertiflora plant ambrosia confertiflora pollen mainly used allergenic testing ,
Sporisorium cruentum,sporisorium cruentum fungus provoke allergic reaction sporisorium cruentum extract used allergenic testing ,
Goose,goose allergenic extract used allergenic testing ,
Concord grape,concord grape allergenic extract used allergenic testing ,
Capra hircus hair,domestic goat hair used allergenic testing ,
Cavia porcellus hair,guinea pig hair used allergenic testing ,
Arrhenatherum elatius pollen,arrhenatherum elatius pollen pollen arrhenatherum elatius plant arrhenatherum elatius pollen mainly used allergenic testing ,
Equus caballus hair,horse hair used allergenic testing ,
Sus scrofa hair,wild boar hair used allergenic testing ,
Carya cordiformis pollen,carya cordiformis pollen pollen carya cordiformis plant carya cordiformis pollen mainly used allergenic testing ,
Carya glabra pollen,carya glabra pollen pollen carya glabra plant carya glabra pollen mainly used allergenic testing ,
Millet seed,millet seed allergenic extract used allergenic testing ,
Mustard greens,mustard green allergenic extract used allergenic testing ,
Quercus muehlenbergii pollen,quercus muehlenbergii pollen allergenic extract used allergenic testing ,
Quercus palustris pollen,quercus palustris pollen pollen quercus palustris plant quercus palustris pollen mainly used allergenic testing ,
Quercus stellata pollen,quercus stellata pollen pollen quercus stellata plant quercus stellata pollen mainly used allergenic testing ,
Quercus garryana pollen,quercus garryana pollen pollen quercus garryana plant quercus garryana pollen mainly used allergenic testing ,
Red bell pepper,red bell pepper allergenic extract used allergenic testing ,
Perch,perch allergenic extract used allergenic testing ,
Pumpkin,pumpkin allergenic extract used allergenic testing ,
Melopsittacus undulatus feather,melopsittacus undulatus feather used allergenic testing ,
Pinus contorta pollen,pinus contorta pollen pollen pinus contorta plant pinus contorta pollen mainly used allergenic testing ,
Pinus sylvestris pollen,pinus sylvestris pollen pollen pinus sylvestris plant pinus sylvestris pollen mainly used allergenic testing ,
Pinus rigida pollen,pinus rigida pollen pollen pinus rigida plant pinus rigida pollen mainly used allergenic testing ,
Capsicum,capsicum chili pepper allergenic extract used allergenic testing ,
Oryctolagus cuniculus hair,european rabbit hair used allergenic testing ,
Sequoia sempervirens pollen,sequoia sempervirens pollen pollen sequoia sempervirens plant sequoia sempervirens pollen mainly used allergenic testing ,
Rumex obtusifolius pollen,rumex obtusifolius pollen pollen rumex obtusifolius plant rumex obtusifolius pollen mainly used allergenic testing ,
Rumex altissimus pollen,rumex altissimus pollen pollen rumex altissimus plant rumex altissimus pollen mainly used allergenic testing ,
Rumex salicifolius var. mexicanus pollen,rumex salicifolius var mexicanus pollen pollen rumex salicifolius var mexicanus plant rumex salicifolius var mexicanus pollen mainly used allergenic testing ,
Sitotroga cerealella,sitotroga cerealella allergenic extract used allergenic testing ,
English sole,english sole allergenic extract used allergenic testing ,
Safflower,safflower allergenic extract used allergenic testing ,
Sugarcane,sugarcane allergenic extract used allergenic testing ,
Sunflower seed,sunflower seed allergenic extract used allergenic testing ,
Platanus hybrida pollen,platanus hybrida pollen pollen platanus hybrida plant platanus hybrida pollen mainly used allergenic testing ,
Artemisia californica pollen,artemisia californica pollen pollen artemisia californica plant artemisia californica pollen mainly used allergenic testing ,
Helianthus annuus pollen,helianthus annuus pollen pollen helianthus annuus plant helianthus annuus pollen mainly used allergenic testing ,
Carpinus caroliniana pollen,carpinus caroliniana pollen pollen carpinus caroliniana plant carpinus caroliniana pollen mainly used allergenic testing ,
Picea pungens pollen,picea pungens pollen pollen picea pungens plant picea pungens pollen mainly used allergenic testing ,
"Starch, tapioca",starch tapioca allergenic extract used allergenic testing ,
Larix occidentalis pollen,larix occidentalis pollen pollen larix occidentalis plant larix occidentalis pollen mainly used allergenic testing ,
Trichophyton rubrum,trichophyton rubrum fungus provoke allergic reaction trichophyton rubrum extract used allergenic testing ,
Salix lucida ssp. lasiandra pollen,salix lucida ssp lasiandra pollen pollen salix lucida ssp lasiandra plant salix lucida ssp lasiandra pollen mainly used allergenic testing ,
Cedar oil,cedar oil juniperus virginiana allergenic extract used allergenic testing ,
Venison,venison allergenic extract used allergenic testing ,
Black walnut,black walnut allergenic extract used allergenic testing ,
Artemisia dracunculus pollen,artemisia dracunculus pollen pollen artemisia dracunculus plant artemisia dracunculus pollen mainly used allergenic testing ,
Pinus banksiana pollen,pinus banksiana pollen pollen pinus banksiana plant pinus banksiana pollen mainly used allergenic testing ,
Pinus resinosa pollen,pinus resinosa pollen pollen pinus resinosa plant pinus resinosa pollen mainly used allergenic testing ,
Pinus nigra pollen,pinus nigra pollen pollen pinus nigra plant pinus nigra pollen mainly used allergenic testing ,
Pinus thunbergii pollen,pinus thunbergii pollen pollen pinus thunbergii plant pinus thunbergii pollen mainly used allergenic testing ,
Carya tomentosa pollen,carya tomentosa pollen pollen carya tomentosa plant carya tomentosa pollen mainly used allergenic testing ,
Iva annua pollen,iva annua pollen pollen iva annua plant iva annua pollen mainly used allergenic testing ,
Bassia scoparia pollen,bassia scoparia pollen pollen bassia scoparia plant bassia scoparia pollen mainly used allergenic testing ,
Cyclachaena xanthifolia pollen,cyclachaena xanthifolia pollen pollen cyclachaena xanthifolia plant cyclachaena xanthifolia pollen mainly used allergenic testing ,
Amaranthus retroflexus whole,amaranthus retroflexus whole allergenic extract used allergenic testing ,
Cephalosporium roseum,cephalosporium roseum allergenic extract used allergenic testing ,
Cochliobolus lunatus,cochliobolus lunatus fungus provoke allergic reaction cochliobolus lunatus extract used allergenic testing ,
Haematonectria haematococca,haematonectria haematococca fungus provoke allergic reaction haematonectria haematococca extract used allergenic testing ,
Chrysonilia sitophila,chrysonilia sitophila fungus provoke allergic reaction chrysonilia sitophila extract used allergenic testing ,
Pleospora betae,pleospora betae fungus provoke allergic reaction pleospora betae extract used allergenic testing ,
Puccinia striiformis var. striiformis,puccinia striiformis var striiformis fungus provoke allergic reaction puccinia striiformis var striiformis extract used allergenic testing ,
Pleospora tarda,pleospora tarda allergenic extract used allergenic testing ,
Acacia pollen,acacia pollen allergenic extract used allergenic testing ,
Bassia hyssopifolia pollen,bassia hyssopifolia pollen pollen bassia hyssopifolia plant bassia hyssopifolia pollen mainly used allergenic testing ,
Brassica rapa pollen,brassica rapa pollen pollen brassica rapa plant brassica rapa pollen mainly used allergenic testing ,
Callistemon citrinus pollen,callistemon citrinus pollen pollen callistemon citrinus plant callistemon citrinus pollen mainly used allergenic testing ,
Dicoria canescens pollen,dicoria canescens pollen pollen dicoria canescens plant dicoria canescens pollen mainly used allergenic testing ,
Krascheninnikovia lanata pollen,krascheninnikovia lanata pollen pollen krascheninnikovia lanata plant krascheninnikovia lanata pollen mainly used allergenic testing ,
Ambrosia ambrosioides pollen,ambrosia ambrosioides pollen pollen ambrosia ambrosioides plant ambrosia ambrosioides pollen mainly used allergenic testing ,
Ambrosia chamissonis pollen,ambrosia chamissonis pollen pollen ambrosia chamissonis plant ambrosia chamissonis pollen mainly used allergenic testing ,
Koeleria macrantha pollen,koeleria macrantha pollen pollen koeleria macrantha plant koeleria macrantha pollen mainly used allergenic testing ,
Phoenix dactylifera pollen,phoenix dactylifera pollen pollen phoenix dactylifera plant phoenix dactylifera pollen mainly used allergenic testing ,
Quercus dumosa pollen,quercus dumosa pollen pollen quercus dumosa plant quercus dumosa pollen mainly used allergenic testing ,
Suaeda moquinii pollen,suaeda moquinii pollen pollen suaeda moquinii plant suaeda moquinii pollen mainly used allergenic testing ,
Tilia cordata pollen,tilia cordata pollen pollen tilia cordata plant tilia cordata pollen mainly used allergenic testing ,
Apis mellifera venom,apis mellifera venom extract apis mellifera venom apis mellifera venom used allergenic testing ,
Vespula maculifrons venom protein,vespula maculifrons venom protein extract vespula maculifrons venom vespula maculifrons venom protein used allergenic testing ,
Dolichovespula arenaria venom protein,dolichovespula arenaria venom protein extract dolichovespula arenaria venom dolichovespula arenaria venom protein used allergenic testing ,
Dolichovespula maculata venom protein,dolichovespula maculata venom protein extract dolichovespula maculata venom dolichovespula maculata venom protein used allergenic testing ,
Polistes fuscatus venom protein,polistes fuscatus venom protein extract polistes fuscatus venom polistes fuscatus venom protein used allergenic testing ,
Hordeum vulgare pollen,hordeum vulgare pollen pollen hordeum vulgare plant hordeum vulgare pollen mainly used allergenic testing ,
Agrostis stolonifera pollen,agrostis stolonifera pollen pollen agrostis stolonifera plant agrostis stolonifera pollen mainly used allergenic testing ,
Phalaris minor pollen,phalaris minor pollen pollen phalaris minor plant phalaris minor pollen mainly used allergenic testing ,
Lolium perenne subsp. multiflorum pollen,lolium perenne subsp multiflorum pollen pollen lolium perenne subsp multiflorum plant lolium perenne subsp multiflorum pollen mainly used allergenic testing ,
Sorghum bicolor subsp. bicolor pollen,sorghum bicolor subsp bicolor pollen pollen sorghum bicolor subsp bicolor plant sorghum bicolor subsp bicolor pollen mainly used allergenic testing ,
Sorghum bicolor subsp. drummondii pollen,sorghum bicolor subsp drummondii pollen pollen sorghum bicolor subsp drummondii plant sorghum bicolor subsp drummondii pollen mainly used allergenic testing ,
Amphiachyris dracunculoides pollen,amphiachyris dracunculoides pollen pollen amphiachyris dracunculoides plant amphiachyris dracunculoides pollen mainly used allergenic testing ,
Iva angustifolia pollen,iva angustifolia pollen pollen iva angustifolia plant iva angustifolia pollen mainly used allergenic testing ,
Neurospora sitophila,neurospora sitophila fungus provoke allergic reaction neurospora sitophila extract used allergenic testing ,
Trichophyton tonsurans,trichophyton tonsurans fungus provoke allergic reaction trichophyton tonsurans extract used allergenic testing ,
Mycogone nigra,mycogone nigra allergenic extract used allergenic testing ,
Absidia capillata,absidia capillata allergenic extract used allergenic testing ,
Thermomyces lanuginosus,thermomyces lanuginosus allergenic extract used allergenic testing ,
Trichosporon cutaneum,trichosporon cutaneum allergenic extract used allergenic testing ,
Tanacetum cinerariifolium flower,tanacetum cinerariifolium flower allergenic extract used allergenic testing ,
Largemouth bass,largemouth bass allergenic extract used allergenic testing ,
Cocoa,cocoa allergenic extract used allergenic testing ,
Blue crab,blue crab allergenic extract used allergenic testing ,
Barley malt,barley malt allergenic extract used allergenic testing ,
Radish,radish allergenic extract used allergenic testing ,
Sage,sage allergenic extract used allergenic testing ,
Thyme,thyme allergenic extract used allergenic testing ,
Peppermint,peppermint allergenic extract used allergenic testing ,
Ulmus rubra pollen,ulmus rubra pollen allergenic extract used allergenic testing ,
Pseudotsuga menziesii pollen,pseudotsuga menziesii pollen pollen pseudotsuga menziesii plant pseudotsuga menziesii pollen mainly used allergenic testing ,
Carya laciniosa pollen,carya laciniosa pollen allergenic extract used allergenic testing ,
Maclura pomifera pollen,maclura pomifera pollen pollen maclura pomifera plant maclura pomifera pollen mainly used allergenic testing ,
Hepatitis A Vaccine,hepatitis viral infection lead significant morbidity mortality sign symptom include anorexia nausea vomiting liver failure a199182 known several trade name havrix twinrix hepatitis vaccine formulated immunization hepatitis virus hav infection safely confers strong protection disease caused infection virus a199185 l12756 u approved vaccine inactivated live hepatitis vaccine currently available country l13392 ,hepatitis vaccine indicated immunization hepatitis virus hav infection patient aged 12 month older first dose administered least 2 week expected exposure hepatitis virus l12756 
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,"haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen active immunization booster dose given intramuscularly pediatric patient received primary series haemophilus b conjugate vaccine licensed primarly immunization vaccine contains haemophilus b capsular polysaccharide polyribosyl-ribitol-phosphate prp high molecular weight polymer prepared haemophilus influenzae type b strain 20,752 heat inactivated purified ",indicated active immunization pediatric patient 15 month 4 year age booster dose prevention invasive disease caused haemophilus influenzae type b 
"Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)",bordetella pertussis toxoid antigen formaldehyde glutaraldehyde inactivated vaccine used prophylaxis pertussis whooping cough caused small gram-negative coccobacillus infects mucosal layer human respiratory tract ,
Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Autologous cultured chondrocytes,autologous cultured chrondrocytes used autologous cell therapy repair articular cartilage injury knee femoral condyle due acute repetitive trauma serf alternative repair treatment patient inadequate response pre-existing surgical method surgical implantation show tolerable safety profile efficacy 4 year indicated patient osteoarthritis used since 1995 carticel gained biologic license 1997 surgical implantation first performed sweden , autologous cultured chondrocytes indicated repair symptomatic single multiple full-thickness cartilage defect knee without bone involvement adult aged 55 year le l41035 indicated use joint knee l41035 
"Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Anthrax vaccine,anthrax vaccine vaccine used pre- post-exposure prophylaxis disease high risk suspected confirmed exposure bacillus anthracis subcutaneously intramuscularly administered derived cell-free filtrate microaerophilic culture avirulent nonencapsulated strain bacillus anthracis grown chemically defined protein-free medium fda label ,
Betula pendula pollen,betula pendula pollen allergenic extract used allergenic testing ,
Ulmus parvifolia pollen,ulmus parvifolia pollen pollen ulmus parvifolia plant ulmus parvifolia pollen mainly used allergenic testing ,
Parkinsonia florida pollen,parkinsonia florida pollen allergenic extract used allergenic testing ,
Cytisus scoparius flowering top,cytisus scoparius flowering top allergenic extract used allergenic testing ,
Poultry,poultry allergenic extract used allergenic testing ,
"Quahog, unspecified",quahog unspecified allergenic extract used allergenic testing ,
"Cod, unspecified",cod unspecified allergenic extract used allergenic testing ,
Crab leg,crab leg allergenic extract used allergenic testing ,
"Salmon, unspecified",salmon unspecified allergenic extract used allergenic testing ,
Yeast,yeast allergenic extract used allergenic testing ,
Canis lupus familiaris dander,canis lupus familiaris dander dander canis lupus familiaris canis lupus familiaris dander used allergenic testing ,
Cavia porcellus dander,cavia porcellus dander allergenic extract used allergenic testing ,
Bos taurus dander,bos taurus dander allergenic extract used allergenic testing ,
Equus caballus dander,equus caballus dander dander equus caballus equus caballus dander used allergenic testing ,
Aspergillus nidulans,aspergillus nidulans fungus provoke allergic reaction aspergillus nidulans extract used allergenic testing ,
Penicillium digitatum,penicillium digitatum allergenic extract used allergenic testing ,
Clonostachys rosea f. rosea,clonostachys rosea f. rosea allergenic extract used allergenic testing ,
Dendryphiella vinosa,dendryphiella vinosa fungus provoke allergic reaction dendryphiella vinosa extract used allergenic testing ,
Solenopsis richteri,solenopsis richteri allergenic extract used allergenic testing extracted black imported fire ant native south amercia specie also introduced north amercia stung bite characterized sterile pustule surrounded reddened swelling along redness extending beyond ,
Polistes annularis venom protein,polistes annularis venom protein extract polistes annularis venom polistes annularis venom protein used allergenic testing ,
Polistes exclamans venom protein,polistes exclamans venom protein extract polistes exclamans venom polistes exclamans venom protein used allergenic testing ,
Polistes metricus venom protein,polistes metricus venom protein extract polistes metricus venom polistes metricus venom protein used allergenic testing ,
Vespula germanica venom protein,vespula germanica venom protein extract vespula germanica venom vespula germanica venom protein used allergenic testing ,
Vespula pensylvanica venom protein,vespula pensylvanica venom protein extract vespula pensylvanica venom vespula pensylvanica venom protein used allergenic testing ,
Vespula squamosa venom protein,vespula squamosa venom protein extract vespula squamosa venom vespula squamosa venom protein used allergenic testing ,
Vespula vulgaris venom protein,vespula vulgaris venom protein extract vespula vulgaris venom vespula vulgaris venom protein used allergenic testing ,
Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Texas/50/2012 X-223 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009(H1N1)-like hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Typhoid Vaccine Live,salmonella typhi ty21a live antigen live attenuated vaccine oral administration contains attenuated strain salmonella typhi ty21a vaccine prevents development typhoid fever acute febrile enteric disease caused salmonella typhi inducing local immune response intestinal tract ,
Azficel-T,azficel-t autologous cellular product composed fibroblast indicated improvement appearance moderate severe nasolabial fold wrinkle adult dermal fibroblast collected post-auricular biopsy tissue aseptically expanded using standard tissue-culture procedure sufficient cell three dos obtained fda label expanded cell suspended cell medium replacement lost dermal constituent aging skin deformation process treatment autologous fibroblast shown improve wrinkle acne scar appearance placebo treatment a31920 a31926 intradermal administration autologous dermal fibroblast irradiated skin following surgical procedure associated improved healing process subsequent surgical wound a31927 azficel-t marketed u laviv intradermal injection ,indicated improvement appearance moderate severe nasolabial fold wrinkle adult fda label 
Human cord blood hematopoietic progenitor cell,human cord blood hematopoietic progenitor cell consist hematopoietic progenitor cell monocyte lymphocyte granulocyte human cord blood used allogeneic unrelated related hematopoietic stem cell transplantation procedure patient disorder affecting hematopoietic system inherited acquired result myeloablative treatment human umbilical cord rich source hematopoietic stem cell progenitor cell capable proliferation _in vitro_ active viable hematopoietic progenitor cell hematopoietic stem cell hscs express cell surface marker cd34 critical cell identification a32216 upon division maturation bone marrow following intravenous administration patient hematopoietic progenitor cell enter systemic circulation restore blood count function fda label first cord blood transplant 1988 patient fanconi anemia a32220 use umbilical cord blood transplantation increased clinical setting human cord blood hematopoietic progenitor cell collected related unrelated donor unrelated donor transplant setting several advantage related donor transplant bone marrow transplantation allows shorter time transplant tolerance 1–2 human leukocyte antigen mismatch due expanded donor pool increase chance finding suitable donor particularly patient requiring urgent transplantation a32219 advantage hsc transplantation include lower risk transmitting infection latent virus improved targeting ethnic minority increased pool rare haplotype a32219 umbilical cord blood cell transplantation also associated reduced incidence severity graft versus host disease gvhd thus improved survival rate transplant patient compared allogeneic bone marrow transplant setting may due `` naive '' nature lymphocyte a32223 hemacord marketed u.s. allogeneic cord blood hematopoietic progenitor cell therapy intravenous use ,human cord hematopoietic progenitor cell indicated use unrelated donor hematopoietic progenitor stem cell transplantation procedure conjunction appropriate preparative regimen hematopoietic immunologic reconstitution patient disorder affecting hematopoietic system inherited acquired result myeloablative treatment l12924 
Stannous chloride,stannous chloride used source tin radiopharmaceutical kit tin reduces technetium-99m active radiological agent allowing form complex phosphate-containing moeities a32700 complex localize primarily bone 40-50 infracted myocardium 0.01-0.02 /g tissue allowing imaging area altered osteogenesis necrotic heart tissue fda label ,stannous chloride component technetium-99m agent indicated imaging skeleton area altered osteogenesis detection infarcted heart tissue fda label 
Mineral oil,mineral oil paraffin oil mixture higher alkane mineral source petroleum petroleum mineral oil manufactured crude oil vacuum distillation produce several distillate residual oil refined modern refining process aromatics reduced solvent extraction catalytic hydrotreating hydrocracking unrefined mildly treated mineral oil classified group 3 carcinogen world health organization chronic exposure aromatics including alkylated polycyclic aromatic compound pac lead skin cancer mineral oil common ingredient baby lotion cold cream ointment cosmetic treat prevent dry rough scaly itchy skin minor skin irritation also used mild laxative human veterinary us ,mineral oil considered active pharmacological ingredient pharmaceutical preparation official indication typically present topical formulation emollient occlusive agent t182 
Petrolatum, colloidal system semisolid hydrocarbon obtained petroleum used ointment base topical protectant lubricant , use counter skin protectant fda label commonly used treat diaper rash chapped lip fda label l858 
Carboxymethylcellulose,carboxymethylcellulose cellulose derivative consists cellulose backbone made glucopyranose monomer hydroxyl group bound carboxymethyl group added food product viscosity modifier thickener emulsifier also one common viscous polymer used artificial tear shown effective treatment aqueous tear-deficient dry eye symptom ocular surface staining a33029 viscous mucoadhesive property well anionic charge allow prolonged retention time ocular surface a33029 sodium carboxymethylcellulose commonly used salt ,indicated symptomatic relief burning irritation discomfort eye due dryness exposure wind sun 
Polyvinyl alcohol,polyvinyl alcohol water-soluble synthetic polymer obtained polymerization vinyl alcohol varying role commercial industrial application papermaking textile printing polyvinyl alcohol found ophthalmic solution lubricant prevent irritation relieve dryness eye l2826 , use lubricant prevent irritation relieve dryness eye l2828 
Povidone,povidone also known polyvinylpyrrolidone pvp polyvidone synthetic water-soluble polymer made monomer n-vinylpyrrolidone used binder many pharmaceutical tablet lubricant eye drop also used many technical application various role adhesive additive emulsifier complex iodine db06812 display antiseptic property iodine bactericidal component mainly contributes effect povidone act carrier a32988 db06812 found over-the-counter topical solution ointment pessary liquid soap surgical scrub clinical effectiveness db06812 wound healing remains somewhat controversial demonstrated clinical study application compound wound associated impaired wound healing reduced wound strength infection open wound a32988 fda withdrew approval use intravenous drug product containing povidone l43942 formulation povidone continue available , complex iodine indicated inducing antisepsis prevention infection minor cut scrape burn 
Octisalate,also known ethylhexyl salicylate octyl salicylate oil soluble chemical sunscreen agent absorbs uvb radiation protect uva octyl salicylate used augment uvb protection sunscreen salicylate weak uvb absorber generally used combination uv filter octyl salicylate appears good safety profile cover wavelength range 295-315 nm peak 307-310 nm ester salicylic acid 2-ethylhexanol salicylate portion molecule absorbs ultraviolet light protect skin harmful effect exposure sunlight ethylhexanol portion function emollient ,ingredient sunscreen protection damage effect sun light provides protection sunburn aging skin cancer 
Polysorbate 80,polysorbate substance formulated reaction sorbitan fatty acid ester nonionic surfactant ethylene oxide used many foreign country including u.s. eu act emulsifier solubilizer many food including bread cake mix salad dressing shortening oil chocolate l1856 polysorbate 80 hydrophilic nonionic surfactant utilized surfactant soap cosmetic also lubricant eye drop food pharmaceutical product act emulsifier polysorbate 80 excipient used stabilize aqueous formulation medication parenteral administration vaccination l1852 solubilizing agent act surfactant increase solubility one agent another substance would normally dissolve particular solution able dissolve use solubilizing agent l1852 also known emulsifier help ingredient mix together prevent separation water-containing small amount salt included several vaccine licensed usa l1844 , used solubilizer antimicrobial preservative disinfectant l1853 
Homosalate,"homosalate organic compound belongs salicylate ester formed salicylic acid 3,3,5-trimethylcyclohexanol derivative cyclohexanol salicylate prevent direct skin exposure sun ’ harmful ray absorbing ultraviolet uv light homosalate specifically absorbs short-wave uvb ray associated dna damage increased risk skin cancer common ingredient many commercially available sunscreen reported adverse effect homosalate ", ingredient many sunscreen protection sunburn skin aging skin cancer 
Pancrelipase amylase,pancrelipase general composed mixture pancreatic enzyme include amylase lipase protease enzyme extracted porcine pancreatic gland l2509 amylase enzyme help chemical process digestion hydrolizing starch available saccharide form t177 pancrelipase amylase single polypeptide chain containing two sh group four disulfide bridge l2512 pancrelipase mixture including pancrelipase amylase developed ortho-mcneil-janssen pharmaceutical inc fda approved april 12 2010 l2510 ,please refer db00085 
Pancrelipase protease,pancrelipase general composed mixture pancreatic enzyme include amylase lipase protease enzyme extracted porcine pancreatic gland l2509 pancrelipase protease mix enzyme formed trypsin chymotrypsin proteolytically cleave peptide bond involved food digestion a32742 l2543 pancrelipase mixture including pancrelipase protease developed ortho-mcneil-janssen pharmaceutical inc fda approved april 12 2010 l2510 ,please refer db00085 
Selenic acid,selenic acid organic compound chemical formula h2seo4 may found over-the-counter daily dietary supplement source db11135 essential trace mineral human health ,indicated use nutritional supplement 
Phenyl salicylate,phenyl salicylate 2-hydroxybenzoic acid phenyl ester utilized manufacturing process polymer lacquer adhesive wax well polish active ingredient pharmaceutical product mild analgesic pain relief releasing salicylate found db00945 phenyl salicylate may also found antiseptic agent l2467 synthesized heating salicylic acid phenol l2468 msds phenyl salicylate used food additive usa l2479 compound belongs class organic compound known depsides depsidones polycyclic compound either polyphenolic compound composed two monocyclic aromatic unit linked ester bond depside compound containing depsidone structure depsidone l2477 ,pain fever l2468 
Hydrogen fluoride,hydrogen fluoride hydrofluoric acid weak acid precursor almost fluorine compound including pharmaceutical db00472 prozac used chemical reagent several industrial process oil refinery also used etchant cleaning agent reagent dissolve oxide silicate ,
Cetylpyridinium,cetylpyridinium quaternary ammonium broad-spectrum antiseptic property salt form cetylpyridinium chloride typically found active ingredient mouthwash toothpaste lozenge throat spray breath spray nasal spray product generally mediates antiseptic activity protective action dental plaque reducing gingivitis ,typically employed cetylpyridinium chloride salt compound commonly used active ingredient various over-the-counter mouthwash toothpaste lozenge mouth spray generally indicated antiseptic action gingivitis plaque prevention well action prevention oropharyngeal bacterial infection a24813 l2754 l2755 
Dimethicone,dimethicone silicone oil also known polydimethylsiloxane pdms viscoelastic property dimethicone used surfactant antifoaming agent carminative various product medical device food product lubricant used number health beauty product including hair care product shampoo conditioner leave-in conditioner de-tangling product skin also observed moisturizing action l1771 l1773 study found 100 dimethicone product safe highly effective head louse treatment child may serve le toxic le resistance-prone alternative pesticide-containing product l1767 ,dimethicone colorless liquid cosmetic therapeutic us used topical cream ointment help distribute active ingredient dimethicone used anti-foaming agent hair skin conditioner treatment head louse anti-bloating/anti-flatulence agent l1765 l1772 
Hypromellose,hypromellose hydroxypropyl methylcellulose hpmc l1812 semisynthetic inert viscoelastic polymer form colloid solution dissolved water act thickening agent coating polymer bioadhesive solubility enhancer solid dispersion binder process granulation modified release formulation a24840 commonly used delivery component oral pharmaceutical product provides release drug controlled fashion effectively increasing duration release drug prolong therapeutic effect a24839 hypromellose also found eye drop lubricant l1803 ,used ophthalmic protectant lubricant artificial tear diagnostic aid contact lens procedure gonioscopy l1805 
Polyethylene glycol 400,polyethylene glycol peg product made condensed ethylene oxide water contain various derivative various function many peg type hydrophilic favorably used enhancer penetration used heavily topical dermatological preparation peg along many nonionic derivative widely utilized cosmetic product surfactant emulsifier cleansing agent humectant skin conditioner l1787 polyethylene glycol 400 peg 400 low-molecular-weight grade polyethylene glycol low-level toxicity hydrophilic render useful ingredient drug formulation augment solubility bioavailability weakly water-soluble drug used ophthalmic solution relief burning irritation and/or discomfort follows dryness eye l1785 peg `` 400 '' indicates average molecular weight specific peg 400 l1788 pegylation occurs peg attached numerous protein medication allowing greater solubility selected drug example pegylated medication peg-interferon alpha pegintron peg-filgrastim addition peg available bowel preparation colonoscopy procedure laxative l1788 ,peg-400 indicated temporary relief burning irritation due dryness eye andfor protection irritation desiccation l1795 l1796 l1797 
Trolamine salicylate,trolamine salicylate organic compound salt formed triethanolamine salicylic acid triethanolamine neutralizes acidity salicylic acid topical analgesic used temporary relief minor pain associated arthritis simple backache muscle strain sprain bruise unlike topical analgesic trolamine salicylate distinct odor improves patient acceptability a32189 also display low systemic absorption upon dermal topical administration a32190 low skin irritant property a32191 salicylate trolamine salicylate inhibitor cyclo-oxygenase cox enzyme reported selectivity towards specific enzyme isoform trolamine salicylate serf active ingredient topical over-the-counter product temporary management mild moderate muscular joint pain ,indicated temporary relief ache pain muscle joint associated backache lumbago strain bruise sprain arthritic rheumatic pain pain tendon ligament l1791 
Silver nitrate,silver nitrate inorganic compound chemical formula agno3 solid form silver nitrate coordinated trigonal planar arrangement often used precursor silver-containing compound used making photographic film laboratory setting staining agent protein visualization page gel scanning electron microscopy ,
Aluminum chloride,aluminum chloride chemical compound chemical formula alcl3 contaminated iron chloride often display yellow color compared white pure compound used various chemical application lewis base anhydrous aluminium trichloride commonly used lewis acid may also found over-the-counter antiperspirant prescription product antihemorrhagic agent antiperspirant product fda approves use aluminum chloride active ingredient 15 calculated hexahydrate form aqueous solution nonaerosol dosage form l2012 , indicated control minor hemorrhage dental restorative procedure indicated reduce underarm perspiration 
Coal tar,coal tar brown black liquid extremely high viscosity coal tar among by-product coal carbonized make coke gasified make coal gas coal tar complex variable mixture phenol polycyclic aromatic hydrocarbon pahs heterocyclic compound indicated local relief itching dryness irritation caused psoriasis seborrhea eczema ,relieving itching irritation redness dryness scaling flaking skin caused psoriasis seborrhea eczema 
Resorcinol,"resorcinol 1,3-isomer meta-isomer benzenediol formula c6h4 oh 2 used antiseptic disinfectant topical pharmaceutical product treatment skin disorder infection acne seborrheic dermatitis eczema psoriasis corn callus wart exerts keratolytic activity resorcinol work helping remove hard scaly roughened skin although primarily indicated use topical application resorcinol also posse well-documented anti-thyroidal activity generally relied upon kind formal therapeutic indication ",contemporary therapeutic us resorcinol primarily revolve around use phenol derivative active ingredient topical antiseptic l2745 l2744 l40069 f61 topical antibacterial skin treatment product condition like acne seborrheic dermatitis eczema others l2746 l2745 l2744 l40069 f61 
Cocoa butter,cocoa butter edible natural fat obtained _theobroma cocoa_ seed predominantly found dark chocolate a33033 rich source monounsaturated saturated fatty acid a33040 mainly contains approximately 33 db04224 25 db03796 33 db03193 a20409 contain caffeine theobromine fat cocoa solid including cocoa butter lower phenolic content non-fat cocoa solid may contain polyphenols different structure flavonoid antioxidant property a33041 cocoa butter included chocolate food product also found over-the-counter skin product lotion cream bar intended maintain skin softness cocoa butter skin moisturizing property shown reduce likelihood developing stria gravidarum stretch mark double-blind randomized clinical trial woman first trimester a33031 still common active ingredient prevention skin dryness cosmetic skincare product oftentimes cocoa butter used over-the-counter pharmaceutical product suppository lipid-lowering effect cocoa butter studied investigated fatty acid constituent cocoa butter known exhibit lipid-lowering property dyslipidemia characterized elevated level plasma triglyceride very-low-density lipoprotein vldl cholesterol due overproduction large triglyceride-enriched vldl cholesterol particle a20409 cocoa butter shown reduce vldl cholesterol level animal study suggesting potential use lipid disorder ,indicated topical use over-the-counter skin product treatment skin dryness reduction stria gravidarum stretch mark 
Pyrethrum extract,pyrethrum crude extract form obtained flower plant chrysanthemum cinerariifolium pyrethrin refers refined extract pyrethrum pyrethrum extract composed 6 ester organic compound mediate insecticidal activity pyrethrum-containing mixture used common insecticide control specific pest specie pyrethrum extract also used used treat head body pubic louse infection active compound absorbed louse destroys acting nervous system thought exert minimal effect human ,
Shark liver oil,shark oil extracted liver shark account 25 total body weight 3 main targeted specie deep sea shark centrophorus squamosus dogfish sqaulus acanthias basking shark cetorhinus maximus shark oil rich source alkylglycerols squalene relatively low amount n-3 polyunsaturated fatty acid however major component considered squalene may range 90 shark oil depending specie potential benefit shark oil experimented different therapeutic implication claimed improve immune response exert antitumor activity ,
Docusate,docusate dioctyl sulfosuccinate stool softener indicated treatment constipation a32201 docusate act increasing amount water stool absorbs gut making stool softer easier pas l1801 docusate orally rectally administered docusate world health organization 's list essential medicine l5915 however effectiveness docusate treating constipation remains unclear several study report docusate effective placebo increasing frequency stool stool softening a32200 a32202 a176987 recently pressure stop prescribing docusate identified ineffective medicine a176972 a176987 l5912 additionally appear lessen symptom associated constipation abdominal cramp still docusate available over-the-counter product common laxative ,indicated treatment constipation associated dry hard stool opioid induced constipation a176984 though recently pressure building end use docusate concern efficacy a176972 a176987 l5912 
Potassium nitrate,potassium nitrate inorganic salt chemical formula kno3 natural source nitrate used constituent several different purpose including food preservative fertilizer tree stump removal rocket propellant firework potassium nitrate common active ingredient toothpaste exerting anti-sensitivity action provides increasing protection painful sensitivity teeth cold heat acid sweet contact l1754 l1755 addition potassium nitrate used diuretic pig cattle horse administered orally dos 30 g per animal per day l1736 , relief tooth sensitivity also used pesticide insecticide food additive rodenticide l1751 l1754 l1757 
Hydrogen peroxide,hydrogen peroxide simplest peroxide chemical formula h2o2 hydrogen peroxide unstable compound presence base catalyst typically stored stabilizer weakly acidic solution heated boiling point may undergo potentially explosive thermal decomposition hydrogen peroxide formed body mammal reduction oxygen either directly two-electron transfer reaction l2024 natural product metabolism readily undergoes decomposition catalase normal cell l2024 due potent broad-spectrum antimicrobial action hydrogen peroxide used liquid gas form preservative disinfection sterilization application oxidative biocide a32369 used industrial cosmetic application bleaching agent hydrogen peroxide also considered generally recognized safe compound fda l2024 used antimicrobial agent starch cheese product oxidizing reducing agent product containing dried egg dried egg white dried egg yolk ,indicated used disinfectant sterilizer 
Stannous fluoride,stannous fluoride tn ii fluoride compound commonly used toothpaste prevention gingivitis dental infection cavity relieve dental hypersensitivity although similar function activity sodium fluoride naf conventionally added ingredient toothpaste stannous fluoride shown effective stopping reversing dental lesion a19581 manages prevents dental caries gingivitis promoting enamel mineralization a19580 reducing gingival inflammation bleeding a19582 a19583 potential broad-spectrum antibiotic effect modulation microbial composition dental biofilm a19581 fda-approved over-the-counter product ,indicated use relieve dental hypersensitivity increase enamel production prevent gingivitis cavity control periodontal infection 
Calcium citrate,calcium citrate salt typically used source calcium variety counter supplement , use counter calcium supplement 
Vitamin D,vitamin ultimately comprises group lipid-soluble secosteroids responsible variety biological effect include increasing intestinal absorption calcium magnesium phosphate reference human use 2 main form vitamin vitamin d3 cholecalciferol vitamin d2 ergocalciferol non-specific reference made 'vitamin reference usually use vitamin d3 and/or d2 vitamin d3 d2 require hydroxylation order become biologically active human body since vitamin endogenously synthesized adequate amount mammal exposed sufficient quantity sunlight vitamin function like hormone vitamin receptor regulate calcium opposition parathyroid hormone vitamin play essential physiological role maintaining calcium homeostasis metabolism several different vitamin supplement given treat prevent osteomalacia rickets meet daily criterion vitamin consumption ,vitamin indicated use treatment hypoparathyroidism refractory rickets also known vitamin resistant rickets familial hypophosphatemia fda label 
Desirudin,desirudin direct inhibitor human thrombin protein structure similar hirudin naturally occurring anticoagulant present peripharyngeal gland medicinal leech hirudo medicinalis hirudin single polypeptide chain 65 amino acid residue contains three disulfide bridge desirudin chemical formula c287h440n80o110s6 molecular weight 6963.52 mainly indicated prevention deep vein thrombosis hip replacement surgery patient common side effect include bleeding gum collection blood skin coughing blood deep dark purple bruise difficulty breathing swallowing ,indicated prophylaxis deep vein thrombosis patient undergoing hip replacement surgery 
Meradimate,meradimate known menthyl anthranilate used maximal concentration 5 different product uv filter t200 currently required named meradimate fda approved otc product meradimate approved fda health canada used ingredient sunblocking product l1113 l2748 ,meradimate used active ingredient sunscreen sunblock factor different product fit category broad-spectrum absorbent agent characteristic important consider due fact kind ingredient either absorb reflect uv radiation also important know type ray cover uva ray responsible causing sun damage reaching deeper layer skin uvb cause sunburn outer layer skin agent broad spectrum mean agent capable acting uva uvb ray l2749 
Plantago seed,platango seed refer seed collected various specie plantago tree found laxative treating occasional constipation restoring regularity bowel movement potential benefit maintaining remission ulcerative colitis studied a27156 regardless agent predominantly used gentle laxative agent many part world commonly referred psyllium psyllium husk ,indication include treatment patient needing high fibre regime perhaps relief constipation including constipation pregnancy maintenance regularity b management bowel function patient colostomy ileostomy hemorrhoid anal fissure chronic diarrhea diverticular disease irritable bowel syndrome ulcerative colitis l1865 
Potassium bicarbonate,potassium bicarbonate white crystalline slightly alkaline salty substance produced passage carbon dioxide aqueous potassium carbonate solution used medicine antacid t141 registered fda section suitable safe effective ingredient otc antacid l1836 fda denomination classifies potassium bicarbonate gras ingredient l1837 ,potassium bicarbonate used antacid electrolyte replenisher potassium supplement also used excipient drug formulation l1837 antacid medication used neutralize gastric acid short timeframe ingestion effect soon overcome meal-stimulated acid secretion a32214 
Allantoin,allantoin substance endogenous human body also found normal component human diet fda label healthy human volunteer mean plasma concentration allantoin 2-3 mg/l exercise plasma allantoin concentration rapidly increase two fold remains elevated fda label human muscle urate oxidized allantoin exercise fda label concentration allantoin muscle increase resting value 5000 ug/kg 16000 ug/kg immediately short-term exhaustive cycling exercise fda label specifically allantoin diureide glyoxylic acid produced uric acid major metabolic intermediate organism allantoin found otc cosmetic product commercial product oral hygiene product shampoo lipstick anti-acne product sun care product clarifying lotion a32213 allantoin also demonstrated ameliorate wound healing process study a23498 ,allantoin commonly applied variety topical vehicle application cosmetic cream toothpaste mouthwash shampoo lipstick anti-acne product lotion a32213 purpose moisturizing skin enhancing smoothness skin stimulating healing wound soothing irritated skin a32213 fda label 
N-acetyltyrosine,n-acetyltyrosine also referred n-acetyl-l-tyrosine used place tyrosine precursor db00135 non-essential amino acid polar side group n-acetyltyrosine administered parenteral nutrition intravenous infusion due enhanced solubility compared tyrosine a32652 typically administered source nutritional support oral nutrition inadequate tolerated ,n-acetyltyrosine indicated combination several amino acid dextrose peripherally administered source nitrogen nutritional support patient adequate store body fat short period oral administration tolerated undesirable inadequate fda label also indicated amino acid 5-10 dextrose fat emulsion parenteral nutrition preserve protein reduce catabolism stress condition oral administration inadequate fda label administered amino acid concentrated dextrose indicated central vein infusion prevent reverse negative nitrogen balance patient alimentary tract oral gastrostomy jejestomy route used patient gastrointestinal absorption protein impaired metabolic requirement protein substantially increased morbidity mortality may reduced replacing amino acid lost tissue breakdown fda label 
Sulfur hexafluoride,sulfur hexafluoride ultrasound contrast agent indicated use •in echocardiography opacify left ventricular chamber improve delineation left ventricular endocardial border adult patient suboptimal echocardiogram •in ultrasonography liver characterization focal liver lesion adult pediatric patient,echocardiography sulfur hexafluoride indicated use adult patient suboptimal echocardiogram opacify left ventricular chamber improve delineation left ventricularendocardial border ultrasonography liver sulfur hexafluoride indicated use ultrasound liver adult pediatric patient characterize focal liver lesion 
Benzalkonium,benzalkonium quaternary ammonium compound used biocide cationic surfactant phase transfer agent fda label benzalkonium commonly contained consumer product salt form benzalkonium chloride fda label salt used great variety international pharmaceutical product eye ear nasal drop spray excipient ingredient serving antimicrobial preservative fda label used ingredient antiseptic disinfectant product however active antimicrobial agent l1806 , used active ingredient product like antibacterial antiseptic disinfectant soap topical sanitizers cleaning agent benzalkonium primarily implemented salt form benzalkonium chloride may often active ingredient present indicated primary purpose topical washing decrease bacteria skin l1806 conversely implemented excipient ingredient variety multidose aqueous nose eye ear product benzalkonium chloride used antimicrobial preservative choice facilitate effective bactericidal fungicidal action help minimize growth unwanted organism multidose container fda label 
Potassium bitartrate,potassium bitartate also referred potassium acid tartrate cream tartar potassium acid salt l- -tartaric acid obtained byproduct wine manufacture fermentation process approved fda direct food substance potassium bitartrate used additive stabilizer ph control agent antimicrobial agent processing aid thickener various food product l2732 potassium bitartrate long history medical use laxative administered rectal suppository approved third-class otc drug japan potassium bitartrate one active ingredient phexxi non-hormonal contraceptive agent approved fda may 2020 l14120 ,indicated treatment constipation 
Aluminum sesquichlorohydrate,aluminum sesquichlorohydrate aluminum salt used antiperspirant agent cosmetic astringent deodorant agent work physically blocking eccrine sweat gland duct a31171 ,
Chlorine,chlorine stongly oxidizing agent third electronegative element belongs group halogen atomic number 17 symbol cl yellow-green gas room temperature chlorine second abundant halogen earth commonly used sanitation disinfection antiseptic process also used chemical warfare rocket fuel ,
Magnesium citrate,magnesium citrate low volume osmotic cathartic agent cathartic action work primarily high osmolarity solution draw large amount fluid space used t215 magnesium citrate considered fda approved inactive ingredient approved drug product specification oral administration maximum concentration 237 mg. l2831 also considered active ingredient over-the-counter product l1113 ,magnesium citrate used bowel preparation prior colonoscopy cathartic agent t215 also used over-the-counter product relieve occasional constipation l2841 magnesium citrate one form used administration dietary supplement l2842 
Lanolin,lanolin yellow fat obtained sheep 's wool used emollient cosmetic pharmaceutic aid l2580 u federal code regulation state lanolin concentration range 12-50 may included counter skin ointment l2583 lanolin purified secreted product sheep sebaceous gland l2584 lanolin primarily consists long-chain waxy ester sterol ester lack glyceride reason also called wool wax wool grease lanolin used protection treatment cosmetic enhancement human skin hydrophobic property help protect skin infection skin irritation help seal moisture already present skin l2587 lanolin used active ingredient counter topical product ointment lubricant lotion facial cosmetic lanolin also frequently used protective baby skin treatment sore nipple breastfeeding mother l2583 a32788 ,used skin protectant relieve dryness irritation skin l2586 l2581 help prevent treat diaper dermatitis l2579 
Castor oil,castor oil vegetable oil obtained pressing seed castor oil plant _ricinus communis_ l. mainly cultivated india south america africa china castor oil rich source db02955 represents 90 total castor oil content also consists 4 linoleic 3 oleic 1 stearic le 1 linolenic fatty acid a31170 db02955 hydroxyl group provides functional group location various chemical reaction making favourable substance industrial application a31170 castor oil contain ricin natural poison found castor oil plant toxic lectin remains bean pulp following oil isolation f70 due renewability high versatility addition commercial source hydroxylated fatty acid a31170 castor oil used vital raw material chemical industry a33045 castor oil mainly used manufacturing soap lubricant coating a31170 fda-approved food additive directly added food product human consumption also found hard candy release agent anti-sticking agent supplementary vitamin mineral oral tablet ingredient protective coating castor oil found over-the-counter oral liquid stimulant laxative also added commercial cosmetic hair skincare product ,indicated over-the-counter use laxative oral use soothing agent topical use skin hair 
Eucalyptus oil,eucalyptus oil distilled oil derived leaf tree eucalyptus shown effective reducing pain swelling inflammation via modulatory effect immune response also shown exhibit antibacterial activity bacterial specie cough suppressant action eucalyptus oil applied directly skin pain swelling respiratory tract mucous membrane joint pain genital herpes nasal stuffiness , active agent eucalyptus oil indicated relief symptom catarrhal cold and/or relief symptom minor muscular sprain cramp l1857 
Ensulizole,ensulizole also known 2-phenylbenzimidazole-5-sulfonic acid water-soluble sunscreen agent absorbs strongly uv-b wavelength commonly found cosmetic product sunscreen formula combination uv filter compound due minimal protection uv-a wavelength due water solubility ensulizole commonly used product formulated feel light le oily a32259 demonstrated study ensulizole treatment provided protection cyclobutane pyrimidine dimer photosensitized formation oxidized guanine base uv-a uv-b exposure a27151 according fda maximal approved concentration ensulizole 148 mm although concentration ranging 74 148mm found commercial sunscreen product a27151 ,indicated used uv-b-absorbing molecule sunscreen formulation 
Aluminum zirconium trichlorohydrex gly,aluminum zirconium trichlorohydrex gly common active ingredient deodorant antiperspirant product over-the-counter use consisted mixture monomeric polymeric zr4+ al3+ complex hydroxide chloride glycine compound form colloidal plug sweat pore preventing sweat leaving body ,
Undecylenic acid,undecylenate undecylenic acid unsaturated fatty acid terminal double bond derived castor oil undecylenic acid also found naturally human sweat used precursor manufacture aromatic chemical polymer modified silicone l1891 undecylenic acid first isolated product distillation castor oil 1877 via pyrolysis ricinoleic acid polymerized vinyl production a32281 suggested many organic fatty acid exert fungicidal fungistatic action undecylenic acid also posse antifungal property never used antifungal purpose salt undecylenate found topical over-the-counter mixture product antifungal agent zinc undecylenate example topical antifungal agent treat skin infection athlete ’ foot relief itching burning irritation associated skin condition due bifunctional property undecylenate also used linking molecule conjugate biomolecules protein serf acid moiety anabolic steroid boldenone ,indicated treatment fungal infection salt form therapeutic indication 
Ammonia,ammonia naturally-occurring compound chemical formula nh3 structure trigonal pyramidal geometry colorless gas pungent smell become nh4 ammonium ion water although ammonia used food additive anhydrous form serf starting material pharmaceutical commercial product caustic hazardous concentrated ammonia gas used clinical setting respiratory stimulant prevent fainting radiolabelled form ammonia ammonia n 13 intravenously administered radioactive diagnostic agent positron emission tomography pet imaging myocardium evaluate myocardial perfusion ammonia natural byproduct biological chemical reaction including decomposition organic matter including plant animal animal waste present normally present tissue constituting metabolic pool mostly taken glutamic acid take part transamination reaction including synthesis protein krebs-hanseleit cycle liver l2033 proposed human adult produce 1000 mmol ammonia daily undergoes excretion urine , indicated use smelling salt treat prevent fainting radiolabelled indicated diagnostic pet imaging myocardium rest pharmacologic stress condition evaluate myocardial perfusion patient suspected existing coronary artery disease fda label 
Sodium iodide,sodium iodide water-soluble ionic compound crystal lattice sodium iodide source iodine administered supplement total parenteral nutrition l2065 commonly used veterinary medicine radiolabelled compound db09293 used diagnostic tool evaluate thyroid function morphology ,indicated use supplement intravenous solution given total parenteral nutrition tpn l2065 
Turpentine,turpentine also known spirit turpentine oil turpentine wood turpentine liquid extracted live tree mainly pine distillation resin used solvent base material organic synthesis reaction turpentine composed terpene mainly monoterpenes alpha-pinene beta-pinene lesser amount carene camphene dipentene terpinolene ,turpentine used experimentally bath treatment disseminated sclerosis sexual dysfunction also studied antibacterial activity inhibition osteoclast activity turpentine utilized experimental model inflammation induce systemic inflammatory immune response animal 
Chloroxylenol,chloroxylenol para-chloro-meta-xylenol pcmx antiseptic disinfectant agent used skin disinfection surgical instrument found antibacterial soap wound-cleansing application household antiseptic halophenol shown effective gram positive bacteria disrupts cell wall due phenolic nature a1351 chloroxylenol world health organization 's list essential medicine , predominant medical application chloroxylenol formally indicated therapeutic use application skin use cut bite sting abrasion use antiseptic hand cleaner l1992 
Hypochlorite,hypochlorite ion composed chlorine oxygen chemical formula clo− unstable pure form hypochlorite commonly used bleaching disinfectation water treatment purpose salt form sodium hypochlorite hypochlorite often used chemical reagent chlorination oxidation reaction ,indicated over-the-counter use disinfectant agent sodium hypochlorite form 
Racepinephrine,racepinephrine racemic mixture consisting d- db00668 l- db00668 enantiomer epinephrine non-selective α- β-adrenergic receptor agonist bronchodilator used temporary relief mild symptom intermittent asthma including wheezing tightness chest shortness breath active ingredient oral inhalation over-the-counter product racepinephrine hydrochloride ,indicated temporary relief mild symptom intermittent asthma 
Benzethonium,benzethonium synthetic quaternary ammonium salt surfactant antiseptic broad spectrum antimicrobial property salt form benzethonium chloride primarily used skin disinfectant concentration 0.1-0.2 safe effective concentration compound specified u.s. food drug administration fda additionally found cosmetic toiletry mouthwash anti-itch ointment shown effective mediating antimicrobial action bacteria fungi mold virus evidence benzethonium act spermatocide may cause vaginal irritation a32304 benzethonium identified novel cancer-specific compound cell-based small-molecule screen a32298 ,indicated antiseptic agent therapeutic indication clinical use 
Calcium gluconate,calcium gluconate used mineral supplement medication insufficient calcium diet supplementation may done treat prevent osteoporosis rickets consequence hypocalcemia also taken mouth recommended injection muscle calcium gluconate injection usp sterile nonpyrogenic supersaturated solution calcium gluconate intravenous use ml contains calcium gluconate 94 mg calcium saccharate tetrahydrate 4.5 mg water injection q.s hydrochloric acid and/or sodium hydroxide may added ph adjustment 6.0 8.2 calcium saccharate provides 6 total calcium stabilizes supersaturated solution calcium gluconate 10 ml injection provides 93 mg elemental calcium ca++ equivalent 1 g calcium gluconate ,oral calcium salt used dietary supplemental therapy person may get enough calcium regular diet calcium gluconate used cardioprotective agent high blood potassium calcium gluconate antidote magnesium sulfate toxicity 
Selenious acid,selenious acid acid form sodium selenite form selenium l1910 selenium essential trace element antioxidant cofactor metabolic enzyme regulation also play important role maintaining general health tissue muscle antioxidant property selenium component glutathione peroxidase enzyme protects cell component oxidative damage due peroxide produced cellular metabolism l1916 selenium se demonstrated prevent cancer numerous animal model administered selenium level exceeding nutritional requirement one study showed efficacy prevention malignancy utilizing selenium supplement human report study heightened interest additional human selenium supplementation study validate result larger population l1918 interestingly selenium studied potential therapy prevention management atherosclerosis l1921 ,selenium injection indicated use supplement intravenous solution given total parenteral nutrition tpn administration selenious acid tpn formula help maintain plasma selenium level also maintain endogenous store prevent deficiency l1922 selenium compound selenium sulfide used topically anti-dandruff shampoo case seborrhea l1916 purpose brevity selenite focus discussion information selenium obtained db11135 
Ammonium molybdate,ammonium molybdate source molybdenum exists several hydrate form intravenously administered additive solution total parenteral nutrition tpn molybdenum essential element present enzyme including xanthine oxidase sulfite oxidase aldehyde oxidase ,
Carbamide peroxide,carbamide peroxide also known urea-hydrogen peroxide water-soluble white crystalline solid compound consisting hydrogen peroxide urea source hydrogen peroxide found disinfecting dental bleaching product adverse effect carbamide peroxide dental bleaching agent include dentin sensitivity and/or gingival irritation led unstable reactive h+ free radical low ph prolonged use may also alter enamel surface morphology via enamel mineral loss surface roughening a32336 fda considers carbamide peroxide safe oral mucosal injury drug product oral wound healing agent although insufficient data establish general recognition effectiveness ingredient oral wound healing agent l1976 available otc otic drug non-water non-oil-based solution used soften loosen remove excessive ear wax cerumen ,indicated dental bleaching agent indicated oral wound healing agent oral mucosal injury indicated aid removal hardened ear wax 
Opium,opium first substance diverse group opiate known long time first evidence poppy culture date 5 thousand year sumerian year opium used sedative hypnotic determined addictive a32171 opium extracted _papaver somniferum_ known poppy plant integrant papaveraceae family characterized solitary leaf capsulated fruit therefore opium sticky brown resin obtained collecting drying latex exudes poppy pod l1761 extracted opium contains two main group alkaloid psychoactive constituent category phenanthrenes alkaloid central nervous system effect category isoquinolines morphine prevalent principal alkaloid opium responsible harmful effect opium l1762 opium gradually superseded variety synthetic opioids general anesthetic isolated derivative opium morphine noscapine strychnine veratrine colchicine codeine quinine a32175 opium prohibited drug abuse country illegal production drug derivative keep registered legal production opium different country obtention alkaloid extraction l1766 ,opium derivative commonly used medication treatment acute chronic pain opium alkaloid-derivatives also used tranquilizer antitussive treatment diarrhea t138 direct use opium common nowadays use derivative morphine codeine well use tincture opium severe diarrhea seen medical practice t139 illegal use opium registered recreational medicinal purpose a32182 
Capsicum oleoresin,capsicum oleoresin oily organic resin derived fruit plant capsicum genus chilli pepper plant finely ground capsicum oleoresin formed extraction process capsaicin using oragnic solvent ethanol commonly used culinary spice intensity biological action toxicological effect capsicum oleoresin direct function amount capsaicinoids capsaicin present compound l1944 capsaicinoids comprise group fat-soluble pungent chemical phenol include db06774 dihydrocapsaicin nordihydrocapsaicin homocapsaicin homodihydrocapsaicin a32318 db06774 dihydrocapsaicin pungent capsaicinoid analogue a32318 capsicum oleoresin contained pepper spray suspended water act active lachrymatory agent induces irritation lacrimation pain temporary blindness contact eye due analgesic property capsicum oleoresin used temporarily relieve minor ache pain muscle joint active ingredient topical otc preparation studied management different model neuropathic pain a32316 suggested capsicum oleoresin rich source phytochemical consist phenolic compound antioxidant antidiabetic activity a32317 ,indicated temporary relief minor ache pain muscle joint associated simple backache arthritis strain sprain 
Silicon dioxide,silicon dioxide silica oxide silicon chemical formula sio2 found nature agate amethyst chalcedony cristobalite flint sand quartz tridymite transparent tasteless crystal inhalation fine crystal toxic human leading respiratory toxicity powdered food product pharmaceutical tablet silicon dioxide added flow agent absorb water colloidal silica also used wine beer juice fining agent stabilizer ,
Omega-3 fatty acids,omega-3 fatty acid polyunsaturated fatty acid pufas double bond third carbon atom end carbon chain three type omega-3 fatty acid involved human physiology α-linolenic acid ala found plant oil eicosapentaenoic acid epa docosahexaenoic acid dha commonly found fish oil originally come microalgae consumed phytoplankton source diet fish omega-3 fatty acid play critical role metabolism cellular function available daily supplement september 8 2004 u.s. food drug administration gave `` qualified health claim '' status epa dha omega-3 fatty acid therapeutic product containing omega-3 fatty acid derivative treatment hypertriglyceridemia include lovaza omtryg epanova vascepa ,provided daily supplement aa preparation omega-3-acid ethyl ester licensed uk prevention recurrent event myocardial infarction addition treatment hypertriglyceridaemia 
Cupric oxide,cupric oxide copper ii oxide inorganic compound chemical formula cuo cupric oxide used precursor many copper-containing product wood preservative ceramic cupric oxide may found over-the-counter vitamin-mineral supplement source db09130 mean daily dietary intake copper adult range 0.9 2.2 mg l2422 common route cupric oxide exposure include ingestion dermal exposure inhalation copper ii oxide nanoparticles npcuo industrial application antimicrobial agent textile paint catalyst organic synthesis a32656 may also produced electronic waste cupric oxide pose potential health environmental concern due toxic mutagenic particle generating reactive oxygen specie a32656 , fda- ema-approved therapeutic indication 
Selenium,selenium trace metal human body particularly important component glutathione peroxidase important enzyme prevention cellular damage free radical reactive oxygen specie fda label , supplementation total parenteral nutrition prevent hyposelenemia fda label 
Chromium,chromium transition element chemical symbol cr atomic number 24 belongs group 6 periodic table used various chemical industrial manufacturing application wood preservation metallurgy us chromium compound depend valency chromium trivalent cr iii compound used dietary cr supplementation hexavalent cr vi compound used corrosion inhibitor commercial setting known human carcinogen l1982 human exposed chromium via ingestion inhalation dermal ocular exposure l1983 trivalent chromium cr iii ion considered essential dietary trace element involved metabolism blood glucose regulation insulin resistance metabolism lipid clinical trial study suggest evidence chromium intake improving glucose tolerance patient type ii diabetes however clinical application standard management type ii diabetes mellitus established chromium deficiency associated diabetic-like state impaired growth decreased fertility increased risk cardiovascular disease a32343 a32351 l1982 according national institute health daily dietary reference intake dri chromium adult male non-pregnant female 35 μg 25 μg respectively l1986 chromium picolinate capsule may used nutritional adjuvant patient risk type 2 diabetes mellitus t2dm improve blood sugar metabolism stabilize level serum cholesterol chromium chloride available intravenous injection use supplement intravenous solution given total parenteral nutrition tpn fda label ,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Molybdenum,molybdenum chemical element symbol mo atomic number 42 naturally occuring free metal earth molybdenum found various oxidation state mineral molybdenum commonly used metallurgy chemical application however essential biological role organism microorganism essential trace dietary element act critical cofactor several molybdenum-dependent enzyme involved important cellular reaction pathway including xanthine oxidoreductase complexed technetium tc 99m molybdenum used radiopharmaceutical agent diagonistic procedure ,
Chromium Cr-51,chromium cr-51 isotope chromium used radioactive label decade used diagnostic radiopharmaceutical agent nephrology determine glomerular filtration rate a249765 a249770 hematology determine red blood cell volume mass study red blood cell survival time evaluate blood loss a249775 l1005 ,
Manganese gluconate,manganese gluconate manganese salt gluconic acid chemical formula c12h22mno14 x 2h2o typically obtained reacting manganese carbonate gluconic acid aqueous medium crystallizing product form slightly pink powder manganese gluconate direct ingredient food substance nutrient supplement pharmaceutical preparation used db06757 supplement ,manganese gluconate currently available combination product indicated prophylactic nutritional supplementation db06757 fda label 
Selenomethionine,selenomethionine naturally occuring amino acid plant material cereal grain soybean enriched yeast synthesized animal human produced post-structural modification vivo selenomethionine play essential role acting antioxidant depletes reactive oxygen specie ro aid formation recycling glutathione another important antioxidant comparison selenite inorganic form selenium organic form selenomethionine readily absorbed human body selenomethionin used biochemical laboratory incorporation protein need visualized enhances performance x-ray crystallography ,
Cresol,cresol hydroxytoluene extracted naturally coal tar made synthetically pure cresol mixture ortho- meta- para- isomer cresol precursor synthetic intermediate various compound material including plastic pesticide pharmaceutical disinfectant dye ingestion cresol induces toxicity human lead burning mouth throat abdominal pain and/or vomiting concentration normally found environment however cresol pose significant risk general population , primary medical indication cresol general include used bactericide pesticide disinfectant l2020 certain isomer cresol like m-cresol may used inactive ingredient purpose serving preservative pharmaceutical l2020 
Oxyquinoline,oxyquinoline heterocyclic phenol derivative quinoline antiseptic disinfectant pesticide property used stabilizer hydrogen peroxide sometimes added cosmetic product ,oxyquinoline used biocidal component several counter product product marketed purpose inhibiting abnormal biological growth vagina restoring natural ph 
Aluminum zirconium pentachlorohydrate,aluminum zirconium pentachlorohydrate common active ingredient personal care product antiperspirant agent main mechanism action blocking pore via formation polymer complex preventing sweat leaving body ,
Butamben,butamben local anesthetic form n-butyl-p-aminobenzoate a27147 structure corresponds standard molecule hydrophilic hydrophobic domain separated intermediate ester found local anesthetic due low water solubility butamben considered suitable topical anesthesia fda removed parenteral butamben product market possibly due poor solubility drug a254247 l43942 ,butamben indicated treatment chronic pain due long-duration effect a32663 also indicated surface anesthetic skin mucous membrane relief pain pruritus associated anorectal disorder l2445 
Aluminum zirconium tetrachlorohydrex gly,aluminum zirconium tetrachlorohydrex gly common active ingredient personal care product antiperspirant agent main mechanism action blocking pore via formation polymer complex preventing sweat leaving body ,
Barium sulfate,barium sulfate inorganic compound chemical formula baso4 l1957 barium sulfate occurs nature mineral _barite_ also used various manufacturing application mixed heavy concrete serve radiation shield l1957 drug used contrast agent diagnostic x-ray procedure therapeutic advantage barium sulfate diagnostic procedure include low water solubility high level clearance body fda label barium sulfate ingested mouth administered rectally combined granule effervescent bicarbonate enhance distension gi tract allowing enhanced gastrointestinal tract visualization l1957 l1959 ,barium sulfate radiographic contrast agent indicated use computed tomography ct abdomen delineate gastrointestinal gi tract adult pediatric patient fda label 
Sodium hydroxide,sodium hydroxide also known _lye_ _soda_ _caustic soda_ l1971 room temperature sodium hydroxide white crystalline odorless solid absorbs moisture air synthetically manufactured substance dissolved water neutralized acid release substantial amount heat may prove sufficient ignite combustible material sodium hydroxide highly corrosive l1965 sodium hydroxide generally used solid diluted 50 solution chemical used manufacture soap rayon paper explosive dyestuff petroleum product l1965 also used processing cotton fabric laundering bleaching metal cleaning processing oxide coating electroplating electrolytic extracting commonly found commercial drain/ oven cleaner l1965 according fda sodium hydroxide considered direct food recognized safe serf ph control agent follows good manufacturing guideline l1967 interestingly sodium hydroxide studied use treatment prion disease occurs mad cow disease kuru use compound shown effectively reduce prion level vitro inactivation assay a32334 ,used destroy kill nail matrix matrixectomies l1968 
Trichloroacetate,trichloroacetate trichloroacetic acid strong acid prepared reaction chlorine acetic acid presence suitable catalyst clinical chemistry biochemistry used precipitant macromolecule including protein dna rna trichloroacetate also found cosmetic treatment topical formulation cauterant remove condyloma wart skin ,
Potassium hydroxide,potassium hydroxide also known _lye_ inorganic compound chemical formula _koh_ also commonly referred _caustic potash_ potent base marketed several form including pellet flake powder used various chemical industrial manufacturing application potassium hydroxide also precursor potassium compound potassium hydroxide used food adjust ph stabilizer thickening agent l1946 l1951 ingredient considered generally safe direct human food ingredient fda based upon observance several good manufacturing practice condition use l1943 addition us potassium hydroxide also used making soap electrolyte alkaline battery electroplating lithography paint varnish remover liquid drain cleaner contain 25 36 potassium hydroxide l1946 medically potassium hydroxide koh widely used wet mount preparation various clinical specimen microscopic visualization fungi fungal element skin hair nail even vaginal secretion a32324 l1946 recently studied efficacy tolerability treatment wart determined topical koh solution found safe effective treatment plane wart l1941 ,medically microscopic examination potassium hydroxide koh preparation utilized diagnosis fungal hypha trichomonad l1950 sample hair skin nail tissue obtained scraping scalpel cotton-tipped applicator inoculated directly onto koh solution l1950 addition potassium hydroxide used softener nail groove l1949 
Zinc citrate,zinc citrate zinc salt citric acid available dietary supplement treatment zinc deficiency source zinc essential trace element zinc citrate demonstrates effective absorption following oral administration a27280 ,
Triclocarban,triclocarban chemical formula c13h9cl3n2o l2675 antibacterial agent particularly effective gram-positive bacteria staphylococcus aureus bacteriostatic compound found antibacterial soap personal care product 2017 u fda prohibited marketing over-the-counter otc consumer antiseptic wash product containing triclocarban due negative health effect bacterial resistance hormonal effect l2672 l2673 ,"triclocarban tcc 3,4,4'-trichlorocarbanilide antibacterial agent used bar liquid soap body wash l2685 "
Pyrantel,pyrantel pyrimidine-derivative anthelmintic agent oral treatment various parasitic worm infection including ascariasis hookworm infection enterobiasis pinworm infection trichostrongyliasis trichinellosis l1904 pyrantel initially described 1965 researcher pfizer sought cyclic amidines suitable pharmacokinetic property specifically duration action use anthelmintic drug pyrantel mainly available formulation dog cat embonate salt containing 34.7 pyrantel base l1900 pyrantel world health organization 's list essential medicine safest effective medicine required functioning health system l1901 l1902 depolarizing neuromuscular-blocking agent causing longstanding nicotinic receptor activation resulting spastic paralysis susceptible nematode worm pyrantel shown effective single dose l1905 human administered pyrantel pamoate a32282 a32283 l1893 l1898 , treatment enterobiasis including roundworm ascariasis pinworm enterobius hookworm strongyloides hookworm ancylostoma pyrantel pamoate form l1893 pyrantel available various formulation human dog cat pamoate u pharmacopeia nomenclature embonate european pharmacopoeia nomenclature salt contains 34.7 pyrantel base combined pamoic acid l1893 l1900 a32283 pyrantel pamoate embonate ingested orally effective removal control ascarid hookworm infection puppy dog adult toxocara canis toxascaris leonina ancylostoma tubaeforme braziliense uncinaria stenocephala cat adult toxocara cati toxa leonina caninum braziliense u. stenocephala horse pony adult immature parascaris equorum adult strongylus vulgaris s. edentatus s. equinus cyathostomes triodontophorus spp. cyathostomum spp. cylicodontophorus spp. cylicocyclus spp. cylicostephanus spp. poteriostomum spp oxyuris equi anoplocephala perfoliata swine adult ascaris suum oesophagostomum dentatum human adult a. lumbricoides enterobius vermicularis duodenale necator americanus l1900 
Anthralin,"anthralin 1,8‐dihydroxy‐9anthrone dithranol older anti-psoriatic agent first synthesized derivative chrysarobin obtained araroba tree brazil 100 year ago adverse effect anthralin include irritation discoloration skin a27277 specific property molecule inspired worker study detail pharmacology important consider drug relatively innocuous yet effective systemic side effect observed anthralin contrast wide variety systemic topical therapy psoriasis l1935 anthralin also known dithranol main active ingredient topical skin formulation treatment psoriasis various formulation drug available including solution foam shampoo l1979 chemical structure anthralin allows dual solubility permitting compound absorbed well epidermis a27276 anthralin also studied treatment wart showing promising result a32307 salicylic acid frequently added anthralin augment stability anthralin increase penetration efficacy l1979 ",stable plaque psoriasis skin scalp l1933 also used topically management psoriasis dermatosis alopecia areata anthralin also used biomedical research due effect egfr autophosphorylation l1936 
Pectin,pectin heteropolysaccharide commercially derived cell wall higher plant a32327 composed partially methylated polygalacturonic acid unit linked position 1-4 l1961 carboxylic group constituent pectin exist form ester free acid ammonium potassium sodium salt acid amide fda regulation pectin qualifies gras generally recognized safe food substance status allows pectin used limitation l1960 ,pectin used food gelling agent stabilizer medical drug obtained great interest potential use source dietary fiber lipid cholesterol serum glucose insulin level lowering effect gastric emptying delay a32327 recent study researched possibility using pectin formation nanoparticles delivery vehicle drug a32331 
Sodium sulfide,sodium sulfide chemical compound chemical formula na2s sodium sulfide used pulp paper industry water treatment textile industry various chemical manufacturing process including production rubber chemical sulfur dye oil recovery along hydrate form sodium sulfide release hydrogen sulfide h2s contact moist air h2s endogenous gaseous transmitter exhibit anti-inflammatory antiapoptotic property along sulfide anti-inflammatory tissue-protective effect sodium sulfide investigated model inflammation oxidative stress interestingly sodium sulfide shown cardioprotective role cardiac ischemia reperfusion injury well protect lung ventilator-induced lung injury a27275 however clinical significance mechanism action sodium sulfide replication result across study yet fully determined ,
Phenyltoloxamine,phenyltoloxamine antihistamine drug sedative analgesic effect h1 receptor blocker member ethanolamine class antihistaminergic drug available combination product also contain analgesic antitussive acetaminophen phenyltoloxamine citrate common salt form act active ingredient pharmaceutical product promotes hay fever relief via reversing effect histamine phenyltoloxamine act adjuvant analgesic augments analgesic effect acetaminophen also potentiates effect drug codeine codeine derivative although phenyltoloxamine 's ability potentiate effect analgesic may explained part chemical nature first-generation h1 antihistamine capable crossing blood-brain barrier causing tranquilizing effect cns histamine receptor many drug 's specific pharmacokinetics readily available perhaps also many early phenyltoloxamine involved study early 1950s first-generation antihistamine optimally investigated a32705 nevertheless phenyltoloxamine used fairly limited extent contemporary medicine product involving active ingredient , primary therapeutic use phenyltoloxamine currently indicated adjuvant therapy various combination product containing analgesic either narcotic non-narcotic expected potentiate pain relieving anti-tussive etc effect analgesic component product regard aforementioned combination product typically indicated temporary relief minor ache pain like headache muscular ache backache minor arthritis pain common cold toothache menstrual cramp etc l2499 perhaps treatment exhausting non-productive cough associated cold upper respiratory allergic condition respond non-narcotic antitussive l2495 
Polyethylene glycol 300,polyethylene glycol 300 peg 300 water-miscible polyether average molecular weight 300 g/mol clear viscous liquid room temperature non-volatile stable property a33116 polyethylene glycol widely used biochemistry structural biology medicine addition pharmaceutical chemical industry serve solubilizers excipients lubricant chemical reagent low molecular weight glycol observed exhibit antibacterial property well peg 300 found eye drop lubricant temporarily relieve redness burning irritation eye ,indicated lubricant over-the-counter ophthalmic solution temporarily relieve redness burning irritation eye 
Bicisate,"bicisate also known ethyl cysteinate dimer ecd n n'-1,2-ethylene-di-yl-bis-l-cysteinate diethyl ester used conjunction technetium tc99m tracer measure cerebral blood flow single-photon emission computed tomography spect a32374 complex bicisate technetium tc99m kit developed lantheus medcl fda-approved november 23 1994 l2029 ",bicisate complex technetium tc-99m used single photon emission computerized tomography spect adjunct conventional ct mri localization stroke patient presence stroke already diagnosed indicated ass functional viability brain tissue distinguish stroke brain lesion l2034 stroke defined condition blood stop flowing part brain causing damage brain cell potential effect stroke depends part brain affected well extension damage l2069 
Rosin,rosin solid form resin obtained pine plant mostly conifer prepared heating fresh liquid resin vaporize volatile liquid terpene component rosin used various commercial industrial application including printing lead-tin industry food production pharmaceutical rosin used film forming coating tablet enterically administered agent well forming microcapsules nanoparticles rosin shown mediate antibacterial action gram-positive bacterial specie a27267 ,
Antithrombin Alfa,antithrombin alfa recombinant antithrombin anticoagulant used prevention thromboembolic event patient hereditary deficiency antithrombin high risk situation ,antithrombin alfa recombinant antithrombin indicated prevention peri-operative peri-partum thromboembolic event patient hereditary deficiency antithrombin 
Calcium threonate,"calcium threonate calcium salt threnoic acid novel drug developed treatment osteoporosis calcium supplement a27266 found dietary supplement source l-threonate used treatment calcium deficiency prevention osteoporosis common form calcium l-threonate 2r,3s -2,3,4-trihydroxy butyric acid calcium a27266 l-threonate active metabolite vitamin c mediates stimulatory action vitamin c uptake a27266 therapeutic efficacy calcium threonate reducing studied investigated due hypothesis may play role mineralization process positive action vitamin c ", approved therapeutic indication 
Ferrous asparto glycinate,ferrous asparto glycinate iron-amino acid chelate available dietary supplement used treatment iron deficiency iron deficiency anemia ,
Ferric sulfate,ferric sulfate molecular formula fe2so4 dark brown yellow chemical agent acidic property produced reaction sulfuric acid oxidizing agent used different field dermatology dentistry thought present hemostatic property interacting chemically blood protein a32355 a32356 fda ferric sulfate direct food substance affirmed gras category generally recognized safe l2003 ,ferric sulfate first used dermatology part monsel 's solution solution antihemorrhagic agent used skin mucosal biopsy use ferric sulfate dermatology review ferric sulfate corrosive injurious cause degenerative change observed alternative like collagen a32357 ferric sulfate also used coagulative hemostatic agent mechanic hemostatic agent used directly damaged tissue a32355 dentistry ferric sulfate used pulpotomy medicament control pulpal bleeding antibacterial agent hemostatic reagent restorative dentistry postextraction hemorrhage periradicular endodontic surgery a32356 
Sesame oil,sesame oil commonly used vegetable oil asia flavoring enhancer various culinary practice extracted sesame seed contains linoleic acid oleic acid palmitic acid stearic acid fatty acid sesame oil reported posse antioxidant antiaging antihypertensive immunoregulatory anticancer property also shown accelerate alcohol decomposition liver a27257 sesame oil considered indirect additive used food cotact substance fda ,
Zinc picolinate,zinc picolinate zinc salt picolinic acid available otc dietary supplement source zinc treat prevent zinc deficiency absorption zinc oral administration zinc picolinate shown effective ,
Zeaxanthin,zeaxanthin common carotenoid alcohol found nature involved xanthophyll cycle coexistent isomer lutein zeaxanthin synthesized plant micro-organism give distinct yellow color many vegetable plant including paprika corn saffron wolfberries zeaxanthin one two primary xanthophyll carotenoid contained within retina eye play predominant component central macula available dietary supplement eye health benefit potential prevention age-related macular degeneration zeaxanthin also added food dye ,
Polysorbate 20,polysorbate 20 polysorbate-type nonionic surfactant used many commercial household pharmaceutical product composed 20 repeated unit polyethylene glycol via ethoxylation polysorbate 20 wetting agent food product well washing agent stabilizer solubilizer labratory assay industrial application also excipient stabilizes emulsion suspension pharmaceutical product lubricant ophthalmic solution ,
Exametazime,exametazime diagnostic radiopharmaceutical agent commonly used preparation tc99m exametazime injection act chelating agent radioisotope technetium-99m form cationic complex used detection altered regional cerebral perfusion radiolabeling autologous leukocyte ,
Tetrofosmin,"tetrofosmin developed overcome non-target uptake radioligands generation hetero-atomic compound present molecular formula 1,2-bis bi 2-ethoxyethyl phosphino ethane tetrofosmin part group diphosphines tetrofosmin used conjunction technetium tc-99m radiopharmaceutical a7788 ",tetrofosmin indicated used complex technetium tc-99m scintigraphic imaging myocardium following separate administration exercise and/or resting condition help delineation region reversible myocardial ischemia absence infarcted myocardium l2001 complex also used scintigraphic imaging myocardium identify change perfusion induced pharmacologic stress patient known suspected coronary artery disease l2001 complex indicated assessment left ventricular function patient evaluated heart disease l2001 
Homatropine,homatropine anticholinergic drug act antagonist muscarinic acetylcholine receptor present antitussive trade name hycodan combination hydrocodone dihydrocodeinone bitartrate indicated symptomatic relief cough oral tablet solution homatropine included subtherapeutic amount homatropine methylbromide discourage deliberate overdosage homatropine hydrobromide administered ophthalmic solution cycloplegic temporarily paralyze accomodation induce mydriasis dilation pupil however therapeutic use approved fda safe effective ,indicated overdose-rescuing agent combination hydrocodone antitussive fda label indicated induction mydriasis ophthalmic solution 
Rose bengal,rose bengal pink stain derived analogue fluorescein disodium salt ophthalmic solution used diagnostic agent suspected damage conjunctival corneal cell also used laboratory setting including preparation foraminifera microscopic analysis suppression bacterial growth several microbiological medium direct cytotoxic effect rose bengal microorganism cancer cell observed questioning potential antitumor action via intralesional injection clinical application rose bengal injectable formulation name pv-10 melanoma breast cancer skin condition eczema psoriasis investigated clinical trial a32399 ,indicated diagnostic agent routine ocular examination superficial conjunctiva corneal tissue change suspected aid diagnosis keratoconjunctivitis sicca keratitis abrasion corrosion well detection foreign body 
Light green SF yellowish,light green sf yellowish green triarylmethane dye used preparation staining solution widely used counterstain used histological application labratory setting usually exists disodium salt maximum absorption light green sf yellowish 630 422 nm although used food colorant discontinued market due low popularity possibly due low durability dye increased tendency dye fade light green sf yellowish also available sterile strip used diagnostic agent superficial corneal conjunctival tissue change suspected ,
Oftasceine,oftasceine also referred fluorexon used ophthalmic solution staining agent fitting soft hard lens fluorescent dye luminescent agent ,
Sulisobenzone,sulisobenzone approved fda concentration 10 canada approved health canada concentration f38 work filter uva uvb ray protecting skin sun uv damage l2153 uv-filter substance sulisobenzone bp-4 widely used ingredient sunscreen personal care product a32927 l2668 fall drug category _benzophenones_ benzophenones group aromatic ketone pharmaceutical industrial application l2671 benzophenones may found organically fruit grape l2669 benzophenones used photoinitiators fragrance enhancer ultraviolet curing agent occasionally flavor ingredient also used manufacture insecticide agricultural chemical pharmaceutical additive plastic coating adhesive l2670 group benzophenones may used delay photodegradation extend shelf life toiletry plastic surface coating l2671 ,sunscreening agent used prevent sunburn actinic keratosis premature skin aging reduce incidence skin cancer l2664 
Pentoxyverine,pentoxyverine also referred carbetapentane non-opioid central acting antitussive antimuscarinic anticonvulsant a32717 local anesthetic property active ingredient over-the-counter cough suppressant combination guaifenesin h1-receptor antagonist a32160 pentoxyverine act sigma-1 receptor well kappa mu-opioid receptor fda withdrew use oral gel drug product containing pentoxyverine citrate l43942 form pentoxyverine citrate continue marketed ,indicated cough suppressant relieve cough caused common cold flu bronchitis sinusitis a32160 
Magnesium glycinate,magnesium glycinate magnesium salt glycine available dietary supplement source magnesium used treatment magnesium deficiency ,
Pantethine,pantethine naturally occurring compound synthesized body pantothenic acid vitamin b5 via addition cysteamine consists two molecule pantetheine form dimer via disufide linkage act intermediate production coenzyme a. coenzyme play essential role cofactor metabolism lipid carbohydrate including fatty acid oxidation carbohydrate metabolism pyruvate degradation amino acid catabolism a27255 pantethine available dietary supplement lowering blood cholesterol triglyceride ,
Cobamamide,cobamamide one active form vitamin b12 also known _adenosylcobalamin_ _dibencozide_ drug available nutritional supplement prevent vitamin b12 deficiency vitamin b12 collective term variously substituted corrinoids principal biochemical participant two coenzyme form vitamin b12 produced activated two separate cellular compartment methylcobalamin cytosol adenosylcobalamin mitochondrion l2053 vitamin b12 cyancobalamin cbl two active co-enzyme form _methylcobalamin mecbl _adenosylcobalamin adcbl shift treatment vitamin b12 deficiency mecbl extensively used promoted exists despite fact mecbl adcbl necessary life vastly different metabolic fate function mecbl mainly involved along folate hematopoiesis growth brain childhood deficiency adcbl disturbs carbohydrate fat amino-acid metabolism therefore interferes formation myelin therefore important treat vitamin b12 deficiency combination mecbl adcbl hydroxocobalamin cobalamin l2054 vitamin b12 important physiological role including dna synthesis myelin formation nervous system red blood cell formation well fatty acid amino acid metabolism l2047 please refer entry db00115 information entry ,
Papain,papain also known papaya proteinase cysteine protease ec 3.4.22.2 enzyme found specie papaya _carica papaya_ _vasconcellea cundinamarcensis_ enzyme found localized skin papaya collected slashed unripe papaya crude latex papain used food pharmaceutical textile cosmetic industry used treatment inflammation pain via topical administration papain also shown anthelmintic tooth-whitening property present over-the-counter mixture product consisting different digestive enzyme active site contains catalytic diad play role breaking peptide bond papain also used ingredient various enzymatic debriding preparation , fda-approved therapeutic indication 
Xylitol,xylitol naturally occurring five-carbon sugar alcohol found plant material including many fruit vegetable xylitol-rich plant material include birch beechwood a22081 widely used sugar substitute `` sugar-free '' food product effect xylitol dental caries widely studied xylitol added chewing gum oral care product prevent tooth decay dry mouth xylitol non-fermentable sugar alcohol plaque bacteria indicating fermented cariogenic acid end-products a32423 work inhibiting growth microorganism present plaque saliva accummulates intracellularly microorganism a32423 recommended dose xylitol dental caries prevention 6–10 g/day adult tolerate 40 g/day without adverse event a22081 ,indicated use sugar substitute oral hygiene active ingredient 
Peppermint oil,extracted stem leaf flower _mentha piperita_ l. plant peppermint oil mentha piperita popular essential oil used aromatherapy external internal use mentha piperita hybrid spearmint mentha spicata water mint mentha aquatica a33065 medicinal use herbal ingredient peppermint oil long history treating digestive disorder upper respiratory symptom cough a33055 various over-the-counter commercial us peppermint oil due carminative cholagogue antibacterial secretolytic choleretic action a33056 peppermint oil contains pulegone naturally-occurring pesticide f77 active constituent peppermint oil include db00825 menthone cineol several volatile oil a33055 a33056 peppermint oil used flavouring agent food fragrance hygienic cosmetic product anti-itch cooling agent topical pharmaceutical product also active ingredient topical analgesic relief joint muscle pain peppermint oil applied topically temporarily relieve tension-type headache use peppermint oil management irritable bowel syndrome ibs investigated many clinical study due relaxing effect smooth muscle however evidence supporting use unclear due effectiveness relaxing gi smooth muscle ability induce gastroesophageal reflux enteric-coated formulation peppermint oil established bypass upper gi tract unmetabolized thereby facilitating effect lower gi tract without effect upper tract a33055 peppermint oil safe well-tolerated commonly recommended dosage a33055 ,indicated over-the-counter use -the symptomatic relief minor spasm gastrointestinal tract flatulence abdominal pain especially patient irritable bowel syndrome -the temporary relief itching associated insect bite eczema minor burn sunburn minor skin irritation minor cut scrape atopic dermatitis skin disorder -the temporary symptomatic relief mild joint muscle pain local topical analgesic -the temporary relief tension-type headache 
Sage oil,"sage oil extracted sage salvia officinalis herb commonly used culinary purpose salvia officinalis common sage member genus salvia includes aromatic perennial plant flower essential oil traditionally used medicine relief pain treatment inflammation infection reported exhibit carminative antispasmodic antiseptic astringent property a27252 main constituent sage oil include camphor 1,8-cineole α-thujone β-thujone borneol viridiflorol thought mainly produce biological effect sage oil sage oil also contains flavonoid polyphenolic compound mediate strong antioxidant radical-scavenging antibacterial activity a27252 found cosmetic personal care product dietary supplement ",
Aluminum zirconium octachlorohydrex gly,aluminum zirconium octachlorohydrex gly complex consists aluminum zirconium octachlorohydrate glycine active antiperspirant agent l2705 l2706 diffuses sweat pore prevents perspiration sweat leaving pore anhydrous form compound also water-absorbing property currently fda allows inclusion substance concentration 20 antiperspirant l2012 interestingly chemical studied relation possible impact microbiome human underarms a32967 ,aluminum-based antiperspirant preparation intended reduction normal underarm perspiration indicated use hyperhidrosis l2708 
Menthyl salicylate,menthyl salicylate ester menthol salicylic acid l2808 product used treat minor ache pain muscles/joints e.g. arthritis backache sprain l2810 , temporary relief pain associated rheumatism arthritis neuralgia sprain strain joint muscle lumbago fibrositis f91 
N-alkyl ethylbenzyl dimethyl ammonium (C12-C14),n-alkyl ethylbenzyl dimethyl ammonium c12-c14 quaternary ammonium compound surfactant property found sanitizing solution soap active ingredient due antimicrobial property employed great variety cleaning agent sanitizing agent posse relatively broad gram-positive gram-negative antibacterial activity relatively little chance systemic absorption exposure although formal mechanism action quaternary ammonium compound like n-alkyl c12-c14 dimethyl ethylbenzyl ammonium chloride difficult elucidate ,n-alkyl c12-c14 dimethyl ethylbenzyl ammonium chloride added product function cleaning agent antimicrobial agent disinfecting cleaning product l2855 
Boron,boron b chemical element atomic number 5 belongs period 2 group 13 periodic table low-abundant metalloid poor electrical conductor room temperature natural boron exists 2 stable isotope however pure boron hard prepare due contamination different element also found application including ceramic high-hardness abrasive compound metal coating detergent bleaching agent insecticide semiconductor magnet wood preservative additive glass fiber boron-containing fiberglass insulation structural material boric acid contains antiseptic antifungal antiviral property thus used water clarifier swimming pool water treatment pharmaceutical agent contain boron molecule structure db09041 db00188 ,
Panthenol,panthenol alcohol derivative pantothenic acid component b complex vitamin essential component normally functioning epithelium panthenol exists racemic mixture containing dextrorotatory form dexpanthenol levorotatory form levopanthenol pantothenic acid optically active dextrorotatory form db09357 biologically active dexpanthenol active form panthenol enzymatically cleaved form pantothenic acid vitamin b5 essential component coenzyme act cofactor many enzymatic reaction important protein metabolism epithelium a32373 due good penetration high local concentration dexpanthanol used many topical product ointment lotion treatment dermatological condition relieve itching promote healing dermatological effect topical use dexpanthenol include increased fibroblast proliferation accelerated re-epithelialization wound healing furthermore act topical protectant moisturizer demonstrated anti-inflammatory property a32377 ,panthenol containing racemic mixture dexpanthenol levopanthenol currently available fda-approved product therefore indication please see db09357 fda-approved us dextrorotatory form panthenol 
Bemotrizinol,bemotrizinol bis-ethylhexyloxyphenol methoxyphenyl triazine organic uv filter found over-the-counter sunscreen product primarily absorbs uv-a ray compared older broad-spectrum chemical agent bemotrizinol fat soluble oil soluble cosmetic oil aid efficacy broad-spectrum activity a19212 claimed photostable increase onset action efficiency providing protection uv-rays upon topical application a19212 a32909 bemotrizinol commonly marketed tinosorb escalol ,indicated active sunscreen agent 
Amiloxate,amiloxate ema-approved chemical uv-filter found over-the-counter sunscreen product concentration 10 f35 often referred isoamyl 4-methoxycinnamate isoamyl p-methoxycinnamate amiloxate cinnamic acid derivative anti-inflammatory activity a32916 ,indicated active sunscreen agent 
Aluminum chlorohydrex propylene glycol,aluminum chlorohydrex propylene glycol complex consisting aluminum chorohydrate propylene glycol pg antiperspirant active ingredient found antiperspirant drug product over-the-counter human use ,
Ferrous bisglycinate,ferrous bisglycinate chelate used source dietary iron forming ring structure reacting glycine ferrous bisglycinate act chelate nutritionally functional a27250 found food food enrichment supplement treatment iron deficiency iron deficiency anemia ,
Arbutin,extracted dried leaf bearberry plant genus _arctostaphylos_ plant commonly _ericaceae_ family arbutin beta-d-glucopyranoside db09526 found food over-the-counter drug herbal dietary supplement f43 commonly active ingredient skincare cosmetic product skin-lightening agent prevention melanin formation various skin condition involve cutaneous hyperpigmentation hyperactive melanocyte function a27248 also used anti-infective urinary system well diuretic f43 arbutin available natural synthetic form synthesized acetobromglucose db09526 f43 arbutin competitive inhibitor tyrosinase e.c.1.14.18.1 melanocyte a27248 inhibition melanin synthesis non-toxic concentration observed _in vitro_ arbutin shown le cytotoxic melanocyte culture compared db09526 a32942 ,indicated over-the-counter use epidermal hyperpigmentation various skin condition melasma freckle senile lentigo 
Tea tree oil,tea tree oil essential oil derived mainly australian native plant _melaleuca alternifolia_ via steam distillation leaf terminal branch a32439 may referred _melaleuca alternifolia_ oil popular ingredient variety household cosmetic product due antiseptic anti-inflammatory broad-spectrum antimicrobial antioxidant property a32438 dermatological use tea tree oil investigated various study several study suggested us oil treatment acne vulgaris seborrheic dermatitis chronic gingivitis a32438 terpene hydrocarbon related alcohol constitute tea tree oil db12816 major antimicrobial component a32439 ,indicated topical use help protect infection minor cut scrape burn fda-approved therapeutic indication 
Enzacamene,commonly known 4-methylbenzylidene-camphor 4-mbc enzacamene camphor derivative organic chemical uv-b filter used cosmetic product sunscreen provide skin protection uv ray effect human reproductive system endocrine disruptor investigated use over-the-counter cosmetic product approved health canada tradenames include eusolex 6300 merck parsol 5000 dsm ,indicated use active sunscreen agent 
Octacosanol,1-octacosanol straight-chain aliphatic 28-carbon primary fatty alcohol used nutritional supplement high–molecular-weight organic compound main component natural product wax extracted plant a27245 1-octacosanol reported posse cholesterol-lowering effect antiaggregatory property cytoprotective use ergogenic property a27245 studied potential therapeutic agent treatment parkinson 's disease ,
Dioxybenzone,dioxybenzone benzophenone-8 organic compound derived db01878 used sunscreen agent absorbed uv-b uv-aii ray dioxybenzone approved sunscreen ingredient concentration 3 l2525 ,indicated use active sunscreen agent 
Benzoin resin,benzoin resin balsamic resin obtained bark several specie tree genus _styrax_ two common kind benzoin benzoin siam benzoin sumatra obtained different specie _styrax_ tree benzoin resin used common ingredient incense-making perfumery also used clinically mild antiseptic agent over-the-counter product clean sore cut wound skin abrasion tincture benzoin benzoin solution alcohol tincture benzoin solution topical adhesive agent used provide tackiness enhance adhesive property tape ,indicated mild antisepsis skin cut abrasion 
Ethylhexyl methoxycrylene,ethylhexyl methoxycrylene photostabilizer preserve effectiveness uv filter interacting singlet triplet state f104 return uv filter ground state without absorbing sunlight f104 used solvent crystalline uv filter easily emulsified suitable use various lotion cream spray stick gel formulation f104 currently enjoys regional approval canada eu u l2847 ,ethylhexyl methoxycrylene employed photostabilizing agent various sunscreen product l2847 
Methylcellulose,methyl cellulose polymer consisting numerous linked glucose molecule used stabiliser thickener emulsifier foodstuff cosmetic degree substitution d given form methyl cellulose defined average number substituted hydroxyl group per glucose theoretical maximum 3 however typical value 1.3 2.6 methyl cellulose hydrophilic white powder pure form dissolve cold hot water forming clear viscous solution gel available variety trade name treatment constipation like cellulose digestible toxic allergenic,solution containing methyl cellulose used substitute tear saliva natural production fluid disturbed also used constipation diverticulosis hemorrhoid irritable bowel syndrome used manufacture capsule nutritional supplement edible nontoxic property provide vegetarian alternative use gelatin 
Padimate A,padimate ester derivative paba ingredient sunscreen absorbs ultraviolet ray thereby preventing sunburn however chemical structure behaviour similar industrial free radical generator europe chemical withdrawn 1989 unstated reason u never approved use sunscreen ,
Magnesium Aluminum Silicate,magnesium aluminum silicate naturally occurring mineral obtained silicate ore montmorillonite group a32782 refined powder use cosmetic pharmaceutical application absorbent anticaking agent opacifying agent viscosity-increasing agent suspending agent tablet capsule disintegrant tablet binder also antacid property used component counter antacid medication ,magnesium aluminum silicate used counter antacid self-treatment heartburn sour stomach acid indigestion fda label 
Lycopene,lycopene naturally occuring red carotenoid pigment responsible red pink color seen tomato pink grapefruit food a27242 chemical formula c40h56 lycopene tetraterpene assembled eight isoprene unit solely composed carbon hydrogen lycophene may undergo extensive isomerization allows 1056 theoretical cis-trans configuration however all-trans configuration lycopene predominant isomer found food a27242 a27243 give red hue lycopene non-essential human nutrient classified non-provitamin carotenoid pigment since lack terminal beta ionone ring a27242 mediate vitamin activity however lycophene potent antioxidant molecule scavenges reactive oxygen specie ro singlet oxygen tomato lycopene extract used color additive food product ,
Poliglusam,poliglusam chitosan linear polysaccharide consisting d-glucosamine n-acetyl-d-glucosamine naturally-occuring poliglusam found cell wall fungi soil sediment produced degradation chitin induced certain group bacteria produce enzyme deacetylase chitosanase enzyme l999 comparison commercial poliglusam derived deacetylation chitin contained shell various sea crustacean shrimp l999 rich source dietary fiber chitosan used food ingredient additive also reported effect protein aggregation emulsification capacity film-forming ability clarifying ability fatty acid absorption capability l999 addition chitosan also exhibit antimicrobial antioxidant activity ,
Thonzylamine,thonzylamine antihistamine anticholinergic drug available combination product db04837 db00388 temporary relief symptom common cold hay fever allergic rhinitis upper respiratory allergy ,thozylamine indicated use symptomatic control allergic rhinitis upper respiratory allergic symptom fda label typically part combination counter product 
Trypsin,trypsin serine protease play essential role protein hydrolysis absorption mammal converted zymogen trypsinogen trypsin available active peptide hydrolase ec 3.4.21.4 form cleave peptide chain mainly carboxyl side amino acid lysine arginine trypsin contains nucleophilic residue ser enzyme active site attack carbonyl moiety substrate peptide bond form acyl-enzyme intermediate a27241 nucleophilic attack facilitated catalytic triad consisting histidine-57 aspartate-102 serine-195 trypsin also contains oxyanion hole stabilizes charge negative charge carbonyl oxygen atom formed cleavage peptide bond therapeutic form trypsin obtained purified extract porcine bovine pancreas intended aid digestion administered orally ,
Borage oil,borage oil borage seed oil rich source gamma-linolenic acid gla obtained seed borago officinalis borage borage oil used herbal treatment skin disorder including eczema seborrheic dermatitis neurodermatitis well inflammatory cardiovascular endocrine disorder although clinical efficacy long-term effect fully elucidated yet gla account approximately 24 oil converted dihomo-γ-linolenic acid dgla act precursor anti-inflammatory mediator 1-series prostaglandin 3-series leukotrienes borage oil may found food skin care product ,
Aluminum sulfate,aluminum al also spelled aluminum chemical element lightweight silvery-white metal main group 13 iiia boron group periodic table l2148 chemical agent used water purification ph regulation garden soil commercial industrial application medically primarily used coagulating agent minor cut abrasion well deodorant l2144 aluminum al ubiquitous represents third common element earth ’ crust commonly exists combined state various element al found material used pharmaceutical industry manufactured foodstuff cosmetic tap water overcoming body barrier al may infiltrate blood lead toxic effect liver bone central nervous system l2145 ,solution containing 5 10 aluminum sulfate used local application ulcer arrest foul discharge mucous surface aluminum sulfate also used preparation aluminum acetate ear drop l2149 often purchased counter available solid stick powder form minor cut abrasion shaving l2157 l2164 aluminum sulfate also used adjuvant vaccine l2158 
Gelatin,gelatin multifunctional ingredient used food pharmaceutical cosmetic photographic film gelling agent stabilizer thickener emulsifier well film former a32432 thermoreversible hydrocolloid small gap melting gelling temperature gelatin provides unique advantage carbohydrate-based gelling agent gelatin mainly produced porcine skin cattle hide bone a32432 alternative raw substance recently garnered attention researcher industry overcome religious concern shared jew muslim also may provide scientific advantage gelatin mammal origin l2121 fish skin number fish specie type substance comprehensively studied source gelatin production fish skin significant potential production high-quality gelatin different melting gelling temperature much larger range mammalian gelatin sufficiently high level gel strength viscosity a32432 interestingly horse gelatin studied found horse gelatin influence homeostasis amino acid required cartilage synthesis a32434 increasing number novel application found collagen gelatin a32426 gelatin generally recognized safe gras fda non-hazardous food food ingredient l2110 fda withdrew approval use intravenous drug product containing gelatin gelatin continues approved route administration l43942 ,gelatin used weight loss treating osteoarthritis rheumatoid arthritis brittle bone osteoporosis people also use strengthening bone joint fingernail gelatin also used improving hair condition shorten recovery exercise sports-related injury l2113 gelatin used preparation food cosmetic medicine l2113 plasma volume expander hypovolaemic shock l2115 haemostatic l2115 gelatin-based hydrogel used drug delivery tissue engineering able promote cell adhesion proliferation addition hydrogel used wound dressing attractive fluid absorbance property manufacturing technology ultraviolet stereolithography two-photon polymerization used prepare structure containing photosensitive gelatin-based hydrogel l2111 
Ethyl macadamiate,ethyl macadamiate derived macadamia terifolia seed oil non-volatile ester ethyl alcohol fatty acid ethyl macadamiate used cosmetic personal care product sunscreen hair care product skin care product emollient skin conditioning agent ,
Cyclomethicone 5,cyclomethicone 5 member cyclomethicone group liquid methyl siloxane low viscosity high volatility cyclomethicones cyclic structure monomer backbone one silicon two oxygen atom bonded together cyclomethicone 5 used cosmetic personal product skin emollient ,
Copper gluconate,copper gluconate copper salt d-gluconic acid display light blue bluish-green color prepared reaction gluconic acid solution cupric oxide basic cupric carbonate according good manufacturing feeding practice fda copper gluconate used nutrient dietary supplement generally recognized safe use level exceeding 0.005 percent ,
Zinc gluconate,zinc gluconate zinc salt gluconic acid comprised two gluconic acid molecule zinc cation 2+ zinc gluconate generally recognized safe gras substance fda l2081 available trace mineral supplement counter lozenge form reduced duration common cold decreased symptom severity although nasally administered treating common cold route administration associated case anosmia a32414 a32409 a32410 l2080 study show zinc may better absorbed human gluconate form a32412 l2105 however result study may vary a27280 l2082 interestingly zinc supplementation become critical intervention treating diarrheal episode child study suggest administration zinc along new low osmolarity oral rehydration solutions/salts oral rehydration solution may reduce duration severity diarrheal episode 12 week l422 information zinc natural form available db01593 ,zinc gluconate mainly indicated condition like zinc deficiency also administered adjunctive therapy alternative drug choice diarrhea l2088 
Glyceryl monostearate,glycerol monostearate commonly known gm glycerol ester stearic acid commonly used emulsifier food ,
Tocopherol,tocopherol exists four different form designated α β δ γ present strong antioxidant activity determined major form vitamin e. tocopherol group composed soluble phenolic compound consist chromanol ring 16-carbon phytyl chain classification tocopherol molecule designated depending number position methyl substituent chromanol ring different type tocopherol presented trimethylated dimethylated methylated position 5- 7- 8- carbon position 5- 7- methylated function electrophilic center trap reactive oxygen nitrogen specie tocopherol found diet part vegetable oil corn soybean sesame cottonseed a32436 currently list substance generally recognized safe gras fda use human consumption l2114 ,tocopherol used dietary supplement patient deficit vitamin e mainly prescribed alpha form a32443 vitamin e deficiency rare primarily found premature baby low birth weight patient fat malabsorption patient abetalipoproteinemia l2120 tocopherol due antioxidant property studied use prevention treatment different complex disease cancer a32436 atherosclerosis cardiovascular disease a32442 age-related macular degeneration a32444 
Poloxamer 407,poloxamer 407 polyoxyethylene polymer hydrophilic non-ionic surfactant consists central hydrophobic block polypropylene glycol flanked side polyethylene glycol block hydrophilic nature poloxamer 407 used emulsifying agent solubilizing agent cosmetic personal product contact lens cleaning solution ,
Xanthan gum,xanthan gum polysaccharide gum derived xanthomonas campestris pure-culture fermentation process purified recovery isopropyl alcohol major constituent include d-glucose d-mannose d-glucuronic acid xanthan gum direct food additive permitted direct addition food human consumption fda used thickening agent stabilizer emulsion ,
Hexylresorcinol,hexylresorcinol substituted dihydroxybenzene exhibit antiseptic anthelmintic local anesthetic property found topical application minor skin infection oral solution throat lozenge pain relief first aid antiseptic compound may also used commonly various commercial cosmetic anti-aging cream ongoing study research possibility using hexylresorcinol anti-cancer therapy indication require study testing current moment ,hexylresorcinol predominantly employed active ingredient lotion spray lozenge indicated topical antiseptic help prevent skin infection minor cut scrape burn b antiseptic local anesthetic relief sore throat associated pain l2734 l2735 addition hexylresorcinol used active ingredient various commercial cosmetic skincare product anti-aging cream l2736 study looked whether compound could used effectively anti-inflammatory agent even anti-cancer therapy l2736 
Chromium picolinate,chromium picolinate chemical formula crpic3 reddish-pink color coordination complex consisting chromium iii picolinic acid chromium picolinate used nutritional supplement optimal insulin function patient type 2 diabetes promotion weight loss chromium ion shown regulate insulin promoting glucose utilization increasing sensitivity insulin receptor a27235 ,
Levomefolic acid,levomefolic acid inn metabolite folic acid vitamin b9 predominant active form folate found food blood circulation accounting 98 folate human plasma a19276 transported across membrane including blood-brain barrier various tissue play essential role dna synthesis cysteine cycle regulation homocysteine methylates homocysteine form methionine tetrahydrofolate thf levomefolate approved food additive designated gras generally regarded safe compound l773 available commercially crystalline form calcium salt metafolin r stability required use supplement a19276 supplementation levomefolic acid desired folic acid due reduced potential masking vitamin b12 deficiency symptom , treatment prevention folate deficiency use antidote folic acid antagonist contained oral contraceptive reduce risk neural tube defect arising folic acid deficiency pregnant woman conceived use shortly discontinuation product studied use treatment cardiovascular disease a19273 adjunct therapy patient undergoing antidepressant pharmacotherapy a19271 a19272 
Fluoride ion, chemical formula f− fluoride ion simplest inorganic monatomic anion fluorine basic property considered trace element fluoride ion found various mineral present trace amount water various salt form mineral play numerous role chemical reagent industrial chemical commercial product also play essential physiological role enhancing resistance profile strength surface tooth enamel ,
Diosmetin,diosmetin o-methylated flavone aglycone part flavonoid glycoside diosmin occurs naturally citrus fruit a27231 pharmacologically diosmetin reported exhibit anticancer antimicrobial antioxidant oestrogenic anti-inflamatory activity a27231 also act weak trkb receptor agonist a27230 ,
Diacetyl benzoyl lathyrol,diacetyl benzoyl lathyrol active ingredient whitening cream also reported skin conditioning agent ,
Bisoctrizole,bisoctrizole methylene bis-benzotriazolyl tetramethylbutylphenol broad-spectrum organic uv filter marketed tinosorb a19212 benzotriazole-based organic compound absorbs reflects scatter uv-a uv-b ray bisoctrizole approved fda approved eu part world uv-filter sunscreen day care product skin lightening product maximum concentration 10 f90 ,indicated use sunscreen agent cosmetic product 
Polydatin,polydatin piceid natural precursor glycoside form resveratrol monocrystalline structure isolated bark picea sitchensis polygonum cuspidatum polydatin may detected grape peanut hop cone red wine hop pellet cocoa-containing product chocolate product many daily diet a27226 polydatin posse anti-inflammatory immunoregulatory anti-oxidative anti-tumor activity shown mediate cytotoxic action colorectal cancer cell inducing cell arrest apoptosis a27229 ,
Calcium glycerophosphate,calcium glycerophosphate db01373 salt glycerophosphoric acid form white fine slightly hygroscopic powder commercial product mixture calcium beta- d- l -alpha-glycerophosphate fda calcium glycerophosphate considered generally recognized safe gras food ingredient nutrient supplement source calcium phosphorus food product gelatin pudding filling also present dental oral hygiene product due cariostatic effect suggested calcium glycerophosphate promotes plaque-ph buffering elevation plaque db01373 phosphate level direct interaction dental mineral a27153 ,calcium glycerophosphate found otc dental product toothpaste prevention dental caries otc product official indication prescription product indicated db01373 phosphate donor replacement supplementation patient insufficient db01373 phosphate 
Curcuma xanthorrhiza oil,_curcuma xanthorrhiza_ oil extracted _curcuma xanthorrhiza_ roxb. member ginger family _zingiberaceae_ widely distributed region southeastern asia a33162 _curcuma xanthorrhiza_ also known javanese turmeric temoe lawak f114 century _curcuma xanthorrhiza_ oil used traditional medicine due antibacterial antispasmodic antioxidative antitumor anti-inflammatory protective effect a33160 used treatment stomach disease liver disorder constipation bloody diarrhoea dysentery child ’ fever hypotriglyceridaemic haemorrhoid skin eruption a33162 _curcuma xanthorrhiza_ oil comprised 1-2 curcumin 3-12 volatile oil mainly contains sesquiterpenes 44.5 xanthorrhizol small amount db01744 f114 however principal active component curcuma xanthorrhiza db11672 xanthorrhizol display wide range pharmacological activity synergistic effect f114 curcumin mixture dicinnamoylmethane derivative phenolic non-phenolic diarylheptanoids f114 _curcuma xanthorrhiza_ oil found active ingredient cosmetic hygienic product marketing product containing _curcuma xanthorrhiza_ oil authorized european country including germany netherlands f114 ,indicated symptomatic relief digestive disturbance feeling fullness slow digestion flatulence f114 
Sea salt,sea salt salt obtained evaporation seawater water saltwater lake sea salt production subject little processing leaf certain trace mineral element behind comparison table salt mined underground sedimentary deposit heavily processed eliminate mineral unlike sea salt table salt usually contains additive prevent clumping involves addition iodine sea salt food ingredient often colored adding charcoal red clay sometimes referred “ hawaiian sea salt ”,
Protocatechualdehyde,also known protocatechuic aldehyde protocatechualdehyde naturally-occuring phenolic aldehyde found barley green cavendish banana grapevine leaf root herb s. miltiorrhiza a27224 protocatechualdehyde posse antiproliferative pro-apoptotic property human breast cancer cell colorectal cancer cell reducing expression pro-oncogenes β-catenin cyclin d1 ,
Diethylamino hydroxybenzoyl hexyl benzoate,diethylamino hydroxybenzoyl hexyl benzoate uv filter high absorption uv-a range minimizing overexposure human skin ultraviolet radiation may lead acute chronic photodamage diethylamino hydroxybenzoyl hexyl benzoate oil-soluble uv filter may incorporated oil phase emulsion f107 diethylamino hydroxybenzoyl hexyl benzoate approved europe 2005 also marketed u.s. south america mexico japan taiwan chemical structure similar classical benxophoenone drug class display good photostability a33171 used concentration 10 sunscreen product either alone combination uv absorber f107 ,indicated use sunscreen agent 
Atractylodes japonica root oil,atractylodes japonica root oil obtained root atractylodes japonica herb native eastern asia present cosmetic product whitening cream active ingredient lubricant skin irritation atractylodes japonica reported anti-inflammatory antinociceptive effect a27223 ,
Polysilicone-15,polysilicone-15 silicone based uvb absorber l2796 l2797 l2799 f87 f88 f89 compound colorless pale yellow viscous liquid soluble organic solvent medium polarity insoluble water l2796 l2797 l2799 f87 f88 f89 first polymeric uvb filer consisting chromophore attached silicone backbone l2796 l2797 l2799 f87 f88 f89 included various cosmetic shampoo conditioner hairsprays compound also function effective photostabilizer product l2796 l2797 l2799 f87 f88 f89 ,polysilicone-15 used uv-filter cosmetic sunscreen product well cosmetic product like shampoo conditioner hairsprays etc confer photostability product l2799 f89 
Methyl undecenoyl leucinate,methyl undecenoyl leucinate active ingredient whitening cream α-msh antagonist inhibits melanin synthesis tyrosinase activity reduces expression various melanogenic gene ,
Dihydroergocornine,"dihydroergocornine one dihydrogenated ergot compound present large hypotensive effect a32962 artificial derivative crude extract ergot later purified ergocornine a32964 formation dihydroergocornine implies hydrogenation double bond lysergic acid a32965 dihydroergocornine present formula 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis 1-methylethyl -ergotaman-3',6',18-trione t190 found one component ergoloid mesylate mixture know mixture please refer db01049 ", know approved indication please visit db01049 
Dihydro-alpha-ergocryptine,alpha-dihydroergocryptine usually referred mixture alpha beta dihydroergocryptine two compound differentiated position methyl group structural difference due proteinogenic amino acid replacement leucine isoleucine t195 compound hydrogenated ergot derivative alpha-dihydroergocryptine approved drug product part ergoloid mixture know mixture please visit db01049 ,alpha-dihydroergocryptine studied early treatment parkinson disease a32980 well use migraine prophylaxis a32983 treatment low blood pressure peripheral vascular disorder know ergoloid mesylate mixture us please visit db01049 
Epicriptine,"epicriptine also known beta-dihydroergocryptine present molecular formula 9,10 alpha-dihydro-13'-epi-b-ergocryptine together alpha-dihydroergocryptine represents one-third ergoloid mesylate mixture epicriptine differs alpha form position one methyl group t195 know mixture please visit db01049 ",please refer db01049 know isomer please refer db11274 
Pine needle oil (pinus mugo),pine needle oil obtained needle pinus mugo tree via steam distillation major component pine needle oil pinus mugo include α-pinene β-pinene δ-3-carene limonene β-phellandrene e -caryophyllene germacrene d. present aromatherapeutic agent massage oil fragrance may also used disinfectant lubricant sanitizer antimicrobial insecticide organic herbicide ,
Aluminum zirconium pentachlorohydrex gly,aluminum zirconium pentachlorohydrex gly aluminum zirconium tetrachlorohydrex glycine commonly used antiperspirant many deodorant product coordination complex aluminum zirconium pentachlorohydrate glycine anhydrous form allows molecule absorb moisture ,
DL-Methylephedrine,methylephedrine sympathomimetic amine appears various over-the-counter cough cold medication throughout world l2838 l2839 l2840 abuse methylephedrine-containing medication reported japan methylephedrine legally available united state identified case drug abuse l2836 ,used antitussive decongestant l2834 
Brilliant green cation,brilliant green ethanaminium derivative triarylmethane dye used dye color silk wool due inhibitory action gram positive microorganism brilliant green found antiseptic product solution swab used prevent infection ,
Diethyltoluamide,diethyltoluamide deet common active ingredient many insect repellent product widely used repel biting pest mosquito tick every year deet formulation used protect population mosquito-borne illness like west nile virus zika virus malaria and/or tick-borne illness like lyme disease rocky mountain spotted fever despite concern excessive exposure chemical appropriate usage chemical recommended dosage route administration generally proven safe even deet product largely designed applied directly human skin exact mechanism action deet capable repelling insect causing toxicity human still fully elucidated ,diethyltoluamide deet active ingredient predominantly indicated insect repellant used repel biting pest like mosquito tick l2774 product containing deet currently available public variety liquid lotion spray impregnated material like towelettes roll-on l2774 
DL-dimyristoylphosphatidylcholine, synthetic phospholipid used liposome lipid bilayers study biological membrane used commercial drug preparation solubilize drug injection a32711 ,dl-dimyristoylphosphatidylcholine active pharmaceutical agent indication 
DL-dimyristoylphosphatidylglycerol,dl-dimyristoylphosphatidylglycerol phospholipid used commercially available pharmaceutical preparation solubilize drug injection ,dl-dimyristoylphosphatidylglycerol considered active pharmacological ingredient pharmaceutical preparation official indication 
Colloidal oatmeal,colloidal oatmeal produced grinding fine granule oatmeal boiling extract colloidal material contains high concentration starch beta-glucan exhibit water-absorbing property phenol also contained colloidal oatmeal posse antioxidant anti-inflammatory activity well uv-absorbing activity colloidal oatmeal fda-approved skin protectant temporarily protects help relieve minor skin irritation itching due rash eczema poison ivy oak sumac insect bite available topical product skin soothing agent ,
Rice bran oil,rice bran oil extracted hard outer brown layer rice chaff rice husk used high-temperature cooking method deep frying stir frying contains monosaturated fatty acid polyunsaturated fatty acid saturated fatty acid major constituent rice bran oil include myristic acid palmitic acid stearic acid oleic acid linoleic acid α-linolenic acid rice bran oil classified indirect additive used food contact substance fda ,
Coccidioides immitis spherule,coccidioides immitis spherule skin test antigen indicated detect delayed-type hypersensitivity coccidioides immitis individual history pulmonary coccidioidomycosis ,indicated detect delayed-type hypersensitivity coccidioides immitis individual history pulmonary coccidioidomycosis use 18-64 year old patient positive result occurs 48h administration diameter induration 5mm 
Trichophyton verrucosum,trichophyton verrucosum fungus provoke allergic reaction trichophyton verrucosum extract used allergenic testing ,
Prezatide,prezatide tripeptide consisting glycine histidine lysine readily form complex copper ion a19503 prezatide used cosmetic product skin hair known aid wound healing potential application chronic obstructive pulmonary disease metastatic colon cancer currently investigated ,commonly used cosmetic product skin hair a19503 
Thioredoxin,thioredoxin small dithiol protein specific reductant major allergenic protein present food animal plant product 12-kd oxidoreductase enzyme encoded txn txn2 gene contains dithiol-disulfide active site play essential role antioxidant neutralizing food allergen redox signalling allergen containing disulfide bond inactivated reduced thioredoxin ,
Vanillyl butyl ether,vanillyl butyl ether ether monohydroxybenzoic acid added food product flavoring agent also present cosmetic personal care product fragrance ingredient oral care agent hair conditioning agent warming cooling agent ,
Thrombin,also known coagulation factor ii thrombin serine protease play physiological role regulating hemostasis maintaining blood coagulation converted prothrombin thrombin convert fibrinogen fibrin combination platelet blood form clot medical thrombin protein substance produced conversion reaction prothrombin bovine origin activated tissue thromboplastin presence calcium chloride thrombin requires intermediate physiological agent action clot fibrinogen blood directly failure clot blood occurs rare case primary clotting defect absence fibrinogen bovine thrombin however capable causing fatal severe bleeding thrombosis fda label thrombosis may result development antibody bovine thrombin fda label bleeding may result development antibody bovine factor v fda label antibody may subsequently cross-react endogenous human factor v lead deficiency fda label patient know suspected antibody bovine thrombin and/or bovine factor v re-exposed product fda label patient administered bovine thrombin monitored abnormal coagulation laboratory value bleeding indeed thrombosis fda label variety human thrombin recombinant thrombin ie thrombin alfa product available alternative using bovine thrombin ,bovine thrombin topical thrombin indicated aid hemostasis whenever oozing blood minor bleeding capillary small venule accessible control bleeding standard surgical technique like suture ligature cautery ineffective impractical fda label additionally topical bovine thrombin also used combination absorbable gelatin sponge usp fda label 
Curcuma aromatica root oil,"curcuma aromatica root oil obtained root curcuma aromatica commonly called wild tumeric via steamed distillation curcuma aromatica belongs family zingiberaceae wild ginger used cosmetic herbal rhizome exhibit distinct fragrance color major constituent curcuma aromatica root oil reported camphor curzerenone α-turmerone ar-turmerone 1,8-cineole a27219 curcuma aromatica root oil also suggested antibacterial activity ",
Hydrogenated soybean oil,extracted seed soybean glycine soja hydrogenated soybean oil major food fat used production margarine shortening salad cooking oil according fda hydrogenated soybean oil generally recognized safe gras food substance linolenic acid stearic acid contained hydrogenated soybean oil hydrogenation result reduced unsaturation linolenic acid may found cosmetic personal care product emollient skin conditioning agent ,
Phenoxyethanol,phenoxyethanol colorless liquid pleasant odor glycol ether used perfume fixative insect repellent antiseptic solvent preservative also anesthetic fish aquaculture phenoxyethanol ether alcohol aromatic property naturally found manufactured synthetically demonstrating antimicrobial ability phenoxyethanol act effective preservative pharmaceutical cosmetic lubricant l2619 phenoxyethanol eu pe commonly used globally-approved preservative personal care formulation easy use various type formulation chemically stable phenoxyethanol colorless clear oily liquid faint aromatic odor room temperature low water solubility evaporation rate produced reacting phenol eu ethylene oxide eu high temperature pressure substance occurs naturally green tea eu l2621 according european union cosmetic regulation ec n.1223/2009 phenoxyethanol authorized preservative cosmetic formulation maximum concentration 1.0 l2625 phenoxyethanol classified antimicrobial preservative health canada l2623 also used vaccine shown inactivate bacteria several type yeast a32838 ,antimicrobial agent used preservative cosmetic l2618 l2619 l2625 
Quaternium-18,quaternium-18 mixture quaternary ammonium chloride salt quaternium-18 hectorite bentonite reaction product quaternium-18 clay compound poorly absorbed skin acute oral percutaneous toxicity test animal indicate exhibit little systemic toxic effect ,
Prothrombin,prothrombin complex concentrate human indicated urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e.g. warfarin therapy adult patient acute major bleeding , use emergency reversal coagulation factor deficiency patient receiving vitamin k antagonist therapy prothrombin administered part cocktail containing several coagulation factor 
Protein C,protein c endogenously occurring plasma protein play key role within coagulation cascade protein c zymogen enzyme precursor vitamin k-dependent anticoagulant glycoprotein serine protease synthesized liver converted thrombin/thrombomodulin-complex endothelial cell surface activated protein c apc activated form apc function serine protease potent anticoagulant effect especially presence cofactor protein s. apc exerts effect inactivating essential component coagulation cascade specifically factor v viii lead decrease thrombin formation therefore reduction clot formation protein c pathway provides natural mechanism control coagulation system prevention excessive procoagulant response activating stimulus lack protein c body would lead unchecked coagulation activation resulting thrombin generation intravascular clot formation protein c available concentrated form product ceprotin indicated use pediatric adult patient severe congenital protein c deficiency prevention treatment venous thrombosis purpura fulminans ,protein c concentrate indicated pediatric adult patient severe congenital protein c deficiency prevention treatment venous thrombosis purpura fulminans l12831 also found component prothrombin complex concentrate i.e factor ix complex human formulation kcentra l12834 
Methscopolamine,methscopolamine quaternary ammonium derivative scopolamine antagonist muscarininc mach receptor methscopolamine bromide common form active ingredient oral pharmaceutical product oral tablet used adjunct therapy treatment peptic ulcer shown effective decreasing rate recurrence peptic ulcer well preventing complication ,
Cod liver oil,cod liver oil extracted liver cod fish mainly consists omega-3 fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha also rich source vitamin cod liver oil taken orally daily supplement used adjunct treatment preventative therapy rickets osteomalacia osteoporosis meeting consumption criterion ,cod liver oil predominantly manufactured marketed used population large general nutraceutical dietary supplement a27154 a33159 l2872 historically cod liver oil often given child vitamin content oil shown prevent treat vitamin deficiency condition rickets associated a33159 time common use child growing may conferred upon cod liver oil identity healthy useful all-purpose dietary supplement however since cod liver oil composite several nutritional compound including omega-3 fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha well vitamin vitamin a33159 l2872 l2871 presence varying amount compound make difficult recommend use cod liver oil appropriate supplement confer one particular health effect one particular nutritional deficiency regardless contain combination number important healthy nutritional compound cod liver oil sometimes recommended literature conferring health effect compound potential use cod liver oil supplement post-heart attack patient secondary prophylaxis associated use omega-3 fatty acid a33165 
Glycol salicylate,glycol salicylate also known _2-hydroxyethyl salicylate_ benzoate ester formed condensation carboxy group salicylic acid one hydroxy group ethylene glycol found active ingredient topical analgesic patch used provide relief mild moderate muscle joint pain l2686 drug belongs _salicylate_ group drug used analgesic agent treatment mild moderate pain l2691 glycol salicylate g composed salicylic acid sa ethylene glycol non-steroidal anti-inflammatory drug l2687 ingredient important component many topical cream spray relief ache pain stiffness muscle joint tendon l2696 , drug recommended topical usage relief muscular rheumatic pain human animal l2687 
Nonivamide,nonivamide found herb spice alkaloid capsicum specie structure db06774 nonivamide differ slightly respect fatty acid moiety side chain 8-methyl nonenoic acid versus nonanoic acid f31 nonivamide flavoring ingredient nonivamide organic compound capsaicinoid amide pelargonic acid _vanillylamine_ naturally found chili pepper manufactured produce synthetic form various pharmacologic preparation l2641 drug studied combination nicarboxil treatment lower back pain l2642 nonivamide also studied anti-inflammatory property well fat loss therapy demonstrated promising result l2643 a32888 a32886 a32884 ,nonivamide used topical analgesic also used flavoring ingredient l2641 a32884 l2642 
Boric acid,boric acid also known hydrogen borate weak monobasic lewis acid boron chemical formula h3bo3 boric acid typically utilized industrial processing manufacturing also used additive pharmaceutical product cosmetic lotion soap mouthwash toothpaste astringent eyewash l2140 known exhibit antibacterial activity infection bacterial vaginosis candidiasis a32449 , fda- ema-approved therapeutic indication 
Dipyrithione,dipyrithione bactericidal fungicidal pyrithione derivate formulated crimanex anti-dandruff shampoo longer available l2611 currently used pesticide used fda approved drug product a32829 interestingly dipyrithione studied shown cytotoxic potent broad-spectrum antitumor activity suggests potential basis anticancer drug development a32825 pyrithione derivative db06815 sodium pyrithione widely used cosmetic preservative anti-dandruff agent shampoo a32825 may combined ingredient triclosan serve antifungal antibacterial skin treatment l2615 dandruff common scalp disease affecting 40 world 's adult population may caused fungi _malassezia globosa_ _m restricta_ a32162 ,scalp dandruff l2610 
Tetradecyl hydrogen sulfate (ester),sodium tetradecyl sulfate anionic surface-active agent used wetting property industry also used medicine blood vessel irritant sclerosing agent hemorrhoid varicose vein l2031 sodium tetradecyl sulfate widely used since 1950s 1978 first successful report injecting 1 solution spider angioma 144 patient made also noted unspecified number episode epidermal necrosis without significant long-term effect 30 incidence post-sclerosis pigmentation resolved within month l2035 ,sotradecol sodium tetradecyl sulfate injection indicated treatment small uncomplicated varicose vein leg showing simple dilation competent valve l2030 sodium tetradecyl sulfate designated orphan drug fda treatment gastrointestinal bleeding due esophageal varix l2041 
C11-12 isoparaffin,c11-12 isoparaffin mixture branched chain hydrocarbon 11c 12c 's alkyl chain found cosmetic personal care product solvent skin conditioning agent ,
Factor IX Complex (Human),factor ix complex sterile lyophilized concentrate composed number vitamin k-dependent clotting factor found functioning human plasma also known prothrombin complex concentrate product containing complex often include factor ix antihemophilic factor b factor ii prothrombin factor x stuart-prower factor low level factor vii proconvertin derived human plasma many commercially available product also contain low level antithrombotic protein example kcentra fda also contains antithrombotic protein c bebulin vh fda contains heparin coagulation factor purified pooled human plasma subsequently sterilized treated although factor ix complex product contain many different coagulation component factor ix lead component potency efficacy particularly used treatment bleeding associated hemophilia b factor ix deficiency product kcentra factor ix complex also indicated urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e.g. warfarin therapy adult patient experiencing acute major bleeding requiring rapid reversal therapy ,factor ix complex indicated prevention control hemorrhagic episode hemophilia b patient also indicated urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e.g. warfarin therapy adult patient acute major bleeding require rapid reversal therapy 
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)),palmitoyloleoyl-phosphatidylglycerol component surfaxin discontinued 2017 acted surfactant fda label product meant compensate alveolar surfactant deficiency reduce likelihood alveolar collapse leading acute respiratory collapse ,palmitoyloleoyl-phosphatidylglycerol component surfaxin indicated prevention respiratory distress syndrome premature infant 
Sinapultide,sinapultide also known kl4 peptide synthetic protein used mimic human lung surfactant protein b l2502 protein weight 2469.40 l2502 sinapultide 21-residue peptide made lysine k leucine l residue sequence kllllkllllkllllkllllk kl4 aqueous dispersion phospholipid dppc dipalmitoylphosphatidylcholine popg palmitoyloleoyl-phosphatidylglycerol palmitic acid create drug lucinactant l2506 product originally developed scripps research institute licensed windtree therapeutic l2502 windtree therapeutic plan phase iii trial respiratory distress syndrome 2018 l2505 respiratory distress syndrome rds major cause mortality morbidity preterm infant surfactant replacement therapy commonly used prevent treat rds newborn standard care first-generation synthetic surfactant previously used _exosurf_ contain surfactant protein large disadvantage overcome animal-derived surfactant product contain specific protein limited must derived animal source led development newer synthetic surfactant lucinactant surfaxin contains sinapultide phase 3 clinical trial surfaxin show promising result similar efficacy animal-derived surfactant avoiding use animal-origin product l2504 windtree currently developing aerosolized kl4 surfactant treat rds premature infant thereafter potentially address range indication neonatal pediatric adult critical care patient population l2511 ,infant respiratory distress syndrome l2502 l2506 l2507 l2511 
Poloxamer 188,poloxamer 188 p188 nonionic block linear copolymer exhibit rheologic anti-thrombotic anti-inflammatory cytoprotective activity various tissue injury model a33121 composed two hydrophilic side-chains attached hydrophobic center core a27218 average molecular weight 8400 dalton p188 originally approved fda 1960s therapeutic agent reduce viscosity blood transfusion however longer available approved product a27217 due sufactant property p188 may also found over-the-counter otc product toothpaste laxative mouthwash used various cosmetic industrial pharmaceutical application evidence p188 increasing structural stability resealing plasma membrane via direct incorporation phospholipid bilayer a27217 ability p188 attenuating membrane damage cell injury demonstrated variety _in vivo_ _in vitro_ model a27218 use p188 potential treatment different pathological condition chronic microvascular disease skeletal muscle deficiency investigation a27217 ,indicated reduce viscosity blood transfusion 
Kinetin,kinetin cytokinin plant hormone promotes cell division plant growth shown naturally exist dna organism including human various plant kinetin used tissue culture produce new plant also found cosmetic product anti-aging agent ,
Zeatin, aminopurine factor plant extract induces cell division grant hackh 's chemical dict 5th ed ,
Clove oil,clove oil obtained extraction dried flower bud clove plant traditionally used flavouring spice food fragrance also found topical analgesic clove oil shown exert antimicrobial activity antioxidant antimicrobial activity clove higher many fruit vegetable spice a33133 clove native indonesia cultured several part world including brazil state _bahia_ plant represents one richest source phenolic compound _eugenol_ _eugenol acetate_ _gallic acid_ great potential pharmaceutical cosmetic food agricultural application a33133 interestingly clove oil studied potential benefit treating neuropathic pain well vaginal candidiasis promising result a33137 a33144 fda categorizes clove oil generally recognized safe gras use dental cement food additive f108 ,clove oil primarily indicated condition like colic flatulence toothache l2849 
Ubiquinol,ubiquinol coqh2 reduced form coenzyme q10 coq10 act active antioxidant prevents initiation propagation lipid peroxidation biological membrane human low-density lipoprotein ldl play essential role maintaining cellular defense oxidative damage also sustains effect vitamin e regenerating vitamin tocopheroxyl radical ubiquinol classified vitamin synthesized human varying concentration ubiquinol food otc product dietary supplement product ,
Ichthammol,ichthammol also referred ammonium bituminosulfonate ammonium bituminosulphonate ammonium salt dark sulfonated shale oil bituminous schist produced via distillation oil followed sulfonation neutralization available otc product active ingredient treatment skin disorder eczema psoriasis boil thought exhibit anti-inflammatory antibacterial antimycotic property l997 ,
Aluminum oxide,aluminum oxide chemical formula al2o3 amphoteric nature used various chemical industrial commercial application considered indirect additive used food contact substance fda ,
Silanol,silanol fda-approved food contact substance commonly used organosilicon chemistry silicate mineralogy ,
(S)-camphor, -camphor l -camphor stereoisomer db01744 bicyclic monoterpene known potentiate heat cold sensation a33087 -camphor naturally-occurring stereoisomer display similar trpv channel affinity current inhibition a33086 db01744 isolated wood camphor laurel tree _cinnamomum camphora_ long history medicinal use used nasal decongestant cough suppressant topically applied due antipruritic analgesic counterirritant property a33086 camphor major active ingredient over-the-counter balm liniment supplied topical analgesic causing sensitization heat coolness relieve minor muscle joint pain a33086 ,indicated temporary symptomatic relief minor ache pain muscle joint topical analgesic 
Calcium Phosphate,calcium phosphate typically available counter supplement antacid added ingredient toothpaste fda label l851 , use counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda label l851 
Cetyl ethylhexanoate,cetyl ethylhexanoate ester cetyl alcohol 2-ethylhexanoic acid present cosmetic product skin conditioning agent emollient ,
Cocamidopropyl betaine,cocamidopropyl betaine mixture closely related organic compound derived coconut oil dimethylaminopropylamine typically act amphoteric surfactant cosmetic personal care product zwitterionic ammonium compound fatty acid amide contains long hydrocarbon chain polar group end cocamidopropyl betaine used foam booster shampoo emulsifying agent thickener antistatic agent rarely antiseptic agent impurity formed manufacturing process thought increase prevalence contact sensitization mild skin irritation ,
Ascorbyl phosphate,ascorbyl phosphate synthetic form vitamin c found different salt form magnesium ascorbyl phosphate sodium ascorbyl phosphate salt present cosmetic product concentration ranging 0.001 3 a27211 vitamin c susceptible breakdown compound discoloration cosmetic formulation ascorbyl phosphate along vitamin c derivative act active stable precursor vitamin c readily absorbed skin hydrating effect skin a27212 ascorbyl phosphate salt provide constant delivery vitamin c skin also mediate antioxidant action act free radical scavenger increase collagen production vitro a27212 ,
Propolis wax,propolis wax naturally produced honeybee mixing resin exudate collected tree bud sap flow botanical source beeswax contains fatty acid bee enzyme propolis contains various chemical compound including flavonoid terpenoids aldehyde aromatic acid aliphatic alcohol ether amino acid sugar often found topical formulation used soothe minor skin irritation ,
Polyquaternium-10 (400 cps at 2%),polyquaternium-10 quaternized hydroxyethyl cellulose polycationic polymer commonly found cosmetic personal care product mainly reduce static electricity form film ,
Linseed oil,linseed oil rich source α-linolenic acid extracted dried ripened seed flax plant linum usitatissimum fatty acid contained linseed oil include palmitic acid stearic acid oleic acid linolenic acid linseed oil particularly susceptible polymerization reaction upon exposure oxygen air due high content di- triunsaturated ester used drying process used industrial commercial application indirect additive used food contact substance ,
Evening primrose oil,evening primrose oil come extraction _oenothera biennis_ seed commonly used alternative source omega-6 essential fatty acid composition present fatty acid db00132 db13854 a33131 evening primrose oil filled fda humanetics corporation april 2000 new dietary ingredient current status `` inadequate basis expectation safety '' l2845 health canada evening primrose oil approved over-the-counter combination dietary supplement l1113 ema evening primrose oil approved herbal preparation l2851 ,evening primrose oil used part over-the-counter dietary supplement l1113 also used treatment systemic inflammatory disease woman 's health condition cyclical mastalgia indication sufficient evidence effectiveness used treatment atopic dermatitis united kingdom currently withdrawn due lack evidence effectiveness a33131 
Guaiacol,guaiacol agent thought disinfectant property used expectorant guaiacol phenolic natural product first isolated guaiac resin oxidation lignin guaiacol also present wood smoke product pyrolysis lignin guaiacol found urine patient neuroblastoma pheochromocytoma , used medicinally expectorant antiseptic local anesthetic guaiacol used traditional dental pulp sedation property inducing cell proliferation guaiacol potent scavenger reactive oxygen radical radical scavenging activity may associated effect cell proliferation 
Lactobacillus plantarum, lactobacillus plantarum member lactobacillus lactic acid bacteria widely used food industry microbial starter probiotic microorganism considered one versatile specie carry fermentative metabolic process exhibiting antagonistic activity pathogenic spoilage microorganism l. plantarum produce different antimicrobial agent organic acid hydrogen peroxide diacetyl bacteriocins antimicrobial peptide a27208 ,
Betula pendula tar oil,betula pendula tar oil essential oil found bud plant name origin plant also known european white silver birch grows mainly northern hemisphere oil usually obtained using hydrodistillation micro-distillation a33154 conformed mainly db11143 db11359 t219 utilization product started second world war sovietic union l2870 betula pendula tar oil approved utilization over-the-counter product combination health canada l1113 fda considered substance approved added food l2862 ema betula pendula tar oil approved category herbal medicine human use l2865 ,betula pendula tar oil used over-the-counter product treatment wound ulcer bedsore shallow inflammatory process thrombophlebitis erysipelas used externally over-the-counter dermatologic combination db11113 l2863 
Selexipag,selexipag approved united state fda december 22 2015 treatment pulmonary arterial hypertension pah delay disease progression reduce risk hospitalization pah relatively rare disease usually poor prognosis requiring treatment option prolong long-term outcome marketed actelion pharmaceutical brand name uptravi selexipag active metabolite act-333679 mre-269 act agonist prostacyclin receptor increase vasodilation pulmonary circulation decrease elevated pressure blood vessel supplying blood lung ,selexipag indicated treatment pulmonary arterial hypertension pah delay disease progression reduce risk hospitalization 
Alectinib,alectinib second generation oral drug selectively inhibits activity anaplastic lymphoma kinase alk tyrosine kinase specifically used treatment non-small cell lung cancer nsclc expressing alk-eml4 echinoderm microtubule-associated protein-like 4 fusion protein cause proliferation nsclc cell inhibition alk prevents phosphorylation subsequent downstream activation stat3 akt resulting reduced tumour cell viability approved accelerated approval 2015 alectinib indicated use patient progressed tolerant crizotinib associated development resistance ,alectinib kinase inhibitor indicated treatment patient anaplastic lymphoma kinase alk -positive metastatic non-small cell lung cancer nsclc progressed intolerant crizotinib indication approved accelerated approval based tumor response rate duration response continued approval indication may contingent upon verification description clinical benefit confirmatory trial 
Pidotimod,pidotimod synthetic dipeptide immunomodulatory property a7956 , use immunostimulant therapy treatment cell-mediated immunosuppression respiratory urinary infection l929 
Sennosides,sennosides also known senna glycoside senna medication used treat constipation fda label l771 empty large intestine surgery medication taken mouth via rectum fda label typically begin working minute given rectum within twelve hour given mouth fda label weaker laxative bisacodyl castor oil a177092 sennoside one sennosides present laxative medication recently proven effective inhibiting ribonuclease h rnase h activity human immunodeficiency virus hiv reverse transcriptase a19231 , counter treatment constipation fda label l771 
Roquinimex,roquinimex derivative quinoline present immunostimulant property effect suggested increase activity nk cell macrophage cytotoxicity additionally roquinimex known inhibit angiogenesis decrease synthesis tnf alpha ,roquinimex investigated used treatment number cancer autoimmune condition well roquinimex researched used adjuvant therapy bone marrow transplantation case acute leukemia 
Cefroxadine,cefroxadine orally available cephalosporin antibiotic part drug class share structural property cefalexin well activity spectrum used italy since withdrawn , used treatment bacterial infection 
Chlorophetanol,chlorophetanol agent known antifungal activity ,
Alfaxalone,alfaxalone also known alphaxalone alphaxolone neuroactive steroid general anaesthetic used veterinary practice trade name alfaxan licensed use dog cat along alfadolone also one constituent anesthetic drug mixture althesin ,
Altrenogest,altrenogest also known allyltrenbolone steroidal progestin widely used veterinary medicine suppress estrus animal ,
Amitraz,amitraz non-systemic acaricide insecticide generated 1969 boot co. england amitraz present insect repellent effect hence used insecticide pesticide insecticide effect due agonistic activity alpha-adrenergic system interaction octopamine receptor central nervous system driven inhibition synthesis monoamine oxidase prostaglandin abovementioned effect translated overexcitation paralysis death insect amitraz present lower effect mammal thus widely used treatment mite- tick-infestation dog ,
Amprolium,amprolium coccidiostat used poultry ,
Azaperone,azaperone pyridinylpiperazine butyrophenone agent capable eliciting neuroleptic sedative antiemetic effect subsequently employed predominantly veterinary tranquilizer mainly pig elephant time agent generally see equine use particular adverse reaction may happen rarely may used human antipsychotic drug uncommon ,
Bambermycins,bambermycins antibiotic complex retrieved organism _streptomyces bambergiensis_ used additive food ingested chicken swine bambermycin complex antibiotic consists primarily moenomycins c ,
Carbarsone,carbarsone compound used antiprotozoal drug treatment histomoniasis blackhead disease addition infectious disease chicken turkey belongs _organoarsenic_ group chemical compound antiamebic property also used food additive goal increasing weight gain controlling occurrence blackhead disease chicken turkey ,
Carbomycin,carbomycin also called magnamycin crystalline macrolide antibiotic antibacterial obtained _streptomyces halstedii_ present large inhibitory effect gram-positive bacteria mycoplasma strain structure carbomycin generated 1957 robert woodward later modified 1965 ,
Chlorobutanol,chlorobutanol chlorbutol alcohol-based preservative surfactant activity a32746 also elicits sedative-hypnotic weak local anesthetic action addition antibacterial antifungal property similar nature chloral hydrate formed simple nucleophilic addition chloroform acetone long-term stabilizer multi-ingredient preparation chlorobutanol normally used concentration 0.5 concentration also conserve antimicrobial activity due long terminal half-life 37 day use chlorobutanol sedative limited considerable accumulation occur following multiple dosing a32743 chlorobutanol common detergent preservative eye drop ophthalmic therapeutic formulation a32744 , approved therapeutic indication 
Chloroform,chloroform organic small molecule member family chloromethanes present formula chcl3 colorless sweet-smelling dense liquid produced large scale precursor ptfe refrigerant latter application declining chloroform part fda drug product withdrawn removed market reason safety effectiveness l43942 ,
Coumaphos, drug fat-soluble phosphorothioate agent kill insect mite non-volatile nature well known variety name _dip_ _wash_ coumaphos widely used farm domestic animal control tick mite fly flea ,
Cythioate,cythioate member organothiophosphate compound used insecticide anthelmintic mainly used veterinary treatment flea ,
Danofloxacin,danofloxacin antibiotic agent family fluoroquinolones used veterinary medicine ,
Decoquinate,decoquinate used veterinary delay growth reproduction coccidian parasite ,
Deracoxib,deracoxib non-steroidal anti-inflammatory drug coxib class used veterinary medicine treat osteoarthritis dog sold tablet added beefy flavour increase palatability deramaxx received fda approval august 2002 `` control post operative pain inflammation associated orthopedic surgery dog ,
Dichlorophen,dichlorophen antimicrobial agent shown exert activity cestode protozoa fungi bacteria often combined toluene remove parasite including ascarids tapeworm hookworm dog cat ,
Dichlorvos,"dichlorvos 2,2-dichlorovinyl dimethyl phosphate drug _organophosphate_ class frequently used insecticide control indoor pest protection stored product insect infestation compound available market since 1961 use controversial topic due environmental health concern dichlorvos found urban waterway toxicity may impact human leading poisoning neurotoxicity cancer ",
Diclazuril,diclazuril coccidiostat ,
Dirlotapide,dirlotapide drug employed treatment obesity dog marketed pfizer zoetis brand name _slentrol_ intended human use ,
Doramectin,doramectin veterinary drug approved food drug administration treatment parasite gastrointestinal roundworm lungworms eyeworms grub sucking louse mange mite cattle ,
Emodepside,emodepside anthelmintic drug effective number gastrointestinal nematode licensed use cat belongs class drug known octadepsipeptides relatively new class anthelmintic ,
Enrofloxacin,enrofloxacin antibiotic agent fluoroquinolone family produced bayer corporation enrofloxacin approved fda veterinary use due identification fluoroquinolone-resistant strain _campylobacter_ september 2005 fda withdrew approval enrofloxacin use water treat flock poultry ,
Fenbendazole,fenbendazole benzimidazole present wide spectrum anthelmintic effect used number gastrointestinal parasite including giardia roundworm hookworm whipworms taenia genus tapeworm pinworm aelurostrongylus paragonimiasis strongyles strongyloides fenbendazole approved administered veterinary sheep cattle horse fish dog cat rabbit seal ,
Fenthion,fenthion _organothiophosphate_ drug used insecticide avicide acaricide mode action explained cholinesterase enzyme inhibition similar organophosphate fenthion listed restricted use compound united state environmental protection agency due potential cause cholinesterase inhibition human animal ,
Florfenicol,florfenicol fluorinated synthetic analog thiamphenicol ,
Gamithromycin,gamithromycin antibiotic used cattle ,
Gleptoferron,colloid solution ferric hydroxide dextran glucoheptonic acid ,
Imidacloprid,imidacloprid neonicotinoid class neuro-active insecticide modeled nicotine imidacloprid patented chemical imidacloprid manufactured bayer cropscience part bayer ag sold trade name kohinor admire advantage gaucho merit confidor hachikusan premise prothor winner marketed pest control seed treatment insecticide spray termite control flea control systemic insecticide ,
Lasalocid,lasalocid agent present antibacterial coccidiostat activity produced strain _streptomyces lasaliensis_ ,
Lufenuron,lufenuron used veterinary control flea ,
Marbofloxacin,marbofloxacin carboxylic acid part third generation antibiotic fluoroquinolones used veterinary medicine formulation marbofloxacin combined clotrimazole dexamethasone available name aurizon ,
Maropitant,maropitant used maropitant citrate neurokinin receptor antagonist developed zoetis specifically treatment motion sickness vomiting dog approved fda 2007 use dog recently also approved use cat ,
Medetomidine,medetomidine synthetic compound used surgical anesthetic analgesic normally found hydrochloride salt medetomidine hydrochloride medetomidine intravenously available alpha-2 adrenergic agonist drug developed orion pharma united state currently approved veterinary use dog distributed pfizer animal health canada medetomidine distributed novartis animal health marketed product racemic mixture two stereoisomers dexmedetomidine main active isomer ,
Mibolerone,mibolerone potent anabolic steroid higher affinity selective androgen receptor metribolone ,
Monensin,monensin polyether isolated _streptomyces cinnamonensis_ present antibiotic property widely used ruminant animal feed ,
Moxidectin,moxidectin potent broad-spectrum endectocide antiparasitic active endo- ecto-parasites activity nematode insect acarus first used cattle followed approved use general animal semi-synthetic methoxine derivative nemadectin 16-member pentacyclic lactone milbemycin class moxidectin differs absence disaccharide moiety carbon 13 substituted olefinic side chain carbon 25 unique methoxime moiety carbon 23 due modification moxidectin classified second generation macrocyclic lactone a33385 moxidectin developed medicine development global health fda approved june 13 2018 l2970 ,moxidectin indicated treatment river blindness also called onchocerciasis patient aged 12 year older river blindness caused parasitic worm _onchocerca volvulus_ manifested severe itching disfiguring skin condition visual impairment caused worm 's larva l2971 transmission _onchocerca volvulus_ performed person person black fly breed fast-flowing river sub-saharan africa yemen south central america larva released adult parasite invade skin eye produce severe disease manifestation l2971 
Narasin,narasin agent coccidiostatic antibacterial property ,
Nequinate,nequinate antiprotozoan used coccidiostat poultry rabbit nequinate belongs family hydroquinolones compound containing hydrogenated quinoline bearing ketone group ,
Nitarsone,nitarsone organoarsenic compound used additive poultry feed improve weight gain feed efficiency preventing blackhead disease marketed histostat zoetis publicly traded subsidiary pfizer ,
Nitenpyram,nitenpyram insecticide used agriculture veterinary medicine kill external parasite pet neonicotinoid neurotoxin block neural message bind particularly tightly central nervous system insect causing rapid death ,
Norgestomet,norgestomet also known 11β-methyl-17-hydroxy-19-norprogesterone acetate steroidal progestin used veterinary medicine control estrus ovulation cattle ,
Oleandomycin,oleandomycin macrolide antibiotic though le effective erythromycin synthesized strain _streptomyces antibioticus_ ,
Orbifloxacin,orbifloxacin fluoroquinolone antibiotic marketed schering-plough animal health approved certain infection dog ,
Oxfendazole,oxfendazole sulfoxide metabolite fenbendazole benzimidazole antihelminthic protects livestock roundworm strongyles pinworn ,
Phenothiazine,phenothiazine ptz organic thiazine compound ,
Phosmet,phosmet phthalimide-derived organophosphate non-specific insecticide mainly used apple tree control codling moth also used fruit crop ornamental vine control aphid sucker mite fruit fly ,
Poloxalene,ethylene oxide/propylene oxide copolymer used food additive belongs family epoxides compound containing cyclic ether three ring atom one oxygen two carbon atom ,
Ponazuril,ponazuril sold bayer corporation trade name marquis drug currently approved treatment equine protozoal myeloencephalitis horse caused sarcocystis neurona ,
Pradofloxacin,pradofloxacin 3rd generation fluoroquinolone antibiotic developed bayer healthcare ag animal health gmbh approved european commission april 2011 bacterial infection dog cat ,
Prostalene,analog prostaglandin f2 alpha ,
Robenacoxib,robenacoxib non-steroidal anti-inflammatory drug used veterinary medicine relief pain inflammation cat dog ,
Rotenone,rotenone isoflavone compound naturally occurs jicama vine plant well many fabaceae plant broad spectrum insecticide pesticide activity also toxic fish ,
Roxarsone,roxarsone organoarsenic molecule added poultry feed addition compound poultry feed improves weight gain feed efficiency well prevent growth coccidian parasite drug also approved united state use pig ,
Selamectin,selamectin topical parasiticide antihelminthic used dog cat treat prevent infection heartworms flea ear mite sarcoptic mange certain type tick dog well prevent heartworms flea ear mite hookworm roundworm cat also remove 2 type lungworm cat one type lungworm dog distributed zoetis former pfizer subsidiary structurally related ivermectin milbemycin selamectin approved human use ,
Squalene,squalene originally obtained shark liver oil natural 30-carbon isoprenoid compound intermediate metabolite synthesis cholesterol susceptible lipid peroxidation provides skin protection ubiquitously distributed human tissue transported serum generally association low density lipoprotein squalene investigated adjunctive cancer therapy ,
Sulfachlorpyridazine, sulfonamide antimicrobial used urinary tract infection veterinary medicine ,
Sulfaquinoxaline,sulfaquinoxaline veterinary medicine given cattle sheep treat coccidiosis.it available pakistan sanna laboratory combination amprolium vitamin k potential treatment coccidiosis ,
Tepoxalin,tepoxalin nonsteroidal anti-inflammatory drug approved veterinary use united state many country primarily used reduce inflammation relief pain caused musculoskeletal disorder hip dysplasia arthritis ,
Thiostrepton,thiostrepton natural cyclic oligopeptide antibiotic derived several strain streptomycetes including streptomyces azureus streptomyces laurentii thiostrepton natural product ribosomally synthesized post-translationally modified peptide class ,
Tiamulin,tiamulin pleuromutilin antibiotic drug used veterinary medicine particularly pig poultry ,
Tildipirosin,tildipirosin veterinary antibiotic ,
Tilmicosin,tilmicosin macrolide antibiotic used veterinary medicine treatment bovine respiratory disease ovine respiratory disease associated _mannheimia haemolytica_ ,
Metrifonate,"metrifonate trichlorfon irreversible organophosphate acetylcholinesterase inhibitor prodrug activated non-enzymatically 2,2-dichlorovinyl dimethyl phosphate ",
Tulathromycin A,tulathromycin macrolide antibiotic used treat bovine respiratory disease cattle swine respiratory disease pig marketed pfizer inc. tradename draxxin ,
Tylosin,tylosin bacteriostatic macrolide antibiotic feed additive used veterinary medicine broad spectrum activity gram-positive organism limited range gram-negative organism tylosin produced fermentation product streptomyces fradiae ,
Virginiamycin,virginiamycin streptogramin antibiotic similar pristinamycin quinupristin/dalfopristin combination pristinamycin iia virginiamycin s1 virginiamycin used fuel ethanol industry prevent microbial contamination livestock prevent treat infection according usda study antibiotic save much 30 feed cost among young swine ,
Xylazine,xylazine clonidine analog used non-opioid tranquilizer veterinary medicine emetic especially cat a9095 l42675 a251420 act agonist α2 adrenoceptors however affinity lower one reported α2 adrenergic receptor agonist detomidine medetomidine a32545 xylazine approved human use requires veterinary licence purchase use l42680 intentional unintentional use xylazine cause concern due side effect a9096 use xylazine lead hypotension bradycardia a9092 a9093 combined central nervous system depressant benzodiazepine alcohol significantly depress vital function increase risk overdose death l42675 xylazine sometimes used adulterant combined opioids recreational drug however antidote use naloxone effect xylazine l42675 l42680 ,
Zeranol,zeranol non-steroidal estrogen agonist mycotoxin derived fungi fusarium family may found contaminant fungus-infected crop 3-4x potent estrogen agonist related compound zearalenone ,
Zilpaterol,zilpaterol β2 adrenergic agonist sold trade name zilmax produced intervet subsidiary merck co. zilpaterol typically fed cattle last three six week life brief washout period clear drug tissue slaughter ,
Zoalene,dinitolmide fodder additive prophylaxis coccidiosis infection poultry ,
Atipamezole,atipamezole synthetic α2 adrenoceptor antagonistused reverse sedative analgesic effect dexmedetomidine medetomidine dog also undergone research potential anti-parkinsonian drug human , reversal sedative analgesic effect dexmedetomidine medetomidine dog 
Balsam of Peru,balsam peru resin come tree myroxylon balsamum pereirae constituted mixture substance major component benzyl cinnamate db00676 balsam peru also presented several allergen cinnamic acid db06770 db02130 f117 fda balsam peru considered inactive ingredient used approved drug product l2878 well approved food additive categorization generally recognized safe gras l2879 health canada balsam peru approved use over-the-counter combination product currently approved veterinary product l1113 ema balsam peru approved categorized herbal medicine product f121 ,balsam peru found diverse cosmetic perfume well flavoring agent cough syrup lozenge chewing gum candy f117 medical agent balsam peru used local treatment burn wound antiseptic a27160 also used expectorant heart stimulant increase blood pressure parasiticide t221 
Ceftiofur,ceftiofur third generation cephalosporin antibiotic first described 1987 used veterinary medicine marketed pharmaceutical company zoetis excenel active ingredient company 's specramast lc lactating cow formula product resistant hydrolysis beta-lactamase activity gram-positive gram-negative bacteria e. coli strain resistant ceftiofur reported metabolite desfurolyceftiofur also antibiotic activity consequently two compound measured together monitor antibiotic activity milk ,
Dexamethasone isonicotinate,dexamethasone isonicotinate anti-inflammatory anti-allergic glucocorticoid administered orally inhalation topically parenterally unintended mineralocorticoid action may cause salt water retention ,
Nalorphine,nalorphine mixed opioid agonist–antagonist act two opioid receptors—at mu receptor antagonistic effect kappa receptor exerts high-efficacy agonistic characteristic used reverse opioid overdose starting 1950s challenge test determine opioid dependence ,used reverse opioid overdose 
Sarafloxacin,sarafloxacin quinolone antibiotic drug discontinued manufacturer abbott laboratory receiving approval use u canada ,
Sodium tripolyphosphate,sodium tripolyphosphate inorganic compound formula na5p3o10 sodium salt polyphosphate penta-anion used component wide range domestic industrial product particularly detergent ,
Bunamidine,bunamidine veterinary anti-platyhelmintic agent used taenia infestation ,
Caramiphen,caramiphen cholinergic antagonist used parkinson 's disease additionally used combination phenylpropanolamine cough suppressant nasal decongestant symptomatic treatment seasonal respiratory condition ,
Cefovecin,cefovecin cephalosporin antibiotic used treatment skin infection cat dog first single-dose injectable antibiotic dog cat assures owner compliance dosing animal used treatment skin infection caused pasturella multocida cat staphylococcus intermedius/s canis dog advantage using injectable antibiotic missing dose allow partially resistant microbe recover missed dos however injectable agent present long-lasting subtherapeutic concentration resolution infection presence low concentration antibiotic related development microbial resistance ,
Deslorelin,deslorelin acetate injectable gonadotropin releasing hormone super-agonist also known lhrh agonist stop production sex hormone ,
Difloxacin,difloxacin synthetic fluoroquinolone used veterinary antibacterial present broad bactericidal spectrum effect dependent concentration however present reduced efficacy compared fluoroquinolone antibacterial ,
Dihydrostreptomycin,dihydrostreptomycin aminoglycoside antibiotic human use dihydrostreptomycin associated ototoxicity fda withdrew approval use drug product containing dihydrostreptomycin sulfate l43942 ,
Dithiazanine,dithiazanine highly potent anthelmintic introduced 1959 treatment strongyloid worm whipworms however use severely limited due toxicity dithiazanine iodide associated eight fatal case severe acidosis shock 1961 1964 dithiazanine iodide withdrawn market country france italy may remain available others a254427 l44032 ,
Flunixin,flunixin non-steroidal anti-inflammatory drug use pig cattle horse exerts analgesic antipyretic effect drug often prepared use meglumine salt form flunixin regulated united state food drug administration fda must prescribed licensed veterinarian flunixin may also referred _banamine_ trade name ,
Hygromycin B,hygromycin b aminoglycoside antibiotic produced bacterium streptomyces hygroscopicus kill bacteria fungi higher eukaryotic cell inhibiting protein synthesis ,
Imidocarb,imidocarb urea derivative used veterinary medicine antiprotozoal agent treatment infection babesia parasite ,
Maduramicin,maduramicin antiprotozoal agent used veterinary medicine prophylaxis coccidiosis naturally occurring compound first isolated actinomycete actinomadura rubra ,
Masitinib,masitinib tyrosine-kinase inhibitor used treatment mast cell tumor dog available europe since 2009 brand name masivet usa distributed name kinavet available veterinary since 2011 ,
Melarsomine,melarsomine trypanocidal agent marketed merial trade name immiticide fda-approved treatment adult heartworm infection dog however approved use dog late-stage infection ,
Melengestrol,melengestrol steroidal progestin antineoplastic agent never marketed acylated derivative melengestrol acetate used growth promoter animal ,
Pirlimycin,pirlimycin hydrochloride antibiotic belonging _lincosamide_ class often marketed _pirsue_ drug used treat mastitis cattle ,
Robenidine,robenidine identified coccidiostat drug slows growth reproductive cycle coccidian parasite robenidine used control coccidiosis lethal infection poultry shown significant economic burden despite availability agent treat coccidiosis robenidine proven effective delaying development antibiotic resistance intermittent rotating use antimicrobial farmer alternate use robenidine antimicrobial agent order maintain effectiveness slowing development antimicrobial resistance ,
Romifidine,romifidine veterinary drug utilized sedative primarily large animal frequently horse also used le commonly wide variety animal specie drug 's chemical structure closely resembles clonidine however romifidine approved use human ,
Tiletamine, drug dissociative anesthetic agent fall drug category _nmda receptor antagonists_ tiletamine chemically similar another dissociative anesthetic ketamine tiletamine hydrochloride salt form exists odorless white crystal ,
Trenbolone,trenbolone also known trienolone trienbolone steroid used livestock increase muscle growth appetite increase effective half-life trenbolone administered prodrug ester conjugate trenbolone acetate trenbolone enanthate trenbolone cyclohexylmethylcarbonate plasma lipase cleave ester group bloodstream leaving free trenbolone ,
Tricaine,tricaine tricaine methanesulfonate white powder used anesthesia sedation euthanasia fish also anesthetic licensed united state use fin fish intended human consumption ,
Zolazepam,zolazepam pyrazolodiazepinone derivative used anaesthetic veterinary medicine zolazepam typically used combination nmda antagonist tiletamine α2 adrenoceptor agonist xylazine around four time potency diazepam water-soluble un-ionized physiological ph meaning onset fast ,
Detomidine,detomidine α2-adrenergic agonist used horse sedative normally administered salt form detomidine hydrochloride drug prescribed veterinarian marketed _dormosedan_ currently approved fda use horse studied use large animal ,used large animal sedative primarily horse 
Toluene,toluene colorless liquid immiscible water mono-substituted benzene derivative used veterinary medicine treatment various parasite dog cat ,used removal ascarids toxocara canis toxascaris leonina hookworm ancylostoma caninum uncinaria stenocephala aid removing tapeworm taenia pisiformis dipylidium caninum echinococcus granulosus dog cat 
Lesinurad,lesinurad oral uric acid transporter 1 urat1 inhibitor indicated treatment hyperuricemia associated gout reduces serum uric acid concentration inhibition urat1 enzyme responsible reuptake uric acid renal tubule oat4 another uric acid transporter associated diuretic-induced hyperuricemia marketed product zurampic indicated use combination xanthine oxidase inhibitor treatment hyperuricemia associated gout patient achieved target serum uric acid level xanthine oxidase inhibitor alone august 2017 combination oral therapy consisting lesinurad db00437 fda-approved brand name duzallo indicated treatment gout-related hyperuricemia patient uncontrolled gout , use combination xanthine oxidase inhibitor treatment hyperuricemia associated gout patient achieved target serum uric acid level xanthine oxidase inhibitor alone 
Aminacrine, highly fluorescent anti-infective dye used clinically topical antiseptic experimentally mutagen due interaction dna also used intracellular ph indicator ,
Bicuculline,bicuculline light-sensitive competitive antagonist gabaa receptor originally identified 1932 plant alkaloid extract isolated dicentra cucullaria adlumia fungosa fumariaceae several corydalis specie ,
Sebelipase alfa, lysosomal acid lipase lal enzyme found lysosome primarily responsible metabolism lipid absence deficiency result accumulation lipid various organ lipid accumulation lead end-organ damage form liver dysfunction malabsorption secondary intestinal dysfunction addition patient lal deficiency typically develop dyslipidemia contributes number adverse cardiovascular outcome l39337 sebelipase alfa recombinant form lal approved treatment lal deficiency first approved fda ema 2015 marketed brand name kanuma alexion pharmaceutical l39337 l39342 ,sebelipase alfa hydrolytic lysosomal cholesteryl ester triacylglycerol-specific enzyme indicated treatment patient diagnosis lysosomal acid lipase lal deficiency l39337 l39342 
Insulin tregopil,, code text 
Ixekizumab,"ixekizumab humanized immunoglobulin g subclass 4 igg4 monoclonal antibody mab interleukin-17a il-17a prevents interacting il-17a receptor il-17a pro-inflammatory cytokine involved inflammation immune response blocking effect beneficial use inflammatory condition particular il-17a found implicated variety autoimmune disease including rheumatoid arthritis plaque psoriasis ixekizumab produced recombinant dna technology recombinant mammalian cell line purified using standard technology bioprocessing ixekizumab comprised two identical light chain polypeptide 219 amino acid two identical heavy chain polypeptide 445 amino acid molecular weight 146,158 dalton protein backbone molecule indicated treatment adult moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy ",ixekizumab indicated treatment patient aged six year older moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy also indicated adult patient active psoriatic arthritis ankylosing spondylitis non-radiographic axial spondyloarthritis objective sign inflammation l40953 
Padimate O,padimate active sunscreen agent cosmetic over-the-counter sunscreen drug product concentration 8 regulated fda l2153 structurally-related compound db02362 absorbs uv-b ray prevent photodamage penetrates human skin shown induce non-ligatable strand break dna _in vitro_ mutagenic effect yeast i_n vivo_ a32458 ,indicated active uv-b filter prevent photodamage 
Human thrombin,human thrombin sterile solution ph 6.8-7.2 containing highly purified human thrombin activation clotting thrombin highly specific serine protease encoded f2 gene transforms soluble fibrinogen insoluble fibrin transformation mimic final coagulation cascade step involves clotting mass adheres wound surface achieves hemostasis sealing open tissue particular human thrombin product made pooled human source plasma recombinant thrombin human coagulation protein produced via recombinant dna technology genetically modified chinese hamster ovary cell line fda label furthermore human thrombin manufactured chromatographic purification prothrombin cryo-poor plasma followed activation calcium chloride fda label ,human thrombin indicated aid hemostasis whenever oozing blood minor bleeding capillary small venule accessible control bleeding standard surgical technique suture ligature cautery ineffective impractical combination fibrinogen used indicated adjunct hemostasis mild moderate bleeding adult undergoing surgery control bleeding standard surgical technique suture ligature cautery ineffective impractical l12936 l12939 
Thrombin alfa,thrombin alfa human coagulation protein produced via recombinant dna technology genetically modified cho cell line thrombin alfa identical amino acid sequence structurally similar naturally occurring human thrombin thrombin alfa precursor secreted culture medium single chain form proteolytically converted two-chain active form using protein derived snake purified chromatographic process yield product hemostatic activity similar native human thrombin cell line used manufacture thrombin alfa tested shown free known infectious agent cell culture process used manufacture thrombin alfa employ additive human animal origin purification process includes solvent-detergent treatment nano-filtration step dedicated viral clearance thrombin alfa product ultimate come recombinant human prethrombin-1 l2079 nevertheless incidence hemostasis within timely manner relatively comparable use thrombin alfa placebo treatment patient subject thrombin alfa currently approved certain organization like european medicine agency l2079 ,indicated aid hemostasis whenever oozing blood minor bleeding capillary small venule accessible control bleeding standard surgical technique suture ligature cautery ineffective impractical adult pediatric population greater equal one month age fda label additionally thrombin alfa used conjunction absorbable gelatin sponge usp fda label 
Aluminum chlorohydrate,aluminum chlorohydrate group water-soluble aluminum complex general formula alncl 3n-m oh m. included 25 over-the-counter hygiene product active antiperspirant agent primary site action aluminum chlorohydrate level stratum corneum layer relatively near skin surface a27159 also used coagulant water purification process ,indicated use antiperspirant 
Elbasvir,elbasvir direct-acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct-acting antiviral daas elbasvir elbasvir inhibitor ns5a protein essential viral replication virion assembly synthesis barrier development resistance ns5a inhibitor lower ns5b inhibitor another class daas a19593 substitution amino acid position 28 30 31 93 known confer resistance elbasvir l10253 despite disadvantage elbasvir still effective hcv particularly paired grazoprevir elbasvir available fixed-dose combination product grazoprevir tradename zepatier used treatment chronic hepatitis c. approved january 2016 fda zepatier indicated treatment hcv genotype 1 4 without ribavirin depending presence resistance-associated amino acid substitution ns5a protein previous treatment failure ribavirin peginterferon alfa-2a peginterferon alfa-2b ns3/4a inhibitor like boceprevir simeprevir telaprevir l10253 elbasvir grazoprevir used without ribavirin intent cure achieve sustained virologic response svr shown achieve svr 94 97 genotype 1 97 100 genotype 4 12 week treatment. l852 svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 computational target-based drug repurposing investigation published april 2020 elbasvir predicted bind stably preferentially three protein necessary viral replication sars-cov-2 human coronavirus responsible covid-19 pandemic a193257 result suggestive antiviral efficacy follow-up clinical trial required validate elbasvir potential therapy sars-cov-2 ,elbasvir used combination grazoprevir combination product zepatier indicated use without ribavirin treatment chronic hcv genotype 1 4 infection adult l10253 
Grazoprevir,grazoprevir direct acting antiviral medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas grazoprevir grazoprevir inhibitor ns3/4a serine protease enzyme encoded hcv genotype 1 4 synthesis enzyme essential viral replication serve cleave virally encoded polyprotein mature protein like ns3 ns4a ns4b ns5a ns5b fda label barrier develoment resistance ns3/4a inhibitor lower ns5b inhibitor another class daas a19593 subtitutions amino acid position 155 156 168 known confer resistance substitution enzyme 's catalytic triad consisting h58 d82 s139 also likely alter affinity drug ns3/4a activity enzyme despite disadvantage grazoprevir still effective hcv particularly paired db11574 joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend grazoprevir first line therapy combination db11574 genotype 1a 1b 4 hepatitis c a19593 grazoprevir db11574 used without db00811 intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality a19626 grazoprevir available fixed dose combination product db11574 tradename zepatier used treatment chronic hepatitis c. approved january 2016 fda zepatier indicated treatment hcv genotype 1 4 without db00811 depending presence resistance associated amino acid substitution ns5a protein previous treatment failure db00811 db00008 db00022 ns3/4a inhibitor like db08873 db06290 db05521 fda label combined together grazoprevir db11574 combination product zepatier shown achieve svr 94 97 genotype 1 97 100 genotype 4 12 week treatment l852 used patient compensated cirrhosis human immunodeficiency virus co-infection severe kidney disease ,grazoprevir indicated combination db11574 fixed dose combination product zepatier without db00811 treatment chronic hcv genotype 1a 1b 4 infection adult 
Ferric oxide,iron iii oxide ferric oxide inorganic compound formula fe2o3 one three main oxide iron two iron ii oxide feo rarer form iron ii iii oxide fe3o4 naturally magnetite ,
Indigotindisulfonic acid,indigotindisulfonic acid blue-colored dye variety us a32490 a32491 a32492 l2222 salt form indigotindisulfonate sodium also known indigo carmine indigotine fd c blue 2 compound acid-base indicator used production food colorants ph test a251405 indigotindisulfonic acid used clinical medicine determine patency urinary collecting system assist specific surgical procedure cystourethroscopy a32490 a32491 a32492 2022 fda approved intravenous use indigotindisulfonate sodium aid visualizing ureter integrity cystoscopic assessment l42600 , main application indigotindisulfonic acid localizing visualizing ureteral orifice cystoscopy ureteral catheterization procedure l2220 indigotindisulfonate sodium salt form indicated use visualization aid cystoscopic assessment integrity ureter adult following urological gynecological open robotic endoscopic surgical procedure l42600 
Ravulizumab,ravulizumab potent selective complement 5 c5 inhibitor humanized monoclonal igg2/4 kappa antibody produced chinese hamster ovary cho cell l39690 ravulizumab engineered eculizumab another complement inhibitor increase duration action reduce frequency drug administration a244460 work blocking terminal complement-mediated inflammation cell activation cell lysis blood disorder associated destruction red blood cell thrombosis impaired bone marrow function a244465 ravulizumab first approved fda december 21 2018 treatment paroxysmal nocturnal hemoglobinuria atypical hemolytic uremic syndrome child adult a244465 later approved european commission july 2 2019 indication l39710 ravulizumab also used treat myasthenia gravis l39690 l39700 ravulizumab currently investigated treatment coronavirus disease covid-19 -induced microvasculature injury endothelial damage leading thrombotic microangiopathy tma causing acute kidney injury aki l39715 ,ravulizumab indicated treatment adult pediatric patient one month age older paroxysmal nocturnal hemoglobinuria pnh l39690 also indicated treatment adult pediatric patient one month age older atypical hemolytic uremic syndrome ahus inhibit complement-mediated thrombotic microangiopathy tma however fda advises use ravulizumab treatment patient shiga toxin e. coli related hemolytic uremic syndrome stec-hus l39690 ravulizumab also indicated treatment adult patient generalized myasthenia gravis gmg anti-acetylcholine receptor achr antibody-positive l39690 l39700 european commission approved ravulizumab treatment paroxysmal nocturnal haemoglobinuria pnh adult child body weight 10 kg following condition hemolysis clinical symptom indicative high disease activity clinically stable treated eculizumab least past six month ravulizumab also indicated treatment hemolytic uremic syndrome ahus patient body weight 10 kg either complement inhibitor treatment-naïve received eculizumab least 3 month evidence response eculizumab l39700 
Venetoclax,venetoclax bcl-2 inhibitor initially approved fda april 2016 fda label protein b cell cll/lymphoma 2 bcl-2 family important regulator apoptotic programmed cell death process a18565 a18566 venetoclax used treat chronic lymphocytic leukemia cll certain type small lymphocytic lymphoma fda label cll prevalent leukemia diagnosed western country a40022 venetoclax developed reverse engineering bcl-2 protein family inhibitor navitoclax a40022 venetoclax approximately 10 time potent navitoclax regard induction apoptosis cll cell a40022 new indication approved 2018 treatment patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll without 17p deletion received least one prior therapy fda label previously drug indicated patient 17p gene deletion f2130 ,venetoclax indicated treatment adult patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll also used combination azacitidine decitabine low-dose cytarabine treatment newly diagnosed acute myeloid leukemia aml adult 75 year older comorbidities preclude use intensive induction chemotherapy l39880 
Thiocolchicoside,thiocolchicoside semi-synthetic derivative colchicine natural anti-inflammatory glycoside originates flower seed _superba gloriosa_ muscle relaxant anti-inflammatory analgesic effect potent convulsant activity administered individual prone seizure l1663 ,thiocolchicoside skeletal muscle-relaxant drug used treatment orthopedic traumatic rheumatologic disorder l1661 indicated adjuvant drug treatment painful muscle contracture indicated acute spinal pathology adult adolescent 16 year age older l1658 recent study examined effect muscle tone stiffness contracture soreness experienced athlete sporting competition l1664 
Cetalkonium,cetalkonium c16 alkyl benzalkonium chloride derivative amphipathic property allows used different type formulation a27143 quaternary ammonium salt act antiseptic variety bacteria fungi l2137 cetalkonium approved fda use over-the-counter product skin protectant l2737 health canada also approved use over-the-counter product l1113 ,cetalkonium used surfactant germicide fungicide mildew preventive agent silicone-based water repellent emulsifier disinfectant topical anti-infective antiseptic antimicrobial pharmaceutical chemical property antiseptical characteristic cetalkonium used wide variety product part formulation also determined active antiseptic ingredient over-the-counter preparation t211 
Pipradrol,pipradrol meratran l2523 initially developed 1950s antidepressant however adverse effect associated use abuse potential led withdrawal international regulation l2524 pipradrol made illegal many country 1970s potential abuse currently classified misuse drug act class c substance l2522 experimentation drug derivative recreational purpose led many case acute toxicity linked three fatality social particular acute clinical harm pipradrol derivative led control misuse drug act 1971 uk 2012 t178 interestingly drug studied bactericidal property however currently used purpose a32725 addition shown favorable effect postpartum depressive symptom l2516 ,used manage fatigue l2522 depression l2515 a32724 l2518 l2523 used adjunct therapy management obesity l2522 
Drometrizole trisiloxane,drometrizole trisiloxane photostable uva uvb light filter a33069 l2780 l2781 l2782 l2783 f81 compound lipophilic benzotriazole derivative marketed meroxyl xl l'oreal although sunscreen drometrizole trisiloxane currently approved use eu canada australia japan among country despite used elsewhere world relatively report adverse reaction fda continues cite existing scientific record sufficient establish compound generally recognized safe effective over-the-counter sunscreen use l2795 f82 ,drometrizole trisiloxane used active ingredient various sunscreen indication protecting skin absorbing damaging uv radiation sunlight a33069 l2780 l2781 l2782 l2783 f81 f82 
Asunaprevir,asunaprevir also named bms-650032 potent hepatitis c virus hcv ns3 protease inhibitor shown high efficacy dual-combination regimen daclatasvir patient chronically infected hcv genotype 1b a32528 developed bristol-myers squibb canada approved health canada april 22 2016 commercialization asunaprevir cancelled one year later october 16 2017 l1113 ,asunaprevir indicated combination agent treatment chronic hepatitis c adult patient hepatitis c virus genotype 1 4 compensated liver cirrhosis l2278 hepatitis c liver disease caused hepatitis c virus chronic state condition account 60-80 case risk cirrhosis liver within 20 year around 15-30 l2281 genotype 1 common type hepatitis c united state difficult treat l2282 
Etafedrine,etafedrine inn ethylephedrine long-acting bronchodilator ingredient combined drug brand name nethaprin a32757 dalmacol l2568 previously available free base hydrochloride salt manufactured sanofi-aventis sanofi discontinued l2563 ethylephedrine formed alkylating ephedrine ethyl iodide hydrochloride prepared passing hydrogen chloride solution ethylephedrine diethyl ether f6 belongs family medication called _decongestants_ act narrowing blood vessel nasal passage helping relieve nasal congestion f6 ,condition characterized bronchial congestion bronchospasm expectorant bronchodilator action required acute bronchitis acute episode chronic bronchitis bronchial asthma l2565 l2566 
Carbon monoxide,carbon monoxide co colorless odorless tasteless gas slightly lower density air toxic hemoglobin utilizing animal including human encountered concentration 35 ppm although also formed normal animal metabolism low quantity thought normal biological/homeostatic function l2529 carbon monoxide co ubiquitous environmental product organic combustion also formed endogenously human body byproduct heme metabolism a32758 exhaled co eco similar exhaled nitric oxide eno evaluated candidate breath biomarker pathophysiological state including smoking status inflammatory disease lung organ exhalation corbon monoxide value studied potential indicator inflammation asthma stable copd exacerbation cystic fibrosis lung cancer surgery critical care l2529 test diffusing capacity lung carbon monoxide dlco one clinically valuable test lung function testing technique first described 100 year ago applied clinical practice many year dlco measure ability lung transfer gas inhaled air red blood cell pulmonary capillary dlco test convenient simple patient undergo ten second breath-holding required dlco maneuver easier patient perform forced exhalation required respiratory test l2557 carbon monoxide presently used small amount low oxygen modified atmosphere packaging system map fresh meat stabilize maintain natural meat color use co generally recognized safe gras several packaging application fresh meat product since 2002 fda favorably reviewed three gras notification carbon monoxide use fresh meat packaging l2537 fda classifies drug permitted food additive packaging preparation food product following federal code regulation l2531 several concern voiced use carbon monoxide food product l2537 l2538 l2539 european union banned use carbon monoxide color stabilizer meat fish december 2001 report european commission 's scientific committee food concluded gas pose risk provided food maintained adequately cold storage transport prevent growth microorganism l2538 new zealand use carbon monoxide fish preparation banned may mask effect food spoilage bacterial growth l2539 ,used marker respiratory status spirometry test l2557 f4 food additive pigment fixation meat l2531 
Neon,neon chemical element chemical symbol ne atomic number 10 noble gas colorless odorless inert monatomic fifth abundant chemical element universe mass rare element earth display reddish-orange light commonly used low-voltage neon glow lamp high-voltage discharge tube sign fluorescent lighting also used vacuum tube high-voltage indicator lightning arrester wave meter tube television tube helium–neon laser neon may used clinical setting diagnostic tracer gas gas analyzer lung diffusion test clinical application neon radiotherapy various cancer a32763 studied ,indicated use diagnostic tracer gas pulmonary function test 
Thimerosal,thiomersal inn commonly known u.s. thimerosal organomercury compound compound well-established widely used antiseptic antifungal agent developed 1927 thimerosal still used preservative cosmetic topical pharmaceutical biological drug product includes vaccine significant concern regarding safety toxicity last several decade although thimerosal banned several country continues included preservative vaccine united state many vaccine developing world l1685 ,used preservative cosmetic topical pharmaceutical biological drug product includes vaccine l1671 l1672 l1673 
Bilastine,bilastine novel new-generation antihistamine highly selective h1 histamine receptor rapid onset prolonged duration action , symptomatic relief nasal non-nasal symptom seasonal rhinitis patient 12 year age older symptomatic relief chronic spontaneous urticaria patient 18 year age older fda label 
Nitrocefin,nitrocefin chromogenic cephalosporin substrate used detect presence beta-lactamase enzyme important mediator bacterial antibiotic resistance detection method exist pcr nitrocefin allows rapid detection using material inexpensive equipment ,
Domiphen,domiphen bromide quaternary ammonium compound predominantly employed topically administered antiseptic agent ,anti-infective topical used treatment acute infectious dental disease condition 
Atezolizumab,atezolizumab humanized monoclonal antibody used prevent interaction pd-l1 pd-1 removing inhibition immune response seen cancer a18493 l7489 medication reserved patient whose tumor express pd-l1 receive platinum-based chemotherapy whose tumor respond platinum-based chemotherapy l7489 atezolizumab granted fda approval 18 october 2016 l7489 november 2022 manufacturer genentech voluntarily withdrew use atezolizumab treatment urothelial carcinoma previously approved fda 's accelerated approval program rest atezolizumab indication remain unaffected l44246 ,atezolizumab approved indication following condition l44336 non-small cell lung cancer nsclc adjuvant treatment following resection platinum-based chemotherapy adult patient stage ii iiia nsclc whose tumour pd-l1 expression ≥ 1 tumour cell determined fda-approved test first-line treatment adult patient metastatic nsclc whose tumour high pd-l1 expression pd-l1 stained ≥ 50 tumour cell tc ≥ 50 pd-l1 stained tumour-infiltrating immune cell ic covering ≥ 10 tumour area ic ≥ 10 determined fdaapproved test egfr alk genomic tumour aberration combination bevacizumab paclitaxel carboplatin first-line treatment adult patient metastatic non-squamous nsclc egfr alk genomic tumour aberration combination paclitaxel protein-bound carboplatin firstline treatment adult patient metastatic non-squamous nsclc egfr alk genomic tumor aberration treatment adult patient metastatic nsclc disease progression following platinum-containing chemotherapy patient egfr alk genomic tumour aberration disease progression fda-approved therapy nsclc harbouring aberration prior receiving atezolizumab small cell lung cancer sclc combination carboplatin etoposide first-line treatment adult patient extensive-stage small cell lung cancer es-sclc hepatocellular carcinoma hcc combination bevacizumab treatment patient unresectable metastatic hcc received prior systemic therapy melanoma combination cobimetinib vemurafenib treatment patient braf v600 mutation-positive unresectable metastatic melanoma alveolar soft part sarcoma asp treatment adult pediatric patient 2 year age older unresectable metastatic asp 
Levoleucovorin,levoleucovorin enantiomerically active form folinic acid also known 5-formyl tetrahydrofolic acid leucovorin commercially available leucovorin composed 1:1 racemic mixture dextrorotary levorotary isomer levoleucovorin contains pharmacologically active levo-isomer vitro levo-isomer shown rapidly converted biologically available methyl-tetrahydrofolate form dextro form slowly excreted kidney despite difference activity two commercially available form shown pharmacokinetically identical may used interchangeably limited difference efficacy side effect kovoor et al 2009 folate analog levoleucovorin leucovorin used counteract toxic effect folic acid antagonist methotrexate act inhibiting enzyme dihydrofolate reductase dhfr indicated use rescue therapy following use high-dose methotrexate treatment osteosarcoma diminishing toxicity associated inadvertent overdosage folic acid antagonist levoleucovorin product fusilev fda additional indication use combination chemotherapy 5-fluorouracil palliative treatment patient advanced metastatic colorectal cancer folic acid essential b vitamin required body synthesis purine pyrimidine methionine incorporation dna protein however order function role must first reduced enzyme dihydrofolate reductase dhfr cofactor dihydrofolate dhf tetrahydrofolate thf important pathway required de novo synthesis nucleic acid amino acid disrupted high-dose methotrexate used cancer therapy methotrexate function dhfr inhibitor prevent dna synthesis rapidly dividing cell also prevents formation dhf thf result deficiency coenzyme resultant buildup toxic substance responsible numerous adverse side effect methotrexate therapy levoleucovorin leucovorin analog tetrahydrofolate thf able bypass dhfr reduction act cellular replacement co-factor thf thereby preventing toxic side effect ,levoleucovorin indicated use rescue therapy following high-dose methotrexate treatment osteosarcoma diminishing toxicity associated inadvertent overdosage folic acid antagonist levoleucovorin product fusilev fda dosed one-half usual dose racemic l-leucovorin additional indication use combination chemotherapy 5-fluorouracil palliative treatment patient advanced metastatic colorectal cancer although mixed infusion precipitate may form 
Human Rho(D) immune globulin,human rho immune globulin medicine given intramuscular intravenous injection used prevent immunological condition known rh disease hemolytic disease newborn rho immune globulin available sterile lyophilized liquid gamma globulin igg fraction containing antibody rh0 antigen antigen name rhophylac im/iv immune globullin purified via ion-exchange chromatography method prepared pool human plasma donor rho -negative donor immunized rho -positive rbc approved fda treatment suppression rhesus rh isoimmunization chronic immune thrombocytopenic purpura itp adult ,indicated suppression rhesus rh isoimmunization nonsensitized rho -negative woman rh-incompatible pregnancy rho -negative individual transfused rh0 -positive red blood cell rbc blood component containing rh0 -positive rbc also indicated rh0 -positive non-splenectomized adult patient chronic immune thrombocytopenic purpura itp raise platelet count 
Antithrombin III human, plasma alpha 2 glycoprotein account major antithrombin activity normal plasma also inhibits several enzyme member serpin superfamily ,antithrombin iii human human antithrombin indicated patient hereditary antithrombin deficiency treatment prevention thromboembolism prevention peri-operative peri-partum thromboembolism
"Starch, corn",corn starch refers starch extracted corn grain commonly used food ingredient chemical additive starch group polysaccharide general formula c6-h10-o5 n composed long-chain polymer glucose form amylose amylopectin starch chief storage form energy reserve carbohydrate plant corn starch may added food product thickening agent anti-caking agent sometimes found topical drug skin protectant ,
Beeswax, wax obtained honeycomb bee consists primarily myricyl palmitate cerotic acid ester high-carbon paraffin beeswax used stiffening agent ointment cream enables water incorporated produce water-in-oil emulsion also used coating manufacture modified-release oral preparation,beeswax also characterized several therapeutic property great interest u thought particularly effective healing bruise inflammation burn recently interest researcher moved even antimicrobial property beeswax although still study literature focused action beeswax study showed antimicrobic effectiveness beeswax overall staphylococcus aureus salmonella enterica candida albicans aspergillus niger sterile preparation white beeswax hard paraffin isopropyl palmitate sterile surgical bone wax used control bleeding damaged bone surgery confused aseptic surgical wax bpc 1949 also known horsley 's wax contained yellow beeswax olive oil phenol mercuric chloride solution used control haemorrhage bone cranial surgery 
Tuberculin purified protein derivative,tuberculin purified protein derivative ppd sterile aqueous solution purified protein fraction intradermal administration aid diagnosis tuberculosis diagnostic test commonly referred mantoux test serf minimize risk transmission infection mycobacterium tuberculosis early diagnosis appropriate therapeutic intervention purified protein fraction isolated culture medium filtrate human strain mycobacterium tuberculosis included world health organization 's list essential medicine ,indicated diagnostic agent mantoux test used detect infection mycobacterium tuberculosis 
Hydroxyethyl cellulose,hydroxyethyl cellulose polysaccharide derivative gel thickening emulsifying bubble-forming water-retaining stabilizing property used key ingredient many household cleaning product lubricant cosmetic due non-ionic water-soluble nature often used ingredient ophthalmic pharmaceutical preparation artificial tear solution adjunct agent topical drug formulation facilitate delivery drug hydrophobic character , alleviating surface irritation topical ocular administration artificial tear solution hydroxyethyl cellulose also found topical formulation aid efficient drug diffusion across membrane 
"Rabies immune globulin, human",imogam rabies pasteurized indicated post-exposure prophylaxis person suspected exposure rabies previously received complete immunization regimen cell culture produced rabies vaccine person previously vaccinated type rabies vaccine adequate antibody level demonstrated receive full post-exposure prophylaxis rig cell culture-produced rabies vaccine imogam rabies pasteurized administered promptly exposure conjunction rabies vaccine imogam rabies pasteurized administered recommended initiation post-exposure rabies vaccine series administered eight day following first dose rabies vaccine since rabies vaccine-induced antibody begin appear within one week value administering rabies immune globulin eight day rabies vaccination begun recommendation passive and/or active immunization exposure animal suspected rabies outlined national advisory committee immunization naci advisory committee immunization practice acip world health organization , human rabies immune globulin used indicated passive transient post-exposure prophylaxis rabies infection person age given immediately contact rabid possibly rabid animal administered concurrently full course rabies vaccine l41200 
"Tetanus immune globulin, human",tetanus immune globulin manufactured human plasma fda label contains antibody tetanus toxoid primarily used prophylaxis tetanus wounded patient , use prophylaxis tetanus patient injured incomplete uncertain immunization status fda label may also used treatment active tetanus 
Myrrh,extractives physically modified derivative tincture concrete absolute essential oil oleoresin terpene terpene-free fraction distillate residue obtained commiphora abyssinica burseraceae ,fda approved use food historically used indigestion ulcer cold cough asthma bronchial congestion arthritic pain cancer leprosy syphilis also used orally stimulant antispasmodic increase menstrual flow topically myrrh used mild inflammation oral pharyngeal mucosa aphthous ulcer gingivitis chapped lip hemorrhoid bedsore wound abrasion furunculosis bad breath loose teeth food beverage myrrh used flavoring component manufacturing myrrh used fragrance fixative cosmetic also used embalming incense 
Susoctocog alfa,intravenous susoctocog alfa recombinant b-domain deleted porcine sequence antihaemophilic factor viii fviii product recently approved treatment bleeding episode adult acquired haemophilia aha aha rare bleeding disorder result prolonged clotting time measured activated partial thromboplastin time aptt assay conventional vitro test biological activity factor viii patient aha normal factor viii gene coagulation pathway develop inhibitory autoantibody directed factor viii autoantibody neutralize circulating human factor viii create functional deficiency procoagulant protein susoctocog alfa serf temporarily restore inhibited endogenous factor viii effective hemostasis global prospective controlled multi-center phase 2/3 open-label clinical trial patient responded susoctocog alfa treatment within 24 hour l1129 susoctocog alfa glycoprotein containing 90 kda heavy chain 80 kda light chain naturally-occuring b domain replaced twenty-four amino acid linker susoctocog alfa approved fda october 2014 marketed brand name obizur intravenous injection first recombinant porcine fviii treatment approved aha allows physician manage treatment 's efficacy safety measuring factor viii activity level addition clinical assessment l1129 recombinant porcine sequence allows le susceptibility inactivation circulating human factor viii antibody ,indicated treatment bleeding episode adult acquired hemophilia 
Efmoroctocog alfa,efmoroctocog alfa fully recombinant factor viii-fc fusion protein rfviiifc extended half-life compared conventional factor viii fviii preparation including recombinant fviii rfviii product db13999 a31551 antihemorrhagic agent used replacement therapy patient haemophilia congenital factor viii deficiency suitable age group haemophilia rare bleeding disorder associated slow clotting process caused deficiency factor viii patient disorder susceptible recurrent bleeding episode excessive bleeding following minor traumatic injury surgical procedure a31551 prophylactic treatment may dramatically improve management severe haemophilia future reducing joint bleeding hemorrhage cause chronic pain disability patient a31551 a31552 prophylaxis also shown reduce formation neutralizing anti-fviii antibody inhibitor a31552 factor viii blood coagulant factor involved intrinsic pathway form fibrin blood clot efmoroctocog alfa first commercially available rfviii-fc fusion protein rfviiifc conjugated molecule rfviii polyethylene glycol covalently fused dimeric fc domain human immunoglobulin g1 long-lived plasma protein fda label b domain factor viii deleted animal model haemophilia efmoroctocog alfa demonstrated approximately two-fold longer t½ commercially available rfviii product a31551 drug product similar structure function efmoroctocog alfa include db13999 produced recombinant dna technology identical sequence endogenously produced factor viii contain b-domain known biological function db13192 purified endogenous factor viii human pooled blood contains a- b-subunits commonly marketed elocta eloctate intravenous injection date confirmed inhibitory autoantibody seen previously treated patient included clinical study treatment-emergent adverse event generally consistent expected patient population studied a31551 extended half-life efmoroctocog alfa provides several clinical benefit patient including reduced frequency injection required improved adherence prophylaxis a31551 ,indicated treatment prophylaxis bleeding patient haemophilia congenital factor viii deficiency fda label 
Eftrenonacog alfa,"eftrenonacog alfa long-acting recombinant fusion protein used treatment hemophilia b comprised single molecule human factor ix fix covalently linked constant region fc domain human igg1 via recombinant dna technology human embryonic kidney cell line hek293h a31556 presence fc domain extends terminal half-life confers clinical benefit prolonged therapeutic efficacy le frequent intravenous injection patient convenience improved adherence prophylaxis hemophilia b blood disorder incidence approximately every 30,000 male birth population ethnic group a31557 x-linked genetic disease caused mutation gene coagulation protein factor ix fix leading decreased level endogenous factor ix increased susceptibility recurrent bleeding episode caused spontaneously result accidental surgical trauma fda label untreated patient die bleeding complication 25 year age a31557 eftrenonacog alfa act replacement therapy restore level factor ix allow normal hemostasis eftrenonacog alfa developed marketed alprolix intravenous injection biogen first approved fda march 2014 later approved ema may 2016 eftrenonacog alfa treatment demonstrated good tolerability report inhibitor development clinical study a31556 ",indicated treatment prophylaxis bleeding patient age haemophilia b congenital factor ix deficiency 
Normethadone,normethadone used opioid antitussive combination db11610 marketed canada valeant tradename cophylac , use treatment cough le potent treatment failed fda label 
Oxilofrine,oxilofrine used combination db11609 antitussive currently marketed canada valeant tradename cophylac ,used combination db11609 antitussive fda label 
Lifitegrast,lifitegrast fda approved drug treatment keratoconjunctivitis sicca dry eye syndrome tetrahydroisoquinoline derivative lymphocyte function-associated antigen-1 lfa-1 antagonist discovered rational design process ophthalmic solution approved july 2016 trade name xiidra shown protect corneal surface alleviate symptom dry eye syndrome fast onset action well tolerated profile local systemic setting a18805 , treatment sign symptom keratoconjunctivitis sicca dry eye syndrome 
Velpatasvir,velpatasvir direct-acting antiviral daa medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 velpatasvir act defective substrate ns5a non-structural protein 5a non-enzymatic viral protein play key role hepatitis c virus replication assembly modulation host immune response a19175 treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas velpatasvir notably velpatasvir significantly higher barrier resistance first generation ns5a inhibitor db09027 db09102 making highly potent reliable alternative treatment chronic hepatitis c a19637 joint recommendation published 2016 american association study liver disease aasld infectious disease society america idsa recommend velpatasvir first line therapy combination sofosbuvir six genotype hepatitis c l852 velpatasvir currently available within fixed dose combination product epclusa db08934 another direct acting antiviral goal therapy epclusa include intent cure achieve sustained virologic response svr 12 week daily therapy svr eradication hcv infection associated significant long-term health benefit including reduced liver-related damage improved quality life reduced incidence hepatocellular carcinoma reduced all-cause mortality risk requiring liver transplant a19626 since june 2016 velpatasvir available fixed dose combination product db08934 commercially available product epclusa epclusa first combination hcv product indicated treatment genotype hepatitis c without cirrhosis also currently potent hcv antiviral medication market sustained virologic response svr 12 week therapy 93-99 depending genotype level cirrhosis high barrier resistance l852 canadian american guideline list epclusa first line recommendation genotype hcv l852 a19626 ,velpatasvir used combination therapy antiviral medication treat chronic hepatitis c virus hcv infected patient hcv genoptypes 1-6 treat hcv hiv co-infected patient depending level cirrhosis decompensation combination therapy also include therapy db00811 used combination db08934 combination product epclusa velpatasvir indicated treatment adult patient chronic hepatitis c virus hcv genotype 1 2 3 4 5 6 infection without cirrhosis compensated cirrhosis combination db00811 associated decompensated cirrhosis fda label 
Rupatadine,rupatadine dual histamine h1 receptor platelet activating factor receptor antagonist used symptomatic relief seasonal perennial rhinitis well chronic spontaneous urticaria approved marketing canada tradename rupall come tablet formulation adult use liquid formulation pediatric use , symptomatic relief nasal non-nasal symptom seasonal allergic rhinitis perennial allergic rhinitis patient 2 year age older fda label also used symptomatic relief chronic spontaneous urticaria patient 2 year age older 
Zorubicin,zorubicin drug anthracycline class class medication historically demonstrated effective chemotherapy variety cancer type ,
Gestrinone,gestrinone also known ethylnorgestrienone synthetic steroid 19-nortestosterone group marketed europe australia latin america though united state canada used primarily treatment endometriosis gestrinone developed early 1970s tested clinically weekly oral contraceptive europe north america without significant advantage oral contraceptive high cost gestrinone longer used stage ii clinical trial however 1982 drug attracted increased interest due significant therapeutic effect treatment endometriosis different endocrine condition gestrinone posse estrogenic progestational androgenic antiestrogenic antiprogesterone action l1696 ,endometriosis without accompanying sterility treatment limited single course 6 month duration per lifetime l1699 l1700 
Human varicella-zoster immune globulin,human varicella-zoster immune globulin solvent/detergent-treated sterile liquid preparation purified human immune globulin g igg containing antibody varicella zoster virus anti-vzv prepared pool healthy human donor plasma via anion-exchange column chromatography approved 2012 name varizig reduce disease severity high-risk patient lack evidence immunity varicella varicella vaccine contraindicated therapeutic efficacy proven administered within 4 day exposure varicella zoster virus ,indicated preventing reducing severity chicken pox varicella zoster virus infection high risk individual within 4 day exposure varicella zoster virus 
Dehydrocholic acid,dehydrocholic acid synthetic bile acid prepared oxidation cholic acid chromic acid a33022 used stimulation biliary lipid secretion use dehydrocholic acid over-the-counter product discontinued health canada , approved therapeutic indication 
Candoxatrilat," dicarboxylic acid monoamide obtained formal condensation amino group cis-4-aminocyclohexanecarboxylic acid cyclopentanecarboxylic acid group 1- 2 -2-carboxy-3- 2-methoxyethoxy propyl cyclopentanecarboxylic acid potent inhibitor neutral endopeptidase nep neprilysin ec 3.4.24.11 used 2,3-dihydro-1h-inden-5-yl ester prodrug treatment chronic heart failure ",
Epoetin delta,epoetin delta ingredient ema-withdrawn product dynepo ,
Perflenapent,dodecafluoropentane ingredient ema-withdrawn product echogen ,
Tasonermin,tasonermin recombinant soluble form tumor necrosis factor alpha produced via _escherichia coli_ cell culture approved use european medicine agency april 1999 use adjunt surgery subsequent removal tumor palliative care irresectable soft tissue sarcoma limb product beromun administered db01042 via mild hyperthermic isolated limb perfusion , use adult adjunct surgery subsequent removal tumour prevent delay amputation palliative care irresectable soft tissue sarcoma limb fda label used combination melphalan via mild hyperthermic isolated limb perfusion 
Hepatitis B Vaccine (Recombinant),hepatitis b vaccine ingredient ema-withdrawn product quintanrix marketed canada engerix b also part twinrix hep a/hep b vaccine available also canada hepatitis b virus induces severe form viral hepatitis causative agent hepatitis virus non-a non-b hepatitis virus hepatitis virus defective virus requiring “ keeper function ” hepatitis b virus occurs either co-infection super-infection hbsag carrier transmission virus occurs percutaneous contact contaminated blood serum plasma infection may also occur exposure mucous surface intact damaged skin body fluid saliva mucosal secretion semen specific treatment hepatitis incubation period may long 6 month followed complex clinical course acute chronic nature often leading hospitalization viral hepatitis caused hepatitis b virus major worldwide health problem though incidence epidemiology vary widely among geographical area population subgroup canada united state northern europe 4 6 population infected lifetime mostly young adult 5 10 infection lead persistent viremia carrier state certain population subgroup area however high risk see indication clinical use asia infection often occurs early life leading hepatitis b marker prevalence 70 general population carrier rate 20 estimated reservoir persistent hepatitis b surface antigen carrier amount 350 million people worldwide carrier high risk developing chronic liver disease may lead cirrhosis primary hepatocellular carcinoma significant reduction incidence hepatocellular carcinoma observed child aged 6 to14 year following nationwide hepatitis b vaccination taiwan resulted significant decline prevalence hepatitis b antigen persistence essential factor development hepatocellular carcinoma vaccination hepatitis b expected long term reduce overall incidence hepatitis b chronic complication chronic active hepatitis cirrhosis ,active immunization hepatitis b virus infection vaccine protect infection caused hepatitis non-a non-b hepatitis virus hepatitis caused delta agent occur absence hepatitis b infection carrier state expected hepatitis also prevented vaccination hepatitis b virus vaccine vaccine administered age birth onwards may used start primary course vaccination booster dose may also used complete primary course vaccination started plasma-derived yeast-derived vaccine booster dose subject previously received primary course vaccination plasma-derived yeast-derived vaccine area low prevalence hepatitis b vaccination strongly recommended subject increased risk infection include following group health professional physician surgeon oral surgeon dentist nurse dental nurse dental hygienist podiatrist iv team operating room personnel paramedical personnel close contact patient staff hemodialysis nephrology hepatology hematology oncology unit laboratory personnel handling blood clinical specimen blood bank plasma fractionation worker pathologist morgue attendant cleaning staff handle waste hospital emergency first aid worker ambulance staff dental medical nursing student patient patient receiving frequent blood transfusion clotting factor concentrate oncology unit thalassemia sickle-cell anemia cirrhosis hemophilia etc patient hemodialysis patient type 2 diabetes personnel resident institution person frequent and/or close contact high-risk group prisoner prison staff resident staff institution developmentally challenged contact aggressive biting resident highest risk person increased risk due sexual practice male sexual contact male others multiple sexual partner recent history sexually transmitted disease person use injectable drug illicitly traveller area high endemicity close contact household contact group patient acute chronic hepatitis b infection infant born hbsag-positive mother chronic liver disease cld subject chronic liver disease subject risk developing cld e.g hepatitis c virus carrier person abuse alcohol others police fire fighter armed force personnel mortician embalmer work personal lifestyle may exposed hepatitis b virus area low high prevalence vaccination offered young child neonate risk well adult high risk group 
Depreotide,depreotide ingredient ema-withdrawn product neospect ,
Laropiprant,laropiprant ingredient ema-withdrawn product pelzont ,
Temoporfin,temoporfin photosensitizing agent used treatment squamous cell carcinoma head neck fda label first authorized market european medicine agency october 2001 currently available brand name foscan , use treatment patient advanced squamous cell carcinoma head neck failing standard therapy unsuitable radiotherapy surgery systemic chemotherapy fda label 
Eptotermin alfa, bone morphogenetic protein widely expressed embryonic development potent osteogenic factor specific regulator nephrogenesis eptotermin alfa ingredient ema-withdrawn product osigraft ,
Opicapone,opicapone potent reversible peripherally-acting third-generation inhibitor catechol-o-methyltransferase comt enzyme involved breakdown various catecholamine including dopamine a36938 a203048 many patient parkinson ’ disease treated levodopa plus dopa decarboxylase ddc inhibitor eg carbidopa experience motor complication time call management symptom use dopamine agonist monoamine oxidase b inhibitor selegiline rasagiline _catechol-o-methyl transferase comt inhibitor amantadine using modified-release formulation levodopa l2336 opicapone used adjunct therapy levodopa carbidopa adult patient parkinson 's disease end-of-dose motor fluctuation opicapone approved use european commission june 2016 l2339 fda april 2020 l13772 marketed brand name ongentys once-daily oral capsule exhibiting long duration action exceeds 24 hour opicapone administered once-daily l2336 demonstrates lowest risk cytotoxicity compared catechol-o-methyltransferase inhibitor a203048 ,opicapone indicated adjunctive therapy adult parkinson ’ disease end-of-dose motor fluctuation “ ” episode whose symptom stabilized combination therapy levodopa dopa decarboxylase inhibitor e.g. carbidopa l2343 l13772 
Isavuconazole,isavuconazole triazole antifungal broad spectrum activity good safety profile a32026 approved fda ema treatment invasive aspergillosis mucormycosis work inhibiting fungal cell membrane synthesis invasive fungal infection pose significant clinical challenge patient especially immunocompromised vitro _candida_ specie _aspergillus_ specie mucorales _cryptococcus_ spp. _fusarium_ specie dermatophytes dimorphic fungi displayed susceptibility isavuconzaole a32029 resistance isavuconazole associated mutation target gene cyp51 fda label cross-resistance isavuconazole azoles also proposed although clinical relevance unclear fda label isavuconazole display low water solubility found active ingredient prodrug db06636 prodrug formulation isavuconazole fda- ema-approved marketed trade name cresemba treatment invasive aspergillosis mucormycosis oral intravenous administration intravenous formulation cyclodextrin-free give isavuconazole advantage azole antifungal requires cyclodextrin facilitating drug solubility cyclodextrin potential nephrotoxicity a32029 proposed intravenous oral dosing used interchangeably l1482 without need repeat loading dose transitioning iv oral formulation a32026 isavuconazonium display excellent water solubility intravenous formulation good absorption enhanced oral bioavailability a32026 following administration isavuconazonium undergoes biotransformation form active moiety isavuconazole antifungal action , indicated patient 18 year age older treatment invasive aspergillosis fda label indicated patient 18 year age older treatment invasive mucormycosis fda label including patient treatment amphotericin b inappropriate l1482 
Colestilan chloride,colestilan ingredient ema-withdrawn product bindren ,
Tocofersolan,d-alpha-tocopheryl polyethylene glycol 1000 succinate tocofersolan vedrop developed europe orally bioavailable source vitamin e child suffering cholestasis l2371 cholestasis reduction stoppage bile flow either impaired secretion _hepatocytes_ liver cell obstruction l2374 l2375 tocofersolan polyethylene glycol derivative α-tocopherol synthetic water-soluble version db11251 tocofersolan oral treatment vitamin e deficiency due digestive malabsorption pediatric patient congenital chronic cholestasis hereditary chronic cholestasis approved european medicine agency ema june 2009 market name vedrop moreover agent capable demonstrating antioxidant effect make popular component include cosmetic pharmaceutical well addition tocofersolan studied promising application absorption enhancer drug delivery msds ,tocofersolan indicated vitamin e deficiency caused digestive malabsorption pediatric patient congenital chronic cholestasis hereditary chronic cholestasis birth full term newborn 18 year age l2371 
Nomegestrol,nomegestrol ingredient ema-authorised product zoely ,
Delamanid,delamanid anti-tuberculosis agent derived nitro-dihydro-imidazooxazole class compound inhibits mycolic acid synthesis bacterial cell wall a31965 used treatment multidrug-resistant extensively drug-resistant tuberculosis tb combination regimen emergence multidrug-resistant extensively drug-resistant tuberculosis creates clinical challenge patient disease associated higher mortality rate insufficient therapeutic response standardized antituberculosis treatment db00951 db01045 multidrug-resistant tuberculosis may also require 2 year chemotherapy second-line therapy narrow therapeutic index a31968 clinical study involving patient pulmonary multidrug-resistant tuberculosis extensively drug-resistant tuberculosis treatment delamanid combination who-recommended optimised background treatment regimen associated improved treatment outcome reduced mortality rate a31965 spontaneous resistance delamanid observed treatment mutation one 5 f420 coenzyme responsible bioactivation delamanid contributes effect l1407 delamanid approved ema marketed trade name deltyba oral tablet marketed otsuka pharmaceutical co. ltd tokyo japan ,indicated use part appropriate combination regimen pulmonary multi-drug resistant tuberculosis mdr-tb adult patient effective treatment regimen otherwise composed reason resistance tolerability l1407 
Artenimol,artenimol artemisinin derivative antimalarial agent used treatment uncomplicated plasmodium falciparum infection fda label first authorized market european medicine agency october 2011 combination db13941 product eurartesim artemisinin combination therapy highly effective malaria stongly recommended world health organization l1156 , treatment uncomplicated plasmodium falciparum infection adult child infant aged 6 month weighing 5 kg fda label used combination db13941 
Dibotermin alfa,dibotermin alfa recombinant human bone morphogenetic protein-2 rhbmp-2 derived recombinant chinese hamster ovary cho cell line fda label implanted patient undergoing bone surgery fracture bmps subfamily transforming growth factor-β tgf-β superfamily different action bone matrix a31946 bmp-2 potent osteoinductive protein play critical role differentiation osteoprogenitor cell osteoblast thus promoting bone cartilage formation a31952 enhancing osteogenesis site implantation dibotermin alfa accelerates healing open tibial shaft fracture reduces need secondary intervention a31945 prospective clinical study patient open tibial fracture administration dibotermin alfa resulted faster fracture- wound-healing significantly fewer secondary invasive intervention reduced infection rate post-operation a31945 dibotermin alfa approved ema 2002 inductos implantation matrix 2004 approved fda marketed infuse infuse rhbmp disulfide-linked dimeric protein molecule two major subunit specie 114 131 amino acid subunit glycosylated high-mannose-type glycans fda label , indicated treatment acute tibia fracture adult adjunct standard care using open fracture reduction intramedullary unreamed nail fixation fda label indicated single-level lumbar interbody spine fusion substitute autogenous bone graft adult degenerative disc disease least 6 month non-operative treatment condition l1391 
Amifampridine,"amifampridine 3,4-diaminopyridine 3,4-dap quaternary ammonium compound block presynaptic potassium channel subsequently prolongs action potential increase presynaptic calcium concentration a33863 first discovered scotland 1970s clinical effectiveness neuromuscular disorder including lambert–eaton myasthenic syndrome lem investigated 1980s l3171 amifampridine phosphate stable salt serf active ingredient ema-approved firdapse previously marketed zenas currently used first-line symptomatic treatment lem adult patient ideally given oral tablet divided dos three four time day firdapse amifampridine formally approved u fda treatment adult lem recently november 2018 l4819 lem rare auto-immune disorder neuromuscular junction characterized proximal muscle weakness depressed tendon reflex posttetanic potentiation addition autonomic dysfunction a33863 50-60 patient develop rapidly progressive lem small cell lung cancer influence prognosis a33863 patient lem develop serum antibody presynaptic p/q-type voltage-gated calcium channel leading decreased presynaptic calcium level reduced quantal release acetylcholine mainly responsible causing symptom lem a33863 reduced acetylcholine release neuromuscular junction lead decreased frequency miniature endplate potential normal amplitude insufficient acetylcholine level activation postsynaptic muscle fiber following single nerve impulse a33863 lead reduction compound muscle action potential cmap a33863 treatment lem include immunotherapy conventional immunosuppression intravenous immunoglobulin however treatment recommended patient symptomatic treatment would suffice a33863 amifampridine nonimmune treatment option lem phase iii clinical trial adult patient lem treatment amifampridine significantly improved symptom lem compared placebo good tolerance a33864 demonstrated clinical study involving healthy volunteer pharmacokinetics systemic exposure amifampridine affected genetic difference n-acetyl-transferase nat enzyme acetylator phenotype nat2 genotype subject genetic variation f272 slow acetylators higher risk experiencing drug-associated adverse reaction paresthesia nausea headache f272 ",amifampridine indicated symptomatic treatment lambert-eaton myasthenic syndrome lem adult pediatric patient l43312 nevertheless current time firdapse brand amifampridine indicated treatment lem adult pediatric patient ruzurgi brand amifampridine indicated treatment lem patient aged 6 le 17 year l43312 l36425 
Vinflunine,"vinflunine third-generation member vinca alkaloid family anti-tumour action first described 1998 pierre fabre research center france like vinca agent vinflunine anti-mitotic agent induces cell cycle arrest g2/m phase promotes cell death via apoptosis l1396 vinflunine microtubule inhibitor bind tubulin near vinca binding site inhibits polymerization microtubule cell proliferation l1396 murine tumor human tumor xenograft vinflunine exhibit antitumor efficacy db00361 db00570 db00541 a31975 incidence 429,700 new case per year worldwide urothelial carcinoma bladder one common malignancy mostly affect individual aged 50–79 year a32626 patient advanced urothelial carcinoma experience inadequate therapeutic response prior platinum-containing regimen patient median survival approximately 4 month poor prognosis l1396 currently standard therapy patient advanced urothelial carcinoma a32626 2009 vinflunine approved european medicine agency ema second-line therapy metastatic advanced urothelial cancer failure platinum-based treatment a32626 vinflunine ditartrate active ingredient ema-authorised product javlor intravenous infusion efficacy safety vinflunine studied patient performance status 2 le clinical use vinflunine urologic malignancy inoperable cancer penis currently investigated a32626 ", use monotherapy adult advanced transitional cell carcinoma urothelial tract failure prior platinum-containing therapy l2381 
Pitolisant,"pitolisant selective antagonist inverse agonist histamine h3 receptor used treat type 1 2 narcolepsy l1471 l8063 narcolepsy chronic neurological disorder affect 1 2,000 individual characterized excessive daytime sleepiness abnormal rem sleep manifestation sleep paralysis hypnagogic hallucination a32025 60-70 patient narcolepsy experience cataplexy sudden loss muscle tone triggered positive negative emotion a32022 histaminergic neuron signalling brain play role maintaining wakefulness blocking histamine autoreceptors pitolisant enhances activity histaminergic neuron well increasing signalling neurotransmitter brain l1471 european clinical trial adult patient narcolepsy reduction epworth sleepiness scale es score pitolisant therapy compared placebo a32024 therapeutic effectiveness pitolisant comparable modafinil a32024 pitolisant therapy also effective treating refractory sleepiness adolescent patient narcolepsy decreased es score increased mean sleep onset latency a32023 adolescent patient cataplexy also experienced slight improvement frequency severity symptom a32023 however safety use adolescent paediatric patient established pitolisant commonly marketed trade name wakix oral pitolisant approved ema 2016 a183062 treatment narcolepsy without cataplexy l1471 fda approved use pitolisant 2019 excessive daytime sleepiness ed associated narcolepsy adult l8063 ",pitolisant indicated treatment narcolepsy without cataplexy l1471 excessive daytime sleepiness narcolepsy adult patient l8063 
Recombinant Cholera Toxin B Subunit,recombinant cholera toxin b subunit ingredient ema-authorised product dukoral ,
Tafamidis,tafamidis tafamidis meglumine fx-1006a benzoxazole derivative a27206 developed foldrx a189717 tafamidis structurally similar diflusinal a189717 tafamidis granted ema market authorisation 16 november 2011 l6247 fda approval 3 may 2019 l11280 ,tafamidis indicated treat cardiomyopathy wild type hereditary transthyretin-mediated amyloidosis adult a189708 a189711 l11280 
PF-4191834,pf-4191834 investigated basic science asthma ,
Conatumumab,conatumumab used trial studying treatment sarcoma lymphoma oncology colon cancer rectal cancer among others ,
Incyclinide,incyclinide used trial studying treatment hiv infection aids-related kaposi sarcoma brain central nervous system tumor unspecified adult solid tumor protocol specific ,
Afuresertib,afuresertib used trial studying treatment cancer neoplasm haematologic ,
Lersivirine,lersivirine used trial studying treatment hiv-1 ,
HT-0712,blx-028914 used trial studying treatment basic science allergic rhinitis age-associated memory impairment aami ,
Dactolisib,dactolisib used trial studying treatment cancer solid tumor renal cancer breast cancer cowden syndrome among others ,
Tucatinib,tucatinib kinase inhibitor drug used trastuzumab capecitabine treatment unresectable metastatic her-2 positive breast cancer developed seattle genetics approved fda april 17 2020 l12951 tucatinib promising new treatment patient metastatic breast cancer responded adequately chemotherapy regimen l12945 ,tucatinib indicated trastuzumab capecitabine treatment adult diagnosed advanced unresectable metastatic her2-positive breast cancer includes patient brain metastasis received one prior anti-her2-based regimen metastatic setting l12945 
Bremelanotide,bremelanotide 7 amino acid peptide used treat hypoactive sexual desire disorder premenopausal woman l9635 bremelanotide interact alcohol a179686 mechanism bremelanotide 's action receptor translates clinical effect still unknown l9635 bremelanotide first described literature 2003 known investigational code pt-141 a179683 since investigated place treating sexual dysfunction men woman indicated woman a179683 a179686 l9635 drug used treat female sexual dysfunction include flibanserin estrogen ospemifene prasterone a179689 bremelanotide granted fda approval 21 june 2019 l9635 ,bremelanotide indicated treat premenopausal woman hypoactive sexual desire disorder due medical psychiatric condition problem relationship effect medication drug l9635 
T-2000,t2000 used trial studying treatment myoclonus essential tremor ,
Evacetrapib,evacetrapib used trial studying basic science treatment dyslipidemia hyperlipidemia hypercholesterolemia hepatic insufficiency cardiovascular disease ,
Rebamipide,rebamipide investigated treatment stomach ulcer keratoconjunctivitis sicca gastric adenoma early gastric cancer ,
Tabalumab,tabalumab used trial studying treatment autoimmune disease rheumatoid arthritis kidney failure chronic connective tissue disease systemic lupus erythematosus among others ,
QAV-680,qav680 used trial studying treatment asthma allergic rhinitis seasonal allergic rhinitis ,
Indium,indium used trial studying basic science clear cell renal cell carcinoma ,
Latanoprostene bunod,latanoprostene bunod used trial studying treatment glaucoma ocular hypertension open-angle glaucoma open angle glaucoma intraocular pressure november 2 2017 fda approved bausch lomb 's vyzulta latanoprostene bunod opthalmic solution 0.024 indication reducing intraocular pressure patient open-angle glaucoma ocular hypertension latanoprostene bunod first prostaglandin analog one metabolite nitric oxide novelty agent subsequently lie proposed dual mechanism action stem prostaglandin f2-alpha analog latanoprost acid metabolite ability donate proposed tissue/cell relaxation effect comparison latanoprost latanoprostene bunod contain latanoprost acid backbone conversely however latanoprostene bunod integrates no-donating moiety lieu isopropyl ester typically found latanoprost ,latanoprostene bunod opthalmic solution indicated reduction intraocular pressure patient open-angle glaucoma ocular hypertension fda label 
Eptacog alfa pegol (activated),eptacog alfa pegol activated used trial studying prevention treatment haemophilia haemophilia b congenital bleeding disorder haemophilia b inhibitor haemophilia inhibitor ,
Rabusertib,rabusertib used trial studying treatment cancer solid tumor advanced cancer pancreatic neoplasm non small cell lung cancer ,
Pictilisib,pictilisib used trial studying treatment solid cancer breast cancer advanced solid tumour metastatic breast cancer non-hodgkin 's lymphoma solid cancer among others ,
Psilocybin,psilocybin investigated treatment anxiety stage iv melanoma november 2019 granted breakthrough therapy status fda ,
BMS-690514,bms-690514 investigated treatment breast cancer ,
Buparlisib,buparlisib used trial studying treatment basic science lymphoma metastasis lung cancer solid tumor breast cancer among others ,
2'-cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine,2'-cyano-2'-deoxy-1- beta-d-arabinofuranosyl cytosine used trial studying treatment advanced colorectal cancer ,
Rusalatide acetate,chrysalin used trial studying treatment radius fracture ,
Ortataxel,ortataxel used trial studying treatment lymphoma lung cancer glioblastoma kidney cancer ,
SP-8203,sp-8203 used trial studying treatment ischemic stroke ,
AZD-4877,azd4877 used trial studying treatment nhl tumor cancer lymphoma neoplasm among others ,
Curcumin,curcumin also known diferuloylmethane active component golden spice turmeric curcuma longa curcuma xanthorrhiza oil highly pleiotropic molecule exhibit antibacterial anti-inflammatory hypoglycemic antioxidant wound-healing antimicrobial activity a33166 due property curcumin investigated treatment supportive care clinical condition including proteinuria breast cancer multiple myeloma depression non small cell lung cancer nsclc despite proven efficacy numerous experimental model poor bioavailability due poor absorption rapid metabolism rapid systemic elimination shown limit therapeutic efficacy curcumin a33166 curcumin investigation treatment supportive care various clinical condition including mucositis rectal cancer prostate cancer chronic schizophrenia mild cognitive impairment mci a33166 , approved therapeutic indication 
Pyridoxamine,pyridoxamine used trial studying treatment kidney stone ,
Equol,equol used trial studying treatment breast cancer ,
Mosapride,mosapride investigation treatment prevention postoperative ileus gastric peroral endoscopic pyloromyotomy g-poem mosapride investigated treatment diagnostic constipation type 2 diabetes functional dyspepsia functional constipation epigastric pain syndrome among others ,
Galidesivir,galidesivir adenosine analogue investigated use zaire ebolavirus a191451 animal study galidesivir effective increasing survival rate infection caused various pathogen including ebola marburg yellow fever zika virus l12084 _in vitro_ displayed broad-spectrum antiviral activity various negative- positive-sense rna virus a191622 including coronaviruses filovirus arenavirus l12039 l12084 phase 1 clinical trial begun determine safety drug human l12042 activity coronaviruses may studied potential therapy covid-19 ,
Triheptanoin,triheptanoin source heptanoate fatty acid metabolized without enzyme long chain fatty acid oxidation l14612 clinical trial patient long chain fatty acid oxidation disorder lc-faods treated triheptanoin le likely develop hypoglycemia cardiomyopathy rhabdomyolysis hepatomegaly a214812 a214817 complication lc-faod patient reduced approximately 60 approximately 10 addition triheptanoin a214817 triheptanoin granted fda approval 30 june 2020 l14612 ,triheptanoin medium chain triglyceride indicated provide calorie fatty acid treat long chain fatty acid oxidation disorder lc-faods l14612 
Treosulfan,treosulfan investigation allogeneic haematopoietic stem cell transplantation treosulfan investigated treatment lymphoblastic leukemia acute childhood ,
Fruquintinib,fruquintinib investigation treatment nsclc fruquintinib investigated treatment colorectal cancer ,
Ficlatuzumab,ficlatuzumab used trial studying treatment acute myeloid leukemia non-small cell lung cancer mullerian mixed tumor ovary relapsed acute myeloid leukemia refractory acute myeloid leukemia among others ,
Tofimilast,tofimilast used trial studying treatment asthma pulmonary disease chronic obstructive ,
Daprodustat,daprodustat small-molecule hypoxia-inducible factor hif prolyl hydroxylase phd inhibitor developed gsk treatment anemia patient chronic kidney disease ckd a254167 a254162 patient ckd diseased kidney induce erythropoietin epo production response hypoxia anemia potent inhibitor phd1 phd2 phd3 ≥ 1000-fold selectivity daprodustat lead stabilization cellular hif1α hif2α induction erythropoiesis a254157 phase 3 clinical trial nct02879305 found patient ckd undergoing dialysis daprodustat non-inferior erythropoiesis-stimulating agent regarding change hemoglobin level baseline cardiovascular outcome a254172 june 2020 daprodustat first approved japan treatment renal anemia a254157 daprodustat currently ema fda review october 2022 fda cardiovascular renal drug advisory committee crdac supported benefit treatment daprodustat outweighs risk adult dialysis patient anemia ckd non-dialysis patient anemia ckd l43857 ,
PF-06282999,pf 06282999 investigation clinical trial nct01626976 study ass safety tolerability pharmacokinetics pf-06282999 administered orally healthy adult subject ,
Eprenetapopt,eprenetapopt used trial studying treatment prostatic neoplasm hematologic neoplasm platinum sensitive recurrent high-grade serous ovarian cancer mutated p53 ,
Figitumumab,figitumumab used trial studying treatment sarcoma solid tumor breast cancer lung neoplasm advanced cancer among others ,
Iferanserin,iferanserin investigated treatment hemorrhoid ,
E-6201,e6201 investigated treatment chronic plaque psoriasis ,
2-chloroethyl-3-sarcosinamide-1-nitrosourea,2-chloroethyl-3-sarcosinamide-1-nitrosourea used trial studying treatment colorectal cancer brain central nervous system tumor unspecified adult solid tumor protocol specific ,
Selumetinib,activation raf-mek-erk signaling pathway known implemented several type malignancy thus mitogen-activated protein kinase kinase mek inhibitor selumetinib important tool target problematic overactivity pathway a193611 result clinical trial investigating earlier developed mek inhibitor underwhelming a193611 however selumetinib demonstrated impressive efficacy tolerability phase trial leading continued investigation treatment various type tumor phase ii trial a193611 currently novel mek 1 2 inhibitor selumetinib approved solely treatment neurofibromatosis type 1 nf-1 limited age group nf-1 considered rare estimated incidence 1/3000 individual a193608 genetic autosomal dominant condition resulting mutation nf1 gene lead various complication including development multiple tumor nervous system a193533 a193608 patient disorder develop plexiform neurofibroma pn however considered relatively uncommon compared variant nf-1 a193608 luckily use selumetinib patient nf-1 shown efficacy shrinking associated tumor linked positive clinical outcome a193533 ,although selumetinib investigated treatment several type cancer currently indicated treatment neurofibromatosis type 1 nf1 patient ≥2 year symptomatic inoperable plexiform neurofibroma pn a193611 l12852 l12969 
Vonapanitase,vonapanitase investigation treatment chronic kidney disease ,
Naldemedine,naldemedine opioid receptor antagonist fda label modified form db00704 side chain added increase molecular weight polar surface area resulting restricted transport across blood brain barrier naldemedine approved 2017 u japan treatment opioid-induced constipation , treatment opioid-induced constipation fda label 
Pavinetant,pavinetant used trial studying basic science treatment safety schizophrenia ,
Voclosporin,lupus nephritis ln type glomerulonephritis occurring patient systemic lupus erythematosus sle ln significant cause renal failure morbidity death patient sle within 10 year diagnosed sle 5-20 suffering ln develop end-stage kidney disease fatal condition early accurate intervention ln important improving clinical outcome a227683 voclosporin marketed lupkynis calcineurin-inhibitor immunosuppressant treatment ln l31218 cyclosporine analog approved fda january 22 2021 following promising result clinical trial early intervention voclosporin coupled kidney response believed prevent irreversible damage kidney lead better long-term clinical outcome patient ln l31208 voclosporin demonstrated stable pharmacokinetic pharmacodynamic relationship cyclosporine higher potency cyclosporine improved metabolic profile compared older calcineurin inhibitor l31253 july 2022 ema 's committee medicinal product human use chmp recommended voclosporin granted marketing authorization use combination mycophenolate mofetil treatment adult patient active lupus nephritis l43080 ,voclosporin used combination background immunosuppressive regimen treatment lupus nephritis safety established combination cyclophosphamide l31218 
Ilorasertib,ilorasertib used trial studying treatment myelodysplasia solid neoplasm advanced cancer advanced solid tumor acute myelogenous leukemia among others ,
Carnosine,carnosine investigated treatment gulf war illness ,
Racecadotril,racecadotril investigated basic science treatment diarrhea acute diarrhea acute gastroenteritis ,
Pacritinib,myelofibrosis mf rare disorder characterized hematopoietic abnormality fibrosis within bone marrow l40793 underlying cause primary mf unknown secondary mf arise patient history polycythemia vera essential thrombocythemia l40793 patient may remain asymptomatic typical symptom mf arise abnormality blood cell production may therefore include various cytopenia infection splenomegaly general systemic symptom fever l40793 approximately 50 patient primary mf mutation _jak2_ gene also commonly mutated patient polycythemia vera essential thrombocythemia l40793 jak2 signaling important hematopoiesis proper immune functioning l40754 precise role play pathogenesis mf remains unclear clear association mf made desirable therapeutic target mf treatment pacritinib inhibitor wild-type mutant v617f jak2 well fms-like tyrosine kinase 3 flt3 granted accelerated approval fda february 2022 treatment primary secondary mf patient platelet count 50 x 10 sup 9 /sup /l l40754 provides treatment option patient mf severe thrombocytopenia occurs approximately one-third mf patient carry particularly poor prognosis l40709 ,pacritinib indicated treatment adult intermediate high-risk primary secondary post-polycythemia vera post-essential thrombocythemia myelofibrosis platelet count 50 x 10 sup 9 /sup /l l40754 indication approved accelerated approval based spleen volume reduction continued approval may contingent upon verification description clinical benefit confirmatory trial l40754 
Ipragliflozin,ipragliflozin investigation type 2 diabetes diabetes mellitus type 2 ,
Tropisetron,tropisetron indole derivative antiemetic activity selective serotonin receptor antagonist tropisetron competitively block action serotonin 5ht3 receptor resulting suppression chemotherapy- radiotherapy-induced nausea vomiting tropisetron appears well tolerated frequently reported adverse effect headache extrapyramidal side effect rare upon using tropisetron , prevention nausea vomiting induced cytotoxic therapy postoperative 
Setmelanotide,setmelanotide first available treatment patient pro-opiomelanocortin proprotein subilisin/kexin type 1 leptin deficiency l24474 agonist melanocortin 4 receptor a224449 earlier attempt agonizing mc4r ly2112688 lead successful weight loss also increase blood pressure heart rate a224449 earlier treatment patient included gastric bypass surgery a224449 patient taking setmelanotide experienced average weight loss 0.6 kg/week a224449 imcivree granted ema orphan designation 19 november 2018 l24559 fda approval 25 november 2020 l24429 ,setmelanotide indicated chronic weight management patient 6 year older obesity due pro-opiomelanocortin pomc deficiency proprotein subtilisin/kexin type 1 pcsk1 deficiency leptin receptor lepr deficiency determined fda-approved test demonstrating variant pomc pcsk1 lepr gene interpreted pathogenic likely pathogenic uncertain significance l42130 condition affect mc4r signalling pathway a224454 setmelanotide also indicated chronic weight management patient 6 year older obesity due bardet-biedl syndrome l42130 
Amenamevir,amenamevir used trial studying treatment herpes zoster herpes simplex herpes genitalis safety amenamevir ,
Antineoplaston A10,antineoplaston a10 used trial studying treatment sarcoma lymphoma lung cancer liver cancer kidney cancer among others ,
Acalabrutinib, date acalabrutinib used trial studying treatment b-all myelofibrosis ovarian cancer multiple myeloma hodgkin lymphoma among others october 31 2017 fda approved astra zeneca 's orally administered calquence acalabrutinib capsule bruton tyrosine kinase btk inhibitor indicated treatment chronic lymphocytic leukemia small lymphocytic lymphoma adult patient mantle cell lymphoma mcl already received least one prior therapy l10241 august 2022 fda approved new tablet formulation calquence enabling co-administration drug proton pump inhibitor ppis l42795 l42800 unlike calquence capsule co-administration calquence tablet ppis effect pharmacokinetics acalabrutinib l10241 l42795 also known acp-196 acalabrutinib also considered second generation btk inhibitor rationally designed potent selective ibrutinib theoretically expected demonstrate fewer adverse effect owing minimized bystander effect target btk nevertheless acalabrutinib approved fda 's accelerated approval pathway based upon overall response rate faciliates earlier approval medicine treat serious condition or/and fill unmet medical need based surrogate endpoint continued approval acalabrutinib 's currently accepted indication may subsequently contingent upon ongoing verification description clinical benefit confimatory trial furthermore fda granted medication priority review breakthrough therapy designation also received orphan drug designation provides incentive assist encourage development drug rare disease time 35 clinical trial across 40 country 2500 patient underway completed regard research better understanding expanding therapeutic us acalabrutinib l1009 ,acalabrutinib currently indicated treatment adult patient mantle cell lymphoma mcl received least one prior therapy l10241 also recently approved chronic lymphocytic leukemia small lymphocytic lymphoma l10241 
Adomeglivant,adomeglivant investigated basic science type 2 diabetes ,
Iomeprol,iomeprol investigated diagnostic coronary artery disease ,
Raxatrigine,raxatrigine investigated treatment bipolar disorder bipolar depression ,
Olaptesed Pegol,olaptesed pegol investigated treatment hematopoietic stem cell transplantation ,
Peficitinib,peficitinib used trial studying treatment basic science psoriasis pharmacodynamics drug interaction colitis ulcerative rheumatoid arthritis among others ,
Acetyl hexapeptide-3,argireline used trial studying treatment wrinkle ,
Trigonellamide,trigonellamide investigation clinical trial nct01930240 safety hypolipidemic agent healthy normal volunteer ,
Navarixin,navarixin investigated treatment asthma ,
Tezacaftor,tezacaftor drug cystic fibrosis transmembrane conductance regulator cftr potentiator class l1595 developed vertex pharmaceutical fda approved combination ivacaftor manage cystic fibrosis l6814 drug approved fda february 12 2018 l4894 cystic fibrosis autosomal recessive disorder caused one several different mutation gene cystic fibrosis transmembrane conductance regulator cftr protein ion channel involved transport chloride sodium ion across cell membrane cftr active epithelial cell organ lung pancreas liver digestive system reproductive tract alteration cftr gene result altered production misfolding function protein consequently abnormal fluid ion transport across cell membrane a20298 a20299 result cf patient produce thick sticky mucus clog duct organ produced making patient susceptible complication infection lung damage pancreatic insufficiency malnutrition a20302 ,tezacaftor combined ivacaftor one product treatment cystic fibrosis cf patient aged 12 year older two copy _f508del_ gene mutation least one mutation cftr gene responsive drug l6814 tezacaftor used combination ivacaftor elexacaftor product trikafta also indicated treatment cf patient 12 year age older least one _f508del_ mutation cftr gene l9395 
Ruzasvir,ruzasvir used trial studying treatment hepatitis c hepatitis c chronic hepatitis c infection ,
Durvalumab,durvalumab human immunoglobulin g1 kappa igg1κ monoclonal antibody novel immune-checkpoint inhibitor cancer treatment a192789 produced recombinant dna technology chinese hamster ovary cho cell suspension culture l12621 durvalumab programmed death-ligand 1 pd-l1 blocking antibody work promote normal immune response attack tumour cell l12621 l12627 durvalumab marketed brand name imfinzi available intravenous injection granted accelerated approval fda may 2017 a192807 treatment selected patient locally advanced metastatic urothelial carcinoma l12621 september 2018 durvalumab approved ema treatment adult patient locally advanced unresectable non-small cell lung cancer nsclc pd-l1 expressed ≥ 1 tumour cell observable disease progression following platinum-based chemoradiation therapy a192789 l12627 march 27 2020 durvalumab approved fda use combination etoposide either carboplatin cisplatin first-line treatment patient extensive-stage small cell lung cancer es-sclc l12624 ,durvalumab indicated treatment adult following condition unresectable stage iii non-small cell lung cancer nsclc whose disease progressed following concurrent platinum-based chemotherapy radiation therapy l44121 metastatic nsclc sensitizing epidermal growth factor receptor egfr mutation anaplastic lymphoma kinase alk genomic tumour aberration combination tremelimumab platinum-based chemotherapy l44121 extensive-stage small cell lung cancer es-sclc combination etoposide either carboplatin cisplatin first-line therapy l12624 locally advanced metastatic biliary tract cancer btc combination gemcitabine cisplatin l43055 unresectable hepatocellular carcinoma uhcc combination tremelimumab l43647 
Bapineuzumab,bapineuzumab investigated treatment alzheimer 's disease ,
Misonidazole,misonidazole investigation clinical trial nct00038038 assessment head neck tumor hypoxia using 18f-fluoromisonidazole ,
Epacadostat,epacadostat used trial studying treatment hl melanoma glioblastoma mucosal melanoma ovarian carcinoma among others ,
Encorafenib,encorafenib also known _braftovi_ kinase inhibitor encorafenib inhibits braf gene encodes b-raf protein proto-oncogene involved various genetic mutation l12216 protein play role regulating map kinase/erk signaling pathway impact cell division differentiation secretion mutation gene frequently v600e mutation commonly identified cancer-causing mutation melanoma isolated various cancer well including non-hodgkin lymphoma colorectal cancer thyroid carcinoma non-small cell lung carcinoma hairy cell leukemia adenocarcinoma lung l3344 june 27 2018 food drug administration approved encorafenib binimetinib braftovi mektovi array biopharma inc. combination patient unresectable metastatic melanoma braf v600e v600k mutation detected fda-approved test l12216 ,encorafenib indicated combination binimetinib treatment unresectable metastatic melanoma braf v600e v600k mutation l12216 also indicated combination cetuximab treatment adult patient metastatic colorectal cancer braf v600e mutation l12216 
UK-390957,"uk-390,957 used trial studying treatment ejaculation ",
Angiotensin 1-7,txa127 investigated treatment miscellaneous peripheral blood cell abnormality ,
Mitoglitazone,mitoglitazone used trial studying treatment type 2 diabetes alzheimer 's disease ,
Dutogliptin,dutogliptin investigated treatment diabetes mellitus type ii ,
Bombesin,bombesin investigation clinical trial nct01205321 pet/ct imaging radiation dosimetry plasma pharmacokinetics biodistribution safety tolerability diagnostic performance bay86-7548 patient prostate cancer healthy volunteer ,
Latrepirdine,latrepirdine investigated treatment alzheimer 's disease huntington 's disease ,
Encenicline,encenicline investigated treatment cognition schizophrenia alzheimer 's disease cardiac repolarization central nervous system disease ,
Endostar,endostar investigation treatment nasopharyngeal carcinoma endostar investigated treatment non-small cell lung cancer ,
GSK-2330672,gsk2330672 investigated treatment diabetes mellitus type 2 ,
Ribociclib,ribociclib selective cyclin-dependent kinase inhibitor class drug help slow progression cancer inhibiting two protein called cyclin-dependent kinase 4 6 cdk4/6 protein over-activated enable cancer cell grow divide quickly targeting cdk4/6 enhanced precision may play role ensuring cancer cell continue replicate uncontrollably ribociclib approved u.s. fda march 2017 kisqali ,kisqali ribociclib selective cyclin-dependent kinase inhibitor class drug help slow progression cancer inhibiting two protein called cyclin-dependent kinase 4 6 cdk4/6 protein over-activated enable cancer cell grow divide quickly targeting cdk4/6 enhanced precision may play role ensuring cancer cell continue replicate uncontrollably 
Depatuxizumab mafodotin,depatuxizumab/denintuzumab mafodotin used trial studying treatment lymphoma gliosarcoma glioblastoma malignant glioma squamous cell tumor glioblastoma multiforme , approved indication 
Lasmiditan,lasmiditan oral medication used termination migraine headache first approved use united state october 2019 l9338 l9356 also approved european commission august 17 2022 l43997 traditionally triptan class anti-migraine medication e.g sumatriptan seen preferential use acute treatment migraine due relatively favourable efficacy safety use devoid concern however vasoconstrictive activity lead blood pressure lability cardiovascular side effect reason medication le suitable use patient pre-existing cardiovascular disorder a187316 triptans abort migraine via action several serotonin receptor including 5-ht sub 1d /sub 5-ht sub 1b /sub receptor activity 5-ht sub 1b /sub receptor specifically implicated vasoconstrictive activity a187316 a187322 lasmiditan contrast highly selective agonist 5-ht sub 1f /sub receptor carrying virtually affinity receptor appear largely responsible adverse effect profile predecessor word lasmiditan ’ selectivity allows successful termination migraine without causing vasoconstriction a187322 a187319 selectivity 5-ht sub 1f /sub lack vasoconstrictive activity ability terminate migraine neuronal inhibition resulted creation new class anti-migraine medication lasmiditan first member neurally-acting anti-migraine medication naamas a187322 a187307 ,lasmiditan indicated acute treatment migraine without aura adult l9338 l43992 
Fedovapagon,fedovapagon used trial studying treatment nocturia ,
Galactose,galactose used trial studying treatment diagnosis hepatitis c hepatic cancer wilson disease diabetic macular oedema focal segmental glomerulosclerosis among others even proposal use accelerating senescence mouse rat drosophila association ovarian cancer even potential treatment focal segmental glomerulosclerosis nevertheless none ongoing study yet provided formal elucidation proposal naturally occurring sugar may found number dairy product even however generally used sweetener considering 30 sweet sucrose regardless although predominantly used pathway generate glucose fuel human body galactose involved ingredient commonly used vaccine non-prescription product , limited therapeutic us galactose formally indicated predominant indication include use galactose facilitate construction structurally immunologically effective attenuated vaccine t188 l2633 b role galactose play essential element formation lactulose synthetic disaccharide indicated treatment constipation and/or hepatic encephalopathy hepatic coma l2632 nevertheless many study looking variety possible us galactose including use monosaccharide sugar accelerating senescence mouse rat drosophila a32853 a32854 proposed association galactose consumed milk ovarian cancer a32855 a32856 possible role therapy focal segmental glomerulosclerosis a32858 among various others regardless none proposed indication yet formally elucidated practical use 
PF-00489791,pf-00489791 used trial studying treatment hypertension raynaud 's disease diabetic nephropathy hypertension pulmonary peripheral vascular disease ,
Icotinib,icotinib potent specific epidermal growth factor receptor egfr tyrosine kinase inhibitor tki icotinib approved china sfda june 2011 january 2014 beta pharma inc. given “ may proceed ” u fda conduct phase study evaluation icotinib treatment egfr+ non-small cell lung cancer nsclc ,icotinib hydrochloride novel epidermal growth factor receptor egfr –tyrosine kinase inhibitor exhibit encouraging efficacy tolerability patient advanced non-small-cell lung cancer nsclc failed previous chemotherapy 
Rilmenidine,rilmenidine used trial studying treatment hypertension chronic kidney disease ,
Vonoprazan,vonoprazan potassium-competitive acid blocker pcab inhibits h sup /sup k sup /sup -atpase-mediated gastric acid secretion pcabs represent alternative proton-pump inhibitor treatment acid-related disorder unlike proton-pump inhibitor pcabs affected cyp2c19 genetic polymorphism require acid-resistant formulation a253702 furthermore vonoprazan 350-times potent proton-pump inhibitor lansoprazole thanks ability accumulate gastric corpus mucosa specifically parietal cell a253707 february 2015 vonoprazan first marketed japan treatment acid-related disorder adjunct _helicobacter pylori_ _h pylori_ eradication a253702 may 2022 fda approved use vonoprazan co-packaged product containing amoxicillin clarithromycin treatment _h pylori_ infection l41695 study shown concomitant use vonoprazan amoxicillin clarithromycin lead _h pylori_ eradication rate approximately 90 a253742 ,vonoprazan combination amoxicillin clarithromycin co-packaged product indicated treatment _helicobacter pylori_ _h pylori_ infection adult another co-packaged product vonoprazan amoxicillin also indicated treatment _h pylori_ infection adult l41695 
MK-1775,mk-1775 used trial studying treatment lymphoma neoplasm ovarian cancer tongue carcinoma adult glioblastoma among others ,
Famitinib,famitinib used trial studying treatment colorectal cancer renal cell cancer colorectal cancer recurrent colorectal cancer metastatic metastatic renal cell cancer among others ,
Ebastine,ebastine investigation treatment irritable bowel syndrome ibs ebastine investigated treatment urticaria ,
Ipatasertib,ipatasertib used trial studying treatment cancer neoplasm solid cancer breast cancer gastric cancer among others ,
Epetraborole,epetraborole used trial studying treatment infection bacterial infection intestinal infection urinary tract community-acquired infection ,
Otenabant,otenabant investigated treatment obesity ,
Onartuzumab,onartuzumab used trial studying treatment neoplasm lung cancer glioblastoma gastric cancer colorectal cancer among others ,
Barasertib,barasertib used trial studying treatment tumor lymphoma solid tumor solid tumour myeloid leukemia among others ,
Benfotiamine,benfotiamine investigated treatment prevention diabetic nephropathy diabetes mellitus type 2 ,
(R)-Praziquantel, r -praziquantel investigation clinical trial nct02271984 relative bioavailability trial l-praziquantel healthy volunteer ,
Clobetasol,clobetasol investigation treatment scleroderma clobetasol investigated prevention psoriasis cutaneous atrophy due corticosteroid ,
Cabotegravir,cabotegravir gsk1265744 hiv-1 integrase inhibitor prescribed non-nucleoside reverse transcriptase inhibitor rilpivirine a227668 l31188 l31193 early research cabotegravir showed lower oral bioavailability dolutegravir a227668 resulted development long acting monthly intramuscular injection formulation cabotegravir a227668 l31193 cabotegravir granted fda approval 21 january 2021 combination rilpivirine treat hiv-1 infection virologically suppressed individual l31198 previously administered monthly combination product granted fda approval dosing every two month february 01 2022 l40084 without need oral lead-in period prior l31193 ,oral cabotegravir indicated combination rilpivirine short-term treatment hiv-1 virologically suppressed adult history treatment failure ass tolerability cabotegravir missed injected dose cabotegravir l31188 intramuscular extended-release cabotegravir combination rilpivirine indicated complete regimen treatment hiv-1 infection adult adolescent 12 year age older weighing least 35 kg replace current antiretroviral regimen virologically suppressed hiv-1 rna 50 copies/ml stable antiretroviral regimen history treatment failure known suspected resistance either cabotegravir rilpivirine l31193 extended-release injectable suspension formulation cabotegravir also indicated prevention sexually-acquired hiv-1 infection i.e pre-exposure prophylaxis prep at-risk adult adolescent weighing least 35kg l39548 
Bryostatin 1,bryostatin 1 investigated treatment hiv infection alzheimer 's disease ,
Rifamycin,rifamycin prime member rifamycin family represented drug product fermentation gram-positive bacterium _amycolatopsis mediterranei_ also known _streptomyces mediterranei_ parent compound rifamycin rifamycin b originally obtained main product presence diethylbarburitic acid small modification performed inactive compound creation rifamycin sv first antibiotic used intravenously treatment tuberculosis a39990 rifamycin several direct derivative product rifamycin sv rifaximin rifampin rifamycin cv derivative slight different physicochemical property compared parent structure a39986 rifamycin developed cosmo technology ltd approved november 16 2018 fda prescription drug granted designation qualified infectious disease product allowed status priority review l4800 drug also sent review ema 2015 dr. falk pharma gmbh granted waiver tested condition l4801 ,rifamycin indicated treatment adult patient traveler diarrhea caused noninvasive strain _e coli_ status disease complicated fever blood stool prevent drug-resistant bacteria important mention use rifamycin indication done case infection proven strongly suspected caused bacteria l4802 travallers diarrhea common problem affecting 20-60 traveller defined increase frequency bowel movement three loose stool per day trip abroad condition rarely life threatening severe case produce dehydration sepsis common cause traveller diarrhea pathogen pathogen identified bacteria common cause followed norovirus rotavirus similar virus a39995 
Lirilumab,lirilumab used trial studying treatment leukemia cancer no multiple myeloma lymphocytic leukemia acute myeloid leukemia among others ,
Tetrahydrocannabivarin,tetrahydrocannabivarin thcv propyl analogue tetrahydrocannabinol δ9-thc one primary pharmacological component medical cannabis δ9-thc currently available several synthetic form including dronabinol purified isolated thcv approved medical us available marketed product major phytocannabinoid however thcv accessible within medical cannabis along identified cannabinoids including cannabidiol cbd cannabinol cbn cannabigerol cbg cannabichromene cbc cannabivarin cbv cannabidivarin cbdv thcv one four cannabinoids identified potential anticonvulsant agent also includes δ9-tetrahydrocannabinolic acid cannabidiol cbd cannabidivarin cbdv a33334 although thcv posse almost identical structure δ9-thc varying length lipophilic alkyl chain different molecular target pharmacological profile a32972 compared thc demonstrates effect weak partial agonist activity endocannabinoid receptor cannabinoid-1 cb1r cannabinoid-2 cb2r thcv act cb1 antagonist partial agonist cb2 a32477 evidence also shown thcv act agonist gpr55 l-α-lysophosphatidylinositol lpi a32974 beyond endocannabinoid system thcv also reported activate 5ht1a receptor produce antipsychotic effect therapeutic potential ameliorating negative cognitive positive symptom schizophrenia a32975 furthermore thcv interacts different transient receptor potential trp channel including trpv2 may contribute analgesic anti-inflammatory anti-cancer effect cannabinoids cannabis extract a32976 also shown antiepileptiform anticonvulsant property suggest possible therapeutic application treatment pathophysiologic hyperexcitability state untreatable epilepsy a33325 cannabinoid receptor utilized endogenously body endocannabinoid system includes group lipid protein enzyme receptor involved many physiological process modulation neurotransmitter release endocannabinoid system regulates cognition pain sensation appetite memory sleep immune function mood among many others effect largely mediated two member g-protein coupled receptor family cannabinoid receptor 1 2 cb1 cb2 a32585 cb1 receptor found central peripheral nervous system majority receptor localized hippocampus amygdala brain physiological effect using cannabis make sense context receptor activity hippocampus amygdala primarily involved regulation memory fear emotion contrast cb2 receptor mainly found peripherally immune cell lymphoid tissue peripheral nerve terminal a32676 reliably studying effect cannabis thcv complicated numerous compound cannabis contains terpene flavonoid phenol amino acid fatty acid among many others potential modulate plant 's pharmacological effect a32832 a32824 ,thcv currently fda health canada ema approved indication 
Solanezumab,solanezumab investigation treatment dementia alzheimers disease alzheimers disease familial ,
Istradefylline,istradefylline kw6002 developed kyowa hakko kirin japan treatment parkinson 's disease adjunct standard therapy a184067 unlike standard dopaminergic therapy parkinson 's istradefylline target adenosine sub 2a /sub receptor basal ganglion a184067 region brain highly involved motor control a184067 istradefylline indicated adjunct treatment levodopa carbidopa parkinson 's disease l8237 drug first approved japan 25 march 2013 a184067 istradefylline granted fda approval 27 august 2019 l8213 ,istradefylline indicated adjunct levodopa carbidopa treatment parkinson 's disease l8237 
Cenicriviroc,cenicriviroc used trial studying treatment hiv-infection/aids aid dementia complex nonalcoholic steatohepatitis human immunodeficiency virus hiv-1-associated cognitive motor complex ,
Pevonedistat,pevonedistat used trial studying treatment lymphoma solid tumor multiple myeloma hodgkin lymphoma metastatic melanoma among others ,
Talazoparib,talazoparib approved fda use germline brca mutated her2 negative locally advanced metastatic breast cancer october 16 2018 trade name talzenna l4661 talzenna granted approval based result embraca trial talazoparib resulted mean 8.6 month progression-free survival time versus physician 's choice chemotherapy resulted 5.6 month progression-free survival ,talazoparib indicated treatment deleterious suspected deleterious germline brca mutated her2 negative locally advanced metastatic breast cancer adult fda label 
Tenapanor,tenapanor novel small molecule medication approved september 2019 treatment constipation-predominant irritable bowel-syndrome ibs-c l8558 first designed synthesized 2012 a185492 inhibitor sodium/hydrogen exchanger isoform 3 nhe3 transporter first currently medication within class a185489 a185492 a185495 therefore exists novel alternative treatment ibs-c ,tenapanor indicated treatment constipation-predominant irritable bowel syndrome ibs-c adult l8558 
Marizomib,marizomib used trial studying treatment cancer melanoma lymphoma glioblastoma malignant glioma among others ,
Momelotinib,momelotinib used trial studying treatment polycythemia vera primary myelofibrosis post-polycythemia vera essential thrombocythemia primary myelofibrosis pmf among others ,
Spebrutinib,spebrutinib used trial studying treatment rheumatoid arthritis lymphoma large b-cell diffuse leukemia lymphocytic chronic b-cell ,
PF-04991532,pf-04991532 used trial studying basic science diabetes mellitus type 2 diabetes mellitus diabetes mellitus type 2 glucose metabolism disorder ,
AZD-1305,azd1305 used trial studying treatment basic science atrial flutter atrial fibrillation left ventricle function ,
Sarilumab,sarilumab fully human anti-il-6r monoclonal igg1 antibody bind membrane bound soluble interleukin 6 il-6 receptor form thus blocking cis- trans-inflammatory signalling cascade il-6 a27262 sarilumab developped sanofi regeneron pharmaceutical inc u fda-approved may 2017 followed eu approval june 2017 treatment moderate severe rheumatoid arthritis ra combination methotrexate a27265 ra chronic inflammatory disease characterized polyarthritis treatment challenged different response every patient a27264 subcutaneous administration sarilumab shown decrease acute-phase reactant level improve clinical ra symptom a27263 ,indicated modere severe reactive ra adult patient irresponsive respond inadequately present intolerance disease-modifying anti-rheumatic drug dmards tumor necrosis factor tnf antagonist indicated used combination methotrexate mtx monotherapy intolerance mtx mtx administration inappropriate 
Zytron,zytron dmpa investigation treatment health service research hiv lactation contraception postpartum depression immune cell mucosal systemic dmpa investigated prevention treatment basic science weight microbiota ,
Funapide,funapide used trial studying treatment pharmacokinetics postherpetic neuralgia osteoarthritis knee ,
Talinolol,talinolol investigated basic science gastrointestinal motility disorder ,
Tremelimumab,tremelimumab formerly known ticilimumab fully human igg2 monoclonal antibody directed cytotoxic t-lymphocyte-associated antigen 4 ctla-4 ctla-4 cell surface receptor expressed activated cell act negative regulator cell a253717 binding ctla-4 tremelimumab enhances cell-mediated killing tumour reduces tumour growth a253717 l43652 ctla-4 immune checkpoint play vital role regulating cell-mediated immune response tremelimumab considered immune checkpoint inhibitor emerging cancer immunotherapy drug class a253712 tremelimumab first approved fda october 2022 used combination durvalumab treat hepatocellular carcinoma l43652 also investigated cancer colon cancer pancreatic cancer non-small cell lung cancer nsclc malignant melanoma a253717 a253722 ,tremelimumab indicated treatment adult patient unresectable hepatocellular carcinoma combination durvalumab l43652 also indicated combination durvalumab platinum-based chemotherapy treatment adult patient metastatic non-small cell lung cancer nsclc sensitizing epidermal growth factor receptor egfr mutation anaplastic lymphoma kinase alk genomic tumor aberration l44126 
Pilaralisib,pilaralisib orally available small molecule selectively inhibits activity phosphoinositide-3 kinase pi3k pilaralisib used trial studying treatment cancer lymphoma solid tumor glioblastoma breast cancer among others ,
BMS-903452,bms-903452 used trial studying treatment diabetes ,
Pazufloxacin,pazufloxacin investigation clinical trial nct02592096 pazufloxacin mesilate ear drop clinical trial protocol ,
PF-03758309,pf-03758309 used trial studying treatment advanced solid tumor ,
Brodalumab,brodalumab used trial studying treatment asthma psoriasis crohn 's disease psoriatic arthritis rheumatoid arthritis brodalumab fda approved february 2017 siliq treatment moderate-to-severe plaque psoriasis ,brodalumab approved treatment psoriasis vulgaris psoriatic arthritis pustular psoriasis psoriatic erythroderma 
Cenderitide,cenderitide investigation treatment st elevation stemi myocardial infarction anterior wall ,
Danusertib,danusertib used trial studying treatment leukemia ,
Danoprevir,danoprevir used trial studying treatment hepatitis c chronic ,
Allicin,allicin used trial studying treatment follicular lymphoma ,
Tosedostat,tosedostat used trial studying treatment supportive care aml leukemia pancreas cancer multiple myeloma pancreatic cancer among others tosedostat inhibitor m1 family aminopeptidases particular pusa lta4 hydrolase demonstrated anti-tumour activity number model cancer single agent synergy cytotoxic agent carboplatin paclitaxel entered clinical trial patient haematological malignancy ,
Birinapant,birinapant investigated treatment myelodysplastic syndrome md chronic myelomonocytic leukemia cmml ,
Imidapril,imidapril investigated treatment kidney polycystic autosomal dominant ,
NRX-1074,nrx-1074 used trial studying treatment schizophrenia ,
Anisodamine,anisodamine investigated treatment intestinal disease ,
Pefcalcitol,pefcalcitol investigated basic science psoriasis ,
Ralimetinib,ralimetinib used trial studying treatment postmenopausal advanced cancer adult glioblastoma fallopian tube cancer metastatic breast cancer among others ,
Neuropeptide Y,neuropeptide investigation basic science type 2 diabetes mellitus ,
Hyodeoxycholic Acid,hyodeoxycholic acid used trial studying treatment hypercholesterolemia ,
Radafaxine,radafaxine used trial studying treatment depressive disorder major ,
Capmatinib,capmatinib small molecule kinase inhibitor targeted c-met a.k.a hepatocyte growth factor receptor hgfr receptor tyrosine kinase healthy human activates signaling cascade involved organ regeneration tissue repair a199122 aberrant c-met activation via mutation amplification and/or overexpression known occur many type cancer lead overactivation multiple downstream signaling pathway stat3 pi3k/atk ras/mapk a199122 mutation _met_ detected non-small cell lung cancer nsclc prevalence _met_ amplification epidermal growth factor receptor tyrosine kinase inhibitor egfr-tki -naive patient nsclc reported 1.4 21 a199122 co-occurrence made c-met desirable target treatment nsclc manufactured novartis marketed brand name tabrecta capmatinib granted accelerated approval fda may 6 2020 l13380 treatment nsclc patient whose tumor mutation lead mesenchymal-epithelial transition met exon 14 skipping l13347 presence mutation must confirmed fda-approved test foundationone cdx assay manufactured foundation medicine inc. approved fda day l13380 indication granted accelerated approval continued approval contingent upon verification capmatinib 's benefit confirmatory trial l13347 capmatinib approved health canada june 8 2022 l42015 , u capmatinib indicated treatment adult patient metastatic non-small cell lung cancer nsclc whose tumor mutation lead mesenchymal-epithelial transition met exon 14 skipping detected fda-approved test l13347 capmatinib approved treat adult locally advanced unresectable metastatic non-small cell lung cancer nsclc met exon 14 skipping alteration canada l42010 
Mirodenafil,mirodenafil used trial studying treatment supportive care kidney disease urologic disease renal insufficiency erectile dysfunction male erectile dysfunction ,
Niraparib,niraparib orally active poly adp-ribose polymerase parp inhibitor blocking enzyme responsible dna repair niraparib induces cytotoxicity cancer cell l43277 niraparib selective towards parp-1 parp-2 a253248 first approved fda march 27 2017 a253912 niraparib used treat epithelial ovarian fallopian tube primary peritoneal cancer l43277 niraparib approved european commission november 16 2017 l43742 health canada june 27 2019 l43747 ,niraparib indicated maintenance treatment adult patient advanced recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response first-line platinum-based chemotherapy l43277 l43742 l43747 
Berzosertib,berzosertib vx-970 used trial studying treatment ovarian neoplasm ovarian serous tumor adult solid neoplasm advanced solid tumor advanced solid neoplasm among others ,
GSK-2636771,gsk2636771 used trial studying treatment cancer lymphoma solid neoplasm recurrent solid neoplasm advanced malignant neoplasm among others ,
Fostemsavir,fostemsavir phosphonooxymethyl prodrug temsavir novel hiv-1 attachment inhibitor l14867 bind inhibits activity gp120 subunit within hiv-1 gp160 envelope glycoprotein facilitates attachment hiv-1 host cell cd4 receptor temsavir prevents first step hiv-1 viral lifecycle l14867 discovery gp120 potential target interest treatment hiv-1 infection relatively recent born desire find alternative target protein i.e mechanistically orthogonal therapy treatment hiv-1 patient resistant infection a215057 fostemavir first attachment inhibitor receive fda approval granted july 2020 use combination antiretrovirals highly treatment-experienced patient multidrug-resistant hiv-1 infection failing current therapy l14867 l14917 targeting gp120 subunit new novel therapeutic approach hiv-1 infection addition attachment inhibitor like temsavir armament therapy targeted hiv-1 fill necessary niche therapeutic option patient left viable treatment ,fostemsavir indicated combination antiretrovirals treatment multidrug-resistant hiv-1 infection heavily treatment-experienced adult failing current antiretroviral therapy due resistance intolerance safety concern l14867 
Aceneuramic acid,aceneuramic acid used trial studying treatment distal myopathy nonaka type hereditary inclusion body myopathy distal myopathy rimmed vacuole ,
Tanzisertib,tanzisertib used trial studying treatment fibrosis discoid lupus pulmonary fibrosis interstitial lung disease lung disease interstitial among others ,
Bictegravir,bictegravir recently approved investigational drug used trial studying treatment hiv-1 hiv-2 infection approved hiv-1 monotherapy combined 2 antiretrovirals single tablet l43677 ,bictegravir indicated management hiv-1 infection patient previously treated antiretroviral therapy additionally bictegravir indicated management hiv-1 infection patient virologically suppressed hiv-1 rna 50 c/ml regular antiretroviral regimen minimum three month without history failure treatment known factor associated resistance individual component medication used combination tenofovir emtricitabine l1219 l1220 l44226 
Tivozanib,renal cell carcinoma rcc responsible 3 cancer case a231314 one 10 common cancer adult average age diagnosis age 65 74 l32529 tivozanib also known fotivda kinase inhibitor developed treat adult patient relapsed refractory advanced renal cell carcinoma rcc prior failed systemic therapy approved march 10 2021 fda marketed aveo oncology tivozanib promising therapy individual rcc treated successfully therapy l32524 ,tivozanib approved usa treatment relapsed refractory renal cell carcinoma adult patient undergone two systemic therapy l32524 uk country indicated first line therapy adult advanced renal cell carcinoma rcc vegfr mtor pathway inhibitor-naïve patient disease progression following one previous treatment cytokine therapy advanced disease l17180 
Rapastinel,rapastinel used trial studying treatment depressive disorder major obsessive-compulsive disorder ocd ,
Sirukumab,sirukumab used trial studying treatment basic science giant cell arteritis arthritis rheumatoid ,
AZD-5672,azd5672 used trial studying basic science treatment pharmacokinetics renal impairment rheumatoid arthritis ,
Saracatinib,saracatinib investigated treatment cancer osteosarcoma ovarian cancer fallopian tube cancer primary peritoneal cancer ,
VTP-194204,nrx194204 used trial studying treatment parkinson 's disease non-small cell lung cancer ,
Dexmecamylamine,dexmecamylamine used trial studying basic science treatment patient depression drug abuse pharmacokinetics renal impairment among others ,
Faldaprevir,faldaprevir investigated treatment chronic hepatitis c ,
Artefenomel,artefenomel investigated treatment malaria ,
Etarfolatide,etarfolatide used trial studying treatment diagnostic breast neoplasm non small cell lung cancer adenocarcinoma lung ,
Arhalofenate,arhalofenate investigated treatment gout hyperuricemia ,
Talaporfin,talaporfin investigated treatment port-wine stain benign prostatic hyperplasia ,
Mipsagargin,mipsagargin used trial studying treatment prostate cancer prostatic neoplasm advanced solid tumor glioblastoma multiforme hepatocellular carcinoma among others ,
PF-03882845,pf-03882845 used trial studying basic science diabetes mellitus type 2 type 2 diabetic nephropathy ,
Tilarginine,tilarginine investigated basic science treatment diagnostic obesity type 2 diabetes ocular physiology regional blood flow ,
Omecamtiv Mecarbil,omecamtiv mecarbil used trial studying treatment basic science heart failure echocardiogram pharmacokinetics chronic heart failure history chronic heart failure among others ,
Baricitinib,baricitinib janus kinase jak inhibitor jak tyrosine protein kinase play important role pro-inflammatory signaling pathway overactive jak implicated autoimmune disorder rheumatoid arthritis inhibiting action jak1 jak2 baricitinib attenuates jak-mediated inflammation immune response l41760 baricitinib first approved european commission ec february 2017 treatment rheumatoid arthritis adult a248395 later approved fda 2018 a248400 ec later approved baricitinib treatment atopic dermatitis making first jak inhibitor used indication europe a248405 baricitinib granted emergency use treatment covid-19 combination remdesivir emergency use authorization eua november 2020 l22619 fda fully approved use baricitinib treatment covid-19 may 2022 l41760 , u europe baricitinib indicated treatment adult patient moderately severely active rheumatoid arthritis inadequate response one tnf blocker baricitinib may used monotherapy combination methotrexate l41760 l41770 dmards l41760 europe baricitinib indicated treatment moderate severe atopic dermatitis adult patient candidate systemic therapy l41770 u baricitinib also indicated treatment coronavirus disease 2019 covid-19 hospitalized adult requiring supplemental oxygen non-invasive invasive mechanical ventilation extracorporeal membrane oxygenation l41760 recently also approved treatment severe alopecia areata adult l42070 
Retosiban,retosiban used trial studying treatment premature labor obstetric labour premature ,
ASP-4058,asp4058 used trial studying food effect asp4058 pharmacokinetics asp4058 ,
Nifurtimox,chaga disease caused parasite known trypanosoma cruzi t.cruzi vector-transmitted disease affecting animal human america commonly known american trypanosomiasis l15366 cdc estimate approximately 8 million people central america south america mexico infected t. cruzi without symptom chaga disease left untreated life-threatening sequela may result l15366 nifurtimox developed bayer nitrofuran antiprotozoal drug used treatment chaga disease august 6 2020 accelerated fda approval granted use pediatric patient response promising result phase iii clinical trial continued approval contingent upon confirmatory data l15361 convenient feature bayer 's formulation ability divide scored tablet manually without need pill-cutting device l15361 ,nifurtimox indicated pediatric patient 18 weighing least 2.5 kg continued approval drug indication dependent upon confirmatory clinical trial result l15361 
Danegaptide,danegaptide investigated treatment focus study stemi ,
TMC-647055,tmc647055 used trial studying treatment hepatitis c chronic hepatitis c hepatitis c chronic chronic hepatitis c virus ,
Esketamine,major depressive disorder mdd significant cause disability worldwide common illness preceding suicide l5596 a175462 march 5 2019 nasal spray drug _esketamine_ also known _spravato_ janssen pharmaceutical approved fda treatment-resistant major depression esketamine s-enantiomer ketamine ketamine mixture two enantiomer mirror image molecule first time fda approved esketamine use fda approved ketamine ketalar 1970 l5593 esketamine may prove promising treatment patient diagnosed major depressive disorder experienced improvement symptom despite treatment various medication therapy intranasal route administration drug allows easy administration fast onset action set apart many antidepressant agent may take several week take effect ,esketamine indicated combination oral antidepressant treatment treatment-resistant depression adult l12999 also indicated treatment depressive symptom adult major depressive disorder experiencing acute suicidal ideation behaviour l12999 
Tofogliflozin,tofogliflozin used trial studying treatment prevention diabetes mellitus type 2 ,
Mirogabalin,mirogabalin used trial studying treatment post-herpetic neuralgia pain associated fibromyalgia diabetic peripheral neuropathic pain ,
Lampalizumab,lampalizumab used trial studying treatment geographic atrophy ,
Ertugliflozin,ertugliflozin belongs class potent selective inhibitor sodium-dependent glucose cotransporters sglt specifically type 2 responsible 90 glucose reabsorption glomerulus a31581 drug developed collaboration merck pfizer fda approved monotherapy combination sitagliptin metformin hydrochloride december 22 2017 l1132 ,ertugliflozin indicated adjunct diet exercise improve glycemic control adult patient type 2 diabetes mellitus l3903 also available combination either metformin sitagliptin indication l1134 l1135 
Neratinib,neratinib approved july 2017 use extended adjuvant therapy human epidermal growth factor receptor 2 her2 positive breast cancer approval granted puma biotechnology inc. tradename nerlynx neratinib currently investigation use many form cancer , use extended adjuvant treatment adult patient early stage her2-overexpressed/amplified breast cancer follow adjuvant trastuzumab-based therapy fda label 
Ruboxistaurin,ruboxistaurin investigated basic science type 2 diabetes mellitus type 1 diabetes mellitus ,
Mocetinostat,mocetinostat used trial studying treatment lymphoma urothelial carcinoma relapsed refractory myelodysplastic syndrome metastatic leiomyosarcoma among others ,
Dinitrochlorobenzene,dinitrochlorobenzene used trial studying treatment hiv infection ,
Crenolanib,crenolanib investigation treatment diffuse intrinsic pontine glioma progressive refractory high-grade glioma ,
Basimglurant,basimglurant used trial studying diagnostic treatment depression fragile x syndrome major depressive disorder ,
Guselkumab,guselkumab human immunoglobulin g1 lambda igg1λ monoclonal antibody selectively block interleukin-23 il-23 inflammatory cytokine activates cd4+ t-helper th17 cell pathway mediate inflammatory cascade induces psoriatic plaque formation a20357 clinical trial guselkumab demonstrated improved skin clearance symptomatic improvement dermatological manifestation psoriasis developed janssen subcutenous injection form guselkumab approved july 2017 market name tremfya treatment adult patient moderate-to-severe plaque psoriasis ,indicated treatment adult moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy 
Indium In-111 pentetreotide,indium 111 pentetreotide octreoscan used trial studying diagnostic sarcoidosis solid tumor cushing syndrome ,
Sapanisertib,sapanisertib used trial studying treatment hcc solid tumor gliosarcoma liver cancer glioblastoma among others ,
Osilodrostat,osilodrostat inhibitor 11β-hydroxylase also referred cyp11b1 enzyme catalyzes final step biosynthesis endogenous cortisol l12123 used lower circulating cortisol level treatment cushing 's disease disorder cortisol level chronically supraphysiologically elevated cushing 's disease often result acth hypersecretion secondary pituitary tumor surgical resection tumour generally treatment choice a191910 orally bioavailable drug therapy osilodrostat provides novel treatment option patient removal causative tumor option previous pituitary surgery curative osilodrostat manufactured novartis brand name isturisa l12123 undergone phase ii clinical trial treatment solid tumour hypertension heart failure development indication discontinued novartis january 2013 a191850 osilodrostat approved use eu january 2020 treatment endogenous cushing 's syndrome i.e cushing 's disease a191850 granted fda approval orphan drug designation u march 2020 indication l12162 ,osilodrostat indicated treatment adult patient cushing 's disease pituitary surgery option curative l12123 a191850 
Revamilast,revamilast used trial studying treatment asthma rheumatoid arthritis ,
PZ-128,pz-128 used trial studying prevention treatment heart disease coronary disease arteriosclerosis vascular disease myocardial ischemia among others ,
Dalotuzumab,dalotuzumab investigated treatment breast cancer non small cell lung cancer metastatic colorectal cancer ,
Entinostat,entinostat investigation treatment volunteer breast cancer human volunteer normal volunteer entinostat investigated treatment non-small lung cancer epigenetic therapy ,
Angiotensin II,angiotensin ii investigation treatment sepsis septic shock diabetes mellitus acute renal failure angiotensin ii investigated treatment basic science diagnostic hypertension renin angiotensin system idiopathic membranous nephropathy december 21 2017 fda approved la jolla pharmaceutical 's giapreza angiotensin ii injection intravenouse infusion indication acting vasoconstrictor increase blood pressure adult septic distributive shock novelty medication lie fact first use synthetic human angiotensin ii help maintain body blood pressure shock inability maintain blood flow vital tissue potential resultant organ failure death within hour matter young ld distributive shock common type shock inpatient setting affect one third patient intensive care unit fda determined need treatment option critically ill hypotensive patient adequately respond currently available therapy ,angiotensin ii vasoconstrictor indicated increasing blood pressure adult septic distributive shock fda label 
PF-04958242,pf-04958242 used trial studying basic science treatment schizophrenia hearing loss sensorineural ,
Pritelivir,pritelivir used trial studying prevention hsv-2 genital herpes ,
Lucitanib,lucitanib used trial studying treatment er+ mbc sclc her2+ nsclc among others ,
Creatinine,creatinine used trial studying treatment amyotrophic lateral sclerosis ,
Cadazolid,cadazolid used trial studying treatment clostridium difficile infection ,
Mannose 6-phosphate,mannose 6-phosphate used trial studying treatment wound cicatrix wound-healing re-epithelialisation ,
Emibetuzumab,emibetuzumab used trial studying treatment advanced cancer renal cell carcinoma hepatocellular cancer gastric adenocarcinoma non-small cell lung cancer among others ,
Ublituximab,cd20 antigen expressed various b cell attractive therapeutic target various cancer autoimmune condition a244195 a244200 a244205 monoclonal antibody b cell depletion rely binding affinity ability clear bound cell mechanism antibody-dependent cellular cytotoxicity adcc mediated interaction antibody fcγ receptor natural killer cell macrophage a244210 ublituximab chimeric anti-cd20 igg1κ antibody produced rat yb2/0 cell line target unique epitope enhance adcc compared approved anti-cd20 antibody rituximab ofatumumab obinutuzumab ocrelizumab a244210 a244215 a241045 ublituximab initially developed lfb group licensed tg therapeutic 2012 investigated use numerous b cell-dependent condition including chronic lymphocytic leukemia non-hodgkin 's lymphoma relapsing multiple sclerosis a241045 ,ublituximab indicated adult patient treatment relapsing form multiple sclerosis m including clinically isolated syndrome relapsing-remitting disease active secondary progressive disease l44488 
Bafetinib,bafetinib used trial studying treatment adult gliosarcoma adult mixed glioma adult glioblastoma chronic myeloid leukemia acute lymphocytic leukemia among others ,
Tegobuvir,tegobuvir investigated treatment hepatitis c chronic ,
Relugolix,relugolix gonadotropin-releasing hormone gnrh receptor antagonist used treatment several hormone-responsive condition first approved japan 2019 brand name relumina symptomatic treatment uterine fibroid a225816 recently united state fda 2020 brand name orgovyx treatment advanced prostate cancer l27991 l27996 branded product later approved european commission april 29 2022 l42150 relugolix also studied symptomatic treatment endometriosis a225761 relugolix first currently orally-administered gnrh receptor antagonist approved treatment prostate cancer similar therapy degarelix require subcutaneous administration therefore provides le burdensome therapeutic option patient might otherwise require clinic visit administration healthcare professional l27996 addition relative ease-of-use relugolix shown superior depression testosterone level compared leuprolide another androgen deprivation therapy used treatment prostate cancer a225926 may 2021 fda approved combination product made relugolix estradiol norethindrone market name myfembree first once-daily treatment management heavy menstrual bleeding associated uterine fibroid premenopausal woman l34289 ,relugolix indicated treatment adult patient advanced prostate cancer l27991 l42145 combination product estradiol norethindrone relugolix indicated once-daily treatment management heavy menstrual bleeding associated uterine fibroid premenopausal woman l34289 
Astodrimer,astodrimer used trial studying treatment prevention bacterial vaginosis lysine-based dendrimer naphthalene disulfonic acid surface group ,
Revefenacin,revefenacin novel biphenyl carbamate tertiary amine agent belongs family long-acting muscarinic antagonist lama labile primary amide structure produce `` soft-drug '' site allows rapid systemic clearance minimizing systemically mediated adverse reaction lama group fall parent category known long-acting inhaled bronchodilator type agent recommended maintenance therapy chronic obstructive pulmonary disease copd a40025 lama group revefenacin first once-daily nebulized lama treatment a40026 developed theravance biopharma fda approved november 9 2018 l4818 ,revefenacin indicated inhalation solution maintenance treatment patient chronic obstructive pulmonary disease copd l4820 copd growing disease third leading cause death u disease characterized fully reversible airflow limitation l4821 
Ligelizumab,ligelizumab humanized igg1k monoclonal antibody targeted immunoglobulin e ige similar mechanism omalizumab another ige-directed monoclonal antibody ligelizumab distinct binding epitope compared peer small degree overlap appears confer greater affinity free serum ige altered sensitivity ige conformation a242292 ligelizumab currently investigation treatment chronic spontaneous urticaria csu autoimmune-driven inflammatory condition precise pathogenesis csu entirely clear autoantibody ige receptor sometimes ige thought exist 30-40 patient a242362 a242367 efficacy anti-ige antibody therapy treatment csu previously established omalizumab initial trial ligelizumab suggest greater efficacy predecessor treatment csu a242367 ,
Seribantumab,seribantumab used trial studying treatment nsclc heregulin adenocarcinoma colorectal cancer solid tumor cancer among others ,
Leukotriene D4,leukotriene d4 used trial studying diagnostic asthma allergic rhinitis ,
Brexanolone, march 2019 brexanolone developed made available commercially sage therapeutic inc. brand name product zulresso first drug ever approved u fda specifically treatment postpartum depression ppd adult female f4066 since ppd like various type depression characterized feeling sadness worthlessness guilt cognitive impairment and/or possibly suicidal ideation considered life-threatening condition f4072 study consequently found ppd genuinely profound negative effect maternal-infant bond later infant development f4072 a176080 a176083 development availability brexanolone treatment ppd adult female subsequently provides new promising therapy existed f4066 particular use brexanolone treating ppd surrounded promise act part synthetic supplement possible deficiency endogenous brexanolone allopregnanolone postpartum woman susceptible ppd whereas many commonly used anti-depressive medication elicit action may modulate presence activity substance like serotonin norepinephrine and/or monoamine oxidase mediate activity directly associated ppd like natural fluctuation level endogenous neuroactive steroid like allopregnanolone f4063 finally although brexanolone may also undergoing clinical trial investigate ability treat super-refractory status epilepticus appears study failed meet primary endpoint compare success weaning third-line agent resolution potentially life-threatening status epilepticus brexanolone vs. placebo added standard-of-care l5750 ,brexanolone synthetic neuroactive steroid gamma-aminobutyric acid gaba receptor positive modulator indicated treatment postpartum depression ppd adult woman fda label a176080 a176083 f4063 f4066 f4072 
Aramchol,aramchol used trial studying treatment hiv gallstone fatty liver metabolic syndrome nonalcoholic steatohepatitis among others ,
Litronesib,litronesib used trial studying treatment solid tumor ovarian cancer gastric cancer prostate cancer acute leukaemia among others ,
Landogrozumab,landogrozumab used trial studying treatment advanced cancer muscular atrophy pancreatic cancer ,
Alvelestat,alvelestat investigated basic science chronic obstructive pulmonary disease ,
Preladenant,preladenant used trial studying treatment brain disease parkinson disease movement disorder antipsychotic agent parkinsonian disorder among others ,
Brivanib alaninate,brivanib alaninate investigated treatment colorectal cancer ,
Romosozumab,"romosozumab humanized monoclonal antibody indicated treatment osteoperosis postmenopausal woman high risk fracture patient failed treatment intolerant osteoperosis therapy l9554 romosozumab prevents bone resorption induces formation bone though associated increased risk cardiac death heart attack stroke one study l5921 l5924 comparison study post menopausal woman osteoporosis past fracture romosozumab 12 month followed alendronic acid 12 month superior alendronic acid alone 24 month a177071 romosozumab also demonstrates faster larger increase bone density teriparatide a177050 romosozumab marketed united state amgen brand name evinity l5921 romosozumab granted fda approval april 9,2019 l5921 ",romosozumab indicated treatment osteoporosis post menopausal woman high risk fracture also patient osteoperosis intolerant treatment failed treatment l9554 
JNJ-39393406,jnj-39393406 used trial studying treatment basic science depression schizophrenia smoking cessation cognition disorder alzheimer 's disease ,
Etiracetam,etiracetam investigation clinical trial nct01137110 comparison short duration levetiracetam extended course seizure prophylaxis subarachnoid hemorrhage sah ,
Valspodar,valspodar used trial studying treatment cancer sarcoma leukemia lymphoma breast cancer among others ,
RG-4733,ro4929097 used trial studying treatment sarcoma lymphoma neoplasm wilm 's tumor osteosarcoma among others ,
PF-00610355,pf-00610355 used trial studying treatment lung disease moxifloxacin pulmonary disease asthma bronchial bronchial disease among others ,
ZD-6126,zd6126 used trial studying treatment kidney neoplasm colorectal neoplasm metastasis neoplasm carcinoma renal cell ,
Verinurad,verinurad used trial studying basic science treatment gout gout hyperuricemia gout asymptomatic hyperuricemia ,
Crocin,crocin investigated treatment hyperglycemia metabolic syndrome hypertriglyceridemia hypercholesterolemia ,
"3,3'-diindolylmethane",diindolylmethane used trial studying prevention treatment sle prostate cancer cervical dysplasia stage prostate cancer stage ii prostate cancer among others ,
Alanyl glutamine,alanyl glutamine investigation clinical trial nct00338221 clinical trial alanyl-glutamine glycine child persistent diarrhea malnutrition ,
Basmisanil,basmisanil used trial studying treatment basic science syndrome ,
Filibuvir,filibuvir used trial studying treatment hepatitis hepatitis c chronic hepatitis c ,
Dusquetide,dusquetide used trial studying treatment oral mucositis ,
Acridine Carboxamide,acridine carboxamide used trial studying treatment lung cancer brain central nervous system tumor ,
AUY922,auy922 used trial studying treatment lymphoma breast cancer metastatic disease advanced solid tumor hematologic neoplasm among others ,
BPC-157,bepecin investigation clinical trial nct02637284 pco-02 safety pharmacokinetics trial ,
SB-705498,sb-705498 investigated treatment rhinitis chronic cough non-allergic rhinitis ,
Vadastuximab talirine,vadastuximab talirine used trial studying treatment acute myeloid leukemia myelodysplastic syndrome acute myelogenous leukemia acute promyelocytic leukemia ,
Anlotinib,anlotinib investigated treatment non-small cell lung cancer metastatic colorectal cancer ,
Infigratinib,infigratinib pan-fibroblast growth factor receptor fgfr kinase inhibitor inhibiting fgfr pathway often aberrated cancer cholangiocarcinoma infigratinib suppresses tumour growth a235174 cholangiocarcinoma common primary malignancy affecting biliary tract second common primary hepatic malignancy a198963 infitratinib pan-fgfr inhibitor atp-competitive inhibitor four fgfr receptor subtypes a235174 may 28 2021 fda granted accelerated approval infigratinib market name truseltiq treatment previously treated unresectable locally advanced metastatic cholangiocarcinoma adult fibroblast growth factor receptor 2 fgfr2 fusion another rearrangement detected fda-approved test l34304 approval follows pemigatinib another fgfr inhibitor approved fda therapeutic indication ,infigratinib indicated treatment previously treated unresectable locally advanced metastatic cholangiocarcinoma adult fibroblast growth factor receptor 2 fgfr2 fusion another rearrangement detected fda-approved test l34299 
Laninamivir octanoate,laninamivir octanoate used trial studying treatment asthma ,
Lanicemine,lanicemine used trial studying treatment basic science depression major depressive disorder treatment resistant major depressive disorder ,
Cilengitide,cilengitide used trial studying treatment sarcoma glioma lymphoma leukemia lung cancer among others ,
Fimepinostat,fimepinostat cudc-907 used trial studying treatment lymphoma solid tumor breast cancer multiple myeloma nut midline carcinoma among others ,
Prulifloxacin,prulifloxacin investigated treatment urinary tract infection ,
Avagacestat,avagacestat investigated basic science treatment alzheimer disease ,
Efatutazone,efatutazone used trial studying treatment lymphoma liposarcoma solid tumor multiple myeloma recurrent thyroid cancer among others ,
Lenomorelin,lenomorelin investigated treatment basic science cancer alcoholism metabolism hypopituitarism frailty syndrome among others ,
Gedatolisib,gedatolisib used trial studying basic science treatment neoplasm ovary cancer breast cancer advanced cancer endometrial cancer among others ,
"2,4-thiazolidinedione",thiazolidinedione investigated treatment type 2 diabetes diabetes mellitus diabetes mellitus type 2 ,
MK-8776,sch 900776 used trial studying treatment neoplasm hodgkin disease adult erythroleukemia lymphoma non-hodgkin myelogenous leukemia acute among others ,
OC-459,oc000459 investigation treatment severe eosinophilic asthma oc000459 investigated treatment bronchial asthma ,
Apalutamide,apalutamide potent androgen receptor ar antagonist selectively bind ligand-binding domain ar block ar nuclear translocation binding androgen response element a31846 used trial studying treatment prostate cancer hepatic impairment prostatic neoplasm castration-resistant prostate cancer prostatic neoplasm castration-resistant among others exerting antitumor action apalutamide blocking effect androgen promote tumor growth target ar ligand-binding domain prevents ar nuclear translocation dna binding transcription ar gene target prostate tumor a31846 mouse bearing human crpc xenograft model apalutamide treatment produced tumor regression dose-dependent manner effective db01128 db08899 unlike bicalutamide apalutamide antagonized ar-mediated signaling ar overexpressing human crpc cell line a31846 androgen-deprivation therapy hormone therapy used part maintenance therapy patient non-metastatic prostate cancer although patient achieve therapeutic response initial hormone therapy many patient progress non-metastatic castration-resistant resistance hormone therapy prostate cancer second-most common cause cancer-related death american male a31852 castration-resistant prostate cancer often incurable pose significant clinical challenge patient approximately 10 20 prostate cancer case castration-resistant 16 patient show evidence cancer metastasis time castration-resistant diagnosis l1295 higher prostate-specific antigen psa shorter psa doubling time psa dt associated higher risk metastasis death a31846 phase-2 multicenter open-label study 89 patient non-metastatic castration-resistant prostate cancer ≥50 psa decline week 12 apalutamide treatment a31846 randomized trial median metastasis-free survival patient taking apalutamide 40.5 month compared 16.2 month patient taking placebo l1295 apalutamide displayed good tolerability safety profile clinical study apalutamide approved february 2018 fda erleada treatment patient non-metastatic prostate cancer resistant treatment hormone therapy castration-resistant available oral tablet apalutamide first fda-approved treatment non-metastatic castration-resistant prostate cancer l1295 ,indicated treatment patient non-metastatic castration-resistant prostate cancer nm-crpc fda label 
Gisadenafil,gisadenafil investigated treatment prostatic hyperplasia ,
GW842166,gw842166x used trial studying treatment pain analgesia inflammation osteoarthritis pain inflammatory among others ,
Flumatinib,flumatinib used trial studying treatment myelogenous leukemia chronic ,
Sutezolid,sutezolid used trial studying treatment tuberculosis ,
Acyline,acyline investigated prevention treatment hypogonadism contraception ,
Rociletinib,rociletinib used trial studying treatment prevention nonsmall cell lung cancer non-small cell lung cancer locally advanced metastatic non-small cell lung cancer ,
Varespladib,varespladib investigated treatment prevention sickle cell disease vaso-occlusive crisis acute coronary syndrome ,
MK-0249,mk0249 used trial studying treatment hypopnea syndrome alzheimer 's disease paranoid schizophrenia sleep apnea obstructive excessive daytime sleepiness among others ,
Galunisertib,galunisertib used trial studying basic science treatment glioma neoplasm solid tumor glioblastoma prostate cancer among others ,
Lanopepden,lanopepden used trial studying treatment pneumonia infection bacterial skin disease infectious skin infection bacterial ,
LY-2090314,ly2090314 used trial studying treatment leukemia advanced cancer pancreatic cancer ,
Lebrikizumab,lebrikizumab used trial studying treatment asthma allergic asthma atopic dermatitis idiopathic pulmonary fibrosis copd chronic obstructive pulmonary disease ,
Valbenazine,valbenazine development name nbi-98854 used trial studying treatment basic science tourette syndrome tardive dyskinesia april 2017 valbenazine approved fda ingrezza first approved treatment adult tardive dyskinesia td , treatment tardive dyskinesia adult fda label 
Indium In-111,indium in-111 investigation clinical trial nct00493454 ibritumomab tiuxetan treatment non-follicular cd20+ indolent lymphoma ,
Vatiquinone,vatiquinone investigated treatment prevention retinopathy rett syndrome genetic disease noise-induced hearing loss methylmalonic aciduria homocystinuria cblc type ,
Guadecitabine,guadecitabine investigation treatment previously treated metastatic colorectal cancer ,
6-O-benzylguanine,6-o-benzylguanine used trial studying treatment hiv infection adult gliosarcoma adult glioblastoma stage adult hodgkin lymphoma stage ii adult hodgkin lymphoma among others ,
Lesogaberan,lesogaberan used trial studying treatment basic science gerd reflux heartburn regurgitation reflux disease among others ,
Deflazacort,deflazacort also known emflaza corticosteroid prodrug used agent manage duchenne muscular dystrophy dmd marketed marathon pharmaceutical approved february 2017 fda l6694 fda label duchenne muscular dystrophy inherited disorder resulting mutation dystrophin gene important muscle function disease cause serious muscle weakness progressive breathing cardiovascular disability severely impacting patient quality life survival a179446 a179449 l6697 disease usually manifest muscle weakness early childhood followed loss ability walk ambulation early age 7 a179449 deflazacort delay onset muscle related complication resulting dmd a179455 prolonging life child diagnosed disease exerting le harmful effect bone health weight steroid medication a179452 a25340 ,deflazacort indicated treatment duchenne muscular dystrophy dmd patient 2 year age older fda label 
Danirixin,danirixin used trial studying treatment basic science virus disease nutritional status pulmonary disease chronic obstructive infection respiratory syncytial virus ,
Decoglurant,decoglurant used trial studying treatment major depressive disorder ,
Safingol,safingol used trial studying treatment unspecified adult solid tumor protocol specific ,
Vistusertib,vistusertib investigation treatment advanced gastric adenocarcinoma ,
Tesidolumab,tesidolumab used trial studying treatment geographic atrophy non-infectious panuveitis exudative macular degeneration non-infectious posterior uveitis age-related macular degeneration among others ,
Lodenafil carbonate,lodenafil carbonate used trial studying treatment coronaropathy erectile dysfunction ,
Vosoritide,achondroplasia autosomal dominant genetic disease common cause dwarfism human a242277 result gain-of-function missense mutation _fgfr3_ result dramatic suppression bone growth volume length a242273 a242277 treatment achondroplasia includes surgical pharmacological intervention latter includes c-type natriuretic peptide cnp analog endogenous cnp first described 1998 primarily responsible stimulation chondrocytes long bone growth via activity npr-b receptor making attractive target treatment condition like achondroplasia a242273 remarkably short half-life endogenous cnp 2 3 minute due rapid degradation endopeptidases make ineffective therapeutic intervention a242273 development peptidase-resistant formulation allowed use viable treatment option achondroplasia vosoritide analog cnp proline-glycine n-terminus convey resistance neutral endopeptidase l39229 approved use brand name voxzogo biomarin pharmaceutical inc. eu august 2021 u november 2021 l39245 l39241 becoming first pharmacological intervention approved treatment achondroplasia region ,vosoritide indicated promotion linear growth pediatric patient achondroplasia 5 year age older open epiphysis l39229 
Vaniprevir,vaniprevir used trial studying treatment diagnostic hepatitis c chronic hepatitis c hepatitis c chronic chronic hepatitis c infection chronic genotype 1 hepatitis c virus infection ,
Varlilumab,varlilumab used trial studying treatment melanoma skin ulcer burkett 's lymphoma mantle cell lymphoma t-cell malignancy among others ,
Abametapir,abametapir novel pediculicidal metalloproteinase inhibitor used treat infestation head louse l15153 life cycle head louse _pediculus capitis_ approximately 30 day seven twelve spent egg laid hair shaft near scalp a216183 topical pediculicide generally lack adequate ovicidal activity a216183 including standard-of-care treatment permethrin many require second administration 7-10 day following first kill newly hatched louse resisted initial treatment necessity follow-up treatment may lead challenge patient adherence resistance agent like permethrin pyrethrins piperonyl butoxide may significant area a216228 investigation novel ovicidal treatment revealed several metalloproteinase enzyme critical egg hatching survival head louse enzyme therefore identified potential therapeutic target a216178 abemetapir inhibitor metalloproteinase enzyme first topical pediculicide take advantage novel target improved ovicidal activity 90-100 _in vitro_ abemetapir allows single administration contrast many topical treatment novel relatively non-specific mechanism may help curb development resistance agent a216178 abametapir first approved use united state brand name xeglyze july 27 2020 l15163 ,abametapir indicated context overall louse management program topical treatment head louse infestation patient 6 month age older l15153 
Riboprine,ipa used trial studying treatment nausea surgical site infection ,
Epelsiban,epelsiban investigated treatment premature ejaculation ,
Flomoxef,flomoxef used trial studying treatment urinary tract infection ,
Bempedoic acid,high level ldl cholesterol ldl-c major risk factor cardiovascular event caused genetic mutation lifestyle factor hypercholesterolemia significantly reduce quality life increase risk mortality cardiovascular disease l12153 1 4 patient 15 million american elevated ldl-c insufficiently managed maximally tolerated statin therapy alone requiring additional treatment hypercholesterolemia l12180 bempedoic acid first-in-class adenosine triphosphate-citrate lyase acl inhibitor used day reducing ldl cholesterol level statin-refractory patient l12144 l12147 developed esperion therapeutic inc. approved fda february 21 2020 combination product bempedoic acid ezetimibe approved february 26 2020 increased control ldl cholesterol level patient experiencing refractory elevation despite previous statin treatment l12144 l12150 ,bempedoic acid indicated adjunct diet maximally tolerated statin therapy adult heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease warrant additional lowering ldl-c. l12144 combination bempedoic ezetimibe also indicated diet management maximally tolerated statin therapy treat elevated ldl-c level adult heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease require lowering ldl-c. l12150 
Kynurenic Acid,kynurenic acid investigation clinical trial nct02340325 fs2 safety tolerability study healthy volunteer ,
Difelikefalin,difelikefalin cr845 agonist kappa opioid receptor kor useful treatment pruritus secondary chronic kidney disease kor first associated itching 1984 a237610 investigation revealed dynorphins endogenous agonist kor work inhibit itching sensation spinal cord level scratching could elicited mouse model administration kor antagonist a237610 revelation led study kor agonist potential treatment option patient suffering pruritic condition pruritus associated chronic kidney disease also called uremic pruritus affect 50-60 patient dialysis 25 non-dialysis patient chronic kidney disease a237615 a237620 clinical burden uremic pruritus patient population increasingly recognized contributing significant reduction patient quality life poor outcome even mortality a237620 option therapy limited fda-approved treatment off-label gabapentin evidence-based widely available treatment a237620 difelikefalin received fda approval august 2021 brand name korsuva becoming first fda-approved therapy patient chronic kidney disease suffering uremic pruritus l36420 l36395 difelikefalin later approved ema april 2022 indication l41665 ,difelikefalin indicated treatment moderate-to-severe pruritus associated chronic kidney disease ckd-ap uremic pruritus adult undergoing hemodialysis l36395 l41660 
Henagliflozin,henagliflozin used trial studying treatment type 2 diabetes ,
Triapine,triapine used trial studying treatment leukemia lung cancer kidney cancer prostate cancer pancreatic cancer among others ,
Tasisulam,tasisulam used trial studying treatment basic science melanoma lymphoma solid tumor breast cancer ovarian cancer among others ,
Selinexor,selinexor first-in-class selective inhibitor nuclear transport sine compound selinexor combination bortezomib dexamethasone currently approved treatment multiple myeloma type cancer formed antibody-producing plasma cell l7117 l7120 l10145 condition typically treated high dose bortezomib dexamethasone chemotherapy followed autologous stem-cell transplant chemotherapy multiple myeloma include lenalidomide dexamethasone thalidomide may include melphalan patient eligible transplant l7123 selinexor also granted accelerated approval treatment adult patient relapsed refractory diffuse large b-cell lymphoma dlbcl gone least 2 line systemic therapy l10145 fda approved selinexor june 2019 l10145 use selinexor combination bortezomib dexamethasone approved health canada june 2022 treatment multiple myeloma adult patient received least one prior therapy ,selinexor indicated combination bortezomib dexamethasone treatment multiple myeloma adult patient received least one prior therapy selinexor also indicated combination dexamethasone treatment relapsed refractory multiple myeloma adult patient received least four prior therapy refractory least two proteasome inhibitor two immunomodulatory agent anti-cd38 monoclonal antibody l10145 selinexor also indicated accelerated approval scheme treatment relapsed refractory diffuse large b-cell lymphoma dlbcl otherwise specified including arising follicular lymphoma adult patient received least two prior line systemic therapy continued approval indication may contingent verification confirmatory clinical trial l10145 
Delafloxacin,delafloxacin fluoroquinolone antibiotic used trial studying treatment basic science gonorrhea hepatic impairment bacterial skin disease skin structure infection community acquired pneumonia among others approved june 2017 trade name baxdela use treatment acute bacterial skin skin structure infection ,delafloxacin indicated treatment acute bacterial skin skin structure infection caused gram-positive organism staphylococcus aureus including methicillin-resistant methicillin-susceptible isolates staphylococcus haemolyticus staphylococcus lugdunensis streptococcus agalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius streptococcus constellatus streptococcus pyogenes enterococcus faecalis well gram-negative organism escherichia coli enterobacter cloaca klebsiella pneumoniae pseudomonas aeruginosa fda label 
Ingavirin,ingavirin used trial studying treatment influenza common cold ,
Avelumab,avelumab programmed death ligand-1 pd-l1 blocking antibody indicated treatment adult pediatric patient 12 year older metastatic merkel cell carcinoma mcc fully human anti-pd immunoglobulin g1 igg1 lambda monoclonal antibody antineoplastic action granted accelerated approval march 2017 name bavencio ,avelumab indicated treatment adult pediatric patient ≥12 year age metastatic merkel cell carcinoma mcc l40373 also indicated maintenance treatment patient locally advanced metastatic urothelial carcinoma uc progressed first-line platinum-containing chemotherapy addition indicated patient locally advanced metastatic uc experience disease progression platinum-containing chemotherapy within 12 month neoadjuvant adjuvant treatment platinum-containing chemotherapy l40373 avelumab additionally indicated first-line treatment combination axitinib treatment advanced renal cell carcinoma rcc l40373 
AZD-1981,azd1981 used trial studying treatment basic science asthma postmenopausal pharmakokinetic asthma patient drug interaction among others ,
Pridopidine,pridopidine used trial studying treatment huntington 's disease ,
Lapachone,lapachone used trial studying treatment cancer carcinoma advanced solid tumor head neck neoplasm carcinoma squamous cell ,
Vestipitant,vestipitant investigated treatment tinnitus ,
Teneligliptin,teneligliptin investigated treatment type 2 diabetes mellitus ,
Lemborexant,lemborexant novel dual orexin receptor antagonist used treatment insomnia characterized difficulty sleep onset and/or sleep maintenance l10863 recent research field sleep disorder revealed insomnia likely driven inability brain `` switch '' sleep-related circuit rather inability `` switch-off '' wake-promoting circuit a189006 a189030 whereas historically popular pharmacologic treatment insomnia e.g zopiclone zolpidem benzodiazepine focus enhancing sleep drive via modulation gaba melatonin receptor lemborexant orexin antagonist e.g suvorexant act counteract inappropriate wakefulness a189006 novel mechanism action offer potential advantage classic hypnotic agent including favorable adverse effect profile potentially greater efficacy may signal beginning new wave treatment option patient suffering insomnia a189006 ,lemborexant indicated treatment adult patient insomnia characterized difficulty sleep onset and/or sleep maintenance l10863 
Duvelisib,duvelisib also known ipi-145 ink-1197 small-molecule inhibitor phosphoinositide-3 kinase designed initially prove simultaneous inhibition isoforms delta gamma produce broad adaptative innate immune cell inhibitory activity work around duvelisib showed agent potent inhibitor form a39025 duvelisib developed verastem inc fda approved september 24 2018 l4585 ,duvelisib indicated treatment relapsed refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll adult patient trialed least two prior therapy l40144 
PF-04447943,pf-04447943 investigated treatment alzheimer 's disease ,
Lomibuvir,lomibuvir used trial studying treatment chronic hepatitis c virus chronic hepatitis c virus infection ,
Avotermin,juvista investigated treatment prevention basic science scar keloid cicatrix ,
Delanzomib,delanzomib used trial studying treatment solid tumor multiple myeloma lymphoma non-hodgkin ,
Idalopirdine,idalopirdine used trial studying treatment cognition schizophrenia alzheimer 's disease ,
Brivanib,brivanib investigation treatment hepatocellular carcinoma brivanib investigated treatment solid tumor hepato cellular carcinoma hcc metastatic colorectal cancer mcrc ,
Crenezumab,crenezumab used trial studying treatment alzheimer 's disease ,
Carboxyamidotriazole,carboxyamidotriazole used trial studying treatment lymphoma lung cancer breast cancer kidney cancer ovarian cancer among others ,
AZD-1236,azd1236 used trial studying basic science treatment cystic fibrosis chronic obstructive pulmonary disease ,
GSK-1059615,gsk1059615 used trial studying treatment lymphoma solid tumour endometrial cancer solid tumor cancer metastatic breast cancer ,
Dacomitinib,dacomitinib designed 2e -n-16-4- piperidin-1-yl but-2-enamide oral highly selective quinazalone part second-generation tyrosine kinase inhibitor characterized irreversible binding atp domain epidermal growth factor receptor family kinase domain a40009 dacomitinib developed pfizer inc approved fda september 27 2018 l4810 evidence literature suggests therapeutic potential dacomitinib epithelial ovarian cancer model a39624 although investigation needed ,dacomitinib indicated first-line treatment patient metastatic non-small cell lung cancer nsclc epidermal growth factor receptor egfr exon 19 deletion exon 21 l858r substitution mutation verified fda-approved test l4812 lung cancer leading cause cancer death nsclc account 85 lung cancer case case nsclc approximately 75 patient present late diagnosis metastatic advanced disease produce survival rate 5 presence mutation egfr account 60 nsclc case overexpression egfr associated frequent lymph node metastasis poor chemosensitivity a40018 a19201 
Ilaprazole,ilaprazole investigated helicobacter infection ,
SJG-136,sjg-136 used trial studying treatment recurrent fallopian tube cancer secondary acute myeloid leukemia de novo myelodysplastic syndrome recurrent ovarian epithelial cancer secondary myelodysplastic syndrome among others ,
BMS-986094,inx-08189 used trial studying treatment hepatitis c hcv genotype 1 hepatitis c virus ,
Binimetinib,binimetinib also known _mektovi_ potent selective oral mitogen-activated protein kinase 1/2 mek 1/2 inhibitor combined encorafenib a34275 l3335 june 27 2018 food drug administration approved combination encorafenib binimetinib braftovi mektovi array biopharma inc. combination patient unresectable metastatic melanoma braf v600e v600k mutation detected fda-approved test l3335 , june 27 2018 food drug administration approved encorafenib binimetinib combination patient unresectable metastatic melanoma braf v600e v600k mutation detected fda-approved test l3335 
MK-7145,mk-7145 used trial studying treatment hypertension renal insufficiency ,
Uprosertib,uprosertib used trial studying treatment cancer melanoma solid tumour cervical cancer her2/neu negative among others ,
Burixafor,burixafor used trial studying treatment multiple myeloma hodgkin 's disease non-hodgkin 's lymphoma ,
Vilaprisan,vilaprisan used trial studying treatment leiomyoma clinical trial phase ,
Rilotumumab,rilotumumab investigated treatment cancer lung cancer solid tumor gastric cancer prostate cancer among others ,
Tesevatinib,tesevatinib used trial studying treatment cancer stomach cancer brain metastasis esophageal cancer leptomeningeal metastasis among others tesevatinib potent inhibitor multiple rtks implicated driving tumor cell proliferation tumor vascularization blood vessel formation tesevatinib inhibits egf her2 vegf rtks target currently approved cancer therapy addition tesevatinib inhibits ephb4 rtk highly expressed many human tumor play role promoting angiogenesis broad array preclinical tumor model including breast lung colon prostate cancer xl647 demonstrated potent inhibition tumor growth cause tumor regression cell culture model tesevatinib retains significant potency mutant egfrs resistant current egfr inhibitor ,
PF-04691502,pf-04691502 used trial studying treatment cancer breast neoplasm early breast cancer phase 2 advanced breast cancer phase 1b ,
TAK-448,tak-448 used trial studying treatment prostate cancer low testosterone prostatic neoplasm hypogonadotropic hypogonadism ,
Anifrolumab,anifrolumab medi-546 type 1 interferon receptor ifnar inhibiting igg1κ monoclonal antibody indicated treatment adult moderate severe systemic lupus erythematosus a237074 l34929 standard therapy systemic lupus erythematosus consists antimalarial like hydroxychloroquine glucocorticoid like dexamethasone disease modifying antirheumatic drug like methotrexate a237079 l34929 three monoclonal antibody anifrolumab rontalizumab sifalimumab target type 1 interferon pathway entered clinical trial potential treatment systemic lupus erythematosus far anifrolumab approved a237054 design early clinical trial anti-interferon treatment anifrolumab rontalizumab sifalimumab come criticism a237054 design clinical trial use different definition autoantibody positivity making comparison trial difficult trial involve large portion patient also using corticosteroid may alter patient response experimental placebo group patient population largely homogenous may increased odds success trial a237054 anifrolumab also investigated treatment scleroderma a237044 anifrolumab granted fda approval 30 july 2021 l34929 ,anifrolumab indicated treatment adult moderate severe systemic lupus erythematosus l34929 
Golvatinib,golvatinib investigated treatment platinum-resistant squamous cell carcinoma head neck ,
Glasdegib,glasdegib also known pf-04449913 small-molecule hedgehog signaling inhibitor selected group benzimidazoles early research benzimidazoles attracted large interest represented class inhibitor low molecular weight potent inhibitory activity lacking unstable functionality great lipophilicity group compound brought interest modification analysis concluded presence p-cyano urea presented good physicochemical pharmacokinetic property glasdegib developed a40310 glasdegib developed pfizer inc approved november 21 2018 fda treatment acute myeloid leukemia l11935 ,glasdegib combination cytarabine indicated treatment newly diagnosed acute myeloid leukemia adult patient 75 year old co-morbidities preclude intensive induction chemotherapy l5080 acute myeloid leukemia characterized abnormal production myeloblast red cell platelet considered cancer blood bone marrow common type acute leukemia adult l4832 
Elagolix,elagolix used trial studying basic science treatment endometriosis folliculogenesis uterine fibroid heavy uterine bleeding heavy menstrual bleeding 24 july 2018 however u.s. food drug administration fda approved abbvie 's elagolix brand name orilissa first oral gonadotropin-releasing hormone gnrh antagonist specifically developed woman moderate severe endometriosis pain f815 determined endometriosis one common gynecologic disorder united state a35868 a35869 f801 particular estimate suggest one ten woman reproductive age affected endometriosis experience debilitating pain symptom a35868 a35869 f801 moreover woman affected condition suffer six ten year visit multiple physician receiving proper diagnosis a35868 a35869 f801 subsequently orilissa elagolix approved fda priority review f815 expedited new approval give healthcare professional another valuable option treating potentially unmet need woman affected endometriosis depending specific type severity endometriosis pain ,elagolix gonadotropin-releasing hormone gnrh receptor antagonist indicated management moderate severe pain associated endometriosis fda label 
Carbon black,carbon black used trial studying atopic hypersensitivity hypersensitivity immediate ,
Elamipretide,elamipretide used trial studying treatment leber 's hereditary optic neuropathy ,
GDC-0623,gdc-0623 used trial studying treatment solid cancer ,
Placulumab,placulumab used trial studying treatment rheumatoid arthritis ,
Letaxaban,letaxaban used trial studying treatment prevention venous thromboembolism acute coronary syndrome ,
Dapaconazole,dapaconazole used trial studying treatment tinea pedis ,
Entrectinib,entrectinib tropomyosin receptor tyrosine kinase trk trka trkb trkc proto-oncogene tyrosine-protein kinase ros1 anaplastic lymphoma kinase alk inhibitor l8081 approved fda august 2019 use treatment ros1-positive metastatic non-small cell lung cancer ntrk gene fusion positive solid tumor l8207 entrectinib 's approved use meant last line therapy due accelerated approval based early trial data therapy offer benefit similar alk inhibitor alectinib ceritinib lorlatinib due wider range target a183929 ,entrectinib indicated treatment metastatic ros1-positive non-small cell lung cancer adult l8081 entrectinib also indicated adult child 12 year old treatment ntrk gene fusion-positive solid tumor metastasized surgical resection likely result severe morbidity progressed previous therapy comparable alternative therapy available 
GSK-2018682,gsk2018682 investigated treatment multiple sclerosis relapsing-remitting ,
Ocrelizumab,ocrelizumab cd20-directed cytolytic antibody indicated treatment patient primary progressive relapsing form multiple sclerosis m l42895 second-generation recombinant humanized monoclonal igg1 antibody selectively target b-cells express cd20 antigen a31739 compared non-humanized cd20 antibody rituximab ocrelizumab expected le immunogenic repeated infusion improving benefit-to-risk profile patient ms. a18875 a251745 m chronic inflammatory autoimmune disease central nervous system lead neurological disability significantly reduced quality life l1199 patient m experience episode relapse worsening function followed recovery period remission primary progressive multiple sclerosis ppms account 10-15 overall population patient m lead gradual worsening neurologic disability symptom onset often without early relapse remission a31741 developed genentech/roche ocrelizumab approved fda march 2017 market name ocrevus intravenous injection later approved health canada august 2017 making drug first available treatment ppms u canada clinical trial patient relapsing form m treatment ocrelizumab resulted reduced relapse rate reduced worsening disability compared interferon beta-1a l1199 phase 3 clinical trial patient ppms treatment ocrelizumab led lower clinical mri progression rate compared placebo a31741 ,ocrelizumab cd20-directed cytolytic antibody indicated treatment relapsing form multiple sclerosis m including clinically isolated syndrome relapsing-remitting disease active secondary progressive disease adult ocrelizumab also indicated treatment primary progressive m adult l42895 
Benznidazole,benznidazole granted accelerated approval treatment chaga disease child 2-12 year age fda august 29 2017 l939 first treatment made available united state chaga disease , use treatment chaga disease child 2-12 year age l939 
MK-0812,mk0812 used trial studying treatment relapsing-remitting multiple sclerosis ,
Oprozomib,oprozomib used trial studying treatment solid tumor multiple myeloma waldenstrom macroglobulinemia advanced hepatocellular carcinoma advanced non-central nervous system cns malignancy ,
Omarigliptin,omarigliptin used trial studying treatment type 2 diabetes mellitus chronic renal insufficiency ,
PF-03463275,pf-03463275 used trial studying treatment schizophrenia cognitive impairment associated schizophrenia ,
Diacerein,diacerein prodrug metabolized rhein currently approved france treatment osteoarthritis although use diacerein restricted due side effect including severe diarrhea l780 diacerein investigation treatment insulin resistance diabetes mellitus type 2 diabetes-related complication , treatment osteoarthritis affecting hip knee l780 
Avatrombopag,"avatrombopag _doptelet_ orally administered small-molecule thrombopoietin receptor c-mpl agonist increase platelet number platelet activation a33097 l2824 decrease need blood transfusion l2824 patient thrombocytopenia chronic liver disease leading thrombocytopenia often require platelet transfusion surgical procedure decrease risk bleeding a33095 thrombocytopenia decreased number platelet common complication patient suffering chronic liver disease either immediate result liver disease consequence interferon-based antiviral therapy f95 avatrombopag approved fda may 21 2018 thrombocytopenia low platelet adult chronic liver disease scheduled undergo procedure l2931 administered orally _avatrombopag maleate_ salt form l2927 _doptelet_ avatrombopag first orally administered treatment option patient chronic liver disease allowing large population patient avoid platelet transfusion procedure increasing platelet count optimal level greater equal 50,000 per microliter l2932 ",indicated treatment thrombocytopenia adult patient chronic liver disease scheduled undergo procedure fda label 
Thymopentin,thymopentin used trial studying treatment prevention hiv infection hepatocellular carcinoma ,
Interleukin-7,interleukin 7 used trial studying treatment metastatic breast cancer ,
Sorivudine,sorivudine used trial studying treatment chickenpox hiv infection ,
Vosaroxin,vosaroxin investigation treatment leukemia myeloid acute ,
Apabetalone,apabetalone investigated treatment diabetes atherosclerosis coronary artery disease ,
Abemaciclib,abemaciclib antitumor agent dual inhibitor cyclin-dependent kinase 4 cdk4 6 cdk6 involved cell cycle promotion cancer cell growth case unregulated activity september 28 2017 fda granted approval abemaciclib treatment market name verzenio treatment hr-positive her2-negative advanced metastatic breast cancer progressed unsuccessful endocrine therapy either given alone patient undergone endocrine therapy chemotherapy metastasis cancer combination db00947 following oral treatment patient hr-positive her2-negative breast cancer abemaciclib demonstrated increased progression-free survival rate objective response rate abemaciclib used trial studying treatment melanoma lymphoma neoplasm solid tumor glioblastoma , indicated combination fulvestrant treatment woman hormone receptor hr -positive human epidermal growth factor receptor 2 her2 -negative advanced metastatic breast cancer disease progression following endocrine therapy inidicated monotherapy treatment adult patient hr-positive her2-negative advanced metastatic breast cancer disease progression following endocrine therapy prior chemotherapy metastatic setting 
AZD-4818,azd4818 used trial studying treatment chronic obstructive pulmonary disease copd ,
Thymosin beta-4,thymosin beta 4 investigated treatment stemi dry eye diabetes pressure ulcer dry eye syndrome among others ,
Briciclib,briciclib used trial studying treatment lymphoma neoplasm advanced solid tumor acute lymphocytic leukemia ,
Nirogacestat,nirogacestat used trial studying treatment breast cancer hiv infection desmoid tumor advanced solid tumor aggressive fibromatosis among others ,
Osugacestat,osugacestat bms-906024 used trial studying treatment cancer lymphoblastic leukemia acute t-cell precursor t-cell lymphoblastic lymphoma ,
Isoflavone,isoflavone soy phytoestrogen biologically active component several agriculturally important legume soy peanut green pea chick pea alfalfa a33103 soybean exceptionally rich source dietary isoflavones average isoflavone content 1-2 mg/gram a33103 main soy isoflavones mostly present glycosylated form include db01645 db13182 glycitein account approximately 50 40 10 respectively total soybean isoflavone content a33098 clinical benefit soy protein studied demonstrated many year evidence soy product associated reduced incidence coronary heart disease atherosclerosis type ii diabetes mellitus breast prostate cancer a33099 existing data consistent inadequate supporting suggested health benefit consuming soy protein isoflavones a33099 trial investigating isoflavone potential treatment atrophy menopause postmenopausal symptom ongoing isoflavone found one constituent oral over-the-counter dietary supplement indicated improved bone mass density body fat regulation ,indicated over-the-counter use dietary supplement increasing bone density regulating blood fat 
Prexasertib,prexasertib used trial studying treatment basic science mcrpc leukemia neoplasm breast cancer ovarian cancer among others ,
GW-406381,gw-406381 used trial studying treatment pain trauma neurodynia dental pain hyperalgesia among others ,
Fostamatinib,fostamatinib investigated treatment basic science rheumatoid arthritis immune thrombocytopenic purpura itp approved april 17 2018 trade name tavalisse use itp l2644 fda label fostamatinib also granted orphan drug status fda l2644 recently fostamatinib identified potential therapeutic controlling acute respiratory distress syndrome ards patient severe covid-19 ability modulate syk kinase a235008 a235013 a235018 ,fostamatinib indicated use treatment chronic immune thrombocytopenia itp patient insufficient response previous therapy fda label 
Fevipiprant,fevipiprant used trial studying treatment asthma atopic dermatitis allergic rhinitis ,
PF-04457845,pf-04457845 investigation fear conditioning pf-04457845 investigated treatment tourette syndrome cannabis dependence ,
Axelopran,axelopran used trial studying treatment oic opioid-induced constipation ,
Ozoralizumab,ozoralizumab used trial studying treatment rheumatoid arthritis active rheumatoid arthritis ,
Alpelisib,alpelisib phosphatidylinositol 3-kinase pi3k inhibitor potent antitumor activity work selectively inhibiting class pi3k p110α a179203 catalytic subunit pi3k lipid kinase play role various biological process including proliferation survival differentiation metabolism alpelisib designed target enzyme appears mutated rate nearly 30 human cancer leading hyperactivation a179209 several isoform-specific pi3k inhibitor clinical development currently approved idelalisib used chronic lymphocytic leukemia cll a179209 approved fda may 2019 alpelisib first approved pi3k inhibitor indicated treatment hormone receptor hr -positive human epidermal growth factor receptor 2 her2 -negative pik3ca-mutated advanced metastatic breast cancer combination fulvestrant postmenopausal woman male patient initiate alpelisib therapy required presence pik3ca mutation tissue and/or liquid biopsy sample collection confirmed via fda-approved diagnostic test alpelisib marketed trade name piqray available oral tablet study evaluating therapeutic effectiveness alpelisib cancer ovarian cancer a179200 colorectal cancer a179203 ongoing investigation alpelisib granted fda approval 24 may 2019 l6652 april 2022 fda granted use alpelisib treatment pik3ca-related overgrowth spectrum pro adult child require systemic therapy l41384 ,alpelisib indicated combination fulvestrant treat postmenopausal woman men advanced metastatic breast cancer cancer must hormone receptor hr -positive human epidermal growth factor receptor 2 her2 -negative pik3ca­ mutated cancer must detected fda-approved test following progression endocrine-based regimen l6652 alpelisib also used treat adult pediatric patient two year age older severe manifestation pik3ca-related overgrowth spectrum pro require systemic therapy indication approved accelerated approval based response rate duration response continued approval indication may contingent upon verification description clinical benefit confirmatory trial l41384 
Ponesimod,ponesimod selective sphingosine 1-phosphate receptor 1 modulator indicated treatment relapsing form multiple sclerosis adult a232079 l32709 ponesimod developed need selective modulator sphingosine 1-phosphate receptor 1 fingolimod a232079 fingolimod 's activity sphingosine 1-phosphate receptor 3 suspected responsible portion 's adverse effect selective modulators developed a232079 ponesimod granted fda approval 18 march 2021 l32709 ,ponesimod indicated treat adult relapsing form multiple sclerosis including clinically isolated syndrome relapsing-remitting disease active secondary progressive disease l32709 
Ozagrel,ozagrel used trial studying treatment dry eye syndrome ,
Ulocuplumab,ulocuplumab investigation solid tumor ,
Tesetaxel,tesetaxel used trial studying treatment cancer melanoma prostate cancer gastric carcinoma advanced melanoma among others ,
Tecovirimat, world health organization declared smallpox contagious sometimes fatal infectious disease eradicated 1980 however longstanding concern smallpox may used bioweapon a35133 l3614 tecovirimat antiviral drug identified via high-throughput screen 2002 a35133 effective orthopoxviruses including vaccinia cowpox ectromelia rabbitpox monkeypox variola smallpox virus a35131 a35143 tecovirimat approved fda july 2018 first drug ever approved treat smallpox l3626 l3614 tecovirimat later approved health canada december 2021 l39397 followed approval european commission january 2022 l40159 smallpox tecovirimat also indicated treat complication due replication vaccinia virus following vaccination smallpox treat monkeypox cowpox adult child l40154 tecovirimat available oral intravenous formulation l41835 ,tecovirimat inhibitor orthopoxvirus vp37 envelope wrapping protein indicated treatment human smallpox disease adult pediatric patient weighing least 3 kg efficacy tecovirimat may reduced immunocompromised patient l8531 l41835 europe also indicated treat complication due replication vaccinia virus following vaccination smallpox l40154 europe tecovirimat also used treat monkeypox cowpox adult child l40154 
Dinaciclib,dinaciclib used trial studying treatment rrmm rrcll rrdlbcl solid tumor solid neoplasm among others ,
Evatanepag,evatanepag used trial studying treatment tibial fracture ,
Benralizumab,benralizumab humanized recombinant monoclonal antibody isotype igg1k immunoglobulin specifically bind alpha chain interleukin 5 receptor il-5r expressed eosinophil basophil a31294 inhibits binding il-5 well hetero-oligomerization alpha beta subunit il-5r thus blocking signal transduction besides afucosylated igg give high affinity fcγriiiα receptor natural killer cell macrophage neutrophil a31293 benralizumab fda approved november 14 2017 developed medimmune astrazeneca 's global biologic research development arm l1019 ,benralizumab indicated maintenance treatment patient 12 year older severe asthma eosinophilic phenotype l1020 pathology severe asthma eosinophilic phenotype also denotated th2-high phenotype patient phenotype characterized expression il-5 il-13 airway hyperresponsiveness responsiveness inhaled corticosteroid high serum ige eosinophilia blood airway th2-high phenotype il-5 present central role responsible eosinophil differentiation survival activation migration lung a31295 
PF-04418948,pf 04418948 investigation clinical trial nct01002963 study investigate safety toleration single dose pf-04418948 healthy volunteer ,
Triptolide,triptolide used trial studying treatment hiv crohn 's disease intestinal disease gastrointestinal disease digestive system disease among others ,
Voxilaprevir,voxilaprevir direct-acting antiviral daa medication used part combination therapy treat chronic hepatitis c infectious liver disease caused infection hepatitis c virus hcv hcv single-stranded rna virus categorized nine distinct genotype genotype 1 common united state affecting 72 chronic hcv patient l852 voxilaprevir exerts antiviral action reversibly binding inhibiting ns3/4a serine protease hepatitis c virus hcv fda label following viral replication hcv genetic material translation single polypeptide nonstructural protein 3 ns3 activating cofactor nonstructural protein 4a ns4a responsible cleaving genetic material following structural nonstructural protein required assembly mature virus ns3 ns4a ns4b ns5a ns5b a19643 inhibiting viral protease ns3/4a voxilaprevir therefore prevents viral replication function treatment option chronic hepatitis c advanced significantly since 2011 development direct acting antiviral daas voxilaprevir voxilaprevir available since july 2017 fixed dose combination product sofosbuvir velpatasvir commercially available product vosevi vosevi approved treatment adult patient chronic hcv infection genotype 1 2 3 4 5 6 infection fda label notably vosevi approved use patient genotype 1-6 previously treated ns5a inhibitor patient genotype 1a 3 infection previously treated hcv regimen containing sofosbuvir without ns5a inhibitor l935 prior vosevi approved retreatment option patient previously received failed regimen containing ns5a inhibitor treatment chronic hcv infection ,vosevi voxilaprevir/ db08934 db11613 approved use patient genotype 1-6 previously treated ns5a inhibitor patient genotype 1a 3 infection previously treated hcv regimen containing db08934 without ns5a inhibitor l935 
Serdemetan,serdemetan used trial studying treatment neoplasm ,
Broxuridine,broxuridine used trial studying treatment leukemia stage prostate cancer stage iib prostate cancer stage iia prostate cancer ,
Chlorogenic Acid,chlorogenic acid used trial studying treatment advanced cancer impaired glucose tolerance ,
Fluorescein lisicol,fluorescein lisicol used trial studying diagnostic pharmacokinetics hepatic cirrhosis hepatitis viral human nonalcoholic steatohepatitis non-alcoholic fatty liver disease ,
Ammonio methacrylate copolymer type A,ammonio methacrylate copolymer type used trial studying treatment gerd ,
Atagabalin,atagabalin used trial studying treatment insomnia primary insomnia nonrestorative sleep ,
Gantenerumab,alzheimer 's disease ad common cause dementia elderly patient classical histopathological hallmark including extracellular amyloid-beta aβ plaque intraneuronal neurofibrillary tangle nfts classical view ad pathology posit aβ accumulation trigger tau hyperphosphorylation aggregation form nfts cause neurodegeneration large effort gone developing treatment reduce aβ aggregation remove aβ plaque a244705 a244710 treatment include related antibody aducanumab granted accelerated fda approval along bapineuzumab crenezumab donanemab lecanemab solanezumab varying stage clinical development despite clear association aβ aggregation ad treatment aimed preventing aβ aggregation removing pre-existing aβ plaque shown little clinical benefit thus far remain controversial a244705 a244710 a244745 gantenerumab fully human igg1κ monoclonal antibody derived morphosys hucal®-fab1 phage display library subsequently optimized _in vitro_ cdr cassette exchange gantenerumab bind unique aβ epitope compared anti-aβ antibody preferentially recognizes aβ oligomers fibril monomer a244720 ,
Sarecycline,sarecycline semi-synthetic derivative tetracycline initially discovered paratek pharmaceutical boston licensed warner chilcott rockaway nj july 2007 a40005 completing various phase-ii phase-iii trial demonstrating effectiveness treating moderate severe facial acne vulgaris a39993 a39994 u food drug administration approved barcelona based almirall s.a. 's seysara sarecylcine new first class narrow spectrum tetracycline derived oral antibiotic treatment inflammatory lesion non-nodular moderate severe acne vulgaris patient nine year age older l4814 seysara sarecycline originally part allergan 's u medical dermatology portfolio almirall acquired portfolio second half 2018 mean consolidating reinforcing dermatology-focused pharmaceutical company 's presence united state l4815 acne vulgaris common chronic skin condition associated blockage and/or inflammation hair follicle accompanying sebaceous gland l4814 acne often present physically mixture non-inflammatory inflammatory lesion mainly face back chest well l4814 based upon data global burden disease study acne vulgaris condition affect 85 young adult aged 12 25 year globally possibility permanent physical mental scarring resulting case severe acne l4814 subsequently number first line tetracycline therapy like doxycycline minocycline exist treating acne vulgaris sarecycline present new innovative therapy choice exhibit necessary antibacterial activity relevant pathogen cause acne vulgaris also posse low propensity resistance development pathogen narrower specific spectrum antibacterial activity resulting fewer off-target antibacterial effect endogenous intestinal flora consequently fewer resultant adverse effect associated diarrhea fungal overgrowth etc ,sarecycline tetracycline-class drug indicated treatment inflammatory lesion non-nodular moderate severe acne vulgaris patient 9 year age older fda label 
Naquotinib,naquotinib used trial studying treatment solid tumor non-small cell lung cancer non-small-cell lung cancer nsclc epidermal growth factor receptor mutation epidermal growth factor receptor egfr mutation among others ,
Vedroprevir,vedroprevir investigated treatment hepatitis c chronic ,
Ulinastatin,ulinastatin investigated prevention cardiovascular disease adverse reaction drug ,
Epicatechin,epicatechin used trial studying treatment pre-diabetes ,
2-octyl cyanoacrylate,dermabond investigated basic science wound healing ,
Mapracorat,mapracorat investigated treatment eczema atopic dermatitis ,
Ibodutant,ibodutant used trial studying treatment irritable bowel syndrome irritable bowel syndrome diarrhea ,
Sepetaprost,sepetaprost used trial studying treatment open angle-glaucoma ocular hypertension mild open angle-glaucoma oag ,
MK-0893,mk0893 used trial studying treatment type 2 diabetes mellitus diabetes mellitus type 2 ,
Mericitabine,mericitabine investigated treatment hepatitis c chronic mericitabine polymerase inhibitor developed treatment chronic hepatitis c. mericitabine prodrug psi-6130 demonstrated excellent potency preclinical study psi-6130 pyrimidine nucleoside analog inhibitor hcv rna polymerase enzyme necessary hepatitis c viral replication ,
Atopaxar,atopaxar investigated treatment coronary artery disease acute coronary syndrome ,
Ganetespib,ganetespib investigation treatment breast cancer small cell lung cancer acute myeloid leukaemia myelodysplastic syndrome ,
Savolitinib,savolitinib used trial studying treatment health service research tumor food effect gastric cancer health subject colorectal cancer among others ,
Dasolampanel etibutil,dasolampanel etibutil used trial studying treatment diabetic neuropathy painful ,
LY-3039478,ly3039478 used trial studying treatment basic science lymphoma neoplasm solid tumor colon cancer breast cancer among others ,
Setrobuvir,setrobuvir used trial studying treatment hepatitis c chronic ,
Icariin,icariin investigated basic science pharmacokinetic profile icariin human ,
Visilizumab,visilizumab investigated treatment ulcerative colitis ,
BQ-123,bq-123 investigated basic science treatment coronary artery disease aorto-coronary bypass grafting st-elevation myocardial infarction ,
MK-0767,mk0767 used trial studying treatment dyslipidemia diabetes mellitus type 2 diabetes mellitus diabetes mellitus type 2 diabetes mellitus type ii among others ,
Trebananib,trebananib investigation treatment ovarian cancer peritoneal cancer fallopian tube cancer trebananib investigated treatment cancer oncology carcinoma metastasis colon cancer among others ,
ORM-12741,orm-12741 used trial studying basic science treatment alzheimer 's disease ,
Recoflavone,recoflavone used trial studying treatment acute gastritis dry eye syndrome chronic gastritis ,
JNJ-40411813,jnj-40411813 used trial studying treatment basic science confusion schizophrenia perceptual disorder major depressive disorder ,
RRx-001,rrx-001 used trial studying treatment lymphoma brain metastasis cholangiocarcinoma colorectal neoplasm malignant solid tumor among others ,
Pardoprunox,pardoprunox used trial studying treatment early stage parkinson 's disease advanced stage parkinson 's disease pardoprunox partial dopamine d2 agonist noradrenergic agonist serotonin 5-ht1a agonist property ,
Volasertib,volasertib used trial studying treatment leukemia neoplasm leukemia myeloid acute myelodysplastic syndrome leukemia monocytic acute among others ,
CERC-301,mk 0657 used trial studying treatment major depressive disorder ,
BMS-777607,bms-777607 investigated basic science malignant solid tumour ,
Radalbuvir,radalbuvir used trial studying treatment chronic hepatitis c chronic hcv infection chronic hepatitis c infection ,
Orteronel,orteronel investigated treatment prostate cancer ,
BMS-394136,bms-394136 used trial studying diagnostic heart disease ,
T-900607,t900607 used trial studying treatment liver cancer gastric cancer ,
Sovaprevir,sovaprevir investigated treatment hepatitis c chronic ,
Letermovir,letermovir recieved approval fda november 8th 2017 use prophylaxis cytomegalovirus cmv infection allogeneic hematopoietic stem cell transplant patient l1021 represents first entry new class cmv anti-infectives dna terminase complex inhibitor a31290 letermovir recieved priority orphan drug status fda currently marketed brand name prevymis l1021 , use prophylaxis cytomegalovirus cmv infection disease adult cmv-seropositive recipient allogeneic hematopoietic stem cell transplant hsct fda label 
Vabicaserin,vabicaserin used trial studying health service research treatment schizophrenia ,
Orantinib,orantinib used trial studying treatment lung cancer breast cancer kidney cancer gastric cancer prostate cancer among others ,
Albaconazole,albaconazole used trial studying basic science onychomycosis ,
Censavudine,censavudine used trial studying treatment hiv-1 infection ,
Nagrestipen,nagrestipen used trial studying treatment cancer neoplasm metastasis radiation oncology neoplasm metastasis ,
Surotomycin,surotomycin used trial studying treatment diarrhea clostridium difficile infection benzenebutanoic acid derivative patented cubist pharmaceutical inc. antibacterial agent treatment gram-positive infection surotomycin fourfold greater vitro potency vancomycin c. difficile gram-positive bacteria minimal impact gram-negative organism intestinal microbiota surotomycin given orally shown highly effective initial relapsing hamster clostridium difficile-associated diarrhea potency similar vancomycin surotomycin non-inferior vancomycin offer promising alternative treatment prevention c. diff infection ,
Urelumab,urelumab used trial studying treatment leukemia multiple myeloma malignant tumor cancer solid tumor b-cell non-hodgkin 's lymphoma urelumab fully human antibody target cd137 antibody product developed using medarex 's ultimab r technology first ultimab- derived antibody clinical development bristol-myers squibb december 2003 agreement medarex ,
Enobosarm,enobosarm used trial studying treatment stress urinary incontinence triple negative breast cancer ,
Gefarnate,gefarnate investigated treatment prevention stomach ulcer duodenal ulcer cardio-cerebrovascular disease ,
Ritobegron,ritobegron investigation clinical trial nct02256735 study investigate effect kuc 7483 cl qt/qtc interval ecg comparison placebo moxifloxacin healthy male female volunteer ,
Anecortave,anecortave investigation clinical trial nct00691717 anecortave acetate safety patient open-angle glaucoma ocular hypertension ,
Vesnarinone,vesnarinone used trial studying treatment hiv infection sarcoma kaposi ,
Mafosfamide,mafosfamide used trial studying treatment lymphoma leukemia meningeal neoplasm brain central nervous system tumor ,
ADP-597,jnj-38431055 used trial studying treatment diabetes mellitus type 2 ,
LCL-161,lcl161 used trial studying treatment leukemia neoplasm solid tumor breast cancer ovarian cancer among others ,
Oxitropium,oxitropium investigated treatment pulmonary disease chronic obstructive ,
Vanillyl alcohol,vanillyl alcohol used trial studying treatment smoking ,
TT-232,tln 232 investigation clinical trial nct00422786 phase ii study cap-232 patient refractory metastatic renal cell carcinoma ,
Lorvotuzumab mertansine,lorvotuzumab mertansine used trial studying treatment sclc leukemia ovarian cancer multiple myeloma merkel cell carcinoma among others ,
Patritumab,patritumab used trial studying treatment lung cancer solid tumor neoplasm site head neck neoplasm non-small cell lung cancer among others ,
Gadolinium,gadolinium investigation hypertension acute kidney injury chronic kidney disease gadolinium investigated basic science cad multiple sclerosis coronary artery disease ,
Naftopidil,naftopidil investigated treatment disorder urinary stent ,
Tetrahydropalmatine,tetrahydropalmatine investigation clinical trial nct02118610 treatment schizophrenia l-tetrahydropalmatine l-thp novel dopamine antagonist anti-inflammatory antiprotozoal activity ,
Semapimod,semapimod used trial studying treatment crohn disease ,
Telotristat ethyl,telotristat ethyl prodrug telotristat approved fda march 2017 xermelo l43342 previously referred telotristat etiprate hippurate salt form however fda recommends use name neutral form rather salt a252937 a252942 currently telotristat ethyl used treat carcinoid syndrome diarrhea neuroendocrine tumor inadequately controlled short-acting somatostatin analog ssa treatment l43342 neuroendocrine cell cell secrete regulatory peptide biogenic amine response chemical neural type stimulus a252947 neuroendocrine tumor net arising cell therefore secrete chemical mediator bloodstream cause side effect distant site phenomenon called carcinoid syndrome a252947 common peptide amine secreted net histamine tachykinins kallikrein serotonin l43367 overexposure serotonin cause severe diarrhea one main clinical symptom carcinoid syndrome a252937 serotonin metabolized urinary metabolite 5-hydroxy indole acetic acid u5-hiaa high level u5-hiaa associated poor survival outcome patient net a252937 first line treatment carcinoid syndrome diarrhea ssa symptom still reoccur course disease a252937 ,xermelo indicated treatment carcinoid syndrome diarrhea combination somatostatin analog ssa therapy adult inadequately controlled ssa therapy l43342 
PF-05175157,pf-05175157 used trial studying basic science treatment acne vulgaris diabetes mellitus type 2 diabetes mellitus diabetes mellitus type 2 diabetes mellitus type 2 among others ,
Mannitol busulfan,mm used trial studying treatment cocaine dependence diabetes mellitus type 2 ,
L-Baclofen,l-baclofen used trial studying treatment trigeminal neuralgia ,
"UK-396,082","uk-396,082 used trial studying basic science safety phase 1 toleration multiple dose pharmacokinetic ",
Abediterol,abediterol used trial studying treatment asthma chronic obstructive pulmonary disease copd chronic obstructive pulmonary disease copd asthma ,
Iberdomide,iberdomide cc-220 used trial studying treatment systemic lupus erythematosus ,
Fulranumab,fulranumab used trial studying treatment pain cystitis neuralgia joint pain arthralgia among others ,
Tarextumab,tarextumab used trial studying treatment solid tumor stage iv pancreatic cancer stage iv small cell lung cancer ,
Imagabalin,imagabalin investigated generalized anxiety disorder ,
PF-06305591,pf 06305591 investigation clinical trial nct01776619 safety tolerability study multiple dos pf-06305591 ,
Vaborbactam,vaborbactam β-lactamase inhibitor based cyclic boronic acid pharmacophore a32053 used trial investigating treatment bacterial infection subject varying degree renal insufficiency august 2017 combination antibacterial therapy market name vabomere approved fda treatment adult patient complicated urinary tract infection cuti vabomere consists vaborbactam meropenem intravenous administration vaborbactam added therapy reduce extent meropenem degradation inhibiting serine beta-lactamase expressed microorganism target label treatment aim resolve infection-related symptom cuti achieve negative urine culture infection proven strongly suspected caused susceptible bacteria ,indicated combination meropenem treatment patient 18 year age older complicated urinary tract infection cuti including pyelonephritis caused following susceptible microorganism _escherichia coli_ _klebsiella pneumoniae_ _enterobacter cloacae_ specie complex fda label 
Taselisib,taselisib used trial studying treatment basic science lymphoma breast cancer ovarian cancer solid neoplasm her2/neu negative among others ,
Devimistat,devimistat cpi-613 used trial studying treatment cancer lymphoma solid tumor advanced cancer pancreatic cancer among others ,
m-Chlorophenylpiperazine,m-chlorophenylpiperazine used trial studying treatment alcoholism ,
MK-212,mk-212 used trial studying treatment alcoholism ,
Zuretinol acetate,zuretinol acetate used trial studying treatment impaired dark adaptation rp retinitis pigmentosa retinitis pigmentosa rp lca leber congenital amaurosis ,
CE-224535,ce-224535 used trial studying treatment osteoarthritis ,
Poziotinib,poziotinib used trial studying treatment breast cancer metastatic breast cancer increased drug resistance adenocarcinoma lung stage iv adenocarcinoma lung stage iiib among others ,
AZD-9164,azd9164 used trial studying basic science treatment chronic obstructive pulmonary disease ,
Epigallocatechin gallate,epigallocatechin gallate investigated treatment hypertension diabetic nephropathy ,
Mitometh,mitometh investigation treatment adenocarcinoma oropharyngeal neoplasm nasopharyngeal carcinoma non-small cell lung cancer stage iv non-small cell lung cancer among others mitometh investigated treatment lung neoplasm untreated childhood medulloblastoma untreated childhood supratentorial primitive neuroectodermal tumor ,
Sotatercept,sotatercept used trial studying supportive care treatment anemia leukemia solid tumor bladder cancer multiple myeloma among others ,
Gevokizumab,gevokizumab used trial studying treatment acne vulgaris osteoarthritis behcet 's uveitis pyoderma gangrenosum behcet 's disease uveitis among others gevokizumab act modulator cytokine imbalance il-1 mediated disease state high binding affinity 300fm block activation il-1 receptor ,
Avoralstat,avoralstat used trial studying prevention hae hereditary angioedema ,
Entospletinib,entospletinib used trial studying treatment oncology follicular lymphoma b-cell malignancy mantle cell lymphoma non-hodgkin lymphoma among others ,
Figopitant,figopitant investigation clinical trial nct02209714 safety tolerability pharmacodynamics oral administration biif 1149 b healthy male volunteer ,
Cinepazide,cinepazide used trial studying treatment ischemic stroke ,
Namitecan,namitecan used trial studying treatment solid tumor ,
Dianicline,dianicline used trial studying treatment smoking smoking cessation tobacco use cessation ,
Bradykinin,bradykinin investigated basic science treatment hypertension diabetes type 2 ,
Sultamicillin,sultamicillin used trial studying prevention treatment ventilator associated pneumonia chronic obstructive pulmonary disease copd ,
Ulimorelin,ulimorelin novel small molecule ghrelin agonist developed tranzyme pharma first-in-class treatment poi diabetic gastroparesis serious medical condition motility gi tract severely impaired ,
Tideglusib,tideglusib investigation development treatment alzheimer 's disease progressive supranuclear palsy reported potent anti-inflammatory neuroprotective non-atp competitive inhibitor glycogen synthase kinase 3 gsk-3 a31601 tideglusib developed spanish pharmaceutic company zeltia group current status withdrawn treatment alzheimer 's disease 2012 ,tideglusib initially formulated treatment alzheimer progressive supranuclear palsy a31601 raising interest use tideglusib come significant upregulation gsk-3 brain patient alzheimer disease function degradant β-catenin also important prevents transcription cell survival gene factor directed current research towards kinase potential target a31603 alzheimer disease prevalent form dementia accepted hypothesis explain disease related presence amyloid β trigger cascade alter tau protein provoke synaptic dysfunction neuronal death a31605 gsk-3 importance tissue repair pathway also pointed novel application tideglusib thus also research natural repair treatment deep caries lesion a31602 
Lorlatinib,lorlatinib third-generation alk tyrosine kinase inhibitor tki patient alk-positive metastatic non-small cell lung cancer l39905 first approved u fda november 2018 subsequently approved ema 2019 treatment select patient previously treated advanced alk-positive non-small cell lung cancer followed expanded approval 2022 include lorlatinib first-line treatment option advanced alk-positive nsclc l13580 ,lorlatinib indicated treatment adult patient alk-positive metastatic non-small cell lung cancer nsclc l39905 eu indicated treatment adult patient alk-positive advanced nsclc previously treated alk inhibitor whose disease progressed using either alectinib ceritinib crizotinib least one alk inhibitor l13580 
Vinpocetine,vinpocetine investigated treatment epilepsy ,
Vanutide cridificar,vanutide cridificar investigated treatment alzheimer disease ,
BLXA4,blxa4 used trial studying treatment gingival inflammation ,
Gepotidacin,gepotidacin used trial studying treatment gonorrhea infection bacterial infection respiratory tract ,
Elubrixin,elubrixin used trial studying treatment cystic fibrosis colitis ulcerative chronic obstructive pulmonary disease copd ,
Solnatide,solnatide used trial studying treatment acute lung injury ,
GSK-256066,gsk256066 used trial studying treatment diagnostic sar asthma mild asthma allergic rhinitis seasonal allergic rhinitis among others ,
PF-03715455,pf-03715455 used trial studying treatment asthma pulmonary disease chronic obstructive chronic obstructive pulmonary disease copd ,
Alisporivir,alisporivir used trial studying treatment hepatitis c chronic hepatitis c ,
Dilmapimod,dilmapimod used trial studying treatment diagnostic nerve trauma inflammation pain neuropathic arthritis rheumatoid coronary heart disease among others dilmapimod sb-681323 p38 map-kinase inhibitor potential us inflammatory condition ra rheumatoid arthritis previous p38 map-kinase inhibitor hindered development liver toxicity methotrexate common treatment ra patient also potential liver toxicity ,dilmapimod used trial studying treatment diagnostic nerve trauma inflammation pain neuropathic arthritis rheumatoid coronary heart disease among others 
Gilteritinib,gilteritinib also known asp2215 small molecule part flt3 tyrosine kinase inhibitor presented greater selectivity potency compared agent group a40036 pyrazinecarboxamide derivative showed high selectivity flt3 preventing c-kit -driven myelosuppression observed therapy a40044 gilteritinib developed astellas pharma fda approved november 28 2018 drug approved designed orphan drug fast track priority review status l4830 ,gilteritinib indicated treatment adult patient relapsed refractory acute myeloid leukemia flt3 mutation detected fda-approved test indication expanded companion diagnostic include use gilteritinib leukostrat cdx flt3 mutation assay l4830 acute myeloid leukemia cancer impact blood bone marrow rapid progression condition produce low number normal blood cell requirement continuous need transfusion l4832 
Duligotuzumab,duligotuzumab used trial studying treatment neoplasm colorectal cancer head neck cancer epithelial tumor malignant ,
Rezatomidine,rezatomidine used trial studying treatment fibromyalgia cystitis interstitial irritable bowel syndrome diabetic neuropathy painful ,
BMS-275183,bms-275183 used trial studying treatment tumor non-small cell lung cancer ,
AZD-0328,azd0328 used trial studying treatment basic science schizophrenia alzheimer 's disease ,
Rigosertib,rigosertib used trial studying treatment basic science md raeb cancer hepatoma neoplasm among others ,
Erdafitinib, early april 2019 u fda approved janssen pharmaceutical company brand name balversa erdafitinib first-ever fibroblast growth factor receptor fgfr kinase inhibitor indicated patient locally advanced metastatic urothelial carcinoma susceptible fgfr3 fgfr2 genetic alteration progressed following platinum-containing chemotherapy including within 12 month neoadjuvant adjuvant platinum-containing chemotherapy l5956 l5959 time fda also approved therascreen fgfr rgq rt-pcr kit qiagen utilization companion diagnostic erdafitinib selecting patient indicated therapy l5956 l5959 erdafitinib 's innovation lie fact first personalized treatment targeting susceptible fgfr genetic alteration patient metastatic bladder cancer demonstrates design erdafitinib developing personalized precision medicine capacity target cancer treatment patient 's specific genetic mutation l5956 l5959 considering urothelial cancer statistically fourth common kind cancer world f4372 introduction erdafitinib offer welcome new option ever-expanding therapeutic tool kit treat prevalent medical condition nevertheless although erdafitinib granted breakthrough therapy designation accelerated approval fda allow agency focus expedite approval process medication indicated serious condition fill unmet medical need using clinical trial data believed predict genuine clinical benefit patient given condition designation mean ongoing clinical trial necessary confirm clinical benefit erdafitinib going forward l5956 l5959 ,erdafitinib pan-fibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda label a177109 a177112 a177115 indicated treatment adult patient locally advanced metastatic urothelial carcinoma susceptible fgfr3 fgfr2 genetic alteration fda label ii progressed following least one line prior platinum-containing chemotherapy including within 12 month neoadjuvant adjuvant platinum-containing chemotherapy fda label selection patient treatment locally advanced metastatic urothelial carcinoma erdafitinib based presence susceptible fgfr genetic alteration tumor specimen detected fda-approved companion diagnostic like fda approved therascreen fgfr rgq rt-pcr kit developed qiagen fda label indication approved accelerated approval u fda based tumor response rate fda label continued approval indication may contingent upon verification description clinical benefit confirmatory trial fda label 
Menatetrenone,menatetrenone used trial studying treatment diabetes osteoporosis prediabetic state hepatocellular carcinoma ,
S-3304,s-3304 used trial studying treatment lung cancer solid tumor non small cell lung cancer stage iiib non small cell lung cancer stage iiia non small cell lung cancer among others ,
Pelubiprofen,pelubiprofen investigated treatment chronic back pain ,
Brincidofovir,brincidofovir oral antiviral drug used treatment human smallpox infection lipid conjugate pro-drug acyclic nucleotide analogue cidofovir l34404 a235725 lipid conjugate improves drug delivery target cell significantly reduces nephrotoxicity typically associated cidofovir therapy a235725 a235735 due formulation pro-drug brincidofovir also carry greater bioavailability cidofovir a235740 a235725 allowing oral administration rather intravenous cidofovir broad antiviral activity several dna virus a235725 resulting brincidofovir investigated prevention treatment cytomegalovirus cmv bk virus bkv adenovirus adv epstein-barr virus ebv amongst others brincidofovir developed chimerix brand name tembexa approved fda treatment smallpox infection june 2021 l34470 smallpox eradicated efficacy tembexa assessed animal infected virus closely related variola approval granted agency ’ animal rule l34480 allows drug approved based result well-controlled animal study human trial would unethical infeasible ,brincidofovir indicated treatment human smallpox disease adult pediatric patient l34404 
Simtuzumab,simtuzumab used trial studying treatment basic science myelofibrosis pancreatic cancer colorectal cancer idiopathic pulmonary fibrosis ,
Citicoline,citicoline donor choline biosynthesis choline-containing phosphoglycerides investigated treatment supportive care diagnosis mania stroke hypomania cocaine abuse bipolar disorder among others ,
Itacitinib,itacitinib used trial studying treatment melanoma carcinoma metastatic cancer endometrial cancer b-cell malignancy among others ,
Napabucasin,napabucasin investigated treatment colorectal carcinoma ,
Cordycepin,cordycepin used trial studying treatment leukemia ,
Fasinumab,fasinumab human igg1k monoclonal antibody targeted nerve growth factor ngf currently investigation treatment osteoarthritic pain a241045 demonstrated significantly greater pain relief functional improvement compared standard therapy i.e nsaid and/or opioids patient population a241165 ngf first discovered 1950s a241180 first neurotrophic factor identified biochemically characterized a241190 since recognized role nociceptive signaling transduction thus become attractive target treatment chronic pain condition ,
Filorexant,filorexant used trial studying prevention treatment migraine headache polysomnography diabetic neuropathy painful major depressive disorder recurrent ,
Dupilumab,dupilumab fully human monoclonal antibody immunoglobulin g4 subclass bind interleukin-4 il-4 receptor inhibiting receptor signaling pathway a180478 interleukin-4 receptor alpha antagonist dupilumab inhibits signaling pro-inflammatory cytokine called interleukin il induce inflammatory immunological reaction several atopic allergic condition eczema allergic reaction rhinosinusitis a180478 dupilumab generated recombinant dna technology chinese hamster ovary cell suspension culture l7186 dupilumab commonly marketed dupixent available formulation subcutaneous injection first approved fda 2017 currently used treat atopic dermatitis asthma add-on maintenance treatment chronic rhinosinusitis nasal polyposis eosinophilic esophagitis l41900 used monotherapy combination drug corticosteroid l7186 l7192 l41439 dupilumab currently investigation potential therapeutic use disease driven allergic reaction type 2 inflammation pediatric atopic dermatitis chronic obstructive pulmonary disease also studied combination another antibody target il-33 l7225 , u dupilumab indicated treatment patient aged six month older moderate-to-severe atopic dermatitis whose disease adequately controlled topical prescription therapy therapy advisable l42005 europe canada drug indication approved patient aged six year older l7192 l41439 europe patient six 11 year age severe atopic dermatitis candidate systemic therapy l7192 dupilumab used without topical corticosteroid condition l7186 l41439 dupilumab indicated add-on maintenance treatment patient aged six year older moderate-to-severe asthma characterized eosinophilic phenotype oral corticosteroid dependent asthma however drug indicated relief acute bronchospasm status asthmaticus l7186 l7192 l41439 dupilumab indicated add-on maintenance treatment adult patient inadequately controlled chronic rhinosinusitis nasal polyposis l7186 canada europe used intranasal corticosteroid l7192 l41439 u dupilumab also indicated treatment adult child aged 12 year older weighing least 40 kg eosinophilic esophagitis eoe l41900 adult prurigo nodularis l43297 
Bucillamine,bucillamine used trial studying treatment prevention gout rheumatoid arthritis ,
Deutetrabenazine,deutetrabenazine novel highly selective vesicular monoamine transporter 2 vmat2 inhibitor indicated management chorea associated huntington ’ disease hexahydro-dimethoxybenzoquinolizine derivative deuterated db04844 a32046 presence deuterium deutetrabenazine increase half-lives active metabolite prolongs pharmacological activity attenuating cyp2d6 metabolism compound a32046 allows le frequent dosing lower daily dose improvement tolerability a32043 decreased plasma fluctuation deutetrabenazine due attenuated metabolism may explain lower incidence adverse reaction associated deutetrabenazine a32042 deutetrabenazine racemic mixture containing rr-deutetrabenazine ss-deutetrabenazine fda label huntington 's disease hd hereditary progressive neurodegenerative disorder characterized motor dysfunction cognitive decline neuropsychiatric disturbance a32043 interfere daily functioning significantly reduce quality life prominent physical symptom hd may increase risk injury chorea involuntary sudden movement affect muscle flow randomly across body region a32046 psychomotor symptom hd chorea related hyperactive dopaminergic neurotransmission a14081 deutetrabenazine depletes level presynaptic dopamine blocking vmat2 responsible uptake dopamine synaptic vesicle monoaminergic neuron exocytotic release a14081 agent treatment neurodegenerative disease deutetrabenazine drug alleviate motor symptom hd proposed halt progression disease t28 clinical trial patient hd 12 week treatment deutetrabenazine resulted overall improvement mean total maximal chorea score motor sign placebo a32046 approved fda april 2017 marketed trade name austedo oral tablet ,deutetrabenazine indicated adult patient treatment tardive dyskinesia chorea associated huntington 's disease l36778 
HX-1171,hx 1171 investigation clinical trial nct01548391 phase clinical study study safety tolerability pharmacokinetics hx-1171 healthy male subject ,
Sarpogrelate,sarpogrelate investigated treatment diabetes mellitus diabetic nephropathy coronary artery disease renal insufficiency chronic ,
Presatovir,presatovir used trial studying treatment rsv infection respiratory syncytial virus rsv respiratory syncytial virus infection respiratory syncytial virus rsv infection ,
LY-3023414,ly3023414 used trial studying treatment neoplasm solid tumor colon cancer breast cancer advanced cancer among others ,
MK-0557,mk0557 investigated treatment schizophrenia paranoid schizophrenia ,
Tralokinumab,atopic dermatitis ad inflammatory skin disorder cause skin inflammation skin barrier dysfunction chronic pruritus a242432 estimated affect 20 adult child worldwide frequently associated atopic condition asthma allergic rhinitis ad heterogenous condition variety apparent genetic environmental cause a242422 primarily driven pro-inflammatory cytokine interleukin-13 il-13 a242427 tralokinumab fully human igg4 monoclonal antibody targeted il-13 neutralizes il-13 activity inhibiting ability bind receptor thus helping alleviate ad symptom tralokinumab first approved treatment atopic dermatitis ema june 2021 brand name adtralza leo pharma subsequently approved canada october 2021 u december 2021 l39287 l39558 ,tralokinumab indicated canada u eu treatment moderate-to-severe atopic dermatitis patient candidate systemic therapy inadequately controlled topical intervention l39282 l39558 l39287 canada u tralokinumab approved adult l39287 l39558 europe approved use patient 12 year age older l39282 
Veledimex,veledimex used trial studying treatment glioblastoma multiforme metastatic breast cancer anaplastic oligoastrocytoma ,
ATU-027,atu027 used trial studying treatment advanced solid tumor ,
Nimorazole,nimorazole used trial studying treatment hypoxia radiotherapy hypoxic modification gene profile gene signature head neck squamous cell carcinoma among others ,
Diphencyprone,diphencyprone used trial studying treatment basic science melanoma ultraviolet ray immunosuppression neoplasm metastasis hypersensitivity delayed among others ,
CUDC-101,cudc-101 used trial studying treatment cancer tumor liver cancer breast cancer gastric cancer among others ,
Tricaprylin,tricaprilin used trial studying supportive care treatment alzheimer 's disease ,
Eplivanserin,eplivanserin used trial studying treatment sleep insomnia chronic pain fibromyalgia primary insomnia among others ,
Telinavir,telinavir used trial studying treatment hiv infection ,
Secoisolariciresinol,secoisolariciresinol used trial studying prevention breast cancer ,
Apitolisib,apitolisib used trial studying treatment solid cancer breast cancer prostate cancer renal cell carcinoma endometrial carcinoma among others ,
Dalcetrapib,dalcetrapib investigation treatment acute coronary syndrome ,
Binetrakin,binetrakin used trial studying treatment hiv infection sarcoma kaposi non-hodgkin 's lymphoma nhl myelodysplastic syndrome md leukemia acute myelogenous aml among others ,
Sapitinib,sapitinib used trial studying treatment basic science neoplasm breast cancer breast neoplasm metastatic cancer metastatic breast cancer among others ,
Gepirone,gepirone used trial studying treatment cocaine-related disorder ,
Exatecan,exatecan used trial studying treatment sarcoma leukemia lymphoma lung cancer liver cancer among others ,
SRT-2104,srt2104 investigated basic science treatment sepsis psoriasis atrophy muscular diabetes mellitus type 2 ,
Abacavir hydroxyacetate,prurisol investigation treatment chronic stable plaque psoriasis prurisol investigated treatment plaque psoriasis ,
Zicronapine,zicronapine used trial studying treatment schizophrenia ,
Etrolizumab,inflammatory bowel disease ibd including ulcerative colitis crohn 's disease typified chronic gastrointestinal inflammatory microenvironment driven part excessive infiltration retention intestinal-homing lymphocyte a244564 a244569 a244579 a244584 recent class drug designed impair lymphocyte homing so-called `` anti-trafficking agent '' atas shown success include approved drug natalizumab vedolizumab target integrins impair interaction adhesion molecule epithelial cell a244574 case natalizumab target α4 integrin subunit also resulted undesirable blockade lymphocyte cns trafficking reported case progressive multifocal leukoencephalopathy pml a244564 a244584 etrolizumab humanized igg1κ monoclonal antibody directed β7 subunit gastrointestinal α4β7 αeβ7 integrins due target specificity appears efficacious vedolizumab without cns effect natalizumab a244564 a244569 a244574 a244584 etrolizumab currently investigation treatment ulcerative colitis crohn 's disease ,
Faropenem,faropenem used trial studying treatment tuberculosis pulmonary tuberculosis community acquired pneumonia ,
Obatoclax,obatoclax used trial studying treatment aml leukemia myelofibrosis hodgkin 's lymphoma mantle-cell lymphoma among others ,
Emeramide,emeramide used trial studying treatment mercury poisoning ,
Ajulemic acid,ajulemic acid used trial studying treatment cystic fibrosis dermatomyositis diffuse cutaneous systemic sclerosis ,
Atamestane,atamestane used trial studying treatment breast cancer breast neoplasm neoplasm hormone-dependent ,
VP-14637,mdt-637 investigated treatment drug safety ,
CP-866087,"cp-866,087 used trial studying treatment obesity alcoholism sexual dysfunction physiological ",
Auriclosene,auriclosene used trial studying treatment impetigo bacterial conjunctivitis asymptomatic bacteriuria adenoviral conjunctivitis ,
Fosdagrocorat,fosdagrocorat used trial studying treatment basic science rheumatoid arthritis ,
TRV-120027,trv120027 used trial studying treatment heart failure kidney disease ,
Tivantinib,tivantinib investigated solid tumor ,
PF-03654746,pf-03654746 investigated treatment narcolepsy schizophrenia tourette 's syndrome excessive daytime sleepiness ,
Zalutumumab,zalutumumab fully human igg1 monoclonal antibody designed bind selectivity epidermal growth factor receptor egfr zalutumumab investigated treatment squamous cell cancer head neck cancer ,
Tozadenant,tozadenant investigated basic science cocaine dependence ,
Terbogrel,terbogrel used trial studying treatment hypertension pulmonary ,
Ganitumab,ganitumab used trial studying treatment colon cancer rectal cancer breast cancer breast tumor breast neoplasm among others ,
N-6022,n6022 used trial studying treatment asthma cystic fibrosis ,
Verdinexor,kpt 335 investigation clinical trial nct02431364 trial safety tolerability oral verdinexor verdinexor healthy adult ,
Iron isomaltoside 1000,iron isomaltoside 1000 investigation iron deficiency anaemia iron isomaltoside 1000 investigated treatment basic science anemia gastric cancer esophageal cancer chronic kidney disease anemia iron-deficiency among others ,
Tirasemtiv,tirasemtiv used trial studying treatment myasthenia gravis intermittent claudication amyotrophic lateral sclerosis ,
AZD-6280,azd6280 used trial studying basic science anxiety ,
PSI-697,psi-697 used trial studying treatment scleritis ,
Landiolol,landiolol rapid-acting beta-blocker used rapid ventricular rate control ,
Etaracizumab,etaracizumab investigated treatment psoriasis renal cell carcinoma stage iv renal cell cancer recurrent renal cell cancer stage iii renal cell cancer ,
Luseogliflozin,luseogliflozin used trial studying treatment diabetes melltius type 2 ,
Bergapten,bergapten investigation clinical trial nct00533195 comparison uva1 phototherapy versus photochemotherapy patient severe generalized atopic dermatitis ,
Capivasertib,capivasertib investigated treatment metastatic breast cancer ,
GSK-424887,gsk424887 used trial studying basic science treatment depressive disorder anxiety disorder ,
ORG-25935,org 25935 used trial studying treatment alcoholism schizophrenia panic disorder ,
Canrenone,canrenone used trial studying diagnostic heart failure ,
Lurtotecan,lurtotecan investigation clinical trial nct00022594 liposomal lurtotecan treating patient metastatic locally recurrent head neck cancer ,
Squaric acid dibutyl ester,squaric acid dibutyl ester investigation clinical trial nct01971385 safety efficacy squaric acid dibutyl ester treatment herpes labialis ,
Oxothiazolidinecarboxylic acid,procysteine used trial studying treatment hiv infection ,
Beclabuvir,beclabuvir used trial studying treatment hepatitis c chronic ,
Terameprocol,terameprocol investigated treatment brain central nervous system tumor ,
Tetulomab tetraxetan Lu-177,betalutin used trial studying treatment non-hodgkin lymphoma relapsed diffuse large b-cell lymphoma ,
Telcagepant,telcagepant investigated treatment migraine antagonist receptor calcitonin gene-related peptide cgrp primary neuropeptide involved pathophysiology migraine cgrp receptor found area central peripheral nervous system important transmission migraine pain migraine attack cgrp activates receptor facilitates transmission pain impulse ,
Cerlapirdine,cerlapirdine investigated treatment alzheimer disease ,
Bunazosin,bunazosin used trial studying treatment high blood pressure ,
Temefos,diphos used trial studying treatment plasmodium falciparum malaria ,
KRN-7000,krn7000 used trial studying treatment lung cancer chronic hepatitis c hepatitis b chronic unspecified adult solid tumor protocol specific prevention gvhd patient hematological malignancy undergoing ahsct ,
Iguratimod,iguratimod investigation rheumatoid arthritis ,
BMS-214662,bms-214662 used trial studying treatment childhood myelodysplastic syndrome refractory anemia excess blast recurrent adult acute myeloid leukemia relapsing chronic myelogenous leukemia adult acute promyelocytic leukemia m3 among others ,
Estetrol,naturally synthetically produced steroid estrogen wide range pharmaceutical us ranging hormonal contraception treatment menopausal symptom l33184 estetrol e4 native estrogen occurring naturally pregnancy synthesized plant source used contraception l33179 potent safer synthetic estrogen ethinylestradiol ee2 found 97 oral contraceptive pill reducing environmental accumulation unwanted endocrine disrupting chemical edcs often lead harmful epigenetic effect l33184 april 15 2021 mayne pharma group limited mithra pharmaceutical granted fda approval oral contraceptive estelle/nextstellis combination drospirenone estetrol estetrol first new estrogen introduced usa 50 year first approved estetrol product world combination drospirenone estetrol offer new choice favourable safety profile woman seeking contraceptive therapy l33179 canada nextstellis approved use march 2021 developed mithra marketed searchlight pharma l33209 ,estetrol indicated combination drospirenone prevention pregnancy l33174 
Bexagliflozin,bexagliflozin investigation treatment type 2 diabetes mellitus bexagliflozin investigated treatment diabetes mellitus type2 diabetes mellitus ,
GW-274150,gw274150 used trial studying treatment prevention asthma migraine migraine disorder arthritis rheumatoid ,
MK-0777,mk-0777 used trial studying treatment schizophrenia anxiety disorder generalized anxiety disorder ,
Balicatib,balicatib used trial studying treatment osteoporosis knee osteoarthritis ,
Polatuzumab vedotin,polatuzumab vedotin cd79b-directed antibody-drug conjugate delivers monomethyl auristatin e mmae anti-mitotic agent cancer cell l6658 drug consists three component humanized immunoglobulin g1 igg1 monoclonal antibody specific human cd79b polatuzumab mmae protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl mc-vc-pab covalently attache mmae polatuzumab l6658 polatuzumab vedotin granted accelerated fda approval june 10 2019 a254936 approved health canada july 9 2020 l44141 , u polatuzumab vedotin used combination bendamustine rituximab treat adult patient relapsed refractory diffuse large b-cell lymphoma otherwise specified least two prior therapy l6658 canada indication approved patient eligible autologous stem cell transplant received least one prior therapy l44141 canada polatuzumab vedotin also used combination rituximab cyclophosphamide doxorubicin prednisone r-chp treat adult patient previously untreated large b-cell lymphoma lbcl including diffuse large b-cell lymphoma dlbcl otherwise specified no high grade b-cell lymphoma epstein-barr viruspositive ebv+ dlbcl no t-cell/histiocyte rich lbcl l44141 
TAK-733,tak-733 used trial studying treatment advanced metastatic melanoma advanced nonhematologic malignancy advanced non-hematologic malignancy ,
AZD-7762,azd7762 investigated treatment cancer solid tumor advanced solid malignancy ,
Edaravone,edaravone free radical scavenger neuroprotective agent antioxidant property a254257 three tautomers a19140 edaravone work scavenge reactive oxygen specie implicated neurological disorder amyotrophic lateral sclerosis al cerebral ischemia a19140 l44007 a254257 intravenous formulation edaravone first approved japan 2001 treatment acute ischemic stroke l44007 later approved treatment amyotrophic lateral sclerosis al japan south korea 2015 followed fda approval may 2017 l41810 health canada approval october 2018 l44007 oral suspension formulation edaravone approved fda may 2022 health canada november 2022 l44017 edaravone initially granted orphan designation european medicine agency june 19 2015 l44007 regulatory review europe however drug manufacturer mitsubishi tanabe pharma withdrew marketing authorization application maa edaravone european market may 24 2019 response request made committee medicinal product human use chmp long-term study demonstrating long-term efficacy safety edaravone l44002 l44012 edaravone also investigated disorder alzheimer 's disease a19138 neuropathic pain ischemia-induced nerve injury a19139 ,edaravone indicated treatment amyotrophic lateral sclerosis al u canada l41810 l43952 also indicated treat acute ischemic stroke japan a19140 a19141 l44007 
CP-601927,"cp-601,927 used trial studying basic science treatment major depressive disorder ",
Triclabendazole,triclabendazole manufactured novartis pharmaceutical antihelminthic drug approved fda february 2019 treatment fascioliasis human fda label l5452 fascioliasis parasitic infection often caused helminth _fasciola hepatica_ also known “ common liver fluke ” “ sheep liver fluke ” _fasciola gigantica_ another helminth parasite infect human following ingestion larva contaminated water food triclabendazole previously used treatment fascioliasis livestock approved human use drug currently fda-approved drug individual fascioliasis affect 2.4 million people worldwide a174988 l5452 , drug indicated treatment fascioliasis patient aged 6 year old fda label l5452 
Inclacumab,inclacumab used trial studying treatment prevention myocardial infarction peripheral arterial disease pad coronary heart disease graft occlusion vascular ,
AZD-4547,azd4547 used trial studying treatment cancer lymphoma gastric cancer adenocarcinoma solid neoplasm among others ,
Tulobuterol,tulobuterol used trial studying treatment chronic obstructive pulmonary disease ,
Stem bromelain, primary therapeutic use stem bromelain currently formally indicated burn wound eschar debridement agent approved ema since 2012 marketed brand name nexobrid fda label bromelain belongs category protein-digesting enzyme obtained commercially fruit stem pineapple a27198 although fruit stem bromelain prepared differently contain different enzymatic composition general term bromelain typically refers stem bromelain a27198 bromelain consequently composite mixture several different endopeptidases facilitate many different reaction many different substrate action allows bromelain demonstrate wide range therapeutic benefit ranging cardiovascular anticancer therapy specific mechanism action elicit effect currently properly understood , primary medical purpose stem bromelain sb currently indicated removal eschar adult deep partial- full-thickness thermal burn fda label besides official indication however also believed sb may used treatment several purpose well including cardiovascular health osteoarthritis autoimmunity blood clotting diarrhea cancer surgery debridement although specific mechanism action indication remain elucidated a27198 
Cixutumumab,cixutumumab used trial studying treatment lung cancer malignant neoplasm leukemia mast-cell non-small-cell lung carcinoma adenocarcinoma prostate cixutumumab highly specific recombinant human monoclonal antibody high affinity insulin-like growth factor-i receptor igf-ir igf-ir overexpressed variety tumour type ,
Moxaverine,moxaverine investigated treatment retina ocular physiology regional blood flow ,
PG-701,hydroxytriptolide investigated treatment rheumatoid arthritis ,
GDC-0810,arn-810 used trial studying basic science treatment breast cancer ,
ABT-751,abt-751 investigated treatment lung cancer non-small cell lung cancer non-small-cell lung cancer ,
Vadadustat,one common symptom advanced renal disease anemia caused primarily inability kidney respond anemic condition corresponding increase erythropoietin epo production a244165 treatment anemia chronic kidney disease ckd traditionally involved administration exogenous erythropoiesis-stimulating agent esas darbepoetin alfa counter decrease endogenous epo production efficacious overuse esas associated cardiovascular complication progression ckd increase overall mortality a244165 relatively new alternative treatment option patient anemia ckd small molecule inhibitor hypoxia-inducible factor prolyl-hydroxylase hif-ph agent inhibit prolyl-hydroxylase domain oxygen sensor essentially mimic hypoxic condition activates hypoxia-inducible factor transcription factor serf multitude role including stimulation erythropoiesis a244165 vadadustat orally administered inhibitor hypoxia-inducible factor prolyl-hydroxylase hif-ph currently approved japan l39610 treatment anemia due ckd dialysis-dependent non-dialysis dependent adult patient currently awaiting regulatory decision fda indication safety efficacy vadadustat shown non-inferior darbepoetin alfa patient anemia ckd undergoing dialysis a244145 a244155 meet prespecified noninferiority criterion cardiovascular safety similar study patient non-dialysis-dependent ckd a244150 ,
Bamosiran,bamosiran used trial studying treatment glaucoma ocular hypertension open angle glaucoma ,
Platinum,platinum investigation treatment metastatic breast cancer non-small cell lung cancer gastric large cell neuroendocrine carcinoma colorectal large cell neuroendocrine carcinoma pancreatic large cell neuroendocrine carcinoma among others platinum investigated treatment supportive care ovarian cancer fallopian tube cancer peritoneal primary cancer non small cell lung cancer primary peritoneal carcinoma among others ,
Abicipar Pegol,abicipar pegol used trial studying treatment macular edema macular degeneration ,
CG-200745,cg200745 used trial studying treatment solid tumour ,
Radiprodil,radiprodil used trial studying treatment infantile spasm diabetic peripheral neuropathic pain ,
Ascrinvacumab,ascrinvacumab used trial studying treatment basic science neoplasm advanced solid tumor carcinoma hepatocellular malignant pleural mesothelioma ,
CRS-3123,crs3123 used trial studying treatment clostridial infection clostridium difficile colitis ,
Begacestat,begacestat used trial studying treatment basic science alzheimer disease ,
Atevirdine,atevirdine used trial studying treatment hiv infection ,
Fexinidazole,"human african trypanosomiasis hat also colloquially referred sleeping sickness caused _t brucei gambiense_ _t brucei rhodesiense_ remains moderate risk 1/10,000 inhabitant per year endemic area despite focussed control effort transmitted bite infected tsetse fly hat biphasic first hemolymphatic stage progress second meningoencephalitic stage patient experience progressively worsening neurological symptom eventually die left untreated a237550 historical treatment option meningoencephalitic hat include melarsoprol eflornithine nifurtimox eflornithine combination therapy nect though melarsoprol highly toxic treatment requires lengthy infusion difficult administer resource-limited setting a237550 a237560 fexinidazole originally developed 1970s/80s hoechst ag subsequently rediscovered drug neglected disease initiative dndi 2005 first all-oral treatment first second stage hat caused _t brucei gambiense_ a237555 a237560 fexinidazole received positive opinion european medicine agency ema november 2018 approved fda july 16 2021 a237555 l35940 currently marketed sanofi-aventis l35940 ",fexinidazole nitroimidazole indicated treatment first-stage hemolymphatic second-stage meningoencephalitic _trypanosoma brucei gambiense_ human african trypanosomiasis hat patient 6 year age older weighing least 20 kg l35940 due decreased efficacy observed patient severe second stage hat cerebrospinal fluid white blood cell count csf-wbc 100 cells/μl fexinidazole used patient available treatment option l35940 
Epofolate,epofolate used trial studying treatment advanced solid tumor epofolate bms-753493 folate conjugate epothilone analog bms-748285 designed selectively target folate receptor expressing cancer cell phase i/iia pharmacokinetic safety study epofolate generally tolerable toxicity known associated epothilone class anticancer agent common although peripheral neuropathy neutropenia appear le frequent le severe compared epothilones antitumor activity demonstrated development bms-753493 discontinued ,
Brigatinib,brigatinib originally named ap26113 reversible dual inhibitor anaplastic lymphoma kinase alk epidermal growth factor receptor egfr present selectivity mutant form egfr compared wild-type a31311 also exhibit selectivity 9 different crizotinib-resistant mutant eml4-alk fusion gene pivotal player transformation susceptible lung parenchyma a31313 brigatinib developed ariad pharmaceutical subsidiary takeda pharmaceutical company limited fda-approved april 28 2017 l1026 , anaplastic lymphoma kinase positive metastatic non-small cell lung cancer alk+ nsclc represents 3-5 nsclc cancer case alk mutation overexpression presence several oncogenic fusion protein solid hematologic tumor pointed importance well potential cancer therapy target a31311 alk-related case nsclc associated presence fusion gene eml4-alk fused alk protein echinoderm microtubule-associated protein like-4 whose original function correct formation microtubule a31313 presence aberrant fusion protein result abnormal signaling provokes increased cell growth proliferation survival a31316 crizotinib indicated treatment case presence alk kinase domain mutation confer resistance treatment thus brigatinib indicated treatment patient alk+ nsclc intolerance crizotinib a31314 
Carmegliptin,carmegliptin used trial studying treatment diabetes mellitus type 2 ,
PF-06273340,pf 06273340 investigation clinical trial nct01934738 study evaluate safety toleration time course plasma concentration multiple oral dos pf-06273340 healthy subject two agegroups aged 18-55 year group 1 aged 56-75 year group 2 ,
Losmapimod,losmapimod investigated prevention chronic obstructive pulmonary disease ,
ORE-1001,ore1001 used trial studying treatment mild moderate ulcerative colitis ace2 inhibitor ,
Vidupiprant,vidupiprant used trial studying treatment basic science asthma ,
Ecopipam,ecopipam used trial studying treatment tourette 's syndrome lesch-nyhan disease pathological gambling self-injurious behavior ,
Aducanumab,aducanumab biib037 monoclonal igg1 antibody target extracellular amyloid-β plaque brain similar gantenerumab bapineuzumab solanezumab a235668 a235730 aducanumab recombinant antibody derived patient slow absent cognitive decline phase 1b clinical trial data shown patient treated aducanumab show reduction amyloid-β plaque a235668 based mini-mental state examination clinical dementia rating cdr patient taking aducanumab showed sign slowing progression however data controversial a235668 a235720 clinical trial showed 23 relative difference experimental placebo group determined cdr however equivalent absolute difference 0.4/18 a235720 although aducanumab 's approval represents first drug treatment alzheimer 's disease approval conditional result l34420 biogen enrolled patient phase 3 clinical trial 2015 increased size trial 1350 patient 1650 patient maintain statistical power face high standard deviation a235720 development aducanumab discontinued march 2019 two phase 3 clinical trial pas futility analysis however biogen sought fda approval october 2019 reanalysis data a235720 aducanumab granted accelerated fda approval 7 june 2021 l34393 continued approval based trial confirming clinical benefit currently available therapy l34420 ,aducanumab indicated treatment alzheimer 's disease l34393 
Seviteronel,seviteronel used trial studying treatment crpc prostate cancer castration-resistant prostate cancer ,
Apomine,apomine used trial studying treatment osteoporosis unspecified adult solid tumor protocol specific ,
Polihexanide,polihexanide used trial studying treatment prevention supportive care caries neoplasm skin disease nail disease dental plaque among others ,
Propiverine,propiverine widely used antimuscarinic drug mixed mode action treatment symptom associated overactive bladder oab a32576 overactive bladder oab chronic condition lower urinary tract characterized urinary urgency increased frequency urination nocturia frequent waking night urinate oab negative impact quality life may lead leakage inconvenient urinary accident l2327 l2328 overactive bladder syndrome affect million elderly individual united state show equal prevalence men woman impact oab quality life sometimes devastating especially elderly patient medical condition l2328 propiverine hydrochloride bladder detrusor muscle relaxant drug dual antimuscarinic calcium-modulating property treatment oab l2317 ,indicated symptomatic treatment urinary incontinence and/or increased urinary frequency urgency patient overactive bladder oab l2315 propiverine may also used patient neurogenic bladder result spinal cord injury a32581 
OBP-801,obp-801 used trial studying treatment solid tumor ,
AZD-5423,azd5423 used trial studying basic science treatment asthma bioavailability auc chronic obstructive pulmonary disease copd ,
Luspatercept,luspatercept recombinant fusion protein comprised modified extracellular domain activin receptor type iib fused fc domain human igg1 a187829 l42455 first approved use united state november 2019 brand name reblozyl® treatment anemia patient beta thalassemia require regular blood transfusion l42455 luspatercept novel ameliorates anemia via action late-stage erythropoiesis contrast typical erythropoiesis-stimulating agent esas darbepoetin alfa epoetin alfa act early-stage erythropoiesis a187835 luspatercept 's novel mechanism action uniquely suited treatment condition late-stage erythropoiesis defective beta thalassemia myelodysplastic disease a187835 a187838 ,luspatercept indicated treatment anemia adult beta thalassemia require regular red blood cell transfusion l42455 
Defactinib,defactinib investigated treatment malignant pleural mesothelioma ,
Balapiravir,balapiravir used trial studying treatment dengue hepatitis c chronic ,
LY-2608204,ly2608204 used trial studying treatment diabetes mellitus type 2 ,
Verubecestat,verubecestat investigation treatment alzheimer 's disease prodromal alzheimer 's disease amnestic mild cognitive impairment verubecestat merck ’ investigational oral β-site amyloid precursor protein cleaving enzyme bace1 β secretase inhibitor july 2013 merck announced positive result phase ib trial verubecestat study administration verubecestat dos 12 40 60 mg resulted dose-dependent sustained reduction level ab40 measure bace1 activity csf baseline 57 79 84 percent respectively ,
Simendan,simendan investigation clinical trial nct00527059 renal effect levosimendan patient admitted acute decompensated heart failure ,
Talsaclidine,talsaclidine used trial studying treatment alzheimer disease ,
Piromelatine,piromelatine used trial studying treatment alzheimer 's disease ,
Darexaban,darexaban used trial studying prevention basic science japanese caucasian thromboembolism pharmacodynamics pharmacokinetics among others ,
Puerarin,puerarin investigated treatment alcohol abuse ,
Tacedinaline,tacedinaline used trial studying treatment lung cancer multiple myeloma pancreatic cancer ,
Barusiban,barusiban used trial studying treatment infertility vitro fertilisation ivf treatment ,
Nefopam,nefopam investigation prevention cholecystitis post anaesthetic shivering nefopam investigated prevention kidney transplantation ,
Anrukinzumab,anrukinzumab used trial studying diagnostic asthma ,
Evodenoson,evodenoson used trial studying treatment open-angle glaucoma ocular hypertension ,
GS-5745,gs-5745 used trial studying treatment tumor breast cancer crohn 's disease colorectal cancer pancreatic cancer among others ,
GLPG-0187,glpg0187 used trial studying treatment solid tumor ,
5-(hydroxymethyl)-2-furaldehyde,aes-103 used trial studying treatment prevention hypoxia anemia sickle cell sickle cell disease ,
Bavisant,bavisant used trial studying basic science treatment alcoholism pharmacokinetics drug interaction attention deficit hyperactivity disorder attention deficit disorder hyperactivity ,
P-nitrobiphenyl,pnb used trial studying treatment pelvic organ prolapse ,
Doravirine,doravirine hiv-1 non-nucleoside reverse transcriptase inhibitor nnrti intended administered combination antiretroviral medicine l12729 l4562 doravirine available combination product doravirine 100 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg l4562 doravirine formally indicated treatment hiv-1 infection adult patient prior antiretroviral treatment experience expanding possibility choice therapeutic treatment available management hiv-1 infection l4562 ,doravirine indicated combination antiretroviral agent treatment hiv-1 infection adult patient prior antiretroviral treatment history l12729 also indicated replace current antiretroviral regimen virologically suppressed hiv-1 rna le 50 copy per ml stable antiretroviral regimen history treatment failure known substitution associated resistance doravirine l12729 
CP-724714,"cp-724,714 used trial studying treatment breast cancer breast neoplasm neoplasm metastasis ",
Motolimod,motolimod used trial studying treatment lymphoma tongue cancer ovarian cancer adult solid neoplasm fallopian tube cancer among others ,
Entolimod,entolimod used trial studying treatment mucositis tongue cancer colorectal cancer stage iva verrucous carcinoma larynx stage ivb verrucous carcinoma larynx among others ,
Dasotraline,dasotraline serotonin norepinephrine dopamine reuptake inhibitor sndri investigation treatment binge eating disorder adult attention hyperactivity disorder attention deficit hyperactivity disorder adult attention deficit hyperactivity disorder ,
Cipargamin,cipargamin used trial studying treatment malaria cure rate plasmodium falciparum malaria ,
Foretinib,foretinib used trial studying treatment cancer breast cancer carcinoma renal cell recurrent breast cancer neoplasm head neck among others foretinib orally available small molecule compound designed target multiple rtks implicated development progression spread cancer inhibits activation met ron erk akt decreased proliferation increased apoptosis ,
Eltanolone,eltanolone investigation clinical trial nct02603926 treatment fragile-x associated tremor/ataxia syndrome fxtas allopregnanolone ,
GI-181771X,gski181771 x investigation clinical trial nct00600743 effect cck-1r agonist food intake human ,
Trehalose,cabaletta used trial studying treatment oculopharyngeal muscular dystrophy ,
CP1-1189,cpi-1189 used trial studying treatment hiv infection aid dementia complex ,
ORG-25435,org 25435 used trial studying treatment anaesthesia ,
Dopexamine,dopexamine used trial studying diagnostic treatment free flap oral cancer hypotension septic shock head neck cancer ,
Chlorproguanil,chlorproguanil used trial studying treatment malaria dichloro-derivative chloroguanide ,
9CUAB30,9 cuab30 used trial studying treatment prevention her2/neu positive her2/neu negative evidence disease estrogen receptor negative estrogen receptor positive among others ,
Vanucizumab,vanucizumab used trial studying treatment colorectal cancer advanced/metastatic solid tumor ,
BMS-599626,bms-599626 used trial studying treatment cancer metastasis her2 egfr expressing advanced solid malignancy ,
Benzbromarone,benzbromarone used trial studying basic science treatment heart failure hyperuricemia chronic kidney disease abnormal renal function gout asymptomatic hyperuricemia ,
Ifetroban,ifetroban used trial studying treatment skin disease autoimmune disease pathologic process scleroderma limited scleroderma diffuse among others ,
GW-870086,gw870086x investigated treatment asthma ,
Radotinib,radotinib investigation treatment leukemia myelogenous chronic bcr-abl positive ,radotinib indicated treatment different type cancer notably philadelphia chromosome-positive ph+ chronic myeloid leukemia cml resistance intolerance bcr-abl tyrosine-kinase inhibitor patient resistant intolerant imatinib 
Idasanutlin,idasanutlin used trial studying treatment neoplasm non-hodgkin 's lymphoma leukemia myeloid acute recurrent plasma cell myeloma neoplasm leukemia acute myeloid leukemia ,
Antroquinonol,antroquinonol used trial studying treatment hyperlipidemia non-small cell lung cancer non-small cell lung cancer stage iv ,
Salvinorin A,salvinorin investigated basic science pharmaceutical preparation ,
Cantharidin,cantharidin naturally occurring odorless colorless fatty substance terpenoid class produced oral fluid alimentary canal male blister beetle a32891 a32892 natural purpose male blister beetle secretes present cantharidin female beetle copulatory gift mating post-copulation female beetle place cantharidin egg protection potential predator available synthetically since 1950s topical application cantharidin used predominantly treatment cutaneous wart since time a32891 a32892 1962 however marketer cantharidin failed produce sufficient efficacy data resulting fda revision approval cantharidin a32892 today topical cantharidin product necessarily demonstrate particular better effectiveness treating topical skin condition like wart commonly available vesicant and/or keratolytics although various study also investigated possibility using cantharidin inflammatory model cancer treatment a32892 regardless onging lack fda approval likely related certain toxic effect observed following oral ingestion includes ulceration gastrointestinal genitourinary tract along electrolyte renal function disturbance human animal a32891 , therapeutic use cantharidin currently primarily indicated active ingredient topical agent treating common wart verruca vulgaris periungual wart plantar wart molluscum contagiosum a32891 a32892 f32 time topical cantharidin application also used number off-label indication like callus removal cutaneous leishmaniasis herpes zoster acquired perforating dermatosis a32892 furthermore since topical cantharidin application commonly available 0.7 formulation potent 1 mixture 0.7 formulation commonly indicated treatment common wart periungual wart molluscum contagiosum potent 1 mixture typically limited use healthcare professional clinical setting treating plantar wart specialized off-label condition a32891 a32892 f32 moreover also study whether cantharidin could effective used inflammatory model cancer treatment either yet formally elucidate result a32892 
Eravacycline,eravacycline known _xerava_ tetraphase pharmaceutical fully synthetic fluorocycline antibiotic tetracycline class activity clinically significant gram-negative gram-positive aerobic facultative bacteria includes bacteria resistant cephalosporin fluoroquinolones β-lactam/β-lactamase inhibitor multidrug-resistant strain carbapenem-resistant enterobacteriaceae majority anaerobic pathogen a38683 first approved fda august 27 2018 l4540 eravacycline demonstrated superior potency antibiotic currently marketed intraabdominal infection a38727 ,eravacycline tetracycline class antibacterial indicated treatment complicated intra-abdominal infection patient 18 year age older fda label 
Blisibimod,blisibimod used trial studying treatment iga nephropathy microscopic polyangiitis systemic lupus erythematosus granulomatosis polyangiitis ,
Labetuzumab govitecan,labetuzumab govitecan used trial studying treatment colon cancer rectal cancer metastatic colorectal cancer ,
Rucaparib,rucaparib anticancer drug poly adp-ribose polymerase parp inhibitor parp enzyme play essential role dna repair a18745 rucaparib proposed work several parp-dependent parp-independent mechanism action however cause unique effect synthetic lethality targeting genetically-mutated cancer cell lack dna repair mechanism rucaparib cause cancer cell death reduces tumour growth a18745 a31354 rucaparib granted fda breakthrough therapy designation april 2015 a18745 accelerated approval december 2016 a249240 drug later approved european commission may 2018 l42185 currently used treat recurrent ovarian prostate cancer adult l42155 l42185 ,rucaparib indicated maintenance treatment adult patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum-based chemotherapy l42155 accelerated approval fda rucaparib also indicated treatment adult patient deleterious brca mutation germline and/or somatic -associated metastatic castration-resistant prostate cancer mcrpc treated androgen receptor-directed therapy taxane-based chemotherapy l42155 
Amcipatricin,amcipatricin used trial studying treatment cryptococcosis aspergillosis infection amcipatricin amcipatricin diascorbate spk-843 water-soluble partricin derivative patented spa societa prodotti antibiotici s.p.a. developed aparts kaken potential treatment systemic fungal infection preclinical model spk-843 show vitro inhibitory activity comparable better amphotericin b candida spp. cryptococcus neoformans aspergillus spp spk-843 exhibit dose-dependent efficacy murine pulmonary aspergillosis model spk-843 dos higher 1.0 mg/kg body weight exhibit renal toxicity tendency toward better survival prolongation estimated maximum tolerated dos amphotericin b fungizone liposomal amphotericin b ,
Milataxel,milataxel used trial studying treatment mesothelioma ,
Tanezumab,tanezumab investigated treatment osteoarthritis knee neuralgia postherpetic ,
GDC-0917,cudc-427 used trial studying treatment lymphoma solid cancer ,
N-acetylsulfanilyl chloride,asc investigated screening patient undergoing screening surveillance colonoscopy ,
Carisbamate,carisbamate investigated alcohol abuse substance abuse alcohol dependence ,
Radezolid,radezolid used trial studying treatment abscess bacterial skin disease streptococcal infection infectious skin disease staphylococcal skin infection among others ,
Navitoclax,navitoclax used trial studying treatment basic science solid tumor non-hodgkin 's lymphoma egfr activating mutation chronic lymphoid leukemia hematological malignancy among others navitoclax orally bioavailable small molecule inhibitor bcl-2 family protein substance studied treatment lymphoma type cancer block enzyme keep cancer cell dying ,
LY-2456302,ly2456302 used trial studying health service research basic science anxiety disorder alcohol dependence ,
Ensituximab,ensituximab used trial studying treatment pancreatic cancer adult metastatic colorectal cancer metastatic pancreatic cancer ,
Temocillin,temocillin investigated infection liver dysfunction urinary tract infection ,
Fezakinumab,fezakinumab used trial studying treatment atopic dermatitis rheumatoid arthritis ,
MBX-2982,mbx-2982 used trial studying treatment diabetes ,
Vatelizumab,vatelizumab used trial studying treatment ulcerative colitis ,
CG-400549,cg400549 used trial studying treatment skin infection ,
"5-amino-1,3,4-thiadiazole-2-thiol",att investigated pulmonary tuberculosis ,
Dulanermin,dulanermin used trial studying treatment colorectal cancer non-hodgkin 's lymphoma metastatic colorectal cancer ,
Rostafuroxin,rostafuroxin used trial studying treatment essential hypertension ,
Siagoside,siagoside sygen agf 2 investigated treatment parkinson disease naturally occurring substance nerve cell ’ membrane thought play role cell growth development repair siagoside completed phase 2 trial parkinson 's disease pd treatment sygen appears beneficial patient severe spinal cord injury treatment result 52 decrease mortality 48 hour induction ischemia gerbil permanent unilateral ligation common carotid artery ,
Bizelesin,bizelesin used trial studying treatment unspecified adult solid tumor protocol specific ,
Ulodesine,ulodesine used trial studying treatment gout arthritis hyperuricemia joint disease ,
Imrecoxib,imrecoxib used trial studying treatment knee osteoarthritis ,
Netazepide,netazepide used trial studying prevention treatment dyspepsia hypergastrinaemia barrett 's esophagus ecl-cell hyperplasia rebound hyperacidity among others ,
Fletikumab,fletikumab investigation clinical trial nct01038674 safety tolerability anti-il-20 subject rheumatoid arthritis ,
BMS-863233,bms-863233 investigated treatment refractory hematologic cancer ,
Enbucrilate,enbucrilate investigation clinical trial nct02468206 secondary prophylaxis gastric variceal bleed ,
BIIB021,biib021 investigated treatment tumor lymphoma ,
PF-03654764,pf-03654764 used trial studying basic science treatment allergic rhinitis ,
Piclozotan,piclozotan investigated treatment parkinson 's disease ,
Diaminopropanol tetraacetic acid,diaminohydroxypropanetetraacetic acid investigated treatment vascular disease coronary disease myocardial ischemia coronary restenosis coronary artery disease among others ,
Dusigitumab,dusigitumab used trial studying treatment cancer advanced solid malignancy unresectable metastatic hepatocellular carcinoma hcc hormone-sensitive her-2 negative metastatic breast cancer ,
Betrixaban,betrixaban non-vitamin k oral anticoagulant whose action driven competitive reversible inhibition factor xa a7708 selected among lead compound due low herg channel affinity sustaining factor xa inhibition capacity a27286 betrixaban developed portola pharmaceutical inc. prescribed venous thromboembolism vte prophylactic adult patient moderate severe restricted motility risk vte a27285 vte manifested deep vein thrombosis pulmonary embolism leading cause preventable death hospitalized patient a27287 ,betrixaban indicated prophylaxis venous thromboembolism vte condition moderate severe restricted mobility patient qualify risk vte 
Perzinfotel,perzinfotel used trial studying treatment diabetes mellitus diabetic neuropathy painful ,
Vestronidase alfa,vestronidase alfa vestronidase alfa-vjbk recombinant human lysosomal beta glucuronidase purified enzyme produced recombinant dna technology chinese hamster ovary cell line enzyme homotetramer consisted 4 monomer 629 amino acid hold amino acid sequence human beta-glucuronidase gu fda label vestronidase alfa enzyme replacement therapy treatment mucopolysaccharidosis type vii mp vii also known sly syndrome inherited rare genetic metabolic condition target small subset population mp vii progressive condition affect tissue organ due lack lysosomal enzyme called beta-glucuronidase leading buildup toxic metabolite disorder initiated skeletal abnormality including short stature along pathological condition including enlarged liver spleen heart valve abnormality narrowed airway lead lung infection trouble breathing last two condition leading cause fatality patient mp vii affected individual survive infancy others may live adolescence adulthood patient may experience developmental delay progressive intellectual disability fda label clinical trial vestronidase alfa treatment demonstrated improvement stabilization motor symptom increasing patient ability walk longer distance comparison treatment placebo patient also experienced improved pulmonary function vestronidase alfa fda-approved november 17th 2017 trade name mepsevii intravenous infusion treatment pediatric adult patient ,indicated pediatric adult patient treatment mucopolysaccharidosis vii mp vii sly syndrome 
Selurampanel,selurampanel investigated adrenocortical adenoma sarcoma endometrial stromal ,
AZD-3839,azd3839 used trial studying basic science safety tolerability alzheimer 's disease blood concentration ,
Sotrastaurin,sotrastaurin used trial studying basic science treatment uveal melanoma richter syndrome prolymphocytic leukemia recurrent mantle cell lymphoma recurrent small lymphocytic lymphoma among others ,
Ipamorelin,ipamorelin investigated treatment ileus ,
Siponimod,siponimod also known _mayzent_ novartis new drug formulated management multiple sclerosis m approved fda march 26 2019 l5792 health canada february 20 2020 l12171 drug considered _sphingosine-1-phosphate s1p receptor modulator_ thought play role suppressing central nervous system inflammation associated m fda label multiple sclerosis m autoimmune disease central nervous system chronic inflammatory disrupting communication brain part body patient diagnosed illness experience initial disease symptom age 20 40 often productive year life symptom may include limited fatigue gait change bowel bladder dysfunction abnormal muscle twitching vision disturbance depressing mood swing l5801 m one common cause neurological disability young adult found occur frequently woman men a176474 l5792 , drug indicated treatment relapsing form multiple sclerosis m include clinically isolated syndrome relapsing-remitting disease active secondary progressive disease adult fda label 
Isunakinra,isunakinra investigated treatment dry eye allergic conjunctivitis ac ,
Velmanase alfa,velmanase alfa recombinant human lysosomal alpha-mannosidase developed enzyme replacement therapy treat alpha-mannosidosis alpha-mannosidosis rare autosomal recessive lysosomal storage disorder patient alpha-mannosidosis genetic mutation cause deficiency lysosomal enzyme alpha-mannosidase enzyme responsible breaking complex sugar body resulting accumulation sugar body lead array clinical manifestation leading progressive neuromuscular skeletal deterioration skeletal abnormality motor function impairment intellectual disability respiratory dysfunction a244509 long-term enzyme replacement therapy velmanase alfa intends supplement restore function deficient alpha-mannosidase velmanase alfa amino acid sequence monomeric protein identical naturally occurring human alpha-mannosidase l39744 granted marketing authorization european commission march 2018 market name lamzede l39754 first human recombinant form alpha-mannosidase a244509 currently approved united state canada ,velmanase alfa enzyme replacement therapy treatment non-neurological manifestation patient mild moderate alpha-mannosidosis l39744 
Oglemilast,oglemilast investigated treatment pulmonary disease chronic obstructive ,
Ricolinostat,ricolinostat investigation treatment breast carcinoma metastatic breast cancer ,
Relebactam,relebactam diazabicyclooctane beta-lactamase inhibitor similar structure avibactam a181195 a181207 includes piperidine ring reduces export bacterial cell producing positive charge a181207 currently available combination product includes imipenem cilastatin treat complicated urinary tract infection utis pyelonephritis complicated intra-abdominal infection adult label considered last-line treatment option gained fda approval part combination product recarbrioⓡ july 2019 l7568 ,relebactam indicated combination imipenem cilastatin treatment complicated urinary tract infection including pyelonephritis complicated intra-abdominal infection caused susceptible organism adult label 
Apricoxib,apricoxib used trial studying treatment prevention lung cancer breast cancer pancreatic cancer non small cell lung cancer metastatic pancreatic cancer among others ,
Indirubin,indirubin investigation clinical trial nct01735864 dosage determination trial indigo naturalis extract oil ointment ,
GDC-0152,gdc-0152 used trial studying treatment solid cancer ,
Merestinib,merestinib used trial studying treatment cancer solid tumor advanced cancer colorectal cancer metastatic cancer among others ,
R-306465,r306465 used trial studying treatment neoplasm ,
Cytochlor,cytochlor used trial studying treatment head neck cancer brain central nervous system tumor ,
Silatecan,silatecan used trial studying treatment gbm tumor gliosarcoma solid malignancy glioblastoma multiforme among others ,
10-hydroxycamptothecin,10-hydroxycamptothecin investigation clinical trial nct00956787 study ar-67 db-67 myelodysplastic syndrome md ,
Bacillus calmette-guerin substrain danish 1331 live antigen,bcg ssi used trial studying tuberculosis ,
OSI-027,osi-027 used trial studying treatment solid tumor lymphoma ,
Evocalcet,evocalcet used trial studying treatment hyperparathyroidism secondary hyperparathyroidism ,
Zamicastat,zamicastat used trial studying treatment hypertension chronic heart failure ,
Seladelpar,seladelpar mbx-8025 used trial studying treatment hyperlipidemia ,
Sagopilone,sagopilone used trial studying treatment melanoma neoplasm cns disease breast cancer breast neoplasm among others so-called fully synthetic epothilone first compound clinical development combat several form cancer epothilones 16-member ring macrolides antimicrotubule activity share similar mechanism action taxanes demonstrated potent antiproliferative activity several different multidrug-resistant paclitaxel-resistant tumor cell line vitro vivo ,
Resminostat,resminostat used trial studying treatment sezary syndrome mycosis fungoides hodgkin 's lymphoma hepatocellular carcinoma lymphoma t-cell cutaneous among others ,
Fanapanel,fanapanel investigated treatment visual acuity ,
Eleclazine,eleclazine used trial studying treatment lqt2 syndrome long qt syndrome ischemic heart disease ventricular arrhythmia long qt syndrome type 3 among others ,
Esreboxetine,esreboxetine used trial studying treatment basic science fibromyalgia ,
Fresolimumab,fresolimumab used trial studying treatment primary brain tumor metastatic breast cancer diffuse systemic sclerosis pleural malignant mesothelioma primary focal segmental glomerulosclerosis ,
DSM-265,dsm265 used trial studying prevention treatment malaria ,
Naproxen etemesil,naproxen etemesil used trial studying treatment osteoarthritis ,
Polmacoxib,polmacoxib used trial studying treatment osteoarthritis osteoarthritis hip osteoarthritis knee localized primary osteoarthritis hip localized primary osteoarthritis knee ,
Voxtalisib,voxtalisib used trial studying treatment cancer melanoma lymphoma glioblastoma breast cancer among others ,
Bromperidol,bromperidol used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder among others ,
Pumosetrag,pumosetrag used trial studying gastroesophageal reflux disease ,
Samarium,samarium used trial studying treatment prevention pain cancer metastasis prostate cancer metastatic osteosarcoma among others ,
Remimazolam,remimazolam ultra short-acting benzodiazepine used induction maintenance sedation short 30 minute procedure l14647 recent trend anesthesia-related drug development touted benefit so-called `` soft drug '' agent remifentanil designed metabolically fragile thus susceptible rapid biotransformation elimination inactive metabolite a214857 `` soft drug '' useful context surgical procedure wherein rapid onset/offset desirable enabling anesthesiologist manipulate drug concentration needed a214852 a214857 remimazolam first `` soft '' benzodiazepine analog developed a214862 approved use fda july 2020 brand name byfavo l14722 ,remimazolam indicated induction maintenance procedural sedation adult undergoing procedure lasting 30 minute le l14647 
Triciribine,triciribine used trial studying treatment leukemia ovarian cancer her2/neu negative breast adenocarcinoma stage iv breast cancer among others ,
Lisofylline,lisofylline investigated treatment type 1 diabetes mellitus ,
Iobitridol,iobitridol used trial studying diagnostic diagnostic imaging coronary artery disease type 2 diabetes mellitus coronary atherosclerosis ,
PF-03635659,pf03635659 used trial studying treatment chronic obstructive pulmonary disease ,
Vatreptacog alfa,vatreptacog alfa activated used trial studying treatment haemophilia b haemophilia congenital bleeding disorder haemophilia inhibitor haemophilia b inhibitor ,
Sabarubicin,sabarubicin used trial studying treatment prostate cancer testicular germ cell tumor unspecified adult solid tumor protocol specific ,
Bemcentinib,bemcentinib investigated treatment non-small cell lung cancer ,
Gemigliptin,gemigliptin investigation type 2 diabetes mellitus gemigliptin investigated treatment cancer cisplatin adverse reaction ,
Indusatumab vedotin,indusatumab vedotin used trial studying treatment pancreatic adenocarcinoma adenocarcinoma stomach recurrent gastric adenocarcinoma metastatic gastric adenocarcinoma advanced gastrointestinal carcinoma among others ,
Usistapide,usistapide used trial studying treatment obesity overweight metabolic disease nutrition disorder nutritional metabolic disease ,
Galeterone,galeterone used trial studying treatment prostate cancer ,
VTP-27999,vtp-27999 used trial studying basic science renal function ,
Anagliptin,anagliptin investigation treatment ldl cholesterol coronary disease diabetes mellitus glycosylated hemoglobin dipeptidyl-peptidase 4 inhibitor ,
Saccharin,saccharin investigated treatment hypertension hyperglycemia ,
HSD-016,hsd 016 investigation clinical trial nct00838461 study evaluating safety pharmacokinetics pk pharmacodynamices pd hsd-016 ,
Diazepinomicin,diazepinomicin used trial studying treatment glioblastoma multiforme proprietary first-in-class small molecule potential treat multiple solid tumour like well known chemotherapeutics doxorubicin mitomycin c. diazepinomicin natural product derived non-pathogenic micro-organism discovered using thallion ’ decipher technology diazepinomicin completed preclinical study conducted national cancer institute thallion establish safety efficacy animal vitro model ,
Somavaratan,somavaratan used trial studying treatment growth disorder adult growth hormone deficiency ,
Sulforaphane,sulforaphane investigation treatment autism spectrum disorder naturally occurring isothiocyanate found high concentration variety broccoli ,
Fozivudine Tidoxil,fozivudine tidoxil used trial studying treatment hiv infection ,
MK-3207,mk3207 used trial studying treatment migraine migraine disorder ,
Liothyronine I-131,liothyronine i-131 used trial studying treatment tricuspid atresia heart defect congenital ,
Bitopertin,bitopertin used trial studying treatment schizophrenia obsessive-compulsive disorder ,
Orvepitant,orvepitant used trial studying treatment depressive disorder depressive disorder major post-traumatic stress disorder posttraumatic stress disorder ptsd ,
PAC-14028,pac-14028 used trial studying treatment skin pruritus papulopustular rosacea erythematotelangiectatic rosacea ,
CI-1040,ci-1040 used trial studying treatment lung cancer breast cancer breast neoplasm pancreatic cancer colorectal cancer among others ,
Muplestim,muplestim investigation clinical trial nct00002258 phase open label trial evaluate safety tolerance biological effect sdz ile-964 recombinant human interleukin-3 rhil-3 hiv infected patient cytopenia ,
CC-401,cc-401 used trial studying treatment myeloid leukemia ,
SCH-900271,sch 900271 used trial studying treatment mixed hyperlipidemia primary hypercholesterolemia ,
Steviolbioside,steviolbioside used trial studying treatment hiv-1 infection ,
Tipelukast,tipelukast investigation treatment ipf idiopathic pulmonary fibrosis ,
Vofopitant,vofopitant used trial studying treatment ptsd primary insomnia sleep initiation maintenance disorder ,
Filociclovir,filociclovir investigation clinical trial nct01433835 safety pharmacokinetics single oral dos filociclovir healthy volunteer ,
Ioforminol,ioforminol used trial studying diagnostic cardio renal safety high-risk elderly subject undergoing coronary cath without pci ,
Verdiperstat,verdiperstat used trial studying basic science treatment multiple system atrophy msa ,
Tavilermide,tavilermide investigated treatment dry eye syndrome ,
Alvespimycin,alvespimycin derivative geldanamycin heat shock protein hsp 90 inhibitor used trial studying treatment solid tumor various cancer antitumor agent comparison first hsp90 inhibitor tanespimycin exhibit pharmacologically desirable property reduced metabolic liability lower plasma protein binding increased water solubility higher oral bioavailability reduced hepatotoxicity superior antitumor activity a19243 ,investigated use antineoplastic agent solid tumor advanced solid tumour acute myeloid leukaemia 
Sonedenoson,sonedenoson used trial studying treatment foot ulcer diabetic diabetes complication ,
Theanine,theanine precursor ethylamine found green tea investigation clinical trial nct00291070 effect l-theanine boy adhd ,
Nitroaspirin,nitroaspirin investigated treatment intermittent claudication ,
Derenofylline,derenofylline used trial studying treatment congestive heart failure acute decompensated heart failure renal dysfunction ,
Nadifloxacin,nadifloxacin used trial studying treatment acne vulgaris ,
Lifibrol,lifibrol used trial studying basic science hyperlipoproteinemia hypercholesterolemia ,
Tempol,tempol used trial studying treatment anal cancer ,
Propyl Gallate,propyl gallate investigation clinical trial nct01450098 study ly2484595 healthy subject ,
SCY-635,scy-635 investigated treatment chronic hepatitis c hepatitis c infection ,
Caprylic alcohol,caprylic alcohol used trial studying treatment essential tremor ,
Chlorine dioxide,chlorine dioxide used trial studying treatment halitosis ,
Zalypsis,zalypsis used trial studying treatment lymphoma solid tumor ewing 's sarcoma endometrial cancer uterine cervical cancer among others ,
Omadacycline,omadacycline used trial studying treatment bacterial pneumonia bacterial infection community-acquired infection skin structure soft tissue infection omadacycline represents significant advance well-known tetracycline family shown highly effective animal model treating increasingly problematic clinically prevalent infection caused gram-positive bacteria methicillin-resistant staphylococcus aureus mrsa gram-negative atypical anaerobic bacteria including resistant currently available class antibiotic known cause disease pneumonia urinary tract infection skin disease blood-borne infection hospital community setting ,omadacycline indicated treatment community acquired bacterial pneumonia acute bacterial skin skin structure infection caused omadacycline-susceptible organism adult fda label 
Bococizumab,bococizumab used trial studying treatment prevention dyslipidemia hyperlipidemia hypercholesterolemia cardiovascular disease heterozygous familial hypercholesterolemia ,
Rimegepant,rimegepant oral antagonist cgrp receptor developed biohaven pharmaceutical l11028 received fda approval february 27 2020 acute treatment migraine headache l11974 subsequently approved european commission april 2022 treatment prevention migraine l41640 several parenteral antagonist cgrp receptor approved migraine therapy e.g erenumab fremanezumab galcanezumab rimegepant ubrogepant cgrp antagonist possessed oral bioavailability a189207 approval atogepant 2021 l38814 current standard migraine therapy involves abortive treatment `` triptans '' sumatriptan medication contraindicated patient pre-existing cerebrovascular cardiovascular disease due vasoconstrictive property a189207 antagonism cgrp pathway become attractive target migraine therapy unlike triptans oral cgrp antagonist observed vasoconstrictive property therefore safer use patient contraindication standard therapy a189330 a189207 ,rimegepant indicated acute treatment migraine without aura adult rimegepant also indicated prevention episodic migraine adult l11971 
Muscimol,muscimol used trial studying treatment epilepsy parkinson 's disease ,
Belotecan,belotecan investigated treatment epithelial ovarian cancer ,
Conbercept,conbercept investigated basic science age-related macular degeneration ,
GLPG-0492,glpg0492 investigation clinical trial nct01130818 first-in-human single ascending dose glpg0492 ,
Ralinepag,ralinepag used trial studying treatment pulmonary arterial hypertension ,
Semagacestat,semagacestat used trial studying treatment alzheimer disease ,
Bevenopran,bevenopran used trial studying treatment renal impairment opioid-induced constipation ,
Ketanserin,ketanserin investigated treatment septic shock severe sepsis diabetic foot ulcer ,
Favipiravir,discovered toyama chemical co. ltd. japan favipiravir modified pyrazine analog initially approved therapeutic use resistant case influenza a191688 a191721 antiviral target rna-dependent rna polymerase rdrp enzyme necessary transcription replication viral genome a191688 a191772 a191775 favipiravir inhibit replication influenza b drug shown promise treatment avian influenza may alternative option influenza strain resistant neuramidase inhibitor a191721 l12090 favipiravir investigated treatment life-threatening pathogen ebola virus lassa virus covid-19 a191724 a191958 a191961 , 2014 favipiravir approved japan treat case influenza unresponsive conventional treatment a191721 given efficacy targetting several strain influenza investigated country treat novel virus including ebola recently covid-19 a191688 a191724 l12012 
TU-100,tu-100 used trial studying treatment abdominal pain colonic transit crohn 's disease rectal sensation gastric emptying among others ,
Pf-04531083,pf-04531083 investigated treatment pain chronic pain ,
Dexelvucitabine,dexelvucitabine used trial studying treatment hiv infection human immunodeficiency virus ,
Ibrexafungerp,"ibrexafungerp also known scy-078 mk-3118 novel enfumafungin derivative oral triterpene antifungal approved treatment vulvovaginal candidiasis vvc also known vaginal yeast infection a235384 l34349 developed need treat fungal infection may become resistant echinocandins azole antifungal a235384 ibrexafungerp orally bioavailable compared echinocandins caspofungin micafungin anidulafungin administered parenterally a235384 a235389 similar echinocandins ibrexafungerp target fungal β-1,3-glucan synthase present human limiting chance renal hepatic toxicity a235414 l34349 ibrexafungerp granted fda approval 1 june 2021 l34349 ",ibrexafungerp indicated treatment vulvovaginal candidiasis post-menarchal patient l34349 also indicated reduction incidence recurrent vulvovaginal candidiasis l44211 
Levodropropizine,levodropropizine investigation clinical trial nct01573663 drug-drug interaction study ambroxol levodropropizine ,
Taurolidine,taurolidine investigated prevention central venous catheter home parenteral nutrition catheter-related infection ,
Lynestrenol,lynestrenol progestin prodrug norethisterone ,
Biphenyl dimethyl dicarboxylate,nissel investigated treatment chronic liver disease ,
CPG-52852,852a used trial studying treatment melanoma neoplasm breast cancer ovarian cancer cervical cancer among others ,
Perfluoro tert-butylcyclohexane,oxycyte used trial studying treatment traumatic brain injury ,
Piribedil,piribedil investigated parkinson 's disease ,
Zabofloxacin,zabofloxacin used trial studying treatment community acquired pneumonia chronic obstructive pulmonary disease ,
Betulinic Acid,betulinic acid used trial studying treatment dysplastic nevus syndrome ,
Barium,barium investigation diagnostic known suspected abdominal disease ,
Acotiamide,acotiamide used trial studying treatment dyspepsia functional dyspepsia ,
Copanlisib,"copanlisib selective pan-class phosphoinositide 3-kinase pi3k/phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase inhibitor first developed bayer healthcare pharmaceutical inc drug target enzyme play role regulating cell growth survival copanlisib granted accelerated approval september 14 2017 market name aliqopa treatment adult patient relapsed follicular lymphoma treatment history least two prior systemic therapy follicular lymphoma slow-growing type non-hodgkin lymphoma caused unregulated proliferation growth lymphocyte active ingredient aliquopa intravenous therapy copanlisib dihydrochloride ",indicated treatment adult patient relapsed follicular lymphoma fl received least two prior systemic therapy 
Tetrahydrouridine,tetrahydrouridine used trial studying treatment neoplasm lung neoplasm breast neoplasm sickle cell disease head neck cancer among others ,
Pimonidazole,pimonidazole investigation diagnostic prostate cancer head neck cancer ,
Elobixibat,elobixibat used trial studying treatment basic science dyslipidemia constipation chronic constipation functional constipation chronic idiopathic constipation ,
Promestriene,promestriene 3-propyl ethyl 17b-methyl estradiol used trial studying prevention hypospadias synthetic estrogen analog used topical estrogen therapy promestriene ’ potential treating vaginal atrophy symptom associated aromatase inhibitor treatment would precluded minimal absorption lead estrogen-like effect cell proliferation estrogen-responsive gene expression concern absorbed vaginal estrogen estrogen analog activate occult site residual breast cancer negate tumor suppressive effect aromatase inhibitor adjuvant therapy promestriene studied phase iv clinical trial improvement hormonal cytology local systemic climacteric complaint well endometrial security patient vaginitis atrophic pelvic organ prolapse endometrial hyperplasia also studied phase iii clinical trial post-operative patient hypospadias addition promestriene phase iv clinical trial study treatment patient vaginosis bacterial studied terminated ,
Mirvetuximab soravtansine,mirvetuximab soravtansine-gynx imgn853 antibody-drug conjugate adc formed monoclonal antibody m9346a target folate receptor alpha frα covalently joined cleavable disulfide linker genotoxic compound dm4 also known soravtansine ravtansine a254392 l43967 dm4 conjugated antibody drug-to-antibody ratio 3.5:1 a254387 antibody component mirvetuximab soravtansine-gynx bind frα receptor overexpressed surface epithelial tumor cell characteristic ovarian endometrial triple-negative breast non-small-cell lung cancer a254382 adc/receptor complex formed mirvetuximab soravtansine-gynx internalized dm4 released inside cell dm4 lead cell-cycle arrest apoptosis also able diffuse neighboring cell induce cell death a254382 november 2022 fda granted accelerated approval mirvetuximab soravtansine-gynx treatment adult patient frα–positive platinum-resistant epithelial ovarian fallopian tube primary peritoneal cancer received 1-3 prior systemic treatment regimen decision supported finding phase 3 soraya trial nct04296890 l43967 l43972 ,mirvetuximab soravtansine indicated treatment adult patient folate receptor alpha frα positive platinum-resistant epithelial ovarian fallopian tube primary peritoneal cancer received one three prior systemic treatment regimen patient selected therapy based fda-approved test l43967 indication approved accelerated approval based tumor response rate durability response continued approval indication may contingent upon verification description clinical benefit confirmatory trial l43967 
Forigerimod,forigerimod investigation treatment lupus erythematosus systemic ,
Fasiglifam,fasiglifam used trial studying treatment chronic kidney disease type 2 diabetes mellitus diabetes mellitus type 2 ,
Piritramide,piritramide investigation treatment colon cancer minimal residual disease piritramide investigated supportive care pain postoperative postoperative nausea vomiting ,
PD-217014,"pd-217,014 used trial studying treatment pain irritable bowel syndrome ",
SGI-1776,sgi-1776 used trial studying treatment prostate cancer non-hodgkins lymphoma relapsed/refractory leukemia ,
Selepressin,selepressin used trial studying treatment septic shock ,
Alagebrium,alagebrium investigated treatment prevention aging heart failure physical activity diabetic nephropathy cardiovascular disease among others ,
Mogamulizumab,mogamulizumab humanized monoclonal antibody mab directed cc chemokine receptor 4 ccr4 treatment mycosis fungoides mf sézary syndrome s common subtypes cutaneous t-cell lymphoma cutaneous t-cell lymphoma occur certain white blood cell called cell become cancerous cancer typically affect skin causing various type skin lesion l4170 august 8 2018 u.s. food drug administration fda approved mogamulizumab injection also known _poteligeo_ intravenous use treatment adult patient relapsed refractory mycosis fungoides mf sézary syndrome s least one prior systemic therapy l4168 approved indication canada june 2022 l42325 mogamulizumab derived kyowa hakko kirin 's potelligent ® technology produce antibody enhanced antibody-dependent cell-mediated cytotoxicity adcc activity approval japan granted april 30 2012 japanese ministry health labour welfare patient relapsed refractory ccr4-positive adult t-cell leukemia-lymphoma a36741 ,mogamulizumab indicated treatment adult patient relapsed refractory mycosis fungoides mf sézary syndrome s least one prior systemic therapy l11770 l42325 
Clascoterone,clascoterone cortexolone 17α-propionate cb-03-01 novel antagonist androgen receptor bind androgen receptor high affinity a218771 competing androgen binding androgen receptor clascoterone work blocking androgen receptor signalling cascade promote acne pathogenesis sebaceous gland proliferation excess sebum production inflammatory pathway a218846 august 2020 fda approved clascoterone first-in-class topical treatment acne acne vulgaris male female patient 12 year older l15621 clascoterone also investigated novel treatment androgenetic alopecia a218766 ,clascoterone indicated topical treatment acne vulgaris patient 12 year age older l15626 
Fedratinib,fedratinib also known sar302503 tg101348 tyrosine kinase inhibitor used treat intermediate-2 high risk primary secondary myelofibrosis a183176 l8090 anilinopyrimidine derivative a183188 fedratinib granted fda approval august 16 2019 l8090 ,fedratinib indicated treat adult primary secondary myelofibrosis either intermediate-2 high risk l8090 
ABT-384,abt-384 used trial studying treatment alzheimer 's disease ,
JNJ-40346527,jnj-40346527 used trial studying treatment health arthritis rheumatoid ,
E-7820,e7820 investigated treatment colon cancer rectal cancer ,
Fenamole,fenamole investigated supportive care side effect dental plaque ,
Atecegatran metoxil,atecegatran metoxil used trial studying basic science prevention nonvalvular atrial fibrillation persistent permanent nonvalvular atrial fibrillation persistent permanent non-valvular atrial fibrillation ,
E7107,e7107 used trial studying treatment cancer ,
Imeglimin,imeglimin used trial studying treatment type 2 diabetes mellitus ,
Ozone,ozone used trial studying treatment mild asthma primary apical periodontite ,
Imiglitazar,imiglitazar used trial studying treatment diabetes mellitus ,
Verucerfont,verucerfont used trial studying treatment congenital adrenal hyperplasia ,
Omaveloxolone,omaveloxolone used trial studying treatment relapsed refractory melanoma metastatic incurable non-small cell lung cancer ,
Iofolastat I-123,iofolastat i-123 investigation clinical trial nct00992745 phase pilot study comparing 123i mip 1072 versus 111in capromab pendetide subject metastatic prostate cancer ,
9-aminocamptothecin,aminocamptothecin used trial studying treatment lymphoma gastric cancer ovarian cancer esophageal cancer ovarian neoplasm among others ,
PF-00446687,pf-00446687 investigated treatment erectile dysfunction ,
Raclopride,raclopride used trial studying parkinson disease ,
Sarcosine,sarcosine investigated treatment schizophrenia ,
Plozalizumab,plozalizumab investigated treatment atherosclerosis plozalizumab novel humanized monoclonal antibody specifically target ccr2 chemokine receptor found surface certain white blood cell including macrophage monocyte preclinical study suggest ccr2 play important role trafficking monocyte macrophage site inflammation recruitment macrophage arterial wall believed critical step development atherosclerosis ,
Methyl pyrrolidone,n methyl pyrrolidone investigation treatment multiple myeloma ,
Toreforant,toreforant used trial studying treatment asthma psoriasis hepatic impairment rheumatoid arthritis ,
Mizolastine,mizolastine investigation clinical trial nct01928316 bioequivalence study domestic made china imported mizolastine tablet healthy volunteer ,
BI-671800,bi 671800 used trial studying treatment asthma rhinitis allergic perennial ,
Molgramostim,molgramostim used trial studying treatment bronchiectasis cystic fibrosis pulmonary alveolar proteinosis acute respiratory distress syndrome autoimmune pulmonary alveolar proteinosis ,
Batefenterol,batefenterol used trial studying treatment pulmonary disease chronic obstructive ,
Sofinicline,sofinicline used trial studying treatment adhd neuralgia diabetic diabetic neuropathy diabetic polyneuropathy diabetic neuropathic pain among others ,
Glyceryl Trierucate,glyceryl trierucate investigated treatment adrenoleukodystrophy ,
Nitrite,nitrite investigation treatment heart failure ,
Inebilizumab,inappropriate growth self-directed antibody production b-cells etiological underpinning variety condition including multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder nmosd a214283 a214286 inebilizumab humanized afucosylated monoclonal igg1 antibody directed broadly expressed b-cell surface antigen cd19 inebilizumab cytolytic resulting b-cell depletion offering therapeutic benefit patient suffering nmosd compared anti-cd20 antibody rituximab also used treat nmosd inebilizumab broader specificity a214280 a214289 a214292 a214295 a214298 a214301 inebilizumab granted fda approval june 11 2020 treatment anti-aquaporin 4 positive nmosd patient l14315 given mechanism action good safety profile may prove useful treatment condition linked autoimmune antibody production b-cell malignancy a214280 a214295 ,inebilizumab indicated treatment aquaporin-4 aqp4 immunoglobulin-positive aqp4-igg neuromyelitis optica spectrum disorder nmosd adult patient l14315 
Lobucavir,lobucavir used trial studying treatment hiv infection cytomegalovirus infection ,
Oxetacaine,oxetacaine also called oxethazaince potent surface analgesic molecular formula n n-bis- n-methyl-n-phenyl-t-butyl-acetamide -beta-hydroxyethylamine conserve unionized form low ph level action shown relieve dysphagia relieve pain due reflux chronic gastritis duodenal ulcer a33104 oxetacaine approved health canada since 1995 use antacid combination over-the-counter preparation l1113 also list approved derivative herbal product ema l2816 ,oxetacaine available over-the-counter antacid used alleviate pain associated gastritis peptic ulcer disease heartburn esophagitis hiatus hernia anorexia a33109 
Cevipabulin,cevipabulin used trial studying treatment educational/counseling/training tumor neoplasm ,
Mavrilimumab,mavrilimumab investigated treatment rheumatoid arthritis ,
AC-430,ac430 investigated treatment rheumatoid arthritis ,
N-acetylmannosamine,n-acetylmannosamine investigation gne myopathy ,
"1,2-Benzodiazepine",benzodiazepine investigation prevention delirium c.surgical procedure cardiac benzodiazepine investigated treatment obesity sleep apnea obstructive disorder gallbladder biliary tract pancrease ,
Nepadutant,nepadutant used trial studying treatment colic infantile colic infantile functional gastrointestinal disorder ,
Oltipraz,oltipraz used trial studying treatment prevention lung cancer liver fibrosis liver cirrhosis non-alcoholic fatty liver disease ,
Lecozotan,lecozotan used trial studying treatment alzheimer disease ,
SAR-405838,sar405838 used trial studying treatment neoplasm malignant ,
GSK-356278,gsk356278 used trial studying treatment basic science anxiety disorder huntington disease depressive disorder huntington disease depressive disorder major among others ,
Samidorphan, olanzapine effective atypical antipsychotic like antipsychotic associated weight gain metabolic dysfunction increased risk type ii diabetes a235638 a235643 samidorphan novel opioid antagonist structurally related naltrexone higher affinity opioid receptor potent μ-opioid receptor antagonism higher oral bioavailability longer half-life making attractive candidate oral dosing a235623 a235638 l34359 although antipsychotic-induced weight gain incompletely understood thought opioid system play key role feeding metabolism opioid antagonism may expected ameliorate negative effect samidorphan shown animal model clinical trial ameliorate olanzapine -induced weight gain metabolic dysfunction a235638 a235643 samidorphan first approved variety fixed-dose combination tablet olanzapine fda may 28 2021 currently marketed trademark lybalvi™ alkermes inc. l34359 ,samidorphan indicated combination olanzapine treatment bipolar disorder either adjunct lithium valproate monotherapy acute treatment manic mixed episode maintenance therapy treatment schizophrenia adult l34359 
Indobufen,indobufen used trial studying supportive care prevention atrial fibrillation ,
LY-2886721,ly2886721 used trial studying basic science alzheimer 's disease ,
Sparsentan,sparsentan used trial studying treatment focal segmental glomerulosclerosis sparsentan first dual-acting angiotensin endothelin receptor antagonist dara development ,
Pyrazoloacridine,pyrazoloacridine used trial studying treatment lung cancer liver cancer breast cancer melanoma skin metastatic cancer among others ,
Taladegib,taladegib used trial studying treatment solid tumor colon cancer breast cancer advanced cancer rhabdomyosarcoma among others ,
Idazoxan,idazoxan used trial studying basic science molecular imaging alzheimer disease major depressive disorder ,
Fluocinolone,fluocinolone used trial studying treatment prevention candida infection oral lichen planus macular degeneration choroidal neovascularization ,
Mebeverine,mebeverine investigated treatment irritable bowel syndrome post-cholecystectomy gastrointestinal spasm ,
Nelotanserin,nelotanserin used trial studying treatment lewy body dementia visual hallucination dementia lewy body rem sleep behavior disorder highly selective antagonist 5-ht2a serotonin receptor increase non-rem sleep restorative phase sleep cycle without sacrificing rem dream sleep nelotanserin work mechanism action different currently marketed drug ,
MK-5108,mk-5108 used trial studying treatment cancer neoplasm tumor ,
FK-614,fk614 used trial studying treatment diabetes mellitus ,
AEE-788,aee788 used trial studying treatment cancer glioblastoma multiforme brain central nervous system tumor ,
EC-17,folate fitc used trial studying diagnostic ovarian cancer ,
Blosozumab,blosozumab used trial studying basic science treatment osteoporosis osteoporosis postmenopausal ,
WNT-974,wnt974 used trial studying treatment metastatic colorectal cancer squamous cell carcinoma head neck ,
Setipiprant,setipiprant investigated treatment seasonal allergic rhinitis ,
MK-0686,mk0686 used trial studying treatment osteoarthritis pain postoperative neuralgia postherpetic ,
Gemcitabine elaidate,gemcitabine elaidate used trial studying treatment solid tumor lung cancer non-small-cell lung cancer metastatic pancreatic adenocarcinoma ,
Abexinostat,abexinostat used trial studying treatment sarcoma lymphoma leukemia lymphocytic hodgkin disease among others novel broad-spectrum hydroxamic acid-based inhibitor histone deacetylase hdac potential antineoplastic activity ,
Decernotinib,decernotinib used trial studying treatment drug interaction rheumatoid arthritis ,
Camicinal,camicinal used trial studying treatment gastroparesis ,
Tecemotide,tecemotide used trial studying treatment prostate cancer carcinoma non-small-cell lung ,
Tonapofylline,tonapofylline used trial studying treatment heart failure renal insufficiency congestive heart failure ,
Onatasertib,onatasertib cc-223 used trial studying treatment basic science multiple myeloma glioblastoma multiforme hepatocellular carcinoma non-small cell lung cancer diffuse large b-cell lymphoma among others ,
Rimacalib,rimacalib used trial studying treatment rheumatoid arthritis ra ,
Pexacerfont,pexacerfont investigated treatment alcoholism anxiety disorder alcohol dependence alcohol-related disorder ,
LY-2452473,ly2452473 investigation supportive care prostate cancer ly2452473 investigated treatment erectile dysfunction ,
LY-295501,ilx-295501 used trial studying treatment ovarian cancer metastatic cancer fallopian tube cancer primary peritoneal cavity cancer ,
Ronopterin,ronopterin used trial studying treatment traumatic brain injury ,
AZD-3043,azd3043 used trial studying treatment basic science safety sedation tolerability pharmacokinetics ,
Fosbretabulin,fosbretabulin investigated treatment anaplastic thyroid cancer ,
Lexaptepid pegol,lexaptepid pegol used trial studying treatment anemia inflammation chronic disease end stage renal disease anemia chronic disease ,
JNJ-37822681,jnj-37822681 used trial studying treatment schizophrenia ,
Tradipitant,tradipitant used trial studying treatment prevention eczema pruritus gastroparesis chronic pruritus atopic dermatitis among others ,
Ozarelix,ozarelix used trial studying treatment prostate cancer benign prostatic hypertrophy benign prostatic hyperplasia bph ,
Piperine,bioperine used trial studying treatment multiple myeloma deglutition disorder ,
Bimagrumab,bimagrumab used trial studying treatment supportive care sarcopenia skeletal muscle mechanical ventilation sporadic inclusion body myositis sporadic inclusion body myositis sibm among others ,
Ondelopran,ondelopran used trial studying treatment alcohol dependence ,
Anhydrovinblastine,anhydrovinblastine used trial studying treatment unspecified adult solid tumor protocol specific ,
Razupenem,razupenem used trial studying treatment skin infection ,
AZD-1480,azd1480 used trial studying treatment solid malignancy post-polycythaemia vera primary myelofibrosis pmf essential thrombocythaemia myelofibrosis ,
Dacetuzumab,dacetuzumab used trial studying treatment multiple myeloma non-hodgkin lymphoma leukemia lymphocytic chronic lymphoma large b-cell diffuse humanized anti-cd40 antibody induces cytotoxicity human multiple myeloma cell ,investigated use/treatment lymphoma non-hodgkin 's multiple myeloma 
Indiplon,indiplon used trial studying treatment insomnia depression ,
BMS-911543,bms-911543 used trial studying treatment cancer ,
Mosedipimod,mosedipimod used trial studying supportive care treatment chemotherapy-induced neutropenia ,
Apaziquone,apaziquone investigated treatment bladder cancer bladder neoplasm ,
AZD-9056,azd9056 used trial studying basic science treatment rheumatoid arthritis ,
Na-1,na 1 investigation clinical trial nct00728182 evaluating neuroprotection aneurysm coiling therapy ,
Combretastatin,combretastatin investigated treatment anaplastic thyroid cancer ,
Asciminib,asciminib tyrosine kinase inhibitor tki used treatment chronic-phase philadelphia chromosome-positive chronic myeloid leukemia ph+ cml specifically inhibitor abl1 kinase activity bcr-abl1 fusion protein l38995 serf driver cml proliferation patient disease l39005 also shown benefit ph+ cml t315i mutation produce mutant bcr-abl1 typically treatment-resistant compared wild-type bcr-abl1 existing inhibitor abl compete atp binding site protein classified target active conformation kinase domain dasatinib bosutinib target inactive kinase domain imatinib nilotinib ponatinib a241065 asciminib unique act allosteric inhibitor binding myristoyl pocket bcr-abl1 protein locking inactive conformation l38995 a241055 asciminib received fda approval october 29 2021 scemblix novartis ag l39000 ,asciminib indicated treatment adult patient philadelphia chromosome-positive chronic myeloid leukemia ph+ cml chronic phase previously treated ≥2 tyrosine kinase inhibitor l38995 l43493 also indicated treatment ph+ cml adult patient t315i mutation l38995 
Nafamostat,nafamostat synthetic serine protease inhibitor commonly formulated hydrochloric acid due basic property used trial studying prevention liver transplantation postreperfusion syndrome use nafamostat asian country approved anticoagulant therapy patient undergoing continuous renal replacement therapy due acute kidney injury ,used anticoagulant patient disseminative blood vessel coagulation hemorrhagic lesion hemorrhagic tendency prevents blood clot formation extracorporeal circulation patient undergoing continuous renal replacement therapy extra corporeal membrane oxygenation 
Sonolisib,sonolisib used trial studying treatment glioblastoma prostate cancer advanced solid tumor advanced braf-mutant cancer non small cell lung cancer nsclc among others ,
Pentetreotide,pentetreotide used trial studying diagnosis cushing 's syndrome ,
Sisomicin,sisomicin used trial studying treatment pyoderma ,
Etripamil,etripamil used trial studying treatment paroxysmal supraventricular tachycardia psvt ,
Netivudine,netivudine used trial studying treatment chickenpox hiv infection ,
Diridavumab,cr6261 investigation clinical trial nct02016066 study ass safety pharmacokinetics immunogenicity diridavumab japanese healthy participant ,
Emixustat,emixustat used trial studying treatment geographic atrophy age-related macular degeneration dry age-related macular degeneration ,
Tovetumab,tovetumab used trial studying treatment cancer glioblastoma multiforme advanced solid malignancy ,
Ebselen,ebselen investigated treatment basic science meniere 's disease type 2 diabetes mellitus type 1 diabetes mellitus ,
PF-477736,pf-00477736 used trial studying treatment neoplasm ,
Ozanimod,ozanimod once-daily sphingosine 1-phosphate receptor modulator treatment relapsing multiple sclerosis m inflammatory bowel disease developed celgene acquired bristol-myers squibb l11025 approved fda march 26 2020 l12573 l12582 u approval followed approval canada october 2 2020 l41524 november 2021 ozanimod also approved european commission treatment adult relapsing remitting multiple sclerosis l39377 l39382 m devastating inflammatory disease often progress cause severe neurological physical cognitive effect a176474 inflammatory bowel disease also chronic inflammatory condition cause persistent abdominal pain diarrhea bloody stool vomiting a189336 clinical trial ozanimod shown well-tolerated resulted higher decrease rate m relapse intramuscular interferon beta-1a current standard m therapy study involving patient inflammatory bowel disease also shown promising result a189318 a189342 ,ozanimod sphingosine 1-phosphate receptor modulator indicated treatment relapsing form multiple sclerosis m include clinically isolated syndrome relapsing-remitting disease active secondary progressive disease adult also used treat moderately severely active ulcerative colitis uc adult l12582 l39382 l41524 
Davunetide,davunetide used trial studying treatment progressive nonfluent aphasia progressive supranuclear palsy predicted tauopathies including corticobasal degeneration syndrome frontotemporal dementia parkinsonism linked chromosome 17 davunetide first drug improve memory performance impacting mechanism lead physical damage brain caused neurofibrillary tangle one two established pathological hallmark common amnestic mild cognitive impairment amci alzheimer 's disease ad davunetide derived naturally occurring neuroprotective brain protein known activity dependent neuroprotective protein ,
Reparixin,reparixin used trial studying treatment prevention breast cancer metastatic breast cancer pancreatectomy chronic pancreatitis islet transplantation diabetes mellitus type 1 pancreatic islet transplantation type 1 diabetes mellitus ,
Plazomicin,developed achaogen biopharmaceuticals plazomicin next-generation aminoglycoside synthetically derived db12604 structure plazomicin established via appending hydroxylaminobutyric acid db12604 position 1 2-hydroxyethyl group position 6 a33942 designed evade clinically relevant aminoglycoside-modifying enzyme contribute main resistance mechanism aminoglycoside therapy a33942 however acquired resistance aminoglycosides may arise expression efflux pump ribosomal modification bacteria result amino acid rrna sequence mutation a33942 like aminoglycosides plazomicin ineffective bacterial isolates produce 16 rrna methyltransferases fda label plazomicin mediates antibacterial activity pathogen including carbapenem-resistant cre extended-spectrum beta-lactamase esbl producing _enterobacteriaceae_ mediates antibacterial activity binding bacterial 30 ribosomal subunit inhibiting protein synthesis fda label june 28th 2018 plazomicin sulfate approved fda use adult patient treatment complicated urinary tract infection cuti including pyelonephritis marketed zemdri administered via once-daily intravenous infusion ,plazomicin indicated treatment patient 18 year age older complicated urinary tract infection cuti including pyelonephritis limited alternative treatment option used treat infection proven strongly suspected caused susceptible microorganism fda label 
Sprifermin,sprifermin used trial studying treatment osteoarthritis knee cartilage injury knee ,
Mizoribine,mizoribine investigated treatment rheumatoid arthritis ,
Apocynin,acetovanillone used trial studying treatment bronchial asthma chronic obstructive pulmonary disease ,
BMS-188797,bms-188797 used trial studying treatment unspecified adult solid tumor protocol specific ,
Nerve Growth Factor,nerve growth factor used trial studying prevention treatment mental handicap alzheimer 's disease traumatic brain injury cerebral palsy child delayed speech development among others ,
ST-101,st101 used trial studying treatment essential tremor alzheimer 's disease ,
Lupeol,lupeol investigated treatment acne ,
Taprenepag,taprenepag used trial studying treatment ocular hypertension glaucoma open-angle ,
Octenidine,octenidine investigation clinical trial nct02697162 antiseptic-coated intermittent urinary catheter ,
Evogliptin,evogliptin used trial studying treatment screening osteoporosis renal impairment type 2 diabetes mellitus diabetes mellitis type 2 diabetes mellitus type 2 ,
Senrebotase,senrebotase used trial studying treatment neuralgia postherpetic urinary bladder overactive ,
GSK-1292263,gsk1292263 investigated treatment diabetes mellitus type 2 ,
Methyl-D9-choline,methyl-d9-choline investigation clinical trial nct01807910 er stress nafld ,
"3,5-diiodothyropropionic acid",ditpa investigated congestive heart failure ,
Isopentyl 2-cyanoacrylate,isoamyl 2 cyanoacrylate investigation clinical trial nct02698644 hysteroscopic tubal occlusion use iso amyl-2-cyanoacrylate ,
Aclerastide,aclerastide investigated treatment diabetic foot diabetic foot ulcer foot ulcer diabetic ,
JNJ-41443532,jnj-41443532 used trial studying basic science treatment diabetes mellitus type 2 ,
BMS-184476,bms-184476 used trial studying treatment unspecified adult solid tumor protocol specific ,
Navicixizumab,navicixizumab investigation clinical trial nct02298387 phase 1 study navicixizumab subject solid tumor ,
Aleplasinin,aleplasinin investigated alzheimer disease ,
Samalizumab,samalizumab used trial studying treatment multiple myeloma b-cell chronic lymphocytic leukemia ,
Onapristone,onapristone used trial studying treatment prostate cancer recurrent prostate cancer metastatic prostate cancer androgen-independent prostate cancer progesterone receptor positive tumor max 1 line prior chemotherapy prior hormone therapy ,
Zelavespib,zelavespib pu-h71 used trial studying treatment lymphoma solid tumor metastatic solid tumor myeloproliferative neoplasm mpn ,
Telbermin,telbermin used trial studying treatment foot ulcer foot ulcer diabetic amyotrophic lateral sclerosis ,
CP-609754,lnk 754 investigated mild alzheimer 's disease ,
Tedatioxetine,tedatioxetine used trial studying treatment major depressive disorder ,
Olumacostat glasaretil,olumacostat glasaretil used trial studying treatment acne vulgaris ,
Nelivaptan,nelivaptan used trial studying treatment anxiety disorder depressive disorder major depressive disorder ,
AZD-2066,azd2066 used trial studying treatment basic science pain chronic pain reflux episode neuropathic pain diabetic neuropathy among others ,
Givinostat,givinostat used trial studying treatment polycythemia vera juvenile idiopathic arthritis duchenne muscular dystrophy dmd chronic myeloproliferative neoplasm polyarticular course juvenile idiopathic arthritis ,
Tocotrienol,tocotrienol investigated treatment cholesterol lowering ,
Nona-arginine,nona-arginine investigation clinical trial nct00264706 polyarginine treated vein graft patent ,
Ibipinabant,ibipinabant used trial studying treatment obesity obesity type 2 diabetes ,
L-deprenyl-D2 C-11,l-deprenyl-d2 c-11 investigation clinical trial nct01701089 study ro4602522 patient alzheimer disease healthy volunteer ,
Bardoxolone,bardoxolone used trial studying treatment lymphoma solid tumor synthetic triterpenoid highly potent activator redox-sensitive signaling pathway induce programmed cell death apoptosis cancer cell high level intrinsic oxidative stress contrast bardoxolone normal cell induces protective antioxidant/anti-inflammatory response ,
Endothelin-1,endothelin 1 investigation clinical trial nct00745693 effect diesel exhaust inhalation vascular function role endothelin ,
GSK-376501,gsk376501 used trial studying treatment diagnostic type 2 diabetes mellitus ,
Patidegib,patidegib investigated treatment conventional chondrosarcoma ,
Somatorelin,somatorelin used trial studying treatment aging elderly sleep disorder hormone deficiency mild cognitive impairment ,
JNJ-42396302,jnj 42396302 investigation clinical trial nct01732237 study investigate pharmacokinetics jnj-42396302 jnj-53773187 jnj-42692507 healthy male participant ,
AFN-1252,afn-1252 used trial studying treatment cellulitis burn infection wound infection cutaneous abscess skin subcutaneous tissue bacterial infection ,
SJ-733,sj-733 used trial studying malaria ,
Samatasvir,samatasvir used trial studying treatment hepatitis c chronic chronic hepatitis c virus chronic hepatitis c infection ,
Urapidil,urapidil investigated treatment hypertension pre-eclampsia ,
Naveglitazar,naveglitazar used trial studying treatment diabetes mellitus non-insulin-dependent ,
Letrazuril,letrazuril used trial studying treatment hiv infection cryptosporidiosis ,
Indantadol,indantadol used trial studying treatment cough diabetic peripheral neuropathic pain ,
Isoquercetin,isoquercetin used trial studying treatment kidney cancer renal cell carcinoma advanced renal cell carcinoma thromboembolism vein pancreatic cancer thromboembolism vein vte colorectal cancer among others ,
Emapunil,emapunil used trial studying basic science diagnostic baseline blocking receptor binding neurodegenerative disorder ,
Protionamide,prothionamide used trial studying treatment mdr-tb hiv infection ,
Metenkefalin,metenkefalin endogenous opioid beta-endorphin a203225 shown reduce chromosomal abberations patient multiple sclerosis a203210 metenkefalin along tridecactide investigation immunomodulatory therapy moderate severe covid-19 l13874 l13877 ,metenkefalin indicated bosnia treatment relapsing-remitting multiple sclerosis l13889 
4SC-203,4sc-203 used trial studying treatment acute myeloid leukemia ,
Rolofylline,rolofylline clinical development pharmaceutical company novacardia treatment congestive heart failure ,
Beloranib,beloranib used trial studying treatment obesity over-weight type 2 diabetes craniopharyngioma hypothalamic injury among others ,
Icaritin,icaritin used trial studying treatment solid tumor metastatic breast cancer hepatocellular carcinoma hcc ,
ATX-914,axt914 investigation clinical trial nct00417261 safety tolerability pharmacodynamic pharmacokinetic effect single multiple-doses atf936 axt914 administered orally healthy subject ,
Lurbinectedin,lurbinectedin dna alkylating agent investigated treatment variety cancer including mesothelioma a214325 chronic lymphocytic leukemia cll a214328 breast cancer a214322 small-cell lung cancer sclc a214310 derivative marine-derived agent ecteinascidin trabectedin anticancer agent found extract tunicate _ecteinascidia turbinata_ primary difference substitution tetrahydroisoquinoline tetrahydro β‐carboline result increased antitumour activity lurbinectedin compared predecessor a214331 june 15 2020 fda granted accelerated approval orphan drug designation lurbinectedin treatment adult patient metastatic sclc experienced disease progression despite therapy platinum-based agent l14336 accelerated approval based rate duration therapeutic response observed ongoing clinical trial contingent verification result confirmatory trial ,lurbinectedin indicated treatment adult patient metastatic small-cell lung cancer sclc disease progression platinum-based chemotherapy l14327 
PF-04995274,pf 04995274 investigation clinical trial nct01193062 study healthy subject evaluate change protein sapp-alpha cerebrospinal fluid following single oral dose pf-04995274 ,
Modufolin,modufolin investigation treatment osteosarcoma ,
Soblidotin,soblidotin used trial studying treatment sarcoma lung cancer unspecified adult solid tumor protocol specific ,
Relamorelin,relamorelin investigated treatment basic science gastroparesis gastric motility diabetes mellitus parkinson 's disease chronic constipation among others ,
WP 1066,wp1066 used trial studying treatment melanoma brain cancer solid tumor central nervous system neoplasm ,
Intepirdine,intepirdine used trial studying treatment alzheimer 's disease ,
Salirasib,salirasib used trial studying diagnostic carcinoma non-small-cell lung ,
Mubritinib,mubritinib used trial studying treatment lung neoplasm renal neoplasm breast neoplasm ovarian neoplasm pancreatic neoplasm ,
Lumretuzumab,lumretuzumab used trial studying treatment neoplasm breast cancer squamous non-small cell lung cancer non-squamous non-small cell lung cancer ,
Aviscumine,cy 503 investigation clinical trial nct00658437 aviscumine treatment malignant melanoma stage iv failure prior therapy ,
K-134,k-134 used trial studying treatment intermittent claudication ,
PHA-793887,pha-793887 used trial studying treatment advanced/metastatic solid tumor ,
Vesatolimod,vesatolimod used trial studying treatment hepatitis b chronic hepatitis b ,
Moxetumomab pasudotox,cd22 lineage-restricted b-cell antigen expressed solely b-chronic lymphocytic leukemia hairy cell leukemia acute lymphocytic leukemiathe burkitt 's lymphoma predecessor moxetumab pasudotox mxp named bl22 first created based antibody rfb4 specifically bind cd22 antibody used generate recombinant immunotoxin stabilized fv segment disulfide bond fused _pseudomonas_ exotoxin pe38 cell-binding portion a38864 mxp appears improved form bl22 mutation fv region antibody phage-displayed well residue ssy heavy chain mutated thw a38864 developed astra zeneca fda approved september 13 2018 granted status fast track priority review orphan drug designation l4568 ,mxp indicated treatment adult patient relapsed refractory hairy cell leukemia hcl received least two prior systemic therapy including treatment purine nucleoside analog use drug recommended patient severe renal impairment crcl 29 ml/min l4568 hcl uncommon type lymphocytic leukemia start b cell b lymphocyte characterized accumulation abnormal b lymphocyte hcl called `` hairy '' produce hair-like projection surface cancer cell usual symptom people hcl presence splenomegaly le often hepatomegaly a38877 
Azeliragon,azeliragon used trial studying treatment alzheimer 's disease ,
LY-2584702,ly2584702 used trial studying treatment cancer advanced cancer renal cell carcinoma metastasis neoplasm neuroendocrine tumor among others ,
UK-432097,"uk-432,097 used trial studying treatment pulmonary disease chronic obstructive ",
Gusperimus,gusperimus used trial studying treatment lupus nephritis wegener granulomatosis wegener 's granulomatosis ,
Ritanserin,ritanserin used trial studying treatment cocaine-related disorder ,
CE-326597,"ce-326,597 used trial studying treatment obesity ",
Phenethyl Isothiocyanate,phenethyl isothiocyanate used trial studying prevention treatment leukemia lung cancer tobacco use disorder lymphoproliferative disorder ,
BMS-582949,bms-582949 investigated treatment psoriasis ,
Methylselenocysteine,methylselenocysteine used trial studying prevention prostate carcinoma evidence disease ,
Ibalizumab,ibalizumab also known _ibalizumab-uiyk_ formerly known tnx-355 monoclonal antibody bind cd4 receptor surface cd4-positive cell preventing hiv particle entry lymphocyte advanced current antibody development treatment hiv/aids developed taimed biologics theratechnologies l1558 l1554 drug approved march 2018 management treatment-resistant hiv l1554 october 2022 fda approved administration trogarzo ibalizumab-uiyk intravenous push allowing faster drug administration l43443 l43448 ,indicated treatment human immunodeficiency virus type 1 hiv-1 infection highly treatment-experienced adult multidrug-resistant hiv-1 infection failing current antiretroviral regimen fda label approval trogarzo supported clinical trial 40 treatment-experienced adult mdr hiv-1 infection persistently elevated level hiv rna blood despite heavy antiretroviral therapy majority study patient previously treated ≥10 antiretroviral medication l1554 
Balugrastim,balugrastim used trial studying treatment solid tumor ,
Solamargine,solamargine used trial studying treatment actinic keratosis ,
Intetumumab,intetumumab used trial studying treatment melanoma ,
Velusetrag,velusetrag used trial studying treatment gastroparesis alzheimer 's disease highly selective serotonin receptor agonist effective patient chronic constipation developed theravance velusetrag discovered theravance application multivalent drug design research program dedicated finding new treatment gi motility disorder ,
Omipalisib,omipalisib used trial studying treatment cancer solid tumour idiopathic pulmonary fibrosis ,
Spiradoline,spiradoline investigated basic science bipolar depression ,
Cenerimod,cenerimod used trial studying treatment systemic lupus erythematosus ,
Seletalisib,seletalisib used trial studying treatment basic science primary sjogren 's syndrome ,
AR-42,ar-42 used trial studying treatment meningioma acoustic neuroma testicular lymphoma intraocular lymphoma vestibular schwannoma among others ,
Sulprostone,sulprostone used trial studying abortion induced ,
Tributyrin,tributyrin used trial studying treatment prostate cancer unspecified adult solid tumor protocol specific ,
Perazine,perazine used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder among others ,
LTX-109,ltx-109 investigated treatment atopic dermatitis mild eczema/dermatoses gram-positive skin infection ,
Pilsicainide,pilsicainide investigated treatment paroxysmal atrial fibrillation ,
Sotagliflozin,sotagliflozin dual inhibitor sglt1 sglt2 first kind a244499 approved use eu combination insulin improve glycemic control patient type 1 diabetes mellitus t1dm bmi ≥27 kg/m sup 2 /sup l39705 potency inhibiting sglt2 similar sglt2 inhibitor canagliflozin dapagliflozin potency inhibiting sglt1 10-fold higher predecessor a244499 added inhibition intestinal sglt1 delay glucose absorption distal small intestine colon thereby reducing post-prandial glucose level a244470 a244499 sotagliflozin approved eu brand name `` zynquista '' april 26 2019 l39734 similar approval also sought u fda since published proposal refuse approval ground data submitted show safe proposed condition use l39739 ,sotagliflozin indicated eu adjunct insulin therapy improve glycemic control adult type 1 diabetes bmi ≥27 kg/m sup 2 /sup unable achieve adequate glycemic control despite optimal insulin therapy l39705 
Nerispirdine,nerispirdine used trial studying treatment neuritis optic nerve multiple sclerosis ,
MSX-122,msx-122 used trial studying treatment solid tumor ,
NB-001,nb-001 investigated treatment recurrent herpes labialis ,
Mibampator,mibampator used trial studying treatment alzheimer 's disease ,
Carlumab,carlumab used trial studying treatment cancer prostate cancer ,
Turofexorate isopropyl,fxr 450 investigation clinical trial nct00509756 study evaluating turofexorate isopropyl healthy japanese men ,
Nivocasan,nivocasan used trial studying treatment hcv infection nonalcoholic steatohepatitis ,
RO-5028442,ro5028442 used trial studying autistic disorder ,
N-sulfoglucosamine sulfohydrolase recombinant,n-sulfoglucosamine sulfohydrolase recombinant investigation treatment mucopolysaccharidosis iii sanfilippo syndrome type mp iiia ,
AZD-7295,azd7295 investigated treatment hepatitis c ,
Felcisetrag,felcisetrag td-8954 used trial studying treatment enteral feeding intolerance gastrointestinal motility disorder ,
Monteplase,monteplase used trial studying treatment pulmonary embolism ,
Perfosfamide,perfosfamide used trial studying treatment lymphoma neuroblastoma multiple myeloma plasma cell neoplasm ,
Fenpropidin,fenpropidin investigated treatment hernia ,
ASP-3026,asp3026 used trial studying treatment solid tumor b-cell lymphoma advanced malignancy positive anaplastic lymphoma kinase positive proto-oncogene tyrosine-protein kinase ro ,
Dolastatin 10,dolastatin 10 used trial studying treatment sarcoma leukemia lymphoma liver cancer kidney cancer among others ,
Daporinad,daporinad used trial studying treatment melanoma cutaneous t-cell lymphoma b-cell chronic lymphocytic leukemia ,
Firategrast,firategrast used trial studying treatment multiple sclerosis ,
Dipraglurant,dipraglurant used trial studying treatment parkinson 's disease metabotropic glutamate receptor 5 mglur5 negative allosteric modulator nam ,
Demcizumab,demcizumab investigation treatment nonsquamous nonsmall cell neoplasm lung ,
Etanidazole,etanidazole used trial studying diagnostic adult ependymoma malignant ascites adult gliosarcoma adult mixed glioma adult glioblastoma among others ,
Brontictuzumab,brontictuzumab used trial studying treatment adenoid cystic carcinoma relapsed refractory solid tumor relapsed refractory lymphoid malignancy ,
Tiplimotide,tiplimotide used trial studying treatment multiple sclerosis ,
Bindarit,bindarit used trial studying prevention treatment coronary restenosis diabetic nephropathy ,
CC-115,cc-115 used trial studying treatment prostate cancer neoplasm metastasis ewing 's osteosarcoma glioblastoma multiforme chronic lymphocytic leukemia among others ,
DTP-348,dtp348 used trial studying treatment solid tumor head neck neoplasm ,
Amuvatinib,amuvatinib used trial studying treatment solid tumor small cell lung carcinoma amuvatinib oral selective multi-targeted tyrosine kinase inhibitor suppresses c-met c-ret mutant form c-kit pdgfr flt3 amuvatinib also suppresses rad51 protein critical component double-stranded dna repair cancer cell ,amuvatinib selective multi-targeted tyrosine kinase inhibitor suppresses c-met c-ret mutant form c-kit pdgfr flt3 amuvatinib also suppresses rad51 protein critical component double-stranded dna repair cancer cell 
Z-160,z160 used trial studying treatment postherpetic neuralgia lumbosacral radiculopathy ,
CGI-1842,ji-101 used trial studying treatment cancer colon cancer neuroendocrine ovarian cancer advanced solid tumor ,
GSK-690693,gsk690693 used trial studying treatment tumor cancer lymphoma ,
AKN-028,akn-028 used trial studying treatment acute myeloid leukemia ,
Tertomotide,tertomotide investigation clinical trial nct01223209 study combination immunologic study ltx-315 adjunct tertomotide patient following curative surgery carcinoma peptide vaccine activates immune system recognizes kill cancer cell developed pharmexa a/s ,
LTX-315,ltx-315 used trial studying treatment cancer lymphoma melanoma carcinoma breast cancer among others ,
Butylphthalide,butylphthalide used trial studying prevention restenosis ,
N-omega-nitro-L-arginine methyl ester,l-name investigated treatment hypotension spinal cord injury ,
Malic acid,malic acid used trial studying treatment xerostomia depression hypertension ,
Bucindolol,bucindolol investigated heart failure ,
Racivir,racivir also known rcv oxothiolane nucleoside reverse transcriptase inhibitor similar emtricitabine lamivudine racivir 50:50 mixture emtricitabine positive enantiomer racivir used trial studying prevention hiv infection ,
Iodide,iodide investigated treatment goiter nodular ,
Zoptarelin doxorubicin,zoptarelin doxorubicin used trial studying treatment breast cancer ovarian cancer prostate cancer endometrial cancer urothelial carcinoma among others ,
TAK-901,tak-901 used trial studying treatment lymphoma myelofibrosis multiple myeloma myeloid metaplasia advanced solid tumor among others ,
Pelitrexol,pelitrexol used trial studying treatment unspecified adult solid tumor protocol specific ,
Atreleuton,atreleuton used trial studying treatment atherosclerosis coronary artery disease ,
Suptavumab,suptavumab used trial studying treatment basic science respiratory syncytial virus infection ,
GW-493838,gw493838 used trial studying treatment neuropathic pain ,
Timcodar,timcodar used trial studying treatment unspecified adult solid tumor protocol specific ,
Rabacfosadine,rabacfosadine used trial studying treatment multiple myeloma non-hodgkin 's lymphoma chronic lymphocytic leukemia ,
MK-1496,mk-1496 used trial studying treatment neoplasm malignant ,
Opaganib,opaganib also known abc294640 selective sphingosine kinase-2 sk2 http //go.drugbank.com/polypeptides/q9nra0 inhibitor orally administered l27436 drug potential anticancer anti-inflammatory antiviral activity potential application oncology inflammation gastrointestinal system covid-19 ,
Methyl isocyanate,methyl isocyanate investigated treatment nosocomial pneumonia ,
Cicletanine,cicletanine investigation treatment diabetes hypokalemia hyponatremia arterial hypertension ,
Gaxilose,gaxilose used trial studying diagnostic lactose intolerance ,
BCG vaccine,bcg vaccine investigated treatment neoplasm bladder cancer neoplasm site urologic disease urologic neoplasm among others ,
Lometrexol,lometrexol used trial studying treatment lung cancer drug/agent toxicity tissue/organ unspecified adult solid tumor protocol specific ,
Lafutidine,lafutidine investigated peptic ulcer community-acquired pneumonia gastroesophageal reflux disease gerd ,
Hydroxytyrosol,hydroxytyrosol used trial studying prevention breast cancer ,
Sifalimumab,sifalimumab fully human monoclonal antibody targeting interferon-alpha level interferon-alpha elevated many patient active systemic lupus erythematosus sle lupus autoimmune disorder may associated disease activity sifalimumab may suppress abnormal immune activity associated lupus binding multiple interferon-alpha subtypes seen serum lupus patient ,
AZD-8055,azd8055 used trial studying treatment cancer lymphoma solid tumor malignant glioma brainstem glioma among others ,
Abituzumab,abituzumab used trial studying treatment prostate cancer metastatic ,
E-6005,e6005 used trial studying treatment atopic dermatitis ,
Somatoprim,somatoprim investigation treatment acromegaly ,
Rivipansel,rivipansel used trial studying basic science treatment pain crisis renal impairment anemia sickle cell sickle cell disease sickle cell disorder among others ,
Higenamine,higenamine investigation clinical trial nct01451229 pharmacokinetics pharmacodynamics higenamine chinese healthy subject ,
Quinfamide,quinfamide used trial studying treatment amoebiasis helminthiasis ,
Balaglitazone,balaglitazone used trial studying treatment diabetes mellitus type 2 ,
SCH-486757,sch 486757 used trial studying treatment cough ,
Benserazide, levodopa used therapy treating parkinson 's disease ubiquitous metabolism dopamine responsible resultant increase level circulating dopamine blood various extracerebral tissue result number side effect like nausea vomiting even cardiac arrhythmia may diminish patient adherence f2 l2553 decarboxylase inhibitor like benserazide consequently effective compound combine levadopa incapable crossing blood-brain barrier act prevent formation dopamine levadopa extracerebral tissue thereby acting minimize occurrence extracerebral side effect f2 l2553 levodopa/benserazide combination product used commonly worldwide management parkinson 's disease particular although specific levodopa/benserazide combination formally approved use canada much europe fda approved another similar levodopa/dopa decarboxylase inhibitor combination form levodopa carbidopa moreover european medcines agency conferred orphan designation upon benseraside since 2015 potential used therapy beta thalassaemia well f3 , primary therapeutic use benserazide currently indicated combination therapy levadopa treatment parkinson 's disease adult 25 year age exception drug-induced parkinsonism f2 l2553 certain dos combination product levodopa benserazide may also used treat restless leg syndrome sometimes associated parkinson 's disease l2553 t181 also study prompted european medicine agency confer orphan designation upon benserazide hydrochloride potential therapy beta thalassaemia f3 although study ongoing evidence formally elucidated yet f3 
NS-018,ns-018 used trial studying treatment primary myelofibrosis post-polycythemia vera myelofibrosis post-essential thrombocythemia myelofibrosis ,
Furaprevir,furaprevir investigation clinical trial nct01523990 study evaluate safety tolerability pk healthy volunteer hcv genotype 1 infected patient ,
Alvircept sudotox,alvircept sudotox used trial studying treatment hiv infection ,
Norethandrolone,norethandrolone investigation clinical trial nct00700544 treatment outcome elderly patient ,
Glucagon-like peptide II,glucagon-like peptide ii investigation basic science short bowel syndrome ,
Dinoprost,dinoprost investigated headache ,
Laninamivir,laninamivir used trial studying treatment influenza ,
Boscalid,boscalid investigated treatment osdi glaucoma staining schirmers disease severity among others ,
Condoliase,condoliase used trial studying treatment lumbar disc disease lumbar vertebra hernia intervertebral disc disease ,
p-Quaterphenyl,p-quaterphenyl used trial studying treatment malaria ,
CMX-2043,cmx-2043 used trial studying treatment prevention non stemi unstable angina stable coronary artery disease percutaneous coronary intervention ,
MRX-I,mrx-i used trial studying treatment bacterial infection ,
Ecromeximab,ecromeximab used trial studying treatment cutaneous melanoma metastatic melanoma ,
Relenopride,relenopride used trial studying treatment chronic idiopathic constipation ,
Laniquidar,laniquidar used trial studying treatment breast cancer ,
CHF-6001,chf6001 used trial studying treatment asthma chronic obstructive pulmonary disease ,
Picropodophyllin,picropodophyllin investigated treatment non small cell lung cancer ,
Dichloroisoproterenol,dichloroisoproterenol used trial studying treatment basic science insulin resistance polycystic ovary syndrome ,
Daniquidone,daniquidone used trial studying treatment neoplasm ,
Ataciguat,ataciguat investigated basic science aortic valve stenosis ,
GSK-1004723,gsk1004723 investigated treatment allergic rhinitis rhinitis allergic seasonal ,
Naptumomab estafenatox,naptumomab estafenatox used trial studying treatment pancreatic cancer renal cell carcinoma non-small-cell lung carcinoma ,
Trifarotene,trifarotene topical retinoid cream used treatment acne vulgaris first approved use united state october 2019 l9013 retinoids class medication structurally functionally analogous vitamin though later generation retinoids trifarotene adapalene bear little structural resemblance vitamin analogous function a187081 trifarotene considered first `` fourth-generation '' retinoids due uniquely selective activity selectivity appears confer improved efficacy reduced side effect compared older le selective retinoids a187054 ,trifarotene indicated topical treatment acne vulgaris patient 9 year age older l9013 
BK-MDA,bk-mda used trial studying treatment bladder exstrophy urinary incontinence ,
AN-2718,an2718 used trial studying tinea pedis ,
Palomid 529,palomid 529 used trial studying treatment age-related macular degeneration ,
Radium Ra-223,radium 223 investigation clinical trial nct02463799 ph 2 study sipuleucel-t w/ w/o radium-223 men asymptomatic minimally symptomatic bone-mcrpc ,
Cepeginterferon alfa-2B,cepeginterferon alfa-2b investigation clinical trial nct01889433 open-label comparative efficacy safety study algeron cepeginterferon alfa-2b treatment-naive patient chronic hepatitis c ,
Crotedumab,crotedumab used trial studying treatment diabetes mellitus type 2 ,
Terpinen-4-ol,terpinen-4-ol investigation clinical trial nct01647217 demodex blepharitis treatment study ,
Zoliflodacin,zoliflodacin used trial studying basic science treatment gonorrhoea ,
NM-3,nm-3 used trial studying treatment neoplasm ,
GSI-136,gsi-136 used trial studying treatment alzheimer disease ,
Concizumab,concizumab used trial studying treatment haemophilia congenital bleeding disorder ,
Perflubutane,perflubutane used trial studying diagnostic liver mass liver disease liver metastasis portal hypertension peripheral artery disease cardiovascular drug designed enable ultrasound compete effectively nuclear stress testing currently leading procedure detecting coronary heart disease ,
Pancreatic Polypeptide,pancreatic polypeptide investigated treatment diabetes mellitus type 1 ,
Tecarfarin,tecarfarin used trial studying prevention thrombosis thromboembolism ,
Monalizumab,monalizumab used trial studying treatment gynecologic cancer chronic lymphocytic leukemia squamous cell carcinoma oral cavity ,
Lefamulin,lefamulin pleuromutilin antibiotic used treatment bacterial community-acquired pneumonia pleuromotilin recently developed type antibiotic derived fungus pleurotus mutilus a183206 lefamulin available intravenous oral preparation granted fda approval august 2019 l8093 drug first semi-synthetic pleuromutilin designed systemic administration lefamulin feature novel mechanism action show benefit resistant bacteria cause pneumonia a183161 chemical structure lefamulin contains tricyclic mutilin core necessary antimicrobial activity a183167 ,lefamulin indicated treat adult diagnosed community-acquired bacterial pneumonia cabp caused susceptible bacteria use reserved confirmed susceptible organism high probability infection susceptible organism list susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillin-susceptible legionella pneumophila haemophilus influenza chlamydophila pneumoniae mycoplasma pneumoniae l8093 
Depatuxizumab,depatuxizumab used trial studying treatment diagnostic adenocarcinoma advanced solid tumor ,
Indoximod,indoximod used trial studying treatment glioma melanoma ependymoma gliosarcoma lung cancer among others ,
Amithiozone,amithiozone used trial studying treatment mycobacterium avium-intracellulare infection ,
Cebranopadol,cebranopadol used trial studying treatment pain neoplasm chronic pain ,
Gabexate,gabexate synthetic serine protease inhibitor used anticoagulant also known decrease production inflammatory cytokine gabexate investigated use cancer ischemia-reperfusion injury pancreatitis a19218 a19219 a19220 , approved indication 
Prednimustine,prednimustine used trial studying treatment lymphoma ,
Tandospirone,tandospirone used trial studying treatment schizophrenia ,
Secnidazole,secnidazole second-generation 5-nitroimidazole antimicrobial agent structurally related 5-nitroimidazoles including db00916 db00911 display improved oral absorption longer terminal elimination half-life drug class secnidazole selective many anaerobic gram-positive gram-negative bacteria well protozoa a27210 enters bacteria parasite secnidazole activated bacterial parasitic enzyme form radical anion thereby damaging killing target pathogen a245503 secnidazole available many country europe asia south america africa decade a245503 a245508 september 2017 fda approved secnidazole market name solosec treatment trichomoniasis bacterial vaginosis l39524 ,secnidazole indicated treating trichomoniasis bacterial vaginosis patient 12 year age older l39524 country also available combination product antibacterial drug itraconazole l16023 
Olipudase alfa,olipudase alfa recombinant human acid sphingomyelinase a251590 first enzyme replacement therapy world treatment acid sphingomyelinase deficiency asmd also known niemann–pick disease l42740 asmd rare lysosomal storage disease caused mutation smpd1 gene leading deficiency acid sphingomyelinase abnormal accumulation primary asm substrate sphingomyelin a251600 olipudase alfa work hydrolyze sphingomyelin accumulated body tissue lung liver spleen kidney bone marrow a251590 olipudase alfa gained first global approval japan march 28 2022 a251590 later approved european commission june 28 2022 l42740 fda august 31 2022 l43145 ,olipudase alfa indicated enzyme replacement therapy treatment non-central nervous system manifestation acid sphingomyelinase deficiency asmd pediatric adult patient type a/b type b l42735 l43140 
Grapiprant,grapiprant also known at-001 cj-023 drug piprant class molecule derived acylsulfonamide characterized novel series para-n-acylaminomethylbenzoic acid known prostaglandin receptor antagonist a39838 type molecule currently development veterinary patient a39816 class drug defined 2013 world health organization l4766 grapiprant approved march 2016 fda 's center veterinary medicine non-cyclooxygenase inhibiting nsaid veterinary use a39836 , effect grapiprant investigated area analgesia anti-inflammation due effect reported molecule a39816 molecule approved widely accepted used veterinary pain reduction arthritis a39835 human researched used control pain inflammation associated osteoarthritis a39844 a39843 effect grapiprant explained function prostaglandin e2 pge2 key mediator swelling redness pain classic sign inflammation effect pge2 result action four receptor ep1 ep2 ep3 ep4 ep4 primary mediator pge2-driven inflammation a39817 
UK-500001,"uk-500,001 used trial studying treatment pulmonary disease chronic obstructive ",
Tetrasul,tetrasul used trial studying treatment erythematous type one rosacea ,
Pegvaliase,"pegvaliase recombinant phenylalanine ammonia lyase pal enzyme derived _anabaena variabilis_ convert phenylalanine ammonia _trans_-cinnamic acid a33284 u.s. food drug administration european medicine agency approved pegvaliase-pqpz may 2018 treatment adult patient phenylketonuria pku phenylketonuria rare autosomal recessive disorder characterized deficiency enzyme phenylalanine hydroxylase pah a33284 affect 1 10,000 15,000 people united state l2925 pah deficiency inability break amino acid phenylalanine phe lead elevated blood phenylalanine concentration accumulation neurotoxic phe brain causing chronic intellectual neurodevelopmental psychiatric disability untreated a33284 individual pku also need strictly restricted diet phe present food product high-intensity sweetener l2925 primary goal lifelong treatment pku recommended american college medical genetics genomics acmg guideline maintain blood phe concentration range 120 µmol/l 3690 µmol/l a33286 pegvaliase-pqpz pegylated pegvaliase used novel enzyme substitution therapy marketed palynziq subcutaneous injection pegvaliase-pqpz homotetrameric protein composed recombinant phenylalanine ammonia lyase ravpal conjugated n-hydroxysuccinimide nh -methoxypolyethylene glycol peg l42725 advantageous currently available management therapy pku db00360 ineffective many patient due long-term adherence issue inadequate phe-lowering effect a33284 presence peg moiety pegvaliase-pqpz allows reduced immune response improved pharmacodynamic stability a33284 ",pegvaliase indicated management phenylketonuria pku adult patient uncontrolled blood phenylalanine concentration greater 600 micromol/l existing management l42725 
Pirnabine,pirnabine used trial studying treatment chronic idiopathic constipation ,
Glial growth factor 2,glial growth factor 2 used trial studying treatment heart failure ,
Pegamotecan,pegamotecan used trial studying treatment cancer stomach sarcoma soft tissue gastroesophageal cancer ,
Oleandrin,oleandrin used trial studying treatment lung cancer chemotherapeutic agent toxicity ,
Rontalizumab,rontalizumab used trial studying treatment systemic lupus erythematosus ,
Amatuximab,amatuximab used trial studying treatment basic science mesothelioma ovarian cancer ovarian neoplasm pancreatic cancer mesothelioma malignant among others ,
Reproterol,reproterol used trial studying treatment asthma exercise-induced ,
Pyroxamide,pyroxamide used trial studying treatment leukemia lymphoma small intestine cancer precancerous condition myelodysplastic syndrome among others ,
PF-04217903,pf-04217903 used trial studying treatment neoplasm ,
Clazakizumab,clazakizumab used trial studying treatment rheumatoid arthritis ,
Etalocib,etalocib used trial studying treatment pancreatic cancer carcinoma non-small-cell lung unspecified adult solid tumor protocol specific ,
Miravirsen,miravirsen investigated treatment hepatitis c hepatitis c chronic ,
MK-0752,mk 0752 investigation clinical trial nct00572182 mk0752 treating young patient recurrent refractory cns cancer ,
DA-6886,da-6886 used trial studying treatment irritable bowel syndrome ,
BMS-908662,bms-908662 used trial studying treatment melanoma colorectal cancer ,
Apricitabine,apricitabine used trial studying treatment hiv infection ,
Timonacic,timonacic used trial studying treatment hiv infection ,
NVP-LEQ-506,leq506 used trial studying treatment advanced solid tumor recurrent refractory medulloblastoma locally advanced metastatic basal cell carcinoma ,
LY-377604,ly377604 used trial studying treatment obesity ,
Tantalum,tantalum investigated treatment prevention osteoarthritis knee osteoarthritis intraoperative bleeding adolescent idiopathic scoliosis ,
Actinium,actinium investigated treatment breast cancer pulmonary disease chronic obstructive ,
Rimeporide,rimeporide used trial studying treatment muscular dystrophy duchenne ,
Glucose oxidase,glucose oxidase investigated treatment upper respiratory tract infection ,
Sivelestat,sivelestat used trial studying treatment acute lung injury respiratory distress syndrome adult ,
Melarsoprol,melarsoprol investigation clinical trial nct00330148 randomized clinical trial three drug combination late-stage gambiense human african trypanosomiasis ,
Etelcalcetide,etelcalcetide calcimimetic drug treatment secondary hyperparathyroidism patient undergoing hemodialysis etelcalcetide approved trade name parsabiv treatment secondary hyperparathyroidism hpt adult patient chronic kidney disease ckd hemodialysis february 2017 ,etelcalcetide calcium-sensing receptor agonist indicated secondary hyperparathyroidism hpt adult patient chronic kidney disease ckd hemodialysis 
Pradigastat,pradigastat used trial studying treatment non-alcoholic fatty liver disease nafld ,
Benperidol,benperidol used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder among others ,
Intoplicine,intoplicine used trial studying treatment unspecified adult solid tumor protocol specific ,
Eliprodil,eliprodil used trial studying treatment parkinson disease movement disorder ,
Buthionine sulfoximine,buthionine sulfoximine used trial studying treatment neuroblastoma melanoma skin ,
Burlulipase,burlulipase used trial studying treatment lung disease cystic fibrosis pancreatic insufficiency digestive system disease respiratory tract disease ,
Vonicog alfa,vonicog alfa recombinant von willebrand factor manufactured baxalta fda approved december 2015 a32230 gen von willebrand factor first cloned 1985 stuart orkin david ginsburg l1849 ema vonicog alfa still clinical analysis l1862 ,vonicog alfa indicated on-demand treatment control bleeding episode adult previously diagnosed von willebrand disease l1866 vonicog alfa contains vwf thus administration offer flexibility administer coagulation factor viii needed von willebrand disease inherited disorder characterized deficiency misfunction von willebrand factor vwf due deficiency blood clot properly patient present disease prone prolonged excessive bleeding three type disease type 3 autosomal recessive inherited disorder marked low absent level vwf l1867 
Dianhydrogalactitol,dianhydrogalactitol used trial studying treatment gbm glioma glioblastoma brain cancer glioblastoma multiforme ,
Quizartinib,quizartinib investigation childhood acute myeloid leukemia/other myeloid malignancy potent inhibitor flt3 ,
Mavatrep,mavatrep used trial studying treatment osteoarthritis knee ,
GS-9256,gs-9256 used trial studying treatment hcv infection chronic hepatitis c infection ,
Oxatomide,oxatomide used trial studying treatment muscular dystrophy duchenne ,
AV-101,av-101 used trial studying treatment neuropathic pain ,
Omigapil,omigapil used trial studying treatment congenital muscular dystrophy ,
Interleukin-10,interleukin-10 used trial studying prevention treatment vasculitis pancreatitis bile duct disease pancreatic disease gallbladder disease among others ,
Indole-3-carbinol,indole 3 carbinol investigation clinical trial nct00033345 indole-3-carbinol preventing breast cancer nonsmoking woman high risk breast cancer ,
Ombrabulin,ombrabulin used trial studying treatment sarcoma neoplasm solid tumor neoplasm malignant advanced solid tumor among others ,
Eltoprazine,eltoprazine used trial studying treatment schizophrenia cognitive impairment ,
Lavoltidine,lavoltidine used trial studying diagnostic reflux gastroesophageal gastroesophageal reflux disease ,
Namodenoson,namodenoson used trial studying treatment chronic hepatitis c hepatocellular carcinoma ,
GSK-1521498,gsk1521498 used trial studying treatment obesity alcoholism ,
Tazemetostat,tazemetostat methyltransferase inhibitor used treat metastatic locally advanced epithelioid sarcoma eligible complete resection l11476 tazemetostat first named literature epz-6438 a190363 tazemetaostat granted fda approval 23 january 2020 l11476 ,tazemetostat indicated treat adult pediatric patient 16 year older metastatic locally advanced epithelioid sarcoma eligible complete resection l11476 also indicated treat adult patient relapsed refractory follicular lymphoma whose tumor positive izh2 mutation received least 2 prior systemic therapy l11476 additionally indicated adult patient relapsed refractory follicular lymphoma satisfactory alternative treatment option l11476 
Ezutromid,ezutromid investigated treatment muscular dystrophy duchenne ,
Velneperit,velneperit used trial studying treatment obesity ,
Dihydrexidine,dihydrexidine used trial studying treatment spd cocaine-related disorder schizotypal personality disorder ,
Ozanezumab,ozanezumab used trial studying treatment multiple sclerosis amyotrophic lateral sclerosis multiple sclerosis relapsing-remitting ,
MGB-BP-3,mgb bp 3 investigation clinical trial nct02518607 safety blood level effect mgb-bp-3 ,
Sacituzumab govitecan,metastatic triple-negative breast cancer mtnbc aggressive form breast cancer limited treatment option involving cytotoxic chemotherapy agent a193653 targeted chemotherapy application antibody-conjugated agent adcs recent advance cancer treatment a193671 one adc sacituzumab govitecan combine humanized anti-trophoblast cell-surface antigen 2 trop-2 antibody topoisomerase inhibitor sn-38 l13002 a193674 sacituzumab govitecan granted fda approval april 22nd 2020 marketed brand name trodelvy™ immunomedics inc. currently indicated accelerated approval treatment mtnbc patient undergone two prior therapy targeted cytotoxic agent hoped provide similar efficacy reduced adverse effect a193653 november 2021 sacituzumab govitecan also approved european commission l39372 ,sacituzumab govitecan indicated adult patient metastatic triple-negative breast cancer mtnbc undergone two prior therapy metastatic disease l13002 sacituzumab govitecan also indicated treatment locally advanced metastatic urothelial cancer adult patient received previous platinum-based therapy either programmed death receptor-1 pd-1 programmed death-ligand 1 pd-l1 inhibitor indication approved accelerated approval continued approval may contingent demonstration clinical benefit confirmatory trial l13002 
Raluridine,raluridine used trial studying treatment hiv infection ,
TD-139,td139 investigated treatment idiopathic pulmonary fibrosis ,
PSI-352938,psi-352938 used trial studying treatment hepatitis c hepatitis c chronic ,
MK-7622,mk-7622 used trial studying treatment alzheimer 's disease ,
Calcitonin eel,hc-58 used trial studying prevention severe upper limb hemiplegia ,
TT-301,tt301 used trial studying treatment traumatic brain injury ,
Irdabisant,irdabisant used trial studying cognitive impairment ,
Fiacitabine,fiacitabine used trial studying treatment hiv infection cytomegalovirus infection ,
Trofosfamide,trofosfamide used trial studying treatment ependymomas medulloblastomas sarcoma soft tissue supratentorial pnets recurrent brain tumor ,
DEBIO-1347,ch5183284 used trial studying treatment solid tumour ,
ZSTK-474,zstk474 used trial studying treatment neoplasm ,
Samarium Sm-153,samarium 153 used trial studying supportive care pain lung cancer breast cancer prostate cancer metastatic cancer ,
LY-2334737,ly2334737 used trial studying treatment solid tumor metastatic tumor malignant solid tumor ,
Mannose,mannose investigation basic science iugr pregnancy ,
Denenicokin,denenicokin investigation clinical trial nct01152788 phase ii study interleukin-21 ril-21 v dacarbazine dtic patient metastatic recurrent melanoma ,
Factor XIII (human),factor xiii human heat-treated lyophilized concentrate coagulation factor xiii endogenous enzyme responsible crosslinking fibrin essential component coagulation cascade fda label people congenital deficiency mutation factor xiii rare bleeding disorder exogenous replacement key coagulation factor essential management prevention bleeding episode also known fibrin stabilizing factor fsf factor xiii endogenously produced coagulation factor final enzyme within blood coagulation cascade within body fxiii circulates heterotetramer composed 2 a-subunits 2 b-subunits a2b2 a32363 activated thrombin site injury fxiii pro-enzyme cleaved resulting activation catalytic a-subunit dissociation carrier b-subunit result active transglutaminase subunit cross-link fibrin protein resulting increased mechanical strength resistance fibrinolysis fibrin clot contributes enhanced platelet clot adhesion injured tissue thereby improving blood coagulation maintenance hemostasis a18581 drug product similar structure function factor xiii human include db09310 recombinant form subunit human coagulation factor xiii compared factor xiii human purified pooled human plasma db09310 produced recombinant dna technology target protein grown yeast isolated fda label factor xiii human available commercially available product corifact approved food drug administration routine prophylactic treatment peri-operative management surgical bleeding adult pediatric patient congenital fxiii deficiency fda label half-life endogenous factor xiii long 5-11 day prophylactic therapy replacement fxiii given every 4-6 maintain hemostasis a32363 ,factor xiii human available commercially available product corifact approved food drug administration routine prophylactic treatment peri-operative management surgical bleeding adult pediatric patient congenital fxiii deficiency fda label 
Emicerfont,emicerfont used trial studying diagnostic treatment social anxiety disorder irritable bowel syndrome ibs ,
Nicoboxil,nicoboxil investigated treatment acute low back pain typically considered effective safe therapeutic option nevertheless predominantly found paired nonivamide combination topical analgesic product proposed mechanism action rubefacient complementary ultimately synergistic nonivamide 's capsaicin activity f11 combination topical analgesic available purchase use human part europe asia like germany australia f11 f16 despite topical nicoboxil/nonivamide topical analgesic medication used since 1950s recent study demonstrate continued interest medication given demonstrated efficacy safety capability used alternative musculoskeletal pain therapy option le systemic side effect compared oral non-steroidal anti-inflammatory drug opioids may typically prescribed a32785 a32786 , primary therapeutic use nicoboxil currently indicated active ingredient combination capsaicinoid nonivamide compound topical analgesic temporary relief pain rheumatism arthritis lumbago muscular ache sprain strain sporting injury condition local warmth beneficial f11 nevertheless available study regarding use nicoboxil nonivamide topical analgesic focus specifically efficacy safety treating acute non-specific low back pain typically finding combination analgesic effective safe well-tolerated medication indication a32785 a32786 
Nolatrexed,nolatrexed investigation clinical trial nct00012324 nolatrexed dihydrochloride compared doxorubicin treating patient recurrent unresectable liver cancer ,
MGL-3196,mgl-3196 used trial studying treatment non-alcoholic steatohepatitis heterozygous familial hypercholesterolemia ,
Corticorelin acetate,corticorelin acetate investigated treatment brain edema brain tumor ,
Mitolactol,mitolactol used trial studying treatment brain central nervous system tumor ,
Bimekizumab,bimekizumab humanized monoclonal antibody directed towards il-17 approved use eu august 20 2021 treatment plaque psoriasis l39665 l39680 first il-17 inhibitor target il-17a il-17f a244455 demonstrated superior efficacy compared another il-17 inhibitor secukinumab well ustekinumab il-12/23 inhibitor adalimumab tnf inhibitor treatment moderate-to-severe psoriasis a244450 a244455 likely owing dual inhibition il-17a il-17f ,bimekizumab indicated eu treatment moderate-to-severe plaque psoriasis adult candidate systemic therapy l39665 
T-62,t-62 used trial studying treatment postherpetic neuralgia ,
Pinometostat,pinometostat used trial studying treatment leukemia acute leukemia acute myeloid leukemia myelodysplastic syndrome acute lymphocytic leukemia among others ,
Chlorsulfaquinoxaline,chlorsulfaquinoxaline used trial studying treatment lung cancer colorectal cancer ,
Gallopamil,gallopamil used trial studying treatment asthma ,
Ozenoxacin, date ozenoxacin used trial studying treatment impetigo december 11 2017 fda approved ferrer internacional s.a. 's xepi ozenoxacin 1 topically applied cream indicated treatment impetigo caused staphylococccus aureus streptococcus pyogenes adult pediatric patient 2 month age older despite common highly contagious bacerial skin infection affect million child adult united state year ozenoxacin cream novel non-fluorinated quinolone demonstrated safe effective therapy adult pediatric population ,ozenoxacin cream indicated topical treatment impetigo caused staphylococcus aureus streptococcus pyogenes patient aged 2 month age older fda label 
Crolibulin,crolibulin used trial studying treatment solid tumor anaplastic thyroid cancer ,
Cafedrine,cafedrine investigation clinical trial nct01311414 effect cafedrine/theodrenaline urapidil cerebral oxygenation ,
Theodrenaline,theodrenaline investigation clinical trial nct01311414 effect cafedrine/theodrenaline urapidil cerebral oxygenation ,
GET-73,get 73 investigated treatment alcohol dependence ,
JNJ-39220675,jnj-39220675 used trial studying treatment allergic rhinitis ,
Opipramol,opipramol used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder ,
Fenobam,fenobam investigation clinical trial nct00637221 open label study investigating safety efficacy fenobam anhydrous 50 mg 150 mg prepulse inhibition test continuous performance task adult fragile x syndrome ,
Merotocin,merotocin used trial studying treatment preterm delivery ,
RO-4987655,ro4987655 used trial studying treatment neoplasm ,
Granotapide,granotapide used trial studying treatment type ii diabetes mellitus ,
Remogliflozin etabonate,remogliflozin etabonate used trial studying treatment basic science type 2 diabetes mellitus diabetes mellitus type 2 ,
Quercetin-3'-O-phosphate,quercetin-3'-o-phosphate used trial studying treatment insulin resistance impaired glucose tolerance ,
Isoxaflutole,balance investigated treatment chronic renal failure peritoneal membrane disorder ,
Nikkomycin Z,nikkomycin z used trial studying treatment basic science coccidioidomycosis ,
Helium He-3,helium he-3 investigation clinical trial nct00846014 asthma exacerbation helium-3 mri ,
Darolutamide,darolutamide nonsteroidal androgen receptor antagonist treatment castrate-resistant non-metastatic prostate cancer nmcrpc condition occurs majority patient advanced prostate cancer treated androgen receptor antagonist a189063 though prior treatment prostate cancer successful patient cancer eventually progress become resistant existing therapy warrant treatment goal treatment darolutamide delay progression prostate cancer metastatic disease increasing quality life life expectancy advanced prostate cancer a189054 a189063 darolutamide developed bayer healthcare pharmaceutical inc. approved fda july 30th 2019 l10887 ,darolutamide indicated treatment adult non-metastatic castration-resistant prostate cancer nmcrpc metastatic hormone-sensitive prostate cancer mhspc combination docetaxel l42765 
Lactitol,lactitol also known 4-β-d-galactopyranosyl-d-glucitol sugar alcohol synthesized lactose a190918 used food manufacturing nutritive sweetener approximately 35 sweet table sugar i.e sucrose a190912 clinically lactitol investigated use osmotic laxative along non-absorbable disaccharide lactulose treatment hepatic encephalopathy patient cirrhosis a190915 a190918 pizensy oral lactitol powder solution approved fda use chronic idiopathic constipation february 2020 l11803 ,lactitol indicated treatment chronic idiopathic constipation adult l11803 
Milatuzumab,milatuzumab used trial studying treatment lupus nephritis multiple myeloma mm gvhd acute chronic myelodysplastic syndrome chronic lymphocytic leukemia among others ,
Phloroglucinol,phloroglucinol used trial studying diagnostic colonoscopy ,
Dihydralazine,dihydralazine investigation clinical trial nct00311974 effect dihydralazine kidney function hormone healthy individual ,
"8-cyclopentyl-1,3-dipropylxanthine",cpx used trial studying treatment cystic fibrosis ,
Doxifluridine,doxifluridine investigated treatment stomach cancer ,
Didox,didox used trial studying supportive care gastric cancer ,
PF-03382792,pf 03382792 investigation clinical trial nct01045863 evaluate safety tolerability plasma drug level biological effect healthy volunteer ,
Albusomatropin,albusomatropin used trial studying treatment growth hormone-deficiency growth hormone deficiency ,
Pivagabine,pivagabine used trial studying treatment stress anxiety ,
Methylprednisone,methylprednisone used trial studying treatment leukemia rheumatoid arthritis renal transplantation kidney transplantation acute lymphocytic leukemia among others ,
Disitertide,disitertide used trial studying treatment skin fibrosis ,
Terizidone,terizidone used trial studying treatment tuberculosis hiv infection multidrug resistant tuberculosis extensively-drug resistant tuberculosis ,
Delparantag,delparantag used trial studying treatment angioplasty coronary artery disease cad percutaneous coronary intervention ,
Vantictumab,vantictumab used trial studying treatment solid tumor pancreatic cancer stage iv pancreatic cancer ,
5-fluoro-2'-deoxycytidine,5-fluoro-2'-deoxycytidine used trial studying treatment neoplasm lung neoplasm breast neoplasm head neck neoplasm urinary bladder neoplasm among others ,
Prothipendyl,prothipendyl used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder ,
IOWH-032,iowh032 investigated treatment cholera diarrhea secretory diarrhea ,
INCB-9471,incb-9471 novel orally available ccr5 antagonist part new class drug treat hiv/aids potent selective inhibitor hiv-1 virus ,
Leukotriene B4,leukotriene b4 used trial studying treatment hiv infection ,
CP-547632,cp-547632 used trial studying treatment ovarian cancer lung neoplasm ovarian neoplasm peritoneal neoplasm fallopian tube cancer among others ,
CCX-354,ccx354-c used trial studying treatment rheumatoid arthritis ,
Lerisetron,lerisetron used trial studying supportive care nausea vomiting testicular germ cell tumor ,
Silver,silver ag chemical element belongs family transition metal periodic table high electrical conductivity thermal conductivity reflectivity silver exists pure elemental form alloy metal mineral critical role various application inducing chemical industrial field silver compound also used field medicine century due broad-spectrum biological action silver nanoparticles especially widely used industrial household healthcare-related product due potent antimicrobial activity db11080 db05245 used topical antibacterial agent treatment skin infection db05245 also valued topical burn treatment a33141 silver compound used trial studying management dental caries since 1800s may found dental paste active ingredient however drawback dental use silver compound include tooth discolouration pulp irritation a33141 ,indicated treatment acne topical use management dental caries dental use 
Falnidamol,falnidamol used trial studying treatment unspecified adult solid tumor protocol specific ,
Mitoguazone,mitoguazone used trial studying treatment lymphoma hiv infection lymphoma non-hodgkin ,
DONU,donu used trial studying treatment psychosis ,
Methylinositol,methylinositol used trial studying treatment dementia alzheimer 's disease ,
Levoglucose,levoglucose used trial studying diagnostic bowel cleansing prior colonoscopy ,
Pactimibe,pactimibe used trial studying treatment atherosclerosis coronary heart disease ,
Sepranolone,sepranolone investigated treatment premenstrual dysphoric disorder ,
Serlopitant,serlopitant investigated treatment prurigo nodularis ,
Roniciclib,roniciclib investigated treatment small cell lung carcinoma ,
Pyronaridine,pyronaridine investigated treatment malaria ,
Robatumumab,robatumumab used trial studying treatment osteosarcoma sarcoma ewing 's peripheral neuroectodermal tumor ,
Simenepag isopropyl,simenepag isopropyl used trial studying treatment ocular hypertension glaucoma open-angle ,
Pexidartinib,pexidartinib selective tyrosine kinase inhibitor work inhibiting colony-stimulating factor csf1 /csf1 receptor pathway pexidartinib originally developed daiichi sankyo inc. approved fda august 2019 first systemic therapy adult patient symptomatic tenosynovial giant cell tumor l7901 tenosynovial giant cell tumor rare form non-malignant tumor cause synovium tendon sheath thicken overgrow leading damage surrounding joint tissue a182240 l7901 debilitating symptom often follow tenosynovial giant cell tumor along risk significant functional limitation reduced quality life patient l7901 surgical resection current standard care tenosynovial giant cell tumor tumor type surgery deemed clinically ineffective high risk lifetime recurrence l7895 pexidartinib work blocking immune response activated tenosynovial giant cell tumor clinical trial pexidartinib shown promote improvement patient symptom functional outcome tgct a182243 pexidartinib available oral formulation commonly marketed turalio l7901 ,pexidartinib indicated treatment adult patient symptomatic tenosynovial giant cell tumor tgct associated severe morbidity functional limitation amenable improvement surgery l7883 
Nepicastat,nepicastat investigated treatment cocaine dependence posttraumatic stress disorder ,
CHS-828,chs-828 used trial studying treatment unspecified adult solid tumor protocol specific ,
XL-888,xl888 used trial studying treatment cancer melanoma ,
Silicon,silicon investigation clinical trial nct00103246 photodynamic therapy using silicon phthalocyanine 4 treating patient actinic keratosis bowen 's disease skin cancer stage stage ii mycosis fungoides ,
Phthalocyanine,phthalocyanine investigation clinical trial nct00103246 photodynamic therapy using silicon phthalocyanine 4 treating patient actinic keratosis bowen 's disease skin cancer stage stage ii mycosis fungoides ,
Larotaxel,larotaxel used trial studying treatment cancer metastasis breast cancer breast neoplasm pancreatic neoplasm among others ,
Quisinostat,quisinostat used trial studying treatment lymphoma neoplasm myelodysplastic syndrome advanced refractory leukemia ,
VS-5584,vs-5584 used trial studying treatment lymphoma metastatic cancer non hematologic cancer ,
Penclomedine,penclomedine used trial studying treatment lymphoma unspecified adult solid tumor protocol specific ,
LY-518674,ly518674 used trial studying treatment metabolic syndrome x ,
Neosaxitoxin,neosaxitoxin investigation clinical trial nct01786655 safety study long-acting local anesthetic ,
Icosabutate,icosabutate investigation clinical trial nct02373176 14c icosabutate -a phase absorption metabolism excretion study ,
Deoxyspergualin,deoxyspergualin used trial studying treatment lupus nephritis chronic rejection diabetes mellitus type 1 ,
Bleomycin A6,bleomycin a6 also known boanmycin used trial studying treatment squamous cell lung cancer developed china antineoplastic antibiotic drug participated clinical trial treatment squamous cell lung cancer shown besides antitumor effect bleomycin a6 ability alter tumor microenvironment could contribute toward lung cancer relapse metastasis long-term treatment development drug apparently discontinued ,
Berkelium,berkelium investigation clinical trial nct02189122 comparative effect aspirin nhp-544c ,
MIP-1095 I-123,123 mip 1095 investigation clinical trial nct00712829 study evaluate safety pharmacokinetics tissue distribution metabolism dosimetry two prostate cancer imaging agent ,
Acteoside,acteoside investigation clinical trial nct02662283 validity security reh-acteoside therapy patient iga nephropathy ,
Brilacidin,brilacidin investigation supportive care mucositis stomatitis mouth disease head neck neoplasm ,
PF-00217830,pf-00217830 used trial studying treatment schizophrenia ,
MK-6186,mk6186 used trial studying treatment hiv-1 infection ,
PCI-27483,pci-27483 used trial studying treatment pancreatic cancer ductal adrenocarcinoma exocrine pancreatic cancer ,
Tinoridine,tinoridine investigation clinical trial nct01224756 efficacy tinoridine treating pain inflammation adult ,
HKI-357,hki 357 investigation clinical trial nct00550381 study evaluating safety tolerability pharmacokinetics pk hki-357 administered orally healthy subject ,
Cortivazol,cortivazol investigation clinical trial nct00804895 cluster headache cortivazol injection chci ,
Mavoglurant,mavoglurant used trial studying treatment patient diagnosed ocd resistant ssri treatment failed ssri 12 week appropriate dos ,
Rebastinib,rebastinib used trial studying treatment chronic myeloid leukemia inhibitor tie2 tyrosine kinase receptor antineoplastic agent ,
Cibinetide,cibinetide used trial studying basic science depression ,
Enfortumab vedotin,enfortumab vedotin antibody-drug conjugate used treatment patient advanced treatment-resistant urothelial cancer l10836 comprised fully human monoclonal antibody targeted nectin-4 microtubule-disrupting chemotherapeutic agent monomethyl auristatin e mmae joined protease-cleavable link l10836 similar brentuximab vedotin another antibody conjugated mmae target cd-30 instead nectin-4 clinical development enfortumab vedotin result collaboration astellas pharma seattle genetics a188868 first approved use united state december 2019 brand name padcev sup tm /sup l10836 enfortumab vedotin later approved european commission april 13 2022 l42000 ,enfortumab vedotin indicated treatment adult patient locally advanced metastatic urothelial cancer previously received programmed death receptor-1 pd-1 programmed death-ligand 1 pd-l1 inhibitor platinum-containing chemotherapy neoadjuvant/adjuvant locally advanced metastatic setting l10836 l41995 
"2,2-bis(4-hydroxy-3-tert-butylphenyl)propane",tbd used trial studying treatment adenocarcinoma ,
Carbendazim,carbendazim used trial studying treatment lymphoma unspecified adult solid tumor protocol specific ,
4-isothioureidobutyronitrile,thioureidobutyronitrile used trial studying treatment solid tumor ovarian cancer ,
Diethylhomospermine,diethylhomospermine used trial studying treatment diarrhea hiv infection ,
AQX-1125,aqx-1125 used trial studying treatment copd atopic dermatitis interstitial cystitis bladder pain syndrome ,
LFF-571,lff571 used trial studying treatment moderate clostridium difficile infection ,
Hypericin,hypericin investigation treatment cutaneous t-cell lymphoma ,
LY-2300559,ly2300559 used trial studying prevention migraine headache ,
Rovalpituzumab tesirine,rovalpituzumab tesirine used trial studying treatment glioblastoma malignant melanoma solid tumor small cell lung cancer medullary thyroid cancer among others ,
Dimiracetam,dimiracetam used trial studying treatment aid neuropathy acquired immunodeficiency syndrome ,
Henatinib,henatinib used trial studying treatment advanced solid cancer ,
Apratastat,tmi 005 investigation clinical trial nct00095342 study evaluating tmi-005 active rheumatoid arthritis ,
123I-iodometomidate,123i-iodometomidate investigation clinical trial nct00454103 evaluation 123i-iodometomidate adrenal scintigraphy ,
LY-2874455,ly2874455 used trial studying treatment advanced cancer ,
IPI-493,ipi-493 used trial studying treatment advanced malignancy ,
MK-8245,mk-8245 used trial studying treatment type 2 diabetes mellitus ,
Tiapride,tiapride selective d2 d3 dopamine receptor blocker brain ,tiapride indicated treatment variety neurological psychiatric disorder including dyskinesia alcohol withdrawal syndrome negative symptom psychosis agitation aggression elderly 
Ornidazole,ornidazole used trial studying prevention elective colorectal surgery ,
Tucaresol,tucaresol used trial studying treatment hiv infection ,
Biapenem,biapenem used trial studying treatment bacterial infection ,
MK-0873,mk-0873 used trial studying treatment rheumatoid arthritis ,
2'-fluoro-5-ethylarabinosyluracil,2'-fluoro-5-ethylarabinosyluracil fau used trial studying treatment small intestine lymphoma stage iv mantle cell lymphoma waldenström macroglobulinemia splenic marginal zone lymphoma recurrent mantle cell lymphoma among others ,
Niobium,niobium used trial studying treatment obesity overweight ,
Enecadin,enecadin investigated treatment stroke ,
Urocortin-2,urocortin 2 investigated basic science heart failure cardiovascular disease ,
Foxy-5,foxy-5 used trial studying treatment prostate cancer colorectal cancer metastatic colon cancer metastatic breast cancer metastatic prostate cancer ,
AG-24322,ag-024322 used trial studying treatment neoplasm lymphoma non-hodgkin ,
Ramatroban,ramatroban used trial studying treatment asthma ,
Namilumab,namilumab used trial studying treatment plaque psoriasis rheumatoid arthritis ,
Glyceryl Trioleate,glyceryl trioleate investigated treatment adrenoleukodystrophy ,
Aminaphthone,aminaftone investigated treatment cockett syndrome may-thurner syndrome iliac vein obstruction ,
Gandotinib,gandotinib used trial studying treatment myelofibrosis polycythemia vera primary myelofibrosis thrombocythemia essential myeloproliferative disorder among others ,
Odalasvir,odalasvir used trial studying treatment hepatitis c chronic chronic hepatitis c infection ,
Fenoverine,fenoverine used trial studying treatment irritable bowel syndrome ,
Gossypol,gossypol used trial studying treatment non-small cell lung cancer ,
Racotumomab,racotumomab used trial studying treatment glioma wilm 's tumor neuroblastoma retinoblastoma ewing 's sarcoma ,
Tocladesine,tocladesine used trial studying treatment colorectal cancer multiple myeloma plasma cell neoplasm ,
Pentavalent Antimony,pentavalent antimony investigated treatment cutaneous leishmaniasis ,
PAC-1,pac-1 used trial studying treatment lymphoma melanoma solid tumor breast cancer thoracic cancer among others ,
Lobaplatin,lobaplatin used trial studying treatment breast cancer hepatocellular carcinoma lobaplatin gemcitabine combination second-line treatment advanced osteosarcoma ,
Tirilazad,tirilazad used trial studying treatment spinal cord injury ,
CH-5132799,ch5132799 used trial studying treatment solid tumor ,
Upamostat,upamostat used trial studying treatment pancreatic cancer ,
CP-195543,"cp-195,543 used trial studying treatment arthritis rheumatoid ",
ACT-451840,act-451840 used trial studying malaria ,
Oteseconazole,oteseconazole azole metalloenzyme inhibitor target fungal cyp51 l41635 cyp51 also known 14α demethylase participates formation ergosterol compound play vital role integrity cell membrane l41635 a247020 binding inhibiting cyp51 oteseconazole active microorganism associated recurrent vulvovaginal candidiasis rvvc l41635 oteseconazole demonstrated activity _candida albicans_ _candida glabrata_ _candida krusei_ _candida parapsilosis_ _candida tropicalis_ _candida lusitaniae_ _candida dubliniensis_ l41635 unlike previous-generation azole antifungal oteseconazole high selectivity cyp51 little interaction human cytochrome p450s a247035 possible thanks tetrazole moiety oteseconazole increase target selectivity a247035 contrast oteseconazole antifungal imidazole triazole moiety ketoconazole fluconazole high number drug-drug interaction due interaction human cyps a247050 use oteseconazole contraindicated female reproductive potential due embryo-fetal toxicity risk l41635 drug approved fda april 26 2022 l41645 ,oteseconazole azole antifungal indicated reduce incidence recurrent vulvovaginal candidiasis rvvc female history rvvc reproductive potential l41635 
Irsogladine,irsogladine investigation clinical trial nct02581696 drug-drug interaction safety lafutidine irsogladine maleate healthy adult volunteer ,
Torapsel,torapsel used trial studying prevention ischemia reperfusion injury ,
Methanesulfonyl Fluoride,methanesulfonyl fluoride used trial studying treatment safety ,
PF-03814735,pf-03814735 used trial studying treatment solid tumor ,
CEP-37440,cep-37440 used trial studying treatment solid tumor ,
MLN8054,mln8054 used trial studying treatment colon neoplasm breast neoplasm bladder neoplasm pancreatic neoplasm advanced malignancy ,
ME-344,me-344 used trial studying treatment solid tumor ,
Parthenolide,parthenolide used trial studying diagnostic allergic contact dermatitis ,
Tramazoline,tramazoline investigation clinical trial nct01601509 nasal tramazoline dexamethazone obstructive sleep apnea osa patient tramazoline ,
LY-2811376,ly2811376 used trial studying basic science alzheimer 's disease ,
Liarozole,liarozole used trial studying treatment ichthyosis lamellar ,
Rotigaptide,rotigaptide investigation basic science heart disease vascular disease ,
9-(N-methyl-L-isoleucine)-cyclosporin A,9- n-methyl-l-isoleucine -cyclosporin nim811 used trial studying treatment chronic hepatitis c genotype-1 relapse ,
Nimustine,nimustine used trial studying treatment glioblastoma ,
Surinabant,surinabant investigated treatment smoking cessation ,
Creatinolfosfate,cop investigation treatment rheumatoid arthritis mature b-cell lymphoma noninflammatory degenerative joint disease cop investigated treatment diabetic retinopathy ,
GDC-0349,gdc-0349 used trial studying treatment non-hodgkin 's lymphoma solid tumor ,
Tregalizumab,tregalizumab used trial studying treatment rheumatoid arthritis ,
Macimorelin,macimorelin novel orally active ghrelin mimetic stimulates gh secretion used diagnosis adult gh deficiency aghd specifically macimorelin peptidomimetic growth hormone secretagogue ghs act agonist gh secretagogue receptor ghrelin receptor ghs-r1a dose-dependently increase gh level a31481 growth hormone secretagogues ghs represent new class pharmacological agent potential used numerous clinical application include treatment growth retardation child cachexia associated chronic disease aid cancer growth hormone gh classically linked linear growth childhood deficiency hormone aghd commonly associated increased fat mass particularly abdominal region decreased lean body mass osteopenia dyslipidemia insulin resistance and/or glucose intolerance overtime addition individual may susceptible cardiovascular complication altered structure function a31484 risk factor aghd include history childhood-onset gh deficiency hypothalamic/pituitary disease surgery irradiation area head trauma evidence pituitary hormone deficiency a31481 various therapy available gh replacement therapy absence panhypopituitarism low serum igf-i level nonspecific clinical symptom pose challenge detection diagnosis aghd diagnosis aghd requires biochemical confirmation least 1 gh stimulation test a31481 macimorelin clinically useful since display good stability oral bioavailability comparable affinity ghrelin receptor endogenous ligand clinical study involving healthy subject macimorelin stimulated gh release dose-dependent manner good tolerability a31481 macimorelin developed aeterna zentaris approved fda december 2017 market name macrilen oral solution ,indicated diagnosis adult growth hormone deficiency aghd fda label 
Menaquinone 7,menaquinone 7 investigation clinical trial nct00402974 effect vitamin k supplementation osteocalcin carboxylation healthy child ,
Yttrium Y-90,yttrium 90 investigated treatment colon cancer colorectal cancer ,
LCB01-0371,lcb01 0371 investigation clinical trial nct01554995 clinical study randomized double-blind placebo-controlled single dose study ,
KOSN-1724,kosn-1724 investigation clinical trial nct01379287 dose-escalation safety pharmacokinetic study iso-fludelone patient advanced solid tumor ,
Roluperidone,roluperidone used trial studying treatment schizophrenia ,
Nefiracetam,nefiracetam used trial studying treatment alzheimer 's disease ,
Talarozole,talarozole investigated treatment psoriasis cutaneous inflammation ,
Pyritinol,pyritinol used trial studying treatment dementia depression schizophrenia anxiety disorder psychosomatic disorder ,
Lumefantrine co-artemether,lumefantrine co-artemether riamet investigated treatment malaria malaria falciparum malaria pregnancy uncomplicated malaria uncomplicated knowlesi malaria lumefantrine co-artemether tablet formulation artemether lumefantrine well-tolerated fast-acting effective blood schizontocidal drug serf primarily treatment uncomplicated falciparum malaria resistant antimalarial artemether artemisinin derivative several proposed mechanism action including interference plasmodial transport protein interference mitochondrial electron transport production free radical reduce blood antioxidant glutathione artemether result rapid defervescence parasite clearance clinical improvement also relatively high recrudescence rate used monotherapy exact mechanism action lumefantrine well defined thought inhibit -hematin formation important detoxification pathway parasite unlike artemether lumefantrine slower onset action resulting clearance residual parasite decrease recrudescence rate combination effective well-tolerated malaria treatment providing high cure rate even area multi-drug resistance ,
Acoziborole,scyx-7158 used trial studying treatment trypanosomiasis parasitic disease protozoan infection trypanosomiasis african ,
Miridesap,miridesap used trial studying prevention hiv ,
AZD-0424,azd0424 used trial studying treatment advanced solid tumour ,
Enoxolone,enoxolone glycyrrhetic acid investigated basic science apparent mineralocorticoid excess ame ,
Zidebactam,zidebactam investigation clinical trial nct02674347 mad study evaluate safety tolerability pharmacokinetics intravenous zidebactam healthy adult ,
Tiropramide,tiropramide investigation clinical trial nct01629212 comparison efficacy safety tiropramide octylonium treatment irritable bowel syndrome ,
Meclocycline,meclocycline investigation clinical trial nct00385515 efficacy snx-1012 treatment oral mucositis l797 ,currently investigation topical treatment ulcerative oral mucositis l797 
TAK-593,tak-593 used trial studying treatment solid tumor ,
Pruvanserin,pruvanserin used trial studying treatment sleep initiation maintenance disorder ,
JTK-853,jtk-853 used trial studying treatment hepatitis c virus infection response therapy ,
Gacyclidine,gacyclidine used trial studying treatment tinnitus ,
1alpha-Hydroxyvitamin D5,1alpha-hydroxyvitamin d5 card-024 used trial studying treatment drug safety heart disease activity ,
CT-2584,ct-2584 used trial studying treatment prostate cancer ,
Valnoctamide,valnoctamide used trial studying treatment mania schizoaffective disorder manic type ,
Biguanide,biguanide investigated treatment diabetes mellitus ,
4SC-202,4sc-202 used trial studying treatment advanced hematologic malignancy ,
AZD-8418,azd8418 investigation clinical trial nct01027234 study ass safety tolerability azd8418 single increasing oral dos ,
Camsirubicin,gpx-150 used trial studying treatment soft tissue sarcoma advanced solid tumor phase 1 population ,
X-396,x-396 used trial studying treatment advanced solid tumor non-small cell lung cancer ,
Resolvin E1,resolvin e1 rx 10001 investigation clinical trial nct00941018 single multiple ascending oral dose study resolvin e1 healthy volunteer ,
Glycovir,glycovir used trial studying treatment hiv infection ,
QGC-001,qgc001 used trial studying treatment essential hypertension ,
Mephedrone,mephedrone investigated alcohol-related disorder amphetamine-related disorder ,
PKI-179,pki-179 used trial studying treatment advanced malignant solid tumor ,
Antimony,antimony used trial studying treatment cutaneous leishmaniasis ,
Chromanol,chromanol used trial studying treatment prostate cancer ,
Dolcanatide,dolcanatide investigated exposure ,
JNJ-38877605,jnj-38877605 used trial studying treatment neoplasm ,
Amitriptylinoxide,amitriptylinoxide used trial studying major depression ,
Saroglitazar,saroglitazar investigated treatment fatty liver ,
Norflurane,norflurane investigation clinical trial nct01673061 vapocoolant spray numbing small boil incision drainage ,
Pentafluoropropane,pentafluoropropane investigation clinical trial nct01673061 vapocoolant spray numbing small boil incision drainage ,
Paquinimod,paquinimod developed treatment sle systemic lupus erythematosus autoimmune disease disease affect mainly woman fertile age progress flare relatively symptom free period current treatment sle nsaid nonsteroidal anti-inflammatory drug corticosteroid antimalarians cytotoxic drug like example cyclophosphamide autoimmune attack affect several different organ system many patient suffer serious secondary disease symptom renal disorder disease progress ,
GSK-364735,gsk-364735 naphthyridinone used trial studying treatment hiv-1 infection infection human immunodeficiency virus ,
Deferitazole,deferitazole used trial studying treatment basic science beta-thalassemia hepatic impairment impaired renal function transfusional iron overload iron overload due repeated red blood cell transfusion ,
Hydroxypropyl tetrahydropyrantriol,hydroxypropyl tetrahydropyrantriol used trial studying basic science aging ,
Trabodenoson,trabodenoson used trial studying treatment ocular hypertension oht primary open-angle glaucoma poag ,
OTX-008,otx008 used trial studying treatment solid tumor ,
Troxerutin,troxerutin used trial studying treatment chronic venous insufficiency ,
Lusutrombopag,"lusutrombopag orally bioavailable thrombopoietin receptor tpor agonist developed shionogi company osaka japan tpor regulatory target site endogenous thrombopoietin act primary cytokine promote megakaryocyte proliferation differentiation affect hematopoietic lineage well including erythroid granulocytic lymphoid lineage a36736 thrombocytopenia indicates abnormally low level platelet common complication related chronic liver disease hematological abnormality especially case severe thrombocytopenia platelet count 50,000/μl creates challenge patient requiring invasive medical procedure significant risk spontaneous bleeding a36732 lusutrombopag bind transmembrane domain tpor expressed megakaryocyte cause proliferation differentiation megakaryocytic progenitor cell hematopoietic stem cell fda label september 2015 lusutrombopag received first global approval japan reduce need platelet transfusion adult chronic liver disease thrombocytopenia schedule undergo invasive medical procedure a36730 lusutrombopag approved fda july 31st 2018 therapeutic indication market name mulpleta two randomized double-blind placebo-controlled trial patient chronic liver disease severe thrombocytopenia undergoing invasive procedure platelet count le 50 x 10^9/l administered lusutrombopag orally l4166 higher percentage 65-78 patient receiving lusutrombopag required platelet transfusion prior primary invasive procedure compared receiving placebo l4166 lusutrombopag currently phase iii development various european country including austria belgium germany uk a36730 ",lusutrombopag indicated treatment thrombocytopenia adult chronic liver disease scheduled undergo medical dental procedure 
BMS-986115,bms-986115 used trial studying treatment various advanced cancer ,
Olokizumab,interleukin-6 il-6 important cytokine role immune cell proliferation/differentiation energy bone metabolism acute phase response innate immune system il-6 pathway dysregulation associated chronic inflammation lymphoproliferation including autoimmune condition rheumatoid arthritis castleman disease cytokine release syndrome targeting il-6 function achieved directly interrupting il-6 receptor gp130 receptor ax a241185 a241175 olokizumab humanized anti-il-6 igg4κ antibody directly block gp130 binding il-6 site 3 a241045 ,
Sizofiran, beta-d-glucan obtained aphyllophoral fungus schizophyllum commune used immunoadjuvant treatment neoplasm especially tumor found stomach sizofiran used trial studying treatment cervical cancer ,
Trimegestone,trimegestone used trial studying treatment postmenopause ,
Serrapeptase,serrapeptase proteolytic enzyme preparation used concomitantly antibiotic osteoarticular infection serratiopeptidase investigation clinical trial nct02493179 efficacy evaluation serodase 5 mg tablet treatment inflammation third molar surgery ,
Artemisinin,artemisinin used trial studying treatment schizophrenia malaria falciparum plasmodium falciparum ,
Von Willebrand factor human, human von willebrand factor vwf human plasma-derived vwf endogenous large multimeric plasma glycoprotein involved hemostasis serf dual role hemostasis mediating platelet adhesion aggregation site blood vessel injury stabilizing procoagulant factor viii fviii a32262 exogenous source vwf used restore functional level vwf blood disorder associated deficient abnormal blood clotting human vwf used manage control bleeding episode patient von willebrand disease hemophilia first approved fda 2015 l40049 vwf normally present blood stable complex coagulation factor iii therapeutic vwf product also available combination product antihemophilic factor human l1878 recombinant form vwf vonicog alfa also available enhance production avoid theoretical risk pathogen transmission plasma donor a32262 , von willebrand factor vwf indicated manage control bleeding episode adult von willebrand disease also used perioperative management bleeding patient also used routine prophylaxis reduce frequency bleeding episode patient severe type 3 von willebrand disease receiving on-demand therapy l40049 combination antihemophilic factor human vwf also used manage control bleeding associated von willebrand disease child adult well perioperative management bleeding patient combination product also used management control bleeding episode adolescent adult hemophilia well routine prophylaxis reduce frequency bleeding episode l1878 
Fluorine F-18,fluorine-18 investigation clinical trial nct00870974 pet brain imaging study mglur5 subject neuropsychiatric condition ,
AGN-201904,agn 201904 used trial studying prevention peptic ulcer ,
Fluindione,fluindione investigation treatment venous thrombosis pulmonary embolism permanent atrial fibrillation anticoagulating treatment duration least 12-month-old superior fluindione investigated treatment blood coagulation disorder ,
PM-060184,pm060184 used trial studying solid tumor ,
Neladenoson bialanate,neladenoson bialanate investigated treatment heart failure ,
Levosalbutamol,levosalbutamol levalbuterol short-acting β2 adrenergic receptor agonist used treatment asthma chronic obstructive pulmonary disease copd salbutamol marketed racemic mixture although beta2-agonist activity resides almost exclusively r -enantiomer enantioselective disposition salbutamol possibility -salbutamol adverse effect led development enantiomerically pure r -salbutamol formulation known levosalbutamol levalbuterol ,indicated management copd chronic obstructive pulmonary disease also known chronic obstructive lung disease asthma 
Bezlotoxumab,bezlotoxumab human monoclonal antibody bind clostridium difficile toxin b neutralizes effect used reduce recurrence clostridium difficle infection adult receiving antibiotic therapy treat c. difficile infection high risk recurrence ,prevents recurrence clostridium difficile infection people 18 year older either currently receiving treatment c. difficile infection high risk recurrence 
Calcium glubionate anhydrous,calcium glubionate glubionate calcium mineral supplement prevent treat low blood calcium level people get enough calcium diet ,calcium glubionate indicated treat condition caused low calcium level bone loss osteoporosis weak bone osteomalacia/rickets decreased activity parathyroid gland hypoparathyroidism certain muscle disease latent tetany may also used certain patient make sure getting enough calcium e.g. woman pregnant nursing postmenopausal people taking certain medication phenytoin phenobarbital prednisone 
Lenograstim,lenograstim recombinant granulocyte colony-stimulating factor used immunostimulating agent , drug used reduce risk life-threatening infection patient neutropenia particularly cytotoxic chemotherapy lenograstim indicated treatment reduce duration neutropenia severity infection patient non-myeloid malignancy undergone autologous allogeneic bone marrow transplantation treatment established cytotoxic chemotherapy addition reduce incidence infection associated established cytotoxic chemotherapy lenograstim also indicated mobilise peripheral blood progenitor cell pbpcs lenograstim alone myelosuppressive chemotherapy order accelerate haematopoietic recovery infusion cell myelosuppressive myeloablative therapy lenograstim also indicated accelerate engraftment cell reinfusion granocyte also indicated treatment severe chronic neutropenia including congenital agranulocytosis kostmann 's syndrome 
Nedaplatin,nedaplatin second generation platinum analog a20300 le nephrotoxic db00515 proven equally effective approved use japan 1995 ,used treatment non-small cell lung cancer small cell lung cancer oesophygeal cancer head neck cancer a20300 
Fluciclovine (18F),fluciclovine 18f -tagged synthetic analog amino acid l-leucine present excellent diagnostic property used positron emission tomography pet imaging a31384 structure fluciclovine allows uptaken tumoral cell amino acid transporter without incorporating metabolism within body a31385 fluciclovine developed blue earth diagnostics ltd. fda approved may 27 2016 l1049 ,fluciclovine indicated detection agent positron emission tomography pet men suspected prostate cancer recurrence based elevated blood prostate specific antigen psa level following prior treatment a31388 overexpression l-type amino acid transporter lat1 lat3 mediate uptake essential amino acid extensively reported tumoral mechanism cell growth a31389 
Pancrelipase lipase,pancrelipase general composed mixture pancreatic enzyme include amylase lipase protease enzyme extracted porcine pancreatic gland l2509 pancrelipase lipase enzyme secreted pancreas responsible hydrolysis dietary fat molecule human digestive system a32748 pancrelipase mixture including pancrelipase lipase developed ortho-mcneil-janssen pharmaceutical inc fda approved april 12 2010 l2510 ,please refer db00085 
Coagulation factor X human,coagulation factor x human plasma-derived human blood coagulation factor used adult child aged 12 year hereditary factor x deficiency however use limited perioperative setting management bleeding major surgery patient moderate severe hereditary factor x deficiency coagulation factor x vitamin k-dependent liver-produced serine protease serf first enzyme coagulation cascade form fibrin two-chain glycoprotein molecular weight approximately 59 kda a31472 factor x normally circulates plasma inactive molecule activation factor x involved intrinsic extrinsic coagulation pathway inherited factor x deficiency rare autosomal recessive bleeding disorder estimated occur 1:1 000 000 individual 1:500 carrier a31471 administration coagulation factor x healthy donor serf restore achieve effective hemostasis coagulation factor x human solution approved fda intravenous injection market name coagadex contains normally 100 iu/ml coagulation factor x derived healthy donor passed viral screening test l41045 , human coagulation factor x indicated adult child hereditary factor x deficiency routine prophylaxis reduce frequency bleeding episode on-demand treatment control bleeding episode perioperative management bleeding patient mild moderate hereditary factor x deficiency l41045 also indicated urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e.g. warfarin therapy adult patient acute major bleeding l12834 
Protein S human,protein human vitamin k-dependent plasma glycoprotein antcoagulant property a19561 serf negative feedback mechanism coagulation cascade , use emergency reversal coagulation factor deficiency patient recieving vitamin k antagonist therapy fda label protein administered part cocktail containing several coagulation factor 
Coagulation factor VII human,coagulation factor vii human serine protease type enzyme involved extrinsic coagulation cascade result blood clotting ,may administered case uncontrolled bleeding factor vii alone used treatment congenital hemophilia b acquired hemophilia congenital factor vii deficiency glanzmann 's thrombasthenia label use treatment refractory bleeding cardiac surgery warfarin related intracerebral hemorrhage brand human factor vii currently combination vitamin k coagulation factor used reverse vitamin k antagonist activity patient acute major bleeds urgent surgery/invasive procedure 
Anti-inhibitor coagulant complex,anti-inhibitor coagulant complex also known feiba factor eight inhibitor bypassing activity contains several protein involved prothrombinase complex used control bleeding hemophilia b patient inhibitor , use control bleeding episode perioperative management routine prophylaxis bleeding episode hemophilia b patient inhibitor fda label indicated absence factor viii ix inhibitor 
Coagulation Factor IX Human,factor ix christmas factor one serine protease coagulation system belongs peptidase family s1 deficiency protein cause hemophilia b ,factor ix used treat christmas disease factor ix deficiency treated injection factor ix produced human plasma tranexamic acid may value patient undergoing surgery inherited factor ix deficiency order reduce perioperative risk bleeding 
Levomenol,bisabolol formally α- − -bisabolol also known levomenol -alpha-bisabolol found fat oil -alpha-bisabolol isolated essential oil matricaria chamomilla german chamomile -alpha-bisabolol belongs family sesquiterpenes terpene three consecutive isoprene unit ,levomenol known elicit number potentially beneficial pharmacological effect including anti-irritant anti-inflammatory anti-microbial action bisabolol also demonstrated enhance percutaneous absorption certain molecule
Parachlorophenol,p-chlorophenol white crystal strong phenol odor slightly soluble soluble water depending isomer denser water noncombustible ,used intermediate organic synthesis dye drug local antibacterial agent root canal therapy topical antiseptic ointment
Esculin,esculin found barley vitamin c2 generally considered bioflavanoid related vitamin p esculin glucoside naturally occurs horse chestnut aesculus hippocastanum california buckeye aesculus californica daphnin dark green resin daphne mezereum esculin belongs family glycosyl compound carbohydrate derivative sugar group bonded anmoeric carbona another group via c- s- n- o- se- glycosidic bond , medication esculin sometimes used vasoprotective agent esculin also used microbiology laboratory aid identification bacterial specie especially enterococci listeria strain group streptococci hydrolyze æsculin 40 bile 
Inosine pranobex,inosine pranobex isoprinosine methisoprinol combination inosine acetamidobenzoic acid dimethylaminoisopropanol used antiviral drug ,inosine pranobex also indicated mucocutaneous infection due herpes simplex virus type 1 type ii treatment genital wart adjunctive therapy podophyllin carbon dioxide laser 
Sodium lauryl sulfoacetate,sodium lauryl sulfoacetate wetting agent surfactant used enema-type laxative product ,sodium lauryl sulfoacetate active pharmacological ingredient pharmaceutical preparation official indication 
Clobetasone,clobetasone corticosteroid often employed topically treatment variety condition eczema psoriasis various form dermatitis also certain ophthalmologic condition topical clobetasone butyrate shown minimal suppression hypothalamic-pituitary-adrenal axis , dermatology topical clobestasone butyrate help reduce itchiness erythema associated eczema dermatitis ophthalmology clobetasone butyrate 0.1 eye drop shown safe effective treatment dry eye sjögren 's syndrome 
Nusinersen, antisense oligonucleotide induces survival motor neuron smn protein expression approved u.s. fda december 2016 spinraza treatment child adult spinal muscular atrophy sma adminstrated direct intrathecal injection ,indicated treatment spinal muscular atrophy sma pediatric adult patient 
Terpin hydrate,terpin hydrate expectorant commonly used loosen mucus ease congestion patient presenting acute chronic bronchitis related pulmonary condition derived source turpentine oregano thyme eucalyptus popular united state since late nineteenth century removed marketed medication 1990s fda stated `` based evidence currently available inadequate data establish general recognition safety effectiveness ingredient '' elixir terpin hydrate still available patient prescription medication prepared specialty compounding pharmacy ,terpin hydrate used treatment acute chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious inflammatory disease upper respiratory tract 
Olmutinib,olmutinib orally active epidermal growth factor receptor inhibitor used treatment t790m mutation positive non-small cell lung cancer available brand name olita made hanmi pharmaceutical a19196 olmutinib developed hanmi pharmaceutical boehringer ingelheim olmutinib recieved breakthrough therapy designation united state december 2015 approved use korea may 2016 , use treatment metastatic t790m mutation positive non-small cell lung cancer a19196 
Ripasudil,ripasudil hydrochloride hydrate k-115 specifc rho-associated coiled-coil containing protein kinase rock inhibitor used treatment glaucoma ocular hypertension first approved treatment japan september 2014 medication available form 0.4 eye drop solution brand name glanatec ripasudil well tolerated medication used drug proven non-effective administered ,ripasudil proven effective twice daily treatment glaucoma ocular hypertension currently study approved diabetic retinopathy diabetic macular oedema 
Zofenopril,zofenopril employed cardioprotective anti-hypertensive agent angiotensin-converting enzyme ace inhibitor ,
Alclofenac,alclofenac non-steroidal anti-inflammatory drug withdrawn market united kingdom 1979 ,alclofenac indicated rheumatology particular treatment rheumatoid arthritis ankylosing spondylitis analgesic painful arthritic pathology 
Omega-6 fatty acids,omega-6 fatty acid polyunsaturated fatty acid final carbon-carbon double bond n-6 position sixth bond counting methyl end family fatty acid molecule act precursor potent lipid mediator signalling molecule either pro-inflammatory anti-inflammatory effect cell involved inflammatory response typically rich n-6 fatty acid arachidonic acid generally eicosanoids derived n-6 pufa pro-inflammatory arachidonic acid main precursor eicosanoids example omega-6 n-6 polyunsaturated fatty acid vegetable oil major dietary source omega-6 fatty acid , current pharmacotherapeutic product based omega-6 fatty acid 
Nandrolone,nandrolone also known 19-nortestosterone 19-norandrostenolone synthetic anabolic-androgenic steroid aa derived testosterone ,
Plecanatide,plecanatide drug approved january 2017 fda treatment chronic idiopathic constipation cic used child le six year age avoided patient six year 18 year age,plecanatide indicated treatment chronic idiopathic constipation cic irritable bowel syndrome constipation ibs-c adult patient l35044 
Tunicamycin,tunicamycin mixture homologous nucleoside antibiotic inhibits udp-hexnac polyprenol-p hexnac-1-p family enzyme one member family enzyme glcnac phosphotransferase gpt catalyzes transfer n-acetylglucosamine-1-phosphate udp-n-acetylglucosamine dolichol phosphate first step glycoprotein synthesis eukaryote tunicamycin block n-linked glycosylation n-glycans resulting cell cycle arrest g1 phase human cell used experimental tool induce unfolded protein response tunicamycin produced streptomyces clavuligerus streptomyces lysosuperficus bacteria along several specie ,
Cerliponase alfa,cerliponase alfa enzyme replacement treatment specific form batten disease first fda-approved treatment slow loss walking ability ambulation symptomatic pediatric patient 3 year age older late infantile neuronal ceroid lipofuscinosis type 2 cln2 also known tripeptidyl peptidase-1 tpp1 deficiency intraventricular administration drug allows significant uptake brain cerliponase alfa approved april 2017 brineura ,cerliponase alfa treatment late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease decelerate progressive motor function decline patient 3 year age older cln2 disease form batten disease rare inherited neurodegenerative disorder associated seizure ataxia rapid loss language motor function blindness early death l755 caused lack lysosomal enzyme tripeptidyl peptidase-1 tpp1 subsequent accumulation lysosomal storage material normally metabolized enzyme central nervous system 
Rhein,rhein anthraquinone metabolite rheinanthrone senna glycoside present many medicinal plant including rheum palmatum cassia tora polygonum multiflorum aloe barbadensis a19247 known hepatoprotective nephroprotective anti-cancer anti-inflammatory several protective effect , approved indication 
Rheinanthrone,rheinanthrone active metabolite senna glycoside db11365 known laxative effect a19235 commonly produced plant rheum specie l772 , approved indication 
Inositol,"inositol collection nine different stereoisomers name usually used describe common type inositol myo-inositol myo-inositol cis-1,2,3,5-trans-4,6-cyclohexanehexol prepared aqueous extract corn kernel precipitation hydrolysis crude phytate molecule structural similarity glucose involved cellular signaling considered pseudovitamin molecule qualify essential vitamin even though presence vital body deficiency molecule translate disease condition l2560 inositol found ingredient otc product health canada current product whose main ingredient inositol discontinued l1113 fda inositol considered list specific substance affirmed generally recognized safe gras l2561 ",inositol may used food without limitation drug inositol used nutrient supplement special dietary food infant formula l2561 present relevant role ensuring oocyte fertility inositol studied use management polycystic ovary a32751 inositol also researched treatment diabetes a32766 prevention metabolic syndrome a32768 aid agent weight loss a32769 treatment depression psychiatric disorder anxiety disorder a32770 prevention cancer a32771 
Troleandomycin, macrolide antibiotic similar erythromycin , treatment bacterial infection 
Gluconic Acid,commonly found salt sodium calcium gluconic acid gluconate used maintain cation-anion balance electrolyte solution , use part electrolyte supplementation total parenteral nutrition fda label 
Oxabolone cipionate,oxabolone cipionate c17β cypionate ester prodrug db01500 synthetic anabolic-androgenic aa steroid derivative 19-nortestosterone nandrolone considered performance enhancing drug thus prohibited use sport ,used performance enhancing drug illicitly athlete 
Calcitonin porcine,calcitonin polypeptide hormone secreted parafollicular cell thyroid gland mammal inhibits bone resorption lower serum urinary calcium concentration human calcitonin available small quantity used study first commercially available preparation britain porcine calcitonin brand name calcitare ,
Phosphocreatine,phosphocreatine creatine phosphate phosphorylated form creatine primarily found endogenously skeletal muscle vertebrate serf critical role rapidly acting energy buffer muscle cell action like contraction via ability regenerate adenosine triphosphate atp adenosine diphosphate adp ,phosphocreatine naturally occuring substance found predominantly skeletal muscle vertebrate primary utility within body serve maintanence recycling adenosine triphosphate atp muscular activity like contraction given utility phosphocreatine recycle atp plausible therapeutic potential use involve condition caused energy shortage increased energy requirement ischemic stroke cerebrovascular disease important note however relatively little clinical research done significantly evidence indication although administered intravenously cardiovascular condition country additionally phosphocreatine regulated controlled substance taken supplement professional athlete mean perhaps increase short burst muscle strength energy professional athletics 
Antihemophilic factor human,antihemophilic factor human also known coagulation factor viii anti-hemophilic factor ahf non-recombinant lyophilized concentrate coagulation factor viii endogenous protein essential component coagulation cascade antihemophilic factor manufactured reduced amount von willebrand factor antigen vwf ag purified extraneous plasma-derived protein affinity chromatography small amount vwf ag used purify factor viii complex removed final preparation final purified concentrate contains albumin stabilizer. l1053 complex developed csl behring baxter healthcare corporation approved 90 endogenous factor viii essential clotting process body due involvement clotting cascade responsible acting co-factor factor ix activation factor ix lead cascade signal result activation factor x result conversion prothrombin thrombin result lead conversion fibrinogen fibrin fibrous protein creates scaffold clot replacement factor viii essential treatment hemophilia caused mutation factor viii gene leading functional deficiency complete loss protein congenital loss deficiency factor viii result physiologic impairment coagulation clotting cascade result lead easy bruising bleeding bleeding range severity minor concern nosebleed serious event hemorrhaging joint brain digestive tract a32280 exogenous replacement factor viii currently cornerstone hemophilia treatment used prophylaxis control bleeding episode treatment drastically improved since 1960s factor viii protein primarily purified human plasma rather produced recombinant dna technology unfortunately purification protein human plasma carry increased risk transmission blood-borne disease hiv hepatitis part contributed tainted blood scandal 1980s 1990s a31551 a32272 drug product similar structure function antihemophilic factor human include db13999 produced recombinant dna technology identical sequence endogenously produced factor viii contain b-domain known biological function db11607 fully recombinant factor viii-fc fusion protein extended half-life compared conventional factor viii due conjugation dimeric fc domain human immunoglobulin g1 long-lived plasma protein a31551 antihemophilic factor human approved food drug administration use hemophilia classical hemophilia prevention control hemorrhagic episode fda label , human antihemophilic factor indicated case hemophilia also known classical hemophilia prevention control hemorrhagic episode l1055 surgery needed patient hemophilia need correction clotting abnormality case human antihemophilic factor may administered followed intermittent maintenance dos l1053 hemophilia characterized deficiency coagulation factor viii result prolonged blood flow injury surgery well recurrent bleeding t56 
Vitex agnus-castus fruit extract,vitex agnus-castus fruit extract obtained dry fruit vitex agnus-castus fruit contain mixture iridoids flavonoid compound leaf flower structurally resemble sex hormone clinical study demonstrates effectiveness vitex agnus-castus fruit extract management premenstrual stress syndrome pm cyclical breast pain mastalgia main mechanism action vitex agnus-castus fruit extract fully elucidated however suggested modulate stress-induced prolactin secretion via dopaminergic action μ mu δ delta -opioid receptor ,
Hedera helix leaf extract,hedera helix leaf extract allergenic extract used allergenic testing ,
Horse chestnut,horse chestnut flowering plant commonly referred aesculus hippocastanum unprocessed horse chestnut seed contain toxin called esculin also spelled aesculin increase risk bleeding due anticoagulant action seed processed remove toxic component resulting purified horse chestnut seed extract hcse a27200 active component pure extract escin aescin promotes blood circulation vein reduces swelling inflammation leg therapeutic potential treatment chronic venous insufficiency studied ,
Valerian,valerian extracted herb perennial flowering plant valerian root reported sedative anxiolytic effect however mechanism action completely understood valerian used treatment condition including sleep disorder anxiety attention deficit-hyperactivity disorder adhd joint pain db00313 derivative valeric acid obtained plant root valerian food ingredient permitted direct addition food human consumption natural flavoring substance ,
Pepsin,pepsin potent enzyme gastric juice digest protein meat egg seed dairy product l2358 study gastric digestion 1820-1840 led discovery pepsin substance presence stomach acid cause nutrient including meat coagulated egg white dissolve soon afterward shown protein nutrient cleaved pepsin product called _peptones_ a32603 pepsin often used replacement enzyme pancreatic insufficiency l2357 stimulation pancreas therefore enzymatic digestion food tightly controlled hormonally mediated process change condition affecting metabolic step successful digestion absorption negatively affect pancreatic enzymatic secretion entry intestine functionality inside intestine appropriate mixing foods/nutrients many cause pancreatic insufficiency require enzyme replacement therapy started including cystic fibrosis pancreatic cancer acute chronic pancreatitis well pancreatic surgery l2357 pepsin approved fda used food level exceed current good manufacturing practice l2363 interestingly used marker laryngopharyngeal reflux lpr common illness otolaryngology ear nose throat specialist visit a32604 interestingly recent research suggested pepsin participates digestion nucleic acid l2391 ,used pancreatic enzyme replacement pancreatic insufficiency l2357 intended mimic naturally produced human pepsin l2360 pepsin powder prepared gastric mucosa pig cattle sheep l2367 laboratory primarily used unspecific hydrolysis protein peptide acidic medium addition provides limited hydrolysis native immunoglobulin yielding biologically active fragment l2353 certain supplement pepsin may combined betaine hcl hydrochloric acid aid digestion various gastrointestinal condition l2360 l2352 
Lipegfilgrastim,"lipegfilgrastim previously known xm22 pegylated recombinant granulocyte colony-stimulating factor g-csf synthetized using highly site-specific glycopegylation technology a32665 used alternate db00019 prophylactic use cancer patient receiving chemotherapy risk developing chemotherapy-induced neutropenia since july 2013 lipegfilgrastim marketed ema lonquex subcutaneously injection administered following cytotoxic chemotherapy chemotherapy cycle adult patient treated cytotoxic chemotherapy malignancy aim reduce duration neutropenia incidence febrile neutropenia neutropenia febrile neutropenia fn frequent potentially fatal complication occur myelosuppressive anticancer treatment a32665 severe chemotherapy-induced neutropenia febrile neutropenia significantly increase risk life-threatening infection sepsis granulocyte colony-stimulating factor g-csfs introduced 1980 's clinical setting stimulate neutrophil proliferation differentiation thereby reducing duration severity chemotherapy-induced neutropenia a32665 lipegfilgrastim covalent conjugate db00099 single methoxy polyethylene glycol peg molecule via carbohydrate linker consisting glycine n-acetylneuraminic acid n-acetylgalactosamine l2441 average molecular mass lipegfilgrastim comprises 18,798 da db00099 203 da galnac 338 da glycylsialic acid approximately 20,000 da peg l2449 peg moiety protects active molecule enzyme degradation allows longer half-life drug le frequent dosing-schedule addition acceptable safety efficacy profile a32665 ",indicated reduction duration neutropenia incidence febrile neutropenia adult patient treated cytotoxic chemotherapy malignancy exception chronic myeloid leukaemia myelodysplastic syndrome l2441 
Trenonacog alfa,human coagulation factor ix ec 3.4.21.22 christmas factor plasma thromboplastin component produced cho cell ,
Bamifylline,bamifylline selective a1 adenosine receptor antagonist ,
Dimethyl carbate,dimethyl carbate used insect repellant ,
Teclozan,teclozan antiprotozoal agent employed typically therapy treat protozoan infection ,
Prednylidene,prednylidene experimental systemic glucocorticoid ,
Bismuth subnitrate,bismuth subnitrate also referred bismuth oxynitrate bismuthyl nitrate highly water-soluble crystalline compound used treatment duodenal ulcer anti-diarrheic agent a33012 use bismuth substrate active ingredient over-the-counter antacid approved fda ,indicated over-the-counter use antacid 
Sodium chlorite,used agent cleaning drinking water also used additive product like toothpaste mouthwash acidified sodium chlorite approved u.s. food drug administration 2004 anti-microbial agent non-toxic drug a174811 l5413 ,
Guanoxan,guanoxan antihypertensive agent similar mechanism action guanethidine may cause liver damage guanoxan approved uk withdrawn market due hepatotoxicity ,
Phenolsulfonphthalein,phenolsulfonphthalein otherwise called phenol red ph indicator commonly used cell biology laboratory phenolsulfonphthalein investigated use clinically due weak estrogen mimicking action a174964 ,
Butaperazine,butaperazine approved 1967 l5143 possibly discontinued 1980s t397 ,
Sulfobromophthalein,sulfobromophthalein otherwise called bromsulphthalein used test liver function human a174970 ,
Oxolamine,oxolamine approved usa may marketed elsewhere internationally cough suppressant l5416 listed prescription drug new zealand legislation l5419 oxolamine also approved taiwan treatment respiratory tract inflamation l5422 ,
Mandelic acid,mandelic acid approved aromatic alpha hydroxy acid l5458 mandelic acid used ingredient cosmetic drug product applied topically ,
Medifoxamine,medifoxamine marketed atypical antidepressant anxiolyitc property france spain morrocco 1990s later withdrawn market due causing case hepatotoxicity l5461 a174976 ,
Ferrous aspartate, use ferrous acetate ferrous sulfate currently undergoing investigation clinical trial l5464 also used dying fabric leather wood preservative ,
Apronalide,apronalide approved japan apronalide withdrawn market many country due patient development thrombocytopenic purpura a174814 ,
Tilbroquinol,tilbroquinol approved france morocco saudi arabia withdrawn france saudi arabia market mainly due hepatotoxicity risk outweighing drug benefit l5467 morocco drug limited use treatment intestinal amoebiasis ,
Fluocortin,fluocortin studied corticosteroid treatment dermatitis eczema spain a174817 ,
Piperidione,piperidione cough medicine marketed roche trade name sedulon ,
Dibenzepin,dibenzepin approved use europe ,
Acetylleucine,used treating vestibular-related imbalance vertigo ,
Tribenoside,anti-inflammatory agent used edema extremity varicose vein phlebitis ,
Flosequinan,flosequinan approved usa uk year prior withdrawn market due increased mortality chronic heart failure patient found drug trial a174979 l43942 ,
Gestonorone,gestonorone often mistaken gestonorone capproate different chemical structure ,
Calcium lactate,calcium lactate salt consists two lactate anion calcium cation ca2+ prepared commercially neutralization lactic acid calcium carbonate calcium hydroxide approved fda direct food substance affirmed generally recognized safe calcium lactate used firming agent flavoring agent leavening agent stabilizer thickener l2741 calcium lactate also found daily dietary supplement source calcium also available various hydrate form calcium lactate pentahydrate common ,indicated use nutritional supplement 
Alaproclate,alaproclate developed one first selective serotonin reuptake inhibitor ssri antidepressant astra ab astrazeneca 1970s development discontinued due concern hepatotoxicity observed animal study alaproclate also found act non-competitive nmda receptor antagonist although without discriminative stimulus property similar phencyclidine ,
Propanidid, intravenous anesthetic used rapid induction anesthesia maintenance anesthesia short duration martindale extra pharmacopoeia 30th ed p918 ,
Perboric acid,perboric acid mainly found salt form sodium perborate found monohydrate tetrahydrate a33037 one peroxy acid salt wide functionality industrial setting f66 perboric acid form sodium perborate approved health canada since 2004 used disinfectant medical instrument l1113 fda sodium perborate approved ointment protection poison ivy dermatitis l2764 , industry sodium perborate used disinfectant also part ingredient detergent bleach powder personal care formulation cosmetic product perboric acid mainly salt used oxidizing agent dyeing permanent waving f66 dentistry sodium perborate monohydrate used aid removal phlegm mucus secretion associated occasional sore mouth cleansing minor wound temporary cleanse canker sore removal foreign material minor wound l2770 ophthalmic preparation sodium perborate used preservative product used dry eye use approved compound rapidly degrades harmless byproduct t203 
Stibophen,stibophen used treatment schistosomiasis disease parasitic flatworm ,
Neltenexine,neltenexine elastase inhibitor may useful preventing pulmonary emphysema ,
Tiazofurine,tiazofurine potential clinical use cancer treatment potential inhibitor inosine- 5 ’ -monophosphate imp dehydrogenase a174991 ,
Aminomethylbenzoic acid,aminomethylbenzoic acid may useful antifibrinolytic agent a174994 ,
Thiram,thiram may used dermatology scabicide t436 thiram mainly used fungicide plant treatment seed however use investigated safety many market including canada l5425 ,
Quinupramine,quinupramine approved france brand name kinupril antidepressant a175003 ,
Pramiracetam,pramiracetam previously approved eastern european country brand name pramistar neupramir remen also previously approved united state orphan drug designation l1469 pramiracetam studied use alzheimer 's disease adjunct treatment restore cognitive functioning post-electroconvulsive therapy severe depression l5470 ,
Phthalylsulfathiazole,phthalylsulfathiazole broad spectrum antibiotic part drug class sulfonamide used antibiotic bowel surgery infection colon a175006 ,
Magnesium silicate,magnesium silicate compound magnesium oxide silicon magnesium salt silicic acid containing unspecified amount water molecular formula expressed clearly mgsio3.xh2o t186 known talc present many us cosmetic industry food industry pharmaceutical industry l2603 fda magnesium silicate determined member substance generally recognized safe gras used anticaking agent l2605 ,magnesium silicate used absorb moisture prevent caking improve feel product pharmaceutical company used dietary supplement part formulation ingredient drug production antacid antiulcer preparation component antiepileptic drug antifungal topical agent treatment acne facial moisturizer l2603 complexed arginine magnesium silicate used antiatherosclerotic agent promote bone cartilage formation mammal t186 
Methylmethionine chloride,methylmethionine chloride may useful helping healing gastric ulcer japan used counter product gastrointestinal health support also called `` vitamin u '' true vitamin ,
Octopamine,octopamine structurally similar norepinephrine used nootropic therefore enantiomer prohibited world anti-doping agency wada 2014 ,
Tropatepine,tropatepine used france antiparkinsons activity a175024 ,
Proxibarbal,proxibarbal derivative barbiturate used treat migraine proxibarbal approved france withdrawn market due risk inducing immunoallergic thrombocytopenia l5476 ,
Prifinium,prifinium antimuscarinic agent antispasmodic antiemetic property may useful treatment irritable bowel syndrome a175027 ,
Clothiapine,clothiapine approved european country atypical antipsychotic shown useful treatment-resistant patient ,
Ferrous sulfate anhydrous,iron deficiency anemia large public health concern worldwide especially young child infant woman childbearing age a190804 type anemia occurs iron intake iron store iron loss adequately support formation erythrocyte also known red blood cell a190528 ferrous sulfate synthetic agent used treatment iron deficiency gold standard oral iron therapy uk many country l2234 l2246 ,ferrous sulfate used prevention treatment iron deficiency anemia adult child a190804 l2240 l11800 
Etofamide,etofamide used antiamoebic agent etofamide brand name kitnos marketed brazil pfizer discontinued l5617 ,
Ethyl chloride,ethyl chloride chloroethane chemical formula c2h5cl commonly used production tetraethyllead tel additive gasoline also used commerical application chemical reagent still used treatment cellulose make ethylcellulose commercial product ethyl chloride used diagnostic tool detect dead tooth nonviable pulp ,
Aceclidine,aceclidine marketed europe used clinically united state used treatment open-angle glaucoma parasympathomimetic agent ,
Penimepicycline,penimepicycline tetracycline-class antibiotic mentioned list produced government canada list antimicrobial active pharmaceutical ingredient l2791 classification active ingredient included list classification document state tetracycline class antibiotic medium importance used human l5620 ,
Hexobendine,hexobendine medication used cause vasodilation treat several condition including angina pectoris approved united state united kingdom used widely austria germany t478 ,
Ritiometan,ritiometan nasal spray marketed name nécyrane france indicated use viral rhinitis/ common cold ,
Acetarsol,acetarsol molecular formula n-acetyl-4-hydroxy-m-arsanilic acid pentavalent arsenical compound antiprotozoal antihelmintic property l2622 first discovered 1921 ernest fourneau pasteur institute developed neolab inc approved health canada antifungal december 31 1964 canceled withdrawn market since august 12 1997 l1113 ,acetarsol used treatment different disease syphilis amoebiasis yaw trypanosomiasis malaria l2624 acetarsol used commonly treatment vaginitis due _trichomonas vaginalis_ _candida albicans_ a32839 a32841 orally administered acetarsol used treatment intestinal amoebiasis form suppository researched treatment proctitis l2626 protozoan infection parasitic disease characterized caused organism classified kingdom protozoa formed great diversity organism l2627 
Dichlorobenzyl alcohol,dichlorobenzyl alcohol mild antiseptic broad spectrum bacterial virus associated mouth throat infection a33047 dichlorobenzyl alcohol considered active ingredient found several marketed otc product health canada categorized agent anatomical therapeutic chemical l1113 hand dichlorobenzyl alcohol categorized fda inactive ingredient approved drug product l2773 ,dichlorobenzyl alcohol combination db13908 available over-the-counter product used symptomatic relief acute sore throat postoperative sore throat a27155 
Dibekacin,dibekacin aminoglycoside antibiotic marketed japan l5623 ,
Sultopride,sultopride used japan hong kong europe treat schizophrenia drug class atypical antipsychotic l5626 ,
Micronomicin,micronomicin aminoglycoside antibiotic marketed japan sold brand name sagamicin luxomicina ,
Clorindione,clorindione vitamin k antagonist may useful decrease prothrombin level human ,
Benziodarone,benziodarone uricostatic uricosuric agent sold also name amplivex-labaz used treatment gout a175630 withdrawn france market british market due effect causing jaundice patient t487 a175636 ,
Bucetin,bucetin analgesic antipyretic medication approved use germany withdrawn market 1986 due renal toxicity caused medication a175636 ,
Carbocromen,carbocromen marketed use germany vasodilator however discontinued due risk arrhythmia development l5635 ,
Aluminium acetoacetate,aluminium acetoacetate aluminum containing antacid ,
Bromelains,bromelain protease enzyme derived stem pineapple composed mixture different thiol endopeptidases component like phosphatase glucosidase peroxidase cellulase escharase several protease inhibitor a27198 work selectively inhibiting biosynthesis proinflammatory prostaglandin a27197 also analgesic property well anticancerous pro-apoptotic effect bromelain hold potential therapeutic effect treatment condition including angina pectoris bronchitis sinusitis surgical trauma osteoarthritis considered safe food supplement ,
Benzododecinium,benzododecinium used antiseptic/disinfectant compound marketed tincture antiseptic product wound czech republic ,
Sulfaisodimidine,sulfaisodimidine also called sulfisomidine antibacterial product studied treatment urinary tract infection 1950s however unclear whether drug officially approved use anywhere a175672 ,
Meticrane,meticrane diuretic medication marketed japan trade name arresten used lower blood pressure l5647 ,
Etilamfetamine,etilamfetamine also known n-ethylamphetamine canadian legislation controlled drug substance act schedule 1 controlled drug like amphetamine amphetamine analog used appetite suppressant 1950s however controlled drug substance act necessitate drug approved sale market ,
Bumadizone,bumadizone approved use germany austria drug anti-inflammatory antipyretic analgesic property marketed treatment rheumatoid arthritis gout l5650 use restricted condition due risk drug pose l5650 ,
Miocamycin,miocamycin macrolide type antimicrobial a176170 drug may marketed japan clinical use listed japanese pharmacopeia l5737 shown effective several gram-positive gram-negative microbe may useful treatment upper lower respiratory tract infection urogenital tract infection alternative erythromycin treatment a176170 ,
Tromantadine,tromantadine marketed viru-merz czech republic l5740 antiviral used treatment herpes zoster simplex ,
Rimazolium,rimazolium experimental analgesic drug a176186 ,
Olaflur,olaflur also referred elmex gel ingredient used toothpaste help prevention dental caries ,
Cloridarol,cloridarol experimental medication treatment heart disease act vasodilation studied treatment coronary insufficiency italy 1970s a176222 ,
Pimethixene,pimethixene approved use brazil marketed trade name muricalm anticholinergic used treatment bronchitis ,
Ipecac,ipecac obtained plant _cephaelis ipecacuanha_ contains number emetic alkaloid including emetine cephaeline l2753 ipecac approved health canada otc product discontinued l1113 fda currently approved product containing ipecac however ipecac ingredient accepted sold counter package 1 fluid ounce 30 ml emergency use cause vomiting poisoning l2752 ,ipecac indicated emetic agent induction vomiting poisoning victim ingested systemic poison order prevent absorption chemical gastrointestinal tract low dos ipecac also used expectorant l2753 report suggested ipecac vastly used patient eating disorder produce vomiting t49 
Chlorquinaldol,chlorquinaldol used historically topical antiseptic trade name sterosan f4549 marketed 1950s iodine-free alternative also unrelated sulfa drug hormone chlorquinaldol currently approved european medicine agency combination tablet promestriene treatment bacterial vaginosis f4552 ,chlorquinaldol used historically topical antiseptic agent skin infection f4549 maintains use european country combination vaginal tablet promestriene use treatment vaginal infection f4552 
Proscillaridin,proscillaridin cardiac glycoside derived plant genus scilla drimia maritima scilla maritima study suggest potential cytotoxic anticancer property proscillaridin based evidence drug potently disrupting topoisomerase ii activity nanomolar drug concentration a27193 triggering cell death blocking cell proliferation glioblastoma cell line a27194 ,
Ormeloxifene,ormeloxifene third-generation selective estrogen receptor er modulator india ormeloxifene marketed since 1990s non-hormonal non-steroidal oral contraceptive taken week a251450 later introduced treatment dysfunctional uterine bleeding a251470 similar selective estrogen receptor modulators serms ormeloxifene estrogenic activity vagina bone cardiovascular central nervous system tissue anti-estrogenic activity uterus breast a251450 a251465 use ormeloxifene treatment perimenopausal bleeding management menorrhagia also investigated a251450 a251460 ormeloxifene marketed india racemic mixture l- levormeloxifene d-isomers d-ormeloxifene _trans_-ormeloxifene a251475 use levormeloxifene treatment reduced bone turnover prevention atherosclerosis evaluated however drug development discontinued due adverse event a251480 ,
Alminoprofen,alminoprofen non-steroidal anti-inflammatory drug nsaid whose physiochemical characteristic make member phenylpropionic acid class chemical substance ,
Trichloroethylene,"trichloroethylene halocarbon commonly used industrial solvent confused similar 1,1,1-trichloroethane also known chlorothene sold variety trade name including trimar trilene used volatile anesthetic inhaled obstetrical analgesic environmental exposure particularly groundwater drinking water contamination industrial discharge major concern human health subject numerous incident lawsuit ",
Pheneticillin,pheneticillin phenethicillin penicillin antibiotic approved use internationally ,
Dihydroergocristine,dihydroergocristine part ergoloid mixture product l2637 semisynthetic ergot alkaloid thus characterized structural skeleton formed alkaloid ergoline a32879 know ergoloid mixture please visit db01049 ,dihydroergocristine used country brasil single agent treatment cerebral peripheric vascular event l2649 know dihydroergocristine part ergoloid mesylate mixture please visit db01049 
Bufexamac,bufexamac non-steroidal anti-inflammatory drug nsaid market name droxaryl malipuran paraderm parfenac typically administered topically treatment subacute chronic eczema skin including atopic eczema inflammatory dermatosis well sunburn minor burn itching also used suppository combination local anaesthetic indicated haemorrhoid use bufexamac discontinued canada united state may due undetermined clinical efficacy high prevalence contact sensitization a32822 bufexamac also withdrawn ema april 2010 ,indicated treatment various skin condition atopic eczema inflammatory dermatosis 
Deanol,deanol commonly referred 2- dimethylamino ethanol dimethylaminoethanol dmae dimethylethanolamine dmea hold tertiary amine primary alcohol group functional group deanol used treatment attention deficit-hyperactivity disorder adhd alzheimer 's disease autism tardive dyskinesia also used ingredient skin care cognitive function- mood-enhancing product ,
Magnesium aspartate,magnesium aspartate magnesium salt aspartic acid commonly used mineral supplement display high oral bioavailability water solubiltiy compared magnesium salt magnesium citrate magnesium carbonate magnesium oxide ,
Vincamine,vincamine monoterpenoid indole alkaloid obtained leaf vinca minor vasodilatory property study indicate vincamine increase regional cerebral blood flow ,
Merbromin,mercurochrome trade name merbromin commonly used topical first-aid antiseptic agent organomercuric disodium salt compound fluorescein available many country except switzerland france germany united state drug withdrawn market due possibility mercury poisoning ,
Pentetrazol,pentetrazol also known pentylenetetrazole gamma-aminobutyric acid type gaba sub /sub receptor antagonist approved fda 1982 a254437 ,
Sulbutiamine,sulbutiamine synthetic derivative thiamine vitamin b1 market name arcalion composed two modified thiamine molecule form dimer highly lipophilic allowing cross blood-brain barrier easily thiamine derivative although clinical efficacy yet defined sulbutiamine used treat asthenia us include improvement erectile dysfunction reduction psycho-behavioural inhibition sulbutiamine showed evidence modulatory effect dopaminergic glutamatergic cortical transmission chronic administration drug demonstrated improve long term memory formation mouse ,
Edoxudine,edoxudine deoxythymidine analog activity herpes simplex virus potent selective inhibitor herpes simplex virus type 1 2 obtained product antiviral ointment l2407 activity edoxudine herpes simplex virus first recognized 1967 later recognized effective vivo preclinical model keratitis caused herpes virus a32643 developed mcneil pharmaceutical approved health canada december 31 1992 medication later discontinued market 1998 l1113 ,edoxudine used europe form topical antiviral treatment human herpes keratitis a32643 human herpes keratitis inflammation cornea eye caused herpes simplex virus infection infection cause significant morbidity whose incidence significantly increased presence recurrent infection even produce corneal blindness a32645 edoxudine 3 cream also indicated treatment dermal herpes simplex virus a32643 virus produce infection ubiquitously highly contagious two type herpes virus type 1 mainly transmitted oral-to-oral contact type 2 sexually transmitted l2411 
Esatenolol,esatenolol beta blocker ,
Ioxitalamic acid,ioxitalamate ionic iodinated contrast medium a27209 first-generation contrast medium formed ionic monomer high osmolarity 1500-1800 mosm/kg a33006 ioxitalamic acid salt form sodium meglumine developed liebel-flarshem canada inc approved health canada 1995 last review 2015 drug still available market l1113 ,ioxitalamate available form indicated exploration digestive tract tomodensitometry regular gastroduodenal radiography use restrained case administration barium sulfate recommended contraindicated f55 intravascular administration ioxitalamate contraindicated may present significant side effect f54 
Midecamycin,midecamycin naturally occurring 16-membered macrolide a33072 fit category acetoxy-substituted macrolide antibiotic molecule acetoxy group substituted position 9 16-member ring position 4 terminal sugar a33075 2017 midecamycin still list approved antimicrobial active pharmaceutical ingredient health canada l2791 ,midecamycin used treatment infection oral cavity upper lower respiratory tract skin soft tissue infection alone use midecamycin mainly used europe japan t207 
Bencyclane, vasodilator agent found effective variety peripheral circulation disorder various potentially useful pharmacological effect mechanism may involve block calcium channel ,
Bendazac,bendazac oxyacetic acid a39863 a39869 despite possessing anti-inflammatory anti-necrotic choleretic anti-lipidemic characteristic research revolved around studying demonstrating agent 's principal action inhibiting denaturation protein effect primarily proven useful managing delaying progression ocular cataract a39863 a39863 bendazac however since withdrawn discontinued various international region due capability risk eliciting hepatotoxicity a39891 a39892 a39893 l4778 patient although small handful region may continue medication available purchase use either topical anti-inflammatory/analgesic cream eye drop formulation ,prior withdrawal bendazac various international region use due concern hepatotoxicity a39891 a39892 a39893 l4778 chemical demonstrated potential usefulness predominantly prescription medication bendazac lysine indication managing level vision patient mild moderate cataract facilitate delaying need surgical intervention a39863 a39869 a39890 elsewhere bendazac may still available limited capacity non-prescription topical cream product treating condition like local pain inflammation dermatitis eczema pruritis hive insect bite burn erythema others l4780 although product may also facing general discontinuation l4781 
Tyrothricin,tyrothricin antibiotic peptide complex produced extracted aerobic gram-positive bacillus brevibacillus parabrevis l4019 l4021 a32851 previously categorized bacillus brevis bacillus aneurinolyticus a36353 complex mixture comprised 60 tyrocidine cationic cyclic decapeptides consisting largely six predominant tyrocidine trca/a1 trcb/b1 trcc/c1 minor contributor 40 neutral linear gramicidin valine-gramicidin often major gramicidin present although mixture composition vary l4019 l4021 l4022 moreover tyrothricin posse broad spectrum gram-positive antibacterial antifungal activity seen many significant reporting microbial resistance 60 year therapeutic use complex provided a36360 nevertheless tyrothricin cytolytic hemolytic demonstrate systemic toxicity l4019 l4021 l4022 although certain formulation safe human use like throat lozenge exist l4028 ,tyrothricin used counter topical antibiotic 
Alginic acid,"alginic acid also referred algin alginate hydrophilic anionic polysaccharide isolated certain brown seaweed _phacophycae_ via alkaline extraction present cell wall brown algae form viscous gel binding water alginic acid linear polymer consisted l-glucuronic acid d-mannuronic acid residue connected via 1,4-glycosidic linkage a32961 available different type salt alginic acid used variety us food cosmetic pharmaceu-tical product 100 year a32961 alginic acid fda-approved food ingredient soup soup mix emulsifier thickener stabilizer l2693 also available oral dietary supplement found antacid gaviscon inhibit gastroesophageal reflux creating physical barrier presence gastric acid f46 alginate-based raft-forming formulation management heartburn gastric acid reflux used worldwide 30 year a32961 ",indicated management gastric reflux reflux oesophagitis hiatus hernia heartburn including heartburn pregnancy similar gastric distress f46 
Metergoline,metergoline ergot-derived psychoactive drug act ligand serotonin dopamine receptor metergoline antagonist various 5-ht receptor subtypes relatively low concentration agonist dopamine receptor a27181 use studied various clinical setting treatment seasonal affective disorder prolactin hormone regulation due inhibitory effect prolactin release a27182 premenstrual dysphoric disorder woman antianxiety treatment a27183 ,
Mepindolol,mepindolol 2-methyl derivative pindolol beta blocker ,
Cyclopenthiazide,cyclopenthiazide thiazide diuretic antihypertensive property double blind randomized crossover study cyclopenthiazide effective reducing diastolic blood pressure mildly hypertensive non-insulin dependent diabetic patient a27180 positive allosteric modulator ampa-a receptor t28 ,
Iodoxamic acid,radiopaque medium used diagnosis gall bladder bile duct disease usually meglumine salt ,
Mephenesin,mephenesin synthetic cresol glyceryl ether produce transient muscle relaxation paralysis via central nervous system depression a32760 first entered use 1950s ,mephenesin used treatment muscle spasticity disease like parkinson 's multiple sclerosis 
Metandienone,metandienone orally active anabolic androgenic steroid introduced market 1960s later discontinued withdrawn market although prohibited outside competition world anti-doping agency metandienone continues marketed misused performance-enhancing drug sport a254432 u metandienone controlled substance controlled substance act l44057 ,
Mesterolone,mesterolone synthetic anabolic-androgenic steroid aa derivative dihydrotestosterone dht inactivated 3α-hydroxysteroid dehydrogenase skeleta muscules considered weak androgen substrate aromatase converted estrogen mesterolone demonstrated minimal effect sperm count level fsh lh a27177 a27178 experiment mesterolone serving potential treatment depression still undergoing ,
Almasilate,almasilate buffering antacid used peptic ulcer dyspepsia crystalline polyhydrate aluminium/magnesium silicate mediates buffering activity binding hydrogen ion within polymer however therapeutic efficacy comparable approved antacid effective neutralizing acid binding bile salt conventional antacid a27138 given generally widely available conventional antacid effective almasilate almasilate product available certain part europe and/or asia ,almasilate indicated use antacid neutralization excess stomach acid f25 subsequently also used symptomatic treatment disease necessary neutralize acid stomach example treating stomach duodenal ulcer heartburn stomach condition caused excess stomach acid f25 
Umifenovir,umifenovir indole-based hydrophobic dual-acting direct antiviral/host-targeting agent used treatment prophylaxis influenza respiratory infection a191475 use russia approximately 25 year china since 2006 invention credited collaboration russian scientist several research institute 40-50 year ago report chemical synthesis date back 1993 a191475 umifenovir 's ability exert antiviral effect multiple pathway resulted considerable investigation use variety enveloped non-enveloped rna dna virus including _flavivirus_ a191388 zika virus a191391 foot-and-mouth disease a191394 lassa virus a191403 ebola virus a191403 herpes simplex a191409 hepatitis b c virus chikungunya virus reovirus hantaan virus coxsackie virus b5 a191475 a191412 dual activity may also confer additional protection viral resistance development resistance umifenovir appear significant a191475 umifenovir currently investigated potential treatment prophylactic agent covid-19 caused sars-cov2 infection combination currently available investigational hiv therapy a191385 a191550 l12012 ,umifenovir currently licensed china russia prophylaxis treatment influenza respiratory viral infection a191475 demonstrated activity number virus investigated treatment _flavivirus_ a191388 zika virus a191391 foot-and-mouth disease a191394 lassa virus a191403 ebola virus a191403 herpes simplex a191409 addition shown _in vitro_ activity hepatitis b c virus chikungunya virus reovirus hantaan virus coxsackie virus b5 a191475 a191412 umifenovir currently investigated potential treatment prophylactic agent prevention covid-19 caused sars-cov-2 infection a191385 a191550 
Mifamurtide,mifamurtide immunomodulator antitumor activity via activation macrophage monocyte also called l-mtp-pe mifamurtide may liposomal form active ingredient mtp-pe synthetic le pyrogenic longer-acting derivative muramyl dipeptide mdp mdp motif present gram-positive gram-negative bacterial wall recognized different signalling molecule activator nucleotide-binding oligomerization domain nod -like receptor nlrs toll-like receptor present macrophage monocyte overall result mdp recognition lead production proinflammatory cytokine promotion bactericidal tumoricidal effect a31745 liposomal formulation mifamurtide demonstrates enhanced tumoricidal effect improved safety profile a31745 mifamurtide marketed europe mepact intravenous infusion administered adjuvant therapy postoperative combination chemotherapy pediatric adolescent adult patient high-grade resectable non-metastatic osteosarcoma macroscopically complete surgical resection u currently investigation hold orphan drug status treatment osteosarcoma a31746 osteosarcoma common primary malignant bone tumor usually arises metaphyses long bone child adolescent a31744 standard therapy osteosarcoma comprised macroscopic surgical resection multi-agent chemotherapy consisting doxorubicin cisplatin high-dose methotrexate leucovorin rescue ifosfamide a31744 90 patient newly diagnosed osteosarcoma may achieve complete remission first-line therapy prognosis still poor patient non-metastatic osteosarcoma lower 5-year event-free survival large randomized open-label multicenter phase iii trial treatment mifamurtide conjunction three- four-drug combination chemotherapy doxorubicin cisplatin high-dose methotrexate without ifosfamide associated significant improvement survival rate good tolerance a31746 adverse event aes associated mifamurtide generally mild moderate severity a31748 ,indicated child adolescent young adult treatment high-grade resectable non-metastatic osteosarcoma macroscopically complete surgical resection typically combination post-operative multi-agent chemotherapy l1203 
Potassium gluconate,potassium gluconate salt db01345 classified food additive fda l2654 also used potassium supplement l2657 potassium essential nutrient abundant cation intracellular fluid play key role maintaining cell function a32222 dietary supplement potassium often present potassium chloride many forms—including potassium citrate phosphate aspartate bicarbonate gluconate —are also used l2652 potassium gluconate believed palatable non-acidifying potassium chloride kcl l2658 , potassium ’ wide-ranging role body low intake increase risk illness l2655 potassium supplement indicated prevent hypokalemia patient would particular risk hypokalemia develop e.g. digitalis treated patient significant cardiac arrhythmia potassium deficiency occurs rate loss renal excretion and/or loss gastrointestinal tract higher rate potassium intake addition serving preventative supplement potassium gluconate also serf treatment decreased potassium level l2655 l2651 l2657 
Loprazolam,loprazolam imidazobenzodiazepine anxiolytic anticonvulsant hypnotic sedative skeletal muscle relaxant property indicated short-term treatment insomnia including difficulty falling asleep and/or frequent nocturnal awakening loprazolam recommended short-term therapy due adverse event associated drug including dependence withdrawal symptom positive modulator gaba-a receptor enhances inhibitory neurotransmission fda-approved drug ,
Alcuronium, non-depolarizing skeletal muscle relaxant similar tubocurarine used anesthesia adjuvant ,
Aloglutamol,aloglutamol antacid salt aluminium gluconic acid tris proprietary name include altris pyre tasto sabro ,
Dexchlorpheniramine,dexchlorpheniramine potent s-enantiomer chlorpheniramine salt form dexchlorpheniramine maleate active ingredient available prescription drug indicated adjunctive therapy allergic anaphylactic reaction antihistamine drug anticholinergic drying sedative action disrupts histamine signaling competing histamine cell receptor site effector cell ,
Niaprazine,niaprazine selective brain catecholamine depletor ,
Distigmine,distigmine parasympathomimetic agent longer duration action enhanced drug accumulation compared db00545 db01400 anticholinergic drug long-acting reversible carbamate cholinesterase inhibitor bind directly competitively agonist binding site muscurinic receptor distigmine available several country treatment underactive detrusor voiding dysfunction urinary tract active ingredient distigmine bromide improves detrusor function thereby restoring normal voiding pattern patient suffering detrusor underactivity a27176 ,
Sodium tartrate,sodium tartrate disodium salt l- -tartaric acid identified transparent colorless odorless crystal obtained byproduct wine manufacturing sodium tartrate generally recognized safe gras direct human food ingredient act emulsifier ph control agent food product l2590 compound commonly used emulsifier cheese/cheese spread product exceed 4 concentration according health canada regulation l2594 , act emulsifier ph control agent food product l2590 l2598 laboratory used performing karl fischer equation used determine water content various substance f18 l2590 
Diphemanil,,used treatment peptic ulcer gastric hyperacidity hypermotility gastritis pylorospasm treatment hyperhidrosis excessive perspiration 
Camostat,camostat mesylate foy-305 synthetic serine protease inhibitor a193842 a193848 first described literature 1981 part research inhibition skin tumor mouse a198807 camostat mesylate inhibits cholecystokinin pro-inflammatory cytokine serine protease leading investigated multiple indication including treatment covid-19 a198771 a198777 a193800 camostat mesylate first approved japan january 2006 l13197 ,camostat mesylate indicated japan treat chronic pancreatitis drug induced lung injury a193845 also investigated potential treatment covid-19 a193800 
Potassium guaiacolsulfonate,guaiacolsulfonate aromatic sulfonic acid potassium guaiacolsulfonate salt expectorant thins mucus lung reduces chest congestion ,
Bemegride,bemegride cns stimulant used induce convulsion experimental animal also used respiratory stimulant treatment barbiturate overdose ,
Bioallethrin,bioallethrin refers mixture two allethrin isomer 1r trans 1r 1r trans 1 approximate ratio 1:1 isomer active ingredient mixture two stereoisomers approximate ratio r 1:3 called esbiothrin mixture containing s-forms allethrin referred esbioallethrin s-bioallethrin bioallethrin synthetic pyrethroid used pesticide household pest insect mosquito housefly cockroach claimed low mammalian toxicity ,bioallethrin used louse scabies infestation pyrethroids used place bioallethrin 
Trolamine,trolamine also referred triethanolamine tea tertiary amine triol bifunctional compound exhibit property alcohol amine trolamine contains small amount diethanolamine ethanolamine may also act antioxidant auto-oxidation animal vegetable fat a27174 commonly used ph adjuster surfactant industrial cosmetic product skin hair conditioning product ,trolamine used alkalizing agent surfactant counter-ion cosmetic pharmaceutical formulation a27174 considered active pharmacological ingredient official indication 
Magnesium gluconate,magnesium gluconate magnesium salt gluconate demonstrates highest oral bioavailability magnesium salt l2608 used mineral supplement magnesium ubiquitous human body naturally present many food added food product available dietary supplement used ingredient medicine antacid laxative l2601 although magnesium available form sulphate lactate hydroxide oxide chloride magnesium gluconate recommended magnesium supplementation appears better absorbed cause le diarrha a32821 drug studied prevention pregnancy-induced hypertension displayed promising result a32807 addition studied effect premature uterine contraction a32808 ,magnesium gluconate mineral supplement used prevent treat low level magnesium magnesium important normal physiologic functioning cell nerve muscle bone heart generally well-balanced diet provides necessary amount magnesium homeostasis however certain condition causing chronic magnesium deficiency may decrease level magnesium condition include treatment diuretic poor diet alcoholism medical condition e.g. severe diarrhea/vomiting stomach/intestinal absorption problem poorly controlled diabetes l2600 
Glycyrrhizic acid,glycyrrhizic acid extracted root licorice plant _glycyrrhiza glabra_ f79 triterpene glycoside glycyrrhetinic acid posse wide range pharmacological biological activity extracted plant obtained form ammonium glycyrrhizin mono-ammonium glycyrrhizin t204 glycyrrhizic acid developed japan china hepatoprotective drug case chronic hepatitis a33062 january 2014 glycyrrhizic acid part licorice extract approved fda existing food sweetener f80 approved health canada used over-the-counter product product currently status canceled post marketed l1113 ,glycyrrhizic acid widely applied food natural sweetener therapeutic agent used vast variety formulation reported anti-inflammatory anti-ulcer anti-allergic antioxidant anti-tumor anti-diabetic hepatoprotective due property indication treatment premenstrual syndrome treatment viral infection anti-lipidemic antihyperglycemic a33063 also known used remedy peptic ulcer stomach disease t205 
Epanolol,epanolol beta blocker ,
Tilactase,tilactase beta-d-galactosidase obtained _aspergillus oryzae_ produced chewable tablet taken consumption lactose-containing meal a27172 beta-d-galactosidase u large monomeric multi-domain enzyme 985 residue present catalytic alpha/beta 8-barrel domain a32591 considered part international nonpropietary name pharmaceutical substance l2338 ,tilactase indicated symptomatic treatment lactose intolerance infant older patient requiring parenteral nutrition fluid diet l2338 lactose intolerance occurs existence inability break lactose commonly found dairy product inability occurs lactase level reduced thus via digest break lactose undigested lactose move large intestine normal flora bacteria interact cause bloating gas diarrhea a32592 
Monoxerutin,monoxerutin flavonol type flavonoid ,
Mercuric chloride,mercury chloride hgcl2 highly toxic compound volatizes slightly ordinary temperature appreciably 100 degree c. corrosive mucous membrane used topical antiseptic disinfectant mercuric chloride used disinfect wound arab physician middle age modern medicine since deemed unsafe use t112 ,
Rufloxacin,rufloxacin quinolone antibiotic a31894 ,
Tertatolol,tertatolol beta blocker ,
Xamoterol,xamoterol β1-adrenoceptor partial agonist shown improve systolic diastolic function study heart failure patient modulates sympathetic control heart agonist action β2-adrenoceptors ,
Acemetacin,acemetacin carboxymethyl ester indometacin potent non-steroidal anti-inflammatory drug derived indol-3-acetic acid whose activity thought mainly active metabolite indomethacin a31352 clinical trial acemetacin exhibit better gastric tolerability compared active metabolite indometacin t50 developed e. merck company germany attempt provide safer drug amelioration gastrointestinal effect metabolism acetamicin led formation indomethacin kept side effect t51 ,acemetacin fda canada ema approved country marketed indicated symptomatic treatment pain swelling acute inflammation joint rheumathoid arthritis osteoarthritis low back pain post-surgical pain l1045 also indicated treatment chronic inflammation joint presence rheumatoid arthritis treatment ankylosing spondylitis treatment irritation joint spinal column caused degenerative disorder treatment inflammatory soft-tissue rheumatism syndrome painful swelling inflammation caused injury l1044 l1046 
Magnesium orotate,magnesium orotate magnesium salt orotic acid poorly soluble water source magnesium used mineral supplement treat mg deficiency orotic acid act transporter carry magnesium cell also exhibit antioxidant property since key intermediate biosynthetic pathway pyrimidine promotes synthesis enzyme act free radical scavenger experiment investigating potential cardioprotective action orotic acid pathological heart condition still ongoing ,
Clopamide,clopamide oral diuretic agent antihypertensive activity like thiazide diuretic aromatic sulfonamide base double-ring structure ,
Calcium levulinate, relatively new calcium levulinate produced direct reaction l- levulinic acid levulose calcium hydroxide l2765 resultant calcium levulinate formulation used calcium supplement posse high calcium content observed 14.8 higher content typically found calcium lactate l2765 formulation considered low molecular weight organic calcium ion type easily absorbed intestinal wall l2765 new application calcium intended use food fortifier fortify food like sauce condiment beer beverage soft drink milk milk product soy milk soy product calcium nutrition l2765 calcium levulinate used alone calcium lactate calcium chloride compound either pharmaceutical tablet capsule injection preparation l2765 , new application calcium intended use food fortifier fortify food like sauce condiment beer beverage soft drink milk milk product soy milk soy product calcium nutrition l2765 calcium levulinate used alone calcium lactate calcium chloride compound either pharmaceutical tablet capsule injection preparation l2765 essence calcium levulinate ultimately relatively new calcium supplementation option l2767 
Reposal,reposal barbiturate derivative invented 1960s denmark sedative hypnotic anticonvulsant property used primarily treatment insomnia ,
Iodoform,"iodoform organoiodine compound formula chi3 tetrahedral molecular geometry relatively water-insoluble yellow solid chemically reactive free-radical reaction a32890 due antimicrobial property following topical administration minimal level iodoform may found disinfectant primarily used veterinary purpose iodoform also found dental paste root canal filling material combination intracanal medication due radiopacity a32893 since beginning 20th century iodoform commonly used healing antiseptic dressing powder wound sore however clinical use date limited iodoform soluble fatty acid decomposes releasing iodine nascent state 96,7 iodine contact secretion endodontic infection a32893 ", approved therapeutic indication 
Metampicillin,metampicillin penicillin antibiotic prepared reaction ampicillin formaldehyde hydrolysed aqueous solution form ampicillin hydrolysis rapid acid condition like stomach ,
Noxytiolin,local antibacterial probably act releasing formaldehyde aqueous solution used therapeutic irrigation infected body cavity bladder peritoneum etc spray burn ,
Clopenthixol,clopenthixol thioxanthene therapeutic action similar phenothiazine antipsychotic antagonist d1 d2 dopamine receptor ,
Etofylline nicotinate,etofylline nicotinate theophylline derivative drug cause vasodilation relaxation smooth muscle ,
Cloprednol,cloprednol synthetic glucocorticoid investigated use treatment asthma a31775 a31776 ,
Etafenone,etafenone vasodilator ,
Fluorodopa (18F),fluorodopa f 18 fluorinated analog levodopa used diagnostic agent positron emission tomography pet evaluation parkinsonian syndrome l12849 fluorodopa f 18 pet used adjunctly diagnostic investigation serf primarily visualize dopaminergic nerve terminal striatum l12849 ,fluorodopa f 18 indicated use positron emission tomography pet visualize dopaminergic nerve terminal striatum evaluation adult patient suspected parkinsonian syndrome p l12849 
Artemotil,artemotil also known β-arteether semi-synthetic derivative artemisinin fast acting blood schizonticide specifically indicated treatment chloroquine-resistant _plasmodium falciparum_ malaria cerebral malaria case ,
Anethole trithione,anethole trithione att appears broad range unique function increasing salivary secretion help treat xerostomia a27165 a32618 a32620 a32621 demonstrating ability inhibit carcinogenesis increasing activity electrophile detoxification enzyme a32619 even used adjunctive therapy cholecystitis gallstone indigestion acute/chronic hepatitis l2388 marketed certain country like france germany china a32614 unfortunately many specific mechanism action activity yet formally elucidated mean study ongoing att necessarily formally indicated many aforementioned function time used limited region around world , typical us anethol trithione currently indicated includes increasing salivary secretion patient experiencing dry mouth used adjunctive therapy cholecystitis gallstone indigestion acute/chronic hepatitis a32614 a32616 l2377 addition although study suggested anethol trithione also posse certain capacity inhibit tumorigenesis potential cancer therapy medication specific mechanism action effect remains elucidated a32619 certain national cancer institute listing agent substance studied treatment cancer l2373 
Gamolenic acid,"gamolenic acid gamma-linolenic acid γ-linolenic acid gla essential fatty acid efa comprised 18 carbon atom three double bond f27 commonly found human milk botanical source a32848 omega-6 polyunsaturated fatty acid pufa also referred 18:3n-6 6,9,12-octadecatrienoic acid cis-6 cis-9 cis-12- octadecatrienoic acid f27 gamolenic acid produced minimally body delta 6-desaturase metabolite db00132 converted db00154 biosynthetic precursor monoenoic prostaglandin pge1 gamolenic acid found naturally fatty acid fraction plant seed oil f27 db11358 db11238 rich source gamolenic acid evening primrose oil investigated clinical use menopausal syndrome diabetic neuropathy breast pain gamolenic acid present concentration 7-14 f27 gamolenic acid may found over-the-counter dietary supplement gamolenic acid also found fungal source also present naturally form triglyceride f27 various clinical indication gamolenic acid studied including rheumatoid arthritis atopic eczema acute respiratory distress syndrome asthma premenstrual syndrome cardiovascular disease ulcerative colitis adhd cancer osteoporosis diabetic neuropathy insomnia ",indicated dietary supplement over-the-counter us 
Demegestone,demegestone progesterone receptor agonist previously used treat luteal insufficiency previously marketed france lutionex since discontinued ,
Dimazole,dimazole diamthazole antifungal withdrawn franch 1972 due neuropsychiatric reaction ,
Iopentol,iopentol used contrast medium ,
Hemoglobin crosfumaril,hemoglobin alpha-subunit cross-linked intramolecularly ,
Etynodiol,etynodiol inn ethynodiol ban steroidal progestin related norethisterone never marketed etynodiol sometimes used synonym etynodiol diacetate usually refers etynodiol diacetate see db00823 etynodiol ,
Fluticasone,fluticasone synthetic glucocorticoid available 2 ester db08906 db00588 f4355 f4358 f4361 f4364 fda label drug available inhaler nasal spray topical treatment various inflammatory indication f4355 f4358 f4361 f4364 fda label db00588 first approved 1990 l5962 db08906 approved 2007 l5965 ,fluticasone 's 2 ester indicated inhaler treatment management asthma prophylaxis fda label f4364 well inflammatory pruritic dermatosis f4355 db00588 nasal spray indicated managing nonallergic rhinitis f4358 db08906 nasal spray indicated treating season perennial allergic rhinitis f4361 a177130 
2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol,timbd azaresveratrol analog ,
Lormetazepam,lormatazepam orally available benzodiazepine used uk treatment short-term insomnia l927 marketed auden mckenzie pharma division 0.5 1 mg tablet formulation , treatment short-term insomnia l927 
Fenofibric acid,fenofibric acid lipid-lowering agent used severe hypertriglyceridemia primary hyperlipidemia mixed dyslipidemia work decrease elevated low-density lipoprotein cholesterol total cholesterol triglyceride apolipoprotein b increasing high-density lipoprotein cholesterol a32038 l12855 due high hydrophilicity poor absorption profile a32038 prodrug fenofibrate conjugated compound fenofibric acid choline fenofibrate developed improved solubility gastrointestinal absorption bioavailability convenient administration a32038 a193362 , use adjunctive therapy diet reduce triglyceride level adult patient severe hypertriglyceridemia b reduce elevated total cholesterol low-density-lipoprotein ldl-c triglyceride apolipoprotein b increase high-density-lipoprotein hdl-c adult patient primary hypercholesterolemia mixed dyslipidemia fredrickson type iia iib fda label 
Enasidenib,enasidenib orally available treatment treatment adult patient relapsed refractory acute myeloid leukemia aml specific mutation isocitrate dehydrogenase 2 idh2 gene recurrent mutation detected 12-20 adult patient aml a20344 a20345 patient eligible treatment selected testing presence idh2 mutation blood bone marrow small molecule act allosteric inhibitor mutant idh2 enzyme prevent cell growth also shown block several enzyme play role abnormal cell differentiation first developed agio pharmaceutical licensed celgene enasidenib approved u.s. food drug administration august 1 2017 ,indicated treatment adult patient relapsed refractory acute myeloid leukemia aml isocitrate dehydrogenase-2 idh2 mutation 
Pibrentasvir,pibrentasvir direct acting antiviral agent hepatitis c virus hcv ns5a inhibitor target viral rna replication viron assembly combination db13879 pibrentastiv useful therapy patient experienced therapeutic failure ns5a inhibitor cell culture emergence amino acid substitution known ns5a inhibitor resistance-associated position hcv genotype 1a 2a 3a replicons led reduced susceptibility resistance pibrentasvir fda label resistance-associated amino acid substitution included q30d/deletion y93d/h/n h58d +y93h genotype 1a replicons f28s m31i p29s k30g genotype 2a replicons y93h genotype 3a replicons individual ns5a amino acid substitution reduced susceptibility pibrentasvir include m28g q30d genotype 1a replicon p32-deletion genotype 1b replicon fda label pibrentasvir available oral combination therapy db13879 brand name mavyret fixed-dose combination therapy fda-approved august 2017 treat adult chronic hepatitis c virus hcv genotype 1-6 without cirrhosis liver disease mild cirrhosis including patient moderate severe kidney disease dialysis l940 mavyret also indicated hcv genotype 1-infected patient previously treated regimen either containing ns5a inhibitor ns3/4a protease inhibitor l940 hepatitis c viral infection often lead decreased liver function subsequent liver failure causing significantly negative impact patient quality life ultimate goal combination treatment achieve sustained virologic response svr cure patient infection clinical trial combination therapy achieved svr12 rate undetectable hepatitis c twelve week end treatment ≥93 across genotype 1a 2a 3a 4 5 6 fda label ,indicated treatment adult patient chronic hepatitis c virus hcv genotype 1 2 3 4 5 6 infection without cirrhosis compensated cirrhosis child-pugh mavyret also indicated treatment adult patient hcv genotype 1 infection previously treated regimen containing hcv ns5a inhibitor ns3/4a protease inhibitor pi fda label 
Glecaprevir,glecaprevir direct acting antiviral agent hepatitis c virus hcv ns3/4a protease inhibitor target viral rna replication combination db13878 glecaprevir useful therapy patient experienced therapeutic failure ns3/4a protease inhibitor demonstrates high genetic barrier resistance mutation virus cell culture emergence amino acid substitution ns3 resistance-associated position a156 d/q168 hcv genotype 1a 2a 3a replicons led reduced susceptibility glecaprevir fda label combination amino acid substitution ns3 position y65h d/q168 also result greater reduction glecaprevir susceptibility ns3 q80r genotype 3a patient also lead glecaprevir resistance fda label glecaprevir available oral combination therapy db13878 brand name mavyret fixed-dose combination therapy fda-approved august 2017 treat adult chronic hepatitis c virus hcv genotype 1-6 without cirrhosis liver disease mild cirrhosis including patient moderate severe kidney disease dialysis l940 mavyret also indicated hcv genotype 1-infected patient previously treated regimen either containing ns5a inhibitor ns3/4a protease inhibitor l940 hepatitis c viral infection often lead decreased liver function subsequent liver failure causing significantly negative impact patient quality life ultimate goal combination treatment achieve sustained virologic response svr cure patient infection clinical trial combination therapy achieved svr12 rate undetectable hepatitis c twelve week end treatment ≥93 across genotype 1a 2a 3a 4 5 6 fda label ,indicated treatment adult patient chronic hepatitis c virus hcv genotype 1 2 3 4 5 6 infection without cirrhosis compensated cirrhosis child-pugh mavyret also indicated treatment adult patient hcv genotype 1 infection previously treated regimen containing hcv ns5a inhibitor ns3/4a protease inhibitor pi fda label 
Tisagenlecleucel,tisagenlecleucel cd19-directed genetically modified autologous cell immunotherapy car-t cell therapy b-cell acute lymphoblastic leukemia granted approval fda august 2017 market name kymriah tisagenlecleucel immunocellular therapy involves autologous cell collected individual patient genetically engineered express specific protein called chimeric antigen receptor car specifically target cd19 antigen modified cell infused back patient 's body cd19-directed chimeric antigen receptor cd19 car-t cell direct cell target kill leukemia cell express cd19 cell surface multicenter clinical trial involving pediatric young adult patient relapsed refractory b-cell precursor overall remission rate within three month treatment 83 percent l942 ,tisagenlecleucel indicated use individual aged 25 year younger b-cell precursor acute lymphoblastic leukemia refractory second later relapse l41230 also used treat adult patient relapsed refractory r/r large b-cell lymphoma two line systemic therapy including diffuse large b-cell lymphoma dlbcl otherwise specified high-grade b-cell lymphoma dlbcl arising follicular lymphoma l41230 tisagenlecleucel also indicated adult patient relapsed refractory follicular lymphoma two line systemic therapy l41230 
Methyl nicotinate,methyl nicotinate methyl ester db00627 used active ingredient rubefacient over-the-counter topical preparation indicated muscle joint pain action methyl nicotinate rubefacient thought involve peripheral vasodilation veterinary purpose methyl nicotinate used treat respiratory disease vascular disorder rheumatoid arthritis muscle joint pain f64 ,indicated temporary relief ache pain muscle tendon joint 
Coral snake (micrurus fulvius) immune globulin antivenin (equine),north american coral snake antivenin equine horse-derived antivenin indicated treatment envenomation caused north american coral snake bite intravenously administered antivenin bind neutralizes coral snake venom antivenin refined concentrated lyophilized preparation serum globulin obtained fractionating blood healthy horse immunized eastern coral snake micrurus fulvius fulvius venom fda label prior lyophilization product contains 0.25 phenol 0.005 thiomerosal mercury derivative fda label , particular antivenin indicated treatment envenomation caused bite eastern coral snake micrurus fulvius fulvius texas coral snake micrurus fulvius tenere fda label l2176 agent neutralize venom arizona sonoran coral snake micruroides euryxanthus south american specie fda label l2176 
Albutrepenonacog alfa,albutrepenonacog alfa rix-rfp recombinant fusion protein link recombinant coagulation factor ix rfix recombinant human albumin ralbumin a32547 developed csl behring canada inc approved health canada april 26 2017 also approved fda ema 2016 currently marketed form 250 500 1000 2000 iu/vial l2305 , ema fda rix-rfp indicated treatment hemophilia b l2306 health canada rix-frp also indicated prevent reduce bleeding episode l2305 hemophilia b second common type hemophilia rare inherited bleeding disorder caused reduced absent level factor ix fix fix vitamin k-dependent plasma protease activated involved blood coagulation cascade a32551 hemophilia b caused mutation _fix_ gene cause different phenotype severe form characterized presence spontaneous recurring bleeds joint muscle excessive bleeding trauma surgery a32552 
Ferric subsulfate,ferric subsulfate stypic hemostatic agent cause agglutination surface protein resulting local hemostasis chemical formula fe4 oh 2 so4 5 used superficial skin biopsy ,
Human cytomegalovirus immune globulin,cytomegalovirus immunoglobulin obtained pooled adult human plasma selected high titer antibody cytomegalovirus cmv contains purified immunoglobulin g igg antibody targeting cytomegalovirus cmv fda label cytomegalovirus member herpes virus family ubiquitous human population leading infection followed life-long dormancy host occasional reactivations recurrent infection seroprevalence antibody adult range 40-100 inverse correlation socioeconomic status transmission cytomegalovirus infection requires intimate contact infected excretion saliva urine cervical vaginal excretion semen breast milk blood l2228 cmv infection lead high fever severe organ-specific damage significant morbidity mortality rate cytomegalovirus cmv may lead wide spectrum infection immunocompetent host site often involved include lung severe community-acquired viral pneumonia liver transaminitis spleen splenomegaly gi tract colitis cns encephalitis hematologic system cytopenia multisystem involvement l2230 span individual 's life virus may reactivate resulting repeated shedding spread virus molecular mechanism identified show cmv interfere host immune system finally however infection normally controlled host 's immune response consequence cmv disease restricted immunocompromised immunologically immature host lead devastating result transplant rejection a32498 l2229 , used prevent cytomegalovirus cmv disease organ transplant l2225 cytomegalovirus immune globulin intravenous human indicated prophylaxis cytomegalovirus disease associated transplantation kidney lung liver pancreas heart fda label transplant organ kidney cmv seropositive donor seronegative recipient prophylactic cmv-igiv considered combination ganciclovir fda label 
Meningococcal polysaccharide vaccine group W-135,meningococcal group w-135 polysaccharide group-specific polysaccharide antigen extracted purified neisseria meningitidis serogroup w-135 n. meningitidis bacteria cause endemic epidemic disease including meningitis meningococcemia subcutaneously administered active immunization invasive meningococcal disease caused serogroup w-135 ,
Meningococcal polysaccharide vaccine group Y,meningococcal group polysaccharide group-specific polysaccharide antigen extracted purified neisseria meningitidis serogroup n. meningitidis bacteria cause endemic epidemic disease including meningitis meningococcemia subcutaneously administered active immunization invasive meningococcal disease caused serogroup ,
Meningococcal polysaccharide vaccine group A,meningococcal group polysaccharide group-specific polysaccharide antigen extracted purified neisseria meningitidis serogroup n. meningitidis bacteria cause endemic epidemic disease including meningitis meningococcemia subcutaneously administered active immunization invasive meningococcal disease caused serogroup ,
Meningococcal polysaccharide vaccine group C,meningococcal group c polysaccharide group-specific polysaccharide antigen extracted purified neisseria meningitidis serogroup c. n. meningitidis bacteria cause endemic epidemic disease including meningitis meningococcemia subcutaneously administered active immunization invasive meningococcal disease caused serogroup c ,
Crotalus scutulatus antivenin,crotalus scutulatus antivenin derived purified immunoglobulin fragment obtained domestic animal sheep previously immunized crotalus scutulatus also known _mojave rattlesnake_ l2856 final purified antivenin product obtained mixing different monospecific snake antivenin isolating antivenin interest fractionation chromatography technique intravenously administered limit systemic toxicity fda label l2857 l2858 crofab crotalidae polyvalent immune fab ovine sheep-derived antivenin used management adult pediatric patient north american crotalid envenomation fda label includes crotalus scutulatus snake mojave snake mojave rattlesnake inhabit desert area southwestern united state central mexico specimen type venom cause different pattern injury rattlesnake reported southern california nevada utah arizona texas new mexico l2856 since approved food drug administration october 2000 crotalidae poyvalent immune fab crofab largely replaced previously used crotaline antivenom crofab specifically tailored crotalids north america le allergenic whole immunoglobulin antivenoms l2861 ,crofab indicated management adult pediatric patient north american crotalid envenomation term crotalid used describe crotalinae subfamily formerly known crotalidae venomous snake includes rattlesnake copperhead cottonmouths/water moccasin fda label 
Crotalus atrox antivenin," year estimated 45,000 snakebite u 300,000 400,000 bite worldwide 8000 snakebite involve venomous snake specie majority people bitten male 50 occur age group 18 28 f113 crotalus atrox antivenin derived purified immunoglobulin fragment obtained domestic animal sheep previously immunized crotalus atrox western diamondback rattlesnake bite snake common state texas usa a33157 final purified antivenin product produced mixing different monospecific snake antivenin isolating antivenin interest fractionation chromatography technique intravenously iv administered prevent/limit systemic toxicity fda label ",crofab indicated management adult pediatric patient north american crotalid envenomation term crotalid used describe crotalinae subfamily formerly known crotalidae venomous snake includes rattlesnake copperhead cottonmouths/water moccasin fda label 
Crotalus adamanteus antivenin," year estimated 45,000 snakebite u 300,000 400,000 bite worldwide 8000 snakebite involve venomous snake specie majority people bitten male 50 occur age group 18 28 f116 eastern diamondback rattlesnake largest 32 specie rattlesnake currently recognized large heavy-bodied snake large broad head two light line face l2877 crotalus adamanteus antivenin derived purified immunoglobulin fragment obtained domestic animal sheep previously immunized crotalus adamanteus eastern diamondback rattlesnake final purified antivenin product obtained mixing different monospecific snake antivenin isolating antivenin interest fractionation chromatography technique intravenously administered limit systemic toxicity fda label ",indicated north american crotalid envenomation crotalinae rattlesnake eg cottonmouths/water moccasin copperhead rattlesnake fda label l2874 
Agkistrodon piscivorus antivenin,agkistrodon piscivorus antivenin derived purified immunoglobulin fragment obtained domestic animal sheep previously immunized agkistrodon piscivorus _cottonmouth_ _water moccasin snake_ final purified antivenin product obtained mixing different monospecific snake antivenin isolating antivenin interest fractionation chromatography technique intravenously iv administered limit/prevent systemic toxicity fda label approximately 99 venomous snake bite united state caused crotalidae also known _pit vipers_ north america member family crotalidae belong three genus rattlesnake crotalus sistrurus spp copperhead cottonmouth water moccasin agkistrodon spp l2891 cottonmouth agkistrodon piscivorus large venomous snake pit viper subfamily crotalinae semi-aquatic viper specie cottonmouth snake strong swimmer frequently found near water l2888 specie snake endemic united state cottonmouth habitat range extends southeastern virginia near junction appomattox james river southern florida west central texas oklahoma arkansas missouri southeastern kansa north middle mississippi river drainage southern illinois l2893 ,crofab sheep-derived antivenin indicated management adult pediatric patient north american crotalid envenomation fda label 
Rhus Glabra Pollen,rhus glabra pollen pollen pollen rhus glabra pollen plant pollen mainly used allergenic testing ,
Talimogene laherparepvec,talimogene laherparepvec oncolytic treatment used local treatment unresectable cutaneous subcutaneous nodal lesion patient recurrent melanoma genetically administered herpes simplex virus 1 hsv-1 express human cytokine granulocyte-macrophage colony stimulating factor gm-csf antitumor immune-stimulating activity specifically replicates within tumor cell cause lysis approved fda 2015 market name imlygic general talimogene laherparepvec modified infect multiply inside melanoma cell l2221 drug subsequently us melanoma cell machinery multiply eventually overwhelming melanoma cell killing l2221 alternatively although talimogene laherparepvec also enters healthy cell designed multiply inside l2221 , medication genetically modified oncolytic viral therapy indicated local treatment unresectable cutaneous subcutaneous nodal lesion patient melanoma recurrent initial surgery fda label elsewhere ema note agent indicated treatment adult unresectable melanoma regionally distantly metastatic stage iiib iiic ivm1a bone brain lung visceral disease l2209 
Equine Botulinum Neurotoxin E Immune FAB2,equine botulinum neurotoxin e immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype e. intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes e adult pediatric patient ,equine botulinum neurotoxin e immune fab2 indicted use documented suspected exposure botulinum toxin serotype e adult pediatric patient fda label 
Equine Botulinum Neurotoxin C Immune FAB2,equine botulinum neurotoxin c immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype c. intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes c adult pediatric patient ,equine botulinum neurotoxin c immune fab2 indicted use documented suspected exposure botulinum toxin serotype c adult pediatric patient fda label 
Equine Botulinum Neurotoxin G Immune FAB2,equine botulinum neurotoxin g immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype g. intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes g adult pediatric patient ,equine botulinum neurotoxin g immune fab2 indicted use documented suspected exposure botulinum toxin serotype g adult pediatric patient fda label 
Equine Botulinum Neurotoxin A Immune FAB2,equine botulinum neurotoxin immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes adult pediatric patient ,equine botulinum neurotoxin immune fab2 indicted use documented suspected exposure botulinum toxin serotype adult pediatric patient fda label 
Equine Botulinum Neurotoxin F Immune FAB2,equine botulinum neurotoxin f immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype f. intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes f adult pediatric patient ,equine botulinum neurotoxin f immune fab2 indicted use documented suspected exposure botulinum toxin serotype f adult pediatric patient fda label 
Equine Botulinum Neurotoxin D Immune FAB2,equine botulinum neurotoxin immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype d. intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes adult pediatric patient ,equine botulinum neurotoxin immune fab2 indicted use documented suspected exposure botulinum toxin serotype adult pediatric patient fda label 
Equine Botulinum Neurotoxin B Immune FAB2,equine botulinum neurotoxin b immune fab2 composed mixture immune globulin fragment purified plasma horse previously immunized botulinum toxin serotype b intravenously administered treatment symptomatic botulism following documented suspected exposure botulinum neurotoxin serotypes b adult pediatric patient ,equine botulinum neurotoxin b immune fab2 indicted use documented suspected exposure botulinum toxin serotype b adult pediatric patient fda label 
Cat dander extract,cat dander extract either subcutaneously intracutaneously administered contains dry cat dander dry defatted cat pelt used diagnosis treatment immunotherapy patient history allergy cat allergic reaction cat induced presence antigen-specific ige antibody bound specific receptor mast cell basophil allergy diagnostic process involves assessing allergy history clinical evaluation skin test reactivity cat dander extract used immunotherapy individual avoid exposure cat allergen initiate hyposensitization ,
Scorpion (centruroides) immune Fab2 antivenin (equine),centruroides scorpion immune f ab 2 equine purified preparation immune globulin f ab ’ 2 fragment derived plasma horse immunized venom c. noxius c. l. limpidus c. l. tecomanus c. s. suffusus intravenously administered patient clinical sign scorpion envenomation fab fragment bind toxin limit systemic toxicity approved fda 2011 marketed name anascorp l2196 anascorp produced equine igg antibody initial development use product mexico venom several centruroides specie endemic mexico pooled diluted l2207 drug polyvalent antivenin proven useful scorpion sting first specific treatment neutralize toxin centruroides scorpion sting particularly _centruroides sculpturatus_ united state l2206 envenomation scorpion sting result serious cardiovascular effect a32483 severe scorpion sting may cause loss muscle control respiratory failure warranting heavy sedation hospitalization intensive care unit commonly child experience severe reaction however adult affected l2195 l2196 l2198 ,indicated treatment clinical sign scorpion envenomation l2195 l2196 
Aloe vera leaf,aloe describes genus including 500 specie flowering succulent plant grow southern peninsula various island aloe vera _aloe barbadensis miller_ common specie aloe cultivated agricultural medical purpose perennial succulent xerophyte elongated leaf contain clear gel aloe vera long history commercial us still widely used cosmetic food pharmaceutical product use aloe vera constipation inflammatory disorder cancer ulcer diabetes also investigated a32476 active constituent aloe vera include polysaccharide protective effect skin exhibit antioxidant anti-inflammatory property a32481 common active polysaccharide include glucomannans polymannose acemannan b- 1–4 -acetylated polymannose a32475 acemannan modified polysaccharide responsible preventing suppression contact hypersensitivity immune suppression induced external factor irradiation a32473 ,indicated use topical agent soothe sensitive skin relieve symptom various skin condition including contact atopic dermatitis eczema dermatitis acne urticata first- second-degree burn radiation dermatitis sunburn 
Fusarium graminearum,fusarium graminearum allergenic extract used allergenic testing ,
Amylmetacresol,amylmetacresol antiseptic available canada over-the-counter number lozenge treatment sore throat minor mouth infection l2570 l2571 amylmetacresol often combined dichlorobenzyl alcohol menthol commonly used sore throat lozenge known strepsils l2575 acute sore throat pharyngitis one common condition child seen primary care setting pharyngitis normally caused virus prof benign self-limiting clinically proven over-the-counter throat lozenge offer rapid effective relief acute sore throat symptom increasingly important management condition a32787 ,sore throat minor mouth throat infection l2570 l2571 a32773 
Bismuth subgallate,bismuth subgallate yellow colored substance present odorless powder undergoes discoloration exposed sunlight heavy metal salt gallic acid highly insoluble poorly absorbed possessing protective effect gastric mucosa strong astringent effect yet elucidated antimicrobial hemostatic action bismuth subgallate commonly available over-the-counter internal deodorant often employed primary active ingredient , common medical purpose bismuth subgallate currently formally indicated use non-prescription internal deodorant product purpose deodorizing flatulence stool l2309 l2312 a32566 additionally also various non-prescription counter bismuth subgallate based wound healing product well ongoing study whether substance utilized legitimate hemostatic agent usually soft tissue surgery otorhinolaryngology and/or dermatologic setting a32567 a32568 a32569 a32570 moreover past bismuth subgallate may seen use treatment helicobacter pylorus infection a32571 contrast contemporary first-line therapy generally involve proton pump inhibitor antibiotic combination therapy generally achieve high rate pathogen eradication ease administration patient compliance 
Valproate bismuth,valproate bismuth available canada over-the-counter medication neo-laryngobis ,
Phloxine B,phloxine b commonly known simply phloxine also known c red 28 color additive used inactive ingredient provide color product colorant dental disclosing tablet tablet allow patient visualise area brushing flossing needed , use dental disclosing product allowing highlighting bacterial placques 
Belladonna,belladonna also known atropa belladonna deadly nightshade perennial herbaceous plant nightshade family _solanaceae_ root leaf fruit contain db00424 db00747 mostly db00572 alkaloid naturally-occurring muscarinic antagonist db00572 non-selective muscarinic antagonist mainly used adjunct anaesthesia name `` belladonna '' originates italian word `` beautiful woman '' historical use herb eye-drop woman dilate pupil eye aesthetic purpose belladonna poisonous plant belladonna intoxication accidental ingestion may result severe anticholinergic syndrome associated central peripheral manifestation a32494 , therapeutic indication 
Volixibat,volixibat also known shp626 lum002 investigational drug potentially used treatment non-alcoholic steatohepatitis nash approved use first available agent treatment nash volixibat selective inhibitor apical sodium-dependent bile acid transporter asbt transmembrane protein primarily expressed enterocytes ileum also known ileal bile acid transporter ibat asbt primarily responsible enterohepatic recirculation bile acid ultimately hepatic lipid glucose metabolism a32120 inhibiting enzyme result decrease bile acid returning liver helpful treatment nash abnormal cholesterol metabolism accumulation free cholesterol liver implicated pathogenesis a32119 according shire pharmaceutical manufacturer volixibat granted fast track status food drug administration due promising initial result need therapeutic treatment nash l1662 ,volixibat investigational drug approved use condition 
Axicabtagene ciloleucel,axicabtagene ciloleucel anti-cd19 chimeric antigen receptor car t-cell therapy drug unique mechanism action utilizes patient 's cell play central role immune response cancer a216163 t-cells collected patient genetically engineered express anti-cd19 car recognize kill cancer cell infused back patient a249030 dose axicabtagene ciloleucel represent patient 's genetically modified t-cells l40054 development resulted early preclinical study conducted group researcher national cancer institute nci demonstrated cell expressing anti-cd19 car produce cytokine efficiently kill leukemic cell _in vitro_ a216163 axicabtagene ciloleucel approved fda october 18th 2017 marketed brand name yescarta used treat large b-cell lymphoma follicular lymphoma adult l40054 axicabtagene ciloleucel later approved ema august 23 2018 l42090 , u axicabtagene ciloleucel indicated treatment adult large b-cell lymphoma refractory first-line chemoimmunotherapy relapse within 12 month first-line chemoimmunotherapy l40054 u europe used treat adult relapsed refractory large b-cell lymphoma two line systemic therapy including diffuse large b-cell lymphoma dlbcl otherwise specified primary mediastinal large b-cell lymphoma high grade b-cell lymphoma dlbcl arising follicular lymphoma l40054 l42090 axicabtagene ciloleucel also used treat adult relapsed refractory follicular lymphoma fl two line systemic therapy u l40054 three line systemic therapy europe l42090 
Toyocamycin,"4-amino-5-cyano-7- d-ribofuranosyl -7h- pyrrolo 2,3-d pyrimidine antibiotic antimetabolite isolated streptomyces toyocaensis culture analog adenosine block rna synthesis ribosome function used mainly tool biochemistry ",
Deoxyepinephrine,sympathomimetic vasoconstrictor agent ,
Diclofop-methyl,herbicide control wild oat foxtail cereal crop ,
Candesartan,candesartan angiotensin-receptor blocker arb may used alone agent treat hypertension available prodrug form candesartan cilexetil ,
Valopicitabine, 3-o-valine ester prodrug nucleoside analog 2'-c-methylcytidine anti-hepatitis c virus hcv activity upon administration valopicitabine converted 2'-c-methylcytidine upon phosphorylation 5-triphosphate form metabolite inhibits viral rna chain elongation viral rna-dependent rna polymerase activity block viral production hcv rna thus viral replication nci ,
2'-C-methylcytidine, nucleoside analog anti-hepatitis c virus hcv activity upon phosphorylation 5-triphosphate form metabolite inhibits viral rna chain elongation viral rna-dependent rna polymerase activity block viral production hcv rna thus viral replication ,
Emicizumab,emicizumab humanized recombinant monoclonal antibody mimic function coagulation factor viii capacity bind simultaneously activated factor ix factor x ability emicizumab bind three different factor allows overcome immunogenicity unstable hemostatic efficacy produced previous factor vii agent emicizumab originated improved form hbs23 approved november 16 2017 a31279 l1016 created chugai pharmaceutical co. ltd. co-developed roche genentech l1015 , main function emicizumab prevention bleeding episode thus emicizumab approved routine prophylaxis prevent reduce frequency bleeding episode adult pediatric patient hemophilia without factor viii inhibitor l4657 hemophilia deficiency coagulation factor viii cause serious bleeding disorder standard treatment done administration recombinant serum-deriver factor viii induces formation anti-factor viii alloantibody factor viii inhibitor render standard treatment ineffective a31286 
Varicella zoster vaccine (recombinant),recombinant zoster vaccine manufactured product shingrix glaxosmithkline adjuvanted non-live recombinant vaccine indicated prevention shingle first approved october 2017 food drug administration shingrix preferred vaccine preventing varicella zoster infection people aged 50 year older replacing zostavax first line therapy l1038 herpes zoster also known shingle caused reactivation varicella zoster virus vzv virus commonly cause chickenpox childhood following initial infection vzv resolution chickenpox child vzv lie dormant within dorsal root ganglion central nervous sytem decade later body 's immune system weakens age vzv able reactivate descend nerve cell surface skin cause painful blistering rash risk factor developing shingle include old age rate increasing substantially person 's age 50 low immune function immunosuppression psychological stress diabetes person 's living hiv cancer taking immunosuppressant transplant recipient particularly risk l1037 one common complication associated shingle development post-herpetic neuralgia phn persistant severe nerve pain develops result chronic pain shingle lesion phn last day month even year following resolution shingle complication also include bacterial infection spread shingle rash eye herpes zoster ophthalmicus ear nerve palsy spread vzv non-immune person via contact varicella lesion numerous advantage using shingrix zostavax clinical trial shingrix shown greater 90 efficacy adult aged 50 older 89 efficacy preventing postherpetic neuralgia patient 70 year older 91 efficacy patient 50-70 year age fda label significant improvement predecessor zostavax reduces risk shingle 51 risk post-herpetic neuralgia 67 a31349 efficacy zostavax also wane time protection shingle phn lasting around 5 year furthermore shingrix inactivated vaccine also used prevent shingle phn individual suppressed immune system already increased risk developing shingle zostavax live attenuated vaccine contraindicated main immunological component shingrix vaccine glycoprotein e ge protein found surface varicella zoster virus vzv immune exposure ge protein stimulates development anti-ge antibody therefore adaptive immunity vzv shingrix also contains adjuvant system as01b intended enhance immunological response vaccine leading longer lasting greater immunogenicity herpes zoster virus l1036 ,varicella zoster vaccine indicated prevention herpes zoster hz shingle adult aged 50 year older adult aged 18 year older increased risk hz due immunodeficiency immunosuppression caused known disease therapy l41255 
Dotatate gallium Ga-68,dotatate gallium ga-68 somatostatin-2 receptor analog radiolabeled gallium 68 positron-emitting radioisotope ga-68 dotatate high affinity somatostatin-2 receptor rapidly excreted nontarget site give ideal candidate imaging neuroendocrine tumor dotatate gallium ga-68 explotes ability detect somatostatin receptor scintigraphy characteristic tends change tumor grade give ga-68 dotate high diagnostic value a31358 dotatate gallium 68 developed advanced accelerator application usa inc. fda approved june 1 2016 ,dotatate gallium 68 one prominent radiopharmaceutical used imaging positron emission tomography bind somatostatin-2 receptor usually overexpressed many neuroendocrine tumor adult pediatric patient a31362 neuroendocrine tumor bening malignant tumor produced hormone producing cell neuroendocrine system l1048 
Cenegermin,"cenegermin human beta-nerve growth factor beta-ngf 1-118 peptide non-covalent dimer produced escherichia coli received european union approval july 2017 treatment moderate severe neurotrophic keratitis cenegermin received approval u fda year later august 2018 l4563 neurotrophic keratitis degenerative disease resulting loss corneal sensation l4563 loss corneal sensation impairs corneal health causing progressive damage top layer cornea including corneal thinning ulceration perforation severe case l4563 prevalence neurotrophic keratitis estimated le five 10,000 individual l4563 prevalence neurotrophic keratitis low impact serious condition associated sequela individual patient debilitating many currently available therapeutic option treating condition involve surgical intervention surgery typically palliative l4563 approval cenegermin consequently provides novel topical treatment potential capacity offer total corneal healing many patient may use agent l4563 particular cenegermin granted priority review designation fda ’ goal take action application within six month application filing agency determines drug approved would provide significant improvement safety effectiveness treatment diagnosis prevention serious condition l4563 cenegermin also received orphan drug designation provides incentive assist encourage development drug rare disease l4563 ",cenegermin indicated treatment moderate persistent epithelial defect severe corneal ulcer neurotrophic keratitis adult fda label f1502 
anle138b,anle138b restores hippocampal synaptic transcriptional plasticity well spatial memory mouse model alzheimer 's disease given orally onset pathology a31409 ,
Semaglutide,semaglutide glucagon-like peptide 1 glp-1 analog used manage type 2 diabetes along lifestyle change dietary restriction increased physical activity a31421 l8681 member drug class include exenatide liraglutide semaglutide developed novo nordisk approved fda subcutaneous injection december 2017 l8681 tablet formulation approved oral administration september 2019 semaglutide work binding activating glp-1 receptor thereby stimulating insulin secretion reducing blood glucose l8678 subcutaneous injection administered weekly tablet administered day semaglutide offer competitive advantage drug used manage diabetes may require several daily dos clinical trial determined drug reduces glycosylated hemoglobin hba1c level reduces body weight proving effective patient type 2 diabetes a186053 june 2021 semaglutide approved fda chronic weight management adult general obesity overweight least one weight-related condition marking semaglutide first approved drug use since 2014 l34485 use semaglutide weight management also approved health canada l39347 ema l41335 ,semaglutide indicated improve glycemic control adult diagnosed type 2 diabetes mellitus used adjunct diet exercise l8678 l8681 however semaglutide suitable first-line drug diabetes controlled diet exercise addition studied patient pancreatitis semaglutide intended use patient type 1 diabetes treat diabetic ketoacidosis l8678 semaglutide indicated chronic weight management adult obesity overweight least one weight-related condition high blood pressure type 2 diabetes high cholesterol use addition reduced-calorie diet increased physical activity l34475 l41335 
Ulixertinib,ulixertinib novel reversible atp-competitive erk1/2 inhibitor high potency erk1/2 selectivity a31474 currently clinical trial treatment wide range tumor ,
Netarsudil, rho kinase inhibitor norepinephrine transport inhibitory activity reduces production aqueous december 18 2017 fda approved aerie pharmaceutical 's rhopressa netarsudil ophthalmic solution 0.02 indication reducing elevated intraocular pressure patient open-angle glaucoma ocular hypertension acting rho kinase inhibitor norepinephrine transport inhibitor netarsudil novel glaucoma medication specifically target conventional trabecular pathway aqueous humour outflow act inhibitor rho kinase norepinephrine transporter found opposed affecting protaglandin f2-alpha analog like mechanism unconventional uveoscleral pathway many glaucoma medication demonstrate ,netarsudil indicated reduction elevated intraocular pressure iop patient open-angle glaucoma ocular hypertension fda label 
Voretigene neparvovec,voretigene neparvovec-rzyl vn-rzyl adeno-associated virus vector-based gene therapy l1094 adeno-associated virus small virus infects human primate pathogenic cause mild immune response type virus vastly used vector gene therapy infect dividing quiescent cell integrating carried gene host genome without fully integrating genome a31477 advantage adeno-associated virus high predictability unlike retrovirus associate specific region human cellular genome localized chromosome 19 used genetic therapy virus modified elimination negligible integrative capacity removal rep cap insertion desired gene promoter inverted terminal repeat a31478 vn-rzyl developed spark therapeutic inc. fda approved december 19 2017 l1095 ,vn-rzyl indicated treatment child adult patient confirmed biallelic rpe65 mutation-associated retinal dystrophy administration vn-rzyl conditioned physician determination presence viable retinal cell fda label rpe65 represents lca2 form leber 's congenital amaurosis lca lca group inherited conditionts involves retinal degeneration severe vision loss early childhood leading total blindness 30-40 year old lca2 form associated mutation interferes isomerohydrolase activity retinal pigment epithelium isomerohydrolase activity transforms trans-retinyl ester 11-cis-retinal natural ligand chromophore opsin rod cone photoreceptors presence rpe65 mutation opsin capture light transduce electrical response initiate vision a31480 
Nonacog beta pegol,nonacog beta pegol recombinant coagulation factor ix derivative produced without animal-derived material attached 40kda polyethylene glycol peg molecule peptide activation site-directed glycopegylation activated activation molecule peg cleaved leave activated factor ix factor ixa a31496 nonacog beta pegol developed novo nordisk received first global approval fda may 31 2017 l1098 followed european commission approval june 2 2017 l41185 nonacog beta pegol approved health canada november 29 2017 l43682 ,nonacog beta pegol indicated adult child hemophilia b congenital factor ix deficiency christmas disease control prevention bleeding episode well control prevention bleeding perioperative setting l41175 l41180 l41185 l43682 also used routine prophylaxis prevent reduce frequency bleeding episode l41180 l43682 
Ligandrol,ligandrol investigational selective androgen receptor modulator sarm treatment condition muscle wasting osteoporosis ,
AC-262536, selective androgen receptor modulator ,
JNJ-28330835, selective androgen receptor modulator minimal prostate hypertrophic activity enhances lean body mass male rat stimulates sexual behavior female rat ,
LGD-3303, androgen receptor modulator ,
S-40503,s-40503 investigational selective androgen receptor modulator sarm developed treatment osteoporosis japanese company kaken pharmaceutical ,
RAD-140,rad140 investigational selective androgen receptor modulator sarm treatment condition muscle wasting breast cancer ,
"2,5-Dimethoxy-4-ethylthioamphetamine","2,5-dimethoxy-4-ethylthioamphetamine aleph-2 phenylisopropylamine derivative alleged anxiolytic hallucinogenic property ",
Piperaquine,piperaquine antimalarial agent first synthesized 1960 's used throughout china a31550 use declined 1980 's piperaquine resistant strain plasmodium falciparum appeared artemisinin derivative became available come back use combination artemisinin derivative db11638 part combination product eurartesim fda label eurartesim first authorized market european medicine agency october 2011 , treatment uncomplicated plasmodium falciparum infection adult child infant aged 6 month weighing 5 kg fda label used combination db11638 
Testosterone cypionate,testosterone cypionate synthetic derivative testosterone form oil-soluble 17 beta -cyclopentylpropionate ester benefit compared testosterone derivative slow rate release injection longer half-life developed company pharmacia upjohn fda approved july 25 1979 ,testosterone cypionate used male present condition derived deficiency absence endogenous testosterone condition 1 primary hypogonadism defined testicular failure due cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy 2 hypogonadotropic hypogonadism characterized idiopathic gonadotropin lhrh deficiency pituitary-hypothalamic injury tumor trauma radiation l1153 
Testosterone enanthate,testosterone enanthate esterified variant testosterone come injectable compound slow-release rate slow release achieved presence enanthate ester functional group attached testosterone molecule a31615 testosterone derivative first approved december 24 1953 l8941 2017 6.5 million retail prescription testosterone therapy filled l4659 majority prescription written injectable 66 topical 32 testosterone product recent 1 october 2018 u fda approved antares pharma inc. 's xyosted subcutaneous testosterone enanthate product once-weekly at-home self-administration easy-to-use single dose disposable autoinjector l4659 first subcutaneous autoinjector product designed testosterone replacement therapy innovative formulation remove transfer concern commonly associated testosterone gel potentially reduces need in-office/in-clinic injection procedure may inconvenience patient frequent visit clinic l4659 ,testosterone enanthate male indicated replacement therapy condition associated deficiency absence endogenous testosterone treated condition 1 primary hypogonadism defined testicular failure due cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy 2 hypogonadotropic hypogonadism due idiopathic gonadotropin luteinizing hormone-releasing hormone deficiency due pituitary-hypothalamic injury tumor trauma radiation case important accompany treatment adrenal cortical thyroid hormone replacement therapy 3 stimulate puberty patient delayed puberty secondary pathological disorder condition 1 2 occur prior puberty androgen replacement therapy needed adolescent year development secondary sexual characteristic prolonged androgen treatment might needed maintain sexual characteristic puberty fda label female testosterone enanthate indicated used secondarily presence advanced inoperable metastatic mammary cancer woman one five year postmenopausal also used premenopausal woman breast cancer benefited oophorectomy considered hormone-responsive tumor fda label testosterone enanthate injection currently formulated subcutaneous use specifically indicated primary hypogonadism hypogonadotropic hypogonadism f1941 use formulation limited safety efficacy subcutaneous product adult male late-onset hypogonadism male le 18 year old yet established f1941 moreover subcutaneously administered testosterone enanthate indicated treatment men hypogonadal condition associated structural genetic etiology considering medication could cause blood pressure increase raise risk major adverse cardiovascular event like non-fatal myocardial infarction non-fatal stroke cardiovascular death f1941 
Testosterone undecanoate,testosterone undecanoate ester prodrug testosterone mid-chain fatty acid carbon 17β position l35970 developed via fatty acid esterification testosterone order achieve orally administer testosterone a246594 oral intramuscular formulation available testosterone undecanoate formulation indicated testosterone replacement therapy adult male hypogonadism l35970 l8932 l41355 testosterone critical male hormone responsible normal growth development male sex organ maintenance secondary sex characteristic male hypogonadism resulting insufficient testosterone secretion result symptom sign testosterone deficiency decreased libido erectile dysfunction loss muscle bone mass testosterone replacement therapy aim restore level testosterone thereby improving symptom sign testosterone deficiency a246614 l35970 ,testosterone undecanoate indicated testosterone replacement therapy adult male condition associated deficiency absence endogenous testosterone condition include congenital acquired primary hypogonadism testicular failure due cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchiectomy klinefelter ’ syndrome chemotherapy toxic damage alcohol heavy metal men usually low serum testosterone concentration gonadotropin follicle-stimulating hormone fsh luteinizing hormone lh normal range l35970 l8932 l41355 congenital acquired hypogonadotropic hypogonadism gonadotropin luteinizing hormone-releasing hormone lhrh deficiency pituitary-hypothalamic injury tumor trauma radiation men low testosterone serum concentration gonadotropin normal low range l35970 l8932 l41355 testosterone undecanoate used treat age-related hypogonadism l35970 l8932 l41355 
"N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine","25cn-nboh n- 2-hydroxybenzyl -2,5-dimethoxy-4-cyanophenylethylamine newly developed selective 5-ht2a agonist tested regard head-twitch-response htr model 5-ht2a activity effect locomotion l1148 discovered 2014 university copenhagen ",
Ferric cation,iron transition metal symbol fe atomic number 26 mass common element earth iron essential element involved various metabolic process including oxygen transport deoxyribonucleic acid dna synthesis energy production electron transport a32514 resulting inadequate supply iron cell due depletion store iron deficiency common nutritional deficiency worldwide particularly affecting child woman childbearing age pregnant woman l2257 iron deficiency may characterized without development anemia may result functional impairment affecting cognitive development immunity mechanism well infant maternal mortality occurs pregnancy a32514 main therapeutic preparation iron db13257 iron-sucrose may also given intravenously t28 iron exists two oxidation state ferrous cation fe2+ ferric cation fe3+ non-haem iron food mainly ferric state insoluble form iron must reduced ferrous cation absorption t28 ferric citrate tetraferric tricitrate decahydrate phosphate binder indicated control serum phosphorus level patient chronic kidney disease dialysis , control serum phosphorus level patient chronic kidney disease dialysis ferric citrate 
WIN 55212-2,"win 55,212-2 chemical described aminoalkylindole derivative produce effect similar cannabinoids tetrahydrocannabinol thc entirely different chemical structure potent cannabinoid receptor agonist found potent analgesic rat model neuropathic pain activates p42 p44 map kinase via receptor-mediated signaling ",
Stanolone acetate,stanolone acetate synthetic androgen anabolic steroid dihydrotestosterone ester never marketed ,
Estradiol acetate,estradiol acetate pro-drug ester db00783 naturally occurring hormone circulates endogenously within human body estradiol potent form mammalian estrogenic steroid act major female sex hormone pro-drug estradiol estradiol acetate therefore downstream effect within body binding estrogen receptor er including erα erβ subtypes located various tissue including breast uterus ovary skin prostate bone fat brain db00783 commonly produced ester side-chain endogenous estradiol low oral bioavailability 2-10 first-pass metabolism gut liver quickly degrades estradiol molecule get chance enter systemic circulation exert estrogenic effect a12102 esterification estradiol aim improves absorption bioavailability oral administration estradiol valerate sustain release depot intramuscular injection estradiol cypionate improved lipophilicity following absorption ester cleaved resulting release endogenous estradiol 17β-estradiol ester pro-drugs estradiol therefore considered bioidentical form estrogen t84 estradiol acetate commercially available femring vaginal ring used treatment moderate severe vasomotor symptom vulvovaginal atrophy due menopause primary source estrogen normally cycling adult woman ovarian follicle secretes 70 500 mcg estradiol daily depending phase menstrual cycle however menopause endogenous estrogen produced conversion androstenedione secreted adrenal cortex estrone peripheral tissue thus estrone sulfate conjugated form estrone sulfate abundant circulating estrogen postmenopausal woman fda label although circulating estrogen exist dynamic equilibrium metabolic interconversions estradiol principal intracellular human estrogen substantially potent metabolite estrone estriol receptor level difference potency estradiol estrone menopause change primary hormone estradiol estrone associated number symptom associated reduction potency estrogenic effect include hot flash vaginal dryness mood change irregular menses chill sleeping problem administration synthetic bioidentical form estrogen estradiol acetate shown improve menopausal symptom ,femring indicated treatment vasomotor urogenital symptom associated menopause use femring estradiol acetate shown improve symptom caused atrophy vagina dryness burning pruritus dyspareunia and/or lower urinary tract urinary urgency dysuria 
Estradiol benzoate,estradiol benzoate pro-drug ester db00783 naturally occurring hormone circulates endogenously within human body estradiol potent form mammalian estrogenic steroid act major female sex hormone pro-drug estradiol estradiol benzoate therefore downstream effect within body binding estrogen receptor er including erα erβ subtypes located various tissue including breast uterus ovary skin prostate bone fat brain db00783 commonly produced ester side-chain endogenous estradiol low oral bioavailability 2-10 first-pass metabolism gut liver quickly degrades estradiol molecule get chance enter systemic circulation exert estrogenic effect a12102 esterification estradiol aim improves absorption bioavailability oral administration estradiol valerate sustain release depot intramuscular injection estradiol cypionate improved lipophilicity following absorption ester cleaved resulting release endogenous estradiol 17β-estradiol ester pro-drugs estradiol therefore considered bioidentical form estrogen t84 estradiol benzoate currently available canada u ,estradiol benzoate currently available fda health canada approved product 
Estradiol cypionate,estradiol cypionate pro-drug ester db00783 naturally occurring hormone circulates endogenously within human body estradiol potent form mammalian estrogenic steroid act major female sex hormone pro-drug estradiol estradiol cypionate therefore downstream effect within body binding estrogen receptor er including erα erβ subtypes located various tissue organ breast uterus ovary skin prostate bone fat brain db00783 commonly produced ester side-chain endogenous estradiol low oral bioavailability 2-10 first-pass metabolism gut liver quickly degrades estradiol molecule get chance enter systemic circulation exert estrogenic effect a12102 esterification estradiol aim improve absorption bioavailability oral administration estradiol valerate sustain release depot intramuscular injection estradiol cypionate improved lipophilicity following absorption ester cleaved resulting release endogenous estradiol 17β-estradiol ester pro-drugs estradiol therefore considered bioidentical form estrogen t84 estradiol cypionate commercially available depo-estradiol intramuscular depot injection used treatment moderate severe vasomotor symptom associated menopause treatment hypoestrogenism due hypogonadism fda label primary source estrogen normally cycling adult woman ovarian follicle secretes 70 500 mcg estradiol daily depending phase menstrual cycle however menopause endogenous estrogen produced conversion androstenedione secreted adrenal cortex estrone peripheral tissue thus estrone sulfate conjugated form estrone sulfate abundant circulating estrogen postmenopausal woman fda label although circulating estrogen exist dynamic equilibrium metabolic interconversions estradiol principal intracellular human estrogen substantially potent metabolite estrone estriol receptor level difference potency estradiol estrone menopause change primary hormone estradiol estrone associated number symptom associated reduction potency estrogenic effect include hot flash vaginal dryness mood change irregular menses chill sleeping problem administration synthetic bioidentical form estrogen estradiol cypionate shown improve menopausal symptom ,depo-estradiol intramuscular depot injection indicated treatment moderate severe vasomotor symptom hypoestrogenism due hypogonadism 
Estradiol dienanthate,estradiol dienanthate pro-drug ester db00783 naturally occurring hormone circulates endogenously within human body estradiol potent form mammalian estrogenic steroid act major female sex hormone pro-drug estradiol estradiol benzoate therefore downstream effect within body binding estrogen receptor er including erα erβ subtypes located various tissue including breast uterus ovary skin prostate bone fat brain estradiol commonly produced ester side-chain endogenous estradiol low oral bioavailability 2-10 first-pass metabolism gut liver quickly degrades estradiol molecule get chance enter systemic circulation exert estrogenic effect a12102 esterification estradiol aim improves absorption bioavailability oral administration estradiol valerate sustain release depot intramuscular injection estradiol cypionate improved lipophilicity following absorption ester cleaved resulting release endogenous estradiol 17β-estradiol ester pro-drugs estradiol therefore considered bioidentical form estrogen t84 estradiol dienanthate currently available commercially available product canada u ,estradiol dienanthate currently available fda health canada approved product 
Estradiol valerate,estradiol valerate also known e2v pro-drug ester db00783 naturally occurring hormone circulates endogenously within human body estradiol potent form mammalian estrogenic steroid act major female sex hormone pro-drug estradiol estradiol acetate therefore downstream effect within body binding estrogen receptor er including erα erβ subtypes located various tissue including breast uterus ovary skin prostate bone fat brain db00783 commonly produced ester side-chain endogenous estradiol low oral bioavailability 2-10 first-pass metabolism gut liver quickly degrades estradiol molecule get chance enter systemic circulation exert estrogenic effect a12102 esterification estradiol aim improves absorption bioavailability oral administration estradiol valerate sustain release depot intramuscular injection estradiol cypionate improved lipophilicity following absorption ester cleaved resulting release endogenous estradiol 17β-estradiol ester pro-drugs estradiol therefore considered bioidentical form estrogen t84 estradiol valerate commercially available intramuscular injection product delestrogen indicated treatment moderate severe vasomotor symptom vulvovaginal atrophy due menopause treatment hypoestrogenism due hypogonadism castration primary ovarian failure treatment advanced androgen-dependent carcinoma prostate palliation estradiol valerate also available combination db09123 commercially available product natazia used prevention pregnancy treatment heavy menstrual bleeding primary source estrogen normally cycling adult woman ovarian follicle secretes 70 500 mcg estradiol daily depending phase menstrual cycle however menopause endogenous estrogen produced conversion androstenedione secreted adrenal cortex estrone peripheral tissue thus estrone sulfate conjugated form estrone sulfate abundant circulating estrogen postmenopausal woman fda label although circulating estrogen exist dynamic equilibrium metabolic interconversions estradiol principal intracellular human estrogen substantially potent metabolite estrone estriol receptor level difference potency estradiol estrone menopause change primary hormone estradiol estrone associated number symptom associated reduction potency estrogenic effect include hot flash vaginal dryness mood change irregular menses chill sleeping problem administration synthetic bioidentical form estrogen estradiol valerate shown improve menopausal symptom ,estradiol valerate commercially available intramuscular injection product delestrogen indicated treatment moderate severe vasomotor symptom vulvovaginal atrophy due menopause treatment hypoestrogenism due hypogonadism castration primary ovarian failure treatment advanced androgen-dependent carcinoma prostate palliation estradiol valerate also available combination db09123 commercially available product natazia used prevention pregnancy treatment heavy menstrual bleeding 
J147,j147 experimental drug reported effect alzheimer 's disease ageing mouse model accelerated aging a31606 a31607 a31608 curcumin derivative potent neurogenic neuroprotective drug candidate initially developed treatment neurodegenerative condition associated aging impact many pathway implicated pathogenesis diabetic neuropathy a31610 ,
Trestolone acetate,trestolone acetate synthetic injected anabolic–androgenic steroid aa derivative nandrolone 19-nortestosterone never marketed androgen ester – specifically c17 acetate ester db05830 ,
Medium-chain triglycerides,medium-chain triglyceride mcts triglyceride made glycerol backbone three fatty acid aliphatic tail six 12 carbon atom mcts found natural food coconut oil palm kernel oil raw coconut meat body mcts broken glycerol free fatty acid directly absorbed blood stream transported target organ exert range biological metabolic effect a246688 mcts used parenteral nutrition therapy serve source calorie essential fatty acid condition associated malnutrition malabsorption l41340 ,medium-chain triglyceride mcts combination compound like fish oil soya oil olive oil indicated adult pediatric patient including term preterm neonate source calorie essential fatty acid parenteral nutrition oral enteral nutrition possible insufficient contraindicated l41340 mcts also available over-the-counter natural product health supplement 
Bronopol,"bronopol 2-bromo-2-nitro-1,3-propanediol organic compound wide-spectrum antimicrobial property first synthesized 1897 bronopol primarily used preservative pharmaceutical registered united state 1984 use industrial bactericide slimicides preservative f13 bronopol used microbicide microbiostat various commercial industrial application including oil field system air washer system air conditioning humidifying system cooling water system papermills absorbent clay metal working fluid printing ink paint adhesive consumer product f13 compared aliphatic halogen-nitro compound bronopol stable hydrolysis aqueous medium normal condition a32792 inhibitory activity various bacteria including _pseudomonas aeruginosa_ demonstrated _in vitro_ a32792 agent largely available commercially antibacterial variety industrial purpose predominantly available purchase pet animal litter antibacterial domestic consumer level f2317 nevertheless ongoing contemporary re-evaluations bronopol use large market canada place various compositional product restriction use agent cosmetic product l4873 product may primarily used role non-medicinal preservative antimicrobial l4874 ",bronopol active ingredient registered commercial biocide preservative many industrial process registered biocidal us include pulp paper mill water cooling tower waste water treatment evaporative condenser heat exchanger food pasteurizing plant metalworking fluid oilfield application f2317 addition preservative us include household product e.g. dishwashing liquid laundry product latex emulsion polymer lattice pigment leather milk sample analysis f2317 bronopol also formulated granular domestic end-use product form cat litter f2317 
Fish oil,fish oil component smoflipid fda approved july 2016 indicated adult source calorie essential fatty acid parenteral nutrition oral enteral nutrition possible insufficient contraindicated commonly fish oil refers omega-3-fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha fda label general dietary pharmaceutical intake acid primarily way increase level human body overall essential element dietary health demonstrated ability minimizing preventing hypertriglyceridemia taken adjunct healthy diet fda label fish oil available non-prescription prescription-only variety different concentration many individual taking non-prescription fish oil part multivitamin regimen effective way supplement diet healthy fatty acid however prescription-only fish oil product sometimes prescribed individual demonstrate severe 500 mg/dl hypertriglyceridemia fda label furthermore variety study regarding additional potential action fish oil omega-3-fatty acid epa dha ongoing experimental action include inflammation modulation cardioprotective effect attenuation oxidative stress regardless specific mechanism action effect yet formally elucidated , fda approval fish oil pharmaceutical typically product consisting combination omega-3-fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha indicated primarily adjunct diet reduce triglyceride level adult patient severe =500 mg/dl hypertriglyceridemia fda label f36 ema approval fish oil pharmaceutical comprised virtually fish fish oil derived omega-3-fatty acid epa dha indicated specifically adjuvant treatment secondary prevention myocardial infarction addition standard therapy ie statin antiplatelet medicinal product beta blocker ace inhibitor b supplement diet dietary measure alone insufficient produce adequate response particularly type iv hypertriglyceridemia monotherapy type iib/iii combination statin control triglyceride insufficient l2661 addition prescribing information ema approved fish oil pharmaceutical also indicated adjunct diet reduce high =500 mg/dl triglyceride level adult patient much like similar fda approved indication f37 fda label 
Calcium saccharate,pharmaceutic aid stabilizer ,
"1,2-dichlorobenzene","1,2-dichlorobenzene also named ortho-dichlorobenzene organic compound non-polar colorless liquid miscible organic solvent derivative benzene differs parent compound presence two adjacent chlorine atom 1,2-dichlorobenzene used precursor agrochemicals solvent fullerene insecticide agent remove carbon-based contamination metal ",
Peanut oil,peanut oil derived _arachis hypogaea_ found south america mexico centro america kernel consumed roasted large percentage used production vegetable oil peanut oil represents 45-52 kernel content mainly formed monounsaturated fat major component db04224 a33169 fda peanut oil categorized approved inactive ingredient use drug product l2242 health canada approved active ingredient over-the-counter combination product l1113 ,peanut oil widely used food even component adulteration olive oil t41 used over-the-counter ear drop help lubricate ear wax f124 also used ingredient cleansing soap emollient cream preparation laxative l2892 f125 peanut oil also used usually solubilize drug poor water solubility part oral formulation t224 orally administered peanut oil well researched used prevent heart disease lower cholesterol level well aid weight loss decrease appetite l2897 
Sarracenia Purpurea,_sarracenia purpurea_ commonly known purple pitcher plant northern pitcher plant turtle sock side-saddle flower perennial carnivorous plant family _sarraceniaceae_ _sarracenia purpurea_ attract trap insect within pitcher fused leaf consume nitrogen digestion process a32509 widely distributed across north america used traditional medicinal herb many aboriginal community a32509 a32510 used injectable pain reliever 19th century _sarracenia purpurea_ used treatment smallpox a32509 compound extracted _sarracenia purpurea_ include phenolic glycoside flavonoid glycoside iridoids _in vitro_ evidence glycoside potentiating glucose uptake potential antidiabetic property a32510 cytoprotection vitro model diabetic neuropathy also studied however use sarracenia purpurea extract clinical setting limited , approved therapeutic indication 
Isopropyl myristate,isopropyl myristate moisturizer polar characteristic used cosmetic topical medical preparation ameliorate skin absorption isopropyl myristate largely studied impulsed skin penetration enhancer a178078 moment primary usage isopropyl myristate formally indicated active ingredient non-prescription pediculicide rinse a32333 l1964 l1966 , primary medical indication isopropyl myristate formally used active ingredient patient care product non-prescription pediculicide rinse a32330 
Patent Blue,"patent blue aniline dye one common dye used a32573 sodium calcium salt diethylammonium hydroxide inner salt a32574 chemical designation 4- alpha- p- diethylamino phenyl -2,4-disulfobenzylidene -2,5-cyclohexadiene-1-ylidene diethylammonium hydroxide patent blue developed guerbet approved health canada december 31 1979 l1113 isomer isosulphan used united state indication patent blue a32574 ",patent blue used marking lymphatic vessel arterial territory well sentinel lymph node prior biopsy patient operable breast cancer clinically negative lymph node combination radiotracer a32575 patent blue also used textile paper agriculture cosmetic industry a32574 
Plasma protein fraction (human), plasma protein fraction human ppfh defined sterile solution protein composed mainly albumin globulin derived human plasma a32512 already reviewed category biologics fda processing required test requirement labeling incorporated biologic come recovered plasma whole blood prepared source plasma final product include type additive composition ppfh 5 protein 83 consist albumin 17 globulin also stated 1 total protein gamma globulin l2260 ppfh sterile frozen solution solvent/detergent treated human plasma l2262 protein ppfh stabilized sodium caprylate acetyltryptophan contains electrolyte sodium potassium chloride l2261 ,ppfh used replacement therapy patient complex deficiency coagulation factor coagulopathy also used substitution therapy emergency case factor deficiency rapid reversal effect oral anticoagulant dangerous hemorrhage fibrinolytic therapy ppfh used therapeutic plasma exchange procedure including thrombotic thrombocytopenic purpura l2264 ppfh used treatment shock predominant loss plasma fluid red blood cell l2261 
Racemethionine, preparation methionine includes mixture d-methionine l-methionine isomer ,
Remestemcel-L,remestemcel-l third-party off-the-shelf suspension ex-vivo cultured adult human mesenchymal stem cell intended intravenous infusion mesenchymal stem cell derived bone marrow unrelated human leukocyte antigen hla –unmatched healthy adult donor ability differentiate different tissue cell approved use canada may 2012 prochymal management refractory acute graft versus host disease agvhd child unresponsive systemic steroid therapy approval conditional upon trial conducted agvhd t-cell mediated disease occurs allogeneic hematopoietic stem cell transplant reaction donor immune cell host tissue a31822 developed 30-80 recipient a31818 agvhd often characterized presence inflammatory cascade signalling activated cell systemic corticosteroid immunosuppressive agent commonly used first-line treatment manage agvhd 30-50 patient agvhd experience inadequately control disease first-line therapy putting risk poor outcome creating significant clinical challenge a31818 estimated patient severe form refractory agvhd respond steroid therapy expected one-year survival rate 5 30 l11022 human mesenchymal stem cell hmscs serve down-regulate inflammatory response produce anti-inflammatory cytokine growth factor promote tissue repair a31818 clinical study patient treated remestemcel-l demonstrated improvement agvhd improved survival rate subsequent day following intravenous infusion l11022 based tolerability safety profile remestemcel-l promising alternative second-line immunosuppressive agent a31818 ,indicated management acute graft versus host disease agvhd pediatric patient acute gvhd refractory treatment systemic corticosteroid therapy and/or immunosuppressive agent remestemcel-l may used grade c disease organ remestemcel-l may also used management grade b agvhd involving visceral organ including gi tract liver excluding skin l11022 
Black cohosh,black cohosh _actaea racemosa_ _cimicifuga racemosa_ member buttercup family perennial plant native north america historical name plant include snakeroot black bugbane rattleweed macrotys rheumatism weed black cohosh long history use native american used purported benefit treating musculoskeletal pain fever cough pneumonia sluggish labor menstrual irregularity european settler said use black cohosh tonic support female reproductive health l2303 hormone replacement therapy hrt standard treatment early symptom post-menopausal woman however increase risk stroke heart disease well breast cancer older woman various study shown number post-menopausal woman using hormone replacement therapy currently low effect hormone replacement therapy reducing menopausal symptom positive expected reason trend toward using alternative therapy relieve menopausal symptom l2301 black cohosh associated serious safety concern a32542 result study suggest c. racemosa posse central activity instead hormonal effect a32543 american college obstetrics gynecology guideline use botanical black cohosh management menopausal symptom use six month especially treating symptom sleep mood disturbance hot flush l2307 ,treatment menopausal symptom menstrual dysfunction l2307 
Sulesomab,market product tc99m-labeled murine antibody fragment nuclear imaging activated granulocyte ,
Potassium carbonate,potassium carbonate k2co3 white salt soluble water insoluble ethanol form strongly alkaline solution made product potassium hydroxide 's absorbent reaction carbon dioxide present large capacity absorb moisture ,
Selisistat,selective inhibitor sirt1 inhibit histone deacetylase hdac sirtuin deacetylase family member ic50 value 98 19600 48700 100000 100000 nm sirt1 sirt2 sirt3 hdac nadase respectively enhances p53 acetylation response dna damaging agent ,
Besilesomab,besilesomab mouse monoclonal antibody labelled radioactive isotope technetium-99m determining location inflammation/infection peripheral bone adult suspected osteomyelitis fda label utilised diagnostic agent besilesomab currently approved emea marketing use various european country like italy france germany spain portugal norway sweden netherlands united kingdom l1564 ,besilesomab radiolabelled sodium pertechnetate tc99m solution develop technetium tc99m besilesomab solution solution indicated adult scintigraphic imaging conjunction appropriate imaging modality possible determining location inflammation/infection peripheral bone adult suspected osteomyelitis fda label utilized medicinal product diagnostic use fda label 
Copper Cu-64,copper-64 radiopharmaceutical usually found +2 oxidation state complex including +1 state tend unstable t604 used molecular radiotherapy positron emission tomography ,
Nomegestrol acetate,nomegestrol acetate also known nomac progestin used oral contraceptive menopausal hormone therapy treatment gynecological disorder ,
"5,7,2′-trihydroxy-6,8-dimethoxyflavone","5,7,2′-trihydroxy-6,8-dimethoxyflavone k36 high-affinity naturally occurring flavonoid derivative isolated medicinal herb _scutellaria baicalensis_ georgi a31656 ",
Cyclopropane,cyclopropane initially investigated thought toxic element ethylene instead turned excellent anesthetic rapid onset recovery maintaining stable hemodynamics use ultimately limited highly explosive ,
Lutetium Lu 177 dotatate, 177lu-labeled somatostatin analog peptide lutetium lu 177 dotatate belongs emerging form treatment called peptide receptor radionuclide therapy prrt involves targeting tumour molecule carrying radioactive particle bind specific receptor expressed tumour lutetium lu 177 dotatate may also referred 177lu-dota-tyr3-octreotate compared alternative somatostatin analogue dota-tyr3-octreotide dotatoc lutetium lu 177 dotatate display higher uptake radioactivity tumor better residence time a31696 term biodistribution lutetium lu 177 dotatate demonstrated lower whole-body retention indicating potentially lower risk bone marrow toxicity a31696 presence radioligand allows monitoring treatment response post therapy prior next fraction dose delivery may clinically beneficial estimating intensity lesion uptake deciding dose subsequent administration a31702 lutetium lu 177 dotatate approved fda lutathera january 2018 intravenous injection first radiopharmaceutical agent approved gastroenteropancreatic neuroendocrine tumor gep-nets indicated adult patient somatostatin receptor-positive gep-nets l1191 targeting pancreas part gastrointestinal tract intestine colon neuroendocrine tumor may commonly metastasize metastasize mesentery peritoneum liver a31697 patient gep-nets limited second-line treatment option metastasis tumor inadequate therapeutic response first-line therapy clinical trial involving patient advanced somatostatin receptor-positive gep-net treatment lutetium lu 177 dotatate combination octreotide resulted longer progression-free survival compared patient receiving octreotide alone evidence overall survival benefit a31697 ,indicated treatment somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumor gep-nets including foregut midgut hindgut neuroendocrine tumor adult l42160 
Strontium chloride,strontium chloride srcl2 salt strontium chloride srcl2 useful reducing tooth sensitivity forming barrier microscopic tubule dentin containing nerve ending become exposed gum recession a33167 a33168 kind barrier protection tooth hypersensitivity however superseded toothpaste formulation ingredient designed nerve calming agent instead a33167 a33168 strontium chloride toothpaste formulation may subsequently available sale anymore certain part world a33167 a33168 , employed ingredient toothpaste formulation strontium chloride predominantly indicated treating teeth hypersensitivity a33167 a33168 l2882 f118 
SB-269970,sb-269970 experimental drug developed glaxosmithkline study performed agent suggested sb-269970 act either selective antagonist inverse agonist serotonin receptor 7 5-ht7 a31816 a31817 ,
Epitizide,epitizide agent commonly found combination triamterene used produce diuresis ,
Dipropyl-4-hydroxytryptamine,dipropyl-4-hydroxytryptamine 4-hydroxyl analog dipropyltryptamine dpt dipropyl-4-hydroxytryptamine first synthesized alexander shulgin agent property n't fully elucidated ,
Pipequaline,pipequaline anticonflict anticonvulsant quinoline derivative anxiolytic drug never marketed present unique chemical structure follow structural property drug class pipequaline similar pharmacological profile reported benzodiazepine however present significant set anxiolytic property little sedative amnestic anticonvulsant effect due difference drug classified nonbenzodiazepine anxiolytic ,
MRK-409,mrk-409 gaba-a receptor agonist a31972 ,
AZD-7325,azd7325 high affinity selective modulator gabaa receptor system l2936 ,
Ferric pyrophosphate citrate,ferric pyrophosphate citrate soluble iron replacement product free iron present several side effect catalyze free radical formation lipid peroxidation well presence interaction iron plasma ferric ion strongly complexed pyrophosphate citrate a31979 fpc categorized japan second class otc drug l1420 category given drug ingredient rare case may cause health problem requiring hospitalization worst l1419 also fda approved since 2015 fda label ,ferric pyrophosphate citrate indicated treatment iron loss iron deficiency maintain hemoglobin reduce prescribed dose erythropoiesis-stimulating agent esa required maintain desired hemoglobin level l1423 iron deficiency appears dietary intake meet body 's requirement chronic external blood loss acute blood loss body iron store sufficient accelerated erythropoiesis restoration iron homeostasis altered homeostasis remains week month supplement needed cause iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 
Baloxavir marboxil,baloxavir marboxil antiviral drug used treat influenza specifically first-in-class cap-dependent endonuclease inhibitor work block influenza virus proliferation a39895 a251755 prodrug baloxavir l42855 improved absorption profile active metabolite due addition phenolic hydroxyl group structure a251760 baloxavir marboxil first globally approved japan february 2018 a39895 followed u approval october 2018 l4779 ,baloxavir marboxil influenza virus polymerase acidic pa endonuclease inhibitor indicated treatment acute uncomplicated influenza patient symptomatic 48 hour otherwise healthy adult pediatric patient five year age older patient 12 year age older high-risk developing influenza-related complication l42855 drug also indicated post-exposure prophylaxis influenza patient five year age older following contact individual influenza l42855 baloxavir marboxil associated risk loss efficacy due change influenza virus change virus subtypes emergence virus resistance change viral virulence therefore drug used considering available information drug susceptibility pattern circulating influenza virus strain l42855 
Lonoctocog alfa,, treatment hemophilia von willebrand disease factor xiii deficiency 
Moroctocog alfa,moroctocog alfa also known bddrfviii b domain deleted recombinant factor viii recombinant dna-based drug functional characteristic comparable endogenous coagulation factor viii essential human blood clotting protein impaired hemophilia a. moroctocog alfa identical sequence endogenously produced factor viii contain b-domain known biological function moroctocog alfa produced recombinant dna technology purification resulting 1438 amino acid 170 kda protein fda label clinical evaluation shown bddrfviii pharmacokinetically equivalent full-length recombinant fviii a32468 fda label also known anti-hemophilic factor ahf endogenous factor viii essential clotting process body due involvement clotting cascade responsible acting co-factor factor ix activation factor ix lead cascade signal result activation factor x result conversion prothrombin thrombin result lead conversion fibrinogen fibrin fibrous protein creates scaffold clot replacement factor viii essential treatment hemophilia caused mutation factor viii gene leading functional deficiency complete loss protein congenital loss deficiency factor viii result physiologic impairment coagulation clotting cascade result lead easy bruising bleeding bleeding range severity minor concern nosebleed serious event hemorrhaging joint brain digestive tract a32280 exogenous replacement factor viii currently cornerstone hemophilia treatment used prophylaxis control bleeding episode treatment drastically improved since 1960s factor viii protein primarily purified human plasma rather produced recombinant dna technology unfortunately purification protein human plasma carry increased risk transmission blood-borne disease hiv hepatitis part contributed tainted blood scandal 1980s a31551 a32272 l2177 use recombinant dna-derived clotting factor treatment moroctocog alfa reduced risk drug product similar structure function moroctocog alfa include db13192 purified factor viii human pooled blood contains a- b-subunits db11607 fully recombinant factor viii-fc fusion protein extended half-life compared conventional factor viii due conjugation dimeric fc domain human immunoglobulin g1 long-lived plasma protein a31551 moroctocog alfa approved health canada european medicine agency control prevention hemorrhagic episode routine surgical prophylaxis patient hemophilia congenital factor viii deficiency classic hemophilia contain von willebrand factor indicated von willebrand ’ disease fda label ,moroctocog alfa indicated use adult child hemophilia congenital factor viii deficiency on-demand treatment control bleeding episode perioperative management routine prophylaxis reduce frequency bleeding episode l41160 l41165 l41170 
alpha-Tocopherol succinate,alpha-tocopherol primary form vitamin e preferentially used human body meet appropriate dietary requirement particular rrr-alpha-tocopherol sometimes called d-alpha-tocopherol stereoisomer stereoisomer considered natural formation alpha-tocopherol generally exhibit greatest bioavailability alpha-tocopherol stereoisomers moreover manufacturer typically convert phenol component vitamin ester using acetic succinic acid making compound alpha-tocopherol succinate stable easier use vitamin supplement a32956 a32957 alpha-tocopherol succinate subsequently commonly indicated dietary supplementation individual may demonstrate genuine deficiency vitamin e. vitamin e naturally found various food added others used commercially available product dietary supplement recommended dietary allowance rdas vitamin e alpha-tocopherol male 4 mg 6 iu female 4 mg 6 iu age 0-6 month male 5 mg 7.5 iu female 5 mg 7.5 iu age 7-12 month male 6 mg 9 iu female 6 mg 9 iu age 1-3 year male 7 mg 10.4 iu female 7 mg 10.4 iu age 4-8 year male 11 mg 16.4 iu female 11 mg 16.4 iu age 9-13 year male 15 mg 22.4 iu female 15 mg 22.4 iu pregnancy 15 mg 22.4 iu lactation 19 mg 28.4 iu age 14+ year l2120 individual obtain adequate vitamin e intake diet genuine vitamin e deficiency considered rare nevertheless vitamin e known fat-soluble antioxidant capability neutralize endogenous free radical biologic action vitamin e consequently continues generate ongoing interest study whether antioxidant ability may used help assist preventing treating number different condition like cardiovascular disease ocular condition diabetes cancer moment however exists lack formal data evidence support additional indication vitamin e use moreover although generally believed alpha-tocopherol succinate would naturally demonstrate general vitamin e-tocopherol pharmacodynamics undergoing logical de-esterification gut a32956 a32957 ongoing research proposes alpha-tocopherol succinate compound capable eliciting anti-cancer l2699 a32959 inflammation mediation a32958 activity unique alpha-tocopherol form alpha-tocopherol ester l2699 a32958 a32959 , primary health-related use alpha-tocopherol succinate formally indicated dietary supplement patient demonstrate genuine vitamin e deficiency time vitamin e deficiency generally quite rare may occur premature baby low birth weight 1500 gram individual fat-malabsorption disorder fat required digestive tract absorb vitamin e individual abetalipoproteinemia rare inherited disorder cause poor absorption dietary fat require extremely large dos supplemental vitamin e daily around 100 mg/kg 5-10 g/day l2120 case alpha-tocopherol largely preferred form vitamin e administered elsewhere vitamin e 's chemical profile fat-soluble antioxidant capable neutralizing free radical body continues generate ongoing interest study regarding whether vitamin help prevent delay various chronic disease associated free radical potential biological effect vitamin e posse like cardiovascular disease diabetes ocular condition immune illness cancer t166 none ongoing study yet elucidate formally significant evidence however t166 similarly effective clinical trial necessary confirm accrued preliminary data come study proposing demonstration alpha-tocopherol succinate 's capability act anti-cancer therapy regulator inflammation l2699 a32958 a32959 
D-alpha-Tocopherol acetate,alpha-tocopherol primary form vitamin e preferentially used human body meet appropriate dietary requirement particular rrr-alpha-tocopherol sometimes called d-alpha-tocopherol stereoisomer stereoisomer considered natural formation alpha-tocopherol generally exhibit greatest bioavailability alpha-tocopherol stereoisomers moreover rrr-alpha-tocopherol acetate relatively stabilized form vitamin e commonly used food additive needed a32451 alpha-tocopherol acetate subsequently commonly indicated dietary supplementation individual may demonstrate genuine deficiency vitamin e. vitamin e naturally found various food added others used commercially available product dietary supplement recommended dietary allowance rdas vitamin e alpha-tocopherol male 4 mg 6 iu female 4 mg 6 iu age 0-6 month male 5 mg 7.5 iu female 5 mg 7.5 iu age 7-12 month male 6 mg 9 iu female 6 mg 9 iu age 1-3 year male 7 mg 10.4 iu female 7 mg 10.4 iu age 4-8 year male 11 mg 16.4 iu female 11 mg 16.4 iu age 9-13 year male 15 mg 22.4 iu female 15 mg 22.4 iu pregnancy 15 mg 22.4 iu lactation 19 mg 28.4 iu age 14+ year l2120 individual obtain adequate vitamin e intake diet genuine vitamin e deficiency considered rare nevertheless vitamin e known fat-soluble antioxidant capability neutralize endogenous free radical biologic action vitamin e consequently continues generate ongoing interest study whether antioxidant ability may used help assist preventing treating number different condition like cardiovascular disease ocular condition diabetes cancer moment however exists lack formal data evidence support additional indication vitamin e use ,_in addition following information owing d-alpha-tocopherol acetate 's closely related chemical nature alpha-tocopherol acetate please also refer drug information page alpha-tocopherol acetate data._ vitamin e known antioxidant activity protective cardiovascular disease form cancer also demonstrated immune-enhancing effect may limited benefit asthma rheumatoid arthritis may helpful neurological disease including alzheimer 's eye disorder including cataract diabetes premenstrual syndrome may also help protect skin ultraviolet irradiation although claim revers skin aging enhances male fertility exercise performance poorly supported may help relieve muscle cramp 
alpha-Tocopherol acetate,alpha-tocopherol primary form vitamin e preferentially used human body meet appropriate dietary requirement particular rrr-alpha-tocopherol sometimes called d-alpha-tocopherol stereoisomer stereoisomer considered natural formation alpha-tocopherol generally exhibit greatest bioavailability alpha-tocopherol stereoisomers moreover rrr-alpha-tocopherol acetate relatively stabilized form vitamin e commonly used food additive needed a32451 alpha-tocopherol acetate subsequently commonly indicated dietary supplementation individual may demonstrate genuine deficiency vitamin e. vitamin e naturally found various food added others used commercially available product dietary supplement recommended dietary allowance rdas vitamin e alpha-tocopherol male 4 mg 6 iu female 4 mg 6 iu age 0-6 month male 5 mg 7.5 iu female 5 mg 7.5 iu age 7-12 month male 6 mg 9 iu female 6 mg 9 iu age 1-3 year male 7 mg 10.4 iu female 7 mg 10.4 iu age 4-8 year male 11 mg 16.4 iu female 11 mg 16.4 iu age 9-13 year male 15 mg 22.4 iu female 15 mg 22.4 iu pregnancy 15 mg 22.4 iu lactation 19 mg 28.4 iu age 14+ year l2120 individual obtain adequate vitamin e intake diet genuine vitamin e deficiency considered rare nevertheless vitamin e known fat-soluble antioxidant capability neutralize endogenous free radical biologic action vitamin e consequently continues generate ongoing interest study whether antioxidant ability may used help assist preventing treating number different condition like cardiovascular disease ocular condition diabetes cancer moment however exists lack formal data evidence support additional indication vitamin e use , primary health-related use alpha-tocopherol acetate formally indicated dietary supplement patient demonstrate genuine vitamin e deficiency time vitamin e deficiency generally quite rare may occur premature baby low birth weight 1500 gram individual fat-malabsorption disorder fat required digestive tract absorb vitamin e individual abetalipoproteinemia rare inherited disorder cause poor absorption dietary fat require extremely large dos supplemental vitamin e daily around 100 mg/kg 5-10 g/day l2120 case alpha-tocopherol largely preferred form vitamin e administered elsewhere vitamin e 's chemical profile fat-soluble antioxidant capable neutralizing free radical body continues generate ongoing interest study regarding whether vitamin help prevent delay various chronic disease associated free radical potential biological effect vitamin e posse like cardiovascular disease diabetes ocular condition immune illness cancer t166 none ongoing study yet elucidate formally significant evidence however t166 
Tildrakizumab,tildrakizumab high-affinity humanized igg1 κ antibody targeting interleukin 23 p19 show promise evolution treatment strategy chronic plaque psoriasis a32255 food drug administration fda approved ilumya tildrakizumab-asmn treatment adult moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy march 2018 approved recommended dosage ilumya subcutaneous injection 100 mg week 0 4 every 12 week thereafter l1858 study performed pharmacokinetics drug various ethnicity pharmacokinetics tildrakizumab similar japanese caucasian chinese subject a32257 ,moderate-severe plaque psoriasis l1858 fda label 
Dimethicone 410,"dimethicone silicone-based polymer used moisturizer different skin otc product a32462 formed repeated polymeric unit ch3 2sio- terminal trimethyl siloxy unit l1769 currently recognized fda skin protectant otc ingredient human use concentration 1-30 l2162 name dimethicone lot nomenclature inconsistency used refer common name generic name trade name even listing mixture reported term dimethicone includes notation polydimethylsiloxane trimethylsiloxy-terminated fluid 20-30,000 cst viscosity l2163 ",dimethicone approved transdermal drug delivery system dimethicone 410 part simethicone element dow corning q7-2242 lva antifoam l2163 l2166 otc 's containing dimethicone used relieve discomfort infant gas caused air swallowing certain formula food l2170 prevent help rash protect relieve chapped cracked skin l2171 anti-lice agent l1769 
Choline salicylate,choline salicylate anti-inflammatory pain reliever agent related aspirin used decrease swelling treat mild-moderate pain used treat arthritis child adult medicine also used fever l2129 choline salicylate choline salt salicylic acid used analgesic antipyretic antirheumatic relief mild moderate pain reduce fever inflammation swelling choline salicylate effective treatment gout rheumatic fever rheumatoid arthritis muscle injury a245119 drug also main ingredient teething gel relieve pain associated tooth growth infant population l2134 uk government regulated use due toxicity 16 year age topical oral salicylate gel longer indicated people younger 16 year pain associated infant teething orthodontic device cold sore mouth ulcer l2134 , oral gel indicated relief pain discomfort common mouth ulcer cold sore denture sore spot infant teething mouth ulcer sore spot due orthodontic device child l2135 
Pentetic acid,pentetic acid also known diethylenetriaminepentaacetic acid dtpa synthetic polyamino carboxylic acid eight coordinate bond forming site sequester metal ion form highly stable dtpa-metal ion complex dtpa along calcium zinc trisodium salt fda approved agent treatment internal contamination transuranics a32501 currently considered dosage form member list approved inactive ingredient drug product fda l2242 dpta developed pharmaceutical company ci u fda approved april 14 2004 l1469 ,dtpa widely used industry medicine medical agent approved use medical imaging decorporation internally deposited radionuclides a32501 fda approved treatment individual known suspected internal contamination plutonium americium curium increase rate elimination l2243 due pharmacokinetic elimination kidney pentetic acid conjugated technetium tc-99m used clinically estimate physiological parameter glomerular filtration rat effective renal plasma flow t168 
Hispidulin,"hispidulin 4',5,7-trihydroxy-6-methoxyflavone potent benzodiazepine bzd receptor ligand positive allosteric property a32513 ",
Medical Cannabis, use plant specie _cannabis sativa_ _cannabis indica_ popularly known marijuana gained popularity recent year management wide variety medical condition wave legalization north america changed public medical opinion use consequently expanding body evidence begun emerge demonstrated potential usefulness management condition chronic pain spasticity inflammation epilepsy chemotherapy-induced nausea vomiting among many others a32585 area research controversial heavily debated however due concern risk addiction long-term health effect cannabis association schizophrenia pharmacological perspective cannabis diverse receptor profile explains potential application wide variety medical condition cannabis contains 400 different chemical compound 61 considered cannabinoids class compound act upon cannabinoid receptor body a32584 tetrahydrocannabinol thc db09061 cbd two type cannabinoids found naturally resin marijuana plant interact cannabinoid receptor found throughout body although thc cbd studied cannabinoids many others identified date including cannabinol cbn cannabigerol cbg db14050 cbdv db11755 thcv shown modify physiological effect cannabis a32830 cbd thc used medicinal purpose different receptor activity function physiological effect thc cbd converted precursor tetrahydrocannabinolic acid-a thca-a cannabidiolic acid cbda decarboxylation unfertilized female cannabis flower activated either heating smoking vaporization baking cannabis natural plant form currently used `` off-label '' management many medical condition thc currently commercially available synthetic form db00486 purified isomer db00470 1:1 formulation cbd purified plant extract db14011 cannabinoid receptor utilized endogenously body endocannabinoid system includes group lipid protein enzyme receptor involved many physiological process modulation neurotransmitter release endocannabinoid system regulates cognition pain sensation appetite memory sleep immune function mood among many others effect largely mediated two member g-protein coupled receptor family cannabinoid receptor 1 2 cb1 cb2 a32585 cb1 receptor found central peripheral nervous system majority receptor localized hippocampus amygdala brain physiological effect using cannabis make sense context receptor activity hippocampus amygdala primarily involved regulation memory fear emotion contrast cb2 receptor mainly found peripherally immune cell lymphoid tissue peripheral nerve terminal a32676 primary psychoactive component cannabis delta 9-tetrahydrocannabinol δ9-thc demonstrates effect weak partial agonist activity cannabinoid-1 cb1r cannabinoid-2 cb2r receptor activity result well-known effect smoking cannabis increased appetite reduced pain change emotional cognitive process contrast thc 's weak agonist activity cbd shown act negative allosteric modulator cannabinoid cb1 receptor abundant g-protein coupled receptor gpcr body a32469 allosteric regulation achieved modulation receptor activity functionally distinct site agonist antagonist binding site therapeutically important direct agonist limited psychomimetic effect direct antagonist limited depressant effect a32469 evidence cbd also activates 5-ht1a serotonergic trpv1–2 vanilloid receptor antagonizes alpha-1 adrenergic µ-opioid receptor inhibits synaptosomal uptake noradrenaline dopamine serotonin gaminobutyric acid cellular uptake anandamide act mitochondrion ca2 store block low-voltage-activated t-type ca2 channel stimulates activity inhibitory glycine-receptor inhibits activity fatty amide hydrolase faah a31555 a31574 due difference receptor profile cbd thc cannabinoids understandably used treat different condition furthermore combined thc cbd shown modulate thc 's activity resulting difference pharmacological effect `` strain '' chemovars cannabis plant bred contain different concentration cbd thc example strain containing high proportion cbd shown reduce psychosis- anxiety-inducing effect thc a32833 reliably studying effect cannabis complicated large variety available strain numerous compound cannabis contains terpene flavonoid phenol amino acid fatty acid among many others shown potential modulate plant 's pharmacological effect a32832 a32824 ,
"5-methoxy-N,N-dimethyltryptamine",5-methoxy-n n-dimethyltryptamine 5-meo-dmt tryptamine psychedelic property found wide variety plant specie single psychoactive toad specie colorado river toad drug well dimethyltryptamine bufotenin registered used south america religious spiritual ritual ,
Nabiximols,nabiximols tradename sativex® whole plant extract cannabis specie _cannabis sativa l._ purified active component cbd cannabidiol thc delta-9-tetrahydrocannabinol trademark purpose purified cbd branded nabidiolex® thc purified product tetrabinex® sativex® available 1:1 formulation thc cbd oro-mucosal pump spray used treatment neuropathic pain multiple sclerosis m intractable cancer pain although still largely debated cannabis shown analgesic anticonvulsant muscle relaxant anxiolytic neuroprotective anti-oxidant anti-psychotic activity a32477 a32469 pharmacological perspective cannabis diverse receptor profile explains potential application wide variety medical condition cannabis contains 400 different chemical compound 61 considered cannabinoids class compound act upon cannabinoid receptor body a32584 tetrahydrocannabinol thc cannabidiol cbd two type cannabinoids found naturally resin marijuana plant interact cannabinoid receptor found human body cbd thc used medicinal purpose different receptor activity function physiological effect cannabis natural plant form currently used `` off-label '' management many medical condition thc currently commercially available synthetic form db00486 purified isomer db00470 1:1 formulation cbd purified plant extract db14011 primary psychoactive component cannabis delta 9-tetrahydrocannabinol δ9-thc demonstrates effect weak partial agonist activity cannabinoid-1 cb1r cannabinoid-2 cb2r receptor activity result well-known effect smoking cannabis increased appetite reduced pain change emotional cognitive process contrast thc 's weak agonist activity cbd shown act negative allosteric modulator cannabinoid cb1 receptor abundant g-protein coupled receptor gpcr body a32469 allosteric regulation achieved modulation receptor activity functionally distinct site agonist antagonist binding site negative allosteric modulatory effect cbd therapeutically important direct agonist limited psychomimetic effect direct antagonist limited depressant effect a32469 canada sativex® received notice compliance noc use adjunctive treatment symptomatic relief spasticity patient multiple sclerosis m responded adequately therapy demonstrate meaningful improvement initial trial therapy sativex® also received notice compliance condition noc/c use adjunctive treatment symptomatic relief neuropathic pain adult patient multiple sclerosis m adjunctive analgesic treatment adult patient advanced cancer experience moderate severe pain highest tolerated dose strong opioid therapy persistent background pain , canada sativex received notice compliance noc use adjunctive treatment symptomatic relief spasticity patient multiple sclerosis m responded adequately therapy demonstrate meaningful improvement initial trial therapy sativex also received notice compliance condition noc/c use adjunctive treatment symptomatic relief neuropathic pain adult patient multiple sclerosis m adjunctive analgesic treatment adult patient advanced cancer experience moderate severe pain highest tolerated dose strong opioid therapy persistent background pain marketing authorisation condition reflect promising nature clinical evidence need confirmatory study verify clinical benefit patient advised conditional nature authorization condition 
Burosumab,"burosumab krn23 entirely human monoclonal igg1 antibody bind excess fibroblast growth factor 23 fgf23 successfully tested clinical trial child x-linked hypophosphatemic rickets a32593 u.s. food drug administration approved crysvita burosumab april 2018 first drug approved treat adult child age 1 year older x-linked hypophosphatemia xlh rare inherited form rickets x-linked hypophosphatemia cause low circulating level phosphorus blood cause impaired bone growth development child adolescent issue bone mineralization throughout patient ’ life l2346 xlh serious disease affect 3,000 child 12,000 adult united state child xlh suffer bowed bent leg short stature bone pain severe dental pain adult condition suffer persistent unrelenting discomfort complication joint pain impaired mobility tooth abscess hearing loss l2346 ", drug indicated treatment x-linked hypophosphatemia radiological evidence bone disease child 1 year age older adolescent growing skeleton l2347 
SR-9009,sr-9009 rev-erb agonist sr-9011 demonstrated specifically lethal cancer cell oncogene-induced senescent cell including melanocytic naevi effect viability normal cell tissue a32628 ,
SR-9011,sr-9011 rev-erb agonist sr-9011 demonstrated specifically lethal cancer cell oncogene-induced senescent cell including melanocytic naevi effect viability normal cell tissue a32628 ,
Sodium bisulfite,sodium bisulfite used externally parasitic skin disease gastrointestinal antiseptic ,
H3B-8800,h3b-8800 novel spliceosome inhibitor developed h3 biomedicine l2551 offer benefit preferentially killing spliceosome-mutant cancer cell whereas splicesome inhibitor pladienolide analogue e7107 show preferential targeting a32749 h3b-8800 granted orphan drug status fda august 2017 clinical trial treatment acute myelogenous leukemia chronic myelomonocytic leukemia l2551 ,
Bromotheophylline,bromotheophylline active moiety pamabrom mixture 2-amino-2-methyl-propanol bromotheophylline mixture bromotheophylline act weak diuretic used along analgesic relieve symptom premenstrual syndrome a33018 bromotheophylline categorized fda drug substance inactive state since march 1980 l1082 also approved health canada used alone combination db00316 otc product l1113 ,bromotheophylline used diuretic also combination db00316 used relief temporary water weight gain bloating swelling full feeling associated premenstrual menstrual period l2737 
Fosnetupitant, april 2018 u.s. food drug administration fda swiss company helsinn approved intravenous formulation akynzeo® nepa fixed antiemetic combination fosnetupitant 235mg palonosetron 0.25mg alternative treatment option patient experiencing chemotherapy-induced nausea vomiting l2631 fosnetupitant pro-drug form netupitant fda label generally 25 30 patient diagnosis cancer receive chemotherapy treatment modality 70 80 patient undergoing chemotherapy treatment may experience nausea vomiting major side effect considered one distressing side effect chemotherapy nausea vomiting immense impact quality life patient receiving certain antineoplastic therapy a32865 ,indicated combination palonosetron drug akynzeo dexamethasone adult prevention acute delayed nausea vomiting associated initial repeat course cancer chemotherapy including limited highly emetogenic chemotherapy fda label following indication listed ema label f29 prevention acute delayed nausea vomiting associated highly emetogenic cisplatin-based cancer chemotherapy f29 prevention acute delayed nausea vomiting associated moderately emetogenic cancer chemotherapy f29 
Benzoin,benzoin white crystalline compound prepared condensation benzaldehyde potassium cyanide used organic synthesis confused benzoin gum styrax see db11222 benzoin fda-approved colour additive used marking fruit vegetable , approved therapeutic indication 
Clinafloxacin,clinafloxacin fluoroquinolone antibacterial currently research proven present good antibiotic property however approval release halted due presence serious side effect ,
Taspoglutide,taspoglutide pharmaceutical drug glucagon-like peptide-1 agonist glp-1 agonist investigation treatment type 2 diabetes codeveloped ipsen roche september 2010 roche halted phase iii clinical trial due incidence serious hypersensitivity reaction gastrointestinal side effect may 2013 new trial registered ,
Nordazepam, intermediate metabolism diazepam oxazepam may action similar diazepam ,
Furafylline,furafylline derivative methylxanthine derivative developed context asthma long-acting alternative theophylline ,
PZM21,pzm21 novel μ-opioid receptor mopr ligand reported induce minimal arrestin recruitment devoid respiratory depressant effect characteristic classical μ-opioid ligand morphine a33051 ,
Tretamine,toxic alkylating agent used industry also antineoplastic research tool produce chromosome aberration cancer ,
Acetyl sulfisoxazole,sulfisoxazole acetyl ester _sulfisoxazole_ broad-spectrum sulfanilamide synthetic analog para-aminobenzoic acid paba antibacterial activity sulfisoxazole acetyl competes paba bacterial enzyme _dihydropteroate synthase_ preventing incorporation paba dihydrofolic acid precursor folic acid process cause inhibition bacterial folic acid synthesis de novo synthesis purine pyrimidine resulting cell growth arrest cell death l2788 often combined erythromycin treat acute otitis medium caused bacteria haemophilus influenzae l2790 ,acute recurrent chronic urinary tract infection primarily pyelonephritis pyelitis cystitis due susceptible organism usually escherichia coli klebsiella-enterobacter staphylococcus proteus mirabilis le frequently proteus vulgaris absence obstructive uropathy foreign body l2804 meningococcal meningitis organism demonstrated susceptible haemophilus influenzae meningitis adjunctive therapy parenteral streptomycin l2804 meningococcal meningitis prophylaxis l2804 acute otitis medium due haemophilus influenzae used concomitantly adequate dos penicillin erythromycin see appropriate labeling prescribing information l2804 trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis adjunctive therapy pyrimethamine malaria due chloroquine-resistant strain plasmodium falciparum used adjunctive therapy l2804 currently increasing frequency resistant organism limitation usefulness antibacterial agent including sulfonamide especially treatment chronic recurrent urinary tract infection l2804 
Englitazone,englitazone hypoglycemic agent ,
beta-Sitosterol,active fraction solanum trilobatum reduces side-effects radiation-induced toxicity ,
Erenumab,erenumab amg-334 inn trade name aimovig human monoclonal antibody designed specifically bind antagonize calcitonin gene-related peptide receptor cgrpr mean prevent migraine aimovig released marketed novartis amgen fact novel therapeutic approach first fda approved treatment specifically developed prevent migraine blocking cgrp receptor believed play critical role migraine l2823 particular erenumab-aooe human immunoglobulin g2 monoclonal antibody high affinity binding cgrp receptor fda label antibody produced utlilizing recombinant dna technology chinese hamster ovary cell fda label composed 2 heavy chain containing 456 amino acid 2 light chain lambda subclass containing 216 amino acid approximate molecular weight 150 kda fda label ,erenumab indicated preventative treatment migraine adult fda label 
Eptinezumab,eptinezumab fully-humanized igg1 antibody manufactured using yeast _pichia pastoris_ developed lundbeck seattle biopharmaceuticals l12318 eptinezumab specifically designed bind alpha beta form human calcitonin gene-related peptide cgrp f94 a33105 a33106 a33108 approved fda february 2020 preventive treatment migraine headache adult l12318 ,eptinezumab indicated preventive treatment migraine adult l12318 
Fremanezumab,fremanezumab humanized monoclonal antibody targeted human calcitonin gene-related peptide cgrp prevention migraine headache l11749 developed teva pharmaceutical usa approved fda september 2018 l11779 along recently approved anti-cgrp therapy galcanezumab erenumab oral cgrp antagonist ubrogepant fremanezumab represents important step forward treatment prevention migraine headache ,fremanezumab indicated preventative treatment migraine adult l11749 
Galcanezumab,galcanezumab humanized monoclonal antibody developed eli lilly company human calcitonin gene-related peptide cgrp a33105 although several small-molecule cgrp receptor antagonist developed humanized monoclonal antibody like galcanezumab specifically designed selectively bind cgrp entity high potency a33112 given target specificity lack off-target toxicity characteristic proteolysis profile immunoglobulin antibody undergo metabolism liver enzyme galcanezumab posse favourable promising safety tolerability a33112 galcanezumab approved fda september 2018 indicated preventive treatment migraine treatment episodic cluster headache l42060 unknown galcanezumab effect pregnancy outcome pregnancy exposure registry established evaluate safety drug pregnant woman l42060 ,galcanezumab indicated adult preventive treatment migraine treatment episodic cluster headache l42060 
Palmidrol, cannabinoid receptor-inactive ecb-related molecule used prophylactic helping prevent respiratory viral infection palmidrol available human use supplement 400 mg capsule food medical purpose italy spain 300 mg 600 mg tablet ,
Hopantenic acid,hopantenic acid pantogam central nervous system depressant hopantenic acid unique spectrum pharmacological effect nootropic anticonvulsant mild activating absence addiction hyperstimulation withdrawal syndrome a33115 ,
Cholesteryl chloride,cholesteryl chloride also known 3-chlorocholest-5-ene organochloride derivative cholesterol presented liquid crystal form clockwise liquid crystal ,
Dichlorobenzene,dichlorobenzene refers mixture three isomer consisting benzene two hydrogen atom replaced chlorine atom ortho- meta- paradichlorobenzene constituent ear-wax removal product cerumol ,
Sodium zirconium cyclosilicate,sodium zirconium cyclosilicate approved trade product lokelma developed astrazeneca insoluble non-absorbed sodium zirconium silicate formulated powder oral suspension act highly selective potassium removing agent l2933 administered orally odorless tasteless stable room temperature l2933 approval medication supported data three double-blind placebo-controlled trial two open-label trial showed onset action approximately 1.0 hour median time achieving normal potassium level blood 2.2 hour 92 patient achieving normal potassium level within 48 hour following administration l2933 treatment effect maintained 12 month l2933 ,sodium zirconium cyclosilicate potassium binder indicated treatment hyperkalemia adult patient l12822 f130 
Cannabidivarin,cannabidivarin also known cannabidivarol cbdv non-psychoactive cannabinoid found within db14009 one 100 cannabinoids identified cannabis plant modulate physiological activity cannabis marijuana a32584 compared homolog db09061 cbdv shortened two methyl ch2 group side chain notably db09061 cbdv demonstrated anticonvulsant activity animal human model demonstrating promising clinical trial result a33327 a31560 a33328 a33329 cannabinoids evidence anti-epileptic activity include db11755 thcv δ9-tetrahydrocannabinolic acid primary component cannabis cbd thc shown modulate many physiological effect binding cannabinoid-1 cb1r cannabinoid-2 cb2r receptor investigational cannabinoids anticonvulsant action mostly use mechanism involve two endocannabinoid receptor anti-epileptic activity cbd cbdv thought modulated effect transient receptor potential cation channel subfamily v member 1 trpv1 also known capsaicin receptor member large family ion channel involved onset progression several type epilepsy cbd cbdv shown dose-dependently activate desensitize trpv1 well trpv2 trpa1 channel a31560 a33334 a32976 desensitization ion channel potential mechanism molecule cause reduction neuronal hyperexcitability contributes epileptic activity seizure cbdv also shown inhibit activity diacylglycerol dag lipase-α primary enzyme responsible synthesis endocannabinoid 2-arachidonoylglycerol 2-ag a33296 a33347 clinical implication unclear however interaction shown affect cbdv 's anticonvulsant activity cannabidivarin actively developed gw pharmaceutical experimental compound gwp42006 `` shown ability treat seizure pre-clinical model epilepsy significantly fewer side effect currently approved anti-epileptic drug '' l2950 unfortunately february 2018 gw pharmaceutical announced phase 2a placebo-controlled study cbdv focal seizure reach primary endpoint continue study use epilepsy however expanding investigation include potential use autism spectrum disorder rett syndrome fragile x among others l2949 october 2017 cbdv given orphan designation european medicine agency use rett syndrome l2952 february 2018 treatment fragile x syndrome l2951 ,cannabidivarin currently fda health canada approved indication however october 2017 cbdv given orphan designation european medicine agency use rett syndrome l2952 february 2018 treatment fragile x syndrome l2951 
Malacidin A,malacidin along db14052 member class chemical made bacteria found soil kill gram-positive bacteria a33312 malacidins 10-member macrocycle lipopeptides discovered via gene sequencing bioinformatic analysis structurally similar macrocycle drug like db00080 db06087 malacidin appears act via distinct mechanism ,malacidin investigated antibiotic action potential use antibacterial agent future a33312 
Malacidin B,malacidin b along db14051 member class chemical made bacteria found soil kill gram-positive bacteria a33312 malacidins 10-member macrocycle lipopeptides discovered via gene sequencing bioinformatic analysis structurally similar macrocycle drug like db00080 db06087 malacidin b appears act via distinct mechanism ,malacidin b investigated antibiotic action potential use antibacterial agent future a33312 
Asiatic acid, centella asiatica plant show variety bioactivities ,
(S)-Warfarin,warfarin consists racemic mixture two active enantiomers—r- s- forms—each cleared different pathway s-warfarin 2-5 time potent r-isomer producing anticoagulant response a7166 ,
Nigericin, polyether antibiotic affect ion transport atpase activity mitochondrion produced streptomyces hygroscopicus merck index 11th ed ,
Valinomycin, cyclododecadepsipeptide ionophore antibiotic produced streptomyces fulvissimus related enniatins composed 3 mole l-valine d-alpha-hydroxyisovaleric acid d-valine l-lactic acid linked alternately form 36-membered ring merck index 11th ed valinomycin potassium selective ionophore commonly used tool biochemical study ,
Basifungin,basifungin also known _aureuobacidin a_ phosphorylceramide synthase inhibitor l2960 a33381 ,
SC-236,sc-236 potent selective orally active inhibitor cyclooxygenase-2 cox-2 l2964 studied cancer therapy a33375 lower back pain a33376 inflammation a33373 a33374 l2962 a33377 ,
NS-398,ns-398 cox-2 inhibitor developed part mechanistic study cyclooxygenase ,
Hycanthone,potentially toxic effective antischistosomal agent metabolite lucanthone hycanthone approved fda 1975 longer used ,
Concanamycin A,concanamycin h+-atpase vacuolar inhibitor ,
Emopamil,prevents renal injury warm cold ischemia ,
Lomerizine,lomerizine diphenylmethylpiperazine calcium channel blocker a245378 a245383 relatively selective central nervous system cns effect a245383 drug used prophylactically treat migraine a245368 a245373 also investigated eye-related disease associated local circulatory disturbance example normal-tension glaucoma a245378 ,
Dofequidar,dofequidar antineoplastic agent ,
ONT-093,ont-093 orally bioavailable inhibitor p-glycoprotein p-gp pre-clinical study ont-093 could inhibit p-gp reverse multidrug resistance nm concentration effect paclitaxel pharmacokinetics ,
Desmethylsertraline,desmethylsertraline metabolite sertraline ,
Reversin 121,reversin 121 hydrophobic peptide chemosensitizer reverse p-glycoprotein-mediated multidrug resistance ,
Icaridin,icaridin also known picaridin hydroxy-ethyl isobutyl piperidine carboxylate cyclic amine member piperidine chemical family piperidines structural component piperine plant extract genus _piper pepper icaridin commonly used topically-applied insect repellent various country officially licensed use united state 2001 canada 2012 l4595 icaridin synthesized bayer 1980s based molecular modeling l4595 considered first choice repellent public health agency canada ’ canadian advisory committee tropical medicine travel traveler six month 12 year age a39203 icaridin reported le irritating diethyltoluamide another common insect repellant product containing 20 icaridin considered safe long-term use adult a39231 ,icaridin indicated use repel insect mosquito biting fly tick chigger flea via topical use clothing l4617 
Imidurea,imidurea antimicrobial preservative used cosmetic act formaldehyde releaser ,
Cadmium, element atomic symbol cd atomic number 48 atomic weight 112.41 metal ingestion lead cadmium poisoning ,
Cianidanol, antioxidant flavonoid occurring especially woody plant -catechin -epicatechin ci form ,
Morrhuic acid,morrhuic acid mixture unsaturated fatty acid obtained cod liver oil ,
Carbomer homopolymer type C,carbomer homopolymer type c high molecular polyanionic substance tested antiulcerogenic activity ,
Pork collagen,pork collagen used within maci® autologous cultured chondrocytes porcine collagen membrane autologous cellularized scaffold product indicated repair single multiple symptomatic full-thickness cartilage defect knee without bone involvement adult serf alternative repair treatment patient inadequate response pre-existing surgical method surgical implantation show tolerable safety profile efficacy 4 year indicated patient osteoarthritis used since 1995 carticel gained biologic license 1997 surgical implantation first performed sweden ,indicated repair single multiple symptomatic full-thickness cartilage defect knee without bone involvement adult 
Triethylhexanoin,triethylhexanoin ingredient cosmetic product fragrant solvent ,
Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate,tetrakis 2-methoxyisobutylisocyanide copper tetrafluoroborate component cardiolite technetium tc99m-based imaging agent used assessing myocardial perfusion l12744 ,
Ceramide NP,ceramide np lipid molecule included group lipid molecule called ceramides ceramides major lipid component stratum corneum human skin ceramide 3 consists phytosphingosine backbone n-acylated saturated fatty acid stearic acid a27233 widely used moisturizer various cosmetic personal product together ceramide 1 synergistically improve skin barrier function human a27232 a27233 ,
Human vaccinia virus immune globulin,human vaccinia immune globulin vig sterile solution containing purified gamma globulin igg fraction plasma taken healthy donor previously vaccinated live vaccinia virus vaccine posse high titer anti-vaccinia virus antibody fda label a33814 igg fraction purified anion-exchange column chromatography method solution solvent/detergent-treated sterilize compound a33814 compound used currently intravenous formulation contain preservative unlike prior intramuscular compound contained thiomersal mercury derivative preservative could potentially teratogenic a33814 nevertheless vig virtue way produced poorly characterized highly variable human product available limited quantity factor may intervene availability effectiveness a33798 a33814 ,cnj-016 vaccinia immune globulin intravenous human vigiv indicated treatment and/or modification eczema vaccinatum b progressive vaccinia c severe generalized vaccinia vaccinia infection individual skin condition burn impetigo varicella-zoster poison ivy individual eczematous skin lesion either activity extensiveness lesion e aberrant infection induced vaccinia virus include accidental implantation eye except case isolated keratitis mouth area vaccinia infection would constitute special hazard fda label 
Black widow spider antivenin (equine),black widow spider _latrodectus mactans_ antivenin treatment black widow spider bite derived serum healthy horse immunized black widow spider venom l12792 ,
Viper antivenom,viper antivenom consists antibody derived horse immunized subsequently developed antibody snake venom anavip equine-derived antivenom made venom _bothrops asper_ _crotalus durissus_ first approved fda october 1 2015 management north american rattlesnake envenomation a250795 ,equine-derived viper antivenom indicated management adult pediatric patient north american pit viper envenomation l42475 
Human botulinum neurotoxin A/B immune globulin,infant botulism rare infectious disease occurring infant _clostridium botulinum_ colonize large intestine produce botulinum neurotoxin directly gut neurotoxin interfere cholinergic nervous transmission patient initially present evident loss muscle tone e.g constipation ptosis feeding difficulty may progress serious symptom respiratory arrest flaccid paralysis l39819 l39824 babybig human-derived botulism immunoglobulin approved use fda 2003 l39814 since used treat 2100 case infant botulism l39834 produced distributed calfornia department public health 's infant botulism treatment prevention program l39829 comprises igg antibody derived pooled adult plasma person immunized recombinant botulinum vaccine high titer neutralizing antibody botulinum toxin l39814 ,human-derived botulism immune globulin indicated treatment infant botulism caused toxin type b patient ≤1 year age l39814 
Phenylethyl resorcinol, tyrosinase inhibitor skin-lightening activity ,
Parasorbic acid,sole constituent `` vogelbeerol '' oil obtained steam distillation acidified juice ripe berry mountain ash ,
Dihydroxymethoxychalcone,cardamonin also known dihydroxymethoxychalcone shown increasing number publication received growing attention scientific community due expectation toward benefit human health cardamonin 's name come fact found cardamom spice ,
Tenofovir,tenofovir acyclic nucleotide diester analog adenosine monophosphate a37693 strict sense due fact present phosphate group bound nitrogenous base determined actual nucleotide analog a37693 antiviral activity tenofovir first reported 1993 agent commercially available since 2008 form tenofovir disoproxil tenofovir alafenamide order obtain oral bioavailability a18473 a178360 ,tenofovir shown effective hiv herpes simplex virus-2 hepatitis b virus a178330 know specific product indication please visit information orally available form tenofovir tenofovir alafenamide tenofovir disoproxil 
Sacubitrilat, metabolite lcz696 neprilysin inhibitory activity ,
Nadide, coenzyme composed ribosylnicotinamide 5'-diphosphate coupled adenosine 5'-phosphate pyrophosphate linkage found widely nature involved numerous enzymatic reaction serf electron carrier alternately oxidized nad+ reduced nadh dorland 27th ed ,
Macelignan,macelignan nsaid antioxidant free radical scavenging neuroprotective activity ,
Basic Fibroblast Growth Factor,basic fibroblast growth factor bfgf single-chain polypeptide growth factor play significant role process wound healing potent inducer physiologic angiogenesis several different form human protein exist ranging 18-24 kda size due use alternative start site within fgf-2 gene 55 percent amino acid residue identity fibroblast growth factor 1 potent heparin-binding activity growth factor extremely potent inducer dna synthesis variety cell type mesoderm neuroectoderm lineage originally named basic fibroblast growth factor based upon chemical property distinguish acidic fibroblast growth factor fibroblast growth factor 1 although approved use canada usa bfgf currently undergoing investigation number clinical trial ,basic fibroblast growth factor currently approved fda health canada approved indication 
8-chlorotheophylline,8-chlorotheophylline stimulant drug xanthine chemical class physiological effect similar caffeine main use combination diphenhydramine antiemetic drug dimenhydrinate stimulant property 8-chlorotheophylline thought ward drowsiness caused diphenhydramine 's anti-histamine activity central nervous system 8-chlorotheophylline produce number effect including nervousness restlessness insomnia headache nausea primarily attributed ability block adenosine receptor a33889 a1539 adenosine cause decrease neuronal firing blockade adenosine receptor cause reverse effect resulting excitation , used combination db01075 antiemetic db00985 8-chlorotheophylline indicated prevention treatment nausea vomiting vertigo motion sickness 
Hypochlorous acid, oxyacid chlorine hclo containing monovalent chlorine act oxidizing reducing agent ,
Hydroxyethyl ethylcellulose,hydroxyethyl ethylcellulose modulates bacterial binding salivary pellicle moderately effective preventing plaque formation ,
Loxicodegol,loxicodegol developed nektar therapeutic opioid analgesic low abuse potential treatment chronic pain l3263 lack abuse potential believed due drug 's slow rate entry brain unique characteristic compared others opioid class a33997 a34016 also thought reason behind reduced frequency cns-mediated adverse effect like sedation seen loxicodegol nektar therapeutic filed application fda approval loxicodegol use treatment chronic lower back pain l3263 ,loxicodegol developed opioid analgesic low abuse potential use treating chronic pain l3263 application filed fda approval loxicodegol use treating chronic lower back pain 
Ginsenosides,dammarane type triterpene saponin based mainly aglycones protopanaxadiol protopanaxatriol ,
Gold, yellow metallic element atomic symbol au atomic number 79 atomic weight 197 used jewelry goldplating metal currency dental restoration many clinical application antirheumatic agent form salt ,
Microcrystalline cellulose, polysaccharide glucose unit linked cellobiose chief constituent plant fiber cotton purest natural form substance raw material form basis many derivative used chromatography ion exchange material explosive manufacturing pharmaceutical preparation ,
Oxidronic acid,,oxidronic acid diagnostic skeletal imaging agent used demonstrate area altered osteogenesis adult pediatric patient l12960 
"Lecithin, soybean"," complex mixture phospholipid glycolipids triglyceride substantial amount phosphatidylcholines phosphatidylethanolamines phosphatidylinositols sometimes loosely termed 1,2-diacyl-3-phosphocholines lecithin component cell membrane commercially extracted soybean egg yolk emulsifying surfactant property useful food additive forming organogels gel ",
Northern bluefin tuna,northern bluefin tuna allergenic extract used allergenic testing ,
Anthoxanthum odoratum,anthoxanthum odoratum allergenic extract used allergenic testing ,anthoxanthum odoratum allergen extract included allergenic testing product called oralair indicated immunotherapy treatment grass pollen-induced allergic rhinitis without conjunctivitis confirmed positive skin test vitro testing pollen38 specific ige antibody five grass specie contained product oralair approved use person 5 65 year age l41190 
Betula lenta whole,betula lenta whole allergenic extract used allergenic testing ,
Culex pipiens,culex pipiens allergenic extract used allergenic testing ,used allergenic testing 
Rumex acetosella whole,rumex acetosella whole allergenic extract used allergenic testing ,used allergenic testing 
Rumex crispus top,rumex crispus top allergenic extract used allergenic testing ,used allergenic testing 
Sarocladium strictum,sarocladium strictum allergenic extract used allergenic testing ,used allergenic testing 
Salix nigra bark,salix nigra bark allergenic extract used allergenic testing ,used allergenic testing 
Artemisia vulgaris root,artemisia vulgaris root allergenic extract used allergenic testing ,used allergenic testing 
Penicillium glaucum,penicillium glaucum allergenic extract used allergenic testing ,used allergenic testing 
Evernia prunastri,evernia prunastri allergenic extract used allergenic testing ,
alpha-Amyl cinnamaldehyde,alpha-amyl cinnamaldehyde jasmine-like odor widely used synthetic fragrance suspected allergen used allergenic testing ,alpha-amyl cinnamaldehyde used allergenic testing 
Benzylparaben,benzylparaben used allergenic testing ,benzylparaben used allergenic testing 
Propylparaben,propylparaben used allergenic testing ,propylparaben used allergenic testing 
Phleum pratense top,phleum pratense top allergenic extract used allergenic testing ,
Nickel sulfate,nickel sulfate used allergenic testing ,
Lanolin alcohols,lanolin alcohol complex combination organic alcohol obtained hydrolysis lanolin administered ointment base topical insulin shown antagonistic wound healing commonly used allergenic testing ,
Geraniol,geraniol monoterpene found within many essential oil fruit vegetable herb including rose oil citronella lemongrass lavender aromatic plant emitted flower many specie plant commonly used food fragrance cosmetic industry l3333 geraniol demonstrated wide spectrum pharmacological activity including antimicrobial anti-inflammatory antioxidant anti-cancer neuroprotective name a34260 a34261 a34262 interestingly geraniol also shown sensitize tumour cell commonly used chemotherapy including db00544 db01248 represents promising cancer chemopreventive agent a34263 due anticancer effect geraniol found effective broad range cancer including breast lung colon prostate pancreatic skin liver kidney oral cancer a34262 pharmacologic effect clinically important geraniol classified generally-recognized-as-safe gras flavor extract manufacturer association fema food drug administration fda united state sensitivity geraniol may identified clinical patch test ,geraniol approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Cinnamaldehyde,cinnamaldehyde naturally occurring flavonoid give spice cinnamon flavour odour occurs naturally bark cinnamon tree specie genus cinnamomum camphor cassia sensitivity cinnamaldehyde may identified clinical patch test ,cinnamaldehyde approved fda use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Aripiprazole lauroxil,aripiprazole lauroxil long-acting injectable atypical antipsychotic drug used treatment schizophrenia adult patient prodrug aripiprazole act partial agonist d2 5-ht1a receptor antagonist 5-ht2a receptor a34289 affecting 1 adult population united state approximately 26 million people worldwide schizophrenia chronic neurological disorder may result impairment cognition executive function a34289 quality life patient greatly reduced due negative health outcome oftentimes patient faced social stigma discrimination schizophrenia characterized positive symptom delusion hallucination thought disorder catanoia negative symptom include social withdrawal anhedonia flattening emotional response t28 d2 receptor common target antipsychotic agent used treatment schizophrenia positive symptom thought arise overactivity mesolimbic dopaminergic pathway activating d2 receptor whereas negative symptom may result decreased activity mesocortical dopaminergic pathway d1 receptor predominating t28 randomized double-blind clinical trial treatment aripiprazole lauroxil adult patient schizophrenia resulted improvement positive negative symptom score day 85 treatment a34289 a34301 aripiprazole lauroxil initially approved fda october 2015 market name aristada treatment schizophrenia administered via intramuscular injection requires establishment tolerability prior dosing treatment-naïve patient fda label july 2nd different formulation aripiprazole lauroxil marketed aristada initio fda-approved immediate initiation aristada dose patient may receive aristada initio combination single 30 mg oral dose aripiprazole achieve appropriate level aripiprazole rapidly long-acting injectable aripiprazole lauroxil displayed comparable efficacy safety aripiprazole a34301 reduced dosing frequency improves patient adherence ,aripiprazole lauroxil indicated treatment schizophrenia related psychotic disorder 
Cinnamyl alcohol,cinnamyl alcohol naturally occurring compound found within cinnamon due low level found cinnamon cinnamyl alcohol usually supplied db14184 within commercial product cinnamyl alcohol shown skin sensitizer noel effect level ~4 a34266 sensitivity cinnamyl alcohol may identified clinical patch test ,cinnamyl alcohol approved fda use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Hydroxycitronellal,hydroxycitronellal synthetic fragrance widely used many cosmetic hygiene product deodorant soap antiseptic household item smell lilac lily lily valley a34269 hydroxycitronellal also shown dermatologic irritant allergen result commercially available product restricted international fragrance association ifra contain 0.1-3.6 sensitivity hydroxycitronellal may identified clinical patch test ,hydroxycitronellal approved fda use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Isoeugenol,isoeugenol commonly used fragrance added many commercially available product occurs naturally essential oil plant ylang-ylang also significant dermatologic sensitizer allergen result restricted 200 p.p.m since 1998 according guideline issued fragrance industry a34278 allergic reactivity isoeugenol may identified patch test ,isoeugenol approved fda use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Ethylenediamine,ethylenediamine organic compound used building block production many chemical product also used excipient many pharmacological preparation cream notably ethylenediamine contact sensitizer capable producing local generalized reaction a34285 sensitivity ethylenediamine may identified clinical patch test ,ethylenediamine approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
p-tert-Butylphenol-formaldehyde resin (low molecular weight),p-tert-butylphenol-formaldehyde resin widely used adhesive chemical used wide variety commercially available product known dermatological sensitizer allergen a34290 a34291 sensitivity p-tert-butylphenol-formaldehyde resin may identified clinical patch test ,p-tert-butylphenol-formaldehyde resin low molecular weight approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Diphenylguanidine,diphenylguanidine complexing agent used detection metal organic base used accelerator vulcanization rubber found rubber product also dermatological sensitizer allergen sensitivity diphenylguanidine may identified clinical patch test ,diphenylguanidine approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Ditiocarb zinc,ditiocarb zinc also known diethyldithiocarbamic acid zinc salt known chelator copper zinc also dermatological sensitizer allergen sensitivity ditiocarb zinc may identified clinical patch test ,ditiocarb zinc approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Zinc dibutyldithiocarbamate,zinc dibutyldithiocarbamate dermatological sensitizer allergen sensitivity zinc dibutyldithiocarbamate may identified clinical patch test ,zinc dibutyldithiocarbamate approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
4-(Isopropylamino)diphenylamine,4- isopropylamino diphenylamine also known ippd chemical compound commonly used antiozonant rubber particularly used tire also known allergen sensitivity compound may identified clinical patch test ,4- isopropylamino diphenylamine approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
"N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine","n-cyclohexyl-n'-phenyl-1,4-phenylenediamine component black rubber also dermatological sensitizer allergen sensitivity n-cyclohexyl-n'-phenyl-1,4-phenylenediamine may identified clinical patch test ","n-cyclohexyl-n'-phenyl-1,4-phenylenediamine approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older "
Methylchloroisothiazolinone,methylchloroisothiazolinone mci isothiazolinone commonly used preservative antibacterial antifungal property found within many commercially available cosmetic lotion makeup remover also known dermatological sensitizer allergen side effect include flaky scaly skin breakout redness itchiness moderate severe swelling eye area american contact dermatitis society named methylchloroisothiazolinone contact allergen year 2013 sensitivity methylchloroisothiazolinone may identified clinical patch test ,methylchloroisothiazolinone approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Quaternium-15,quaternium-15 quaternary ammonium salt used surfactant preservative many product including cosmetic anti-microbial agent virtue formaldehyde releaser however also cause contact dermatitis symptom allergic reaction especially sensitive skin 2005 quaternium-15 named top 15 frequently positive allergen identified patch test north american contact dermatitis group nacdg a34326 sensitivity quaternium-15 may identified clinical patch test ,quaternium-15 approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Bromothalonil,bromothalonil also known methyldibromo glutaronitrile mdbgn widely used preservative found many personal hygiene industrial product also known allergen dermatological irritant banned many eu country due increasing rate contact allergy a34322 2005 mdbgn named top 15 frequently positive allergen identified patch test north american contact dermatitis group nacdg a34326 sensitivity bromothalonil may identified clinical patch test ,bromothalonil approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
Thiohexam,thiohexam rubber cure accelerator also known allergen dermatological sensitizer sensitivity thiohexam may identified clinical patch test ,thiohexam approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older 
"2,2'-Dibenzothiazyl disulfide","2,2'-dibenzothiazyl disulfide accelerator used processing process natural synthetic rubber plastic regeneration also known allergen dermatological sensitizer sensitivity 2,2'-dibenzothiazyl disulfide may identified clinical patch test ","2,2'-dibenzothiazyl disulfide approved use within allergenic epicutaneous patch test indicated use aid diagnosis allergic contact dermatitis acd person 6 year age older "
Disperse Blue 106,disperse blue 106 used allergenic testing ,
Fosinoprilat,fosinoprilat active phosphinic acid metabolite prodrug fosinopril activated esterases vivo bind zinc phosphinic acid group ,
Ramiprilat, active metabolite prodrug ramipril ,
Trandolaprilat, active metabolite prodrug trandolapril ,
Moexiprilat, active metabolite prodrug moexipril ,
Methylparaben,methylparaben used allergenic testing ,
Perindoprilat, active metabolite prodrug perindopril ,
Quinaprilat, active metabolite prodrug quinapril ,
Telotristat, tryptophan hydroxylase inhibitor telotristat ethyl brand name xermelo prodrug telotristat ,
Beclomethasone 17-monopropionate, ester beclomethasone ,
Technetium Tc-99m,technetium-99m metastable isotope technetium commonly symbolized 99mtc used area medical diagnosis technetium-99m commonly used medical radioisotope ,
Lowbush blueberry,ingredient used over-the-counter medication ,
Albumin Aggregated,albumin aggregated ingredient draximage maa kit preparation technetium tc99m albumin aggregated injection l12816 imaging agent used ass lung perfusion evaluation peritoneovenous leveen shunt patency ,albumin aggregated ingredient draximage maa kit preparation technetium tc99m albumin aggregated injection indicated assessment lung perfusion evaluation peritoneovenous leveen shunt patency l12816 
Egg phospholipids,egg phospholipid primarily mixture naturally occurring phospholipid isolated egg yolk egg phospholipid available intravenous fat emulsion indicated source calorie patient requiring parenteral nutrition , use source calorie patient requiring parenteral nutrition 
"Caviar, unspecified",caviar unspecified animal extract used otc over-the-counter product approved drug ,
Honey,honey animal extract used otc over-the-counter product approved drug ,
Sus scrofa placenta,sus scrofa placenta animal extract used otc over-the-counter product approved drug ,
Garden snail mucin,garden snail mucin animal extract used otc over-the-counter product approved drug ,
"Snail, unspecified",snail unspecified animal extract used otc over-the-counter product approved drug ,
"Marine collagen, soluble",marine collagen soluble animal extract used otc over-the-counter product approved drug ,
Moschus berezovskii musk sac resin,moschus berezovskii musk sac resin animal extract used otc over-the-counter product approved drug ,
Bos taurus gallstone,bos taurus gallstone animal extract used otc over-the-counter product approved drug ,
Pearl (hyriopsis cumingii),pearl hyriopsis cumingii animal extract used otc over-the-counter product approved drug ,
Royal jelly,royal jelly animal extract used otc over-the-counter product approved drug ,
Ostrea edulis shell,ostrea edulis shell animal extract used otc over-the-counter product approved drug ,
Jojoba oil,jojoba oil plant/plant extract used otc over-the-counter product approved drug ,
Avena sativa flowering top,avena sativa flowering top plant/plant extract used otc over-the-counter product approved drug ,
Aloe vera flower,aloe vera flower plant/plant extract used otc over-the-counter product approved drug ,
Angelica dahurica root,angelica dahurica root plant/plant extract used otc over-the-counter product approved drug ,
Centella asiatica,centella asiatica plant/plant extract used otc over-the-counter product approved drug ,
Aloe ferox leaf,aloe ferox leaf plant/plant extract used otc over-the-counter product approved drug ,
Elm,elm plant/plant extract used otc over-the-counter product approved drug ,
Eucommia ulmoides bark,eucommia ulmoides bark plant/plant extract used otc over-the-counter product approved drug ,
Stypocaulon scoparium,stypocaulon scoparium plant/plant extract used otc over-the-counter product approved drug ,
Panax ginseng fruit,panax ginseng fruit plant/plant extract used otc over-the-counter product approved drug ,
Bird pepper,bird pepper plant/plant extract used otc over-the-counter product approved drug ,
Calendula officinalis flower,calendula officinalis flower plant/plant extract used otc over-the-counter product approved drug ,
Maclura tricuspidata whole,maclura tricuspidata whole plant/plant extract used otc over-the-counter product approved drug ,
Momordica charantia fruit,momordica charantia fruit plant/plant extract used otc over-the-counter product approved drug ,
Tribulus terrestris root,tribulus terrestris root plant/plant extract used otc over-the-counter product approved drug ,
Rumex crispus whole,rumex crispus whole plant/plant extract used otc over-the-counter product approved drug ,
Swertia japonica whole flowering,swertia japonica whole flowering plant/plant extract used otc over-the-counter product approved drug ,
Nardostachys chinensis whole,nardostachys chinensis whole plant/plant extract used otc over-the-counter product approved drug ,
Simmondsia chinensis seed,simmondsia chinensis seed plant/plant extract used otc over-the-counter product approved drug ,
Morus alba root bark,morus alba root bark plant/plant extract used otc over-the-counter product approved drug ,
Rosemary,rosemary plant/plant extract used otc over-the-counter product approved drug ,
Ocimum tenuiflorum top,ocimum tenuiflorum top plant/plant extract used otc over-the-counter product approved drug ,
Salix alba bark,salix alba bark plant/plant extract used otc over-the-counter product approved drug ,
Indian frankincense,indian frankincense plant/plant extract used otc over-the-counter product approved drug ,
Turmeric,turmeric plant/plant extract used otc over-the-counter product approved drug ,
Tripterygium wilfordii whole,tripterygium wilfordii whole plant/plant extract used otc over-the-counter product approved drug ,
Carthamus tinctorius flower bud,carthamus tinctorius flower bud plant/plant extract used otc over-the-counter product approved drug ,
Corydalis ambigua tuber,corydalis ambigua tuber plant/plant extract used otc over-the-counter product approved drug ,
Lonicera caprifolium flower,lonicera caprifolium flower plant/plant extract used otc over-the-counter product approved drug ,
Lagerstroemia indica whole,lagerstroemia indica whole plant/plant extract used otc over-the-counter product approved drug ,
Phellinus linteus mycelium,phellinus linteus mycelium plant/plant extract used otc over-the-counter product approved drug ,
Angelica archangelica root,angelica archangelica root plant/plant extract used otc over-the-counter product approved drug ,
Panax ginseng whole,panax ginseng whole plant/plant extract used otc over-the-counter product approved drug ,
Ginkgo biloba leaf oil,ginkgo biloba leaf oil plant/plant extract used otc over-the-counter product approved drug ,
Panax ginseng root oil,panax ginseng root oil plant/plant extract used otc over-the-counter product approved drug ,
Trametes versicolor fruiting body,trametes versicolor fruiting body plant/plant extract used otc over-the-counter product approved drug ,
Kaempferia galanga root,kaempferia galanga root plant/plant extract used otc over-the-counter product approved drug ,
Larix sibirica wood,larix sibirica wood plant/plant extract used otc over-the-counter product approved drug ,
Rehmannia glutinosa root,rehmannia glutinosa root plant/plant extract used otc over-the-counter product approved drug ,
Wormwood,wormwood plant/plant extract used otc over-the-counter product approved drug ,
Acorus calamus root,acorus calamus root plant/plant extract used otc over-the-counter product approved drug ,
Eutrema japonicum whole,eutrema japonicum whole plant/plant extract used otc over-the-counter product approved drug ,
Styphnolobium japonicum flower bud,styphnolobium japonicum flower bud plant/plant extract used otc over-the-counter product approved drug ,
Reynoutria multiflora root,reynoutria multiflora root plant/plant extract used otc over-the-counter product approved drug ,
Panax quinquefolius whole,panax quinquefolius whole plant/plant extract used otc over-the-counter product approved drug ,
Arnica montana,arnica montana plant/plant extract used otc over-the-counter product approved drug ,
Gambir,gambir plant/plant extract used otc over-the-counter product approved drug ,
Mucuna pruriens seed,mucuna pruriens seed plant/plant extract used otc over-the-counter product approved drug ,
Erythroxylum catuaba bark,`` catuaba '' general term medicinal infusion created bark plant belonging _erythroxylum_ genus though name also applied infusion plant belonging genus a215262 infusion thought carry stimulant aphrodisiac effect a215262 catuaba made specifically _trichilia catigua_ investigated use depression a215267 ,
Epimedium grandiflorum top,epimedium grandiflorum top plant/plant extract used otc over-the-counter product approved drug ,
Turnera diffusa leaf,turnera diffusa leaf plant/plant extract used otc over-the-counter product approved drug ,
Eleuthero,eleuthero plant/plant extract used otc over-the-counter product approved drug ,
Panax notoginseng root,panax notoginseng root plant/plant extract used otc over-the-counter product approved drug ,
Tribulus terrestris fruit,tribulus terrestris fruit plant/plant extract used otc over-the-counter product approved drug ,
Juglans regia shell,juglans regia shell plant/plant extract used otc over-the-counter product approved drug ,
Green tea leaf,green tea leaf plant/plant extract used otc over-the-counter product approved drug ,
Camellia japonica seed oil,camellia japonica seed oil plant/plant extract used otc over-the-counter product approved drug ,
Meadowfoam seed oil,meadowfoam seed oil plant/plant extract used otc over-the-counter product approved drug ,
Argan oil,argan oil plant/plant extract used otc over-the-counter product approved drug ,
Shea butter,shea butter plant/plant extract used otc over-the-counter product approved drug ,
Glycyrrhiza glabra,glycyrrhiza glabra plant/plant extract used otc over-the-counter product approved drug ,
Lawsonia inermis leaf,lawsonia inermis leaf plant/plant extract used otc over-the-counter product approved drug ,
Indigofera tinctoria leaf,indigofera tinctoria leaf plant/plant extract used otc over-the-counter product approved drug ,
Calendula officinalis whole,calendula officinalis whole plant/plant extract used otc over-the-counter product approved drug ,
Tangerine peel,tangerine peel plant/plant extract used otc over-the-counter product approved drug ,
Pomegranate,pomegranate plant/plant extract used otc over-the-counter product approved drug ,
Macadamia seed oil glycereth-8 esters,macadamia seed oil glycereth-8 ester plant/plant extract used otc over-the-counter product approved drug ,
Magnolia kobus flowering top,magnolia kobus flowering top plant/plant extract used otc over-the-counter product approved drug ,
Eucalyptus globulus leaf,eucalyptus globulus leaf plant/plant extract used otc over-the-counter product approved drug ,
Bambusa vulgaris top,bambusa vulgaris top plant/plant extract used otc over-the-counter product approved drug ,
Coconut oil,coconut oil plant/plant extract used otc over-the-counter product approved drug ,
Grape seed oil,grape seed oil plant/plant extract used otc over-the-counter product approved drug ,
Apricot kernel oil,apricot kernel oil plant/plant extract used otc over-the-counter product approved drug ,
Schisandra chinensis fruit,schisandra chinensis fruit plant/plant extract used otc over-the-counter product approved drug ,
Amber,amber plant/plant extract used otc over-the-counter product approved drug ,
Purslane,purslane plant/plant extract used otc over-the-counter product approved drug ,
Chamaemelum nobile flower,chamaemelum nobile flower plant/plant extract used otc over-the-counter product approved drug ,
Sunflower oil,sunflower oil plant/plant extract used otc over-the-counter product approved drug ,
Macadamia oil,macadamia oil plant/plant extract used otc over-the-counter product approved drug ,
Heterotheca inuloides flower,heterotheca inuloides flower plant/plant extract used otc over-the-counter product approved drug ,
Inonotus obliquus fruiting body,inonotus obliquus fruiting body plant/plant extract used otc over-the-counter product approved drug ,
Nelumbo nucifera flower,nelumbo nucifera flower plant/plant extract used otc over-the-counter product approved drug ,
Hydrogenated coconut oil,hydrogenated coconut oil plant/plant extract used otc over-the-counter product approved drug ,
Bergamot oil,bergamot oil plant/plant extract used otc over-the-counter product approved drug ,
Angelica sinensis root,angelica sinensis root plant/plant extract used otc over-the-counter product approved drug ,
Salvia miltiorrhiza root,salvia miltiorrhiza root plant/plant extract used otc over-the-counter product approved drug ,
Atractylodes lancea root oil,atractylodes lancea root oil plant/plant extract used otc over-the-counter product approved drug ,
Scutellaria lateriflora,scutellaria lateriflora plant/plant extract used otc over-the-counter product approved drug ,
Prunus armeniaca seed,prunus armeniaca seed plant/plant extract used otc over-the-counter product approved drug ,
Chamaecyparis obtusa wood oil,chamaecyparis obtusa wood oil plant/plant extract used otc over-the-counter product approved drug ,
Taraxacum officinale leaf,taraxacum officinale leaf plant/plant extract used otc over-the-counter product approved drug ,
Arnica montana flower,arnica montana flower plant/plant extract used otc over-the-counter product approved drug ,
Lonicera confusa flower,lonicera confusa flower plant/plant extract used otc over-the-counter product approved drug ,
Forsythia suspensa fruit,forsythia suspensa fruit plant/plant extract used otc over-the-counter product approved drug ,
Mentha arvensis top,mentha arvensis top plant/plant extract used otc over-the-counter product approved drug ,
Platycodon grandiflorus root,platycodon grandiflorus root plant/plant extract used otc over-the-counter product approved drug ,
Citrus junos fruit,citrus juno fruit plant/plant extract used otc over-the-counter product approved drug ,
Equisetum arvense top,equisetum arvense top plant/plant extract used otc over-the-counter product approved drug ,
Inula helenium root,inula helenium root plant/plant extract used otc over-the-counter product approved drug ,
Usnea barbata,usnea barbata plant/plant extract used otc over-the-counter product approved drug ,
Azadirachta indica leaf,azadirachta indica leaf plant/plant extract used otc over-the-counter product approved drug ,
Zanthoxylum clava-herculis whole,zanthoxylum clava-herculis whole plant/plant extract used otc over-the-counter product approved drug ,
Salix alba bark volatile oil,salix alba bark volatile oil plant/plant extract used otc over-the-counter product approved drug ,
Apple fruit oil,apple fruit oil plant/plant extract used otc over-the-counter product approved drug ,
Platycodon grandiflorus leaf,platycodon grandiflorus leaf plant/plant extract used otc over-the-counter product approved drug ,
Chamomile,chamomile plant/plant extract used otc over-the-counter product approved drug ,
Tribulus terrestris,tribulus terrestris plant/plant extract used otc over-the-counter product approved drug ,
Tremella fuciformis whole,tremella fuciformis whole plant/plant extract used otc over-the-counter product approved drug ,
Saw palmetto,saw palmetto plant/plant extract used otc over-the-counter product approved drug ,
Rice bran,rice bran plant/plant extract used otc over-the-counter product approved drug ,
Moringa oleifera leaf,moringa oleifera leaf plant/plant extract used otc over-the-counter product approved drug ,
Rosa centifolia flower oil,rosa centifolia flower oil plant/plant extract used otc over-the-counter product approved drug ,
Scutellaria baicalensis root,scutellaria baicalensis root plant/plant extract used otc over-the-counter product approved drug ,
Garcinia gummi-gutta fruit,garcinia gummi-gutta fruit plant/plant extract used otc over-the-counter product approved drug ,
Ilex paraguariensis leaf,ilex paraguariensis leaf plant/plant extract used otc over-the-counter product approved drug ,
Chondrus crispus,chondrus crispus plant/plant extract used otc over-the-counter product approved drug ,
Capsicum annuum whole,capsicum annuum whole plant/plant extract used otc over-the-counter product approved drug ,
Typhonium giganteum whole,typhonium giganteum whole plant/plant extract used otc over-the-counter product approved drug ,
Phellodendron amurense bark,phellodendron amurense bark plant/plant extract used otc over-the-counter product approved drug ,
Mangostin,mangostin plant/plant extract used otc over-the-counter product approved drug ,
Melaleuca alternifolia leaf,melaleuca alternifolia leaf plant/plant extract used otc over-the-counter product approved drug ,
Quercus acutissima whole,quercus acutissima whole plant/plant extract used otc over-the-counter product approved drug ,
Pumice,pumice plant/plant extract used otc over-the-counter product approved drug ,
Milk thistle,milk thistle plant/plant extract used otc over-the-counter product approved drug ,
Chicory leaf,chicory leaf plant/plant extract used otc over-the-counter product approved drug ,
Palm oil,palm oil plant/plant extract used otc over-the-counter product approved drug ,
Camphor leaf oil,camphor leaf oil plant/plant extract used otc over-the-counter product approved drug ,
Zanthoxylum clava-herculis bark,zanthoxylum clava-herculis bark plant/plant extract used otc over-the-counter product approved drug ,
Influenza A virus A/California/7/2009 (H1N1)-like hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Texas/6/2011 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Bordetella pertussis toxoid antigen (formaldehyde inactivated),bordetella pertussis toxoid antigen formaldehyde inactivated vaccine ,
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Texas/50/2012 X-223 (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/361/2011 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Wisconsin/1/2010 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Brisbane/10/2010 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/9/2014 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Human adenovirus e serotype 4 strain cl-68578 antigen,human adenovirus e serotype 4 strain cl-68578 antigen vaccine ,
Human adenovirus b serotype 7,human adenovirus b serotype 7 vaccine ,
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/South Australia/55/2014 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Slovenia/2903/2015 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/New caledonia/71/2014 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen,neisseria meningitidis group capsular oligosaccharide diphtheria crm197 protein conjugate antigen vaccine ,
Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen,neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen vaccine ,
Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen,neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen vaccine ,
Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen,neisseria meningitidis group capsular oligosaccharide diphtheria crm197 protein conjugate antigen vaccine ,
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/gp2050/2015 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Hong Kong/259/2010 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Hong Kong/4801/2014 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/GP1908/2015 IVR-180A (H1N1) hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/46/2015 hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 BVR-1B hemagglutinin antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Vibrio cholerae CVD 103-HgR strain live antigen,_vibrio cholerae_ cvd 103-hgr strain live antigen component vaxchora oral vaccine immunization _vibrio cholerae_ serogroup o1 l12801 cholera acute bacterial disease small intestine caused _vibrio cholerae_ gram-negative bacteria two serogroups _v cholerae_ o1 o139 causative agent epidemic cholera serogroup o1 responsible majority cholera outbreak a244494 cholera outbreak remain major global public health problem mainly affect country limited access clean water poor hygiene proper sanitation thus effective vaccine protect individual cholera disease critical a244489 fda approved cholera vaccine containing _vibrio cholerae_ cvd 103-hgr strain live antigen brand name vaxchora june 2016 making first vaccine indicated cholera prevention become available u.s. a244494 vaxchora later approved european commission april 2020 l39729 indicated individual aged two year older l12801 ,_vibrio cholerae_ cvd 103-hgr strain live antigen indicated active oral immunization infection caused _vibrio cholerae_ serogroup o1 patient 2 64 year age l12801 l39720 
Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/South Dakota/6/2007 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Uruguay/716/2007(H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Texas/6/2011 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/9/2014 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Hong Kong/259/2010 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/GP1908/2015 IVR-180A (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Insulin-like growth factor II, insulin-like growth factor ii well-characterized neutral peptide believed secreted liver circulate blood factor present effect related growth regulation insulin-like mitogenic activity perform biological activity growth factor present dependence somatotropin believed major fetal growth factor contrast insulin-like growth factor major growth factor adult ,
Beroctocog alfa,,beroctocog alfa indicated prevention control bleeding patient hemophilia acquired factor viii fviii deficiency l11752 also indicated surgical/invasive procedure adult pediatric patient von willebrand disease desmopression either ineffective contraindicated l11752 indicated patient severe i.e type 3 von willebrand disease undergoing major surgery l11752 
Povidone K30, polyvinyl polymer variable molecular weight used suspending dispersing agent vehicle pharmaceutical also used blood volume expander see povidone full detail , complex iodine indicated inducing antisepsis prevention infection minor cut scrape burn 
Calcium phosphate dihydrate,, use counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda label l851 
Zinc acetate,,zinc used treatment prevention zinc deficiency/its consequence including stunted growth acute diarrhea child slowed wound healing also utilized boosting immune system treating common cold recurrent ear infection well preventing lower respiratory tract infection l2172 
Ferrous gluconate,,used preventing treating iron-deficiency anemia 
Ferrous succinate,,used preventing treating iron-deficiency anemia 
Ferrous ascorbate,,used preventing treating iron-deficiency anemia 
Ferrous fumarate,used treatment iron deficiency anemia ,used preventing treating iron-deficiency anemia 
Zinc glycinate,glycoprotein marker gastrointestinal cancer ,
Potassium acetate,,potassium used regulate hypokalemia primary condition secondary medical condition 
Potassium sulfate,,potassium used regulate hypokalemia primary condition secondary medical condition 
Potassium,potassium essential nutrient like calcium magnesium identified shortfall nutrient 2015-2020 advisory committee dietary guideline american a186928 many condition disease interfere normal body potassium balance underconsumption potassium one example hypokalemia low potassium hyperkalemia high potassium may result manifesting various sign symptom example potassium-related complication include life-threatening arrhythmia neuromuscular dysfunction diarrhea nausea vomiting a32222 a38081 l2652 various pharmacological preparation formulated replenish potassium available assortment tablet injection form depending setting condition treated potassium often key ingredient intravenous fluid given patient clinical setting rehydration nutrition replenishment electrolyte example potassium formulation include potassium citrate potassium chloride potassium dextrose sodium chloride l8744 l8747 l8753 l8759 , general us potassium potassium indicated treat variety condition firstly used replenish potassium depleted condition including limited malabsorption decreased intake excess sodium intake cause potassium deficiency numerous following indication potassium comprehensive include main indication nutrient used various product preparation contain potassium potassium chloride potassium chloride one main preparation potassium used clinical setting oral solution indicated prevention treatment hypokalemia presenting without metabolic alkalosis patient failed conservative management potassium-rich food diuretic dose titration l8744 injection form potassium chloride indicated replenish potassium patient feasible candidate oral potassium highly concentrated potassium intended treatment potassium deficiency fluid restricted individual tolerate fluid volume normally associated injected potassium solution contain lower concentration l8768 finally extended-release tablet preparation potassium chloride used treat hypokalemia without metabolic alkalosis treat digitalis intoxication manage patient hypokalemic familial periodic paralysis also used prevention hypokalemia high risk negative clinical outcome hypokalemia occurs patient digitalis cardiac arrhythmia would particular risk negative outcome l8771 potassium chloride dextrose sodium chloride liquid preparation indicated clinical setting source water calorie electrolyte l8747 potassium acetate solution meant alternative potassium chloride replenishing potassium added large volume infusion fluid intravenous injection l8759 potassium citrate potassium citrate preparation used management renal tubular acidosis rta calcium stone nephrolithiasis calcium oxalate stone cause uric acid nephrolithiasis without calcium stone regimen also includes adequate water intake leading urine put 2 l/day sodium restriction l8753 
Ferrous glycine sulfate,,used preventing treating iron-deficiency anemia 
"Sodium phosphate, dibasic",,used treat constipation clean bowel colonoscopy fda label 
"Sodium phosphate, monobasic, unspecified form",,used treat constipation clean bowel colonoscopy fda label 
Sodium borate,, fda- ema-approved therapeutic indication 
Lithium hydroxide,used tryptophan determination protein food ,
Lithium citrate,,lithium used mood stabilizer used treatment depression mania often used bipolar disorder treatment 
Lithium carbonate,lithium used treat manic episode since 19th century a176642 though widely used mechanism action still unknown fda label a14585 a176642 a176651 l5843 lithium carbonate narrow therapeutic range careful monitoring required avoid adverse effect fda label ,lithium carbonate indicated monotherapy treatment acute manic mixed episode associated bipolar 1 disorder patient ≥7 year age l1275 also indicated maintenance treatment bipolar 1 disorder patient ≥7 year age l1275 
Mometasone furoate,mometasone furoate corticosteroid drug used treatment asthma rhinitis certain skin condition fda label f4292 f4295 glucocorticoid receptor binding affinity 22 time stronger dexamethasone higher many corticosteroid well a176906 mometasone furoate formulated dry powder inhaler nasal spray ointment different indication fda label f4292 f4295 ,inhaled mometasone furoate indicated prophylaxis asthma patient ≥4 year l9560 applied topically ointment mometasone furoate indicated symptomatic treatment dermatitis pruritis patient ≥2 year l9590 mometasone furoate nasal spray available over-the-counter otc prescription otc nasal spray formulation mometasone furoate indicated treatment upper respiratory allergic symptom e.g rhinorrhea sneezing patient ≥2 year age l42300 prescription formulation indicated treatment chronic rhinosinusitis nasal polyp patient ≥18 year old prophylaxis seasonal allergic rhinitis patient ≥12 year old l9563 also approved combination olopatadine symptomatic treatment seasonal allergic rhinitis patient ≥12 year l39845 
Magnesium,magnesium classified alkaline earth metal 2 hydration shell a19349 element found abundance hydrosphere mineral salt dolomite magnesium carbonate a19349 common dietary source magnesium include nut cashew peanut almond bean banana apple carrot broccoli leafy green a188120 l2601 magnesium important enzyme cofactor essential several metabolic process a32810 mineral help regulate blood pressure necessary rna dna protein synthesis among several function a32810 despite importance magnesium availability via several food source estimated 56 68 adult live developed western country meet recommended daily intake rdi magnesium a39559 several factor common behaviour reduce availability magnesium diet food processing cooking vegetable normally rich source magnesium a39559 ,healthy level magnesium achieved well balanced diet food source insufficient magnesium supplement used prevent treat magnesium deficiency l2601 medicine various magnesium salt may used laxative antacid product a19349 example magnesium citrate available over-the-counter may used manage occasional constipation l10349 magnesium sulfate may used total parenteral nutrition treat hypomagnesemia l10355 magnesium sulfate also indicated prevent seizure pregnant woman pre-eclampsia manage seizure associated eclampsia a188087 l10355 
Tetraferric tricitrate decahydrate,tetraferric tricitrate decahydrate iron containing phosphate binder used treat hyperphosphatemia iron deficiency anemia adult chronic kidney disease a25965 tetraferric tricitrate decahydrate granted fda approval 5 september 2014 l9926 ,tetraferric tricitrate decahydrate indicated control serum phosphorous adult chronic kidney disease require dialysis l9926 tetraferric tricitrate decahydrate also indicated treat iron deficiency anemia adult chronic kidney disease dialysis l9926 
Chromic citrate,,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Chromic nitrate,,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Chromium gluconate,,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Chromium nicotinate,,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Chromous sulfate,,indicated use supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda label 
Zinc chloride,zinc chloride solution ion indicated use total parenteral nutrition maintain zinc level prevent deficiency syndrome l14189 zinc chloride granted fda approval 26 june 1986 l14189 ,zinc chloride injection indicated use total parenteral nutrition maintain zinc serum level prevent deficiency syndrome l14189 
Hydrocortisone aceponate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone acetate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone butyrate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone cypionate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone phosphate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone probutate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
Hydrocortisone valerate,, relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis also used treat endocrine hormonal disorder adrenal insufficiency addisons disease also used treat many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn 's disease 
"Zinc sulfate, unspecified form",zinc sulfate common zinc supplement parenteral nutrition a216916 l12888 ,zinc sulfate common zinc supplement parenteral nutrition a216916 l12888 
Gallium chloride Ga-67,gallium chloride ga-67 chloride salt gallium radioisotope typically complexed sodium citrate generate gallium citrate ga 67 used image certain cancer inflammatory lesion l12705 ,following complexation sodium citrate yield gallium citrate ga 67 gallium chloride ga-67 used demonstrate presence hodgkin 's disease lymphoma bronchogenic carcinoma acute inflammatory lesion l12705 
Phosphorus P-32,phosphorus p-32 radioactive isotope phosphorus beta particle-emitting radiocytotoxic activity emitted phosphorus p32 beta particle directly damage cellular dna ionizing intracellular water produce several type cytotoxic free radical superoxide indirectly damage intracellular biological macromolecule resulting tumor cell death ,
Peracetic acid, liquid function strong oxidizing agent acrid odor used disinfectant ,
Ethylhexylglycerin, emollient solvent antimicrobial activity ,
Influenza A virus A/Singapore/INFIMH-16-0019/2016 NIB-104 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Maryland/15/2016 BX-69A antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Andexanet alfa,andexanet alfa recombinant human coagulation factor xa promotes blood coagulation developed portola pharmaceutical approved may 2018 marketed andexxa intravenous injection infusion indicated reversal anticoagulation combination rivaroxaban apixaban case life-threatening uncontrolled bleeding rivaroxaban apixaban factor xa inhibitor promote anticoagulation situation blood clotting unfavourable deep vein thrombosis pulmonary embolism however use agent associated risk uncontrollable bleeding episode lead cause serious fatal bleeding andexanet alfa currently regulatory review european union undergoing clinical development japan a35518 andexanet alfa work binding factor xa inhibitor prevent interacting endogenous factor xa displayed high affinity 0.53–1.53 nmol/l apixaban betrixaban edoxaban rivaroxaban a35518 however effectiveness andexanet alfa treating bleeding related fxa inhibitor apixaban rivaroxaban demonstrated thus use limited l3725 pharmacokinetic property reported affected factor xa inhibitor a35518 andexanet alfa retains structural similarity endogenous human factor xa exists mature functional form without need activation via intrinsic extrinsic coagulation pathway a35558 remains catalytically inactive due structural modification a35518 procoagulation potential andexanet alfa eliminated removal 34-residue fragment containing gla via truncation andexanet alfa unable bind membrane surface assemble prothrombinase complex a35558 also prevents andexanet alfa taking space phospholipid surface membrane native fxa may bind assemble prothrominase complex a35558 amino acid residue modification serine alanine binding site catalytic domain allows effective binding fxa inhibitor deters andexanet alfa converting prothrombin thrombin a35558 ,andexanet alfa indicated patient treated rivaroxaban apixaban reversal anticoagulation needed due life-threatening uncontrolled bleeding l3725 andexxa shown effective indicated treatment bleeding related factor xa inhibitor apixaban rivaroxaban l3725 
Ivosidenib,ivosidenib first-in-class isocitrate dehydrogenase-1 idh1 inhibitor idh1 enzyme often mutated overexpressed cancer leading aberrant cell growth proliferation a248750 ivosidenib inhibits mutated idh1 blocking enzymatic activity differentiation cancer cell a248745 ivosidenib granted accelerated approval fda july 2018 treatment relapsed refractory acute myeloid leukemia adult a248745 currently approved also treat newly diagnosed acute myeloid leukemia older adult combination azacitidine monotherapy well locally advanced metastatic cholangiocarcinoma adult drug effective patient susceptible idh1 mutation l41870 ,ivosidenib isocitrate dehydrogenase-1 idh1 inhibitor indicated treatment patient susceptible idh1 mutation detected fda-approved test newly diagnosed acute myeloid leukemia aml combination azacitidine monotherapy treatment newly diagnosed aml adult 75 year older comorbidities preclude use intensive induction chemotherapy l41870 relapsed refractory aml adult l41870 locally advanced metastatic cholangiocarcinoma adult previously treated l41870 
Tedizolid,drug-resistant bacteria methicillin-resistant _staphylococcus aureus_ vancomycin-resistant _enterococcus faecium_ penicillin-resistant _streptococcus penumoniae_ represent massive public health threat a199086 a199131 tedizolid member oxazolidinone class antibiotic includes previously approved linezolid generally effective multidrug-resistant gram-positive bacteria tedizolid indicated treatment acute bacterial skin skin structure infection absssi generally effective tolerable linezolid l11232 a199086 a199050 tedizolid approved fda june 20 2014 sale cubist pharmaceutical tedizolid phosphate sivextro® product currently available oral tablet powder intravenous injection l11232 ,tedizolid indicated treatment acute bacterial infection skin skin structure absssi prevent drug resistance tedizolid used infection caused susceptible bacteria l11232 
Cobalt, trace element component vitamin b12 atomic symbol co atomic number 27 atomic weight 58.93 used nuclear weapon alloy pigment deficiency animal lead anemia excess human lead erythrocytosis except radioactive form cobalt cobalamin fda withdrew approval use drug product containing cobalt salt l43942 ,
Eslicarbazepine,eslicarbazepine anti-epileptic medication available commercially eslicarbazepine acetate ,
Lecanemab,lecanemab humanized igg1 monoclonal version mab158 murine monoclonal antibody reduces level pathogenic amyloid beta aβ prevent aβ deposition a253947 a253952 due amyloid plaque-lowering activity high selectively aβ protofibrils 1000-fold higher selectivity compared monomer lecanemab currently investigated disease-modifying biologic treatment alzheimer 's disease a253947 a253957 phase 2 clinical study showed lecanemab meet 12-month primary endpoint reaching 80 probability ≥25 clinical reduction alzheimer 's disease decline versus placebo however 18-month analysis demonstrated reduction brain amyloid accompanied consistent reduction clinical decline across several clinical biomarker endpoint phase 3 clinical study early alzheimer 's disease currently developed a253962 ,
CPI-1205,potent selective histone methyltransferase ezh2 inhibitor ,
Patisiran,parisiran first class short interfering rna treatment patient polyneuropathy caused hereditary transthyretin-mediated amyloidosis l4220 marketed onpattro formulated patisiran within liposome envelope better delivery liver transthyretin produced approval onpattro granted alnylam pharmaceutical inc. august 2018 onpattro granted fast track priority review breakthrough therapy orphan drug designation ,patisirant indicated treatment hereditary transthyretin-mediated amyloidosis adult fda label administered pre-medication reduce complication fda label include intravenous corticosteroid equivalent 10 mg dexamethasone 500 mg oral acetaminophen intravenous histamine h1 blocker equivalent 50 mg diphenhydramine intravenous histamine h2 blocker equivalent 50 mg ranitidine
Segesterone acetate,segesterone acetate steroidal progestin synthetic progesterone 19-norprogesterone derivative ch3 group radical position 6 a37048 animal study segesterone acetate shown one potent progestin a37090 mediates progestational activity 100 time higher progesterone a37092 commonly sold brand name nestorone elcometrine serf active component hormonal contraceptive also used treatment endometriosis south american country segesterone acetate bind selectively progesterone receptor androgen receptor a37083 due rapid hepatic metabolism segesterone acetate must administered parenterally a37090 segesterone acetate orally active compound proved potent anti-ovulatory agent given implant vaginal ring percutaneous gel a37090 august 10 2018 annovera™ containing segesterone acetate ethinyl estradiol granted approval u.s. food drug administration fda first contraceptive provides entire year protection unintended pregnancy entirely woman 's control according center disease control 43 million woman u.s. risk unintended pregnancy may associated elevated risk improper prenatal care premature low-birth-weight infant physical mental health risk l4246 introduction new contraceptive method offer expansion birth control option woman maintaining high efficacy acceptability similar existing shorter-acting combined hormonal method a37083 clinical trial annovera™ achieved 97.3 success pregnancy prevention l4246 annovera™ administered vaginal ring place 21 day removed 7 day cycle hormonal contraceptive annovera™ carry risk serious cardiovascular event ,segesterone acetate combination ethinyl estradiol indicated use female reproductive potential prevent pregnancy combination hormonal contraceptive chc induces contraception thirteen 28-day cycle 1 year following vaginal administration vaginal system must remain place continuously 3 week 21 day followed 1-week 7-day vaginal system-free interval use female body mass index 29 kg/m^2 adequately evaluated fda label 
Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Maryland/15/2016 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Maryland/15/2016 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Maryland/15/2016 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Lanadelumab,lanadelumab also known dx-2930 human igg1 monoclonal antibody designed subcutaneous self-injection l4538 fully human immunoglobulin k-light-chain made recombinant chinese hamster ovary cell l4537 fda eu granted designation priority review breakthrough therapy orphan drug rare disease based result reported clinical trial a38676 lanadelumab developed shire fda approved august 28 2018 l4537 ,lanadelumab indicated prophylaxis treatment prevent attack patient 12 year older hereditary angioedema l4537 hereditary angioedema hea autosomal dominant disorder resulted presence c1 deficiency report indicated high prevalence case result spontaneous mutation inherited condition manifested attack subcutaneous submucosal edema face larynx gi tract limb genitalia type attack serious laryngeal compromise airway rest attack accompanied pain considerable dysfunction a38679 
Edetate calcium disodium anhydrous,edetate calcium disodium metal ion chelator used reduce blood concentration depot store lead body l12774 world health organization model list essential medicine a204173 edetate calcium disodium granted fda approval 16 july 1953 l12774 ,edetate calcium disodium indicated reduce blood level depot store lead acute chronic lead poisoning l12774 
Edetate disodium anhydrous,edetate disodium anhydrous polyvalent chelating agent used treat hypercalcemia digitalis toxicity associated ventricular arrhythmia a204275 ,edetate disodium indicated emergency treatment hypercalcemia digitalis toxicity associated ventricular arrhythmia l14222 
Barley malt syrup,barley malt syrup allergenic extract used allergenic testing ,
"Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Texas/50/2012 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Massachusetts/2/2012 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Wisconsin/1/2010) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/59/2007 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/59/2007 (H1N1) hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Oxyphenisatin acetate,"oxyphenisatin acetate pro-drug oxyphenisatin 3,3-bis 4-hydroxyphenyl -1h-indol-2-one fda withdrew approval use oxyphenisatin acetate due safety reason l43942 ",
Prednisolone phosphate,prednisolone phosphate glucocorticoid similar cortisol used anti-inflammatory immunosuppressive anti-neoplastic vasoconstrictive effect a187463 prednisolone phosphate granted fda approval 19 december 1973 l14144 ,prednisolone phosphate indication number condition including treat allergic state dermatologic disease edematous state endocrine disorder gastrointestinal disease hematologic disorder neoplastic disease nervous system ophthalmic disease respiratory disease rheumatic disorder l9437 l9440 
Fluprednidene acetate,fluprednidene acetate corticosteroid anti-inflammatory anti-allergic property ,
Curcumin sulfate,, approved therapeutic indication 
Diloxanide furoate,,diloxanide used alone primary agent treatment asymptomatic cyst passer intestinal amebiasis caused entamoeba histolytica diloxanide may also used concurrently sequentially agent nitroimidazoles eg metronidazole treatment invasive extraintestinal form amebiasis 
Methylprednisolone hemisuccinate, water-soluble ester methylprednisolone used cardiac allergic hypoxic emergency ,
Dexamethasone acetate,commonly known decadron dexamethasone acetate glucocorticosteroid previously marketed usa treatment inflammatory respiratory allergic autoimmune condition t797 l10695 l14348 developed 1957 dexamethasone structurally similar corticosteroid hydrocortisone prednisolone a188724 dexamethasone acetate largely replaced dexamethasone phosphate continues administered large variety inflammatory condition l10701 recently dexamethasone drug interest treatment covid-19 june 16 2020 press release highlighting early result clinical trial randomized evaluation covid-19 therapy recovery reported dexamethasone reduced covid-19 death approximately one-fifth one-third patient oxygen therapy mechanical ventilation respectively dexamethasone therefore recommended life-saving treatment covid-19 patient experiencing severe respiratory symptom l14318 ,
Drostanolone propionate,, use female palliation androgenresponsive recurrent mammary cancer woman one year le five year postmenopausal 
Melengestrol acetate, 6-methyl progesterone acetate reported glucocorticoid activity effect estrus ,
Betamethasone phosphate,betamethasone phosphate prodrug rapidly hydrolyzed providing rapidly accessible betamethasone agonize glucocorticoid receptor l11994 betamethasone provides greater anti-inflammatory activity prednisolone le sodium water retention l11994 betamethasone sodium phosphate granted fda approval 3 march 1965 l11994 ,betamethasone phosphate indicated intramuscularly treat allergic state dermatologic disease endocrine disorder gastrointestinal disease hematologic disorder neoplastic disease nervous system condition ophthalmic disease renal disease respiratory disease rheumatic disorder trichinosis neurologic myocardial involvement tuberculous meningitis subarachnoid block impending block l11994 also used intra-articularly treatment acute gouty arthritis acute subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis l11994 intralesional betamethasone phospahte indicated treatment alopecia areata discoid lupus erythematosus keloid lichen planus lichen simplex chronicus psoriatic plaque necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesion granuloma annulare l11994 
Estramustine phosphate, nitrogen mustard linked estradiol usually phosphate used treat prostatic neoplasm also radiation protective property ,
Cortisone, naturally occurring glucocorticoid used replacement therapy adrenal insufficiency anti-inflammatory agent cortisone inactive converted liver active metabolite hydrocortisone martindale extra pharmacopoeia 30th ed p726 ,
Prezatide copper,prezatide tripeptide consisting glycine histidine lysine readily form complex copper ion a19503 prezatide used cosmetic product skin hair known aid wound healing potential application chronic obstructive pulmonary disease metastatic colon cancer currently investigated ,commonly used cosmetic product skin hair a19503 
Calcium polycarbophil,calcium polycarbophil stool stabilizer based chemical structure synthetic polymer polyacrylic acid cross-linked divinyl glycol presenting calcium atom counter-ion polycarbophil used treat constipation drug may also used help relieve symptom irritable bowel syndrome diarrhea le gas bloating compared psyllium laxative product cause heartburn belly cramp insoluble water dilute acid dilute alkali material posse exceptionally high water-binding capacity absorbed interfere activity digestive enzyme intestinal absorption posse satisfactory stability physiologically inert cause gastrointestinal irritation ,polycarbophil used treat constipation help maintain regular bowel movement 
Beef liver,beef liver allergenic extract used allergenic testing ,
Ferric oxyhydroxide, antiferromagnetic material constitutes core natural ferritin ,
Influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Colorado/06/2017 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (UV,formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (UV,formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Damoctocog alfa pegol, recent year various extended half-life factor viii factor ix preparation studied gained approval order extend half-lives technique fusion protein conjugate fc part igg1 albumin chemical modification pegylation protein sequence modification utilized a38907 also known bay94-9027 damoctocog alfa pegol longer-acting factor viii therapy formulated polyethylene glycol peg reduce number infusion necessary prevent bleeds patient diagnosed haemophilia l4576 a38909 label product engineered bayer l4576 biological license application filed fda august 2017 fda approved august 2018 f1609 ,indicated use previously treated adult adolescent 12 year age hemophilia congenital factor viii deficiency on-demand treatment control bleeding episode fda label perioperative management bleeding fda label routine prophylaxis reduce frequency bleeding episode fda label 
Cemiplimab,cemiplimab fully human monoclonal antibody work programmed death receptor-1 pd-1 negative regulator cell function blocking pd-1 cemiplimab work enhance cell-mediated antitumour response l39804 cemiplimab first approved fda september 28 2018 first fda-approved treatment advanced cutaneous squamous cell carcinoma cscc a39201 a254177 l4615 later approved used basal cell carcinoma non-small non-small cell lung cancer l39804 cemiplimab also approved european commission june 28 2019 l43872 october 2022 ema 's committee medicinal product human use chmp recommended cemiplimab granted marketing authorization treatment cervical cancer l43867 ,cemiplimab indicated treat locally advanced metastatic cutaneous squamous cell carcinoma mcscc patient candidate curative surgery curative radiation l39804 l43872 locally advanced basal cell carcinoma labcc previously treated patient hedgehog pathway inhibitor hedgehog pathway inhibitor appropriate l39804 l43872 metastatic basal cell carcinoma mbcc patient previously treated hedgehog pathway inhibitor hedgehog pathway inhibitor appropriate indication approved accelerated approval based tumour response rate durability response continued approval mbcc may contingent upon verification description clinical benefit l39804 l43872 locally advanced non-small cell lung cancer nsclc combination platinum‐based chemotherapy first‐line treatment adult egfr alk ros1 aberration candidate surgical resection definitive chemoradiation also indicated treat metastatic nsclc combination platinum‐based chemotherapy first-line treatment adult l43902 locally advanced metastatic nsclc monotherapy first-line treatment adult whose tumour high pd-l1 expression tumor proportion score tps ≥ 50 determined fda-approved test egfr alk ros1 aberration patient locally advanced nsclc must candidate surgical resection definitive chemoradiation l43902 recurrent metastatic cervical cancer adult disease progression platinum-based chemotherapy l43872 
Tosylchloramide,tosylchloramide also known chloramine-t chlorinated deprotonated sulfonamide used mild disinfectant stable water dissolved form ,
Bean,bean allergenic extract used allergenic testing ,
Camponotus pennsylvanicus,camponotus pennsylvanicus allergenic extract used allergenic testing ,
"Smallpox (Vaccinia) Vaccine, Live", new york city board health strain _vaccinia_ viral strain used component smallpox vaccination l12747 acam2000 percutaneously administered smallpox vaccine approved fda 2007 contains live antigen strain l12747 , live antigen new york city board health strain _vaccinia_ indicated within acam2000 formulation active immunization smallpox disease patient determined high risk contracting smallpox infection l12747 
Elapegademase,elapegademase pegylated recombinant adenosine deaminase defined molecularly genetically modified bovine adenosine deaminase modification cysteine 74 serine 13 methoxy polyethylene glycol chain bound via carbonyl group alanine lysine residue f1937 elapegademase generated _e coli_ developed leadiant bioscience fda approved october 5 2018 l4654 f1939 ,elapegademase approved treatment adenosine deaminase severe combined immune deficiency ada-scid pediatric adult patient l4654 condition previously treated use bovine pegamedase part enzyme replacement therapy l4655 ada-scid genetically inherited disorder rare characterized deficiency adenosine deaminase enzyme patient suffering disease often present compromised immune system condition characterized low level white blood cell immunoglobulin level result severe recurring infection l4656 
Inotersen,inotersen transthyretin-directed antisense oligonucleotide treatment polyneuropathy caused hereditary transthyretin-mediated amyloidosis adult fda approved october 2018 l11761 inotersen shown improve course neurologic disease quality life patient hereditary transthyretin amyloidosis a39493 hereditary transthyretin amyloidosis caused single-nucleotide variant gene encoding transthyretin ttr lead transthyretin misfolding deposition amyloid substance systemically progressive amyloid accumulation may lead multiorgan dysfunction death a39493 ,inotersen transthyretin-directed antisense oligonucleotide indicated treatment polyneuropathy hereditary transthyretin-mediated amyloidosis adult l11761 
MK-1454, synthetic cyclic dinucleotide cdn agonist stimulator interferon gene protein sting potential immunoactivating antineoplastic activity upon intratumoral administration sting agonist mk-1454 bind sting activates sting pathway promotes ikk-related kinase tank-binding kinase 1 tbk1 signaling activates nuclear factor-kappa b nf-kb interferon regulatory factor 3 irf3 immune cell tumor microenvironment lead production pro-inflammatory cytokine including interferon ifns specifically expression ifn-beta ifnb enhances cross-presentation tumor-associated antigen cd8alpha-positive cd103-positive dendritic cell dc cytotoxic lymphocyte ctls result ctl-mediated immune response tumor cell cause tumor cell lysis l4741 ,
ADU-S100,adu-s100 miw815 synthetic cyclic dinucleotide cdn agonist activator stimulator interferon gene sting receptor crucial activate innate endogenous immune system adu-s100 miw815 activates known human mouse sting effectively induces expression cytokine chemokines leading robust durable antigen-specific t-cell mediated immune response cancer cell l4742 ,
Larotrectinib,larotrectinib orally administered tropomyosin receptor kinase trk inhibitor demonstrated antineoplastic activity upon administration larotrectinib bind trk thereby preventing neurotrophin-trk interaction trk activation result induction cellular apoptosis inhibition cell growth tumor overexpress trk trk receptor tyrosine kinase activated neurotrophins mutated variety cancer cell type play important role tumor cell growth survival originally discovered array biopharma agent ultimately licensed loxo oncology 2013 larotrectinib another example innovative new cancer therapy medication target key specific genetic biomarker driver cancer rather particular type tumor l4847 ,larotrectinib tyrosine kinase inhibitor currently indicated treatment adult pediatric patient solid tumor either neurotrophic receptor tyrosine kinase ntrk gene fusion without known acquired resistance mutation b metastatic surgical resection likely result severe morbidity c satisfactory alternative treatment progressed following treatment fda label moment us larotrectinib approved auspex accelerated approval u fda based overall response rate duration response continuation support indication may contingent upon verification description continued clinical benefit confirmatory trial fda label 
Emapalumab,emapalumab also known ni-0501 fully human monoclonal antibody target interferon gamma emapalumab development sponsored novimmune sa developed sobi fda approved november 20 2018 a38676 l4840 approval emapalumab followed designation orphan drug priority review breakthrough therapy l4840 well emapalumab given status prime ema l4845 ,emapalumab indicated treatment pediatric adult patient primary hemophagocytic lymphohistiocytosis hlh refractory recurrent progressive disease intolerance conventional hlh therapy l4840 hlh condition hyperinflammatory status characterized overwhelming activation normal lymphocyte macrophage lead disturbance hematology profile even death part condition profile report proving massive overexpression interferon-gamma thought drive immune hyperactivation leading organ failure a38676 condition usually developed present symptomatic profile within first month year life symptom consist fever enlarged liver spleen lower number blood cell l4840 
Dabigatran,dabigatran active form orally bioavailable prodrug dabigatran etexilate ,
Mebenil, obsolete fungicide used control various pathogen cereal seed potato ,
Rebeccamycin,rebeccamycin weak topoisomerase inhibitor isolated _nocardia sp_ ,
Calaspargase pegol,asparaginase important agent used treat acute lymphoblastic leukemia a40270 asparagine incorporated protein synthesis protein stopped asparagine absent inhibits rna dna synthesis resulting halt cellular proliferation form basis asparaginase treatment a40270 a40273 f2432 calaspargase pegol also known _asparlas_ asparagine specific enzyme indicated part multi-agent chemotherapy regimen treatment l4890 asparagine specific enzyme derived escherichia coli conjugate l-asparaginase l-asparagine amidohydrolase monomethoxypolyethylene glycol mpeg succinimidyl carbonate sc linker create stable molecule increase half-life decrease dosing frequency fda label a40270 calaspargase pegol _shire_ pharmaceutical approved fda december 20 2018 acute lymphoblastic anemia l4890 , drug asparagine specific enzyme indicated component multi-agent chemotherapeutic regimen treatment acute lymphoblastic leukemia pediatric young adult patient age 1 month 21 year fda label pharmacokinetics calaspargase pegol examined given combination multiagent chemotherapy 124 patient b-cell lineage l4890 fda approval drug based achievement maintenance nadir serum asparaginase activity level 0.1 u/ml administering calaspargase 2500 u/m2 intravenously 3-week interval 
Tagraxofusp,tagraxofusp cd123-directed cytotoxin fusion protein composed human interleukin-3 il-3 genetically fused catalytic translocation domain truncated diphtheria toxin dt produced _escherichia coli_ a253762 a253887 l43702 tagraxofusp received first global approval fda december 21 2018 first fda-approved treatment blastic plasmacytoid dendritic cell neoplasm myeloid malignancy dendritic cell lineage a253762 also approved european commission january 7 2021 l43712 ,tagraxofusp indicated treatment blastic plasmacytoid dendritic cell neoplasm bpdcn u approved use adult pediatric patient 2 year old l43702 europe approved use adult l43712 
Queuine,queuine derivative 7-deazaguanine bacteria posse exclusive ability synthesize queuine salvaged passed plant animal quantity queuine found tomato wheat coconut water milk human cow goat human salvage recover queuine either ingested food gut flora eukaryotic organism including human transform queuine queuosine placing wobble position anticodon several trna including aspartic acid asparagine histidine tyrosine endogenously determined queuine contributes generating various important biochemicals like tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipid others a173830 a173833 a173851 ,current on-going research suggests queuine natural biochemical compound found endogenously human body play essential role generation critical bodily chemical including tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipid others a173830 a173833 a173851 research subsequently proposes queuine could utilized pharmaceutic may considered so-called 'putative longevity vitamin indicated age-delaying and/or prolonged survival functionality perhaps via maintaining ongoing generation aforementioned bodily chemical human body a173830 a173833 a173851 
Ceftobiprole medocaril,ceftobiprole medocaril ceftobiprole prodrug ,
Cannabigerol, natural product found cannabis sativa helichrysum specie ,
Cannabichromene, natural product found cannabis sativa helichrysum specie ,
Cannabivarin, natural product found cannabis sativa ,
Cannabinol,cannabinol cbn physiologically inactive constituent cannabis sativa ,
Turoctocog alfa pegol,turoctocog alfa pegol pegylated version turoctocog alfa novo nordisk 's brand name esperoct turoctocog alfa pegol n8-gp approved u fda february 19 2019 fundamentally n8-gp moiety identical turoctocog alfa recombinant human clotting factor viii rfviii truncated b-domain made sequence coding 10 amino acid n-terminus 11 amino acid c-terminus naturally occurring b-domain f3685 turoctocog alfa produced chinese hamster ovary cho cell without addition human animal-derived material f3685 secretion rfviii molecule cleaved c-terminal heavy chain hc amino acid 720 monoclonal antibody binding c-terminal position used purification process allowing isolation intact rfviii a31504 developed novo nordisk approved u fda october 16 2013 l1104 essential difference turoctocog alfa n8-gp however specific attachment 40-kda polyethylene glycol peg group specific _o_-glycan truncated b-domain general turoctocog alfa rfviii structure a31506 a32069 modification general turoctocog alfa rfviii structure make n8-gp extended half-life factor viii molecule factor viii replacement therapy patient factor viii deficiency hemophilia f3649 turoctocog alfa pegol valuable expansion drug therapy available treating hemophilia ultimately provides le burdensome convenient dosing regimen patient le frequent turoctocog alfa ,turoctocog alfa pegol indicated use adult child hemophilia on-demand treatment control bleeding episode perioperative management bleeding routine prophylaxis reduce frequency bleeding episode indicated treatment von willebrand disease l41000 
Hyaluronidase,hyaluronidase enzyme used improve absorption dispersion parenterally administered fluid drug contrast agent l13338 action hyaluronidase first described 1936 named 1939 a199026 early research hyaluronidase identified `` spreading factor '' allowed increased permeability connective tissue a199026 hyaluronidase used surgical setting least past 60 year improve diffusion local anesthetic a199047 hyaluronidase first used prescription product united state 5 may 2004 l13338 ,hyaluronidase indicated subcutaneous fluid administration hydration increasing resorption radiopaque agent subcutaneous urography l13338 hyaluronidase also indicated multiple route increase dispersion injectable drug l13338 
Polymyxin B,polymyxin b discovered 1940s a176429 basic polypeptide eight amino acid cationic detergent action cell membrane a176426 polymyxin b used infection gram-negative organism may neurotoxic nephrotoxic a176426 fda label gram-positive bacteria fungi gram-negative cocci resistant a176426 appropriate treatment infection urinary tract meninges blood stream caused susceptible strain _pseudomonas aeruginosa_ fda label polymyxin b narrow therapeutic index use limited unlikely used first line a176429 ,polymyxin b indicated treatment infection urinary tract meninges blood stream caused susceptible strain pseudomonas aeruginosa /i fda label 
Mecasermin rinfabate,mecasermin rinfabate approved severe primary insulin-like growth factor igf deficiency patient gh gene deletion developed antibody growth hormone gh a176020 mecasermin rinfabate similar db01277 drug contain recombinant dna origin insulin-like growth factor 1 igf-1 mecasermin rinfabate however already bound recombinant dna origin insulin-like growth factor binding protein 3 igfbp-3 a12605 binding igf-1 igfbp-3 said extend half life reduce clearance igf-1 patient growth hormone resistant syndrome low level igfbp-3 though may represent 500 patient worldwide a176065 mecasermin rinfabate manufactured insmed incorporated brand name iplex approved fda 2005 l5722 2007 insmed withdrew application marketing authorization european medicine agency f4075 ,mecasermin rinfabate approved treatment severe primary insulin-like growth factor igf deficiency patient gh gene deletion developed antibody growth hormone gh a176020 severe primary igf-1 deficiency defined fda label height standard deviation sd score le equal 3 sd normal b basal igf-1 sd score le equal 3 sd normal c normal normal level growth hormone 2007 insmed mecasermin rinfabate 's manufacturer made agreement tercica mecasermin 's manufacturer mecasermin would longer available indication could developed non short stature condition severe insulin resistance myotonic muscular dystrophy hiv associated adipose redistribution syndrome a176125 
Hydroxystilbamidine,hydroxystilbamidine isethionate used therapy patient nonprogressive blastomycosis skin pulmonary systemic blastomycosis child fewer side effect amphotericin b. hydroxystilbamidine isethionate also used pathology diagnostic purpose ,used treatment nonprogressive blastomycosis skin mycoses 
Solriamfetol,solriamfetol marketed brand name sunosi jazz pharmaceutical united state dopamine norepinephrine reuptake inhibitor dnri indicated treating daytime sleepiness associated narcolepsy obstructive sleep apnea fda label solriamfetol given fda approval 2019 fda label ,solriamfetol indicated treatment daytime sleepiness associated obstructive sleep apnea narcolepsy treatment underlying airway obstruction apnea patient fda label a176534 a176744 
Agrostis gigantea top,agrostis gigantea top flowering part agrostis gigantea plant agrostis gigantea top mainly used allergenic testing ,
Catfish,catfish unspecified allergenic extract used allergenic testing ,
Red pepper,red pepper allergenic extract used allergenic testing ,
Remdesivir,severe acute respiratory syndrome coronavirus 2 sars-cov-2 causative agent coronavirus disease 2019 covid-19 respiratory disease capable progressing viral pneumonia acute respiratory distress syndrome ards covid-19 fatal like rna virus sars-cov-2 depends rna-dependent rna polymerase rdrp enzyme complex genomic replication inhibited class drug known nucleoside analogue a222398 remdesivir gs-5734 adenosine triphosphate analogue first described literature 2016 potential treatment ebola a191379 a222393 broad antiviral activity remdesivir suggested mechanism action a222398 date demonstrated _in vitro_ activity _arenaviridae_ _flaviviridae_ _filoviridae_ _paramyxoviridae_ _pneumoviridae_ _coronaviridae_ viral family a222393 remdesivir activity _coronaviridae_ family first demonstrated 2017 a191382 leading considerable interest remdesivir possible treatment covid-19 a191427 a198810 remdesivir confirmed non-obligate chain terminator rdrp sars-cov-2 related sars-cov mers-cov a222398 investigated multiple covid-19 clinical trial l12174 l12177 initially granted fda emergency use authorization eua may 1st 2020 l13236 remdesivir fully approved fda treatment covid-19 october 22 2020 l18438 remdesivir currently marketed trademark name veklury gilead science inc. l18438 remdesivir also approved european commission july 3 2020 l39640 remdesivir combination baricitinib treatment covid-19 granted fda emergency use authorization november 19 2020 l22619 ,remdesivir indicated treatment adult pediatric patient 28 day age older weighing least 3 kg coronavirus disease 2019 covid-19 infection requiring hospitalization also indicated treatment non-hospitalized patient mild-to-moderate covid-19 high risk progression severe covid-19 including hospitalization death l18438 remdesivir originally granted fda emergency use authorization eua l12609 may 1 2020 use adult child suspected confirmed covid-19 hospital setting spo2 ≤94 l13239 following fda approval eua revised cover hospitalized pediatric patient 3.5 40 kg well 12 year age weigh least 3.5 kg suspected laboratory-confirmed covid-19 l13236 l39645 on-label eua indication patient needing invasive mechanical ventilation extracorporeal membrane oxygenation ecmo treated 5 day including loading dose day 1 may extended 10 day show improvement patient requiring invasive mechanical ventilation ecmo treated 10 day l13239 l18438 europe remdesivir approved treatment adult adolescent weighing least 40 kg pneumonia requiring supplemental oxygen low- high-flow oxygen non-invasive ventilation start treatment also indicated treatment covid-19 adult require supplemental oxygen increased risk progressing severe covid-19 l39645 
Risankizumab,risankizumab fully humanized igg1 monoclonal antibody mab directed interleukin 23 il-23 l39885 gained first global approval japan march 2019 followed approval canada u europe april 2019 a254716 risankizumab used treat plaque psoriasis psoriatic arthritis crohn 's disease l39885 l44191 l44231 risankizumab investigated atopic dermatitis a254716 ,risankizumab indicated treat moderate-to-severe plaque psoriasis adult candidate systemic therapy phototherapy l39885 l44191 l44231 active psoriatic arthritis adult l39885 l44191 l44231 canada europe may used alone combination conventional non-biologic disease-modifying antirheumatic drug cdmard e.g. methotrexate l44191 l44231 moderately severely active crohn 's disease adult l39885 l44191 l44231 canada used patient inadequate response intolerance demonstrated dependence corticosteroid inadequate response intolerance loss response immunomodulators biologic therapy l44191 
Cycloguanil,cycloguanil active metabolite proguanil ,
Rivoceranib,rivoceranib investigation clinical trial nct02726854 apatinib second-line treatment advanced pancreatic cancer ,
Etrasimod,etrasimod investigation clinical trial nct03945188 etrasimod versus placebo treatment moderately severely active ulcerative colitis ,
Peginterferon lambda-1a,peginterferon lambda-1a investigation clinical trial nct01754974 safety efficacy study peginterferon lambda-1a vs. peginterferon alfa-2a plus ribavirin subject genotype 1 hepatitis c ,
PF-06459988,pf-06459988 investigation clinical trial nct02297425 study patient egfrm epidermal growth factor receptor mutant lung cancer ,
Pamiparib,pamiparib investigation clinical trial nct03933761 pamiparib fusion positive reversion negative high grade serous ovarian cancer carcinosarcoma brca1/2 gene mutation progression substrate poly adp ribose polymerase inhibitbor parpi chemotherapy ,
Lanraplenib,lanraplenib investigation clinical trial nct03285711 safety efficacy filgotinib lanraplenib adult lupus membranous nephropathy lmn ,
Polyacrylamide (crosslinked; 2 mole percent bisacrylamide),polyacrylamide crosslinked 2 mole percent bisacrylamide investigation clinical trial nct00629083 bulking agent treatment stress urinary incontinence female ,
DCFBC F-18,dcfbc f-18 investigation clinical trial nct02190279 18f-dcfbc pet/ct prostate cancer ,
Lifirafenib,lifirafenib investigation clinical trial nct03641586 study bgb-283 chinese subject local advanced metastatic malignant solid tumor ,
Balipodect,balipodect investigation clinical trial nct01892189 effect tak-063 preventing ketamine-induced brain activity change well psychotic-like symptom healthy male adult ,
Cavosonstat,cavosonstat investigation clinical trial nct02589236 study cavosonstat n91115 patient cf homozygous f508del-cftr mutation ,
Camrelizumab,camrelizumab investigation clinical trial nct03417895 shr-1210 combined apatinib treatment ed-sclc failure first line standard therapy ,
Murepavadin,murepavadin investigation clinical trial nct02110459 pharmacokinetics safety pol7080 patient renal impairment ,
Setrusumab,setrusumab investigation clinical trial nct01406548 safety efficacy multiple dosing regimen bps804 post menopausal woman low bone mineral density ,
LGD-6972,lgd-6972 investigation clinical trial nct01919684 study evaluate safety tolerability pharmacokinetics pharmacodynamics lgd-6972 healthy subject subject type 2 diabetes mellitus ,
Pegzilarginase,pegzilarginase investigation clinical trial nct02488044 phase 1/2 study aeb1102 patient arginase deficiency ,
Vofatamab,vofatamab investigation clinical trial nct02401542 dose escalation expansion study vofatamab b-701 treatment locally advanced metastatic urothelial cell carcinoma ,
Tofersen,tofersen investigation clinical trial nct03764488 study evaluate safety tolerability distribution microdose radiolabeled biib067 99mtc-mag3-biib067 co-administered biib067 healthy adult ,
Diroximel fumarate,multiple sclerosis m chronic debilitating neurological disease lead profound cognitive physical symptom severely affecting quality life a176474 main cause neurological disability caused trauma young adult population north america europe relapsing-remitting form m lead neurological symptom resolve recur periodically 80 patient suffering disease relapsing-remitting ms. a187535 diroximel fumarate new drug fumarate class formulated treat various relapsing form m drug bioequivalent dimethyl fumarate a187544 l9626 initially manufactured 2013 le likely cause gastrointestinal side effect owing unique chemical structure diroximel fumarate formulated alkermes collaboration biogen approved fda october 2019 l9626 ema november 2021 l39225 ,diroximel fumarate indicated treatment relapsing form multiple sclerosis m adult specifically active secondary progressive disease clinically isolated syndrome well relapsing-remitting ms. l9623 l9629 l9632 
Gancotamab,gancotamab investigation clinical trial nct02213744 mm-302 plus trastuzumab v chemotherapy physician 's choice plus trastuzumab her2-positive locally advanced/metastatic breast cancer patient ,
Fenebrutinib,fenebrutinib investigation clinical trial nct03174041 drug-drug interaction study gdc-0853 midazolam itraconazole rosuvastatin simvastatin ,
Nerofe,nerofe investigation clinical trial nct03059615 phase 2a open-label two stage study nerofe nerofe doxorubicin subject aml md ,
BMS-830216,bms-830216 investigation clinical trial nct00909766 safety pharmacokinetics pharmacodynamics study evaluate bms-830216 obese subject ,
Prasinezumab,prasinezumab investigation clinical trial nct03100149 study evaluate efficacy prasinezumab ro7046015/prx002 participant early parkinson 's disease ,
Dectrekumab,dectrekumab investigation clinical trial nct00987545 efficacy 2 part study identification keloid biomarkers effect qax576 keloid recurrence ,
Zatolmilast,bpn-14770 investigation clinical trial nct02840279 multiple ascending dose study bpn14770 healthy young elderly male female subject ,
GDC-0425,gdc-0425 investigation clinical trial nct01359696 study evaluating safety tolerability pharmacokinetics gdc-0425 administered without gemcitabine patient refractory solid tumor lymphoma ,
AZD-5991,azd-5991 investigation clinical trial nct03218683 study azd5991 relapsed refractory haematologic malignancy ,
RO-5045337,ro-5045337 investigation clinical trial nct01164033 study ro5045337 patient solid tumor ,
Glepaglutide,glepaglutide investigation clinical trial nct00868660 healthy normal single ascending dose crohn 's patient multiple ascending dose ,
AZD-3759,azd-3759 investigation clinical trial nct03360929 evaluate safety tolerability pharmacokinetics anti-tumor activity azd3759 ,
Talacotuzumab,talacotuzumab igg1 monoclonal antibody directed toward il3 receptor α–subunit also known cd123 investigation clinical trial nct01632852 study csl362 patient cd123+ acute myeloid leukemia currently remission ,
SEphB4-HSA,sephb4-hsa investigation clinical trial nct02495896 recombinant ephb4-hsa fusion protein standard chemotherapy regimen treating patient advanced metastatic solid tumor ,
Afasevikumab,afasevikumab investigation clinical trial nct01480310 study investigate safety pharmacokinetics immunogenicity subcutaneous mcaf5352a healthy volunteer ,
PF-06821497,pf-06821497 investigation clinical trial nct03460977 pf-06821497 treatment relapsed/refractory sclc castration resistant prostate cancer follicular lymphoma ,
GP-100 antigen,gp-100 antigen investigation clinical trial nct00006385 vaccine therapy without biological therapy treating patient metastatic melanoma ,
Lanifibranor,lanifibranor investigation clinical trial nct03008070 phase 2b study nash ass iva337 ,
ONO-2952,ono-2952 investigation clinical trial nct01887002 study evaluate effect ono-2952 pain perception produced rectal distention female subject diarrhea-predominant irritable bowel syndrome ibs-d ,
AMY-101,amy-101 investigation clinical trial nct03694444 study c3 complement inhibitor amy-101 adult gingivitis ,
Iodine I-125,iodine i-125 investigation clinical trial nct00079417 neoadjuvant carboplatin vincristine standard local ophthalmic therapy treating patient intraocular retinoblastoma ,
Piflufolastat F 18,prostate cancer common non-cutaneous malignancy affecting men north america a235344 despite ongoing challenge prostate cancer therapy difficulty imaging extent location tumor metastasis recurrence l34319 image generated positron emission tomography pet le detailed obtained via mri ct sensitive reveal cancerous tissue area body provided tissue expressing appropriate target protein prostate-specific membrane antigen psma transmembrane glycoprotein expressed many tissue play role folate uptake neurotransmitter release expressed prostate level roughly 1000-fold greater elsewhere body even higher prostate cancer tissue a235169 become desirable target pet imaging prostate cancer tissue piflufolastat f18 also called f-18 -dcfpyl urea-based radiopharmaceutical bind psma allows visualization cancerous prostate tissue first approved fda may 2021 l34324 brand name pylarify aim allow earlier accurate detection suspected prostate cancer metastasis recurrence ,piflufolastat f18 indicated positron emission tomography pet prostate-specific membrane antigen psma positive lesion men prostate cancer suspected metastasis candidate initial definitive therapy men suspected recurrence prostate cancer based elevated prostate-specific antigen psa level l34294 
Avexitide,avexitide investigation clinical trial nct02996812 evaluation single ascending dos subcutaneous exendin 9-39 patient post-bariatric hypoglycemia ,
Demplatin pegraglumer,demplatin pegraglumer investigation clinical trial nct02043288 combination therapy nc-6004 gemcitabine versus gemcitabine alone pancreatic cancer ,
Lumicitabine,lumicitabine investigation clinical trial nct03010059 study ass relative bioavailability jnj64041575 administered 2 different new concept formulation oral suspension tablet compared respective current formulation ass effect food pharmacokinetics 2 new concept formulation ,
Anetumab ravtansine,anetumab ravtansine investigation clinical trial nct03455556 anetumab ravtansine atezolizumab treating participant advanced non-small cell lung cancer ,
AZD-1656,azd-1656 investigation clinical trial nct00747175 study evaluate safety tolerability p-glucose multiple ascending oral dos azd1656 type 2 diabetes ,
Isatuximab,isatuximab formerly sar650984 humanized igg1-derived monoclonal antibody mab produced chinese hamster ovary cho cell line l12099 a191799 structurally isatuximab comprised two identical immunoglobulin kappa light chain two identical immunoglobulin gamma heavy chain l12099 cytolytic antibody targeted cd38 glycoprotein found surface immune cell highly expressed malignant plasma cell multiple myeloma l12099 along daratumumab another anti-cd38 mab isatuximab constitutes novel treatment modality patient difficult-to-treat multiple myeloma following three consecutive year yearly `` antibody watch '' list published `` mab '' peer-reviewed scientific journal dedicated antibody research a38676 a191826 a191829 isatuximab granted orphan drug designation approved march 2nd 2020 treatment multiple myeloma l12099 l12102 manufactured sanofi-aventis u.s. brand name sarclisa l12102 ,isatuximab indicated combination pomalidomide dexamethasone treatment multiple myeloma adult received least two prior therapy including lenalidomide proteasome inhibitor l12099 also indicated combination carfilzomib dexamethasone treatment adult patient relapsed refractory multiple myeloma received 1 3 prior line therapy l12099 
Procalcitonin,procalcitonin investigation clinical trial nct03440060 procalcitonin-guided antibiotic therapy severe exacerbation copd ,
PF-232798,pf-232798 investigation clinical trial nct01140425 study evaluate effect multiple oral dose pf-00232798 qt interval healthy subject ,
Lanabecestat,lanabecestat investigation clinical trial nct03499041 study ly3314814 participant liver impairment ,
Ginsenoside B2,ginsenoside b2 investigation clinical trial nct00781534 clinical trial ginseng diabetes ,
Biropepimut-S,biropepimut-s investigation clinical trial nct02873819 safety efficacy study gl-0817 cyclophosphamide prevention recurrence squamous cell carcinoma oral cavity ,
Pegapamodutide,pegapamodutide investigation clinical trial nct02188303 study ly2944876 healthy japanese non-japanese participant ,
Osocimab,osocimab investigation clinical trial nct03276143 factor xia inhibition prevention venous thromboembolism patient undergoing total knee arthroplasty ,
Cobitolimod,cobitolimod investigation clinical trial nct03178669 efficacy cobitolimod patient moderate severe active ulcerative colitis ,
Profoxydim,profoxydim investigation clinical trial nct02728011 pilot trial comparing computerised cognitive exercise tetri adolescent adhd ,
Macozinone,macozinone investigation clinical trial nct03036163 phase 1 study pbtz169 ,
SB-649868,sb-649868 investigation clinical trial nct01030939 study investigate safety tolerability pharmacokinetics cardiac function repeat dos sb-649868 healthy-volunteers ,
Balovaptan,balovaptan investigation clinical trial nct01793441 study rg7314 investigate efficacy safety individual autism spectrum disorder asd ,
Icrucumab,icrucumab investigation clinical trial nct01111604 study imc-1121b imc-18f1 colorectal cancer ,
Danvatirsen,danvatirsen investigation clinical trial nct03334617 phase ii umbrella study novel anti-cancer agent patient nsclc progressed anti-pd-1/pd-l1 containing therapy ,
Topramezone,topramezone investigation clinical trial nct00559520 role preoperative oral immunonutrition major vascular surgery ,
Modotuximab,modotuximab investigation clinical trial nct03549338 sym004 versus futuximab modotuximab patient mcrc ,
ABX-464,abx-464 investigation clinical trial nct03905109 safety evaluation abx464 patient moderate severe active crohn 's disease ,
Uproleselan,uproleselan novel specific e-selectin antagonist investigation clinical trial nct02306291 study determine safety pharmacokinetics efficacy gmi-1271 combination chemotherapy aml ,
Fluoromisonidazole F-18,fluoromisonidazole f-18 investigation clinical trial nct01507428 study positron emission tomography computed tomography guiding radiation therapy patient stage iii non-small cell lung cancer ,
BMS-986012,bms-986012 human antifucosyl-gm1 antibody investigation clinical trial nct02815592 trial bms-986012 combination platinum etoposide ,
Polydioxanone,polydioxanone investigation clinical trial nct00998907 pd plus wound infection laparotomy ,
Recombinant human lecithin:cholesterol acyltransferase,recombinant human lecithin cholesterol acyltransferase investigation clinical trial nct03578809 study evaluate safety efficacy medi6012 acute st elevation myocardial infarction ,
Olendalizumab,olendalizumab investigation clinical trial nct01883544 study evaluate safety tolerability pharmacokinetics pharmacodynamics alxn1007 healthy male female subject ,
SUVN-G3031,suvn-g3031 investigation clinical trial nct02342041 study investigate safety tolerability pharmacokinetics suvn-g3031 healthy subject ,
Polydextrose,polydextrose investigation clinical trial nct02258750 assessing polydextrose containing soup food intake appetite biomarkers satiation satiety ,
Telisotuzumab,telisotuzumab investigation clinical trial nct01472016 study abt-700 subject advanced solid tumor ,
TOP-1288,top-1288 investigation clinical trial nct02888379 phase 2a study evaluate safety/tolerability efficacy top1288 200 mg rectal solution daily 4 week ulcerative colitis ,
Ripretinib,ripretinib kinase inhibitor used treatment advanced gastrointestinal stromal tumor gist adequately responded kinase inhibitor sunitinib imatinib ripretinib also known qinlock manufactured deciphera pharmaceutical initially approved fda may 15 2020 l13769 first drug approved fourth-line therapy specific setting prior treatment minimum 3 kinase inhibitor l13778 ,ripretinib indicated treat adult diagnosed advanced gastrointestinal stromal tumor gist prior therapy least 3 kinase inhibitor including imatinib l13769 
Centanafadine,centanafadine investigation clinical trial nct02827513 phase 1 study investigate safety tolerance food effect pharmacokinetics pharmacodynamics single multiple dos extended release formulation centanafadine ctn young healthy subject ,
Codrituzumab,codrituzumab investigation clinical trial nct01507168 study ro5137382 gc33 patient advanced metastatic hepatocellular carcinoma ,
Dordaviprone,dordaviprone onc-201 investigation clinical trial nct03394027 onc201 recurrent/refractory metastatic breast cancer advanced endometrial carcinoma ,
Filgotinib,rheumatoid arthritis ra chronic autoimmune systemic inflammatory disease cause synovial joint symptom limit range motion severe case a221451 a221456 disease associated extra-articular manifestation progressive disability comorbidities including cardiovascular disease mental disorder a189165 50-70 patient ra unable achieve sustained clinical remission despite availability several treatment including disease-modifying anti-rheumatic drug dmards like methotrexate interleukin-6 il-6 blocker tumor necrosis factor tnf inhibitor a189165 new therapeutic development target inflammatory pathway implicated ra including janus kinase jak signaling pathway seen filgotinib a221456 four jak subtypes include jak1 jak2 jak3 tyrosine kinase 2 a189165 non-selective jak inhibitor like tofacitinib target jak1 jak3 subtypes minimal activity jak2 contrast newly approved filgotinib highly selective jak1 inhibitor a189165 jak2 jak3 play important role immune hematologic function therefore selectivity jak1 aim improve safety profile filgotinib maintaining clinical efficacy a189165 filgotinib currently reserved patient tolerate dmards unable achieve remission response one dmards l16616 ,filgotinib indicated treatment active moderate severe rheumatoid arthritis alone combination methotrexate l16616 filgotinib currently reserved patient unable tolerate responded adequately one disease-modifying anti-rheumatic drug dmards l16616 filgotinib also indicated treatment moderately severely active ulcerative colitis adult patient inadequate response lost response intolerant either conventional therapy biologic agent l39209 
Bimiralisib,bimiralisib investigation clinical trial nct02723877 pqr309 eribulin metastatic her2 negative triple-negative breast cancer piqhasso ,
Azintuxizumab vedotin,azintuxizumab vedotin investigation clinical trial nct02951117 study venetoclax abbv-838 combination therapy dexamethasone participant multiple myeloma whose cancer come back response recent cancer treatment ,
Tibulizumab,tibulizumab investigation clinical trial nct03736772 study ly3090106 japanese caucasian healthy participant ,
Nebicapone,nebicapone investigation clinical trial nct03097211 effect bia 6-512 steady-state levodopa pharmacokinetics single-dose levodopa/benserazide 200/50 mg single-dose levodopa/benserazide 200/50 mg plus single-dose nebicapone 150 mg ,
Deleobuvir,deleobuvir investigation clinical trial nct01983566 effect food increased gastric ph value bioavailability single dose bi 207127 healthy caucasian japanese subject ,
Relatlimab,relatlimab human igg4 monoclonal antibody novel immune checkpoint inhibitor target lymphocyte activation gene-3 lag-3 a246165 l41265 first commercially developed anti-lag-3 antibody entering clinical trial 2013 a246155 garnered interest treatment variety cancer including leukemia a246160 melanoma l41305 immune checkpoint inhibitor limited efficacy used alone drug like relatlimab trialed combination checkpoint inhibitor example pd-1 inhibitor like nivolumab ctla-4 inhibitor like ipilimumab enhance efficacy a246155 relatlimab received fda approval march 2022 alongside pd-1 inhibitor nivolumab combination product opdualag bristol-myers squibb treatment unresectable metastatic melanoma l41265 l41300 first anti-lag-3 antibody demonstrate benefit phase 3 study well first receive fda approval l41300 ,relatlimab indicated combination nivolumab combination product opdualag treatment adult pediatric patient ≥12 year old unresectable metastatic melanoma l41265 
PRM-151,prm-151 investigation clinical trial nct01981850 phase 2 study prm-151 subject myelofibrosis ,
Myrcludex B,myrcludex b investigation clinical trial nct03546621 multicenter open-label randomized clinical study ass efficacy safety 3 dos myrcludex b 24 week combination tenofovir compared tenofovir alone suppress hbv replication patient chronic hepatitis ,
TC-6987,tc-6987 investigation clinical trial nct01296087 tc-6987 treatment mild moderate asthma ,
2-(aminomethyl)phenol,2- aminomethyl phenol investigation clinical trial nct03556319 2-hoba multiple dosing study older adult ,
PF-05089771,pf-05089771 investigation clinical trial nct01529671 safety tolerability study pf-05089771 healthy subject subject otseoarthritis knee ,
Avadomide,avadomide investigation clinical trial nct02031419 novel combination cc-122 cc-223 cc-292 rituximab diffuse large b-cell lymphoma follicular lymphoma ,
Tadekinig alfa,tadekinig alfa investigation clinical trial nct03113760 therapeutic use tadekinig alfa nlrc4 mutation xiap deficiency ,
Fosifloxuridine nafalbenamide,fosifloxuridine nafalbenamide investigation clinical trial nct03428958 safety study nuc-3373 combination standard agent used colorectal cancer treatment ,
Ensartinib,ensartinib investigation clinical trial nct03420508 treating patient melanoma alk alteration ensartinib ,
PF-06815345,pf-06815345 investigation clinical trial nct02654899 single dose study pf-06815345 healthy subject ,
Brolucizumab,brolucizumab also known rth258 esba1008 a187211 monoclonal antibody indicated treat neovascular age related macular degeneration l9089 brolucizumab granted fda approval october 2019 l9089 ,brolucizumab monoclonal antibody indicated treat neovascular age related macular degeneration a187208 l9089 
Human interleukin-2,human interleukin-2 investigation clinical trial nct03475134 til-act nma chemo il-2 nivo rescue mmel ,
Amcasertib,amcasertib investigation clinical trial nct02483247 study bbi503 combination selected anti-cancer therapeutic adult patient advanced cancer ,
Parsaclisib,parsaclisib investigation clinical trial nct03126019 open-label study parsaclisib relapsed refractory follicular lymphoma citadel-203 ,
AZD-8848,azd-8848 investigation clinical trial nct01818869 ass safety tolerability pharmacokinetics pharmacodynamics multiple dos azd8848 healthy subject ,
Remetinostat,remetinostat investigation clinical trial nct02213861 efficacy safety tolerability study shape ia ib iia cutaneous t-cell lymphoma ,
PF-5190457,pf-5190457 investigation clinical trial nct01522807 study three pf-05190457 formulation healthy volunteer ,
Xentuzumab,xentuzumab investigation clinical trial nct02191891 xentuzumab bi 836845 plus afatinib patient epidermal growth factor receptor egfr mutant non-small cell lung cancer nsclc ,
Lucerastat,lucerastat investigation clinical trial nct03425539 efficacy safety lucerastat oral monotherapy adult subject fabry disease ,
Enadenotucirev,enadenotucirev investigation clinical trial nct02636036 phase study enadenotucirev pd-1 inhibitor subject metastatic advanced epithelial tumor ,
Cergutuzumab amunaleukin,cergutuzumab amunaleukin investigation clinical trial nct02004106 study evaluate safety pharmacokinetics efficacy ro6895882 participant advanced and/or metastatic solid tumor ,
AZD-4017,azd-4017 investigation clinical trial nct01173471 phase iia study ass tolerability safety efficacy azd4017 raised intra-ocular pressure ,
TAS-116,tas-116 investigation clinical trial nct02965885 study tas-116 patient solid tumor ,
Lintuzumab,lintuzumab investigation clinical trial nct00016159 chemotherapy plus monoclonal antibody treating patient acute promyelocytic leukemia ,
Liafensine,liafensine investigation clinical trial nct00892840 multiple-ascending dose study ,
Cefiderocol,cefiderocol cephalosporin antibacterial drug exerts mechanism action similar β-lactam antibiotic fda label unlike agent category cefiderocol siderophore able undergo active transport bacterial cell iron channel a189057 represents significant addition antibacterial treatment option proven effective vitro multidrug resistant strain including extended spectrum β-lactamase producer carbapenemase producing bacteria cefiderocol granted designation qualified infectious disease product granted priority review status fda november 14 2019 l10893 indicated use complicated urinary tract infection patient limited alternative treatment available fda label indication supported positive clinical trial composed 448 patient complicated urinary tract infection demonstrated 72.6 rate symptom resolution bacterial eradication cefiderocol compared 54.6 comparator imipenem/cilastatin a189150 concern noted trial 0.3 higher rate cause mortality cause determined ,cefiderocol indicated treatment complicated urinary tract infection without pyelonephritis fda label 
Uteroglobin,uteroglobin investigation clinical trial nct01473264 safety pk anti-inflammatory effect cc10 protein premature infant respiratory distress syndrome rds ,
Oliceridine,severe acute pain occurs nociceptive signalling involving ascending descending spinal pathway nerve conductance mediated part action opioid receptor a218041 a218046 opioid receptor seven-transmembrane g-protein-coupled receptor gpcrs μ-opioid receptor subtype predominantly targeted responsible effect opioid agonist a218031 a218046 however due ability opioid agonist bind target well activation additional downstream pathway opioid receptor involving β-arrestin beneficial analgesic effect opioids coupled severe adverse effect constipation respiratory depression a218026 a218031 a218036 a218041 a218046 oliceridine formerly known trv130 `` biased agonist '' μ-opioid receptor preferentially activating g-protein pathway minimal receptor phosphorylation recruitment β-arrestin a218026 a218031 acting biased agonist oliceridine provides comparable analgesia compared traditional opioids morphine comparable decreased risk opioid-related adverse effect constipation respiratory depression a218026 a218031 a218051 a218056 a218061 a218066 a218071 l15516 oliceridine first reported 2013 a218026 a218086 initially approved fda due concern raised anesthetic analgesic drug product advisory committee a218041 oliceridine gained fda approval august 7 2020 currently marketed trevena inc olinvyk™ l15516 ,oliceridine indicated management acute pain adult severe enough require intravenous opioid analgesic acceptable alternative treatment exist l15516 
CEP-9722,cep-9722 investigation clinical trial nct01345357 study cep-9722 combination gemcitabine cisplatin patient advanced solid tumor mantle cell lymphoma ,
Lorecivivint,lorecivivint investigation clinical trial nct03246399 study safety tolerability pharmacokinetics sm04690 injectable suspension following single intradiscal injection subject degenerative disc disease ,
Imgatuzumab,imgatuzumab investigation clinical trial nct01326000 study ro5083945 combination folfiri versus folfiri plus cetuximab folfiri alone second line treatment patient metastatic colorectal cancer ,
PF-05180999,pf-05180999 investigation clinical trial nct01530529 study ass relative bioavailability modified-release formulation pf-05180999 ,
BIO-11006,bio-11006 investigation clinical trial nct03202394 evaluation safety efficacy bio-11006 inhalation solution patient ards ,
PF-04620110,pf-04620110 investigation clinical trial nct01146327 multiple dose study pf-04620110 healthy overweight obese subject ,
IQP-0528,iqp-0528 investigation clinical trial nct03082690 imquest iqp duogel phase 1 pharmacokinetic study ,
Derazantinib,derazantinib investigation clinical trial nct03230318 derazantinib subject fgfr2 gene fusion positive inoperable advanced intrahepatic cholangiocarcinoma ,
Obicetrapib,obicetrapib investigation clinical trial nct02241772 study effect ta-8995 lp subject elevated lp ,
Vobarilizumab,vobarilizumab investigation clinical trial nct02101073 alx-0061 phase bioavailability study healthy volunteer ,
Spartalizumab,spartalizumab investigation clinical trial nct02605967 safety efficacy study pdr001 patient recurrent metastatic nasopharyngeal carcinoma ,
Galicaftor,galicaftor investigation clinical trial nct03540524 study looking safety tolerability efficacy combination study drug glpg2451 glpg2222 without glpg2737 patient cystic fibrosis ,
Vibegron,vibegron potent selective beta-3 adrenergic receptor β3 agonist relaxes detrusor smooth muscle bladder thereby increasing bladder capacity l28305 vibegron first approved japan september 2018 treatment overactive bladder a226050 condition associated distressing symptom urge urinary incontinence urgency urinary frequency reduced quality life patient december 23 2020 vibegron approved indication adult available oral tablet market name gemtesa l28310 vibegron second beta-3 adrenergic agonist approved treatment overactive bladder following mirabegron approved 2012 unlike mirabegron vibegron le likely associated drug-drug interaction involving cyp3a4 2d6 2c9 enzyme a226065 ,vibegron indicated treatment overactive bladder oab symptom urge urinary incontinence urgency urinary frequency adult l28305 
Selitrectinib,selitrectinib investigation clinical trial nct03215511 phase 1/2 study loxo-195 patient previously treated ntrk fusion cancer ,
Parsatuzumab,parsatuzumab investigation clinical trial nct01366131 study evaluating safety efficacy megf0444a combination carboplatin paclitaxel bevacizumab patient advanced recurrent non-squamous non-small cell lung cancer received prior chemotherapy advanced disease nile ,
Retagliptin,retagliptin investigation clinical trial nct02822534 pharmacokinetics pharmacodynamics study single multiple dose sp2086 type 2 diabetes patient ,
Tavapadon,tavapadon investigation clinical trial nct02262767 study investigate safety tolerability pharmacokinetics pf-06649751 co-administered trimethobenzamide hydrochloride healthy subject ,
ISO-1 F-18,iso-1 f-18 investigation clinical trial nct00968656 assessment cellular proliferation tumor positron emission tomography pet using 18f iso-1 ,
Inclisiran,inclisiran long-acting synthetic small interfering rna sirna directed proprotein convertase subtilisin-kexin type 9 pcsk9 serine protease regulates plasma low-density lipoprotein cholesterol ldl-c level binding pcsk9 messenger rna inclisiran prevents protein translation pcsk9 leading decreased concentration pcsk9 plasma concentration ldl cholesterol a225953 a225958 lowering circulating plasma ldl-c level offer additional benefit reducing risk cardiovascular disease cvd improving cardiovascular outcome hypercholesterolemia major known risk factor cvd a225953 a225958 december 11 2020 european commission ec granted authorization marketing inclisiran first approved sirna treatment adult primary hypercholesterolemia heterozygous familial non-familial mixed dyslipidemia alone combination lipid-lowering therapy l28178 inclisiran later approved fda december 22 2021 treatment heterozygous familial hypercholesterolemia hefh clinical atherosclerotic cardiovascular disease adult l39593 marketed trade name leqvio , europe inclisiran indicated treatment primary hypercholesterolemia heterozygous familial non-familial mixed dyslipidemia adult adjunct diet used combination statin statin lipid-lowering therapy patient reach ldl-c goal maximum tolerated dose statin patient tolerate statin statin contraindicated inclisiran used monotherapy combination lipid-lowering therapy l30468 u inclisiran indicated adjunct diet maximally tolerated statin therapy treatment adult heterozygous familial hypercholesterolemia hefh clinical atherosclerotic cardiovascular disease ascvd require additional lowering lowdensity lipoprotein cholesterol ldl-c l39598 
JHU-75528 C-11,jhu-75528 c-11 investigation clinical trial nct03204305 brain imaging cannabinoid receptor ,
Rovafovir etalafenamide,rovafovir etalafenamide investigation clinical trial nct03472326 efficacy gs-9131 functional monotherapy hiv-1-infected adult failing nucleos ide reverse transcriptase inhibitor-containing regimen ,
Pimasertib,pimasertib investigation clinical trial nct01378377 combination trial pimasertib msc1936369b temsirolimus ,
Emactuzumab,emactuzumab investigation clinical trial nct01494688 study ro5509554 monotherapy combination paclitaxel participant advanced solid tumor ,
Adafosbuvir,adafosbuvir investigation clinical trial nct02894905 study evaluate effect renal impairment pharmacokinetics al-335 ,
Bevacizumab zirconium Zr-89,bevacizumab zirconium zr-89 investigation clinical trial nct01338090 89zr-bevacizumab pet imaging patient neuroendocrine tumor ,
Refanezumab,refanezumab investigation clinical trial nct00833989 safety escalating repeat iv stroke patient ,
Imetelstat,imetelstat investigation clinical trial nct01916187 imetelstat given intravenously alone standard 13-cis-retinoic acid child neuroblastoma ,
Mirikizumab,mirikizumab investigation clinical trial nct03053622 study mirikizumab ly3074828 injection healthy participant ,
Risuteganib,risuteganib investigation clinical trial nct02348918 phase 2 randomized clinical trial luminate® compared avastin® treatment diabetic macular edema ,
Pegvorhyaluronidase alfa,pegvorhyaluronidase alfa investigation clinical trial nct02241187 two stage study single dose pegph20 cetuximab patient pancreatic adenocarcinoma prior surgical resection ,
5-methyl-2'-fluoroarauracil F-18,5-methyl-2'-fluoroarauracil f-18 investigation clinical trial nct02809690 18f-fmau pet/ct diagnosing characterizing prostate cancer ,
Flortaucipir F-18,flortaucipir f-18 also known sup 18 /sup f-t807 sup 18 /sup f-av-1451 small indole molecule synthesized radioactive fluorine isotope a203933 used marker positron emission tomography pet imaging patient suspected alzheimer 's disease crossing blood-brain barrier flortaucipir f-18 bind aggregated tau protein hallmark alzheimer 's disease whose incidence correlate well disease progression a203933 a203936 a203939 although flortaucipir f-18 display low level background binding throughout brain a203936 display off-target binding monoamine oxidase mao-a mao-b well region containing high level melanin neuromelanin iron a203942 a203945 approved fda may 28 2020 sale avid radiopharmaceutical name tauvid™ first fda-approved molecule imaging aggregated tau protein brain l14114 ,flortaucipir f-18 radioactive agent indicated positron emission tomography pet imaging aggregated tau neurofibrillary tangle nfts adult patient evaluation alzheimer 's disease flortaucipir f-18 indicated use patient evaluation chronic traumatic encephalopathy l14114 
CODA-001,coda-001 investigation clinical trial nct01165450 efficacy safety study nexagon persistent corneal epithelial defect ,
Selonsertib,selonsertib investigation clinical trial nct03053050 safety efficacy selonsertib adult nonalcoholic steatohepatitis nash bridging f3 fibrosis ,
Ceralasertib,ceralasertib investigation clinical trial nct03682289 phase ii trial azd6738 alone combination olaparib ,
Branaplam,branaplam investigation clinical trial nct02268552 open label study lmi070 branaplam type 1 spinal muscular atrophy sma ,
Rozanolixizumab,rozanolixizumab investigation clinical trial nct03861481 study ass efficacy safety tolerability rozanolixizumab subject chronic inflammatory demyelinating polyradiculoneuropathy ,
Iboctadekin,iboctadekin investigation clinical trial nct00500058 phase dose-escalation study ass safety biological activity recombinant human interleukin-18 ,
Mavacamten,mavacamten myosin inhibitor indicated treatment adult symptomatic new york heart association nyha class ii-iii obstructive hypertrophic cardiomyopathy hcm received initial u fda approval 2022 one first myosin inhibitor used human a248440 mavacamten also approved health canada october 2022 l44106 ,mavacamten indicated treatment adult symptomatic new york heart association nyha class ii-iii obstructive hypertrophic cardiomyopathy hcm improve functional capacity symptom l41680 l44106 
Tislelizumab,tislelizumab investigation clinical trial nct02660034 safety pharmacokinetics antitumor activity bgb-a317 combination bgb-290 subject advanced solid tumor ,
Satavaptan,satavaptan investigation clinical trial nct00359437 satavaptan prevention ascites recurrence patient ascites due cirrhosis liver ,
PF-06651600,pf-06651600 investigation clinical trial nct02974868 study evaluate efficacy safety profile pf-06651600 pf-06700841 subject alopecia areata ,
Tenofovir exalidex,tenofovir exalidex investigation clinical trial nct01080820 safety tolerability pharmacokinetic study single dose cmx157 healthy volunteer ,
Astuprotimut-R,astuprotimut-r investigation clinical trial nct00257738 0804 gcc mage-a3/hpv 16 vaccine squamous cell carcinoma head neck ,
Amylopectin,amylopectin investigation clinical trial nct01708694 role slowly digesible starch diabetes risk factor ,
Lacnotuzumab,lacnotuzumab investigation clinical trial nct01643850 mcs110 patient pigmented villonodular synovitis pvns ,
Elsulfavirine,elsulfavirine investigation clinical trial nct03706898 study evaluate safety pk elpida® healthy subject patient hepatic impairment ass impact food intake drug-drug interaction antiviral drug ,
Alovudine F-18,alovudine f-18 investigation clinical trial nct02819024 dexamethasone effect patient refractory non-small cell lung cancer using flt positron emission tomography ,
Cobomarsen,cobomarsen investigation clinical trial nct02580552 safety tolerability pharmacokinetics mrg-106 patient mycosis fungoides mf cll dlbcl atll ,
Coleneuramide,coleneuramide investigation clinical trial nct00307749 safety efficacy mcc-257 treatment diabetic polyneuropathy ,
Nicotinamide riboside,nicotinamide riboside investigation clinical trial nct03432871 nicotinamide riboside mitochondrial biogenesis ,
GDC-0927,gdc-0927 investigation clinical trial nct02316509 study gdc-0927 postmenopausal woman locally advanced metastatic estrogen receptor positive breast cancer ,
Serabelisib,serabelisib investigation clinical trial nct02625259 study evaluate relative bioavailability effect food gastric potential hydrogen ph modification pharmacokinetics tak-117 mln1117 healthy participant ,
Menaquinone 6,menaquinone 6 investigation clinical trial nct01194778 comparison efficacy different dosage vitamin k2 ,
MK-8666,mk-8666 investigation clinical trial nct01971554 safety tolerability pharmacodynamics pharmacokinetics mk-8666 participant type 2 diabetes mellitus mk-8666-003 ,
Flurbiprofen axetil,flurbiprofen axetil investigation clinical trial nct02043366 effect butorphanol combined flurbiprofen axetil preventing hyperalgesia induced remifentanil patient ,
Motixafortide,motixafortide investigation clinical trial nct01838395 phase iia study evaluating safety efficacy bl-8040 relapsed/refractory aml patient ,
Aspartyl-alanyl-diketopiperazine,aspartyl-alanyl-diketopiperazine investigation clinical trial nct03349645 open label extension study ass safety long-term treatment ampion severe oa knee ,
BMS-817399,bms-817399 investigation clinical trial nct01404585 proof-of-concept study bms-817399 treat moderate severe rheumatoid arthritis ,
BMS-986141,bms-986141 investigation clinical trial nct02985632 study evaluate pharmacokinetics bms-986141 participant hepatic impairment compared healthy participant ,
LGH-447,lgh-447 investigation clinical trial nct02160951 dose escalation study lgh447 japanese patient relapsed and/or refractory hematologic malignancy ,
Tarloxotinib,tarloxotinib investigation clinical trial nct03743350 nsclc exon 20 her2-activating mutation ,
Florbenazine F-18,florbenazine f-18 investigation clinical trial nct01515384 trial 18f-av-133 positron emission tomography pet ,
PCO-371,pco-371 investigation clinical trial nct02475616 single ascending dose study pco371 healthy volunteer ,
Bermekimab,bermekimab investigation clinical trial nct01384630 safety pharmacokinetics efficacy ra-18c3 subject moderate severe psoriasis ,
BMS-986020,bms-986020 investigation clinical trial nct02017730 evaluate relationship plasma drug level receptor binding lung using pet positron emission tomography healthy volunteer ,
AZD-7687,azd-7687 investigation clinical trial nct01119352 azd7687 multiple ascending dose study ,
BMS-929075,bms-929075 investigation clinical trial nct01525212 multiple ascending dose study bms-929075 hepatitis c virus hcv infected patient ,
Etirinotecan pegol,etirinotecan pegol investigation clinical trial nct01663012 phase ii nktr-102 bevacizumab-resistant high grade glioma ,
Pamrevlumab,pamrevlumab investigation clinical trial nct00913393 study fibrogen fg -3019 subject type 2 diabetes mellitus kidney disease acei and/or arb therapy ,
Firtecan pegol,firtecan pegol investigation clinical trial nct01036113 phase 2 study ezn-2208 patient metastatic breast cancer ,
PIK3CA,pik3ca investigation clinical trial nct02957266 cervical cancer radiotherapy use vmat individualized polyradiosensitization interstitial brachytherapy ,
PF-04634817,pf-04634817 investigation clinical trial nct01140672 multiple dose study determine safety tolerability pharmacokinetics pf-04634817 healthy adult subject ,
Davalintide,davalintide investigation clinical trial nct00785408 study examine safety tolerability effect body weight subcutaneous ac2307 obese overweight subject ,
MK-3577,mk-3577 investigation clinical trial nct00868790 study safety efficacy mk-3577 participant type 2 diabetes mellitus mk-3577-009 ,
Selicrelumab,selicrelumab investigation clinical trial nct01008527 phase oncovir poly ic lc ny-eso-1/gp100 ,
Opicinumab,opicinumab investigation clinical trial nct02641041 safety tolerability pharmacokinetics single multiple dos biib033 healthy japanese participant ,
Somatrogon,somatrogon long-acting recombinant human growth hormone growth hormone peptide hormone secreted pituitary gland play crucial role promoting longitudinal growth childhood adolescence regulating metabolic function adulthood a241515 recombinant growth hormone therapy growth hormone deficiency condition available since 1985 daily administration standard treatment many year recently longer-acting form growth hormone developed improve patient adherence thus improve therapeutic efficacy treatment a241485 somatrogon produced chinese hamster ovary cho cell using recombinant dna technology chimeric product generated fusing three copy c-terminal peptide ctp 28 carboxy-terminal residue beta chain human chorionic gonadotropin hcg n-terminus c-terminus human growth hormone a241515 l39362 glycosylation presence ctps protein sequence prolongs half-life somatrogon allows once-weekly dosing l39362 october 2021 health canada approved somatrogon market name ngenla long-term treatment pediatric patient growth failure due inadequate secretion endogenous growth hormone caused growth hormone deficiency marking canada first country approve drug l39060 available once-weekly subcutaneous injection l39080 ,somatrogon indicated long-term treatment pediatric patient growth failure due inadequate secretion endogenous growth hormone growth hormone deficiency l39362 
Seltorexant,seltorexant investigation clinical trial nct03494907 study evaluate effect single-dose seltorexant electrocardiogram interval healthy adult participant ,
Trastuzumab deruxtecan,trastuzumab deruxtecan her-2 directed antibody attached topoisomerase inhibitor approved use certain type metastatic unresectable breast cancer l10842 classified antibody-drug conjugate cleavable peptide linker used bind antibody drug product distinguishes member class a188988 trastuzumab deruxtecan granted fda approval specific patient her-2 positive breast cancer failed treatment l10842 promising result clinical trial prompted accelerated fda approval indication december 20 2019 l10845 trastuzumab deruxtecan developed daiichi sankyo collaboration astrazeneca may 2022 trastuzumab deruxtecan fully approved fda l10842 ,trastuzumab deruxtecan indicated treatment adult patient unresectable metastatic her2-positive breast cancer received prior anti-her2-based regimen either metastatic setting neoadjuvant adjuvant setting developed disease recurrence within six month completing therapy l10842 also indicated treat adult unresectable metastatic her2-low ihc 1+ ihc 2+/ish- breast cancer received prior chemotherapy metastatic setting developed disease recurrence within 6 month completing adjuvant chemotherapy l10842 trastuzumab deruxtecan also indicated treat adult patient locally advanced metastatic her2-positive gastric gastroesophageal junction adenocarcinoma received prior trastuzumab-based regimen l10842 
Konjac mannan,konjac mannan investigation clinical trial nct01709955 effect glucomannan weight loss ,
Narnatumab,narnatumab investigation clinical trial nct01119456 study imc-ron8 advanced solid tumor ,
CTT-1057,ctt-1057 investigation clinical trial nct03427476 ctt1057 small molecular inhibitor psma novel imaging agent neovascularization renal cell carcinoma ,
Venglustat,venglustat investigation clinical trial nct01674036 safety tolerability pharmacokinetics genz-682452 healthy men ,
Margetuximab, her2 oncoprotein product human _erbb2_/mouse _neu_ gene member family receptor tyrosine kinase includes epidermal growth factor receptor egfr various subtypes breast cancer her2-positive breast cancer characterized _erbb2_ overexpression higher grade aggressive phenotype worse prognosis compared her2-negative cancer a225751 introduction trastuzumab improved patient outcome her2-positive breast cancer notably depended substantially polymorphism fcγriiia/cd16a receptor whereby low affinity 158f cd16a variant associated shorter progression-free survival worse patient outcome a225756 margetuximab formerly mgah22 fc-engineered human/mouse chimeric anti-her2 igg1κ monoclonal antibody derived mouse 4d5 clone trastuzumab derived produced chinese hamster ovary cho culture a225751 a225756 a225766 a191829 l27986 margetuximab bind epitope her2 extracellular domain induces effect trastuzumab however due modified fc region margetuximab bind higher affinity cd16a variant exhibit weaker binding inhibitory cd32b fc receptor resulting efficient antibody-dependent cell-mediated cytotoxicity adcc increased efficacy compared trastuzumab a225751 a225756 a225766 a191829 l27986 margextuximab granted fda approval december 16 2020 currently marketed trademark margenza™ macrogenics inc. l27986 ,margetuximab anti-her2 monoclonal antibody indicated combination chemotherapy treatment metastatic her2-positive breast cancer adult patient received two prior anti-her2 regimen least one prior regimen metastatic disease l27986 
Bacillus calmette-guerin substrain tokyo 172-1 live antigen,bacillus calmette-guerin substrain tokyo 172-1 live antigen investigation clinical trial nct03091660 s1602 different strain bcg without vaccine high grade non- muscle invasive bladder cancer ,
GTX-758,gtx-758 investigation clinical trial nct01420861 gtx-758 serum prostate-specific antigen psa men castrate resistant prostate cancer ,
Alobresib,alobresib investigation clinical trial nct02607228 safety tolerability pharmacokinetics pharmacodynamics gs-5829 single agent combination enzalutamide participant metastatic castrate-resistant prostate cancer ,
Iomazenil,iomazenil investigation clinical trial nct01590277 ability partial inverse agonist iomazenil block ethanol effect human ,
Methamidophos,methamidophos investigation clinical trial nct03223753 web-based physical activity intervention improving long term health child adolescent newly diagnosed acute lymphoblastic leukemia first remission ,
Abrocitinib,abrocitinib oral small-molecule inhibitor janus kinase 1 jak1 janus kinase intracellular enzyme involved transduction pathway regulate hematopoiesis immune cell function l39774 janus kinase jak –signal transducer activator transcription stat signalling pathway play central role pathogenesis variety autoimmune inflammatory disease including atopic dermatitis chronic inflammatory skin disease complex pathogenesis atopic dermatitis characterized epidermal hyperplasia skin barrier dysfunction aberrant activation immune cell patient moderate-to-severe atopic dermatitis report reduced quality life often face limited treatment option jak inhibitor recently attracted attention potential treatment inflammatory disorder jak inhibition associated rapid sustained anti-inflammatory efects a244549 abrocitinib approved european commission december 10 2021 treatment moderate-to-severe atopic dermatitis ad adult candidate systemic therapy l39784 january 14 2022 fda approved abrocitinib treatment refractory moderate-to-severe ad adult whose disease adequately controlled systemic drug product including biologics use therapy inadvisable l39779 health canada also approved use abrocitinib pediatric patient 12 year older l42395 ,abrocitinib indicated treatment moderate-to-severe atopic dermatitis adult candidate systemic therapy l39774 u indicated treat refractory moderate-to-severe atopic dermatitis whose disease adequately controlled systemic drug product including biologics use therapy inadvisable l39769 abrocitinib recommended use combination jak inhibitor biologic immunomodulators immunosuppressant l39769 
Pimodivir,pimodivir investigation clinical trial nct02658825 study evaluate effect jnj-63623872 cardiac repolarization interval healthy participant ,
Voxelotor,"voxelotor novel hemoglobin polymerization inhibitor treatment sickle cell disease genetically inherited condition prevalent middle east africa certain part india sickle cell disease lead excruciating pain stroke infection various complication arising blockage blood vessel t734 voxelotor granted accelerated fda approval november 25 2019 likely promising treatment 100,000 individual u.s. suffering disease addition 20 million others worldwide l10403 developed global blood therapeutic inc. l10403 unique drug used treat sickle cell anemia hydroxyurea l-glutamine crizanlizumab a188135 a188138 due novel mechanism action ema approved use voxelotor treatment hemolytic anemia associated sickle cell disease february 2022 l41419 l41424 ", u voxelotor indicated treat sickle cell disease adult pediatric patient aged 4 year older l10397 europe indicated treatment hemolytic anemia due sickle cell disease scd adult pediatric patient 12 year age older monotherapy combination hydroxyurea l41419 
Relacorilant,relacorilant investigation clinical trial nct02804750 study evaluate cort125134 patient cushing 's syndrome ,
Padsevonil,padsevonil investigation clinical trial nct03695094 study participant epilepsy evaluate pharmacokinetics safety tolerability oxcarbazepine padsevonil ,
MIP-1095 I-131,mip-1095 i-131 investigation clinical trial nct03030885 use experimental radiopharmaceutical 131i-mip-1095 men metastatic castration-resistant prostate cancer mcrpc ,
Martinostat,martinostat investigation clinical trial nct03721211 imaging 11c martinostat breast cancer ,
AZD-6482,azd-6482 investigation clinical trial nct00688714 study investigate safety tolerability single dose azd6482 ,
Phytic acid,phytic acid investigation clinical trial nct01000233 value oral phytate insp6 prevention progression cardiovascular calcification ,
Miransertib,miransertib investigation clinical trial nct01473095 phase 1 dose escalation study arq 092 adult subject advanced solid tumor recurrent malignant lymphoma ,
Cimlanod,cimlanod investigation clinical trial nct02819271 first-in-human study safety single continuous intravenous iv infusion cxl-1427 48 hour healthy volunteer ,
Casimersen,duchenne muscular dystrophy dmd x-linked recessive allelic disorder characterized lack functional dystrophin protein lead progressive impairment ambulatory pulmonary cardiac function invariably fatal related albeit le severe form muscular dystrophy known becker muscular dystrophy bmd characterized shortened partially functional dystrophin protein production although corticosteroid effectively slow disease progression dmd bmd patient address underlying molecular pathogenesis a218171 a218176 a229988 application antisense oligonucleotides dmd patient specific mutation allows exon skipping produce truncated bmd-like dystrophin protein restore partial muscle function slow disease progression a218171 a218176 a229993 a188574 l32118 casimersen phosphorodiamidate morpholino oligonucleotide pmo pmos oligonucleotides five-membered ribofuranosyl ring replaced six-membered morpholino ring phosphodiester link nucleotide replaced phosphorodiamidate linkage a218186 l32118 manner pmos much le susceptible endo- exonuclease exhibit drastically reduced metabolic degradation compared traditional synthetic oligonucleotides a218186 casimersen recent line approved pmos treating dmd including eteplirsen viltolarsen however specific mutation hence precise exon skipping targeted different casimersen granted accelerated fda approval february 25 2021 based data showing increase dystrophin level skeletal muscle patient treated casimersen approval contingent verification confirmatory trial casimersen currently marketed tradename amondys 45™ sarepta therapeutic inc. l32118 ,casimersen indicated treatment duchenne muscular dystrophy dmd patient confirmed _dmd_ gene mutation amenable exon 45 skipping indication represents accelerated approval based observed efficacy continued approval indication may contingent verification safety efficacy confirmatory trial l32118 
Enarodustat,enarodustat investigation clinical trial nct02581124 study evaluate effect lapatinib pharmacokinetics jtz-951 subject end-stage renal disease ,
Linrodostat,linrodostat investigation clinical trial nct03247283 pharmacokinetics metabolism study healthy male participant ,
Difamilast,difamilast investigation clinical trial nct01702181 safety study evaluate use effectiveness topical ointment treat adult atopic dermatitis ,
Dalantercept,dalantercept investigation clinical trial nct00996957 study ace-041 patient advanced solid tumor relapsed/refractory multiple myeloma ,
Umbralisib,marginal zone lymphoma rare slowly progressing type non-hodgkin lymphoma initially treated rituximab anti-cd20 drug either alone combination chemotherapy unfortunately many patient experience relapse develop resistance drug treatment option become limited alternate treatment lymphoma required control disease progression a229363 follicular lymphoma also treated rituximab chemotherapeutic agent may show similar progression a229668 february 5 2021 food drug administration granted accelerated approval umbralisib kinase inhibitor pi3k-delta casein kinase ck1-epsilon based promising result clinical trial marketed ukoniq tg therapeutic approved treatment relapsing refractory marginal cell lymphoma follicular lymphoma adult l31863 umbralisib inhibits casein kinase primary regulator protein translation kinase-1ε distinguishing lymphoma treatment initially offered promising therapy patient experiencing relapsing refractory disease a229363 umbralisib withdrawn market due safety concern drug associated possible increased risk death outweighing benefit l41930 ,umbralisib approved therapeutic indication 
Bazlitoran,bazlitoran investigation clinical trial nct02092909 phase 1/2 dose escalation study patient relapsed refractory waldenstrom 's macroglobulinemia ,
Nomacopan,nomacopan investigation clinical trial nct03427060 coversin pnh patient resistance eculizumab due complement c5 polymorphism ,
Pegunigalsidase alfa,pegunigalsidase alfa investigation clinical trial nct02921620 study evaluate safety efficacy prx-102 gastrointestinal symptom naïve fabry disease ,
Pyrotinib,pyrotinib investigation clinical trial nct03756064 neoadjuvant study pyrotinib patient her2 positive breast cancer ,
NP-G2-044,np-g2-044 investigation clinical trial nct03199586 phase 1 clinical trial metastasis inhibitor np-g2-044 patient advanced metastatic solid tumor including lymphoma ,
Sutimlimab,cold agglutinin disease cad type autoimmune hemolytic anemia aiha autoantibody directed red blood cell surface antigen cause hemolysis low 3-4°c temperature a245154 l40114 cold subtype account approximately 15-25 aiha common elderly a245159 l40114 approximately 90 case patient develop immunoglobulin igm autoantibody towards antigen erythrocyte antibody react optimally 4°c therefore referred `` cold agglutinin '' a245144 hemolysis patient cad driven complement activation initiate cascade ultimately lead intra- extravascular hemolysis a245159 common presenting symptom patient cad chronic anemia acrocyanosis raynaud phenomenon a245159 treatment option patient cad limited addition non-pharmacological strategy counseling patient keep warm use red blood cell transfusion approximately 70 patient require pharmacological treatment a245159 pharmacologic strategy included targeting b-cells agent like rituximab well targeting complement system drug like eculizumab anti-c5 mab pegcetacoplan novel inhibitor c3 a245154 notably none agent approved use treatment cad sutimlimab first-in-class humanized monoclonal antibody targeted complement subunit c1s responsible activating classic complement pathway a245144 received fda approval february 2022 brand name enjamyo sutimlimab-jome becoming first approved therapy patient cad l40114 a245144 sutimlimab also approved european commission november 2022 l44116 ,sutimlimab indicated decrease need red blood cell transfusion due hemolysis adult patient cold agglutinin disease l40109 l44111 
Pateclizumab,pateclizumab investigation clinical trial nct01225393 study evaluate efficacy safety mlta3698a combination disease-modifying anti-rheumatic drug dmard compared adalimumab combination dmard patient active rheumatoid arthritis ,
Olorinab,olorinab investigation clinical trial nct03155945 tolerability pharmacokinetics efficacy apd371 subject crohn 's disease experiencing abdominal pain ,
Human interferon beta,human interferon beta polypeptide used management relapsing form multiple sclerosis m initially approved fda 1992 l12081 multiple sclerosis devastating neurodegenerative disease usually progressive significantly debilitating profound impact quality life a191784 interferon beta currently studied possible treatment covid-19 result infection novel 2019 sars-cov-2 virus l12078 interferon-beta used past clinical study coronaviruses due demonstrated activity virus causing middle eastern respiratory syndrome mers therefore potential drug candidate sars-cov-2 based viral genetic similarity a191733 l12012 , drug indicated treat relapsing form multiple sclerosis m adult includes clinically isolated syndrome relapsing-remitting disease well active secondary progressive disease l12081 
Dianexin,dianexin investigation clinical trial nct00615966 phase 2 study safety diannexin kidney transplant recipient ,
Eflapegrastim,febrile neutropenia fn defined co-occurrence fever temperature 38 ◦c severe neutropenia anc 500 cells/mm sup 3 /sup potential side effect myelosuppressive chemotherapy patient develops infection period significant neutropenia a252320 typically develops first cycle chemotherapy associated increased risk morbidity mortality primary factor associated fn risk chemotherapy regimen administered regimen classified either high- intermediate- low-risk fn relevant guideline recommend use pharmacologic prophylaxis fn patient receiving high-risk regimen receiving intermediate-risk regimen ≥1 additional risk factor a252320 granulocyte-colony stimulating factor g-csfs include filgrastim pegfilgrastim first used clinically 1990s primary mean prophylaxis chemotherapy-induced neutropenia including fn a252320 trigger signaling pathway control differentiation proliferation migration survival neutrophil thereby helping restore depressed neutrophil count l43135 eflapegrastim form recombinant human g-csf comprising human g-csf analog coupled fc fragment human igg4 via polyethylene glycol linker l43135 september 2022 eflapegrastim approved u fda prophylactic infection manifested febrile neutropenia patient receiving certain myelosuppressive anti-cancer drug l43170 ,eflapegrastim indicated decrease incidence infection manifested febrile neutropenia adult patient non-myeloid malignancy receiving myelosuppressive anti-cancer drug associated clinically significant incidence febrile neutropenia l43135 
Fitusiran,fitusiran investigation clinical trial nct02554773 open-label extension study investigational drug aln-at3sc patient moderate severe hemophilia b ,
PF-06700841,pf-06700841 investigation clinical trial nct03236493 safety pharmacokinetic study pf-06700841 japanese healthy volunteer ,
MS-1819,ms-1819 investigation clinical trial nct03481803 phase iia study escalating dose ms1819-sd ,
Viltolarsen,duchenne muscular dystrophy dmd x-linked recessive allelic disorder characterized lack functional dystrophin protein lead progressive ambulatory pulmonary cardiac function invariably fatal related albeit le severe form muscular dystrophy known becker muscular dystrophy bmd characterized production shortened partially functional dystrophin protein although corticosteroid effective slowing disease progression dmd bmd patient address underlying molecular pathogenesis a218171 a218176 a218191 application antisense oligonucleotides dmd patient specific mutation allows exon skipping retains productive reading frame result production truncated bmd-like dystrophin protein a218161 a218166 a218171 a218176 a218181 a218191 l15526 shortened form dystrophin restore partial muscle function slow progression dmd viltolarsen phosphorodiamidate morpholino oligonucleotide pmo pmos oligonucleotides five-membered ribofuranosyl ring replaced six-membered morpholino ring phosphodiester link nucleotide replaced phosphorodiamidate linkage a218186 l15526 manner pmos much le susceptible endo- exonuclease exhibit drastically reduced metabolic degradation compared traditional synthetic oligonucleotides a218186 hence viltolarsen similar another pmo eteplirsen gained fda approval september 19 2016 however eteplirsen specific exon 51 skipping viltolarsen specific exon 53 skipping a218176 viltolarsen granted accelerated fda approval august 12 2020 based data showing increase dystrophin level skeletal muscle patient treated viltolarsen approval contingent verification confirmatory trial viltolarsen developed nippon shinyaku co ltd marketed name viltepso™ l15526 ,viltolarsen indicated treatment duchenne muscular dystrophy patient confirmed _dmd_ gene mutation amenable exon 53 skipping indication represents accelerated approval based observed efficacy continued approval indication may contingent verification safety efficacy confirmatory trial l15526 
Flufenoxuron,flufenoxuron investigation clinical trial nct00922870 evaluation hemodynamic effect cascade hemofiltration septic shock ,
Sevuparin,sevuparin investigation clinical trial nct03853421 placebo-controlled study determine safety tolerability subcutaneous dos sevuparin ,
GO-203-2C,go-203-2c investigation clinical trial nct02204085 phase i/ii trial muc1 inhibitor go-203-2c patient relapsed refractory acute myeloid leukemia ,
PF-04937319,pf-04937319 investigation clinical trial nct01513928 study compare pharmacokinetics different formulation pf-04937319 healthy subject ,
Edasalonexent,edasalonexent investigation clinical trial nct01511900 multiple ascending dose study cat-1004 patient type 2 diabetes ,
Avacopan,"anti-neutrophil cytoplasmic auto antibody anca -associated vasculitis aav rare estimated incidence 3 case per 100,000 per year form `` pauci-immune '' systemic small-vessel vasculitis typified presence ancas serum a240249 a240254 a227003 full spectrum aav includes granulomatosis polyangiitis gpa microscopic polyangiitis mpa eosinophilic granulomatosis polyangiitis egpa drug-induced aav aav may associated necrotizing crescentic glomerulonephritis ncgn a240249 a240254 despite complex pathophysiology study past ~2 decade identified key role alternative complement pathway particular interaction anaphylatoxin fragment c5a cognate c5ar receptor aav a240254 a240259 a240264 a240269 avacopan formerly ccx168 allosteric c5ar antagonist indicated use aav a240269 a240329 l38919 avacopan granted fda approval october 8 2021 currently marketed name tavneos chemocentryx inc. l38919 january 19 2022 european commission approved avacopan treatment adult patient severe active granulomatosis polyangiitis gpa microscopic polyangiitis mpa two main form anca-associated vasculitis combination rituximab cyclophosphamide l39850 avacopan approved health canada april 20 2022 l41650 ",avacopan indicated adjunctive treatment adult patient severe active anti-neutrophil cytoplasmic autoantibody anca -associated vasculitis granulomatosis polyangiitis microscopic polyangiitis gpa/mpa combination standard therapy including glucocorticoid avacopan eliminate need glucocorticoid l38919 europe avacopan approved treatment adult severe active granulomatosis polyangiitis gpa microscopic polyangiitis mpa combination rituximab cyclophosphamide l40149 
Farampator,farampator investigation clinical trial nct00113022 org 24448 treat major depression ,
TAK-243,tak-243 investigation clinical trial nct03816319 tak-243 treating patient relapsed refractory acute myeloid leukemia refractory myelodysplastic syndrome chronic myelomonocytic leukemia ,
Gremubamab,gremubamab investigation clinical trial nct02255760 phase 1 randomized double-blind placebo controlled study evaluate safety pk medi3902 healthy adult ,
Recombinant CD40-ligand,recombinant cd40-ligand investigation clinical trial nct00053391 vaccine therapy treating patient stage iii stage iv melanoma ,
Palladium Pd-103,palladium pd-103 investigation clinical trial nct00247312 pd-103 dose de-escalation early stage prostate cancer prospective randomized trial ,
Enoblituzumab,enoblituzumab investigation clinical trial nct02982941 enoblituzumab mga271 child b7-h3-expressing solid tumor ,
Agatolimod,agatolimod investigation clinical trial nct00471471 vaccine therapy treating patient recurrent stage iii stage iv melanoma removed surgery ,
Mongersen,mongersen investigation clinical trial nct02957474 study evaluate effect food formulation strength proton pump inhibitor ged 0301 pharmacokinetics healthy adult subject ,
Mureletecan,mureletecan investigation clinical trial nct00004076 pnu 166148 treating patient metastatic solid tumor ,
Leriglitazone,leriglitazone investigation clinical trial nct03917225 clinical study evaluate effect min-102 progression friedreich 's ataxia male female patient ,
Apomab,apomab investigation clinical trial nct00851136 study pro95780 administered combination folfox regimen bevacizumab patient previously untreated locally advanced recurrent metastatic colorectal cancer apm4566g ,
BMS-791826,bms-791826 investigation clinical trial nct03198013 study pharmacokinetics pk pharmacodynamics pd relation prednisolone healthy male ,
Apararenone,apararenone investigation clinical trial nct02531568 drug interaction study warfarin mt-3995 ,
Girentuximab I-124,girentuximab i-124 investigation clinical trial nct01762592 redect 2 renal mass pivotal trial detect clear cell renal cell carcinoma pet/ct ,
CXA-10,cxa-10 investigation clinical trial nct03422510 firstx study oral cxa-10 primary focal segmental glomerulosclerosis fsgs ,
Adriforant,adriforant investigation clinical trial nct00992342 phase 1 study evaluate safety tolerability different dos pf-03893787 healthy adult volunteer ,
MK-1064,mk-1064 investigation clinical trial nct02549014 single dose study safety pharmacokinetics pharmacodynamics mk-1064 mk-1064-001 ,
AZD-8186,azd-8186 investigation clinical trial nct03218826 pi3kbeta inhibitor azd8186 docetaxel treating patient advanced solid tumor pten pik3cb mutation metastatic removed surgery ,
GTI-2040,gti-2040 investigation clinical trial nct00084643 gti-2040 oxaliplatin capecitabine treating patient locally advanced metastatic colorectal cancer solid tumor ,
Daridorexant,daridorexant formerly known nemorexant selective dual orexin receptor antagonist used treat insomnia insomnia characterized difficulty sleep onset and/or sleep maintenance impairment daytime functioning chronically affect person 's daily functioning long-term health effect insomnia often associated comorbidities hypertension diabetes depression conventional treatment insomnia include drug targeting gamma-aminobutyric acid type-a gaba-a serotonin histamine melatonin receptor however undesirable side effect frequently reported next-morning residual sleepiness motor incoordination fall memory cognitive impairment novel drug target orexin receptor gained increasing attention discovering role orexin signalling pathway wakefulness almorexant orexin receptor antagonist improved sleep daridorexant designed via intensive drug discovery program improve potency maximize duration action minimizing next-morning residual activity a244225 daridorexant work orexin receptor ox1r ox2r block binding orexins wake-promoting neuropeptides endogenous ligand receptor daridorexant reduces overactive wakefulness investigational trial daridorexant reportedly improved sleep daytime functioning patient insomnia a244225 approved fda january 10 2022 name quviviq l39660 second orexin receptor antagonist approved treat insomnia following suvorexant a244280 daridorexant approved european commission may 3 2022 first dual orexin receptor antagonist approved market l41725 , u europe daridorexant indicated treatment adult patient insomnia characterized difficulty sleep onset and/or sleep maintenance l39655 european prescribing information state insomnia characterized symptom present least 3 month considerable impact daytime functioning l41720 
Obexelimab,obexelimab investigation clinical trial nct02725515 study effect xmab®5871 patient systemic lupus erythematosus ,
Flortaucipir,flortaucipir investigation clinical trial nct03507257 longitudinal early-onset alzheimer 's disease study protocol ,
PRI-724,pri-724 investigation clinical trial nct03620474 safety effectiveness pri-724 hepatitis c b virus derived liver cirrhosis ,
Zanubrutinib,zanubrutinib novel bruton 's tyrosine kinase btk inhibitor used treatment adult patient mantle cell lymphoma mcl received least one prior therapy l10163 mantle cell lymphoma aggressive mature b-cell non-hodgkin lymphoma associated early relapse poor clinical outcome long-term survival a187967 btk enzyme play role oncogenic signalling pathway promotes survival proliferation malignant b cell a187985 compared first-generation btk inhibitor ibrutinib zanubrutinib display higher potency selectivity btk fewer off-target effect a187958 due enhanced selectivity towards btk zanubrutinib belongs second-generation btk inhibitor drug group also includes acalabrutinib approved fda 2017 zanubrutinib granted accelerated approval fda november 2019 based clinical trial result demonstrated 84 overall response rate zanubrutinib therapy patient mcl l10166 measure proportion patient trial whose tumour entirely partially destroyed drug l10169 currently marketed trade name brukinsa™ available oral capsule august 2021 fda granted accelerated approval zanubrutinib treatment adult waldenström ’ macroglobulinemia l39030 indication valid u europe canada l39367 september 2021 zanubrutinib granted another accelerated approval treatment relapsed refractory marginal zone lymphoma received least one anti-cd20-based regimen l39025 october 2022 ema 's committee medicinal product human use chmp recommended zanubrutinib granted marketing authorization treatment chronic lymphocytic leukaemia l43737 ,zanubrutinib indicated treatment adult patient mantle cell lymphoma mcl received least one prior therapy l10163 l40788 used treat waldenström ’ macroglobulinemia adult l10163 l40788 zanubrutinib also indicated treatment relapsed refractory marginal zone lymphoma mzl adult received least one anti-cd20-based regimen l10163 l40788 
Sitravatinib,sitravatinib investigation clinical trial nct03680521 neoadjuvant sitravatinib combination nivolumab patient clear cell renal cell carcinoma ,
Poly(lactic acid),poly lactic acid investigation clinical trial nct00126308 facial lipoatrophy trial immediate versus deferred injection poly-l-lactic acid hiv facial lipoatrophy ,
Litoxetine,litoxetine investigation clinical trial nct03397771 dbpc trial evaluate safety tolerability efficacy oral litoxetine subject urinary incontinence ,
ITI-214,iti-214 investigation clinical trial nct03489772 study iti-214 healthy volunteer determine cns engagement ,
TP-271,tp-271 investigation clinical trial nct02724085 phase 1 study ass safety tolerability pk iv tp-271 ,
Florilglutamic acid F-18,florilglutamic acid f-18 investigation clinical trial nct02370563 pet imaging intracranial cancer 18f-fspg ,
Tavolixizumab,tavolixizumab investigation clinical trial nct02318394 phase 1 study medi0562 adult subject selected advanced solid tumor ,
Toripalimab,toripalimab investigation clinical trial nct03919383 phase ii lenvatinib plus toripalimab advanced hcc ,
Tafasitamab,tafasitamab humanized cd19-directed cytolytic monoclonal antibody intended treatment b-cell malignancy l15302 produced using recombinant dna technology chinese hamster ovary cell contains igg1/2 hybrid fc-domain modified 2 amino acid substitution enhance cytotoxicity relative non-engineered anti-cd19 antibody l15292 a191829 cd19 surface protein highly expressed surface b-cells appears play role enhancing b-cell receptor signaling l15302 relative ubiquity across different stage b-cell development including pre-b mature b-lymphocytes l15292 well presence several b-cell malignancy e.g chronic lymphocytic leukemia cll small lymphocytic lymphoma sll diffuse large b-cell lymphoma dlbcl l15302 made desirable target treatment b-cell malignancy tafasatimab designed bind block activity cd19 surface antigen ultimately result lysis b-cells healthy malignant l15292 previously received breakthrough therapy fast track orphan designation fda a191829 tafasatimab-cxix monjuvi® received accelerated approval july 31st 2020 treatment relapsed refractory dlbcl adult patient receive autologous stem cell transplant l15307 must used combination lenalidomide combination result greater efficacy compared either agent alone l15292 ,tafasitamab indicated combination lenalidomide treatment adult patient relapsed refractory diffuse large b-cell lymphoma dlbcl otherwise specified ineligible autologous stem cell transplant asct l15292 
Ipafricept,ipafricept investigation clinical trial nct01608867 dose escalation study omp-54f28 subject solid tumor ,
LY-2881835,ly-2881835 investigation clinical trial nct01358981 study ly2881835 healthy people people diabetes ,
BMS-919373,bms-919373 investigation clinical trial nct02153437 study effect bms-919373 electrical activity heart using pacemaker ,
Licogliflozin,licogliflozin investigation clinical trial nct03320941 dose-finding study evaluate change weight treatment lik066 japanese patient obesity ,
Sucralose,sucralose artificial sweetener used sugar substitute ,
Neopterin,neopterin investigation clinical trial nct02974192 neopterin effect ischemic stroke ,
Ethaselen,ethaselen investigation clinical trial nct02166242 ethaselen treatment thioredoxin reductase high expression advanced non-small cell lung cancer ,
Ansofaxine,ansofaxine investigation clinical trial nct02271412 multiple ascending dose study healthy subject evaluate safety tolerability pharmacokinetics ly03005 ,
Lintuzumab satetraxetan AC-225,lintuzumab actinium ac-225 investigation clinical trial nct00672165 targeted atomic nano-generators actinium-225-labeled humanized anti-cd33 monoclonal antibody hum195 patient advanced myeloid malignancy ,
TAS-117,tas-117 investigation clinical trial nct03017521 k-basket tas-117 pi3k/akt gene aberration ,
ABT-639,abt-639 investigation clinical trial nct01345045 multicenter study comparing analgesic effect safety abt-639 compared placebo subject diabetic neuropathic pain ,
Bifenthrin,bifenthrin investigation clinical trial nct01560247 percutaneous recanalization ischemic stroke management europe observational registry ,
NUC-1031,nuc-1031 investigation clinical trial nct03610100 acelarin first line randomised pancreatic study ,
Flutemetamol,flutemetamol investigation clinical trial nct02353949 investigating clinical consequence flutemetamol-pet-scanning ,
Aprocitentan,aprocitentan investigation clinical trial nct03541174 research study show effect aprocitentan treatment difficult control resistant high blood pressure hypertension find safety ,
Lefitolimod,lefitolimod investigation clinical trial nct03837756 combining tlr9 agonist bnabs reservoir reduction immunological control hiv ,
Inarigivir,inarigivir investigation clinical trial nct03434353 study evaluate antiviral activity inarigivir gs-9992 plus tenofovir alafenamide taf 12 week adult chronic hepatitis b chb ,
Inarigivir soproxil,inarigivir soproxil investigation clinical trial nct03434353 study evaluate antiviral activity inarigivir gs-9992 plus tenofovir alafenamide taf 12 week adult chronic hepatitis b chb ,
Teprasiran,teprasiran investigation clinical trial nct03510897 qpi-1002 phase 3 prevention major adverse kidney event make subject high risk aki following cardiac surgery ,
PF-06291874,pf-06291874 investigation clinical trial nct02175121 safety tolerability pharmacokinetics pharmacodynamics study pf-06291874 oral monotherapy treat adult type 2 diabetes mellitus ,
Givosiran,givosiran small interfering rna sirna directed towards 5-aminolevulinic acid synthase critical enzyme heme biosynthesis pathway l10202 manufactured alnylam pharmaceutical first approved use united state november 2019 treatment adult acute hepatic porphyria genetic disorder overproduction toxic heme intermediate lead neuro- nephro- gastrotoxicity l10202 givosiran represents important step forward treatment acute hepatic porphyria first approved pharmacotherapy prevention acute attack previous strategy involved non-therapeutic measure e.g trigger avoidance intravenous hemin treatment attack liver transplantation refractory case a187991 givosiran second-ever fda-approved member sirna drug class first patisiran new class drug promising important exciting step forward treatment genetic disorder ,givosiran indicated treatment adult acute hepatic porphyria l10202 
Volanesorsen,volanesorsen antisense oligonucleotide bind apoc-iii mrna prevent translation l16621 indicated treat familial chylomicronemia genetic condition prevents breakdown triglyceride chylomicron l16621 drug commonly prescribed used adjunct diet patient high risk pancreatitis inadequate response triglyceride lowering therapy l16621 volanesorsen granted conditional approval european medicine agency l16621 ,volanesorsen conditionally approved ema adjunct diet adult familial chylomicronemia high risk pancreatitis inadequate response diet triglyceride lowering therapy l16621 
Agerafenib,agerafenib investigation clinical trial nct03052569 expanded access rxdx-105 cancer ret alteration ,
Pexastimogene devacirepvec,pexastimogene devacirepvec investigation clinical trial nct00429312 study recombinant vaccinia virus treat malignant melanoma ,
GI heptapeptide,gi heptapeptide investigation clinical trial nct01391208 esophageal protocol detection neoplasia digestive tract ,
Omidenepag isopropyl,omidenepag isopropyl topical ocular hypotensive agent used reduce intraocular pressure iop patient glaucoma ocular hypertension l43503 omidenepag isopropyl quickly metabolized active metabolite omidenepag molecule high selectivity agonistic activity towards prostaglandin e2 ep2 receptor a253263 a253268 prostanoid fp receptor agonist fp agonist latanoprost part first-line therapy ocular hypertension primary open-angle glaucoma however patient achieve adequate iop reduction fp agonist require change treatment use ep2 receptor agonist omidenepag represents alternative scenario omidenepag iop-lowering effect comparable one observed latanoprost a253253 2018 omidenepag isopropyl approved japan treatment glaucoma ocular hypertension a253268 september 2022 fda approved use omidenepag isopropyl l43503 ,omidenepag isopropyl ophthalmic solution 0.002 indicated reduction elevated intraocular pressure iop patient open-angle glaucoma ocular hypertension l43503 
Beinaglutide,beinaglutide investigation clinical trial nct03829891 study beinaglutide versus glargine therapy glycemic variability type 2 diabetes mellitus ,
Ribose,ribose investigation clinical trial nct01727479 ribose sport performance ,
Aglatimagene besadenovec,aglatimagene besadenovec investigation clinical trial nct00638612 adv-tk therapy surgery chemoradiation pancreas cancer patk01 ,
4-demethyl-4-cholesteryloxycarbonylpenclomedine,4-demethyl-4-cholesteryloxycarbonylpenclomedine investigation clinical trial nct01048008 study 4-demethylcholesteryloxycarbonylpenclomedine dm-choc-pen patient advanced cancer ,
Abrilumab,abrilumab investigation clinical trial nct01290042 study evaluate safety tolerability pharmacokinetics pharmacodynamics amg 181 ,
Efinopegdutide,efinopegdutide investigation clinical trial nct03606057 study investigate effect jnj-64565111 cardiac repolarization corrected qt interval compared placebo healthy adult thorough ecg study employing placebo jnj-64565111 positive control moxifloxacin ,
Rogaratinib,rogaratinib investigation clinical trial nct03762122 rogaratinib patient advanced pretreated squamous-cell non-small cell lung cancer sqclc ,
Troriluzole,troriluzole investigation clinical trial nct03701399 troriluzole adult subject spinocerebellar ataxia ,
ELX-02,elx-02 investigation clinical trial nct03309605 phase 1 study elx-02 healthy adult subject ,
Melanoma antigen recognized by T-cells 1,melanoma antigen recognized t-cells 1 investigation clinical trial nct01748747 vaccine therapy resiquimod treating patient stage ii-iv melanoma removed surgery ,
Cabiralizumab,cabiralizumab investigation clinical trial nct03502330 apx005m nivolumab cabiralizumab advanced melanoma non-small cell lung cancer renal cell carcinoma ,
Domagrozumab,domagrozumab investigation clinical trial nct01616277 phase 1 study evaluate safety tolerability pf-06252616 healthy subject ,
GS-9191,gs-9191 investigation clinical trial nct00499967 safety effectiveness study experimental topical ointment gs-9191 treatment genital wart ,
Fulacimstat,fulacimstat investigation clinical trial nct02452515 single-blind pilot study investigate safety tolerability chymase inhibitor bay1142524 clinically stable patient left-ventricular dysfunction ,
Ocrylate,ocrylate investigation clinical trial nct01918059 cosmetic outcome study lid laceration repair suture versus tissue adhesive ,
Psicose,psicose investigation clinical trial nct02459834 fructose allulose catalytic effect face trial ,
Oleclumab,oleclumab investigation clinical trial nct03819465 study novel anti-cancer agent patient previously untreated nsclc ,
Frovocimab,frovocimab investigation clinical trial nct01671085 study ly3015014 healthy participant high cholesterol ,
Tezepelumab,asthma heterogeneous chronic obstructive respiratory disease `` type 2 '' t2 t2-low endotypes characterized reduced airflow chronic inflammation airway remodelling a243764 a243769 thymic stromal lymphopoietin tslp innate pleiotropic il-2-family cytokine emerged key upstream regulator chronic inflammation across asthma endotypes blocking interaction tslp receptor tslpr il-7rα improves asthma-associated biomarkers including eosinophil count ige feno il-5 il-13 level a243764 a243769 a243774 existing asthma treatment omalizumab mepolizumab reslizumab benralizumab dupilumab act specific downstream mediator inflammatory response mostly limited treating t2 asthma a243769 conversely tezepelumab target upstream master regulator tslp potential effective across asthma endotypes a243764 a243769 a243774 tezepelumab human monoclonal igg2λ antibody directed tslp produced chinese hamster ovary cho cell recombinant dna technology granted fda approval december 17 2021 currently marketed trademark tezspire amgen/astrazeneca l39504 ,tezepelumab indicated add-on maintenance treatment patient aged 12 year older severe asthma l39504 tezepelumab indicated relief acute bronchospasm status asthmaticus l39504 
Upadacitinib,upadacitinib oral janus kinase jak 1-selective inhibitor disease-modifying antirheumatic drug dmard used treatment rheumatoid arthritis slow disease progression rheumatoid arthritis chronic autoimmune inflammatory disease affecting peripheral joint characterized synovial inflammation hyperplasia autoantibody production cartilage damage bone destruction leading co-morbidities a189165 despite variety therapeutic agent available treatment 40 patient respond current therapy including biological therapy a189171 etiology disease mostly unknown however role jak driver immune-mediated condition discovered leading use jak therapeutic target rheumatoid arthritis a189168 reduce dose-related toxicity seen pan-jak inhibitor without significantly affecting efficacy selective jak1 inhibitor upadacitinib filgotinib developed a189165 fda approved upadacitinib august 2019 used treatment active rheumatoid arthritis psoriatic arthritis atopic dermatitis ulcerative colitis ankylosing spondylitis l10896 december 2019 additionally approved european commission l10899 upadacitinib marketed brand name rinvoq oral administration l10896 ,upadacitinib indicated treatment moderately severely active rheumatoid arthritis active psoriatic arthritis adult patient inadequate response intolerance one disease-modifying anti-rheumatic drug dmards tnf blocker l10896 l39474 europe upadacitinib may used monotherapy combination methotrexate rheumatoid psoriatic arthritis l39474 upadacitinib indicated use patient 12 year age older refractory moderate-to-severe atopic dermatitis whose disease inadequately controlled systemic therapy therapy inadvisable l10896 l39474 upadacitinib indicated treatment active ankylosing spondylitis radiographic axial spondyloarthritis adult patient inadequate response conventional therapy l10896 l39474 also indicated treat non-radiographic axial spondyloarthritis objective sign inflammation adult inadequate response intolerance tnf blocker therapy l10896 upadacitinib also indicated treat moderately severely active ulcerative colitis adult inadequate response intolerance either conventional therapy biologic agent l39474 one tnf blocker l10896 combining upadacitinib jak inhibitor biologic dmards potent immunosuppressive agent recommended l10896 
LY-2624803,ly-2624803 investigation clinical trial nct01236105 effect activated charcoal time dose pharmacokinetics ly2624803 healthy subject ,
Somapacitan,somapacitan also known nnc0195-0092 a219136 growth hormone analog indicated treat adult growth hormone deficiency a219126 l15661 human growth hormone analog differs creation albumin binding site prolonging effect requires weekly dosing rather daily a219146 somapacitan granted fda approval 28 august 2020 l15666 ,somapacitan indicated replacement growth hormone adult patient growth hormone deficiency l15661 
Anfibatide,anfibatide investigation clinical trial nct01585259 anfibatide phase ib-iia clinical trial ,
Leridistim,leridistim investigation clinical trial nct00004215 leridistim compared filgrastim treating older patient acute myeloid leukemia ,
18-methoxycoronaridine,18-methoxycoronaridine investigation clinical trial nct03084952 phase 2 trial evaluate 18-methoxycoronaridine efficacy safety tolerability cutaneous leishmaniasis patient ,
Gefapixant,gefapixant investigation clinical trial nct02397460 effect gefapixant af-219/mk-7264 cough reflex sensitivity ,
Morinidazole,morinidazole investigation clinical trial nct03380793 trial ass efficacy safety morinidazole patient appendicitis ,
GW-468816,gw-468816 investigation clinical trial nct00218465 effectiveness gw468816 nmda glycine site antagonist prevention relapse smoking ,
Cusatuzumab,cd70 ligand expressed surface activated lymphocyte mature dendritic cell binding cd27 receptor play important role cell proliferation survival overexpression cd70 result proliferation malignant cell documented variety solid hematological malignancy a241975 cusatuzumab humanized igg1 antibody targeted cd70 a241045 currently investigated phase 2 culminate trial combination azacitidine treatment newly-diagnosed acute myeloid leukemia aml high-risk myelodysplastic syndrome md patient unsuitable chemotherapy a241045 l39120 ,
Tigatuzumab,tigatuzumab investigation clinical trial nct00991796 cs-1008 carboplatin/paclitaxel chemotherapy naïve subject metastatic unresectable non-small cell lung cancer nsclc ,
Pemigatinib,pemigatinib small molecule kinase inhibitor antitumour activity work inhibiting fibroblast growth factor receptor fgfrs receptor tyrosine kinase activate signalling pathway tumour cell a193719 fgfrs gained attention potential therapeutic target selected cancer fgfr gene alteration observed wide variety cancer including urinary bladder breast ovary prostate endometrium lung stomach a198984 deregulated fgfr signalling pathway lead development oncogene tumour-promoting physiological process cancer cell proliferation enhanced angiogenesis evasion cell death a193716 april 2020 pemigatinib approved fda treatment unresectable locally advanced metastatic cholangiocarcinoma previously treated adult patient fibroblast growth factor receptor 2 fgfr2 gene fusion rearrangement detected fda-approved test l13068 cholangiocarcinoma common primary malignancy affecting biliary tract second common primary hepatic malignancy malignancy account 15 20 primary hepatobiliary malignancy account 13 overall cancer-related global mortality increasing research pathogenesis cholangiocarcinoma potential therapeutic target anticancer drug treatment recent study show 45 patient intrahepatic cholangiocarcinoma exhibited gene rearrangement resulting oncogenic fibroblast growth factor 2 fgfr2 fusion protein a198963 fda-approved indication pemigatinib granted accelerated approval based overall response rate duration response pre-marketing clinical trial pemigatinib marketed brand name pemazyre available oral tablet l13050 ,pemigatinib indicated treatment unresectable locally advanced metastatic cholangiocarcinoma previously-treated adult patient fibroblast growth factor receptor 2 fgfr2 fusion rearrangement detected fda-approved test l13050 also indicated treatment adult relapsed refractory myeloid/lymphoid neoplasm mlns fgfr1 rearrangement l43005 
Telisotuzumab vedotin,telisotuzumab vedotin investigation clinical trial nct02099058 study evaluating safety pharmacokinetics pk preliminary efficacy abbv-399 subject advanced solid tumor ,
PF-06751979,pf-06751979 investigation clinical trial nct03126721 study evaluate effect multiple dos pf-06751979 pharmacokinetics midazolam healthy adult ,
Surufatinib,surufatinib investigation clinical trial nct02588170 phase iii study surufatinib treating advanced extrapancreatic neuroendocrine tumor ,
Fludeoxyglucose,fludeoxyglucose investigation clinical trial nct03262389 comparison f-18 fdg c-11 acetate pet multiple myeloma ,
Tipranavir C-14,tipranavir c-14 investigation clinical trial nct02253797 pharmacokinetics tipranavir/ritonavir metabolite healthy male subject ,
Ingenol disoxate,ingenol disoxate investigation clinical trial nct02120456 safety efficacy escalating dos leo 43204 applied daily two consecutive day approximately 250 cm2 trunk extremity subject actinic keratosis ,
Onvansertib,onvansertib investigation clinical trial nct03303339 onvansertib combination either low-dose cytarabine decitabine adult patient acute myeloid leukemia aml ,
Acetic acid C-11,acetic acid c-11 investigation clinical trial nct01953965 look way heart function people pulmonary hypertension ph near normal right ventricle rv function people pulmonary hypertension impaired rv function using imaging study pet scan cardiac mri ,
Somatropin pegol,somatropin pegol investigation clinical trial nct00715689 dose study growth hormone deficient adult investigating safety pharmacokinetics pharmacodynamics nnc126-0083 ,
Utomilumab,utomilumab investigation clinical trial nct03318900 cell immunotherapy advanced ovarian cancer ,
Vamorolone,vamorolone investigation clinical trial nct03439670 study ass efficacy safety vamorolone boy duchenne muscular dystrophy dmd ,
Nimacimab,nimacimab investigation clinical trial nct03261739 safety tolerability pk ryi-018 repeat dosing subject non-alcoholic fatty liver disease nafld ,
Ramatercept,ramatercept investigation clinical trial nct00952887 safety tolerability pharmacokinetic pharmacodynamic study ace-031 healthy postmenopausal woman ,
Transfluthrin,transfluthrin investigation clinical trial nct02394522 spatial repellent product control vector borne disease malaria zambia sr-m-zm ,
Zolbetuximab,zolbetuximab investigation clinical trial nct01630083 efficacy safety imab362 combination eox regimen cldn18.2-positive gastric cancer ,
Ropeginterferon alfa-2b,polycythemia vera pv common philadelphia chromosome-negative myeloproliferative neoplasm mpn characterized increased hematocrit platelet/leukocyte count increased risk hemorrhage thromboembolic event long-term propensity myelofibrosis leukemia a242000 a242005 interferon alfa-2b used decade treat pv requires frequent dosing tolerated patient a242005 ropeginterferon alfa-2b next-generation mono-pegylated type interferon produced proline-ifn-α-2b _escherichia coli_ high tolerability long half-life a242015 l39170 ropeginterferon alfa-2b shown efficacy pv _in vitro_ _in vivo_ model clinical trial a242010 a242015 ropeginterferon alfa-2b approved fda november 12 2021 currently marketed trademark besremi pharmaessentia corporation l39170 ,ropeginterferon alfa-2b indicated treatment adult patient polycythemia vera l39170 
GSK-239512,gsk-239512 investigation clinical trial nct00474513 imaging study investigate distribution gsk239512 brain ,
AT-001,at-001 investigation clinical trial nct03062384 at-001 long-term preservation brain health aging ,
PCS-499,pcs-499 investigation clinical trial nct01487109 phase 2 study evaluate safety efficacy ctp-499 type 2 diabetic nephropathy patient ,
Dorzagliatin,dorzagliatin investigation clinical trial nct03173391 long-term efficacy safety hms5552 t2dm ,
PF-05241328,pf-05241328 investigation clinical trial nct01165736 calculate pharmacokinetics concentration compound rate excretion blood following low dose compound pharmacological activity ,
Belapectin,belapectin investigation clinical trial nct02575404 gr-md-02 plus pembrolizumab melanoma non-small cell lung cancer squamous cell head neck cancer patient ,
IMG-7289,img-7289 investigation clinical trial nct03136185 img-7289 patient myelofibrosis ,
Hydrogen,hydrogen investigation clinical trial nct02830854 molecular hydrogen cognitive function performance elderly ,
Remtolumab,remtolumab investigation clinical trial nct02433340 phase 2 multicenter open-label extension ole study abt-122 rheumatoid arthritis subject completed preceding m12-963 study ,
Pegadricase,pegadricase investigation clinical trial nct01021241 safety efficacy study intravenous uricase-peg 20 ,
Dexpramipexole,dexpramipexole investigation clinical trial nct01511029 study evaluate qtc interval healthy volunteer dosed dexpramipexole qtc electrocardiogram ecg interval measured onset qrs complex end wave corrected heart rate ,
Interferon alfa-2c,interferon alfa-2c investigation clinical trial nct00485563 phase ii study ec17 folate-hapten conjugate patient progressive metastatic renal cell carcinoma ,
AZD-8165,azd-8165 investigation clinical trial nct01150812 oral azd8165 single oral ascending dos healthy male subject ,
Tepotinib,tepotinib met tyrosine kinase inhibitor intended treat variety met-overexpressing solid tumor a228058 originally developed partnership emd serono university texas m.d anderson cancer center 2009 since investigated treatment neuroblastoma a228053 gastric cancer a228033 non-small cell lung cancer hepatocellular carcinoma a228058 met desirable target treatment certain solid tumor appears play critical role directly indirectly growth proliferation tumor overexpressed and/or mutated tepotinib first approved japan march 2020 treatment non-small cell lung cancer nsclc _met_ alteration subsequently granted accelerated approval u fda february 2021 brand name tepmetko treatment adult patient metastatic nsclc _met_ exon 14 skipping alteration l31443 l31473 first oral met-targeted tyrosine kinase inhibitor allow once-daily dosing l31473 advantage may aid easing pill burden often associated chemotherapeutic regimen february 2022 tepotinib approved use europe l42200 ,tepotinib indicated treatment adult patient metastatic non-small cell lung cancer nsclc mesenchymal-epithelial transition _met_ exon 14 skipping alteration l31443 
Fluoroazomycin arabinoside F-18,fluoroazomycin arabinoside f-18 investigation clinical trial nct03257150 study use irreversible electroporation pancreatic ductal cancer ,
Ponezumab,ponezumab investigation clinical trial nct00607308 phase single dose study pf-04360365 japanese patient mild moderate alzheimer 's disease ,
Rebaudioside A,rebaudioside investigation clinical trial nct03510624 acute effect rebaudioside glucose excursion oral glucose tolerance test type 2 diabetes mellitus ,
VK-2809,vk-2809 investigation clinical trial nct02927184 safety tolerability vk2809 patient primary hypercholesterolemia non-alcoholic fatty liver disease ,
AZD-9496,azd-9496 investigation clinical trial nct02248090 azd9496 first time patient ascending dose study ,
Bifunctional epoxide hydrolase 2,bifunctional epoxide hydrolase 2 investigation clinical trial nct00654966 evaluation effect urotensin-ii soluble epoxide hydrolase inhibitor skin microvessel tone patient heart failure healthy volunteer ,
Bempegaldesleukin,bempegaldesleukin investigation clinical trial nct03729245 study nktr-214 combination nivolumab compared investigator 's choice tyrosine kinase inhibitor tki therapy either sunitinib cabozantinib monotherapy advanced metastatic renal cell carcinoma rcc ,
Deutivacaftor,deutivacaftor investigation clinical trial nct03227471 study vx-445 healthy subject subject cystic fibrosis ,
PF-06650833,pf-06650833 investigation clinical trial nct02609139 study evaluate pharmacokinetics modified release formulation pf-06650833 healthy subject ,
Altropane I-123,altropane i-123 investigation clinical trial nct01950468 cross-over multi-center trial evaluate diagnostic efficacy safety 123i nav5001 imaging agent aid diagnosis parkinsonian syndrome ,
Ziresovir,ziresovir investigation clinical trial nct03699202 anti-rsv study chinese patient ascent ,
Adrabetadex,adrabetadex investigation clinical trial nct03887533 combined intrathecal intravenous vts-270 therapy liver neurological disease associated niemann-pick disease type c1 ,
Tinostamustine,tinostamustine investigation clinical trial nct03452930 tinostamustine without radiation therapy treating patient newly diagnosed mgmt-unmethylated glioblastoma ,
Lenzilumab,lenzilumab investigation clinical trial nct02546284 study lenzilumab previously treated patient chronic myelomonocytic leukemia cmml ,
Futibatinib,futibatinib inhibitor fibroblast growth factor receptor fgfr comprises group receptor tyrosine kinase play key role cell proliferation differentiation migration survival fgfr investigated oncology therapeutic target fgfr genomic aberration dysregulated fgfr signalling pathway observed cancer cholangiocarcinoma urothelial malignancy a253193 a253198 novel inhibitor fgfr futibatinib first approved fda september 2022 treat different type intrahepatic cholangiocarcinoma l43347 ,futibatinib indicated treat adult previously treated unresectable locally advanced metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 fgfr2 gene fusion rearrangement l43347 indication approved accelerated approval based overall response rate duration response continued approval indication may contingent upon verification description clinical benefit confirmatory trial l43347 
Fibronectin,fibronectin investigation clinical trial nct01812239 vaginal progesterone twin short cervix ,
RO-6870810,ro-6870810 investigation clinical trial nct02308761 study ro6870810/ten-010 participant acute myeloid leukemia myelodysplastic syndrome ,
TMC-649128,tmc-649128 investigation clinical trial nct01391117 tmc649128hpc1002 trial ingenotype 1 hepatitis c virus hcv infected participant determine safety tolerability pharmacokinetics antiviral activity tmc649128 alone combined pegylated interferon ribavirin ,
Dezamizumab,dezamizumab investigation clinical trial nct03417830 biodistribution 89zirconium-labelled gsk2398852 using pet imaging ,
Vunakizumab,vunakizumab investigation clinical trial nct03463187 multi-dose study shr-1314 subject moderate-to-severe plaque psoriasis ,
Pepinemab,pepinemab investigation clinical trial nct03769155 vx15/2503 without ipilimumab and/or nivolumab patient resectable stage iiib-d melanoma ,
ABT-072,abt-072 investigation clinical trial nct00890318 study healthy adult subject evaluate safety tolerability pharmacokinetic profile multiple dos abt-072 used treat hepatitis c ,
Voruciclib,voruciclib investigation clinical trial nct03547115 phase 1 study voruciclib subject b-cell malignancy aml ,
BPI-3016,bpi-3016 investigation clinical trial nct03188848 dose escalating study bpi-3016 healthy subject ,
Trevogrumab,trevogrumab investigation clinical trial nct02943239 study safety tolerability pharmacokinetics regn2477 alone combination regn1033 healthy postmenopausal woman healthy adult men ,
Asunercept,asunercept investigation clinical trial nct02853565 study can008 newly diagnosed glioblastoma multiforme ,
Pittsburgh Compound B,pittsburgh compound b investigation clinical trial nct01723553 amyloid-related imaging abnormality microbleeds atypical ad ,
Pegilodecakin,pegilodecakin investigation clinical trial nct03382912 study pegilodecakin ly3500518 nivolumab compared nivolumab alone second-line tx participant metastatic non-small cell lung cancer ,
Selatogrel,selatogrel investigation clinical trial nct03814200 study investigate effect rifampicin uptake breakdown act-246475 healthy subject ,
Apadamtase alfa,apadamtase alfa investigation clinical trial nct03922308 study radamts-13 shp655 treatment participant acquired thrombotic thrombocytopenic purpura attp ,
Avacincaptad pegol,avacincaptad pegol investigation clinical trial nct03362190 zimura combination lucentis patient neovascular age related macular degeneration nvamd ,
Albuvirtide,albuvirtide investigation clinical trial nct03719664 albuvirtide 3bnc117 long-acting maintenance therapy virologically suppressed subject ,
Fallypride,fallypride investigation clinical trial nct02310360 striatal extra-striatal dopamine release response food healthy human ,
Cilofexor,cilofexor investigation clinical trial nct02943447 safety tolerability efficacy cilofexor adult primary biliary cholangitis without cirrhosis ,
H3B-6527,h3b-6527 investigation clinical trial nct03424577 study evaluate food-effect h3b-6527 ,
Evobrutinib,evobrutinib investigation clinical trial nct03934502 effect meal composition timing evobrutinib bioavailability ,
Tirzepatide,tirzepatide novel dual glucose-dependent insulinotropic polypeptide gip glucagon-like peptide-1 glp-1 receptor agonist dual gip/glp-1 agonist gained increasing attention new therapeutic agent glycemic weight control demonstrated better glucose control weight loss compared selective glp-1 receptor agonist preclinical clinical trial a246260 tirzepatide comprises 39 amino acid linear synthetic peptide conjugated c20 fatty diacid moiety a246260 protein sequence based sequence endogenous gip pharmacological action glp-1 receptor comparable endogenous gip however long half-life tirzepatide allows once-weekly dosing a246265 tirzepatide approved fda may 13 2022 treatment adult type 2 diabetes making first gip glp-1 receptor agonist indication l41820 september 15 2022 tirzepatide also approved european commission l44386 ,tirzepatide indicated adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus l41815 l44376 europe may used monotherapy combination drug used treat diabetes l44376 drug studied patient history pancreatitis tirzepatide indicated use patient type 1 diabetes mellitus l41815 
Suvratoxumab,suvratoxumab investigation clinical trial nct02296320 study efficacy safety medi4893 ,
JNJ-42165279,jnj-42165279 investigation clinical trial nct02498392 efficacy safety tolerability study jnj-42165279 participant major depressive disorder anxious distress ,
Ofranergene obadenovec,ofranergene obadenovec investigation clinical trial nct01229865 safety efficacy vb-111 subject advanced differentiated thyroid cancer ,
Quilizumab,quilizumab investigation clinical trial nct01160861 study investigate safety tolerability pharmacokinetics memp1972a patient allergic rhinitis ,
VX-659,vx-659 investigation clinical trial nct03224351 study evaluating safety efficacy vx-659 combination therapy subject cystic fibrosis ,
Tomuzotuximab,tomuzotuximab investigation clinical trial nct02052960 cetugex™ comparison cetuximab treatment patient head neck cancer ,
alpha-Lactalbumin,alpha-lactalbumin investigation clinical trial nct02082418 effect alpha-lactalbumin intake metabolic cognitive function elderly ,
Fosmanogepix,fosmanogepix investigation clinical trial nct03604705 efficacy safety study apx001 non-neutropenic patient candidemia ,
Rasdegafusp alfa,rasdegafusp alfa investigation clinical trial nct03206047 atezolizumab guadecitabine cdx-1401 vaccine treating patient recurrent ovarian fallopian tube primary peritoneal cancer ,
Paxalisib,gdc-0084 investigation clinical trial nct03696355 study gdc-0084 pediatric patient newly diagnosed diffuse intrinsic pontine glioma diffuse midline glioma ,
Dubermatinib,dubermatinib investigation clinical trial nct03572634 phase 1/2 study tp-0903 inhibitor axl kinase patient previously treated cll ,
Livoletide,livoletide investigation clinical trial nct03790865 effect livoletide azp-531 food-related behavior patient prader-willi syndrome ,
Birabresib,birabresib investigation clinical trial nct02698176 dose exploration study mk-8628 participant selected advanced solid tumor mk-8628-006 ,
GLPG-0259,glpg-0259 investigation clinical trial nct01024517 glpg0259 solid formulation bioavailability food effect ,
MAX-40279,max-40279 investigation clinical trial nct03412292 max-40279 subject acute myelogenous leukemia aml ,
ABT-288,abt-288 investigation clinical trial nct01018875 efficacy safety study abt-288 subject mild-to-moderate alzheimer 's disease ,
BMS-955176,bms-955176 investigation clinical trial nct02415595 dose-finding study bms-955176 treat hiv-1 infected treatment-naive adult ,
Cotadutide,cotadutide investigation clinical trial nct03444584 study medi0382 combination dapagliflozin metformin overweight/obese subject type 2 diabetes ,
Mibenratide,mibenratide investigation clinical trial nct01798745 study ass pharmacokinetics pharmacodynamics jnj-54452840 participant heart failure anti-beta1-adrenergic receptor autoantibody ,
RSV-604,rsv-604 investigation clinical trial nct00416442 safety tolerability pharmacokinetic study single multiple intravenous dos rsv604 healthy subject ,
Dextromethadone,dextromethadone investigation clinical trial nct00588640 study d-methadone patient chronic pain ,
Ciraparantag,ciraparantag investigation clinical trial nct01826266 effect double-blind single dose per977 administered alone following single dose edoxaban ,
Bixalomer,bixalomer investigation clinical trial nct01115985 study ass effect asp1585 pharmacokinetics atorvastatin healthy volunteer ,
Norbixin,norbixin investigation clinical trial nct03820245 effect short-term annatto carotenoid supplementation oxidative stress status healthy individual ,
Fluoroacetic acid F-18,fluoroacetic acid f-18 investigation clinical trial nct01320787 18-f-fluoroacetate pet imaging agent ,
JNJ-26489112,jnj-26489112 investigation clinical trial nct00579384 study effect jnj-26489112 photic induced paroxysmal electroencephalogram eeg response patient photosensitive epilepsy ,
Fosravuconazole,fosravuconazole investigation clinical trial nct03378661 bendita benznidazole new dos improved treatment association ,
Capromorelin,capromorelin investigation clinical trial nct00527046 effect oral growth hormone secretagogue older functionally limited adult ,
Uprifosbuvir,uprifosbuvir investigation clinical trial nct02332707 efficacy safety grazoprevir mk-5172 uprifosbuvir mk-3682 elbasvir mk-8742 ruzasvir mk-8408 chronic hepatitis c genotype gt 1 gt2 infection mk-3682-011 ,
Esaxerenone,esaxerenone investigation clinical trial nct02722265 long-term study cs-3150 monotherapy combination antihypertensive drug japanese patient essential hypertension ,
NOP-1A,nop-1a investigation clinical trial nct01198197 pet brain whole body distribution study nociceptin/orphanin fq peptide nop receptor using 11c nop-1a ,
MK-0736,mk-0736 investigation clinical trial nct00679055 study mk-0736 affect arterial plaque 0736-006 terminated ,
Chlorotoxin,chlorotoxin investigation clinical trial nct00733798 safety efficacy study intravenous 131i-tm601 adult patient malignant melanoma ,
Duvortuxizumab,duvortuxizumab investigation clinical trial nct02743546 study safety pharmacokinetics pharmacodynamics efficacy duvortuxizumab jnj-64052781 plus ibrutinib lymphoma ,
Pemafibrate,pemafibrate investigation clinical trial nct03350165 study pemafibrate patient nonalcoholic fatty liver disease nafld ,
25-desacetylrifapentine,25-desacetylrifapentine investigation clinical trial nct00023387 tbtc study 25pk intensive pharmacokinetic study three dos rifapentine 25-desacetyl rifapentine ,
BMS-986104,bms-986104 investigation clinical trial nct02211469 randomized placebo-controlled double-blind single ascending dose study evaluate safety tolerability pharmacokinetics pharmacodynamics bms-986104 healthy male subject ,
KRN-5500,krn-5500 investigation clinical trial nct00002923 krn5500 treating patient metastatic solid tumor ,
Amylose,amylose investigation clinical trial nct01027325 resistant starch insulin sensitivity trial ,
Gastric inhibitory polypeptide,gastric inhibitory polypeptide investigation clinical trial nct03081676 effect gip glp-1 insulin glucagon secretion patient hnf1a-diabetes treated without sulphonylurea ,
Pozelimab,pozelimab investigation clinical trial nct03115996 study safety tolerability pharmacokinetics pharmacodynamics regn3918 healthy volunteer ,
Tomivosertib,tomivosertib investigation clinical trial nct03318562 pd study oral eft508 subject advanced tnbc hcc ,
Seliforant,seliforant investigation clinical trial nct01260753 proof activity study ur-63325 allergic rhinitis induced nasal challenge ,
PF-06260414,pf-06260414 investigation clinical trial nct02070939 study evaluate safety tolerability single multiple ascending dos pf- 06260414 healthy western japanese male subject ,
GS-6620,gs-6620 investigation clinical trial nct01316237 study evaluating safety tolerability pharmacokinetics antiviral activity gs-6620 treatment naïve subject chronic hepatitis c virus infection ,
Flotetuzumab,flotetuzumab investigation clinical trial nct02152956 safety study mgd006 relapsed/refractory acute myeloid leukemia aml intermediate-2/high risk md ,
Lisavanbulin,lisavanbulin investigation clinical trial nct02895360 phase 1/2a study bal101553 48-hour infusion patient advanced solid tumor recurrent glioblastoma ,
Mitazalimab,mitazalimab investigation clinical trial nct02379741 adc-1013 first-in-human study ,
Dasiglucagon,dasiglucagon glucagon analog act increase blood sugar level l39190 consists 29 amino acid similar endogenous glucagon however contains seven substituted amino acid improved physical chemical stability drug formulation l39195 march 2021 fda approved dasiglucagon treat severe hypoglycemia patient six year older diabetes available subcutaneous injection marketed zegalogue l39190 severe hypoglycemia acute life-threatening medical condition resulting profound drop blood glucose level characterized neurological impairment manifestation like loss consciousness seizure hypoglycemia common side effect antidiabetic treatment notably insulin sulfonylurea although tends common type 1 diabetes mellitus occurring 22 46 patient annually 7 25 patient type 2 diabetes mellitus treated insulin experience severe hypoglycemia year l39195 even close monitoring blood glucose level always possible prevent severe hypoglycemic event patient diabetes child particularly risk experiencing severe hypoglycemia l39200 treatment severe hypoglycemia mostly limited intravenous dextrose different glucagon formulation l39195 approval dasiglucagon mark first glucagon analog approved severe hypoglycemia treatment require administration healthcare professional l39195 ,dasiglucagon antihypoglycemic agent indicated treatment severe hypoglycemia pediatric adult patient diabetes aged 6 year l39190 
Tirabrutinib,tirabrutinib investigation clinical trial nct02626026 safety pharmacokinetics gs-4059 healthy volunteer subject rheumatoid arthritis ra ,
Avidin,avidin investigation clinical trial nct00345618 clinical study assessing idrabiotaparinux sodium injection once-weekly pulmonary embolism therapeutic approach ,
CNV-2197944,cnv-2197944 investigation clinical trial nct01893125 efficacy safety cnv2197944 versus placebo patient diabetic peripheral neuropathy ,
Dithiopyr,dithiopyr investigation clinical trial nct01236781 comparison full-field digital mammography digital breast tomography screening call-back rate ,
Brimapitide,brimapitide investigation clinical trial nct01570205 safety tolerability pk single iv infusion 10 40 80 µg/kg xg-102 administered healthy volunteer ,
Telaglenastat,telaglenastat investigation clinical trial nct02071862 study glutaminase inhibitor cb-839 solid tumor ,
Avapritinib,avapritinib blu-285 a189327 selective tyrosine kinase inhibitor kit platelet derived growth factor receptor alpha indicated treatment unresectable metastatic gastrointestinal stromal tumor advanced systemic mastocytosis a189339 l40363 one first medication available treatment multidrug resistant cancer a189327 avapritinib share similar mechanism ripretinib avapritinib granted fda approval 9 january 2020 l40363 ema approval 24 september 2020 l41464 ,avapritinib indicated treatment adult unresectable metastatic gist harboring platelet-derived growth factor receptor alpha pdgfra exon 18 mutation including pdgfra d842v mutation l40363 also used treat adult patient advanced systemic mastocytosis advsm advsm includes patient aggressive systemic mastocytosis asm systemic mastocytosis associated hematological neoplasm sm-ahn mast cell leukemia however recommended treatment patient advsm platelet count le 50 x 10 sup 9 /sup l. l40363 
Semorinemab,semorinemab investigation clinical trial nct03289143 study evaluate efficacy safety ro7105705 patient prodromal mild alzheimer 's disease ,
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone,di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone investigation clinical trial nct02688101 dose-finding pharmacokinetic study dpc administered orally patient advanced solid tumor ,
Fucose,fucose investigation clinical trial nct03354533 study orl-1f l-fucose patient leukocyte adhesion deficiency type ii ,
Fluciclovine,fluciclovine investigation clinical trial nct03036943 fluciclovine 18f imaging breast cancer ,
Olinciguat,olinciguat investigation clinical trial nct03892499 trial evaluate effect itraconazole itz cyp3a4 inhibitor pharmacokinetics soluble guanylate cyclase stimulator olinciguat iw-1701 healthy volunteer ,
PTI-428,pti-428 investigation clinical trial nct03258424 study assessing pti-428 safety tolerability pharmacokinetics subject cystic fibrosis kalydeco® background therapy ,
Elezanumab,elezanumab investigation clinical trial nct03737812 study ass safety efficacy elezanumab added standard care progressive form multiple sclerosis ,
Methylsamidorphan,methylsamidorphan investigation clinical trial nct01418092 alk37-007 evaluation safety efficacy alks 37 rdc-1036 adult opioid-induced constipation oic ,
MK-0533,mk-0533 investigation clinical trial nct00543959 efficacy tolerability mk0533 patient type 2 diabetes 0533-005 ,
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a,2- 1-hexyloxyethyl -2-devinyl pyropheophorbide-a investigation clinical trial nct01668823 photodynamic therapy treating patient lung cancer ,
Iopofosine I-131,iopofosine i-131 nm-404 i-131 investigation clinical trial nct01495663 dose escalation study i-131-clr1404 subject cancer respond treatment returned ,
Olorofim,olorofim investigation clinical trial nct03340597 assessment varying oral dosing regimen f901318 healthy subject ,
Salvianolic acid A,salvianolic acid investigation clinical trial nct03908242 phase study continuous administration salvianolic acid tablet ,
Vorolanib,vorolanib investigation clinical trial nct03904719 cm082 js001 patient advanced small-cell lung cancer sclc ,
Bulevirtide,hepatitis considered severe type viral hepatitis lead rapid development cirrhosis severe decompensation liver function increased risk mortality a226340 l30235 recently extremely limited treatment available hepatitis infection a226305 bulevirtide also known hepcludex first-in-class entry inhibitor treatment chronic hepatitis infection developed myr pharmaceutical part gilead first approved use eu may 28 2020 bulevirtide granted prime scheme eligibility orphan drug designation european medicine agency l30215 usa bulevirtide granted orphan drug designation breakthrough therapy designation l30260 l30275 due potentially beneficial synergistic effect treating chronic hepatitis bulevirtide also investigation clinical trial nct03852433 phase 2b study bulevirtide peginterferon alfa-2a patient chd completion clinical trial anticipated early 2023 l30240 ,bulevirtide indicated treatment chronic hepatitis infection hdv-rna positive adult patient compensated liver disease l30215 
MK-6325,mk-6325 investigation clinical trial nct01329913 safety pharmacokinetics pharmacodynamics mk-6325 hepatitis c virus hcv infection mk-6325-003 ,
Vercirnon,vercirnon novel orally active anti-inflammatory agent target chemokine receptor protein implicated crohn 's disease ulcerative colitis two principal form ibd investigation clinical trial nct01611805 japanese phase gsk1605786 ,
Antipain,antipain serine/cysteine protease inhibitor originally isolated various strain actinomycete a214481 early study investigated potential antipain alter dna damage chromosomal aberration irradiated cell treated chemical mutagen _n_-methyl-_n_'-nitro-_n_-nitrosoguanidine mnng a214484 a214487 antipain used 2010 obtain crystal structure _leishmania major_ oligopeptidase b opb serine protease serf virulence factor trypanosomatids a214490 binding antipain opb used molecular dynamic study identify opb inhibitor favourable pharmacodynamic pharmacokinetic property potential development anti-trypanosomatid drug a214493 a214496 ,
Nemolizumab,nemolizumab investigation clinical trial nct03921411 pharmacokinetics safety study nemolizumab adolescent subject atopic dermatitis ad ,
Bleselumab,bleselumab investigation clinical trial nct02921789 study ass efficacy safety bleselumab preventing recurrence focal segmental glomerulosclerosis de novo kidney transplant recipient ,
RO-5126766 free base,ro-5126766 free base investigation clinical trial nct03875820 phase trial vs-6063 ro5126766 ,
Reldesemtiv,reldesemtiv investigation clinical trial nct03160898 study evaluate efficacy safety tolerability ck-2127107 patient amyotrophic lateral sclerosis al ,
Milademetan,milademetan investigation clinical trial nct02319369 safety tolerability pharmacokinetics milademetan alone 5-azacitidine aza acute myelogenous leukemia aml high-risk myelodysplastic syndrome md ,
Imlifidase,chronic kidney disease ckd progressive irreversible disease represents significant burden individual healthcare system large a225916 currently available treatment end-stage renal disease limited dialysis renal transplantation former associated significant cost lower quality life a225836 a225916 patient developed human leukocyte antigen hla sensitization prior exposure blood product pregnancy circumstance may resulted exposure non-self hla antigen face additional barrier transplantation a225836 a225921 highly sensitized individual carry high level anti-hla antibody significant risk antibody-mediated rejection occurs mainly complement-dependent cytotoxicity cdc antibody-dependent cellular cytotoxicity adcc a225836 high level anti-hla antibody also contribute poor graft survival a225836 result highly sensitized individual experience marked delay transplant list due challenge associated procuring hla compatible donor graft a225836 a225921 imlifidase cysteine protease eliminates fc-dependent effector function cdc adcc cleaving heavy chain human immunoglobulin g igg antibody l28001 result risk antibody-mediated rejection reduced allowing kidney transplantation highly sensitized patient proceed a225836 l28001 ,imlifidase indicated desensitization highly sensitized adult kidney transplant patient positive crossmatch available deceased donor l28001 treatment reserved patient unlikely receive transplant available kidney allocation system including prioritization program highly sensitized patient l28001 
VB-201,vb-201 investigation clinical trial nct01001468 study ass vb-201 patient psoriasis ,
Iscalimab,iscalimab investigation clinical trial nct03905525 study safety efficacy multiple dos cfz533 two distinct population patient sjögren 's syndrome ,
Butafenacil,butafenacil investigation clinical trial nct03760328 effect upper airway stimulation patient obstructive sleep apnea ,
Futuximab,futuximab investigation clinical trial nct01955473 japanese phase 1 trial sym004 solid tumor ,
Thyrotropin,thyrotropin investigation clinical trial nct01348191 detection thyrotrophin receptor human myometrium ,
PD-0299685,pd-0299685 investigation clinical trial nct00314964 study evaluating pd-0299685 treatment vasomotor symptom hot flash flush associated menopause ,
USL-311,usl-311 investigation clinical trial nct02765165 phase 1/2 study usl311 alone combination lomustine subject advanced solid tumor relapsed/recurrent glioblastoma multiforme gbm ,
Tovorafenib,tovorafenib tak-580 investigation clinical trial nct02723006 study evaluate safety tolerability pharmacodynamics investigational treatment combination standard care immune checkpoint inhibitor participant advanced melanoma ,
Lesinidase alfa,lesinidase alfa investigation clinical trial nct02324049 safety pharmacokinetics pharmacodynamics/efficacy sbc-103 mucopolysaccharidosis iii type b mp iiib ,
Afabicin,afabicin investigation clinical trial nct03723551 study ass safety tolerability efficacy afabicin treatment participant bone joint infection due staphylococcus ,
ALK-4290,alk-4290 investigation clinical trial nct03558061 evaluate effect safety alk4290 patient newly diagnosed wet age-related macular degeneration ,
Efgartigimod alfa,myasthenia gravis mg autoimmune disorder characterized significant muscle weakness particularly eye throat extremity caused autoantibody attacking neuromuscular junction a243759 production igg autoantibody acetylcholine receptor achrs one common pathophysiological mechanism behind mg result destruction receptor reduction electrical nerve impulse a243759 a243784 efgartigimod alfa first-in-class l39501 antagonist neonatal fc receptor fcrn used treatment myasthenia gravis mg l39496 igg antibody including autoantibody responsible mg symptom 'recycled process significantly extends half-life evading lysosomal degradation via binding fcrn l39509 antagonizing interaction efgartimod alfa prevents recycling phase thus decrease half-life igg effectively lowering circulating level igg autoantibody achrs efgartimod alfa granted fda approval december 17 2021 l39501 european commission approval august 11 2022 l43190 ,efgartigimod alfa indicated treatment generalized myasthenia gravis adult patient anti-acetylcholine receptor antibody-positive l39496 l43185 
Crizanlizumab,crizanlizumab humanized igg2 monoclonal antibody used reduce frequency vaso-occlusive crisis patient sickle cell disease l10097 sickle cell disease genetically inherited condition prevalent middle east africa certain part india genetic mutation associated disease lead formation abnormal sickle shaped red blood cell aggregate block blood vessel throughout body causing vaso-occlusive crisis sickle cell disease lead excruciating pain stroke infection various complication arising blockage blood vessel t734 currently patient prescribed hydroxyurea raise level fetal hemoglobin method reducing morbidity mortality a187904 though hydroxyurea shown reduce frequency vaso-occlusive crisis adherence therapy difficult due adverse effect high variability response drug patient a187907 crizanlizumab seg101 given every 4 week may improve patient adherence developed novartis granted fda approval november 15 2019 l10097 ,crizanlizumab indicated reduce frequency vaso-occlusive crisis patient sickle cell disease ≥16 year old l10097 
Edratide,edratide investigation clinical trial nct00203151 study evaluate tolerability safety effectiveness edratide treatment lupus ,
VS-4718,vs-4718 investigation clinical trial nct02215629 dose escalation study acute myeloid b-cell acute lymphoblastic leukemia ,
Pertussis vaccine,pertussis vaccine investigation clinical trial nct01698346 pertussis tdap vaccination pregnancy ,
GDC-0077,gdc-0077 investigation clinical trial nct03006172 evaluate safety tolerability pharmacokinetics gdc-0077 single agent participant solid tumor combination endocrine targeted therapy participant breast cancer ,
PR1 leukemia peptide vaccine,pr1 leukemia peptide vaccine investigation clinical trial nct00513578 vaccine therapy gm-csf treating patient low-risk intermediate-risk myelodysplastic syndrome ,
Gedivumab,gedivumab investigation clinical trial nct01877785 study mhaa4549a ass safety pharmacokinetics healthy volunteer ,
Marzeptacog alfa (activated),marzeptacog alfa activated investigation clinical trial nct01439971 phase 1 safety pharmacokinetics pharmacodynamics study recombinant factor viia variant 813d adult subject hemophilia ,
CB-103,cb-103 investigation clinical trial nct03422679 study cb-103 adult patient advanced metastatic solid tumour haematological malignancy ,
Gimsilumab,gimsilumab investigation clinical trial nct01357759 safety tolerability morab-022 healthy rheumatoid arthritis subject ,
Ravoxertinib,ravoxertinib investigation clinical trial nct01875705 dose-escalation study gdc-0994 patient locally advanced metastatic solid tumor ,
Fluorofuranylnorprogesterone F-18,fluorofuranylnorprogesterone f-18 investigation clinical trial nct02455453 assessment functional status estrogen receptor breast cancer positron emission tomography ,
Tebentafusp,tebentafusp gp100 peptide-hla-directed cd3 cell engager l39995 bispecific fusion protein first-in-class drug immune-mobilizing monoclonal cell receptor cancer immtacs recently developed cancer immunotherapy novel mechanism action immtacs bind target cancer cell express specific antigen interest recruit cytotoxic cell lyse cell melanocyte a244815 a244910 uveal melanoma rare ocular tumour often poor prognosis limited treatment option even surgical ablation removal ocular tumour almost 50 patient uveal melanoma develop metastatic disease a244815 january 26 2022 tebentafusp first approved fda treatment hla-a 02:01-positive adult unresectable metastatic uveal melanoma approval mark first bispecific cell engager approved fda treat solid tumour first therapy treatment unresectable metastatic uveal melanoma approved fda l39995 tebentafusp subsequently approved indication eu april 2022 l41675 ,tebentafusp indicated treatment hla-a 02:01-positive adult patient unresectable metastatic uveal melanoma l39985 
Sulopenem,sulopenem investigation clinical trial nct03357614 sulopenem followed sulopenem-etzadroxil/probenecid v ertapenem followed cipro complicated uti adult ,
ARC-19499,arc-19499 investigation clinical trial nct01191372 first-in-human proof-of-mechanism study arc19499 administered hemophilia patient ,
CB-1158,cb-1158 investigation clinical trial nct03910530 study incmga00012 incb001158 combination japanese participant advanced solid tumor ,
Elismetrep,elismetrep investigation clinical trial nct02429102 study investigate safety tolerability pharmacokinetics mt-8554 healthy subject ,
Etamicastat,etamicastat investigation clinical trial nct02840565 tolerability pharmacokinetics pharmacodynamics six multiple rising dose regimen bia 5-453 ,
Perillyl alcohol,perillyl alcohol investigation clinical trial nct02704858 safety efficacy study recurrent grade iv glioma ,
Pegteograstim,pegteograstim investigation clinical trial nct02787876 pegteograstim child solid tumor ,
BMS-986142,bms-986142 investigation clinical trial nct02880670 pharmacokinetics metabolism study radiolabeled bms-986142 healthy male subject ,
Foliglurax,foliglurax investigation clinical trial nct02639221 phase double blind placebo controlled first human single multiple ascending oral dose safety tolerability pharmacokinetic study healthy male female subject ,
Epalrestat,epalrestat investigation clinical trial nct03244358 evaluation epalrestat metastatic triple-negative breast cancer ,
SB-1578,sb-1578 investigation clinical trial nct01235871 single multiple-dose study sb1578 ,
Tenalisib,tenalisib investigation clinical trial nct03711604 compassionate use study tenalisib rp6530 ,
D-fluoromethyltyrosine F-18,d-fluoromethyltyrosine f-18 investigation clinical trial nct01089998 pet/ct imaging radiation dosimetry plasma pharmacokinetics safety tolerability healthy volunteer safety tolerability diagnostic performance bay86-9596 patient non-small cell lung cancer breast cancer head neck cancer patient inflammation ,
Petesicatib,petesicatib investigation clinical trial nct02295332 study rg7625 healthy volunteer ,
Ontamalimab,ontamalimab investigation clinical trial nct03627091 efficacy safety study shp647 maintenance treatment participant moderate severe crohn 's disease carmen cd 307 ,
Navtemadlin,navtemadlin amg-232 investigation clinical trial nct03041688 mdm2 inhibitor amg-232 decitabine treating patient relapsed refractory newly-diagnosed acute myeloid leukemia ,
Hydroquinidine,hydroquinidine investigation clinical trial nct00927732 hydroquinidine versus placebo patient brugada syndrome ,
Bevifimod,bevifimod investigation clinical trial nct01749787 safety study prtx-100 methotrexate leflunomide treat active rheumatoid arthritis ,
2-fluorofucose,2-fluorofucose investigation clinical trial nct02952989 safety study sgn-2ff patient advanced solid tumor ,
Faricimab,retinal vascular disease rvds diabetic macular edema dme age-related macular degeneration amd retinal vein occlusion rvo typically caused retinal ischemia subsequent neovascularization nv a225985 a225990 a225995 vascular endothelial growth factor vegf-a well-known mediator retinal nv many currently approved rvd therapy aflibercept ranibizumab solely target vegf-a however another set factor tie/ang axis comprising transmembrane tie-2 receptor soluble ligand ang-1 ang-2 shown play critical role mediating vegf-a-induced nv a225985 a225990 a225995 faricimab igg sub 1 /sub -derived bispecific antibody capable simultaneously binding depleting vegf-a ang-2 developed improve therapeutic efficacy especially patient respond poorly anti-vegf-a monotherapy a225985 a225990 a225995 a226000 a226005 a226010 faricimab approved fda january 28 2022 currently marketed trademark vabysmo genentech inc. l40026 received subsequent approval indication canada may 2022 l42305 july 2022 ema 's committee medicinal product human use chmp recommended faricimab granted marketing authorization treatment neovascular age-related macular degeneration diabetic macular edema l43085 ,faricimab indicated treatment neovascular wet age-related macular degeneration namd diabetic macular edema dme l40026 
iota-Carrageenan,iota-carrageenan investigation clinical trial nct01944631 iota-carrageenan nasal spray common cold ,
Risdiplam,risdiplam orally bioavailable mrna splicing modifier used treatment spinal muscular atrophy sma l12615 increase systemic smn protein concentration improving efficiency _smn2_ gene transcription mechanism action similar predecessor nusinersen biggest difference route administration nusinersen requires intrathecal administration one-time gene therapy onasemnogene abeparvovec whereas risdiplam offer ease oral bioavailability l15351 a216871 risdiplam approved fda august 2020 treatment spinal muscular atrophy sma l15331 l15336 set substantially cheaper available sma therapy l15351 risdiplam appears provide novel relatively accessible treatment option patient sma regardless severity type ,risdiplam indicated treatment spinal muscular atrophy sma l41935 
MEDI-6469,medi-6469 monoclonal antibody investigation clinical trial nct02205333 phase 1b/2 safety tolerability medi6469 combination therapeutic immune agent monoclonal antibody ,
Atabecestat,atabecestat investigation clinical trial nct02211079 study ass effect jnj-54861911 pharmacokinetics cocktail representative cytochrome p450 cyp 3a4 cyp2b6 cyp2c9 cyp1a2 substrate ,
Ridinilazole,ridinilazole investigation clinical trial nct02092935 study smt19969 compared vancomycin treatment clostridium difficile-associated diarrhoea cdad ,
Vactosertib,vactosertib investigation clinical trial nct03724851 vactosertib combination pembrolizumab metastatic colorectal gastric cancer ,
Davanat,davanat investigation clinical trial nct00054977 safety gm-ct-01 without 5-fluorouracil patient solid tumor ,
Orilanolimab,orilanolimab investigation clinical trial nct03075878 safety study synt001 subject chronic stable warm autoimmune hemolytic anemia waiha ,
DAS-181,das-181 investigation clinical trial nct00527865 single dose escalating study das181 adult ,
Modimelanotide,modimelanotide investigation clinical trial nct01897519 safety efficacy trial multiple dosing regimen abt-719 prevention acute kidney injury subject undergoing high risk surgery ,
Coblopasvir,coblopasvir investigation clinical trial nct03416491 safety efficacy kw-136 sofosbuvir treatment chronic hepatitis c ,
Florasulam,florasulam investigation clinical trial nct01193465 temperature humidity among different anesthesia work-station ,
Posiphen,posiphen investigation clinical trial nct02925650 safety tolerability pk pd posiphen® subject early alzheimer 's disease ,
Neodymium,neodymium investigation clinical trial nct03525522 nd yttrium aluminum garnet laser treatment lichen sclerosus ,
VM4-037,vm4-037 investigation clinical trial nct00884520 exploratory open label multi-center non-randomized study f-18 vm4-037 ,
Tefinostat,tefinostat investigation clinical trial nct02759601 dose escalation trial tefinostat cancer associated inflamation hepatocellular carcinoma hcc ,
Lacutamab,lacutamab investigation clinical trial nct02593045 study iph4102 patient relapsed/refractory cutaneous t-cell lymphoma ctcl ,
Trelagliptin,trelagliptin investigation clinical trial nct03555591 specified drug-use survey trelagliptin tablet `` survey long-term use patient type 2 diabetes mellitus '' ,
ORM-13070 C-11,orm-13070 c-11 investigation clinical trial nct00735774 suitability 11c-orm-13070 pet tracer ,
ONO-8539,ono-8539 investigation clinical trial nct01707901 study effect ono-8539 oesophageal pain hypersensitivity patient non-erosive reflux disease ,
CXL-1020,cxl-1020 investigation clinical trial nct01092325 safety hemodynamic effect pharmacokinetics cxl-1020 patient stable heart failure ,
Abivertinib,abivertinib tyrosine kinase inhibitor targeted mutant form human epidermal growth factor receptor egfr bruton 's tyrosine kinase btk l17383 investigated use treatment non-small cell lung cancer nsclc b-cell malignancy binding inhibiting egfr btk receptor abivertinib exerts immunomodulatory effect preventing production release pro-inflammatory cytokine e.g tnf-alpha interleukin l17388 abivertinib 's potential depress cytokine production led investigation treatment hospitalized patient moderate-to-severe covid-19 l17388 l17393 cytokine storm associated covid-19 thought contribute disease progression associated poor outcome patient abivertinib inhibits release multiple cytokine may provide pronounced clinical benefit compared agent targeting single pathway e.g interleukin-6 inhibitor study expected completed march 2021 l17398 ,
Ubrogepant,ubrogepant indicated acute treatment migraine headache without aura adult l10926 approved fda december 23 2019 first oral calcitonin gene-related peptide cgrp receptor antagonist approved acute treatment migraine l10959 several oral small molecule cgrp receptor antagonist belonging class medication referred `` gepants '' investigated migraine ubrogepant rimegepant remain clinical development a189207 a189213 previous agent within class efficacious limited liver toxicity led development ubrogepant designed hepatoxicity-free alternative predecessor a189195 several parenteral monoclonal antibody acting cgrp pathway e.g erenumab fremanezumab galcanezumab also approved recent year a189207 ubrogepant approved health canada november 10 2022 l43987 compared current standard therapy migraine treatment namely triptans sumatriptan almotriptan cgrp antagonist present several advantage a189195 appear better tolerated contribute medication overuse headache carry apparent cardiovascular risk making suitable use patient cardiovascular disease a189195 development oral gepants including ubrogepant may therefore constitute significant advance migraine headache treatment may become new standard therapy treatment debilitating condition ,ubrogepant indicated acute treatment migraine without aura adult l10926 l43987 
Nattokinase,nattokinase investigation clinical trial nct00749801 efficacy safety geneferm nattokinase ,
Nesvacumab,nesvacumab investigation clinical trial nct01997164 study intravitreal ivt regn910-3 ivt regn910 patient either neovascular wet age related macular degeneration amd diabetic macular edema dme ,
Vocimagene amiretrorepvec,vocimagene amiretrorepvec investigation clinical trial nct02576665 study toca 511 retroviral replicating vector combined toca fc patient solid tumor lymphoma toca 6 ,
Radavirsen,radavirsen investigation clinical trial nct01375985 safety study single administration intravenous treatment influenza ,
AZD-1386,azd-1386 investigation clinical trial nct00945178 double-blind placebo-controlled 2-part study assessing safety tolerability pk azd1386 healthy volunteer ,
Biochanin A,biochanin investigation clinical trial nct02174666 isoflavone treatment postmenopausal osteopenia ,
Formononetin,formononetin investigation clinical trial nct02174666 isoflavone treatment postmenopausal osteopenia ,
Valanafusp alfa,valanafusp alfa investigation clinical trial nct03071341 extension study evaluating long term safety activity agt-181 child mp ,
Rovatirelin,rovatirelin investigation clinical trial nct01384435 phase ii double blind comparative study kps-0373 patient spinocerebellar degeneration scd ,
Methcathinone,methcathinone investigation clinical trial nct02617862 pci imaging system pediatric ophthalmology ,
EC-0652,ec-0652 investigation clinical trial nct02202447 phase 1 ec1169 patient recurrent mcrpc ,
Dinalbuphine sebacate,dinalbuphine sebacate investigation clinical trial nct02468128 study intramuscular sebacoyl dinalbuphine ester post-hemorrhoidectomy pain management ,
Panobacumab,panobacumab investigation clinical trial nct00851435 safety pharmacokinetics kbpa-101 hospital acquired pneumonia caused o11 pseudomonas aeruginosa ,
Tuspetinib,tuspetinib hm-43239 investigation clinical trial nct03850574 clinical trial evaluate safety tolerability pharmacokinetics pharmacodynamics hm43239 patient relapsed refractory acute myeloid leukemia ,
beta-Hydroxyisovaleric acid,beta-hydroxyisovaleric acid investigation clinical trial nct03018496 investigating effect beta-hydroxy-beta-methylbutyrate glucose handling older younger men ,
GSK-945237,gsk-945237 investigation clinical trial nct01039610 single center four part study healthy adult subject evaluate safety tolerability pharmacokinetics single oral dose repeat escalating oral dos gsk945237 effect linezolid hematology safety parameter effect gsk945237 moxifloxacin qtc ,
GLPG-1205,glpg-1205 investigation clinical trial nct03725852 clinical study test effective safe glpg1205 patient idiopathic pulmonary fibrosis ipf ,
Branebrutinib,branebrutinib investigation clinical trial nct02705989 safety tolerability relative bioavailability study bms-986195 healthy subject ,
Ampreloxetine,ampreloxetine investigation clinical trial nct03750552 clinical effect td-9855 treating snoh subject primary autonomic failure ,
Sofituzumab vedotin,sofituzumab vedotin investigation clinical trial nct01335958 safety pharmacokinetics dmuc5754a administered intravenously patient platinum-resistant ovarian cancer unresectable pancreatic cancer ,
D-chiro-Inositol,d-chiro-inositol investigation clinical trial nct03201601 evaluation mixture myoinositol d-chiro-inositol 3.6:1 woman polycystic ovary syndrome ,
Dihematoporphyrin ether,dihematoporphyrin ether investigation clinical trial nct00118222 high light low light dose pdt glioma ,
Vorsetuzumab mafodotin,vorsetuzumab mafodotin investigation clinical trial nct01677390 phase 1b study sgn-75 combination everolimus patient renal cell carcinoma ,
Nacubactam,nacubactam investigation clinical trial nct03174795 study investigate pharmacokinetics ro7079901 meropenem participant complicated urinary tract infection ,
Evinacumab,evinacumab recombinant human igg4 monoclonal antibody targeted angiopoietin-like protein 3 angptl3 first drug kind angptl family protein serve number physiologic function including involvement regulation lipid metabolism made desirable therapeutic target recent year a229273 loss-of-function mutation _angptl3_ noted result hypolipidemia subsequent reduction cardiovascular risk whereas increase function appear associated cardiovascular risk observation provided rationale development therapy targeted angptl3 a229278 february 2021 evinacumab became first-and-only inhibitor angptl3 receive fda approval granted approval adjunctive treatment homozygous familial hypercholesterolemia hofh brand name `` evkeeza '' l31838 evinacumab novel mechanism action compared lipid-lowering therapy therefore provides unique synergistic therapeutic option treatment hofh ,evinacumab indicated adjunct lipid-lowering therapy treatment familial homozygous hypercholesterolemia hofh patient 12 year age older l31833 
PL-3994,pl-3994 investigation clinical trial nct01304628 cross-over study subcutaneous study drug treatment patient mild moderate asthma ,
SLV-334,slv-334 investigation clinical trial nct00735085 phase 2a dose escalation study slv334 patient traumatic brain injury ,
Xanomeline,xanomeline investigation clinical trial nct02831231 pilot study comparing effect xanomeline alone xanomeline plus trospium ,
JNJ-54175446,jnj-54175446 investigation clinical trial nct02933762 study healthy participant evaluate effect jnj-54175446 amyloid biomarkers cytokine profile cerebrospinal fluid plasma ,
Xanthohumol,xanthohumol investigation clinical trial nct01367431 xanthohumol metabolic syndrome ,
"Carfentanil, C-11",carfentanil c-11 investigation clinical trial nct01899170 towards individualized deep brain stimulation treatment chronic neuropathic pain ,
Thallium Tl-201,thallium tl-201 investigation clinical trial nct02697760 czt dynamic myocardial perfusion imaging ,
LSZ-102,lsz-102 investigation clinical trial nct02734615 phase i/ib trial lsz102 single agent lsz102 lee011 lsz102 byl719 er+ breast cancer ,
Istiratumab,istiratumab investigation clinical trial nct02399137 phase 2 study mm-141 plus nab-paclitaxel gemcitabine front-line metastatic pancreatic cancer ,
Pegbelfermin,pegbelfermin investigation clinical trial nct03486899 study experimental medication bms-986036 adult nonalcoholic steatohepatitis nash stage 3 liver fibrosis ,
SOR-C13,sor-c13 investigation clinical trial nct01578564 safety tolerability study sor-c13 subject advanced cancer commonly known express trpv6 channel ,
LY-2623091,ly-2623091 investigation clinical trial nct02194465 study ly2623091 participant high blood pressure ,
Yttrium Y-90 clivatuzumab tetraxetan,yttrium y-90 clivatuzumab tetraxetan investigation clinical trial nct00603863 safety efficacy study different dos 90y-hpam4 combined gemcitabine pancreatic cancer ,
Aganirsen,aganirsen investigation clinical trial nct02947867 trial aganirsen icrvo patient risk developing nvg ,
Balixafortide,balixafortide investigation clinical trial nct03786094 pivotal study her2 negative locally recurrent metastatic breast cancer ,
MK-2748,mk-2748 investigation clinical trial nct01593735 multiple dose study evaluate safety efficacy mk-2748 hepatitis c-infected participant mk-2748-002 am1 ,
JNJ-27548547,jnj-27548547 investigation clinical trial nct01705002 intravenously administered pegylated liposomal mitomycin-c lipid-based prodrug promitil cancer patient solid tumor ,
Tilmanocept,tilmanocept investigation clinical trial nct03241446 pharmacokinetics dosimetry tc 99m tilmanocept following single intravenous dose administration male female subject diagnosed rheumatoid arthritis ra ,
Cobalt Co-60,cobalt co-60 investigation clinical trial nct02891083 adjuvant therapy surgery alone high risk pn0 esophageal cancer ,
Tozuleristide,tozuleristide investigation clinical trial nct02464332 safety study blz-100 adult subject sarcoma undergoing surgery ,
Gosuranemab,gosuranemab investigation clinical trial nct02460094 multiple ascending dose study intravenously administered bms-986168 biib092 patient progressive supranuclear palsy ,
ATB-346,atb-346 investigation clinical trial nct03220633 study ass safety tolerability pk atb-346 healthy subject ,
Vopratelimab,vopratelimab investigation clinical trial nct02904226 jtx-2011 alone combination anti-pd-1 anti-ctla-4 subject advanced and/or refractory solid tumor ,
Hydroxypropyl betadex,hydroxypropyl betadex investigation clinical trial nct03471143 study iv vts-270 infantile liver disease associated niemann-pick disease type c ,
Flutriciclamide F-18,flutriciclamide f-18 investigation clinical trial nct02350426 study ass inflammation rheumatoid arthritis using molecular imaging technique ,
Menaquinone,menaquinone investigation clinical trial nct01533441 vitamin k2 intervention patient vitamin k antagonist ,
SAR-125844,sar-125844 investigation clinical trial nct01391533 study sar125844 single agent administered slow intravenous infusion adult patient advanced malignant solid tumor ,
Pidilizumab,pidilizumab investigation clinical trial nct01952769 anti pd1 antibody diffuse intrinsic pontine glioma ,
Simotaxel,simotaxel investigation clinical trial nct00088647 study evaluating mst-997 advanced malignant solid tumor ,
Acebilustat,acebilustat investigation clinical trial nct01748838 phase 1 study assessing safety tolerability ctx-4430 ,
ALT-801,alt-801 investigation clinical trial nct01478074 alt-801-activated natural killer cell flag induction acute myeloid leukemia ,
Bintrafusp alfa,bintrafusp alfa investigation clinical trial nct03833661 m7824 monotherapy locally advanced metastatic second line 2l biliary tract cancer cholangiocarcinoma gallbladder cancer ,
Anti-GD2 monoclonal antibody 3F8,anti-gd2 monoclonal antibody 3f8 investigation clinical trial nct00089258 biological therapy treating patient neuroblastoma responded previous treatment ,
Teceleukin,teceleukin investigation clinical trial nct03610490 autologous tumor infiltrating lymphocyte mda-til treating patient recurrent refractory ovarian cancer osteosarcoma pancreatic ductal adenocarcinoma ,
Efizonerimod alfa,efizonerimod alfa investigation clinical trial nct02221960 phase 1 study evaluate medi6383 alone combination medi4736 adult subject select advanced solid tumor ,
Elenbecestat,elenbecestat investigation clinical trial nct02956486 24-month study evaluate efficacy safety elenbecestat e2609 subject early alzheimer 's disease ,
Cesium,cesium investigation clinical trial nct02794675 intraoperative placement cesium-131 permanent interstitial brachytherapy head neck cancer ,
Telatinib,telatinib investigation clinical trial nct03817411 telatinib combination capecitabine/ oxaliplatin 1st line gastric gej cancer ,
gamma-Tocopherol,gamma-tocopherol investigation clinical trial nct00836368 vitro basophil responsiveness allergen challenge gamma-tocopherol supplementation allergic asthmatic ,
PF-06863135,pf-06863135 investigation clinical trial nct03269136 phase 1 study pf-06863135 bcma- cd3 bispecific ab relapse/ refractory multiple myeloma ,
Vamotinib,vamotinib pf-114 investigation clinical trial nct02885766 study evaluate tolerability safety pharmacokinetics preliminary efficacy pf-114 oral administration adult ph+ chronic myeloid leukemia resistant 2-nd generation bcr-abl inhibitor t315i mutation bcr-abl gene ,
GMA-161,gma-161 investigation clinical trial nct00244257 safety study gma161 patient idiopathic thrombocytopenic purpura itp ,
Dihydrocapsiate,dihydrocapsiate investigation clinical trial nct00999297 effect 4-week dihydrocapsiate ingestion resting metabolic rate ,
BMS-754807,bms-754807 investigation clinical trial nct00908024 combination study bms-754807 erbitux® subject advanced metastatic solid tumor ,
Lifastuzumab vedotin,lifastuzumab vedotin investigation clinical trial nct01363947 safety pharmacokinetics escalating dos dnib0600a participant non-small cell lung cancer nsclc platinum resistant ovarian cancer ,
Danicopan,danicopan investigation clinical trial nct03459443 proof concept study 12 month treatment patient c3 glomerulopathy c3g immune-complex membranoproliferative glomerulonephritis ic-mpgn ,
Tucotuzumab celmoleukin,tucotuzumab celmoleukin investigation clinical trial nct00016237 interleukin-2 combined monoclonal antibody therapy treating patient kidney bladder lung cancer responded previous treatment ,
Ziritaxestat,ziritaxestat investigation clinical trial nct03798366 clinical study test effective safe glpg1690 patient systemic sclerosis ,
"Heparin, bovine",heparin bovine investigation clinical trial nct01072747 efficacy safety unfractionated heparin patient cardiovascular surgery using cardiopulmonary bypass ,
FET F-18,fet f-18 investigation clinical trial nct01756352 fet-pet evaluation response recurrent gbm avastin ,
GLPG-0974,glpg-0974 investigation clinical trial nct01721980 multiple ascending dose study glpg0974 healthy subject ,
Acalisib,acalisib investigation clinical trial nct01705847 phase 1b study evaluating gs-9820 subject lymphoid malignancy ,
Silmitasertib,silmitasertib investigation clinical trial nct03904862 testing safety tolerability cx-4945 patient recurrent medulloblastoma may may surgery ,
Ladiratuzumab vedotin,ladiratuzumab vedotin investigation clinical trial nct01969643 safety study sgn-liv1a breast cancer patient ,
(S)-Propafenone, -propafenone investigation clinical trial nct02710669 new formulation propafenone treat atrial fibrillation ,
ABP-700,abp-700 investigation clinical trial nct02800590 study investigate safety efficacy 3 dosing regimen abp-700 procedural sedation adult participant undergoing colonoscopy ,
LB-100,lb-100 investigation clinical trial nct03886662 study lb-100 patient low intermediate-1 risk myelodysplastic syndrome md ,
Pafolacianine,pafolacianine otl38 folate analogue conjugated fluorescent dye absorbs light near-infrared nir spectrum a242572 within range 760 nm 785 nm peak absorption 776 nm emits fluorescence within range 790 nm 815 nm peak emission 796 nm l39332 longer wavelength allows deeper penetration fluorescent light tissue better imaging detection tumour pafolacianine target folate receptor alpha frα upregulated numerous epithelial malignancy a242572 november 29 2021 fda approved pafolacianine adjunct imaging agent intraoperative identification malignant lesion adult patient ovarian cancer l39332 currently investigation use frα-positive pituitary adenoma lung cancer a242577 renal-cell carcinoma thought second-highest folate receptor-expressing cancer a242572 ,pafolacianine optical imaging agent indicated adult patient ovarian cancer adjunct intraoperative identification malignant lesion l39332 
CM-4307,cm-4307 investigation clinical trial nct03602495 donafenib 131i-refractory differentiated thyroid cancer ,
Tomaralimab,tomaralimab investigation clinical trial nct01794663 placebo-controlled study evaluate safety efficacy opn-305 preventing delayed renal graft function ,
PX-102,px-102 investigation clinical trial nct01998672 multiple ascending oral dose phase study px-102 ,
Recanaclotide,recanaclotide investigation clinical trial nct01712412 phase 2a study iw-9179 treat functional dyspepsia ,
AZD-9977,azd-9977 investigation clinical trial nct03843060 phase 1 study ass pharmacokinetics azd9977 administered alone combination itraconazole healthy volunteer ,
Nanatinostat,nanatinostat investigation clinical trial nct00697879 safety study histone deacetylase inhibitor chr-3996 patient advanced solid tumour ,
Coagulation factor XIa,coagulation factor xia investigation clinical trial nct01701947 hemoleven® expanded access program prevention surgical/postpartum hemorrhage severe inherited factor xi deficiency ,
Cetrelimab,cetrelimab investigation clinical trial nct03547037 study evaluate safety pharmacokinetics pharmacodynamics immunogenicity jnj-63723283 anti-programmed cell death pd -1 monoclonal antibody monotherapy combination erdafitinib japanese participant advanced solid cancer ,
ILS-920,ils-920 investigation clinical trial nct00827190 study evaluating single ascending dos ils-920 ,
Disaccharide tripeptide glycerol dipalmitoyl,disaccharide tripeptide glycerol dipalmitoyl investigation clinical trial nct00003667 combination chemotherapy biological therapy treating patient high-risk ewing 's sarcoma ,
Bfpet F-18,bfpet f-18 investigation clinical trial nct03265431 evaluation pet/mr patient selected ablation therapy ,
CYC-065,cyc-065 investigation clinical trial nct03739554 cyc065 cdk inhibitor venetoclax study relapsed/refractory cll ,
Giripladib,giripladib investigation clinical trial nct00396955 study comparing 4 dose regimen pla-695 naproxen placebo subject osteoarthritis knee ,
Fialuridine,fialuridine investigation clinical trial nct01337466 biodistribution dosimetry evaluation 124i fiau ,
Vesencumab,vesencumab investigation clinical trial nct00747734 study mnrp1685a patient locally advanced metastatic solid tumor ,
Thioglycolic acid,thioglycolic acid investigation clinical trial nct03238105 treatment periorbicular hyperchromia comparing 10 thioglycolic acid peeling versus pulsed intense light ,
Elgemtumab,elgemtumab investigation clinical trial nct02167854 open-label study evaluating safety tolerability ljm716 byl719 trastuzumab patient metastatic her2+ breast cancer ,
M-2698,m-2698 investigation clinical trial nct01971515 first-in-human dose escalation trial subject advanced malignancy ,
Pinatuzumab vedotin,pinatuzumab vedotin investigation clinical trial nct01691898 study pinatuzumab vedotin dcdt2980s combined rituximab polatuzumab vedotin dcds4501a combined rituximab obinutuzumab participant relapsed refractory b-cell non-hodgkin 's lymphoma nhl ,
AVI-7537,avi-7537 investigation clinical trial nct01593072 study ass safety tolerability pharmacokinetics avi-7537 healthy adult volunteer ,
Mosunetuzumab,mosunetuzumab humanized anti-cd20/cd3 bispecific antibody l42230 recognize bind two different target simultaneously cd20 cancer b-cells cd3 t-cells allowing redirect t-cell cytotoxic activity cancer cell a249320 standard care patient b-cell lymphoma includes anti-cd20 monoclonal antibody rituximab combination chemotherapy however patient certain type b-cell lymphoma follicular lymphoma fl chronic lymphocytic leukemia cll aggressive b-cell lymphoma high probability relapse recurrence treatment a249320 a249390 mosunetuzumab potential circumvent resistance rituximab patient follicular lymphoma a249320 l42230 unlike car-t therapy axicabtagene ciloleucel tisagenlecleucel “ off-the-shelf ” alternative readily available patient l42245 june 2022 european medicine agency approved mosunetuzumab treatment adult patient relapsed refractory r/r fl received least two prior systemic therapy l42245 ,mosunetuzumab monotherapy indicated treatment adult patient relapsed refractory follicular lymphoma fl received least two prior systemic therapy l42230 
BMS-986158,bms-986158 investigation clinical trial nct02419417 study bms-986158 subject select advanced cancer ,
Glucoraphanin,glucoraphanin investigation clinical trial nct01879878 pilot study evaluating broccoli sprout advanced pancreatic cancer pouder trial ,
Rocacetrapib,rocacetrapib investigation clinical trial nct02156544 study investigate safety/tolerability pharmacokinetics/pharmacodynamics ckd-519 ,
Artemin,artemin investigation clinical trial nct01842126 phase 1 subcutaneous single multiple ascending dose study bg00010 neublastin ,
Navoximod,"navoximod investigation clinical trial nct02048709 indoleamine 2,3-dioxygenase ido inhibitor advanced solid tumor ",
GSK-3117391,gsk-3117391 investigation clinical trial nct02965599 efficacy safety tolerability pharmacokinetics pharmacodynamics gsk3117391 subject rheumatoid arthritis ,
Lulizumab pegol,lulizumab pegol investigation clinical trial nct02843659 proof concept study evaluate efficacy safety bms-931699 lulizumab bms-986142 primary sjögren 's syndrome ,
Trilaciclib,trilaciclib g1t28 cdk4 cdk6 inhibitor indicated reduce incidence chemotherapy induced myelosuppression patient topotecan-containing platinum etoposide-containing chemotherapy extensive stage small cell lung cancer l31828 cdk4 cdk6 inhibitor investigated since mid 1990s use tumorigenesis chemotherapy a229323 trilaciclib first described literature 2016 a229313 trilaciclib granted fda approval 12 february 2021 l31823 ,trilaciclib indicated reduce incidence chemotherapy induced myelosuppression patient prior receiving platinum etoposide-containing topotecan-containing chemotherapy regimen extensive-stage small cell lung cancer l31828 
Lorukafusp alfa,lorukafusp alfa investigation clinical trial nct01334515 biological therapy sargramostim isotretinoin treating patient relapsed refractory neuroblastoma ,
Elexacaftor,elexacaftor previously vx-445 small molecule next-generation corrector cystic fibrosis transmembrane conductance regulator cftr protein a187361 received fda approval october 2019 combination tezacaftor ivacaftor combination product trikafta sup tm /sup l9395 elexacaftor considered next-generation cftr corrector posse different structure mechanism compared first generation correctors like tezacaftor a187361 dual corrector/potentiator combination therapy proven useful treatment subset cf patient a187358 use typically limited patient homozygous _f508del-cftr_ gene a187361 elexacaftor along vx-659 designed fill need efficacious cf therapy patient heterozygous _f508del-cftr_ gene produce protein produce protein unresponsive ivacaftor tezacaftor a187361 triple combination product trikafta sup tm /sup manufactured vertex pharmaceutical first product approved treatment cf individual either homo- _or_ heterozygous _f508del-cftr_ gene represents approximately 70 a187373 -90 a187361 a187355 cf patient ,elexacaftor combination ivacaftor tezacaftor combination product trikafta sup tm /sup indicated treatment cystic fibrosis cf patient 12 year age older least one _f508del_ mutation ctfr gene l9395 
Iodohippuric acid,iodohippuric acid investigation clinical trial nct02599844 impact pediatric acute renal injury severe sepsis young adult ,
Vidofludimus,vidofludimus investigation clinical trial nct03722576 vidofludimus calcium primary sclerosing cholangitis ,
Setogepram,setogepram investigation clinical trial nct03184584 open-label rollover study pbi 4050 subject alström syndrome ,
Acumapimod,acumapimod investigation clinical trial nct02926326 effect azithromycin bct197 exposure healthy male volunteer ,
Citarinostat,citarinostat investigation clinical trial nct02886065 study pvx-410 cancer vaccine citarinostat +/- lenalidomide smoldering mm ,
PF-05105679,pf-05105679 investigation clinical trial nct01393652 single dose dose escalation healthy volunteer study pf-05105679 ,
SOBI-003,sobi-003 investigation clinical trial nct03811028 study ass safety tolerability efficacy long-term sobi003 treatment pediatric mp iiia patient ,
Technetium Tc-99m epratuzumab,technetium tc-99m epratuzumab investigation clinical trial nct00003337 radiolabeled monoclonal antibody detection staging patient non-hodgkin 's lymphoma ,
Naratuximab emtansine,naratuximab emtansine investigation clinical trial nct01534715 imgn529 treating patient relapsed refractory non-hodgkin 's lymphoma chronic lymphocytic leukemia ,
Cenersen,cenersen investigation clinical trial nct02243124 study aezea® cenersen transfusion dependent anemia associated myelodysplastic syndrome md ,
Vericiguat,vericiguat direct stimulator soluble guanylate cyclase sgc used management systolic heart failure reduce mortality hospitalization l31153 key component no-sgc-cgmp signaling pathway help regulate cardiovascular system sgc enzyme intracellular enzyme found vascular smooth muscle cell amongst cell type catalyze synthesis cyclic guanosine monophosphate cgmp response activation nitric oxide a227458 a227488 cyclic gmp act second messenger activating number downstream signaling cascade elicit broad variety effect diverse cellular effect implicated deficiency production primarily due insufficient bioavailability pathogenesis various cardiovascular disease a227458 direct stimulator sgc vericiguat mitigates need functional no-sgc-cgmp axis thereby help prevent myocardial vascular dysfunction associated decreased sgc activity heart failure l31178 vericiguat approved fda january 2021 developed merck brand name verquvo use certain patient systolic heart failure l31178 although first sgc stimulator granted fda approval riociguat approved 2013 use pulmonary hypertension l3955 vericiguat unique amongst peer modification structure dramatically decreased susceptibility oxidative metabolism a227458 resulting relatively long half-life allowing once-daily dosing ,vericiguat indicated adult symptomatic chronic heart failure ejection fraction 45 reduce risk cardiovascular death heart failure-related hospitalization following hospitalization heart failure need outpatient intravenous diuretic l31153 
Snubh-nm-333 F-18,snubh-nm-333 f-18 investigation clinical trial nct02149017 phase 1 phase 2 clinical trial snubh-nm-333 18f ,
Norleucine,norleucine investigation clinical trial nct00081952 amino acid therapy hot flash postmenopausal woman ,
AGG-523,agg-523 investigation clinical trial nct00380900 study evaluating safety tolerability pharmacokinetics pharmacodynamics multiple ascending dos healthy subject subject osteoarthritis ,
Yersinia pestis 195/p antigen (formaldehyde inactivated),yersinia pestis 195/p antigen formaldehyde inactivated investigation clinical trial nct02596308 immunogenicity safety subunit plague vaccine ,
Fucoxanthin,fucoxanthin investigation clinical trial nct03613740 effect fucoxanthin component metabolic syndrome insulin sensitivity insulin secretion fucoxanthin isi marine carotenoid mainly found brown algae giving brown olive-green color fucoxanthin investigated anti-inflammatory antinociceptive anti-cancer effect vivo study demonstrated oral administration fucoxanthin inhibited carcinogenesis animal model duodenal skin colon liver cancer fucoxanthin cause antitumor anticarcinogenic effect inducing g1 cell-cycle arrest apoptosis modulating expression various cellular molecule cellular signal transduction pathway exact mechanism anti-cancer action fucoxanthin fully elucidated fucoxanthin regulates lipid metabolism effect likely mediated amk-activated protein kinase clinical trial fucoxanthin non-alcoholic fatty liver disease ongoing ,
Belzutifan,belzutifan inhibitor hypoxia-inducible factor 2α hif-2α used treatment von hippel-lindau vhl disease-associated cancer l35995 hif-2α protein first identified 1990s researcher ut southwestern medical center key player growth certain cancer l36105 initially considered undruggable binding pocket eventually discovered hif-2α molecule allowed compound bind inhibit protein discovery led initial development belzutifan time called pt2977 developed spin-off company named peloton pharmaceutical eventually acquired merck 2019 l36105 belzutifan inhibits complexation hif-2α another transcription factor hif-1β necessary step activation preventing formation complex belzutifan slow stop growth vhl-associated tumor belzutifan received fda approval treatment select vhl-associated cancer august 13 2021 l36000 ,belzutifan indicated treatment adult patient von hippel-lindau vhl disease require therapy associated renal cell carcinoma rcc central nervous system cns hemangioblastomas pancreatic neuroendocrine tumor pnet require immediate surgery l35995 
Urolithin A,urolithin metabolite ellagic acid demonstrated stimulate mitophagy improve muscle health old animal preclinical model aging a179494 ,
Benzhydrocodone,benzhydrocodone benzylic prodrug hydrocodone l4894 developed effort reduce parenteral bioavailability active metabolite deterrent abuse a182177 benzhydrocodone indicated use short-term management pain first approved fda february 2018 combination acetaminophen trade name apadaz marketed kvk tech developed kempharm l7859 l7862 ,benzyhydrocodone indicated combination acetaminophen short-term management acute pain requiring opioid therapy l4894 
Tallimustine,tallimustine benzoyl mustard derivative distamycin alkylating agent bind minor groove dna a182036 a182039 's association severe myelotoxicity lead end development favour α-halogenoacrylamide derivative brostallicin favourable cytotoxicity/myelotoxicity ratio a182039 a182045 newer generation dna minor groove binding agent specifically recognize base pair sequence a182051 ,tallimustine investigated use treating tumor a182036 a182039 derivative tallimustine similar dna binding ability reduced myelotoxicity investigated antitumor activity a182039 
Zanidatamab,according zymeworks `` zw25 bispecific antibody simultaneously bind two non-overlapping epitope known biparatopic binding her2 resulting dual her2 signal blockade increased binding removal her2 protein cell surface potent effector function combined mechanism action led significant anti-tumor activity preclinical model breast gastric cancer `` l8219 ,
Zanidatamab zovodotin,according zymeworks `` zw49 zanidatamab zovodotin bispecific anti-her2 adc based antibody framework zw25 armed cytotoxic payload `` l8234 investigated several indication characterized her2 expression including breast gastric cancer progressed refractory existing her2-targeted therapy her2 expressing solid tumor ,
Modified vaccinia ankara,modified vaccinia ankara mva refers attenuated strain vaccinia virus vaccine using mva live non-replicating produced using modified vaccinia ankara-bavarian nordic mva-bn l42660 l42670 ,modified vaccinia ankara vaccine indicated prevention smallpox monkeypox disease adult 18 year age older determined high risk smallpox monkeypox infection l41155 eu additionally indicated prevention disease caused vaccinia virus l42670 
Echinacoside,echinacoside phenylethanoid glycoside isolated _echinacea angustifolia_ 1950 currently investigated treatment parkinson 's alzheimer 's atherosclerosis osteoporosis acute colitis wound treatment hepatitis a184577 echinacoside demonstrated inhibition apoptosis neural cell line demonstrating potential use treatment neurological condition a184592 ,
Mexazolam,mexazolam cs-386 benzodiazepine indicated treatment anxiety without psychoneurotic condition a184910 mexazolam 's structure similar benzodiazepine oxazolam cloxazolam a184910 use benzodiazepine treatment anxiety generally second line measure a184910 ,mexazolam indicated treatment anxiety without psychoneurotic condition a184910 
Cambinol,cambinol beta-naphtol derivative inhibits nad-dependant deacetylases reduce cell survival stress activity currently investigated use cancer treatment ,
Edotreotide gallium Ga-68,"edotreotide gallium ga-68 8 amino acid peptide bound chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid dota l8603 edotreotide gallium ga-68 indicated localizing somatostatin receptor positive neuroendocrine tumor positron emission tomography l8597 dotatate gallium ga-68 used similar indication a185852 dotatate gallium ga-68 lower tumor uptake data highly variable patient a185852 edotreotide gallium ga-68 granted fda approval 21 august 2019 l8597 ",edotreotide gallium ga-68 radioactive diagnostic compound used positron emission tomography pet diagnose somatostatin receptor positive neuroendocrine tumor pediatrics adult l8597 
Rocaglamide,rocaglamide also referred rocaglamide-a eponymous member class anti-cancer phytochemical known rocaglamides a186760 rocaglamides secondary metabolite plant genus _aglaia_ extract plant traditionally used form insect repellant due natural insecticidal property a186796 report _aglaia_ anti-tumor activity date back far 1973 rocaglamide-a first isolated 1982 specie _a elliptifolia_ a186760 rocaglamide number derivative e.g didesmethylrocaglamide currently studied use chemotherapeutic agent treatment various leukemia lymphoma carcinoma well adjuvant therapy treatment certain chemotherapy-resistant cancer a186781 a186784 a186799 a186766 ,
Didesmethylrocaglamide,didesmethylrocaglamide naturally-occurring derivative rocaglamide belongs class anti-cancer phytochemical referred `` rocaglamides '' derived plant genus _aglaia_ a186760 traditionally used insecticidal benefit a186796 class compound studied use chemotherapeutic agent treatment various leukemia lymphoma carcinoma a186802 a186763 a186781 a186784 known derivative rocaglamide didesmethylrocaglamide appears carry potent anti-tumour activity a186802 a186805 ,
BOS172722,bos172722 novel selective monopolar spindle 1 mps1 kinase inhibitor identified potential anticancer agent a187123 normally mps1 support proper division cancer cell ensuring survival replication key role mps1 growth cancer cell render appealing target cancer treatment inhibition could lead favorable effect a187120 vivo study combined bos172722 paclitaxel treatment triple hormone receptor negative breast cancer demonstrated promising synergistic effect a187123 ,
Cerdulatinib,cerdulatinib investigation clinical trial nct04021082 celtic-1 phase 2b study cerdulatinib patient relapsed/refractory peripheral t-cell lymphoma ptcl ,
Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Baccharis sarothroides whole,baccharis sarothroides whole allergenic extract used allergenic testing ,
Amaranthus hybridus pollen,amaranthus hybridus pollen allergenic extract used allergenic testing ,
Acacia dealbata pollen,acacia dealbata pollen allergenic extract used allergenic testing ,
"Influenza A virus A/Idaho/07/2018 (H1N1) antigen (MDCK cell derived, propiolactone inactivated", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Indiana/08/2018 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability , combination influenza virus subtypes type b strain influenza b viral strain used active immunization adult child aged 6 month older prevention influenza disease caused influenza virus subtypes type b l41345 
"Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Alnus serrulata pollen,alnus serrulata pollen allergenic extract used allergenic testing ,
Prosopis velutina seed,prosopis velutina seed allergenic extract used allergenic testing ,
Gibberella fujikuroi,gibberella fujikuroi allergenic extract used allergenic testing ,
Mucor circinelloides f. circinelloides,mucor circinelloides f. circinelloides allergenic extract used allergenic testing ,
Influenza A virus A/Switzerland/3330/2017 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Mucor circinelloides f. lusitanicus,mucor circinelloides f. lusitanicus allergenic extract used allergenic testing ,
Eurotium amstelodami,eurotium amstelodami allergenic extract used allergenic testing ,
Onasemnogene abeparvovec,onasemnogene abeparvovec adeno-associated virus vector-based gene therapy approved fda may 2019 treatment infant patient le 2 year age spinal muscular atrophy sma specific mutation survival motor neuron 1 smn1 gene l9194 sma rare genetic disease affect survival function motor neuron leading debilitating often fatal muscle weakness a187250 cure sma onasemnogene abeparvovec disease-modifying agent decelerates disease progression improves motor function manages symptom use effectiveness onasemnogene abeparvovec patient advanced sma complete paralysis limb permanent dependence ventilator evaluated onasemnogene abeparvovec first gene therapy approved indication usa nusinersen another gene therapy currently approved fda treatment sma pediatric adult patient developed avexis novartis company a187253 onasemnogene abeparvovec commonly marketed zolgensma® available single-dose intravenous infusion l9194 onasemnogene abeparvovec therapeutic use marketing currently assessed eu intrathecal formulation drug currently undergoing clinical development usa a187253 ,onasemnogene abeparvovec indicated treatment pediatric patient le 2 year age neonatal infant patient spinal muscular atrophy sma bi-allelic mutation survival motor neuron 1 smn1 gene l9194 
Leucanthemum vulgare pollen,leucanthemum vulgare pollen allergenic extract used allergenic testing ,
Trifolium pratense pollen,trifolium pratense pollen allergenic extract used allergenic testing ,
Colchiceine,colchiceine one several metabolite anti-gout medication colchicine a192714 ,
Sea scallop,sea scallop allergenic extract used allergenic testing ,
Northern brown shrimp,northern brown shrimp allergenic extract used allergenic testing ,
Rainbow trout,rainbow trout allergenic extract used allergenic testing ,
Yellowfin tuna,yellowfin tuna allergenic extract used allergenic testing ,
Atlantic mackerel,atlantic mackerel allergenic extract used allergenic testing ,
Pacific ocean perch,pacific ocean perch allergenic extract used allergenic testing ,
Myristica fragrans fruit,myristica fragrans fruit allergenic extract used allergenic testing ,
Pisum sativum whole,pisum sativum whole allergenic extract used allergenic testing ,
Skim milk,skim milk allergenic extract used allergenic testing ,
Black sea bass,black sea bass allergenic extract used allergenic testing ,
Channel catfish,channel catfish allergenic extract used allergenic testing ,
Atlantic halibut,atlantic halibut allergenic extract used allergenic testing ,
Pradefovir,pradefovir prodrug adefovir ,
Leptazoline A,leptazoline polar oxazoline cyanobacterium leptolyngbya sp also see leptazoline b leptazoline c leptazoline ,
Leptazoline B,leptazoline b polar oxazoline cyanobacterium leptolyngbya sp also see leptazoline leptazoline c leptazoline ,
Leptazoline C,leptazoline c polar oxazoline cyanobacterium leptolyngbya sp also see leptazoline leptazoline b leptazoline ,
Leptazoline D,leptazoline polar oxazoline cyanobacterium leptolyngbya sp also see leptazoline leptazoline b leptazoline c ,
"24-Homo-1,25-dihydroxyvitamin D3","24-homo-1,25-dihydroxyvitamin d3 novel vitamin analogue ",
Imalumab,imalumab investigation clinical trial nct02540356 phase 1/2a two-arm dose-escalation study bax69 subject malignant ascites ovarian cancer ,
Zenocutuzumab,zenocutuzumab investigation clinical trial nct03321981 mcla-128 trastuzumab/chemotherapy her2+ endocrine therapy er+ low her2 breast cancer ,
Reloxaliase,reloxaliase investigation clinical trial nct03456830 evaluate alln-177 patient enteric hyperoxaluria ,
Valoctocogene roxaparvovec,valoctocogene roxaparvovec adeno-associated virus serotype 5 aav5 based gene therapy vector express b-domain deleted sq form human coagulation factor viii hfviii-sq l43282 expression hfviii-sq driven liver-specific promoter enables hepatocytes produce factor viii protein increase level active factor viii blood l43282 a252807 valoctocogene roxaparvovec approved ema september 2022 indicated treatment severe hemophilia approved use united state l43292 hemophilia treatment prophylactic regimen exogenous factor viii emicizumab improve clinical outcome patient eliminate breakthrough bleeding a252797 opposed therapy valoctocogene roxaparvovec offer advantage continuous measurable steady-state level coagulation factor viii a252807 ,valoctocogene roxaparvovec indicated treatment severe hemophilia congenital factor viii deficiency adult patient without history factor viii inhibitor without detectable antibody adeno-associated virus serotype 5 aav5 l43282 
"Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Iowa/06/2017 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Prednisolone acetate,prednisolone acetate prednisolone molecule bound acetate functional group ester bond l9449 prednisolone acetate granted fda approval 1955 l9449 ,prednisolone acetate indicated anti-inflammatory immunosuppressive agent allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious condition l9449 prednisolone acetate also indicated organ transplant patient well endocrine neoplastic condition l9449 
PCLX-001,pclx-001 first-in-kind n-myristoyltransferase nmt inhibitor developed pacylex pharmaceutical http //pacylex.com current study shown pclx-001 work differently known cancer drug high activity positive result breast lung bladder pancreas cancer l9470 ,
Adagrasib,adagrasib mrtx849 oral small-molecule kras inhibitor developed mirati therapeutic kras mutation highly common cancer account approximately 85 ra family mutation a254941 however development kras inhibitor challenging due high affinity guanosine triphosphate gtp guanosine diphosphate gdp well lack clear binding pocket a187559 adagrasib target kras sup g12c /sup one common kras mutation cysteine 12 residue inhibits kras-dependent signalling a254052 phase i/ib clinical study included patient kras sup g12c /sup -mutated advanced solid tumor nct03785249 adagrasib exhibited anti-tumor activity phase ii study showed patient kras sup g12c /sup -mutated non-small-cell lung cancer nsclc adagrasib efficient without new safety signal a254052 a254057 a254946 february 2022 fda accepted new drug application nda adagrasib treatment patient previously treated kras sup g12c /sup –positive nsclc l43847 december 2022 fda granted accelerated approval adagrasib treatment kras sup g12c /sup -mutated locally advanced metastatic nsclc received least one prior systemic therapy l44361 l44366 adagrasib join sotorasib another kras sup g12c /sup inhibitor approved fda a254062 ,adagrasib indicated treatment adult patient kras g12c-mutated locally advanced metastatic non-small cell lung cancer nsclc determined fda-approved test received least one prior systemic therapy l44361 indication approved accelerated approval based objective response rate orr duration response dor continued approval indication may contingent upon verification description clinical benefit confirmatory trial l44361 
Sotorasib,sotorasib also known amg-510 acrylamide-derived kras inhibitor developed amgen a187547 a187556 indicated treatment adult patient kras g12c mutant non-small cell lung cancer l34288 mutation make 50 kras mutation a187550 mutant kras discovered 1982 considered druggable target mid-2010s a235168 first experimental kras inhibitor a187547 drug mrtx849 also currently developed target a187547 sotorasib granted fda approval may 28 2021 l34288 followed european commission 's approval january 10 2022 l39675 ,sotorasib indicated treatment kras g12c-mutated locally advanced metastatic non-small cell lung cancer nsclc adult received least one prior systemic therapy l34288 
FLX475,flx475 small molecule ccr4 antagonist investigated treatment cancer l9875 ,
CTX001,ctx001 developed crispr therapeutic vertex autologous crispr-cas9 modified cd34+ human hematopoietic stem progenitor cell clinical trial treatment severe sickle cell disease severe beta-thalassemia l10139 ,
Padeliporfin,padeliporfin water-soluble chlorophyll derivative cytotoxic photosensitizer used vascular-targeted photodynamic therapy malignancy a244559 vascular-targeted photodynamic therapy vtp vascular targeted photochemotherapy focal treatment localized prostate cancer aim destroy cancerous lesion prostate rather ablating entire prostate gland a244699 padeliporfin first approved european commission november 10 2017 treatment low-risk prostate cancer adult meeting certain clinical criterion l39799 ,padeliporfin indicated treatment adult previously untreated unilateral low-risk adenocarcinoma prostate life expectancy greater equal 10 year patient must meet following criterion clinical stage t1c t2a gleason score ≤ 6 based high-resolution biopsy strategy psa ≤ 10 ng/ml 3 positive cancer core maximum cancer core length 5 mm one core 1-2 positive cancer core ≥ 50 cancer involvement one core psa density ≥ 0.15 ng/ml/cm sup 3 /sup l39794 
Desfesoterodine,desfesoterodine metabolite tolterodine ,
Echinomycin,echinomycin cytotoxic polypeptide quinoxaline antibiotic isolated _streptomyces echinatus_ bind dna inhibits rna synthesis ,
Fluazuron,fluazuron benzoyl phenylurea compound ,
ORG-31710,org-31710 progestational hormone antagonist ,
Antimony potassium tartrate,antimony potassium tartrate schistosomicide possibly useful parasite irritant emetic property may cause lethal cardiac toxicity among adverse effect ,
Zingerone,zingerone pungent component ginger ,
beta-Apopicropodophyllin,beta-apopicropodophyllin component freshwater plant _micranthemum umbrosum_ ,
Cucurbita pepo subsp. ovifera whole,cucurbita pepo subsp ovifera whole allergenic extract used allergenic testing ,
Golodirsen,golodirsen morpholino antisense oligomer designed treat 8 patient duchenne muscular dystrophy dmd x-linked condition leading progressive muscle degeneration begin early childhood rendering many patient wheelchair-bound age 12 often patient succumb condition age 30 younger due cardiac respiratory complication a188580 t756 similar drug used treatment type dmd eteplirsen target different genetic mutation l10773 golodirsen developed sarepta therapeutic granted accelerated fda approval december 12 2019 due urgent need drug patient suffering certain form dmd continued approval drug depend result clinical trial confirm clinical benefit l10755 l10758 golodirsen initially rejected fda approval concern potential renal toxicity however clinical trial show significant toxicity l10755 ,golodirsen indicated treat duchenne muscular dystrophy dmd patient confirmed mutation dmd gene would benefit exon 53 skipping continued fda approval drug contingent upon result clinical trial confirm benefit l10755 l10758 
Brilliant blue G,brilliant blue g used ophthalmic solution staining internal limiting membrane ilm eye ophthalmic procedure a188841 a188844 membrane thin translucent making difficult identify eye surgery require high level visual accuracy brilliant blue g like name imparts vibrant blue color facilitating identification ilm approved fda ophthalmic use december 20 2019 l10830 , drug indicated selectively staining internal limiting membrane ilm l10830 
"Ebola Zaire vaccine (live, attenuated)","ebola virus vaccine vaccine used prevent ebola virus disease caused _zaire ebolavirus_ adult prevent outbreak reduce extent virus spreading case outbreak l10854 ebola virus disease formerly known ebola hemorrhagic fever rare severe often deadly disease highly contagious human human transmission occurs contact body fluid infected patient a189024 characterized fever headache myalgia gastrointestinal symptom may accompanied hypotension respiratory kidney liver failure well internal external bleeding a188994 a188997 _filoviridae_ family five unique ebolavirus specie named geographical region first identified mortality rate zaire specie 80 a188997 confirmed outbreak ebola virus disease documented since 1970s mostly sub-saharan africa ebola first appeared 1976 near ebola river zaire presently referred democratic republic congo sudan a188994 2014 2016 ebola outbreak occurred west africa leading 11,310 total death time guinea liberia sierra leone a188997 2016 epidemic exhausted country declared ebola-free 2016 world health organization lifted public health emergency international concern pheic status west africa ebola outbreak l10884 first live attenuated ebola virus vaccine developed team canadian researcher canada ’ national microbiology laboratory later patented canadian government l10866 non-human primate clinical trial vaccine effective inducing immune response ebola virus a189018 vaccine later sold newlink genetics biotech company held license vaccine 2010 2014 although vaccine marketed l10866 2014 merck inc. signed licensing agreement newlink development marketing ervebo marketed ebola virus vaccine merck first approved european commission november 2019 european medicine agency recommended licensed december 2019 ervebo approved fda united state ervebo consists envelope glycoprotein zaire ebolavirus kikwit 1995 strain fused vesicular stomatitis virus vsv backbone l10854 introducing relatively inactive viral protein patient patient ’ immune system learns recognize attack virus exposed future ",ebola zaire vaccine indicated active immunization individual 18 year age older protect ebola virus disease evd caused _zaire ebolavirus_ l10857 
Ferric maltol,ferric maltol iron iii atom complexed 3 maltol molecule increase bioavailability compared iron ii without depositing duodenum insoluble ferric hydroxide phosphate a189288 ferric maltol described literature since least late 1980s potential treatment iron deficiency a189291 ferric maltol granted fda approval 25 july 2019 l10974 ,ferric maltol indicated treat iron deficiency adult l10974 
NNZ-2591,nnz-2591 cyclo-l-glycyl-l-2-allylproline a189390 investigational synthetic analog cyclic glycine-proline cgp breakdown product human insulin-like growth factor 1 igf-1 chemically modified increase half-life stability oral bioavailability l11106 currently development neuren pharmaceutical symptomatic treatment angelman phelan-mcdermid pitt hopkins syndrome granted orphan drug designation fda october 2019 l11103 granted patent european patent office december 2019 l11100 clinical trial expected begin 2020 l11103 l11100 ,
Cashew fruit,cashew fruit extract used allergenic testing ,
"Coffea arabica seed, roasted",coffea arabica seed roasted allergenic extract used allergenic testing ,
Lactuca sativa whole,lactuca sativa whole allergenic extract used allergenic testing ,
Field mushroom,field mushroom allergenic extract used allergenic testing ,
White mustard seed,white mustard seed allergenic extract used allergenic testing ,
Theobroma cacao whole,theobroma cacao whole allergenic extract used allergenic testing ,
JPC-3210,jpc-3210 potent antimalarial agent erythrocytic schizonticide potent vitro antimalarial activity multidrug-resistant _plasmodium falciparum_ line low cytotoxicity potent vivo efficacy murine malaria favourable preclinical pharmacokinetics including lengthy plasma elimination half-life a189444 ,
Muskmelon,muskmelon allergenic extract used allergenic testing ,
American hazelnut,american hazelnut allergenic extract used allergenic testing ,
Musa acuminata fruit,musa acuminata fruit allergenic extract used allergenic testing ,
REC-994,rec-994 cleared fda july 2018 phase trial treatment cerebral cavernous malformation ccm ,
Ferric derisomaltose,iron deficiency extremely common condition frequent cause anemia worldwide iron deficiency result iron intake iron store loss iron body adequately support production erythrocyte also known red blood cell though generally considered non life-threatening iron deficiency may considerably affect quality life a190528 ferric derisomaltose form iron used treatment iron deficiency drug complex iron iii hydroxide derisomaltose latter iron carbohydrate oligosaccharide work release iron ferric derisomaltose developed pharmacosmos therapeutic ad granted fda approval january 2020 l11581 l11587 clinical trial show non-inferior iron sucrose another form iron often administered iron deficiency le likely cause serious hypersensitivity associated form injectable iron a190519 a188021 , drug indicated treatment iron deficiency anemia adult patient experienced intolerance oral iron preparation insufficient clinical response orally administered iron ferric derisomaltase also indicated patient non-hemodialysis dependent chronic kidney disease l11581 australia united kingdom ferric derisomaltase indicated case rapid delivery iron required l11617 l11620 
"(5E,7E,9)-decatrien-2-one"," compound produced _fomitopsis betulina_ edible fungus commonly called birch polypore similar 5z,7e,9 -decatrien-2-one strong pineapple aroma a191116 ",
"(5Z,7E,9)-decatrien-2-one"," compound produced _fomitopsis betulina_ edible fungus commonly called birch polypore similar 5e,7e,9 -decatrien-2-one strong pineapple aroma a191116 ",
Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Triazavirin,triazavirin guanine nucleotide analog antiviral originally developed russia shown efficacy influenza b including h5n1 strain a191709 a191625 a191916 appears triazavirin shown promise reducing influenza disease severity associated complication l12087 given similarity sars-cov-2 h5n1 health official investigating triazavirin option combat sars-cov-2 coronavirus responsible covid-19 a191625 ,triazavirin developed russia potential treatment influenza b infection a191706 
TMC-310911,tmc-310911 also known asc-09 novel investigational protease inhibitor pi structurally similar currently available darunavir l12045 investigated use hiv-1 infection tmc-310911 shown marked activity variety hiv-1 strain including multi-pi-resistant strain may le likely generate resistance making potentially desirable therapy treatment-naive pi-experienced patient l12045 a191643 tmc-310911 currently investigated combination hiv therapy antiviral potential treatment covid-19 caused sars-cov-2 l12012 ,
Spesolimab,spesolimab interleukin-36 il-36 receptor antagonist humanized monoclonal immunoglobulin g1 antibody produced chinese hamster ovary cho cell recombinant dna technology biosimilar drug spesolimab-sbzo first approved fda september 2022 treat generalized pustular psoriasis flare spesolimab work inhibiting inflammatory signaling pathway il-36 l43090 often overexpressed aberrantly overactive generalized pustular psoriasis a252220 a252225 october 2022 ema 's committee medicinal product human use chmp recommended spesolimab granted marketing authorization treatment flare adult patient generalised pustular psoriasis l43782 ,spesolimab indicated treatment generalized pustular psoriasis gpp flare adult l43090 
Dostarlimab,dostarlimab igg sub 4 /sub humanized monoclonal antibody targeted human programmed death receptor-1 pd-1 l33320 pd-1 receptor found t-cells activated serve inhibit immune response cancer leverage system overexpressing pd-1 ligand thereby effectively inhibiting anti-tumor immune response would typically attempt destroy cancerous cell a234379 agent acting pd-1 pathway nivolumab pembrolizumab facilitate endogenous immune-mediated anti-tumor activity may therefore used treat wide variety cancer including skin lung kidney liver april 2021 dostarlimab granted accelerated approval fda glaxosmithkline 's dostarlimab-gxly jemperli treatment adult patient recurrent advanced mismatch repair deficient dmmr endometrial cancer experiencing disease progression despite treatment platinum-containing chemotherapy regimen l33340 accelerated approval granted treatment dmmr endometrial cancer approved alongside companion diagnostic device ventana mmr rxdx panel use selecting appropriate patient treatment l33340 dostarlimab currently investigation treatment rectal cancer mismatch repair deficiency prospective phase ii study patient mismatch repair-deficient locally advanced rectal cancer resulted twelve patient exhibiting complete clinical response a248905 ,dostarlimab-gxly indicated treatment adult patient mismatch repair deficient dmmr recurrent advanced endometrial cancer progressed despite ongoing prior treatment platinum-containing chemotherapy regimen l33320 
Inolimomab,inolimomab investigation agent treat steroid-resistant graft v host disease thus far offered similar efficacy monoclonal antibody option though may carry higher risk infection a241385 ,
Garadacimab,garadacimab investigation clinical trial nct04281524 clinical study test efficacy safety csl312 catheter-associated blood clot formation subject cancer receive chemotherapy picc line ,
Glumetinib,glumetinib investigation clinical trial nct04270591 ass anti-tumor activity safety glumetinib patient advanced c-met-positive non-small cell lung cancer ,
Edodekin alfa,edodekin alfa investigation clinical trial nct01468896 cetuximab recombinant interleukin-12 treating patient squamous cell carcinoma head neck recurrent metastatic removed surgery ,
Zalifrelimab,zalifrelimab investigation clinical trial nct03894215 phase 2 study anti-pd-1 independently combination anti-ctla-4 second-line cervical cancer ,
Pabinafusp alfa,pabinafusp alfa investigation clinical trial nct03568175 study jr-141 patient mucopolysaccharidosis ii ,
Temelimab,temelimab investigation clinical trial nct02782858 clinical trial assessing herv-w env antagonist gnbac1 efficacy m ,
Omburtamab,cd276 b7-h3 b7/cd28 immunoglobulin superfamily member frequently expressed among solid human tumour a242487 a242492 omburtamab formerly murine anti-b7-h3 antibody 8h9 humanized form currently clinical development use various cancer a191829 omburtamab investigation clinical trial nct03275402 131i-omburtamab radioimmunotherapy neuroblastoma central nervous system/leptomeningeal metastasis ,
Zilucoplan,zilucoplan investigation clinical trial nct04225871 open-label extension zilucoplan subject generalized myasthenia gravis ,
Fluzoparib,fluzoparib investigation clinical trial nct03863860 trial maintenance treatment fluzoparib versus placebo relapsed ovarian cancer patient ,
Brensocatib,brensocatib investigation clinical trial nct03218917 assessment ins1007 subject non-cystic fibrosis bronchiectasis ,
AMG-337,amg-337 investigation clinical trial nct03147976 quilt-3.036 amg 337 subject advanced metastatic solid tumor ,
CDC-801,cdc-801 investigation clinical trial nct00006097 chemotherapy treating patient chronic lymphocytic leukemia ,
Droloxifene,droloxifene derivative triphenylethylene drug tamoxifen novel selective estrogen receptor modulator serm droloxifene also exhibit rapid pharmacokinetics reaching peak concentration eliminated much rapidly tamoxifen higher affinity estrogen receptor higher anti-estrogenic estrogenic ratio effective inhibition cell growth division estrogen receptor-positive cell line lower toxicity give theoretical advantage tamoxifen treatment human breast cancer short-term toxicity generally mild similar seen antiestrogens droloxifene appears active tolerable may particular role situation rapid pharmacokinetics increased antiestrogenic estrogenic ratio required droloxifene may also potentially useful agent treatment postmenopausal osteoporosis prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy droloxifene may effect bone breast tissue induces apoptosis droloxifene anti-implantation effect rat effect appears completely due anti-estrogenic activity l34184 ,
Molidustat,molidustat investigation clinical trial nct03350321 study molidustat correction renal anemia non-dialysis subject ,
N-(2-Aminoethyl)-1-aziridineethanamine,first described literature 2004 n- 2-aminoethyl -1-aziridineethanamine experimental angiotensin converting enzyme 2 inhibitor investigated use treating cardiovascular disease activity severe acute respiratory syndrome sars a192426 , experimental drug researched use treatment cardiovascular disease sars-cov infection a192426 
Ochromycinone,ochromycinone investigation clinical trial nct01047943 sta-21 topical efficacy psoriasis ,
Dihydromyricetin,dihydromyricetin investigation clinical trial nct03606694 effect dihydromirycetin glycemic control insulin sensitivity insulin secretion type 2 diabetes mellitus ,
Fasitibant,fasitibant investigation clinical trial nct02205814 fasitibant intra-articular injection patient symptomatic osteoarthritis knee ,
Ketodarolutamide,ketodarolutamide nonsteroidal antiandrogen nsaa major active metabolite darolutamide ,
Efpeglenatide,efpeglenatide investigation clinical trial nct03713684 efficacy safety efpeglenatide versus placebo patient type 2 diabetes mellitus inadequately controlled basal insulin alone combination oral antidiabetic drug ,
Valomaciclovir stearate,valomaciclovir stearate investigation clinical trial nct00831103 phase 2b trial epb-348 treatment herpes zoster ,
Ravidasvir,ravidasvir investigation clinical trial nct02961426 sofosbuvir plus ravidasvir treatment hcv chronic infection ,
Islatravir,islatravir investigation clinical trial nct04233216 doravirine/islatravir dor/isl heavily treatment-experienced hte participant human immunodeficiency virus type 1 hiv-1 infection mk-8591a-019 ,
Moderna COVID-19 Vaccine, moderna covid-19 vaccine mrna-1273 novel mrna-based vaccine encapsulated lipid nanoparticle encodes full-length pre-fusion stabilized spike protein severe acute respiratory syndrome coronavirus 2 sars-cov-2 coronavirus disease 2019 covid-19 highly contagious infectious disease caused novel coronavirus sars-cov-2 leading respiratory illness alongside complication covid-19 high interpatient variability symptom ranging mild symptom severe illness l28026 phase open-label dose-ranging clinical trial nct04283461 initiated march 2020 45 subject received two intramuscular dos day 1 29 l12660 trial later followed phase ii iii trial moderna covid-19 vaccine demonstrated vaccine efficacy 94.1 l28026 december 18 2020 fda first issued emergency use authorization eua moderna covid-19 vaccine second vaccine prevention covid-19 caused sars-cov-2 patient aged 18 year older eua issued pfizer-biontech covid-19 vaccine december 11 2020 moderna covid-19 vaccine administered series two intramuscular injection one month 28 day apart clinical trial difference safety profile younger older 65 year age older study participant l28026 december 23 2020 health canada issued expedited authorization moderna covid-19 vaccine l28143 november 2021 health canada ema authorized use moderna covid-19 vaccine booster shot given least six month following primary vaccination series half 50 mcg regular strength l39160 l39277 similar booster dose also available u patient 18 year age older l39217 moderna covid-19 vaccine fully approved fda january 31 2022 l40079 health canada expanded use moderna covid-19 vaccine include individual aged six 11 l39307 moderna covid-19 vaccine also approved use fourth booster shot adult 50 year age older l41350 , moderna covid-19 vaccine indicated active immunization prevent coronavirus disease 2019 covid-19 caused severe acute respiratory syndrome coronavirus 2 sars-cov-2 individual 18 year age older u europe l3927 l40074 individual 6 month age older canada l39307 u emergency use authorization moderna covid-19 vaccine used prevention covid-19 child 6 month age older l42770 administered two dos one month 28 day apart l28026 booster dose vaccine given least 6 month following initial vaccine series approved use patient 18 year age older canada u l39160 l39217 l39277 moderna covid-19 vaccine also approved use fourth booster shot adult 50 year age older l41350 new bivalent formulation moderna vaccine includes davesomeran approved november 2022 health canada august 2022 fda ba.4 ba.5 omicron variant l43862 
Ad5-nCoV,ad5-ncov recombinant adenovirus type-5 vector ad5 vaccine currently investigated prophylaxis sars-cov-2 l12675 l12678 developed cansino biologics inc. partnership beijing institute biotechnology march 2020 announced approval phase clinical trial chictr2000030906 l12675 expected completion december 2020 study evaluate antibody response healthy patient age 18 60 receive one three study dos follow-up taking place week 2 4 month 3 6 post-vaccination l12678 ,
AstraZeneca COVID-19 Vaccine, astrazeneca covid-19 vaccine previously known chadox1 ncov-19 azd1222 one several vaccine developed 2020 prevention covid-19 caused sars-cov-2 l12669 l32649 chadox1 viral vector developed university oxford investigated potential vector vaccine another human coronavirus middle eastern respiratory syndrome coronavirus mers-cov a192822 l12672 chadox1 ncov-19 vaccine produced partnership university oxford 's jenner institute italian pharmaceutical manufacturer advent srl consists replication-deficient adenovirus capable producing spike protein sars-cov-2 allowing formation endogenous antibody protein consequently sars-cov-2 l12672 university oxford struck development distribution deal astrazeneca may 2020 l32659 paved way vaccine 's subsequent approval usage dozen region across globe including canada mexico uk eu australia amongst others l32649 l32664 march 2021 several eu member country halted administration astrazeneca 's covid-19 vaccine due signal increased risk blood clot associated thrombocytopenia including development cerebral venous sinus thrombosis cvst upon review european medicine agency ema determined vaccine associated higher overall risk blood clot may associated rare instance blood clot association thrombocytopenia causal link vaccine proven possible requires analysis despite concern ema concluded review reiterating benefit vaccine prevention covid-19 condition lead blood clot continue outweigh risk associated administration l32674 phase i/ii single-blinded randomized placebo-controlled trial investigate safety efficacy immunogenicity vaccine began april 2020 expected completion date october 2021 l12669 trial taking place uk vaccine administered intramuscularly healthy adult volunteer age 18 55 l12669 , astrazeneca covid-19 vaccine indicated active immunization individual 18 year age older prevention covid-19 l32649 
Ala-geninthiocin,ala-geninthiocin novel thiopeptide antibacterial compound derived marine _streptomyces_ specie a192840 exhibited potent _in vitro_ activity gram-positive bacteria including _staphylococcus aureus_ _bacillus subtilis_ _mycobacterium smegmatis_ _micrococcus luteus_ a192840 ,
N4-Hydroxycytidine,n4-hydroxyctidine eidd-1931 ribonucleoside analog induces mutation rna virion a193008 a193011 n4-hydroxycytidine first described literature 1980 potent mutagen bacteria phage a193023 shown antiviral activity venezuelan equine encephalitis virus a193008 human coronavirus hcov-nl63 _in vitro_ a193017 n4-hydroxycytodine shown inhibit sars-cov-2 well human bat coronaviruses mouse human airway epithelial cell a193014 orally bioavailable mouse distributes tissue becoming active 5 ’ -triphosphate form incorporated genome new virion resulting accumulation inactivating mutation a193011 non-human primate n4-hydroxycytidine poorly orally bioavailable a193026 remdesivir resistant mutant mouse hepatitis virus also shown increased sensitivity n4-hydroxycytidine a193014 prodrug n4-hydroxycytidine eidd-2801 also investigated broad spectrum activity coronavirus family virus a193014 ,n4-hydroxycytidine prodrug eidd-2801 studied activity number viral infection including influenza mers-cov sars-cov-2 a193014 a193029 
Molnupiravir,molnupiravir eidd-2801 mk-4482 isopropylester prodrug n4-hydroxycytidine a193014 a193026 improved oral bioavailability non-human primate hydrolyzed _in vivo_ distributes tissue becomes active 5 ’ -triphosphate form a193026 active drug incorporates genome rna virus leading accumulation mutation known viral error catastrophe a193029 recent study shown molnupiravir inhibits replication human bat coronaviruses including sars-cov-2 mouse human airway epithelial cell a193014 remdesivir resistant mutant mouse hepatitis virus also shown increased sensitivity n4-hydroxycytidine a193014 molnupiravir granted approval uk 's medicine health product regulatory agency mhra 4 november 2021 prevent severe outcome hospitalization death due covid-19 adult l39050 molnupiravir also granted emergency use authorization fda december 23 2021 however yet fully approved l39588 , n4-hydroxycytidine prodrug molnupiravir studied activity number viral infection including influenza mers-cov sars-cov-2 a193014 a193029 molnupiravir approved uk reducing risk hospitalization death mild moderate covid-19 case patient increased risk severe disease eg obesity diabetes mellitus heart disease 60 year old l39050 l39055 u molnupiravir authorized emergency use treatment high-risk adult mild moderate covid-19 l39588 
SEP-363856,sep-363856 novel psychotropic drug investigated treatment schizophrenia unlike drug used condition sep-363856 bind dopamine d2 receptor exerts action trace amine–associated receptor 1 taar1 5-hydroxytryptamine type 1a 5-ht1a a193506 sep-363856 developed sunovion pharmaceutical l12891 initial clinical study shown drug may effective positive negative symptom schizophrenia negative symptom schizophrenia difficult treat may include flattened affect anhedonia social withdrawal additional clinical trial sep-363856 required confirm safety efficacy drug a193506 ,
Fezolinetant,fezolinetant investigation clinical trial nct04234204 study find fezolinetant help reduce moderate severe hot flash woman asia going menopause ,
Gusacitinib,gusacitinib investigation clinical trial nct02550678 study efficacy safety asn-002 adult patient low-risk nodular basal cell carcinoma ,
Rilematovir,rilematovir investigation clinical trial nct04056611 effect jnj-53718678 adult adolescent participant hematopoietic stem cell transplantation infected respiratory syncytial virus rsv ,
Lenacapavir,hiv/aids remains area concern despite introduction numerous successful therapy mainly due emergence multidrug resistance patient difficulty adhering treatment regimen a244170 a244175 lenacapavir first-in-class capsid inhibitor demonstrates picomolar hiv-1 inhibition monotherapy _in vitro_ little cross-resistance existing antiretroviral agent extended pharmacokinetics subcutaneous dosing a244170 a244175 a244180 a244190 lenacapavir first globally approved august 22 2022 european commission treat adult multi-drug resistant hiv infection l42995 december 22 2022 also approved fda l44473 ,lenacapavir combination antiretroviral indicated treatment multidrug-resistant human immunodeficiency virus type 1 hiv-1 infection heavily treatment-experienced adult experiencing failure current antiretroviral regimen due resistance intolerance safety consideration l42990 l44468 
Sisunatovir,sisunatovir investigation clinical trial nct04267822 study rv521 treatment adult subject undergone hct urti rsv ,
Baloxavir,baloxavir investigation clinical trial nct04327791 combination therapy baloxavir oseltamavir 1 hospitalized patient influenza combo trial 1 ,
Selpercatinib,selpercatinib kinase inhibitor enhanced specificity ret tyrosine kinase receptor rtks rtk class a202055 a202052 l13604 enhanced ret rearranged transfection oncogene expression hallmark many cancer although multikinase inhibitor including cabozantinib ponatinib sorafenib sunitinib vandetanib shown efficacy ret-driven cancer lack specificity generally associated substantial toxicity selpercatinib loxo-292 pralsetinib blu-667 represent first generation specific ret rtk inhibitor treatment ret-driven cancer a202049 a202055 a202052 l13604 although selpercatinib currently still investigation clinical trial nct04211337 granted accelerated fda approval may 8 2020 specific ret-driven cancer indication currently marketed brand name retevmo™ loxo oncology inc. l13604 selpercatinib also approved european commission ,selpercatinib approved treat adult locally advanced metastatic non-small cell lung cancer nsclc rearranged transfection ret gene fusion l43267 europe patient require systemic therapy following prior treatment immunotherapy and/or platinum-based chemotherapy l41895 adult child 12 year age older advanced metastatic medullary thyroid cancer mtc ret mutation require systemic therapy l43267 europe patient previously treated sorafenib and/or lenvatinib l41895 adult child 12 year older advanced ret-mutant medullary thyroid cancer mtc require systemic therapy following prior treatment cabozantinib and/or vandetanib l41895 adult child 12 year age older advanced metastatic thyroid cancer ret gene fusion require systemic therapy radioactive iodine-refractory radioactive iodine appropriate l43267 adult locally advanced metastatic solid tumor ret gene fusion progressed following prior systemic treatment satisfactory alternative treatment option l43267 selpercatinib currently approved indication accelerated approval scheme continued approval may contingent future confirmatory trial l13604 
GS-441524,gs-441524 adenosine nucleotide analog antiviral similar remdesivir a203057 l13239 molecule patented 2009 l13775 _in vitro_ study gs-441524 determined higher ec sub 50 /sub remdesivir number virus meaning gs-441524 le potent a203057 a203057 gs-441524 continues studied treatment feline infectious peritonitis virus coronavirus infects cat a198840 ,
Tridecactide,tridecactide also known alpha-corticotropin 1-13 deacetylated deaminated alpha-melanocyte stimulating hormone may antipyretic anti-inflammatory antimicrobial effect a203210 tridecactide along metenkefalin investigation immunomodulatory therapy moderate severe covid-19 l13874 l13877 ,
Zavegepant,zavegepant antagonist calcitonin gene-related peptide cgrp receptor currently phase 3 trial intranasal formulation treatment migraine fda approved join previously-approved `` -gepant '' drug rimegepant ubrogepant additional treatment alternative patient migraine particularly traditional triptan therapy proven ineffective april 15th 2020 phase 2 clinical trial nct04346615 safety efficacy trial vazegepant intranasal hospitalized patient covid-19 requiring supplemental oxygen l13868 began investigate use intranasally administered zavegepant combat acute respiratory distress syndrome ards sometimes seen patient covid-19 acute lung injury activates release cgrp play role development ards cgrp antagonist may help blunt significant inflammation associated covid-19 l13886 clinical trial expected complete september 2020 l13868 ,
Azoximer bromide,azoximer bromide investigation clinical trial nct04381377 efficacy safety polyoxidonium® hospitalized patient coronavirus disease covid-19 ,
Fluoroestradiol F-18,fluoroestradiol f-18 imaging agent used positron emission tomography pet detect estrogen receptor-positive breast cancer lesion l14096 ability image er-positive tumor _in vivo_ advantageous helping visualize tumor progression/regression may also used ass heterogeneity er expression across metastasis i.e identify site longer express er without need multiple biopsy a203912 fluoroestradiol f-18 first granted fda approval may 2020 developed petnet solution inc. zionexa usa brand name cerianna l14117 expected available late 2020/early 2021 l14117 ,fluoroestradiol f-18 radioactive diagnostic agent indicated use positron emission tomography pet imaging detection estrogen receptor-positive lesion adjunct biopsy patient recurrent metastatic breast cancer l14096 
Anti-SARS-CoV-2 REGN-COV2,anti-sars-cov-2 regn-cov2 combination novel antibody designed regeneron prevention treatment sars-cov-2 virus cause covid-19 drug combination antibody regn10933 regn10987 derived humanized velocimmune® mouse addition blood sample patient recovered covid-19 antibody formulated bind multiple location sars-cov-2 spike protein preventing viral escape l14303 two upcoming publication journal _science_ provide additional information preclinical research anti-sars-cov-2 regn-cov2 antibody cocktail l14306 clinical trial drug started june 11 2020 regeneron 's clinical trial study effect drug hospitalized covid-19 patient symptomatic covid-19 patient non-hospitalized uninfected individual high-risk infection including contact infected individual l14303 ,
COVID-19 convalescent plasma,covid-19 convalescent plasma plasma collected patient acquired subsequently recovered covid-19 contains antibody causative agent sars-cov-2 l14333 investigational covid-19 treatment currently available three main pathway use registered clinical trial use expanded access covid-19 protocol 21 cfr 312.305 use single patient emergency ind eind 21 cfr 312.310 l14333 although formal clinical trial result safety efficacy covid-19 convalescent plasma early result 5000 patient fda expanded access program suggest convalescent plasma transfusion covid-19 patient safe a214316 ,
INO-4800,ino-4800 dna vaccine containing full sequence sars-cov-2 spike protein development immunization covid-19 a214475 early _in vitro_ study using hek-293t cell demonstrated transfection ino-4800 result expression protein human cell a214475 a214478 follow study balb/c mouse hartley guinea pig demonstrated ability ino-4800 induce humoral cell-mediated immunity sars-cov-2 including lung furthermore antibody produced capable inhibiting binding sars-cov-2 ace2 receptor thought critical host cell entry a214475 phase 1 clinical trial ino-4800 u.s. nct04336410 started april 3 2020 expected completion date july 2021 l14372 phase 1/2 clinical trial south korea 's seoul national university hospital announced june 4 2020 expected start later month l14375 ,
Cedazuridine,myelodysplastic syndrome md group hematopoietic neoplasm give rise variable cytopenia progressing secondary acute myeloid leukemia saml invariably fatal untreated a215082 a215092 a215097 hypomethylating agent decitabine azacitidine used treat md inducing dna hypomethylation apoptosis cancerous cell a215127 l14897 although effective compound rapidly metabolized cytidine deaminase cda prior reaching systemic circulation administered orally necessitating intramuscular intravenous administration route a215107 a215112 a215117 a215127 cedazuridine fluorinated tetrahydrouridine derivative specifically designed inhibit cda facilitate oral administration hypomethylating agent a215107 a215112 a215117 a215127 l14897 cedazuridine first reported 2014 a215107 subsequently approved fda july 7 2020 combination decitabine sale astex pharmaceutical inc name inqovi® l14897 ,cedazuridine combination decitabine indicated treatment myelodysplastic syndrome md including md refractory anemia md refractory anemia ringed sideroblast md refractory anemia excess blast md scoring intermediate-1 intermediate-2 high-risk international prognostic scoring system ip chronic myelomonocytic leukemia cmml l14897 
BNT162b1 SARS-CoV-2 Vaccine,bnt162b1 one four advanced mrna-based vaccine developed `` project lightspeed '' joint program pfizer biontech l15002 l15007 bnt162b1 nucleoside modified mrna modrna vaccine encoding receptor-binding domain rbd sars-cov-2 spike protein together `` foldon '' trimerization domain derived t4 fibritin increase immunogenicity l15012 modrna formulated lipid nanoparticles delivery via intramuscular injection l15007 l15012 early result phase 1/2 study 45 healthy adult volunteer demonstrated rbd-binding immunoglobulin level 50 serum neutralizing titer higher observed covid-19 convalescent plasma 28 day initial immunization either 10 30μg bnt162b1 improvement following second dose l15012 bnt162b1 undergoing evaluation clinical trial usa nct04368728 germany nct04380701 l15017 l15022 bnt162b1 received fast track designation fda july 13 2020 l15027 ,
Tozinameran, pfizer-biontech covid-19 vaccine also known bnt162b2 tozinameran comirnaty one four advanced mrna-based vaccine developed `` project lightspeed '' joint program pfizer biontech l15002 l15007 l36025 comirnaty nucleoside modified mrna modrna vaccine encoding optimized full-length version severe acute respiratory syndrome coronavirus 2 sars-cov-2 spike protein designed induce immunity sars-cov-2 virus responsible causing covid-19 l15002 modrna formulated lipid nanoparticles administration via intramuscular injection two dos three week apart a225386 l15007 comirnaty undergoing evaluation clinical trial usa nct04368728 germany nct04380701 l15017 l15022 comirnaty received fast track designation u.s. fda july 13 2020 l15027 december 11 2020 fda issued emergency use authorization eua based 95 efficacy clinical trial similar safety profile viral vaccine span approximately 2 month a225386 comirnaty granted eua uk december 2 2020 l26676 canada december 9 2020 l26671 active immunization sars-cov-2 l26996 full fda approval granted august 23 2021 l36025 currently sufficient data available determine longevity protection covid-19 direct evidence vaccine prevents transmission sars-cov-2 virus one individual another l26956 fact sheet caregiver recipient healthcare provider available l26966 l26976 november 2021 health canada l39115 ema l39272 approved vaccine administered booster dose approximately six month second dose comirnaty also approved use fourth booster shot adult 50 year age older l41350 ,comirnaty fully approved fda health canada active immunization prevent covid-19 caused sars-cov-2 individual aged five year older l36030 l39020 l39221 third booster shot also approved health canada individual five year older fda individual 16 older given 6 month second immunization l39115 l39272 l39449 interchangeability comirnaty covid-19 vaccine manufacturer complete primary vaccination course booster dose third dose established l39272 comirnaty also approved use fourth booster shot adult 50 year age older l41350 u emergency use authorization comirnaty used prevention covid-19 child 6 month age older l42770 comirnaty also available omicron ba.4/ba.5 bivalent-adapted booster l44421 vaccine administered appropriate medical treatment immediate allergic reaction immediately available case acute anaphylactic reaction vaccine administration l26996 l26671 l26676 l36030 comirnaty administration postponed individual suffering acute febrile illness immunocompromised individual maybe weaker immune response comirnaty l36030 
BNT162a1 SARS-CoV-2 Vaccine,bnt162a1 one four advanced mrna-based vaccine developed `` project lightspeed '' joint program pfizer biontech l15002 l15007 bnt162a1 uridine mrna urna vaccine formulated lipid nanoparticles delivery via intramuscular injection l15002 l15007 bnt162a1 undergoing evaluation clinical trial usa nct04368728 germany nct04380701 l15017 l15022 ,
BNT162c2 SARS-CoV-2 Vaccine,bnt162c2 one four advanced mrna-based vaccine developed `` project lightspeed '' joint program pfizer biontech l15002 l15007 bnt162c2 self-amplifying mrna sarna vaccine formulated lipid nanoparticles delivery via intramuscular injection l15002 l15007 bnt162c2 undergoing evaluation clinical trial usa nct04368728 germany nct04380701 l15017 l15022 ,
Brexucabtagene autoleucel,mantle cell lymphoma heterogeneous sub-category non-hodgkin 's lymphoma classified either aggressive nodal indolent leukemic non-nodal variant despite introduction bruton 's tyrosine kinase btk inhibitor ibrutinib acalabrutinib prognosis mcl patient remains poor relapse following btk inhibitor therapy treatment option a216153 a216158 recently chimeric antigen receptor car cell therapy developed modify patient 's cell using viral transduction bind destroy cancerous cell therapy differ manufacturing methodology viral vector chimeric antigen choice internal co-stimulatory domain chimeric antigen a216188 similar axicabtagene ciloleucel brexucabtagene autoleucel employ murine anti-cd19 single-chain variable fragment scfv linked internal cd28- cd3ζ-derived co-stimulatory domain a216148 a216163 l15148 however preparation brexucabtagene autoleucel previously referred kte-x19 us method cell enrichment decrease prevalence cd19-expressing tumour cell car cell preparation l15148 brexucabtagene autoleucel granted accelerated approval treatment relapsed refractory mcl fda july 24 2020 currently available kite pharma inc. tradename tecartus l15148 ,brexucabtagene autoleucel modified autologous chimeric antigen receptor car cell immunotherapy indicated treatment relapsed refractory mantle cell lymphoma mcl adult patient l15148 additionally indicated treatment adult relapsed refractory b-cell precursor acute lymphoblastic leukemia l15148 brexucabtagene autoleucel granted accelerated approval based result single-arm open-label multicentre clinical trial continued approval may contingent confirmatory trial l15148 
Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Minnesota/41/2019 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Nebraska/14/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability , combination influenza virus subtypes type b strain influenza b viral strain used active immunization adult child aged 6 month older prevention influenza disease caused influenza virus subtypes type b l41345 
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Theralizumab,theralizumab humanized anti-cd28 monoclonal antibody designed treating autoimmune disease cancer first human trial withdrawn due severe toxicity likely due lymphopenia human cytokine release a216527 a216532 ,
Bamlanivimab,bamlanivimab ly-cov555 also known ly3819253 synthetic monoclonal antibody mab derived one first blood sample united state patient recovered covid-19 a224039 l15311 l15316 bamlanivimab neutralizing igg1κ mab directed sars-cov-2 spike protein described block viral entry human cell a224039 l15311 l15316 l20979 abcellera initially discovered bamlanivimab collaboration national institute allergy infectious disease niaid subsequently developed collaboration eli lilly company bamlanivimab consists two identical light chain 214 amino acid two identical heavy chain 455 amino acid fc region unmodified l20979 bamlanivimab produced chinese hamster ovary cho cell l20979 based phase 2 clinical trial blaze-1 interim result bamlanivimab granted emergency use authorization eua fda november 10 2020 a224044 l20974 set enter phase 3 clinical trial l15316 l15321 eua granted february 2021 bamlanivimab used combination etesevimab treat mild moderate covid-19 adult pediatric patient high risk progressing severe covid-19 l40179 eua later expanded december 2021 include younger child high risk including newborn l40174 eua currently allows bamlanivimab etesevimab post-exposure prophylaxis covid-19 adult child l40179 ,bamlanivimab currently approved indication fda l20974 bamlanivimab authorized emergency use authorization eua treatment mild moderate covid-19 patient aged 12 year older weighing least 40 kg high risk progressing severe covid-19 and/or hospitalization due covid-19 patient confirmed covid-19 identification sars-cov-2 viral load approved test l20974 l20979 eua bamlanivimab authorized patient hospitalized due covid-19 require oxygen due covid-19 patient oxygen therapy non-covid-19-related comorbidity require increased oxygen flow rate due covid-19 l20974 l20979 bamlanivimab combination etesevimab used treat mild moderate coronavirus disease 2019 covid-19 adult pediatric patient including neonate positive result direct sars-cov-2 viral testing high risk progression severe covid-19 including hospitalization death combination regimen also used post-exposure prophylaxis covid-19 unvaccinated immunocompromised adult pediatric individual including neonate high risk progression severe covid-19 including hospitalization death l40184 
Belantamab mafodotin,belantamab mafodotin gsk2857916 afucosylated monoclonal antibody target b cell maturation antigen conjugated microtubule disrupter monomethyl auristatin-f mmaf a216756 belantamab mafodotin granted fda accelerated approval 5 august 2020 treatment multiple myeloma l15326 however manufacturer began process withdrawal u marketing authorization november 2022 meantime belantamab mafodotin available patient risk evaluation mitigation strategy rem program enrol compassionate use program l44236 ,belantamab mafodotin indicated treatment adult relapsed refractory multiple myeloma received least 4 prior therapy including anti-cd38 monoclonal antibody proteasome inhibitor immunomodulatory agent l15326 
Natural Killer Cell,natural killer nk cell originate differentiate hematopoietic stem cell various signalling pathway involving cytokine interleukin cell arise cd34+ lymphoid progenitor comprise 10-15 lymphocyte human peripheral blood completely differentiated nk cell lack b cd19- cd3- lymphocyte marker carry unique cd56+ status instead two maturate variant nk cell cd56dim cd56bright exert cytotoxicity release toxic chemical cytokine secretion respectively nk cell express feature innate immune response respond molecule appear foreign body standard utilized source nk cell directly peripheral blood donor leukapheresis technique immune cell separated red blood cell generally number nk cell collected peripheral blood mononuclear cell pbmc low sufficient potency ex vivo expansion performed expansion involves use feeder cell line system bioreactors enhance number nk cell desired cytotoxicity cell also purified using cell-separation system processing technique involve using umbilical cord blood ucb directly nk cell heterogeneous cd56 expression considered suitable immunotherapy also possible culture ucb cd34+ hematopoietic stem cell hscs stimulation il-2 il-15 stem cell factor scf system develop nk cell induced pluripotent stem cell ipscs human embryonic stem cell hescs also used generate nk cell two-step culture method resulting cd34+ cell ,
CYNK-001,cynk-001 novel allogenic off-the-shelf natural killer nk cell therapy originating human placental cd34+ hematopoietic stem cell enriched cd56+/cd3- ,
Umbilical Cord Blood Hematopoietic Stem Cells, use umbilical cord blood ucb therapy advantageous ease access non-invasive collection procedure plasticity multi-differentiation ucb contains large source hematopoietic stem cell hscs capable self-renewal increased sensitivity various factor able generate erythroid myeloid progenitor colony specifically proliferation capacity human umbilical cord blood mononuclear progenitor cell hucbc much higher similar cell bone marrow ucb mononuclear cell isolated cultured medium expanded differentiated desired cell type hucbc cd34+ cell cultured various cytokine interleukin give rise various cell type red blood cell b- t- natural killer cell content cell depends change based gestational age hucbc largely immature express class ii hla antigen produce many cytokine immunoglobulin adult lymphocyte transplantation cell mean low level cytotoxicity immunological reaction cord blood transplant used treat condition aplastic anemia b-thalassemia x-linked lymphoproliferative syndrome hunter ’ syndrome acute lymphoid leukemia chronic myeloid leukemia neuroblastoma highlight adaptive nature cell ,
Human umbilical cord blood mononuclear cell-conditioned medium,transplantation human umbilical cord blood mononuclear cell hucbc demonstrated promising result various disease state positive result credited hucbcs ’ differentiation potential growth factor cytokine cell secrete also implicated hucbcs secrete growth factor anti-inflammatory cytokine thought reduce inflammation associated damage thus medium cultured believed also therapeutic potential human umbilical cord mononuclear cell extracted umbilical cord expanded cultured dulbecco ’ modified eagle ’ medium medium filtered separated hucbcs ,
IL15-NK Cell,natural killer nk cell incubated ‘ feeder cell ’ expressing certain cytokine prior maturation enhance activity particular incubation il-15 allows nk cell lyse broad range fresh cultured tumor target cell normally sensitive ,
Human Umbilical Cord Mesenchymal Stem Cells,stem cell obtained amniotic fluid umbilical cord uc placenta gaining popularity stem cell umbilical cord offer several advantage including non-invasive collection procedure hearty steady growth bone-marrow derived stem cell maintain steady doubling time dt 10 passage higher differentiation capability faster self-renewal cell express low level major histo-compability complex mhc class generally lack mhc class ii co-stimulatory ligand like cd40 cd80 cd86 thus characterized low immunogenicity umbilical cord start developing fifth week gestation contains different compartment stem cell originate cord lining wharton ’ jelly perivascular region uc mesenchymal cell derived wharton ’ jelly studied offer stable better osteogenic adipogenic differentiation potential cell extracted either explant enzymatic digestion method though neither method characterized ‘ standard ’ thus far explant method requires manual mincing tissue fragment result inconsistent number extracted msc contrast enzymatic digestion method us enzyme break non-required cell fragment result consistent cell number regardless extraction method cell usually expanded vitro laboratory using culture system bioreactors cord lining uc generally isolated explant method -- resulting two kind msc cord lining mesenchymal stem cell clmc used aid burn diabetic ulcer wound healing cord lining epithelial stem cell clec used persistent corneal epithelial defect skin improvement currently many company creating version stem cell one aspire creating version named act-20 ,
NKG2D-ACE2 CAR-NK Cell, cell prepared universal off-the-shelf car-nk cell cord blood nkg2d-ace2 protein engineered part car cell secretes il-15 gm-csf chimeric antigen receptor car artificial receptor consisting antibody-derived antigen binding domain transmembrane signaling domain t-cell receptor signalling moiety first used autologous human cell car-t cancer immunotherapy receptor engineered onto natural killer nk cell due lower potential graft-versus-host disease cytokine release syndrome il-15 superagonist increase activity nk cell improves target cytotoxicity gm-csf act neutralizer car-t cell-mediated cytokine release neurotoxicity transmembrane nkg2d intracellular 2b4 domain required optimal nk signalling subsequent cell-mediated cytotoxicity ace2 receptor sars-cov-2 binding s-protein viral envelope competitively inhibiting sars-cov-2 infection type ii alveolar epithelial cell ,
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media,umbilical-cord derived msc currently tested numerous clinical application due immunosuppressive anti-inflammatory property comparison bone-marrow derived msc cell resilient easier extract generally regarded le immunogenic condition medium cm derived msc also implicated therapeutic property msc isolated tissue extraction procedure cultured dulbecco ’ modified eagle ’ medium dmem separate soluble factor liquid many company creating version medium one company aspire created product act-20 conditioned medium product testing ,
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins,adipose mesenchymal stem cell amscs msc derived adipose tissue accessible le painful stem cell extracted source autologous stem cell derived patient ’ cell allogeneic stem cell derived donor lipoaspiration also known liposuction possible method extraction followed purification expansion cell vitro amscs multipotent capability forming different tissue include bone muscle neural chondrocyte explains amscs utilized repairing craniofacial bone defect also potential treatment scarred vocal fold ,
Placental Mesenchymal Stem Cells, placenta serf many purpose one many bank mesenchymal stem cell msc obtained relatively easily medical waste msc non-invasively extracted without ethical issue come embryonic stem cell placental msc pmscs obtained either fetal side hold chorionic plate-derived msc maternal side contributes decidual parietalis-dreived msc although pmscs multi-lineage differentiation potential fetal-side pmscs greater expansion capacity proliferation differentiation potential maternal-side pmscs also found fetal-side pmscs express different surface marker ,
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells,orbcel-c™ trade name product composed highly purified stromal cell derived human umbilical cord isolated cell expanded culture able used allogenically -- meaning one donor ’ cell given unrelated patient cell cd362 enriched umbilical cord-derived mesenchymal stem cell uc-mscs uc-mscs share stemness marker embryonic stem cell escs adult mesenchymal stem cell msc feature allows hypoimmunogenic non-inducible tumorigenesis regarding modification uc-mscs cd362 also known syndecan-2 surface marker identified msc enhanced clonogenicity immunomodulatory property enrichment cd362 expression msc investigated role immune modulation injured tissue ,
FT516,ft516 investigational engineered off-the-shelf natural killer nk cell therapy originating induced pluripotent stem cell ipsc compound express high-affinity 158v cd16 hncd16 fc receptor enhanced binding ability tumor-targeting antibody resistant downregulation ft516 currently tested acute myeloid leukemia b-cell lymphoma solid tumor combination compound also potential therapy covid-19 ,
Lactobacillus coryniformis K8,lactobacillus common bacteria found gut lactobacillus coryniformis k8 originally isolated artisan goat cheese ,
Human Embryonic Stem Cell-derived M Cell,castem composed immunity- matrix-regulatory cell imrcs also known cell administered injection imrcs differentiated human embryonic stem cell expanded harvested cell currently investigated lung injury fibrosis -- condition outcome lung disorder including covid-19 imrcs similar msc term capacity self-renewal tri-lineage differentiation however difference come imrcs displaying higher quality consistency stronger immunomodulatory anti-fibrotic function stronger potential treatment lung injury fibrosis ,
Virus Specific T-Cell,virus specific t-cells vsts target therapy generated specific viral antigen product generated virus-naive virus-experienced autologous allogenic source antigen identified immune target presented antigen-presenting cell apc t-cells along molecule stimulate growth activation t-cells isolated donor expanded culture generate vsts case cell created blood sample patient recovered viral infection ,
Alunacedase alfa,alunacedase alfa recombinant soluble glycosylated form human ace2 recombinant version enzyme antihypertensive potential antineoplastic activity ,
Dental Mesenchymal Pulp Stem Cells,dental pulp soft connective tissue present dental crown third molar first premolar teeth dental pulp stem cell dpscs exhibit fibro-blast like plasticity adherent property harvested surgical extraction wisdom teeth adult procedure favoured non-invasive easily accessible allows alternate use teeth usually discarded dpscs remain stable medium extracted high proliferation regeneration capacity dpscs multiple property express surface antigen like cd90 cd29 cd105 cd14 cd45 also express specific pluripotency marker like myc sox2 absent msc cell innate neurogenic potential origin traced embryonic neural crest potential cell create neuron glial cell addition able differentiate chondrocytes adipocytes odontoblasts appropriate condition ,
Human Menstrual Blood-derived Stem Cells,stem cell self-renewing proliferate without differentiation two major group embryonic stem cell escs adult stem cell asc differentiation occurs different condition different cell type escs inner cell mass blastocyst ascs deposited adult tissue restricted differentiation potency also lack tumorigenicity menstrual blood-derived stem cell menscs mesenchymal-like ascs non-invasively derived menstrual blood shed endometrium human female cell posse high rate proliferation multi-lineage differentiation potency menscs special compared older method adult stem cell extraction bone marrow stem cell extraction mensc extraction non-invasive method non-invasive way obtain stem cell simple easy obtain stem cell absence ethical issue may come obtaining stem cell embryonic kind ,
Mesenchymoangioblast-derived mesenchymal stem cells,mesenchymoangioblast mca -derived mesenchymal stem cell msc originate mesoderm common precursor endothelial cell activated fibroblast growth factor-2 fgf-2 mcas create colony specific phenotype cell able differentiate bone cartilage adipose tissue mca-derived msc obtained induced pluripotent stem cell ipscs expanded medium cell advantage msc large amount obtained single healthy blood donor negating risk donor-and expansion dependent variability cell used treat chronic allergic airway disease fibrosis among pathology ,
Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,human olfactory mucosa-derived mesenchymal stem cell om-mscs reside accessible location nasal cavity property multipotency high proliferation contributes high potential regenerative medicine human om-mscs derived olfactory mucosa collected vivo rhinoscopy technique nasal forceps om-mscs also immunomodulatory potential treating immunological disease currently om-mscs wide application yet standard unambiguous protocol om-msc collection isolation therapeutic application ,
Recombinant Bacterial ACE2 Receptors-like Enzyme,b38-cap structured carboxypeptidase derived _paenibacillus sp._ molecule angiotensin converting enzyme 2 ace2 -like enzyme share structural similarity mammalian ace2 b38-cap ace2-like enzyme decrease angiotensin ii level investigated treating hypertension myocardial fibrosis cardiac dysfunction ,
MultiStem,multistem intravenously-administered off-the-shelf proprietary product developed comprises multipotent adult progenitor cell mapcs like mesenchymal stem cell mapcs derived bone-marrow stroma non-hematopoietically adherent immunomodulatory pro-angiogenic property also mostly non-immunogenic additional benefit multistem include low immunogenicity meaning administered without tissue matching concurrent immunosuppressive agent cell creation product isolated qualified donor expanded large scale frozen use administration cell cleared body time currently multistem investigated neurological inflammatory immune cardiovascular disease condition ,
Stem-cell derived exosome vesicle products,mesenchymal stem cell msc exert therapeutic effect multiple modality including paracrine factor exosomes exosomes nanometer-sized membrane-bound vesicle secreted purpose cell-cell communication secreted extracellular fluid exosomes taken target cell carried distant target site various bioactive molecule including lipid protein mrna trna used enrich exosomes many contain conserved set protein also carry unique tissue type-specific protein product originate multiple cellular type including immunocytes tumor cell mesenchymal stem cell msc originating various tissue exosomes msc carry cytokine growth factor like tgfb1 il-6 il-10 hepatocyte growth factor hgf shown immunomodulatory exosomes also consist vegf matrix metalloproteinase-9 mmp-9 aid angiogenesis tissue repair ,
CAP-1002,cardiosphere-derived cell cdc derived human neonatal heart tissue distinct antigenic profile cd105+ cd45- cd90low exert effect secreting exosomes nanometer-sized membrane-bound vesicle used purpose cell-cell communication cdc target multiple cytokine pathway associated poor outcome e.g tnfa ifn-y il-1b il-15 anti-inflammatory effect cdc work polarizing macrophage restoring tissue function ,
Washed Microbiota Transplantation,fecal microbiota transplantation fmt effective enhancing gut microbiota patient experiencing high range disease state including clostridioides difficile c. diff infection crohn ’ disease ulcerative colitis washed microbiota preparation wmt involves method wherein fmt used preparation undergoes microfiltration automatic purification system combined repeated centrifugation suspension fecal particle parasite egg fungus potentially harmful thing removed resulting suspension shown decrease fmt-related adverse event ,
Recombinant Human Plasma Gelsolin,plasma gelsolin pgsn protein found blood healthy individual scavenges compound left damaged tissue ,
CoviGlobulin,coviglobulin rabbit polyclonal antibody specifically designed potential therapy covid-19 rabbit polyclonal antibody derived rabbit common animal host polyclonal production antibody produced response immunogen derived antibody-producing plasma cell b-cell clone different antibody different mechanism action depending target current application antibody include limited targeting cancer inflammatory disease organ transplantation cardiovascular disease infection respiratory disease ophthalmologic disease ,
Viral Macrophage-Inflammatory Protein,viral macrophage inflammatory protein-ii vmip highly basic protein human chemokine analog encoded human herpesvirus-8 structure vmip consists 71 residue monomer condition help virus evade host immune system selectively blocking activating different receptor preferentially inhibiting acute th1-associated inflammation also upregulating th2 associated immune response ,
Interferon Kappa,interferon kappa subclass type interferon mediating host defence consists 207 amino acid 30 homology others class consists series cysteine 27-amino acid signal peptide conserved type interferon gene encoding interferon expressed human epidermal keratinocytes ,
Trefoil Factor 2, trefoil factor 2 tff2 peptide low-molecular weight protein one three trefoil-motif-containing protein expressed predominantly gastric tissue source predominantly stromal cell although expression tff2 mrna transcript also occurs tissue macrophage peptide abundant mucous cell gastric mucosa tff2 detected mucous layer tissue ,
MRx-4DP0004,mrx-4dp0004 lyophilised formulation bifidobacterium breve strain commensal bacteria live biotherapeutic derived microbiota healthy human infant ,
Recombinant Super-Compound Interferon,recombinant super-compound interferon rsifn-co recombinant version interferon alpha modified spatial configuration interferon antiviral antitumor activity ,
Interferon Gamma,interferon gamma type 1 inflammatory cytokine type ii interferon antitumor property antiviral activity important immunoregulatory function interferon primarily produced activated lymphocyte natural killer cell ,
Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Hong Kong/2671/2019 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Washington/02/2019 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Satralizumab,satralizumab recombinant humanized monoclonal antibody targeted human interleukin-6 il-6 receptor similar tocilizumab produced chinese hamster ovary cell based igg2 framework l15536 satralizumab used treatment neuromyelitis optica spectrum disorder nmosd rare autoimmune inflammatory disorder central nervous system cns involving demyelinating lesion optic nerve spinal cord brainstem cerebrum a218551 pro-inflammatory mechanism involved nmosd thought mediated least part il-6 including increased production anti-aquaporin-4 aqp4 autoantibody increased permeability blood-brain barrier allows passage pro-inflammatory mediator cns a218546 a218551 satralizumab thought exert therapeutic benefit blocking il-6 receptor subsequently inflammatory response enspryng® satralizumab formulation developed chugai pharmaceutical roche l15536 uniquely formulated `` recycling antibody technology '' whereby association satralizumab il-6 receptor occurs ph-dependent manner a218551 allows satralizumab bind il-6 receptor reach endosome drug may dissociate receptor move back plasma act novel mechanism effectively increase duration action satralizumab allows single drug molecule interact multiple endogenous il-6 receptor prior elimination satralizumab first approved use canada june 2020 treatment aqp4 antibody-positive patient nmosd a218551 received subsequent approval switzerland japan a218551 approved use fda august 2020 l15566 becoming 3rd treatment receive fda approval nmosd eculizumab june 2019 inebilizumab june 2020 ,satralizumab indicated treatment neuromyelitis optica spectrum disorder nmosd adult patient anti-aquaporin-4 aqp4 antibody positive l15536 canada also used adolescent patient indication l15546 
CA-170,ca-170 selective small molecule inhibitor pd-l1 ,
anti-OX40 antibody BMS 986178, macrocyclic peptide bms-986189 activity binding functional assay comparable pd-l1 antibody ,
Hu-rhEGF-rP64k/Mont,hu-rhegf-rp64k/mont therapeutic vaccine composed antigen recombinant human egf rhegf chemically conjugated recombinant p64k rp64k adjuvant montanide isa51vg investigated treatment advanced non-small cell lung cancer nsclc ,
AZD7442,azd7442 combination sars-cov-2 antibody azd8895 azd1061 currently undergoing phase clinical trial prevention treatment covid-19 l15596 developed astrazeneca goal conferring least 6 month protection covid-19 significantly longer window efficacy vaccine l15591 ,
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
GC-376 free acid,gc-376 3c-like protease 3cl sup pro /sup sup pro /sup inhibitor stop cleavage activation functional viral protein required replication transcription host cell a219036 compound known direct acting antiviral daa coronaviruses initially developed using structure-guided design combat mers-cov infection a219036 a219056 addition gc-376 display potent activity various coronaviruses feline ferret mink sup pro /sup coronavirus a219026 a219031 a219036 a219041 prodrug gc-373 gc-376 recently used test inhibition sars-cov-2 sup pro /sup _in vitro_ result show potent inhibition target a219036 result suggest gc-376 metabolite may therapeutic potential covid-19 ,
GC-373,gc-373 peptide aldehyde metabolized bisulfide adduct gc-376 free acid a219031 a219036 inhibitor sup pro /sup otherwise known 3cl sup pro /sup viral encoded protease cleaves activates functional protein involved viral replication transcription a219036 gc-373 shown inhibit sup pro /sup target various coronavirus strain including feline mink ferret sup pro /sup a219041 along prodrug gc-376 gc-373 recently investigated _in vitro_ cell culture sars-cov-2 sup pro /sup a219036 result showed potent inhibition target suggesting gc-373 hold therapeutic potential covid-19 a219036 ,
Mycobacterium w. Vaccine, mycobacterium w m.w vaccine heat-killed suspension derived non-pathogenic mycobacterium mycobacterium indicus pranii immunotherapy m.w used leprosy compound also share antigen m. tuberculosis use shown clinical improvement rapid bacterial clearance enhanced immune response mycobacterium leprae antigen m.w immunization activates macrophage lymphocyte upon administration protective efficacy m. tuberculosis m. leprae august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
LNP-nCoVsaRNA Vaccine,lnp-ncovsarna purified synthetic mrna vaccine candidate encoding glycoprotein sars-cov-2 used primarily virus attach invade human cell vaccine developed tested medical research council clinical trial unit ucl uk jointly funded uk research innovation july 2020 clinical trial covac1 underway isrctn17072692 test safety immunogenicity vaccine ,
VA-MENGOC-BC®,va-mengoc-bc meningococcal b c vaccine outer membrane vesicle omv -based vaccine omvs contain 100 protein derived meningococcal group b capsular polysaccharide meningococcal group c. already exists polysaccharide-based vaccine meningococcal disease originating serogroups c w135 vaccine created use serogroups b c. vaccine cause induction bactericidal antibody broad cross-reactivity novel antigen γ-glutamyltranspeptidase exopolyphosphatase cell-binding factor protein also identified administration vaccine study vaccine may also induce moderate protection n. gonorrhoeae august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
VPM1002, bacille calmette-guérin bcg vaccine protects severe extrapulmonary form tuberculosis tb adequately protect pulmonary tb -- prevalent form tb recombinant bcg vpm1002 created response investigated preventing pulmonary tb newborn tb recurrence adult post-exposure immunization currently recombinant vaccine found efficacious safer bcg preclinical study vpm1002 recombinant bcg vaccine candidate expressing listeriolysin deficient urease generated genetic background bcg prague better safety profile bcg version due lack rd2 genome segment vaccine ’ urease c gene replaced listeriolysin encoding gene listeria monocytogenes reducing urease c phagosome acidification occur promoting phagolysosome fusion also providing optimal low ph listeriolysin stability vpm1002 facilitates mycobacterial antigen released cytosol also triggering autophagy inflammasome activation apoptosis antigen bacterial dna released cytosol host cell due listeriolysin expression vaccine mycobacterial antigen accessing cytosol also improves antigen presentation ability mycobacterial antigen reach cytosol due vaccine engineered secrete hly perforates phagosomal membrane hly active acidic ph similar listeriolysin deletion urease c also beneficial hly optimal bioactivity phagosome august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
AV-COVID-19,av-covid-19 vaccine composed autologous dendritic cell loaded sars-cov-2 antigen without granulocyte-macrophage colony-stimulating factor gm-csf vaccine created receiving patient ’ isolated peripheral blood monocyte monocyte differentiated vitro dendritic cell il-4 gm-csf incubated sars-cov-2 antigen prior administration vaccine developed tested aivita biomedical inc .. july 2020 company pursuing adaptive phase ib-ii randomized clinical trial nct04386252 test vaccine ,
Dendritic cells vaccine, recombinant chimeric dc vaccine subunit-based vaccine candidate investigated safety effectiveness sars-cov-2-induced pneumonia better safety profile inactivated live-attenuated virus virus-vector vaccine recombinant chimeric dc vaccine reduces risk virulence recovery pre-existing anti-vector immunity incomplete viral inactivation august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
LV-SMENP Vaccine,lv-smenp-dc vaccine candidate developed shenzhen geno-immune medical institute comprises dendritic cell modified lentiviral vector-expressing synthetic minigene based domain selected viral protein vaccine also administered antigen-specific cytotoxic lymphocyte ctls august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
SCB-2019,scb-2019 recombinant trimeric protein subunit vaccine candidate investigated covid-19 vaccine candidate resembles native trimeric viral spike produced mammalian cell-culture vaccine developed tested clover biopharmaceuticals au pty ltd .. june 2020 company pursuing randomized double blind placebo controlled study nct04405908 test safety immunogenicity vaccine ,
CoronaVac,coronavac previously known picovacc sars-cov-2 purified inactivated adsorbed vaccine candidate developed sinovac biotech corporation a219758 developed propagating sars-cov-2 cn2 strain inside vero cell inactivating b-propiolactone a219481 a219758 preclinical trial picovacc induced sars-cov-2-specific neutralizing antibody rat mouse rhesus macaque antibody found neutralize 10 representative sars-cov-2 strain august 2020 vaccine tested numerous human clinical trial assessing safety immunogenicity ,
BBIBP-CorV,bbibp-corv vaccine contains sars-cov-2 strain inactivated inside vero cell investigation show vaccine induces neutralizing antibody several mammalian specie also showing protective efficacy sars-cov-2 challenge rhesus macaque a219763 august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
CIGB 2020 Vaccine,cigb 2020 vaccine candidate administered nasally sublingually working strengthen immunity area administered vaccine developed tested center genetic engineering biotechnology cigb havana cuba july 2020 randomized control clinical trial rpcec00000306 underway evaluate prophylaxis potential suspected contact covid-19 patient ,
CIGB-258 peptide,cigb-258 peptide immunoregulatory derived heat shock protein 60 cellular variant 2020 center genetic engineering biotechnology cigb havana cuba testing treatment efficacy peptide patient covid-19 intensive therapy regimen rpcec00000313 ,
Nuvaxovid,sars-cov-2 causative agent covid-19 relies interaction trimeric spike glycoprotein angiotensin-converting enzyme 2 hace2 expressed host cell order establish productive infection human a243789 antibody directed protein capable blocking s-hace2 interaction neutralizing viral particle present convalescent patient inoculated covid-19 nuvaxovid nvx-cov2373 contains recombinant mutant protein codon-optimized baculovirus-mediated expression sf9 cell derived _spodoptera frugiperda_ together matrix-m adjuvant fraction c _quillaja saponaria_ extract a243789 l39534 resulting stable perfusion protein nanoparticles thermostable capable inducing productive cellular humoral immune response human across wide range animal model a243789 a243794 a243799 european commission granted novavax conditional marketing authorization nuvaxovid active immunization prevent covid-19 caused sars-cov-2 december 20 2021 l39534 february 17 2022 nuvaxovid approved health canada l40548 l40553 july 13 2022 nuvaxovid granted emergency use authorization fda prevention covid-19 adult expanded include patient ≥12 year age august 2022 l42450 l42965 ,nuvaxovid indicated active immunization prevent covid-19 caused sars-cov-2 patient 12 year age older l39534 l44426 nuvaxovid also available u emergency use authorization eua prevention covid-19 patient ≥12 year age l42965 
BacTRL-spike,bactrl-spike composed bacterial medium colony-forming-units live bifidobacterium longum engineered deliver synthetic dna encoding spike protein sars-cov-2 contained plasmid vaccine developed symvivo corporation june 2020 company pursuing phase 1 randomized observer-blind placebo-controlled trial nct04334980 test safety immunogenicity vaccine ,
V-SARS, covid-19 convalescent plasma currently acquired recovered covid-19 patient used prophylaxis virus therapeutic concept applied development v-sars heat inactivates plasma package once-daily pill form immunitor inc. sponsor currently testing oral vaccine immunogenicity 20 healthy volunteer phase 1 clinical trial nct04380532 ,
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine, analysis potential immunogenic target sars-cov2 genome synthetic ‘ minigene ’ developed using domain viral structural protein polyprotein protease specifically covid-19 infection relies binding spike protein aceii receptor described approach vaccine us engineered minigenes express viral protein modify artificial antigen presenting cell aapc activate t-cells august 2020 vaccine tested prophylaxis covid-19 human clinical trial ,
COVID19 s-vax loaded autologous dendritic cell vaccine,dendritic cell dc derived differentiated peripheral blood mononuclear cell presence specific cytokine growth factor cell loaded antigen produced virus tumor cell administered vaccine dendritic cell dc showing potential natural adjuvant vaccine due ability prime boost cell response considered powerful antigen-presenting cell able present antigen costimulatory signal required activation cd4+ cd8+ t-cells dc-based vaccine currently used cancer therapeutic tested covid-19 rationale loading dc cell sars-cov-2 antigen administering vaccine induce prolific immune response vaccine developed tested beijing til therapeutic may 2020 company pursuing human clinical trial chictr2000033003 test safety immunogenicity vaccine ,
Boldo leaf extract,boldo leaf extract allergenic extract used allergenic testing ,
Pralsetinib,pralsetinib similar previously approved selpercatinib kinase inhibitor enhanced specificity ret tyrosine kinase receptor rtks rtk class a202055 a219751 l15986 enhanced ret rearranged transfection oncogene expression hallmark many cancer including non-small cell lung cancer although multikinase inhibitor including cabozantinib ponatinib sorafenib sunitinib vandetanib shown efficacy ret-driven cancer lack specificity generally associated substantial toxicity a202055 pralsetinib blu-667 selpercatinib loxo-292 represent first generation specific ret rtk inhibitor treatment ret-driven cancer a202049 a202055 l15986 although phase 1/2 trial pralsetinib termed arrow nct03037385 still ongoing pralsetinib granted accelerated fda approval september 4 2020 treatment metastatic ret-fusion positive non-small cell lung cancer currently marketed brand name gavreto™ blueprint medicine l15986 ,pralsetinib indicated treatment metastatic non-small cell lung cancer nsclc adult patient confirmed posse rearranged transfection ret gene fusion determined fda approved test l15986 also indicated adult pediatric patient 12 year age older treatment advanced metastatic _ret_-mutant medullary thyroid cancer population treatment advanced metastatic _ret_ fusion-positive thyroid cancer require systemic therapy radioactive iodine appropriate l15986 pralsetinib currently approved indication accelerated approval scheme continued approval may contingent future confirmatory trial l15986 
Ferrimannitol ovalbumin,ferrimannitol-ovalbumin fmoa adduct ovalbumin complex fe iii -mannitol ,
Lecithin, complex mixture phospholipid glycolipids triglyceride phosphatidylcholines phosphatidylethanolamines phosphatidylinositols ,
CVnCoV Vaccine, cvncov vaccine cv07050101 development curevac ag vaccine us mrna technology create protein associated sars-cov2 upon administration replication initiate subsequent immune response body june 2020 company received regulatory approval german belgian authority commence phase 1 clinical trial vaccine nct04449276 ,
CVnCoV, cvncov vaccine cv07050101 development curevac ag vaccine us mrna technology create protein associated sars-cov2 upon administration replication initiate subsequent immune response body june 2020 company received regulatory approval german belgian authority commence phase 1 clinical trial vaccine nct04449276 ,
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection, july 2020 medicine invention design inc. sponsoring small controlled clinical trial covid-19 ap tp vaccine ‘ proof concept. ’ vaccine utilizes granulocyte macrophage-colony stimulating factor gm-csf cytokine known enhance vaccine efficacy prolongation humoral cell immunity ,
Covax-19™,covax-19™ protein-based vaccine developed partnership apc vaxine us insect-cell-produced recombinant sars-cov-2 spike protein vaxine ’ adjuvant advax-sm adjuvant designed circumvent high fever fatigue ache experienced vaccine using traditional adjuvant covax-19™ tested animal study shown achieve potent antibody t-cell response covid-19 spike protein june 2020 vaccine phase 1 trial evaluate safety immune response nct04428073 phase 2 3 trial planned september 2020 vaccine expected launch early 2021 ,
BBV152,bbv152 vaccine candidate created indian council medical research icmr candidate whole virion inactivated sars-cov-2 vaccine developed well-known sars-cov-2 strain vero cell platform ccl-81 adjunct either aluminum hydroxide gel algel novel tlr7/8 agonist adsorbed gel component vaccine include bbv152a bbv152b bbv152c animal study mouse rat rabbit reported bbv152 immunogenicity two separate antigen concentration type adjuvant formulation tlr7/8 adjuvant specifically induced significant th1 biased antibody response increased sars-cov-2 lymphocyte response thus july 2020 bbv152 phase 1/2 clinical trial assessing safety immunogenicity human nct04471519 ,
Gam-COVID-Vac,gam-covid-vac created gamaleya research institute epidemiology microbiology russia vaccine candidate heterologous covid-19 vaccine containing two component recombinant adenovirus type 26 rad26 vector recombinant adenovirus type 5 rad5 vector carry sars-cov-2 spike glycoprotein vaccine offered frozen gam-covid-vac freeze-dried formulation lyophilizate gam-covid-vac lyo phase 1/2 human trial 76 participant evaluated safety tolerability immunogenicity frozen gam-covid-vac nct04436471 freeze-dried gam-covid-vac lyo nct04437875 vaccine candidate june 2020 completed early august 2020 preliminary result suggested participant developed antibody sars-cov-2 glycoprotein good safety profile trial ,
SARS-CoV-2 Sclamp, university queensland uq partnership coalition epidemic preparedeness inovations cepi csl developed covid-19 candidate sars-cov-2 sclamp vaccine developed using uq ’ rapid response ‘ molecular clamp ’ vaccine platform lock surface protein configuration allows robust immune response combination well-established adjuvant technology mf59 seqirus sars-cov-2 sclamp vaccine developed within 3 week moved immediately preclinical testing partnership dutch company viroclinics xplore preclinical trial showed vaccine candidate produced high level neutralizing antibody induced strong t-cell response july 13 2020 candidate tested safety immunogenicity phase 1 clinical trial queensland actrn12620000674932 tetraq australian national university anu university melbourne peter doherty institute infection immunity also involved clinical component ,
IMM-101,imm-101 heat-inactivated immune-activating mycobacterial product shown safe well tolerated complement conventional cancer therapy patient melanoma pancreatic ductal adenocarcinoma a220013 a220018 a220023 study imm-101 showed vaccine ’ ability stimulate cancer patient ’ immune system help kill cancer cell july 2020 researcher ottawa hospital queen ’ university partnership canadian cancer society-funded canadian cancer trial group cctg conducting trial 1500 participant evaluate vaccine ’ protective effect cancer patient severe covid-19 infection nct04442048 ,
IMM101,imm-101 heat-inactivated immune-activating mycobacterial product shown safe well tolerated complement conventional cancer therapy patient melanoma pancreatic ductal adenocarcinoma pmid 21930686 pmid 30107850 pmid 27599039 study imm-101 showed vaccine ’ ability stimulate cancer patient ’ immune system help kill cancer cell july 2020 researcher ottawa hospital queen ’ university partnership canadian cancer society-funded canadian cancer trial group cctg conducting trial 1500 participant evaluate vaccine ’ protective effect cancer patient severe covid-19 infection nct04442048 ,
Coronavirus-Like Particle COVID-19 Vaccine, coronavirus-like particle covid-19 vaccine development testing meidcago quebec city canada vaccine developed creating sars-cov-2 virus-like particle covlps mimic structure virus without carrying genetic component required infection vlps thought multiple mechanism involving immune system engage humoral cellular response july 2020 medicago partnered dynavax test vaccine adjuvant cpg 1018 also known iss-1018 meant provide enhanced immune response vaccine addition medicago partnered glaxosmithkline gsk test adjuvant as03 phase 1 clinical trial launched july 2020 evaluating safety tolerability immunogenicity vaccine candidate without either cpg 1018 as03 nct04450004 adult aged 18-55 year ,
RUTI® Vaccine, ruti® vaccine contains fragmented purified liposomed heat-inactivated mycobacterium tuberculosis bacillus vaccine demonstrated reasonable safety profile potent stimulation immune response tuberculosis much like bcg vaccine ruti® vaccine also tested prophylactic sars-cov2 sponsored fundació institut german trias pujol ruti® vaccine tested prevention covid-19 infection controlled trial 315 healthcare worker participant nct04453488 ,
MVC-COV1901,mvc-cov1901 vaccine candidate developed commercialized medigen vaccine biologics corporation vaccine candidate contains perfusion form sars-cov2 recombinant spike protein medigen combined force dynavax offer advanced adjuvant cpg 1018 also known iss-1018 use vaccine september 2020 vaccine candidate phase 1 clinical trial ass safety immunogenicity nct04487210 ,
SARS-CoV-2 mRNA vaccine,sars-cov-2 mrna vaccine arcov novel mrna coronavirus vaccine consists lipid nanoparticle-encapsulated mrna encoding receptor binding domain sars-cov-2 a220048 first covid-19 mrna vaccine approved clinical trial china co-developed abogen bioscience walvax biotechnolgoy co. ltd. people ’ liberation army pla academy military science preclinical study mouse non-human primate shown intramuscular administration arcov elicited th1-biased cellular response robust antibody sars-cov-2 a220048 manufactured liquid arcov thermostable room temperature least 1 week july 2020 vaccine candidate set phase 1 clinical trial investigate safety tolerance immunogenicity chictr2000034112 ,
AG0301-COVID19,ag0301-covid19 vaccine candidate developed anges inc. osaka university candidate plasmid dna vaccine developed using intradermal gene transfer method targeting sars-cov-2 spike protein gene transfer method increase efficiency gene expression antibody production capability garnering efficient dna vaccine product september 8 2020 anges announced collaboration brickell biotech inc. following completion phase 1/2 clinical study nct04463472 ,
Janssen COVID-19 Vaccine, janssen covid-19 vaccine ad26.cov2.s recombinant vaccine contains adenovirus serotype 26 ad26 vector expressing stabilized sars-cov-2 spike protein vaccine created collaboration johnson johnson j j janssen pharmaceutical beth israel deaconess medical center preclinical study hamster infected sars-cov-2 infection a220053 showed single immunization vaccine-elicited neutralizing response protected sars-cov-2 induced pneumonia mortality providing protection disease progression follow-up preclinical study rhesus monkey a220058 showed ad26 vaccine produced robust response provided near perfect protection nasal swab bronchoalveolar lavage following sars-cov-2 challenge june 2020 phase 1/2 clinical trial adult human announced evaluate safety immunogenicity efficacy ad26.cov.s vaccine 1045 healthy adult age 18-55 nct04436276 janssen covid-19 vaccine available emergency use authorization eua u l41745 ,janssen covid-19 vaccine indicated active immunization prevention coronavirus disease-2019 covid-19 caused sars-cov-2 virus individual 18 year age older l39180 u janssen covid-19 vaccine authorized use emergency use authorization eua active immunization prevent covid-19 caused sars-cov-2 individual 18 year age older fda-authorized approved covid-19 vaccine accessible clinically appropriate individual 18 year age older elect receive janssen covid19 vaccine would otherwise receive covid-19 vaccine l41745 
KBP-COVID-19, kbp-201 covid-19 vaccine developed british american tobacco ’ bat u.s. biotech subsidiary kentucky bioprocessing kbp kbp cloned covid-19 ’ genetic sequence identified potential antigen inserted tobacco plant reproduction upon harvest antigen purified component underwent preclinical testing animal july 2020 kbp conducting phase 1/2 clinical trial evaluate safety immunogenicity kbp-covid-19 vaccine healthy patient nct04473690 ,
NasoVAX,nasovax contains replication-deficient adenovirus vector suspension vaccine administered nasal spray express influenza hemagglutinin nasal epithelial cell l16313 created altimmune inc. nasovax currently developed seasonal pandemic use activate humoral cellular immune response compound already shown tolerated adverse effect fever healthy individual nearly 6-fold cellular immune response comparison injectable vaccine l16313 june 2020 nasovax evaluated phase 2 clinical trial safety effectivness preventing worsening symptom hospitalized covid-19 patient nct04442230 ,
Inactivated SARS-Cov-2 Vaccine,developed sinopharm 's wuhan institute biological product co. vaccine consists wiv04 strain sars-cov-2 strain isolated patient wuhan cultivated vero cell line subsequently inactivated using b-propiolactone a220158 double-blind randomized placebo-controlled phase 1 96 participant phase 2 224 participant carried healthy adult 18-59 year a220158 result trial showed low rate adverse reaction demonstrated immunogenicity a220158 currently vaccine tested phase 3 clinical trial abu dhabi chictr2000034780 a219758 ,
Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences), sars-cov-2 inactivated vaccine purified vaccine contains multiple antigen virus inactivated vero cell a219758 vaccine specifically developed collaboration chinese academy medical science west china second university hospital yunan center disease control prevention june 2020 safety immunogenicity trial currently underway vaccine nct04470609 nct04412538 ,
Oral Polio Vaccine, oral polio vaccine opv live attenuated vaccine containing mixture one strain poliovirus serotypes strain virus selected based reduced incidence spreading central nervous system still ability mimic immune response occurs infection wild poliovirus l16348 vaccine created weakening wildtype placed oral vaccine administration opv strain extensively multiply intestinal tract becoming widely spread community immunize sizable proportion unvaccinated population a220163 administration vaccine prevents case paralytic poliomyelitis polio vaccine either administered inactivated form oral form although series comprises 4 dos also interchangeable administration form long 4 dos completed a220168 ,
Pentaglobin,pentaglobin also known igm-enriched immunoglobulin fall group polyclonal immunoglobulin preparation a220173 comprised immunoglobulin g igg http //www.drugbank.ca/drugs/db00028 immunoglobulin iga also enriched immunoglobulin igm l16353 ,
CK0802,ck0802 off-the-shelf product composed allogeneic umbilical cord blood derived regulatory t-cells t-reg cell used intravenously without hla matching l16358 surface t-reg cell t-cell lung homing marker expressed ,
Autologous Non-Hematopoietic Peripheral Blood Stem Cells,autologous non-hematopoietic peripheral blood stem cell created formulation use clinical trial nct04473170 abu dhabi stem cell center cell characterization cd90+ cd133+ oct-4+ cd45- cd71- l16363 ,
Amniotic Epithelial Cells,amniotic epithelial cell aec multipotent stem-like cell derived basement collagenous membrane human amnion layer placenta closest fetus a220183 t823 cell potential candidate allogeneic cell therapy regenerative medicine due potential differentiation multiplication a220183 ,
Platelet Lysate,platelet lysate acellular compound composed platelet protein also void cellular debris thus making lysate rich growth factor a220188 extracted lysis plasma membrane platelet white cell antigen low prepared lysate minimized likelihood immune response ,
Probiorinse,probiorinse intranasal probiotic treatment composed pre-mixed buffered sinus irrigation solution contains probiotic bacteria lactococcus lactis w136 l16368 strain bacteria said salubrious effect microbiome nasal cavity sinus a220193 ,
Human Amniotic Fluid,human amniotic fluid liquid surrounding human embryo fetus l16373 physically fluid provides protection cushioning chemically fluid provides protection inherent antibacterial property fluid contains carbohydrate protein lipid electrolyte urea immunoglobulin growth factor vitamin l16373 l16378 ,
Copper oxodotreotide Cu-64,copper cu 64 dotatate newly approved cu labeled somatostatin analog several advantage sup 68 /sup ga-labeled somatostatin analog positron emission tomography pet a220348 copper cu 64 dotatate longer half-life produced day opposed several time day lower positron energy lending improved spatial resolution a220348 study performed compare two tracer pet using copper cu 64 dotatate found perform better current gold standard single-photon emission computed tomography spect using 111in-dtpa-octreotide a220348 head-to-head trial former tracer detected twice many lesion latter a220348 ,copper cu 64 dotatate radiopharmaceutical used positron emission tomography pet locate somatostatin receptor-positive neuroendocrine tumor l16393 
Agalsidase alfa,agalsidase alfa recombinant human α-galactosidase similar agalsidase beta patient generally experience clinically significant difference outcome two drug patient may experience greater benefit agalsidase beta a220228 a220233 use agalsidase beta decreased europe favor agalsidase alfa contamination event 2009 a220343 agalsidase alfa granted ema approval 3 august 2001 l16413 ,agalsidase alfa indicated treatment fabry disease l16398 
RAPA-501-Allo,rapa-501-allo composed t-cells extracted healthy volunteer cell reprogrammed _ex vivo_ process involves de-differentiation re-differentiation l16483 ,
GX-19 Vaccine, gx-19 vaccine dna vaccine created genexine inc. company gyeonggi korea a219758 june 2020 vaccine candidate undergoing phase phase iia trial determine dose level safety efficacy a219758 l16488 ,
ZYCOV-D, zycov-d vaccine candidate developed cadila healthcare ltd. based india a219758 vaccine developed using dna vaccine platform non-replicating non-integrating plasmid carrying gene interest l16503 plasmid dna introduced host cell viral protein translated elicits strong immune response stimulating humoral cellular component immune system l16503 dna vaccine platform offer minimal biosafety requirement improved vaccine stability lower cold chain requirement l16503 phase clinical trial vaccine candidate completed july 2020 company reporting successful dosing tolerance a219758 l16493 august 2020 candidate phase ii clinical trial a219758 ,
CHO Cells Recombinant Vaccine, vaccine candidate developed china us sars-cov-2 protein subunit entirely engineered created secreted chinese hamster ovary cho cell a219758 vaccine candidate sponsored anhui zhifei longcom biologic pharmacy co. ltd. undergoing phase clinical trial evaluate safety tolerability ,
XAV-19,xav-19 intravenous antibody-based treatment targeted towards sars-cov-2 coronaviruses l16553 l16558 therapy concept based covid-19 convalescent plasma however rather using human plasma xav-19 heterologous swine glyco-humanized polyclonal antibody target spike protein sars-cov-2 l16553 l16558 therapy offer three beneficial effect ability neutralize virus reduce inflammatory response absence aggravating reaction following treatment l16563 xenothera partnered lfb pharmaceutical company develop xav-19 nantes university hospital test treatment patient l16553 l16558 july 2020 company conducting phase 2 randomized clinical trial define dosing safety efficacy xav-19 nct04453384 ,
Etesevimab,etesevimab ly-cov016 also known js016 fully human recombinant monoclonal antibody target sars-cov-2 surface spike protein receptor binding domain l16651 l16661 eua granted february 2021 etesevimab used combination bamlanivimab treat mild moderate covid-19 adult pediatric patient high risk progressing severe covid-19 l40179 eua later expanded december 2021 include younger child high risk including newborn l40174 eua currently allows bamlanivimab etesevimab post-exposure prophylaxis covid-19 adult child l40179 ,etesevimab combination bamlanivimab used treat mild moderate coronavirus disease 2019 covid-19 adult pediatric patient including neonate positive result direct sars-cov-2 viral testing high risk progression severe covid-19 including hospitalization death combination regimen also used post-exposure prophylaxis covid-19 unvaccinated immunocompromised adult pediatric individual including neonate high risk progression severe covid-19 including hospitalization death l40184 
Atoltivimab,"ebola virus ebov remains important human pathogen within _ebolavirus_ genus responsible least 17 known outbreak average case fatality rate 43.92 a221825 immune therapy using monoclonal antibody mabs becoming increasingly attractive therapeutic method combat infectious disease due rapid development low toxicity high specificity a222078 chief surface target ebov particle gp sub 1,2 /sub glycoprotein also appears surface ebov-infected cell offering opportunity neutralizing cytotoxic i.e fc-mediated immune effector function antibody effect play role combatting ebov infection a221825 a221830 recent large-scale study elucidated neutralizing fc-mediated function antibody important therapeutic benefit animal model ebov infection a222078 inmazeb™ formerly referred regn-eb3 combine three humanized igg1κ mabs atoltivimab regn 3470 odesivimab regn 3471 maftivimab regn 3479 equimolar proportion three mabs bind distinct portion gp sub 1,2 /sub glycoprotein collectively provide neutralizing fc-mediated immune effector function ebov _in vitro_ protection ebov infection _in vivo_ inmazeb™ produced regeneron pharmaceutical granted fda approval october 14 2020 l17320 ",atoltivimab indicated combination odesivimab maftivimab treatment _zaire ebolavirus_ infection adult pediatric patient including neonate born mother confirmed positive rt-pcr _zaire ebolavirus_ infection combination established efficacious specie within either _ebolavirus_ _marburgvirus_ genus special care taken evaluate susceptibility circulating _zaire ebolavirus_ strain beginning treatment possible emergence resistance monitored l17320 
Maftivimab,"ebola virus ebov remains important human pathogen within _ebolavirus_ genus responsible least 17 known outbreak average case fatality rate 43.92 a221825 immune therapy using monoclonal antibody mabs becoming increasingly attractive therapeutic method combat infectious disease due rapid development low toxicity high specificity a222078 chief surface target ebov particle gp sub 1,2 /sub glycoprotein also appears surface ebov-infected cell offering opportunity neutralizing cytotoxic i.e fc-mediated immune effector function antibody effect play role combatting ebov infection a221825 a221830 recent large-scale study elucidated neutralizing fc-mediated function antibody important therapeutic benefit animal model ebov infection a222078 inmazeb™ formerly referred regn-eb3 combine three humanized igg1κ mabs maftivimab regn 3479 odesivimab regn 3471 atoltivimab regn 3470 equimolar proportion three mabs bind distinct portion gp sub 1,2 /sub glycoprotein collectively provide neutralizing fc-mediated immune effector function ebov _in vitro_ protection ebov infection _in vivo_ inmazeb™ produced regeneron pharmaceutical granted fda approval october 14 2020 l17320 ",maftivimab indicated combination odesivimab atoltivimab treatment _zaire ebolavirus_ infection adult pediatric patient including neonate born mother confirmed positive rt-pcr _zaire ebolavirus_ infection combination established efficacious specie within either _ebolavirus_ _marburgvirus_ genus special care taken evaluate susceptibility circulating _zaire ebolavirus_ strain beginning treatment possible emergence resistance monitored l17320 
Odesivimab,"ebola virus ebov remains important human pathogen within _ebolavirus_ genus responsible least 17 known outbreak average case fatality rate 43.92 a221825 immune therapy using monoclonal antibody mabs becoming increasingly attractive therapeutic method combat infectious disease due rapid development low toxicity high specificity a222078 chief surface target ebov particle gp sub 1,2 /sub glycoprotein also appears surface ebov-infected cell offering opportunity neutralizing cytotoxic i.e fc-mediated immune effector function antibody effect play role combatting ebov infection a221825 a221830 recent large-scale study elucidated neutralizing fc-mediated function antibody important therapeutic benefit animal model ebov infection a222078 inmazeb™ formerly referred regn-eb3 combine three humanized igg1κ mabs odesivimab regn 3471 maftivimab regn 3479 atoltivimab regn 3470 equimolar proportion three mabs bind distinct portion gp sub 1,2 /sub glycoprotein collectively provide neutralizing fc-mediated immune effector function ebov _in vitro_ protection ebov infection _in vivo_ inmazeb™ produced regeneron pharmaceutical granted fda approval october 14 2020 l17320 ",odesivimab indicated combination maftivimab atoltivimab treatment _zaire ebolavirus_ infection adult pediatric patient including neonate born mother confirmed positive rt-pcr _zaire ebolavirus_ infection combination established efficacious specie within either _ebolavirus_ _marburgvirus_ genus special care taken evaluate susceptibility circulating _zaire ebolavirus_ strain beginning treatment possible emergence resistance monitored l17320 
Chlormadinone acetate,chlormadinone acetate progesterone derivative first synthesized 1961 u chlormadinone acetate formerly marketed component combination drug product estalor-21 c-quens however use drug associated development mammary tumor dog 1972 fda withdrew approval use chlormadinone acetate product l43942 l42975 chlormadinone acetate continues used country due high contraceptive efficacy tolerability a254422 l33974 ,
Lumasiran,lumasiran small interfering rna used treatment primary hyperoxaluria type 1 ph1 l23554 condition caused deficiency enzyme alanine-glyoxylate aminotransferase lead accumulation oxalate causing calcium crystal formation l23554 patient experience frequent kidney stone nephrocalcinosis renal failure l23554 oxlumo producted alnylam pharmaceutical represents first approved treatment ph1 l23394 prior approval therapy consisted symptomatic treatment hyperhydration inhibitor crystallization pyridoxine renal transplant l23554 lumasiran granted fda approval 23 november 2020 l23394 ,lumasiran indicated treatment primary hyperoxaluria type 1 ph1 lower urinary plasma oxalate level pediatric adult patient l23394 l23519 l43413 
Imdevimab,imdevimab monoclonal antibody combined casirivimab regeneron 's antibody cocktail known regen-cov2 treatment covid-19 l23539 drug combination antibody derived humanized velocimmune® mouse addition blood sample patient recovered covid-19 a224429 antibody formulated bind multiple location sars-cov-2 spike protein preventing viral escape a221495 november 21 2020 fda authorized emergency approval regn-cov2 treat mild moderate covid-19 patient aged 12 year older casirivimab imdevimab investigational recombinant human igg1 monoclonal antibody time officially approved fda reserved emergency use authorization eua l23524 november 2021 indication approved ema l39130 l39135 full safety efficacy data imdevimab yet available evaluation investigational therapy continue l23529 l23539 l14303 ,according emergency use authorization eua fda ema indevimab used casirivimab prevent covid-19 treat mild moderate covid-19 laboratory-confirmed sars-cov-2 infection patient aged 12 year age older weigh least 40 kg treatment reserved patient high risk progressing require hospitalization severe covid-19 l23524 l23534 l39135 combination may administered intravenous infusion healthcare setting immediate access treatment infusion reaction anaphylaxis ability activate emergency medical system em required l23534 l23539 limitation use imdevimab casirivimab use patient currently hospitalized due covid-19 patient requiring oxygen therapy due covid-19 patient requiring increase baseline oxygen flow rate covid-19 patient oxygen therapy non-covid-19 related morbidity l23524 l23534 
Casirivimab,casirivimab monoclonal antibody combined imdevimab regeneron 's antibody cocktail known regn-cov2 treatment covid-19 l23539 drug combination antibody derived humanized velocimmune® mouse addition blood sample patient recovered covid-19 a224429 antibody formulated bind multiple location sars-cov-2 spike protein preventing viral escape a221495 november 21 2020 fda authorized emergency approval regen-cov2 treat mild moderate covid-19 patient aged 12 year older casirivimab imdevimab investigational recombinant human igg1 monoclonal antibody time officially approved fda reserved emergency use authorization eua l23524 november 2021 indication approved ema l39130 l39135 full safety efficacy data yet available evaluation investigational therapy continue l23539 l23529 l14303 ,according emergency use authorization eua fda ema indevimab used casirivimab prevent covid-19 treat mild moderate covid-19 laboratory-confirmed sars-cov-2 infection patient aged 12 year age older weigh least 40 kg treatment reserved patient high risk progressing require hospitalization severe covid-19 l23524 l23534 l39135 combination may administered intravenous infusion healthcare setting immediate access treatment infusion reaction anaphylaxis ability activate emergency medical system em required l23539 l23534 limitation use imdevimab casirivimab use patient currently hospitalized due covid-19 patient requiring oxygen therapy due covid-19 patient requiring increase baseline oxygen flow rate covid-19 patient oxygen therapy non-covid-19 related morbidity l23524 l23534 
Piroctone,piroctone olamine used combination substance part shampoo effectively reduced amount dandruff time provided hair conditioning advantage recently shown piroctone olamine could induce apoptosis possessed significant vivo effect myeloma l34189 ,
Naxitamab,naxitamab humanized 3f8 hu3f8 igg1 monoclonal antibody directed oncofetal differentiation antigen gd2 disialoganglioside l24454 a224604 normally expressed fetal development mature neuron pain fiber skin cell gd2 constitutes highly efficient target treatment neuroblastoma widely expressed across within neuroblastoma neuroectodermal tumor a224609 rarely subject antigen loss a224604 first anti-gd2-monoclonal igg antibody approved fda treatment neuroblastoma dinutuximab brand name unituxin 2015 a224474 one stark disadvantage therapy requirement concurrent use granulocyte-macrophage colony-stimulating factor gm-csf interleukin-2 il-2 13-cis-retinoic acid ra l24929 naxitamab-gqgk danyelza granted accelerated approval fda november 2020 treatment high-risk relapsed/refractory neuroblastoma bone bone marrow l24454 approval requires naxitamab co-administered gm-csf factor known enhance granulocyte-mediated antibody-dependent cytotoxicity anti-gd2 therapy a224604 making administration naxitamab therapy markedly simpler predecessor ,naxitamab-gqgk indicated combination granulocyte-macrophage colony-stimulating factor gm-csf treatment patient 1 year age older relapsed refractory high-risk neuroblastoma bone bone marrow demonstrated partial response minor response stable disease prior therapy l24454 
Berotralstat,berotralstat selective inhibitor plasma kallikrein used prophylaxis attack hereditary angioedema hae l26661 work blocking enzymatic activity plasma kallikrein releasing bradykinin major biologic peptide promotes swelling pain associated attack hae a225166 berotralstat strictly used prevent treat attack l26656 developed biocryst pharmaceutical berotralstat marketed name orladeyo oral capsule a225106 berotralstat first approved fda december 3 2020 first once-daily oral therapy prevent angioedema attack hae adult pediatric patient 12 year older l26661 berotralstat approved european commission april 30 2021 l41965 health canada june 06 2022 l41960 ,berotralstat indicated prophylaxis attack hereditary angioedema hae adult pediatric patient 12 year older used treatment acute hae attack l26661 l41965 l41990 
Rurioctocog alfa pegol,rurioctocog alfa pegol pegylated recombinant human coagulation factor viii antihemophilic factor factor viii essential protein involved normal blood clotting thus deficient level functional factor viii associated elevated risk excessive bleeding caused spontaneous secondary event like trauma surgery a245149 hemophilia common inherited bleeding disorder leading deficiency factor viii caused defect f8c gene encodes coagulation factor viii bleeding joint common manifestation hemophilia bleeding episode severe life-threatening like intracranial hemorrhage a245139 rurioctocog alfa pegol aim restore functional level factor viii patient hemophilia manage prevent bleeding episode first approved european commission january 2018 l40119 rurioctocog alfa pegol covalent conjugate octocog alfa recombinant factor viii produced recombinant dna technology chinese hamster ovary cell line presence polyethylene glycol peg moiety increase plasma half-life drug thereby increasing drug 's duration action l40099 ,rurioctocog alfa pegol indicated treatment prophylaxis bleeding patient 12 year hemophilia congenital factor viii deficiency l40099 
Nifekalant,nifekalant investigation clinical trial nct03855826 evaluation efficacy safety nifekalant hydrochloride nif injection ,
LX-7101,lx-7101 investigation clinical trial nct01528111 study evaluate safety tolerability efficacy lx7101 subject primary open-angle glaucoma ocular hypertension ,
Iseganan,iseganan investigation clinical trial nct00022373 iseganan hydrochloride preventing oral mucositis patient undergoing radiation therapy head neck cancer ,
Levophencynonate,levophencynonate investigation clinical trial nct02299804 clinical trial evaluate efficacy safety levophencynonate hydrochloride patient vertigo ,
Celivarone,celivarone investigation clinical trial nct00233441 placebo controlled double-blind dose ranging study efficacy safety ssr149744c 50 100 200 300 mg od amiodarone calibrator maintenance sinus rhythm patient recent atrial fibrillation/flutter ,
SER-100,ser-100 investigation clinical trial nct01987284 ser100 isolated systolic hypertension ,
Bicyclol,bicyclol investigation clinical trial nct02944552 multi center randomized double-blind positive controlled study bicyclol treatment acute dili ,
Bisphosphocin Nu-3,bisphosphocin nu-3 investigation clinical trial nct02737722 topically applied bisphosphocin nu-3 infected diabetic ulcer subject type ii diabetes mellitus ,
Histamine glutarimide,histamine glutarimide investigation clinical trial nct03450434 xc8 treatment patient bronchial asthma ,
Inodiftagene vixteplasmid,inodiftagene vixteplasmid plasmid dna vector encoding diphtheria toxin dt-a gene transcriptional regulation promoter region human h19 gene imprinted maternally expressed non-protein coding gene ,
Gallium Ga-68 gozetotide,gallium ga 68 prostate-specific membrane antigen psma -11 ga-68 gozetotide radiopharmaceutical agent used identify ass prostate-specific membrane antigen psma -positive lesion adult men prostate cancer positron emission tomography pet l26981 prostate cancer one commonly diagnosed cancer among men western country many patient treated androgen-deprivation therapy relapse castration-resistant prostate cancer a225396 nearly prostate cancer malignant cell express transmembrane protein called prostate-specific membrane antigen psma a225396 ga-68 psma-11 imaging agent bind psma positron emission tomography emits positron indicate presence psma-positive prostate cancer lesion patient suspected prostate cancer patient may recurrent prostate cancer l27006 december 1 2020 ga-68 psma-11 approved fda first molecular-targeted drug positron emission tomography pet imaging prostate-specific membrane antigen psma positive lesion men prostate cancer l27006 administered intravenously october 2022 ema 's committee medicinal product human use chmp recommended ga-68 gozetotide granted marketing authorization diagnosis prostate cancer l43542 ,gallium ga-68 gozetotide gallium ga-68 psma-11 radioactive diagnostic agent indicated positron emission tomography pet prostate-specific membrane antigen psma -positive lesion patient suspected prostate cancer metastasis also candidate initial surgical radiation therapy also indicated patient suspected prostate cancer recurrence based elevated serum prostate-specific antigen psa level l26981 l39553 
NCX-1000,ncx-1000 investigation clinical trial nct00414869 preliminary efficacy tolerability ncx-1000 repeated oral dos patient elevated portal pressure ,
alpha-Hydroxylinoleic acid,alpha-hydroxylinoleic acid investigation clinical trial nct04431258 abtl0812 combination folfirinox first-line treatment metastatic pancreatic study ,
Azemiglitazone,azemiglitazone investigation clinical trial nct01280695 randomized double-blind comparator- placebo-controlled multiple-dose study evaluate safety tolerability efficacy three dose level msdc-0602 type 2 diabetic patient ,
2-(5-fluoro-pentyl)-2-methyl-malonic-acid,2- 5-fluoro-pentyl -2-methyl-malonic-acid investigation clinical trial nct00696943 18f ml-10 early detection response brain metastasis sr ,
VLX1570,vlx1570 investigation clinical trial nct02372240 study vlx1570 dexamethasone myeloma patient ,
TRO40303,tro40303 investigation clinical trial nct01374321 safety efficacy study tro40303 reduction reperfusion injury patient undergoing percutaneous coronary intervention acute myocardial infarction ,
GW810781,gw810781 investigation clinical trial nct00046332 study comparing 4 dos gw810781 versus placebo hiv-infected patient ,
GSK2798745,gsk2798745 investigation clinical trial nct03372603 study ass effectiveness side effect gsk2798745 participant chronic cough ,
JBPOS0101,jbpos0101 investigation clinical trial nct03976076 study orally administered jbpos0101 refractory infantile spasm patient ,
BFH772,bfh772 investigation clinical trial nct01449591 safety tolerability efficacy bfh772 rosacea patient ,
ABX-1431,abx-1431 investigation clinical trial nct03625453 study abx-1431 adult patient tourette syndrome chronic motor tic disorder ,
BI 44370 TA,bi 44370 ta investigation clinical trial nct00751803 bi 44370 ta acute migraine attack ,
PLX8394,plx8394 investigation clinical trial nct02428712 study plx8394 single agent patient advanced unresectable solid tumor ,
AN2898,an2898 investigation clinical trial nct01301508 efficacy safety an2898 an2728 topical ointment treat mild-to-moderate atopic dermatitis ,
DU125530,du125530 investigation clinical trial nct01119430 fluoxetine versus fluoxetine plus du125530 major depressive disorder ,
EPI-589,epi-589 investigation clinical trial nct02460679 safety biomarker study epi-589 participant amyotrophic lateral sclerosis al ,
SB-773812,sb-773812 investigation clinical trial nct00259870 sb-773812 administered adult schizophrenia ,
PF-06882961,pf-06882961 investigation clinical trial nct03985293 16 week study evaluate efficacy safety pf-06882961 adult type 2 diabetes mellitus ,
PF-05212377,pf-05212377 investigation clinical trial nct01712074 study evaluating thesafety efficacy pf-05212377 placebo subject alzheimer 's disease existing neuropsychiatric symptom donepezil ,
TERN-101,tern-101 investigation clinical trial nct04328077 lift study safety tolerability efficacy pharmacokinetics study tern-101 subject non-cirrhotic non-alcoholic steatohepatitis nash ,
TRC150094,trc150094 investigation clinical trial nct03254446 safety efficacy study trc150094 improve cv risk subject diabetes dyslipidemia hypertension ,
Elraglusib,elraglusib investigation clinical trial nct04218071 actuate 1901 9-ing-41 myelofibrosis ,
BTRX-246040,btrx-246040 investigation clinical trial nct03193398 btrx-246040 administered daily patient major depressive disorder ,
Farudodstat,farudodstat aslan003 investigation clinical trial nct03451084 dose optimisation study aslan003 acute myeloid leukemia ,
FF-10101-01,ff-10101-01 investigation clinical trial nct03194685 study ff-10101-01 patient relapsed refractory acute myeloid leukemia ,
MOL-4239,mol-4239 investigation clinical trial nct01826201 paired psoriasis lesion comparative study evaluate mol4239 psoriasis ,
2'-Fucosyllactose,2'-fucosyllactose investigation clinical trial nct03847467 pilot feasibility study 2'-fl dietary supplement ibd patient receiving stable maintenance anti-tnf therapy ,
ARRY-502,arry-502 investigation clinical trial nct01561690 study arry-502 patient persistent asthma ,
INCB-057643,incb-057643 investigation clinical trial nct02959437 azacitidine combined pembrolizumab epacadostat subject advanced solid tumor echo-206 ,
PT-2385,pt-2385 investigation clinical trial nct03108066 pt2385 treatment von hippel-lindau disease-associated clear cell renal cell carcinoma ,
GZ-389988,gz-389988 investigation clinical trial nct02845271 proof-of-concept study ass efficacy tolerability safety single intraarticular dose gz389988 versus placebo patient painful osteoarthritis knee ,
OBI-3424,obi-3424 investigation clinical trial nct04315324 study test akr1c3-activated prodrug obi-3424 obi-3424 patient relapsed/refractory t-cell acute lymphoblastic leukemia t-all ,
AK106-001616,ak106-001616 investigation clinical trial nct01285752 study ak106-001616 patient rheumatoid arthritis ra ,
IDE-196,ide-196 investigation clinical trial nct03947385 study ide196 patient solid tumor harboring gnaq/11 mutation prkc fusion ,
V116517,v116517 investigation clinical trial nct01688947 analgesic efficacy safety v116517 subject moderate severe chronic pain due postherpetic neuralgia phn ,
Samuraciclib,samuraciclib investigation clinical trial nct03363893 modular study evaluate ct7001 alone cancer patient advanced malignancy ,
Ro 24-7429,ro 24-7429 investigation clinical trial nct00002314 study ro 24-7429 patient hiv-related kaposi 's sarcoma ,
2X-121,2x-121 investigation clinical trial nct03562832 investigation anti-tumour effect tolerability parp inhibitor 2x-121 patient metastatic breast cancer selected 2x-121 drp ,
LY-3200882,ly-3200882 investigation clinical trial nct04158700 study ly3200882 pembrolizumab participant advanced cancer ,
Proxalutamide,proxalutamide investigation clinical trial nct03899467 safety tolerability proxalutamide gt0918 subject metastatic castrate resistant prostate cancer ,
CCX-140,ccx-140 investigation clinical trial nct01440257 study evaluate effect ccx140-b urinary albumin excretion subject type 2 diabetes albuminuria ,
TAK-831,tak-831 investigation clinical trial nct03214588 efficacy tolerability pharmacokinetics multiple dos oral tak-831 adult friedreich ataxia ,
BTRX-335140,btrx-335140 investigation clinical trial nct04221230 study major depressive disorder btrx-335140 v placebo ,
SP-420,sp-420 investigation clinical trial nct03801889 sp-420 subject transfusion-dependent beta-thalassemia rare anemia ,
KZR-616,kzr-616 investigation clinical trial nct04033926 phase 2 study kzr-616 evaluate safety efficacy patient active polymyositis dermatomyositis ,
4'-Thio-fac,4'-thio-fac investigation clinical trial nct02661542 study ff-10502-01 patient advanced solid tumor lymphoma ,
ORP-101,orp-101 investigation clinical trial nct04129619 comparison effect orp-101 versus placebo adult patient irritable bowel syndrome diarrhea ibs-d ,
AZD8529,azd8529 investigation clinical trial nct00921804 study ass efficacy safety tolerability azd8529 adult schizophrenia patient ,
LY2828360,ly2828360 investigation clinical trial nct01319929 study ly2828360 patient osteoarthritic knee pain ,
8-Chloroadenosine,8-chloroadenosine investigation clinical trial nct02509546 8-chloroadenosine treating patient relapsed refractory acute myeloid leukemia ,
GSK2245035,gsk2245035 investigation clinical trial nct02833974 effect gsk2245035 allergen-induced asthmatic response ,
Abagovomab,abagovomab investigation clinical trial nct00418574 efficacy multicentre trial immunotherapy vaccination abagovomab treat ovarian cancer patient ,
Abeprazan,abeprazan investigation clinical trial nct04341454 study evaluate efficacy safety dwp14012 patient acute chronic gastritis ,
Aclimostat,aclimostat investigation clinical trial nct03254368 study ass effect safety zgn-1061 overweight obese participant type 2 diabetes ,
Acolbifene,acolbifene investigation clinical trial nct01452373 dehydroepiandrosterone dhea acolbifene vasomotor symptom hot flush postmenopausal woman ,
Acrizanib,acrizanib investigation clinical trial nct02355028 lha510 proof-of-concept study maintenance therapy patient wet age-related macular degeneration ,
Adagloxad simolenin,adagloxad simolenin investigation clinical trial nct03562637 study adagloxad simolenin obi-822 /obi-821 adjuvant treatment patient globo h positive tnbc ,
Adelmidrol,adelmidrol investigation clinical trial nct01420510 saginil v placebo gynecologic oncology patient affected vaginitis ,
Aganepag isopropyl,aganepag isopropyl investigation clinical trial nct01110499 safety efficacy agn-210961 ophthalmic solution compared bimatoprost ophthalmic solution patient glaucoma ocular hypertension ,
Aldafermin,aldafermin investigation clinical trial nct03912532 evaluation efficacy safety tolerability aldafermin phase 2b randomized double-blind placebo-controlled multi-center study subject nonalcoholic steatohepatitis stage 2/3 fibrosis alpine 2/3 ,
Alflutinib,alflutinib investigation clinical trial nct03452592 efficacy safety alflutinib locally advanced metastatic non-small cell lung cancer patient t790m ,
Anivamersen,anivamersen investigation clinical trial nct01848106 study determine efficacy safety reg1 compared bivalirudin patient undergoing pci ,
CX-2009,cx-2009 investigation clinical trial nct03149549 proclaim-cx-2009 trial find safe active dos investigational drug cx-2009 patient selected solid tumor ,
EMB-01,emb-01 investigation clinical trial nct03797391 dose escalation study emb-01 participant advanced/metastatic solid tumor ,
RO6874281,ro6874281 investigation clinical trial nct03193190 study multiple immunotherapy-based treatment combination participant metastatic pancreatic ductal adenocarcinoma morpheus-pancreatic cancer ,
PEGylated Recombinant Factor VIII,pegylated recombinant factor viii investigation clinical trial nct02585960 bax 855 pk-guided dosing ,
Antithrombin gamma,antithrombin gamma investigation clinical trial nct04182373 kw-3357 study patient early onset severe preeclampsia ,
APG-1387,apg-1387 investigation clinical trial nct04568265 clinical study apg-1387 combination entecavir patient chronic hepatitis b ,
Apitegromab,apitegromab investigation clinical trial nct03921528 active treatment study srk-015 patient type 2 type 3 spinal muscular atrophy ,
Artemisone,artemisone investigation clinical trial nct00936767 artemisone treatment uncomplicated falciparum malaria western cambodia ,
Atogepant,atogepant oral antagonist calcitonin gene-related peptide cgrp receptor indicated prevention episodic migraine headache developed abbvie received fda approval brand name qulipta september 2021 l38814 approval predated two member drug family namely ubrogepant rimegepant agent indicated abortive migraine therapy atogepant novel first oral cgrp antagonist approved preventative use migraine l38814 patient requiring preventative migraine therapy current practice guideline recommend use certain anti-epileptic medication e.g valproic acid topiramate beta-blockers e.g propranolol associated significant adverse effect a239094 `` gepants '' family drug including atogepant comparatively well-tolerated a189207 l38739 may provide desirable treatment option patient struggling adverse reaction preventative therapy ,atogepant indicated prevention episodic migraine adult l38739 
Avalglucosidase alfa,avalglucosidase alfa neogaa drug enzyme replacement therapy specifically designed pompe disease rare inherited neuromuscular disorder caused deficiency alpha-glucosidase gaa enzyme gaa essential enzyme hydrolyzes glycogen free glucose use cellular function pompe disease gaa enzyme missing patient unable properly break glycogen resulting accumulation glycogen within lysosome progressive disruption cellular function especially smooth cardiac skeletal muscle cell pompe disease characterized progressive muscle weakness loss motor function including respiratory muscle weakness lead premature death debilitating effect people ’ life a232955 avalglucosidase alfa recombinant form gaa restores deficient enzyme level first developed sanofi genzyme avalglucosidase alfa chemically modified version alglucosidase alfa synthetic bis-phosphorylated oligosaccharide attached structure improve cellular uptake drug better muscle targeting a232960 august 6 2021 avalglucosidase alfa-ngpt approved fda market name nexviazyme treat patient one year age older late-onset pompe disease l35160 late-onset pompe disease associated range debilitating physical symptom progressive muscle weakness including respiratory muscle weakness loss motor function a232955 clinical trial avalglucosidase alfa improved lung function patient pompe disease l35160 avalglucosidase alfa approved health canada november 15 2021 treatment patient older six month age late-onset pompe disease l39205 ema approved drug june 24 2022 l42720 ,avalglucosidase alfa hydrolytic lysosomal glycogen-specific enzyme indicated treatment patient late-onset pompe disease lysosomal acid alpha-glucosidase gaa deficiency l35155 l39357 l42720 u approved patient one year age older l35155 
Axomadol,axomadol investigation clinical trial nct01043263 efficacy safety en3324 axomadol subject chronic low back pain ,
Baicalein,baicalein investigation clinical trial nct03830684 randomized double-blind placebo-controlled multicenter phase ⅱa clinical trial effectiveness safety baicalein tablet treatment improve aspect healthy adult influenza fever ,
Bakuchiol,bakuchiol investigation clinical trial nct03112863 comparison cosmetic effect bakuchiol retinol ,
Batabulin,batabulin investigation clinical trial nct00057382 t138067 versus doxorubicin chemotherapy-naive unresectable hepatocellular carcinoma patient ,
Batoclimab,batoclimab investigation clinical trial nct04428255 clinical study efficacy safety hbm9161 patient itp ,
Bemarituzumab,bemarituzumab investigation clinical trial nct03694522 study bemarituzumab fpa144 combined modified folfox6 mfolfox6 gastric/gastroesophageal junction cancer fight ,
GSK2256098,gsk2256098 investigation clinical trial nct02523014 vismodegib fak inhibitor gsk2256098 treating patient progressive meningioma ,
BI 2536,bi 2536 investigation clinical trial nct00376623 efficacy safety bi 2536 advanced metastatic non small cell lung cancer ,
TAK-715,tak-715 investigation clinical trial nct00760864 safety efficacy tak-715 subject rheumatoid arthritis ,
GED-0507-34-Levo,ged-0507-34-levo investigation clinical trial nct02808390 efficacy safety study ged-0507-34-levo treatment uc ,
GSK232802,gsk232802 investigation clinical trial nct00604825 treatment hot flashes/flushes postmenopausal woman warm study ,
CR6086,cr6086 investigation clinical trial nct03163966 study ep4 antagonist cr6086 combination methotrexate dmard-naïve patient early rheumatoid arthritis ,
OT-730,ot-730 investigation clinical trial nct00753168 phase 1-2 evaluation ot-730 eye drop reducing intraocular pressure patient ocular hypertension open-angle glaucoma ,
Bizalimogene ralaplasmid,bizalimogene ralaplasmid investigation clinical trial nct03499795 vgx-3100 delivered intramuscularly im followed electroporation ep treatment hpv-16 and/or hpv-18 related anal anal/peri-anal high grade squamous intraepithelial lesion hsil individual seronegative human immunodeficiency virus hiv -1/2 ,
HIV Integrase Inhibitor,hiv integrase inhibitor investigation clinical trial nct00397566 multiple ascending dose study bms-707035 hiv-1 infected subject ,
Brazikumab,brazikumab investigation clinical trial nct03759288 active placebo-controlled study brazikumab participant moderately severely active crohn 's disease ,
Brivoligide,brivoligide investigation clinical trial nct04104919 study evaluate preop dose brivoligide injection pain mastectomy patient high pc score ,
Buprenorphine hemiadipate,buprenorphine hemiadipate investigation clinical trial nct01582347 transfer subject subutex/suboxone rbp-6300 ,
Capadenoson,capadenoson investigation clinical trial nct00518921 capadenoson angina pectoris ,
Carotegrast methyl,carotegrast methyl investigation clinical trial nct03531892 study evaluate safety efficacy ajm300 participant active ulcerative colitis ,
Epigallo Catechin Gallate,epigallo catechin gallate investigation clinical trial nct00799890 sunphenon progressive form multiple sclerosis ,
Cemdisiran,cemdisiran investigation clinical trial nct03841448 study cemdisiran adult immunoglobulin nephropathy igan ,
Centhaquine,centhaquine investigation clinical trial nct04045327 efficacy pmz-2010 centhaquine resuscitative agent hypovolemic shock ,
Ceralifimod,ceralifimod investigation clinical trial nct01226745 phase 2 extension trial patient relapsing-remitting multiple sclerosis rrms ,
Chiauranib,chiauranib investigation clinical trial nct03974243 chiauranib combination chidamide patient relapsed/refractory non-hodgkin 's lymphoma ,
Ciforadenant,ciforadenant investigation clinical trial nct02253745 safety tolerability pk efficacy v81444 volunteer attention deficit/ hyperactivity disorder adhd ,
Cinaciguat,cinaciguat investigation clinical trial nct01067859 phase iib study investigate efficacy tolerability lower dos cinaciguat 25 μg/h 10 μg/h given intravenously patient acute decompensated chronic congestive heart failure adhf ,
Cinpanemab,cinpanemab investigation clinical trial nct03318523 evaluating efficacy safety pharmacokinetics pharmacodynamics biib054 participant parkinson 's disease ,
Crovalimab,crovalimab investigation clinical trial nct03157635 study ass safety efficacy pharmacokinetics pharmacodynamics crovalimab healthy volunteer participant paroxysmal nocturnal hemoglobinuria ,
TZP-102,tzp-102 investigation clinical trial nct01452815 affect once-daily oral administration tzp-102 treatment symptom associated diabetic gastroparesis ,
Dapansutrile,dapansutrile investigation clinical trial nct01768975 phase 2 efficacy trial olt1177 gel subject moderate severe pain associated oa knee ,
Dapirolizumab pegol,dapirolizumab pegol investigation clinical trial nct02804763 phase 2 efficacy safety study dapirolizumab pegol dzp systemic lupus erythematosus ,
Deferitrin,deferitrin investigation clinical trial nct00069862 iron balance study dfo gt56-252 patient transfusional iron overload secondary beta-thalassemia ,
Delgocitinib,delgocitinib investigation clinical trial nct03683719 phase 2b dose-ranging trial evaluate delgocitinib cream 1 3 8 20 mg/g compared delgocitinib cream vehicle 16-week treatment period adult subject chronic hand eczema ,
Denagliptin,denagliptin investigation clinical trial nct00387972 study denagliptin subject type 2 diabetes mellitus t2dm ,
Desidustat,desidustat investigation clinical trial nct04012957 desidustat treatment anemia ckd ,
Dexisometheptene mucate,dexisometheptene mucate investigation clinical trial nct02423408 safety efficacy study tnx-201 capsule treatment single tension-type headache ,
Dezapelisib,dezapelisib investigation clinical trial nct02456675 incb040093 incb040093 combined itacitinib incb039110 relapsed/refractory hodgkin lymphoma ,
Diflomotecan,diflomotecan investigation clinical trial nct00080015 diflomotecan bn80915 administered every 3 week treating patient sensitive small cell lung cancer sclc ,
DAR-0100A,dar-0100a investigation clinical trial nct01466205 clinical testing d1 agonist cognitive enhancement schizotypal personality disorder ,
Dilpacimab,dilpacimab investigation clinical trial nct03368859 study abt-165 plus folfiri v bevacizumab plus folfiri subject metastatic colorectal cancer previously treated fluoropyrimidine oxaliplatin bevacizumab ,
Dimethandrolone Undecanoate,dimethandrolone undecanoate investigation clinical trial nct03455075 study spermatogenesis suppression dmau alone lng versus placebo alone normal men ,
Acetyldinaline,acetyldinaline investigation clinical trial nct00005624 ci-994 treating patient advanced myeloma ,
Dirocaftor,dirocaftor investigation clinical trial nct03251092 study designed ass safety tolerability pk pti-808 healthy volunteer adult cystic fibrosis ,
Dopastatin,dopastatin investigation clinical trial nct04335357 tbr-760 adult patient non-functioning pituitary adenoma ,
Dotinurad,dotinurad investigation clinical trial nct03372200 febuxostat-controlled double-blind comparative study fyu-981 hyperuricemia without gout ,
Dynorphin,dynorphin investigation clinical trial nct00000244 effect dynorphin 1-13 heroin addiction 1 ,
Ebopiprant,ebopiprant investigation clinical trial nct03369262 poc study obe022 threatened preterm labour ,
Ecraprost,ecraprost investigation clinical trial nct00059657 efficacy/safety ecraprost lipid emulsion treatment critical leg ischemia due peripheral arterial disease ,
Efavaleukin alfa,efavaleukin alfa investigation clinical trial nct03422627 safety efficacy amg 592 subject steroid refractory chronic graft versus host disease ,
Eftilagimod alfa,eftilagimod alfa investigation clinical trial nct02614833 imp321 eftilagimod alpha adjunctive standard chemotherapy paclitaxel metastatic breast carcinoma ,
Efungumab,efungumab investigation clinical trial nct00217815 preliminary study mycograb docetaxel advanced breast cancer ,
VEGFR2-169,vegfr2-169 investigation clinical trial nct00655785 antiangiogenic peptide vaccine therapy gemcitabine treating patient pancreatic cancer phase1/2 ,
Eltanexor,eltanexor investigation clinical trial nct02649790 study safety tolerability efficacy kpt-8602 patient relapsed/refractory cancer indication ,
Eluforsen,eluforsen investigation clinical trial nct02532764 dose escalation study qr-010 homozygous δf508 cystic fibrosis patient ,
Empegfilgrastim,empegfilgrastim investigation clinical trial nct01569087 dose-finding study empegfilgrastim neutropenia prophylaxis patient breast cancer ,
Enapotamab vedotin,enapotamab vedotin investigation clinical trial nct02988817 enapotamab vedotin humax-axl-adc safety study patient solid tumor ,
Ensifentrine,ensifentrine investigation clinical trial nct04535986 phase 3 clinical trial evaluate safety efficacy ensifentrine patient copd ,
Epafipase,epafipase investigation clinical trial nct00037687 safety efficacy recombinant human platelet-activating factor acetylhydrolase treatment severe sepsis ,
Esflurbiprofen,esflurbiprofen investigation clinical trial nct03434197 safety efficacy sfpp knee osteoarthritis ,
ASTX660,astx660 investigation clinical trial nct02503423 phase 1-2 study astx660 subject advanced solid tumor lymphoma ,
Exebacase,exebacase investigation clinical trial nct03163446 safety efficacy pharmacokinetics cf-301 v placebo addition antibacterial therapy treatment s. aureus bacteremia ,
Exicorilant,exicorilant investigation clinical trial nct03437941 study evaluate cort125281 combination enzalutamide patient mcrpc ,
Fasoracetam,fasoracetam investigation clinical trial nct03609619 part b efficacy safety aevi-001 child adolescent adhd without mglur mutation ,
Fenpyroximate,fenpyroximate investigation clinical trial nct02533336 effectiveness non-pyrethroid insecticide-treated durable wall liner method malaria control endemic rural tanzania ,
Finerenone,finerenone bay 94-8862 mineralocorticoid receptor antagonist indicated reduce risk sustained decline glomerular filtration rate end stage kidney disease cardiovascular death heart attack hospitalization due heart failure adult chronic kidney disease associated type ii diabetes mellitus a236519 l34739 patient kidney disease would originally given spironolactone eplerenone antagonize mineraclocorticoid receptor a236544 spironolactone low selectivity affinity receptor dissociates quickly also effect androgen progesterone glucocorticoid receptor a236544 eplerenone selective longer lasting effect a236544 selective nonsteroidal mineralocorticoid antagonist apararenone esaxerenone finerenone later developed a236544 far finerenone nonsteroidal mineralocorticoid receptor antagonist fda approved a236544 l34739 finerenone granted fda approval 9 july 2021 l34739 followed ema approval 11 march 2022 l41449 , u finerenone indicated reduce risk sustained decline glomerular filtration rate end stage kidney disease cardiovascular death heart attack hospitalization due heart failure adult chronic kidney disease associated type ii diabetes mellitus l34739 europe finerenone indicated treatment chronic kidney disease stage 3 4 albuminuria associated type 2 diabetes adult l41444 
Firsocostat,firsocostat investigation clinical trial nct02781584 safety tolerability efficacy selonsertib firsocostat cilofexor adult nonalcoholic steatohepatitis nash ,
Fisogatinib,fisogatinib investigation clinical trial nct04194801 phase ib/ii study fisogatinib blu-554 subject hepatocellular carcinoma ,
Fluorocyclopentenylcytosine,fluorocyclopentenylcytosine investigation clinical trial nct03189914 rx-3117 combination abraxane® subject metastatic pancreatic cancer ,
Fonadelpar,fonadelpar investigation clinical trial nct03527212 study ass safety effectiveness sjp-0035 treatment patient dry eye disease ,
Foralumab,foralumab investigation clinical trial nct03291249 assessment safety foralumab oral anti-cd3 antibody patient nash t2dm ,
Foscarbidopa,foscarbidopa investigation clinical trial nct04379050 extension study evaluate safety tolerability 24-hour daily exposure continuous subcutaneous infusion abbv-951 adult participant parkinson 's disease ,
Foslinanib,foslinanib investigation clinical trial nct03600233 study cvm-1118 patient advanced neuroendocrine tumor ,
Ganaplacide,ganaplacide investigation clinical trial nct03167242 efficacy safety kaf156 combination lum-sdf adult child uncomplicated plasmodium falciparum malaria ,
Giroctocogene fitelparvovec,giroctocogene fitelparvovec investigation clinical trial nct04370054 study evaluate efficacy safety pf-07055480 moderately severe severe hemophilia adult ,
AIM-102,aim-102 investigation clinical trial nct01501942 efficacy safety tolerability pharmacodynamics pharmacokinetics oral administration aim-102 patient mild moderate allergic asthma ,
ABH001,abh001 investigation clinical trial nct01749306 study efficacy safety abh001 treatment patient epidermolysis bullosa wound healing ,
Glymera,glymera investigation clinical trial nct01658501 phase 2b multicenter randomized double-blind placebo- active-controlled parallel-group study ass pd response safety three dose level pb1023 injection following 20 week weekly sc dosing adult t2dm ,
Gontivimab,gontivimab investigation clinical trial nct03468829 efficacy safety alx-0171 adult hematopoietic stem cell transplant hsct recipient present respiratory syncytial virus rsv infection ,
GP2 peptide,gp2 peptide investigation clinical trial nct00524277 vaccine therapy treating patient breast cancer ,
ISIS 2503,isi 2503 investigation clinical trial nct00004193 isi 2503 treating patient metastatic and/or locally recurrent colorectal cancer ,
CXD101,cxd101 investigation clinical trial nct03873025 study cxd101 combination pembrolizumab relapsed refractory diffuse large b-cell lymphoma ,
Hemoporfin,hemoporfin investigation clinical trial nct03125057 pilot study hemoporfin pdt child port-wine stain ,
Hetrombopag,hetrombopag investigation clinical trial nct03976882 hetrombopag treatment chemotherapy-induced thrombocytopenia subject malignancy ,
HQP1351,hqp1351 investigation clinical trial nct03883100 pivotal study hqp1351 patient chronic myeloid leukemia accelerated phase t315i mutation ,
PEN-866,pen-866 investigation clinical trial nct03221400 pen-866 patient advanced solid malignancy ,
C-peptide,c-peptide investigation clinical trial nct00278980 effect c-peptide diabetic peripheral neuropathy ,
Ibezapolstat,ibezapolstat investigation clinical trial nct04247542 acx-362e ibezapolstat oral treatment clostridioides difficile infection ,
Idursulfase beta,idursulfase beta investigation clinical trial nct01645189 safety efficacy hunterase ,
Ifidancitinib,ifidancitinib investigation clinical trial nct03585296 study ati-502 topical solution treatment atopic dermatitis ,
Imaradenant,imaradenant investigation clinical trial nct03381274 oleclumab medi9447 egfrm nsclc novel combination study ,
IMR-687,imr-687 investigation clinical trial nct04474314 study imr-687 subject sickle cell disease ,
Imidazole-4-carboxylic acid,imidazole-4-carboxylic acid investigation clinical trial nct00583895 safety efficacy study imcooh cream patient suffering moderate atopic dermatitis ,
Indatuximab ravtansine,indatuximab ravtansine investigation clinical trial nct01001442 safety dose determining multi-dose study bt062 patient relapsed refractory multiple myeloma ,
INVAC-1,invac-1 investigation clinical trial nct03265717 dna plasmid encoding modified human telomerase reverse transcriptase htert invac-1 chronic lymphocytic leukemia ,
Iodine I-131 monoclonal antibody 81C6,neuradiab investigation clinical trial nct00615186 glioblastoma multiforme gbm locoregional agent survival study anti-tenascin radiolabeled antibody therapy ,
IONIS-FGFR4Rx,ionis-fgfr4rx investigation clinical trial nct02476019 safety tolerability pk pd study weekly isis-fgfr4rx sc obese patient ,
AKCEA-TTR-LRx,akcea-ttr-lrx investigation clinical trial nct04136184 neuro-ttransform study evaluate efficacy safety akcea-ttr-lrx participant hereditary transthyretin-mediated amyloid polyneuropathy ,
Iptacopan,iptacopan investigation clinical trial nct04578834 study efficacy safety lnp023 primary iga nephropathy patient ,
ISIS 104838,isi 104838 investigation clinical trial nct00048321 isi 104838 inhibitor tumor necrosis factor active rheumatoid arthritis ,
IONIS-HBVRx,ionis-hbvrx investigation clinical trial nct04544956 mechanistic study gsk3228836 fine needle aspiration fna participant chronic hepatitis b ,
Isopentane,isopentane investigation clinical trial nct00752089 experimental dentifrice remineralization/fluoride uptake situ model ,
"Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-","isoquinoline 7- 2- 3,6-dihydro-4- 3- trifluoromethyl phenyl -1 2h -pyridinyl ethyl investigation clinical trial nct00545454 activity safety oral administration ssr150106xb reduction inflammation patient active rheumatoid arthritis ",
Ispronicline,ispronicline investigation clinical trial nct00109564 safety efficacy study ispronicline tc-1734-112 subject age associated memory impairment aami ,
Itepekimab,itepekimab investigation clinical trial nct03546907 proof-of-concept study ass efficacy safety tolerability sar440340 anti-il-33 mab patient moderate-to-severe chronic obstructive pulmonary disease copd ,
Itolizumab,itolizumab investigation clinical trial nct04605926 study evaluate efficacy safety itolizumab subject hospitalized covid-19 ,
Ivuxolimab,ivuxolimab investigation clinical trial nct02554812 study avelumab combination cancer immunotherapy advanced malignancy javelin medley ,
Janagliflozin,janagliflozin investigation clinical trial nct03851432 janagliflozin treat type 2 diabetes mellitus t2dm inadequately controlled metformin ,
Kisspeptin-10,kisspeptin-10 investigation clinical trial nct03771326 kp-10 insulin secretion men ,
KAI-1678,kai-1678 investigation clinical trial nct01106716 safety efficacy study kai-1678 treat pain subject postherpetic neuralgia ,
Ladarixin,ladarixin investigation clinical trial nct04628481 study oral ladarixin new-onset type 1 diabetes low residual β-cell function ,
Ladostigil,ladostigil investigation clinical trial nct01429623 3 year study evaluate safety efficacy low dose ladostigil patient mild cognitive impairment ,
Landipirdine,landipirdine investigation clinical trial nct02258152 syn120 study evaluate safety tolerability efficacy parkinson 's disease dementia synapse ,
Lapaquistat,lapaquistat investigation clinical trial nct00256178 efficacy lapaquistat acetate simvastatin subject primary dyslipidemia ,
Lazertinib,lazertinib investigation clinical trial nct04487080 study amivantamab lazertinib combination therapy versus osimertinib locally advanced metastatic non-small cell lung cancer ,
Leniolisib,leniolisib investigation clinical trial nct02435173 study efficacy cdz173 patient apds/pasli ,
Lerociclib,lerociclib investigation clinical trial nct02983071 g1t38 cdk 4/6 inhibitor combination fulvestrant hormone receptor-positive her2-negative locally advanced metastatic breast cancer ,
Levonadifloxacin,levonadifloxacin investigation clinical trial nct03405064 comparative study levonadifloxacin iv oral linezolid iv oral acute bacterial skin skin structure infection absssi ,
Lonapegsomatropin,lonapegsomatropin also known transcon hgh acp 001 methoxypegylated prodrug human growth hormone somatropin indicated treatment child 1 year older weighing least 11.5 kg growth failure due insufficient growth hormone secretion a237605 l36380 l36405 unlike somatropin requires daily dosing lonapegsomatropin administered single weekly dose l36380 l10971 lonapegsomatropin granted fda approval 25 august 2021 l36380 later approved european commission 13 january 2022 l39900 , u lonepegsomatropin indicated treatment growth failure due inadequate growth hormone secretion patient one year older weigh least 11.5 kg l36380 europe lonepegsomatropin indicated treat growth failure child adolescent aged three year 18 year due insufficient endogenous growth hormone secretion growth hormone deficiency l40139 
Lonaprisan,lonaprisan investigation clinical trial nct00555919 zk 230211 postmenopausal woman metastatic breast cancer ,
Loncastuximab tesirine,relapsed refractory b-cell acute lymphoblastic leukemia b-all therapeutic challenge patient undergone prior systemic therapy limited success a234439 prognosis poor effective therapy needed treat relapsed/refractory case improve survival a234444 april 23 2021 food drug administration granted accelerated approval antibody-drug conjugate loncastuximab tesirine-lpyl also known zynlonta therapy developed adc therapeutic accelerated approval relapsed refractory b-cell lymphoma based promising result lotis-2 clinical trial l33559 l33634 ,loncastuximab tesirine indicated treatment adult relapsed refractory large b-cell lymphoma undergone two prior line systemic therapy including diffuse large b-cell lymphoma dlbcl otherwise specified dlbcl arising low-grade lymphoma high-grade b-cell lymphoma indication approved accelerated fda approval following result clinical study continued approval dependant upon result confirmatory clinical trial l33529 
Lunasine,lunasine investigation clinical trial nct02709330 al reversal lunasin regimen ,
Lutikizumab,lutikizumab investigation clinical trial nct02087904 study evaluating safety efficacy pharmacodynamic effect abt-981 patient knee osteoarthritis ,
Magrolimab,magrolimab investigation clinical trial nct02953782 trial magrolimab hu5f9-g4 combination cetuximab participant solid tumor advanced colorectal cancer ,
Maralixibat,maralixibat also known shp625 lum001 lopixibat ileal bile acid transporter inhibitor like odevixibat a236823 a239249 l38834 maralixibat indicated treatment cholestatic pruritus patient alagille syndrome least 1 year old l38834 previously patient cholestatic pruritus associated alagille syndrome treated antihistamine rifampin ursodeoxycholic acid cholestyramine naltrexone sertraline alone combination a239249 clinical trial performed ass efficacy treatment cholestatic pruritus treatment given based prescriber 's clinical experience a239249 surgical intervention partial external bile diversion ileal exclusion also used treatment a239249 maralixibat represents first fda-approved treatment cholestatic pruritus patient alagille syndrome granted fda approval 29 september 2021 l38834 october 2022 ema 's committee medicinal product human use chmp recommended maralixibat granted marketing authorization treatment cholestatic pruritus patient alagille syndrome l43547 maralixibat granted marketing authorization europe 13 december 2022 l44396 ,maralixibat indicated treatment cholestatic pruritus patient alagille syndrome l38834 approved use patient least one year old u l38834 two month age older europe l44391 
Masilukast,masilukast investigation clinical trial nct01740986 safety efficacy sa09012 asthma ,
Mavelertinib,mavelertinib investigation clinical trial nct02349633 study patient nsclc egfr mutation del 19 l858r +/- t790m ,
Mesdopetam,mesdopetam investigation clinical trial nct04435431 clinical study mesdopetam patient parkinson 's disease experiencing levodopa induced dyskinesia ,
NSI-189,nsi-189 investigation clinical trial nct02695472 study nsi-189 major depressive disorder ,
Methfuroxam,methfuroxam investigation clinical trial nct01213407 dendritic cell cancer vaccine high-grade glioma ,
Milciclib Maleate,milciclib maleate investigation clinical trial nct01301391 study oral pha-848125ac patient malignant thymoma previously treated multiple line chemotherapy ,
Milvexian,milvexian investigation clinical trial nct03766581 study bms-986177 prevention stroke patient receiving aspirin clopidogrel ,
Miricorilant,miricorilant investigation clinical trial nct03818256 study evaluating safety efficacy pharmacokinetics miricorilant cort118335 obese adult patient schizophrenia recent weight gain taking antipsychotic medication gratitude ,
Mitapivat,mitapivat novel first-in-class pyruvate kinase activator work increase activity erythrocyte pyruvate kinase key enzyme involved survival red blood cell defect pyruvate kinase enzyme various red blood cell disorder lead lack energy production red blood cell leading lifelong premature destruction red blood cell chronic hemolytic anemia a245478 february 17 2022 fda approved mitapivat first disease-modifying treatment hemolytic anemia adult pyruvate kinase pk deficiency rare inherited disorder leading lifelong hemolytic anemia l40533 mitapivat also investigated hereditary red blood cell disorder associated hemolytic anemia sickle cell disease alpha- beta-thalassemia a245478 ,mitapivat indicated treatment hemolytic anemia adult pyruvate kinase pk deficiency l40528 
Modipafant,modipafant investigation clinical trial nct02569827 celgosivir modipafant treatment adult participant uncomplicated dengue fever singapore ,
Modithromycin,modithromycin investigation clinical trial nct00270517 comparative study edp-420 versus another antibiotic treatment community acquired pneumonia ,
Molibresib,molibresib investigation clinical trial nct01943851 dose escalation study investigate safety pharmacokinetics pk pharmacodynamics pd clinical activity gsk525762 subject relapsed refractory hematologic malignancy ,
BMS-813160,bms-813160 investigation clinical trial nct03496662 bms-813160 nivolumab gemcitabine nab-paclitaxel borderline resectable locally advanced pancreatic ductal adenocarcinoma pdac ,
ACT-709478,act-709478 investigation clinical trial nct03239691 study evaluate effect act-709478 photosensitive epilepsy patient ,
CC-11050,cc-11050 investigation clinical trial nct01300208 evaluate preliminary safety tolerability pharmacokinetics pharmacodynamics efficacy cc-11050 subject discoid lupus erythematosus subacute cutaneous lupus erythematosus ,
TBA-7371,tba-7371 investigation clinical trial nct04176250 early bactericidal activity tba-7371 pulmonary tuberculosis ,
MK-0773,mk-0773 investigation clinical trial nct00529659 study safety efficacy mk-0773 woman sarcopenia loss muscle mass mk-0773-005 ,
Human Lactoferrin Peptide hLF1-11,human lactoferrin peptide hlf1-11 investigation clinical trial nct00509834 study tolerability early efficacy hlf1-11 patient proven candidaemia ,
Nafithromycin,nafithromycin investigation clinical trial nct02903836 phase ii study oral nafithromycin cabp ,
Nangibotide,nangibotide investigation clinical trial nct04055909 efficacy safety tolerability nangibotide patient septic shock ,
Nanoparticle Epirubicin,nanoparticle epirubicin investigation clinical trial nct03168061 dose-escalation expansion trial nc-6300 patient advanced solid tumor soft tissue sarcoma novel epirubicin drug-conjugated polymeric micelle ,
Naphthoquine,naphthoquine investigation clinical trial nct01930331 safety tolerability pharmacokinetics efficacy arco ,
Nazartinib,nazartinib investigation clinical trial nct03529084 phase iii study nazartinib egf816 versus erlotinib/gefitinib first-line locally advanced metastatic nsclc egfr activating mutation ,
Necuparanib,necuparanib investigation clinical trial nct01621243 m402 combination nab-paclitaxel gemcitabine pancreatic cancer ,
Nedisertib,nedisertib investigation clinical trial nct03770689 study m3814 combination capecitabine radiotherapy rectal cancer ,
Nemiralisib,nemiralisib investigation clinical trial nct03345407 dose finding study nemiralisib gsk2269557 subject acute moderate severe exacerbation chronic obstructive pulmonary disease copd ,
Nevanimibe,nevanimibe investigation clinical trial nct03053271 study atr-101 treatment endogenous cushing 's syndrome ,
Nidufexor,nidufexor investigation clinical trial nct03804879 safety tolerability efficacy lmb763 patient diabetic nephropathy ,
Ningetinib,ningetinib investigation clinical trial nct03758287 ningetinib ct053ptsa plus gefitinib stage iiib iv nsclc patient egfr mutation t790m negative ,
Nipocalimab,nipocalimab investigation clinical trial nct04119050 efficacy safety m281 adult warm autoimmune hemolytic anemia ,
Nirsevimab,nirsevimab medi8897 recombinant human immunoglobulin g1 kappa igg1ĸ monoclonal antibody used prevent respiratory syncytial virus rsv lower respiratory tract disease neonate infant l44146 bind prefusion conformation rsv f protein glycoprotein involved membrane fusion step viral entry process neutralizes several rsv b strain l44146 a254571 compared palivizumab another anti-rsv antibody nirsevimab show greater potency reducing pulmonary viral load animal model addition nirsevimab developed single-dose treatment infant experiencing first rsv season whereas palivizumab requires five monthly dos cover rsv season a254691 due modification fc region nirsevimab grant longer half-time compared typical monoclonal antibody a254571 l44146 november 2022 nirsevimab approved ema prevention rsv lower respiratory tract disease newborn infant first rsv season l44146 ,nirsevimab indicated prevention respiratory syncytial virus rsv lower respiratory tract disease neonate infant first rsv season l44146 
Nolasiban,nolasiban investigation clinical trial nct03081208 phase 3 placebo controlled study nolasiban improve pregnancy rate woman undergoing ivf/icsi ,
norUrsodeoxycholic acid,norursodeoxycholic acid investigation clinical trial nct03872921 norursodeoxycholic acid v placebo psc ,
Odevixibat,odevixibat a4250 ileal sodium/bile acid cotransporter inhibitor indicated treatment pruritus patient older 3 month progressive familiar intrahepatic cholestasis pfic a236808 l34793 odevixibat first approved non-surgical treatment option pfic l34803 previous therapy pfic included bile acid sequestrant ursodeoxycholic acid a236808 odevixibat granted fda approval 20 july 2021 l34793 ,odevixibat indicated treatment pruritus patient older 3 month progressive familiar intrahepatic cholestasis pfic l34793 may effective pfic type 2 abcb11 variant l34793 patient lack functional bile salt export pump l34793 
Olacaftor,olacaftor investigation clinical trial nct02951182 study evaluating safety efficacy vx-440 combination therapy subject cystic fibrosis ,
Olaparib-bodipy FL,olaparib-bodipy fl investigation clinical trial nct03085147 dye detection cancer tongue mouth ,
Olenasufligene relduparvovec,olenasufligene relduparvovec investigation clinical trial nct03612869 study aavrh10-h.sgsh gene therapy patient mucopolysaccharidosis type iiia mp iiia ,
Olinvacimab,olinvacimab investigation clinical trial nct03033524 trial evaluate safety ttac-0001 tanibirumab recurrent glioblastoma ,
Olodanrigan,olodanrigan investigation clinical trial nct03297294 safety efficacy ema401 patient painful diabetic neuropathy pdn ,
Olutasidenib,olutasidenib ft-2102 selective potent isocitrate dehydrogenase-1 idh1 inhibitor approved fda december 2022 l44256 l44261 indicated treatment relapsed refractory acute myeloid leukemia aml patient susceptible idh1 mutation determined fda-approved test l44256 idh1 mutation common different type cancer glioma aml intrahepatic cholangiocarcinoma chondrosarcoma myelodysplastic syndrome md lead increase 2-hydroxyglutarate 2-hg metabolite participates tumerogenesis a254726 a254731 olutasidenib inhibits mutated idh1 specifically provides therapeutic benefit idh1-mutated cancer a254726 l44256 idh1 inhibitor ivosidenib also approved treatment relapsed refractory aml a254736 a254741 olutasidenib orally bioavailable capable penetrating blood-brain barrier also evaluated treatment myelodysplastic syndrome md well solid tumor glioma nct03684811 a254741 ,olutasidenib indicated treatment adult patient relapsed refractory acute myeloid leukemia aml susceptible isocitrate dehydrogenase-1 idh1 mutation detected fda-approved test l44256 
Olvimulogene nanivacirepvec,olvimulogene nanivacirepvec investigation clinical trial nct01443260 study gl-onc1 oncolytic vaccinia virus patient advanced peritoneal carcinomatosis ,
Onfekafusp alfa,onfekafusp alfa investigation clinical trial nct02938299 neoadjuvant l19il2/l19tnf- pivotal study ,
Ontuxizumab,ontuxizumab humanized monoclonal antibody target endosialin tumour endothelial marker 1 tem-1 investigation clinical trial nct01574716 sarcoma study morab-004 utilization research clinical evaluation ,
Opiranserin,opiranserin investigation clinical trial nct03997838 evaluate efficacy safety vvz-149 injection treatment post-operative pain following abdominoplasty ,
Orelabrutinib,orelabrutinib investigation clinical trial nct04305197 study icp-022 patient systemic lupus erythematosus sle ,
Osalmid,osalmid investigation clinical trial nct03670173 safety efficacy assessment osalmid multiple myeloma ,
Osoresnontrine,osoresnontrine investigation clinical trial nct02281773 study investigate efficacy safety tolerability four different dos bi 409306 compared placebo given 12 week patient schizophrenia stable antipsychotic treatment ,
Otlertuzumab,otlertuzumab investigation clinical trial nct01188681 safety efficacy study tru-016 plus bendamustine vs. bendamustine relapsed chronic lymphocytic leukemia ,
Oxymatrine,oxymatrine investigation clinical trial nct02202473 oxymatrine plus lamivudine combination therapy versus lamivudine monotherapy chronic hepatitis b infected subject ,
Paltusotine,paltusotine investigation clinical trial nct04261712 study evaluate long-term safety efficacy paltusotine treatment acromegaly acrobat advance ,
Parathyroid Hormone-Related Protein 1-36,parathyroid hormone-related protein 1-36 investigation clinical trial nct00853723 comparison study pthrp pth treat osteoporosis ,
Pecavaptan,pecavaptan investigation clinical trial nct03901729 trial study bay1753011 patient congestive heart failure ,
Pegcantratinib,pegcantratinib investigation clinical trial nct03448081 safety tolerability efficacy sna-120 treatment pruritus psoriasis subject treated calcipotriene ,
Pegcrisantaspase,pegcrisantaspase investigation clinical trial nct02257684 dose confirmation pharmacokinetic study pegcrisantaspase administered intravenous iv infusion child young adult acute lymphoblastic leukemia /lymphoblastic lymphoma lbl following hypersensitivity pegaspargase oncaspar ,
Pegylated Recombinant Human Arginase I,pegylated recombinant human arginase investigation clinical trial nct03455140 study evaluating safety activity pegylated recombinant human arginase bct-100 ,
Pelacarsen,pelacarsen investigation clinical trial nct03070782 phase 2 study isi 681257 akcea-apo -lrx participant hyperlipoproteinemia cardiovascular disease ,
Pelcitoclax,pelcitoclax investigation clinical trial nct04210037 study combination apg-1252 plus paclitaxel patient relapsed/refractory small cell lung cancer ,
Pemlimogene merolisbac,pemlimogene merolisbac investigation clinical trial nct03371381 efficacy safety study jnj-64041757 live attenuated listeria monocytogenes immunotherapy combination nivolumab versus nivolumab monotherapy participant advanced adenocarcinoma lung ,
"Penequinine, Penehyclidine",penequinine penehyclidine investigation clinical trial nct02644876 preventive effect penehyclidine hydrochloride inhalation postoperative pulmonary complication ,
Peoniflorin,peoniflorin investigation clinical trial nct02878863 paeoniflorin combination hepatoprotective drug versus hepatoprotective drug auto-immune hepatitis ,
B27PD,b27pd investigation clinical trial nct01195948 optiquel® corticosteroid-sparing therapy chronic noninfectious uveitis ,
Perfluorodecalin,perfluorodecalin investigation clinical trial nct03668665 influencing wound healing application hyaluronic acid perfluorodecalin physalis angulata extract split skin removal thigh study `` split wound design '' ,
Pexiganan,pexiganan investigation clinical trial nct01594762 pexiganan versus placebo control treatment mild infection diabetic foot ulcer ,
Pexmetinib,pexmetinib investigation clinical trial nct04074967 study arry-614 plus either nivolumab ipilimumab ,
HSK-3486,hsk-3486 investigation clinical trial nct04620031 study evaluating sedation intravenous administration hsk3486 injectable emulsion icu patient undergoing mechanical ventilation ,
IPI-549,ipi-549 investigation clinical trial nct03795610 window opportunity study ipi-549 patient locally advanced hpv+ hpv- head neck squamous cell carcinoma ,
PMPBB3 F-18,pmpbb3 f-18 investigation clinical trial nct04305210 alzheimer 's disease clinical investigation neuroimage study including 18f-pm-pbb3 18f-florbetapir av-45 pet examination ,
Polifeprosan 20,polifeprosan 20 investigation clinical trial nct00003878 carmustine implant treating patient brain metastasis ,
Poseltinib,poseltinib investigation clinical trial nct02628028 study ly3337641 rheumatoid arthritis ,
Praliciguat,praliciguat investigation clinical trial nct03254485 study effect iw-1973 exercise capacity patient heart failure preserved ejection fraction hfpef ,
Preimplantation factor,preimplantation factor investigation clinical trial nct03593460 phase ii autoimmune hepatitis ,
BP-14979,bp-14979 investigation clinical trial nct01785147 efficacy safety bp1.4979 smoking cessation ,
TAK-653,tak-653 investigation clinical trial nct03312894 efficacy safety tak-653 treatment-resistant depression ,
Racemetyrosine,racemetyrosine investigation clinical trial nct03512756 randomized phase 2/3 multi-center study sm-88 patient metastatic pancreatic cancer ,
A-dmDT390-bisFv(UCHT1),a-dmdt390-bisfv ucht1 investigation clinical trial nct02943642 safety effectiveness a-dmdt390-bisfv ucht1 fusion protein subject mycosis fungoides ,
Revaprazan,revaprazan investigation clinical trial nct01750437 phase 2 clinical trial investigate safety tolerability efficacy yh1885l patient non-erosive reflux disease nerd ,
Revusiran,revusiran investigation clinical trial nct02319005 endeavour phase 3 multicenter study revusiran aln-ttrsc patient transthyretin ttr mediated familial amyloidotic cardiomyopathy fac ,
Rezafungin,rezafungin investigation clinical trial nct04368559 study rezafungin compared standard antimicrobial regimen prevention invasive fungal disease adult undergoing allogeneic blood marrow transplantation ,
Ribaxamase,ribaxamase investigation clinical trial nct02563106 study syn-004 prevention c.diff patient lrti ,
TNP-2092,tnp-2092 investigation clinical trial nct03964493 tnp-2092 treat acute bacterial skin skin structure infection ,
Rinucumab,rinucumab investigation clinical trial nct02418754 study intravitreal regn2176-3 participant neovascular `` wet '' age-related macular degeneration amd ,
Ripertamab,ripertamab investigation clinical trial nct02772822 study comparing efficiency safety s-chop cyclophosphamide hydroxydaunomycin oncovin prednisone versus r-chop untreated cd20 cluster differentiation antigen 20 -positive dlbcl patient ,
Rivenprost,rivenprost investigation clinical trial nct00296556 therapeutic study ono-4819cd ulcerative colitis ,
Rocakinogene sifuplasmid,rocakinogene sifuplasmid investigation clinical trial nct03491683 ino-5401 ino-9012 delivered electroporation ep combination cemiplimab regn2810 newly-diagnosed glioblastoma gbm ,
Roledumab,roledumab investigation clinical trial nct02287896 pharmacokinetics safety roledumab rhd-negative pregnant woman carrying rhd-positive foetus ,
Romilkimab,romilkimab investigation clinical trial nct02345070 efficacy safety sar156597 treatment idiopathic pulmonary fibrosis ,
GSK-2981278,gsk-2981278 investigation clinical trial nct03004846 study gsk2981278 ointment subject plaque psoriasis ,
Rovazolac,rovazolac investigation clinical trial nct03175354 study subject moderate atopic dermatitis ,
S-777469,s-777469 investigation clinical trial nct00703573 randomized double-blind study evaluate safety efficacy 2 dos s-777469 patient atopic dermatitis ,
Sabatolimab,sabatolimab investigation clinical trial nct03946670 study mbg453 combination hypomethylating agent subject ipss-r intermediate high high risk myelodysplastic syndrome md ,
Selgantolimod,selgantolimod investigation clinical trial nct03491553 safety tolerability antiviral activity selgantolimod virally-suppressed adult chronic hepatitis b ,
Selodenoson,selodenoson investigation clinical trial nct00040001 safety efficacy study a1-adenosine receptor agonist slow heart rate atrial fibrillation ,
Sepiapterin,sepiapterin investigation clinical trial nct03519711 study cnsa-001 primary tetrahydrobiopterin bh4 deficient participant hyperphenylalaninemia ,
Sepofarsen,sepofarsen investigation clinical trial nct03913143 study evaluate efficacy safety tolerability exposure repeat-dose sepofarsen qr-110 lca10 illuminate ,
Seviprotimut-L,seviprotimut-l investigation clinical trial nct01546571 study melanoma vaccine stage iib iic iii melanoma patient ,
siG12D LODER,sig12d loder investigation clinical trial nct01676259 phase 2 study sig12d loder combination chemotherapy patient locally advanced pancreatic cancer ,
Simurosertib,simurosertib investigation clinical trial nct03261947 study evaluate safety tolerability activity tak-931 participant metastatic pancreatic cancer metastatic colorectal cancer advanced solid tumor ,
Sodelglitazar,sodelglitazar investigation clinical trial nct00196989 study people type 2 diabetes ,
Sonlicromanol,sonlicromanol investigation clinical trial nct04165239 khenergyze study ,
STX-100,stx-100 investigation clinical trial nct01371305 stx-100 patient idiopathic pulmonary fibrosis ipf ,
Sulopenem etzadroxil,sulopenem etzadroxil investigation clinical trial nct03354598 oral sulopenem-etzadroxil/probenecid versus ciprofloxacin uncomplicated urinary tract infection adult woman ,
Tafolecimab,tafolecimab investigation clinical trial nct04031742 study evaluate safety efficacy ibi306 pcsk9 monoclonal antibody chinese subject homozygous familial hypercholesterolemia ,
Talditercept alfa,talditercept alfa investigation clinical trial nct03039686 clinical trial evaluate efficacy safety tolerability ro7239361 ambulatory boy duchenne muscular dystrophy ,
Taniborbactam,taniborbactam investigation clinical trial nct03840148 safety efficacy study cefepime/vnrx-5133 patient complicated urinary tract infection ,
ABX-196,abx-196 investigation clinical trial nct03897543 abx196 combination nivolumab patient hepatocellular carcinoma ,
Tetrafluoroborate,tetrafluoroborate investigation clinical trial nct02907073 positron emission tomography pet imaging study ni reporter ,
Tilsotolimod,tilsotolimod investigation clinical trial nct03865082 study tilsotolimod combination nivolumab ipilimumab treatment solid tumor illuminate-206 ,
Trastuzumab duocarmazine,trastuzumab duocarmazine investigation clinical trial nct03262935 syd985 v physician 's choice participant her2-positive locally advanced metastatic breast cancer ,
Tropifexor,tropifexor investigation clinical trial nct02516605 multi-part double blind study ass safety tolerability efficacy tropifexor ljn452 pbc patient ,
Tulrampator,tulrampator investigation clinical trial nct02626572 efficacy safety 3 dos s47445 versus placebo patient alzheimer 's disease mild moderate stage depressive symptom ,
Uracil C-13,uracil c-13 investigation clinical trial nct01677338 phase 2 study evaluate preliminary performance c13-ura breath test kit dyspeptic subject ,
Veliflapon,veliflapon investigation clinical trial nct00353067 veliflapon dg-031 prevent heart attack stroke patient history heart attack unstable angina ,
Velsecorat,velsecorat investigation clinical trial nct02479412 multiple dosing 14 day study ass efficacy safety three dose level azd7594 given daily inhalation patient mild moderate asthma ,
Viagenpumatucel-L,viagenpumatucel-l investigation clinical trial nct02117024 phase 2 study viagenpumatucel-l hs-110 patient non-small cell lung cancer ,
Vicagrel,vicagrel investigation clinical trial nct03599284 efficacy safety pharmacokinetic antiplatelet therapy vicagrel ,
Vixarelimab,vixarelimab investigation clinical trial nct03816891 study ass efficacy safety tolerability kpl-716 reducing pruritus prurigo nodularis ,
Volinanserin,volinanserin investigation clinical trial nct00464243 efficacy safety volinanserin sleep maintenance insomnia polysomnographic study ,
Vonlerolizumab,vonlerolizumab investigation clinical trial nct03029832 study moxr0916 combination atezolizumab versus atezolizumab alone participant untreated locally advanced metastatic urothelial carcinoma ineligible cisplatin-based therapy ,
Razuprotafib,razuprotafib also known akb-9778 small-molecule inhibitor restoring tie2 activation inhibiting ve-ptp l27171 l27176 investigation diabetes covid-19 razuprotafib self-administered patient subcutaneous injection ,
Avasopasem manganese,avasopasem manganese also known gc4419 highly-selective small molecule mimetic superoxide dismutase sod investigated reduction radiation-induced severe oral mucositis l27246 l27256 drug potential application radiation-induced esophagitis oral mucositis addition currently tested covid-19 ,
Sotrovimab,sotrovimab vir-7831 also known gsk4182136 monoclonal antibody neutralize sars-cov-2 virus l34440 sotrovimab initially granted emergency use authorization eua treat mild-to-moderate covid-19 may 26 2021 based interim result clinical trial sotrovimab found reduce risk death hospitalization high-risk adult covid-19 outpatient setting l34425 l34430 l34440 however april 2022 fda removed eua sotrovimab due rising covid-19 case caused omicron ba.2 sub-variant drug ineffective l41369 sotrovimab granted marketing authorization european union december 2021 brand name xevudy l39625 l39620 , europe sotrovimab indicated treatment covid-19 patient ≥12 year old weighing ≥40kg require supplemental oxygen high risk progressing severe disease l39620 
Anti-SARS-CoV-2 IgY,anti-sars-cov-2 igy chicken egg antibody sars-cov-2 potential provide temporary protection virus administered intranasal drop l27381 create antibody chicken injected chest spike protein surface protein sars-cov-2 result immune response mounted chicken towards injected spike protein chicken antibody harvested egg yolk egg laid chicken formulated nasal drop administered antibody currently investigated covid-19 trial nct04567810 safety tolerability pharmacokinetics anti-severe acute respiratory syndrome coronavirus 2 sars-cov-2 chicken egg antibody igy covid-19 ,
BGB-DXP593,bgb-dxp593 sars-cov-2 neutralizing antibody l27401 currently investigated covid-19 clinical trial nct04551898 severe acute respiratory syndrome coronavirus 2 sars-cov-2 neutralizing antibody bgb-dxp593 participant mild-to-moderate coronavirus disease 2019 covid-19 beigene ,
MW33,mw33 recombinant fully human antibody sars-cov-2 l27411 antibody injection currently investigated covid-19 clinical trial nct04533048 clinical study evaluate mw33 injection ,
CSL324,csl324 fully human anti-g-csfr antibody shown ability control g-csf-mediated neutrophilia cynomolgus macaque a225626 potential application various inflammatory condition cystic fibrosis inflammatory bowel disease rheumatoid arthritis vasculitis l27516 ,
Anti-SARS-CoV-2 immunoglobulin,hyperimmune immunoglobulin sars-cov-2 hivig obtained plasma patient recover covid-19 develop neutralizing antibody l27521 anti-coronavirus immunoglobulin derived covid-19 convalescent plasma http //go.drugbank.com/drugs/db15692 contains sars-cov-2 neutralizing antibody found convalescent plasma http //go.drugbank.com/drugs/db15692 antibody highly purified concentrated l27521 l27526 ,
Descartes-30,descartes-30 rna-engineered off-the-shelf allogeneic mesenchymal stem cell msc product developed cartesian therapeutic l27531 rna-engineering performed cartesian therapeutic ’ proprietary rna armory platform activates provides cell mrna-based therapeutic ,
PlasmaCord,plasmacord platelet-poor plasma derived fractionation sterile umbilical cord placental blood l27581 developed cellpraxis currently investigated severe acute respiratory syndrome sars ,
Recombinant Human Thrombopoietin,recombinant human thrombopoietin full-length glycosylated cytokine produced chinese hamster ovary cell used promote generation megakaryocyte platelet a225691 a225696 drug used treatment thrombocytopenia ,
Treamid,treamid also known bisamide derivative dicarboxylic acid bdda complexing agent found chelate metal ion including calcium copper iron magnesium zinc a225701 drug shown regenerative property restoration function various tissue organ investigated clinical trial nct04428593 study ass safety tolerability pharmacokinetics treamid healthy volunteer nct04527354 pilot study ass efficacy safety treamid rehabilitation patient covid-19 pneumonia pharmenterprises ,
F-652,f-652 recombinant il-22-fc fusion protein manufactured chinese hamster ovary cell composed 2 human interleukin 22 il-22 molecule linked immunoglobulin constant region igg2-fc a225706 l27661 developed evive biotech previously known generon biomed inc l27666 ,
Autologous peripheral blood-derived CD34+ cells,autologous peripheral blood-derived cd34+ cell clbs119 proprietary version developed caladrius bioscience inc. hematopoietic stem cell l27741 also cell therapy investigated caladrius bioscience clinical trial nct04522817 clbs119 repair covid-19 induced pulmonary damage ,
Anti-SARS-CoV-2 equine immunoglobulin fragments,anti-sars-cov-2 equine immunoglobulin fragment also known inosars polyvalent passive immunization tested clinical trial nct04514302 safety efficacy anti-sars-cov-2 equine antibody fragment inosars hospitalized patient covid-19 l27796 inosars composed f ab ’ 2 fragment extracted hyperimmune equine serum ,
Matrix-M,matrix-m saponin-based adjuvant made nanometer particle cholesterol phospholipid developed novavax l27981 compound administered alongside vaccine enhance biological function creating robust long-lasting immune response may allow dose-sparing vaccine ,
Mezagitamab,mezagitamab investigation clinical trial nct04278924 study evaluate safety tolerability efficacy tak-079 participant persistent/chronic primary immune thrombocytopenia ,
Glofitamab,glofitamab investigation clinical trial nct04408638 phase iii study evaluating glofitamab combination gemcitabine oxaliplatin v rituximab combination gemcitabine oxaliplatin participant relapsed/refractory diffuse large b-cell lymphoma ,
Cobolimab,cobolimab investigation clinical trial nct04655976 study cobolimab combination dostarlimab docetaxel advanced nsclc participant ,
Melrilimab,melrilimab investigation clinical trial nct03207243 efficacy safety study gsk3772847 subject moderately severe asthma ,
Telazorlimab,telazorlimab investigation clinical trial nct03568162 phase 2b study evaluate efficacy safety isb 830 adult moderate severe atopic dermatitis ,
Felzartamab,felzartamab investigation clinical trial nct04145440 trial ass safety efficacy mor202 anti-pla2r membranous nephropathy amn ,
Actoxumab,actoxumab investigation clinical trial nct01241552 study mk-3415 mk-6072 mk-3415a participant receiving antibiotic therapy clostridium difficile infection mk-3415a-001 ,
Tesnatilimab,tesnatilimab investigation clinical trial nct04655807 study jnj-64304500 add-on therapy participant active crohn 's disease ,
Tefibazumab,tefibazumab investigation clinical trial nct00198289 aurexis® cystic fibrosis subject chronically colonized staphylococcus aureus lung ,
Garetosmab,fibrodysplasia ossificans progressiva fop rare autosomal dominant disorder episodic progressive heterotropic ossification fop characterized episodic inflammatory episode may precipitated trauma including immunization minor tissue damage usually result ossification lesion a242297 patient experience abnormal cartilage formation growth plate dysplasia joint issue resulting progressive immobility associated comorbidities a242297 a242307 discovery activating mutation acvr1 receptor render responsive normally antagonistic activin led interest activin therapeutic target a242302 a242307 garetosmab investigation clinical trial nct04577820 study ass efficacy safety garetosmab japanese adult patient fibrodysplasia ossificans progressiva fop ,
Coprelotamab,coprelotamab investigation clinical trial nct04170595 clinical study recombinant anti-her2 humanized monoclonal antibody injection ,
Zampilimab,zampilimab investigation clinical trial nct04335578 study evaluate safety tolerability pharmacokinetics efficacy ucb7858 adult kidney transplant recipient chronic allograft injury ,
Bexmarilimab,bexmarilimab investigation clinical trial nct03733990 study evaluate safety tolerability preliminary efficacy fp-1305 cancer patient ,
Toralizumab,toralizumab investigation clinical trial nct03605927 cd40-l blockade prevention acute graft-versus-host disease ,
Ansuvimab,"infection pathogenic filovirus _zaire ebolavirus_ ebola virus ebov cause severe hemorrhagic fever human resulting frequent outbreak case fatality rate high 90 a225933 a225938 virtually step ebov lifecycle targeted therapeutic development however date successful method appears development monoclonal antibody mabs gp sub 1,2 /sub surface glycoprotein evidenced previously approved inmazeb™ regn-eb3 cocktail atoltivimab odesivimab maftivimab approved ansuvimab zmapp remains clinical trial a225933 ansuvimab formerly mab114 fully human igg1 mab derived survivor 1995 kikwit ebov outbreak 11 year infection display strong glycan-independent binding conserved region gp sub 1,2 /sub protein responsible interacting host npc1 protein mediate ebov endolysosomal escape key step ebov lifecycle a225943 a225948 a226035 randomized controlled trial four investigational therapy ebola virus disease evd democratic republic congo previous outbreak began 2018 compared ansuvimab regn-eb3 zmapp remdesivir nucleoside analogue designed inhibit viral replication showed ansuvimab regn-eb3 superior improved patient survival faster viral clearance rate a207646 ansuvimab received fda approval december 21 2020 currently marketed ebanga ridgeback biotherapeutics lp ansuvimab second fda-approved treatment evd l29560 ",ansuvimab indicated treatment _zaire ebolavirus_ infection adult pediatric patient including neonate born mother test positive _zaire ebolavirus_ rt-pcr l29560 ansuvimab shown effective specie within _ebolavirus_ _marburgvirus_ genus factor possible emergence resistant strain suggest local information circulating _zaire ebolavirus_ strain consulted initiating treatment l29560 
Astegolimab,astegolimab investigation clinical trial nct04386616 study evaluate safety efficacy mstt1041a astegolimab uttr1147a patient severe covid-19 pneumonia ,
Levilimab,levilimab investigation clinical trial nct04227366 study efficacy safety bcd-089 combination methotrexate patient active rheumatoid arthritis ,
Axatilimab,axatilimab investigation clinical trial nct04301778 durvalumab combination csf-1r inhibitor sndx-6532 following chemo radio-embolization patient intrahepatic cholangiocarcinoma ,
Zansecimab,zansecimab investigation clinical trial nct04342897 study ly3127804 participant covid-19 ,
Mobocertinib,mobocertinib kinase inhibitor targeted human epidermal growth factor receptor egfr used specifically treatment non-small cell lung cancer nsclc caused exon 20 insertion mutation _egfr_ gene l38368 typically associated poorer prognosis compared `` classical '' _egfr_ mutant causing nsclc associated resistance standard targeted egfr inhibitor a238828 mobocertinib appears effective mean treating otherwise treatment-resistant nsclc exerting inhibitory effect _egfr_ exon 20 insertion mutant variant concentration 1.5- 10-fold lower required inhibit wild-type egfr l38319 mobocertinib brand name exkivity takeda pharmaceutical inc. granted accelerated approval fda september 2021 treatment locally advanced metastatic nsclc patient _egfr_ exon 20 insertion mutation failed previous therapy l38368 ,mobocertinib indicated treatment adult patient locally advanced metastatic non-small cell lung cancer nsclc epidermal growth factor receptor egfr exon 20 insertion mutation whose disease progressed platinum-based chemotherapy l38319 
Daxdilimab,daxdilimab investigation clinical trial nct04526912 treatment prevention acute lung injury ali patient covid-19 infection ,
Avdoralimab,avdoralimab investigation clinical trial nct04333914 prospective study patient advanced metastatic cancer sars-cov-2 infection ,
Cilgavimab,sars-cov-2 causative agent covid-19 enters cell via interaction trimeric spike glycoprotein host cell angiotensin-converting enzyme 2 ace2 blocking interaction receptor-binding domain rbd s1 subunit ace2 inhibits viral host cell entry animal study indicate antibody capable blocking interaction reduce viral load improve clinical symptom infection a243356 a243361 cilgavimab formerly azd1061 recombinant monoclonal antibody produced chinese hamster ovary cho cell derived neutralizing antibody isolated patient natural history sars-cov-2 infection modified targeted amino acid substitution exhibit extended ~85-day half-life a243351 a243356 l39411 rbd binding site cilgavimab overlap tixagevimab two administered synergistically impair sars-cov-2 infection individual may exposed virus a243351 a243361 l39411 cilgavimab approved indication fda cilgavimab combination tixagevimab issued fda emergency use authorization eua december 9 2021 pre-exposure prophylaxis covid-19 individual increased risk vaccination recommended combination co-packaged available name evusheld formerly azd7442 l39411 evusheld granted marketing authorization ema march 28 2022 l41454 approved canada soon april 14 2022 l41549 october 2022 fda health canada released safety alert regarding risk developing covid-19 exposed sars-cov-2 variant neutralized evusheld certain sars-cov-2 omicron subvariants may associated resistance monoclonal antibody evusheld fda health canada advise healthcare provider inform patient risk l43772 l43777 ,cilgavimab issued emergency use authorization eua fda combination tixagevimab pre-exposure prophylaxis covid-19 adult pediatric patient aged 12 year older weighing least 40 kg furthermore patient must currently infected sars-cov-2 known exposure individual infected sars-cov-2 must either immunocompromised due medical condition medication treatment otherwise ineligible vaccination eligible covid-19 vaccine due history severe adverse reaction l39411 u combination cilgavimab tixagevimab authorized treatment post-exposure prophylaxis covid-19 substitute covid-19 vaccination individual receiving therapy following covid-19 vaccination wait least two week l39411 europe canada cilgavimab combination tixagevimab approved pre-exposure prophylaxis therapy covid-19 adult adolescent aged 12 year older weighing least 40 kg l41459 l41549 
Tixagevimab,sars-cov-2 causative agent covid-19 enters cell via interaction trimeric spike glycoprotein host cell angiotensin-converting enzyme 2 ace2 blocking interaction receptor-binding domain rbd s1 subunit ace2 inhibits viral host cell entry animal study indicate antibody capable blocking interaction reduce viral load improve clinical symptom infection a243356 a243361 tixagevimab formerly azd8895 recombinant monoclonal antibody produced chinese hamster ovary cho cell derived neutralizing antibody isolated patient natural history sars-cov-2 infection modified targeted amino acid substitution exhibit extended ~85-day half-life a243351 a243356 l39411 rbd binding site tixagevimab overlap cilgavimab two administered synergistically impair sars-cov-2 infection individual may exposed virus a243351 a243361 l39411 tixagevimab approved indication fda tixagevimab combination cilgavimab issued fda emergency use authorization eua december 9 2021 pre-exposure prophylaxis covid-19 individual increased risk vaccination recommended combination co-packaged available name evusheld formerly azd7442 l39411 evusheld granted marketing authorization ema march 28 2022 l41454 approved canada soon april 14 2022 l41549 october 2022 fda health canada released safety alert regarding risk developing covid-19 exposed sars-cov-2 variant neutralized evusheld certain sars-cov-2 omicron subvariants may associated resistance monoclonal antibody evusheld fda health canada advise healthcare provider inform patient risk l43772 l43777 ,tixagevimab issued emergency use authorization eua fda combination cilgavimab pre-exposure prophylaxis covid-19 adult pediatric patient aged 12 year older weighing least 40 kg furthermore patient must currently infected sars-cov-2 known exposure individual infected sars-cov-2 must either immunocompromised due medical condition medication treatment otherwise ineligible vaccination eligible covid-19 vaccine due history severe adverse reaction l39411 u combination tixagevimab cilgavimab authorized treatment post-exposure prophylaxis covid-19 substitute covid-19 vaccination individual receiving therapy following covid-19 vaccination wait least two week l39411 europe canada cilgavimab combination tixagevimab approved pre-exposure prophylaxis therapy covid-19 adult adolescent aged 12 year older weighing least 40 kg l41459 l41549 
Efineptakin alfa,efineptakin alfa also known nt-i7 long-acting human interleukin-7 il-7 fusion protein promotes t-cell development contributing immune response compared endogenous il-7 nt-i7 stable potent longer half-life better bioavailability drug currently investigated area oncology immunology infectious disease ,
Goflikicept,goflikicept investigation clinical trial nct04380519 study efficacy safety single administration olokizumab rph-104 standard therapy patient severe severe acute respiratory syndrome coronavirus 2 sars-cov-2 infection covid-19 ,
Terevalefim,terevalefim investigation clinical trial nct02474667 reduce severity dgf recipient deceased donor kidney ,
Efmarodocokin alfa,efmarodocokin alfa investigation clinical trial nct04386616 study evaluate safety efficacy mstt1041a astegolimab uttr1147a patient severe covid-19 pneumonia ,
Modakafusp alfa,modakafusp alfa investigation clinical trial nct03215030 study investigate safety tolerability efficacy pharmacokinetics immunogenicity tak-573 participant refractory multiple myeloma mm ,
Sibofimloc,sibofimloc investigation clinical trial nct03943446 tak-018 prevention recurrence postoperative crohn 's disease cd ,
Pidacmeran,pidacmeran investigation clinical trial nct04380701 trial investigating safety effect four bnt162 vaccine covid-2019 healthy adult ,
BNT-162A1,bnt-162a1 investigation clinical trial nct04380701 trial investigating safety effect four bnt162 vaccine covid-2019 healthy adult ,
Isoquercitrin,isoquercitrin investigation clinical trial nct04622865 masitinib combined isoquercetin best supportive care hospitalized patient moderate severe covid-19 ,
Regdanvimab,regdanvimab ct-p59 recombinant human igg1 monoclonal antibody directed receptor binding domain rbd sars-cov-2 spike protein l39140 block interaction viral spike protein angiotensin-converting enzyme 2 ace2 allows viral entry cell thereby inhibiting virus ability replicate trial investigating use regdanvimab therapeutic candidate treatment covid-19 began mid-2020 a235830 a241995 received first full approval south korea september 2021 a241995 followed eu november 2021 l39130 ,regdanvimab indicated eu treatment adult patient covid-19 require supplemental oxygen risk progressing severe covid-19 l39140 
Subasumstat,subasumstat investigation clinical trial nct03648372 study evaluate safety tolerability preliminary efficacy pharmacokinetics pk tak-981 adult participant advanced metastatic solid tumor relapsed/refractory hematologic malignancy subset coronavirus disease 2019 covid-19 ,
Azvudine,azvudine investigation clinical trial nct04668235 study safety clinical efficacy azvudine covid-19 patient sars-cov-2 infected ,
Zotatifin,zotatifin investigation clinical trial nct04092673 study eft226 subject selected advanced solid tumor malignancy ,
Tiragolumab,tiragolumab investigation clinical trial nct04513925 study atezolizumab tiragolumab compared durvalumab participant locally advanced unresectable stage iii non-small cell lung cancer nsclc ,
Datopotamab deruxtecan,datopotamab deruxtecan investigation clinical trial nct04656652 study ds-1062a versus docetaxel previously treated advanced metastatic non-small cell lung cancer without actionable genomic alteration tropion-lung01 ,
Camidanlumab tesirine,camidanlumab tesirine investigation clinical trial nct04639024 adct-301 patient r/r aml md mds/mpn ,
Adebrelimab,adebrelimab investigation clinical trial nct03711305 study carboplatin plus etoposide without shr-1316 participant untreated extensive-stage e small cell lung cancer sclc ,
Sotigalimab,sotigalimab investigation clinical trial nct03123783 cd40 agonistic antibody apx005m combination nivolumab ,
Birtamimab,birtamimab investigation clinical trial nct02312206 vital amyloidosis study global phase 3 efficacy safety study neod001 patient al amyloidosis ,
Feladilimab,feladilimab investigation clinical trial nct04128696 study gsk3359609 pembrolizumab programmed death receptor 1-ligand 1 positive recurrent metastatic head neck squamous cell carcinoma ,
Vilobelimab,vilobelimab investigation clinical trial nct03895801 study ifx-1 replace steroid patient granulomatosis polyangiitis microscopic polyangiitis ,
Geptanolimab,geptanolimab investigation clinical trial nct03502629 clinical trial chinese patient relapsed refractory peripheral cell lymphoma gb226 ,
Narsoplimab,thrombotic microangiopathies tma including thrombotic thrombocytopenic purpura atypical hemolytic uremic syndrome associated injury dysregulation microvascular endothelium platelet a241030 evidence increasingly point role complement system tma a241030 a241040 mannan-associated lectin-binding serine protease-2 masp-2 major effector complement lectin pathway a241030 a241040 narsoplimab oms721 human igg4λ anti-masp-2 antibody consideration treatment hematopoietic stem cell transplant-associated tma hsct-tma/ta-tma iga nephropathy a241045 a241050 narsoplimab investigation clinical trial nct03205995 safety efficacy study oms721 patient atypical hemolytic uremic syndrome ,
Ieramilimab,ieramilimab investigation clinical trial nct02460224 safety efficacy lag525 single agent combination pdr001 patient advanced malignancy ,
Vibostolimab,vibostolimab investigation clinical trial nct04303169 substudy 02c safety efficacy pembrolizumab combination investigational agent pembrolizumab alone participant stage iii melanoma candidate neoadjuvant therapy mk-3475-02c/keymaker-u02 ,
Volagidemab,volagidemab investigation clinical trial nct03117998 multiple dose study evaluate efficacy safety pharmacodynamics remd-477 subject type 1 diabetes mellitus ,
Quavonlimab,quavonlimab investigation clinical trial nct03179436 study quavonlimab mk-1308 combination pembrolizumab mk-3475 advanced solid tumor mk-1308-001 ,
AK119,ak119 humanized anti-cd73 monoclonal antibody investigated clinical trial nct04516564 study ak119 anti-cd73 antibody treatment covid-19 healthy subject l28315 ,
Allocetra,allocetra novel therapy billion early apoptotic cell infused bloodstream patient using body 's natural regulation mechanism rebalance unbalanced immune system without immune system suppression infusion body 's macrophage dendritic cell feed early apoptotic allocetra cell thus result macrophage dendritic cell releasing fewer cytokine alert signal immune system rebalanced back normal -- averting cytokine storm drug currently investigated organ failure associated sepsis organ failure associated covid-19 post-bone marrow transplantation complication solid tumor ,
SARS-CoV-2 vaccine,sars-cov-2 vaccine adjuvanted recombinant protein-based covid-19 vaccine candidate developed collaboratively glaxosmithkline gsk sanofi l30405 l30410 l30415 vaccine candidate composed spike protein antigen aim stimulate immune system production antibody sars-cov-2 us technology previously employed recombinant influenza vaccine l30405 ,
GRAd-COV2,grad-cov2 covid-19 vaccine candidate developed reithera l30420 l30423 therapy based novel replication-incompetent simian adenoviral vector encodes full-length sars-cov-2 spike protein grad-cov2 l30420 l30423 preclinical clinical study show grad-cov2 induce robust cellular humoral immune response l30423 ,
CoVac-1,sponsored university hospital tuebingen germany covac-1 multi-peptide covid-19 vaccine candidate created hla class hla-dr t-cell epitope s-protein a226588 investigated clinical trial nct04546841 safety immunogenicity trial multi-peptide vaccination prevent covid-19 infection adult pvac l30428 aim induce broad t-cell immunity a226588 ,
TMV-083,tmv-083 attenuated live virus covid-19 vaccine candidate employ measles vaccine vector l30433 express spike protein antigen sars-cov-2 l30433 ,
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine,receptor binding domain sars-cov-2 hepatitis b surface antigen virus-like particle vaccine rbd sars-cov-2 hbsag vlp vaccine virus-like particle vaccine candidate rbd antigen conjugated hepatitis b surface antigen a226593 virus-like particle vlps protein-based vaccine stimulate high immune response vlps ’ repetitive structure a226598 regarding vaccine specifically stimulates immune system produce anti-receptor binding domain antibody a226593 ,
MVA-SARS-2-S,mva-sars-2-s covid-19 vaccine candidate contains modified vaccinia virus ankara mva vector expressing sars-cov-2 spike protein l30453 mva highly attenuated poxvirus vector a226603 high-level biological safety due quality non-replicating virus mammalian host l30458 used develop vaccine infectious disease cancer a226603 ,
VXA-CoV2-1,vxa-cov2-1 non-replicating adenoviral vector-based oral tableted vaccine candidate express sars-cov-2 antigen dsrna adjuvant l30493 oral vaccine aim induce immunogenicity induction potent serum neutralizing antibody sars-cov-2 spike protein induction mucosal immune response induction t-cell response vaccine antigen sars-cov-2 nucleocapsid spike protein l30498 ,
IN01, in01 vaccine sponsored instituto oncologico dr rosell in3bio pangaea compound containing recombinant bacteria l30543 culture contain egf-4-egf cholera toxin b-subunit domain g33d sequence l30543 administration vaccine stimulates production anti-epidermal growth factor anti-egf neutralizing antibody l30543 note in01 vaccine tested phase clinical trial patient fibrosing interstitial lung disease resulting sars-cov-2 infection nct04537130 study explore effect vaccine pulmonary function oxygen saturation quality life fibrosing status addition biomarkers molecular marker vaccine ,
AG0302-COVID19,sponsored anges inc. japan ag0302-covid19 dna-based vaccine recently completed phase i/ii trial nct04527081 a226813 l30548 ,
AdimrSC-2f, adimrsc-2f sars-cov-2 vaccine developed adimmune corporation influenza vaccine manufacturer eu gmp u fda certification asia l30553 phase study nct04522089 investigate safety immunogenicity vaccine l30553 l30548 ,
V590, v590 vaccine developed merck ’ recombinant vesicular stomatitis virus rvsv platform previously used develop ebola zaire virus vaccine ervebo® a226818 l30573 l30578 teaming iavi merk developed vaccine require freezing requires one dose l30583 feature vaccine include potential activity oral administration _via_ swish-and-swallow protocol l30583 merck currently underway begin phase trial vaccine intramuscular administration nct04569786 ,
V591, v591 vaccine part merck ’ covid-19 vaccine programming developed using modified measles vaccine virus vector covid-19 antigen delivery l30593 merck ’ acquisition thermis may 2020 able leverage thermis ’ platform knowledge accelerate development v591 phase clinical trial nct04498247 l30593 ,
EpiVacCorona,epivaccorona vaccine developed vektor state research center virology biotechnology russia based peptide-antigens facilitate immunity sars-cov-2 virus l30608 currently tested phase i/ii clinical trial safety immunogenicity nct04527575 l30608 l30613 ,
QazCovid-in, qazcovid-in vaccine inactivated vaccine developed tested kazakh research institute biological safety problem l30628 demonstrated high efficacy safety immunogenicity 96 initial phase ii trial nct04530357 undergoing upcoming phase iii trial l30633 l30638 ,
BNT162b3, bnt162b3 vaccine latest addition biontech partner pfizer ’ mrna covid-19 vaccine program similar bnt162b2 bnt162b3 us nucleoside-modified rna modrna technology pfizer biontech deemed compound promising preclinical trial decided initiate testing bnt162b3 entered phase i/ii study early september 2020 nct04537949 ,
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell), recombinant sars-cov-2 vaccine created inserting gene sars-cov-2 spike protein ’ receptor-binding domain baculovirus expression system f4738 a226853 pre-clinical trial testing mouse rabbit non-human primate candidate able induce functional antibody response within 7-14 day initial injection a226853 also provided protection non-human primate vivo challenge sars-cov-2 a226853 promising result secured phase trial nct04530656 evaluate safety efficacy immunogenicity healthy chinese participant ,
UB-612, ub-612 covid-19 vaccine developed united biomedical inc asia taipei first covid-19 “ multi-tope ” protein-peptide vaccine made eight rationally designed component l30653 vaccine incorporates strong s1-rbd component linked single chain fragment region sfc human igg1 facilitates cell attachment act principal neutralizing domain virus l30658 l30663 addition vaccine contains proprietary peptide ubith®1a enhanced immunogenicity five identified peptide th ctl epitope improve peptide solubility aluminum phosphate adjuvant l30658 vaccine designed induce broad immune response able reduce viral load prevent covid-19 infection mouse challenge model rhesus macaque l30653 l30658 rat toxicity study far shown favourable safety vaccine l30653 l30658 phase 1 trial currently ongoing taiwan nct04545749 ,
ChulaCov19 mRNA vaccine, chulacov19 vaccine mrna-based developed thailand ’ chulalongkorn university collaboration university pennsylvania u l30673 l30678 pre-clinical study mouse monkey showed evidence vaccine facilitates impressive generation neutralizing antibody l30678 next phase study phase ii clinical trial nct04566276 beginning january 2021 ,
Vafidemstat,vafidemstat investigation clinical trial nct03867253 testing safety preliminary efficacy new drug ory-2001 mild moderate alzheimer 's disease ,
Thymoquinone,thymoquinone natural compound widespread protective effect including anti-oxidative anti-inflammatory immunomodulatory anti-cancer anti-microbial ,
CD24Fc,cd24fc biological immunomodulator originally developed address graft-versus-host disease stem cell transplantation leukemia patient ,
Rexin G,rexin-g tumor-targeted injectable retroviral vector carrying mutant form cyclin g1 gene development epeius biotechnology potential treatment metastatic cancer also investigated preventing sarscov-2 viral entry ,
ATYR1923,atyr1923 fusion protein comprised immuno-modulatory domain histidyl trna synthetase fused fc region human antibody selective modulator neuropilin-2 downregulates innate adaptive immune response inflammatory disease state ,
Meplazumab,meplazumab humanized anti-cd147 antibody investigated add-on therapy patient covid-19 pneumonia ,
PF-07304814,pf-07304814 small molecule prodrug target 3cl sup pro /sup protease sup pro /sup used virus like sars-cov-2 assemble multiply l31718 administered intravenous infusion compound cleaved pf-00835231 exert anti-viral effect l31718 pf-07304814 developed pfizer first identified sars outbreak 2002-2003 subsequently shelved outbreak controlled l31728 tested regarding novel sars-cov-2 virus including study conjunction remdesivir treat covid-19 infection vitro data showed synergistic effect article published preprint server l31733 l31125 phase 1b study also exploring safety tolerability pf-07304814 covid-19 patient hospitalized nct04535167 ,
PLN-74809,pln-74809 small-molecule dually inhibits α sub v /sub β sub 6 /sub α sub v /sub β sub 1 /sub treat idiopathic pulmonary fibrosis ipf primary sclerosing cholangitis psc l31693 compound granted orphan drug designation u fda august 2018 treatment ipf pliant therapeutic recently raised 100 million series c financing support clinical development compound l31708 phase 2a study currently evaluating pln-74809 safety efficacy participant ipf nct04396756 across 10 participating country l31703 participant psc nct04480840 addition compound also currently phase 2a trial nct04565249 treatment covid-19 related acute respiratory distress syndrome l31713 , dual inhibition integrins α sub v /sub β sub 6 /sub α sub v /sub β sub 1 /sub pln-74809 reduces subsequent activation tgf-β1 actively involved growth fibrotic tissue lung bile duct l31693 study showed pln-74809 inhibited collagen gene expression psc ipf patient tissue l31698 
Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/South Australia/55/2014 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Zofin,zofin previously known organicell flow nanoparticle-based therapeutic derived perinatal source manufactured way retains naturally occurring micrornas without addition substance l31323 ,
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection,covid-19 spike-gm-csf protein lactated ringer 's injection intradermal injection currently investigated clinical trial nct03348670 discovery stage proof-of-concept covid-19 antigen presentation therapeutic biologics covid-19 -- ap ap-tp-bio l31333 ,
Prolectin-M,prolectin-m 1-6 -alpha-d-mannopyranose l31338 act antagonist galectin l31343 investigated clinical trial nct04512027 prolectin-m covid-19 patient mild moderate symptom requiring oxygen support prolectin-m ,
Sodium copper chlorophyllin,sodium copper chlorophyllin scc water-soluble bright green mixture derived natural chlorophyll potential antimutagenic antioxidant property a227718 compound used food colorant supplement a227718 scc commercial-grade prepared reaction crude chlorophyll extract methanolic sodium hydroxide followed replacement central magnesium atom heavy metal a227718 ,
Deoxyribonuclease I,deoxyribonuclease dnase human enzyme responsible digestion extracellular dna7 a227723 normally found saliva urine pancreatic secretion blood a227723 hypothesis increased concentration high-molecular-weight dna factor airway obstruction abnormal viscoelastic property sputum recurrent exacerbation respiratory symptom requiring parenteral antibiotic aerosolized human dnase administered patient cystic fibrosis a227723 currently dnase investigated respiratory failure covid-19 clinical trial nct04541979 aerosoliserat dnase treatment respiratory failure severe covid-19 ,
FINLAY-FR-1,finlay-fr-1 also known soberana 01 vaccine candidate covid-19 led developmentally finlay vaccine institute l31373 currently tested clinical trial rpcec00000332 phase ii randomized controlled adaptive double-blind multicenter study evaluate safety reactogenicity immunogenicity prophylactic finlay-fr-1 anti-sars-cov-2 vaccine candidate two-doses schedule covid-19 soberana 01 ,
Collagen-polyvinylpyrrolidone,collagen-polyvinylpyrrolidone copolymer generated mixture type collagen low-molecular-weight pvp undergone γ irradiation a227733 characterized antifibrotic fibrolytic immunomodulatory property a227733 ,
BACTEK-R,mv130 contains different component whole heat-inactivated gram-positive -negative bacteria involved upper lower respiratory infection include streptococcus pneumoniae staphylococcus aureus though study shown reduces rate infection recurrent respiratory tract infection rrtis complete mechanism fully understood ,
Gatralimab,gatralimab investigation clinical trial nct02389452 study safety efficacy 6 ml synvisc-one hylan g-f 20 indian patient symptomatic osteoarthritis knee initial repeat treatment ,
Biomodulin T,biomodulin polypeptide fraction bovine thymus immunomodulatory effect ,
Dialyzable leukocyte extract,transferon comprised several peptide mixed human dialyzable leucocyte extract act immunomodulator thought widespread effect immune system effective treating infection immunological issue ,
KB109,kb109 prebiotic feed healthy bacteria outcompete multi-drug resistance organism ,
LL-37,ll-37 human cathelicidin inhibits viral replication also playing role host defense infection ,
OM85,om-85 bacterial extract immunomodulator interferon-β production inflammasome activity ,
Birch bark extract,birch bark extract rich triterpenoids beneficial biological pharmacological activity compound identified include betulin lupeol betulinic acid oleanolic acid erythrodiol a249945 birch bark extract obtained white part birch tree bark main specie tree used production _betula pendula_ roth silver birch _betula pubescens_ ehrh white birch although hybrid specie used well l42380 two oleogel formulation birch bark extract oleogel-s10 10 triterpene dry extract sunflower oil approved european medicine agency l42365 l42370 filsuvez one two formulation approved treatment partial thickness wound patient epidermolysis bullosa eb rare group hereditary disorder skin mucous membrane internal epithelial lining characterized extreme skin fragility blister development l42390 ema marketing authorization episalvan l42370 withdrawn manufacturer 2022 ,filsuvez preparation birch bark extract indicated treatment partial thickness wound associated dystrophic junctional epidermolysis bullosa eb patient 6 month older l42365 
Furvina,furvina g1 antimicrobial agent active gram-positive gram-negative bacteria yeast filamentous fungi furvina marketed cuba dermofural® ointment containing g1 active principle ingredient used treat dermatological infection a228063 ,
Lactoferrin,lactoferrin investigation clinical trial nct03748043 effectiveness lactoferrin treatment iron deficiency anemia child chronic tonsillitis ,
Tosatoxumab,tosatoxumab fully-human monoclonal antibody igg1λ targeting staphylococcus aureus alpha-toxin s. aureus alpha-hemolysin a191829 l31568 l31573 thereby preserving human immune cell protecting destruction host cell mediated toxin l31573 ,
Afimetoran,afimetoran immunomodulator antagonist toll-like receptor 7 8 l32018 l32023 also investigation clinical trial nct04269356 study ass way body absorbs distributes break eliminates radioactive bms-986256 healthy male participant ,
Darvadstrocel,darvadstrocel suspension expanded human allogeneic adipose-derived mesenchymal stem cell extracted subdermal adipose tissue healthy donor via liposuction a244524 darvadstrocel first approved european commission march 23 2018 brand name alofisel indicated treatment complex perianal fistula adult patient non-active mildly active luminal crohn ’ disease fistula shown inadequate response least one conventional biologic therapy l39759 first mesenchymal stem cell therapy approved europe therapeutic indication perianal fistula common manifestation crohn ’ disease often difficult manage may associated complex presentation symptom darvadstrocel exhibit immunomodulatory anti-inflammatory effect aim reduce local inflammation enhance tissue repair perianal fistula a244524 ,darvadstrocel indicated treatment complex perianal fistula adult patient non-active mildly active luminal crohn ’ disease fistula shown inadequate response least one conventional biologic therapy darvadstrocel used conditioning fistula l39759 
Lisocabtagene maraleucel,lisocabtagene maraleucel chimeric antigen receptor car t-cell therapy similar brexucabtagene autoleucel axicabtagene ciloleucel a228493 l31588 lisocabtagene maraleucel genetically modified autologous t-cell therapy target cd19 b-lymphocyte surface antigen b4 l31588 car t-cell therapy changed treatment b-cell lymphoma significantly increasing survival rate standard therapy a228493 however data efficacy car t-cell therapy le severe form b-cell lymphoma lacking a228493 despite adverse reaction majority patient given lisocabtagene maraleucel reported overall increase quality life 1 year period a228493 lisocabtagene maraleucel granted fda approval 5 february 2021 l31583 ec approval 5 april 2022 l42210 later granted health canada approval 6 may 2022 l43322 ,lisocabtagene maraleucel indicated treat adult relapsed refractory large b-cell lymphoma ≥2 systemic therapy diffuse large b-cell lymphoma high-grade b-cell lymphoma primary mediastinal large b-cell lymphoma grade 3b follicular lymphoma l31588 l42205 
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Tick-borne encephalitis vaccine (whole virus, inactivated)",tick-borne encephalitis tbe disease caused tbe virus tbev transmitted tick genus _ixodes_ disease course variable patient asymptomatic experience mild febrile illness others experience full course including neurological symptom a237505 tbe often manifest biphasic manner patient experiencing flu-like illness followed variable asymptomatic period second phase characterized various neurological symptom falling categorization meningitis diffuse/focal meningoencephalitis meningoencephalomyelitis a237505 a237520 patient recover fully following neurological tbe neurological sequela last year rare chronic form disease also noted a237520 due paucity effective safe effective acute therapeutic agent vaccination remains important defence tbe endemic area a237520 ticovac also known ticovac fsme-immun first approved vaccine tbe europe first approved 1976 a237520 a237525 second similar vaccine encepur followed 1991 a237520 vaccine based formaldehyde-inactivated whole virus a237520 l36050 although ticovac originally based master seed virus passaged mouse brain propagated chicken embryo fibroblast cef cell since 1990 's whole process carried cef cell a237520 originally developed baxter international inc. ticovac subsequently acquired pfizer inc. 2014 l36120 ticovac granted fda approval august 13 2021 l36050 ,ticovac indicated active immunization tick-borne encephalitis tbe patient one year age older l36050 
Methopterin,methopterin thought effect osteoclast inhibit inflammatory bone destruction a229843 ,
Tyrosinase,tyrosinase multi-copper-containing multifunctional metalloenzyme 4 possible oxidation state a231829 a231834 a231839 responsible producing melanin pigment across phylogenetic spectrum a231829 a231834 a231839 within mammal tyrosinase found specifically melanocyte glycosylated form play critical role regulating process melanin biosynthesis also known melanogenesis a231829 a231839 recognized main enzyme responsible enzymatic browning melanogenesis mammal thus causing undesired browning fruit vegetable disease resulting melanin overproduction a231829 ,
Melphalan flufenamide,melphalan flufenamide also known melflufen j1 prodrug melphalan a230123 l32173 melphalan flufenamide readily uptaken cell melphalan cleaved active metabolite aminopeptidases a230123 _in vitro_ model show melphalan 10 hundred time potent melphalan a230123 increased potency make melphalan flufenamide treatment option patient relapsed refractory multiple myeloma attempted least 4 line therapy already a230143 l32173 melphalan flufenamide granted fda approval 26 february 2021. l32173 since withdrawn market wake phase 3 ocean trial showed decrease overall survival comparison standard treatment pomalidomide dexamethasone despite superior progression-free survival l39085 l39090 ,melphalan flufenamide indicated combination dexamethasone treat adult relapsed refractory multiple myeloma received ≥4 therapy refractory least one proteasome inhibitor immunomodulatory agent anti-cd38 monoclonal antibody l32173 fda withdrawn drug market indication following phase 3 trial data showing decreased overall survival l39090 
Fosdenopterin,molybdenum cofactor deficiency mocd exceptionally rare autosomal recessive disorder resulting deficiency three molybdenum-dependent enzyme sulfite oxidase sox xanthine dehydrogenase aldehyde oxidase a230088 sign symptom begin shortly birth caused build-up toxic sulfites resulting lack sox activity a230088 l32163 patient mocd may present metabolic acidosis intracranial hemorrhage feeding difficulty significant neurological symptom muscle hyper- hypotonia intractable seizure spastic paraplegia myoclonus opisthotonus addition patient mocd often born morphologic evidence disorder microcephaly cerebral atrophy/hypodensity dilated ventricle ocular abnormality a230088 mocd incurable median survival untreated patient approximately 36 month a230088 treatment focused improving survival maintaining neurological function common subtype mocd type involves mutation _mocs1_ wherein first step molybdenum cofactor synthesis conversion guanosine triphosphate cyclic pyranopterin monophosphate cpmp interrupted a230088 a230593 past management strategy disorder involved symptomatic supportive treatment l32163 though effort made develop suitable exogenous replacement missing cpmp 2009 recombinant e. coli-produced cpmp granted orphan drug designation fda becoming first therapeutic option patient mocd type a230088 fosdenopterin approved fda februrary 26 2021 reduction mortality patient mocd type l32163 becoming first therapy approved treatment mocd improving three-year survival rate 55 84 l32288 considering lack alternative therapy available fosdenopterin appears poised become standard therapy management debilitating disorder july 2022 ema 's committee medicinal product human use chmp recommended fosdenopterin granted marketing authorization exceptional circumstance treatment patient molybdenum cofactor deficiency mocd type l43075 september 2022 ema approved use fosdenopterin l43372 l43433 ,fosdenopterin indicated reduce risk mortality patient molybdenum cofactor deficiency mocd type l32288 
Serdexmethylphenidate,attention deficit hyperactivity disorder adhd early-onset neurodevelopmental disorder often extends adulthood characterized developmentally inappropriate impaired attention impulsivity motor hyperactivity a230698 a230703 underlying cause adhd unclear likely involves dysfunction dopaminergic noradrenergic neurotransmission evidenced clear beneficial effect cns stimulant methylphenidate amphetamine increase extracellular dopamine norepinephrine level a230698 a230708 serdexmethylphenidate prodrug cns stimulant dexmethylphenidate common first-line treatment adhd combined dexmethylphenidate provide extended plasma concentration therapeutic benefit once-daily dosing l32298 l32323 serdexmethylphenidate granted fda approval march 2 2021 currently marketed combination capsule dexmethylphenidate trademark azstarys™ kempharm inc ,serdexmethylphenidate prodrug dexmethylphenidate indicated combination dexmethylphenidate treatment attention deficit hyperactivity disorder adhd patient aged six year older l32298 
OPB-111077,opb-111077 novel inhibitor stat3 mitochondrial oxidative phosphorylation demonstrated promising anticancer activity preclinical model ,
Almonertinib,almonertinib third-generation egfr tyrosine kinase inhibitor targeting egfr-sensitizing t790m resistance mutation a231859 a231864 a231869 investigated advanced metastatic egfr-mutated non-small cell lung cancer nsclc a231869 ,
Sugemalimab,sugemalimab fully human full-length igg4 monoclonal anti-pd-l1 antibody discovered cstone pharmaceutical investigated relapsed refractory extranodal natural killer nk /t-cell lymphoma r/r enktl adult patient t-cell lymphoma l32868 l32873 granted breakthrough therapy designation fda treat r/r enktl orphan drug designation treat t-cell lymphoma l32868 study sugemalimab well tolerated shown antitumor activity multiple tumor type l32868 sugemalimab investigation clinical trial nct03802591 study cs1001 subject gastric adenocarcinoma gastro-esophageal junction adenocarcinoma ,
Donanemab,donanemab ly3002813 humanized igg1 monoclonal antibody targeted epitope n-terminal specific type amyloid beta aβ pyroglutamate aβ found brain amyloid plaque associated alzheimer 's disease ad a232214 work inducing microglial-mediated clearance existing aβ plaque intent slowing progressive decline cognitive function associated ad phase ii study conducted eli lilly published march 2021 trailblazer-alz l32724 looked 257 patient early symptomatic ad found patient receiving donanemab experienced roughly 30 slower progression ad measured disease rating scale iadrs a232239 although result secondary endpoint mixed a232234 l32719 march 2021 eli lilly announced expanded trial named trailblazer-alz 2 seek confirm result first trial expanded patient population order address deficiency original l32714 ,
Bacillus calmette-guerin substrain russian BCG-I live antigen,bacillus calmette-guerin bcg substrain russian bcg-i live bcg vaccine administered directly bladder adjuvant treatment papillary urothelial cell carcinoma bladder live bcg vaccine administered intravesically gold standard therapy adjuvant treatment non-muscle-invasive bladder cancer decade a232264 used tumor resection thought work stimulating local immune inflammatory response bladder l32729 a232264 live russian bcg-i substrain bcg granted notice compliance condition health canada february 2021 l32734 marketed verity pharmaceutical trade name verity-bcg manufactured serum institute india developed alleviate canada 's multi-year shortage bcg vaccine expected available mid-2021 l32734 , live bcg vaccine substrain russian bcg-i i.e verity-bcg indicated adjuvant therapy following transurethral resection primary relapsing superficial papillary urothelial cell carcinoma bladder stage ta grade 2 3 t1 grade 1 2 3 without concomitant carcinoma situ l32729 may also used stage ta grade 1 papillary tumor risk recurrence high 50 l32729 
Ordesekimab,ordesekimab investigation clinical trial nct02633020 study evaluate efficacy safety amg 714 adult patient type ii refractory celiac disease ,
Deucravacitinib,deucravacitinib novel oral selective tyrosine kinase 2 tyk2 inhibitor unlike janus kinase 1/2/3 inhibitor bind conserved active domain non-receptor tyrosine kinase deucravacitinib bind regulatory domain tyk2 high selectivity therapeutic target a246938 a246943 selectivity towards tyk2 may lead improved safety profile deucravacitinib nonselective jak inhibitor associated range adverse effect altered cholesterol triglyceride level liver kidney dysfunction a246943 deucravacitinib first approved fda september 2022 treat moderate-to-severe plaque psoriasis l43150 later approved health canada november 2022 l44216 ,deucravacitinib tyrosine kinase 2 tyk2 inhibitor indicated treatment adult moderate-to-severe plaque psoriasis candidate systemic therapy phototherapy recommended use combination potent immunosuppressant l43150 l44216 
Botensilimab,botensilimab investigation clinical trial nct03860272 fc-engineered anti-ctla-4 monoclonal antibody advanced cancer ,
Avotaciclib,avotaciclib investigation clinical trial nct03579836 evaluation safety efficacy bey1107 monotherapy gemcitabine combination patient pancreatic cancer ,
Orticumab,orticumab investigation clinical trial nct04776629 proof-of-activity study orticumab subject psoriasis cardiometabolic risk factor ,
Nivatrotamab,nivatrotamab investigation clinical trial nct03860207 study safety efficacy humanized 3f8 bispecific antibody hu3f8-bsab patient relapsed/refractory neuroblastoma osteosarcoma solid tumor cancer ,
Teclistamab,teclistamab igg4-paa bispecific antibody target cd3 receptor expressed surface cell b cell maturation antigen bcma expressed malignant multiple myeloma cell a253587 teclistamab consists anti-bcma arm anti-cd3 arm connected via two interchain disulfide bond a253587 l43622 allowing drug recruit cd3-expressing cell bcma-expressing cell promote cell–mediated cytotoxicity a253587 august 24 2022 european commission ec granted conditional marketing authorization teclistamab first-in-class bispecific antibody treatment multiple myeloma marking first global approval l43612 teclistamab later granted accelerated approval fda october 25 2022 l43617 ,teclistamab indicated monotherapy treatment adult patient relapsed refractory multiple myeloma received least three prior therapy including immunomodulatory agent proteasome inhibitor anti-cd38 antibody demonstrated disease progression last therapy l43597 l43622 teclistamab approved ec fda conditional marketing authorization accelerated approval respectively new evidence drug continuously monitored reviewed affect continued approval drug 's indication 
Zotiraciclib,zotiraciclib investigation clinical trial nct02942264 zotiraciclib tg02 plus dose-dense metronomic temozolomide followed randomized phase ii trial zotiraciclib tg02 plus temozolomide versus temozolomide alone adult recurrent anaplastic astrocytoma glioblastoma ,
Vecabrutinib,vecabrutinib investigation clinical trial nct03037645 safety pk pd antitumor activity vecabrutinib sns-062 b lymphoid cancer ,
Imsidolimab,imsidolimab investigation clinical trial nct03633396 study evaluate efficacy safety anb019 subject palmoplantar pustulosis ,
Bentracimab,bentracimab investigation clinical trial nct04286438 bentracimab pb2452 ticagrelor-treated patient uncontrolled major life-threatening bleeding requiring urgent surgery invasive procedure ,
Izencitinib,izencitinib investigation clinical trial nct03920254 td-1473 long-term safety lts ulcerative colitis uc study ,
Etokimab,etokimab investigation clinical trial nct03614923 etokimab adult patient chronic rhinosinusitis nasal polyp crswnp ,
Efanesoctocog alfa,efanesoctocog alfa investigation clinical trial nct04759131 safety efficacy pk bivv001 pediatric patient hemophilia ,
Oxelumab,oxelumab investigation clinical trial nct00983658 study humab ox40l prevention allergen-induced airway obstruction adult mild allergic asthma ,
Bucelipase alfa,bucelipase alfa investigation clinical trial nct00743483 efficacy bucelipase alfa bssl patient cystic fibrosis pancreatic insufficiency ,
Idecabtagene vicleucel,multiple myeloma cancer plasma cell rapidly divide control a232563 cancerous cell generally express b-cell maturation antigen rarely expressed non-cancerous cell a232563 multiple myeloma typically treated immunomodulatory agent like lenalidomide a232593 proteasome inhibitor like bortezomib anti-cd38 monoclonal antibody like isatuximab a232608 idecabtagene vicleucel also known bb2121 chimeric antigen receptor car t-cell therapy like axicabtagene ciloleucel brexucabtagene autoleucel a232558 a232563 l32858 therapy involve extracting genetically manipulating t-cells patient express car tumor specific antigen a232558 chimeric antigen receptor idecabtagene vicleucel includes anti-b-cell maturation antigen scfv-targeting domain cd3ζ t-cell activation domain 4-1bb costimulatory domain l32858 idecabtagene vicleucel indicated fifth line treatment adult patient relapsed refractory multiple myeloma l32858 idecabtagene vicleucel granted fda approval 26 march 2021 l32863 ,idecabtagene vicleucel indicated treat adult patient relapsed refractory multiple myeloma tried least 4 line therapy including immunomodulatory agent proteasome inhibitor anti-cd38 monoclonal antibody l32858 
Ianalumab,ianalumab investigation clinical trial nct01930175 study efficacy safety vay736 patient pemphigus vulgaris ,
Pimivalimab,pimivalimab investigation clinical trial nct04549025 study pd-1 inhibitor jtx-4014 alone combination vopratelimab biomarker-selected subject metastatic nsclc one prior platinum-containing regimen ,
Budigalimab,budigalimab investigation clinical trial nct04807972 study evaluate adverse event change disease activity intravenous iv infusion abbv-927 administered combination iv modified folfirinox mffx without iv budigalimab compared mffx adult participant untreated pancreatic cancer metastasis ,
Surzebiclimab,surzebiclimab investigation clinical trial nct03744468 study bgb-a425 combination tislelizumab advanced solid tumor ,
Garivulimab,garivulimab investigation clinical trial nct03379259 study bgb-a333 alone combination tislelizumab advanced solid tumor ,
Torudokimab,torudokimab investigation clinical trial nct03831191 study ly3375880 adult moderate-to-severe atopic dermatitis ,
Epcoritamab,epcoritamab investigation clinical trial nct04628494 phase 3 trial epcoritamab r/r dlbcl ,
Mibavademab,mibavademab investigation clinical trial nct04159415 study regn4461 leptin receptor agonist antibody patient generalized lipodystrophy ,
Zagotenemab,zagotenemab investigation clinical trial nct03518073 study ly3303560 participant early symptomatic alzheimer 's disease ,
Uliledlimab,uliledlimab investigation clinical trial nct04322006 phase i/ii study tj004309 advanced solid tumor ,
Ravagalimab,ravagalimab investigation clinical trial nct03695185 study investigate well ravagalimab abbv-323 work safe participant moderate severe ulcerative colitis failed prior therapy ,
Nadecnemab,nadecnemab investigation clinical trial nct03956550 study examine efficacy safety regn5069 patient pain due osteoarthritis knee ,
Talquetamab,talquetamab investigation clinical trial nct04634552 study talquetamab participant relapsed refractory multiple myeloma ,
Letaplimab,letaplimab investigation clinical trial nct04485052 efficacy safety evaluation ibi188 combination azacitidine treatment patient acute myeloid leukemia ,
Cadonilimab,cadonilimab investigation clinical trial nct04220307 study pd-1/ctla-4 bispecific antibody ak104 patient metastatic nasopharyngeal carcinoma ,
Alomfilimab,alomfilimab investigation clinical trial nct03829501 safety efficacy ky1044 atezolizumab advanced cancer ,
Abelacimab,abelacimab investigation clinical trial nct04755283 safety tolerability abelacimab maa868 vs. rivaroxaban patient atrial fibrillation ,
Foslevodopa,foslevodopa investigation clinical trial nct04750226 study ass adverse event change disease activity 24-hour continuous subcutaneous infusion abbv-951 adult participant advanced parkinson 's disease ,
Odronextamab,odronextamab hinge-stabilized fully human immunoglobulin g4 igg4 -based cd20×cd3 bispecific antibody currently evaluated treatment relapsed/refractory r/r b-cell non-hodgkin lymphoma nhl a254187 a254197 preliminary study shown patient r/r nhl use odronextamab lead development neurologic toxicity however lead development cytokine release syndrome cr serious condition associated use immunotherapy a254187 december 2020 fda placed partial clinical hold requested drug developer regeneron pharmaceutical amend clinical protocol reduce incidence cr partial clinical hold later lifted may 2021 l43887 l43892 phase clinical study nct02290951 showed heavily pre-treated patient b-cell non-hodgkin lymphoma odronextamab elicited durable response manageable safety profile a254192 ,
Tebotelimab,tebotelimab investigation clinical trial nct04082364 combination margetuximab incmga00012 mgd013 chemotherapy phase 2/3 trial her2+ gastric/gej cancer mahogany ,
Efmitermant alfa,efmitermant alfa locally-acting gdf/activin ligand trap investigation clinical trial nct03124459 study ace-083 patient charcot-marie-tooth disease ,
Reltecimod,reltecimod investigation clinical trial nct02469857 phase iii efficacy safety study ab103 treatment patient necrotizing soft tissue infection ,
Reproxalap,reproxalap previously adx 102 ns-2 small molecule inhibitor developed aldeyra therapeutic investigated dry eye disease allergic conjunctivitis noninfectious anterior uveitis sjögren-larsson syndrome l32990 ns-2 orphan drug status due investigated treatment sjogren-larsson syndrome l32990 ,
Tengonermin,tengonermin also known ngr-htnf vascular-targeting drug a233265 recombinant protein peptide-targeted agent consisting human tumour necrosis factor-α tnf-α conjugated cngrcg peptide l33050 drug work modifying tumor microenvironment increasing intratumoral chemotherapy penetration t-cell infiltration a233265 ngr-htnf specifically target angiogenic tumor blood vessel using ngr motif a233270 literature demonstrates ngr-peptides bind cd13 isoform expression restricted tumor vasculature cell a233270 study also demonstrated binding ngr-motif cd13 determined homing ngr-htnf tumor vessel increase antiangiogenic activity a233270 ,
Tegoprazan,tegoprazan also known cj-12420 novel therapeutic developed cj healthcare corp treating acid-related gastrointestinal disease a234215 a234220 drug potent high-selective potassium-competitive acid blocker p-cab fast onset action ability control gastric ph prolonged period time a234215 a234220 tegoprazan ’ strong sustained effect due ability slowly cleared gastric gland exertion effect independent acid level a234220 also observed efficacious independent food intake a234220 ,
Nirmatrelvir,nirmatrelvir pf-07321332 orally bioavailable 3c-like protease 3cl sup pro /sup inhibitor subject clinical trial nct04756531 l33354 3cl sup pro /sup responsible cleaving polyproteins 1a 1ab sars-cov-2 a234224 without activity sars-cov-2 3cl sup pro /sup nonstructural protein including protease released perform function inhibiting viral replication a234224 a234229 a234234 2020 pfizer investigating another potential treatment sars-cov-2 pf-07304814 l33359 drug inhibitor sars-cov-2 3cl sup pro /sup nirmatrelvir advantage orally bioavailable l33359 nirmatrelvir advantageous prescribed patient require hospitalization pf-07304814 requires intravenous administration hospital l33359 december 2021 fda granted emergency use authorization paxlovid co-packaged product containing nirmatrelvir ritonavir treatment certain patient mild-to-moderate covid-19 l39544 paxlovid approved use canada january 2022 treatment adult patient mild-moderate covid-19 l39544 later granted conditional marketing authorization european commission january 27 2022 l40094 ,nirmatrelvir received fda emergency use authorization combination ritonavir treatment mild-to-moderate coronavirus disease 2019 covid-19 adult pediatric patient 12 year age older weighing least 40 kg positive result direct severe acute respiratory syndrome coronavirus 2 sars-cov-2 viral testing high risk progression severe covid-19 including hospitalization death l39544 canada nirmatrelvir indicated combination ritonavir treatment sars-cov-2 positive adult patient mild-to-moderate covid-19 high risk progression severe disease l39840 therapeutic usage also valid europe conditional marketing authorization l40089 
Axalimogene filolisbac,axalimogene filolisbac investigation clinical trial nct02853604 study adxs11-001 subject high risk locally advanced cervical cancer ,
Pegcetacoplan,pegcetacoplan complement inhibitor indicated treatment paroxysmal nocturnal hemoglobinuria pnh a235000 l34095 prior fda approval patient pnh typically treated c5 inhibiting monoclonal antibody eculizumab a235000 patient given eculizumab experienced le hemolysis caused membrane attack complex still somewhat susceptible hemolysis caused c3b opsonization a235000 a235005 pegcetacoplan developed need inhibitor complement mediated hemolysis upstream c5 a235000 a235005 pegcetacoplan pegylated c3 inhibitor disrupt process leading form hemolysis threaten patient pnh a235000 pegcetacoplan granted fda approval 14 may 2021 l34095 ,pegcetacoplan indicated treat adult paroxysmal nocturnal hemoglobinuria pnh l34095 
Amivantamab,amivantamab also known jnj-61186372 anti-egfr-met bispecific antibody derived chinese hamster ovary cell approved treatment adult patient locally advanced metastatic non-small cell lung cancer nsclc epidermal growth factor receptor egfr exon 20 insertion mutation detected fda-approved test whose disease progressed platinum-based chemotherapy a235103 l34193 patient nsclc often develop resistance drug target egfr met individually amivantamab developed attack target reducing chance resistance developing a235103 a235118 amivantamab found effective egfr inhibitor erlotinib met inhibitor crizotinib _in vivo_ a235103 a235123 patient nsclc exon 20 insertion mutation egfr respond tyrosine kinase inhibitor generally treated platinum-based therapy a235133 amivantamab granted fda approval 21 may 2021 l34193 followed approval ema 9 december 2021 l41474 health canada 30 march 2022 l41469 ,amivantamab indicated treatment adult patient locally advanced metastatic non-small cell lung cancer nsclc epidermal growth factor receptor egfr exon 20 insertion mutation whose disease progressed platinum-based chemotherapy l34193 l41469 l41479 l43842 
Glutazumab,glutazumab novel long-lasting glp-1/anti-glp-1r antibody fusion protein exerting anti-diabetic effect a235745 ,
Neihulizumab,neihulizumab novel immune checkpoint agonistic antibody bind human cd162 psgl-1 thereby preferentially inducing apoptosis late stage activated cell l34450 ,
Vutrisiran,vutrisiran double-stranded small interfering ribonucleic acid sirna target wild-type mutant transthyretin ttr messenger rna mrna l42065 sirna therapeutic indicated treatment neuropathy associated hereditary transthyretin-mediated amyloidosis attr condition caused mutation ttr gene a249010 130 ttr mutation identified far a249015 common one replacement valine methionine position 30 val30met a249010 val30met variant prevalent among hereditary attr patient polyneuropathy especially portugal france sweden japan a249010 ttr mutation lead formation misfolded ttr protein form amyloid fibril deposit different type tissue targeting ttr mrna vutrisiran reduces serum level ttr l34490 l42065 vutrisiran commercially available conjugate n-acetylgalactosamine galnac residue enables delivery sirna hepatocytes a249025 l42065 delivery platform give vutrisiran high potency metabolic stability allows subcutaneous injection take place every three month l42085 another sirna indicated treatment polyneuropathy associated hereditary attr patisiran a249010 vutrisiran approved fda june 2022 ,vutrisiran indicated treatment polyneuropathy hereditary transthyretin-mediated amyloidosis adult l42065 
Plasminogen,plasminogen pro-enzyme i.e zymogen cleaved form plasmin also known fibrinolysin part fibrinolytic pathway break fibrin blood clot a236035 pathway activated clot longer needed prevent clot extending beyond site injury l34635 june 2021 fda approved plasma-derived plasminogen ryplazim human plasminogen-tvmh l34620 treatment type 1 plasminogen deficiency hypoplasminogenemia l34615 first fda-approved treatment condition cause wood-like lesion form mucous membrane patient providing unmet medical need patient rare congenital disease ,plasma-derived human plasminogen marketed brand name ryplazim indicated treatment patient plasminogen deficiency type 1 hypoplasminogenemia l34620 
Famprofazone,famprofazone nonsteroidal anti-inflammatory agent found combination product ‘ gewodin ’ marketed taiwan l34724 important note drug metabolized methamphetamine amphetamine body lead positive test result illicit drug use a236369 l34724 famprofazone included list prohibited substance specified ‘ world anti-doping agency ’ wada l34729 ,
Belumosudil,belumosudil used treatment chronic graft-versus-host disease gvhd investigated treatment pulmonary arterial hypertension a236634 inhibitor rho-associated coiled-coil-containing protein kinase rock significantly selectivity rock2 compared rock1 ic sub 50 /sub 100 nm vs. 3 μm respectively l34749 treatment gvhd condition donor t-cells begin attack recipient tissue following allogeneic hematopoeitic stem cell transplantation hsct belumosudil help resolve immune dysregulation shifting balance th17 cell t-regulatory cell thereby dampening inflammatory cascade occasionally fatal a236644 l34759 belumosudil first approved fda july 2021 brand name rezurock treatment chronic gvhd patient tried failed least two prior line systemic therapy l34754 july 2022 belumosudil approved health canada brand name rholistiq treat condition adult pediatric patient 12 year older l42925 ,belumosudil indicated treatment chronic graft-versus-host disease gvhd adult pediatric patient 12 year age older following failure least two line systemic therapy l34749 
Durlobactam,durlobactam investigation clinical trial nct03894046 study evaluate efficacy safety intravenous sulbactam-etx2514 treatment patient infection caused acinetobacter baumannii-calcoaceticus complex ,
Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Wisconsin/588/2019 (H1N1) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Gavorestat,gavorestat investigation clinical trial nct04902781 clinical benefit safety pk pd study at-007 pediatric subject classic galactosemia ,
Cipaglucosidase alfa,cipaglucosidase alfa investigation clinical trial nct03911505 zip study study safety pharmacokinetics efficacy pharmacodynamics immunogenicity atb200/at2221 pediatric subject aged 0 18 year pompe disease ,
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen,stratagraft allogeneic cultured keratinocytes dermal fibroblast murine collagen-dsat allogeneic cellularized scaffold product used treatment adult thermal burn containing intact dermal element surgical intervention clinically indicated also known deep partial-thickness burn l35505 developed alternative autografting process patient 's skin harvested grafted onto burn site disadvantage creating new wound site graft taken l35525 stratagraft consists two kind lab-grown skin cell keratinocytes dermal fibroblast grown together murine collagen matrix make bi-layered construct i.e cellularized scaffold sheet containing scaffold product applied burn site contain metabolically active viable cell provide variety human growth factor cytokine well extracellular matrix protein known involved wound repair product remain permanently engrafted instead replaced patient 's cell time reduce even eliminate need autografting l35505 stratagraft early stage development far back 2009 a237275 granted full fda approval june 2021 l35525 ,stratagraft allogeneic cellularized scaffold product indicated treatment adult thermal burn containing intact dermal element surgical intervention clinically indicated deep partial-thickness burn l35505 
Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 22f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 22f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 33f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 33f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 contained vaccine market name prevnar contains saccharide serotypes 4 6b 9v 14 18c 19f 23f intramuscular injection saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 8 capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 8 individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 10a capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 10a individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 11a capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 11a individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 12F capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 12f capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 12f individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen,streptococcus pneumoniae type 15b capsular polysaccharide diphtheria crm197 protein conjugate antigen sterile vaccine contains saccharide capsular antigen streptococcus pneumoniae serotype 15b individually conjugated crm197 protein nontoxic variant diphtheria toxin isolated culture corynebacterium diphtheriae strain c7 β197 saccharide vaccine prepared purified polysaccharide chemically activated conjugated protein carrier crm197 form glycoconjugate ,
Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability , combination influenza virus subtypes type b strain influenza viral strain used active immunization adult child aged 6 month older prevention influenza disease caused influenza virus subtypes type b l41345 
"Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine protects infection influenza virus vaccine provide protection influenza exposing immune system virus part virus stimulates immunological defence future exposure virus `` antigen '' defence includes production humoral immunity development antibody memory b cell cell-mediated immunity production t-lymphocytes upon re-exposure infectious influenza virus immune system prepared identify destroy virus circulating antibody recognize particular component virus previously exposed two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde 3 inactivated virus replicate therefore cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability , combination influenza virus subtypes type b strain influenza viral strain used active immunization adult child aged 6 month older prevention influenza disease caused influenza virus subtypes type b l41345 
Lirentelimab,lirentelimab investigation clinical trial nct04856891 study lirentelimab ak002 patient active eosinophilic duodenitis ,
Favezelimab,favezelimab investigation clinical trial nct04626479 substudy 03a study immune targeted combination therapy participant first line 1l renal cell carcinoma mk-3475-03a ,
Enibarcimab,enibarcimab investigation clinical trial nct03989531 adrecizumab cardiogenic shock ,
Tisotumab vedotin,tisotumab vedotin tissue factor-directed antibody-drug conjugate adc comprised anti-tissue factor tf human igg1-kappa antibody conjugated monomethyl auristatin e mmae microtubule-disrupting agent via protease-cleavable valine-citrulline linker monoclonal antibody molecule carry average four mmae molecule tisotumab vedotin first tf-directed adc a238914 work binding tfs expressed solid tumour tf primary initiator extrinsic blood coagulation cascade l38424 play key role tumor-associated angiogenesis progression metastasis tumor survival tf novel target cancer often overexpressed solid tumour including cervical cancer associated poor clinical outcome tisotumab vedotin target tf-expressing cell deliver mmae induce direct cytotoxicity bystander killing neighboring cell a238914 september 20 2021 fda granted accelerated approval tisotumab vedotin-tftv treatment recurrent metastatic cervical cancer adult disease progressed chemotherapy first approved antibody-drug conjugate therapeutic indication approval based tumour response durability response demonstrated innovatv 204 nct03438396 trial objective response rate 24 median response duration 8.3 month l38429 tisotumab vedotin-tftv marketed trade name tivdak intravenous injection tisotumab vedotin currently investigation treatment solid tumor including ovarian lung colorectal pancreatic head neck cancer also investigated combination use chemotherapeutic agent recurrent metastatic cervical cancer a238924 ,tisotumab vedotin indicated treatment adult patient recurrent metastatic cervical cancer disease progression chemotherapy l38424 
Rimtuzalcap,rimtuzalcap novel modulator small-conductance calcium-activated potassium channel investigation treatment essential tremor l38414 ,
STG-001,stg-001 investigation clinical trial nct04489511 study stg-001 subject stargardt disease ,
PAT-1251,pat-1251 investigation clinical trial nct04054245 pat-1251 treating patient primary myelofibrosis post-polycythemia vera myelofibrosis post-essential thrombocytosis myelofibrosis ,
Allogeneic processed thymus tissue,allogeneic processed thymus tissue used immune reconstitution immune disorder patient severely immunocompromised due absence functional thymus congenital athymia part immune system thymus organ responsible maturation selection cell a239814 thus patient without functional thymus experience profound immunodeficiency placed higher risk developing life-threatening fatal infection immune dysregulation l38929 congenital athymia rare condition lead absence thymus birth high premature mortality rate patient typically dying age two three l38929 multiple factor contribute development congenital athymia genetic abnormality congenital syndrome environmental factor allogeneic processed thymus tissue implantation work migrating recipient ’ bone marrow-derived stem cell implanted cultured thymus tissue develops immunocompetent naïve cell a239814 october 8 2021 fda approved allogeneic processed thymus tissue-agdc market name rethymic one-time regenerative tissue-based therapy immune reconstitution pediatric patient congenital athymia mark first fda-approved treatment therapeutic indication l38929 ,allogeneic processed thymus tissue indicated immune reconstitution pediatric patient congenital athymia indicated treatment patient severe combined immunodeficiency scid l38924 
Ciltacabtagene autoleucel,"multiple myeloma malignancy involving plasma cell bone marrow rare malignancy estimated yearly incidence 6.5 people per 100,000 l40749 variable presentation patient may remain entirely asymptomatic others may experience range symptom including bone pain hematologic abnormality end-organ damage l40749 number treatment developed multiple myeloma e.g daratumumab although none curative a245854 b-cell maturation antigen bcma transmembrane glycoprotein member tumor necrosis factor receptor superfamily 17 tnfrsf17 used biomarker multiple myeloma a245854 normally expressed plasma blast plasma cell bcma widely expressed malignant plasma cell multiple myeloma cell line making choice target development immunotherapy multiple myeloma a245854 ciltacabtagene autoleucel carvykti jannsen biotech inc. bcma-directed genetically modified autologous t-cell immunotherapy l40739 patient t-cells reprogrammed transgene encoding specific chimeric antigen receptor car feature two bcma-targeting single-domain antibody l40739 re-infusion modified t-cells lead targeted elimination malignant plasma cell bcma highly expressed a245854 carvykti first approved fda february 2022 treatment relapsed refractory multiple myeloma treatment-experienced patient l40744 ",ciltacabtagene autoleucel indicated treatment adult patient relapsed refractory multiple myeloma ≥4 prior line therapy including proteasome inhibitor immunomodulatory agent anti-cd38 monoclonal antibody l40739 
MK-886,mk-886 experimental inhibitor leukotriene synthesis ,
PXT 3003,pxt 3003 phase 3 clinical trial treatment charcot-marie-tooth disease type 1a adult ,
Elivaldogene autotemcel,elivaldogene autotemcel gene therapy consisting genetically modified autologous cell used provide functional copy human adrenoleukodystrophy protein aldp patient adrenoleukodystrophy l39491 x-linked genetic disorder characterized missing non-functional _abcd1_ gene code aldp a243691 aldp key protein normally break fatty substance body called long-chain fatty acid vlcfas without sufficient level functional aldp vlcfas accumulate body leading inflammation destruction myelin insulating layer essential component nerve l40298 cerebral adrenoleukodystrophy inflammatory cerebral phenotype commonly affect young men associated progressive brain function loss poor survival rate without treatment allogeneic hematopoietic stem-cell transplantation primary treatment option however associated risk graft failure graft-versus-host disease gvhd calling alternative treatment option gene therapy autologous hematopoietic stem cell introduced investigated possible treatment patient adrenoleukodystrophy a243691 elivaldogene autotemcel work delivering gene patient 's body produce functional aldps approved european commission july 2021 market name skysona later withdrawn november 2021 request marketing-authorization holder l40298 september 2022 skysona approved fda l43247 ,elivaldogene autotemcel indicated slow progression neurologic dysfunction boy 4-17 year age early active cerebral adrenoleukodystrophy cald early active cald refers asymptomatic mildly symptomatic neurologic function score nfs ≤ 1 boy gadolinium enhancement brain magnetic resonance imaging mri loes score 0.5-9 l43247 
TPMPA,"tpmpa 1,2,5,6-tetrahydropyridine-4-yl methylphosphinic acid selective antagonist gaba sub c /sub receptor also known gaba-ρ gaba sub a-ρ /sub receptor a245303 gaba sub c /sub receptor found primarily retina although may present tissue including hippocampus spinal cord superior colliculus pituitary gut a245308 a245313 tpmpa used pharmacological probe investigation gaba sub c /sub receptor function a245313 ",
Bebtelovimab,bebtelovimab ly-cov1404 ly-3853113 human monoclonal antibody approved emergency use treatment covid-19 bind portion sars-cov-2 spike protein 's receptor-binding domain thereby preventing spike protein interaction ace2 subsequent viral entry host cell bebtelovimab notable epitope bind appears infrequently mutated making viable candidate use resistant sars-cov-2 strain i.e variant concern vocs including b.1.617.2 delta b.1.1.529 omicron variant a245353 contrast previously developed covid-19 monoclonal antibody treatment including bamlanivimab etesevimab casirivimab imdevimab found ineffective treatment covid-19 caused omicron variant l40328 bebtelovimab issued emergency use authorization eua fda february 11 2022 treatment mild-to-moderate covid-19 select patient l40313 november 2022 fda updated health care provider fact sheet bebtelovimab inform expected reduced activity certain emerging omicron subvariants sars-cov-2 l43827 november 30 2022 eua bebtelovimab officially withdrawn due lack efficacy omicron subvariants therefore bebtelovimab longer authorized emergency use u l44241 ,bebtelovimab currently approved indication 
Ivarmacitinib,ivarmacitinib shr0302 selective inhibitor janus kinase 1 jak1 investigation treatment various immuno-inflammatory condition ivarmactinib yet receive marketing authorization february 2022 clinical trial ongoing completed evaluating use atopic dermatitis l40604 l40619 l40629 ankylosing spondylitis l40584 rheumatoid arthritis l40589 psoriatic arthritis l40594 graft-versus-host disease a245653 l40599 vitiligo l40609 ulcerative colitis l40614 alopecia areata l40624 primary membranous nephropathy l40634 ,
"Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine", covifenz covid-19 vaccine plant-based virus-like particle vlp recombinant adjuvanted plant-based vaccine developed partnership medicago glaxosmithkline approved canada prevention covid-19 l40694 composed vlps expressing sars-cov-2 spike protein trimer stabilized pre-fusion conformation mixed as03 adjuvant system prior administration l40694 concept plant-based vlps vaccine new a245824 novel approach covid-19 vaccination previously approved covid-19 vaccine mostly comprising viral vector e.g astrazeneca covid-19 vaccine nucleic acid vaccine e.g moderna covid-19 vaccine a245819 plant-based vlps offer number advantage compared vaccine platform including speed ease manufacturing increased immunogenicity a245824 addition vlps contain viral material therefore inherently non-infectious making potentially safer alternative traditional vaccine a245824 , covifenz covid-19 vaccine indicated active immunization prevent covid-19 caused sars-cov-2 patient 18-64 year old l40694 
Lutetium Lu-177 vipivotide tetraxetan,lutetium lu-177 vipivotide tetraxetan radioligand therapeutic agent consists radionuclide lutetium lu-177 linked moiety bind psma transmembrane protein expressed prostate cancer l41280 lutetium lu-177 vipivotide tetraxetan first approved fda march 23 2022 treatment prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer l41290 october 2022 ema 's committee medicinal product human use chmp recommended lutetium lu-177 vipivotide tetraxetan granted marketing authorization treatment prostate cancer l43787 ,lutetium lu 177 vipivotide tetraxetan radioligand therapeutic agent indicated treatment adult patient prostate-specific membrane antigen psma -positive metastatic castration-resistant prostate cancer mcrpc treated androgen receptor ar pathway inhibition taxane-based chemotherapy l41280 
Resamirigene bilparvovec,at132 investigation clinical trial nct03199469 gene transfer clinical study x-linked myotubular myopathy ,
Eladocagene exuparvovec,eladocagene exuparvovec recombinant adeno-associated virus-2 aav2 -based gene therapy express human aromatic l-amino acid decarboxylase aadc used treat aadc deficiency fatal rare genetic disorder cause severe disability pediatric patient l43642 l43672 patient aadc mutation dopa decarboxylase ddc gene encodes aadc enzyme promoting expression aadc eladocagene exuparvovec lead development motor function patient aadc deficiency eladocagene exuparvovec infused directly brain putamen bilateral intraputaminal infusion one surgical session l43642 eladocagene exuparvovec received ema approval july 2022 a253697 l43672 approval gene therapy treatment option patient aadc deficiency limited attempt increase monoamine neurotransmitter production decrease neurotransmitter catabolism via monoamine oxidase mao inhibition address symptom a253687 ,eladocagene exuparvovec indicated treatment patient aged 18 month older clinical molecular genetically confirmed diagnosis aromatic l-amino acid decarboxylase aadc deficiency severe phenotype l43642 
Volrubigene ralaparvovec,volrubigene ralaparvovec investigation clinical trial nct03223194 gene transfer clinical study crigler-najjar syndrome ,
Etranacogene dezaparvovec,"hemophilia b also called factor ix deficiency christmas disease x-linked genetic disorder resulting absence deficiency clotting factor ix l44176 clotting factor including factor ix necessary component signaling cascade responsible blood clotting subsequent wound healing l44181 symptom hemophilia b therefore involve heightened susceptibility bleeding episode mild case bleeding may occur injury severe case bleeding may occur minor injury even spontaneously l44181 hemophilia b second common type hemophilia l44181 prevalence approximately one 40,000 l44161 men likely experience symptomatic illness due x-linked provenance disorder l44161 treatment hemophilia b primarily involves routine replacement factor ix using recombinant donor-derived factor ix product effective may burdensome patient due requirement routine intravenous infusion l44161 l44181 etranacogene dezaparvovec hemgenix csl bering llc gene therapy treatment hemophilia b provides new treatment modality patient therapy involves one-time infusion viral vector carrying codon-optimized dna sequence gain-of-function padua variant human factor ix controlled liver-specific promotor 1 l44156 delivers copy deficient gene result cell transduction eventual increase circulating factor ix activity l44156 etranacogene dezaparvovec approved fda november 2022 treatment select patient hemophilia b becoming first gene therapy approved indication l44161 additionally notable cost per treatment approximately 3.5 million usd earning title expensive drug world l44186 ",etranacogene dezaparvovec hemgenix indicated treatment adult hemophilia b fit one following criterion l44156 currently use factor ix prophylaxis therapy current historical life-threatening hemorrhage repeated serious spontaneous bleeding episode
Letibotulinumtoxina, aesthetic utility botulinum toxin discovered incidentally following initial use treatment facial spasmodic disorder early 1970s a249920 first aesthetic use botulinum toxin reported 1989 onabotulinumtoxina botox used treatment facial asymmetry resulting iatrogenic facial nerve damage a249920 subsequently approved fda 1992 use aesthetic procedure since become one popular cosmetic procedure worldwide a249920 letibotulinumtoxina type botulinum neurotoxin produced fermentation _clostridium botulinum_ strain cbfc26 l42330 900 kda multimeric complex comprising 150 kda toxin 130 kda non-toxic non-haemagglutinating protein various haemagglutinins l42330 letibotulinumtoxina market-leading cosmetic product south korea number year recently approved european union l42335 approved use canada june 2022 treatment glabellar line l42330 l42335 ,letibotulinumtoxina indicated temporary improvement appearance moderate-to-severe glabellar line associated corrugator and/or procerus muscle activity adult patient ≤65 year age l42330 
Betibeglogene autotemcel,betibeglogene autotemcel autologous gene therapy add functional copy β-globin gene β sup a-t87q /sup -globin hematopoietic stem cell order treat β-thalassemia l42940 β-thalassemia condition caused mutation β-globin gene hbb lead significant decrease production β-globin affect hemoglobin level patient severe form disease long-term red cell transfusion required survival prevention serious complication a251770 allogeneic hematopoietic-cell transplantation would therapeutic option patient β-thalassemia however process reserved young child hla-identical sibling donor due risk graft rejection graft-versus-host disease treatment-related toxic effect a251770 patient treated betibeglogene autotemcel given infusion hematopoietic stem cell previously enriched cd34+ transduced _ex vivo_ bb305 lvv self-inactivating lentiviral vector lvv l42940 bb305 lvv encodes β sup a-t87q /sup -globin compensating lack β-globin patient use betibeglogene autotemcel effective patient β-thalassemia residual β-globin synthesis non-β sup 0 /sup /β sup 0 /sup genotype compared detectable β-globin production β sup 0 /sup /β sup 0 /sup a251770 a251785 betibeglogene autotemcel approved fda august 2022 first ex-vivo lentiviral vector gene therapy available u.s. treatment people β-thalassemia l42960 ,betibeglogene autotemcel indicated treatment adult pediatric patient β-thalassemia require regular red blood cell rbc transfusion l42940 
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
"Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated), seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus two basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability ,
Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus three basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv recombinant influenza vaccine riv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability recombinant influenza vaccine produced synthesizing recombinant influenza hemagglutinin antigen laboratory require use candidate virus egg-based manufacturing process ,
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen, seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus three basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv recombinant influenza vaccine riv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability recombinant influenza vaccine produced synthesizing recombinant influenza hemagglutinin antigen laboratory require use candidate virus egg-based manufacturing process ,
"Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus three basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv recombinant influenza vaccine riv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability recombinant influenza vaccine produced synthesizing recombinant influenza hemagglutinin antigen laboratory require use candidate virus egg-based manufacturing process ,
"Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)", seasonally-specific component influenza vaccine influenza vaccine also known `` flu shot '' vaccine help protect infection influenza virus vaccine provide protection influenza exposing immune system virus part virus result immunological defense future exposure virus `` antigen '' defense includes production humoral immunity development antibody cell-mediated immunity production t-lymphocytes upon re-exposure influenza virus immune system prepared circulating antibody identify destroy virus three basic type vaccine available inactivated influenza vaccine iiv live attenuated influenza vaccine laiv recombinant influenza vaccine riv inactivated vaccine contain virus particle grown medium subsequently killed inactivated exposure heat chemical formaldehyde inactivated virus replicate thus cause disease infection even immunocompromised individual contrast live vaccine produced `` wild-type '' disease-causing virus attenuated weakened various laboratory technique live vaccine maintain replicative ability recombinant influenza vaccine produced synthesizing recombinant influenza hemagglutinin antigen laboratory require use candidate virus egg-based manufacturing process ,
ALMB-0168,almb-0168 humanized connexin 43 cx43 monoclonal antibody investigated osteosarcoma ,
GTX-102,investigational antisense oligonucleotide specific antisense transcript ube3a ,
SRP-6004, recombinant aavrh74 gene therapy expressing dysferlin transgene control muscle-specific promoter raavrh74.mhck7.dysf.dv ,
VY-HTT01,vy-htt01 gene therapy designed reduce expression huntingtin thereby altering disease progression vy-htt01 comprised adeno-associated virus capsid aav1 proprietary transgene harness canonical rna interference pathway selectively knock level htt mrna ,
ACT-101,act-101 recombinant human alpha-fetoprotein rhafp ,
AT-GTX-502,at-gtx-502 experimental one-time gene therapy us aav9 deliver functional copy cln3 ,
PR006,pr006 non-replicating recombinant adeno-associated virus serotype 9 containing progranulin gene ,
MRK-003,mrk-003 potent selective γ-secretase inhibitor developed merck preclinical analog mk-0752 drug clinical development a252682 ,
MK-4541,mk-4541 4-azasteroid selective androgen receptor modulator sarm mk-4541 act dual selective sarm potent androgen receptor antagonist 5α-reductase inhibitor a252687 ,
AMZ002,amz002 sterile injectable hormone developed purified synthetic polypeptide alternative current fda-approved epileptic seizure treatment ,
IMCY-0141,imcy-0141 synthetic peptide based mog myelin oligodendrocyte glycoprotein dominant autoantigen designed stop progression multiple sclerosis m destruction myelin sheath protecting nerve l43287 ,
JQ1,first-in-class potent selective inhibitor brd4 signaling pathway a252967 ,
Arachidonyltrifluoromethane,specific inhibitor phospholipase a2 a252972 ,
ABT-737, inhibitor member bcl‑2 family apoptosis regulator a252977 ,
Chelerythrine, benzophenanthridine alkaloid evaluated kinase-inhibitor a252982 ,
Diphenyleneiodonium, nadph oxidase 2 nox2 inhibitor a252987 ,
Ellipticine,ellipticine potent antineoplastic agent a252992 ,
GBR-12783, selective inhibitor dopamine uptake a252997 ,
Go-6976, inhibitor calcium-dependent isoforms protein kinase c. a253002 a253007 ,
GSK-269962A,gsk-269962a rho kinase rock inhibitor rock1 rock2 affinity a253012 ,
Homidium,homidium group ii compound trypanocidal effect a253017 ,
Indatraline,indatraline nonselective monoamine reuptake inhibitor a253022 ,
JTC-801 free base, antagonist nociceptin receptor analgesic agent evaluated use cancer treatment a253027 ,
Dacinostat,dacinostat novel histone deacetylase inhibitor a253032 ,
LY-2183240,ly-2183240 inhibitor endocannabinoid reuptake/breakdown a253037 ,
N-oleoyldopamine,n-oleoyldopamine olda amide dopamine oleic acid a253042 ,
NNC-55-0396 free base,nnc-55-0396 t-type ca 2+ channel inhibitor a253047 ,
NSC-663284,nsc-663284 potent quinolinedione cdc25 phosphatase inhibitor a253052 ,
Nutlin-3,nutlin-3 small molecule inhibitor target p53-mdm2 interaction a253057 ,
PD-169316,pd-169316 p38 map kinase inhibitor a253062 ,
PD-173952,pd-173952 potent myt1 kinase inhibitor a253067 ,
PD-98059,pd-98059 inhibitor map-kinase kinase activation a253072 ,
PHA-767491,pha-767491 cdc7/cdk9 inhibitor a253077 ,
Phenylmercuric acetate,phenylmercuric acetate organomercurial compound used fungicide slimicide a253082 ,
Phorbol 12-myristate 13-acetate diester,phorbol 12-myristate 13-acetate diester inducer neutrophil extracellular trap net a253087 ,
PI-103,pi-103 inhibitor p110α class pi3k a253092 ,
PIK-75,pik-75 preferential p110 alpha/gamma pi3k inhibitor a253097 ,
Plumbagin,plumbagin compound investigated anticancer activity found inactivates akt/nf-kb mmp-9 vegf pathway a253102 ,
Pristimerin,pristimerin quinone methide triterpenoid researched anti-cancer potential a253107 ,
RS-39604,rs-39604 selective 5-ht4 receptor antagonist a253112 ,
SB-218078,sb-218078 specific inhibitor chk1 a253117 ,
SB 224289,sb-224289 small molecule high affinity human 5-ht1b receptor a253122 ,
Scriptaid,scriptaid histone deacetylase hdac inhibitor researched anti-tumor property a253127 ,
SKF-96365 free base,skf-96365 receptor-mediated calcium entry rmce inhibitor structurally different calcium antagonist a253132 ,
SNX-2112,snx-2112 heat shock protein 90 hsp90 inhibitor a253137 ,
Spiperone,spiperone dopamine antagonist bind dopamine serotonin receptor a253142 ,
SRT-1720,srt-1720 activator nad -dependent histone deacetylase sirt1 a253147 ,
TPCA-1,tpca-1 selective inhibitor human iκb kinase 2 ikk-2 a253152 ,
TW-37,tw-37 small-molecule inhibitor bcl-2 investigated anti-cancer property a253157 ,
U-0126,u-0126 direct inhibitor mitogen-activated protein-kinase kinase family member mek-1 mek-2 a253162 ,
Sepantronium,sepantronium compound suppresses survivin expression dose time-dependent manner cause broad-range apoptosis a253167 ,
ZK-93423,zk-93423 beta-carboline muscle relaxant activity agonistic property benzodiazepine receptor a253172 ,
ZM-39923,zm-39923 small molecule inhibits janus kinase human tissue transglutaminase tgm2 a253177 ,
Autologous Hematopoietic Peripheral Blood Stem Cells,autologous hematopoietic peripheral blood stem cell tested clinical trial nct00424489 northwestern university treatment refractory myasthenia gravis ,
JZP-386 free base,jzp-386 deuterium-containing analog sodium oxybate safety pharmacokinetics pharmacodynamics evaluated clinical trial nct02215499 ,
αAβ–Gas6,αaβ–gas6 chimeric fusion protein investigated preclinical study immunotherapeutic agent alzheimer 's disease ad made single chain variable fragment scfv amyloid β aβ -targeting monoclonal antibody fused truncated receptor binding domain growth arrest-specific 6 gas6 ligand receptor kinase expressed glial cell a253203 a253208 αaβ–gas6 phagocyte inducer aβ a253203 main component amyloid plaque found individual ad considered contribute pathophysiology ad a253213 experimental drug gained attention associated fewer inflammatory side effect previously-approved aβ antibody-based immunotherapy aducanumab l43428 ,
LY3884961,ly3884961 previously pr001 developed prevail therapeutic single-dose gene therapy patient parkinson 's disease gaucher disease l43468 ,
Tabelecleucel,tabelecleucel innovative therapy us epstein-barr virus ebv -specific allogeneic cytotoxic cell ctls produced mixing t-cells b-cells infected epstein-barr virus ebv t-cells b-cells obtained donor t-cells grown increase number given patient ebv-associated post-transplant lymphoproliferative disorder ptld following solid organ transplantation sot hematopoietic cell transplant t-cells attack patient 's infected b-cells thereby helping control condition a253292 a253297 l43557 october 2022 ema 's committee medicinal product human use chmp recommended tabelecleucel granted marketing authorization treatment adult pediatric patient experience ebv-associated post-transplant lymphoproliferative disorder ptld following solid organ transplantation sot bone marrow transplantation hematopoietic cell transplant hct l43557 fda granted tabelecleucel breakthrough therapy designation ebv-associated ptld following allogeneic hct l43562 ,
MYR-101,myr-101 raav-olig001-aspa recombinant adeno-associated virus raav vector-based gene therapy intended treat canavan disease canavan disease fatal childhood genetic disorder characterized white matter degeneration brain caused mutation aspartoacylase gene _aspa_ lead deficiency aspartoacylase enzyme aspa aspa produced oligodendrocyte participates metabolism n-acetylaspartate naa properly metabolized naa accumulates brain negatively affect myelin production myr-101 target oligodendrocyte delivers functional aspa l43567 fda granted myr-101 fast track rare pediatric disease rpd orphan drug designation treatment patient canavan disease l43572 ,
KW-6356,kw-6356 selective antagonist adenosine a2a receptor developed kyowa kirin l43822 ,
PF-07284890,pf-07284890 potent selective highly brain-penetrant small-molecule inhibitor braf v600 mutation a253992 ,
Linzagolix,linzagolix non-peptide selective antagonist gonadotropin-releasing hormone gnrh receptor studied treatment estrogen-dependent condition uterine fibroid endometriosis a253642 a253647 similar gnrh receptor antagonist like cetrorelix relugolix elagolix uterine fibroid occur 70 woman reproductive age symptomatic associated heavy menstrual bleeding anemia abdominal pain pressure bloating increased urinary frequency reproductive dysfunction a253662 fibroid essentially estrogen-dependent phenomenon hormone therapy suppress estrogen activity including gnrh receptor antagonist like linzagolix thought beneficial preventing intramyometrial growth endometrial gland a253667 linzagolix approved use european union june 2022 management symptom caused uterine fibroid l43627 ,linzagolix indicated treatment moderate severe symptom uterine fibroid adult woman reproductive age l43627 
Gadopiclenol,gadopiclenol gadolinium-based contrast agent gbca based pyclen macrocyclic structure indicated use magnetic resonance imaging mri detect visualize lesion abnormal vascularity central nervous system body l43817 2006 use gbcas associated development nephrogenic systemic fibrosis nsf rare disorder characterized thickening hardening skin subcutaneous tissue however study revealed nsf associated linear gbcas macrocyclic gbcas gadopiclenol a254002 gadopiclenol high kinetic stability high r1 relaxivity allowing used lower dos classic extracellular gbcas a254002 a254012 september 2022 use gadopiclenol approved fda product label includes black box warning regarding increased risk nsf among patient impaired elimination drug l43817 ,gadopiclenol indicated adult pediatric patient aged 2 year older use magnetic resonance imaging mri detect visualize lesion abnormal vascularity central nervous system brain spine associated tissue body head neck thorax abdomen pelvis musculoskeletal system l43817 
KDT-3594,kdt-3594 non-ergot dopamine receptor agonist developed kissei pharmaceutical ,
AVI-014,avi-014 glycosylated recombinant human granulocyte colony-stimulating factor g-csf ,
JNJ-17216498,jnj-17216498 histamine receptor h3 antagonist developed johnson johnson treatment narcolepsy a253997 ,
Famtozinameran, omicron variant sars-cov-2 variant concern first reported november 2021 l43922 tends cause le severe disease significantly virulent original virus earlier variant e.g delta l43917 november 2022 primary circulating variant concern according world health organization l43922 omicron variant comprises several distinct lineage sublineages e.g ba.4 ba.5 although similar may behave differently one another l43917 famtozinameran mrna vaccine encoding glycoprotein sars-cov-2 omicron variant lineage ba.4 ba.5 administered combination tozinameran active immunization covid-19 caused sars-cov-2 including infection caused omicron ba.4/ba.5 l43907 l43912 , u famtozinameran combination tozinameran comirnaty original omicron ba.4/ba.5 bivalent mrna vaccine indicated booster dose active immunization covid-19 may given third dose three-dose primary series monovalent pfizer biontech covid-19 vaccine patient 6 month 4 year age may used patient ≥5 year age single booster dose least two month following completion primary vaccination covid-19 vaccine following receipt recent booster dose approved monovalent covid-19 vaccine l44316 canada famtozinameran indicated combination tozinameran booster dose patient ≥12 year age l43907 
Davesomeran,davesomeran mrna vaccine used conjunction elasomeran part moderna bivalent covid-19 vaccine similar previous moderna covid-19 vaccine moderna bivalent vaccine encodes full-length pre-fusion stabilized spike protein elicit immune response l43882 l28026 however addition davesomeran moderna bivalent vaccine offer protection severe acute respiratory syndrome coronavirus 2 sars-cov-2 omicron variant l43882 phase 2 3 open-label study participant 18 year older previously received two-dose primary series one booster dose moderna covid-19 vaccine demonstrated moderna bivalent vaccine elicit higher seroresponse original sars-cov-2 strain ba.4/5 strain compared moderna covid-19 vaccine l43882 october 22nd 2022 fda approved moderna bivalent vaccine booster patient 6 year older administered least 2 month completion primary vaccination receipt recent booster dose authorized approved monovalent covid-19 vaccine l43882 november 3rd 2022 health canada also approved moderna bivalent vaccine booster shot individual 18 year age older l43862 ,moderna covid-19 vaccine bivalent original omicron ba.4/ba.5 mixture 2 mrna vaccine davesomeran elasomeran indicated active immunization covid-19 may used patient 6 month 5 year age single booster dose least 2 month following completion primary vaccination series monovalent moderna covid-19 vaccine also indicated use patient ≥6 year age single booster dose following completion either primary vaccination authorized covid-19 vaccine following receipt recent booster dose authorized monovalent covid-19 vaccine l44316 
UCB7362,ucb7362 orally active plasmepsin x pmx inhibitor currently investigated treatment malaria a254222 plasmepsins aspartyl protease produced malaria parasite _plasmodium falciparum_ pmx considered essential parasite egress invasion a254232 ucb7362 estimated achieve significant reduction asexual blood-stage parasite shown high potency biochemical ic sub 50 /sub 7 nm _in vitro_ _p falciparum_ 3d7 lactate dehydrogenase growth inhibition assay ic sub 50 /sub 10 nm _in vivo_ 50 mg/kg dose mouse study a254222 ,
ATG-101,atg-101 novel pd-l1/4-1bb bispecific antibody designed block binding immunosuppressive pd-1/pd-l1 conditionally induce 4-1bb stimulation thus activating anti-tumor immune effector delivering enhanced anti-tumor activity improved safety profile l44076 ,
ZB131,zb131 monoclonal antibody high affinity specificity cancer-specific plectin csp cell surface protein identified wide range cancer correlate poor prognosis aggressive tumor l44081 ,
KT-333,kt-333 small molecule targeted protein degrader stat3 l44086 ,
ALM201,alm201 anti-angiogenic synthetic peptide identified endogenous human protein fkbpl a254556 ,
OS2966,os2966 humanized integrin β1 cd29 blocking antibody currently evaluated treatment acute myeloid leukemia glioblastoma ovarian cancer a254561 ,
Disitamab vedotin,disitamab vedotin antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 her2 currently investigated cancer a254721 ,
SBT-100,sbt-100 anti-signal transducer activator transcription 3 stat3 b vhh13 single-domain antibody sdab granted orphan drug designation fda treatment pancreatic cancer osteosarcoma l44131 l44136 ,
PRGN-3006,prgn-3006 autologous cd3+ cell genetically modified using non-viral system express cd33 car membrane-bound interleukin-15 truncated form human her1t kill switch cell surface ,
BCL-005,bcl-005 product formed fused hybrid melanoma-dendritic cell ,
GI-101,gi-101 bi-specific fragment crystallizable region fc fusion protein containing cluster differentiation 80 ectodomain n-terminal moiety interleukin-2 variant c-terminal moiety conjugated human immunoglobulin g4 fc ,
OTX-2002,otx-2002 bicistronic messenger ribonucleic acid mrna encoding zf-dnmt zf-krab protein encapsulated lipid nanoparticle lnp ,
ISB 1342,isb 1342 bispecific antibody simultaneously targeting cd38 cd3 ,
GALE-301,gale-301 investigational cancer immunotherapy made e39 immunogenic peptide derived folate binding protein fbp immune adjuvant granulocyte macrophage-colony stimulating factor gm-csf a254696 l44166 l44171 ,
MGD-024,mgd-024 anti-cd123/anti-cd3 bispecific dart molecule ,
TNB-383B,tnb-383b cd3 b-cell maturation antigen t-cell engaging bispecific antibody ,
ST101 peptide,st101 cell-penetrating peptide disrupts protein-protein interaction driving atf5-regulated gene transcription ,
ST-36,st-36 cell-penetrating dominant-negative form activating transcription factor 5 ,
IMAB027,imab027 chimeric monoclonal antibody claudin 6 ,
Dasiprotimut-T,dasiprotimut-t personalized therapeutic vaccine b-cell lymphoma a254701 investigated clinical trial ,
LV305,lv305 lentiviral vector encoding ny-eso-1 gene ,
CNDO-109,cndo-109 cndo-109-activated allogeneic natural killer cell ,
YS-ON-001,ys-on-001 combination inactivated purified rabies virus iprv pika adjuvant poly c kanamycin calcium ,
G305,g305 ny-eso-1 recombinant protein plus gla-se ,
Tavokinogene telseplasmid,tavokinogene telseplasmid consists dna plasmid vector encoding il-12 ,
SNS01-T,sns01-t gene therapy nanoparticle composed three component b cell-specific plasmid expressing eif5ak50r sirna target native eif5a promotes growth/anti-apoptosis cancer cell polyethylenimine a254706 ,
Leuvectin,"leuvectin formerly known vcl-1102 gene therapy consists plasmid encoding human interleukin il -2 formulated cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine dmrie/dope a254711 ",
CAR BCMA-CS1,car bcma-cs1 lentiviral transfected chimeric antigen receptor car t-cell therapy modified target b-cell maturation antigen cs1 ,
Maveropepimut-S,maveropepimut-s cell activating immunotherapy ,
ENB-003,enb-003 selective potent inhibitor endothelin b receptor etbr investigated cancer ,
NC-6300,nc-6300 also known k-912 novel epirubicin drug-conjugated polymeric micelle ,
MORAb-066,morab-066 humanized antibody directed tissue factor tf investigated pancreatic cancer ,
AMG 424,amg 424 novel humanized anti-cd3/cd38 bispecific monoclonal antibody investigated multiple myeloma ,
Ocaratuzumab,ocaratuzumab humanized monoclonal antibody directed cd20 investigated cancer autoimmune disorder ,
Autologous DNP-conjugated tumour vaccine,autologous dnp-conjugated tumour vaccine melanoma vaccine investigational autologous cell vaccine technology melanoma a254806 ,
Obecabtagene autoleucel,obecabtagene autoleucel investigational autologous cd19 car cell therapy ,
AMG-119,amg-119 car-t cell targeting delta-like ligand 3 dll3 a254811 ,
AUTO3,auto3 bicistronic chimeric antigen receptor t-cell therapy investigated acute lymphoblastic leukemia investigational chimeric antigen receptor car cell treatment targeting cd19 cd22 ,
SynKIR-110,synkir-110 autologous cell genetically engineered express anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor kir-car ,
MB-102 CD123 CAR,mb-102 autologous cell genetically modified express cd123-specific hinge-optimized cd28-costimulatory chimeric receptor truncated human epidermal growth factor receptor ,
Gavocabtagene autoleucel,gavocabtagene autoleucel novel cell therapy consisting autologous genetically engineered cell expressing single-domain antibody recognizes human mesothelin fused cd3-epsilon subunit upon expression incorporated endogenous cell receptor tcr complex l44271 ,
LioCyx-M004,liocyx-m004 autologous cell transduced retroviral vector encoding hepatitis b virus antigen-specific cell receptor ,
RR001,rr001 investigational gene therapy consisting autologous human adipose perivascular stromal cell genetically modified secrete soluble tumour necrosis factor-related apoptosis-inducing ligand ad-pc strail l44276 ,
TBX-3400,tbx-3400 investigational cell-based immunotherapy consisting autologous peripheral blood mononuclear cell pbmcs treated ex vivo tbx-4000 recombinant tat-myc fusion protein l44281 l44286 ,
P-BCMA-101,p-bcma-101 autologous car-t therapy developed using poseida ’ piggybac platform technology ,
BB 21217,bb 21217 anti-bcma car cell therapy us car molecule idecabtagene vicleucel bb2121 add pi3k inhibitor bb007 ex vivo culture enrich drug product dp memory-like cell l44291 ,
Zanolimumab,zanolimumab fully human monoclonal antibody directed cd4 ,
Bersanlimab,bersanlimab investigational monoclonal antibody directed intercellular adhesion molecule 1 icam-1 ,
MVR-T3011,mvr-t3011 genetically modified oncolytic herpes simplex virus hsv-1 2 exogenous gene encoding active heterodimer human interleukin 12 il-12 fab fragment anti-human pd-1 antibody ,
(-)-Gossypol, -gossypol r -gossypol r-isomer gossypol ,
Saposin C,saposin c lysosomal protein recombinant non-glycosylated saposin c active ingredient bxq-350 novel investigational anti-neoplastic therapy bxq-350 consists saposin c phospholipid dioleoylphosphatidyl-serine dops phospholipid located cell membrane ,
Nadofaragene firadenovec,nadofaragene firadenovec nadofaragene firadenovec-vncg recombinant non-replicating adenovirus serotype 5 vector containing transgene encoding human interferon alfa-2b ifnα2b l44381 approved fda december 2022 treatment high-risk bacillus calmette-guérin bcg -unresponsive non-muscle invasive bladder cancer nmibc carcinoma _in situ_ ci without papillary tumor first gene therapy approved fda treatment bladder cancer l44381 l44431 bcg-unresponsive nmibc high recurrence notably difficult treat patient condition undergo radical cystectomy since non-surgical treatment far le effective use nadofaragene firadenovec provides therapeutic alternative patient seeking non-surgical alternative treatment bcg-unresponsive nmibc a255111 nadofaragene firadenovec formulated excipient syn-3 facilitates gene transfer across urothelium promotes transduction ifnα2b localized expression gene induces anti-tumor effect a255106 l44381 nadofaragene firadenovec also manageable adverse event profile compared pembrolizumab smaller proportion patient experienced grade 3-4 adverse event 4 v 12.7 a255111 ,nadofaragene firadenovec indicated treatment adult patient high-risk bacillus calmetteguérin bcg -unresponsive non-muscle invasive bladder cancer nmibc carcinoma _in situ_ ci without papillary tumor l44381 
AUM-601,aum-601 highly selective pan-trk tropomyosin receptor kinase currently investigated clinical trial treatment cancer ,
